BARCODE,COMBI_ID,Tissue,CELL_LINE_NAME,SIDM,COSMIC_ID,ANCHOR_ID,ANCHOR_NAME,ANCHOR_TARGET,ANCHOR_PATHWAY,ANCHOR_DRUG_TYPE,ANCHOR_Clin_Rel,ANCHOR_CONC,LIBRARY_ID,LIBRARY_NAME,LIBRARY_TARGET,LIBRARY_PATHWAY,LIBRARY_DRUG_TYPE,LIBRARY_Clin_Rel,LIBRARY_CONC,ANCHOR_VIABILITY,LIBRARY_RMSE,LIBRARY_EMAX,LIBRARY_XMID,LIBRARY_XMID_uM,LIBRARY_AUC,LIBRARY_fAUC,SYNERGY_RMSE,SYNERGY_EXP_EMAX,SYNERGY_OBS_EMAX,SYNERGY_DELTA_EMAX,SYNERGY_XMID,SYNERGY_XMID_uM,SYNERGY_DELTA_XMID,SYNERGY_DELTA_XMID_uM,SYNERGY_EXP_AUC,SYNERGY_OBS_AUC,SYNERGY_EXP_fAUC,SYNERGY_OBS_fAUC,SYNERGY_DELTA_AUC,SYNERGY_DELTA_fAUC,Synergy,DAY1_NORM_MEAN,DAY1_NORM_SD,GROWTH_RATE,DOUBLING_TIME
14576,1011:1007,Breast,CAL-120,SIDM00940,906826,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1007,Docetaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.0125,0.283484548338709,0.055755094980629,0.613821324407456,9.83431125347511,0.0223,0.90404989022627,0.912569211629941,0.0528242035218281,0.174008860910316,0.0994520858583554,0.0745567750519605,7.89196977771695,0.0058,1.94234147575816,0.0165,0.256284174806454,0.184615095388298,0.258699270786726,0.230386911002527,0.0716690794181555,0.0283123597841992,True,0.45268617874145,0.0619180719759428,0.767468512851341,64.0728989737934
14577,1179:1011,Breast,CAL-120,SIDM00940,906826,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.59148156468649,0.103162076983888,0.121612570822384,5.44016726331254,0.848,0.633507043085208,0.625635748765272,0.0305435903368593,0.0719315936755703,0.0139201440045423,0.058011449671028,2.29265640036365,0.0957,3.14751086294889,0.7523,0.374707737083951,0.191489181880521,0.370052011603487,0.208078607952855,0.183218555203429,0.161973403650632,True,0.45268617874145,0.0619180719759428,0.767468512851341,64.0728989737934
14577,1011:1012,Breast,CAL-120,SIDM00940,906826,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,5.0,0.251275587746141,0.0952072335648409,0.518506228631407,9.13333523314711,5.4841,0.850533909432513,0.882395231797411,0.0289044549864365,0.130287957349392,0.0401051066803375,0.0901828506690541,6.00924670720787,0.629,3.12408852593924,4.8551,0.213718407990677,0.16638297892555,0.221724380494286,0.169171537373141,0.0473354290651278,0.0525528431211453,True,0.45268617874145,0.0619180719759428,0.767468512851341,64.0728989737934
14923,1011:1017,Breast,CAL-120,SIDM00940,906826,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.210724597152126,0.071275317991434,0.898002594179941,12.9162722648907,150.9786,0.948879648225014,0.980710033362263,0.0544173136246668,0.189231234900132,0.181126049385076,0.0081051855150561,12.2613635819329,95.8889,0.654908682957869,55.0897,0.199952281618067,0.161931840279148,0.206659726703311,0.205006210333442,0.0380204413389197,0.0016535163698695,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
14578,1011:1021,Breast,CAL-120,SIDM00940,906826,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.241120404495817,0.0933354841089233,0.851742797969336,12.1477009993731,88.6242,0.930284863630387,0.971230147250321,0.0524064747297236,0.205372567972765,0.0713433125022409,0.134029255470524,7.43908581227599,3.3894,4.70861518709708,85.2348,0.224310662614895,0.176857614247395,0.234183405963529,0.188652502592965,0.0474530483674993,0.0455309033705646,True,0.45268617874145,0.0619180719759428,0.767468512851341,64.0728989737934
14578,1190:1022,Breast,CAL-120,SIDM00940,906826,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.01,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.994280825679684,0.083322554760222,0.746174753110532,10.9413942505197,3.8408,0.914082831627642,0.947522057931501,0.0918775647635755,0.741907249624074,0.337320626051801,0.404586623572272,7.79987336378419,0.4352,3.14152088673555,3.4056,0.908855032570355,0.780748673316274,0.942103014109846,0.802117803385129,0.128106359254082,0.139985210724717,True,0.45268617874145,0.0619180719759428,0.767468512851341,64.0728989737934
14578,1017:1022,Breast,CAL-120,SIDM00940,906826,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.926560081037689,0.083322554760222,0.746174753110532,10.9413942505197,3.8408,0.914082831627642,0.947522057931501,0.061877622516663,0.691375739710372,0.470663249242318,0.220712490468054,9.05739008913917,1.0406,1.88400416138057,2.8002,0.846952662548069,0.777835915994825,0.87793611478201,0.81419270478121,0.069116746553244,0.0637434100008004,True,0.45268617874145,0.0619180719759428,0.767468512851341,64.0728989737934
14579,1011:1049,Breast,CAL-120,SIDM00940,906826,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.325457399928819,0.0863145969041701,0.786029418718387,11.3425983839965,50.7215,0.897098452961029,0.956843023200917,0.0538307292298927,0.255819090883647,0.177828004623916,0.0779910862597309,9.33507529912242,12.6144,2.00752308487411,38.1071,0.291967329980862,0.247928521528047,0.311411642471001,0.290229526112238,0.0440388084528156,0.0211821163587623,True,0.45268617874145,0.0619180719759428,0.767468512851341,64.0728989737934
14579,1549:1049,Breast,CAL-120,SIDM00940,906826,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.966711479030238,0.0863145969041701,0.786029418718387,11.3425983839965,50.7215,0.897098452961029,0.956843023200917,0.0718190532343168,0.75986366193053,0.781730602764305,-0.0218669408337742,11.5948378660018,60.4121,-0.252239482005271,-9.6906,0.867235372297695,0.857944320768887,0.924991134158322,0.929905086161411,0.0092910515288079,-0.0049139520030888,True,0.45268617874145,0.0619180719759428,0.767468512851341,64.0728989737934
14580,1594:1053,Breast,CAL-120,SIDM00940,906826,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.920746926528932,0.0772702898055411,0.809786020696576,11.608093586369,60.9697,0.920837498197176,0.962177872762651,0.0280613771758807,0.745607989702467,0.486384711319636,0.25922327838283,9.20366305368975,11.5162,2.40443053267925,49.4535,0.847858296297641,0.815028290136597,0.885922319120357,0.815526264703865,0.0328300061610439,0.0703960544164918,True,0.45268617874145,0.0619180719759428,0.767468512851341,64.0728989737934
14580,1049:1053,Breast,CAL-120,SIDM00940,906826,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.905088072444634,0.0772702898055411,0.809786020696576,11.608093586369,60.9697,0.920837498197176,0.962177872762651,0.0963041236474514,0.732927668564874,0.499278894420508,0.233648774144367,9.3731897881133,12.9521,2.2349037982557,48.0176,0.833439036278021,0.730002223838844,0.870855716207626,0.808665149794041,0.103436812439177,0.0621905664135854,True,0.45268617874145,0.0619180719759428,0.767468512851341,64.0728989737934
14580,1179:1053,Breast,CAL-120,SIDM00940,906826,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.771452332850911,0.0772702898055411,0.809786020696576,11.608093586369,60.9697,0.920837498197176,0.962177872762651,0.0874602561920229,0.62471131477643,0.384752822191612,0.239958492584818,8.99091370458398,9.9372,2.61717988178502,51.0325,0.710382236160808,0.608104469867228,0.742274364560275,0.675367990467073,0.10227776629358,0.0669063740932019,True,0.45268617874145,0.0619180719759428,0.767468512851341,64.0728989737934
14920,1049:1083,Breast,CAL-120,SIDM00940,906826,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.95097053850587,0.107418139415902,0.671179814068995,10.2846309900603,24.362,0.912435974327012,0.928555931844957,0.113397260461098,0.638272229219462,0.511769243963975,0.126502985255487,9.27530967739541,12.1025,1.0093213126649,12.2595,0.867699729857887,0.891168214120297,0.883029334539419,0.845453442260975,-0.0234684842624107,0.0375758922784438,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
14920,1011:1083,Breast,CAL-120,SIDM00940,906826,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.23030961524183,0.107418139415902,0.671179814068995,10.2846309900603,24.362,0.912435974327012,0.928555931844957,0.055989907975603,0.154579164736313,0.0474856767168322,0.107093488019481,6.57289128848941,1.8594,3.71173970157089,22.5026,0.210142778180059,0.118811864902602,0.213855359393731,0.165450051073264,0.0913309132774569,0.048405308320467,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
14920,1594:1083,Breast,CAL-120,SIDM00940,906826,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.936912437628772,0.107418139415902,0.671179814068995,10.2846309900603,24.362,0.912435974327012,0.928555931844957,0.0649762477461267,0.628836715686608,0.502478929501507,0.126357786185101,9.26197739570043,11.9912,1.02265359435988,12.3708,0.854872612886904,0.864308787904082,0.869975601579514,0.83238129175091,-0.009436175017178,0.0375943098286047,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
14921,1011:1190,Breast,CAL-120,SIDM00940,906826,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.221509389727692,0.134199231195951,0.380948778575536,8.1258650890533,5.4558,0.730483887034271,0.827374197588285,0.0525085260863911,0.0843837314597765,0.0268976765482741,0.0574860549115024,5.4370723196344,0.8462,2.6887927694189,4.6096,0.161809040022874,0.0975970949755777,0.18327115358422,0.138525834027652,0.0642119450472959,0.0447453195565679,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
14922,1594:1372,Breast,CAL-120,SIDM00940,906826,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.723643478691944,0.103013269066662,0.754585634057502,11.0222445492323,4.0622,0.884576636258143,0.949529717548833,0.0938219476071176,0.546050973200337,0.339952471012832,0.206098502187505,8.78209466228683,0.8598,2.24014988694549,3.2024,0.640118114231461,0.560146778372549,0.687120987928417,0.625782271725453,0.0799713358589125,0.0613387162029639,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
14922,1011:1372,Breast,CAL-120,SIDM00940,906826,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.57815280611961,0.103013269066662,0.754585634057502,11.0222445492323,4.0622,0.884576636258143,0.949529717548833,0.0753550832545673,0.43626580178789,0.281689759033546,0.154576042754344,8.90797037593715,0.9382,2.11427417329517,3.124,0.511420464480491,0.447144306773678,0.548973270694819,0.503731566619655,0.0642761577068127,0.0452417040751631,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
14922,1058:1372,Breast,CAL-120,SIDM00940,906826,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.929552451415327,0.103013269066662,0.754585634057502,11.0222445492323,4.0622,0.884576636258143,0.949529717548833,0.195711655654058,0.701426925940939,0.387849452911519,0.31357747302942,8.39848583436557,0.6591,2.62375871486676,3.4031,0.822260380698481,0.615328971529569,0.882637676639221,0.784170827860137,0.206931409168912,0.0984668487790837,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
14922,1561:1372,Breast,CAL-120,SIDM00940,906826,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.903254558496361,0.103013269066662,0.754585634057502,11.0222445492323,4.0622,0.884576636258143,0.949529717548833,0.143431689170465,0.681582913738305,0.46585616131032,0.215726752427985,9.1134835576963,1.0818,1.90876099153603,2.9804,0.798997879039545,0.668171411401325,0.857667045803746,0.796168132517122,0.13082646763822,0.0614989132866237,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
14922,1559:1372,Breast,CAL-120,SIDM00940,906826,1559,Luminespib,HSP90,Protein stability and degradation,Targeted,Early clinical trials,0.01,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.778758008921227,0.103013269066662,0.754585634057502,11.0222445492323,4.0622,0.884576636258143,0.949529717548833,0.160852760884285,0.587639605939182,0.351958802479992,0.235680803459189,8.6528840691406,0.7862,2.36936048009173,3.276,0.688871139990628,0.532236205129554,0.739453872249865,0.668063737392755,0.156634934861074,0.0713901348571099,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
14924,1011:1510,Breast,CAL-120,SIDM00940,906826,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.222871122719789,0.0542601784126793,0.91518280512338,13.2824731969349,194.6045,0.963749457945097,0.984107383438738,0.0942242187306682,0.203967819271693,0.0771111785566787,0.126856640715015,7.8536634193645,4.5177,5.42880977757038,190.0868,0.214791923712812,0.0888440732117773,0.219329117423825,0.18057643222826,0.125947850501034,0.038752685195565,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
14924,1594:1510,Breast,CAL-120,SIDM00940,906826,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.930061756875832,0.0542601784126793,0.91518280512338,13.2824731969349,194.6045,0.963749457945097,0.984107383438738,0.0306250155153674,0.851176527595604,0.569222851130275,0.281953676465329,9.82069424126037,17.6626,3.4617789556745,176.9419,0.896346514044548,0.841901584448776,0.915280641995511,0.848258594277147,0.0544449295957724,0.0670220477183642,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
14924,1083:1549,Breast,CAL-120,SIDM00940,906826,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.947637307213568,0.0774387521266379,0.919015001560451,13.3732366232639,103.6204,0.932210494489191,0.984856526202109,0.0936339070133051,0.87089290136762,0.598576302025799,0.27231659934182,9.97096790252702,9.8008,3.40226872073687,93.8196,0.883397442753966,0.788812829050071,0.933286786481876,0.869639574469951,0.094584613703895,0.0636472120119246,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
14924,1021:1549,Breast,CAL-120,SIDM00940,906826,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.92995784087484,0.0774387521266379,0.919015001560451,13.3732366232639,103.6204,0.932210494489191,0.984856526202109,0.0351142936377894,0.854645206582745,0.860060355209426,-0.0054151486266809,13.5189507303511,114.633,-0.145714107087164,-11.0126,0.866916458696035,0.91012350474369,0.915875048678409,0.916928119260239,-0.0432070460476545,-0.0010530705818299,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
14924,1594:1549,Breast,CAL-120,SIDM00940,906826,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.704606534349121,0.0774387521266379,0.919015001560451,13.3732366232639,103.6204,0.932210494489191,0.984856526202109,0.0652388502602909,0.647543975264361,0.408120852507769,0.239423122756593,9.57534319779758,7.4502,3.79789342546631,96.1702,0.656841605805909,0.592823877691876,0.693936343758382,0.635689027718316,0.0640177281140332,0.0582473160400663,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
14925,1021:1558,Breast,CAL-120,SIDM00940,906826,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.994762044608002,0.0695943433944192,0.862357438830148,12.303748128959,98.7478,0.971188424712462,0.973449920422527,0.0728732671163005,0.857840449033598,0.822110113132193,0.0357303359014044,11.8096955849227,70.1137,0.494052544036302,28.6341,0.966101383066594,0.929084530371056,0.96835103316301,0.960766491487333,0.0370168526955377,0.007584541675677,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
14925,1049:1558,Breast,CAL-120,SIDM00940,906826,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.866980720514686,0.0695943433944192,0.862357438830148,12.303748128959,98.7478,0.971188424712462,0.973449920422527,0.0781984162935851,0.74764727365816,0.48084898701259,0.26679828664557,9.39496177468034,13.1491,2.90878635427863,85.5987,0.842001640212733,0.775584623061123,0.843962313392886,0.775455159536773,0.0664170171516102,0.0685071538561131,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
14925,1047:1558,Breast,CAL-120,SIDM00940,906826,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.921203518804202,0.0695943433944192,0.862357438830148,12.303748128959,98.7478,0.971188424712462,0.973449920422527,0.054053378191154,0.794406707117311,0.749445865699317,0.0449608414179939,11.6524359589391,62.8728,0.651312170019859,35.875,0.89466219426703,0.909356225483209,0.896745492072902,0.88712726060719,-0.014694031216179,0.009618231465712,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
14925,1007:1558,Breast,CAL-120,SIDM00940,906826,1007,Docetaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.001,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.901144891545317,0.0695943433944192,0.862357438830148,12.303748128959,98.7478,0.971188424712462,0.973449920422527,0.0608371440061418,0.777109000687891,0.732198651875646,0.044910348812245,11.6402323297301,62.3432,0.66351579922884,36.4046,0.875181487657579,0.866705835909802,0.877219422963955,0.867605991653182,0.0084756517477768,0.0096134313107735,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
14925,1510:1558,Breast,CAL-120,SIDM00940,906826,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.971742418904469,0.0695943433944192,0.862357438830148,12.303748128959,98.7478,0.971188424712462,0.973449920422527,0.138407305025049,0.83798930356907,0.525089597035836,0.312899706533235,9.29128156941735,12.2373,3.01246655954161,86.5105,0.943744989042109,0.903433383256604,0.945942580353749,0.864630514906017,0.0403116057855046,0.0813120654477326,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
14925,1083:1558,Breast,CAL-120,SIDM00940,906826,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.988843865371074,0.0695943433944192,0.862357438830148,12.303748128959,98.7478,0.971188424712462,0.973449920422527,0.115202398991996,0.852736863144302,0.592506141645587,0.260230721498715,9.72393031906919,16.5168,2.57981780988977,82.231,0.960353715896315,0.931452245186191,0.962589982055776,0.89812101638549,0.0289014707101241,0.064468965670285,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
14925,1179:1558,Breast,CAL-120,SIDM00940,906826,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.453292002052378,0.0695943433944192,0.862357438830148,12.303748128959,98.7478,0.971188424712462,0.973449920422527,0.0804641881881572,0.390899729932078,0.193002037327404,0.197897692604674,8.46150896872418,6.8849,3.84223916023478,91.8629,0.440231945408007,0.359750097644737,0.441257063326055,0.384034853468113,0.0804818477632697,0.0572222098579425,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
14925,1005:1558,Breast,CAL-120,SIDM00940,906826,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.967281492113845,0.0695943433944192,0.862357438830148,12.303748128959,98.7478,0.971188424712462,0.973449920422527,0.134095227031868,0.834142390167099,0.441515981705597,0.392626408461502,8.68557647815775,8.0417,3.61817165080121,90.7061,0.939412588579566,0.832744648092067,0.941600091524406,0.831501436110917,0.106667940487498,0.110098655413489,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
14925,1012:1558,Breast,CAL-120,SIDM00940,906826,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.677574033847871,0.0695943433944192,0.862357438830148,12.303748128959,98.7478,0.971188424712462,0.973449920422527,0.119268978309833,0.584311008446861,0.334162134244823,0.250148874202038,8.95084139919557,9.665,3.35290672976339,89.0828,0.658052058558782,0.624956081172054,0.65958438932958,0.591824290149626,0.0330959773867281,0.0677600991799538,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
14925,1011:1558,Breast,CAL-120,SIDM00940,906826,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.194752539432721,0.0695943433944192,0.862357438830148,12.303748128959,98.7478,0.971188424712462,0.973449920422527,0.0359197075184253,0.167946301110869,0.0769691360964843,0.0909771650143845,8.23403342850054,5.8806,4.06971470045842,92.8672,0.189141411980416,0.151734377974171,0.189581844012867,0.162409547774548,0.0374070340062447,0.0271722962383193,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
14926,1054:1561,Breast,CAL-120,SIDM00940,906826,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.995946790055155,0.0567333503993024,0.529815391806319,9.21497335874426,11.6068,0.862055517445445,0.886251288923021,0.111309052418034,0.527667938791317,0.310737665352173,0.216930273439145,7.57629001070676,3.7275,1.63868334803749,7.8793,0.858561425449127,0.701880140360663,0.882659126385126,0.788620264120239,0.156681285088464,0.0940388622648869,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
14926,1179:1561,Breast,CAL-120,SIDM00940,906826,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.430439331823715,0.0567333503993024,0.529815391806319,9.21497335874426,11.6068,0.862055517445445,0.886251288923021,0.117571780089447,0.228053383239031,0.169557559936937,0.0584958233020945,8.22425365387232,5.8409,0.990719704871937,5.7659,0.371062600924164,0.268068552611533,0.381477412631931,0.358702927192001,0.102994048312631,0.0227744854399297,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
14926,1005:1561,Breast,CAL-120,SIDM00940,906826,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.944879562647518,0.0567333503993024,0.529815391806319,9.21497335874426,11.6068,0.862055517445445,0.886251288923021,0.134354690439122,0.500611735693878,0.409577172081213,0.0910345636126648,8.5180217591097,7.16,0.696951599634559,4.4468,0.814538640301733,0.718464379132673,0.837400730273383,0.803532592966799,0.09607426116906,0.0338681373065844,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
14926,1011:1561,Breast,CAL-120,SIDM00940,906826,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.243602979169645,0.0567333503993024,0.529815391806319,9.21497335874426,11.6068,0.862055517445445,0.886251288923021,0.0523604017989413,0.129064607853952,0.0399203066723597,0.0891443011815922,6.0659304040885,1.3084,3.14904295465576,10.2984,0.20999929225934,0.120738225889359,0.215893454274586,0.165136293163557,0.0892610663699814,0.0507571611110288,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
14926,1058:1594,Breast,CAL-120,SIDM00940,906826,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.949258718784091,0.084550381132,0.35207155696884,7.90185462740802,1.8685,0.832104250155322,0.813330613585929,0.0773213450034831,0.334206995088561,0.192755095427262,0.141451899661299,6.53833913877055,0.7261,1.36351548863747,1.1424,0.789882214397237,0.667358939193303,0.772061176200457,0.679369273714663,0.122523275203934,0.092691902485794,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
14926,1083:1594,Breast,CAL-120,SIDM00940,906826,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.903250830577869,0.084550381132,0.35207155696884,7.90185462740802,1.8685,0.832104250155322,0.813330613585929,0.0320467938972194,0.318008926254948,0.211126209105298,0.10688271714965,6.86236931831573,0.909,1.03948530909228,0.9595,0.75159885508017,0.671118308177029,0.734641552255898,0.668924371493397,0.0804805469031403,0.0657171807625008,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
14926,1561:1594,Breast,CAL-120,SIDM00940,906826,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.913825377780318,0.084550381132,0.35207155696884,7.90185462740802,1.8685,0.832104250155322,0.813330613585929,0.0319592001056012,0.321731923552755,0.157132607146721,0.164599316406034,6.17001301460099,0.5625,1.73184161280702,1.306,0.760397980750795,0.633573731498975,0.743242155220459,0.627209528413622,0.12682424925182,0.116032626806837,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
15760,1179:1005,Breast,CAL-148,SIDM00938,924106,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.155542653082292,0.149933587249045,0.665085674461507,10.685601135348,12.867,0.868348757584679,0.901897832573783,0.0551324682891412,0.103449190332768,0.0538967084076136,0.0495524819251548,7.44121647121352,1.3577,3.24438466413453,11.5093,0.135065269555433,0.0622295146078634,0.140283581687695,0.116249998425139,0.0728357549475698,0.0240335832625566,True,0.881422581552557,0.144019781847702,0.113687909514015,400.083390307117
15760,1011:1005,Breast,CAL-148,SIDM00938,924106,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.559231255349353,0.149933587249045,0.665085674461507,10.685601135348,12.867,0.868348757584679,0.901897832573783,0.0839669527034017,0.371936696643979,0.0987630022085977,0.273173694435382,5.21740148079905,0.2907,5.468199654549,12.5763,0.485607765785131,0.308448304019655,0.504369457107097,0.331522837018653,0.177159461765476,0.172846620088444,True,0.881422581552557,0.144019781847702,0.113687909514015,400.083390307117
15760,1559:1005,Breast,CAL-148,SIDM00938,924106,1559,Luminespib,HSP90,Protein stability and degradation,Targeted,Early clinical trials,0.01,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.599692270550663,0.149933587249045,0.665085674461507,10.685601135348,12.867,0.868348757584679,0.901897832573783,0.0614656741001478,0.39884673822854,0.203080459987849,0.195766278240691,7.35539477713683,1.2793,3.33020635821122,11.5877,0.520742038065803,0.430868093087885,0.540861159020894,0.444979801883194,0.0898739449779181,0.0958813571377,True,0.881422581552557,0.144019781847702,0.113687909514015,400.083390307117
15760,1594:1005,Breast,CAL-148,SIDM00938,924106,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.778174040284483,0.149933587249045,0.665085674461507,10.685601135348,12.867,0.868348757584679,0.901897832573783,0.0587912698776053,0.517552406431041,0.41895327147881,0.0985991349522314,9.37794081177155,5.1979,1.3076603235765,7.6691,0.675726461065681,0.678542682030927,0.701833480297759,0.662565817526021,-0.002816220965246,0.0392676627717377,True,0.881422581552557,0.144019781847702,0.113687909514015,400.083390307117
15761,1561:1011,Breast,CAL-148,SIDM00938,924106,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.272989478566279,0.144270394023131,0.269009550962435,6.543854060454,1.8223,0.673065943051663,0.688539177513284,0.0425363751052771,0.073436777046584,0.0233638784165798,0.0500728986300042,3.17993607252141,0.177,3.36391798793259,1.6453,0.183739920834394,0.0874871675889683,0.187963951041806,0.119347896187615,0.0962527532454261,0.0686160548541915,True,0.881422581552557,0.144019781847702,0.113687909514015,400.083390307117
15761,1073:1011,Breast,CAL-148,SIDM00938,924106,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,10.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.63706841185457,0.144270394023131,0.269009550962435,6.543854060454,1.8223,0.673065943051663,0.688539177513284,0.0638212844921491,0.17137748740535,0.0206347091651307,0.150742778240219,0.653638742004405,0.0307,5.89021531844959,1.7916,0.428789051413322,0.120472361900266,0.43864656031804,0.164717245569237,0.308316689513056,0.273929314748803,True,0.881422581552557,0.144019781847702,0.113687909514015,400.083390307117
15761,1083:1011,Breast,CAL-148,SIDM00938,924106,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.446959026231459,0.144270394023131,0.269009550962435,6.543854060454,1.8223,0.673065943051663,0.688539177513284,0.0482145054442016,0.120236246945132,0.0278774132875879,0.0923588336575443,2.34092591357875,0.099,4.20292814687524,1.7233,0.30083289849593,0.142655313300072,0.307748800303547,0.167347429166998,0.158177585195858,0.140401371136549,True,0.881422581552557,0.144019781847702,0.113687909514015,400.083390307117
15761,1179:1011,Breast,CAL-148,SIDM00938,924106,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.141595281569784,0.144270394023131,0.269009550962435,6.543854060454,1.8223,0.673065943051663,0.688539177513284,0.0418872969870447,0.0380904831134872,0.0156711226305324,0.0224193604829548,3.87996139173333,0.2876,2.66389266872067,1.5347,0.0953029617214325,0.0259927596168728,0.097493898711821,0.0694909451406231,0.0693102021045598,0.0280029535711979,True,0.881422581552557,0.144019781847702,0.113687909514015,400.083390307117
15761,1005:1011,Breast,CAL-148,SIDM00938,924106,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.551507375653862,0.144270394023131,0.269009550962435,6.543854060454,1.8223,0.673065943051663,0.688539177513284,0.0575884167965213,0.148360751477117,0.0220517219129474,0.126309029564169,1.19053561626718,0.0446,5.35331844418682,1.7777,0.371200831894415,0.126161095232896,0.37973443482522,0.161840352368667,0.245039736661519,0.217894082456553,True,0.881422581552557,0.144019781847702,0.113687909514015,400.083390307117
15761,1012:1011,Breast,CAL-148,SIDM00938,924106,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.492642974349669,0.144270394023131,0.269009550962435,6.543854060454,1.8223,0.673065943051663,0.688539177513284,0.0542731844365553,0.132525665314603,0.032109351858342,0.100416313456261,2.4564301822832,0.1072,4.0874238781708,1.7151,0.331581208118436,0.165665151621451,0.339203988366419,0.188638650374643,0.165916056496985,0.150565337991776,True,0.881422581552557,0.144019781847702,0.113687909514015,400.083390307117
15761,1017:1011,Breast,CAL-148,SIDM00938,924106,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.933149775458371,0.144270394023131,0.269009550962435,6.543854060454,1.8223,0.673065943051663,0.688539177513284,0.0996381745371885,0.251026202076754,0.178127126629271,0.072899075447483,5.45148106719491,0.8547,1.09237299325908,0.9676,0.628071333627336,0.582322891263637,0.642510178890812,0.569478177935177,0.045748442363699,0.0730320009556351,True,0.881422581552557,0.144019781847702,0.113687909514015,400.083390307117
15761,1190:1011,Breast,CAL-148,SIDM00938,924106,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.01,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.570544426434749,0.144270394023131,0.269009550962435,6.543854060454,1.8223,0.673065943051663,0.688539177513284,0.0572773431159186,0.153481899959332,0.0238617180391295,0.129620181920203,1.30568417622102,0.0483,5.23816988423297,1.774,0.384014022431175,0.151747960839931,0.392842190112171,0.171848972504391,0.232266061591244,0.220993217607779,True,0.881422581552557,0.144019781847702,0.113687909514015,400.083390307117
15761,1559:1011,Breast,CAL-148,SIDM00938,924106,1559,Luminespib,HSP90,Protein stability and degradation,Targeted,Early clinical trials,0.01,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.622818601145951,0.144270394023131,0.269009550962435,6.543854060454,1.8223,0.673065943051663,0.688539177513284,0.0817364351464471,0.167544152225324,0.0524456534913507,0.115098498733973,3.13634413636028,0.1717,3.40750992409372,1.6506,0.419197989130417,0.260219360243633,0.428835007373007,0.270226799726588,0.158978628886784,0.158608207646419,True,0.881422581552557,0.144019781847702,0.113687909514015,400.083390307117
15761,1021:1011,Breast,CAL-148,SIDM00938,924106,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,4.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.713104705469936,0.144270394023131,0.269009550962435,6.543854060454,1.8223,0.673065943051663,0.688539177513284,0.0617113413081284,0.191831976607667,0.0557923091029522,0.136039667504715,2.93975883855165,0.1499,3.60409522190235,1.6724,0.479966491081701,0.289536542790097,0.491000527385122,0.298790678631105,0.190429948291604,0.192209848754017,True,0.881422581552557,0.144019781847702,0.113687909514015,400.083390307117
15761,1594:1011,Breast,CAL-148,SIDM00938,924106,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.82123415915419,0.144270394023131,0.269009550962435,6.543854060454,1.8223,0.673065943051663,0.688539177513284,0.0794129475643218,0.220919832389082,0.1293976605659,0.0915221718231815,4.88094395861721,0.5755,1.66291010183679,1.2468,0.552744743797355,0.477701811568275,0.56545189248984,0.465996916287298,0.0750429322290795,0.0994549762025421,True,0.881422581552557,0.144019781847702,0.113687909514015,400.083390307117
15761,1047:1011,Breast,CAL-148,SIDM00938,924106,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.615681261401843,0.144270394023131,0.269009550962435,6.543854060454,1.8223,0.673065943051663,0.688539177513284,0.0852193758684393,0.165624139665695,0.0348462093136569,0.130777930352039,2.08718302614681,0.083,4.45667103430719,1.7393,0.414394088824669,0.186316807917621,0.423920669335966,0.219150573269508,0.228077280907048,0.204770096066458,True,0.881422581552557,0.144019781847702,0.113687909514015,400.083390307117
15078,1011:1017,Breast,CAL-148,SIDM00938,924106,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.793856359190768,0.108136525201399,0.850572022963698,13.2729506114699,193.3242,0.90874327628937,0.960970460952614,0.128579851893371,0.675232009379488,0.284293440398623,0.390938568980865,7.56622811378168,3.7016,5.70672249768821,189.6226,0.72141162875417,0.528152767331811,0.762872511421717,0.599440814756139,0.193258861422359,0.163431696665578,True,0.920602720223482,0.156348479856104,0.0702170609140754,610.559201373973
15078,1561:1017,Breast,CAL-148,SIDM00938,924106,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.741527744448854,0.108136525201399,0.850572022963698,13.2729506114699,193.3242,0.90874327628937,0.960970460952614,0.0654755713924794,0.630722753679571,0.389989534509896,0.240733219169674,9.25503998556835,11.9337,4.01791062590154,181.3905,0.673858351949919,0.58641371640469,0.712586258392168,0.62723497490985,0.0874446355452284,0.0853512834823178,True,0.920602720223482,0.156348479856104,0.0702170609140754,610.559201373973
15078,1179:1017,Breast,CAL-148,SIDM00938,924106,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.123274189612889,0.108136525201399,0.850572022963698,13.2729506114699,193.3242,0.90874327628937,0.960970460952614,0.0324471060185935,0.104853576838246,0.10566495974467,-0.0008113829064244,13.4025708997171,211.4978,-0.129620288247176,-18.1736,0.112024590950734,0.0903877916567053,0.118462854815858,0.11869167604588,0.0216367992940288,-0.0002288212300219,True,0.920602720223482,0.156348479856104,0.0702170609140754,610.559201373973
15762,1007:1021,Breast,CAL-148,SIDM00938,924106,1007,Docetaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.001,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.996377518274945,0.098162397491293,0.523549181977611,9.23161246287892,11.7415,0.843449567819426,0.844790782006218,0.141389101029758,0.52165263463373,0.203192582828161,0.318460051805569,5.65381004064163,0.9833,3.57780242223729,10.7582,0.840394187173995,0.604459503388262,0.841730542836906,0.622935769005813,0.235934683785732,0.218794773831093,True,0.881422581552557,0.144019781847702,0.113687909514015,400.083390307117
15762,1011:1021,Breast,CAL-148,SIDM00938,924106,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.553303159877639,0.098162397491293,0.523549181977611,9.23161246287892,11.7415,0.843449567819426,0.844790782006218,0.0705690306933027,0.289681416739565,0.113735918111337,0.175945498628229,5.67835726886919,1.0002,3.55325519400973,10.7413,0.466683311071918,0.337519108466071,0.467425409119542,0.34692107248443,0.129164202605846,0.120504336635113,True,0.881422581552557,0.144019781847702,0.113687909514015,400.083390307117
15762,1073:1022,Breast,CAL-148,SIDM00938,924106,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,10.0,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.664680886532803,0.102457444962349,0.671982396714632,10.7620721227569,3.3918,0.885685570920124,0.904368334604716,0.0868117289830841,0.446653855182719,0.337718536855917,0.108935318326802,9.0795275757156,1.0567,1.68254454704135,2.3351,0.5886982704685,0.505184333141624,0.601116346397257,0.556781345299707,0.0835139373268761,0.0443350010975498,True,0.881422581552557,0.144019781847702,0.113687909514015,400.083390307117
15762,1005:1022,Breast,CAL-148,SIDM00938,924106,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,1.0,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.797291723971227,0.102457444962349,0.671982396714632,10.7620721227569,3.3918,0.885685570920124,0.904368334604716,0.031039516615788,0.535766003554926,0.411361497791106,0.124404505763819,9.15679522802595,1.1148,1.60527689473099,2.277,0.706149775735346,0.688603702499729,0.721045388601981,0.670772616870605,0.0175460732356164,0.0502727717313757,True,0.881422581552557,0.144019781847702,0.113687909514015,400.083390307117
15762,1190:1022,Breast,CAL-148,SIDM00938,924106,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.01,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.45038867078426,0.102457444962349,0.671982396714632,10.7620721227569,3.3918,0.885685570920124,0.904368334604716,0.0605622063692121,0.302653258446724,0.0887272343539076,0.213926024092817,5.54757084630645,0.0914,5.2145012764505,3.3004,0.398902747019513,0.236060346911388,0.407317252121993,0.278062667088861,0.162842400108124,0.129254585033132,True,0.881422581552557,0.144019781847702,0.113687909514015,400.083390307117
15762,1179:1022,Breast,CAL-148,SIDM00938,924106,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.404398322955998,0.102457444962349,0.671982396714632,10.7620721227569,3.3918,0.885685570920124,0.904368334604716,0.0692109059024197,0.271748554287349,0.0932521783641014,0.178496375923248,6.0394281195767,0.1285,4.72264400318025,3.2633,0.358169759546424,0.229619797787836,0.365725037848656,0.264133304732645,0.128549961758588,0.101591733116012,True,0.881422581552557,0.144019781847702,0.113687909514015,400.083390307117
15763,1011:1047,Breast,CAL-148,SIDM00938,924106,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.539700643380236,0.0728842912683421,0.377036515048285,7.76622898093169,4.252,0.780987198957052,0.767177915621674,0.0688137459017972,0.203486849749401,0.0577036166114686,0.145783233137933,3.78473314662059,0.2692,3.9814958343111,3.9828,0.421499293748849,0.229978574057141,0.414046414648125,0.260920217305466,0.191520719691708,0.153126197342659,True,0.881422581552557,0.144019781847702,0.113687909514015,400.083390307117
15763,1179:1049,Breast,CAL-148,SIDM00938,924106,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.119031953467422,0.147351180857652,0.915138034069015,14.8428596554512,573.9526,0.898311741854258,0.978600038968846,0.0455183263090041,0.108930667887571,0.0679237718576362,0.0410068960299351,9.69887193881136,16.2324,5.14398771663982,557.7202,0.106927801455635,0.0633783997000437,0.116484674301757,0.102998112690476,0.0435494017555914,0.0134865616112815,True,0.881422581552557,0.144019781847702,0.113687909514015,400.083390307117
15763,1073:1049,Breast,CAL-148,SIDM00938,924106,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,2.5,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.907640052031621,0.147351180857652,0.915138034069015,14.8428596554512,573.9526,0.898311741854258,0.978600038968846,0.134093027884582,0.830615932858517,0.681744311563212,0.148871621295305,11.7139527675401,65.6117,3.12890688791104,508.3409,0.815343716117215,0.788524809537849,0.88821659028783,0.845075325550295,0.0268189065793657,0.0431412647375351,True,0.881422581552557,0.144019781847702,0.113687909514015,400.083390307117
15763,1559:1049,Breast,CAL-148,SIDM00938,924106,1559,Luminespib,HSP90,Protein stability and degradation,Targeted,Early clinical trials,0.01,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.710350192444533,0.147351180857652,0.915138034069015,14.8428596554512,573.9526,0.898311741854258,0.978600038968846,0.155961841133798,0.650068478614237,0.29229346791307,0.357775010701167,8.12074189895994,5.4365,6.72211775649125,568.5161,0.638115918701356,0.473389960610484,0.695148726007748,0.559576795296386,0.164725958090872,0.135571930711362,True,0.881422581552557,0.144019781847702,0.113687909514015,400.083390307117
15764,1179:1054,Breast,CAL-148,SIDM00938,924106,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.391732254177019,0.0968906168447721,0.834934639035315,12.9828218611631,63.2425,0.921125544909467,0.956503439719259,0.0938237791551938,0.32707082823978,0.272722576705886,0.0543482515338943,11.037465628198,16.4209,1.94535623296512,46.8216,0.360834586087421,0.312210137919748,0.374693248569298,0.357593001741517,0.0486244481676731,0.0171002468277807,True,0.881422581552557,0.144019781847702,0.113687909514015,400.083390307117
15764,1053:1054,Breast,CAL-148,SIDM00938,924106,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.769086337464479,0.0968906168447721,0.834934639035315,12.9828218611631,63.2425,0.921125544909467,0.956503439719259,0.136373665091909,0.642136823557897,0.466744647056254,0.175392176501642,10.0668884356598,8.3796,2.91593342550333,54.8629,0.708425071679394,0.581326826655558,0.73563372722586,0.676792470420686,0.127098245023836,0.0588412568051738,True,0.881422581552557,0.144019781847702,0.113687909514015,400.083390307117
15765,1053:1058,Breast,CAL-148,SIDM00938,924106,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.431440711408525,0.112252711530227,0.267372993191295,6.52336628415407,0.7187,0.702068908997331,0.687131082691171,0.0516083073799226,0.115355594393879,0.040629379749086,0.0747262146447929,3.4380130502878,0.0847,3.08535323386627,0.634,0.302901109555615,0.162838209133858,0.296456323147189,0.197111786202326,0.140062900421757,0.0993445369448627,True,0.881422581552557,0.144019781847702,0.113687909514015,400.083390307117
15765,1011:1073,Breast,CAL-148,SIDM00938,924106,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,20.0,0.524438207628391,0.0938568838930033,0.477554033556039,8.77925291806042,17.1624,0.817778367000912,0.822956695199359,0.0923526193560018,0.250447581403837,0.085395147199324,0.165052434204513,4.97713817841481,1.2303,3.80211473964561,15.9321,0.42887422102723,0.298011349340841,0.431589934186135,0.301406634087931,0.13086287168639,0.130183300098204,True,0.881422581552557,0.144019781847702,0.113687909514015,400.083390307117
15076,1047:1191,Breast,CAL-148,SIDM00938,924106,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.02,0.639309520103792,0.0812016315985898,0.725698521357217,11.3904295441639,0.1049,0.919268325577194,0.922804474616812,0.0650340094017604,0.463945973428914,0.107850056102985,0.356095917325929,5.08137183116699,0.0013,6.3090577129969,0.1036,0.587696992071372,0.359581350464841,0.589957685816906,0.372457551820461,0.228115641606531,0.217500133996445,True,0.920602720223482,0.156348479856104,0.0702170609140754,610.559201373973
15076,1053:1191,Breast,CAL-148,SIDM00938,924106,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.02,0.687469307069572,0.0812016315985898,0.725698521357217,11.3904295441639,0.1049,0.919268325577194,0.922804474616812,0.0706151879953179,0.498895459618859,0.264966897347018,0.233928562271841,7.85358903720412,0.009,3.53684050695977,0.0959,0.631968758795559,0.523764049943648,0.63439975272552,0.530965483943868,0.108204708851911,0.103434268781652,True,0.920602720223482,0.156348479856104,0.0702170609140754,610.559201373973
15076,1594:1191,Breast,CAL-148,SIDM00938,924106,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.02,0.936673274820276,0.0812016315985898,0.725698521357217,11.3904295441639,0.1049,0.919268325577194,0.922804474616812,0.147191438246445,0.679742410531896,0.498608215572869,0.181134194959028,9.31806618737887,0.0249,2.07236335678502,0.08,0.861054072956942,0.835314659821908,0.864366289258133,0.794993876910648,0.0257394131350337,0.0693724123474854,True,0.920602720223482,0.156348479856104,0.0702170609140754,610.559201373973
15076,1073:1191,Breast,CAL-148,SIDM00938,924106,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,2.5,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.02,0.969632618845594,0.0812016315985898,0.725698521357217,11.3904295441639,0.1049,0.919268325577194,0.922804474616812,0.135203207718233,0.703660957755974,0.662583122320226,0.0410778354357483,10.889767644748,0.0741,0.500661899415887,0.0308,0.891352553951219,0.797172413810296,0.894781319405132,0.880796215197754,0.0941801401409232,0.0139851042073783,True,0.920602720223482,0.156348479856104,0.0702170609140754,610.559201373973
15076,1012:1191,Breast,CAL-148,SIDM00938,924106,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.02,0.946805662531453,0.0812016315985898,0.725698521357217,11.3904295441639,0.1049,0.919268325577194,0.922804474616812,0.11613281405908,0.687095469311716,0.573824200082866,0.11327126922885,10.0584605593029,0.0417,1.33196898486096,0.0632,0.870368456042295,0.891641665952725,0.87371650197656,0.832879393986565,-0.0212732099104296,0.0408371079899952,True,0.920602720223482,0.156348479856104,0.0702170609140754,610.559201373973
15076,1372:1191,Breast,CAL-148,SIDM00938,924106,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.02,0.854743980928232,0.0812016315985898,0.725698521357217,11.3904295441639,0.1049,0.919268325577194,0.922804474616812,0.160312784096537,0.620286443098599,0.404503988861205,0.215782454237395,8.7368085201436,0.0167,2.65362102402029,0.0882,0.785739068145081,0.7717788093075,0.78876157025236,0.701581182013055,0.013960258837581,0.0871803882393049,True,0.920602720223482,0.156348479856104,0.0702170609140754,610.559201373973
15076,1558:1191,Breast,CAL-148,SIDM00938,924106,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.02,0.962791139827971,0.0812016315985898,0.725698521357217,11.3904295441639,0.1049,0.919268325577194,0.922804474616812,0.143623530450213,0.698696106548988,0.521410816845214,0.177285289703775,9.40941272921461,0.0266,1.98101681494928,0.0783,0.885063398990217,0.879451506354057,0.888467971954672,0.821106038712207,0.0056118926361602,0.0673619332424654,True,0.920602720223482,0.156348479856104,0.0702170609140754,610.559201373973
15076,1549:1191,Breast,CAL-148,SIDM00938,924106,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.02,0.967912244207575,0.0812016315985898,0.725698521357217,11.3904295441639,0.1049,0.919268325577194,0.922804474616812,0.144322867058024,0.702412484424983,0.514536086255659,0.187876398169324,9.31091713084671,0.0248,2.07951241331718,0.0801,0.889771068038362,0.862626665856748,0.893193749991151,0.821194072573928,0.0271444021816144,0.0719996774172234,True,0.920602720223482,0.156348479856104,0.0702170609140754,610.559201373973
15076,1561:1191,Breast,CAL-148,SIDM00938,924106,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.02,0.743232805581262,0.0812016315985898,0.725698521357217,11.3904295441639,0.1049,0.919268325577194,0.922804474616812,0.147460511521615,0.539362948034498,0.330595984929214,0.208766963105284,8.45535545870151,0.0137,2.93507408546238,0.0912,0.683230376700727,0.63140740708733,0.685858558672396,0.599148000516504,0.0518229696133974,0.0867105581558923,True,0.920602720223482,0.156348479856104,0.0702170609140754,610.559201373973
15076,1011:1191,Breast,CAL-148,SIDM00938,924106,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.02,0.782924272919597,0.0812016315985898,0.725698521357217,11.3904295441639,0.1049,0.919268325577194,0.922804474616812,0.192996488366509,0.568166987192426,0.310482953565861,0.257684033626565,7.96859051483288,0.0098,3.42183902933101,0.0951,0.71971748542054,0.683696884268176,0.722486022336318,0.609940011009792,0.0360206011523637,0.112546011326527,True,0.920602720223482,0.156348479856104,0.0702170609140754,610.559201373973
15076,1058:1191,Breast,CAL-148,SIDM00938,924106,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.02,0.901215036608816,0.0812016315985898,0.725698521357217,11.3904295441639,0.1049,0.919268325577194,0.922804474616812,0.192894745778245,0.654010419491908,0.366537712046417,0.287472707445491,8.07233115071759,0.0105,3.3180983934463,0.0944,0.828458437688376,0.751172634682228,0.83164526837457,0.707457153952988,0.0772858030061483,0.124188114421582,True,0.920602720223482,0.156348479856104,0.0702170609140754,610.559201373973
15077,1190:1372,Breast,CAL-148,SIDM00938,924106,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.01,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.694562271700425,0.0977772998865147,0.879455155526854,13.8827433370727,29.5021,0.926161663675484,0.969013652029865,0.16627706000487,0.610836370681382,0.416713483280519,0.194122887400863,9.9958746918681,1.9943,3.88686864520461,27.5078,0.643276949084289,0.459041760030102,0.673040323462588,0.609310341684002,0.184235189054187,0.0637299817785861,True,0.920602720223482,0.156348479856104,0.0702170609140754,610.559201373973
15077,1047:1372,Breast,CAL-148,SIDM00938,924106,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.792566492709575,0.0977772998865147,0.879455155526854,13.8827433370727,29.5021,0.926161663675484,0.969013652029865,0.0934257318970147,0.697026688111273,0.668385253159754,0.0286414349515192,13.1354276889632,17.5747,0.747315648109549,11.9274,0.734044701461343,0.68272250876306,0.768007751577007,0.759998531461074,0.0513221926982835,0.0080092201159329,True,0.920602720223482,0.156348479856104,0.0702170609140754,610.559201373973
15077,1561:1372,Breast,CAL-148,SIDM00938,924106,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.766141517912436,0.0977772998865147,0.879455155526854,13.8827433370727,29.5021,0.926161663675484,0.969013652029865,0.0919120063508141,0.673787107791261,0.692225568930122,-0.0184384611388606,14.4962617183229,45.1377,-0.613518381250188,-15.6356,0.709570902840642,0.686159051055405,0.742401590244034,0.747386491693759,0.0234118517852366,-0.0049849014497255,True,0.920602720223482,0.156348479856104,0.0702170609140754,610.559201373973
15077,1179:1372,Breast,CAL-148,SIDM00938,924106,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.505873330230468,0.0977772998865147,0.879455155526854,13.8827433370727,29.5021,0.926161663675484,0.969013652029865,0.131530032120158,0.444892908314724,0.274594689981876,0.170298218332848,9.421799937774,1.3396,4.46094339929871,28.1625,0.468520485135308,0.310557901800023,0.490198163191136,0.431706587501083,0.157962583335285,0.0584915756900537,True,0.920602720223482,0.156348479856104,0.0702170609140754,610.559201373973
15078,1190:1375,Breast,CAL-148,SIDM00938,924106,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.1,1375,Temozolomide,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved,30.0,0.48799229861269,0.0776163693080569,0.935912011682659,15.5878595709167,2885.7891,0.9550020105637,0.984013521536034,0.0277072672553014,0.456717853880248,0.434258785447501,0.0224590684327463,14.1341506948166,1053.5487,1.45370887610008,1832.2404,0.46603362631472,0.471584855435583,0.480191020240337,0.474258024773877,-0.0055512291208629,0.0059329954664602,True,0.920602720223482,0.156348479856104,0.0702170609140754,610.559201373973
15079,1561:1549,Breast,CAL-148,SIDM00938,924106,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.758700258327664,0.114419901574725,0.889972301392723,14.1362500823023,175.8472,0.90997528416858,0.971878217439823,0.117492934006141,0.675222214971124,0.464027769527633,0.211194445443491,10.1156729900434,10.8348,4.02057709225898,165.0124,0.69039848317049,0.581703541961967,0.737364254634623,0.669058955246547,0.108694941208523,0.0683052993880751,True,0.920602720223482,0.156348479856104,0.0702170609140754,610.559201373973
15080,1047:1558,Breast,CAL-148,SIDM00938,924106,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.769812533990679,0.121077646064987,0.841386009225705,13.099689183912,171.4468,0.932881539792048,0.958356208764362,0.0761940063103746,0.647709495826345,0.572599553036882,0.0751099427894628,11.6189191486661,61.429,1.48077003524586,110.0178,0.718143902060443,0.731142966590805,0.737754621534594,0.714942994455108,-0.0129990645303615,0.0228116270794857,True,0.920602720223482,0.156348479856104,0.0702170609140754,610.559201373973
15080,1561:1558,Breast,CAL-148,SIDM00938,924106,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.654645326938717,0.121077646064987,0.841386009225705,13.099689183912,171.4468,0.932881539792048,0.958356208764362,0.0442508940850106,0.550809419091224,0.474565407347854,0.0762440117433693,11.3808271640647,52.0835,1.71886201984725,119.3633,0.610706540612259,0.632522668506642,0.627383413610295,0.60394100167346,-0.0218161278943826,0.0234424119368354,True,0.920602720223482,0.156348479856104,0.0702170609140754,610.559201373973
15080,1190:1558,Breast,CAL-148,SIDM00938,924106,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.1,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.467558589900423,0.121077646064987,0.841386009225705,13.099689183912,171.4468,0.932881539792048,0.958356208764362,0.11766666824246,0.393397256035515,0.267389433553379,0.126007822482136,9.7114072377612,16.374,3.38828194615076,155.0728,0.436176777289305,0.332052282313952,0.448087677592181,0.404821385619742,0.104124494975353,0.0432662919724388,True,0.920602720223482,0.156348479856104,0.0702170609140754,610.559201373973
15080,1083:1558,Breast,CAL-148,SIDM00938,924106,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.561359035582842,0.121077646064987,0.841386009225705,13.099689183912,171.4468,0.932881539792048,0.958356208764362,0.111959014399887,0.472319638691837,0.310979711129147,0.16133992756269,9.53255564813423,14.4649,3.56713353577773,156.9819,0.5236814814907,0.432053896587504,0.537981917096791,0.481779005703505,0.0916275849031962,0.0562029113932859,True,0.920602720223482,0.156348479856104,0.0702170609140754,610.559201373973
15080,1179:1558,Breast,CAL-148,SIDM00938,924106,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.113390393256601,0.121077646064987,0.841386009225705,13.099689183912,171.4468,0.932881539792048,0.958356208764362,0.0385436569945731,0.0954050904667045,0.0555305723353497,0.0398745181313548,8.89904325378705,9.3241,4.20064593012491,162.1227,0.105779804658843,0.0581024436973776,0.108668387391696,0.0939924346034802,0.0476773609614659,0.0146759527882158,True,0.920602720223482,0.156348479856104,0.0702170609140754,610.559201373973
15080,1005:1558,Breast,CAL-148,SIDM00938,924106,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.728412450406922,0.121077646064987,0.841386009225705,13.099689183912,171.4468,0.932881539792048,0.958356208764362,0.109269181995101,0.612876044718196,0.525311394374564,0.0875646503436324,11.334853913561,50.45,1.76483527035094,120.9968,0.679522528339308,0.629607413475143,0.698078594388737,0.67108895427082,0.0499151148641653,0.026989640117916,True,0.920602720223482,0.156348479856104,0.0702170609140754,610.559201373973
15080,1011:1558,Breast,CAL-148,SIDM00938,924106,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.689289980287236,0.121077646064987,0.841386009225705,13.099689183912,171.4468,0.932881539792048,0.958356208764362,0.105884324719808,0.579958945713142,0.25362317526782,0.326335770445323,7.67069534195027,3.9796,5.42899384196168,167.4672,0.643025898173588,0.546789304207684,0.660585332247338,0.524860004190062,0.0962365939659039,0.135725328057276,True,0.920602720223482,0.156348479856104,0.0702170609140754,610.559201373973
15080,1053:1558,Breast,CAL-148,SIDM00938,924106,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.657982655931006,0.121077646064987,0.841386009225705,13.099689183912,171.4468,0.932881539792048,0.958356208764362,0.149031218438763,0.553617401013519,0.343064141303928,0.210553259709591,9.21032758735449,11.5695,3.88936159655747,159.8773,0.613819873221378,0.568441745137484,0.630581763570744,0.555210419766504,0.0453781280838937,0.0753713438042408,True,0.920602720223482,0.156348479856104,0.0702170609140754,610.559201373973
16401,1012:1561,Breast,CAL-148,SIDM00938,924106,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.47815547331094,0.102798760273758,0.106008989488468,3.76125966212114,0.2648,0.475054568335452,0.481650420534092,0.0503017072877972,0.0506887785440727,0.0157762780276681,0.0349125005164046,0.700563231224836,0.0317,3.0606964308963,0.2331,0.227149941970963,0.0852158248247303,0.230303784800892,0.125046688944984,0.141934117146232,0.105257095855908,True,0.954044599921099,0.155762534662919,0.0383552755018417,1069.87392189818
16401,1011:1561,Breast,CAL-148,SIDM00938,924106,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.696040657749009,0.102798760273758,0.106008989488468,3.76125966212114,0.2648,0.475054568335452,0.481650420534092,0.0920702465906673,0.0737865667708607,0.0234434184556618,0.0503431483151989,0.752948870272459,0.0329,3.00831079184868,0.2319,0.33065729421088,0.130222611693945,0.335248275513636,0.18434485981592,0.200434682516935,0.150903415697717,True,0.954044599921099,0.155762534662919,0.0383552755018417,1069.87392189818
16401,1053:1561,Breast,CAL-148,SIDM00938,924106,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.46141610845642,0.102798760273758,0.106008989488468,3.76125966212114,0.2648,0.475054568335452,0.481650420534092,0.0603642744133904,0.0489142553911662,0.0101231001496473,0.0387911552415189,-0.329947997323822,0.0155,4.09120765944496,0.2493,0.219197830225789,0.0675669703314519,0.222241262679239,0.0925763602064393,0.151630859894337,0.1296649024728,True,0.954044599921099,0.155762534662919,0.0383552755018417,1069.87392189818
16401,1012:1594,Breast,CAL-148,SIDM00938,924106,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.924436438820743,0.106996800793154,0.450999950498898,8.51687742886215,2.8617,0.781654862894962,0.809407496393338,0.051581104589848,0.416920788147533,0.36282496230898,0.0540958258385527,7.9265630361847,1.9007,0.590314392677449,0.961,0.722590237841535,0.732632942484356,0.748245783520671,0.717932426448448,-0.0100427046428213,0.0303133570722233,True,0.954044599921099,0.155762534662919,0.0383552755018417,1069.87392189818
16401,1011:1594,Breast,CAL-148,SIDM00938,924106,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.696040657749009,0.106996800793154,0.450999950498898,8.51687742886215,2.8617,0.781654862894962,0.809407496393338,0.109451604408689,0.313914302190023,0.118935722336858,0.194978579853165,5.11931799092338,0.2716,3.39755943793878,2.5901,0.544063564902121,0.398289799836895,0.563380526176598,0.407497955350116,0.145773765065226,0.155882570826482,True,0.954044599921099,0.155762534662919,0.0383552755018417,1069.87392189818
16401,1053:1594,Breast,CAL-148,SIDM00938,924106,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.687147870170045,0.106996800793154,0.450999950498898,8.51687742886215,2.8617,0.781654862894962,0.809407496393338,0.0468274366020158,0.309903655432114,0.158677097966125,0.151226557465989,6.04394680238561,0.5155,2.47293062647654,2.3462,0.537112474246331,0.451621261709603,0.556182637246351,0.4490336749737,0.0854912125367288,0.107148962272651,True,0.954044599921099,0.155762534662919,0.0383552755018417,1069.87392189818
14500,1049:1005,Breast,CAL-51,SIDM00933,910927,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.901037158635581,0.062740916140844,0.689324898638566,10.2798754009192,9.7127,0.936292220884512,0.940395244478745,0.0464976409115257,0.621107348046053,0.656878701031267,-0.0357713529852139,10.5893665601844,12.0367,-0.309491159265191,-2.324,0.843634082358379,0.875278726378868,0.847331059079541,0.855411083323037,-0.0316446440204893,-0.0080800242434961,True,0.20582734564427,0.0370736838822833,1.52479319969527,32.4793821045494
14500,1022:1005,Breast,CAL-51,SIDM00933,910927,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.840430148542587,0.062740916140844,0.689324898638566,10.2798754009192,9.7127,0.936292220884512,0.940395244478745,0.0250784023415705,0.579329426956913,0.320396162886276,0.258933264070638,8.22218715746388,2.333,2.05768824345531,7.3797,0.786888210277239,0.720263841468295,0.790336515006014,0.710705319334067,0.066624368808944,0.0796311956719465,True,0.20582734564427,0.0370736838822833,1.52479319969527,32.4793821045494
14500,1047:1005,Breast,CAL-51,SIDM00933,910927,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.829169384185996,0.062740916140844,0.689324898638566,10.2798754009192,9.7127,0.936292220884512,0.940395244478745,0.0552786934619442,0.571567101708214,0.364598379411678,0.206968722296536,8.61085264277131,3.0543,1.66902275814788,6.6584,0.776344844208949,0.70177689152117,0.77974694575588,0.720096702294513,0.0745679526877797,0.0596502434613666,True,0.20582734564427,0.0370736838822833,1.52479319969527,32.4793821045494
14500,1190:1005,Breast,CAL-51,SIDM00933,910927,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.1,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.342628265493266,0.062740916140844,0.689324898638566,10.2798754009192,9.7127,0.936292220884512,0.940395244478745,0.0413755917908698,0.236182194381853,0.0765825815440575,0.159599612837796,7.00012962113632,1.0001,3.27974577978287,8.7126,0.320800179636498,0.223239703085115,0.322205991493868,0.260563551409719,0.0975604765513829,0.0616424400841492,True,0.20582734564427,0.0370736838822833,1.52479319969527,32.4793821045494
14500,1179:1005,Breast,CAL-51,SIDM00933,910927,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.216259478679039,0.062740916140844,0.689324898638566,10.2798754009192,9.7127,0.936292220884512,0.940395244478745,0.05565831070837,0.149073043220057,0.108883430867509,0.0401896123525488,9.02238792949487,4.0626,1.25748747142432,5.6501,0.202482067579724,0.145648688183176,0.20336938532322,0.192495376315034,0.0568333793965481,0.0108740090081868,True,0.20582734564427,0.0370736838822833,1.52479319969527,32.4793821045494
14500,1012:1005,Breast,CAL-51,SIDM00933,910927,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.816006157629177,0.062740916140844,0.689324898638566,10.2798754009192,9.7127,0.936292220884512,0.940395244478745,0.0647019875420293,0.562493361896178,0.250720985388652,0.311772376507526,7.6943901223351,1.6182,2.58548527858409,8.0945,0.764020217582059,0.655135312879424,0.767368310099851,0.661944325131994,0.108884904702635,0.105423984967857,True,0.20582734564427,0.0370736838822833,1.52479319969527,32.4793821045494
14500,1011:1005,Breast,CAL-51,SIDM00933,910927,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.826587471199971,0.062740916140844,0.689324898638566,10.2798754009192,9.7127,0.936292220884512,0.940395244478745,0.0740988450966549,0.569787324800829,0.242682637983236,0.327104686817593,7.59001416950107,1.5053,2.68986123141812,8.2074,0.773927419165134,0.686126875088337,0.777318927062164,0.66453151231593,0.0878005440767968,0.112787414746235,True,0.20582734564427,0.0370736838822833,1.52479319969527,32.4793821045494
14500,1559:1005,Breast,CAL-51,SIDM00933,910927,1559,Luminespib,HSP90,Protein stability and degradation,Targeted,Early clinical trials,0.01,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.849837085070985,0.062740916140844,0.689324898638566,10.2798754009192,9.7127,0.936292220884512,0.940395244478745,0.087771425894932,0.585813862525851,0.319016906206281,0.26679695631957,8.18229040392063,2.2694,2.09758499699855,7.4433,0.795695851771132,0.696656311995627,0.799182753382432,0.716563313256326,0.0990395397755052,0.0826194401261061,True,0.20582734564427,0.0370736838822833,1.52479319969527,32.4793821045494
14500,1011:1007,Breast,CAL-51,SIDM00933,910927,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1007,Docetaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.0125,0.826587471199971,0.0895704248067067,0.402643379393989,8.36651733559618,0.0081,0.799372904388162,0.854377293753265,0.0835866987524139,0.332819972768688,0.123558420972653,0.209261551796035,6.20778334694402,0.0018,2.15873398865216,0.0063,0.660751627583988,0.585226168561693,0.706217566694186,0.575777795422968,0.0755254590222947,0.130439771271218,True,0.20582734564427,0.0370736838822833,1.52479319969527,32.4793821045494
14501,1021:1011,Breast,CAL-51,SIDM00933,910927,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.766098175641102,0.181170256291335,0.285757758730848,7.52883716012959,3.6069,0.838461844597573,0.799629672155096,0.0827337096403532,0.218918497638993,0.120679683916772,0.0982388137222203,6.30723096120414,1.5467,1.22160619892545,2.0602,0.642344089490874,0.546599459453613,0.612594833026511,0.540009889941672,0.0957446300372605,0.0725849430848386,True,0.20582734564427,0.0370736838822833,1.52479319969527,32.4793821045494
14501,1047:1011,Breast,CAL-51,SIDM00933,910927,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.840707856962514,0.181170256291335,0.285757758730848,7.52883716012959,3.6069,0.838461844597573,0.799629672155096,0.0923205443878162,0.240238792953022,0.110642481325436,0.129596311627586,5.96987049535322,1.2242,1.55896666477637,2.3827,0.704901460516462,0.579454909952689,0.672254948041148,0.568659480556476,0.125446550563773,0.103595467484672,True,0.20582734564427,0.0370736838822833,1.52479319969527,32.4793821045494
14501,1190:1011,Breast,CAL-51,SIDM00933,910927,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.299274751571973,0.181170256291335,0.285757758730848,7.52883716012959,3.6069,0.838461844597573,0.799629672155096,0.042260465184337,0.0855200822539384,0.0131741800786613,0.072345902175277,4.05679106382258,0.325,3.47204609630701,3.2819,0.250930460244517,0.122036590327992,0.239308971483795,0.151192305240601,0.128893869916525,0.0881166662431931,True,0.20582734564427,0.0370736838822833,1.52479319969527,32.4793821045494
14501,1005:1011,Breast,CAL-51,SIDM00933,910927,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.661174963940729,0.181170256291335,0.285757758730848,7.52883716012959,3.6069,0.838461844597573,0.799629672155096,0.0371423726575438,0.188935875824652,0.0109805441322041,0.177955331692448,2.44593714949404,0.1064,5.08290001063555,3.5005,0.554369979867478,0.228374955288105,0.528695119653083,0.237805163391147,0.325995024579373,0.290889956261936,True,0.20582734564427,0.0370736838822833,1.52479319969527,32.4793821045494
14732,1047:1017,Breast,CAL-51,SIDM00933,910927,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.866229301563772,0.10965220840472,0.690901476397972,10.2917145667388,24.4819,0.865203535572813,0.940761074848083,0.0740697490489214,0.598479103349594,0.325763333451313,0.272715769898281,8.18697764193615,5.6919,2.10473692480263,18.79,0.749464654329744,0.674859698229022,0.814914808804039,0.730636997493418,0.0746049561007223,0.0842778113106208,True,0.218939108051275,0.0311632196373379,1.45948419261854,33.8852467669645
14732,1375:1017,Breast,CAL-51,SIDM00933,910927,1375,Temozolomide,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved,30.0,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.96292943698227,0.10965220840472,0.690901476397972,10.2917145667388,24.4819,0.865203535572813,0.940761074848083,0.07870214175455,0.665289369678118,0.334681194195699,0.330608175482419,7.988650183968,4.9608,2.30306438277078,19.5211,0.833129953384198,0.758956573369925,0.9058865321383,0.800077642924371,0.0741733800142739,0.105808889213929,True,0.218939108051275,0.0311632196373379,1.45948419261854,33.8852467669645
14732,1011:1017,Breast,CAL-51,SIDM00933,910927,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.746544031783071,0.10965220840472,0.690901476397972,10.2917145667388,24.4819,0.865203535572813,0.940761074848083,0.0188721893946053,0.515788373755018,0.230582851347518,0.2852055224075,7.70654438668942,4.0797,2.58517018004937,20.4022,0.645912535759496,0.590227556777739,0.702319565761664,0.606220474127713,0.0556849789817568,0.0960990916339507,True,0.218939108051275,0.0311632196373379,1.45948419261854,33.8852467669645
15767,1011:1021,Breast,CAL-51,SIDM00933,910927,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.829537093911919,0.0714384552066378,0.529084372947906,9.18704179713313,11.3843,0.858386540322892,0.898047022866651,0.0762518215625136,0.438895113169416,0.122379138750322,0.316515974419094,6.18297803118931,1.419,3.00406376594382,9.9653,0.712063476112558,0.572991898956792,0.744963317545053,0.576103347026502,0.139071577155767,0.16885997051855,True,0.411687103763168,0.0498687498213965,0.862492322973888,57.1759451016027
15767,1190:1022,Breast,CAL-51,SIDM00933,910927,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.01,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.804966900946999,0.101937278993044,0.333748399737086,7.88984813593112,0.4632,0.78617629175798,0.82440176754952,0.0620114268537195,0.268656415032382,0.0449842347975901,0.223672180234792,4.46004338152489,0.043,3.42980475440624,0.4202,0.632845893174425,0.421988746123884,0.663616135959565,0.436325719668634,0.210857147050541,0.227290416290932,True,0.411687103763168,0.0498687498213965,0.862492322973888,57.1759451016027
15767,1179:1022,Breast,CAL-51,SIDM00933,910927,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.716421095247911,0.101937278993044,0.333748399737086,7.88984813593112,0.4632,0.78617629175798,0.82440176754952,0.0994924097717016,0.239104394076881,0.0330180736942352,0.206086320382645,4.13396415366081,0.0343,3.75588398227031,0.4289,0.563233279999193,0.346626141387096,0.590618817232141,0.366990333008748,0.216607138612097,0.223628484223392,True,0.411687103763168,0.0498687498213965,0.862492322973888,57.1759451016027
14632,1017:1047,Breast,CAL-51,SIDM00933,910927,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.735423517937304,0.0776601185325675,0.522536659185422,9.14486795061102,11.0563,0.860376744338714,0.896054687150639,0.0733238001647836,0.384285748149349,0.116156572137045,0.268129176012304,6.31230852104804,1.5521,2.83255942956298,9.5042,0.632741292073022,0.468265450303763,0.658979690288533,0.518698449681767,0.164475841769258,0.140281240606766,True,0.118054306599581,0.0194202103612205,2.07524751002625,23.9625571314569
14632,1561:1047,Breast,CAL-51,SIDM00933,910927,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.805559644237073,0.0776601185325675,0.522536659185422,9.14486795061102,11.0563,0.860376744338714,0.896054687150639,0.0389827834511247,0.420934445274237,0.28696726276238,0.133967182511857,8.04968689116767,5.1752,1.09518105944335,5.8811,0.693084784079346,0.683516869979332,0.72182549499803,0.672491259639494,0.0095679141000134,0.0493342353585364,True,0.118054306599581,0.0194202103612205,2.07524751002625,23.9625571314569
14632,1005:1047,Breast,CAL-51,SIDM00933,910927,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.46052457883107,0.0776601185325675,0.522536659185422,9.14486795061102,11.0563,0.860376744338714,0.896054687150639,0.0547309418866878,0.240640974895161,0.247066671697482,-0.0064256968023214,9.23481776693303,11.7676,-0.0899498163220152,-0.7113,0.396224637822633,0.371829617495905,0.412655207409654,0.414596881524814,0.0243950203267286,-0.0019416741151596,True,0.118054306599581,0.0194202103612205,2.07524751002625,23.9625571314569
14632,1011:1047,Breast,CAL-51,SIDM00933,910927,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.848306348035319,0.0776601185325675,0.522536659185422,9.14486795061102,11.0563,0.860376744338714,0.896054687150639,0.0723399068055034,0.443271165068162,0.181212300273662,0.262058864794499,6.9070440998047,2.344,2.23782385080632,8.7123,0.729863053924492,0.625833294629795,0.760128879296689,0.639008586720576,0.104029759294698,0.121120292576113,True,0.118054306599581,0.0194202103612205,2.07524751002625,23.9625571314569
14632,1559:1049,Breast,CAL-51,SIDM00933,910927,1559,Luminespib,HSP90,Protein stability and degradation,Targeted,Early clinical trials,0.01,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.690164493016393,0.122559065668044,0.72421245429978,10.5504579934571,29.291,0.846412154057351,0.948301934910926,0.107960579056836,0.499825721357966,0.175265943567313,0.324559777790653,7.26933759298968,3.0131,3.28112040046742,26.2779,0.584163615187905,0.477425439121418,0.654484324134263,0.538891200123402,0.106738176066488,0.115593124010861,True,0.118054306599581,0.0194202103612205,2.07524751002625,23.9625571314569
14632,1561:1049,Breast,CAL-51,SIDM00933,910927,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.805559644237073,0.122559065668044,0.72421245429978,10.5504579934571,29.291,0.846412154057351,0.948301934910926,0.047137051758669,0.583396327037788,0.529632429269381,0.0537638977684076,10.0471447951681,20.6644,0.503313198289003,8.6266,0.681835473700375,0.727679573999082,0.763913769316173,0.751441828061117,-0.0458441002987071,0.0124719412550565,True,0.118054306599581,0.0194202103612205,2.07524751002625,23.9625571314569
14503,1058:1053,Breast,CAL-51,SIDM00933,910927,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.949598574216386,0.0678927386473653,0.629642216028038,9.85224206278945,18.053,0.897193861307822,0.925895308901402,0.0355534377362859,0.597907350606671,0.543385666998801,0.0545216836078696,9.46723426928657,13.8246,0.385007793502878,4.2284,0.851974011493602,0.85166428646834,0.879228865206412,0.864695342861374,0.000309725025262,0.0145335223450379,True,0.20582734564427,0.0370736838822833,1.52479319969527,32.4793821045494
14503,1190:1053,Breast,CAL-51,SIDM00933,910927,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.1,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.295316390679043,0.0678927386473653,0.629642216028038,9.85224206278945,18.053,0.897193861307822,0.925895308901402,0.0430764749510164,0.185943666656555,0.125647305508779,0.0602963611477758,8.51762292487625,7.158,1.33461913791319,10.895,0.26495605286082,0.224616807877571,0.27343206077142,0.254914026442431,0.0403392449832486,0.0185180343289884,True,0.20582734564427,0.0370736838822833,1.52479319969527,32.4793821045494
14503,1179:1053,Breast,CAL-51,SIDM00933,910927,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.19925145350068,0.0678927386473653,0.629642216028038,9.85224206278945,18.053,0.897193861307822,0.925895308901402,0.0414960836243458,0.125457126728976,0.084768138343018,0.0406889883859578,8.51740100812764,7.1569,1.33484105466181,10.8961,0.178767180937471,0.128558983810363,0.184485986088066,0.171989246490078,0.0502081971271082,0.0124967395979879,True,0.20582734564427,0.0370736838822833,1.52479319969527,32.4793821045494
14503,1594:1053,Breast,CAL-51,SIDM00933,910927,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.935998305689012,0.0678927386473653,0.629642216028038,9.85224206278945,18.053,0.897193861307822,0.925895308901402,0.0569721195878052,0.589344047392518,0.371735650120559,0.217608397271959,8.3297834176329,6.2841,1.52245864515655,11.7689,0.839771934058704,0.809996879323039,0.866636440377117,0.797642534485002,0.0297750547356653,0.0689939058921144,True,0.20582734564427,0.0370736838822833,1.52479319969527,32.4793821045494
14503,1073:1054,Breast,CAL-51,SIDM00933,910927,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,10.0,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.704690163841929,0.0937700939830954,0.776679327009613,11.001669738308,16.0185,0.898924666358986,0.959504725922578,0.10029428192331,0.547318282203043,0.516570114424903,0.03074816777814,10.6222059803793,12.3138,0.379463757928701,3.7047,0.633463370418065,0.59354780205311,0.676153542517486,0.669627306613664,0.039915568364955,0.0065262359038222,True,0.20582734564427,0.0370736838822833,1.52479319969527,32.4793821045494
14503,1058:1054,Breast,CAL-51,SIDM00933,910927,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.949598574216386,0.0937700939830954,0.776679327009613,11.001669738308,16.0185,0.898924666358986,0.959504725922578,0.0986999326382172,0.737533581551671,0.582647330496704,0.154886251054967,9.74250980202764,6.6923,1.25915993628032,9.3262,0.853617581502434,0.786979375751107,0.911144319689965,0.875298700871082,0.0666382057513275,0.0358456188188829,True,0.20582734564427,0.0370736838822833,1.52479319969527,32.4793821045494
14504,1510:1058,Breast,CAL-51,SIDM00933,910927,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.941153696605154,0.0699824699797154,0.406165033107579,8.38999797577996,2.6208,0.844246909152709,0.85576898058847,0.107591562261147,0.382263722340953,0.171574623034494,0.210689099306459,6.58976937904869,0.7525,1.80022859673127,1.8683,0.794566099396548,0.609112715950493,0.805410139520863,0.685227845058311,0.185453383446055,0.120182294462552,True,0.20582734564427,0.0370736838822833,1.52479319969527,32.4793821045494
14504,1083:1058,Breast,CAL-51,SIDM00933,910927,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.932003754875115,0.0699824699797154,0.406165033107579,8.38999797577996,2.6208,0.844246909152709,0.85576898058847,0.0596421088640874,0.378547335955239,0.169989747396606,0.208557588558634,6.59073069875979,0.753,1.79926727702017,1.8678,0.786841289372035,0.639400939295085,0.797579903214104,0.678638498016435,0.147440350076951,0.118941405197669,True,0.20582734564427,0.0370736838822833,1.52479319969527,32.4793821045494
14504,1179:1058,Breast,CAL-51,SIDM00933,910927,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.195738947932594,0.0699824699797154,0.406165033107579,8.38999797577996,2.6208,0.844246909152709,0.85576898058847,0.0393298447455596,0.0795023162674849,0.0367148575444348,0.0427874587230501,6.64589883284084,0.7824,1.74409914293913,1.8384,0.165252001792896,0.106946188787951,0.167507319933736,0.143398100287743,0.0583058130049454,0.024109219645993,True,0.20582734564427,0.0370736838822833,1.52479319969527,32.4793821045494
14729,1058:1083,Breast,CAL-51,SIDM00933,910927,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.871823941054299,0.0864722120992243,0.593217198817172,9.60588975575877,15.2192,0.884677227178774,0.916356249073261,0.0671196408969341,0.517180956173979,0.303496006377835,0.213684949796144,7.99254748687265,4.9742,1.61334226888612,10.245,0.771282786759988,0.742549505386313,0.798901316476785,0.724600353219014,0.0287332813736756,0.0743009632577708,True,0.218939108051275,0.0311632196373379,1.45948419261854,33.8852467669645
14729,1561:1083,Breast,CAL-51,SIDM00933,910927,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.65848557366793,0.0864722120992243,0.593217198817172,9.60588975575877,15.2192,0.884677227178774,0.916356249073261,0.050301834496143,0.390624967472808,0.194708425150899,0.195916542321909,7.60620597802787,3.8056,1.9996837777309,11.4136,0.582547191449769,0.538296549441804,0.603407370355199,0.530133738667995,0.0442506420079646,0.0732736316872036,True,0.218939108051275,0.0311632196373379,1.45948419261854,33.8852467669645
14729,1011:1083,Breast,CAL-51,SIDM00933,910927,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.838016479349543,0.0864722120992243,0.593217198817172,9.60588975575877,15.2192,0.884677227178774,0.916356249073261,0.0754703164153933,0.497125788442365,0.111277547586324,0.385848240856041,5.98639585908289,1.2383,3.61949389667588,13.9809,0.741374095281073,0.573832114019331,0.767921637678327,0.568023068702363,0.167541981261741,0.199898568975965,True,0.218939108051275,0.0311632196373379,1.45948419261854,33.8852467669645
14729,1022:1179,Breast,CAL-51,SIDM00933,910927,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,10.0,0.866503434246446,0.10083225562827,0.152122336408255,6.24091832871494,1.4772,0.692108807894493,0.69934950012892,0.0591897742337187,0.131814526923346,0.0838032592580414,0.0480112676653048,5.41189126832501,0.8315,0.82902706038993,0.6457,0.599714658912792,0.537325496962318,0.605988743600244,0.543982439319059,0.0623891619504737,0.0620063042811846,True,0.218939108051275,0.0311632196373379,1.45948419261854,33.8852467669645
14731,1179:1372,Breast,CAL-51,SIDM00933,910927,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.542055396813796,0.163480412111906,0.534864280489719,9.22432334204889,1.1682,0.757712472230003,0.899785423469247,0.126419359367903,0.28992606980238,0.0888250465014908,0.201101023300889,6.38275383680851,0.163,2.84156950524038,1.0052,0.410722134805397,0.29193776912479,0.487733544765892,0.385480008975819,0.118784365680607,0.102253535790073,True,0.218939108051275,0.0311632196373379,1.45948419261854,33.8852467669645
14732,1017:1375,Breast,CAL-51,SIDM00933,910927,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,1375,Temozolomide,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved,30.0,0.745656926633368,0.0738309097864947,0.904470428191265,12.6100072104476,366.304,0.941037790525366,0.983908990946439,0.0716760094458705,0.674424639715866,0.379606663137664,0.294817976578202,9.05839982993077,31.2393,3.55160738051684,335.0647,0.701691346729,0.604637009019288,0.73365855427606,0.665039512647858,0.0970543377097125,0.068619041628202,True,0.218939108051275,0.0311632196373379,1.45948419261854,33.8852467669645
14735,1047:1561,Breast,CAL-51,SIDM00933,910927,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.607521495421976,0.101936898450794,0.254661873550019,7.27538249090047,3.0258,0.709941105406334,0.781262879727137,0.0831057641222138,0.15471256224607,0.0266787404868496,0.12803382175922,4.05273041325847,0.3241,3.22265207764199,2.7017,0.431304482017987,0.284206872279973,0.474633993009509,0.306691536005786,0.147097609738014,0.167942457003724,True,0.218939108051275,0.0311632196373379,1.45948419261854,33.8852467669645
14735,1179:1561,Breast,CAL-51,SIDM00933,910927,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.13803107002942,0.101936898450794,0.254661873550019,7.27538249090047,3.0258,0.709941105406334,0.781262879727137,0.0297174428075931,0.035151250901806,0.0303356847981403,0.0048155661036657,6.96530710486778,2.4406,0.310075386032685,0.5852,0.0979939304371059,0.0783391924628774,0.107838551263003,0.104599702587689,0.0196547379742285,0.0032388486753144,True,0.218939108051275,0.0311632196373379,1.45948419261854,33.8852467669645
14735,1012:1594,Breast,CAL-51,SIDM00933,910927,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.748714099374084,0.0904692259110303,0.522953753259946,9.14755281349543,4.4308,0.838262887157758,0.896182340132854,0.091419712515949,0.391542848386317,0.16903886132545,0.222503987060867,7.02094096634827,1.0146,2.12661184714716,3.4162,0.62761924259704,0.508137484413668,0.670984353667529,0.570583202082145,0.119481758183372,0.100401151585383,True,0.218939108051275,0.0311632196373379,1.45948419261854,33.8852467669645
14735,1561:1594,Breast,CAL-51,SIDM00933,910927,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.907828251595208,0.0904692259110303,0.522953753259946,9.14755281349543,4.4308,0.838262887157758,0.896182340132854,0.0819780996102281,0.474752191487129,0.319191599001788,0.155560592485341,8.01713853990328,2.0239,1.13041427359214,2.4069,0.760998731225579,0.713235519033705,0.813579646953311,0.755967914648854,0.0477632121918737,0.0576117323044572,True,0.218939108051275,0.0311632196373379,1.45948419261854,33.8852467669645
14735,1179:1594,Breast,CAL-51,SIDM00933,910927,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.67992380471824,0.0904692259110303,0.522953753259946,9.14755281349543,4.4308,0.838262887157758,0.896182340132854,0.0713680546514098,0.355568705608187,0.10506586520735,0.250502840400837,6.27065354993292,0.6032,2.87689926356251,3.8276,0.5699548915904,0.451473409093199,0.609335706424426,0.477194341547867,0.118481482497201,0.132141364876559,True,0.218939108051275,0.0311632196373379,1.45948419261854,33.8852467669645
14735,1053:1594,Breast,CAL-51,SIDM00933,910927,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.950976385658,0.0904692259110303,0.522953753259946,9.14755281349543,4.4308,0.838262887157758,0.896182340132854,0.0742529361740049,0.497316670141429,0.292246905088246,0.205069765053183,7.69483285439584,1.6187,1.45271995909959,2.8121,0.797168210660525,0.731449813038664,0.85224824271007,0.771461174245976,0.0657183976218612,0.080787068464094,True,0.218939108051275,0.0311632196373379,1.45948419261854,33.8852467669645
14689,1011:1007,Breast,UACC-893,SIDM01186,909778,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1007,Docetaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.0125,0.797669482171301,0.0681532066807414,0.576478505261733,9.61263219747438,0.0191,0.870504175709225,0.891506864724968,0.0771377607359698,0.459839310775012,0.269887821420853,0.189951489354159,7.66742503841835,0.005,1.94520715905603,0.0141,0.694374615065933,0.595166977425019,0.711127819137325,0.627923759757883,0.099207637640914,0.0832040593794422,True,0.678328971510318,0.0750169221954795,0.372078986621175,130.307810275055
14690,1549:1011,Breast,UACC-893,SIDM01186,909778,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.387640403133858,0.0933880103919374,0.524125849696347,9.19189280745398,11.4226,0.863681768437388,0.872813478427061,0.0311675335137845,0.203172355669168,0.0435804825663442,0.159591873102823,4.89462900231382,0.581,4.29726380514016,10.8416,0.334797948896432,0.197840109329516,0.33833776863813,0.22317967951076,0.136957839566916,0.11515808912737,True,0.678328971510318,0.0750169221954795,0.372078986621175,130.307810275055
14690,1558:1011,Breast,UACC-893,SIDM01186,909778,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.469348314662868,0.0933880103919374,0.524125849696347,9.19189280745398,11.4226,0.863681768437388,0.872813478427061,0.0448605152599703,0.245997584226224,0.0447084311316385,0.201289153094586,4.52730266151152,0.4504,4.66459014594246,10.9722,0.405367582421133,0.227750481938193,0.409653535114776,0.255690770625324,0.177617100482941,0.153962764489452,True,0.678328971510318,0.0750169221954795,0.372078986621175,130.307810275055
14690,1372:1011,Breast,UACC-893,SIDM01186,909778,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.816240328454772,0.0933880103919374,0.524125849696347,9.19189280745398,11.4226,0.863681768437388,0.872813478427061,0.0384949781308613,0.427812655707782,0.275217708248599,0.152594947459183,7.6570486698783,3.9421,1.53484413757568,7.4805,0.704971890349731,0.634111733066809,0.712425560311056,0.641992490892508,0.0708601572829227,0.0704330694185477,True,0.678328971510318,0.0750169221954795,0.372078986621175,130.307810275055
14690,1007:1011,Breast,UACC-893,SIDM01186,909778,1007,Docetaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.001,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.89811549782519,0.0933880103919374,0.524125849696347,9.19189280745398,11.4226,0.863681768437388,0.872813478427061,0.102692686033015,0.470725548423085,0.221602122099996,0.249123426323089,6.78246937785715,2.1501,2.40942342959683,9.2725,0.775685981422685,0.627119372895488,0.783887311686056,0.651909946892801,0.148566608527197,0.131977364793255,True,0.678328971510318,0.0750169221954795,0.372078986621175,130.307810275055
14690,1053:1011,Breast,UACC-893,SIDM01186,909778,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.418134946024171,0.0933880103919374,0.524125849696347,9.19189280745398,11.4226,0.863681768437388,0.872813478427061,0.0581720613634817,0.219155333872655,0.0759245044759499,0.143230829396705,6.00833316864812,1.2572,3.18355963880586,10.1654,0.361135529627628,0.239939282656178,0.364953816691268,0.278801689666796,0.12119624697145,0.0861521270244723,True,0.678328971510318,0.0750169221954795,0.372078986621175,130.307810275055
14691,1005:1021,Breast,UACC-893,SIDM01186,909778,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.786772230132528,0.115907371869402,0.837703696403892,12.2610014686635,95.8648,0.903629352624048,0.965064417054968,0.0941044617527662,0.659082005409953,0.421662340402803,0.23741966500715,9.28612824173576,12.1936,2.97487322692778,83.6712,0.710950480977235,0.658751353879266,0.759285883627885,0.690147192515762,0.052199127097969,0.0691386911121235,True,0.678328971510318,0.0750169221954795,0.372078986621175,130.307810275055
14692,1058:1049,Breast,UACC-893,SIDM01186,909778,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.654117139963455,0.105538432103282,0.827252419513771,12.1120578726838,86.4615,0.905486142880186,0.962589442428977,0.0638901355125295,0.541119986680196,0.471459673250761,0.0696603134294346,10.884031858898,36.9105,1.22802601378586,49.551,0.592294006057328,0.558062793028403,0.629646253040659,0.611886831599863,0.0342312130289247,0.0177594214407956,True,0.678328971510318,0.0750169221954795,0.372078986621175,130.307810275055
14692,1073:1049,Breast,UACC-893,SIDM01186,909778,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,2.5,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.975573760521257,0.105538432103282,0.827252419513771,12.1120578726838,86.4615,0.905486142880186,0.962589442428977,0.153364486108584,0.807045753805358,0.497110974616659,0.309934779188699,9.07596930364915,10.5407,3.03608856903468,75.9208,0.883368521509511,0.711738192261009,0.939077002188497,0.846098341725232,0.171630329248502,0.0929786604632648,True,0.678328971510318,0.0750169221954795,0.372078986621175,130.307810275055
14692,1559:1049,Breast,UACC-893,SIDM01186,909778,1559,Luminespib,HSP90,Protein stability and degradation,Targeted,Early clinical trials,0.01,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.787057961778387,0.105538432103282,0.827252419513771,12.1120578726838,86.4615,0.905486142880186,0.962589442428977,0.13182392929431,0.651095603178747,0.426068555746617,0.22502704743213,9.32933399590965,12.5643,2.78272387677419,73.8972,0.712670078033852,0.567455700319703,0.757613684587544,0.691947815922403,0.145214377714149,0.0656658686651412,True,0.678328971510318,0.0750169221954795,0.372078986621175,130.307810275055
15797,1549:1053,Breast,UACC-893,SIDM01186,909778,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.400531181570822,0.0814024921127916,0.128168723186384,5.19059560201543,0.7133,0.5876725542068,0.600428970698226,0.0583139957399249,0.0513355701382658,0.0108646951650451,0.0404708749732208,1.8873056266132,0.0723,3.30328997540223,0.641,0.235381182513193,0.0848670971985181,0.240490525083113,0.130179065305925,0.150514085314675,0.110311459777188,True,0.901449070210816,0.0955196683609458,0.0938965642384567,485.544529453628
15798,1558:1073,Breast,UACC-893,SIDM01186,909778,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,20.0,0.233038671210227,0.0926292433340706,0.871665998376994,12.8064671427537,279.8278,0.930570225269132,0.97290059419495,0.0513079179228781,0.203131886000911,0.102672334595899,0.100459551405012,8.52551389139947,14.3945,4.28095325135422,265.4333,0.21685884876452,0.155234081945495,0.226723461690832,0.195467813449797,0.0616247668190253,0.0312556482410349,True,0.901449070210816,0.0955196683609458,0.0938965642384567,485.544529453628
15970,1558:1083,Breast,UACC-893,SIDM01186,909778,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.262680713833525,0.060308654309724,0.920713523396115,13.8720706515943,292.8461,0.965724922693483,0.983698365180595,0.045464243293757,0.241853685561871,0.133001489675007,0.108852195886865,9.05026179636585,10.3545,4.82180885522848,282.4916,0.25367731205995,0.192152809203567,0.25839858876251,0.227490421935205,0.0615245028563833,0.0309081668273051,True,0.662784224955705,0.066362054321179,0.39629307250161,122.841440277152
15972,1012:1372,Breast,UACC-893,SIDM01186,909778,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.927220937140398,0.136496407808915,0.395025101582205,8.15310315226336,0.556,0.722819423069726,0.817428440356158,0.110584556990925,0.366275544883033,0.268891598079923,0.0973839468031104,7.22092466485835,0.2914,0.932178487405013,0.2646,0.670213302841994,0.641509299366633,0.757936764512251,0.70208230674151,0.0287040034753608,0.0558544577707411,True,0.662784224955705,0.066362054321179,0.39629307250161,122.841440277152
15972,1058:1372,Breast,UACC-893,SIDM01186,909778,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.971651315851023,0.136496407808915,0.395025101582205,8.15310315226336,0.556,0.722819423069726,0.817428440356158,0.122414497122377,0.383826659746534,0.178502929722195,0.205323730024339,6.03670842154737,0.1282,2.11639473071599,0.4278,0.702328443548377,0.576516146422925,0.79425541968611,0.650047610398947,0.125812297125452,0.144207809287164,True,0.662784224955705,0.066362054321179,0.39629307250161,122.841440277152
15972,1011:1372,Breast,UACC-893,SIDM01186,909778,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.841539763212304,0.136496407808915,0.395025101582205,8.15310315226336,0.556,0.722819423069726,0.817428440356158,0.100376265054231,0.332429330448406,0.0606438423055129,0.271785488142893,3.92259702869144,0.0296,4.23050612357192,0.5264,0.608281286135352,0.388625758964908,0.687898536140324,0.415229618045365,0.219655527170445,0.272668918094959,True,0.662784224955705,0.066362054321179,0.39629307250161,122.841440277152
15972,1594:1372,Breast,UACC-893,SIDM01186,909778,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.654884213997698,0.136496407808915,0.395025101582205,8.15310315226336,0.556,0.722819423069726,0.817428440356158,0.0347399405542477,0.258695703159024,0.0496489200736961,0.209046783085327,4.0314462778958,0.0319,4.12165687436756,0.5241,0.473363029739288,0.302315398450729,0.535320981662007,0.329193745984696,0.171047631288558,0.206127235677311,True,0.662784224955705,0.066362054321179,0.39629307250161,122.841440277152
15972,1053:1372,Breast,UACC-893,SIDM01186,909778,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.752984696741479,0.136496407808915,0.395025101582205,8.15310315226336,0.556,0.722819423069726,0.817428440356158,0.086634546238171,0.297447856320149,0.0755267999031005,0.221921056417049,4.64099285048271,0.0487,3.51211030178065,0.5073,0.544271964079009,0.376515678647943,0.615511106269442,0.417447540890998,0.167756285431066,0.198063565378444,True,0.662784224955705,0.066362054321179,0.39629307250161,122.841440277152
15974,1549:1510,Breast,UACC-893,SIDM01186,909778,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.414115089863689,0.0796694010809711,0.854145507116118,12.5118517455736,114.0703,0.939392042106842,0.968896668757295,0.071952366267246,0.353714543436058,0.147523024127681,0.206191519308376,7.82427367182197,4.4266,4.68757807375167,109.6437,0.389016419934309,0.287750643727993,0.401234731051056,0.33015167398766,0.101265776206316,0.0710830570633966,True,0.662784224955705,0.066362054321179,0.39629307250161,122.841440277152
15974,1558:1510,Breast,UACC-893,SIDM01186,909778,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.448960956381189,0.0796694010809711,0.854145507116118,12.5118517455736,114.0703,0.939392042106842,0.968896668757295,0.0804805576176022,0.383477983763548,0.157419180549368,0.226058803214181,7.77552331846407,4.2795,4.73632842710957,109.7908,0.421750349641166,0.288591515114528,0.434996775039824,0.356543058022744,0.133158834526638,0.0784537170170792,True,0.662784224955705,0.066362054321179,0.39629307250161,122.841440277152
15974,1561:1510,Breast,UACC-893,SIDM01186,909778,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.407272226315503,0.0796694010809711,0.854145507116118,12.5118517455736,114.0703,0.939392042106842,0.968896668757295,0.0605987782530639,0.347869742280566,0.181585892449399,0.166283849831167,8.56801078244729,7.4124,3.94384096312635,106.6579,0.38258828837192,0.302244688150253,0.394604703354458,0.342560769018011,0.0803436002216678,0.0520439343364472,True,0.662784224955705,0.066362054321179,0.39629307250161,122.841440277152
15974,1372:1510,Breast,UACC-893,SIDM01186,909778,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.877115160315898,0.0796694010809711,0.854145507116118,12.5118517455736,114.0703,0.939392042106842,0.968896668757295,0.0665837731391265,0.749183973407258,0.578829411629652,0.170354561777606,10.3172352287739,24.9188,2.19461651679977,89.1515,0.823955001612022,0.756369596449176,0.849833956946595,0.805265657387562,0.0675854051628457,0.0445682995590331,True,0.662784224955705,0.066362054321179,0.39629307250161,122.841440277152
15974,1005:1510,Breast,UACC-893,SIDM01186,909778,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.757573451323174,0.0796694010809711,0.854145507116118,12.5118517455736,114.0703,0.939392042106842,0.968896668757295,0.060694013016508,0.64707795975814,0.432703420572842,0.214374539185298,9.56950342256273,14.8401,2.94234832301091,99.2302,0.711658471484404,0.658608130331773,0.73401039332599,0.674005228890867,0.0530503411526313,0.060005164435123,True,0.662784224955705,0.066362054321179,0.39629307250161,122.841440277152
15974,1011:1510,Breast,UACC-893,SIDM01186,909778,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.873309647738547,0.0796694010809711,0.854145507116118,12.5118517455736,114.0703,0.939392042106842,0.968896668757295,0.0741459989147747,0.74593351193704,0.409215361086677,0.336718150850362,8.74995470904555,8.4087,3.76189703652809,105.6616,0.820380133380721,0.684119445499097,0.846146808487485,0.74305210993552,0.136260687881623,0.103094698551965,True,0.662784224955705,0.066362054321179,0.39629307250161,122.841440277152
15974,1053:1510,Breast,UACC-893,SIDM01186,909778,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.420339426259566,0.0796694010809711,0.854145507116118,12.5118517455736,114.0703,0.939392042106842,0.968896668757295,0.0561983830248745,0.359031032403375,0.198532393995949,0.160498638407425,8.77973984356437,8.5841,3.73211190200927,105.4862,0.394863512011992,0.313591405989074,0.407265469850246,0.358298034695645,0.0812721060229176,0.0489674351546013,True,0.662784224955705,0.066362054321179,0.39629307250161,122.841440277152
15975,1058:1558,Breast,UACC-893,SIDM01186,909778,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.649569789924107,0.0738618191841835,0.101160756651387,4.65980204988074,0.4937,0.552171096275688,0.555978468232209,0.0582644621390993,0.0657109714466051,0.0120170254165867,0.0536939460300184,1.10935005990907,0.0421,3.55045198997167,0.4516,0.358673663009963,0.141795327077816,0.361146816811923,0.172946496170272,0.216878335932146,0.188200320641651,True,0.662784224955705,0.066362054321179,0.39629307250161,122.841440277152
15975,1053:1558,Breast,UACC-893,SIDM01186,909778,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.405713085111334,0.0738618191841835,0.101160756651387,4.65980204988074,0.4937,0.552171096275688,0.555978468232209,0.0462148786653391,0.041042242673231,0.0090066120753492,0.0320356305978817,1.47906467078512,0.0544,3.18073737909562,0.4393,0.224023038979316,0.0836694427868954,0.225567739601963,0.119118994724351,0.140353596192421,0.106448744877613,True,0.662784224955705,0.066362054321179,0.39629307250161,122.841440277152
15976,1558:1594,Breast,UACC-893,SIDM01186,909778,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.236760543955876,0.0680357278978972,0.331379688663416,7.60528384237243,1.5213,0.775764783336087,0.783144092506391,0.0429938139260985,0.078457635343879,0.0115403141809607,0.0669173211629183,3.09642207605964,0.0668,4.50886176631278,1.4545,0.183670492084464,0.0831236826304381,0.185417621337644,0.100270618539979,0.100546809454026,0.085147002797665,True,0.662784224955705,0.066362054321179,0.39629307250161,122.841440277152
15976,1549:1594,Breast,UACC-893,SIDM01186,909778,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.719938797429655,0.0680357278978972,0.331379688663416,7.60528384237243,1.5213,0.775764783336087,0.783144092506391,0.0663848636425859,0.238573094548953,0.11036899188444,0.128204102664513,5.60451736511961,0.3801,2.00076647725282,1.1412,0.558503165203259,0.469593025632513,0.563815816173189,0.456740466426747,0.0889101395707463,0.107075349746442,True,0.662784224955705,0.066362054321179,0.39629307250161,122.841440277152
15976,1561:1594,Breast,UACC-893,SIDM01186,909778,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.434724074009938,0.0680357278978972,0.331379688663416,7.60528384237243,1.5213,0.775764783336087,0.783144092506391,0.0371294300904059,0.144058728299905,0.0490721404121457,0.0949865878877592,4.90369460729103,0.2339,2.70158923508139,1.2874,0.337243627085301,0.244024370938309,0.340451590431194,0.250618039290265,0.0932192561469912,0.0898335511409286,True,0.662784224955705,0.066362054321179,0.39629307250161,122.841440277152
15976,1053:1594,Breast,UACC-893,SIDM01186,909778,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.697264295974134,0.0680357278978972,0.331379688663416,7.60528384237243,1.5213,0.775764783336087,0.783144092506391,0.0379051739233057,0.231059225316024,0.0962216677462869,0.134837557569737,5.35995420084322,0.3208,2.24532964152921,1.2005,0.540913085494364,0.41832169034316,0.546058414307771,0.42841398689728,0.122591395151204,0.117644427410491,True,0.662784224955705,0.066362054321179,0.39629307250161,122.841440277152
14525,1372:1011,Breast,CAL-85-1,SIDM00928,910852,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.916980150196073,0.156899727025097,0.449009972504716,8.57620446871108,7.4546,0.852585577003347,0.836224411969395,0.0957150535907903,0.411733232026909,0.305480994521757,0.106252237505152,7.56294129850105,3.6932,1.01326317021003,3.7614,0.781804050455534,0.709820929182317,0.766801186885319,0.711287249729082,0.071983121273217,0.0555139371562373,True,0.861215134817706,0.0962582006702287,0.139139728297033,337.225557240147
14525,1179:1011,Breast,CAL-85-1,SIDM00928,910852,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.663282150290232,0.156899727025097,0.449009972504716,8.57620446871108,7.4546,0.852585577003347,0.836224411969395,0.0742512285521709,0.297820300064686,0.122672825004874,0.175147475059812,5.9289176558294,1.1899,2.64728681288168,6.2647,0.565504794821218,0.419516680897614,0.554652726096246,0.436249292958369,0.145988113923604,0.118403433137877,True,0.861215134817706,0.0962582006702287,0.139139728297033,337.225557240147
14527,1372:1053,Breast,CAL-85-1,SIDM00928,910852,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.867438633294194,0.0674834339213733,0.8288319828011,12.2661253095111,96.2059,0.941361380164944,0.96146818858538,0.04021464758211,0.718960882391503,0.711105421178463,0.0078554612130397,12.1366274785218,87.9466,0.129497830989248,8.2593,0.816573229046215,0.835870968640209,0.834014651462346,0.832060473707752,-0.0192977395939946,0.001954177754593,True,0.861215134817706,0.0962582006702287,0.139139728297033,337.225557240147
14527,1510:1053,Breast,CAL-85-1,SIDM00928,910852,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.919295298119898,0.0674834339213733,0.8288319828011,12.2661253095111,96.2059,0.941361380164944,0.96146818858538,0.14734524644638,0.761941344720443,0.516713061468262,0.245228283252181,9.51680061951927,14.3078,2.7493246899918,81.8981,0.865389090617291,0.686395689363104,0.883873185058395,0.810812064867985,0.178993401254186,0.07306112019041,True,0.861215134817706,0.0962582006702287,0.139139728297033,337.225557240147
16031,1005:1190,Breast,CAL-85-1,SIDM00928,910852,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.951748689749727,0.164306841535984,0.481692680089898,8.8483027479144,9.0019,0.747234837277023,0.850525047892426,0.078231077420384,0.458450377137595,0.0566545358035646,0.40179584133403,3.28519972857711,0.1904,5.5631030193373,8.8115,0.711179777313757,0.406279064998374,0.80948609993094,0.419178165758268,0.304900712315383,0.390307934172672,True,0.394220121786343,0.0456799825875106,0.897148420932123,54.8081727162373
16031,1011:1190,Breast,CAL-85-1,SIDM00928,910852,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.788916322686299,0.164306841535984,0.481692680089898,8.8483027479144,9.0019,0.747234837277023,0.850525047892426,0.138825648589659,0.38001521784143,0.0414705407996603,0.33854467704177,3.01245539301775,0.1576,5.83584735489665,8.8443,0.589505760007684,0.323756499983887,0.670993093135881,0.329707133266862,0.265749260023796,0.341285959869019,True,0.394220121786343,0.0456799825875106,0.897148420932123,54.8081727162373
18150,1022:1190,Breast,CAL-85-1,SIDM00928,910852,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.735186951399858,0.145297066084765,0.335610772605444,7.58594563161644,3.7526,0.728005763945575,0.777179666433846,0.133196920301706,0.246736660768748,0.0692753810085002,0.177461279760247,4.31406531505242,0.3885,3.27188031656402,3.3641,0.535220338196672,0.37651922237255,0.571372349655458,0.386882742059996,0.158701115824122,0.184489607595462,True,0.362682475102563,0.050059513408619,0.94130905591124,51.5364996307316
14755,1049:1372,Breast,CAL-85-1,SIDM00928,910852,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.897785644895238,0.137492871980275,0.361949288342634,7.82614169374824,0.4432,0.696896197732748,0.792470104019695,0.114584277378813,0.324952875254064,0.461215866634996,-0.136262991380932,9.11371381648696,1.082,-1.28757212273872,-0.6388,0.625663402306534,0.684082884600769,0.711468283397518,0.775367163823736,-0.0584194822942352,-0.0638988804262182,True,0.538758409193892,0.0714331582641527,0.597562110379776,81.9631720304769
14755,1011:1372,Breast,CAL-85-1,SIDM00928,910852,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.740474464928098,0.137492871980275,0.361949288342634,7.82614169374824,0.4432,0.696896197732748,0.792470104019695,0.0809471907632818,0.268014205616618,0.136924018981023,0.131090186635594,5.92844673954349,0.119,1.89769495420475,0.3242,0.516033839126582,0.436637456714916,0.586803876245498,0.48699244650154,0.0793963824116666,0.0998114297439575,True,0.538758409193892,0.0714331582641527,0.597562110379776,81.9631720304769
14755,1561:1372,Breast,CAL-85-1,SIDM00928,910852,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.864908836110302,0.137492871980275,0.361949288342634,7.82614169374824,0.4432,0.696896197732748,0.792470104019695,0.113019471332916,0.31305313771138,0.11265614513829,0.20039699257309,5.06846225057659,0.0655,2.75767944317165,0.3777,0.602751679270726,0.459974706019893,0.685414395319885,0.50918383411932,0.142776973250833,0.176230561200565,True,0.538758409193892,0.0714331582641527,0.597562110379776,81.9631720304769
14755,1053:1372,Breast,CAL-85-1,SIDM00928,910852,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.948410929820582,0.137492871980275,0.361949288342634,7.82614169374824,0.4432,0.696896197732748,0.792470104019695,0.160522049835076,0.343276661104935,0.238292828132352,0.104983832972584,6.73903436183935,0.2086,1.08710733190889,0.2346,0.660943970880143,0.577348230009137,0.751587308208332,0.681776291502549,0.0835957408710061,0.0698110167057835,True,0.538758409193892,0.0714331582641527,0.597562110379776,81.9631720304769
14757,1549:1510,Breast,CAL-85-1,SIDM00928,910852,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.615639781096815,0.095540653992585,0.604983528695768,9.88264765438249,18.4376,0.872893691644395,0.897018052265465,0.0889911318269868,0.372451927173442,0.239652843614187,0.132799083559255,8.06747286793832,5.2394,1.81517478644417,13.1982,0.537388081244746,0.432857301676576,0.552239997336603,0.496958879740851,0.104530779568171,0.0552811175957515,True,0.538758409193892,0.0714331582641527,0.597562110379776,81.9631720304769
14757,1594:1510,Breast,CAL-85-1,SIDM00928,910852,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.846591401085026,0.095540653992585,0.604983528695768,9.88264765438249,18.4376,0.872893691644395,0.897018052265465,0.059128592085783,0.512173853191913,0.315552731418884,0.196621121773029,7.92222764863343,4.7376,1.96042000574906,13.7,0.738984293407509,0.659455036009427,0.759407769665981,0.67593441795097,0.0795292573980817,0.0834733517150118,True,0.538758409193892,0.0714331582641527,0.597562110379776,81.9631720304769
14757,1083:1549,Breast,CAL-85-1,SIDM00928,910852,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.907369688031299,0.146921622003077,0.445579512680955,8.54747249165211,3.6538,0.726042226474699,0.834664471250201,0.116643501290324,0.404305343414456,0.180845888338252,0.223459455076204,6.12055283837627,0.6795,2.42691965327585,2.9743,0.658788708533897,0.548103187372027,0.757349240889104,0.610271832907677,0.110685521161869,0.147077407981427,True,0.538758409193892,0.0714331582641527,0.597562110379776,81.9631720304769
14757,1510:1549,Breast,CAL-85-1,SIDM00928,910852,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.595073786383186,0.146921622003077,0.445579512680955,8.54747249165211,3.6538,0.726042226474699,0.834664471250201,0.0797058997948411,0.265152687745831,0.206221864938862,0.0589308228069689,7.6867225061073,2.012,0.860749985544818,1.6418,0.432048696782378,0.407194325542364,0.496686947266377,0.46633967221531,0.0248543712400139,0.0303472750510669,True,0.538758409193892,0.0714331582641527,0.597562110379776,81.9631720304769
14758,1372:1558,Breast,CAL-85-1,SIDM00928,910852,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.81585202010802,0.0972443839708798,0.347270847670562,7.69332517161346,4.0425,0.763681933064926,0.784088400404123,0.0521735934485303,0.283321622596652,0.154093652429978,0.129227970166675,5.98241419053713,1.2349,1.71091098107633,2.8076,0.623051447811018,0.529824777639797,0.63970010541297,0.539998622856176,0.093226670171221,0.0997014825567937,True,0.538758409193892,0.0714331582641527,0.597562110379776,81.9631720304769
14759,1372:1561,Breast,CAL-85-1,SIDM00928,910852,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.837648156764862,0.0735091921431816,0.350091027028598,7.71903832122803,4.1152,0.757531024395211,0.785725333531169,0.0699267261912054,0.293253103490423,0.163249564985096,0.130003538505327,6.06275129330312,1.3056,1.65628702792492,2.8096,0.634544466276847,0.524813807340936,0.65816137735584,0.559644234825256,0.109730658935911,0.0985171425305837,True,0.538758409193892,0.0714331582641527,0.597562110379776,81.9631720304769
14759,1011:1561,Breast,CAL-85-1,SIDM00928,910852,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.77334144765743,0.0735091921431816,0.350091027028598,7.71903832122803,4.1152,0.757531024395211,0.785725333531169,0.0673922068165909,0.270739901654172,0.0976289350527807,0.173110966601392,4.9942065437524,0.6225,2.72483177747563,3.4927,0.585830139051208,0.42660485849931,0.607633966894111,0.450566635803412,0.159225280551898,0.157067331090699,True,0.538758409193892,0.0714331582641527,0.597562110379776,81.9631720304769
14759,1510:1594,Breast,CAL-85-1,SIDM00928,910852,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.603317644709426,0.092626046143717,0.327207471448041,7.50741461152023,1.4215,0.742875492661952,0.772053684897835,0.0256142106051377,0.197410041005359,0.246036347037344,-0.0486263060319851,8.22757025683531,2.3417,-0.720155645315081,-0.9202,0.448189892545163,0.495841614624122,0.465793610761796,0.492706737296963,-0.0476517220789588,-0.0269131265351673,True,0.538758409193892,0.0714331582641527,0.597562110379776,81.9631720304769
16369,1022:1005,Breast,OCUB-M,SIDM00241,909256,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.879282996936719,0.0702731638934544,0.864868181475147,11.5755832102138,23.8445,0.951831221236947,0.979873137302709,0.0607756829056817,0.760463886562677,0.471887073590606,0.288576812972071,9.20389345293153,4.6072,2.37168975728226,19.2373,0.836929008787159,0.763620620450343,0.861585788785311,0.803433971851438,0.0733083883368164,0.0581518169338725,True,0.514735242874012,0.0632060795802208,0.643216599582744,76.3072343025709
16369,1179:1005,Breast,OCUB-M,SIDM00241,909256,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.512978711723521,0.0702731638934544,0.864868181475147,11.5755832102138,23.8445,0.951831221236947,0.979873137302709,0.0826013136520036,0.443658965543785,0.049544742980264,0.394114222563521,5.89792835167854,0.4658,5.67765485853525,23.3787,0.488269153648355,0.296933998148563,0.502654059626028,0.347111550326662,0.191335155499791,0.155542509299366,True,0.514735242874012,0.0632060795802208,0.643216599582744,76.3072343025709
16370,1179:1012,Breast,OCUB-M,SIDM00241,909256,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,5.0,0.841616019596585,0.110646780512787,0.241478278473145,7.41192165411123,1.6631,0.794022899796742,0.803167548952371,0.0969343692516811,0.203231987547603,0.146197213951672,0.0570347735959317,6.83617208710443,1.1158,0.575749567006796,0.5473,0.668262392395472,0.664685223310679,0.675958675618439,0.637634660774482,0.0035771690847931,0.038324014843957,True,0.514735242874012,0.0632060795802208,0.643216599582744,76.3072343025709
16371,1012:1022,Breast,OCUB-M,SIDM00241,909256,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.924261854779501,0.0941085013686812,0.656691134113695,9.89988495606929,1.8659,0.885832553627531,0.941705189598741,0.055443316788899,0.606954565633178,0.388760802222332,0.218193763410846,8.5556809464995,0.7349,1.34420400956979,1.131,0.818741239039843,0.777373309890334,0.870382185194014,0.813334704542256,0.0413679291495092,0.057047480651758,True,0.514735242874012,0.0632060795802208,0.643216599582744,76.3072343025709
16371,1005:1022,Breast,OCUB-M,SIDM00241,909256,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,1.0,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.925956251813929,0.0941085013686812,0.656691134113695,9.89988495606929,1.8659,0.885832553627531,0.941705189598741,0.0885044819771058,0.608067261143356,0.560102271021845,0.0479649901215111,9.59089960195294,1.5062,0.308985354116359,0.3597,0.82024219109171,0.833129046417391,0.871977807674576,0.861434095045911,-0.0128868553256816,0.0105437126286649,True,0.514735242874012,0.0632060795802208,0.643216599582744,76.3072343025709
16371,1190:1022,Breast,OCUB-M,SIDM00241,909256,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.01,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.964060693257448,0.0941085013686812,0.656691134113695,9.89988495606929,1.8659,0.885832553627531,0.941705189598741,0.135642211133551,0.633090110009669,0.136287403064959,0.49680270694471,6.49705457121348,0.1764,3.40283038485581,1.6895,0.853996345760173,0.660780405964621,0.907860957928698,0.702975288309391,0.193215939795552,0.204885669619307,True,0.514735242874012,0.0632060795802208,0.643216599582744,76.3072343025709
16371,1058:1022,Breast,OCUB-M,SIDM00241,909256,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.95785363897268,0.0941085013686812,0.656691134113695,9.89988495606929,1.8659,0.885832553627531,0.941705189598741,0.0909298861242496,0.6290139924919,0.483157404463927,0.145856588027973,9.02451285006303,1.0171,0.875372106006267,0.8488,0.848497935012592,0.79755525626013,0.902015742696612,0.867000878659746,0.0509426787524622,0.0350148640368658,True,0.514735242874012,0.0632060795802208,0.643216599582744,76.3072343025709
16371,1558:1022,Breast,OCUB-M,SIDM00241,909256,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.560357920169764,0.0941085013686812,0.656691134113695,9.89988495606929,1.8659,0.885832553627531,0.941705189598741,0.092430382693774,0.367982078105874,0.109383377136633,0.25859870096924,7.03458728721846,0.2561,2.86529766885083,1.6098,0.496383287369394,0.378599782219277,0.527691961456623,0.433577613025017,0.117783505150117,0.0941143484316068,True,0.514735242874012,0.0632060795802208,0.643216599582744,76.3072343025709
16371,1179:1022,Breast,OCUB-M,SIDM00241,909256,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.905340010540435,0.0941085013686812,0.656691134113695,9.89988495606929,1.8659,0.885832553627531,0.941705189598741,0.0563875422859579,0.594528758280303,0.125620509288858,0.468908248991445,6.4669531409264,0.1728,3.43293181514289,1.6931,0.801979653438209,0.66360913309495,0.852563386277307,0.657826077122146,0.138370520343259,0.194737309155161,True,0.514735242874012,0.0632060795802208,0.643216599582744,76.3072343025709
16372,1191:1047,Breast,OCUB-M,SIDM00241,909256,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.0025,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.761585436719323,0.0594372406640008,0.913906574918486,12.27759613332,96.9739,0.952225139725618,0.987518787240818,0.119711770903765,0.696017937979956,0.399601427319123,0.296416510660833,9.13717505997782,10.9975,3.14042107334222,85.9764,0.725200798893053,0.61829287531761,0.752079926849335,0.69350795033999,0.106907923575443,0.0585719765093444,True,0.514735242874012,0.0632060795802208,0.643216599582744,76.3072343025709
16372,1375:1047,Breast,OCUB-M,SIDM00241,909256,1375,Temozolomide,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved,30.0,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.955749886541826,0.0594372406640008,0.913906574918486,12.27759613332,96.9739,0.952225139725618,0.987518787240818,0.0406610122472655,0.873466105288172,0.857043336479075,0.0164227688090971,11.9987742675127,79.9321,0.278821865807352,17.0418,0.910089069255034,0.915607365892533,0.943820968863334,0.941306042350809,-0.0055182966374992,0.0025149265125249,True,0.514735242874012,0.0632060795802208,0.643216599582744,76.3072343025709
16372,1021:1049,Breast,OCUB-M,SIDM00241,909256,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,4.0,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.69485947377877,0.089307834050801,0.854648713502996,11.4579412043743,54.9432,0.915982112080909,0.978225340220018,0.118444089949898,0.593860755330395,0.355345763350479,0.238514991979916,9.06323633136752,10.4481,2.39470487300673,44.4951,0.636478848391307,0.539715457190416,0.679729145142341,0.630273972717819,0.0967633912008915,0.0494551724245212,True,0.514735242874012,0.0632060795802208,0.643216599582744,76.3072343025709
16372,1549:1049,Breast,OCUB-M,SIDM00241,909256,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.619012370552178,0.089307834050801,0.854648713502996,11.4579412043743,54.9432,0.915982112080909,0.978225340220018,0.0351873263348387,0.529038126134858,0.314420217193053,0.214617908941805,9.04406120639022,10.3101,2.41387999798403,44.6331,0.567004258582594,0.52889138594954,0.605533586783804,0.56089550984326,0.0381128726330542,0.044638076940544,True,0.514735242874012,0.0632060795802208,0.643216599582744,76.3072343025709
16372,1179:1049,Breast,OCUB-M,SIDM00241,909256,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.467815406878903,0.089307834050801,0.854648713502996,11.4579412043743,54.9432,0.915982112080909,0.978225340220018,0.132806006533515,0.399817835645935,0.19735550133557,0.202462334310365,8.5627867235845,7.3856,2.89515448078975,47.5576,0.428510544456927,0.284820018563051,0.457628885554281,0.411861649703244,0.143690525893877,0.045767235851037,True,0.514735242874012,0.0632060795802208,0.643216599582744,76.3072343025709
16372,1011:1049,Breast,OCUB-M,SIDM00241,909256,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.662212220552305,0.089307834050801,0.854648713502996,11.4579412043743,54.9432,0.915982112080909,0.978225340220018,0.0758205148791225,0.565958822360989,0.223695736545392,0.342263085815598,8.06608429827381,5.2344,3.39185690610044,49.7088,0.606574548427289,0.498886802305398,0.647792774747632,0.562628889485955,0.107687746121891,0.0851638852616771,True,0.514735242874012,0.0632060795802208,0.643216599582744,76.3072343025709
16373,1549:1053,Breast,OCUB-M,SIDM00241,909256,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.660341962365527,0.0527488398770326,0.0367377164563756,4.46782350466921,0.4322,0.540025646231945,0.544259275810404,0.0548171854112576,0.0242594557776313,0.0024070094320441,0.0218524463455871,1.21533506523009,0.0454,3.25248843943913,0.3868,0.356601594960515,0.140404385811279,0.359397238224283,0.162853428034812,0.216197209149235,0.196543810189471,True,0.514735242874012,0.0632060795802208,0.643216599582744,76.3072343025709
16373,1561:1053,Breast,OCUB-M,SIDM00241,909256,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.466623014955736,0.0527488398770326,0.0367377164563756,4.46782350466921,0.4322,0.540025646231945,0.544259275810404,0.0453312758185172,0.017142664015463,0.0009447022645457,0.0161979617509173,0.397204554241928,0.0257,4.07061895042728,0.4065,0.25198839519817,0.0552738903808845,0.253963904196277,0.0852248782436965,0.196714504817286,0.16873902595258,True,0.514735242874012,0.0632060795802208,0.643216599582744,76.3072343025709
16373,1561:1054,Breast,OCUB-M,SIDM00241,909256,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.466623014955736,0.0874347912049047,0.893895407741797,11.9569093493279,31.0584,0.927932348059159,0.98444952259631,0.056386802099082,0.417112170215565,0.37979376020665,0.0373184100089142,11.0474572664181,16.5351,0.909452082909782,14.5233,0.432994589926321,0.435357456559401,0.459366804305626,0.453303998411614,-0.0023628666330807,0.0060628058940115,True,0.514735242874012,0.0632060795802208,0.643216599582744,76.3072343025709
16374,1549:1058,Breast,OCUB-M,SIDM00241,909256,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.629773125067896,0.0902713797425118,0.13967143182077,6.4775631865153,0.6962,0.709651148089934,0.727515114923284,0.0451980577072826,0.087961314100474,0.0111642028946716,0.0767971112058025,3.42966998179073,0.0842,3.04789320472456,0.612,0.446919221240619,0.261423516326844,0.458169467459366,0.280922166657698,0.185495704913774,0.177247300801669,True,0.514735242874012,0.0632060795802208,0.643216599582744,76.3072343025709
16374,1558:1058,Breast,OCUB-M,SIDM00241,909256,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.634933158881283,0.0902713797425118,0.13967143182077,6.4775631865153,0.6962,0.709651148089934,0.727515114923284,0.0300312970360904,0.0886820234114333,0.0105138036916113,0.078168219719822,3.33341843239997,0.0787,3.14414475411533,0.6175,0.450581045160471,0.258650944699232,0.46192347005212,0.277466552127181,0.191930100461239,0.184456917924939,True,0.514735242874012,0.0632060795802208,0.643216599582744,76.3072343025709
16374,1012:1058,Breast,OCUB-M,SIDM00241,909256,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.502097445649668,0.0902713797425118,0.13967143182077,6.4775631865153,0.6962,0.709651148089934,0.727515114923284,0.052118532205758,0.0701286691474404,0.0062842294962215,0.0638444396512189,2.9393473395305,0.0599,3.53821584698479,0.6363,0.35631402875831,0.17339004007778,0.365283480874506,0.200874818224962,0.182923988680531,0.164408662649543,True,0.514735242874012,0.0632060795802208,0.643216599582744,76.3072343025709
17530,1549:1083,Breast,OCUB-M,SIDM00241,909256,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.658118537650803,0.110708680493547,0.621796259593651,9.68981781949313,16.1308,0.875776982307604,0.93413824587208,0.0625524099543746,0.409215645080513,0.192574556062325,0.216641089018188,7.77525468007764,4.2787,1.9145631394155,11.8521,0.576365066904513,0.493897706597276,0.61477369633702,0.546069150004397,0.082467360307237,0.0687045463326227,True,0.616972729262291,0.0642704860222736,0.46687642032904,104.667299796029
17530,1510:1083,Breast,OCUB-M,SIDM00241,909256,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.90684630562683,0.110708680493547,0.621796259593651,9.68981781949313,16.1308,0.875776982307604,0.93413824587208,0.0565544711884161,0.563873640865084,0.415267791530545,0.148605849334539,8.76593774455373,8.5024,0.923880074939403,7.6284,0.794195120958664,0.795302653819509,0.847119817213823,0.808683811644064,-0.0011075328608448,0.0384360055697597,True,0.616972729262291,0.0642704860222736,0.46687642032904,104.667299796029
17530,1012:1083,Breast,OCUB-M,SIDM00241,909256,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.389643083060152,0.110708680493547,0.621796259593651,9.68981781949313,16.1308,0.875776982307604,0.93413824587208,0.0622480006583117,0.242278611623341,0.2516605393006,-0.0093819276772593,9.83380103832226,17.8238,-0.143983218829128,-1.693,0.341240443459451,0.351392824993024,0.363980506126,0.36603205140056,-0.0101523815335724,-0.0020515452745596,True,0.616972729262291,0.0642704860222736,0.46687642032904,104.667299796029
17530,1011:1083,Breast,OCUB-M,SIDM00241,909256,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.713838442052024,0.110708680493547,0.621796259593651,9.68981781949313,16.1308,0.875776982307604,0.93413824587208,0.0621602241228147,0.443862073222108,0.214208709833546,0.229653363388562,7.82493516462806,4.4286,1.86488265486508,11.7022,0.625163276635483,0.58565238481213,0.666823790094536,0.594791568176808,0.0395108918233523,0.0720322219177287,True,0.616972729262291,0.0642704860222736,0.46687642032904,104.667299796029
15964,1011:1372,Breast,OCUB-M,SIDM00241,909256,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.654107749163289,0.104451928855569,0.901213803436009,12.0673807687274,8.3825,0.918742512460224,0.985579890875486,0.138440194171044,0.589490932480414,0.255120038858884,0.33437089362153,8.37953171245377,0.6505,3.68784905627368,7.732,0.600956596885981,0.443419617791899,0.644675444041164,0.568763601820697,0.157536979094082,0.0759118422204673,True,0.555386750055326,0.063085709639025,0.570398383899931,86.0068564322594
15966,1190:1510,Breast,OCUB-M,SIDM00241,909256,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.1,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.612622221848769,0.098423094636099,0.770645451551091,10.6815481541881,32.0772,0.91328543689289,0.963883472309096,0.117236852947186,0.472114528786878,0.533690097434749,-0.0615755686478716,11.6517558191204,62.8432,-0.970207664932341,-30.766,0.559498953531446,0.508393023306734,0.590496434409305,0.600907353799852,0.0511059302247124,-0.0104109193905468,True,0.555386750055326,0.063085709639025,0.570398383899931,86.0068564322594
15966,1011:1510,Breast,OCUB-M,SIDM00241,909256,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.697657675971224,0.098423094636099,0.770645451551091,10.6815481541881,32.0772,0.91328543689289,0.963883472309096,0.077084494938018,0.537646714726929,0.223319058368429,0.314327656358501,7.95479683019184,4.8458,2.72675132399626,27.2314,0.637160595401058,0.523278257436123,0.672460703198238,0.587545403479312,0.113882337964935,0.0849152997189259,True,0.555386750055326,0.063085709639025,0.570398383899931,86.0068564322594
15966,1012:1549,Breast,OCUB-M,SIDM00241,909256,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.924865005448421,0.0915745550563507,0.356606203081222,8.18122387231455,2.8346,0.795082264002829,0.85712091550271,0.106522844692223,0.329812597955655,0.17311697042122,0.156695627534436,6.96260330119272,1.218,1.21862057112183,1.6166,0.735343762428919,0.66410029634852,0.79272114018637,0.710251399036448,0.0712434660803994,0.0824697411499212,True,0.555386750055326,0.063085709639025,0.570398383899931,86.0068564322594
15966,1058:1549,Breast,OCUB-M,SIDM00241,909256,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.91484475899252,0.0915745550563507,0.356606203081222,8.18122387231455,2.8346,0.795082264002829,0.85712091550271,0.0826821917059352,0.326239315913078,0.0825946737907738,0.243644642122305,5.79470110111619,0.5421,2.38652277119836,2.2925,0.727376842190895,0.587841437261639,0.784132577370525,0.610543572236401,0.139535404929256,0.173589005134124,True,0.555386750055326,0.063085709639025,0.570398383899931,86.0068564322594
15966,1053:1549,Breast,OCUB-M,SIDM00241,909256,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.755807252188559,0.0915745550563507,0.356606203081222,8.18122387231455,2.8346,0.795082264002829,0.85712091550271,0.120937441952172,0.269525554464214,0.0176198979749244,0.251905656489289,3.81759334522744,0.1377,4.3636305270871,2.6969,0.600928941219837,0.309182530053169,0.647818203939445,0.364849858218548,0.291746411166668,0.282968345720897,True,0.555386750055326,0.063085709639025,0.570398383899931,86.0068564322594
15967,1058:1558,Breast,OCUB-M,SIDM00241,909256,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.946852407156683,0.11504743890058,0.163662832960641,6.73673867845481,2.083,0.691733648479533,0.749401102220484,0.0619607034640728,0.154964547350865,0.0069829211492895,0.147981626201575,2.19827912803812,0.0896,4.53845955041669,1.9934,0.65496967017412,0.330926185387636,0.709572237563336,0.314348155796925,0.324043484786485,0.395224081766412,True,0.555386750055326,0.063085709639025,0.570398383899931,86.0068564322594
15967,1561:1558,Breast,OCUB-M,SIDM00241,909256,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.445747102136713,0.11504743890058,0.163662832960641,6.73673867845481,2.083,0.691733648479533,0.749401102220484,0.0339387468888587,0.0729522335196905,0.0013000545145736,0.0716521790051169,0.904954532214011,0.0366,5.8317841462408,2.0464,0.308338269260207,0.0831878290066958,0.334043369652839,0.0986982329766889,0.225150440253512,0.23534513667615,True,0.555386750055326,0.063085709639025,0.570398383899931,86.0068564322594
15967,1179:1558,Breast,OCUB-M,SIDM00241,909256,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.5429611856054,0.11504743890058,0.163662832960641,6.73673867845481,2.083,0.691733648479533,0.749401102220484,0.0666691770865812,0.088862565823848,0.0105546619194575,0.0783079039043905,3.55998199143062,0.2304,3.1767566870242,1.8526,0.375584521901596,0.238892747788183,0.406895710955627,0.248875261195881,0.136691774113413,0.158020449759747,True,0.555386750055326,0.063085709639025,0.570398383899931,86.0068564322594
15967,1012:1558,Breast,OCUB-M,SIDM00241,909256,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.557686535621312,0.11504743890058,0.163662832960641,6.73673867845481,2.083,0.691733648479533,0.749401102220484,0.03635035418112,0.0912725583237892,0.0039496617222351,0.0873228966015541,2.141690092815,0.0862,4.59504858563981,1.9968,0.385770541993241,0.181542529481892,0.417930904488135,0.182306418379269,0.20422801251135,0.235624486108866,True,0.555386750055326,0.063085709639025,0.570398383899931,86.0068564322594
15967,1594:1558,Breast,OCUB-M,SIDM00241,909256,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.969248325862702,0.11504743890058,0.163662832960641,6.73673867845481,2.083,0.691733648479533,0.749401102220484,0.0888862392002061,0.158629926853048,0.0182184249385892,0.140411501914459,3.51243035939634,0.2229,3.22430831905847,1.8601,0.670461680731686,0.462094747721543,0.726355763726868,0.439919065767237,0.208366933010143,0.286436697959631,True,0.555386750055326,0.063085709639025,0.570398383899931,86.0068564322594
15967,1053:1558,Breast,OCUB-M,SIDM00241,909256,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.270495356924606,0.11504743890058,0.163662832960641,6.73673867845481,2.083,0.691733648479533,0.749401102220484,0.0489172228507718,0.0442700364169807,0.0007583273697385,0.0435117090472421,0.849923748711075,0.0352,5.88681492974374,2.0478,0.187110740142231,0.0267323669521828,0.202709518624823,0.0587150278585442,0.160378373190048,0.143994490766279,True,0.555386750055326,0.063085709639025,0.570398383899931,86.0068564322594
15968,1053:1561,Breast,OCUB-M,SIDM00241,909256,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.242536575543062,0.0790189538810212,0.0058395587879575,1.87226752350984,0.0715,0.290164431885315,0.3028998137339,0.0475164955435219,0.0014163065911136,0.0002806618505248,0.0011356447405888,-0.380078060687169,0.015,2.25234558419701,0.0565,0.0703754876538626,0.0109138814568919,0.0734642835556515,0.0316366848431373,0.0594616061969707,0.0418275987125142,True,0.555386750055326,0.063085709639025,0.570398383899931,86.0068564322594
15968,1549:1594,Breast,OCUB-M,SIDM00241,909256,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.904986983681852,0.0919131978546664,0.134984831552259,6.4226709999869,0.6702,0.698040963423717,0.722805099875012,0.0632031298354166,0.122159515549282,0.0765939184792435,0.0455655970700387,5.69649332101927,0.4051,0.726177678967625,0.2651,0.631717985975203,0.592882438557085,0.654129207125747,0.595922381240478,0.0388355474181176,0.0582068258852686,True,0.555386750055326,0.063085709639025,0.570398383899931,86.0068564322594
15968,1561:1594,Breast,OCUB-M,SIDM00241,909256,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.510512524004898,0.0919131978546664,0.134984831552259,6.4226709999869,0.6702,0.698040963423717,0.722805099875012,0.0426998768366698,0.06891144705812,0.0044124146513671,0.0644990324067529,2.42021939636713,0.0418,4.00245160361977,0.6284,0.356358654096252,0.175242924385127,0.369001055900805,0.179770145544221,0.181115729711126,0.189230910356584,True,0.555386750055326,0.063085709639025,0.570398383899931,86.0068564322594
15968,1053:1594,Breast,OCUB-M,SIDM00241,909256,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.772489340122568,0.0919131978546664,0.134984831552259,6.4226709999869,0.6702,0.698040963423717,0.722805099875012,0.0702670091388543,0.104274343452361,0.0120008291493262,0.0922735143030347,3.24343856766934,0.074,3.17923243231756,0.5962,0.539229203213708,0.31511063796394,0.558359234639675,0.331041738182227,0.224118565249768,0.227317496457447,True,0.555386750055326,0.063085709639025,0.570398383899931,86.0068564322594
16616,1011:1007,Breast,EFM-19,SIDM01056,906851,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1007,Docetaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.0125,0.686223655315137,0.0940478045428824,0.536173856709741,9.4101637506354,0.0166,0.845728000531398,0.830681361507807,0.12826147443265,0.367935183835773,0.186365676622698,0.181569507213075,6.20816356189859,0.0018,3.20200018873681,0.0148,0.580358559927018,0.460270442275465,0.570033200296043,0.447746075373607,0.120088117651553,0.122287124922436,True,0.647027768334058,0.0579605854386392,0.418780285727006,116.185304965541
16617,1083:1011,Breast,EFM-19,SIDM01056,906851,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.868033047216536,0.096896502014408,0.41061012179641,7.97721646326752,4.9217,0.777881703027399,0.759738479201232,0.147944640353075,0.356423155240891,0.140526014776414,0.215897140464477,4.34729132066424,0.3976,3.62992514260327,4.5241,0.675227025052861,0.467041623398694,0.659478107188702,0.455351346328979,0.208185401654167,0.204126760859723,True,0.647027768334058,0.0579605854386392,0.418780285727006,116.185304965541
16617,1021:1011,Breast,EFM-19,SIDM01056,906851,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,4.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.855471105422003,0.096896502014408,0.41061012179641,7.97721646326752,4.9217,0.777881703027399,0.759738479201232,0.0728880312382196,0.351265094790638,0.154030150544268,0.197234944246369,4.71018181183413,0.5113,3.26703465143339,4.4104,0.665455320376399,0.476085856318032,0.649934316633909,0.470646625651727,0.189369464058367,0.179287690982182,True,0.647027768334058,0.0579605854386392,0.418780285727006,116.185304965541
16617,1594:1011,Breast,EFM-19,SIDM01056,906851,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.794750184445404,0.096896502014408,0.41061012179641,7.97721646326752,4.9217,0.777881703027399,0.759738479201232,0.100460889854215,0.326332470032846,0.275008582444055,0.0513238875887909,7.19880169371167,2.8694,0.778414769555849,2.0523,0.61822162695773,0.618687631913213,0.603802296475449,0.568165694450433,-0.0004660049554834,0.0356366020250161,True,0.647027768334058,0.0579605854386392,0.418780285727006,116.185304965541
16617,1053:1011,Breast,EFM-19,SIDM01056,906851,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.567912190145164,0.096896502014408,0.41061012179641,7.97721646326752,4.9217,0.777881703027399,0.759738479201232,0.0598819860447741,0.233190493565172,0.08334726893058,0.149843224634592,4.0190312874789,0.3166,3.95818517578862,4.6051,0.44176850164014,0.271328030930771,0.431464743660728,0.284721478639223,0.17044047070937,0.146743265021505,True,0.647027768334058,0.0579605854386392,0.418780285727006,116.185304965541
16617,1058:1011,Breast,EFM-19,SIDM01056,906851,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.764177923775685,0.096896502014408,0.41061012179641,7.97721646326752,4.9217,0.777881703027399,0.759738479201232,0.0709704292705589,0.313779190355661,0.19723712261925,0.116542067736411,6.01224824082892,1.2607,1.9649682224386,3.661,0.594440024762571,0.484362861338813,0.580575373648493,0.4887252842867,0.110077163423758,0.0918500893617938,True,0.647027768334058,0.0579605854386392,0.418780285727006,116.185304965541
16617,1561:1011,Breast,EFM-19,SIDM01056,906851,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.403197380091611,0.096896502014408,0.41061012179641,7.97721646326752,4.9217,0.777881703027399,0.759738479201232,0.0684620051958192,0.16555692534741,0.0697298116446063,0.0958271137028035,4.5717256941548,0.4645,3.40549076911272,4.4572,0.313639864681848,0.204226812075274,0.306324564368722,0.217895388596487,0.109413052606574,0.0884291757722345,True,0.647027768334058,0.0579605854386392,0.418780285727006,116.185304965541
16618,1011:1021,Breast,EFM-19,SIDM01056,906851,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.707933812535766,0.0620772839059721,0.778982652794804,12.5647292831335,118.3288,0.916038341359149,0.931657068460433,0.0925899347445853,0.55146815929225,0.237852310856985,0.313615848435265,7.07223782464582,2.6284,5.49249145848768,115.7004,0.648494515427322,0.505531046046075,0.659551540451089,0.50067469615205,0.142963469381247,0.158876844299039,True,0.647027768334058,0.0579605854386392,0.418780285727006,116.185304965541
16618,1073:1022,Breast,EFM-19,SIDM01056,906851,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,10.0,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.798344538712364,0.0716132978894021,0.705913385851251,11.4777518432347,5.5703,0.890229952498534,0.904871896570645,0.0922337738285938,0.5635620963983,0.410885633391632,0.152676463006668,9.16611887955006,1.122,2.31163296368468,4.4483,0.710710220775372,0.575899676688242,0.722399536861474,0.654424414669778,0.13481054408713,0.0679751221916952,True,0.647027768334058,0.0579605854386392,0.418780285727006,116.185304965541
16618,1190:1022,Breast,EFM-19,SIDM01056,906851,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.01,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.859311213586167,0.0716132978894021,0.705913385851251,11.4777518432347,5.5703,0.890229952498534,0.904871896570645,0.0736090090288779,0.606599288282558,0.569583810208034,0.0370154780745239,10.9127909768825,3.7654,0.564960866352264,1.8049,0.764984580852271,0.76600948008411,0.777566567582137,0.762901294004925,-0.001024899231839,0.014665273577212,True,0.647027768334058,0.0579605854386392,0.418780285727006,116.185304965541
16619,1058:1049,Breast,EFM-19,SIDM01056,906851,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.75721648985529,0.0804870067050773,0.760376062613108,12.2675942128794,96.3039,0.879562218028092,0.925073268172652,0.0994053170139978,0.575769293101884,0.393523586610217,0.182245706491667,9.22306990273127,11.6721,3.04452431014812,84.6318,0.666019015344565,0.54498005777841,0.700480732984657,0.622678354559065,0.121038957566155,0.0778023784255919,True,0.647027768334058,0.0579605854386392,0.418780285727006,116.185304965541
16619,1011:1049,Breast,EFM-19,SIDM01056,906851,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.703788014574224,0.0804870067050773,0.760376062613108,12.2675942128794,96.3039,0.879562218028092,0.925073268172652,0.0686659439304855,0.535143559436245,0.333469415785279,0.201674143650966,8.70341011057949,8.1417,3.5641841022999,88.1622,0.619025347120491,0.512541779452222,0.65105547874292,0.561389373880971,0.106483567668269,0.0896661048619488,True,0.647027768334058,0.0579605854386392,0.418780285727006,116.185304965541
16620,1011:1053,Breast,EFM-19,SIDM01056,906851,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.708967617810673,0.094245014389827,0.335328520649177,7.06395794912294,2.6133,0.660622854816191,0.706728920136287,0.0642726959662951,0.237737062468624,0.0642877131075359,0.173449349361088,2.47641152037445,0.1087,4.58754642874848,2.5046,0.468360211650321,0.231945062596597,0.501047918946933,0.278904818872957,0.236415149053724,0.222143100073976,True,0.647027768334058,0.0579605854386392,0.418780285727006,116.185304965541
16621,1011:1058,Breast,EFM-19,SIDM01056,906851,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.690177221934737,0.0668244902753144,0.327367121182287,6.9622713498608,0.9742,0.681491335538312,0.700495262160338,0.069137354680088,0.225941330250363,0.071011813592294,0.154929516658069,2.87217346778795,0.0572,4.09009788207285,0.917,0.470349796734426,0.254007578485853,0.483465874016267,0.290327853468514,0.216342218248573,0.193138020547754,True,0.647027768334058,0.0579605854386392,0.418780285727006,116.185304965541
16621,1022:1073,Breast,EFM-19,SIDM01056,906851,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,20.0,0.980494679077882,0.0699783005312608,0.647555589299181,10.7213501121187,65.949,0.853190173321462,0.881494787341347,0.0678981757159824,0.634924809714989,0.470211994428517,0.164712815286473,8.7685823092356,17.0359,1.95276780288308,48.9131,0.83654842518323,0.781375521460945,0.86430094862308,0.785255072245049,0.0551729037222847,0.0790458763780312,True,0.647027768334058,0.0579605854386392,0.418780285727006,116.185304965541
16907,1011:1083,Breast,EFM-19,SIDM01056,906851,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.602675669106877,0.0487992764083061,0.71944366471202,11.6647550127905,63.412,0.927337612520093,0.910026808060811,0.0944738622967991,0.43359119201502,0.143430758896103,0.290160433118918,5.70696981210236,1.0202,5.95778520068813,62.3918,0.558883816113521,0.372199435463378,0.548451015453245,0.373098392188732,0.186684380650143,0.175352623264513,True,1.08033415175254,0.102687876423374,-0.0884941079295758,-653.448477589067
16907,1011:1179,Breast,EFM-19,SIDM01056,906851,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,10.0,0.602675669106877,0.0809685661497159,0.508523462780707,9.09648530042995,10.6917,0.845671866568354,0.816514672575346,0.0797514325430657,0.306474718187909,0.142253561842706,0.164221156345203,5.67640506895352,0.9988,3.42008023147644,9.6929,0.509665858028944,0.364666771534335,0.492093526629929,0.371851150010886,0.14499908649461,0.120242376619043,True,1.08033415175254,0.102687876423374,-0.0884941079295758,-653.448477589067
16908,1022:1190,Breast,EFM-19,SIDM01056,906851,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.931630793838506,0.0962114130015077,0.868196946643781,14.334327432049,403.4526,0.919248362954993,0.961256914568064,0.167358121024329,0.808839010609913,0.52259828590788,0.286240724702033,9.69333286632557,16.1701,4.64099456572343,387.2825,0.856400082114508,0.659217571216872,0.895536542401799,0.785178129023457,0.197182510897636,0.110358413378342,True,1.08033415175254,0.102687876423374,-0.0884941079295758,-653.448477589067
16908,1011:1190,Breast,EFM-19,SIDM01056,906851,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.561293377740123,0.0962114130015077,0.868196946643781,14.334327432049,403.4526,0.919248362954993,0.961256914568064,0.143944755513453,0.487313196725349,0.165140681340089,0.32217251538526,6.52399185122491,1.7974,7.81033558082409,401.6552,0.515968018625086,0.293588292269695,0.539547140453957,0.377723035103327,0.222379726355391,0.161824105350631,True,1.08033415175254,0.102687876423374,-0.0884941079295758,-653.448477589067
16911,1561:1510,Breast,EFM-19,SIDM01056,906851,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.578372570106931,0.0615947366665234,0.885452413257163,14.7870781410678,552.1844,0.946913595939708,0.966641186505412,0.0612989961711409,0.512121387962929,0.336274372153128,0.175847015809801,9.92979973573787,19.0501,4.85727840532992,533.1343,0.547668850152845,0.43437246353759,0.559078747410348,0.4930233656178,0.113296386615254,0.0660553817925482,True,1.08033415175254,0.102687876423374,-0.0884941079295758,-653.448477589067
16912,1510:1558,Breast,EFM-19,SIDM01056,906851,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.963202306106357,0.0724853059041825,0.748310825466503,12.0833263705208,84.7566,0.915062891494751,0.920720720021554,0.0693617061999017,0.720774712773688,0.729344295386266,-0.0085695826125782,12.218610118688,93.089,-0.135283748167183,-8.33239999999999,0.881390687320096,0.910123968032684,0.886840320804667,0.889938035788811,-0.0287332807125883,-0.0030977149841436,True,1.08033415175254,0.102687876423374,-0.0884941079295758,-653.448477589067
16912,1011:1558,Breast,EFM-19,SIDM01056,906851,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.654835216273866,0.0724853059041825,0.748310825466503,12.0833263705208,84.7566,0.915062891494751,0.920720720021554,0.108534500819467,0.490020281234433,0.192396953799978,0.297623327434455,6.51847292111644,1.7905,5.56485344940433,82.9661,0.599215406456154,0.437500434061739,0.602920351823144,0.44044065346102,0.161714972394415,0.162479698362124,True,1.08033415175254,0.102687876423374,-0.0884941079295758,-653.448477589067
16912,1011:1559,Breast,EFM-19,SIDM01056,906851,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1559,Luminespib,HSP90,Protein stability and degradation,Targeted,Early clinical trials,0.1,0.654835216273866,0.0732614783438656,0.671018241360507,11.0170054212275,0.4047,0.891895083457919,0.891126848747816,0.10932397487046,0.439406375205017,0.177402094519815,0.262004280685201,6.19856531447959,0.0143,4.81844010674788,0.3904,0.584044309869764,0.376243511645124,0.583541242727224,0.4268534647427,0.20780079822464,0.156687777984524,True,1.08033415175254,0.102687876423374,-0.0884941079295758,-653.448477589067
16913,1047:1594,Breast,EFM-19,SIDM01056,906851,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.913254510007692,0.070534139266534,0.602534205868732,10.1772629362946,9.0459,0.835686301924352,0.862040434318125,0.0601240151705035,0.550267080943523,0.349943818822304,0.200323262121218,7.65288855162745,1.5723,2.52437438466711,7.4736,0.763194284184064,0.648564491318987,0.787262314450017,0.67722844453515,0.114629792865077,0.110033869914868,True,1.08033415175254,0.102687876423374,-0.0884941079295758,-653.448477589067
16913,1011:1594,Breast,EFM-19,SIDM01056,906851,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.634658560939523,0.070534139266534,0.602534205868732,10.1772629362946,9.0459,0.835686301924352,0.862040434318125,0.0709328620990405,0.382403492013488,0.0856353218792787,0.296768170134209,3.74226413585981,0.1045,6.43499880043475,8.9414,0.530375465776181,0.281627921632233,0.547101341516023,0.305749617496763,0.248747544143947,0.24135172401926,True,1.08033415175254,0.102687876423374,-0.0884941079295758,-653.448477589067
14997,1558:1011,Breast,EFM-192A,SIDM01002,1290798,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.665719350905509,0.0617032627864713,0.830236986250899,13.8359538725982,285.6059,0.93889991943638,0.945648850478837,0.0359433540688668,0.552704827584695,0.323454264326629,0.229250563258065,8.82778014121776,8.8748,5.00817373138042,276.7311,0.625043844932422,0.50925758331009,0.629536738925312,0.527222386726684,0.115786261622332,0.102314352198628,True,0.643957981346452,0.0614233520202142,0.422623269778819,115.011601888654
14997,1561:1011,Breast,EFM-192A,SIDM01002,1290798,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.739391584128978,0.0617032627864713,0.830236986250899,13.8359538725982,285.6059,0.93889991943638,0.945648850478837,0.027538532054364,0.613870240466521,0.471000480666482,0.142869759800039,10.7134720434732,32.7949,3.12248182912499,252.811,0.694214698770635,0.634639744690871,0.699204801585295,0.642571893021912,0.0595749540797648,0.0566329085633827,True,0.643957981346452,0.0614233520202142,0.422623269778819,115.011601888654
14997,1190:1011,Breast,EFM-192A,SIDM01002,1290798,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.932956308522461,0.0617032627864713,0.830236986250899,13.8359538725982,285.6059,0.93889991943638,0.945648850478837,0.0784966485289218,0.774574833891452,0.511247875477875,0.263326958413577,9.58660109043547,15.017,4.24935278216272,270.5889,0.875952602909401,0.732471130145967,0.882249060701244,0.770654353765806,0.143481472763434,0.111594706935438,True,0.643957981346452,0.0614233520202142,0.422623269778819,115.011601888654
14997,1549:1011,Breast,EFM-192A,SIDM01002,1290798,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.813063817352448,0.0617032627864713,0.830236986250899,13.8359538725982,285.6059,0.93889991943638,0.945648850478837,0.0396895552479749,0.675035653348348,0.520336219350736,0.154699433997612,10.7525264372985,33.6948,3.08342743529964,251.9111,0.763385552608849,0.721120907289089,0.768872864245277,0.70767894401541,0.0422646453197599,0.0611939202298668,True,0.643957981346452,0.0614233520202142,0.422623269778819,115.011601888654
14997,1179:1011,Breast,EFM-192A,SIDM01002,1290798,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.708151646612439,0.0617032627864713,0.830236986250899,13.8359538725982,285.6059,0.93889991943638,0.945648850478837,0.0975807417588288,0.587933688892123,0.354038456916471,0.233895231975652,8.99935696313156,9.9955,4.83659690946663,275.6104,0.664883523953159,0.493051788641028,0.669662790583748,0.5665364366571,0.171831735312131,0.103126353926648,True,0.643957981346452,0.0614233520202142,0.422623269778819,115.011601888654
15769,1011:1058,Breast,EFM-192A,SIDM01002,1290798,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.953070870575911,0.0961692395498355,0.546119380955805,9.56363855618902,5.912,0.865139013845141,0.82506391792982,0.108843818822283,0.520490473845927,0.317107342947139,0.203383130898787,6.87984118014634,0.9201,2.68379737604267,4.9919,0.824538793094574,0.685547737783351,0.786344386542145,0.654615462517849,0.138991055311223,0.131728924024296,True,0.796727647259104,0.0689359789599768,0.212502747806865,222.535270332721
16406,1558:1083,Breast,EFM-192A,SIDM01002,1290798,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.621195771484076,0.0639229852917855,0.84933022525992,14.2687283191252,385.5185,0.941017473956437,0.952268466769318,0.0524325580740061,0.527600344525081,0.284111387503635,0.243488957021445,8.47912547977878,6.9695,5.78960283934641,378.549,0.584556075714366,0.45496956976429,0.591545144874725,0.481392021683132,0.129586505950076,0.110153123191593,True,0.945435144312692,0.0867886654970215,0.0432645969770826,900.624555956825
16407,1011:1190,Breast,EFM-192A,SIDM01002,1290798,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.93227713924681,0.099517813657064,0.813472201101855,13.4868812754563,224.2259,0.888617940731348,0.939715501073403,0.148400522219566,0.758381536500043,0.425929792516587,0.332451743983456,8.47308875453424,6.9404,5.01379252092209,217.2855,0.828438191668413,0.622448098936434,0.876075279046594,0.722181195717093,0.205990092731978,0.153894083329502,True,0.945435144312692,0.0867886654970215,0.0432645969770826,900.624555956825
16408,1011:1558,Breast,EFM-192A,SIDM01002,1290798,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.930919442786355,0.0774371372615827,0.335247689721939,6.91443882212869,2.356,0.651072616738462,0.688911958831582,0.0550556426279461,0.31208859251136,0.140422558516472,0.171666033994888,3.73539069287257,0.2601,3.17904812925612,2.0959,0.606096157587622,0.431071224225933,0.641321536844352,0.448828690690068,0.175024933361689,0.192492846154285,True,0.945435144312692,0.0867886654970215,0.0432645969770826,900.624555956825
16409,1012:1561,Breast,EFM-192A,SIDM01002,1290798,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.824147556114564,0.115878967452573,0.37583855606919,7.45459420711525,3.426,0.658871547344697,0.720283206510289,0.12701317012253,0.30974642747805,0.132498972387555,0.177247455090495,3.96541941948248,0.3051,3.48917478763277,3.1209,0.543007375537554,0.365271873914981,0.593619644355817,0.410148980167667,0.177735501622573,0.18347066418815,True,0.945435144312692,0.0867886654970215,0.0432645969770826,900.624555956825
16409,1561:1594,Breast,EFM-192A,SIDM01002,1290798,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.760238336652168,0.0840928632122752,0.551913136548355,9.63493045591574,6.2115,0.842872628261471,0.828065781586305,0.0454919596469066,0.419585524906003,0.263511142063649,0.156074382842354,7.06859740588244,1.0487,2.5663330500333,5.1628,0.640784084919142,0.522352654549086,0.629527352431751,0.530668426171068,0.118431430370056,0.0988589262606826,True,0.945435144312692,0.0867886654970215,0.0432645969770826,900.624555956825
16409,1053:1594,Breast,EFM-192A,SIDM01002,1290798,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.944968857354382,0.0840928632122752,0.551913136548355,9.63493045591574,6.2115,0.842872628261471,0.828065781586305,0.0567124066026318,0.521540726002972,0.299436422040247,0.222104303962725,6.65965306169617,0.7899,2.97527739421957,5.4216,0.796488384423527,0.605264337181867,0.782496375439874,0.636507790017091,0.19122404724166,0.145988585422783,True,0.945435144312692,0.0867886654970215,0.0432645969770826,900.624555956825
14605,1559:1012,Breast,HCC1419,SIDM00882,907045,1559,Luminespib,HSP90,Protein stability and degradation,Targeted,Early clinical trials,0.01,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,5.0,0.961333999165722,0.119159694793832,0.629968436490859,10.9243031469858,18.9777,0.849305061188255,0.846019814101104,0.190484113064477,0.605610076399935,0.384296905587382,0.221313170812553,7.52990143644951,1.8048,3.39440171053633,17.1729,0.816465830983794,0.691502295140376,0.813307611263256,0.673962868591287,0.124963535843417,0.139344742671969,True,0.86672035535975,0.121566817041664,0.130504748385284,353.002659817512
15032,1012:1558,Breast,HCC1419,SIDM00882,907045,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.959756473556875,0.110868280615993,0.3684124110789,7.05055370994245,2.5892,0.634470626846211,0.675943793376294,0.1043686215467,0.353586196471671,0.188883567049047,0.164702629422624,3.91369942366693,0.2944,3.13685428627552,2.2948,0.60893729139734,0.431771853179729,0.648741431453489,0.474918723870797,0.177165438217611,0.173822707582692,True,0.603681068257239,0.0898369406052483,0.485157943606178,100.41440238462
15032,1011:1558,Breast,HCC1419,SIDM00882,907045,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.866863473232057,0.110868280615993,0.3684124110789,7.05055370994245,2.5892,0.634470626846211,0.675943793376294,0.0966210037755992,0.319363262249652,0.135580608630769,0.183782653618882,2.90525397410862,0.1463,4.14529973583383,2.4429,0.549999411251627,0.345323077214327,0.585950984435826,0.376883608013016,0.204676334037299,0.20906737642281,True,0.603681068257239,0.0898369406052483,0.485157943606178,100.41440238462
15033,1017:1561,Breast,HCC1419,SIDM00882,907045,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.906795905257169,0.155252706557983,0.711029096331478,12.2563028517475,95.5531,0.836334198437052,0.885799513060029,0.0597881764319616,0.64475827307209,0.430103289356045,0.214654983716045,8.62804974872159,7.7274,3.62825310302592,87.8257,0.758384426569256,0.667742591709593,0.803239371321629,0.6843073619082,0.0906418348596628,0.118932009413429,True,0.603681068257239,0.0898369406052483,0.485157943606178,100.41440238462
15033,1049:1561,Breast,HCC1419,SIDM00882,907045,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.906994344922056,0.155252706557983,0.711029096331478,12.2563028517475,95.5531,0.836334198437052,0.885799513060029,0.078383072086568,0.644899369447691,0.738268188892133,-0.0933688194444426,14.338148242279,404.5226,-2.08184539053145,-308.9695,0.758550388447327,0.825195445001554,0.803415149080158,0.844165526465251,-0.066645056554227,-0.0407503773850934,True,0.603681068257239,0.0898369406052483,0.485157943606178,100.41440238462
15033,1012:1561,Breast,HCC1419,SIDM00882,907045,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.987565042510198,0.155252706557983,0.711029096331478,12.2563028517475,95.5531,0.836334198437052,0.885799513060029,0.141434617456566,0.702187479744584,0.423884811583019,0.278302668161565,7.96918926195781,4.8944,4.2871135897897,90.6587,0.825934418232219,0.631464060072612,0.874784633770641,0.714209311009769,0.194470358159608,0.160575322760872,True,0.603681068257239,0.0898369406052483,0.485157943606178,100.41440238462
15033,1011:1561,Breast,HCC1419,SIDM00882,907045,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.875197154644414,0.155252706557983,0.711029096331478,12.2563028517475,95.5531,0.836334198437052,0.885799513060029,0.0564787444076218,0.622290641978699,0.363957260194067,0.258333381784632,7.77108464221879,4.2664,4.48521820952872,91.2867,0.731957310803925,0.60369803239386,0.775249213415545,0.624306484661982,0.128259278410065,0.150942728753563,True,0.603681068257239,0.0898369406052483,0.485157943606178,100.41440238462
15033,1058:1594,Breast,HCC1419,SIDM00882,907045,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.981731505257208,0.117633279941261,0.712707074528197,12.2858892270966,39.0132,0.893250847818746,0.886578453167317,0.0845535351252473,0.699686989084028,0.538690040255131,0.160996948828896,9.70695377051468,6.5294,2.57893545658191,32.4838,0.876932499401374,0.727346153413503,0.870381999356557,0.786567175858016,0.149586345987871,0.0838148234985405,True,0.603681068257239,0.0898369406052483,0.485157943606178,100.41440238462
15033,1053:1594,Breast,HCC1419,SIDM00882,907045,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.817268833261639,0.117633279941261,0.712707074528197,12.2858892270966,39.0132,0.893250847818746,0.886578453167317,0.0878172692002601,0.582473279256975,0.41307934347324,0.169393935783735,9.07868142314042,4.2242,3.20720780395617,34.789,0.730026078206796,0.575082947952002,0.724572938014961,0.633266136273569,0.154943130254794,0.0913068017413921,True,0.603681068257239,0.0898369406052483,0.485157943606178,100.41440238462
15003,1011:1007,Breast,HCC1428,SIDM00881,1290905,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1007,Docetaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.0125,0.628486879046112,0.0890225567136416,0.752627852102403,10.551422270215,0.0366,0.901450334510814,0.960410925480876,0.0577698394000282,0.473016729851018,0.102921399999821,0.370095329851197,6.72655653595434,0.0026,3.82486573426067,0.034,0.566549707351775,0.427576601095354,0.603605665157264,0.470274910896528,0.138973106256421,0.133330754260736,True,0.706080010294335,0.0506859132941628,0.333977805022992,145.111948393998
15004,1012:1011,Breast,HCC1428,SIDM00881,1290905,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.428248446031216,0.100623365867936,0.215302784093326,7.19679847953904,2.8654,0.759684296658316,0.786263288011402,0.0594820889052865,0.0922030827141611,0.0045191897535428,0.0876838929606183,2.66874735601522,0.1242,4.52805112352381,2.7412,0.325333619518241,0.148769080290472,0.336716031262278,0.160631044620665,0.176564539227769,0.176084986641613,True,0.706080010294335,0.0506859132941628,0.333977805022992,145.111948393998
15947,1179:1017,Breast,HCC1428,SIDM00881,1290905,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.802828399692347,0.078748375391225,0.846553448310348,11.3812405172516,52.0985,0.920350592474031,0.97679263359332,0.0469815656123064,0.679637150161035,0.368133323033801,0.311503827127234,8.76826533330325,8.5161,2.61297518394832,43.5824,0.73888359331183,0.707897226378929,0.784196866858998,0.715651025439852,0.0309863669329014,0.0685458414191455,True,0.701959941674579,0.0572411115791267,0.340512448545019,142.625385214841
15947,1022:1017,Breast,HCC1428,SIDM00881,1290905,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.918457233149529,0.078748375391225,0.846553448310348,11.3812405172516,52.0985,0.920350592474031,0.97679263359332,0.0661194894482229,0.777523137848315,0.459428287444225,0.31809485040409,9.00121248589528,10.0084,2.38002803135629,42.0901,0.845302658691229,0.784052939026466,0.897142259610962,0.829845379449537,0.0612497196647627,0.0672968801614248,True,0.701959941674579,0.0572411115791267,0.340512448545019,142.625385214841
15005,1011:1021,Breast,HCC1428,SIDM00881,1290905,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.661797924713124,0.0643216787315546,0.673748472691294,10.0111408218913,20.155,0.91024823332494,0.944990549868034,0.057346674028288,0.445885341005735,0.149047062977435,0.2968382780283,7.27728480250887,3.0298,2.73385601938239,17.1252,0.602400391788233,0.483136525880367,0.625392784776179,0.524486453337308,0.119263865907866,0.100906331438871,True,0.706080010294335,0.0506859132941628,0.333977805022992,145.111948393998
15005,1179:1022,Breast,HCC1428,SIDM00881,1290905,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.927864770983503,0.109443678159469,0.751793922184399,10.5451839315968,2.9184,0.897060048344578,0.960256504082499,0.091193230488851,0.697563095434417,0.355213876335439,0.342349219098979,8.33413622305935,0.6303,2.21104770853741,2.2881,0.832350416315692,0.767915531266955,0.890988181245928,0.80380470794138,0.0644348850487375,0.0871834733045476,True,0.706080010294335,0.0506859132941628,0.333977805022992,145.111948393998
15005,1017:1022,Breast,HCC1428,SIDM00881,1290905,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.888689427545267,0.109443678159469,0.751793922184399,10.5451839315968,2.9184,0.897060048344578,0.960256504082499,0.116774522971639,0.668111310338065,0.464692798747046,0.203418511591019,9.12779041503573,1.0926,1.41739351656104,1.8258,0.797207780837072,0.728625126253256,0.853369802909695,0.808435674429532,0.0685826545838163,0.0449341284801628,True,0.706080010294335,0.0506859132941628,0.333977805022992,145.111948393998
15005,1073:1022,Breast,HCC1428,SIDM00881,1290905,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,2.5,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.994110553564352,0.109443678159469,0.751793922184399,10.5451839315968,2.9184,0.897060048344578,0.960256504082499,0.11430214202112,0.747366272149048,0.492179433062035,0.255186839087013,8.97264416843534,0.9812,1.57253976316142,1.9372,0.891776861240293,0.793398573340927,0.954601124837222,0.89677528165084,0.0983782878993653,0.0578258431863824,True,0.706080010294335,0.0506859132941628,0.333977805022992,145.111948393998
15005,1190:1022,Breast,HCC1428,SIDM00881,1290905,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.982727749339435,0.109443678159469,0.751793922184399,10.5451839315968,2.9184,0.897060048344578,0.960256504082499,0.13525650498734,0.738808749115341,0.439338073280543,0.299470675834798,8.70362790893048,0.8143,1.84155602266629,2.1041,0.881565802331992,0.810335554549133,0.943670713045549,0.872545510074497,0.0712302477828595,0.0711252029710511,True,0.706080010294335,0.0506859132941628,0.333977805022992,145.111948393998
15006,1179:1047,Breast,HCC1428,SIDM00881,1290905,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.666863292221816,0.0400539192949593,0.957750436379683,13.3516477196758,204.1627,0.981105482166671,0.993985737869967,0.0731890995161326,0.638688609131036,0.428502528816638,0.210186080314398,9.81778151710442,17.6269,3.53386620257137,186.5358,0.654263231854538,0.578294797075155,0.662852601577497,0.625778244164958,0.0759684347793828,0.0370743574125393,True,0.706080010294335,0.0506859132941628,0.333977805022992,145.111948393998
15946,1191:1190,Breast,HCC1428,SIDM00881,1290905,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.0025,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.793175796180466,0.0490751244630532,0.937220111586995,12.7692286398525,136.3487,0.962243003225455,0.990966834849207,0.103726844836678,0.74338030820436,0.512230539111462,0.231149769092897,9.83744646040199,17.8688,2.93178217945052,118.4799,0.763227860202433,0.653274924277692,0.786010908219956,0.744863045875019,0.109952935924741,0.0411478623449371,True,0.701959941674579,0.0572411115791267,0.340512448545019,142.625385214841
15946,1022:1190,Breast,HCC1428,SIDM00881,1290905,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.862436101111757,0.0490751244630532,0.937220111586995,12.7692286398525,136.3487,0.962243003225455,0.990966834849207,0.149219773800293,0.808292458920613,0.292023773183813,0.5162686857368,8.06647225644221,5.2358,4.7027563834103,131.1129,0.829873104023829,0.615513580531682,0.854645573378409,0.732393654990853,0.214359523492147,0.122251918387556,True,0.701959941674579,0.0572411115791267,0.340512448545019,142.625385214841
15950,1012:1561,Breast,HCC1428,SIDM00881,1290905,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.43306001620769,0.06143434207488,0.896267994905716,12.0067410271345,80.3747,0.961682081474586,0.984742436025676,0.109634507102756,0.388137832400303,0.120992159328415,0.267145673071888,7.6788936149207,4.0023,4.32784741221379,76.3724,0.416466057790029,0.260554270912161,0.426452575305679,0.356183067165998,0.155911786877868,0.0702695081396816,True,0.701959941674579,0.0572411115791267,0.340512448545019,142.625385214841
15950,1011:1561,Breast,HCC1428,SIDM00881,1290905,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.663729368997412,0.06143434207488,0.896267994905716,12.0067410271345,80.3747,0.961682081474586,0.984742436025676,0.0239724279798911,0.594879390711347,0.295406193664398,0.299473197046949,8.69240098620849,8.0799,3.314340040926,72.2948,0.638296641113245,0.572194752979014,0.653602475688297,0.588900777314888,0.0661018881342312,0.064701698373409,True,0.701959941674579,0.0572411115791267,0.340512448545019,142.625385214841
15950,1011:1594,Breast,HCC1428,SIDM00881,1290905,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.663729368997412,0.0940621688986724,0.615893693974803,9.65833283823001,6.313,0.875481676492579,0.932486963329587,0.0549017117914729,0.408786732871382,0.104666155144123,0.304120577727258,6.66384366969084,0.7921,2.99448916853917,5.5209,0.581082900707216,0.447935406406968,0.61891898376906,0.49316878434508,0.133147494300248,0.125750199423981,True,0.701959941674579,0.0572411115791267,0.340512448545019,142.625385214841
14983,1049:1012,Breast,HCC1500,SIDM00879,1303900,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,5.0,0.92203625823457,0.0860521313780325,0.501125780617992,9.00651630290855,5.0226,0.861650136832173,0.900166419893288,0.101756869496749,0.462056139665891,0.233274350646407,0.228781789019484,7.4332956352497,1.6879,1.57322066765885,3.3347,0.794472668072042,0.749122185558928,0.829986077586816,0.739054328205399,0.0453504825131135,0.0909317493814171,True,0.928903034321778,0.0946339731956178,0.0619903676153645,684.408293042164
14983,1011:1012,Breast,HCC1500,SIDM00879,1303900,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,5.0,0.0752636276274133,0.0860521313780325,0.501125780617992,9.00651630290855,5.0226,0.861650136832173,0.900166419893288,0.0325593820095824,0.0377165441469293,0.0072087476762341,0.0305077964706951,5.75132078356598,0.526,3.25519551934257,4.4966,0.0648509150436463,0.0425639556355384,0.0677497902295502,0.0498183961766978,0.0222869594081079,0.0179313940528524,True,0.928903034321778,0.0946339731956178,0.0619903676153645,684.408293042164
16331,1073:1022,Breast,HCC1500,SIDM00879,1303900,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,10.0,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.814194476376966,0.0770163664907832,0.808291051065761,11.0822392390249,4.2346,0.913022014926337,0.969235981692187,0.0965513536367309,0.658106109082675,0.515206804048245,0.142899305034429,9.78744132966314,1.726,1.29479790936172,2.5086,0.743377481363591,0.677115843152045,0.789146582599585,0.760345077712468,0.066261638211546,0.0288015048871166,True,0.681270234582842,0.0650332885274441,0.37194216851201,131.321668703675
14985,1049:1047,Breast,HCC1500,SIDM00879,1303900,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.919668329401551,0.0756038934642885,0.556292336975645,9.32722097792807,12.5459,0.890015458526258,0.91525053117412,0.0782491716320701,0.511604444205277,0.513670702036403,-0.0020662578311259,9.34039946740915,12.6611,-0.0131784894810849,-0.1152,0.8185190298844,0.82935267317252,0.841726926988786,0.842262372950502,-0.0108336432881204,-0.0005354459617157,True,0.928903034321778,0.0946339731956178,0.0619903676153645,684.408293042164
14985,1594:1047,Breast,HCC1500,SIDM00879,1303900,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.933151643455511,0.0756038934642885,0.556292336975645,9.32722097792807,12.5459,0.890015458526258,0.91525053117412,0.0617686655436321,0.51910510849053,0.39027677863239,0.12882832985814,8.52243714548827,7.1819,0.804783832439798,5.364,0.830519387824588,0.839673486752114,0.85406753733866,0.815629242319638,-0.0091540989275261,0.0384382950190221,True,0.928903034321778,0.0946339731956178,0.0619903676153645,684.408293042164
14985,1012:1049,Breast,HCC1500,SIDM00879,1303900,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.873639084872516,0.113172692681433,0.808476792959345,11.083974429097,42.3974,0.875388861969526,0.969269189716455,0.0602863512182396,0.70631692554167,0.602778045511513,0.103538880030156,10.1575663200107,22.3081,0.926408109086369,20.0893,0.76477392427865,0.797235932687784,0.846791447899009,0.826778617051253,-0.0324620084091336,0.0200128308477555,True,0.928903034321778,0.0946339731956178,0.0619903676153645,684.408293042164
16332,1049:1053,Breast,HCC1500,SIDM00879,1303900,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.942754655695705,0.0510010539671779,0.936773150304059,12.9008592464782,149.3742,0.966516168703433,0.99055838785607,0.0260600030403605,0.883147248779885,0.903769084095054,-0.0206218353151688,13.5486651872873,234.0371,-0.647805940809107,-84.6629,0.911187617850337,0.92686059058375,0.933853531889742,0.936999110919441,-0.0156729727334132,-0.0031455790296994,True,0.681270234582842,0.0650332885274441,0.37194216851201,131.321668703675
17720,1049:1083,Breast,HCC1500,SIDM00879,1303900,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.807618467595629,0.0606313356430803,0.825768754405216,11.2515272426836,47.6187,0.962828839241241,0.97232783895188,0.0887705710863197,0.666906096021092,0.365525541818456,0.301380554202636,8.72479227927285,8.2633,2.52673496341071,39.3554,0.777598351704889,0.706225206520417,0.785269919294887,0.7151123618639,0.0713731451844725,0.0701575574309866,True,0.731969844038953,0.0690028322264646,0.293892972592799,162.461350658444
17720,1012:1083,Breast,HCC1500,SIDM00879,1303900,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.94067997528488,0.0606313356430803,0.825768754405216,11.2515272426836,47.6187,0.962828839241241,0.97232783895188,0.0530956775605944,0.776784131484925,0.633134703030262,0.143649428454664,10.0448660020167,20.6317,1.20666124066684,26.987,0.905713808701021,0.904234301118988,0.914649327514055,0.886852458318008,0.001479507582033,0.0277968691960475,True,0.731969844038953,0.0690028322264646,0.293892972592799,162.461350658444
17720,1558:1083,Breast,HCC1500,SIDM00879,1303900,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.877063989616971,0.0606313356430803,0.825768754405216,11.2515272426836,47.6187,0.962828839241241,0.97232783895188,0.0817300920613156,0.724252038239676,0.621892462430266,0.10235957580941,10.2890869062457,24.4373,0.96244033643789,23.1814,0.844462503063201,0.857747382760349,0.852793733646784,0.833480399444064,-0.0132848796971479,0.0193133342027199,True,0.731969844038953,0.0690028322264646,0.293892972592799,162.461350658444
17721,1047:1190,Breast,HCC1500,SIDM00879,1303900,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.892987809529294,0.106300495328429,0.595345816834888,9.55872406861245,14.7297,0.865499988074469,0.925051617978325,0.120775019335157,0.531636556887815,0.198801090995784,0.332835465892031,7.19054283835676,2.853,2.36818123025569,11.8767,0.77288093849825,0.612997152269257,0.826059818039994,0.699312749226597,0.159883786228994,0.126747068813397,True,0.731969844038953,0.0690028322264646,0.293892972592799,162.461350658444
17725,1049:1558,Breast,HCC1500,SIDM00879,1303900,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.899887487952027,0.0699797116132392,0.807195643012697,11.0720319856403,42.0478,0.947570213431995,0.969039983071222,0.0638080749992855,0.726385259476517,0.676657340012335,0.0497279194641824,10.6047349882136,30.414,0.467296997426686,11.6338,0.852706579023484,0.873346629975705,0.872026956091037,0.862804211889324,-0.0206400509522211,0.0092227442017133,True,0.731969844038953,0.0690028322264646,0.293892972592799,162.461350658444
17725,1047:1558,Breast,HCC1500,SIDM00879,1303900,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.892602278958113,0.0699797116132392,0.807195643012697,11.0720319856403,42.0478,0.947570213431995,0.969039983071222,0.0415661853241033,0.720504670518193,0.666025062503631,0.0544796080145621,10.5602809854867,29.4911,0.511751000153602,12.5567,0.845803331982225,0.846700294150672,0.864967297290904,0.854824801939227,-0.0008969621684474,0.0101424953516767,True,0.731969844038953,0.0690028322264646,0.293892972592799,162.461350658444
17725,1012:1558,Breast,HCC1500,SIDM00879,1303900,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.860972719591448,0.0699797116132392,0.807195643012697,11.0720319856403,42.0478,0.947570213431995,0.969039983071222,0.107319511987617,0.694973428007009,0.430622978734408,0.2643504492726,9.00091847701799,10.0064,2.07111350862229,32.0414,0.815832103662393,0.78696643409588,0.83431698961768,0.774778540277938,0.0288656695665134,0.059538449339742,True,0.731969844038953,0.0690028322264646,0.293892972592799,162.461350658444
17725,1011:1558,Breast,HCC1500,SIDM00879,1303900,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.0339858114364734,0.0699797116132392,0.807195643012697,11.0720319856403,42.0478,0.947570213431995,0.969039983071222,0.0248534158385541,0.0274331989157724,0.0251573400026444,0.002275858913128,10.5153154689875,28.5861,0.556716516652809,13.4617,0.0322039425965186,0.0072375623197468,0.0329336101390619,0.0325082440993299,0.0249663802767718,0.000425366039732,True,0.731969844038953,0.0690028322264646,0.293892972592799,162.461350658444
17726,1012:1594,Breast,HCC1500,SIDM00879,1303900,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.951917011608893,0.0831216367498525,0.708154374597486,10.2827284020407,9.7319,0.902558265972375,0.950122378826826,0.0520218254216149,0.674104196024603,0.552588145222968,0.121516050801635,9.47004535925499,5.5406,0.812683042785705,4.1913,0.859160567347328,0.840658240226379,0.904437655515564,0.877099842764291,0.0185023271209487,0.0273378127512737,True,0.731969844038953,0.0690028322264646,0.293892972592799,162.461350658444
17726,1047:1594,Breast,HCC1500,SIDM00879,1303900,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.825727911674997,0.0831216367498525,0.708154374597486,10.2827284020407,9.7319,0.902558265972375,0.950122378826826,0.0542589094420358,0.584742832879896,0.15336733472316,0.431375498156736,6.86130372736218,0.9083,3.42142467467851,8.8236,0.745267552126376,0.612037195588389,0.784542567704355,0.625099785658156,0.133230356537988,0.159442782046199,True,0.731969844038953,0.0690028322264646,0.293892972592799,162.461350658444
17726,1021:1594,Breast,HCC1500,SIDM00879,1303900,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.867556035116611,0.0831216367498525,0.708154374597486,10.2827284020407,9.7319,0.902558265972375,0.950122378826826,0.077129277019786,0.614363601476278,0.676660534469742,-0.0622969329934636,10.8311737389701,14.2331,-0.548445336929452,-4.5012,0.783019870688717,0.796957980029457,0.824284403850563,0.836393197534784,-0.0139381093407397,-0.0121087936842209,True,0.731969844038953,0.0690028322264646,0.293892972592799,162.461350658444
14682,1179:1005,Breast,HCC1569,SIDM00878,907046,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.3695968726529,0.0601958361357609,0.936400361998377,14.1763541174208,144.6431,0.958448032504057,0.987424804273819,0.0838699615202648,0.346090645345643,0.192617154854967,0.153473490490676,9.16296318224533,4.4783,5.0133909351755,140.1648,0.354239395413824,0.257109193276373,0.364949119639505,0.323598000827483,0.0971302021374512,0.041351118812022,True,0.640511972123213,0.0730772870264483,0.428405641961098,113.584058514122
14682,1011:1005,Breast,HCC1569,SIDM00878,907046,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.168016201682522,0.0601958361357609,0.936400361998377,14.1763541174208,144.6431,0.958448032504057,0.987424804273819,0.0627191883389554,0.157330432077106,0.100129174820865,0.0572012572562406,9.74796919580006,6.7177,4.42838492162077,137.9254,0.161034797931418,0.0884784112157132,0.165903365061195,0.151399295830159,0.0725563867157047,0.0145040692310358,True,0.640511972123213,0.0730772870264483,0.428405641961098,113.584058514122
14683,1191:1012,Breast,HCC1569,SIDM00878,907046,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.000625,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,5.0,0.928692008681588,0.0822619274346667,0.416804056567561,8.35348005425096,3.1941,0.834780063059062,0.833048467103667,0.0903576656261521,0.387082596520362,0.426119826817217,-0.0390372302968552,8.68238866552713,4.012,-0.328908611276168,-0.817899999999999,0.775253573569663,0.832874475244041,0.773645454243623,0.790603608357819,-0.0576209016743777,-0.0169581541141959,True,0.640511972123213,0.0730772870264483,0.428405641961098,113.584058514122
18180,1011:1017,Breast,HCC1569,SIDM00878,907046,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.433210906568614,0.0461242013833081,0.937678484015973,14.218052826055,372.212,0.980976810595301,0.987685781558605,0.0503889829473868,0.406212546130443,0.251256318389649,0.154956227740794,9.62113213233308,15.3808,4.59692069372188,356.8312,0.424969853440778,0.354368159401634,0.427876252833934,0.38812341878731,0.070601694039144,0.0397528340466238,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
18180,1058:1017,Breast,HCC1569,SIDM00878,907046,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.756595142365289,0.0461242013833081,0.937678484015973,14.218052826055,372.212,0.980976810595301,0.987685781558605,0.185806857397047,0.709442986106933,0.417485460627369,0.291957525479564,9.4001952394601,13.1969,4.81785758659485,359.0151,0.742202289669399,0.521129646178874,0.747278264510504,0.670665451439398,0.221072643490525,0.0766128130711063,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
18180,1073:1017,Breast,HCC1569,SIDM00878,907046,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,2.5,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.982442888618746,0.0461242013833081,0.937678484015973,14.218052826055,372.212,0.980976810595301,0.987685781558605,0.029033051889522,0.921215558432299,0.885800369073525,0.0354151893587735,13.2641187831604,192.1444,0.953934042894604,180.0676,0.963753691469252,0.972192587825863,0.9703448722821,0.962976704488364,-0.0084388963566113,0.0073681677937359,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
18177,1191:1179,Breast,HCC1569,SIDM00878,907046,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.000625,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,10.0,0.914145021169113,0.0797604267730647,0.386311665174844,8.10916694763854,5.393,0.795672587424824,0.818626487101027,0.0327870509761032,0.353144885339133,0.449824680100284,-0.0966797947611507,8.93895470510269,9.5857,-0.829787757464148,-4.1927,0.727360134275149,0.789378683596885,0.748343327380565,0.790380039277918,-0.0620185493217363,-0.0420367118973523,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
18178,1191:1190,Breast,HCC1569,SIDM00878,907046,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.0025,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.866065830779894,0.129554041144695,0.753080820086602,11.1462541930026,44.2677,0.861706859808828,0.945768199391389,0.190959288034554,0.652217566092707,0.453282150771508,0.198935415321199,9.18013472221614,11.3299,1.96611947078643,32.9378,0.746294867429066,0.654274393104573,0.819097521331107,0.758980952628954,0.0920204743244935,0.0601165687021528,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
18178,1011:1190,Breast,HCC1569,SIDM00878,907046,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.196548228639588,0.129554041144695,0.753080820086602,11.1462541930026,44.2677,0.861706859808828,0.945768199391389,0.0548237813195959,0.14801670121047,0.0420024980106938,0.106014203199776,6.49257700986298,1.7587,4.65367718313959,42.509,0.169366956902007,0.092983628345073,0.18588906429403,0.138933837055144,0.076383328556934,0.0469552272388862,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
18179,1073:1372,Breast,HCC1569,SIDM00878,907046,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,10.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.982278332475318,0.0758447073979869,0.709859484864756,10.7220316695512,3.299,0.903787784529018,0.934478212916721,0.146375954611683,0.697279591084741,0.300886639514718,0.396392951570023,7.42674366965062,0.336,3.29528799990061,2.963,0.887771157898726,0.644467035670216,0.917917700718352,0.760952321565915,0.24330412222851,0.156965379152436,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
18179,1058:1372,Breast,HCC1569,SIDM00878,907046,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.881164084821352,0.0758447073979869,0.709859484864756,10.7220316695512,3.299,0.903787784529018,0.934478212916721,0.160512047354421,0.625502683332609,0.488637061421664,0.136865621910945,9.42153727662389,1.3394,1.30049439292734,1.9596,0.79638533602723,0.650632553053297,0.823428639270255,0.781918505178179,0.145752782973933,0.0415101340920763,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
18179,1558:1372,Breast,HCC1569,SIDM00878,907046,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.821043156064759,0.0758447073979869,0.709859484864756,10.7220316695512,3.299,0.903787784529018,0.934478212916721,0.131306600718814,0.582825271815863,0.218465902292536,0.364359369523328,7.047227247665,0.2583,3.67480442188623,3.0407,0.742048775022481,0.539934319042341,0.7672469412069,0.614221963794329,0.20211445598014,0.153024977412571,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
18179,1549:1372,Breast,HCC1569,SIDM00878,907046,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.868322304700743,0.0758447073979869,0.709859484864756,10.7220316695512,3.299,0.903787784529018,0.934478212916721,0.126824501237377,0.616386823911447,0.547961540798604,0.0684252831128433,10.0330964652931,2.0464,0.688935204258085,1.2526,0.784779092022616,0.730503528896083,0.811428275532479,0.791925079468796,0.0542755631265327,0.0195031960636821,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
18181,1058:1510,Breast,HCC1569,SIDM00878,907046,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.882589568066454,0.0599195673866629,0.852761469080963,12.380591642204,104.1501,0.963000416731013,0.969528318400752,0.122012839461375,0.752638376659881,0.64693688829708,0.105701488362801,10.9437339588347,38.47,1.43685768336934,65.6801,0.849934121850439,0.750818197409439,0.855695579765514,0.830167887312295,0.0991159244410009,0.0255276924532192,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
18181,1191:1510,Breast,HCC1569,SIDM00878,907046,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.0025,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.919698960345367,0.0599195673866629,0.852761469080963,12.380591642204,104.1501,0.963000416731013,0.969528318400752,0.166861158475898,0.784283836536349,0.483588370894309,0.30069546564204,9.19889498174462,11.4782,3.1816966604594,92.6719,0.885670482079668,0.699885379570558,0.891674186458563,0.806794234898986,0.18578510250911,0.0848799515595769,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
18181,1049:1510,Breast,HCC1569,SIDM00878,907046,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.852144767852889,0.0599195673866629,0.852761469080963,12.380591642204,104.1501,0.963000416731013,0.969528318400752,0.0905606927167299,0.726676224103885,0.661828745348051,0.0648474787558342,11.3987927968746,52.7362,0.98179884532939,51.4139,0.820615766557484,0.763255033947669,0.82617848381041,0.81095185616569,0.057360732609815,0.0152266276447199,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
18181,1558:1510,Breast,HCC1569,SIDM00878,907046,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.938991200534533,0.0599195673866629,0.852761469080963,12.380591642204,104.1501,0.963000416731013,0.969528318400752,0.173462287069655,0.800735515621926,0.545949348722764,0.254786166899162,9.63247561231737,15.5022,2.74811602988665,88.6479,0.90424891742151,0.701799238088438,0.910378559647349,0.841705753965847,0.202449679333071,0.0686728056815019,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
18181,1179:1510,Breast,HCC1569,SIDM00878,907046,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.382108193304211,0.0599195673866629,0.852761469080963,12.380591642204,104.1501,0.963000416731013,0.969528318400752,0.0554453488085012,0.325847144269972,0.234768402648829,0.0910787416211429,9.89663669852504,18.6172,2.48395494367897,85.5329,0.36797034938829,0.313610341758232,0.370464714101381,0.34653973084227,0.0543600076300576,0.023924983259111,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
18181,1011:1510,Breast,HCC1569,SIDM00878,907046,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.218465917689029,0.0599195673866629,0.852761469080963,12.380591642204,104.1501,0.963000416731013,0.969528318400752,0.057754210901244,0.186299316912617,0.0674425425314286,0.118856774381188,7.4483871424917,3.4113,4.93220449971232,100.7388,0.210382769776058,0.118514730316056,0.211808893804921,0.169562993318785,0.0918680394600018,0.0422459004861364,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
18181,1053:1510,Breast,HCC1569,SIDM00878,907046,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.745570273498158,0.0599195673866629,0.852761469080963,12.380591642204,104.1501,0.963000416731013,0.969528318400752,0.114959909257684,0.635793601731385,0.274430728115614,0.36136287361577,7.95978581061764,4.8626,4.42080583158637,99.2875,0.717984484080982,0.516971816722166,0.722851493514258,0.60350784422032,0.201012667358815,0.119343649293937,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
18181,1049:1549,Breast,HCC1569,SIDM00878,907046,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.67895974005918,0.0823234690284153,0.756499525411164,11.1818063473701,22.6861,0.906538951933143,0.946633575612912,0.100952749770686,0.513632721128058,0.281921097987862,0.231711623140196,8.3409707183976,3.1665,2.8408356289725,19.5196,0.615503451158049,0.504606934186765,0.642726086429436,0.565116927249244,0.110896516971283,0.0776091591801912,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
18181,1058:1549,Breast,HCC1569,SIDM00878,907046,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.882589568066454,0.0823234690284153,0.756499525411164,11.1818063473701,22.6861,0.906538951933143,0.946633575612912,0.192311441160356,0.667678589375117,0.250406351898091,0.417272237477026,7.21754712539386,1.4534,3.96425922197623,21.2327,0.800101822022088,0.521719601335091,0.835488918617403,0.670948871545734,0.278382220686997,0.164540047071669,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
18181,1559:1549,Breast,HCC1569,SIDM00878,907046,1559,Luminespib,HSP90,Protein stability and degradation,Targeted,Early clinical trials,0.01,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.972556283907897,0.0823234690284153,0.756499525411164,11.1818063473701,22.6861,0.906538951933143,0.946633575612912,0.15959765082322,0.73573836721197,0.490036305657043,0.245702061554927,9.02975037598493,5.1042,2.15205597138516,17.5819,0.881660154309857,0.743193432257153,0.920654432520539,0.845267156445766,0.138466722052704,0.0753872760747732,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
18181,1021:1549,Breast,HCC1569,SIDM00878,907046,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.859063278703028,0.0823234690284153,0.756499525411164,11.1818063473701,22.6861,0.906538951933143,0.946633575612912,0.0750989683963563,0.649880962636999,0.465074758507047,0.184806204129952,9.31926216158349,6.2385,1.8625441857866,16.4476,0.778774324319692,0.706000352320074,0.813218143196399,0.758375242341108,0.0727739719996178,0.054842900855291,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
18181,1510:1549,Breast,HCC1569,SIDM00878,907046,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.831207332603343,0.0823234690284153,0.756499525411164,11.1818063473701,22.6861,0.906538951933143,0.946633575612912,0.161370402888326,0.628807952632709,0.422205472027214,0.206602480605494,9.06115229620423,5.2165,2.12065405116586,17.4696,0.753521824137378,0.601656369970224,0.786848769337974,0.72369371323152,0.151865454167154,0.0631550561064531,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
18182,1021:1558,Breast,HCC1569,SIDM00878,907046,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.877492633761309,0.118955079744646,0.613365124785611,9.88820946951783,18.5088,0.869399671650138,0.906592743999859,0.106022730096683,0.53822337880546,0.281011060342441,0.257212318463019,7.55136681346745,3.6637,2.33684265605038,14.8451,0.762891807667497,0.627747358851973,0.795528454681328,0.687155566481436,0.135144448815523,0.108372888199892,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
18182,1191:1558,Breast,HCC1569,SIDM00878,907046,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.0025,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.879054704681227,0.118955079744646,0.613365124785611,9.88820946951783,18.5088,0.869399671650138,0.906592743999859,0.160862752342233,0.53918149863018,0.179699040189096,0.359482458441084,6.38457245799409,1.6318,3.50363701152374,16.877,0.764249871612368,0.547461032904099,0.79694461684294,0.614061907696472,0.21678883870827,0.182882709146468,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
18182,1049:1558,Breast,HCC1569,SIDM00878,907046,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.824252744265171,0.118955079744646,0.613365124785611,9.88820946951783,18.5088,0.869399671650138,0.906592743999859,0.0839266163238249,0.505567887341089,0.193077003374827,0.312490883966262,6.72020292193665,2.0593,3.16800654758118,16.4495,0.716605065220865,0.557365414489958,0.747261557172775,0.596846740492129,0.159239650730907,0.150414816680646,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
18182,1372:1558,Breast,HCC1569,SIDM00878,907046,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.810115089632504,0.118955079744646,0.613365124785611,9.88820946951783,18.5088,0.869399671650138,0.906592743999859,0.0814165422630242,0.496896343043148,0.41041559982114,0.0864807432220077,9.05092237383982,10.3593,0.837287095678017,8.1495,0.704313792925322,0.723625933132411,0.734444462065624,0.704925771788051,-0.0193121402070895,0.0295186902775727,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
18182,1007:1558,Breast,HCC1569,SIDM00878,907046,1007,Docetaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.001,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.892125076815418,0.118955079744646,0.613365124785611,9.88820946951783,18.5088,0.869399671650138,0.906592743999859,0.101962899738897,0.547198409065262,0.531045364765587,0.016153044299675,9.7424502374475,16.7301,0.145759232070336,1.7787,0.775613248854178,0.776499108106923,0.808794121381175,0.803696094104388,-0.0008858592527449,0.0050980272767868,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
18182,1510:1558,Breast,HCC1569,SIDM00878,907046,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.90840113491718,0.118955079744646,0.613365124785611,9.88820946951783,18.5088,0.869399671650138,0.906592743999859,0.0313202128824702,0.557181575473867,0.330888984877487,0.22629259059638,7.92804539770908,4.7567,1.96016407180875,13.7521,0.789763648423609,0.733059409083263,0.823549877557153,0.733512450405717,0.0567042393403465,0.0900374271514361,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
18182,1083:1558,Breast,HCC1569,SIDM00878,907046,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.771731772515155,0.118955079744646,0.613365124785611,9.88820946951783,18.5088,0.869399671650138,0.906592743999859,0.0688851563695566,0.473353354949779,0.133849372482977,0.339503982466803,5.99469984134265,1.2454,3.89350962817518,17.2634,0.670943349626655,0.499605686596172,0.69964642527639,0.515381047600814,0.171337663030483,0.184265377675576,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
18182,1012:1558,Breast,HCC1569,SIDM00878,907046,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.870743569898795,0.118955079744646,0.613365124785611,9.88820946951783,18.5088,0.869399671650138,0.906592743999859,0.172130203031831,0.534083738407243,0.264827571674111,0.269256166733132,7.40699878606209,3.3148,2.48121068345574,15.194,0.757024173761482,0.618624761696248,0.789409802354782,0.673375373394187,0.138399412065234,0.116034428960595,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
18182,1011:1558,Breast,HCC1569,SIDM00878,907046,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.205847918998073,0.118955079744646,0.613365124785611,9.88820946951783,18.5088,0.869399671650138,0.906592743999859,0.0578627677597703,0.126259934523112,0.0466720141357899,0.0795879203873217,6.63865351272731,1.9461,3.24955595679052,16.5627,0.178964113186789,0.0981004143644054,0.186620229731124,0.147794516849695,0.0808636988223837,0.0388257128814288,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
18182,1073:1559,Breast,HCC1569,SIDM00878,907046,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,10.0,1559,Luminespib,HSP90,Protein stability and degradation,Targeted,Early clinical trials,0.1,0.962423979109349,0.065632018481271,0.518395911541865,9.14169034221834,0.1103,0.872252487341652,0.874532385352977,0.180397155501558,0.49891665594014,0.188946466613077,0.309970189327063,6.28726565409758,0.0153,2.85442468812075,0.095,0.83947670965538,0.562317605282888,0.841670938171403,0.665013274213465,0.277159104372492,0.176657663957939,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
18182,1058:1559,Breast,HCC1569,SIDM00878,907046,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1559,Luminespib,HSP90,Protein stability and degradation,Targeted,Early clinical trials,0.1,0.927274527962384,0.065632018481271,0.518395911541865,9.14169034221834,0.1103,0.872252487341652,0.874532385352977,0.173331962070244,0.480695324172612,0.0892460015949941,0.391449322577618,4.68933675738224,0.005,4.4523535848361,0.1053,0.808817513463745,0.457721252225971,0.810931604815999,0.518548912957643,0.351096261237774,0.292382691858356,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
18183,1073:1594,Breast,HCC1569,SIDM00878,907046,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,10.0,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.960859201763385,0.0762985885087926,0.647323548004228,10.168860549126,8.9934,0.881319278393362,0.916873235273433,0.18945364956862,0.621986787617985,0.309766096481937,0.312220691136047,7.57026573354764,1.4848,2.59859481557832,7.5086,0.846823738335728,0.628807797776538,0.880986084963043,0.753650513141388,0.21801594055919,0.127335571821655,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
18183,1083:1594,Breast,HCC1569,SIDM00878,907046,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.811745331350179,0.0762985885087926,0.647323548004228,10.168860549126,8.9934,0.881319278393362,0.916873235273433,0.0931498459027446,0.525461867965465,0.271219695346967,0.254242172618499,7.67270260667573,1.5941,2.49615794245023,7.3993,0.71540680966472,0.600963815977019,0.744267568173143,0.642185618100191,0.114442993687701,0.102081950072953,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
18183,1007:1594,Breast,HCC1569,SIDM00878,907046,1007,Docetaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.001,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.847200786413882,0.0762985885087926,0.647323548004228,10.168860549126,8.9934,0.881319278393362,0.916873235273433,0.0348960888448482,0.548413018933406,0.548554489858542,-0.0001414709251356,10.1702685167446,9.0021,-0.0014079676186238,-0.008700000000001,0.746654385736571,0.765555800065673,0.776775725965493,0.776817425484539,-0.0189014143291018,-4.16995190466452e-05,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
18183,1058:1594,Breast,HCC1569,SIDM00878,907046,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.846700754916501,0.0762985885087926,0.647323548004228,10.168860549126,8.9934,0.881319278393362,0.916873235273433,0.151778008405119,0.548089336770407,0.247462549034223,0.300626787736184,7.29779612588113,1.2293,2.87106442324484,7.7641,0.746213698338125,0.53555183250076,0.77631726046875,0.648412143433472,0.210661865837365,0.127905117035278,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
18183,1559:1594,Breast,HCC1569,SIDM00878,907046,1559,Luminespib,HSP90,Protein stability and degradation,Targeted,Early clinical trials,0.01,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.925382995483555,0.0762985885087926,0.647323548004228,10.168860549126,8.9934,0.881319278393362,0.916873235273433,0.175262155886641,0.599022203899195,0.218024324321775,0.38099787957742,6.73476140356574,0.8321,3.43409914556022,8.1613,0.815557873817054,0.596023470197528,0.848458900936027,0.671082653094007,0.219534403619526,0.17737624784202,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
18183,1191:1594,Breast,HCC1569,SIDM00878,907046,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.000625,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.935943362181988,0.0762985885087926,0.647323548004228,10.168860549126,8.9934,0.881319278393362,0.916873235273433,0.0808220894645031,0.60585817793865,0.509342861792033,0.0965153161466173,9.34119799375575,5.0672,0.827662555370217,3.9262,0.824864928575286,0.803338176367264,0.858141418516493,0.827173608173601,0.021526752208022,0.0309678103428919,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
18028,1558:1011,Breast,HCC202,SIDM00870,1290906,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.687053320348345,0.146157026096771,0.445777857580214,8.53610678843586,7.2503,0.835370205371996,0.83028430094151,0.0722644193268318,0.306273157188258,0.123797819728095,0.182475337460163,5.77219899980818,1.0674,2.76390778862768,6.1829,0.573943873320909,0.406396395629703,0.570449585794969,0.442176051250532,0.167547477691206,0.128273534544437,True,1.01237943559951,0.0809399617114915,-0.022305328138984,-4097.33970093886
18028,1561:1011,Breast,HCC202,SIDM00870,1290906,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.550087249057207,0.146157026096771,0.445777857580214,8.53610678843586,7.2503,0.835370205371996,0.83028430094151,0.0303216724476533,0.245216715366915,0.148804493967047,0.0964122213998688,6.88652912998137,2.3109,1.64957765845449,4.9394,0.459526498217436,0.402538442497025,0.456728807040301,0.399721026490448,0.0569880557204104,0.0570077805498531,True,1.01237943559951,0.0809399617114915,-0.022305328138984,-4097.33970093886
16634,1549:1053,Breast,HCC202,SIDM00870,1290906,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.736076996646645,0.141466819167187,0.368127411402573,7.84900907433733,4.5032,0.707773660378433,0.790419586015972,0.143753917492681,0.270970119368509,0.110142403532056,0.160827715836454,5.29841340163512,0.7686,2.5505956727022,3.7346,0.520975910236959,0.384513765369546,0.581809674965321,0.446143947240155,0.136462144867414,0.135665727725166,True,0.94997128976248,0.102918455811318,0.0405457633931613,982.663432579057
16634,1372:1053,Breast,HCC202,SIDM00870,1290906,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.928010916797391,0.141466819167187,0.368127411402573,7.84900907433733,4.5032,0.707773660378433,0.790419586015972,0.109914338127141,0.341626256553952,0.13496491908187,0.206661337472081,5.22726815003846,0.7316,2.62174092429886,3.7716,0.656821683452835,0.502611682397139,0.733518004673297,0.557180386880494,0.154210001055696,0.176337617792803,True,0.94997128976248,0.102918455811318,0.0405457633931613,982.663432579057
15783,1022:1005,Breast,HCC2157,SIDM00774,749715,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.97285680542331,0.0729935734943708,0.960448813505259,13.7074061437947,104.5034,0.960962947085961,0.994051538262611,0.0277564796709015,0.934379164479334,0.813696251868915,0.120682912610419,11.4079687336424,21.2291,2.29943741015234,83.2743,0.934879342832217,0.948748561672655,0.967069803940291,0.947239925812901,-0.0138692188404382,0.0198298781273901,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
15783,1179:1005,Breast,HCC2157,SIDM00774,749715,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.372611960368959,0.0729935734943708,0.960448813505259,13.7074061437947,104.5034,0.960962947085961,0.994051538262611,0.0592981082039308,0.357874715234235,0.0872808010473349,0.2705939141869,7.25192559033699,1.1908,6.45548055345775,103.3126,0.358066287555632,0.249630168873808,0.370395492379811,0.29300548407959,0.108436118681825,0.077390008300221,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
15783,1012:1005,Breast,HCC2157,SIDM00774,749715,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.0926121845976388,0.0729935734943708,0.960448813505259,13.7074061437947,104.5034,0.960962947085961,0.994051538262611,0.0367508105090919,0.0889492628129323,0.0556856546345251,0.0332636081784071,9.60623336616689,6.0891,4.10117277762786,98.4143,0.0889968778470161,0.0567777299501894,0.0920612845611438,0.0856699415328124,0.0322191478968267,0.0063913430283313,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
15783,1011:1005,Breast,HCC2157,SIDM00774,749715,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.363522564025902,0.0729935734943708,0.960448813505259,13.7074061437947,104.5034,0.960962947085961,0.994051538262611,0.0654076498036148,0.349144815301067,0.212690090411908,0.136454724889159,9.50717116637329,5.685,4.20023497742145,98.8184,0.349331714458575,0.282452163353275,0.361360163963116,0.334810640459957,0.0668795511053002,0.0265495235031591,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
15784,1021:1011,Breast,HCC2157,SIDM00774,749715,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.961391056510819,0.123369351392127,0.051242962908539,4.69286671162332,0.5052,0.535714277606743,0.56460802992338,0.077575411107643,0.0492645262493852,0.0316773101405844,0.0175872161088008,4.01297884466114,0.3153,0.679887866962185,0.1899,0.515030915336277,0.47782608402635,0.542809110402531,0.481861771310248,0.037204831309927,0.0609473390922827,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
15784,1549:1011,Breast,HCC2157,SIDM00774,749715,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.611020230173747,0.123369351392127,0.051242962908539,4.69286671162332,0.5052,0.535714277606743,0.56460802992338,0.0385098100591643,0.0313104869911603,0.0040286710701236,0.0272818159210367,1.59891731931347,0.0592,3.09394939230985,0.446,0.327332261210634,0.174721306511866,0.344986928401729,0.172503382994927,0.152610954698769,0.172483545406803,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
15784,1558:1011,Breast,HCC2157,SIDM00774,749715,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.643752662504369,0.123369351392127,0.051242962908539,4.69286671162332,0.5052,0.535714277606743,0.56460802992338,0.0556384711797882,0.0329877938069847,0.0046627655876531,0.0283250282193316,1.73858668846704,0.0652,2.95428002315628,0.44,0.344867492550945,0.194342852598579,0.363467922534523,0.189406944588021,0.150524639952366,0.174060977946502,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
15784,1007:1011,Breast,HCC2157,SIDM00774,749715,1007,Docetaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.001,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.816070633398838,0.123369351392127,0.051242962908539,4.69286671162332,0.5052,0.535714277606743,0.56460802992338,0.0756161294647626,0.0418178771980047,0.0040008789187301,0.0378169982792745,1.15914808898125,0.0436,3.53371862264207,0.4616,0.437180689847335,0.230050188628569,0.460760032601643,0.20069035395656,0.207130501218766,0.260069678645083,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
15784,1179:1011,Breast,HCC2157,SIDM00774,749715,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.346466091869587,0.123369351392127,0.051242962908539,4.69286671162332,0.5052,0.535714277606743,0.56460802992338,0.0565332096290076,0.0177539490947397,0.0008322087286027,0.0169217403661369,0.102529219616167,0.021,4.59033749200716,0.4842,0.185606832121147,0.0591246441156108,0.19561753756574,0.0579045560735057,0.126482188005536,0.137712981492235,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
15054,1011:1017,Breast,HCC2157,SIDM00774,749715,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.48552177800064,0.0734963492323673,0.899129066394672,12.2283634986389,93.7204,0.940095158135039,0.984327256385051,0.114326541684654,0.436546742967997,0.251947861408922,0.184598881559075,9.11175029483649,10.8054,3.1166132038024,82.915,0.456436672667517,0.33146186251967,0.477912319654562,0.438593878293074,0.124974810147847,0.0393184413614876,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
15054,1022:1017,Breast,HCC2157,SIDM00774,749715,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.936693729031066,0.0734963492323673,0.899129066394672,12.2283634986389,93.7204,0.940095158135039,0.984327256385051,0.0544630678429366,0.842208558081447,0.718835189732605,0.123373368348842,10.7617491702383,33.9109,1.46661432840062,59.8095,0.88058123931756,0.865991007069644,0.922013168370232,0.900147593065504,0.0145902322479156,0.0218655753047277,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
15785,1191:1021,Breast,HCC2157,SIDM00774,749715,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.0025,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.99361517303449,0.052850215706816,0.806800213920662,11.109388159027,43.1508,0.97097338255605,0.9683586747564,0.0609988282916593,0.801648934159042,0.676666219468307,0.124982714690734,10.1192762066998,21.7238,0.990111952327231,21.427,0.964773885520313,0.924843298709311,0.962175872177529,0.937360701751772,0.0399305868110023,0.0248151704257571,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
15785,1549:1021,Breast,HCC2157,SIDM00774,749715,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.557954739004562,0.052850215706816,0.806800213920662,11.109388159027,43.1508,0.97097338255605,0.9683586747564,0.0448951918984791,0.450158002786927,0.364414802274444,0.085743200512483,9.93387793979263,19.104,1.17551021923436,24.0468,0.541759200244437,0.500818267261188,0.54030031163651,0.522928540906932,0.0409409329832493,0.0173717707295786,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
15785,1510:1021,Breast,HCC2157,SIDM00774,749715,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.999094532812314,0.052850215706816,0.806800213920662,11.109388159027,43.1508,0.97097338255605,0.9683586747564,0.0266878018619729,0.806069682799938,0.598016764822367,0.208052917977571,9.58951461814812,15.0474,1.51987354087886,28.1034,0.970094198018028,0.90955027425577,0.967481857750497,0.923535032671793,0.0605439237622581,0.043946825078704,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
15785,1083:1021,Breast,HCC2157,SIDM00774,749715,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.942947210853669,0.052850215706816,0.806800213920662,11.109388159027,43.1508,0.97097338255605,0.9683586747564,0.0578549289615071,0.760770011432631,0.443513204911504,0.317256806521127,8.82475588188934,8.8562,2.28463227713764,34.2946,0.915576642894379,0.81424134720966,0.913111111467502,0.838162154788697,0.101335295684719,0.0749489566788047,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
15785,1012:1021,Breast,HCC2157,SIDM00774,749715,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.0712837335876611,0.052850215706816,0.806800213920662,11.109388159027,43.1508,0.97097338255605,0.9683586747564,0.0248875620160789,0.0575117315075885,0.0457984216637909,0.0117133098437976,9.86501639460927,18.2136,1.24437176441772,24.9372,0.0692146079228356,0.0421115146920983,0.0690282217886358,0.0666362491207729,0.0271030932307373,0.0023919726678628,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
15785,1011:1021,Breast,HCC2157,SIDM00774,749715,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.34027016074622,0.052850215706816,0.806800213920662,11.109388159027,43.1508,0.97097338255605,0.9683586747564,0.0614779065290632,0.274530038480868,0.0498562863149548,0.224673752165913,6.39946033417516,1.6488,4.70992782485183,41.502,0.330393268962647,0.218780936244886,0.329503561919356,0.244158257310696,0.111612332717761,0.0853453046086599,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
15785,1594:1021,Breast,HCC2157,SIDM00774,749715,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.84469297870694,0.052850215706816,0.806800213920662,11.109388159027,43.1508,0.97097338255605,0.9683586747564,0.100558398207405,0.68149847591804,0.35073438527846,0.33076409063958,8.49466448324393,7.045,2.61472367578306,36.1058,0.820174398756423,0.664590063778776,0.817965773436688,0.735326613290106,0.155584334977647,0.0826391601465829,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
15785,1053:1021,Breast,HCC2157,SIDM00774,749715,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.467255218917519,0.052850215706816,0.806800213920662,11.109388159027,43.1508,0.97097338255605,0.9683586747564,0.0454913781809981,0.3769816105782,0.236201064336322,0.140780546241878,9.03251303339844,10.2279,2.07687512562854,32.9229,0.453692380429311,0.388649863495641,0.452470644563981,0.420290911601623,0.0650425169336699,0.0321797329623577,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
15785,1005:1022,Breast,HCC2157,SIDM00774,749715,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,1.0,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.934506728651249,0.0670552840202067,0.733585606188014,10.4947907114739,2.8182,0.926256688521718,0.954340266785908,0.0812577689949398,0.685540685024405,0.420127201669417,0.265413483354988,8.70129926171435,0.813,1.79349144975958,2.0052,0.865593107881769,0.783413203713703,0.89183740073426,0.824444420006783,0.0821799041680662,0.0673929807274763,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
15785,1190:1022,Breast,HCC2157,SIDM00774,749715,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.01,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,1.0,0.0670552840202067,0.733585606188014,10.4947907114739,2.8182,0.926256688521718,0.954340266785908,0.133934093065739,0.733585606188014,0.165893852215128,0.567691753972886,6.61661922327919,0.1917,3.87817148819474,2.6265,0.926256688521718,0.764503921182829,0.954340266785908,0.73573628713164,0.161752767338889,0.218603979654268,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
15785,1058:1022,Breast,HCC2157,SIDM00774,749715,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.849624999387132,0.0670552840202067,0.733585606188014,10.4947907114739,2.8182,0.926256688521718,0.954340266785908,0.0809512159757261,0.6232726702079,0.407002130077404,0.216270540130496,8.87618369823195,0.9178,1.61860701324198,1.9004,0.786970838417591,0.701987589582651,0.810831348583093,0.757500172353578,0.0849832488349406,0.0533311762295143,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
15785,1179:1022,Breast,HCC2157,SIDM00774,749715,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.919443861183583,0.0670552840202067,0.733585606188014,10.4947907114739,2.8182,0.926256688521718,0.954340266785908,0.0791300641370207,0.674490782262207,0.103968652073008,0.570522130189199,5.96039168936198,0.1216,4.53439902211195,2.6966,0.851641026141528,0.603714913839285,0.877462299776607,0.624895185744689,0.247926112302243,0.252567114031918,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
15786,1594:1047,Breast,HCC2157,SIDM00774,749715,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.574386160584562,0.0318692507182464,0.951482597484073,13.3920258523168,209.9576,0.984324872354165,0.99266902562171,0.0443865440486471,0.546518436031903,0.51927462403707,0.0272438119948331,12.3102523420737,99.194,1.0817735102431,110.7636,0.565382584199398,0.543080558236526,0.570175350358072,0.56584616046747,0.0223020259628722,0.0043291898906027,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
15786,1012:1047,Breast,HCC2157,SIDM00774,749715,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.769451400257027,0.0318692507182464,0.951482597484073,13.3920258523168,209.9576,0.984324872354165,0.99266902562171,0.109814661294629,0.732119616954314,0.435296357592629,0.296823259361685,9.39022502334812,13.106,4.00180082896871,196.8516,0.757390151340732,0.632751457807171,0.763810571756404,0.704865222606338,0.124638693533561,0.058945349150066,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
15786,1179:1047,Breast,HCC2157,SIDM00774,749715,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.925604242690266,0.0318692507182464,0.951482597484073,13.3920258523168,209.9576,0.984324872354165,0.99266902562171,0.0541371395034273,0.880696329077212,0.756197903613204,0.124498425464008,11.2077504210433,46.1954,2.18427543127354,163.7622,0.911095278036569,0.882503112500215,0.918818661702667,0.89802682027034,0.0285921655363542,0.0207918414323273,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
15786,1011:1047,Breast,HCC2157,SIDM00774,749715,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.324310259511235,0.0318692507182464,0.951482597484073,13.3920258523168,209.9576,0.984324872354165,0.99266902562171,0.0420691170089644,0.308575568110484,0.12075522988236,0.187820338228124,8.2293980523331,5.8617,5.16262779998373,204.0959,0.319226654796543,0.252179091361257,0.321932749308142,0.277119024450194,0.0670475634352856,0.0448137248579481,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
15786,1053:1049,Breast,HCC2157,SIDM00774,749715,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.406042301476728,0.0697402241749947,0.870769544452798,11.8154371882446,70.3933,0.952724472779993,0.97960363525221,0.0722238798300871,0.353569269885456,0.188662757904088,0.164906511981368,8.7909078437582,8.6508,3.02452934448641,61.7425,0.386846437600791,0.305279555546199,0.397760514592777,0.360190749359147,0.0815668820545922,0.0375697652336293,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
15786,1179:1049,Breast,HCC2157,SIDM00774,749715,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.338735780459289,0.0697402241749947,0.870769544452798,11.8154371882446,70.3933,0.952724472779993,0.97960363525221,0.101272730216516,0.294960801240398,0.135360986679349,0.159599814561049,8.39920769273571,6.5939,3.4162294955089,63.7994,0.322721867849796,0.196413196714597,0.331826801927914,0.292967269911996,0.126308671135199,0.0388595320159189,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
15786,1073:1049,Breast,HCC2157,SIDM00774,749715,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,2.5,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.966608681362812,0.0697402241749947,0.870769544452798,11.8154371882446,70.3933,0.952724472779993,0.97960363525221,0.0226325823826505,0.841693401134416,0.809332385165128,0.0323610159692873,11.4176083007875,53.4285,0.397828887457091,16.9648,0.920911746335949,0.942167844398617,0.946893378129356,0.941308140437397,-0.0212560980626676,0.0055852376919588,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
15786,1083:1049,Breast,HCC2157,SIDM00774,749715,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.95352045034291,0.0697402241749947,0.870769544452798,11.8154371882446,70.3933,0.952724472779993,0.97960363525221,0.173086689050454,0.830296568171523,0.460826600697213,0.36946996747431,8.90132119887199,9.3389,2.91411598937262,61.0544,0.90844226833789,0.699332929755163,0.934072099443239,0.851370902372751,0.209109338582727,0.0827011970704881,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
15786,1058:1049,Breast,HCC2157,SIDM00774,749715,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.814736049277916,0.0697402241749947,0.870769544452798,11.8154371882446,70.3933,0.952724472779993,0.97960363525221,0.141145757789512,0.709447338479004,0.124137229884045,0.585310108594959,6.46733234780103,1.7282,5.34810484044358,68.6651,0.776218973003157,0.495789919162267,0.798118395643671,0.589275438358511,0.28042905384089,0.20884295728516,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
15786,1021:1049,Breast,HCC2157,SIDM00774,749715,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.951516556412898,0.0697402241749947,0.870769544452798,11.8154371882446,70.3933,0.952724472779993,0.97960363525221,0.103784474534382,0.828551638366955,0.757312503773995,0.0712391345929596,11.0083207682267,40.2314,0.807116420017872,30.1619,0.906533109549913,0.848077002115968,0.93210907766474,0.919502030322483,0.0584561074339447,0.0126070473422574,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
15786,1558:1049,Breast,HCC2157,SIDM00774,749715,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.439697658108805,0.0697402241749947,0.870769544452798,11.8154371882446,70.3933,0.952724472779993,0.97960363525221,0.110886985469085,0.382875329448367,0.0856923432767943,0.297182986171572,6.90655425948789,2.3432,4.90888292875673,68.0501,0.418910719504309,0.259816736039901,0.430729424295269,0.333888033494951,0.159093983464409,0.0968413908003185,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
15786,1561:1049,Breast,HCC2157,SIDM00774,749715,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.819951204192005,0.0697402241749947,0.870769544452798,11.8154371882446,70.3933,0.952724472779993,0.97960363525221,0.034128889587028,0.713988536547796,0.657074565662335,0.0569139708854611,11.058405094225,41.6526,0.757032094019612,28.7407,0.781187578719148,0.804884059884143,0.803227180355915,0.793189042695726,-0.0236964811649946,0.0100381376601895,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
15786,1510:1049,Breast,HCC2157,SIDM00774,749715,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.853204105139394,0.0697402241749947,0.870769544452798,11.8154371882446,70.3933,0.952724472779993,0.97960363525221,0.0597393839305646,0.742944149957487,0.508390723656281,0.234553426301206,9.57296168866312,14.8757,2.2424754995815,55.5176,0.812868431242655,0.790051262167678,0.835801843006659,0.788110227677411,0.022817169074977,0.0476916153292477,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
15787,1011:1053,Breast,HCC2157,SIDM00774,749715,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.331764818966705,0.0653579111724198,0.0808192672058573,5.41201798110127,0.8316,0.613886880530598,0.630667365983052,0.0379921683586031,0.0268129895535729,0.0053262853456534,0.0214867042079194,2.92635523801219,0.1485,2.48566274308908,0.6831,0.203666069785269,0.0965369048254828,0.209233244503576,0.132778715356615,0.107129164959786,0.0764545291469608,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
15787,1012:1054,Breast,HCC2157,SIDM00774,749715,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.768553486290573,0.0564587488645045,0.942998899978849,13.1409916911734,70.5704,0.963097367935498,0.991348879588601,0.0374393287903563,0.72474509214692,0.68401737797229,0.0407277141746307,12.0855385391379,33.9547,1.05545315203549,36.6157,0.740191839764102,0.768553486290573,0.761904637538073,0.755352940131091,-0.0283616465264716,0.0065516974069816,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
15787,1558:1054,Breast,HCC2157,SIDM00774,749715,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.416406322025767,0.0564587488645045,0.942998899978849,13.1409916911734,70.5704,0.963097367935498,0.991348879588601,0.104764480734191,0.392670703614537,0.256519184119569,0.136151519494968,9.69764670351931,6.4874,3.44334498765412,64.083,0.401039832734717,0.315879858593375,0.412803940793854,0.386679160329783,0.0851599741413423,0.0261247804640706,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
15051,1058:1083,Breast,HCC2157,SIDM00774,749715,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.88958351687985,0.0626678730137774,0.678121888880616,10.0996731929547,21.4306,0.936561636986499,0.942756958653696,0.111629431024621,0.603246054783625,0.371967105689652,0.231278949093973,8.51236404082739,7.1319,1.58730915212731,14.2987,0.833149794805199,0.790561627099144,0.838661050842107,0.775320906297665,0.0425881677060557,0.0633401445444415,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
15051,1549:1083,Breast,HCC2157,SIDM00774,749715,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.634544639723873,0.0626678730137774,0.678121888880616,10.0996731929547,21.4306,0.936561636986499,0.942756958653696,0.0496783281991964,0.430298609668623,0.159551636288773,0.27074697337985,7.39003882685701,3.2761,2.70963436609768,18.1545,0.594290166520799,0.487179151163056,0.598221374676084,0.505582880316067,0.107111015357742,0.0926384943600166,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
15051,1558:1083,Breast,HCC2157,SIDM00774,749715,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.647178378750875,0.0626678730137774,0.678121888880616,10.0996731929547,21.4306,0.936561636986499,0.942756958653696,0.0687107835143004,0.438865824641238,0.293352411063572,0.145513413577666,8.72339638693816,8.2553,1.37627680601654,13.1753,0.606122441825188,0.595215312816821,0.610131920057605,0.571738932020613,0.0109071290083664,0.0383929880369914,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
15051,1372:1083,Breast,HCC2157,SIDM00774,749715,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.89315466183185,0.0626678730137774,0.678121888880616,10.0996731929547,21.4306,0.936561636986499,0.942756958653696,0.0472423773810507,0.605667726343942,0.324522664202656,0.281145062141286,8.17227510981048,5.6342,1.92739808314422,15.7964,0.83649439216736,0.75591082054937,0.842027772595965,0.759974098684358,0.0805835716179902,0.0820536739116069,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
15051,1011:1083,Breast,HCC2157,SIDM00774,749715,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.512807422407668,0.0626678730137774,0.678121888880616,10.0996731929547,21.4306,0.936561636986499,0.942756958653696,0.071499619678768,0.347745937915088,0.112810468935152,0.234935468979936,7.13205229980401,2.7396,2.96762089315069,18.691,0.480275758988953,0.388452601479283,0.483452765924095,0.398521344651236,0.0918231575096698,0.0849314212728584,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
15052,1558:1190,Breast,HCC2157,SIDM00774,749715,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.716205698787288,0.0502358149430837,0.882817486288606,11.9801411721201,78.9063,0.961337479590796,0.981628866457742,0.0269290361190674,0.632278914668968,0.508863986973257,0.12341492769571,10.3249613450114,25.0526,1.65517982710864,53.8537,0.688515381340736,0.691785351535153,0.70304818825114,0.680129600098489,-0.0032699701944169,0.0229185881526509,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
15052,1561:1190,Breast,HCC2157,SIDM00774,749715,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.844156480538286,0.0502358149430837,0.882817486288606,11.9801411721201,78.9063,0.961337479590796,0.981628866457742,0.063399464215797,0.745236102183046,0.596410793998899,0.148825308184147,10.2965002627645,24.5632,1.68364090935554,54.3431,0.811519263380912,0.773504277348933,0.828648369103754,0.800936161824327,0.0380149860319791,0.0277122072794272,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
15052,1022:1190,Breast,HCC2157,SIDM00774,749715,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.893605688961189,0.0502358149430837,0.882817486288606,11.9801411721201,78.9063,0.961337479590796,0.981628866457742,0.175906495180251,0.788890728061914,0.367162317953967,0.421728410107947,8.46822282746037,6.917,3.5119183446597,71.9893,0.859056640773946,0.643466076314133,0.877189139515161,0.776523314926453,0.215590564459813,0.100665824588708,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
15052,1179:1190,Breast,HCC2157,SIDM00774,749715,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.321594346361149,0.0502358149430837,0.882817486288606,11.9801411721201,78.9063,0.961337479590796,0.981628866457742,0.097308034803172,0.283909112459177,0.0365823257212556,0.247326786737921,5.97030212822203,1.2245,6.00983904389803,77.6818,0.309160698381477,0.149282275348502,0.315686293677713,0.218849656855819,0.159878423032975,0.0968366368218944,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
15052,1012:1190,Breast,HCC2157,SIDM00774,749715,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.248027060303029,0.0502358149430837,0.882817486288606,11.9801411721201,78.9063,0.961337479590796,0.981628866457742,0.0747831819762242,0.218962625908273,0.0620084135793898,0.156954212328883,7.37875751697746,3.2506,4.6013836551426,75.6557,0.238437709022028,0.144634668671953,0.243470522056109,0.197410547568542,0.0938030403500754,0.0460599744875663,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
15052,1011:1190,Breast,HCC2157,SIDM00774,749715,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.503428432951944,0.0502358149430837,0.882817486288606,11.9801411721201,78.9063,0.961337479590796,0.981628866457742,0.134524711301097,0.444435423704847,0.220572409878048,0.223863013826798,8.63295927824542,7.7537,3.34718189387464,71.1526,0.483964620888365,0.330733863051645,0.494179881981214,0.442228248873325,0.15323075783672,0.0519516331078883,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
15052,1594:1190,Breast,HCC2157,SIDM00774,749715,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.857518390060928,0.0502358149430837,0.882817486288606,11.9801411721201,78.9063,0.961337479590796,0.981628866457742,0.0527018176325125,0.757032229559841,0.610944885207741,0.1460873443521,10.3390313832525,25.2981,1.64110978886757,53.6082,0.824364567803929,0.816878360726427,0.841764805202177,0.814671761673346,0.0074862070775023,0.0270930435288308,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
15053,1561:1372,Breast,HCC2157,SIDM00774,749715,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.891714846187038,0.0605296902763253,0.956239232050583,13.5516617886652,23.4524,0.957049823574083,0.993404069961649,0.0220227584562038,0.852692719725997,0.804692298319011,0.0480004214069863,12.2825358240289,9.7306,1.26912596463626,13.7218,0.853415536221695,0.882928442186935,0.88583315744743,0.878217927883102,-0.02951290596524,0.0076152295643273,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
15053,1011:1372,Breast,HCC2157,SIDM00774,749715,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.646475887552142,0.0605296902763253,0.956239232050583,13.5516617886652,23.4524,0.957049823574083,0.993404069961649,0.0819175039330134,0.618185606252079,0.493770678185232,0.124414928066848,10.7319028459554,3.3217,2.8197589427098,20.1307,0.618709634126676,0.564440136241087,0.642211777826367,0.620801332126797,0.0542694978855892,0.02141044569957,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
15053,1179:1372,Breast,HCC2157,SIDM00774,749715,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.821493944592509,0.0605296902763253,0.956239232050583,13.5516617886652,23.4524,0.957049823574083,0.993404069961649,0.0270702577238815,0.785544738711345,0.760571434733345,0.0249733039780007,12.7255233317052,13.228,0.826138456959987,10.2244,0.786210634739438,0.813976431317321,0.816075428007048,0.81216344685161,-0.0277657965778828,0.0039119811554378,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
15053,1053:1372,Breast,HCC2157,SIDM00774,749715,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.757990740346839,0.0605296902763253,0.956239232050583,13.5516617886652,23.4524,0.957049823574083,0.993404069961649,0.0768433531601802,0.724820483450714,0.491286406440599,0.233534077010115,9.90152573165429,1.868,3.65013605701089,21.5844,0.725434904319731,0.65593491783548,0.752991086453794,0.709551841290608,0.0694999864842504,0.0434392451631856,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
15053,1058:1372,Breast,HCC2157,SIDM00774,749715,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.47942680038716,0.0605296902763253,0.956239232050583,13.5516617886652,23.4524,0.957049823574083,0.993404069961649,0.0999135116271389,0.458446715426686,0.307935504100882,0.150511211325804,9.86385127454695,1.8199,3.68781051411823,21.6325,0.458835334727218,0.376528935228243,0.476264534753296,0.448149678478409,0.0823063994989753,0.0281148562748865,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
15053,1012:1372,Breast,HCC2157,SIDM00774,749715,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.841298810801008,0.0605296902763253,0.956239232050583,13.5516617886652,23.4524,0.957049823574083,0.993404069961649,0.0371331887323961,0.804482928765424,0.749346998929841,0.0551359298355831,12.0960650905383,8.5508,1.45559669812693,14.9016,0.80516487845019,0.819090710202376,0.835749662703617,0.826945780329145,-0.0139258317521858,0.0088038823744716,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
15054,1179:1375,Breast,HCC2157,SIDM00774,749715,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1375,Temozolomide,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved,30.0,0.394475318925731,0.0344557520803609,0.959316841765047,13.6640218784898,760.557,0.982054584382124,0.993877710725557,0.063427543098888,0.378426817106092,0.246105092743758,0.132321724362333,9.74680845330681,50.3423,3.917213425183,710.2147,0.387396295376614,0.309541413335005,0.392060226911639,0.367049466200297,0.0778548820416095,0.025010760711342,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
15055,1058:1510,Breast,HCC2157,SIDM00774,749715,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.785569532196433,0.0822619382850033,0.858901723542242,11.6655256143078,63.4458,0.939838843203211,0.977581134663069,0.134133427017995,0.674727025165789,0.32648683261685,0.348240192548938,8.49699877130387,7.0564,3.16852684300394,56.3894,0.738308760395183,0.577339882183233,0.767957954641325,0.683965061424574,0.16096887821195,0.083992893216751,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
15055,1549:1510,Breast,HCC2157,SIDM00774,749715,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.622166976856723,0.0822619382850033,0.858901723542242,11.6655256143078,63.4458,0.939838843203211,0.977581134663069,0.150076504012267,0.534380288753305,0.148049270319002,0.386331018434304,7.28234033004949,3.0404,4.38318528425833,60.4054,0.584736691808261,0.378605928632856,0.608218699185486,0.490683038439892,0.206130763175405,0.117535660745594,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
15055,1073:1510,Breast,HCC2157,SIDM00774,749715,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,2.5,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.979280528306269,0.0822619382850033,0.858901723542242,11.6655256143078,63.4458,0.939838843203211,0.977581134663069,0.0350012003187731,0.841105733593611,0.899890690673054,-0.0587849570794422,12.5830168889833,119.8383,-0.917491274675477,-56.3925,0.920365878894793,0.979280528306269,0.957326170015092,0.967076742358438,-0.0589146494114756,-0.009750572343346,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
15055,1558:1510,Breast,HCC2157,SIDM00774,749715,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.663808402378237,0.0822619382850033,0.858901723542242,11.6655256143078,63.4458,0.939838843203211,0.977581134663069,0.152876129299442,0.57014618090449,0.0615999774784395,0.50854620342605,5.63533869016074,0.9708,6.03018692414707,62.475,0.623872920999734,0.345835828440295,0.648926571195796,0.432005149290979,0.278037092559439,0.216921421904817,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
15055,1012:1510,Breast,HCC2157,SIDM00774,749715,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.190277326483829,0.0822619382850033,0.858901723542242,11.6655256143078,63.4458,0.939838843203211,0.977581134663069,0.0796370810290123,0.163429523667971,0.0702196289199696,0.0932098947480012,8.20848087815399,5.7774,3.45704473615382,57.6684,0.178830022410362,0.0898574272454093,0.186011524724717,0.16233987452924,0.0889725951649526,0.0236716501954767,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
15055,1011:1510,Breast,HCC2157,SIDM00774,749715,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.464339968155351,0.0822619382850033,0.858901723542242,11.6655256143078,63.4458,0.939838843203211,0.977581134663069,0.066781107432196,0.39882239895818,0.151513246804979,0.247309152153201,7.93010443117757,4.7635,3.73542118313025,58.6823,0.436404738524141,0.346222463070287,0.453929992938721,0.38775620205372,0.0901822754538534,0.0661737908850005,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
15055,1083:1549,Breast,HCC2157,SIDM00774,749715,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.965406726437803,0.165363149539602,0.434311595827127,8.6099828107971,3.8156,0.759530217803924,0.87714122653089,0.184619843402569,0.419287335981444,0.100384090543686,0.318903245437758,5.82156585296439,0.5523,2.78841695783271,3.2633,0.733255581200678,0.545419377180849,0.846798040128826,0.644309625664469,0.187836204019829,0.202488414464357,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
15055,1012:1549,Breast,HCC2157,SIDM00774,749715,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.766175238458949,0.165363149539602,0.434311595827127,8.6099828107971,3.8156,0.759530217803924,0.87714122653089,0.177632435730631,0.332758790498335,0.0688131633302015,0.263945627168134,5.58225892898671,0.4679,3.0277238818104,3.3477,0.581933245742699,0.415192325335052,0.67204388839948,0.49497539083236,0.166740920407647,0.177068497567119,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
15055,1007:1549,Breast,HCC2157,SIDM00774,749715,1007,Docetaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.001,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.751340480616909,0.165363149539602,0.434311595827127,8.6099828107971,3.8156,0.759530217803924,0.87714122653089,0.103311411513918,0.32631588314625,0.454732989220852,-0.128417106074601,9.63059593009075,7.741,-1.02061311929365,-3.9254,0.570665798887866,0.629385908359242,0.659031710710624,0.695744578541935,-0.0587201094713755,-0.036712867831311,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
15055,1058:1549,Breast,HCC2157,SIDM00774,749715,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.785569532196433,0.165363149539602,0.434311595827127,8.6099828107971,3.8156,0.759530217803924,0.87714122653089,0.140888792324092,0.341181957161402,0.0792773947405728,0.261904562420829,5.7723874595422,0.5338,2.83759535125491,3.2818,0.596663797889283,0.457997408480815,0.689055422996077,0.520857500631263,0.138666389408469,0.168197922364814,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
15055,1011:1549,Breast,HCC2157,SIDM00774,749715,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.464339968155351,0.165363149539602,0.434311595827127,8.6099828107971,3.8156,0.759530217803924,0.87714122653089,0.0657821926068146,0.201668232575867,0.006046597778792,0.195621634797075,2.61286391999139,0.0597,5.99711889080572,3.7559,0.3526802371481,0.148443209269698,0.407291729195099,0.172543693360279,0.204237027878403,0.23474803583482,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
15055,1510:1549,Breast,HCC2157,SIDM00774,749715,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.748072229310954,0.165363149539602,0.434311595827127,8.6099828107971,3.8156,0.759530217803924,0.87714122653089,0.100112248008005,0.324896443705997,0.0584962678263558,0.266400175879641,5.35911688232326,0.4008,3.25086592847384,3.4148,0.568183463261616,0.435246775806465,0.656164992751508,0.468193563832923,0.132936687455151,0.187971428918584,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
15055,1053:1549,Breast,HCC2157,SIDM00774,749715,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.700159565066068,0.165363149539602,0.434311595827127,8.6099828107971,3.8156,0.759530217803924,0.87714122653089,0.152730386687599,0.304087418037471,0.101690822182399,0.202396595855072,6.38429716606498,0.8158,2.22568564473213,2.9998,0.531792346952131,0.398333053475771,0.614138819669386,0.50149440713207,0.133459293476361,0.112644412537316,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
15056,1058:1558,Breast,HCC2157,SIDM00774,749715,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.845308182010052,0.0938916461681532,0.220506590284518,7.13652554568071,2.7481,0.732703018431804,0.777483463317165,0.127045327332483,0.186396024954641,0.0112373312097103,0.175158693744931,2.64376172555336,0.1221,4.49276382012735,2.626,0.619359856463866,0.347585148318115,0.657213132919512,0.31647895369961,0.271774708145751,0.340734179219902,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
15056,1012:1558,Breast,HCC2157,SIDM00774,749715,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.206513475657072,0.0938916461681532,0.220506590284518,7.13652554568071,2.7481,0.732703018431804,0.777483463317165,0.0576867090669092,0.0455375823649458,0.0045165079619764,0.0410210744029693,3.39133083941453,0.2049,3.74519470626619,2.5432,0.151313046960779,0.0558006792754766,0.160560812275525,0.091529385960403,0.0955123676853027,0.0690314263151222,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
15056,1011:1558,Breast,HCC2157,SIDM00774,749715,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.473113219929688,0.0938916461681532,0.220506590284518,7.13652554568071,2.7481,0.732703018431804,0.777483463317165,0.0371819594194371,0.104324582945225,0.0055667094293162,0.0987578735159086,2.46133084335406,0.1076,4.67519470232666,2.6405,0.346651484302472,0.149057356572435,0.36783770477207,0.169321532405966,0.197594127730037,0.198516172366103,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
15056,1012:1559,Breast,HCC2157,SIDM00774,749715,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1559,Luminespib,HSP90,Protein stability and degradation,Targeted,Early clinical trials,0.1,0.774132170204665,0.122963354977273,0.182163672068946,6.78375841688793,0.0215,0.73973811723447,0.749453037514818,0.157800096533541,0.141018758791184,0.0535079200017066,0.0875108387894777,5.1625828147352,0.007,1.62117560215273,0.0145,0.572655074077834,0.403052415960398,0.580175706397825,0.470624352888503,0.169602658117436,0.109551353509322,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
15057,1054:1561,Breast,HCC2157,SIDM00774,749715,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.976781406302127,0.0614663893517765,0.0789393095741929,5.37426901495385,0.8101,0.623376670319089,0.627242953292182,0.146766685580949,0.0771064498183991,0.0066379968378301,0.0704684529805689,1.64384650865557,0.061,3.73042250629828,0.7491,0.608902740690217,0.311923859171552,0.612679254009837,0.279489071940734,0.296978881518665,0.333190182069103,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
15057,1558:1561,Breast,HCC2157,SIDM00774,749715,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.703131567979884,0.0614663893517765,0.0789393095741929,5.37426901495385,0.8101,0.623376670319089,0.627242953292182,0.07940899846123,0.0555047205161517,0.0006793761371927,0.054825344378959,-1.24352535907856,0.0082,6.6177943740324,0.8019,0.43831581564354,0.10771863526684,0.441034321252665,0.063615924607157,0.3305971803767,0.377418396645508,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
15057,1058:1561,Breast,HCC2157,SIDM00774,749715,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.430474248671854,0.0614663893517765,0.0789393095741929,5.37426901495385,0.8101,0.623376670319089,0.627242953292182,0.0784367447360872,0.0339813399796256,0.0013285572966282,0.0326527826829973,0.473461873200177,0.0271,4.90080714175367,0.783,0.268347603795172,0.105558700705827,0.270011939053167,0.0831599310948572,0.162788903089345,0.18685200795831,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
15057,1053:1561,Breast,HCC2157,SIDM00774,749715,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.439100445006434,0.0614663893517765,0.0789393095741929,5.37426901495385,0.8101,0.623376670319089,0.627242953292182,0.0591435032010413,0.0346622859625288,0.0017244126771537,0.0329378732853751,0.830296304620952,0.0347,4.54397271033289,0.7754,0.273724973343741,0.104479861917776,0.275422659917747,0.0965801146189356,0.169245111425965,0.178842545298812,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
15057,1012:1594,Breast,HCC2157,SIDM00774,749715,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.742311558977116,0.122465492444228,0.32826726002565,7.94330355534962,1.9229,0.783194954892049,0.835954463957919,0.154681578225488,0.243676581550787,0.0216269477785043,0.222049633772282,3.8255780836763,0.1108,4.11772547167332,1.8121,0.581374667948929,0.333632668549929,0.620538661374482,0.359056022499528,0.247741999399,0.261482638874954,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
15057,1011:1594,Breast,HCC2157,SIDM00774,749715,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.43176975801148,0.122465492444228,0.32826726002565,7.94330355534962,1.9229,0.783194954892049,0.835954463957919,0.0389889216612943,0.141735875424366,0.0260257481349317,0.115710127289435,4.94660752417035,0.2409,2.99669603117927,1.682,0.338159896149552,0.239272643339012,0.360939856611727,0.253918276923667,0.0988872528105402,0.10702157968806,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
16334,1179:1005,Breast,HCC38,SIDM00675,749717,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.598628716442096,0.0357445695800368,0.922600878207494,12.7657262874049,54.4072,0.982513870251003,0.98777657628132,0.0807441215920109,0.552295379509702,0.44083558110346,0.111459798406242,10.5611432722806,11.8035,2.20458301512431,42.6037,0.588161017034914,0.50828755931764,0.591311423990854,0.570841843908248,0.0798734577172736,0.0204695800826066,True,0.797699660075126,0.0674135427308555,0.213696941821463,223.25402421726
16334,1011:1005,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.328116547425096,0.0357445695800368,0.922600878207494,12.7657262874049,54.4072,0.982513870251003,0.98777657628132,0.0910652814311699,0.302720614808805,0.136656201296822,0.166064413511983,8.48759632584772,2.8042,4.27812996155719,51.603,0.322379058904028,0.206167018958036,0.324105839836809,0.284542456241298,0.116212039945992,0.0395633835955115,True,0.797699660075126,0.0674135427308555,0.213696941821463,223.25402421726
16334,1011:1007,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1007,Docetaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.0125,0.328116547425096,0.0814076987153517,0.570041355951137,9.42853707195132,0.0168,0.846676960652135,0.914754311952829,0.0716391350908497,0.187040001604207,0.102916808615089,0.0841231929891186,7.81010824642745,0.0055,1.61842882552387,0.0113,0.277808721113553,0.212872291539559,0.300146026580182,0.270459568310711,0.0649364295739934,0.029686458269471,True,0.797699660075126,0.0674135427308555,0.213696941821463,223.25402421726
16335,1191:1012,Breast,HCC38,SIDM00675,749717,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.000625,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,5.0,0.951956053646321,0.0611928886547084,0.576086568303951,9.46608277076485,6.9068,0.898138683849771,0.916353392046759,0.0291012304204851,0.548409096121281,0.574709800208669,-0.0263007040873878,9.63967116256612,7.7899,-0.17358839180126,-0.883100000000001,0.854988557104729,0.876644377270312,0.872328158838253,0.879088292373855,-0.0216558201655825,-0.0067601335356015,True,0.797699660075126,0.0674135427308555,0.213696941821463,223.25402421726
16335,1011:1012,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,5.0,0.302462459642535,0.0611928886547084,0.576086568303951,9.46608277076485,6.9068,0.898138683849771,0.916353392046759,0.040932900633015,0.17424456041624,0.0316017722373342,0.142642788178906,5.73545939041348,0.5203,3.73062338035137,6.3865,0.271653235417311,0.182005915860271,0.277162500860243,0.19919350518396,0.0896473195570406,0.0779689956762831,True,0.797699660075126,0.0674135427308555,0.213696941821463,223.25402421726
17525,1011:1017,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.25234400752661,0.0378389712569036,0.92759810554708,12.8753523340735,146.7565,0.973708242607324,0.988596170864501,0.0635836520116334,0.234073823327841,0.145306205532824,0.0887676177950169,9.46446073344416,13.798,3.41089160062932,132.9585,0.245709440101224,0.182600430217389,0.249466319581409,0.23121897240354,0.0631090098838351,0.0182473471778693,True,0.86745510200284,0.0704104497686588,0.127561946758892,355.802950364596
16336,1011:1021,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.313484350242537,0.0594559055292998,0.844311504583513,11.5690115349131,59.3403,0.958788473191661,0.974323300533341,0.050911167782367,0.264678443416661,0.0967637709499045,0.167914672466757,7.77474966028854,4.2772,3.7942618746246,55.0631,0.300565181538522,0.233298389364949,0.305435106793858,0.257638414599189,0.0672667921735728,0.0477966921946689,True,0.797699660075126,0.0674135427308555,0.213696941821463,223.25402421726
16337,1011:1047,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.341990414133429,0.03045870932532,0.946893609109284,13.3775917986417,207.8674,0.98960937974148,0.991719974157052,0.0844745851273091,0.323828537519582,0.211843940224622,0.11198459729496,9.74029776531488,16.7052,3.63729403332679,191.1622,0.338436921608115,0.23304727588777,0.339158724666364,0.317146245843413,0.105389645720344,0.0220124788229514,True,0.797699660075126,0.0674135427308555,0.213696941821463,223.25402421726
16337,1011:1049,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.341990414133429,0.0780442494048166,0.784843137312346,10.9664460990671,39.0804,0.910063821041805,0.963243929332643,0.0395810931598733,0.268408829559229,0.235287256939983,0.0331215726192454,10.2015763641963,22.9991,0.764869734870761,16.0813,0.311233103045938,0.308121398170767,0.329420190303982,0.322588916047488,0.003111704875171,0.0068312742564941,True,0.797699660075126,0.0674135427308555,0.213696941821463,223.25402421726
16337,1549:1049,Breast,HCC38,SIDM00675,749717,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.937477095655714,0.0780442494048166,0.784843137312346,10.9664460990671,39.0804,0.910063821041805,0.963243929332643,0.155845699542233,0.735772464912896,0.677865528256727,0.0579069366561691,10.4583856889239,27.4801,0.508060410143177,11.6003,0.853163987811612,0.740252576961752,0.903019121278764,0.891363514258592,0.11291141084986,0.0116556070201715,True,0.797699660075126,0.0674135427308555,0.213696941821463,223.25402421726
16338,1011:1053,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.348853819984005,0.090776819395893,0.799751120200913,11.1041503798456,42.9944,0.912955011068479,0.966098178349155,0.0652361646053233,0.278996233318576,0.0541112140299225,0.224885019288653,6.42430758055247,1.6774,4.67984279929318,41.317,0.318487843084778,0.185462096689839,0.337027039996691,0.250463886036893,0.133025746394939,0.0865631539597979,True,0.797699660075126,0.0674135427308555,0.213696941821463,223.25402421726
16338,1594:1054,Breast,HCC38,SIDM00675,749717,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.864927606869582,0.150495398945734,0.918399299192865,12.678464548611,51.2139,0.913360234738392,0.987084038355188,0.0466684105320138,0.794348908001586,0.811552891884039,-0.0172039838824527,13.1355659085063,70.3055,-0.457101359895272,-19.0916,0.789990482042117,0.827951419628298,0.853756235073715,0.85656811000076,-0.0379609375861817,-0.0028118749270446,True,0.797699660075126,0.0674135427308555,0.213696941821463,223.25402421726
16338,1510:1054,Breast,HCC38,SIDM00675,749717,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.888871092463579,0.150495398945734,0.918399299192865,12.678464548611,51.2139,0.913360234738392,0.987084038355188,0.0797223671576401,0.816338588391347,0.383154351058565,0.433184237332782,8.57827206228527,2.9861,4.10019248632571,48.2278,0.811859509664705,0.702406292773183,0.877390467526137,0.775457694005542,0.109453216891522,0.101932773520595,True,0.797699660075126,0.0674135427308555,0.213696941821463,223.25402421726
16338,1561:1054,Breast,HCC38,SIDM00675,749717,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.898976483124274,0.150495398945734,0.918399299192865,12.678464548611,51.2139,0.913360234738392,0.987084038355188,0.0701058992809681,0.8256193720922,0.758894848745384,0.0667245233468161,11.5674518187961,23.7105,1.11101272981487,27.5034,0.821089371650681,0.816374371012797,0.887365337348653,0.875871930701769,0.0047150006378844,0.0114934066468838,True,0.797699660075126,0.0674135427308555,0.213696941821463,223.25402421726
16339,1011:1058,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.327254216202451,0.0706217233220639,0.698386168734447,10.2758331303665,9.6855,0.899967230734171,0.945542480163692,0.0638343213223037,0.228549818255824,0.0718625703358879,0.156687247919936,7.0731738171192,1.052,3.20265931324735,8.6335,0.294518070701801,0.190467387644492,0.30943276323209,0.252113127334682,0.10405068305731,0.0573196358974079,True,0.797699660075126,0.0674135427308555,0.213696941821463,223.25402421726
16339,1011:1073,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,20.0,0.327254216202451,0.0929467690738749,0.626084457250417,9.78324872961417,34.42,0.858455712048456,0.928970839988653,0.0766165709554707,0.204888778334022,0.0992198610648372,0.105668917269185,7.73551259755647,8.3249,2.0477361320577,26.0951,0.280933251190934,0.209062757974979,0.304009624115419,0.268068037078319,0.0718704932159552,0.0359415870370996,True,0.797699660075126,0.0674135427308555,0.213696941821463,223.25402421726
16339,1022:1073,Breast,HCC38,SIDM00675,749717,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,20.0,0.916734088985802,0.0929467690738749,0.626084457250417,9.78324872961417,34.42,0.858455712048456,0.928970839988653,0.155439805466812,0.573952964545632,0.177316619975438,0.396636344570194,6.83022708252781,4.4449,2.95302164708636,29.9751,0.7869756151194,0.605377288086593,0.851619236691373,0.688683410771693,0.181598327032807,0.16293582591968,True,0.797699660075126,0.0674135427308555,0.213696941821463,223.25402421726
17522,1011:1083,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.307357711382844,0.0619108502032216,0.803267199186035,11.137734004683,44.007,0.940952411985757,0.966763616729396,0.0311241797780651,0.246890367970727,0.0571800827213317,0.189710285249395,6.75722923399367,2.1128,4.38050477068929,41.8942,0.289208979868109,0.200662328565131,0.297142252686148,0.229093307879524,0.0885466513029777,0.0680489448066247,True,0.86745510200284,0.0704104497686588,0.127561946758892,355.802950364596
17526,1011:1510,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.241559984669916,0.082018558153635,0.886345547010316,12.1210253573644,87.0006,0.939444287850186,0.981694152568334,0.0595259937749424,0.21410561674806,0.0996401840729459,0.114465432675114,8.46254819976259,6.8899,3.65847715760184,80.1107,0.226932147771331,0.150212665518722,0.237138024444953,0.209127571341388,0.0767194822526091,0.028010453103565,True,0.86745510200284,0.0704104497686588,0.127561946758892,355.802950364596
17528,1049:1561,Breast,HCC38,SIDM00675,749717,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.836987568555961,0.116130090377679,0.760683136214456,10.7572252143598,33.8047,0.884991545755488,0.95850134688858,0.0423359588563025,0.63668232862166,0.454736542092334,0.181945786529326,9.26385186997604,12.0068,1.4933733443838,21.7979,0.740726922074467,0.742199939288682,0.802253711789886,0.75954275496328,-0.0014730172142148,0.0427109568266063,True,0.86745510200284,0.0704104497686588,0.127561946758892,355.802950364596
17528,1012:1561,Breast,HCC38,SIDM00675,749717,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.938554042196025,0.116130090377679,0.760683136214456,10.7572252143598,33.8047,0.884991545755488,0.95850134688858,0.110968672930146,0.713942232324427,0.571993816456939,0.141948415867487,9.67613723982612,15.9786,1.08108797453372,17.8261,0.830612392578121,0.763410118221192,0.899605313572611,0.868055560169896,0.0672022743569298,0.0315497534027147,True,0.86745510200284,0.0704104497686588,0.127561946758892,355.802950364596
17528,1011:1561,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.257963361991508,0.116130090377679,0.760683136214456,10.7572252143598,33.8047,0.884991545755488,0.95850134688858,0.0748900451564171,0.196228379228125,0.0584602512010561,0.137768128027069,7.13480573160788,2.7449,3.62241948275196,31.0598,0.228295394477147,0.123318951717915,0.247258229916767,0.199959743503092,0.104976442759233,0.047298486413675,True,0.86745510200284,0.0704104497686588,0.127561946758892,355.802950364596
17528,1011:1594,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.257963361991508,0.0599916168220963,0.802498491986469,11.1303533741797,17.513,0.955675092711933,0.966618383127966,0.026118050106907,0.207015208985945,0.0912644962410114,0.115750712744934,8.08459517386244,2.1208,3.04575820031724,15.3922,0.246529159887516,0.199961516323216,0.249352127874486,0.217333336882211,0.0465676435643,0.0320187909922748,True,0.86745510200284,0.0704104497686588,0.127561946758892,355.802950364596
16644,1191:1005,Breast,HCC70,SIDM00673,907048,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.0025,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.764377445774011,0.0772691945213295,0.901406344183639,14.0057133093848,128.5079,0.936791167692623,0.976817828061496,0.0353788239939094,0.689014678971579,0.440446631009847,0.248568047961732,9.69502366656906,6.4756,4.3106896428157,122.0323,0.71606203998454,0.65675701064862,0.746657516400164,0.670583115753135,0.0593050293359204,0.0760744006470282,True,0.751636007345609,0.0754635152121225,0.270967850338608,177.028524620649
16645,1190:1011,Breast,HCC70,SIDM00673,907048,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.01,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.904308480449934,0.0828015261585049,0.72346945964361,11.1754588663209,45.1729,0.90962386462042,0.927816649350247,0.0750762013457421,0.654239567702248,0.481454608409139,0.172784959293109,9.29357563029773,12.2567,1.8818832360232,32.9162,0.822580574795888,0.731055439192142,0.839032464310071,0.777514061822413,0.0915251356037458,0.0615184024876584,True,0.751636007345609,0.0754635152121225,0.270967850338608,177.028524620649
16645,1372:1011,Breast,HCC70,SIDM00673,907048,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.744001400762549,0.0828015261585049,0.72346945964361,11.1754588663209,45.1729,0.90962386462042,0.927816649350247,0.0466411703377947,0.53826229138377,0.248419120092719,0.289843171291051,7.4378195248223,3.3864,3.73763934149862,41.7865,0.676761429444636,0.559595210258314,0.690296886767399,0.563384814422945,0.117166219186321,0.126912072344454,True,0.751636007345609,0.0754635152121225,0.270967850338608,177.028524620649
16645,1005:1011,Breast,HCC70,SIDM00673,907048,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.99909684619791,0.0828015261585049,0.72346945964361,11.1754588663209,45.1729,0.90962386462042,0.927816649350247,0.116462636515502,0.722816055450436,0.571038550024515,0.151777505425921,9.65190524082623,15.7124,1.5235536254947,29.4605,0.908802334368615,0.807456181934336,0.926978688215743,0.874703289993885,0.10134615243428,0.0522753982218583,True,0.751636007345609,0.0754635152121225,0.270967850338608,177.028524620649
16645,1191:1011,Breast,HCC70,SIDM00673,907048,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.0025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.723287862249898,0.0828015261585049,0.72346945964361,11.1754588663209,45.1729,0.90962386462042,0.927816649350247,0.0578356643690899,0.523276678868716,0.129808348369271,0.393468330499445,5.56187241770909,0.9226,5.61358644861183,44.2503,0.657919900492794,0.455059581266016,0.671078520868404,0.451005383553631,0.202860319226778,0.220073137314773,True,0.751636007345609,0.0754635152121225,0.270967850338608,177.028524620649
16645,1047:1011,Breast,HCC70,SIDM00673,907048,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.946644732654802,0.0828015261585049,0.72346945964361,11.1754588663209,45.1729,0.90962386462042,0.927816649350247,0.121974108547574,0.684868553208239,0.652476595341316,0.0323919578669228,10.8019709402323,34.8696,0.373487926088639,10.3033,0.861090640140024,0.91109153576553,0.878312743976838,0.868113492580872,-0.0500008956255054,0.010199251395966,True,0.751636007345609,0.0754635152121225,0.270967850338608,177.028524620649
16645,1191:1012,Breast,HCC70,SIDM00673,907048,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.000625,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,5.0,0.901436283394546,0.0882670555735329,0.530097421240142,9.27265230225716,6.0401,0.878591546989589,0.858829716065417,0.0956020528946555,0.477849049239747,0.570073648468498,-0.0922245992287509,10.2272585309586,11.7061,-0.95460622870146,-5.666,0.79199429874016,0.853822851074697,0.774180267318803,0.809421964451561,-0.0618285523345373,-0.0352416971327573,True,0.751636007345609,0.0754635152121225,0.270967850338608,177.028524620649
16647,1083:1049,Breast,HCC70,SIDM00673,907048,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.828588687777143,0.100963368682231,0.818039083035061,12.4000683942975,105.5656,0.915748603545482,0.955172806455881,0.0959013655712882,0.677817930362438,0.426279223253259,0.251538707109179,9.13090926106688,10.9498,3.26915913323058,94.6158,0.758778933745502,0.623925953486087,0.791445382301689,0.706133758714828,0.134852980259415,0.0853116235868604,True,0.751636007345609,0.0754635152121225,0.270967850338608,177.028524620649
16647,1058:1049,Breast,HCC70,SIDM00673,907048,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.865851973422593,0.100963368682231,0.818039083035061,12.4000683942975,105.5656,0.915748603545482,0.955172806455881,0.137103951168559,0.708300754382716,0.499991636692125,0.208309117690591,9.70651553806438,16.3186,2.69355285623308,89.247,0.79290273553884,0.638369361208783,0.827038259429421,0.760018384946935,0.154533374330057,0.0670198744824864,True,0.751636007345609,0.0754635152121225,0.270967850338608,177.028524620649
16649,1372:1073,Breast,HCC70,SIDM00673,907048,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,20.0,0.867684566411109,0.0770648249608292,0.87417178984578,13.3845882426372,417.7559,0.936298965515405,0.969972015549546,0.0503904397339593,0.758505370441159,0.65462071174666,0.103884658694499,11.5390250144106,116.2392,1.84556322822655,301.5167,0.812412161924404,0.77923331227348,0.841629747743018,0.813147430476537,0.0331788496509243,0.0284823172664808,True,0.751636007345609,0.0754635152121225,0.270967850338608,177.028524620649
16649,1011:1073,Breast,HCC70,SIDM00673,907048,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,20.0,0.927220011144454,0.0770648249608292,0.87417178984578,13.3845882426372,417.7559,0.936298965515405,0.969972015549546,0.056332750938027,0.810549576722972,0.58083520090831,0.229714375814662,10.1692708482111,44.9796,3.21531739442609,372.7763,0.868155137239735,0.806683625482043,0.899377463067659,0.830619096470231,0.0614715117576916,0.0687583665974278,True,0.751636007345609,0.0754635152121225,0.270967850338608,177.028524620649
16940,1191:1190,Breast,HCC70,SIDM00673,907048,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.0025,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.525893465451051,0.118699299967489,0.742963871610115,11.4009670160232,52.8157,0.861903822605633,0.933732913779375,0.109274632091285,0.390719845145973,0.211390662477885,0.179329182668088,8.10133715924205,5.3638,3.29962985678114,47.4519,0.453269588155584,0.341745301872803,0.491044037833142,0.419585821521207,0.111524286282781,0.0714582163119358,True,0.784783808476337,0.0656455979200144,0.228492415126846,208.481482025778
16940,1372:1190,Breast,HCC70,SIDM00673,907048,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.729620464657368,0.118699299967489,0.742963871610115,11.4009670160232,52.8157,0.861903822605633,0.933732913779375,0.0840360126126045,0.542081645227809,0.36690942550696,0.17517221972085,9.02603242983153,10.1821,2.37493458619165,42.6336,0.628862667539484,0.556876224646878,0.681270642417585,0.618119985777964,0.0719864428926064,0.0631506566396218,True,0.784783808476337,0.0656455979200144,0.228492415126846,208.481482025778
16940,1005:1190,Breast,HCC70,SIDM00673,907048,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.743171812138207,0.118699299967489,0.742963871610115,11.4009670160232,52.8157,0.861903822605633,0.933732913779375,0.112640975938146,0.552149806817707,0.0977254543585091,0.454424352459198,4.72982264706949,0.5183,6.6711443689537,52.2974,0.640542625734676,0.412296053055349,0.693923981586506,0.414970348886561,0.228246572679327,0.278953632699944,True,0.784783808476337,0.0656455979200144,0.228492415126846,208.481482025778
16940,1011:1190,Breast,HCC70,SIDM00673,907048,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.853567252716322,0.118699299967489,0.742963871610115,11.4009670160232,52.8157,0.861903822605633,0.933732913779375,0.144936425179832,0.634169630757728,0.345113144827057,0.289056485930671,8.12346514520716,5.4467,3.27750187081603,47.369,0.735692877967187,0.569927469125954,0.797003837985467,0.682115718953582,0.165765408841233,0.114888119031885,True,0.784783808476337,0.0656455979200144,0.228492415126846,208.481482025778
16941,1012:1372,Breast,HCC70,SIDM00673,907048,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.928677231315273,0.156540889374648,0.682745164356931,10.7336414064286,3.3257,0.785719123590034,0.914934427424871,0.152043359369293,0.634049888928885,0.651708171135266,-0.017658282206381,10.9355817588932,3.8253,-0.201940352464536,-0.4996,0.729679460287055,0.722764386390102,0.849678770895954,0.855349461624607,0.0069150738969535,-0.0056706907286534,True,0.784783808476337,0.0656455979200144,0.228492415126846,208.481482025778
16941,1191:1372,Breast,HCC70,SIDM00673,907048,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.000625,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.939480420157209,0.156540889374648,0.682745164356931,10.7336414064286,3.3257,0.785719123590034,0.914934427424871,0.119844060082288,0.641425713870352,0.709007178096401,-0.067581464226049,11.5418905006502,5.8235,-0.808249094221521,-2.4978,0.738167732355919,0.7752696014,0.859562980293413,0.880495677846639,-0.0371018690440806,-0.0209326975532252,True,0.784783808476337,0.0656455979200144,0.228492415126846,208.481482025778
16941,1561:1372,Breast,HCC70,SIDM00673,907048,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.881626815752567,0.156540889374648,0.682745164356931,10.7336414064286,3.3257,0.785719123590034,0.914934427424871,0.12153328724631,0.601926445222464,0.643173144916637,-0.0412466996941729,11.2444543800508,4.7386,-0.510812973622171,-1.4129,0.692711049006579,0.71686912271202,0.806630725872987,0.819624241338255,-0.0241580737054408,-0.0129935154652684,True,0.784783808476337,0.0656455979200144,0.228492415126846,208.481482025778
16941,1053:1372,Breast,HCC70,SIDM00673,907048,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.566456238603837,0.156540889374648,0.682745164356931,10.7336414064286,3.3257,0.785719123590034,0.914934427424871,0.111595415277239,0.386745257726586,0.247626997600231,0.139118260126355,8.4283174767202,0.6728,2.30532392970844,2.6529,0.445075499347914,0.365382849477739,0.518270314328248,0.462397731360476,0.0796926498701752,0.0558725829677721,True,0.784783808476337,0.0656455979200144,0.228492415126846,208.481482025778
16943,1007:1549,Breast,HCC70,SIDM00673,907048,1007,Docetaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.001,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.895987506507028,0.096111898476552,0.866813724456048,13.2369152708967,94.2776,0.898376984409349,0.968086345557418,0.166621669790843,0.776654267581444,0.541059652865681,0.235594614715763,9.95369734330973,9.6842,3.28321792758699,84.5934,0.804934554164236,0.647344776963437,0.867393270839492,0.795352066845243,0.157589777200798,0.0720412039942482,True,0.784783808476337,0.0656455979200144,0.228492415126846,208.481482025778
16944,1047:1558,Breast,HCC70,SIDM00673,907048,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.974658787446531,0.0629756406174779,0.661178526609982,10.5122680295539,28.5258,0.906570152520666,0.907803058796562,0.0603401628267791,0.644423461031369,0.468696223534598,0.175727237496772,8.82693851240214,8.8696,1.68532951715178,19.6562,0.883596565591009,0.806064481198961,0.884798228526909,0.81608968659554,0.0775320843920478,0.0687085419313692,True,0.784783808476337,0.0656455979200144,0.228492415126846,208.481482025778
16944,1011:1558,Breast,HCC70,SIDM00673,907048,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.912260782173776,0.0629756406174779,0.661178526609982,10.5122680295539,28.5258,0.906570152520666,0.907803058796562,0.178835056957342,0.603167239841728,0.376907167070643,0.226260072771084,8.20619605018401,5.7682,2.30607197936992,22.7576,0.827028396433903,0.789348597664519,0.828153128477499,0.733353170965268,0.0376797987693839,0.0947999575122305,True,0.784783808476337,0.0656455979200144,0.228492415126846,208.481482025778
16945,1047:1561,Breast,HCC70,SIDM00673,907048,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.810075965254734,0.0718697329409003,0.362179121906496,7.71988649178906,4.1176,0.772809199050976,0.775006384463645,0.112873355477117,0.293392601773517,0.088517765524228,0.204874836249289,4.2538285062066,0.3726,3.46605798558246,3.745,0.626034157878957,0.414977949840955,0.627814044972969,0.421530039923765,0.211056208038002,0.206284005049204,True,0.784783808476337,0.0656455979200144,0.228492415126846,208.481482025778
16945,1047:1594,Breast,HCC70,SIDM00673,907048,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.810075965254734,0.0632418181405504,0.540627902731149,9.36841514397368,5.1637,0.854899140796158,0.863180282497977,0.042944509700979,0.437949670148578,0.22952205871004,0.208427611438538,6.90089199516667,0.9336,2.467523148807,4.2301,0.69253324667589,0.567695184055643,0.699241600533402,0.584476646977914,0.124838062620247,0.114764953555488,True,0.784783808476337,0.0656455979200144,0.228492415126846,208.481482025778
14494,1058:1007,Breast,HDQ-P1,SIDM01062,1290922,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1007,Docetaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.0125,0.925000715323092,0.106335712200493,0.785395177295319,12.4350558249351,0.1352,0.902614721240324,0.937691804091444,0.149748451334038,0.726491100809476,0.508898629873912,0.217592470935565,9.53302399061112,0.0181,2.90203183432397,0.1171,0.834919262808453,0.671542209854311,0.867365589537186,0.783198102610023,0.163377052954142,0.0841674869271639,True,0.708189887369254,0.089418288813517,0.330370805894907,146.4465421407
14494,1011:1007,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1007,Docetaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.0125,0.413409520935502,0.106335712200493,0.785395177295319,12.4350558249351,0.1352,0.902614721240324,0.937691804091444,0.0705861371863843,0.324689843990711,0.107228760551756,0.217461083438955,6.2220361843571,0.0018,6.21301964057799,0.1334,0.373149519497294,0.221332211785931,0.387650719514591,0.272630949460221,0.151817307711363,0.115019770054369,True,0.708189887369254,0.089418288813517,0.330370805894907,146.4465421407
14495,1179:1011,Breast,HDQ-P1,SIDM01062,1290922,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.67877870257912,0.118589527881296,0.177635498608063,4.94257955388417,0.6006,0.581695246262916,0.56914874557751,0.0512480494330485,0.120575193277176,0.0201643985307398,0.100410794746436,-0.230355229049311,0.0166,5.17293478293348,0.584,0.394842344554784,0.0995862514832098,0.386326047097636,0.14716388015169,0.295256093071574,0.239162166945946,True,0.708189887369254,0.089418288813517,0.330370805894907,146.4465421407
14495,1011:1012,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,5.0,0.402196398524273,0.0681620489698752,0.733759290651926,11.6841544267692,32.1352,0.92356663813576,0.920225253672959,0.0666166081238648,0.29511534408393,0.153007136836384,0.142108207247546,7.70865735874897,2.0429,3.97549706802026,30.0923,0.371455175655373,0.312067176686007,0.370111282858349,0.303178283769126,0.0593879989693659,0.066932999089223,True,0.708189887369254,0.089418288813517,0.330370805894907,146.4465421407
14496,1011:1021,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.478475623569523,0.0575130063133407,0.829865024957508,13.1956841968146,183.2427,0.963441500650945,0.951862809847344,0.0553235649659142,0.397070185295082,0.134685950502599,0.262384234792483,6.51891101388432,1.7911,6.67677318293027,181.4516,0.460983272796719,0.294256631776385,0.455443151494346,0.325077518086746,0.166726641020333,0.130365633407601,True,0.708189887369254,0.089418288813517,0.330370805894907,146.4465421407
14496,1073:1022,Breast,HDQ-P1,SIDM01062,1290922,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,10.0,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.939834876538298,0.0785756629130881,0.782970019765556,12.3971152732665,10.535,0.934772282066752,0.936896742075576,0.0328033235536106,0.73586253185955,0.543002032856364,0.192860499003186,9.83030348877952,1.7781,2.56681178448695,8.7569,0.878531592307629,0.777174390568332,0.880528233917732,0.80745381044952,0.101357201739297,0.0730744234682118,True,0.708189887369254,0.089418288813517,0.330370805894907,146.4465421407
14638,1011:1049,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.634604092187199,0.0818888602304874,0.827574301217489,13.1529548095047,177.8951,0.918464660592083,0.951151070615146,0.0426084776513316,0.525182038141581,0.500448411350762,0.0247336267908189,12.4856657465545,112.0185,0.667289062950216,65.8766,0.582861432141063,0.569618001723858,0.603604361700607,0.595727375509437,0.0132434304172053,0.0078769861911702,True,0.426909348050011,0.0513172991523152,0.830347464497082,59.4624675532501
14638,1558:1049,Breast,HDQ-P1,SIDM01062,1290922,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.718403455088296,0.0818888602304874,0.827574301217489,13.1529548095047,177.8951,0.918464660592083,0.951151070615146,0.0557002561813371,0.594532237336926,0.488008422649211,0.106523814687715,10.9871743273251,39.646,2.16578048217959,138.2491,0.659828185545851,0.629329247182058,0.683310215440852,0.646894516471775,0.0304989383637931,0.0364156989690768,True,0.426909348050011,0.0513172991523152,0.830347464497082,59.4624675532501
14497,1372:1053,Breast,HDQ-P1,SIDM01062,1290922,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.872486265248851,0.0446997286085792,0.785532131531626,12.4372076759473,108.3185,0.941467488489994,0.937736631935568,0.0605788869132297,0.685365995672998,0.572785282872569,0.112580712800429,10.7149631696714,32.8288,1.72224450627586,75.4897,0.821417452885851,0.721554917845187,0.818162331784501,0.778021526430209,0.0998625350406633,0.0401408053542919,True,0.708189887369254,0.089418288813517,0.330370805894907,146.4465421407
14497,1549:1053,Breast,HDQ-P1,SIDM01062,1290922,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.7274334711629,0.0446997286085792,0.785532131531626,12.4372076759473,108.3185,0.941467488489994,0.937736631935568,0.0429666671964789,0.571422365150043,0.44010958049718,0.131312784652862,10.1290021293361,21.8707,2.30820554661124,86.4478,0.684854963139294,0.626226365845153,0.682141013205497,0.633509326762754,0.0586285972941408,0.0486316864427435,True,0.708189887369254,0.089418288813517,0.330370805894907,146.4465421407
14497,1011:1053,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.417746279361684,0.0446997286085792,0.785532131531626,12.4372076759473,108.3185,0.941467488489994,0.937736631935568,0.0430093545880664,0.32815312526639,0.189696765588341,0.138456359678049,8.51246897018087,7.1324,3.92473870576644,101.1861,0.393294540456683,0.298333983789161,0.39173598901224,0.33343208049307,0.0949605566675226,0.0583039085191702,True,0.708189887369254,0.089418288813517,0.330370805894907,146.4465421407
14497,1558:1053,Breast,HDQ-P1,SIDM01062,1290922,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.787993332654628,0.0446997286085792,0.785532131531626,12.4372076759473,108.3185,0.941467488489994,0.937736631935568,0.0438563887817173,0.6189940822329,0.325719552981897,0.293274529251003,8.07299662937077,5.2595,4.36421104657654,103.059,0.741870103841213,0.57189177887622,0.738930213751235,0.610345522901237,0.169978324964993,0.128584690849998,True,0.708189887369254,0.089418288813517,0.330370805894907,146.4465421407
14498,1011:1073,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,20.0,0.288385351217114,0.0991329610922524,0.8513186799559,13.6201329061601,491.8454,0.930124560266563,0.958437309132398,0.0678167654601245,0.245507836516772,0.123168051935176,0.122339784581596,8.22234817925526,11.6663,5.39778472690483,480.1791,0.268234297988137,0.215715684173277,0.276399280013732,0.225736093189899,0.0525186138148595,0.0506631868238335,True,0.708189887369254,0.089418288813517,0.330370805894907,146.4465421407
14970,1549:1083,Breast,HDQ-P1,SIDM01062,1290922,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.448881587592194,0.128892517864098,0.59895030794983,10.0619622826869,20.8777,0.897146600471176,0.868314524077089,0.0706880441622075,0.268857765121353,0.139861818911679,0.128995946209674,6.90105955144686,2.3343,3.16090273124003,18.5434,0.402712590322441,0.336305625242254,0.389770402097084,0.316155820553826,0.0664069650801871,0.0736145815432578,True,0.351434956207464,0.0555390287068316,0.99773143132984,49.1756587478151
14970,1558:1083,Breast,HDQ-P1,SIDM01062,1290922,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.617602502673385,0.128892517864098,0.59895030794983,10.0619622826869,20.8777,0.897146600471176,0.868314524077089,0.134478163794726,0.36991320916681,0.166444007659745,0.203469201507065,6.35985106451236,1.6041,3.70211121817453,19.2736,0.554079985715918,0.450677486660564,0.536273223177659,0.413041189851027,0.103402499055354,0.123232033326633,True,0.351434956207464,0.0555390287068316,0.99773143132984,49.1756587478151
14970,1011:1083,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.264436318453093,0.128892517864098,0.59895030794983,10.0619622826869,20.8777,0.897146600471176,0.868314524077089,0.0517892694341045,0.158384214370599,0.0644837522438002,0.093900462126799,6.00372069385389,1.2532,4.058241588833,19.6245,0.237238144141305,0.157911946801697,0.229613896006295,0.170435171731821,0.0793261973396087,0.0591787242744735,True,0.351434956207464,0.0555390287068316,0.99773143132984,49.1756587478151
14770,1011:1190,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.468653499654622,0.113453548891613,0.403807533175829,7.96840148166594,4.8917,0.710296535744346,0.768706209782022,0.0589331886871636,0.189245813609752,0.0204361225228629,0.168809691086889,0.824066246272372,0.0346,7.14433523539356,4.8571,0.332882957269142,0.0840360161371203,0.360256855420585,0.130439435712796,0.248846941132022,0.229817419707789,True,0.571767757671913,0.0869986500856014,0.535957339471168,90.8697484849991
14771,1058:1372,Breast,HDQ-P1,SIDM01062,1290922,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.435226061455132,0.169119186911174,0.219463745637425,5.64065310649607,0.0974,0.551514105637392,0.619187984816202,0.111265790766834,0.0955163416459673,0.0566942926993392,0.0388220489466281,3.97306561291944,0.0307,1.66758749357663,0.0667,0.240033312033512,0.166796724520061,0.269486747931896,0.216748896929405,0.0732365875134509,0.0527378510024912,True,0.571767757671913,0.0869986500856014,0.535957339471168,90.8697484849991
14771,1011:1372,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.528531954686299,0.169119186911174,0.219463745637425,5.64065310649607,0.0974,0.551514105637392,0.619187984816202,0.0696501235447474,0.115993602464525,0.0303847607851989,0.0856088416793259,1.59459054193386,0.0059,4.04606256456221,0.0915,0.291492828289597,0.128145173622052,0.327260635933178,0.173444178617352,0.163347654667545,0.153816457315826,True,0.571767757671913,0.0869986500856014,0.535957339471168,90.8697484849991
14773,1549:1510,Breast,HDQ-P1,SIDM01062,1290922,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.50274044386651,0.0928409836065706,0.463679826900601,8.61466610616379,7.656,0.792126682452037,0.803430266129781,0.0934115856072016,0.233110601987955,0.0612776283237066,0.171832973664248,3.7717037240887,0.2668,4.84296238207509,7.3892,0.398234119934443,0.210136925152112,0.403916888609874,0.24291197220837,0.188097194782331,0.161004916401505,True,0.571767757671913,0.0869986500856014,0.535957339471168,90.8697484849991
14773,1558:1510,Breast,HDQ-P1,SIDM01062,1290922,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.677140971770711,0.0928409836065706,0.463679826900601,8.61466610616379,7.656,0.792126682452037,0.803430266129781,0.0400902892569286,0.313976608577948,0.122545583918119,0.191431024659829,5.0026665386781,0.6262,3.61199956748569,7.0298,0.536381431521082,0.375234597133403,0.544035551157121,0.388347215801202,0.16114683438768,0.155688335355918,True,0.571767757671913,0.0869986500856014,0.535957339471168,90.8697484849991
14773,1372:1510,Breast,HDQ-P1,SIDM01062,1290922,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.767255383361314,0.0928409836065706,0.463679826900601,8.61466610616379,7.656,0.792126682452037,0.803430266129781,0.133779455269938,0.355760843345528,0.165091098123595,0.190669745221933,5.5738292835074,0.9303,3.04083682265639,6.7257,0.607763461415464,0.424554338227445,0.616436196843487,0.471452964142789,0.183209123188018,0.144983232700698,True,0.571767757671913,0.0869986500856014,0.535957339471168,90.8697484849991
14773,1011:1510,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.563455249444439,0.0928409836065706,0.463679826900601,8.61466610616379,7.656,0.792126682452037,0.803430266129781,0.0651775712975369,0.261262832528632,0.0955426505878123,0.16572018194082,4.79362504819668,0.5417,3.82104105796711,7.1143,0.446327937452609,0.304194606449359,0.452697001013368,0.314578787780931,0.14213333100325,0.138118213232437,True,0.571767757671913,0.0869986500856014,0.535957339471168,90.8697484849991
14773,1083:1549,Breast,HDQ-P1,SIDM01062,1290922,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.970518879368068,0.127996991811922,0.243791749109282,6.00283227332928,0.6262,0.595829289949442,0.644461264776069,0.0778775403310712,0.236604495144722,0.0881259605259569,0.148478534618765,2.9001140976462,0.0729,3.10271817568308,0.5533,0.578263574776403,0.390457452279983,0.625461824486598,0.407085769787299,0.18780612249642,0.218376054699299,True,0.571767757671913,0.0869986500856014,0.535957339471168,90.8697484849991
14773,1011:1549,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.563455249444439,0.127996991811922,0.243791749109282,6.00283227332928,0.6262,0.595829289949442,0.644461264776069,0.0449172658423607,0.137365740806867,0.0431983575894138,0.0941673832174529,2.4112221398567,0.0519,3.59161013347258,0.5743,0.335723141194766,0.19345699618628,0.363125082701679,0.216634798408878,0.142266145008485,0.1464902842928,True,0.571767757671913,0.0869986500856014,0.535957339471168,90.8697484849991
14773,1510:1549,Breast,HDQ-P1,SIDM01062,1290922,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.444009160690545,0.127996991811922,0.243791749109282,6.00283227332928,0.6262,0.595829289949442,0.644461264776069,0.0624015267545714,0.108245769905292,0.063253213688375,0.0449925562169173,4.24740060415322,0.1855,1.75543166917606,0.4407,0.264553662945295,0.198894700579336,0.28614670527079,0.230099436122424,0.0656589623659591,0.0560472691483657,True,0.571767757671913,0.0869986500856014,0.535957339471168,90.8697484849991
14774,1058:1558,Breast,HDQ-P1,SIDM01062,1290922,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.854687949046106,0.115874980070616,0.305272059098694,6.82277693599888,2.211,0.713408123523732,0.699287358937068,0.0697861020159335,0.260912350092145,0.0839758800734951,0.17693647001865,3.13068647226561,0.1711,3.69209046373327,2.0399,0.60974132592733,0.35439627675521,0.597672478603791,0.372797930784339,0.25534504917212,0.224874547819452,True,0.571767757671913,0.0869986500856014,0.535957339471168,90.8697484849991
14774,1179:1558,Breast,HDQ-P1,SIDM01062,1290922,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.285827562160165,0.115874980070616,0.305272059098694,6.82277693599888,2.211,0.713408123523732,0.699287358937068,0.0334105895507716,0.0872551684477937,0.0708702543006133,0.0163849141471804,6.06217656885219,1.305,0.760600367146696,0.906,0.203911704772046,0.173375408968857,0.199875601054402,0.185372675777107,0.0305362958031896,0.0145029252772953,True,0.571767757671913,0.0869986500856014,0.535957339471168,90.8697484849991
14774,1011:1558,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.57797527150629,0.115874980070616,0.305272059098694,6.82277693599888,2.211,0.713408123523732,0.699287358937068,0.0467427587227279,0.176439701240852,0.0549661292777726,0.12147357196308,3.03511477402903,0.1601,3.78766216196985,2.0509,0.412332253888422,0.224159828735938,0.404170801142569,0.24808503679514,0.188172425152484,0.156085764347428,True,0.571767757671913,0.0869986500856014,0.535957339471168,90.8697484849991
14774,1011:1559,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1559,Luminespib,HSP90,Protein stability and degradation,Targeted,Early clinical trials,0.1,0.57797527150629,0.137661821997502,0.396634872504202,7.88928593810373,0.0463,0.793120181684516,0.764223443090599,0.10418534637938,0.229245148124479,0.113578244847337,0.115666903277142,5.27142579588252,0.0075,2.61786014222121,0.0388,0.458403852346226,0.341045512987318,0.441702252011761,0.342684664398544,0.117358339358908,0.0990175876132171,True,0.571767757671913,0.0869986500856014,0.535957339471168,90.8697484849991
14775,1011:1594,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.586369287572937,0.0804050064683791,0.441327998253213,8.37574800771505,2.595,0.784576976971107,0.790993423287597,0.0208531700731977,0.258781183921727,0.152679894927097,0.10610128899463,6.23587314960337,0.5888,2.13987485811168,2.0062,0.460051843032677,0.391749336629971,0.463814250088027,0.387243472206519,0.0683025064027054,0.0765707778815076,True,0.571767757671913,0.0869986500856014,0.535957339471168,90.8697484849991
14590,1022:1005,Breast,JIMT-1,SIDM01037,1298157,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.876528502404674,0.0480990004386974,0.93727401399007,14.5384629168488,185.9103,0.966208304231152,0.98683634567177,0.0461888367611167,0.821547387825534,0.480537581371283,0.341009806454251,9.39633570731071,5.2646,5.1421272095381,180.6457,0.846909117918691,0.780523271821703,0.864990184190178,0.769742110347246,0.0663858460969884,0.0952480738429313,True,0.505648476069936,0.0582043536125789,0.661021359282736,74.3055738857419
14590,1179:1005,Breast,JIMT-1,SIDM01037,1298157,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.374489429549573,0.0480990004386974,0.93727401399007,14.5384629168488,185.9103,0.966208304231152,0.98683634567177,0.0397165354209711,0.35099921083078,0.195337536151458,0.155661674679322,9.17715013602012,4.5226,5.3613127808287,181.3877,0.361834796677584,0.299463321912468,0.369559780149406,0.325102213105939,0.062371474765116,0.0444575670434674,True,0.505648476069936,0.0582043536125789,0.661021359282736,74.3055738857419
14591,1007:1011,Breast,JIMT-1,SIDM01037,1298157,1007,Docetaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.001,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.814064497855888,0.159161351940314,0.29919699883216,7.25681447137355,2.9871,0.792523327444637,0.75646895194682,0.0303122947178813,0.243565654614291,0.0598355317553253,0.183730122858966,3.80992557971788,0.2739,3.44688889165567,2.7132,0.645165104595297,0.378180756012247,0.615814517510158,0.394039845555912,0.266984348583049,0.221774671954246,True,0.505648476069936,0.0582043536125789,0.661021359282736,74.3055738857419
14591,1179:1011,Breast,JIMT-1,SIDM01037,1298157,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.383959861571885,0.159161351940314,0.29919699883216,7.25681447137355,2.9871,0.792523327444637,0.75646895194682,0.048205212914275,0.11487963825432,0.0104335214178971,0.104446116836422,1.67198220089559,0.0622,5.58483227047796,2.9249,0.304297147098132,0.0827126378643494,0.29045371407293,0.119301905170655,0.221584509233783,0.171151808902274,True,0.505648476069936,0.0582043536125789,0.661021359282736,74.3055738857419
14591,1058:1012,Breast,JIMT-1,SIDM01037,1298157,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,5.0,0.964952461190202,0.0738309792149694,0.523326836835715,9.19124130385939,5.7087,0.882008310796125,0.868784405868267,0.105522711159688,0.504985519211506,0.295745897276913,0.209239621934593,7.32754028900297,1.5686,1.86370101485642,4.1401,0.851096090292933,0.73617516546376,0.838335650686252,0.734597510747913,0.114920924829172,0.103738139938339,True,0.505648476069936,0.0582043536125789,0.661021359282736,74.3055738857419
14591,1011:1012,Breast,JIMT-1,SIDM01037,1298157,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,5.0,0.820577338021919,0.0738309792149694,0.523326836835715,9.19124130385939,5.7087,0.882008310796125,0.868784405868267,0.0927048544145318,0.429430142686082,0.206229579248545,0.223200563437537,6.76435671227832,1.0616,2.42688459158107,4.6471,0.723756031786294,0.610763279827625,0.712904795082338,0.592231868140138,0.112992751958668,0.1206729269422,True,0.505648476069936,0.0582043536125789,0.661021359282736,74.3055738857419
14591,1594:1012,Breast,JIMT-1,SIDM01037,1298157,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,5.0,0.900986701759338,0.0738309792149694,0.523326836835715,9.19124130385939,5.7087,0.882008310796125,0.868784405868267,0.10727581335305,0.471510520662758,0.253768728995192,0.217741791667566,7.08244936210217,1.3235,2.10879194175721,4.3852,0.794677758868526,0.701481621420205,0.782763196383197,0.670705950256236,0.093196137448321,0.11205724612696,True,0.505648476069936,0.0582043536125789,0.661021359282736,74.3055738857419
14592,1011:1021,Breast,JIMT-1,SIDM01037,1298157,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.929950097187786,0.0572229533179177,0.889942166867612,13.2808304083267,194.383,0.967473887386375,0.976311272961972,0.0841989224210628,0.827601804570044,0.302783527802894,0.52481827676715,7.50858815192938,3.5566,5.77224225639728,190.8264,0.899702435601605,0.742926311948858,0.907920763176517,0.719195549064023,0.156776123652747,0.188725214112493,True,0.505648476069936,0.0582043536125789,0.661021359282736,74.3055738857419
14592,1561:1021,Breast,JIMT-1,SIDM01037,1298157,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.852589568237815,0.0572229533179177,0.889942166867612,13.2808304083267,194.383,0.967473887386375,0.976311272961972,0.0335140423787034,0.758755407806283,0.611318848422401,0.147436559383882,10.9041135856337,37.4279,2.37671682269292,156.9551,0.82485814392811,0.799349154507232,0.832392806680359,0.795022452915796,0.0255089894208785,0.0373703537645639,True,0.505648476069936,0.0582043536125789,0.661021359282736,74.3055738857419
14592,1011:1022,Breast,JIMT-1,SIDM01037,1298157,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.773456327168547,0.0792326026329241,0.509680564217706,9.0793168396125,1.0565,0.874132911144013,0.863451761981579,0.105258447006531,0.39421565722902,0.176458262255424,0.217757394973596,6.5037192835863,0.1772,2.57559755602621,0.8793,0.676103630910598,0.575734320895223,0.667842228509483,0.543368327195708,0.100369310015375,0.124473901313774,True,0.505648476069936,0.0582043536125789,0.661021359282736,74.3055738857419
14594,1549:1053,Breast,JIMT-1,SIDM01037,1298157,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.920998346790399,0.0748299892594506,0.77708733198599,11.5576072268454,58.873,0.921403011513098,0.948791178684808,0.0733179226573597,0.715696148070858,0.506364623263301,0.209331524807557,9.40933562943705,13.2807,2.14827159740837,45.5923,0.848610650331258,0.765187843885865,0.873835107018022,0.809326803092066,0.0834228064453932,0.0645083039259556,True,0.505648476069936,0.0582043536125789,0.661021359282736,74.3055738857419
14594,1049:1053,Breast,JIMT-1,SIDM01037,1298157,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.937150506010011,0.0748299892594506,0.77708733198599,11.5576072268454,58.873,0.921403011513098,0.948791178684808,0.0667702848212189,0.728247786384639,0.671052461248841,0.0571953251357978,10.8944536130034,37.1781,0.663153613842034,21.6949,0.863493298478647,0.826102095283329,0.889160133202302,0.873619899043468,0.0373912031953183,0.015540234158834,True,0.505648476069936,0.0582043536125789,0.661021359282736,74.3055738857419
14594,1558:1053,Breast,JIMT-1,SIDM01037,1298157,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.974636156881371,0.0748299892594506,0.77708733198599,11.5576072268454,58.873,0.921403011513098,0.948791178684808,0.0427964135933414,0.757377410808023,0.507083003834842,0.250294406973181,9.16622694569547,11.2212,2.39138028114995,47.6518,0.898032690080047,0.823574029081875,0.924726188076307,0.845599668777103,0.0744586609981724,0.0791265192992047,True,0.505648476069936,0.0582043536125789,0.661021359282736,74.3055738857419
14594,1372:1053,Breast,JIMT-1,SIDM01037,1298157,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.960568576230317,0.0748299892594506,0.77708733198599,11.5576072268454,58.873,0.921403011513098,0.948791178684808,0.072123050845938,0.746445672092398,0.46209199363192,0.284353678460477,8.84476938056062,8.9799,2.71283784628479,49.8931,0.885070778903463,0.774976348142194,0.91137899164915,0.818208001862523,0.110094430761268,0.0931709897866275,True,0.505648476069936,0.0582043536125789,0.661021359282736,74.3055738857419
14594,1510:1053,Breast,JIMT-1,SIDM01037,1298157,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.940634521939279,0.0748299892594506,0.77708733198599,11.5576072268454,58.873,0.921403011513098,0.948791178684808,0.0566182150065747,0.730955171027711,0.523606483750837,0.207348687276874,9.46612010900321,13.8139,2.0914871178422,45.0591,0.866703481248035,0.785443069306931,0.892465736782389,0.828935958260594,0.0812604119411042,0.0635297785217959,True,0.505648476069936,0.0582043536125789,0.661021359282736,74.3055738857419
14594,1011:1053,Breast,JIMT-1,SIDM01037,1298157,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.802848571480764,0.0748299892594506,0.77708733198599,11.5576072268454,58.873,0.921403011513098,0.948791178684808,0.0568268975252476,0.62388345440075,0.314965808230211,0.308917646170539,8.10373023675623,5.3727,3.45387699008918,53.5003,0.739747091551365,0.616696069745351,0.761735642440649,0.650908770421664,0.123051021806014,0.110826872018985,True,0.505648476069936,0.0582043536125789,0.661021359282736,74.3055738857419
14594,1594:1053,Breast,JIMT-1,SIDM01037,1298157,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.996093876730846,0.0748299892594506,0.77708733198599,11.5576072268454,58.873,0.921403011513098,0.948791178684808,0.0215795730940313,0.774051933076355,0.549780035220754,0.2242718978556,9.4270197254959,13.4445,2.13058750134951,45.4285,0.917803897769559,0.872393223667385,0.94508508338418,0.876097290880271,0.0454106741021736,0.0689877925039089,True,0.505648476069936,0.0582043536125789,0.661021359282736,74.3055738857419
14944,1558:1083,Breast,JIMT-1,SIDM01037,1298157,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.857401308419076,0.062211655822021,0.661770152011441,10.374667383811,25.9308,0.915010489161561,0.916238649046991,0.0433097801496992,0.5674025942073,0.377230189542044,0.190172404665257,8.50582097597382,7.0997,1.86884640783721,18.8311,0.784531190624301,0.702271537604008,0.785584216517017,0.714907109971488,0.0822596530202926,0.0706771065455291,True,0.44752476350186,0.0619279773970352,0.778495579017442,63.1728640303715
14944,1011:1083,Breast,JIMT-1,SIDM01037,1298157,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.279209907038354,0.062211655822021,0.661770152011441,10.374667383811,25.9308,0.915010489161561,0.916238649046991,0.0501554369114187,0.184772782623872,0.0596070124170667,0.125165770206805,6.3291842326445,1.5704,4.04548315116654,24.3604,0.255479993617918,0.167005737709812,0.255822908025358,0.192480066041414,0.0884742559081063,0.0633428419839432,True,0.44752476350186,0.0619279773970352,0.778495579017442,63.1728640303715
14945,1179:1190,Breast,JIMT-1,SIDM01037,1298157,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.332421110276689,0.119996606637991,0.595916953999734,9.79564646764408,17.3586,0.836031327688437,0.895029109201394,0.0791291093531438,0.198095375481294,0.0537785912218397,0.144316784259455,5.63076983989568,0.9677,4.1648766277484,16.3909,0.277914462176285,0.164911337223711,0.297526570210684,0.211027832411902,0.113003124952574,0.0864987377987814,True,0.44752476350186,0.0619279773970352,0.778495579017442,63.1728640303715
14945,1005:1190,Breast,JIMT-1,SIDM01037,1298157,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.957501399212369,0.119996606637991,0.595916953999734,9.79564646764408,17.3586,0.836031327688437,0.895029109201394,0.103453482835214,0.570591317269118,0.267343956886997,0.303247360382122,7.05761845734915,2.6019,2.73802801029493,14.7567,0.800501166047053,0.730031532848202,0.856991624396135,0.711110737502716,0.070469633198851,0.145880886893419,True,0.44752476350186,0.0619279773970352,0.778495579017442,63.1728640303715
14945,1011:1190,Breast,JIMT-1,SIDM01037,1298157,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.323238392297621,0.119996606637991,0.595916953999734,9.79564646764408,17.3586,0.836031327688437,0.895029109201394,0.0495326825012292,0.192623238153769,0.0566131349244035,0.136010103229366,5.82626291241339,1.1082,3.96938355523069,16.2504,0.270237422272456,0.174776612295868,0.28930777031783,0.210225390594834,0.0954608099765873,0.0790823797229961,True,0.44752476350186,0.0619279773970352,0.778495579017442,63.1728640303715
14946,1011:1372,Breast,JIMT-1,SIDM01037,1298157,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.317817346817383,0.171951456165201,0.530561530457373,9.25068438270967,1.1898,0.736107549756122,0.87155622550281,0.0811587210282936,0.168621657933332,0.0215454897267932,0.147076168206539,3.63171118316619,0.0242,5.61897319954347,1.1656,0.233947748435735,0.0898045318624683,0.276995687191475,0.149086220186113,0.144143216573267,0.127909467005363,True,0.44752476350186,0.0619279773970352,0.778495579017442,63.1728640303715
14946,1053:1372,Breast,JIMT-1,SIDM01037,1298157,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.912459773684126,0.171951456165201,0.530561530457373,9.25068438270967,1.1898,0.736107549756122,0.87155622550281,0.15025033555894,0.484116054006638,0.350373670501849,0.133742383504789,8.03195718210945,0.5112,1.21872720060021,0.6786,0.671668528257647,0.618360723438533,0.795259996275285,0.735846215636797,0.0533078048191137,0.0594137806384873,True,0.44752476350186,0.0619279773970352,0.778495579017442,63.1728640303715
14948,1011:1549,Breast,JIMT-1,SIDM01037,1298157,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.278108121174532,0.0928030119923708,0.49434618212687,8.95367976200317,4.842,0.800138057658645,0.857288954068634,0.0457244898543638,0.137481687921107,0.0966175490900325,0.0408641388310744,7.70879110328619,2.043,1.24488865871698,2.799,0.222524891895685,0.177517301034295,0.238419020319708,0.218693024340611,0.0450075908613906,0.0197259959790969,True,0.44752476350186,0.0619279773970352,0.778495579017442,63.1728640303715
14949,1011:1558,Breast,JIMT-1,SIDM01037,1298157,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.268091134352426,0.126119834090239,0.360913911605216,7.82971811704992,4.4433,0.813687469137553,0.794005018581217,0.0544620750501582,0.0967578199658135,0.0268102807146569,0.0699475392511566,4.4999705969477,0.4419,3.32974752010222,4.0014,0.218142396609441,0.104047236105383,0.212865706112957,0.145286170087361,0.114095160504058,0.0675795360255959,True,0.44752476350186,0.0619279773970352,0.778495579017442,63.1728640303715
14518,1179:1005,Breast,MDA-MB-157,SIDM00529,925338,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.301083698009921,0.0438579591821818,0.955076527569648,15.244674763306,303.3154,0.977045443480989,0.990682134386107,0.0455710968374867,0.287557972803144,0.18275837160442,0.104799601198724,9.88808610632915,7.4029,5.35658865697685,295.9125,0.294172455246999,0.236609800559321,0.29827824057333,0.270675165206998,0.0575626546876781,0.0276030753663327,True,0.88269461541052,0.0932134688289197,0.112250489232927,404.708980486918
14518,1011:1007,Breast,MDA-MB-157,SIDM00529,925338,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1007,Docetaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.0125,0.814282484164291,0.0702898278410919,0.651672913669912,10.27964856129,0.0303,0.866444065192814,0.913337703549262,0.0746120164860711,0.530645839005717,0.490777552839581,0.039868286166136,9.85141586036666,0.0226,0.428232700923299,0.0077,0.705530225794612,0.757771608778203,0.743714894127002,0.730877078515291,-0.0522413829835909,0.012837815611711,True,0.88269461541052,0.0932134688289197,0.112250489232927,404.708980486918
14520,1510:1021,Breast,MDA-MB-157,SIDM00529,925338,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.879153097637823,0.0737705509230625,0.639659346201638,10.1723680058733,22.5381,0.89757974741936,0.909580431403529,0.0585898122235378,0.562358495646154,0.538310113897241,0.0240483817489137,9.93361291172717,19.1005,0.238755094146086,3.4376,0.789110015320705,0.818038115132209,0.79966045381916,0.791904591433601,-0.0289280998115037,0.007755862385559,True,0.88269461541052,0.0932134688289197,0.112250489232927,404.708980486918
14522,1179:1073,Breast,MDA-MB-157,SIDM00529,925338,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,20.0,0.590016718995571,0.151088915111774,0.599608684524624,9.82497773902456,35.4302,0.790746439399218,0.896530507691621,0.131313919992117,0.353779148724469,0.0257214638718913,0.328057684852578,2.69113705142379,0.2523,7.13384068760077,35.1779,0.466553619731757,0.204811956601662,0.528967988627644,0.230732708722078,0.261741663130095,0.298235279905566,True,0.88269461541052,0.0932134688289197,0.112250489232927,404.708980486918
14522,1022:1073,Breast,MDA-MB-157,SIDM00529,925338,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,20.0,0.868912433606641,0.151088915111774,0.599608684524624,9.82497773902456,35.4302,0.790746439399218,0.896530507691621,0.119990139897567,0.521007441281967,0.0799013548789334,0.441106086403034,4.32187834948209,0.7812,5.50309938954248,34.649,0.68708941302416,0.428324539635531,0.779006505240924,0.457956794083769,0.25876487338863,0.321049711157155,True,0.88269461541052,0.0932134688289197,0.112250489232927,404.708980486918
14972,1191:1083,Breast,MDA-MB-157,SIDM00529,925338,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.000625,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.935039246703921,0.0443474913710911,0.776232558445605,11.540999647674,58.1992,0.949480859956192,0.948693955922479,0.0379658827702926,0.725807906716036,0.752462089304739,-0.026654182588703,11.8930514466945,74.284,-0.352051799020527,-16.0848,0.887801868053229,0.916043631186951,0.887066081898318,0.893889993396066,-0.0282417631337222,-0.0068239114977486,True,0.635112423093796,0.0628373315311006,0.431274880766871,111.964055716369
14972,1372:1083,Breast,MDA-MB-157,SIDM00529,925338,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.909494962683179,0.0443474913710911,0.776232558445605,11.540999647674,58.1992,0.949480859956192,0.948693955922479,0.0367451628599985,0.705979601776954,0.575806009667499,0.130173592109456,10.1145052835187,21.6521,1.42649436415532,36.5471,0.86354805929425,0.845687820434241,0.862832374039473,0.825367679223975,0.0178602388600089,0.0374646948154976,True,0.635112423093796,0.0628373315311006,0.431274880766871,111.964055716369
14972,1594:1083,Breast,MDA-MB-157,SIDM00529,925338,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.931533065741698,0.0443474913710911,0.776232558445605,11.540999647674,58.1992,0.949480859956192,0.948693955922479,0.0729963397827556,0.723086294897356,0.606439121779689,0.116647173117667,10.2737024521682,24.1781,1.26729719550575,34.0211,0.884472816338055,0.88536499830343,0.883739789211086,0.850613359614305,-0.0008921819653747,0.0331264295967807,True,0.635112423093796,0.0628373315311006,0.431274880766871,111.964055716369
14778,1022:1190,Breast,MDA-MB-157,SIDM00529,925338,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.286578604900193,0.177476898991617,0.0434056540529019,2.68186674679442,0.1253,0.414489386874783,0.390305585775987,0.0846770681924215,0.0124391317832611,0.0603226510265169,-0.0478835192432558,6.29942371617375,1.5383,-3.61755696937933,-1.413,0.118783790236512,0.156198074937056,0.111853230256435,0.196969784162601,-0.0374142847005442,-0.0851165539061655,True,1.16233266115988,0.12451110912926,-0.158516925774237,-334.669355656386
14778,1179:1190,Breast,MDA-MB-157,SIDM00529,925338,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.165571231044847,0.177476898991617,0.0434056540529019,2.68186674679442,0.1253,0.414489386874783,0.390305585775987,0.0357987142992729,0.0071867275758457,0.0215417691044369,-0.0143550415285912,5.11851874174845,0.6785,-2.43665199495403,-0.5532,0.0686275180398817,0.0834685322166124,0.0646233763206102,0.0982419034778007,-0.0148410141767307,-0.0336185271571905,True,1.16233266115988,0.12451110912926,-0.158516925774237,-334.669355656386
14973,1049:1558,Breast,MDA-MB-157,SIDM00529,925338,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.959641487337631,0.0752853326122851,0.769163767689821,11.4587756803945,54.975,0.92745349599807,0.946843155743309,0.0446762567750853,0.738121462032075,0.64498196976419,0.0931394922678849,10.4662236418662,27.6298,0.992552038528354,27.3452,0.890022852336073,0.850349754537615,0.908629974252965,0.882461364773909,0.039673097798459,0.026168609479056,True,0.635112423093796,0.0628373315311006,0.431274880766871,111.964055716369
14973,1179:1558,Breast,MDA-MB-157,SIDM00529,925338,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.153682830608024,0.0752853326122851,0.769163767689821,11.4587756803945,54.975,0.92745349599807,0.946843155743309,0.0292043600301832,0.118207265019704,0.0796466074917102,0.0385606575279942,9.14922056877559,11.0897,2.30955511161894,43.8853,0.142533678522291,0.115414500904335,0.145513536316466,0.133264639925938,0.0271191776179561,0.0122488963905283,True,0.635112423093796,0.0628373315311006,0.431274880766871,111.964055716369
14640,1011:1007,Breast,MDA-MB-175-VII,SIDM00633,908120,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1007,Docetaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.0125,0.803902248470925,0.0950551264494394,0.563134681806519,9.70372447407394,0.0204,0.816161315871784,0.846606130635428,0.0934703672672236,0.45270523689622,0.249641759582524,0.203063477313696,6.78924886691343,0.0027,2.91447560716051,0.0177,0.656113916944316,0.562116042721221,0.68058857198709,0.556348896384378,0.0939978742230956,0.124239675602712,True,0.598112586962495,0.093053735965983,0.491764104536414,98.803679052796
16659,1021:1011,Breast,MDA-MB-175-VII,SIDM00633,908120,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.841043624429815,0.119567720704606,0.613719280904812,10.2832354745639,24.3384,0.887316882844365,0.869368950243233,0.0963834408049411,0.516164688394643,0.460165969915057,0.0559987184795859,9.52415856635236,14.3809,0.759076908211584,9.9575,0.74627220716519,0.747417818943144,0.731177212879312,0.705635521577916,-0.0011456117779532,0.0255416913013962,True,,,,
16659,1191:1011,Breast,MDA-MB-175-VII,SIDM00633,908120,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.0025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.866890375681244,0.119567720704606,0.613719280904812,10.2832354745639,24.3384,0.887316882844365,0.869368950243233,0.140551844556525,0.532027337986396,0.301455578660344,0.230571759326052,7.25666049854755,2.9868,3.02657497601639,21.3516,0.769206465917262,0.66641963019815,0.753647575881965,0.625004320863715,0.102786835719112,0.12864325501825,True,,,,
16659,1549:1011,Breast,MDA-MB-175-VII,SIDM00633,908120,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.210348703561651,0.119567720704606,0.613719280904812,10.2832354745639,24.3384,0.887316882844365,0.869368950243233,0.063674213322042,0.129095055089116,0.0600269406685832,0.069068114420533,6.45559734472974,1.7142,3.8276381298342,22.6242,0.186645955954678,0.0930962214223668,0.182870631600418,0.14106799300134,0.093549734532311,0.041802638599078,True,,,,
16659,1558:1011,Breast,MDA-MB-175-VII,SIDM00633,908120,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.284401402683202,0.119567720704606,0.613719280904812,10.2832354745639,24.3384,0.887316882844365,0.869368950243233,0.0553740698429556,0.174542624343055,0.0689644867979333,0.105578137545121,5.8427911542333,1.1209,4.44044432033064,23.2175,0.252354166105424,0.15693884007687,0.247249748898399,0.179125996013197,0.0954153260285539,0.0681237528852016,True,,,,
16659,1047:1011,Breast,MDA-MB-175-VII,SIDM00633,908120,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.811249749211919,0.119567720704606,0.613719280904812,10.2832354745639,24.3384,0.887316882844365,0.869368950243233,0.155528112196615,0.497879612720548,0.37920861234178,0.118671000378768,8.63847166754364,7.7834,1.6447638070203,16.555,0.719835598678993,0.688487849579053,0.705275342857452,0.647088921723946,0.0313477490999398,0.0581864211335058,True,,,,
16659,1561:1011,Breast,MDA-MB-175-VII,SIDM00633,908120,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.710823458305557,0.119567720704606,0.613719280904812,10.2832354745639,24.3384,0.887316882844365,0.869368950243233,0.0737018293859737,0.436246061681558,0.372021411840456,0.0642246498411028,9.25925460892008,11.9686,1.02398086564386,12.3698,0.630725655276339,0.60178722734557,0.617967843755367,0.588063024116323,0.0289384279307691,0.0299048196390442,True,,,,
16659,1190:1011,Breast,MDA-MB-175-VII,SIDM00633,908120,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.60442948536751,0.119567720704606,0.613719280904812,10.2832354745639,24.3384,0.887316882844365,0.869368950243233,0.0713526460802784,0.370950029117414,0.0723312309423385,0.298618798175075,3.46881891918728,0.2162,6.81441655537666,24.1222,0.536320486855522,0.240069096127665,0.52547222719001,0.279220695853918,0.296251390727858,0.246251531336092,True,,,,
16659,1372:1011,Breast,MDA-MB-175-VII,SIDM00633,908120,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.764443526709663,0.119567720704606,0.613719280904812,10.2832354745639,24.3384,0.887316882844365,0.869368950243233,0.0905238548269117,0.469153731504593,0.324366330481819,0.144787401022775,8.15441089001009,5.5648,2.12882458455385,18.7736,0.678303647230572,0.617837174564968,0.664583466335815,0.590455016273068,0.0604664726656036,0.0741284500627474,True,,,,
16659,1510:1011,Breast,MDA-MB-175-VII,SIDM00633,908120,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.912287965827525,0.119567720704606,0.613719280904812,10.2832354745639,24.3384,0.887316882844365,0.869368950243233,0.123859127123348,0.559888714365783,0.391132935940082,0.1687557784257,8.20451418610797,5.7615,2.07872128845597,18.5769,0.809488514094507,0.756691509313132,0.793114831171011,0.707110354446597,0.0527970047813744,0.0860044767244134,True,,,,
16659,1053:1011,Breast,MDA-MB-175-VII,SIDM00633,908120,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.523562940344108,0.119567720704606,0.613719280904812,10.2832354745639,24.3384,0.887316882844365,0.869368950243233,0.0659466713795102,0.321320671256395,0.178299957990808,0.143020713265587,7.16833446304261,2.8094,3.11490101152133,21.529,0.464566236198964,0.354764381981431,0.455169363833218,0.374668830680915,0.109801854217533,0.0805005331523024,True,,,,
14642,1011:1021,Breast,MDA-MB-175-VII,SIDM00633,908120,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.912412069444896,0.0707767133630781,0.723507227729146,11.6661957879411,63.4753,0.898918441398167,0.913151303557714,0.0965338718845077,0.66013672691069,0.331691142764145,0.328445584146545,7.44764980912769,3.4095,4.21854597881344,60.0658,0.820184035378282,0.693114109481691,0.833170270595399,0.668237243854172,0.127069925896592,0.164933026741227,True,0.598112586962495,0.093053735965983,0.491764104536414,98.803679052796
14952,1549:1083,Breast,MDA-MB-175-VII,SIDM00633,908120,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.209389118972983,0.0521307976142084,0.867285593859416,14.202999378525,368.3485,0.962849266848194,0.961681675471606,0.0503900824632502,0.181600166396184,0.0933139035303874,0.0882862628657962,8.39501717868746,6.5748,5.80798219983754,361.7737,0.201610159689126,0.13209684904146,0.201365678759462,0.164407070827129,0.0695133106476663,0.0369586079323334,True,0.492633513852012,0.0797582499680435,0.680783591662838,71.8826484127235
14952,1558:1083,Breast,MDA-MB-175-VII,SIDM00633,908120,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.268695386572927,0.0521307976142084,0.867285593859416,14.202999378525,368.3485,0.962849266848194,0.961681675471606,0.0593490667147374,0.233035637911186,0.100386656907854,0.132648981003333,7.56765282164416,3.7053,6.63534655688084,364.6432,0.258713155967235,0.17931142572003,0.258399429550943,0.198681470476356,0.0794017302472047,0.0597179590745875,True,0.492633513852012,0.0797582499680435,0.680783591662838,71.8826484127235
14954,1058:1372,Breast,MDA-MB-175-VII,SIDM00633,908120,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.836068655596064,0.13222419925216,0.240768891375697,5.81675837276362,0.1101,0.583495212475629,0.628065019599045,0.059994898396013,0.201299323321834,0.118534436618618,0.0827648867032159,4.00918106882616,0.0314,1.80757730393746,0.0787,0.487842057841239,0.38997484591462,0.525105476563089,0.418584891386958,0.0978672119266192,0.106520585176131,True,0.492633513852012,0.0797582499680435,0.680783591662838,71.8826484127235
14954,1011:1372,Breast,MDA-MB-175-VII,SIDM00633,908120,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.921252102170758,0.13222419925216,0.240768891375697,5.81675837276362,0.1101,0.583495212475629,0.628065019599045,0.066293428668204,0.221808847317184,0.0715431070016692,0.150265740315514,2.14110183564385,0.0086,3.67565653711977,0.1015,0.537546191099746,0.308873873075939,0.578606219605538,0.34000745603792,0.228672318023807,0.238598763567618,True,0.492633513852012,0.0797582499680435,0.680783591662838,71.8826484127235
14954,1561:1372,Breast,MDA-MB-175-VII,SIDM00633,908120,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.694051036664958,0.13222419925216,0.240768891375697,5.81675837276362,0.1101,0.583495212475629,0.628065019599045,0.0681401492552484,0.167105898655975,0.0781053002470387,0.0890005984089365,3.27610410559322,0.0189,2.5406542671704,0.0912,0.40497545710775,0.276512262063056,0.435909177945714,0.311088536303798,0.128463195044695,0.124820641641916,True,0.492633513852012,0.0797582499680435,0.680783591662838,71.8826484127235
14954,1053:1372,Breast,MDA-MB-175-VII,SIDM00633,908120,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.684258989651618,0.13222419925216,0.240768891375697,5.81675837276362,0.1101,0.583495212475629,0.628065019599045,0.0614391689902217,0.164748278352275,0.059538750799971,0.105209527552304,2.4845665076649,0.0109,3.33219186509872,0.0992,0.39926184455513,0.234550027512281,0.429759135746366,0.268647374913627,0.164711817042849,0.16111176083274,True,0.492633513852012,0.0797582499680435,0.680783591662838,71.8826484127235
14956,1191:1510,Breast,MDA-MB-175-VII,SIDM00633,908120,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.0025,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.487636143181659,0.0923278533244352,0.850055533751523,13.8090478738843,280.3288,0.935999531956903,0.9562945806539,0.0307502261773432,0.414517801968819,0.272339026462752,0.142178775506067,9.65143537079799,15.7073,4.15761250308628,264.6215,0.456427201783302,0.426344158047326,0.46632380105559,0.411768913906661,0.0300830437359756,0.0545548871489288,True,0.492633513852012,0.0797582499680435,0.680783591662838,71.8826484127235
14956,1549:1510,Breast,MDA-MB-175-VII,SIDM00633,908120,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.23261796354563,0.0923278533244352,0.850055533751523,13.8090478738843,280.3288,0.935999531956903,0.9562945806539,0.0745453112171972,0.197738187161973,0.0243471845279301,0.173391002634043,3.05070204071213,0.1618,10.7583458331721,280.167,0.217730305003477,0.0296777420157333,0.222451297901432,0.100545299526642,0.188052562987744,0.12190599837479,True,0.492633513852012,0.0797582499680435,0.680783591662838,71.8826484127235
14956,1558:1510,Breast,MDA-MB-175-VII,SIDM00633,908120,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.279232879082326,0.0923278533244352,0.850055533751523,13.8090478738843,280.3288,0.935999531956903,0.9562945806539,0.0632875839570644,0.237363454069301,0.0295334471175326,0.207830006951769,3.08309891851914,0.1655,10.7259489553651,280.1633,0.261361844128036,0.062185512061061,0.267028889006814,0.121333790758986,0.199176332066975,0.145695098247829,True,0.492633513852012,0.0797582499680435,0.680783591662838,71.8826484127235
14956,1372:1510,Breast,MDA-MB-175-VII,SIDM00633,908120,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.720421187228267,0.0923278533244352,0.850055533751523,13.8090478738843,280.3288,0.935999531956903,0.9562945806539,0.0531753848531669,0.61239801683523,0.53273482148818,0.0796631953470501,11.891608203394,74.2097,1.9174396704903,206.1191,0.674313894057494,0.688015515886468,0.68893487713464,0.662053094440574,-0.0137016218289744,0.0268817826940655,True,0.492633513852012,0.0797582499680435,0.680783591662838,71.8826484127235
15960,1372:1561,Breast,MDA-MB-175-VII,SIDM00633,908120,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.76871915454381,0.118140051269836,0.204634923967386,5.23717645404359,0.7367,0.554586014142615,0.588024815368812,0.0876926788006665,0.157306785742346,0.0718023587227521,0.085504427019594,2.70056124131937,0.127,2.53661521272422,0.6097,0.426320891913532,0.285316658484277,0.452025938921094,0.313346847580676,0.141004233429255,0.138679091340417,True,0.606724998772362,0.0809637616729586,0.484316154961979,101.093913374266
15960,1011:1561,Breast,MDA-MB-175-VII,SIDM00633,908120,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.952298217961637,0.118140051269836,0.204634923967386,5.23717645404359,0.7367,0.554586014142615,0.588024815368812,0.106639250817481,0.194873473426857,0.0685323840431292,0.126341089383728,1.91301096325847,0.0736,3.32416549078512,0.6631,0.528131272974459,0.297524784027975,0.559974983792941,0.336826220680512,0.230606488946484,0.223148763112429,True,0.606724998772362,0.0809637616729586,0.484316154961979,101.093913374266
15960,1011:1594,Breast,MDA-MB-175-VII,SIDM00633,908120,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.952298217961637,0.0900233471330413,0.458314815073671,8.53676494992871,2.9014,0.772069326373995,0.792491809247465,0.126115537628286,0.436452381660074,0.210182843957661,0.226269537702413,5.5033919753765,0.3544,3.03337297455221,2.547,0.735240243648798,0.596368569287615,0.754688537695555,0.577622569255343,0.138871674361182,0.177065968440212,True,0.606724998772362,0.0809637616729586,0.484316154961979,101.093913374266
16349,1011:1012,Breast,MDA-MB-330,SIDM00631,1330941,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,5.0,0.110091064985896,0.08843951306571,0.570811823587083,9.73989755058139,8.3503,0.86888227803997,0.85862163618144,0.0369383224352804,0.0628412815652435,0.0267538633279932,0.0360874182372503,6.05193099090029,0.6479,3.6879665596811,7.7024,0.0956561753367919,0.0830555554249425,0.0945265703471473,0.0715087358866535,0.0126006199118494,0.0230178344604938,True,1.2687345046887,0.126619903169921,-0.246402683295768,-211.666710732691
16352,1510:1053,Breast,MDA-MB-330,SIDM00631,1330941,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.943595191796218,0.0873240448330276,0.532355225730595,9.33627021810267,12.6249,0.81467515463419,0.84120846683648,0.0637041739875055,0.50232783132698,0.27068878964351,0.23163904168347,6.63722853071976,1.9442,2.69904168738291,10.6807,0.768723558788662,0.63077499534742,0.793760264605171,0.650440798081612,0.137948563441243,0.143319466523559,True,1.2687345046887,0.126619903169921,-0.246402683295768,-211.666710732691
16352,1594:1053,Breast,MDA-MB-330,SIDM00631,1330941,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.862520716805121,0.0873240448330276,0.532355225730595,9.33627021810267,12.6249,0.81467515463419,0.84120846683648,0.0508050324424562,0.459167410892105,0.162806293576253,0.296361117315852,5.21673013586655,0.7263,4.11954008223612,11.8986,0.702674198338404,0.496143853391694,0.725559729798337,0.508899376992179,0.206530344946709,0.216660352806158,True,1.2687345046887,0.126619903169921,-0.246402683295768,-211.666710732691
16353,1510:1058,Breast,MDA-MB-330,SIDM00631,1330941,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.921342058000037,0.082941474073318,0.44188435414427,8.3941054875114,2.6283,0.79003339720849,0.794947869896303,0.0509440359106369,0.407126640245298,0.214743408248222,0.192383231997077,5.90973760119886,0.4697,2.48436788631253,2.1586,0.727890996072831,0.591032659986354,0.732418906453005,0.589299977800966,0.136858336086477,0.14311892865204,True,1.2687345046887,0.126619903169921,-0.246402683295768,-211.666710732691
17410,1549:1083,Breast,MDA-MB-330,SIDM00631,1330941,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.773941174326045,0.0884540340270005,0.882558296736826,14.2330795946841,376.1092,0.947097468531858,0.968315763561602,0.0861254365905093,0.683048204587693,0.474738650026258,0.208309554561435,10.1977981882757,22.9389,4.03528140640837,353.1703,0.732997726996771,0.654028660821583,0.749419439169287,0.678463549727674,0.0789690661751876,0.0709558894416128,True,0.866011726594057,0.0829583284765429,0.12999515883458,351.428580224315
17410,1559:1083,Breast,MDA-MB-330,SIDM00631,1330941,1559,Luminespib,HSP90,Protein stability and degradation,Targeted,Early clinical trials,0.01,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.768115371525269,0.0884540340270005,0.882558296736826,14.2330795946841,376.1092,0.947097468531858,0.968315763561602,0.0438367342345157,0.677906593990716,0.361231113879305,0.316675480111411,8.69121010111167,8.0732,5.54186949357239,368.036,0.72748012391199,0.626188406916187,0.743778222481894,0.622462053748425,0.101291716995803,0.12131616873347,True,0.866011726594057,0.0829583284765429,0.12999515883458,351.428580224315
17410,1558:1083,Breast,MDA-MB-330,SIDM00631,1330941,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.540713905129216,0.0884540340270005,0.882558296736826,14.2330795946841,376.1092,0.947097468531858,0.968315763561602,0.0403809921955633,0.477211543132759,0.223731206215699,0.25348033691706,8.09602354777814,5.3441,6.13705604690592,370.7651,0.512108770747856,0.404716465740502,0.523581797913573,0.421061186119648,0.107392305007354,0.102520611793925,True,0.866011726594057,0.0829583284765429,0.12999515883458,351.428580224315
17414,1549:1510,Breast,MDA-MB-330,SIDM00631,1330941,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.586139916672875,0.0604601144420831,0.823480860020199,12.9960296708747,159.5603,0.941192101686368,0.950784276009073,0.0615341339556702,0.482675002673947,0.286833647397805,0.195841355276142,8.88955941456995,9.2631,4.10647025630477,150.2972,0.551670260055616,0.443714879417365,0.557292616313838,0.480780061867929,0.107955380638251,0.0765125544459086,True,0.866011726594057,0.0829583284765429,0.12999515883458,351.428580224315
17414,1558:1510,Breast,MDA-MB-330,SIDM00631,1330941,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.713607151116501,0.0604601144420831,0.823480860020199,12.9960296708747,159.5603,0.941192101686368,0.950784276009073,0.122733739978501,0.58764183051798,0.207258881588602,0.380382948929378,6.68232435835746,2.0059,6.31370531251727,157.5544,0.671641414337761,0.418595174267939,0.678486458529199,0.494034451853912,0.253046240069822,0.184452006675287,True,0.866011726594057,0.0829583284765429,0.12999515883458,351.428580224315
17414,1561:1510,Breast,MDA-MB-330,SIDM00631,1330941,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.701112945406877,0.0604601144420831,0.823480860020199,12.9960296708747,159.5603,0.941192101686368,0.950784276009073,0.0806842560685258,0.577353091254949,0.432705864916667,0.144647226338283,10.2390779802383,23.6048,2.75695169063642,135.9555,0.659881966607018,0.584708853743642,0.666607164199266,0.615695386501455,0.0751731128633766,0.0509117776978112,True,0.866011726594057,0.0829583284765429,0.12999515883458,351.428580224315
17414,1053:1510,Breast,MDA-MB-330,SIDM00631,1330941,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.694164834730167,0.0604601144420831,0.823480860020199,12.9960296708747,159.5603,0.941192101686368,0.950784276009073,0.0838746252438912,0.571631455099377,0.388136505698724,0.183494949400653,9.6166919261756,15.3336,3.37933774469913,144.2267,0.653342459716457,0.552410983416839,0.66000100981988,0.592441786797492,0.100931476299617,0.0675592230223885,True,0.866011726594057,0.0829583284765429,0.12999515883458,351.428580224315
17415,1510:1558,Breast,MDA-MB-330,SIDM00631,1330941,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.922612471179166,0.106557222492178,0.352829316874069,7.42602637217017,3.3588,0.682658527952897,0.739593048873157,0.0736337521315205,0.325524727945642,0.100955540884068,0.224569187061573,3.5599722768393,0.2304,3.86605409533088,3.1284,0.629829271446154,0.416255283593598,0.682357770487797,0.43105895782228,0.213573987852555,0.251298812665517,True,0.866011726594057,0.0829583284765429,0.12999515883458,351.428580224315
14507,1058:1012,Breast,MDA-MB-361,SIDM00528,908121,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,5.0,0.813931320857027,0.0956659354912788,0.478818093070644,8.77236261313141,4.2702,0.83455355206835,0.80922236869248,0.138380465409212,0.389725042943232,0.253732441418002,0.135992601525231,6.87337929132206,1.145,1.89898332180935,3.1252,0.679269274960915,0.57081467827791,0.658651431416922,0.570536916378048,0.108454596683005,0.0881145150388735,True,0.722925912554769,0.0808144967118259,0.305675402240378,156.308743573886
14508,1558:1021,Breast,MDA-MB-361,SIDM00528,908121,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.767351168977369,0.0423110623301303,0.882323258353724,14.4094243491736,425.0098,0.9698980956263,0.967246325844199,0.0735543549899464,0.677051783713651,0.580305020995805,0.0967467627178455,12.0400526695748,82.2521,2.36937167959876,342.7577,0.744252437467765,0.697363882379432,0.742217598825611,0.711381719551485,0.0468885550883331,0.0308358792741256,True,0.722925912554769,0.0808144967118259,0.305675402240378,156.308743573886
14508,1561:1021,Breast,MDA-MB-361,SIDM00528,908121,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.506453372794591,0.0423110623301303,0.882323258353724,14.4094243491736,425.0098,0.9698980956263,0.967246325844199,0.0437705143998322,0.446855590088357,0.312109922369525,0.134745667718832,10.2720026987529,24.1497,4.1374216504207,400.8601,0.49120816179699,0.422770580003505,0.48986516404697,0.442653213728525,0.068437581793485,0.0472119503184454,True,0.722925912554769,0.0808144967118259,0.305675402240378,156.308743573886
14508,1011:1021,Breast,MDA-MB-361,SIDM00528,908121,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.932230233932012,0.0423110623301303,0.882323258353724,14.4094243491736,425.0098,0.9698980956263,0.967246325844199,0.0998902293318013,0.822528417538748,0.369189617862605,0.453338799676143,7.86678171133053,4.559,6.54264263784304,420.4508,0.904168328575919,0.722244249160081,0.901696268611617,0.709420124449539,0.181924079415838,0.192276144162078,True,0.722925912554769,0.0808144967118259,0.305675402240378,156.308743573886
14745,1549:1083,Breast,MDA-MB-361,SIDM00528,908121,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.795669103263514,0.0823004870697446,0.652351172095563,10.6899680316842,32.265,0.872157024716238,0.888731396937288,0.0585153343600406,0.519055672114179,0.300467538702513,0.218588133411666,7.65846245434237,3.946,3.03150557734182,28.319,0.693948397760944,0.611197423198456,0.707136113643222,0.595945069472986,0.0827509745624877,0.111191044170236,True,0.813827197542428,0.069538610118369,0.19218275946973,245.304040617928
14745,1011:1083,Breast,MDA-MB-361,SIDM00528,908121,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.876051481117895,0.0823004870697446,0.652351172095563,10.6899680316842,32.265,0.872157024716238,0.888731396937288,0.119350428782112,0.571493210523313,0.310015131644308,0.261478078879004,7.38347712736246,3.2612,3.30649090432173,29.0038,0.764054453270037,0.677513400464351,0.778574456602887,0.641838206504088,0.0865410528056864,0.136736250098799,True,0.813827197542428,0.069538610118369,0.19218275946973,245.304040617928
14750,1561:1558,Breast,MDA-MB-361,SIDM00528,908121,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.456220879033995,0.10017241201178,0.576612894986961,9.82938140318287,17.7692,0.790667818100688,0.856879177534946,0.0503119517080667,0.263062841813288,0.143780765628715,0.119282076184573,6.91604103322511,2.3587,2.91334036995777,15.4105,0.360719166997787,0.291456032396464,0.39092617160092,0.321033160817961,0.0692631346013228,0.0698930107829586,True,0.813827197542428,0.069538610118369,0.19218275946973,245.304040617928
14750,1510:1558,Breast,MDA-MB-361,SIDM00528,908121,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.904354092770866,0.10017241201178,0.576612894986961,9.82938140318287,17.7692,0.790667818100688,0.856879177534946,0.0764287550603718,0.521462231525916,0.270224717115477,0.251237514410438,6.70962230374449,2.0442,3.11975909943839,15.725,0.715043677321568,0.578457187465636,0.774922191213862,0.624402310733833,0.136586489855932,0.150519880480029,True,0.813827197542428,0.069538610118369,0.19218275946973,245.304040617928
14750,1012:1558,Breast,MDA-MB-361,SIDM00528,908121,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.53918519911993,0.10017241201178,0.576612894986961,9.82938140318287,17.7692,0.790667818100688,0.856879177534946,0.0596502821583691,0.310901138598664,0.151434352996902,0.159466785601762,6.47545129226967,1.7379,3.3539301109132,16.0313,0.42631638494034,0.326162634830016,0.462016569960902,0.36401299805528,0.100153750110324,0.0980035719056214,True,0.813827197542428,0.069538610118369,0.19218275946973,245.304040617928
14750,1011:1558,Breast,MDA-MB-361,SIDM00528,908121,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.874661635617935,0.10017241201178,0.576612894986961,9.82938140318287,17.7692,0.790667818100688,0.856879177534946,0.0647249707431547,0.504341177847687,0.184131032771209,0.320210145076478,5.45081662222016,0.8543,4.37856478096272,16.9149,0.691566807010412,0.502062948089138,0.749479342949667,0.529059907877061,0.189503858921274,0.220419435072606,True,0.813827197542428,0.069538610118369,0.19218275946973,245.304040617928
14750,1053:1558,Breast,MDA-MB-361,SIDM00528,908121,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.559801956983443,0.10017241201178,0.576612894986961,9.82938140318287,17.7692,0.790667818100688,0.856879177534946,0.0444219532329377,0.322789027035589,0.156346157677086,0.166442869358503,6.45455147080223,1.7129,3.37482993238064,16.0563,0.442617391896594,0.350586758781388,0.479682640482426,0.37715775309663,0.0920306331152057,0.102524887385796,True,0.813827197542428,0.069538610118369,0.19218275946973,245.304040617928
14751,1011:1594,Breast,MDA-MB-361,SIDM00528,908121,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.870344814442934,0.0742870611759776,0.424849557370943,8.18669616313041,2.2763,0.760873120623782,0.778782322238526,0.119067338319581,0.369765609176176,0.155106888344323,0.214658720831853,4.89584082693934,0.2326,3.29085533619107,2.0437,0.662221974983922,0.514102598479236,0.677809155740127,0.491929319722752,0.148119376504686,0.185879836017376,True,0.813827197542428,0.069538610118369,0.19218275946973,245.304040617928
17269,1011:1012,Breast,MDA-MB-415,SIDM00630,924240,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,5.0,0.522458556691706,0.0677810588327861,0.704656728023604,10.6502706990504,15.6946,0.929966127591671,0.933977703788555,0.0211732612252755,0.368153937086312,0.132623784353105,0.235530152733207,6.95378444943874,1.2106,3.69648624961166,14.484,0.48586876079372,0.381346537736596,0.487964643103602,0.388007284445114,0.104522223057124,0.0999573586584882,True,0.500087383377548,0.0606704736940203,0.66984436935954,73.2329577461578
17270,1073:1022,Breast,MDA-MB-415,SIDM00630,924240,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,10.0,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.950650644015996,0.0601895652205597,0.916262059159091,13.5406849480293,23.2746,0.949185418067585,0.983492490114404,0.0906623524069061,0.871045116627013,0.726454114325674,0.144591002301338,11.2311476208061,4.6951,2.3095373272232,18.5795,0.902343728976542,0.8384291820894,0.934957769112154,0.902410811098102,0.0639145468871417,0.0325469580140521,True,0.500087383377548,0.0606704736940203,0.66984436935954,73.2329577461578
17270,1190:1022,Breast,MDA-MB-415,SIDM00630,924240,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.01,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.997076695334758,0.0601895652205597,0.916262059159091,13.5406849480293,23.2746,0.949185418067585,0.983492490114404,0.0876019737116086,0.913583546006968,0.688182308512906,0.225401237494062,10.5202373534331,2.8684,3.02044759459621,20.4062,0.946410659906769,0.891614379007679,0.980617441929823,0.927353773837993,0.0547962808990896,0.0532636680918297,True,0.500087383377548,0.0606704736940203,0.66984436935954,73.2329577461578
17271,1058:1049,Breast,MDA-MB-415,SIDM00630,924240,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.932769150961873,0.0900997437487324,0.81486041688485,11.8123560277722,70.2431,0.901334753568143,0.961366647141427,0.0559204643378281,0.760076659210119,0.537346270561852,0.222730388648266,9.58202908489394,14.9695,2.23032694287824,55.2736,0.840737252818185,0.792595509999533,0.896733151217171,0.835808938035126,0.048141742818652,0.0609242131820448,True,0.500087383377548,0.0606704736940203,0.66984436935954,73.2329577461578
17738,1012:1372,Breast,MDA-MB-415,SIDM00630,924240,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.962641938911368,0.0772574781738433,0.789772798775481,11.5118394733251,5.7035,0.917186888895812,0.955469984185195,0.109278724200934,0.760268418312687,0.779960504529611,-0.0196920862169242,11.7546491072031,6.7489,-0.242809633878039,-1.0454,0.88292256507075,0.830051324116642,0.919775478147651,0.924417148079857,0.0528712409541074,-0.0046416699322058,True,0.844201963167864,0.0760324142463055,0.153488688192871,299.008832805555
17740,1594:1549,Breast,MDA-MB-415,SIDM00630,924240,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.720359754984847,0.121698546910544,0.867127660544737,12.5598798526062,58.9659,0.922101267042331,0.973092934708459,0.184835066361914,0.62464386909059,0.228072429190668,0.396571439899922,7.53983748966798,1.8173,5.02004236293822,57.1486,0.66424464279783,0.423237157587376,0.700976988024071,0.564642334909162,0.241007485210454,0.136334653114909,True,0.844201963167864,0.0760324142463055,0.153488688192871,299.008832805555
17740,1058:1549,Breast,MDA-MB-415,SIDM00630,924240,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.723589892497686,0.121698546910544,0.867127660544737,12.5598798526062,58.9659,0.922101267042331,0.973092934708459,0.0990031414601622,0.627444810675336,0.414341062387866,0.213103748287471,9.55518722196508,7.3468,3.00469263064111,51.6191,0.66722315669114,0.557279522072924,0.704120212015952,0.647554266415007,0.109943634618216,0.0565659456009444,True,0.844201963167864,0.0760324142463055,0.153488688192871,299.008832805555
17740,1561:1549,Breast,MDA-MB-415,SIDM00630,924240,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.898298907313774,0.121698546910544,0.867127660544737,12.5598798526062,58.9659,0.922101267042331,0.973092934708459,0.185846996941792,0.778939829968886,0.471382107282392,0.307557722686494,9.18803336282772,5.696,3.37184648977848,53.2699,0.828322560616772,0.617010370709111,0.874128319963362,0.789161325560615,0.211312189907661,0.0849669944027471,True,0.844201963167864,0.0760324142463055,0.153488688192871,299.008832805555
16362,1083:1005,Breast,MRK-nu-1,SIDM00562,908151,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.730181182787594,0.0323177924247441,0.912502509789906,12.6143670585946,48.9884,0.987187479444636,0.985907092597786,0.0841969059474373,0.666292161895041,0.619715349987065,0.0465768119079768,11.6585440499078,25.2558,0.955823008686805,23.7326,0.720825721373988,0.67193637675739,0.719890806991729,0.711747674180936,0.0488893446165973,0.0081431328107924,True,0.244760879046097,0.0343275144163184,1.3890488223372,35.8115362683557
16362,1179:1005,Breast,MRK-nu-1,SIDM00562,908151,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.364235841349031,0.0323177924247441,0.912502509789906,12.6143670585946,48.9884,0.987187479444636,0.985907092597786,0.0436377569083893,0.332366119386429,0.288459310173906,0.043906809212523,11.0607355500704,16.688,1.55363150852425,32.3004,0.359569062144746,0.324532502915835,0.359102699364331,0.351161458149874,0.0350365592289109,0.007941241214457,True,0.244760879046097,0.0343275144163184,1.3890488223372,35.8115362683557
16362,1594:1005,Breast,MRK-nu-1,SIDM00562,908151,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.503887946327187,0.0323177924247441,0.912502509789906,12.6143670585946,48.9884,0.987187479444636,0.985907092597786,0.0854144382566947,0.459799015676439,0.249139328507124,0.210659687169316,8.96567671299188,3.906,3.64869034560274,45.0824,0.49743187165727,0.383751074006203,0.496786700158506,0.449296622449868,0.113680797651067,0.0474900777086378,True,0.244760879046097,0.0343275144163184,1.3890488223372,35.8115362683557
16363,1047:1011,Breast,MRK-nu-1,SIDM00562,908151,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.611797741291628,0.166529706275853,0.378208639554911,8.23358847985799,5.8788,0.894735267593244,0.850496004334105,0.0618159247662476,0.231387191416674,0.119137812613389,0.112249378803285,6.81166323787859,2.194,1.4219252419794,3.6848,0.547397015767507,0.460838001946794,0.52033153442916,0.458081336787956,0.0865590138207125,0.0622501976412035,True,0.244760879046097,0.0343275144163184,1.3890488223372,35.8115362683557
16363,1179:1011,Breast,MRK-nu-1,SIDM00562,908151,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.410192871168886,0.166529706275853,0.378208639554911,8.23358847985799,5.8788,0.894735267593244,0.850496004334105,0.0755457558784405,0.155138487759907,0.0267918924513788,0.128346595308528,4.89787384973565,0.5823,3.33571463012235,5.2965,0.367014028350134,0.189530667129264,0.348867397935471,0.23901901996446,0.17748336122087,0.109848377971011,True,0.244760879046097,0.0343275144163184,1.3890488223372,35.8115362683557
16363,1594:1011,Breast,MRK-nu-1,SIDM00562,908151,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.495712052816788,0.166529706275853,0.378208639554911,8.23358847985799,5.8788,0.894735267593244,0.850496004334105,0.0399042942375928,0.187482581106809,0.0091231537874111,0.178359427319398,2.86973262756554,0.1428,5.36385585229246,5.736,0.443531056226225,0.166863623422616,0.421601120220935,0.196377369296126,0.276667432803609,0.225223750924809,True,0.244760879046097,0.0343275144163184,1.3890488223372,35.8115362683557
16364,1011:1021,Breast,MRK-nu-1,SIDM00562,908151,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.948031050538318,0.0875901315399937,0.534171954949906,9.2110446924178,11.5753,0.880837678601871,0.903541591059972,0.104312381906643,0.506411599619267,0.153633075063872,0.352778524555395,6.46715136547853,1.728,2.74389332693927,9.8473,0.835061469798665,0.690158130305145,0.856585483777649,0.683216645667252,0.14490333949352,0.173368838110398,True,0.244760879046097,0.0343275144163184,1.3890488223372,35.8115362683557
16364,1011:1022,Breast,MRK-nu-1,SIDM00562,908151,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.87224054114721,0.0649150099504625,0.834070456216824,11.4892791382289,5.615,0.965981717085906,0.972076620625599,0.0525284515827645,0.727510066085463,0.591709836128282,0.135800229957181,10.150534960048,2.22,1.33874417818098,3.395,0.842568415649322,0.840985284956501,0.847884637611024,0.820159340447911,0.0015831306928209,0.0277252971631126,True,0.244760879046097,0.0343275144163184,1.3890488223372,35.8115362683557
16364,1179:1022,Breast,MRK-nu-1,SIDM00562,908151,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.906897526679524,0.0649150099504625,0.834070456216824,11.4892791382289,5.615,0.965981717085906,0.972076620625599,0.0699135451372344,0.756416433819499,0.117670333059724,0.638746100759776,6.06610860830367,0.1309,5.42317052992527,5.4841,0.876046430042847,0.636519936011656,0.881573882988345,0.622815289935391,0.239526494031192,0.258758593052955,True,0.244760879046097,0.0343275144163184,1.3890488223372,35.8115362683557
16364,1190:1022,Breast,MRK-nu-1,SIDM00562,908151,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.467481754328676,0.0649150099504625,0.834070456216824,11.4892791382289,5.615,0.965981717085906,0.972076620625599,0.02862608247181,0.38991272010596,0.280281510887609,0.109631209218351,9.62220721163127,1.5392,1.86707192659767,4.0758,0.451578827752746,0.429276772315452,0.454428083951946,0.430688426885493,0.0223020554372937,0.023739657066453,True,0.244760879046097,0.0343275144163184,1.3890488223372,35.8115362683557
16364,1372:1022,Breast,MRK-nu-1,SIDM00562,908151,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.942269498732847,0.0649150099504625,0.834070456216824,11.4892791382289,5.615,0.965981717085906,0.972076620625599,0.0809527366409145,0.785919150687304,0.565146535539105,0.220772615148199,9.62359174823197,1.5407,1.86568738999697,4.0743,0.910215108343632,0.852963540249736,0.915958150046803,0.868159918722629,0.0572515680938959,0.0477982313241747,True,0.244760879046097,0.0343275144163184,1.3890488223372,35.8115362683557
16366,1594:1053,Breast,MRK-nu-1,SIDM00562,908151,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.579667164944133,0.0161705250660063,0.959610557948424,13.883673635295,295.2108,0.998739286891231,0.993654282499855,0.075456806015299,0.55625473157642,0.379982859616691,0.176271871959729,9.99183712118182,19.8872,3.89183651411323,275.3236,0.578936370950564,0.484920798555787,0.575988760871287,0.541999221851266,0.094015572394777,0.0339895390200214,True,0.244760879046097,0.0343275144163184,1.3890488223372,35.8115362683557
16367,1083:1058,Breast,MRK-nu-1,SIDM00562,908151,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.702912702025381,0.0488426627334458,0.595890452114295,9.59870610353989,6.0574,0.924045168018047,0.920351637757446,0.0630198916161643,0.418858967806785,0.517769057887549,-0.0989100900807638,10.5853603978182,12.0033,-0.986654294278345,-5.9459,0.649523085845063,0.624537665215177,0.646926856509572,0.66984573322093,0.0249854206298863,-0.0229188767113586,True,0.244760879046097,0.0343275144163184,1.3890488223372,35.8115362683557
16367,1011:1058,Breast,MRK-nu-1,SIDM00562,908151,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.891816383587554,0.0488426627334458,0.595890452114295,9.59870610353989,6.0574,0.924045168018047,0.920351637757446,0.0987449600150846,0.531424868018923,0.274840872093681,0.256583995925242,7.75341843257815,1.6858,1.84528767096174,4.3716,0.824078620013409,0.766462641439216,0.820784669213729,0.730461307390945,0.0576159785741933,0.0903233618227837,True,0.244760879046097,0.0343275144163184,1.3890488223372,35.8115362683557
16367,1011:1073,Breast,MRK-nu-1,SIDM00562,908151,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,20.0,0.891816383587554,0.0767738553827148,0.464397907234844,8.78009345052977,17.1724,0.852058227250148,0.88202906378602,0.0469209577352752,0.414157662175807,0.19803540855898,0.216122253616827,7.06730057875172,5.2388,1.71279287177805,11.9336,0.75987948683225,0.695641030598354,0.786607969884765,0.685664833910301,0.0642384562338958,0.100943135974464,True,0.244760879046097,0.0343275144163184,1.3890488223372,35.8115362683557
16443,1049:1083,Breast,MRK-nu-1,SIDM00562,908151,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.928411952357908,0.0720087713162289,0.713086443436441,10.4034910748954,26.4541,0.933912331474033,0.94796540711308,0.0716817439174796,0.662037977150783,0.700284254767513,-0.0382462776167302,10.7290104729229,33.15,-0.325519398027533,-6.6959,0.867055370994933,0.911659472970909,0.880102414385614,0.888123970132697,-0.0446041019759751,-0.0080215557470834,True,0.546240230992684,0.067647548697751,0.590265691223004,83.4315535725408
16443,1011:1083,Breast,MRK-nu-1,SIDM00562,908151,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.929533741335123,0.0720087713162289,0.713086443436441,10.4034910748954,26.4541,0.933912331474033,0.94796540711308,0.0796180117654303,0.662837909662831,0.250548311509117,0.412289598153714,7.46312151545836,3.4463,2.94036955943701,23.0078,0.868103023554066,0.734351606334342,0.881165831530094,0.742259340665142,0.133751417219723,0.138906490864952,True,0.546240230992684,0.067647548697751,0.590265691223004,83.4315535725408
16443,1594:1083,Breast,MRK-nu-1,SIDM00562,908151,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.654119208215523,0.0720087713162289,0.713086443436441,10.4034910748954,26.4541,0.933912331474033,0.94796540711308,0.0493947165748706,0.466443539769868,0.259600337713256,0.206843202056612,8.35481077192808,6.3941,2.0486803029673,20.06,0.610889994806508,0.577545508475056,0.620082381516514,0.561163373815442,0.0333444863314524,0.0589190077010724,True,0.546240230992684,0.067647548697751,0.590265691223004,83.4315535725408
16443,1022:1179,Breast,MRK-nu-1,SIDM00562,908151,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,10.0,0.916631878571607,0.132598754764627,0.442924523010002,8.6465127998636,7.8269,0.896083126238016,0.87475531384445,0.104047997787537,0.405998737592091,0.390002466175749,0.0159962714163422,8.53699457700473,7.2547,0.109518222858874,0.5722,0.821378359359871,0.810941969201129,0.801828606619734,0.796168406647728,0.0104363901587418,0.0056601999720065,True,0.546240230992684,0.067647548697751,0.590265691223004,83.4315535725408
16444,1011:1190,Breast,MRK-nu-1,SIDM00562,908151,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.906442867294971,0.185799879562576,0.0342984309980106,3.85457145431499,0.2825,0.493089991174397,0.486551167356859,0.0882381689460862,0.0310895681375555,0.0043261100271969,0.0267634581103585,0.767827973486601,0.0333,3.08674348082839,0.2492,0.446957905434572,0.193631499219549,0.441030835224667,0.198122570507761,0.253326406215023,0.242908264716906,True,0.546240230992684,0.067647548697751,0.590265691223004,83.4315535725408
16445,1594:1372,Breast,MRK-nu-1,SIDM00562,908151,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.265601147198077,0.0604122735440178,0.941891764483822,13.2942088548356,19.6194,0.964432065129737,0.990785811152884,0.0480968917766189,0.250167533183324,0.169910975133154,0.0802565580501702,9.88511410490184,1.8469,3.4090947499338,17.7725,0.256154262893069,0.198802488465778,0.263153848069783,0.247345426296277,0.0573517744272908,0.015808421773506,True,0.546240230992684,0.067647548697751,0.590265691223004,83.4315535725408
16447,1190:1510,Breast,MRK-nu-1,SIDM00562,908151,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.1,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.588325554506364,0.0797567925453092,0.925235877776097,12.8781780360851,147.0442,0.95256467218649,0.988039858007452,0.0734174292680913,0.544339910841805,0.558502956766059,-0.0141630459242538,13.516829744657,228.9292,-0.638651708571828,-81.885,0.56041813896729,0.521788335630017,0.581289097336624,0.583614912678533,0.0386298033372729,-0.0023258153419093,True,0.546240230992684,0.067647548697751,0.590265691223004,83.4315535725408
16448,1011:1558,Breast,MRK-nu-1,SIDM00562,908151,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.903207842369321,0.0620632405814131,0.855728612888131,11.7444150849036,67.0118,0.96228036830748,0.976021408534222,0.118751201568764,0.772900794100381,0.55847932244022,0.214421471660161,9.74375299022705,16.7453,2.00066209467658,50.2665,0.869139175213355,0.856373352853383,0.88155019050846,0.836402577562017,0.0127658223599723,0.0451476129464439,True,0.546240230992684,0.067647548697751,0.590265691223004,83.4315535725408
16448,1594:1558,Breast,MRK-nu-1,SIDM00562,908151,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.664106287161365,0.0620632405814131,0.855728612888131,11.7444150849036,67.0118,0.96228036830748,0.976021408534222,0.0469692459775067,0.568294751922881,0.524509983956749,0.0437847679661324,11.0406091703944,41.1419,0.703805914509221,25.8699,0.639056442604951,0.640090065291931,0.648181953811667,0.639988967180582,-0.0010336226869803,0.0081929866310855,True,0.546240230992684,0.067647548697751,0.590265691223004,83.4315535725408
16448,1049:1558,Breast,MRK-nu-1,SIDM00562,908151,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.999969786493879,0.0620632405814131,0.855728612888131,11.7444150849036,67.0118,0.96228036830748,0.976021408534222,0.163358938041161,0.855702758326447,0.600825055795175,0.254877702531273,9.63047640338841,15.4808,2.11393868151523,51.531,0.962251294443682,0.964655238128969,0.975991919505421,0.921596542328548,-0.0024039436852864,0.0543953771768724,True,0.546240230992684,0.067647548697751,0.590265691223004,83.4315535725408
16449,1047:1561,Breast,MRK-nu-1,SIDM00562,908151,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.793953121619693,0.148937713018602,0.573882499991066,9.45894412947942,13.7454,0.879285240570256,0.914565420823549,0.0287225152534436,0.45563580231082,0.412642383195478,0.0429934191153427,9.12173374724364,10.8804,0.33721038223578,2.865,0.698111261544878,0.719236091778157,0.726122070788286,0.714025054001147,-0.0211248302332789,0.0120970167871386,True,0.546240230992684,0.067647548697751,0.590265691223004,83.4315535725408
16449,1083:1561,Breast,MRK-nu-1,SIDM00562,908151,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.836781802334218,0.148937713018602,0.573882499991066,9.45894412947942,13.7454,0.879285240570256,0.914565420823549,0.0750352417005598,0.480214432670591,0.272037297781637,0.208177134888954,7.87397459238439,4.5818,1.58496953709503,9.1636,0.735769888370255,0.679900683417324,0.765291701189282,0.6922450672775,0.0558692049529309,0.0730466339117819,True,0.546240230992684,0.067647548697751,0.590265691223004,83.4315535725408
16449,1011:1561,Breast,MRK-nu-1,SIDM00562,908151,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.91010273147533,0.148937713018602,0.573882499991066,9.45894412947942,13.7454,0.879285240570256,0.914565420823549,0.105185508579514,0.52229203078776,0.293402605509513,0.228889425278248,7.85485449090958,4.5214,1.60408963856984,9.224,0.800239899188933,0.791108115717717,0.832348487604397,0.751730067384386,0.009131783471216,0.0806184202200112,True,0.546240230992684,0.067647548697751,0.590265691223004,83.4315535725408
16449,1594:1561,Breast,MRK-nu-1,SIDM00562,908151,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.7323951906516,0.148937713018602,0.573882499991066,9.45894412947942,13.7454,0.879285240570256,0.914565420823549,0.0815087370449384,0.420308782992573,0.184415296629514,0.235893486363059,7.32114101070084,3.1233,2.13780311877859,10.6221,0.64398428140459,0.518417738259677,0.669823315747424,0.577194664171907,0.125566543144914,0.0926286515755173,True,0.546240230992684,0.067647548697751,0.590265691223004,83.4315535725408
15753,1179:1005,Breast,BT-20,SIDM00893,906801,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.541541303130983,0.0528175900980348,0.931791490177612,15.124001163245,278.9768,0.967447173388572,0.983692400258579,0.0575576903901482,0.504603577837144,0.357817162549489,0.146786415287655,10.5613371339688,11.8051,4.56266402927626,267.1717,0.523912602987233,0.44720111840779,0.532710064316075,0.489885276479644,0.0767114845794429,0.0428247878364313,True,1.1926925983823,0.112043708874309,-0.185164772227284,-286.001373898576
15753,1011:1007,Breast,BT-20,SIDM00893,906801,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1007,Docetaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.0125,0.887780935335307,0.0795122740170953,0.635447060818121,10.3015079115712,0.0308,0.891963290350254,0.895667086820898,0.0705993291135088,0.564137786009183,0.283585512470354,0.280552273538829,7.22833199148487,0.0037,3.07317592008634,0.0271,0.791868004191907,0.661792649700745,0.795156164086906,0.65658117911953,0.130075354491161,0.138574984967376,True,1.1926925983823,0.112043708874309,-0.185164772227284,-286.001373898576
15754,1021:1011,Breast,BT-20,SIDM00893,906801,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.955802718232384,0.115768553456179,0.522773836635193,9.21351913868378,11.5951,0.883342174324911,0.851050462821688,0.0924932935655348,0.49966865407669,0.442600243231891,0.0570684108447984,8.65333344841624,7.864,0.560185690267533,3.7311,0.844300851349054,0.798680581929149,0.813436345717897,0.787046537371289,0.0456202694199049,0.0263898083466084,True,1.1926925983823,0.112043708874309,-0.185164772227284,-286.001373898576
15754,1549:1011,Breast,BT-20,SIDM00893,906801,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.866604286564301,0.115768553456179,0.522773836635193,9.21351913868378,11.5951,0.883342174324911,0.851050462821688,0.0466713058621356,0.453038047731724,0.117436747561585,0.335601300170139,4.65959605349066,0.4936,4.55392308519311,11.1015,0.765508114772997,0.454830228379519,0.737523979163807,0.478258265787758,0.310677886393478,0.259265713376049,True,1.1926925983823,0.112043708874309,-0.185164772227284,-286.001373898576
15754,1558:1011,Breast,BT-20,SIDM00893,906801,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.914493753360705,0.115768553456179,0.522773836635193,9.21351913868378,11.5951,0.883342174324911,0.851050462821688,0.0849025478498882,0.478073408023294,0.295162653612848,0.182910754410446,7.26409995440036,3.0022,1.94941918428342,8.5929,0.807810900500193,0.694467559059028,0.77828033204517,0.678464017139127,0.113343341441166,0.0998163149060433,True,1.1926925983823,0.112043708874309,-0.185164772227284,-286.001373898576
15754,1561:1011,Breast,BT-20,SIDM00893,906801,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.693154866191221,0.115768553456179,0.522773836635193,9.21351913868378,11.5951,0.883342174324911,0.851050462821688,0.0744524704781904,0.362363228781138,0.15744676917948,0.204916459601658,6.13186549874822,1.3696,3.08165363993556,10.2255,0.612292926645245,0.43580697793229,0.589909769679143,0.460065802727404,0.176485948712955,0.129843966951739,True,1.1926925983823,0.112043708874309,-0.185164772227284,-286.001373898576
15754,1190:1011,Breast,BT-20,SIDM00893,906801,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.891004998440396,0.115768553456179,0.522773836635193,9.21351913868378,11.5951,0.883342174324911,0.851050462821688,0.12714722751063,0.46579410149582,0.191283074508155,0.274511026987666,5.96222160719109,1.2177,3.25129753149268,10.3774,0.787062292656703,0.512900183723078,0.758290216299137,0.580318666905433,0.274162108933625,0.177971549393704,True,1.1926925983823,0.112043708874309,-0.185164772227284,-286.001373898576
15754,1179:1011,Breast,BT-20,SIDM00893,906801,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.515443075253262,0.115768553456179,0.522773836635193,9.21351913868378,11.5951,0.883342174324911,0.851050462821688,0.0616559264194907,0.26946015401719,0.0338357569829153,0.235624397034275,2.77979828300401,0.1341,6.43372085567977,11.461,0.455312606834935,0.167255836131809,0.438668067752523,0.208555601510101,0.288056770703126,0.230112466242421,True,1.1926925983823,0.112043708874309,-0.185164772227284,-286.001373898576
15754,1054:1012,Breast,BT-20,SIDM00893,906801,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,5.0,0.941938967082863,0.166247594602188,0.799315311244014,12.237088069297,47.1445,0.924348498989915,0.94835418126802,0.191587796313075,0.752906238646704,0.501968911027559,0.250937327619144,9.3087871856826,6.1933,2.92830088361436,40.9512,0.870679870363155,0.84085950886959,0.893291757932313,0.80576364114808,0.0298203614935648,0.087528116784233,True,1.1926925983823,0.112043708874309,-0.185164772227284,-286.001373898576
15754,1058:1012,Breast,BT-20,SIDM00893,906801,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,5.0,0.821868770044732,0.166247594602188,0.799315311244014,12.237088069297,47.1445,0.924348498989915,0.94835418126802,0.166983122759501,0.65693229173004,0.32537619381364,0.3315560979164,8.01018134146514,2.5177,4.22690672783181,44.6268,0.759693163957535,0.609404128194267,0.779422684525526,0.64756024447027,0.150289035763268,0.131862440055256,True,1.1926925983823,0.112043708874309,-0.185164772227284,-286.001373898576
15754,1073:1012,Breast,BT-20,SIDM00893,906801,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,2.5,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,5.0,0.969738528597196,0.166247594602188,0.799315311244014,12.237088069297,47.1445,0.924348498989915,0.94835418126802,0.199359319903163,0.77512685381098,0.40082081358412,0.37430604022686,8.17968129646695,2.8316,4.05740677283001,44.3129,0.896376353321507,0.809834838603321,0.919655588331848,0.77352364919131,0.0865415147181856,0.146131939140538,True,1.1926925983823,0.112043708874309,-0.185164772227284,-286.001373898576
15755,1011:1021,Breast,BT-20,SIDM00893,906801,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.746446249507837,0.0683687910404592,0.847892457915958,13.0244371143212,162.7332,0.941725938350988,0.961939090271661,0.116911294076028,0.632906145197349,0.361248689708311,0.271657455489038,8.84964925456328,9.0103,4.17478785975788,153.7229,0.702947794746344,0.612165945973615,0.718035826188262,0.622144649089847,0.0907818487727285,0.0958911770984149,True,1.1926925983823,0.112043708874309,-0.185164772227284,-286.001373898576
15755,1179:1022,Breast,BT-20,SIDM00893,906801,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.491995545185697,0.0537141290212208,0.86551535022812,13.3610448162077,20.5497,0.95101114346724,0.96667896595011,0.0362983268402742,0.425829696602073,0.306090383769035,0.119739312833038,10.1679665824191,2.2469,3.1930782337886,18.3028,0.467893246007838,0.416172160018438,0.47560174487217,0.438279258495731,0.0517210859893997,0.0373224863764385,True,1.1926925983823,0.112043708874309,-0.185164772227284,-286.001373898576
15755,1073:1022,Breast,BT-20,SIDM00893,906801,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,2.5,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,1.0,0.0537141290212208,0.86551535022812,13.3610448162077,20.5497,0.95101114346724,0.96667896595011,0.109905873257618,0.86551535022812,0.575181871485919,0.290333478742201,9.70977171055112,1.6355,3.65127310565655,18.9142,0.95101114346724,0.796121975078096,0.96667896595011,0.872863393562852,0.154889168389144,0.0938155723872578,True,1.1926925983823,0.112043708874309,-0.185164772227284,-286.001373898576
15755,1190:1022,Breast,BT-20,SIDM00893,906801,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.893530889658063,0.0537141290212208,0.86551535022812,13.3610448162077,20.5497,0.95101114346724,0.96667896595011,0.136841681327224,0.773364700902042,0.524051658615851,0.249313042286191,9.81861914573203,1.7637,3.54242567047564,18.786,0.849757833097015,0.664891536584075,0.863757516459138,0.783909817213094,0.18486629651294,0.0798476992460435,True,1.1926925983823,0.112043708874309,-0.185164772227284,-286.001373898576
15755,1005:1022,Breast,BT-20,SIDM00893,906801,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,1.0,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.986911282642743,0.0537141290212208,0.86551535022812,13.3610448162077,20.5497,0.95101114346724,0.96667896595011,0.072163584034106,0.854186864440617,0.671190624021803,0.182996240418815,10.7665416116803,3.4024,2.59450320452738,17.1473,0.938563627406796,0.924231083316146,0.954026378189584,0.899308112707442,0.01433254409065,0.054718265482142,True,1.1926925983823,0.112043708874309,-0.185164772227284,-286.001373898576
15757,1058:1053,Breast,BT-20,SIDM00893,906801,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.965027633842029,0.0644159803427253,0.529020030494554,9.27219882707906,12.0765,0.857220097559681,0.853759387508618,0.052439905338996,0.510518948283197,0.352816317851856,0.157702630431341,7.70909578403034,4.0869,1.56310304304871,7.9896,0.827241082429852,0.721783805686349,0.823901401597862,0.743009088034233,0.105457276743503,0.080892313563629,True,1.1926925983823,0.112043708874309,-0.185164772227284,-286.001373898576
15757,1558:1053,Breast,BT-20,SIDM00893,906801,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.989699240430431,0.0644159803427253,0.529020030494554,9.27219882707906,12.0765,0.857220097559681,0.853759387508618,0.0492859030029233,0.523570722352943,0.363213501621913,0.16035722073103,7.72313719279028,4.1269,1.54906163428878,7.9496,0.848390079436516,0.729932888683124,0.844965017327629,0.762852434440037,0.118457190753392,0.0821125828875914,True,1.1926925983823,0.112043708874309,-0.185164772227284,-286.001373898576
15758,1011:1073,Breast,BT-20,SIDM00893,906801,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,20.0,0.779115227851881,0.0688322481529984,0.850171779263641,13.0660898893086,335.0002,0.9353708830189,0.962557567118555,0.0466538585506819,0.662381779514231,0.557190620054967,0.105191159459264,11.1562379683647,89.1502,1.90985192094389,245.85,0.728761698649286,0.695128906254941,0.749943258226126,0.718948919664524,0.033632792394345,0.0309943385616012,True,1.1926925983823,0.112043708874309,-0.185164772227284,-286.001373898576
15758,1022:1073,Breast,BT-20,SIDM00893,906801,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,20.0,0.970411383050103,0.0688322481529984,0.850171779263641,13.0660898893086,335.0002,0.9353708830189,0.962557567118555,0.0208198229575401,0.825016372145397,0.744105723634058,0.0809106485113388,11.7880155970554,138.1358,1.27807429225318,196.8644,0.907694552255167,0.919401104441353,0.934076819972859,0.911020455093253,-0.0117065521861858,0.0230563648796066,True,1.1926925983823,0.112043708874309,-0.185164772227284,-286.001373898576
17275,1561:1083,Breast,BT-20,SIDM00893,906801,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.663470377569103,0.0553049003139351,0.908318069242275,14.3714937646744,413.9813,0.963925110063115,0.977806962949411,0.059839954401337,0.602642132353011,0.491385354529336,0.111256777823676,11.4576206617278,54.931,2.91387310294653,359.0503,0.639535756721915,0.639460333327986,0.648745954897744,0.617569111590225,7.54233939288529e-05,0.031176843307519,True,0.802413807119885,0.06096543888917,0.205441224801666,229.724500357527
17276,1005:1190,Breast,BT-20,SIDM00893,906801,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,1.0,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.995299131881917,0.0848656297406453,0.688833223472332,10.8613451976714,36.3346,0.870772483526645,0.914165558862411,0.0514511784678902,0.685595109333435,0.325534420494792,0.360060688838643,7.31013801892309,3.0996,3.55120717874833,33.235,0.866679096920731,0.733034882165485,0.909868187132104,0.741377537779561,0.133644214755246,0.168490649352543,True,0.802413807119885,0.06096543888917,0.205441224801666,229.724500357527
17276,1011:1190,Breast,BT-20,SIDM00893,906801,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.663730293957171,0.0848656297406453,0.688833223472332,10.8613451976714,36.3346,0.870772483526645,0.914165558862411,0.0911259660672367,0.457199477902757,0.0898110281799669,0.36738844972279,4.65557156867194,0.4923,6.20577362899948,35.8423,0.577958076460956,0.329864219152234,0.606759375109269,0.366087900027367,0.248093857308722,0.240671475081902,True,0.802413807119885,0.06096543888917,0.205441224801666,229.724500357527
17277,1011:1372,Breast,BT-20,SIDM00893,906801,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.666755038518851,0.0857997971329455,0.564806370349524,9.61061513979368,1.5269,0.807409619260768,0.86870322400972,0.099021187115226,0.376587493218089,0.0819854736476258,0.294602019570463,4.39816640403446,0.0412,5.21244873575922,1.4857,0.538344431790704,0.301932395916637,0.579212251586051,0.354290296114044,0.236412035874067,0.224921955472007,True,0.802413807119885,0.06096543888917,0.205441224801666,229.724500357527
17279,1058:1549,Breast,BT-20,SIDM00893,906801,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.928256821878484,0.0762976442343355,0.718440336027846,11.1941094601281,22.8804,0.867007912538662,0.923827807510033,0.0601201586340605,0.666897143030518,0.49459281131987,0.172304331710649,9.30792812451151,6.1896,1.88618133561659,16.6908,0.804806009436637,0.744347038822869,0.857549464562232,0.79402322766229,0.0604589706137678,0.0635262368999413,True,0.802413807119885,0.06096543888917,0.205441224801666,229.724500357527
17279,1011:1549,Breast,BT-20,SIDM00893,906801,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.677085760838658,0.0762976442343355,0.718440336027846,11.1941094601281,22.8804,0.867007912538662,0.923827807510033,0.0860206549489589,0.486445721536595,0.108871717219813,0.377574004316782,5.12977463271381,0.3419,6.06433482741429,22.5385,0.587038712114377,0.345533211060682,0.625510653931841,0.39841437142413,0.241505501053695,0.22709628250771,True,0.802413807119885,0.06096543888917,0.205441224801666,229.724500357527
17279,1561:1549,Breast,BT-20,SIDM00893,906801,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.707794239348272,0.0762976442343355,0.718440336027846,11.1941094601281,22.8804,0.867007912538662,0.923827807510033,0.101454827667519,0.508507931155946,0.271656127241899,0.236851803914047,7.89111018311462,2.3183,3.30299927701348,20.5621,0.613663205964235,0.474475386109213,0.653880000305346,0.552717886223004,0.139187819855022,0.101162114082342,True,0.802413807119885,0.06096543888917,0.205441224801666,229.724500357527
17279,1053:1549,Breast,BT-20,SIDM00893,906801,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.939881807042927,0.0762976442343355,0.718440336027846,11.1941094601281,22.8804,0.867007912538662,0.923827807510033,0.0853603034112911,0.67524900127838,0.56731182116028,0.1079371801181,9.98489447225586,9.8958,1.20921498787224,12.9846,0.814884963557354,0.763096505608989,0.868288949119036,0.830755120964161,0.0517884579483653,0.0375338281548744,True,0.802413807119885,0.06096543888917,0.205441224801666,229.724500357527
17280,1011:1558,Breast,BT-20,SIDM00893,906801,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.629703115218268,0.108457625842802,0.488038559430414,8.88791012967751,9.2525,0.867965146529528,0.835386309184831,0.0779348265301463,0.307319401219968,0.107989005531141,0.199330395688827,5.31068714744215,0.7752,3.57722298223536,8.4773,0.546560356670525,0.380405465192906,0.52604536130438,0.379285176523237,0.166154891477618,0.146760184781142,True,0.802413807119885,0.06096543888917,0.205441224801666,229.724500357527
17280,1058:1559,Breast,BT-20,SIDM00893,906801,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1559,Luminespib,HSP90,Protein stability and degradation,Targeted,Early clinical trials,0.1,0.749341672793617,0.0589757774852953,0.694752560175891,10.9263737923844,0.3801,0.906559741322897,0.91612946915731,0.0736415834914515,0.520607045619851,0.335918287393946,0.184688758225904,8.51373130342498,0.0714,2.41264248895939,0.3087,0.679322993050249,0.633068097030148,0.686493988913867,0.611515940033679,0.0462548960201009,0.0749780488801884,True,0.802413807119885,0.06096543888917,0.205441224801666,229.724500357527
17281,1058:1594,Breast,BT-20,SIDM00893,906801,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.977097600969274,0.0597484838838319,0.679454377237569,10.7596789922766,13.5449,0.915880458718293,0.911019744302,0.0581486252838011,0.663893241966901,0.530142838341742,0.133750403625159,9.39980275231962,5.2773,1.35987623995701,8.2676,0.894904598988283,0.831377977381042,0.890155206593126,0.839844638439829,0.0635266216072405,0.0503105681532966,True,0.802413807119885,0.06096543888917,0.205441224801666,229.724500357527
17281,1558:1594,Breast,BT-20,SIDM00893,906801,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.856858789352807,0.0597484838838319,0.679454377237569,10.7596789922766,13.5449,0.915880458718293,0.911019744302,0.0738035424444552,0.582196455100249,0.383293612369041,0.198902842731208,8.50463393490228,2.8375,2.25504505737435,10.7074,0.784780221049251,0.688525784308338,0.780615275179116,0.698840306357686,0.0962544367409129,0.0817749688214302,True,0.802413807119885,0.06096543888917,0.205441224801666,229.724500357527
17281,1561:1594,Breast,BT-20,SIDM00893,906801,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.722571184280987,0.0597484838838319,0.679454377237569,10.7596789922766,13.5449,0.915880458718293,0.911019744302,0.0330701780935695,0.490954154025451,0.295122174412571,0.19583197961288,8.13231030102992,2.1921,2.62736869124671,11.3528,0.661788827715891,0.560093952131854,0.658276615543658,0.574418452397222,0.101694875584037,0.0838581631464366,True,0.802413807119885,0.06096543888917,0.205441224801666,229.724500357527
17281,1053:1594,Breast,BT-20,SIDM00893,906801,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.976216420151807,0.0597484838838319,0.679454377237569,10.7596789922766,13.5449,0.915880458718293,0.911019744302,0.0496961475338781,0.663294519803335,0.446991787082687,0.216302732720648,8.60445161610079,3.0408,2.15522737617583,10.5041,0.894097542696967,0.811360286079078,0.889352433470113,0.801358389839545,0.0827372566178889,0.0879940436305675,True,0.802413807119885,0.06096543888917,0.205441224801666,229.724500357527
14513,1549:1011,Breast,BT-474,SIDM00963,946359,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.623333303365097,0.113724493127514,0.595430132144569,10.258188248195,23.9195,0.876939153244287,0.841297148210476,0.0902104843423867,0.371151431192791,0.206926726015056,0.164224705177734,6.72331252363958,2.0637,3.53487572455538,21.8558,0.546625379241952,0.438217765320779,0.524408530505672,0.417647515677532,0.108407613921173,0.106761014828139,True,0.774847864796851,0.0785104052850785,0.242224976597007,197.879738128388
14513,1558:1011,Breast,BT-474,SIDM00963,946359,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.66442791159315,0.113724493127514,0.595430132144569,10.258188248195,23.9195,0.876939153244287,0.841297148210476,0.0852041369545128,0.39562039920045,0.232879040916823,0.162741358283626,6.99169699356488,2.4857,3.26649125463007,21.4338,0.582662850184367,0.475912495617146,0.558981307214759,0.455464607092325,0.106750354567221,0.103516700122434,True,0.774847864796851,0.0785104052850785,0.242224976597007,197.879738128388
17507,1022:1005,Breast,MDA-MB-468,SIDM00628,908123,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.925079606604151,0.0693930253928768,0.55328190311646,9.38497643954811,5.2234,0.907349213361777,0.894052012831766,0.0524240426700874,0.51182980527617,0.240011579332451,0.27181822594372,7.11266991468678,1.0812,2.27230652486132,4.1422,0.839370253349299,0.696284016582243,0.827069284314059,0.702310792058337,0.143086236767056,0.124758492255722,True,0.660792385706973,0.0641938333175871,0.395246334080991,122.353733044505
17507,1179:1005,Breast,MDA-MB-468,SIDM00628,908123,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.436959365125303,0.0693930253928768,0.55328190311646,9.38497643954811,5.2234,0.907349213361777,0.894052012831766,0.0445917449219931,0.241761709121088,0.0804081747750476,0.16135353434604,6.31995170719689,0.6241,3.06502473235122,4.5993,0.396474736217506,0.278447944674537,0.390664399915968,0.305196213299221,0.118026791542969,0.0854681866167472,True,0.660792385706973,0.0641938333175871,0.395246334080991,122.353733044505
17508,1179:1011,Breast,MDA-MB-468,SIDM00628,908123,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.779459106063061,0.0959279322929231,0.342371713311362,7.82541495077242,4.4301,0.821535390621811,0.808452399658249,0.0522112521582256,0.266864749598953,0.0900307556251865,0.176833993973766,5.33681733942846,0.7894,2.48859761134396,3.6407,0.640353241173245,0.472733534173497,0.630155584732155,0.48079906614632,0.167619706999748,0.149356518585836,True,0.660792385706973,0.0641938333175871,0.395246334080991,122.353733044505
17508,1190:1011,Breast,MDA-MB-468,SIDM00628,908123,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.497675064444221,0.0959279322929231,0.342371713311362,7.82541495077242,4.4301,0.821535390621811,0.808452399658249,0.108819459956176,0.17038986448611,0.0316992759194822,0.138690588566628,4.16333792850439,0.35,3.66207702226803,4.0801,0.408857678470918,0.224820798792174,0.402346600100004,0.256014429748693,0.184036879678744,0.146332170351311,True,0.660792385706973,0.0641938333175871,0.395246334080991,122.353733044505
17508,1191:1012,Breast,MDA-MB-468,SIDM00628,908123,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.000625,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,5.0,0.983663081098962,0.115760229194118,0.4657899765248,8.75337631149694,4.2143,0.896934351108861,0.863312284102922,0.0702520235351889,0.458180403453398,0.45087033070411,0.0073100727492883,8.69957512990061,4.0601,0.0538011815963344,0.154199999999999,0.88228120735524,0.861970829740857,0.849208421331262,0.846385263359928,0.0203103776143829,0.0028231579713333,True,0.660792385706973,0.0641938333175871,0.395246334080991,122.353733044505
16958,1022:1017,Breast,MDA-MB-468,SIDM00628,908123,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.918387183530119,0.111476837188621,0.680312181737992,10.3589649906451,25.6501,0.871567860740069,0.931010205230853,0.0356453701237492,0.624789988507585,0.499583346559243,0.125206641948342,9.31737412320263,12.4606,1.04159086744245,13.1895,0.800436752880443,0.824356418518069,0.855027840219761,0.818303247371662,-0.0239196656376265,0.036724592848099,True,0.447961253764776,0.072648180317143,0.773897121755163,63.4088040692738
17509,1005:1022,Breast,MDA-MB-468,SIDM00628,908123,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,1.0,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.814958431891978,0.0571173138501748,0.562008451807507,9.44863662990896,1.3647,0.885827022385614,0.896848602063741,0.099258826904401,0.458013526595084,0.192627619228489,0.265385907366595,6.88974923685161,0.2316,2.55888739305735,1.1331,0.72191220109092,0.57774595235698,0.730894330382379,0.605252995181333,0.144166248733941,0.125641335201046,True,0.660792385706973,0.0641938333175871,0.395246334080991,122.353733044505
17509,1190:1022,Breast,MDA-MB-468,SIDM00628,908123,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.01,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.939326266995001,0.0571173138501748,0.562008451807507,9.44863662990896,1.3647,0.885827022385614,0.896848602063741,0.0563827142774699,0.527909301055985,0.144712680553731,0.383196620502255,5.93532831721393,0.1195,3.51330831269503,1.2452,0.832080590140776,0.612677947026265,0.842433449436219,0.626718710638849,0.219402643114511,0.21571473879737,True,0.660792385706973,0.0641938333175871,0.395246334080991,122.353733044505
17509,1179:1022,Breast,MDA-MB-468,SIDM00628,908123,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.717672955195954,0.0571173138501748,0.562008451807507,9.44863662990896,1.3647,0.885827022385614,0.896848602063741,0.0528141405030778,0.403338266453796,0.122646159039529,0.280692107414267,6.15810639246714,0.1395,3.29053023744182,1.2252,0.635734096947916,0.48058105484334,0.643643986606445,0.49191145197701,0.155153042104577,0.151732534629435,True,0.660792385706973,0.0641938333175871,0.395246334080991,122.353733044505
17509,1017:1022,Breast,MDA-MB-468,SIDM00628,908123,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.803352685587537,0.0571173138501748,0.562008451807507,9.44863662990896,1.3647,0.885827022385614,0.896848602063741,0.0732704780260913,0.451490999082454,0.141526253102472,0.309964745979983,6.22429934710688,0.146,3.22433728280208,1.2187,0.711631517399494,0.520925067985585,0.720485733033335,0.554937447481875,0.19070644941391,0.16554828555146,True,0.660792385706973,0.0641938333175871,0.395246334080991,122.353733044505
17511,1549:1053,Breast,MDA-MB-468,SIDM00628,908123,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.688050355047508,0.102184616592005,0.673528122526275,10.3031441140613,24.6766,0.898540087275501,0.929217043408747,0.134196070032986,0.463421263838685,0.174111395955151,0.289309867883534,7.05224721598147,2.5922,3.25089689807984,22.0844,0.618240826074327,0.414657272023602,0.639348116633584,0.519314623665238,0.203583554050725,0.120033492968346,True,0.660792385706973,0.0641938333175871,0.395246334080991,122.353733044505
17511,1049:1053,Breast,MDA-MB-468,SIDM00628,908123,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.980252529082485,0.102184616592005,0.673528122526275,10.3031441140613,24.6766,0.898540087275501,0.929217043408747,0.0481805686056762,0.660227645514559,0.710256824030233,-0.0500291785156741,10.740475386016,33.4145,-0.437331271954678,-8.7379,0.880796193033807,0.937351797449043,0.910867356867974,0.923680334389366,-0.0565556044152354,-0.0128129775213922,True,0.660792385706973,0.0641938333175871,0.395246334080991,122.353733044505
17511,1558:1053,Breast,MDA-MB-468,SIDM00628,908123,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.849007244539672,0.102184616592005,0.673528122526275,10.3031441140613,24.6766,0.898540087275501,0.929217043408747,0.0834515872443744,0.571830255426012,0.47236209943974,0.0994681559862717,9.40747413273511,13.2636,0.895669981326208,11.413,0.76286704360621,0.704564434223663,0.788912001603762,0.759901052348527,0.0583026093825468,0.0290109492552347,True,0.660792385706973,0.0641938333175871,0.395246334080991,122.353733044505
17511,1510:1053,Breast,MDA-MB-468,SIDM00628,908123,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.971263242206343,0.102184616592005,0.673528122526275,10.3031441140613,24.6766,0.898540087275501,0.929217043408747,0.0803320972631615,0.654173108002021,0.440823193134912,0.213349914867109,8.66698628279068,7.9388,1.63615783127063,16.7378,0.872718958419573,0.769811718250452,0.902514358294572,0.834008884179372,0.102907240169122,0.0685054741151994,True,0.660792385706973,0.0641938333175871,0.395246334080991,122.353733044505
17511,1594:1053,Breast,MDA-MB-468,SIDM00628,908123,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.986039042886149,0.102184616592005,0.673528122526275,10.3031441140613,24.6766,0.898540087275501,0.929217043408747,0.0584041707513824,0.664125025292713,0.504783074818477,0.159341950474237,9.08588734982771,10.6134,1.21725676423361,14.0632,0.885995607651972,0.882117559426988,0.916244284116259,0.867886851974541,0.003878048224984,0.0483574321417177,True,0.660792385706973,0.0641938333175871,0.395246334080991,122.353733044505
17511,1083:1054,Breast,MDA-MB-468,SIDM00628,908123,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.709427513096934,0.076090792643215,0.909039821170753,13.1422992304463,70.6344,0.938532138810675,0.982908674845227,0.131342478100422,0.644897859639249,0.414447226914411,0.230450632724838,9.61188342580746,6.113,3.53041580463884,64.5214,0.665820521198004,0.547381851631648,0.697302456796853,0.64115954210348,0.118438669566356,0.0561429146933728,True,0.660792385706973,0.0641938333175871,0.395246334080991,122.353733044505
17512,1510:1058,Breast,MDA-MB-468,SIDM00628,908123,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.986082493853171,0.0762761100688281,0.545049931757746,9.32514407236054,5.0112,0.874023465695273,0.891373477359694,0.0820765147086023,0.537464195982178,0.33000673528165,0.207457460700529,7.76347684207671,1.6976,1.56166723028383,3.3136,0.861859238738986,0.778748310287913,0.87896778150942,0.793206363168254,0.0831109284510733,0.0857614183411664,True,0.660792385706973,0.0641938333175871,0.395246334080991,122.353733044505
17512,1549:1058,Breast,MDA-MB-468,SIDM00628,908123,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.710609142013459,0.0762761100688281,0.545049931757746,9.32514407236054,5.0112,0.874023465695273,0.891373477359694,0.0630751181704504,0.387317464360866,0.194305674645525,0.193011789715341,7.24145520522542,1.1822,2.08368886713512,3.829,0.621089065057348,0.509107631800936,0.633418141960126,0.546104364435534,0.111981433256411,0.087313777524592,True,0.660792385706973,0.0641938333175871,0.395246334080991,122.353733044505
17512,1558:1058,Breast,MDA-MB-468,SIDM00628,908123,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.711165188534099,0.0762761100688281,0.545049931757746,9.32514407236054,5.0112,0.874023465695273,0.891373477359694,0.0514947060368032,0.387620537478995,0.101122959569156,0.286497577909839,5.76602550917897,0.4251,3.55911856318157,4.5861,0.621575062764406,0.427105573842412,0.633913787080803,0.464493778221091,0.194469488921994,0.169420008859712,True,0.660792385706973,0.0641938333175871,0.395246334080991,122.353733044505
17512,1561:1073,Breast,MDA-MB-468,SIDM00628,908123,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,20.0,0.907497499494198,0.0993241777029802,0.829141369926536,11.8423456232355,143.437,0.911596157165265,0.966427532336863,0.0525024887970181,0.752443719935525,0.745266491563643,0.0071772283718822,11.7436746905072,133.9548,0.0986709327283233,9.48220000000001,0.827271233175997,0.844163211680398,0.877030569038051,0.875472754619222,-0.0168919785044002,0.0015578144188296,True,0.660792385706973,0.0641938333175871,0.395246334080991,122.353733044505
16957,1190:1372,Breast,MDA-MB-468,SIDM00628,908123,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.01,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.911138162792911,0.136316677517845,0.56273727214574,9.45396549007874,1.3698,0.78993380586274,0.897080211769534,0.090100859912712,0.512731404277964,0.229937792657383,0.28279361162058,7.04569990398477,0.258,2.40826558609397,1.1118,0.719738836601789,0.634388938357306,0.817364016029569,0.687253874279524,0.0853498982444832,0.130110141750046,True,0.447961253764776,0.072648180317143,0.773897121755163,63.4088040692738
16957,1053:1372,Breast,MDA-MB-468,SIDM00628,908123,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.953147436228822,0.136316677517845,0.56273727214574,9.45396549007874,1.3698,0.78993380586274,0.897080211769534,0.138691821715011,0.536371588216113,0.326466896704093,0.20990469151202,7.82655667396124,0.4434,1.6274088161175,0.9264,0.752923381848547,0.654761276906806,0.855049703939741,0.770645088841076,0.0981621049417406,0.0844046150986646,True,0.447961253764776,0.072648180317143,0.773897121755163,63.4088040692738
16959,1561:1549,Breast,MDA-MB-468,SIDM00628,908123,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.95513167202201,0.149232435269779,0.441490370218088,8.57691863115354,3.7291,0.742722256118899,0.853752705529329,0.122420960652363,0.421681435488018,0.426412107584244,-0.0047306720962254,8.61302256424037,3.8237,-0.036103933086828,-0.0946000000000002,0.709397550334804,0.751120920039456,0.815446249125543,0.817347088967889,-0.0417233697046528,-0.0019008398423469,True,0.447961253764776,0.072648180317143,0.773897121755163,63.4088040692738
16959,1594:1549,Breast,MDA-MB-468,SIDM00628,908123,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.939693647336213,0.149232435269779,0.441490370218088,8.57691863115354,3.7291,0.742722256118899,0.853752705529329,0.173785256192807,0.41486569625405,0.145852330782058,0.269013365471993,5.95119374318523,0.6042,2.62572488796831,3.1249,0.69793138581015,0.541779648716011,0.802265993782015,0.628193343929012,0.156151737094139,0.174072649853004,True,0.447961253764776,0.072648180317143,0.773897121755163,63.4088040692738
16959,1053:1549,Breast,MDA-MB-468,SIDM00628,908123,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.92287281904189,0.149232435269779,0.441490370218088,8.57691863115354,3.7291,0.742722256118899,0.853752705529329,0.147281046024944,0.407439462543014,0.12689061314132,0.280548849401695,5.69573777468819,0.5062,2.88118085646534,3.2229,0.685438182269601,0.538112561153366,0.787905166116493,0.597340329039328,0.147325621116235,0.190564837077165,True,0.447961253764776,0.072648180317143,0.773897121755163,63.4088040692738
16959,1058:1549,Breast,MDA-MB-468,SIDM00628,908123,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.819101665398845,0.149232435269779,0.441490370218088,8.57691863115354,3.7291,0.742722256118899,0.853752705529329,0.123390752031985,0.361625497503189,0.0854426502170554,0.276182847286133,5.13080152307454,0.3422,3.44611710807899,3.3869,0.608365036915778,0.445377076174664,0.699310262937843,0.49074288285439,0.162987960741115,0.208567380083453,True,0.447961253764776,0.072648180317143,0.773897121755163,63.4088040692738
16961,1549:1561,Breast,MDA-MB-468,SIDM00628,908123,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.603916879812018,0.0685848108434161,0.521104081173359,9.15199415965345,11.111,0.881435010180067,0.883347284311061,0.0530741319432839,0.314703550759524,0.195590878079932,0.119112672679592,7.6755236050532,3.9929,1.47647055460025,7.1181,0.532313481105021,0.477853761407669,0.533468335731556,0.482270391085519,0.0544597196973516,0.0511979446460369,True,0.447961253764776,0.072648180317143,0.773897121755163,63.4088040692738
16961,1594:1561,Breast,MDA-MB-468,SIDM00628,908123,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.970551821399841,0.0685848108434161,0.521104081173359,9.15199415965345,11.111,0.881435010180067,0.883347284311061,0.0388558670714741,0.505758515121694,0.380494020091556,0.125264495030139,8.21048656121291,5.7854,0.941507598440534,5.3256,0.855478354575852,0.825764100810651,0.857334315716704,0.808055551784337,0.0297142537652016,0.0492787639323674,True,0.447961253764776,0.072648180317143,0.773897121755163,63.4088040692738
16961,1053:1594,Breast,MDA-MB-468,SIDM00628,908123,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.902725347952866,0.0807907898646119,0.449106776934351,8.63240557573862,3.1003,0.825517219731314,0.856804035919816,0.0559508249858291,0.405420071476052,0.25300980150991,0.152410269966142,7.30291709615522,1.2336,1.3294884795834,1.8667,0.745215319423033,0.717123567677681,0.773458721453136,0.697702915245515,0.0280917517453521,0.0757558062076201,True,0.447961253764776,0.072648180317143,0.773897121755163,63.4088040692738
17730,1012:1372,Breast,HCC1599,SIDM00877,749713,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.901830394848349,0.0643640868680808,0.909829440057579,14.7796248198466,54.9339,0.958981190532906,0.976826126875853,0.0700077412611648,0.820511843171779,0.791422124400087,0.029089718771692,13.9247461376193,30.3736,0.854878682227298,24.5603,0.86483838571043,0.853906722254758,0.880931491698634,0.872958705548656,0.0109316634556719,0.0079727861499779,True,0.814920841818228,0.0980167703260647,0.195265483487689,245.928386598538
17731,1017:1375,Breast,HCC1599,SIDM00877,749713,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,1375,Temozolomide,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved,30.0,0.861943361283753,0.0661141738479411,0.919784171638843,15.0993257798298,2056.8436,0.957624149129904,0.979492537714082,0.0739248086830545,0.792801860557976,0.386407976870959,0.406393883687017,8.48106474060546,20.9366,6.61826103922438,2035.907,0.825417777947523,0.659703870845824,0.844267090309629,0.693844073596057,0.165713907101699,0.150423016713572,True,0.814920841818228,0.0980167703260647,0.195265483487689,245.928386598538
17732,1011:1549,Breast,HCC1599,SIDM00877,749713,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.961330596717223,0.125830885954776,0.693681736616643,11.043733022568,20.6156,0.829093775937468,0.910567918361145,0.150570787320881,0.666857477793517,0.435153886605265,0.231703591188252,8.52509580343752,3.5976,2.51863721913048,17.018,0.797033214356502,0.661091282711962,0.875356800309679,0.776081941005665,0.13594193164454,0.099274859304014,True,0.814920841818228,0.0980167703260647,0.195265483487689,245.928386598538
17732,1510:1549,Breast,HCC1599,SIDM00877,749713,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.512448034663919,0.125830885954776,0.693681736616643,11.043733022568,20.6156,0.829093775937468,0.910567918361145,0.0754833833717867,0.355475842611453,0.162121168394885,0.193354674216568,7.07344699637807,1.3153,3.97028602618992,19.3003,0.424867476031243,0.310591146014604,0.466618740192184,0.36996659053432,0.114276330016639,0.0966521496578645,True,0.814920841818228,0.0980167703260647,0.195265483487689,245.928386598538
17732,1049:1549,Breast,HCC1599,SIDM00877,749713,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.683117004544396,0.125830885954776,0.693681736616643,11.043733022568,20.6156,0.829093775937468,0.910567918361145,0.105984227123144,0.473865790024716,0.339771017668256,0.13409477235646,8.97382981802215,4.9101,2.06990320454584,15.7055,0.566368056704806,0.481585555047451,0.622024428825091,0.566964435024397,0.0847825016573546,0.0550599938006946,True,0.814920841818228,0.0980167703260647,0.195265483487689,245.928386598538
17733,1012:1558,Breast,HCC1599,SIDM00877,749713,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.644532462317321,0.113751155052444,0.4537953863071,8.53657258634873,7.2526,0.812176402118682,0.807902436842742,0.0700996982233286,0.292485857724755,0.123203664529058,0.169282193195697,5.39318322595179,0.8208,3.14338936039694,6.4318,0.523474056293577,0.359650196567295,0.520719346930416,0.389908818267256,0.163823859726281,0.130810528663161,True,0.814920841818228,0.0980167703260647,0.195265483487689,245.928386598538
17734,1012:1561,Breast,HCC1599,SIDM00877,749713,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.58928799439285,0.173629136837521,0.265490395968206,6.45561347784427,1.7142,0.608281911076071,0.680778744046612,0.07935699449207,0.156450302970668,0.0502611610465333,0.106189141924134,3.06790928849256,0.1638,3.38770418935171,1.5504,0.358453227403468,0.229817621777708,0.401174740704512,0.253017986528386,0.12863560562576,0.148156754176126,True,0.814920841818228,0.0980167703260647,0.195265483487689,245.928386598538
17734,1011:1561,Breast,HCC1599,SIDM00877,749713,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.933762324893491,0.173629136837521,0.265490395968206,6.45561347784427,1.7142,0.608281911076071,0.680778744046612,0.10297945471616,0.247904929376165,0.0845762516460918,0.163328677730073,3.23270013204005,0.1836,3.22291334580422,1.5306,0.567990731477048,0.392189450257393,0.635685542779035,0.412498288609816,0.175801281219654,0.22318725416922,True,0.814920841818228,0.0980167703260647,0.195265483487689,245.928386598538
17734,1012:1594,Breast,HCC1599,SIDM00877,749713,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.924231692223155,0.128542137231353,0.591117317501373,9.92158347451178,7.5768,0.835985814511909,0.871697382435004,0.0552457792361568,0.546329358656706,0.422662460049371,0.123666898607335,8.57202586210374,2.9732,1.34955761240804,4.6036,0.772644584020894,0.735470076784406,0.805650346874399,0.748402801516732,0.0371745072364885,0.0572475453576666,True,0.814920841818228,0.0980167703260647,0.195265483487689,245.928386598538
17734,1011:1594,Breast,HCC1599,SIDM00877,749713,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.933762324893491,0.128542137231353,0.591117317501373,9.92158347451178,7.5768,0.835985814511909,0.871697382435004,0.0512982292563598,0.551963080674886,0.267560037311272,0.284403043363614,6.71908474614106,0.8231,3.20249872837072,6.7537,0.780612057736618,0.633423779432661,0.81395817442608,0.652369609201894,0.147188278303957,0.161588565224186,True,0.814920841818228,0.0980167703260647,0.195265483487689,245.928386598538
14583,1011:1007,Breast,HCC1937,SIDM00874,749714,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1007,Docetaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.0125,0.743061066782718,0.0923214568912977,0.757603188512237,11.5358538579568,0.0725,0.89029471999225,0.939022529921862,0.0580079868558925,0.562945433453892,0.271860325275465,0.291085108178427,7.77612413606162,0.0054,3.75972972189521,0.0671,0.661543344388463,0.554380707194184,0.697751082816745,0.579976604060945,0.107162637194279,0.117774478755801,True,0.616359485554619,0.0695836798035186,0.463787726370159,104.791341233405
14584,1179:1011,Breast,HCC1937,SIDM00874,749714,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.558846148340319,0.141697285178952,0.327605903058749,7.39997419744779,3.2987,0.77142512347853,0.756722186694272,0.053792311267521,0.183081297097934,0.0498149672473132,0.13326632985062,3.82809727710164,0.2774,3.57187692034615,3.0213,0.431107958988931,0.247227321596838,0.422891279397757,0.271654757128742,0.183880637392093,0.151236522269015,True,0.616359485554619,0.0695836798035186,0.463787726370159,104.791341233405
14584,1011:1012,Breast,HCC1937,SIDM00874,749714,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,5.0,0.712682705855048,0.0573192211370029,0.639316707852204,10.2737300824533,12.0893,0.875393400923105,0.901851231514387,0.0631469781206066,0.45562996125045,0.248099862306994,0.207530098943456,7.60408419968905,1.9,2.66964588276425,10.1893,0.623877737657531,0.554527593578309,0.64273377595438,0.548623354392307,0.0693501440792216,0.0941104215620732,True,0.616359485554619,0.0695836798035186,0.463787726370159,104.791341233405
15173,1022:1190,Breast,HCC1937,SIDM00874,749714,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.704894923531675,0.0568247568859318,0.912135445553069,14.2070576717776,369.3861,0.982627203274473,0.979774586613871,0.0649709018402815,0.642959645143661,0.615444305715592,0.0275153394280682,13.2917377458515,195.8582,0.915319925926086,173.5279,0.692648927312303,0.692096387406412,0.690638132309463,0.683863439091312,0.0005525399058906,0.0067746932181508,True,0.804340836007785,0.094706923743366,0.204229433252746,232.010888483592
15173,1005:1190,Breast,HCC1937,SIDM00874,749714,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.976343026743466,0.0568247568859318,0.912135445553069,14.2070576717776,369.3861,0.982627203274473,0.979774586613871,0.0702841270609325,0.890557081711283,0.282661323795178,0.607895757916105,7.00225484481353,2.5039,7.20480282696411,366.8822,0.959381217805466,0.737012509254585,0.956596085420915,0.712913982707291,0.22236870855088,0.243682102713624,True,0.804340836007785,0.094706923743366,0.204229433252746,232.010888483592
15173,1011:1190,Breast,HCC1937,SIDM00874,749714,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.777690667548358,0.0568247568859318,0.912135445553069,14.2070576717776,369.3861,0.982627203274473,0.979774586613871,0.109607448947249,0.709359223546685,0.534434790829226,0.174924432717459,10.7514818054451,33.6704,3.45557586633257,335.7157,0.764180005665701,0.643782128542074,0.761961552310658,0.713652491949766,0.120397877123627,0.0483090603608919,True,0.804340836007785,0.094706923743366,0.204229433252746,232.010888483592
17264,1011:1049,Breast,MFM-223,SIDM00332,910948,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.781703487475243,0.198190554797049,0.165736860692484,5.32571496666347,0.7833,0.523087557939789,0.605026968909077,0.067460345356298,0.129557082006513,0.0173496753961389,0.112207406610374,0.393825224812645,0.0257,4.93188974185083,0.7576,0.408899368296441,0.13488327572008,0.472951691612801,0.181896717673781,0.274016092576361,0.29105497393902,True,0.399757664452004,0.0545312508158561,0.891775238419063,55.3353490020201
17264,1561:1049,Breast,MFM-223,SIDM00332,910948,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.657702605019055,0.198190554797049,0.165736860692484,5.32571496666347,0.7833,0.523087557939789,0.605026968909077,0.145876467281746,0.109005565025127,0.0281097726212617,0.080895792403865,1.93183916222395,0.0745,3.39387580443952,0.7088,0.344036049510055,0.220008349774514,0.397927813558283,0.222669000074753,0.124027699735541,0.17525881348353,True,0.399757664452004,0.0545312508158561,0.891775238419063,55.3353490020201
17264,1053:1049,Breast,MFM-223,SIDM00332,910948,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.720316761347656,0.198190554797049,0.165736860692484,5.32571496666347,0.7833,0.523087557939789,0.605026968909077,0.176986456876912,0.119383038729937,0.0315521909334273,0.0878308477965102,1.99026662792909,0.0776,3.33544833873438,0.7057,0.376788735636443,0.249767192117081,0.435811066772576,0.246994274933219,0.127021543519363,0.188816791839356,True,0.399757664452004,0.0545312508158561,0.891775238419063,55.3353490020201
15041,1011:1561,Breast,MFM-223,SIDM00332,910948,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.62000345174137,0.118513870769036,0.367537319029073,7.76596133374901,4.2513,0.741347764588691,0.777200145053937,0.0603802131103173,0.227874406441794,0.0321395532767489,0.195734853165045,2.39232878862298,0.1025,5.37363254512603,4.1488,0.459638172985736,0.193536271871934,0.481866772627334,0.231416123449285,0.266101901113803,0.250450649178049,True,0.588351541501767,0.0776253401710523,0.512285809100232,95.4234882407677
15083,1558:1083,Breast,T47D,SIDM00097,905945,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.847561402787158,0.093031693658323,0.654509246857942,10.9936884734584,39.8254,0.89776955063947,0.874347546194126,0.110569980857848,0.554736775404083,0.448255312078766,0.106481463325317,9.36082705154258,12.8416,1.63286142191586,26.9838,0.760914819719586,0.735275949320061,0.741063232775803,0.68848120231602,0.0256388703995242,0.0525820304597824,True,0.638863803485452,0.0687318649181346,0.430421244441089,112.980276379217
15084,1022:1190,Breast,T47D,SIDM00097,905945,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.910674782531789,0.0914833931239375,0.824388770819116,13.8252990195971,283.5044,0.90208037912945,0.94242608508788,0.137993469361357,0.750750064587347,0.484977169200367,0.26577289538698,9.40681512073584,13.2576,4.4184838988613,270.2468,0.821501853089906,0.648943425517755,0.85824367008969,0.74156907090904,0.172558427572151,0.116674599180651,True,0.638863803485452,0.0687318649181346,0.430421244441089,112.980276379217
15084,1179:1190,Breast,T47D,SIDM00097,905945,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.811024249269634,0.0914833931239375,0.824388770819116,13.8252990195971,283.5044,0.90208037912945,0.94242608508788,0.192692332827856,0.66859928395989,0.342200797715953,0.326398486243937,8.01760744363822,5.0614,5.80769157595892,278.443,0.73160906226433,0.48315995955077,0.764330408150518,0.606337437665102,0.248449102713559,0.157992970485417,True,0.638863803485452,0.0687318649181346,0.430421244441089,112.980276379217
15084,1012:1190,Breast,T47D,SIDM00097,905945,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.713940168373185,0.0914833931239375,0.824388770819116,13.8252990195971,283.5044,0.90208037912945,0.94242608508788,0.112056038367626,0.588564257843563,0.356425487768802,0.232138770074761,8.99047896374367,9.9342,4.83482005585348,273.5702,0.644031417761826,0.488100714528238,0.672835837866923,0.568068185364886,0.155930703233588,0.104767652502037,True,0.638863803485452,0.0687318649181346,0.430421244441089,112.980276379217
15084,1011:1190,Breast,T47D,SIDM00097,905945,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.900296819757207,0.0914833931239375,0.824388770819116,13.8252990195971,283.5044,0.90208037912945,0.94242608508788,0.134427260866155,0.742194588612004,0.379512606314367,0.362681982297636,8.01255427663121,5.0437,5.81274474296593,278.4607,0.81214009649562,0.595945181645484,0.848463207260854,0.672840242772304,0.216194914850137,0.17562296448855,True,0.638863803485452,0.0687318649181346,0.430421244441089,112.980276379217
15085,1012:1372,Breast,T47D,SIDM00097,905945,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.87552201718737,0.0788344449742857,0.866877207898163,14.8464695212989,57.5391,0.924432767444262,0.957360601458044,0.153808709144444,0.758970081712754,0.48840996942694,0.270560112285815,9.72530991566839,1.6533,5.12115960563053,55.8858,0.809361241306903,0.722681958484894,0.83819028496426,0.724712389411621,0.0866792828220092,0.11347789555264,True,0.638863803485452,0.0687318649181346,0.430421244441089,112.980276379217
15087,1372:1510,Breast,T47D,SIDM00097,905945,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.914254897541713,0.0927421562175262,0.78111030533354,12.9696180428255,156.6658,0.917660316597791,0.926441451230925,0.0725405163889983,0.714133922171492,0.706692428227768,0.0074414939437238,12.823004989624,141.527,0.146613053201525,15.1388,0.838975438729209,0.81809557791638,0.847003634073525,0.844169518842594,0.0208798608128297,0.0028341152309311,True,0.638863803485452,0.0687318649181346,0.430421244441089,112.980276379217
15088,1017:1558,Breast,T47D,SIDM00097,905945,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.938824764035431,0.126705748146979,0.641133045568776,10.8107249188382,35.0819,0.863444018256967,0.868299143340217,0.141963092066657,0.601911580221424,0.314942218144436,0.286969362076988,6.86697577845326,2.2798,3.94374914038493,32.8021,0.810622626697901,0.620760931528778,0.815180738358546,0.641497346156216,0.189861695169123,0.17368339220233,True,0.638863803485452,0.0687318649181346,0.430421244441089,112.980276379217
15088,1047:1558,Breast,T47D,SIDM00097,905945,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.938568043777778,0.126705748146979,0.641133045568776,10.8107249188382,35.0819,0.863444018256967,0.868299143340217,0.0521473821430937,0.601746988380776,0.674491286083099,-0.0727442977023236,11.9260626378317,76.0033,-1.11533771899354,-40.9214,0.810400963127065,0.879518483308633,0.814957828378748,0.84641984968249,-0.0691175201815681,-0.0314620213037425,True,0.638863803485452,0.0687318649181346,0.430421244441089,112.980276379217
15088,1011:1558,Breast,T47D,SIDM00097,905945,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.931299642851973,0.126705748146979,0.641133045568776,10.8107249188382,35.0819,0.863444018256967,0.868299143340217,0.184215799878032,0.597086976358799,0.326294384070484,0.270792592288315,7.07334617205987,2.6304,3.73737874677832,32.4515,0.804125105825386,0.715071143672916,0.808646682081418,0.647597880886141,0.0890539621524699,0.161048801195277,True,0.638863803485452,0.0687318649181346,0.430421244441089,112.980276379217
15089,1049:1594,Breast,T47D,SIDM00097,905945,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.81708535885964,0.110483450156215,0.538664947893604,9.48356658255984,5.5928,0.797322490891107,0.817610712703402,0.106257472936139,0.440135242254755,0.214599935242227,0.225535307012528,5.7788438174194,0.4289,3.70472276514044,5.1639,0.651480533596622,0.449057359544491,0.668057742596746,0.503709559596826,0.202423174052131,0.164348182999919,True,0.638863803485452,0.0687318649181346,0.430421244441089,112.980276379217
16652,1549:1011,Breast,ZR-75-30,SIDM00971,909907,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.628515284746525,0.0622636399262511,0.892444961117567,18.0257531632874,5212.2164,0.950914719179713,0.9563641833593,0.097890129204498,0.560915298857409,0.262158399792448,0.298756899064961,7.57249335599601,3.7177,10.4532598072914,5208.4987,0.597664435494899,0.390549218902534,0.601089507025448,0.427808747991298,0.207115216592365,0.17328075903415,True,0.762816347961741,0.0805084232141152,0.2558813203898,186.752329474812
16652,1558:1011,Breast,ZR-75-30,SIDM00971,909907,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.679874218978025,0.0622636399262511,0.892444961117567,18.0257531632874,5212.2164,0.950914719179713,0.9563641833593,0.0676765119766024,0.606750320920679,0.301239829671991,0.305510491248689,8.02461963441398,5.0861,10.0011335288735,5207.1303,0.646502402017015,0.436436475406365,0.650207352219961,0.476818551811283,0.21006592661065,0.173388800408677,True,0.762816347961741,0.0805084232141152,0.2558813203898,186.752329474812
16656,1011:1058,Breast,ZR-75-30,SIDM00971,909907,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.924303693002805,0.0896316692384461,0.779374535744231,14.3832380261748,166.946,0.884549676011447,0.905101727292725,0.106900761661523,0.72037876162074,0.464826137210971,0.255552624409769,9.04936672604532,4.1392,5.33387130012946,162.8068,0.817592532181815,0.716396148148924,0.836588869079884,0.689004823139305,0.101196384032891,0.147584045940579,True,0.762816347961741,0.0805084232141152,0.2558813203898,186.752329474812
17870,1011:1558,Breast,ZR-75-30,SIDM00971,909907,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.969781980816459,0.0822484863737372,0.304560087646317,5.47803258922462,0.8705,0.562252710110724,0.577344822758826,0.0946111993104134,0.29535688507528,0.14458179635428,0.150775088721,1.57033884697784,0.058,3.90769374224677,0.8125,0.545262546930601,0.324434975677249,0.559898605829181,0.363078373327649,0.220827571253352,0.196820232501533,True,0.904356873847144,0.0949684076752773,0.0883337129884524,502.224815162437
17870,1011:1559,Breast,ZR-75-30,SIDM00971,909907,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1559,Luminespib,HSP90,Protein stability and degradation,Targeted,Early clinical trials,0.1,0.969781980816459,0.093103077696299,0.692979861399813,12.472535523322,1.11,0.872657387863334,0.861309441114062,0.0909394107652896,0.672039382654226,0.663030646113936,0.0090087365402903,12.2878207024658,0.9766,0.18471482085617,0.1334,0.846287410176222,0.873861688785267,0.835282375899512,0.830445160886131,-0.0275742786090455,0.0048372150133811,True,0.904356873847144,0.0949684076752773,0.0883337129884524,502.224815162437
17871,1011:1561,Breast,ZR-75-30,SIDM00971,909907,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.920033579598601,0.107054673463758,0.53018488384567,9.51564818339656,14.2964,0.718500276044194,0.764131551471072,0.0850239634552272,0.4877878965336,0.266732413052308,0.221055483481292,5.17894868205917,0.7075,4.3366995013374,13.5889,0.661044380911522,0.487137257127336,0.703026686584162,0.516925796764129,0.173907123784186,0.186100889820033,True,0.904356873847144,0.0949684076752773,0.0883337129884524,502.224815162437
17871,1558:1594,Breast,ZR-75-30,SIDM00971,909907,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.487134077059966,0.0675263433676703,0.720122921291875,13.0312542466973,65.4016,0.87655092842027,0.875558287161371,0.0841523820263392,0.350796414633244,0.263164781714848,0.087631632918396,9.68791210967132,6.4438,3.34334213702597,58.9578,0.426997827512065,0.340874828563285,0.426514278128559,0.375489609622197,0.0861229989487795,0.0510246685063624,True,0.904356873847144,0.0949684076752773,0.0883337129884524,502.224815162437
14482,1022:1005,Breast,HCC1806,SIDM00875,907047,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.226798403699603,0.0550791680611876,0.852341522067509,11.7957588180701,27.7758,0.979811630865938,0.974573004811907,0.036731283340445,0.193309696611801,0.117095744980886,0.0762139516309148,9.10400790232762,4.299,2.6917509157425,23.4768,0.222219713806699,0.175303409164539,0.221031601780066,0.202952197892962,0.0469163046421607,0.0180794038871046,True,0.31142702381149,0.0418583218870999,1.13649394755681,43.5498732511249
14483,1190:1011,Breast,HCC1806,SIDM00875,907047,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.333368459390928,0.157392577275175,0.369527205125181,8.14800381359628,5.5402,0.856086451791973,0.841749992799377,0.0666430128661589,0.123188715075617,0.0383189615926532,0.0848697534829638,5.7447686742076,1.0473,2.40323513938868,4.4929,0.285392221539336,0.178589241826691,0.280612898291853,0.219126273072156,0.106802979712644,0.0614866252196972,True,0.31142702381149,0.0418583218870999,1.13649394755681,43.5498732511249
14483,1179:1011,Breast,HCC1806,SIDM00875,907047,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.138498823634262,0.157392577275175,0.369527205125181,8.14800381359628,5.5402,0.856086451791973,0.841749992799377,0.0673017781970275,0.0511790832106942,0.0462905986572938,0.0048884845534004,7.90103086072473,4.6685,0.246972952871554,0.8717,0.118566966502417,0.0584567419163599,0.116581383796862,0.11437589058651,0.0601102245860576,0.0022054932103525,True,0.31142702381149,0.0418583218870999,1.13649394755681,43.5498732511249
14740,1022:1017,Breast,HCC1806,SIDM00875,907047,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.747898193052918,0.0732456501366894,0.722025128508917,10.522249682073,28.7239,0.896408128222746,0.948175327152254,0.0571499107574488,0.54000128895062,0.241988524463174,0.298012764487446,7.82391220866963,4.4255,2.69833747340338,24.2984,0.67042201933574,0.606029883641457,0.70913861387453,0.613784926493486,0.0643921356942827,0.0953536873810445,True,0.428017105138178,0.0447464302810151,0.827032152393697,59.674248378581
14484,1011:1021,Breast,HCC1806,SIDM00875,907047,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.984641669118532,0.05334116648849,0.81270607395815,11.3406209960032,50.6521,0.952801530637293,0.966996339190324,0.0859648085336183,0.800224265164921,0.509866438077172,0.290357827087749,9.1137183953899,10.8201,2.22690260061326,39.832,0.938168089465396,0.801436275992187,0.952144889451871,0.88157381620585,0.136731813473209,0.0705710732460207,True,0.31142702381149,0.0418583218870999,1.13649394755681,43.5498732511249
14484,1558:1021,Breast,HCC1806,SIDM00875,907047,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.788928166085435,0.05334116648849,0.81270607395815,11.3406209960032,50.6521,0.952801530637293,0.966996339190324,0.0917449605449171,0.641166712494297,0.428299856161499,0.212866856332798,9.27426085967075,12.0937,2.06636013633241,38.5584,0.751691964209075,0.645438584439003,0.762890648488752,0.71227374850798,0.106253379770073,0.0506168999807728,True,0.31142702381149,0.0418583218870999,1.13649394755681,43.5498732511249
14485,1549:1053,Breast,HCC1806,SIDM00875,907047,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.712951542181967,0.0455454149806284,0.735351716701064,10.6297655028955,30.9463,0.945495892974473,0.951084422582549,0.0705531017586302,0.52427014046818,0.386922781759669,0.137347358708511,9.2730868095349,12.0839,1.35667869336055,18.8624,0.674092755022866,0.578287568976002,0.678077105825473,0.643641084471517,0.0958051860468647,0.0344360213539563,True,0.31142702381149,0.0418583218870999,1.13649394755681,43.5498732511249
14485,1558:1053,Breast,HCC1806,SIDM00875,907047,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.798190913147188,0.0455454149806284,0.735351716701064,10.6297655028955,30.9463,0.945495892974473,0.951084422582549,0.0452126669420711,0.586951058237975,0.45538457287669,0.131566485361285,9.45287590049137,13.6877,1.17688960240408,17.2586,0.754686230190211,0.697200761348211,0.759146943741231,0.726934653222989,0.0574854688419995,0.0322122905182423,True,0.31142702381149,0.0418583218870999,1.13649394755681,43.5498732511249
14485,1372:1053,Breast,HCC1806,SIDM00875,907047,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.778239523460783,0.0455454149806284,0.735351716701064,10.6297655028955,30.9463,0.945495892974473,0.951084422582549,0.055302808389257,0.572279769581505,0.557002389127824,0.0152773804536814,10.4725012689238,27.7503,0.157264233971677,3.196,0.735822273182582,0.713437359153405,0.740171487801617,0.73682198775244,0.0223849140291766,0.0033495000491772,True,0.31142702381149,0.0418583218870999,1.13649394755681,43.5498732511249
14485,1012:1053,Breast,HCC1806,SIDM00875,907047,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.809691111767951,0.0455454149806284,0.735351716701064,10.6297655028955,30.9463,0.945495892974473,0.951084422582549,0.0849901971438986,0.595407749036156,0.351644457703859,0.243763291332297,8.57842319918256,7.4661,2.05134230371289,23.4802,0.765559620754532,0.650383629883859,0.770084603506043,0.702313000793996,0.115175990870674,0.0677716027120476,True,0.31142702381149,0.0418583218870999,1.13649394755681,43.5498732511249
14485,1011:1053,Breast,HCC1806,SIDM00875,907047,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.960416670588878,0.0455454149806284,0.735351716701064,10.6297655028955,30.9463,0.945495892974473,0.951084422582549,0.0554437189227193,0.706244047465852,0.462531173042728,0.243712874423124,8.88253572666652,9.2181,1.74722977622893,21.7282,0.908070017586001,0.797738622607373,0.913437334585676,0.848818478946664,0.110331394978628,0.064618855639012,True,0.31142702381149,0.0418583218870999,1.13649394755681,43.5498732511249
14485,1594:1053,Breast,HCC1806,SIDM00875,907047,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.958096177632855,0.0455454149806284,0.735351716701064,10.6297655028955,30.9463,0.945495892974473,0.951084422582549,0.0668450544565927,0.704537668987048,0.439554442783319,0.264983226203728,8.7364508588972,8.3304,1.89331464399825,22.6159,0.905876001026405,0.792726421079782,0.911230349882491,0.839381807520984,0.113149579946624,0.0718485423615068,True,0.31142702381149,0.0418583218870999,1.13649394755681,43.5498732511249
14737,1011:1083,Breast,HCC1806,SIDM00875,907047,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.872904193881294,0.0865423156623286,0.433590995555633,8.57385529048247,7.4425,0.840898857531436,0.867126412966381,0.0708025304799499,0.378483398449678,0.175960130352718,0.20252326809696,6.80488952131014,2.1838,1.76896576917233,5.2587,0.73402413936918,0.629652533005155,0.756918282503597,0.650992454223724,0.104371606364025,0.105925828279872,True,0.428017105138178,0.0447464302810151,0.827032152393697,59.674248378581
14741,1058:1510,Breast,HCC1806,SIDM00875,907047,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.966076596751635,0.0416235977440002,0.810669592267219,11.3193732319721,49.9115,0.967042299597207,0.966597152813209,0.0152099555335169,0.783168920787551,0.673381924071552,0.109786996715999,10.3287304620249,25.1182,0.990642769947211,24.7933,0.934236933709745,0.910183877827761,0.933806887819606,0.910595902578795,0.0240530558819835,0.0232109852408111,True,0.428017105138178,0.0447464302810151,0.827032152393697,59.674248378581
14741,1549:1510,Breast,HCC1806,SIDM00875,907047,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.706701896450316,0.0416235977440002,0.810669592267219,11.3193732319721,49.9115,0.967042299597207,0.966597152813209,0.119953710641052,0.572901738249849,0.270229067156373,0.302672671093476,8.23538020160497,5.8861,3.08399303036713,44.0254,0.683410627073021,0.505263406284662,0.683096040996571,0.598700503881688,0.178147220788359,0.0843955371148831,True,0.428017105138178,0.0447464302810151,0.827032152393697,59.674248378581
14741,1558:1510,Breast,HCC1806,SIDM00875,907047,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.830432284980462,0.0416235977440002,0.810669592267219,11.3193732319721,49.9115,0.967042299597207,0.966597152813209,0.134761514267172,0.673206201870647,0.340490044884876,0.33271615698577,8.41966247911548,6.6881,2.89971075285663,43.2234,0.803063146527269,0.608187022166196,0.802693482266282,0.71271889834636,0.194876124361073,0.0899745839199227,True,0.428017105138178,0.0447464302810151,0.827032152393697,59.674248378581
14741,1561:1510,Breast,HCC1806,SIDM00875,907047,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.97224054268407,0.0416235977440002,0.810669592267219,11.3193732319721,49.9115,0.967042299597207,0.966597152813209,0.0229102333463765,0.788165844323355,0.644974630273013,0.143191214050343,10.0819490238657,21.1689,1.23742420810637,28.7426,0.940197730158839,0.915645244972881,0.939764940407992,0.908758144579175,0.0245524851859584,0.0310067958288173,True,0.428017105138178,0.0447464302810151,0.827032152393697,59.674248378581
14741,1559:1510,Breast,HCC1806,SIDM00875,907047,1559,Luminespib,HSP90,Protein stability and degradation,Targeted,Early clinical trials,0.01,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.958590489023529,0.0416235977440002,0.810669592267219,11.3193732319721,49.9115,0.967042299597207,0.966597152813209,0.0403659762295456,0.777100160887939,0.566952358876393,0.210147802011545,9.58996253709605,15.0521,1.72941069487606,34.8594,0.926997550877324,0.898019851910732,0.926570837403965,0.878503093078112,0.0289776989665923,0.0480677443258528,True,0.428017105138178,0.0447464302810151,0.827032152393697,59.674248378581
14741,1510:1549,Breast,HCC1806,SIDM00875,907047,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.678010524800687,0.135931796683999,0.474594159166821,8.83779493776718,4.4683,0.765156633201634,0.881476484674366,0.145857366884214,0.321779834924037,0.191209866270385,0.130569968653652,7.50971915056036,1.7797,1.32807578720682,2.6886,0.518784250431767,0.424043283586678,0.597650333973532,0.541664024443705,0.0947409668450888,0.055986309529827,True,0.428017105138178,0.0447464302810151,0.827032152393697,59.674248378581
14742,1510:1558,Breast,HCC1806,SIDM00875,907047,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.920910965542062,0.0859811615981186,0.432307228365106,8.56551609205293,7.3996,0.816144440884424,0.866655598474539,0.0917931865288208,0.398116467084523,0.164914171109501,0.233202295975021,6.57179189993789,1.858,1.99372419211504,5.5416,0.751596365076661,0.62199627186846,0.798112643983621,0.669582366667666,0.129600093208201,0.128530277315955,True,0.428017105138178,0.0447464302810151,0.827032152393697,59.674248378581
14530,1012:1007,Breast,EVSA-T,SIDM01042,906862,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1007,Docetaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.0125,0.803721668932519,0.153739765929605,0.603203737025879,9.62371931386773,0.0193,0.818664542603154,0.924840279837605,0.100228720003217,0.484807914228772,0.415345978948348,0.0694619352804238,9.09998210843125,0.0134,0.523737205436483,0.0059,0.657978432476884,0.655569876139112,0.743314173207098,0.724845524236036,0.0024085563377725,0.0184686489710623,True,0.666529034164887,0.0968520929255177,0.391569991468467,124.458093668511
14530,1011:1007,Breast,EVSA-T,SIDM01042,906862,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1007,Docetaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.0125,0.804590642233767,0.153739765929605,0.603203737025879,9.62371931386773,0.0193,0.818664542603154,0.924840279837605,0.0564777089576034,0.48533208217146,0.0891681167783661,0.396163965393094,5.89899147606411,0.0015,3.72472783780362,0.0178,0.658689830107084,0.507591559523958,0.744117834718195,0.542172457211066,0.151098270583127,0.201945377507129,True,0.666529034164887,0.0968520929255177,0.391569991468467,124.458093668511
14530,1561:1007,Breast,EVSA-T,SIDM01042,906862,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1007,Docetaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.0125,0.94460362761334,0.153739765929605,0.603203737025879,9.62371931386773,0.0193,0.818664542603154,0.924840279837605,0.0532496336502244,0.569788438184569,0.636435200313382,-0.0666467621288125,10.0800123276223,0.0264,-0.456293013754539,-0.0071,0.773313496741355,0.858748582901605,0.873607483297539,0.889138360844828,-0.0854350861602496,-0.0155308775472895,True,0.666529034164887,0.0968520929255177,0.391569991468467,124.458093668511
14531,1083:1011,Breast,EVSA-T,SIDM01042,906862,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.819740501721927,0.140749664967791,0.297224394682431,7.71847961961302,4.1136,0.796987653786229,0.81974803001835,0.0925660365767353,0.243646874420972,0.0268172997389966,0.216829574681975,3.95660088199561,0.3032,3.76187873761741,3.8104,0.653323059180905,0.405739639452869,0.671980661412803,0.406552101113503,0.247583419728036,0.2654285602993,True,0.666529034164887,0.0968520929255177,0.391569991468467,124.458093668511
14531,1053:1011,Breast,EVSA-T,SIDM01042,906862,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.363921818617505,0.140749664967791,0.297224394682431,7.71847961961302,4.1136,0.796987653786229,0.81974803001835,0.0590709025391536,0.108166442250317,0.003405293496536,0.104761148753781,2.05710174361914,0.0813,5.66137787599387,4.0323,0.290041196381583,0.0936338122564074,0.298324193892395,0.117290258974779,0.196407384125175,0.181033934917615,True,0.666529034164887,0.0968520929255177,0.391569991468467,124.458093668511
14531,1053:1012,Breast,EVSA-T,SIDM01042,906862,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,5.0,0.695274560827399,0.104872384210299,0.296110757457752,7.71053153131977,2.0455,0.776970671640185,0.819191293221447,0.0644544849554947,0.205878276847707,0.0598879903087112,0.145990286538996,5.48290093417903,0.4367,2.22763059714075,1.6088,0.540207942500399,0.408961139883203,0.569562866628171,0.44273692836794,0.131246802617196,0.126825938260231,True,0.666529034164887,0.0968520929255177,0.391569991468467,124.458093668511
15771,1073:1022,Breast,EVSA-T,SIDM01042,906862,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,10.0,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.947220508415286,0.103123169593246,0.383848007078074,8.29524662545634,0.6135,0.841444209110881,0.857698605351523,0.0882353940022086,0.363588704418687,0.198424507408178,0.16516419701051,7.0222732816341,0.2539,1.27297334382224,0.3596,0.797033211557107,0.713461683140558,0.812429709028152,0.727372088284638,0.0835715284165495,0.0850576207435139,True,0.51432967263968,0.0822651455982873,0.644386945256132,76.1949995482601
15771,1190:1022,Breast,EVSA-T,SIDM01042,906862,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.01,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.821845380773317,0.103123169593246,0.383848007078074,8.29524662545634,0.6135,0.841444209110881,0.857698605351523,0.069390675774784,0.315463711536158,0.0962579681820012,0.219205743354157,5.9919167205434,0.1243,2.30332990491294,0.4892,0.691537036436235,0.567067078222346,0.704895636903866,0.560494979872447,0.124469958213888,0.144400657031419,True,0.51432967263968,0.0822651455982873,0.644386945256132,76.1949995482601
15771,1179:1022,Breast,EVSA-T,SIDM01042,906862,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.929967734342151,0.103123169593246,0.383848007078074,8.29524662545634,0.6135,0.841444209110881,0.857698605351523,0.0794925324869107,0.356966261474146,0.0370100085575565,0.31995625291659,4.25939479980091,0.0374,4.03585182565544,0.5761,0.782515964722169,0.454582853826866,0.797632028767179,0.487475907368616,0.327933110895304,0.310156121398563,True,0.51432967263968,0.0822651455982873,0.644386945256132,76.1949995482601
14622,1012:1049,Breast,EVSA-T,SIDM01042,906862,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.863338384738209,0.098783064274622,0.816576590075392,11.2238381903657,46.7135,0.907245147365761,0.969864474056408,0.0595735135176939,0.704981914290723,0.752463300507243,-0.0474813862165198,11.8517159927969,72.1858,-0.627877802431149,-25.4723,0.783259560088335,0.824182505654886,0.837321228446831,0.84568920760572,-0.0409229455665518,-0.0083679791588883,True,0.411239252531202,0.0694267259215029,0.859568603803156,57.2585134666797
14764,1053:1375,Breast,EVSA-T,SIDM01042,906862,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1375,Temozolomide,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved,30.0,0.240236813624119,0.0879002800856243,0.931767980923433,12.8929882148331,445.6844,0.936303028339724,0.989488921373187,0.055938822090626,0.223844970774025,0.123198537855035,0.100646432918989,9.07638957987998,31.6313,3.81659863495312,414.0531,0.224934456114949,0.15784500587973,0.237711665587061,0.216385947087605,0.0670894502352184,0.0213257184994563,True,0.540059535548512,0.101926717214927,0.591317168673672,82.5223742080519
14765,1012:1549,Breast,EVSA-T,SIDM01042,906862,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.763466607907693,0.0992629452908272,0.820282857193715,11.2609807924333,23.9659,0.908184832223293,0.970537856261109,0.019012699234403,0.626258570506516,0.518409549191669,0.107849021314847,10.115809941581,10.8358,1.14517085085234,13.1301,0.693368793210734,0.721580364423586,0.740973244965673,0.719520191750614,-0.0282115712128514,0.0214530532150585,True,0.540059535548512,0.101926717214927,0.591317168673672,82.5223742080519
14765,1058:1549,Breast,EVSA-T,SIDM01042,906862,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.856079993695205,0.0992629452908272,0.820282857193715,11.2609807924333,23.9659,0.908184832223293,0.970537856261109,0.0839069487307242,0.70222774321468,0.451801014831104,0.250426728383576,9.16550329918507,5.6078,2.09547749324823,18.3581,0.777478865443797,0.70242448319177,0.830858041868968,0.774738920331459,0.0750543822520269,0.0561191215375094,True,0.540059535548512,0.101926717214927,0.591317168673672,82.5223742080519
14765,1559:1549,Breast,EVSA-T,SIDM01042,906862,1559,Luminespib,HSP90,Protein stability and degradation,Targeted,Early clinical trials,0.01,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.811299511539222,0.0992629452908272,0.820282857193715,11.2609807924333,23.9659,0.908184832223293,0.970537856261109,0.0890652036203374,0.665495081365259,0.447351158800937,0.218143922564322,9.30726682445511,6.1868,1.95371396797818,17.7791,0.736809910770088,0.728920722027699,0.787396888714962,0.739496662091863,0.0078891887423888,0.0479002266230988,True,0.540059535548512,0.101926717214927,0.591317168673672,82.5223742080519
14765,1558:1549,Breast,EVSA-T,SIDM01042,906862,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.936205156743316,0.0992629452908272,0.820282857193715,11.2609807924333,23.9659,0.908184832223293,0.970537856261109,0.110046880776791,0.767953040892897,0.564944810922248,0.20300822997065,9.62519723499116,7.7121,1.63578355744213,16.2538,0.85024732320351,0.85374875070165,0.908622545846254,0.86589501471358,-0.0035014274981397,0.0427275311326739,True,0.540059535548512,0.101926717214927,0.591317168673672,82.5223742080519
14765,1561:1549,Breast,EVSA-T,SIDM01042,906862,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.897358837730338,0.0992629452908272,0.820282857193715,11.2609807924333,23.9659,0.908184832223293,0.970537856261109,0.0546883280827406,0.736088071341473,0.678711962611914,0.0573761087295589,10.6868601303151,16.0978,0.574120662118178,7.8681,0.814967685488216,0.838603225739004,0.870920722667763,0.86009266169681,-0.0236355402507877,0.0108280609709527,True,0.540059535548512,0.101926717214927,0.591317168673672,82.5223742080519
14765,1053:1549,Breast,EVSA-T,SIDM01042,906862,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.51837400623081,0.0992629452908272,0.820282857193715,11.2609807924333,23.9659,0.908184832223293,0.970537856261109,0.0385343873255463,0.425213310925962,0.13968713969758,0.285526171228382,7.51482703020073,1.786,3.74615376223256,22.1799,0.470779409877644,0.383809876654406,0.503101596748733,0.41740138992014,0.0869695332232389,0.0857002068285932,True,0.540059535548512,0.101926717214927,0.591317168673672,82.5223742080519
14662,1191:1011,Breast,HCC1187,SIDM00885,749711,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.0025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.931408357965517,0.0969305965476611,0.780154359751491,12.5734086367076,119.0428,0.899194159954146,0.932243752727214,0.106987784247928,0.726642291175776,0.463281996758341,0.263360294417435,8.97065153434034,9.7986,3.60275710236726,109.2442,0.837516956015074,0.787501644533448,0.868299622951266,0.755451825997063,0.0500153114816262,0.112847796954203,True,0.82031107607249,0.0817711462283047,0.186988129075804,254.509802028371
14662,1510:1011,Breast,HCC1187,SIDM00885,749711,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.783962042831936,0.0969305965476611,0.780154359751491,12.5734086367076,119.0428,0.899194159954146,0.932243752727214,0.0519072760079177,0.61161140559502,0.471210541211631,0.14040086438339,10.1564544924823,22.2909,2.41695414422532,96.7519,0.704934090540199,0.651627143449168,0.730843716805337,0.675568405340135,0.0533069470910307,0.055275311465202,True,0.82031107607249,0.0817711462283047,0.186988129075804,254.509802028371
14663,1179:1022,Breast,HCC1187,SIDM00885,749711,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.214791264558106,0.0867987043547974,0.647752735140289,10.7186892138703,3.2914,0.852425859480957,0.881881807122148,0.0284525816145506,0.139131629101755,0.144945827244497,-0.0058141981427419,11.0597877472137,4.1692,-0.341098533343423,-0.8778,0.183093628299945,0.174304958881425,0.189420508542554,0.19179462565341,0.0087886694185203,-0.0023741171108555,True,0.82031107607249,0.0817711462283047,0.186988129075804,254.509802028371
14663,1073:1022,Breast,HCC1187,SIDM00885,749711,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,2.5,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,1.0,0.0867987043547974,0.647752735140289,10.7186892138703,3.2914,0.852425859480957,0.881881807122148,0.0991993779924078,0.647752735140289,0.363971453864268,0.283781281276021,7.42522050832716,0.3357,3.29346870554315,2.9557,0.852425859480957,0.74189914779745,0.881881807122148,0.728746545184807,0.110526711683506,0.153135261937341,True,0.82031107607249,0.0817711462283047,0.186988129075804,254.509802028371
14663,1190:1022,Breast,HCC1187,SIDM00885,749711,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,1.0,0.0867987043547974,0.647752735140289,10.7186892138703,3.2914,0.852425859480957,0.881881807122148,0.0822622969411253,0.647752735140289,0.309241286330468,0.338511448809821,6.7325804322468,0.2077,3.98610878162351,3.0837,0.852425859480957,0.700498023810267,0.881881807122148,0.686519180086381,0.151927835670689,0.195362627035767,True,0.82031107607249,0.0817711462283047,0.186988129075804,254.509802028371
14663,1005:1022,Breast,HCC1187,SIDM00885,749711,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,1.0,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.971675663340691,0.0867987043547974,0.647752735140289,10.7186892138703,3.2914,0.852425859480957,0.881881807122148,0.0616025793683292,0.629405568598187,0.530701760825398,0.0987038077727898,9.52255237214043,1.4365,1.19613684172988,1.8549,0.828281462459917,0.842544096275915,0.856903089923501,0.812370508674311,-0.0142626338159973,0.04453258124919,True,0.82031107607249,0.0817711462283047,0.186988129075804,254.509802028371
14666,1179:1073,Breast,HCC1187,SIDM00885,749711,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,20.0,0.781661543033153,0.080516810393978,0.924978695986355,16.0871920453345,2719.4895,0.942092075924356,0.978658134401001,0.119117762697859,0.723020274777488,0.362905857957122,0.360114416820366,8.59614210509703,15.1167,7.4910499402375,2704.3728,0.736397145746338,0.548028348176807,0.764979427437833,0.619682029814026,0.188368797569531,0.145297397623808,True,0.82031107607249,0.0817711462283047,0.186988129075804,254.509802028371
14666,1022:1073,Breast,HCC1187,SIDM00885,749711,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,20.0,0.902198206735782,0.080516810393978,0.924978695986355,16.0871920453345,2719.4895,0.942092075924356,0.978658134401001,0.0786792223645383,0.834514120787692,0.461928726480996,0.372585394306695,9.13549074843479,21.9693,6.95170129689974,2697.5202,0.849953781478944,0.699762960619629,0.882943613863969,0.738715843850531,0.150190820859315,0.144227770013439,True,0.82031107607249,0.0817711462283047,0.186988129075804,254.509802028371
15043,1191:1179,Breast,HCC1187,SIDM00885,749711,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.000625,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,10.0,0.902972326993612,0.0974028939324298,0.679380590685798,11.1186165614001,43.4277,0.874649730168217,0.894754566943619,0.0642335034475845,0.61346187288585,0.685961016809413,-0.0724991439235626,12.2469947147715,94.9386,-1.12837815337141,-51.5109,0.78978450215433,0.867136566890971,0.807938613401242,0.835263949515197,-0.077352064736641,-0.0273253361139559,True,0.934669109050124,0.0762688209910443,0.0583235645058913,745.300579577589
15044,1022:1190,Breast,HCC1187,SIDM00885,749711,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.891532452635318,0.0427120857696372,0.952667663481378,17.4698549825185,3545.5238,0.986166359112116,0.986724188995592,0.150507590290688,0.849334138569911,0.276824792129812,0.572509346440098,6.74924528840558,2.1011,10.7206096941129,3543.4227,0.879199312845666,0.533893991526025,0.879696636289835,0.612989666485592,0.345305321319641,0.266706969804243,True,0.934669109050124,0.0762688209910443,0.0583235645058913,745.300579577589
15044,1179:1190,Breast,HCC1187,SIDM00885,749711,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.212024821456167,0.0427120857696372,0.952667663481378,17.4698549825185,3545.5238,0.986166359112116,0.986724188995592,0.0243342473708963,0.201989191256703,0.120211007639615,0.0817781836170873,9.76031008166582,16.9385,7.70954490085266,3528.5853,0.209091746216824,0.160735539561796,0.209210019998271,0.179385437502233,0.0483562066550288,0.0298245824960384,True,0.934669109050124,0.0762688209910443,0.0583235645058913,745.300579577589
15047,1179:1510,Breast,HCC1187,SIDM00885,749711,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.280272766981234,0.112653798647418,0.838867144141304,13.6547053971525,251.8871,0.900557168086835,0.951989365393632,0.0235025356010614,0.235111615618129,0.248304279607,-0.013192663988871,14.7834687595349,550.8046,-1.12876336238246,-298.9175,0.252401649324481,0.27577311325003,0.266816693575582,0.270989724704701,-0.0233714639255488,-0.0041730311291193,True,0.934669109050124,0.0762688209910443,0.0583235645058913,745.300579577589
15047,1012:1510,Breast,HCC1187,SIDM00885,749711,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.938756161909326,0.112653798647418,0.838867144141304,13.6547053971525,251.8871,0.900557168086835,0.951989365393632,0.0616936027892627,0.787491700585927,0.520143881409669,0.267347819176259,9.61268223518395,15.291,4.04202316196852,236.5961,0.845403590693129,0.810339475595658,0.893685882835421,0.788459243261091,0.0350641150974711,0.105226639574329,True,0.934669109050124,0.0762688209910443,0.0583235645058913,745.300579577589
15047,1011:1510,Breast,HCC1187,SIDM00885,749711,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.961362058222954,0.112653798647418,0.838867144141304,13.6547053971525,251.8871,0.900557168086835,0.951989365393632,0.0520449361092783,0.806455044267295,0.519008578627144,0.287446465640151,9.45088087342984,13.6687,4.20382452372262,238.2184,0.865761492659394,0.799940001592253,0.915206455721186,0.800762638822532,0.0658214910671419,0.114443816898654,True,0.934669109050124,0.0762688209910443,0.0583235645058913,745.300579577589
15047,1083:1549,Breast,HCC1187,SIDM00885,749711,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.993809107376524,0.107771962264507,0.897522194645664,15.1222754608284,348.3041,0.928786060828961,0.970425411300398,0.150507189109604,0.891965731111426,0.562075640576511,0.329890090534916,9.7443474640914,8.3761,5.37792799673699,339.928,0.923036046056188,0.718646822119276,0.964417611779945,0.840167087858858,0.204389223936912,0.124250523921087,True,0.934669109050124,0.0762688209910443,0.0583235645058913,745.300579577589
15048,1510:1558,Breast,HCC1187,SIDM00885,749711,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.838400580116028,0.0918172695153719,0.912010950418969,15.5975239236238,968.3951,0.940867393428137,0.974799727048393,0.0881752716693739,0.764630509903434,0.596642383643414,0.167988126260019,11.5487381653577,58.5122,4.04878575826607,909.8829,0.788823768462405,0.773154789387857,0.817272656654319,0.76068698946741,0.015668979074548,0.0565856671869084,True,0.934669109050124,0.0762688209910443,0.0583235645058913,745.300579577589
15048,1179:1558,Breast,HCC1187,SIDM00885,749711,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.320014082689889,0.0918172695153719,0.912010950418969,15.5975239236238,968.3951,0.940867393428137,0.974799727048393,0.0591907207095162,0.291856347701461,0.279935330225826,0.0119210174756345,14.4838654543103,447.5154,1.11365846931347,520.8797,0.301090815840733,0.253375083027981,0.311949640457746,0.308305758143436,0.0477157328127518,0.0036438823143101,True,0.934669109050124,0.0762688209910443,0.0583235645058913,745.300579577589
15049,1047:1561,Breast,HCC1187,SIDM00885,749711,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.948353662405468,0.111473269164314,0.833599096186697,13.546167188865,233.6322,0.884532919802641,0.95027304178414,0.0421858355365934,0.790546755846542,0.868937006686485,-0.0783902508399434,15.7502227829526,1076.5136,-2.20405559408757,-842.8814,0.838850034013037,0.927925322762417,0.901194919461173,0.925658921480569,-0.0890752887493804,-0.0244640020193959,True,0.934669109050124,0.0762688209910443,0.0583235645058913,745.300579577589
15049,1012:1561,Breast,HCC1187,SIDM00885,749711,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.964441114176167,0.111473269164314,0.833599096186697,13.546167188865,233.6322,0.884532919802641,0.95027304178414,0.093271720408141,0.803957241102544,0.314371847907842,0.489585393194702,6.95029260028247,2.4153,6.59587458858258,231.2169,0.853079914699957,0.699956249943349,0.916482391189871,0.675208940343604,0.153123664756609,0.241273450846267,True,0.934669109050124,0.0762688209910443,0.0583235645058913,745.300579577589
15049,1017:1561,Breast,HCC1187,SIDM00885,749711,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.983921008185007,0.111473269164314,0.833599096186697,13.546167188865,233.6322,0.884532919802641,0.95027304178414,0.0630242573829706,0.820195663142126,0.886217286443194,-0.066021623301068,15.2211094158591,746.0029,-1.67494222699408,-512.3707,0.870310522225043,0.918388414694943,0.934993609323285,0.95577155589352,-0.0480778924699,-0.020777946570235,True,0.934669109050124,0.0762688209910443,0.0583235645058913,745.300579577589
16341,1179:1005,Breast,MDA-MB-231,SIDM00146,905960,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.458785284915213,0.0628735045294186,0.893127767493907,13.4595627087425,88.008,0.973457058582263,0.976473982297391,0.11021129942586,0.40975387727538,0.266493029545897,0.143260847729484,9.68545981280947,6.4329,3.77410289593306,81.5751,0.446607773974389,0.307645292930129,0.447991894180601,0.407028293690571,0.13896248104426,0.0409636004900303,True,0.175479159839648,0.0297945796611651,1.69057344824462,29.3660054974797
16341,1011:1005,Breast,MDA-MB-231,SIDM00146,905960,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.630958188854751,0.0628735045294186,0.893127767493907,13.4595627087425,88.008,0.973457058582263,0.976473982297391,0.0853367703082165,0.563526278593843,0.31571759087463,0.247808687719213,9.00317588032435,4.0088,4.45638682841818,83.9992,0.614210702610938,0.505042076803968,0.616114255334149,0.540321444656015,0.109168625806971,0.075792810678134,True,0.175479159839648,0.0297945796611651,1.69057344824462,29.3660054974797
16341,1011:1007,Breast,MDA-MB-231,SIDM00146,905960,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1007,Docetaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.0125,0.630958188854751,0.135207509942157,0.494468936292152,8.9535261031367,0.0121,0.784146386984981,0.853897920159813,0.0524225955139598,0.311989224487832,0.0424766672661016,0.26951255722173,3.47864497208816,0.0003,5.47488113104854,0.0118,0.49476358412904,0.251415396540792,0.538773885170875,0.288198469493771,0.243348187588248,0.250575415677104,True,0.175479159839648,0.0297945796611651,1.69057344824462,29.3660054974797
16342,1179:1011,Breast,MDA-MB-231,SIDM00146,905960,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.418861318896607,0.138940549238126,0.250615698535668,6.69925651110971,2.0296,0.755756271196107,0.714633672760134,0.0433048932499986,0.104973222024844,0.0121301013889205,0.0928431206359239,1.62207193606939,0.0601,5.07718457504031,1.9695,0.316557068517583,0.0893005760863245,0.299332402700236,0.129441249087899,0.227256492431259,0.169891153612337,True,0.175479159839648,0.0297945796611651,1.69057344824462,29.3660054974797
16342,1012:1011,Breast,MDA-MB-231,SIDM00146,905960,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.591027743438745,0.138940549238126,0.250615698535668,6.69925651110971,2.0296,0.755756271196107,0.714633672760134,0.0720542526173537,0.148120830775861,0.0064379523448713,0.141682878430989,-0.470524837458345,0.0141,7.16978134856805,2.0155,0.446672923554715,0.0820633064490078,0.422368326996764,0.101321461922417,0.364609617105707,0.321046865074347,True,0.175479159839648,0.0297945796611651,1.69057344824462,29.3660054974797
16342,1011:1012,Breast,MDA-MB-231,SIDM00146,905960,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,5.0,0.572331392995402,0.126784264636472,0.374090972192179,7.91885989750419,2.3633,0.841343692557617,0.796453685114936,0.097119993458708,0.214104007221754,0.0874295646849785,0.126674442536775,5.40160592870279,0.4128,2.5172539688014,1.9505,0.481527407549396,0.367651096511112,0.455835447058152,0.352030667496009,0.113876311038284,0.103804779562143,True,0.175479159839648,0.0297945796611651,1.69057344824462,29.3660054974797
16430,1011:1017,Breast,MDA-MB-231,SIDM00146,905960,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.554915319305637,0.0860562926767188,0.830940136029236,12.3446366708604,101.5865,0.920540416544942,0.96146471600457,0.0488770121601283,0.461101410908533,0.161629519132566,0.299471891775966,7.13217269841764,2.7399,5.21246397244279,98.8466,0.51082197918078,0.396291305275033,0.533531499882779,0.41354015079829,0.114530673905747,0.119991349084489,True,0.265815665486094,0.04582338468735,1.28256605294822,38.5674140343485
16343,1011:1021,Breast,MDA-MB-231,SIDM00146,905960,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.679523974313059,0.0771083701105164,0.663472519265258,10.4258355300642,26.867,0.900680487288558,0.914733151399425,0.103262159896094,0.450845483138626,0.087216130190472,0.363629352948154,4.97620369961739,0.6148,5.44963183044682,26.2522,0.612033984308543,0.366039732801374,0.621583106474846,0.394555022524418,0.245994251507169,0.227028083950428,True,0.175479159839648,0.0297945796611651,1.69057344824462,29.3660054974797
16343,1559:1022,Breast,MDA-MB-231,SIDM00146,905960,1559,Luminespib,HSP90,Protein stability and degradation,Targeted,Early clinical trials,0.01,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.817767347701825,0.0861838576239326,0.595700546076567,9.81411663679172,1.7582,0.890989057345621,0.89240712540171,0.0722927565383987,0.487144455589563,0.275648646805147,0.211495808784415,7.579310014939,0.3735,2.23480662185272,1.3847,0.728621758256878,0.608376623839033,0.729781408009967,0.633841067649346,0.120245134417844,0.0959403403606204,True,0.175479159839648,0.0297945796611651,1.69057344824462,29.3660054974797
16343,1179:1022,Breast,MDA-MB-231,SIDM00146,905960,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.818324132588834,0.0861838576239326,0.595700546076567,9.81411663679172,1.7582,0.890989057345621,0.89240712540171,0.110867911310341,0.487476132650801,0.159396060555193,0.328080072095608,6.01892324994243,0.1267,3.79519338684928,1.6315,0.729117847498498,0.5690925800354,0.730278286810449,0.543113363111642,0.160025267463098,0.187164923698807,True,0.175479159839648,0.0297945796611651,1.69057344824462,29.3660054974797
16343,1190:1022,Breast,MDA-MB-231,SIDM00146,905960,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.626864752112903,0.0861838576239326,0.595700546076567,9.81411663679172,1.7582,0.890989057345621,0.89240712540171,0.0750084145684998,0.373423675149808,0.242560146651758,0.13086352849805,8.03337970069356,0.5117,1.78073693609816,1.2465,0.558529634568272,0.460901240419133,0.559418571448731,0.503617341077112,0.0976283941491388,0.0558012303716193,True,0.175479159839648,0.0297945796611651,1.69057344824462,29.3660054974797
16344,1011:1047,Breast,MDA-MB-231,SIDM00146,905960,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.573298184602507,0.0687909790414518,0.909996367449224,13.859697408285,290.3452,0.952157403211419,0.980366940696018,0.0497630071745534,0.521699265453516,0.24284712525104,0.278852140202477,8.35299041651351,6.386,5.50670699177145,283.9592,0.545870110716944,0.455655515551196,0.562042587345341,0.471253832902707,0.0902145951657475,0.0907887544426343,True,0.175479159839648,0.0297945796611651,1.69057344824462,29.3660054974797
16345,1190:1053,Breast,MDA-MB-231,SIDM00146,905960,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.1,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.683426073131955,0.0839078820149806,0.799156985406627,11.9008617850543,74.6872,0.913785066174772,0.953358572781861,0.121046920632229,0.546164720352423,0.303215843792381,0.242948876560042,8.52470002383235,7.1932,3.37616176122195,67.494,0.624504539462448,0.481105879635291,0.651550105682993,0.568296268325044,0.143398659827157,0.0832538373579489,True,0.175479159839648,0.0297945796611651,1.69057344824462,29.3660054974797
16345,1372:1053,Breast,MDA-MB-231,SIDM00146,905960,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.763615765086353,0.0839078820149806,0.799156985406627,11.9008617850543,74.6872,0.913785066174772,0.953358572781861,0.106685974876161,0.610248872835385,0.360103382464287,0.250145490371098,8.76092944797021,8.4729,3.13993233708408,66.2143,0.697780682431532,0.581341380973734,0.727999635956455,0.644580203868949,0.116439301457798,0.0834194320875062,True,0.175479159839648,0.0297945796611651,1.69057344824462,29.3660054974797
16345,1012:1053,Breast,MDA-MB-231,SIDM00146,905960,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.649501650972239,0.0839078820149806,0.799156985406627,11.9008617850543,74.6872,0.913785066174772,0.953358572781861,0.107341279788401,0.519053781407602,0.168660855981947,0.350392925425655,6.79941876792225,2.1755,5.10144301713205,72.5117,0.593504909114291,0.441020715285421,0.619207966990357,0.468842926710688,0.15248419382887,0.150365040279669,True,0.175479159839648,0.0297945796611651,1.69057344824462,29.3660054974797
16345,1011:1053,Breast,MDA-MB-231,SIDM00146,905960,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.621121574062751,0.0839078820149806,0.799156985406627,11.9008617850543,74.6872,0.913785066174772,0.953358572781861,0.0617943317857153,0.496373644699007,0.355249247698127,0.14112439700088,9.60873215894245,15.2492,2.29212962611185,59.438,0.567571618657509,0.540014386558504,0.592151577372487,0.549062007230755,0.0275572320990047,0.0430895701417324,True,0.175479159839648,0.0297945796611651,1.69057344824462,29.3660054974797
16345,1594:1054,Breast,MDA-MB-231,SIDM00146,905960,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.802484271601919,0.0844793224552544,0.746271474377774,11.2660711380729,19.2405,0.896224759827701,0.93913589763204,0.0665207322147121,0.598871120533338,0.350626128858595,0.248244991674743,8.46721277036387,2.7649,2.798858367709,16.4756,0.719206273581937,0.614491272947155,0.753641786746462,0.664765543793966,0.104715000634782,0.0888762429524954,True,0.175479159839648,0.0297945796611651,1.69057344824462,29.3660054974797
16346,1372:1058,Breast,MDA-MB-231,SIDM00146,905960,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.56110743864395,0.0841431102941319,0.651842889137244,10.3173280947047,9.9682,0.872508752090922,0.911066784168885,0.0802081961377076,0.365753893922071,0.167696063392749,0.198057830529322,7.20889798513037,1.1558,3.10843010957436,8.8124,0.489571151080167,0.360092073119691,0.511206349698584,0.421103288410424,0.129479077960476,0.0901030612881601,True,0.175479159839648,0.0297945796611651,1.69057344824462,29.3660054974797
16346,1179:1058,Breast,MDA-MB-231,SIDM00146,905960,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.858734000958075,0.0841431102941319,0.651842889137244,10.3173280947047,9.9682,0.872508752090922,0.911066784168885,0.0520209966839897,0.559759652184896,0.330863612479471,0.228896039705425,8.01876282586358,2.0262,2.29856526884114,7.942,0.749252931553975,0.689790102309752,0.782364024709354,0.689145254695348,0.0594628292442231,0.0932187700140055,True,0.175479159839648,0.0297945796611651,1.69057344824462,29.3660054974797
16427,1011:1083,Breast,MDA-MB-231,SIDM00146,905960,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.466550863898367,0.110382548787159,0.570116989312411,9.59303102275616,15.0841,0.910682959261247,0.883321265992511,0.0683946069294035,0.265988573886841,0.0752426510211777,0.190745922865664,5.53674303729388,0.9067,4.05628798546228,14.1774,0.424879921380856,0.273748222009762,0.412114299748605,0.292004922835628,0.151131699371094,0.120109376912977,True,0.265815665486094,0.04582338468735,1.28256605294822,38.5674140343485
16429,1058:1372,Breast,MDA-MB-231,SIDM00146,905960,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.877746424396043,0.16589188496789,0.273574524223158,6.94873170676347,0.2413,0.634122140550287,0.732457447400982,0.133005831661155,0.240129060442726,0.0740052118783336,0.166123848564392,3.99000919045585,0.031,2.95872251630762,0.2103,0.55659844149838,0.410610638338492,0.642911905478464,0.43814479260631,0.145987803159888,0.204767112872154,True,0.265815665486094,0.04582338468735,1.28256605294822,38.5674140343485
16429,1594:1372,Breast,MDA-MB-231,SIDM00146,905960,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.857218841505508,0.16589188496789,0.273574524223158,6.94873170676347,0.2413,0.634122140550287,0.732457447400982,0.151081689542132,0.234513236719996,0.0505693760459871,0.183943860674009,3.18257438415262,0.0177,3.76615732261085,0.2236,0.54358144669551,0.360478664233841,0.627876324513151,0.370633373353764,0.18310278246167,0.257242951159387,True,0.265815665486094,0.04582338468735,1.28256605294822,38.5674140343485
16430,1011:1375,Breast,MDA-MB-231,SIDM00146,905960,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1375,Temozolomide,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved,30.0,0.554915319305637,0.0452991631402387,0.927379247811048,14.3502089283302,1223.7554,0.982949274205824,0.984304501048147,0.0727392671664756,0.514616951416489,0.32472457141487,0.189892380001618,9.72271709218762,49.5086,4.62749183614256,1174.2468,0.545453610357168,0.446858826068636,0.546205646493108,0.493163105250253,0.098594784288532,0.0530425412428544,True,0.265815665486094,0.04582338468735,1.28256605294822,38.5674140343485
16431,1011:1510,Breast,MDA-MB-231,SIDM00146,905960,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.553294832534978,0.0648195343641629,0.938299842096715,14.7171058095444,526.0419,0.96307561399396,0.986741000126265,0.0610128205104732,0.519156454000498,0.302474794550304,0.216681659450195,9.39334438524814,13.1343,5.32376142429626,512.9076,0.532864760563309,0.467374057071953,0.545958696420258,0.483932567474501,0.0654907034913568,0.0620261289457569,True,0.265815665486094,0.04582338468735,1.28256605294822,38.5674140343485
16431,1594:1510,Breast,MDA-MB-231,SIDM00146,905960,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.916413237903308,0.0648195343641629,0.938299842096715,14.7171058095444,526.0419,0.96307561399396,0.986741000126265,0.0291503410948891,0.859870396420014,0.81652331248897,0.0433470839310435,13.4131227814173,213.0504,1.3039830281271,312.9915,0.882575241765922,0.908228573445871,0.904262514897659,0.894398741276714,-0.0256533316799489,0.0098637736209445,True,0.265815665486094,0.04582338468735,1.28256605294822,38.5674140343485
14490,1179:1022,Breast,MDA-MB-436,SIDM00629,1240172,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.908628976795854,0.0851892846280233,0.78414067362193,12.741638853431,13.3766,0.883700168680497,0.931997347446513,0.0381616654116052,0.712492937937105,0.5057087050474,0.206784232889705,9.65907633255299,1.5791,3.082562520878,11.7975,0.802955580062483,0.759716489197438,0.846839796186775,0.760790866478972,0.0432390908650446,0.0860489297078032,True,0.469525132607619,0.0693475984508189,0.733401964218077,67.0704811351562
14630,1179:1049,Breast,MDA-MB-436,SIDM00629,1240172,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.936003026528613,0.0402974640622339,0.907462220693746,15.6221295973984,985.0531,0.982381643975717,0.9727741153359,0.0712759860891545,0.849387385029723,0.241552162137876,0.607835222891847,5.93688130248648,1.1965,9.68524829491189,983.8566,0.919512191967426,0.553779778364488,0.910519516083097,0.592020765643508,0.365732413602938,0.318498750439589,True,0.622557878157838,0.0607964690281783,0.459460831750423,106.52735599365
14630,1190:1049,Breast,MDA-MB-436,SIDM00629,1240172,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.1,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.720652776909468,0.0402974640622339,0.907462220693746,15.6221295973984,985.0531,0.982381643975717,0.9727741153359,0.0672411929122239,0.653965169283381,0.656889971043016,-0.0029248017596357,15.7651617620822,1087.7188,-0.143032164683859,-102.6657,0.707956059715989,0.643834115881207,0.701032367522467,0.701932622314602,0.064121943834782,-0.0009002547921346,True,0.622557878157838,0.0607964690281783,0.459460831750423,106.52735599365
14492,1022:1073,Breast,MDA-MB-436,SIDM00629,1240172,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,20.0,0.957629362972587,0.0757156891733492,0.765782018237921,12.436160670864,216.4798,0.902540135815799,0.925405231259795,0.0479896680580616,0.733335346301042,0.687681086847033,0.0456542594540094,11.712319015206,131.0749,0.723841655658033,85.4049,0.864298935318475,0.866526336602396,0.886195222102817,0.869098752237017,-0.0022274012839206,0.0170964698658,True,0.469525132607619,0.0693475984508189,0.733401964218077,67.0704811351562
14791,1053:1594,Breast,MDA-MB-436,SIDM00629,1240172,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.939847309323115,0.103343024358854,0.640857257513118,10.6796886962908,12.8144,0.844653322401755,0.876066236116592,0.0514690922186739,0.602307969133894,0.444458027776199,0.157849941357695,8.6853209401095,3.2161,1.99436775618132,9.5983,0.793845152370119,0.709444727018029,0.823368494803007,0.745201486763228,0.0844004253520899,0.0781670080397796,True,0.531829920452055,0.0634298480843635,0.612309966072266,80.1680346364017
17494,1549:1011,Breast,HCC2218,SIDM00772,749716,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.417958908424847,0.0745685590254449,0.856426364337593,14.1607504760572,357.7179,0.948285064789162,0.956731316043079,0.0643511074426234,0.357951028384801,0.139887238706578,0.218063789678222,7.01466308716097,2.5255,7.14608738889618,355.1924,0.396344190554864,0.270854263408226,0.399874376509233,0.293078133470358,0.125489927146638,0.106796243038875,True,1.44786602651262,0.148037981229386,-0.377364988454773,-136.040892578833
17494,1558:1011,Breast,HCC2218,SIDM00772,749716,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.346121451308819,0.0745685590254449,0.856426364337593,14.1607504760572,357.7179,0.948285064789162,0.956731316043079,0.0618474527518427,0.296427536163663,0.0852209475691357,0.211206588594527,5.7667528687991,1.0634,8.39399760725806,356.6545,0.328221802879302,0.149977552148233,0.331145231621427,0.215125051602516,0.178244250731069,0.116020180018911,True,1.44786602651262,0.148037981229386,-0.377364988454773,-136.040892578833
17494,1561:1011,Breast,HCC2218,SIDM00772,749716,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.840907650708817,0.0745685590254449,0.856426364337593,14.1607504760572,357.7179,0.948285064789162,0.956731316043079,0.0739686720033257,0.720175482040218,0.634695379254834,0.0854801027853848,12.2486989460724,95.0508,1.91205152998475,262.6671,0.797420166034112,0.812957684312386,0.80452268333334,0.775011311723182,-0.0155375182782733,0.0295113716101574,True,1.44786602651262,0.148037981229386,-0.377364988454773,-136.040892578833
17494,1510:1011,Breast,HCC2218,SIDM00772,749716,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.850374585869629,0.0745685590254449,0.856426364337593,14.1607504760572,357.7179,0.948285064789162,0.956731316043079,0.122466680706184,0.728283214901413,0.554808417329534,0.173474797571879,10.819722896758,35.3013,3.34102757929917,322.4166,0.806397519256438,0.766155861688832,0.813579996668639,0.749511937111594,0.0402416575676064,0.0640680595570444,True,1.44786602651262,0.148037981229386,-0.377364988454773,-136.040892578833
17495,1179:1022,Breast,HCC2218,SIDM00772,749716,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.763680231588919,0.0839574367245673,0.81668791812958,13.3173857442823,19.9371,0.898351648933214,0.943514588049321,0.0315787988730356,0.62368841845307,0.599369608829099,0.0243188096239707,12.7396009478678,13.3577,0.577784796414518,6.5794,0.686053395305604,0.710409650243929,0.720543439109029,0.712108172177722,-0.0243562549383242,0.0084352669313065,True,1.44786602651262,0.148037981229386,-0.377364988454773,-136.040892578833
17497,1372:1053,Breast,HCC2218,SIDM00772,749716,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.912273834516257,0.110488794638947,0.740049635163096,12.023267149872,81.3007,0.85479699180557,0.916180344698989,0.0766747884804402,0.675127918402595,0.354852401293061,0.320275517109534,7.69496066143817,4.0471,4.32830648843381,77.2536,0.779808929447428,0.637098727348392,0.835807356166972,0.676052036102874,0.142710202099036,0.159755320064099,True,1.44786602651262,0.148037981229386,-0.377364988454773,-136.040892578833
17497,1510:1053,Breast,HCC2218,SIDM00772,749716,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.905480725951912,0.110488794638947,0.740049635163096,12.023267149872,81.3007,0.85479699180557,0.916180344698989,0.0878595092997994,0.670100680887928,0.652658305908733,0.0174423749791952,11.7404818957248,66.8294,0.282785254147209,14.4713,0.774002200681618,0.804615694086271,0.829583643620913,0.822976080044899,-0.0306134934046528,0.0066075635760146,True,1.44786602651262,0.148037981229386,-0.377364988454773,-136.040892578833
17498,1549:1058,Breast,HCC2218,SIDM00772,749716,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.447943237920903,0.0967164710005792,0.704097488687696,11.505031361911,22.7065,0.868329397517342,0.902408363116646,0.0596537697931344,0.315395708894742,0.230160837751897,0.085234871142845,9.15974755288599,4.4684,2.34528380902501,18.2381,0.388962281905825,0.308087530374751,0.404227724101372,0.365540836881256,0.0808747515310738,0.038686887220116,True,1.44786602651262,0.148037981229386,-0.377364988454773,-136.040892578833
17498,1372:1058,Breast,HCC2218,SIDM00772,749716,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.916174593869156,0.0967164710005792,0.704097488687696,11.505031361911,22.7065,0.868329397517342,0.902408363116646,0.0564797996473111,0.645076230742742,0.4028364618605,0.242239768882243,8.29952811567951,2.4615,3.2055032462315,20.245,0.7955413331151,0.688513585997818,0.826763615582523,0.709029896131141,0.107027747117282,0.117733719451382,True,1.44786602651262,0.148037981229386,-0.377364988454773,-136.040892578833
18187,1558:1372,Breast,HCC2218,SIDM00772,749716,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.313241485337076,0.0881727677745178,0.818165499167833,13.3459957528572,20.3364,0.896166664905184,0.944016995915047,0.0798555424483765,0.256283376210882,0.219008263405062,0.0372751128058199,11.4369789156279,5.4151,1.90901683722933,14.9213,0.280716577224473,0.203742291150896,0.295705285983873,0.282063817640026,0.0769742860735772,0.0136414683438469,True,1.13793756258385,0.138313222234702,-0.148464709671008,-394.233743116163
18187,1561:1372,Breast,HCC2218,SIDM00772,749716,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.825410253581309,0.0881727677745178,0.818165499167833,13.3459957528572,20.3364,0.896166664905184,0.944016995915047,0.0768241397988487,0.675322192139599,0.531012619506146,0.144309572633453,10.7044946332248,3.2591,2.64150111963237,17.0773,0.739705154130504,0.668920967347785,0.779201307983304,0.724319315075677,0.0707841867827191,0.0548819929076272,True,1.13793756258385,0.138313222234702,-0.148464709671008,-394.233743116163
18187,1594:1372,Breast,HCC2218,SIDM00772,749716,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.78128516735459,0.0881727677745178,0.818165499167833,13.3459957528572,20.3364,0.896166664905184,0.944016995915047,0.147910454656136,0.639220568941092,0.437213363077866,0.202007205863226,9.6922850401548,1.6158,3.65371071270241,18.7206,0.700161722768052,0.541972743592414,0.737546476639065,0.655736222372955,0.158188979175638,0.0818102542661101,True,1.13793756258385,0.138313222234702,-0.148464709671008,-394.233743116163
18187,1053:1372,Breast,HCC2218,SIDM00772,749716,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.779388746652753,0.0881727677745178,0.818165499167833,13.3459957528572,20.3364,0.896166664905184,0.944016995915047,0.103827617213883,0.637668982950942,0.442247432901558,0.195421550049384,9.78416669574702,1.7221,3.56182905711018,18.6143,0.69846221375243,0.567696377807588,0.735756223265126,0.657100143483074,0.130765835944841,0.0786560797820517,True,1.13793756258385,0.138313222234702,-0.148464709671008,-394.233743116163
18191,1549:1561,Breast,HCC2218,SIDM00772,749716,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.542163215281474,0.0846425256493333,0.544705108218642,9.51811866261929,14.3209,0.784565691880252,0.831937536456346,0.0871849857093832,0.295319072852062,0.136502647579637,0.158816425272425,5.85263175290138,1.1286,3.66548690971791,13.1923,0.425362658109332,0.284741508257771,0.451045929678521,0.340064756535195,0.140621149851561,0.110981173143326,True,1.13793756258385,0.138313222234702,-0.148464709671008,-394.233743116163
18191,1372:1561,Breast,HCC2218,SIDM00772,749716,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.88390129412703,0.0846425256493333,0.544705108218642,9.51811866261929,14.3209,0.784565691880252,0.831937536456346,0.0896423378636242,0.481465550072062,0.294843103470349,0.186622446601712,7.00010083574645,2.5002,2.51801782687284,11.8207,0.693478630380624,0.581475558724005,0.735350665106618,0.619021642227192,0.112003071656619,0.116329022879426,True,1.13793756258385,0.138313222234702,-0.148464709671008,-394.233743116163
18191,1011:1561,Breast,HCC2218,SIDM00772,749716,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.923680197138304,0.0846425256493333,0.544705108218642,9.51811866261929,14.3209,0.784565691880252,0.831937536456346,0.0874919926783965,0.503133321741637,0.292526455614919,0.210606866126718,6.77784704434624,2.1432,2.74027161827306,12.1777,0.724687792943902,0.588193674712032,0.768444227680753,0.634281873137356,0.13649411823187,0.134162354543397,True,1.13793756258385,0.138313222234702,-0.148464709671008,-394.233743116163
14536,1022:1005,Breast,AU565,SIDM00898,910704,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.98614298790833,0.0722136703188202,0.86437680072621,12.9780562991071,63.0339,0.953652478644312,0.969016239349262,0.0832710056249585,0.852399120946788,0.607082542323184,0.245316578623604,10.0115614031511,8.0644,2.96649489595605,54.9695,0.940437704716486,0.848596061412941,0.955588569603575,0.884641223582471,0.0918416433035448,0.0709473460211043,True,0.739914939909053,0.0777793877201037,0.28600901378736,167.873971611092
14538,1073:1022,Breast,AU565,SIDM00898,910704,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,10.0,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.741513051185257,0.0823844684263556,0.625089165977612,10.0979836210944,2.1406,0.871931657973665,0.900302918803278,0.0888854607961681,0.463511774726907,0.225441892872528,0.238069881854379,7.2212056210278,0.2914,2.87677800006655,1.8492,0.646548704129072,0.519064995720348,0.667586364312811,0.555316485611004,0.127483708408724,0.112269878701807,True,0.739914939909053,0.0777793877201037,0.28600901378736,167.873971611092
14538,1005:1022,Breast,AU565,SIDM00898,910704,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,1.0,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.959707989903293,0.0823844684263556,0.625089165977612,10.0979836210944,2.1406,0.871931657973665,0.900302918803278,0.111096546527518,0.5999030669907,0.507244433438179,0.0926586335525209,9.24546640167733,1.1855,0.852517219417022,0.9551,0.836799778806951,0.868427784480013,0.864027904508762,0.830013173040974,-0.0316280056730612,0.0340147314677876,True,0.739914939909053,0.0777793877201037,0.28600901378736,167.873971611092
14538,1190:1022,Breast,AU565,SIDM00898,910704,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.01,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.906680085328233,0.0823844684263556,0.625089165977612,10.0979836210944,2.1406,0.871931657973665,0.900302918803278,0.0941118791186901,0.566755898346335,0.111827398707983,0.454928499638352,4.78767591946797,0.0539,5.31030770162638,2.0867,0.79056307005195,0.488355881347339,0.816286727241813,0.511855105758104,0.302207188704611,0.304431621483709,True,0.739914939909053,0.0777793877201037,0.28600901378736,167.873971611092
15017,1022:1073,Breast,AU565,SIDM00898,910704,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,20.0,0.975838391619603,0.138295221902817,0.374162103583515,7.8951515559131,9.299,0.741483530792412,0.792242234488187,0.136464749309107,0.365121745365944,0.108332073794799,0.256789671571145,4.53160880417594,0.9035,3.36354275173717,8.3955,0.723568096100891,0.519897782501224,0.773100387876072,0.530508120200416,0.203670313599667,0.242592267675656,True,0.435913704812337,0.0512344835420922,0.808204657103178,61.0178763511101
14599,1011:1021,Breast,CAMA-1,SIDM00920,946382,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.824522641708191,0.0982761385283321,0.746700834308523,10.9559428102123,38.7969,0.887232478397275,0.94739809962304,0.0532284700324807,0.615671744469773,0.322310119184347,0.293361625285427,8.19759138033057,5.7339,2.75835142988174,33.063,0.731543266897426,0.677944527534368,0.781151183850509,0.685325717820442,0.0535987393630581,0.0958254660300673,True,0.717069956261618,0.0796455145986675,0.317764512703512,151.963460710734
17712,1011:1083,Breast,CAMA-1,SIDM00920,946382,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.82095688686233,0.0724610820647559,0.691493161942797,10.4602435014307,27.5155,0.920767163225173,0.933577999064105,0.0903456879496519,0.567686073515148,0.303719332870722,0.263966740644426,8.03677098603976,5.1291,2.42347251539091,22.3864,0.755910143846398,0.637828325526293,0.766427287754831,0.674266504061308,0.118081818320105,0.0921607836935231,True,0.631235615604717,0.0695455608990484,0.442469752279753,110.018627600449
17712,1053:1083,Breast,CAMA-1,SIDM00920,946382,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.73759599700793,0.0724610820647559,0.691493161942797,10.4602435014307,27.5155,0.920767163225173,0.933577999064105,0.0536137437033034,0.510042588207363,0.24897796177352,0.261064626433843,7.78018926472565,4.2934,2.68005423670502,23.2221,0.679154173771235,0.550453951501908,0.688603395004356,0.593704904960178,0.128700222269327,0.0948984900441781,True,0.631235615604717,0.0695455608990484,0.442469752279753,110.018627600449
17716,1053:1549,Breast,CAMA-1,SIDM00920,946382,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.867834452877192,0.0746878718626742,0.910788647620004,13.2033807238222,92.1115,0.948813692720436,0.98316425342854,0.0907265159846815,0.790413767694064,0.595502882843504,0.194910884850559,10.4155133503212,13.3377,2.78786737350099,78.7738,0.823413211904428,0.742796971598646,0.85322381196257,0.808990270856114,0.0806162403057821,0.0442335411064563,True,0.631235615604717,0.0695455608990484,0.442469752279753,110.018627600449
17717,1049:1558,Breast,CAMA-1,SIDM00920,946382,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.94726124064909,0.089610843250187,0.780260209201003,11.2926218469578,48.9946,0.912217143541507,0.955310580814976,0.0535304112063382,0.739110253796861,0.845269229552365,-0.106158975755504,12.8260812406736,141.8291,-1.53345939371583,-92.8345,0.864107943132497,0.904399982247984,0.904928685987997,0.927819783773765,-0.0402920391154865,-0.0228910977857683,True,0.631235615604717,0.0695455608990484,0.442469752279753,110.018627600449
17717,1053:1558,Breast,CAMA-1,SIDM00920,946382,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.752388250630076,0.089610843250187,0.780260209201003,11.2926218469578,48.9946,0.912217143541507,0.955310580814976,0.0464035135024012,0.587058613837,0.382769354376364,0.204289259460635,9.06325080526114,10.4482,2.22937104169665,38.5464,0.686341460823959,0.629184805740609,0.718764456707781,0.660914657388014,0.0571566550833501,0.0578497993197665,True,0.631235615604717,0.0695455608990484,0.442469752279753,110.018627600449
17718,1011:1561,Breast,CAMA-1,SIDM00920,946382,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.853138207774778,0.0847113993951574,0.484282851657715,8.88621898474791,9.2416,0.83845025909076,0.86958010791352,0.105397043894069,0.413160204119322,0.174786039593612,0.23837416452571,6.54650065628644,1.8257,2.33971832846147,7.4159,0.715313951348989,0.563137458393087,0.741872014781939,0.610799051302488,0.152176492955903,0.131072963479451,True,0.631235615604717,0.0695455608990484,0.442469752279753,110.018627600449
14976,1021:1011,Breast,BT-483,SIDM00892,949093,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.941667904609352,0.126470568534485,0.664173908203415,11.5849096050277,59.9978,0.882265104140429,0.858349645729562,0.0715536235122244,0.625431252434114,0.511550242211117,0.113881010222998,9.6572173051211,15.7704,1.9276922999066,44.2274,0.83080073192587,0.763883248971975,0.808280312316337,0.744698335885668,0.0669174829538949,0.0635819764306688,True,0.643614695201627,0.0677934078902963,0.424788000467702,114.720138875284
14976,1058:1011,Breast,BT-483,SIDM00892,949093,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.894467926332458,0.126470568534485,0.664173908203415,11.5849096050277,59.9978,0.882265104140429,0.858349645729562,0.115876515457067,0.594082258394834,0.518959616098457,0.0751226422963761,10.2263876683173,23.398,1.3585219367104,36.5998,0.78915783817598,0.780315007574002,0.767766227683922,0.726990631795437,0.0088428306019781,0.040775595888485,True,0.643614695201627,0.0677934078902963,0.424788000467702,114.720138875284
14976,1047:1011,Breast,BT-483,SIDM00892,949093,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.882052104231639,0.126470568534485,0.664173908203415,11.5849096050277,59.9978,0.882265104140429,0.858349645729562,0.138849908040795,0.585835993306574,0.502336166130946,0.0834998271756285,10.0607467883484,20.8601,1.52416281667927,39.1377,0.778203791597212,0.775457297944014,0.757109111182243,0.711421690878435,0.0027464936531979,0.045687420303808,True,0.643614695201627,0.0677934078902963,0.424788000467702,114.720138875284
14976,1561:1011,Breast,BT-483,SIDM00892,949093,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.81317231870179,0.126470568534485,0.664173908203415,11.5849096050277,59.9978,0.882265104140429,0.858349645729562,0.110224446360077,0.540087836955001,0.406139193409861,0.13394864354514,8.99166617328067,9.9424,2.59324343174703,50.0554,0.717433560443549,0.667925316199609,0.697986171674768,0.620513054943365,0.04950824424394,0.0774731167314026,True,0.643614695201627,0.0677934078902963,0.424788000467702,114.720138875284
14976,1179:1011,Breast,BT-483,SIDM00892,949093,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.773122654456908,0.126470568534485,0.664173908203415,11.5849096050277,59.9978,0.882265104140429,0.858349645729562,0.035257668957372,0.513487894931243,0.356728166662343,0.1567597282689,8.41377035079247,6.6608,3.17113925423523,53.337,0.682099139247749,0.554691991161124,0.663609556558585,0.569946882028906,0.127407148086625,0.0936626745296792,True,0.643614695201627,0.0677934078902963,0.424788000467702,114.720138875284
14976,1594:1011,Breast,BT-483,SIDM00892,949093,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.941170839102575,0.126470568534485,0.664173908203415,11.5849096050277,59.9978,0.882265104140429,0.858349645729562,0.0524293577272048,0.625101114493845,0.538686583529816,0.0864145309640292,10.1048368566944,21.5075,1.48007274833329,38.4903,0.830362188374769,0.790150647029205,0.80785365631469,0.760672968433425,0.0402115413455635,0.0471806878812653,True,0.643614695201627,0.0677934078902963,0.424788000467702,114.720138875284
14979,1012:1053,Breast,BT-483,SIDM00892,949093,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.856261616791606,0.0881472929000871,0.776688641185803,13.7247100934569,264.411,0.881105491165398,0.911921145407969,0.0953516085615635,0.665048671645431,0.479608318073722,0.185440353571709,9.91594545440341,18.8681,3.80876463905345,245.5429,0.754456812429246,0.618690313181604,0.78084307435348,0.685871887417201,0.135766499247642,0.0949711869362795,True,0.643614695201627,0.0677934078902963,0.424788000467702,114.720138875284
14979,1594:1053,Breast,BT-483,SIDM00892,949093,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.93086903565627,0.0881472929000871,0.776688641185803,13.7247100934569,264.411,0.881105491165398,0.911921145407969,0.142113934982218,0.722995406425807,0.518983826722119,0.204011579703688,9.87608263208082,18.3538,3.84862746137605,246.0572,0.820193818872579,0.645936234711548,0.848879157220477,0.744194145130683,0.174257584161031,0.104685012089794,True,0.643614695201627,0.0677934078902963,0.424788000467702,114.720138875284
14980,1558:1058,Breast,BT-483,SIDM00892,949093,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.979700625103108,0.0798850008462557,0.736580413639032,12.8976221385207,59.6158,0.880035148355081,0.893680632723947,0.0786096714673798,0.721628291680866,0.550267185158115,0.17136110652275,9.93979717549355,7.673,2.95782496302714,51.9428,0.862170984956179,0.718900226226849,0.875539474522192,0.785649678943876,0.14327075872933,0.0898897955783162,True,0.643614695201627,0.0677934078902963,0.424788000467702,114.720138875284
14980,1012:1058,Breast,BT-483,SIDM00892,949093,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.822028781121742,0.0798850008462557,0.736580413639032,12.8976221385207,59.6158,0.880035148355081,0.893680632723947,0.0711723956227284,0.605490299621842,0.457804274589128,0.147686025032714,9.86677045404863,7.2943,3.03085168447205,52.3215,0.723414220346618,0.660504394127517,0.734631201230173,0.656882736967903,0.0629098262191011,0.0777484642622707,True,0.643614695201627,0.0677934078902963,0.424788000467702,114.720138875284
14980,1011:1058,Breast,BT-483,SIDM00892,949093,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.909719357415662,0.0798850008462557,0.736580413639032,12.8976221385207,59.6158,0.880035148355081,0.893680632723947,0.123207437236489,0.670081460580663,0.324628171556199,0.345453289024464,6.76708550985383,0.8509,6.13053662866686,58.7649,0.800585009664781,0.614147966750322,0.812998570936451,0.596184016273379,0.186437042914459,0.216814554663072,True,0.643614695201627,0.0677934078902963,0.424788000467702,114.720138875284
14980,1594:1058,Breast,BT-483,SIDM00892,949093,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.922114547433916,0.0798850008462557,0.736580413639032,12.8976221385207,59.6158,0.880035148355081,0.893680632723947,0.0564915731365107,0.679211514771443,0.533811254579897,0.145400260191546,10.2063366281822,9.23,2.69128551033853,50.3858,0.811493212551385,0.707393658325503,0.824075912194698,0.748774559668361,0.104099554225882,0.0753013525263373,True,0.643614695201627,0.0677934078902963,0.424788000467702,114.720138875284
17709,1011:1558,Breast,BT-483,SIDM00892,949093,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.834600167869619,0.0741025674326197,0.739751901399107,12.9598206053867,155.6054,0.906952479745828,0.895155364306428,0.111072694366451,0.617397061089565,0.359176399866772,0.258220661222793,7.93718054848788,4.787,5.02264005689878,150.8184,0.756942691845635,0.596993864729326,0.747096817319534,0.596473948773754,0.159948827116309,0.15062286854578,True,0.731107322694025,0.0632466572623584,0.295926276950934,161.729424507952
17710,1011:1561,Breast,BT-483,SIDM00892,949093,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.859553450580237,0.155836768535401,0.602008295202968,10.5686461411345,29.6626,0.755300982337181,0.825144166246465,0.0553342706719653,0.517458307419637,0.145431432264022,0.372026875155615,2.96804734436855,0.1528,7.60059879676594,29.5098,0.649221565594567,0.331097506952125,0.709255515323302,0.378711509345168,0.318124058642441,0.330544005978135,True,0.731107322694025,0.0632466572623584,0.295926276950934,161.729424507952
17710,1083:1594,Breast,BT-483,SIDM00892,949093,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.966218317618391,0.0839525536531507,0.640506330218844,11.189230019197,18.2425,0.846727916728091,0.846048155493018,0.0806310790504506,0.618868948807981,0.408211973534924,0.210656975273057,7.81516233632341,1.7595,3.3740676828736,16.483,0.818124023181541,0.638436174450751,0.817467225424606,0.684811089688489,0.17968784873079,0.132656135736117,True,0.731107322694025,0.0632466572623584,0.295926276950934,161.729424507952
17710,1011:1594,Breast,BT-483,SIDM00892,949093,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.859553450580237,0.0839525536531507,0.640506330218844,11.189230019197,18.2425,0.846727916728091,0.846048155493018,0.189525840582193,0.550549426258092,0.341506902298497,0.209042523959595,7.42052394222068,1.3384,3.76870607697633,16.9041,0.727807902526246,0.657667356923771,0.727223611411068,0.592360666076764,0.0701405456024753,0.134862945334304,True,0.731107322694025,0.0632466572623584,0.295926276950934,161.729424507952
16355,1022:1005,Breast,MDA-MB-453,SIDM00272,908122,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.848270991812519,0.0623176201525742,0.896209022455923,13.9636018283,124.811,0.957279739222437,0.975115664936686,0.0845606360736814,0.760228116350014,0.509680835884418,0.250547280465595,9.94168755158928,7.6831,4.02191427671077,117.1279,0.812032633832246,0.710371844162356,0.827162332227767,0.750455946525982,0.10166078966989,0.0767063857017843,True,0.432610485048045,0.0538067672074313,0.82017465097266,60.2817438436054
16355,1179:1005,Breast,MDA-MB-453,SIDM00272,908122,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.331623344944938,0.0623176201525742,0.896209022455923,13.9636018283,124.811,0.957279739222437,0.975115664936686,0.0714769519950482,0.297203833796666,0.164542249547003,0.132661584249663,8.96474511767547,3.9034,4.99885671062458,120.9076,0.317456309168962,0.221411768004867,0.323371118514511,0.279112564119318,0.0960445411640949,0.0442585543951928,True,0.432610485048045,0.0538067672074313,0.82017465097266,60.2817438436054
16356,1561:1011,Breast,MDA-MB-453,SIDM00272,908122,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.365091756046347,0.161315930568158,0.516247497050375,9.14968867359494,11.0933,0.869429799501156,0.850556098592844,0.0349266448577723,0.188477705252653,0.0907632726040278,0.0977144326486247,6.45332948835586,1.7115,2.69635918523908,9.3818,0.3174216522589,0.253944024613722,0.310531019651191,0.251326949073952,0.0634776276451782,0.0592040705772396,True,0.432610485048045,0.0538067672074313,0.82017465097266,60.2817438436054
16356,1190:1011,Breast,MDA-MB-453,SIDM00272,908122,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.558543406457983,0.161315930568158,0.516247497050375,9.14968867359494,11.0933,0.869429799501156,0.850556098592844,0.119412130454293,0.288346635577924,0.0694872484534008,0.218859387124523,4.50715767440629,0.4441,4.64253099918865,10.6492,0.485614281889456,0.263095121543564,0.475072500691659,0.301767821990132,0.222519160345893,0.173304678701527,True,0.432610485048045,0.0538067672074313,0.82017465097266,60.2817438436054
16356,1012:1011,Breast,MDA-MB-453,SIDM00272,908122,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.202296168442901,0.161315930568158,0.516247497050375,9.14968867359494,11.0933,0.869429799501156,0.850556098592844,0.039213126223189,0.104434890621529,0.037770164291098,0.0666647263304307,5.61183677949146,0.9551,3.53785189410348,10.1382,0.175882317169164,0.0965762355316765,0.172064239791075,0.126693610767972,0.0793060816374872,0.0453706290231029,True,0.432610485048045,0.0538067672074313,0.82017465097266,60.2817438436054
16356,1053:1011,Breast,MDA-MB-453,SIDM00272,908122,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.386820855216608,0.161315930568158,0.516247497050375,9.14968867359494,11.0933,0.869429799501156,0.850556098592844,0.0283846416026117,0.199695298312459,0.0708371619292951,0.128858136383164,5.5571359261152,0.9196,3.59255274747973,10.1737,0.336313578593841,0.230714095668517,0.329012837467386,0.240647297156616,0.105599482925324,0.0883655403107696,True,0.432610485048045,0.0538067672074313,0.82017465097266,60.2817438436054
16357,1179:1022,Breast,MDA-MB-453,SIDM00272,908122,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.928511385076421,0.118556605570938,0.401415102383846,8.08000613577627,0.5285,0.822576454538479,0.794260998969727,0.10765647920626,0.372718492705018,0.136564612149882,0.236153880555136,4.95299819923014,0.0605,3.12700793654613,0.468,0.763771603134775,0.547103779249071,0.737480380265563,0.534264139142765,0.216667823885704,0.203216241122797,True,0.432610485048045,0.0538067672074313,0.82017465097266,60.2817438436054
16359,1549:1054,Breast,MDA-MB-453,SIDM00272,908122,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.790601597735627,0.089940060511526,0.686214912950798,10.8016242174148,13.9445,0.866524247583761,0.914662150403267,0.138285332021977,0.542522606568915,0.32556437692617,0.216958229642745,8.17904605512966,2.2643,2.62257816228513,11.6802,0.685075454616384,0.540524118770863,0.723133357497127,0.632444677502082,0.144551335845521,0.0906886799950449,True,0.432610485048045,0.0538067672074313,0.82017465097266,60.2817438436054
16359,1058:1054,Breast,MDA-MB-453,SIDM00272,908122,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.516924981418556,0.089940060511526,0.686214912950798,10.8016242174148,13.9445,0.866524247583761,0.914662150403267,0.0646060410227407,0.354721631126227,0.334466106340147,0.0202555247860807,10.3953073244972,10.5218,0.406316892917575,3.4227,0.447928030580964,0.42429954426436,0.472811715101465,0.465949259486383,0.0236284863166047,0.006862455615082,True,0.432610485048045,0.0538067672074313,0.82017465097266,60.2817438436054
16359,1594:1054,Breast,MDA-MB-453,SIDM00272,908122,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.930658364920838,0.089940060511526,0.686214912950798,10.8016242174148,13.9445,0.866524247583761,0.914662150403267,0.169863090456294,0.638631648871085,0.377924355318888,0.260707293552197,8.1246493593288,2.1805,2.67697485808599,11.764,0.806438039420563,0.617915717793805,0.851237981349282,0.741584695390025,0.188522321626758,0.109653285959257,True,0.432610485048045,0.0538067672074313,0.82017465097266,60.2817438436054
16360,1179:1073,Breast,MDA-MB-453,SIDM00272,908122,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,20.0,0.407455511843134,0.131867818609621,0.650301763980435,10.4283593245084,53.8281,0.820378223361816,0.902524740322449,0.118615286038268,0.264969038095141,0.061092526302468,0.203876511792673,5.00503016403875,1.2544,5.42332916046967,52.5737,0.334267628904849,0.170631583287638,0.367738680019175,0.236107540833696,0.163636045617211,0.131631139185479,True,0.432610485048045,0.0538067672074313,0.82017465097266,60.2817438436054
16360,1022:1073,Breast,MDA-MB-453,SIDM00272,908122,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,20.0,0.983393623634337,0.131867818609621,0.650301763980435,10.4283593245084,53.8281,0.820378223361816,0.902524740322449,0.161014039771548,0.639502608136521,0.551066617478673,0.0884359906578481,9.55874262664666,29.4597,0.86961669786176,24.3684,0.806754713822476,0.736996425565229,0.887537074805332,0.854557603838383,0.0697582882572473,0.0329794709669489,True,0.432610485048045,0.0538067672074313,0.82017465097266,60.2817438436054
16437,1594:1372,Breast,MDA-MB-453,SIDM00272,908122,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.596069489152148,0.092436016659668,0.774290412516257,11.8382208767756,7.1514,0.897155827065011,0.941972045247607,0.0789298022740936,0.461530890643971,0.368540276027912,0.0929906146160598,10.1104040218249,2.1591,1.7278168549507,4.9923,0.534767215528513,0.469503807584885,0.561480795806345,0.531179290543267,0.065263407943628,0.0303015052630777,True,0.537901110701962,0.0623502917795008,0.599845033657154,81.7095318851693
16439,1594:1549,Breast,MDA-MB-453,SIDM00272,908122,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.905729126128379,0.0932610762747561,0.68527318417552,10.7915625472131,17.3095,0.876366910696809,0.914351912937316,0.047463477190199,0.620671882262505,0.342379580737846,0.278292301524659,7.85342701287007,2.2585,2.938135534343,15.051,0.793751036193248,0.673094726696729,0.828155159078527,0.707269776067707,0.120656309496519,0.12088538301082,True,0.537901110701962,0.0623502917795008,0.599845033657154,81.7095318851693
16439,1012:1549,Breast,MDA-MB-453,SIDM00272,908122,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.867451018708196,0.0932610762747561,0.68527318417552,10.7915625472131,17.3095,0.876366910696809,0.914351912937316,0.0504147204795869,0.594440921706463,0.319611851886308,0.274829069820155,7.75927038473317,2.1158,3.03229216247989,15.1937,0.760205369446101,0.64384429654237,0.793155498335262,0.672434175926846,0.11636107290373,0.120721322408416,True,0.537901110701962,0.0623502917795008,0.599845033657154,81.7095318851693
16439,1049:1549,Breast,MDA-MB-453,SIDM00272,908122,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.710217321102984,0.0932610762747561,0.68527318417552,10.7915625472131,17.3095,0.876366910696809,0.914351912937316,0.0564154987766196,0.486692885088849,0.233085959608714,0.253606925480135,7.35056292565919,1.5938,3.44099962155387,15.7157,0.622410959618385,0.49885937885545,0.649388566151729,0.53231808712159,0.123551580762935,0.117070479030139,True,0.537901110701962,0.0623502917795008,0.599845033657154,81.7095318851693
16439,1058:1549,Breast,MDA-MB-453,SIDM00272,908122,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.905068369288552,0.0932610762747561,0.68527318417552,10.7915625472131,17.3095,0.876366910696809,0.914351912937316,0.111600212716334,0.620219083318911,0.250678183456435,0.369540899862476,6.79072472144436,1.0812,4.0008378257687,16.2283,0.793171970762807,0.565772572132622,0.827550994798044,0.644484290778127,0.227399398630185,0.183066704019917,True,0.537901110701962,0.0623502917795008,0.599845033657154,81.7095318851693
16439,1559:1549,Breast,MDA-MB-453,SIDM00272,908122,1559,Luminespib,HSP90,Protein stability and degradation,Targeted,Early clinical trials,0.01,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.840789712065685,0.0932610762747561,0.68527318417552,10.7915625472131,17.3095,0.876366910696809,0.914351912937316,0.135808237742979,0.57617064320927,0.195486961461557,0.380683681747713,6.25035872560216,0.7434,4.5412038216109,16.5661,0.736840282508664,0.501991366276229,0.768777681605274,0.566506157388076,0.234848916232434,0.202271524217198,True,0.537901110701962,0.0623502917795008,0.599845033657154,81.7095318851693
16440,1012:1558,Breast,MDA-MB-453,SIDM00272,908122,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.234358758726767,0.109585766889668,0.249670132394917,6.46645149681414,1.7271,0.680148232104261,0.689329759289651,0.0532984916191214,0.0585123823192202,0.0164670951845898,0.0420452871346304,3.05362374118741,0.1622,3.41282775562673,1.5649,0.159398695426159,0.0550048828079269,0.161550466740543,0.0996305638223519,0.104393812618232,0.0619199029181915,True,0.537901110701962,0.0623502917795008,0.599845033657154,81.7095318851693
16441,1559:1594,Breast,MDA-MB-453,SIDM00272,908122,1559,Luminespib,HSP90,Protein stability and degradation,Targeted,Early clinical trials,0.01,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.910056696503653,0.104765067949827,0.41102647702959,8.1717556569841,2.2529,0.788774540765795,0.799537905954234,0.16643281013634,0.374057397861083,0.165206449079262,0.208850948781821,5.53254480738249,0.3616,2.63921084960162,1.8913,0.717829552855506,0.530196326126362,0.727624825422159,0.564453835066348,0.187633226729144,0.163170990355811,True,0.537901110701962,0.0623502917795008,0.599845033657154,81.7095318851693
15010,1179:1005,Breast,HCC1954,SIDM00872,749709,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.428802622785644,0.05546381717167,0.923934349866526,13.9046186069428,119.8112,0.970679799664777,0.984560050246412,0.0726919230710199,0.396185472504515,0.257877836127812,0.138307636376703,9.80778905113658,7.0021,4.0968295558062,112.8091,0.4162300439813,0.317460518993347,0.422181931835627,0.386316412886929,0.0987695249879529,0.0358655189486984,True,0.55166784925832,0.0485019310584803,0.577495538584205,85.0076002818603
15010,1011:1007,Breast,HCC1954,SIDM00872,749709,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1007,Docetaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.0125,0.965049997495661,0.0572500024363996,0.571457823799587,9.56529102446322,0.0185,0.892559432594531,0.890995884388206,0.0749214052210925,0.551485371426667,0.340689975459082,0.210795395967585,7.81019584205512,0.0055,1.7550951824081,0.013,0.86136447819008,0.78338095844515,0.859855575997483,0.769811555994834,0.0779835197449303,0.0900440200026489,True,0.55166784925832,0.0485019310584803,0.577495538584205,85.0076002818603
15011,1021:1011,Breast,HCC1954,SIDM00872,749709,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.900231486522389,0.0568970876205071,0.79423453942864,11.6528897448285,62.8926,0.933156932836243,0.955062883844101,0.04422976044112,0.71499494007727,0.70542351684901,0.0095714232282594,11.5274622385468,57.6557,0.125427506281717,5.2369,0.840057252805844,0.857590961355035,0.859777679645335,0.857413195683058,-0.0175337085491903,0.0023644839622772,True,0.55166784925832,0.0485019310584803,0.577495538584205,85.0076002818603
15011,1561:1011,Breast,HCC1954,SIDM00872,749709,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.663914452337295,0.0568970876205071,0.79423453942864,11.6528897448285,62.8926,0.933156932836243,0.955062883844101,0.0604323221833168,0.52730378927213,0.445912927334044,0.0813908619380855,10.4056023459239,26.4928,1.24728739890463,36.3998,0.619536374008725,0.561233248258951,0.634080051475034,0.61240130364526,0.0583031257497734,0.0216787478297739,True,0.55166784925832,0.0485019310584803,0.577495538584205,85.0076002818603
15011,1179:1011,Breast,HCC1954,SIDM00872,749709,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.43667656781488,0.0568970876205071,0.79423453942864,11.6528897448285,62.8926,0.933156932836243,0.955062883844101,0.109217163364774,0.346823612717731,0.0616855908895176,0.285138021828213,5.45496519571703,0.8567,6.19792454911151,62.0359,0.407487766663592,0.189874914526378,0.417053582164424,0.271959561126011,0.217612852137214,0.145094021038413,True,0.55166784925832,0.0485019310584803,0.577495538584205,85.0076002818603
15011,1058:1012,Breast,HCC1954,SIDM00872,749709,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,5.0,0.988582466256974,0.0574838828898773,0.76444245666512,11.3122039149074,24.8321,0.927281628506596,0.947612635587142,0.0458306620752279,0.755714409121544,0.656857570623631,0.0988568384979125,10.3418445435117,12.6738,0.970359371395677,12.1583,0.916694359223834,0.89321709646651,0.936793236345008,0.909805239949857,0.0234772627573243,0.0269879963951504,True,0.55166784925832,0.0485019310584803,0.577495538584205,85.0076002818603
15011,1053:1012,Breast,HCC1954,SIDM00872,749709,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,5.0,0.972358592875529,0.0574838828898773,0.76444245666512,11.3122039149074,24.8321,0.927281628506596,0.947612635587142,0.0658715231642699,0.743312191497208,0.665080147016643,0.0782320444805644,10.5166399706193,14.3062,0.795563944288119,10.5259,0.901650259494002,0.858352841644055,0.921419288930584,0.90036014180297,0.0432974178499473,0.0210591471276141,True,0.55166784925832,0.0485019310584803,0.577495538584205,85.0076002818603
15012,1011:1021,Breast,HCC1954,SIDM00872,749709,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.92947895663382,0.0636539580664556,0.76631761484474,11.3327144334641,50.3752,0.945659205984026,0.948089991758251,0.0639461339983818,0.712276097096006,0.418599824397106,0.2936762726989,8.60870274942266,7.6244,2.72401168404145,42.7508,0.878970332109199,0.787925327621624,0.881229696334426,0.785210204107709,0.0910450044875741,0.0960194922267172,True,0.55166784925832,0.0485019310584803,0.577495538584205,85.0076002818603
15012,1179:1022,Breast,HCC1954,SIDM00872,749709,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.917342207332185,0.0783249992237228,0.396130966274159,8.17188157729708,0.5633,0.839090587882679,0.819948878021329,0.0878505511131426,0.363387654994568,0.113458440050312,0.249929214944256,5.15412021368593,0.0695,3.01776136361116,0.4938,0.769733212039958,0.554353523339265,0.752173713663634,0.548440552190939,0.215379688700693,0.203733161472696,True,0.55166784925832,0.0485019310584803,0.577495538584205,85.0076002818603
15014,1549:1053,Breast,HCC1954,SIDM00872,749709,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.811104591403647,0.0584468392005528,0.536756908178248,9.28930914273968,12.2205,0.871846666247663,0.87882726543776,0.0614137246111738,0.435365992691002,0.204841055868449,0.230524936822553,6.86871790989117,2.2825,2.42059123284852,9.938,0.707158833993443,0.566381932654561,0.712820830047278,0.594735680285929,0.140776901338882,0.118085149761349,True,0.55166784925832,0.0485019310584803,0.577495538584205,85.0076002818603
15014,1049:1053,Breast,HCC1954,SIDM00872,749709,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.966003177438465,0.0584468392005528,0.536756908178248,9.28930914273968,12.2205,0.871846666247663,0.87882726543776,0.0428739373843642,0.518508878812234,0.443761305354592,0.0747475734576419,8.68014671176482,8.0115,0.609162430974864,4.209,0.842206649834375,0.820387334525948,0.848949930832433,0.819777070505402,0.0218193153084277,0.0291728603270304,True,0.55166784925832,0.0485019310584803,0.577495538584205,85.0076002818603
15014,1558:1053,Breast,HCC1954,SIDM00872,749709,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.88993860638389,0.0584468392005528,0.536756908178248,9.28930914273968,12.2205,0.871846666247663,0.87882726543776,0.0593324649486553,0.477680694831075,0.285776778855506,0.191903915975569,7.52956152957027,3.6087,1.75974761316941,8.6118,0.775890007140886,0.644377226386042,0.782102311855845,0.6936353776633,0.131512780754844,0.0884669341925454,True,0.55166784925832,0.0485019310584803,0.577495538584205,85.0076002818603
15015,1022:1073,Breast,HCC1954,SIDM00872,749709,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,20.0,0.946002031979605,0.0756319081974746,0.831872860646948,12.1406270877771,176.3815,0.916547596770343,0.964088425385972,0.0841849601733436,0.786953416520699,0.549419174473904,0.237534242046795,9.64027351997762,31.1725,2.50035356779951,145.209,0.867055888950768,0.794163825222493,0.912029609423147,0.845858669511893,0.0728920637282752,0.0661709399112547,True,0.55166784925832,0.0485019310584803,0.577495538584205,85.0076002818603
16420,1022:1190,Breast,HCC1954,SIDM00872,749709,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.68655360163118,0.0543935526404283,0.926837594697817,13.9872166982127,317.1771,0.964345802499972,0.985172182657608,0.194409964481347,0.636323688766965,0.295352899105743,0.340970789661222,8.4479704526053,6.8206,5.53924624560739,310.3565,0.662075083924266,0.450187686564369,0.676373510230431,0.573899283526376,0.211887397359897,0.102474226704055,True,0.735938825388516,0.0673460875008856,0.29436551473555,164.496524781276
16420,1179:1190,Breast,HCC1954,SIDM00872,749709,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.425094385507945,0.0543935526404283,0.926837594697817,13.9872166982127,317.1771,0.964345802499972,0.985172182657608,0.0947656551910041,0.39399345778373,0.226772844773985,0.167220613009746,9.26331497061092,12.0023,4.72390172760177,305.1748,0.409937986330891,0.301245876755348,0.418791163606357,0.373076708316187,0.108692109575543,0.0457144552901695,True,0.735938825388516,0.0673460875008856,0.29436551473555,164.496524781276
16421,1561:1372,Breast,HCC1954,SIDM00872,749709,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.542162599554494,0.0789790367010351,0.665041308674675,10.3471099572276,2.544,0.8665605621709,0.920487842637639,0.075303118089818,0.360560524722185,0.292568140806061,0.0679923839161236,9.31202831923825,1.2415,1.0350816379894,1.3025,0.469816727057979,0.415646204152019,0.49905408162273,0.47702963654542,0.0541705229059596,0.0220244450773101,True,0.735938825388516,0.0673460875008856,0.29436551473555,164.496524781276
16423,1179:1510,Breast,HCC1954,SIDM00872,749709,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.440726930541753,0.0318030060788815,0.903586225045905,13.395266627103,210.4297,0.988752776888071,0.980215374302795,0.0543962404122962,0.398234783444291,0.270412027199691,0.1278227562446,9.90803118322468,18.7648,3.48723544387831,191.6649,0.435769976422514,0.357101196271767,0.432007313186306,0.398775862493078,0.078668780150747,0.0332314506932287,True,0.735938825388516,0.0673460875008856,0.29436551473555,164.496524781276
16423,1561:1549,Breast,HCC1954,SIDM00872,749709,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.568081237286738,0.0789713414273137,0.679662604994962,10.477491077679,13.9232,0.898090984559462,0.924720429254739,0.0831725170208141,0.386103573583065,0.141207043274247,0.244896530308818,6.82711343829154,1.1088,3.65037763938748,12.8144,0.510188637704604,0.346216269571479,0.525316325595356,0.414812233455006,0.163972368133125,0.110504092140349,True,0.735938825388516,0.0673460875008856,0.29436551473555,164.496524781276
16423,1594:1549,Breast,HCC1954,SIDM00872,749709,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.844948824409834,0.0789713414273137,0.679662604994962,10.477491077679,13.9232,0.898090984559462,0.924720429254739,0.0830849836403556,0.574280119085818,0.365816439258881,0.208463679826938,8.46997811478094,3.4627,2.00751296289808,10.4605,0.758840921616588,0.643033386665807,0.781341439606549,0.707346027601129,0.115807534950781,0.0739954120054199,True,0.735938825388516,0.0673460875008856,0.29436551473555,164.496524781276
16423,1053:1549,Breast,HCC1954,SIDM00872,749709,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.970570721924356,0.0789713414273137,0.679662604994962,10.477491077679,13.9232,0.898090984559462,0.924720429254739,0.0585530572985032,0.659660625194949,0.465629855743493,0.194030769451456,8.84080344097556,4.4776,1.63668763670346,9.4456,0.871660815237633,0.801499079808788,0.897506574599973,0.831816748449756,0.0701617354288452,0.0656898261502165,True,0.735938825388516,0.0673460875008856,0.29436551473555,164.496524781276
16423,1058:1549,Breast,HCC1954,SIDM00872,749709,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.829002687270177,0.0789713414273137,0.679662604994962,10.477491077679,13.9232,0.898090984559462,0.924720429254739,0.106493251275514,0.563442125977872,0.257580485979747,0.305861639998126,7.43495723893425,1.6898,3.04253383874477,12.2334,0.744519839612914,0.562870822465517,0.766595720825811,0.640878638502466,0.181649017147396,0.125717082323344,True,0.735938825388516,0.0673460875008856,0.29436551473555,164.496524781276
16424,1179:1558,Breast,HCC1954,SIDM00872,749709,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.480008264014868,0.118683403206313,0.388229246147575,8.10677100571566,5.3841,0.814624040346162,0.816052782180238,0.0567282891308307,0.186353246483098,0.0354773278418117,0.150875918641287,4.03433190371126,0.32,4.0724391020044,5.0641,0.391026271431339,0.203702333313161,0.391712079318839,0.241412395215363,0.187323938118179,0.150299684103477,True,0.735938825388516,0.0673460875008856,0.29436551473555,164.496524781276
16425,1179:1561,Breast,HCC1954,SIDM00872,749709,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.446186698315862,0.186012124124558,0.11322365398656,4.95729152537328,0.6068,0.540706642377894,0.581368125955964,0.0479918640581468,0.0505188883435207,0.011634903584375,0.0388839847591457,1.88910539641667,0.0723,3.06818612895661,0.5345,0.241256111520048,0.124164541709084,0.259398724626371,0.144714745650137,0.117091569810963,0.114683978976234,True,0.735938825388516,0.0673460875008856,0.29436551473555,164.496524781276
16425,1049:1594,Breast,HCC1954,SIDM00872,749709,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.952125507908656,0.0833444951707476,0.604531290635854,9.83355779935862,7.1283,0.880191960056533,0.901931683642506,0.0490695136303069,0.575589662143338,0.35000598821446,0.225583673928878,7.93442674621723,1.9111,1.89913105314138,5.2172,0.838053217025942,0.764971596180704,0.85875216238703,0.766940655431343,0.0730816208452382,0.0918115069556867,True,0.735938825388516,0.0673460875008856,0.29436551473555,164.496524781276
16425,1058:1594,Breast,HCC1954,SIDM00872,749709,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.986608967654293,0.0833444951707476,0.604531290635854,9.83355779935862,7.1283,0.880191960056533,0.901931683642506,0.0643640639472399,0.596435992568958,0.391939589469986,0.204496403098971,8.18114184894772,2.2676,1.6524159504109,4.8607,0.868405281048985,0.777386160329154,0.889853887293231,0.809511644750615,0.0910191207198311,0.0803422425426156,True,0.735938825388516,0.0673460875008856,0.29436551473555,164.496524781276
16425,1179:1594,Breast,HCC1954,SIDM00872,749709,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.891714920992504,0.0833444951707476,0.604531290635854,9.83355779935862,7.1283,0.880191960056533,0.901931683642506,0.0255158667204137,0.539069572066847,0.373383596921526,0.165685975145321,8.35573592342668,2.5593,1.47782187593193,4.569,0.784880304120048,0.744976646782056,0.804265940019913,0.740730704348229,0.0399036573379928,0.063535235671684,True,0.735938825388516,0.0673460875008856,0.29436551473555,164.496524781276
16425,1053:1594,Breast,HCC1954,SIDM00872,749709,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.979916055843095,0.0833444951707476,0.604531290635854,9.83355779935862,7.1283,0.880191960056533,0.901931683642506,0.0823432336906001,0.592389917953622,0.320493262510729,0.271896655442893,7.5828444120486,1.4978,2.25071338731001,5.6305,0.862514233883401,0.741986902851264,0.883817338074886,0.767228545176093,0.120527331032136,0.116588792898793,True,0.735938825388516,0.0673460875008856,0.29436551473555,164.496524781276
14675,1022:1005,Breast,DU-4475,SIDM01001,906844,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.69137435404499,0.0467383203615916,0.67758421091494,9.69278428192079,6.4656,0.958805319018487,0.963694335806391,0.048647035500381,0.468464346132401,0.0481149783812757,0.420349367751126,6.58128744974836,0.7481,3.11149683217243,5.7175,0.662893408091307,0.527909683316726,0.666273548914959,0.519517821179452,0.134983724774581,0.146755727735507,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14675,1558:1005,Breast,DU-4475,SIDM01001,906844,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.97101897632659,0.0467383203615916,0.67758421091494,9.69278428192079,6.4656,0.958805319018487,0.963694335806391,0.0242074361369367,0.657947126857686,0.542185945477139,0.115761181380546,9.21878061283816,4.655,0.474003669082625,1.8106,0.931018159369821,0.9050138988962,0.935765487446455,0.918238093582625,0.0260042604736203,0.01752739386383,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14675,1007:1005,Breast,DU-4475,SIDM01001,906844,1007,Docetaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.001,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.825844180054183,0.0467383203615916,0.67758421091494,9.69278428192079,6.4656,0.958805319018487,0.963694335806391,0.0872320214316766,0.559578977080709,0.2932404005464,0.266338576534309,8.44331787810036,2.7195,1.24946640382043,3.7461,0.791823792516412,0.683409818510096,0.795861358576889,0.746084314943827,0.108413974006316,0.0497770436330628,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14675,1012:1005,Breast,DU-4475,SIDM01001,906844,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.176217714214848,0.0467383203615916,0.67758421091494,9.69278428192079,6.4656,0.958805319018487,0.963694335806391,0.049424345778417,0.119402340835502,0.0061133437594833,0.113288997076019,5.89755885099223,0.4657,3.79522543092856,5.9999,0.168958481694476,0.0754003956261446,0.169820013057599,0.120976925458142,0.0935580860683315,0.0488430875994565,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14675,1011:1005,Breast,DU-4475,SIDM01001,906844,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.440023011044417,0.0467383203615916,0.67758421091494,9.69278428192079,6.4656,0.958805319018487,0.963694335806391,0.0216354838333153,0.298152644722947,0.0131050183910353,0.285047626331912,5.75049482436903,0.4206,3.94228945755175,6.045,0.421896403479917,0.287268208802055,0.424047683367978,0.295825820309095,0.134628194677863,0.128221863058883,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14675,1559:1005,Breast,DU-4475,SIDM01001,906844,1559,Luminespib,HSP90,Protein stability and degradation,Targeted,Early clinical trials,0.01,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.575401743621875,0.0467383203615916,0.67758421091494,9.69278428192079,6.4656,0.958805319018487,0.963694335806391,0.0894898909405961,0.389883136411109,0.0403897572598051,0.349493379151304,6.5899079985265,0.7526,3.10287628339429,5.713,0.551698252357166,0.42743973141382,0.554511401141522,0.432834005660097,0.124258520943346,0.121677395481425,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14675,1011:1007,Breast,DU-4475,SIDM01001,906844,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1007,Docetaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.0125,0.440023011044417,0.070471434343773,0.0866081866834995,6.80253301643446,0.0027,0.758428234252214,0.771824747087811,0.0645585294441002,0.0381095950855703,0.0013651836092074,0.0367444114763629,3.61546637449063,0.0003,3.18706664194383,0.0024,0.33372587529676,0.181511611514053,0.339620649212174,0.203253904644082,0.152214263782707,0.136366744568092,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14676,1022:1011,Breast,DU-4475,SIDM01001,906844,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.69468183233506,0.136951323355275,0.0467511994745812,6.18756904977172,1.4236,0.640485810802064,0.714332716532231,0.0273068750119072,0.0324772089148639,0.0007186923814362,0.0317585165334276,2.58909529307768,0.1175,3.59847375669404,1.3061,0.444933856632584,0.259605210461804,0.496233960417491,0.250628491945661,0.185328646170781,0.24560546847183,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14676,1191:1011,Breast,DU-4475,SIDM01001,906844,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.000625,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.970267118438974,0.136951323355275,0.0467511994745812,6.18756904977172,1.4236,0.640485810802064,0.714332716532231,0.079399221531862,0.0453611515977674,0.0208455289826049,0.0245156226151625,5.43789731856253,0.8466,0.749671731209196,0.577,0.621442322047968,0.60649655822269,0.693093546476412,0.622773354070813,0.0149457638252786,0.0703201924055987,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14676,1558:1011,Breast,DU-4475,SIDM01001,906844,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.995787507128496,0.136951323355275,0.0467511994745812,6.18756904977172,1.4236,0.640485810802064,0.714332716532231,0.109940528732945,0.0465542603800602,0.0193057421590147,0.0272485182210455,5.3401023383858,0.7912,0.847466711385928,0.6324,0.63778776888976,0.610265810270621,0.711323595055956,0.629624666618381,0.0275219586191399,0.0816989284375748,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14676,1047:1011,Breast,DU-4475,SIDM01001,906844,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.400068501690739,0.136951323355275,0.0467511994745812,6.18756904977172,1.4236,0.640485810802064,0.714332716532231,0.0289357985921587,0.0187036823260406,1.42360599820757e-05,0.0186894462660585,-0.555227059814904,0.0133,6.74279610958663,1.4103,0.25623819868176,0.0346275637885373,0.285782019611725,0.0358134945835481,0.221610634893223,0.249968525028177,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14676,1190:1011,Breast,DU-4475,SIDM01001,906844,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.249918246291309,0.136951323355275,0.0467511994745812,6.18756904977172,1.4236,0.640485810802064,0.714332716532231,0.0321696378878563,0.0116839777847024,0.0001046887839035,0.0115792890007989,1.74515458613128,0.0655,4.44241446364044,1.3581,0.160069090610119,0.0553810721666061,0.178524779784242,0.0697942051451534,0.104688018443513,0.108730574639088,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14676,1073:1011,Breast,DU-4475,SIDM01001,906844,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,10.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.586609098174628,0.136951323355275,0.0467511994745812,6.18756904977172,1.4236,0.640485810802064,0.714332716532231,0.0215527202052789,0.0274246789623662,0.0001825458799481,0.0272421330824181,1.46781115756434,0.054,4.71975789220738,1.3696,0.375714803868244,0.150451042140054,0.419034070641604,0.148498479489975,0.22526376172819,0.270535591151629,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14676,1007:1011,Breast,DU-4475,SIDM01001,906844,1007,Docetaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.001,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.784409876398531,0.136951323355275,0.0467511994745812,6.18756904977172,1.4236,0.640485810802064,0.714332716532231,0.0991186600254306,0.0366721026013392,0.0005688217612649,0.0361032808400743,2.25734088700899,0.0934,3.93022816276273,1.3302,0.50240339568626,0.244209317837898,0.560329637882474,0.257650023809483,0.258194077848362,0.30267961407299,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14676,1510:1011,Breast,DU-4475,SIDM01001,906844,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.828243572771293,0.136951323355275,0.0467511994745812,6.18756904977172,1.4236,0.640485810802064,0.714332716532231,0.0630169305357147,0.0387213804841705,0.0023370800313067,0.0363843004528638,3.52671166551883,0.2251,2.66085738425289,1.1985,0.53047825624802,0.383844270733617,0.591641481288078,0.375304442969176,0.146633985514403,0.216337038318902,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14676,1083:1011,Breast,DU-4475,SIDM01001,906844,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.430722728948199,0.136951323355275,0.0467511994745812,6.18756904977172,1.4236,0.640485810802064,0.714332716532231,0.0487409180328726,0.0201368042192931,5.75113061545007e-05,0.0200792929131386,0.678377675931278,0.0313,5.50919137384045,1.3923,0.275871796281265,0.0811794091575873,0.307679337041742,0.0784365616799378,0.194692387123677,0.229242775361804,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14676,1179:1011,Breast,DU-4475,SIDM01001,906844,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.0488497861621679,0.136951323355275,0.0467511994745812,6.18756904977172,1.4236,0.640485810802064,0.714332716532231,0.0185032204161959,0.0022837860971581,0.0003862536183409,0.0018975324788171,4.49263402936923,0.4397,1.69493502040249,0.9839,0.0312875948975836,0.0099801390065142,0.03489500045124,0.0268078388520439,0.0213074558910693,0.008087161599196,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14676,1005:1011,Breast,DU-4475,SIDM01001,906844,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.565491499971725,0.136951323355275,0.0467511994745812,6.18756904977172,1.4236,0.640485810802064,0.714332716532231,0.0182646387479769,0.0264374059163581,4.47335096417367e-05,0.0263926724067164,0.190015086963419,0.0223,5.9975539628083,1.4013,0.362189281861065,0.0745393816587984,0.403949079350688,0.0802798179266084,0.287649900202267,0.323669261424079,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14676,1012:1011,Breast,DU-4475,SIDM01001,906844,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.153279680261852,0.136951323355275,0.0467511994745812,6.18756904977172,1.4236,0.640485810802064,0.714332716532231,0.0594670649525019,0.0071660089073217,4.46936573226253e-05,0.0071213152499991,1.40709031910779,0.0518,4.78047873066394,1.3718,0.0981734602919932,0.0060203951622299,0.10949269039064,0.0379354638919599,0.0921530651297633,0.0715572264986804,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14676,1017:1011,Breast,DU-4475,SIDM01001,906844,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.791864105836271,0.136951323355275,0.0467511994745812,6.18756904977172,1.4236,0.640485810802064,0.714332716532231,0.0497801930216209,0.0370205967687123,0.0001746917261976,0.0368459050425146,1.14683368180272,0.0432,5.040735367969,1.3804,0.507177723871595,0.187960333201381,0.565654437846389,0.177031223274647,0.319217390670214,0.388623214571742,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14676,1559:1011,Breast,DU-4475,SIDM01001,906844,1559,Luminespib,HSP90,Protein stability and degradation,Targeted,Early clinical trials,0.01,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.624016172231265,0.136951323355275,0.0467511994745812,6.18756904977172,1.4236,0.640485810802064,0.714332716532231,0.0616562125185314,0.0291735045433484,0.0005736112944236,0.0285998932489248,2.47872690090838,0.1089,3.70884214886335,1.3147,0.399673504025142,0.222089394910816,0.445755167470004,0.218405657937465,0.177584109114326,0.227349509532539,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14676,1021:1011,Breast,DU-4475,SIDM01001,906844,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,4.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.414618113634862,0.136951323355275,0.0467511994745812,6.18756904977172,1.4236,0.640485810802064,0.714332716532231,0.0224481936995704,0.019383894136318,0.0002040283023049,0.0191798658340131,1.89544380605587,0.0727,4.29212524371585,1.3509,0.265557018684647,0.11771344435958,0.29617528343626,0.121728806754436,0.147843574325067,0.174446476681824,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
15198,1375:1017,Breast,DU-4475,SIDM01001,906844,1375,Temozolomide,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved,30.0,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.983722552718734,0.0997598121575535,0.513983197993639,9.05218781602052,10.3684,0.877088820951329,0.937917954977577,0.166000717127789,0.505616863584841,0.113282265607117,0.392334597977725,7.09790848603668,2.6756,1.95427932998384,7.6928,0.862812053907305,0.690264530677686,0.922651044911276,0.785398519495436,0.17254752322962,0.13725252541584,True,0.755252545647994,0.089812823923721,0.27319382048135,178.959809306494
15198,1559:1017,Breast,DU-4475,SIDM01001,906844,1559,Luminespib,HSP90,Protein stability and degradation,Targeted,Early clinical trials,0.01,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.935137272753707,0.0997598121575535,0.513983197993639,9.05218781602052,10.3684,0.877088820951329,0.937917954977577,0.140017092407405,0.480644846013001,0.251465911414518,0.229178934598482,8.06703974747716,5.2378,0.985148068543362,5.1306,0.82019844798719,0.741469115761124,0.877082038484466,0.820576161081578,0.0787293322260659,0.0565058774028883,True,0.755252545647994,0.089812823923721,0.27319382048135,178.959809306494
15198,1011:1017,Breast,DU-4475,SIDM01001,906844,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.355199379136707,0.0997598121575535,0.513983197993639,9.05218781602052,10.3684,0.877088820951329,0.937917954977577,0.0520338907109139,0.18256651281404,0.0019181591573436,0.180648353656696,4.1346006883293,0.3431,4.91758712769122,10.0253,0.311541404649658,0.150989260228151,0.333147875289206,0.182335813341506,0.160552144421507,0.1508120619477,True,0.755252545647994,0.089812823923721,0.27319382048135,178.959809306494
15198,1558:1017,Breast,DU-4475,SIDM01001,906844,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.649837514701886,0.0997598121575535,0.513983197993639,9.05218781602052,10.3684,0.877088820951329,0.937917954977577,0.0892130435695876,0.334005563982714,0.0722068496817611,0.261798714300953,7.06033221464521,2.6068,1.99185560137531,7.7616,0.569965219579819,0.471141869067231,0.609494272856904,0.516661405402544,0.0988233505125881,0.0928328674543609,True,0.755252545647994,0.089812823923721,0.27319382048135,178.959809306494
15198,1022:1017,Breast,DU-4475,SIDM01001,906844,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.937711208327108,0.0997598121575535,0.513983197993639,9.05218781602052,10.3684,0.877088820951329,0.937917954977577,0.0429919367386067,0.481967805650447,0.0627097006278879,0.419258105022559,6.5414055456158,1.8192,2.51078227040472,8.5492,0.822456018104469,0.673648720923354,0.879496178873714,0.701138656484178,0.148807297181115,0.178357522389536,True,0.755252545647994,0.089812823923721,0.27319382048135,178.959809306494
14677,1073:1022,Breast,DU-4475,SIDM01001,906844,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,10.0,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.595726430683122,0.0585296816111684,0.187612448077931,7.63288654503961,0.3877,0.836358562244656,0.843916029133383,0.035582309073848,0.111765694045189,0.0020515274211359,0.109714166624053,3.71311530225336,0.0256,3.91977124278625,0.3621,0.498240901057277,0.265787412780992,0.502743083831904,0.280935130765402,0.232453488276285,0.221807953066502,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14677,1005:1022,Breast,DU-4475,SIDM01001,906844,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,1.0,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.926309630969653,0.0585296816111684,0.187612448077931,7.63288654503961,0.3877,0.836358562244656,0.843916029133383,0.0388239869100739,0.173787217544382,0.014509829969256,0.159277387575126,5.13764648442287,0.0688,2.49524006061674,0.3189,0.774726991151158,0.542043613449969,0.781727545515919,0.567291773048256,0.232683377701188,0.214435772467663,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14677,1190:1022,Breast,DU-4475,SIDM01001,906844,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.01,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.633256347091283,0.0585296816111684,0.187612448077931,7.63288654503961,0.3877,0.836358562244656,0.843916029133383,0.0184920267118291,0.118806773538684,0.0017865982980213,0.117020175240663,3.52656488416779,0.0225,4.10632166087182,0.3652,0.529629367985569,0.280322015431406,0.534415181860787,0.286940111859478,0.249307352554163,0.24747507000131,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14677,1179:1022,Breast,DU-4475,SIDM01001,906844,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.199210436535158,0.0585296816111684,0.187612448077931,7.63288654503961,0.3877,0.836358562244656,0.843916029133383,0.0705847670372683,0.0373743576810344,0.0011182844880579,0.0362560731929764,4.17094442719666,0.0352,3.46194211784295,0.3525,0.166611354284675,0.0512107376357533,0.168116880562678,0.102978572703368,0.115400616648922,0.0651383078593104,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14677,1017:1022,Breast,DU-4475,SIDM01001,906844,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.573011090943307,0.0585296816111684,0.187612448077931,7.63288654503961,0.3877,0.836358562244656,0.843916029133383,0.0435517941694599,0.10750401354768,0.0006545567067415,0.106849456840938,2.68161200638782,0.0125,4.95127453865179,0.3752,0.479242732171586,0.208527032884313,0.483573244518264,0.211921954885849,0.270715699287273,0.271651289632415,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14678,1005:1047,Breast,DU-4475,SIDM01001,906844,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.613625693034048,0.0743226622463747,0.0741919114578296,6.64559729066275,1.9555,0.737088225364109,0.757394626626378,0.101224183570931,0.0455260630858313,0.0009769825324491,0.0445490805533821,2.99175082897355,0.1554,3.6538464616892,1.8001,0.452296273116288,0.207191531492464,0.464756802663875,0.245640325913289,0.245104741623824,0.219116476750586,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14678,1011:1047,Breast,DU-4475,SIDM01001,906844,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.434650711210396,0.0743226622463747,0.0741919114578296,6.64559729066275,1.9555,0.737088225364109,0.757394626626378,0.059984742857004,0.0322475670812044,0.0008444012075249,0.0314031658736794,3.17770722630379,0.1767,3.46789006435896,1.7788,0.320375921379318,0.140249365966133,0.329202113130087,0.181963026772432,0.180126555413185,0.147239086357655,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14678,1083:1049,Breast,DU-4475,SIDM01001,906844,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.396970211416259,0.0869814439540082,0.785097530833364,10.2085600460106,23.1107,0.93573748944512,0.977431674593915,0.0549901905667506,0.311660332797304,0.142354159571802,0.169306173225501,8.457632952586,6.8664,1.7509270934246,16.2443,0.371459909015149,0.32421865789665,0.388011258508495,0.358996371705728,0.0472412511184994,0.0290148868027671,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14678,1011:1049,Breast,DU-4475,SIDM01001,906844,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.434650711210396,0.0869814439540082,0.785097530833364,10.2085600460106,23.1107,0.93573748944512,0.977431674593915,0.0658083540668212,0.341243200146247,0.11115961057214,0.230083589574107,8.00357694702204,5.0124,2.20498309898856,18.0983,0.406718965293551,0.331872047404928,0.424841372521813,0.379368103825053,0.0748469178886237,0.0454732686967605,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14678,1558:1049,Breast,DU-4475,SIDM01001,906844,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.75589473484641,0.0869814439540082,0.785097530833364,10.2085600460106,23.1107,0.93573748944512,0.977431674593915,0.0815896765486613,0.593451089897857,0.243769198899032,0.349681890998824,8.30753655307335,6.188,1.90102349293725,16.9227,0.707319041469964,0.630497409117798,0.73883545649765,0.67610323802524,0.076821632352166,0.0627322184724098,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14678,1561:1049,Breast,DU-4475,SIDM01001,906844,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.842537439756207,0.0869814439540082,0.785097530833364,10.2085600460106,23.1107,0.93573748944512,0.977431674593915,0.0459122279725128,0.661474063587262,0.725693924559275,-0.0642198609720133,10.7035691342175,32.5706,-0.495009088206903,-9.4599,0.788393868640992,0.812862690931934,0.823522780648979,0.830804731790291,-0.0244688222909419,-0.0072819511413124,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14678,1179:1049,Breast,DU-4475,SIDM01001,906844,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.206241633985883,0.0869814439540082,0.785097530833364,10.2085600460106,23.1107,0.93573748944512,0.977431674593915,0.0941184879406324,0.161919797597355,0.0086500959569637,0.153269701640391,6.08160694864049,1.3227,4.1269530973701,21.788,0.192988028805009,0.0911820644143949,0.201587105677807,0.145237631894352,0.101805964390614,0.0563494737834548,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14678,1510:1049,Breast,DU-4475,SIDM01001,906844,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.176111032921097,0.0869814439540082,0.785097530833364,10.2085600460106,23.1107,0.93573748944512,0.977431674593915,0.0137961931805547,0.138264337098867,0.0785378634134399,0.0597264736854268,8.7975617660969,8.6908,1.4109982799137,14.4199,0.164793695809174,0.168976575747154,0.172136501822532,0.162845585966054,-0.0041828799379794,0.009290915856478,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14678,1053:1049,Breast,DU-4475,SIDM01001,906844,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.999503469053151,0.0869814439540082,0.785097530833364,10.2085600460106,23.1107,0.93573748944512,0.977431674593915,0.0966754855691576,0.78470770561301,0.569827879360918,0.214879826252092,9.26333354822091,12.0025,0.945226497789683,11.1082,0.935272866823483,0.85749308934426,0.976946349519048,0.94711465236601,0.0777797774792234,0.0298316971530384,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14678,1022:1049,Breast,DU-4475,SIDM01001,906844,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.96176625250799,0.0869814439540082,0.785097530833364,10.2085600460106,23.1107,0.93573748944512,0.977431674593915,0.0298632695011365,0.755080310082881,0.682272876782706,0.0728074333001751,9.83247996638459,17.8074,0.376080079626,5.3033,0.899960738554868,0.913698940025432,0.940060798756799,0.930964596486739,-0.0137382014705645,0.0090962022700598,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14679,1049:1053,Breast,DU-4475,SIDM01001,906844,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.753388145275598,0.112410123158647,0.444636957001577,8.79257855141842,8.6608,0.869681550222857,0.924399255217426,0.0887765258129674,0.334984212356404,0.126217696045004,0.2087665163114,7.50452269340132,3.5466,1.2880558580171,5.1142,0.655207770102805,0.588991665631371,0.696431440382401,0.627842375734963,0.0662161044714341,0.0685890646474381,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14679,1594:1053,Breast,DU-4475,SIDM01001,906844,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.790827825114314,0.112410123158647,0.444636957001577,8.79257855141842,8.6608,0.869681550222857,0.924399255217426,0.108962315838518,0.351631277671004,0.140550406765943,0.211080870905061,7.5711035767133,3.7141,1.22147497470512,4.9467,0.687768368904787,0.589529757946234,0.731040652540889,0.663399138128063,0.098238610958553,0.0676415144128253,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14679,1012:1053,Breast,DU-4475,SIDM01001,906844,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.81989202591422,0.112410123158647,0.444636957001577,8.79257855141842,8.6608,0.869681550222857,0.924399255217426,0.0835375812091419,0.364554295472357,0.218274930985013,0.146279364487344,8.05426421430036,5.1916,0.738314337118055,3.4692,0.713044968112437,0.641199247818363,0.757907578113811,0.718682164107946,0.0718457202940744,0.0392254140058654,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14679,1054:1053,Breast,DU-4475,SIDM01001,906844,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,1.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.985359843487212,0.112410123158647,0.444636957001577,8.79257855141842,8.6608,0.869681550222857,0.924399255217426,0.0447265550506412,0.438127402359704,0.48998851402474,-0.0518611116650357,8.98980849532089,9.9296,-0.197229943902473,-1.2688,0.85694927621131,0.923438355844539,0.910865905440738,0.92114810486425,-0.0664890796332293,-0.0102821994235118,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14679,1558:1053,Breast,DU-4475,SIDM01001,906844,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.974162653126992,0.112410123158647,0.444636957001577,8.79257855141842,8.6608,0.869681550222857,0.924399255217426,0.1330796562224,0.433148717710969,0.302867459267907,0.130281258443062,8.25757029956172,5.9773,0.535008251856699,2.6835,0.847211286340694,0.851168017793283,0.900515231011224,0.868005149800846,-0.0039567314525891,0.0325100812103781,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14680,1191:1058,Breast,DU-4475,SIDM01001,906844,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.0025,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.287720101943585,0.0889459413304717,0.640241326475908,9.5376778763611,5.8065,0.907497946082968,0.958406584580388,0.0712070345955386,0.184210299722144,0.0418101887310629,0.142400110991081,7.34723831044637,1.2721,2.19043956591473,4.5344,0.261105401560585,0.173184241600824,0.275752840218872,0.235956041120625,0.0879211599597609,0.0397967990982473,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14680,1073:1058,Breast,DU-4475,SIDM01001,906844,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,2.5,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.732794995828337,0.0889459413304717,0.640241326475908,9.5376778763611,5.8065,0.907497946082968,0.958406584580388,0.0833495473082121,0.469165640164042,0.310423614831368,0.158742025332674,8.71274638755215,3.2778,0.824931488808948,2.5287,0.665009953614093,0.643275653446523,0.702315549149437,0.674084806396866,0.0217343001675705,0.0282307427525704,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14680,1022:1058,Breast,DU-4475,SIDM01001,906844,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.757040207534525,0.0889459413304717,0.640241326475908,9.5376778763611,5.8065,0.907497946082968,0.958406584580388,0.0459159732796868,0.4846884266675,0.24633773132203,0.23835069534547,8.31990943588453,2.4965,1.21776844047657,3.31,0.687012433439805,0.66654914401127,0.725552319693192,0.677761000300502,0.0204632894285346,0.0477913193926901,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14680,1047:1058,Breast,DU-4475,SIDM01001,906844,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.320697082571568,0.0889459413304717,0.640241326475908,9.5376778763611,5.8065,0.907497946082968,0.958406584580388,0.0213074483567334,0.205323525542574,0.210649597974419,-0.0053260724318445,9.60565338635479,6.0867,-0.067975509993687,-0.280200000000001,0.291031943748498,0.305858064986756,0.307358195592311,0.30812425968202,-0.0148261212382576,-0.0007660640897084,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14680,1510:1058,Breast,DU-4475,SIDM01001,906844,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.840920154830238,0.0889459413304717,0.640241326475908,9.5376778763611,5.8065,0.907497946082968,0.958406584580388,0.0977004972631354,0.538391835388837,0.252553970131699,0.285837865257138,8.21110664259688,2.3152,1.32657123376422,3.4913,0.763133313328213,0.698326104578799,0.80594341349566,0.746569511046743,0.0648072087494141,0.0593739024489168,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14680,1005:1058,Breast,DU-4475,SIDM01001,906844,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.59926545908807,0.0889459413304717,0.640241326475908,9.5376778763611,5.8065,0.907497946082968,0.958406584580388,0.0929348177142197,0.38367451243774,0.181654610742184,0.202019901695556,8.22349581259308,2.3351,1.31418206376803,3.4714,0.543832173280891,0.441989668865718,0.574339961901596,0.532546687356313,0.101842504415172,0.0417932745452825,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14680,1012:1058,Breast,DU-4475,SIDM01001,906844,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.175088598822816,0.0889459413304717,0.640241326475908,9.5376778763611,5.8065,0.907497946082968,0.958406584580388,0.0626044793011413,0.112098956761128,0.0049609840393459,0.107137972721782,5.70259730537564,0.4069,3.83508057098546,5.3996,0.15889254381425,0.0579664716851238,0.167806065996741,0.11689776062281,0.100926072129127,0.0509083053739307,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14680,1011:1073,Breast,DU-4475,SIDM01001,906844,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,20.0,0.395004436096053,0.105752128510487,0.431902995129913,8.74432726839391,16.7519,0.866466460287138,0.921688939707292,0.0542825643538301,0.170603599039488,0.0043939067883409,0.166209692251147,4.81405930924747,1.0988,3.93026795914644,15.6531,0.342258095541864,0.188468995199168,0.364071219885048,0.22931804639996,0.153789100342696,0.134753173485088,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14680,1179:1073,Breast,DU-4475,SIDM01001,906844,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,20.0,0.244809694670758,0.105752128510487,0.431902995129913,8.74432726839391,16.7519,0.866466460287138,0.921688939707292,0.0752920850919237,0.10573404036514,0.0011024729524621,0.104631567412678,3.96435190668662,0.6097,4.77997536170729,16.1422,0.212119389585347,0.0781316604129718,0.225638387911157,0.12154031439121,0.133987729172375,0.104098073519947,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
14680,1022:1073,Breast,DU-4475,SIDM01001,906844,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,20.0,0.884645527202433,0.105752128510487,0.431902995129913,8.74432726839391,16.7519,0.866466460287138,0.921688939707292,0.103367477598643,0.382081052827012,0.008358325043319,0.373722727783693,4.66019960286326,0.9877,4.08412766553065,15.7642,0.766515678563941,0.52120122368775,0.815367997984009,0.500134540679421,0.245314454876191,0.315233457304588,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
16403,1073:1179,Breast,DU-4475,SIDM01001,906844,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,10.0,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,10.0,0.446201756931022,0.077889766900837,0.055052910944084,6.34819922409999,1.5912,0.709482833463988,0.729573168293229,0.061932701310859,0.0245647055874174,0.0048056421951385,0.0197590633922788,4.78359419717359,0.5379,1.5646050269264,1.0533,0.316572486804031,0.237594240988861,0.325536829502171,0.25769864936988,0.0789782458151703,0.0678381801322903,True,0.80323186776311,0.0682276954276743,0.213002767823073,229.021029302879
16403,1190:1179,Breast,DU-4475,SIDM01001,906844,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.01,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,10.0,0.570267620359792,0.077889766900837,0.055052910944084,6.34819922409999,1.5912,0.709482833463988,0.729573168293229,0.0326034194595024,0.0313948925179623,0.001100800583805,0.0302940919341573,3.17172780267457,0.176,3.17647142142542,1.4152,0.404595087125631,0.245736984450238,0.416051954560934,0.23840146737024,0.158858102675394,0.177650487190694,True,0.80323186776311,0.0682276954276743,0.213002767823073,229.021029302879
15198,1017:1375,Breast,DU-4475,SIDM01001,906844,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,1375,Temozolomide,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved,30.0,0.636627565247298,0.0426527249935145,0.959708738531096,11.9574435719852,233.0239,0.980058105665077,0.996163898369953,0.0105103314396372,0.610977037557607,0.264543543943065,0.346433493614542,8.68180841729242,24.0622,3.27563515469279,208.9617,0.623932005610436,0.583481354548836,0.634185397206519,0.584478988619341,0.0404506510616002,0.0497064085871782,True,0.755252545647994,0.089812823923721,0.27319382048135,178.959809306494
15198,1561:1375,Breast,DU-4475,SIDM01001,906844,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1375,Temozolomide,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved,30.0,0.940661913265639,0.0426527249935145,0.959708738531096,11.9574435719852,233.0239,0.980058105665077,0.996163898369953,0.0126057029947158,0.902761458164414,0.771851815214849,0.130909642949565,10.4178756516816,80.1575,1.53956792030365,152.8664,0.921903332786408,0.924316411666856,0.937053438566837,0.923307125872632,-0.0024130788804471,0.0137463126942045,True,0.755252545647994,0.089812823923721,0.27319382048135,178.959809306494
15198,1510:1375,Breast,DU-4475,SIDM01001,906844,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1375,Temozolomide,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved,30.0,0.889445985795947,0.0426527249935145,0.959708738531096,11.9574435719852,233.0239,0.980058105665077,0.996163898369953,0.0765031224646693,0.853609085019776,0.495855153477987,0.357753931541789,9.21545107393757,34.832,2.74199249804764,198.1919,0.871708747930583,0.781295883672358,0.886033980599996,0.8409681872011,0.0904128642582246,0.0450657933988965,True,0.755252545647994,0.089812823923721,0.27319382048135,178.959809306494
15198,1012:1375,Breast,DU-4475,SIDM01001,906844,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1375,Temozolomide,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved,30.0,0.218369772620851,0.0426527249935145,0.959708738531096,11.9574435719852,233.0239,0.980058105665077,0.996163898369953,0.0442133958529498,0.209571379015279,0.0998356549147996,0.10973572410048,8.83986083684362,26.8482,3.11758273514159,206.1757,0.214015065689305,0.167796486788105,0.217532083980147,0.202427767748499,0.0462185789011997,0.0151043162316478,True,0.755252545647994,0.089812823923721,0.27319382048135,178.959809306494
15199,1558:1510,Breast,DU-4475,SIDM01001,906844,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.934372859616922,0.105773587933719,0.303656090667141,8.225823146102,5.8472,0.869216610137581,0.888827859860504,0.0838429815260177,0.283728009776752,0.229661436639095,0.0540665731376571,7.95415927538414,4.8436,0.271663870717865,1.0036,0.812172409640779,0.821256792047991,0.830496629125048,0.812071962845135,-0.0090843824072122,0.018424666279913,True,0.755252545647994,0.089812823923721,0.27319382048135,178.959809306494
15199,1049:1549,Breast,DU-4475,SIDM01001,906844,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.618097451064084,0.0606255768500722,0.90352652502791,11.0867124214056,21.2389,0.954222586738432,0.990536963635798,0.0492559636822655,0.55846744208854,0.356615024154829,0.201852417933711,9.28943883439074,6.1108,1.79727358701488,15.1281,0.589802548610802,0.562968233647965,0.612248372408044,0.586388070156125,0.0268343149628361,0.0258603022519186,True,0.755252545647994,0.089812823923721,0.27319382048135,178.959809306494
15199,1011:1549,Breast,DU-4475,SIDM01001,906844,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.364696239408464,0.0606255768500722,0.90352652502791,11.0867124214056,21.2389,0.954222586738432,0.990536963635798,0.0516998788433368,0.329512725883477,0.0987533907255447,0.230759335157932,8.07591461528239,2.6351,3.01079780612324,18.6038,0.348001388942124,0.27578623720617,0.361245105633054,0.320254604790892,0.0722151517359533,0.0409905008421625,True,0.755252545647994,0.089812823923721,0.27319382048135,178.959809306494
15199,1558:1549,Breast,DU-4475,SIDM01001,906844,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.625414035854077,0.0606255768500722,0.90352652502791,11.0867124214056,21.2389,0.954222586738432,0.990536963635798,0.100162409732496,0.565078170518915,0.135109502588105,0.42996866793081,7.79767344395569,2.1729,3.28903897744993,19.066,0.5967841990752,0.470946265536095,0.619495720090107,0.536024621618229,0.125837933539105,0.0834710984718782,True,0.755252545647994,0.089812823923721,0.27319382048135,178.959809306494
16404,1021:1561,Breast,DU-4475,SIDM01001,906844,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.72064255451911,0.0483671730142474,0.811102831670099,10.3592713343761,25.6556,0.966911975835144,0.980471301232369,0.0294973181563327,0.584515216592424,0.60628421740984,-0.021769000817416,10.5559246013073,29.4022,-0.196653266931198,-3.7466,0.696797916260958,0.694232914236586,0.706569343152771,0.709027309376915,0.0025650020243724,-0.002457966224144,True,0.80323186776311,0.0682276954276743,0.213002767823073,229.021029302879
16404,1049:1561,Breast,DU-4475,SIDM01001,906844,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.923504230814571,0.0483671730142474,0.811102831670099,10.3592713343761,25.6556,0.966911975835144,0.980471301232369,0.0563876684646937,0.749056896673015,0.67665843416587,0.0723984625071451,9.94063990075714,19.1938,0.418631433618989,6.4618,0.892947300509031,0.890095886312215,0.90546939488036,0.896713187522102,0.002851414196816,0.0087562073582588,True,0.80323186776311,0.0682276954276743,0.213002767823073,229.021029302879
16404,1558:1561,Breast,DU-4475,SIDM01001,906844,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.960481024655804,0.0483671730142474,0.811102831670099,10.3592713343761,25.6556,0.966911975835144,0.980471301232369,0.0411741715175234,0.779048878863721,0.688502913071794,0.0905459657919269,9.86638438155203,18.2309,0.492886952824099,7.4247,0.928700605302107,0.935649526971591,0.941724080053275,0.930654702076156,-0.006948921669484,0.0110693779771193,True,0.80323186776311,0.0682276954276743,0.213002767823073,229.021029302879
16404,1047:1561,Breast,DU-4475,SIDM01001,906844,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.384720493542167,0.0483671730142474,0.811102831670099,10.3592713343761,25.6556,0.966911975835144,0.980471301232369,0.0998661953318286,0.31204788171357,0.0800848718967377,0.231963009816832,7.75374940017381,4.2154,2.60552193420232,21.4402,0.371990852555128,0.237679229074713,0.377207402914048,0.328401691037478,0.134311623480416,0.0488057118765691,True,0.80323186776311,0.0682276954276743,0.213002767823073,229.021029302879
16404,1012:1561,Breast,DU-4475,SIDM01001,906844,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.325834409993935,0.0483671730142474,0.811102831670099,10.3592713343761,25.6556,0.966911975835144,0.980471301232369,0.0701247881606114,0.264285212601637,0.000206043030307,0.26407916957133,2.12951664131489,0.0855,8.22975469306124,25.5701,0.315053193162314,0.0703344812452746,0.319471287953035,0.102994163306628,0.24471871191704,0.216477124646407,True,0.80323186776311,0.0682276954276743,0.213002767823073,229.021029302879
16404,1011:1561,Breast,DU-4475,SIDM01001,906844,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.272879751884373,0.0483671730142474,0.811102831670099,10.3592713343761,25.6556,0.966911975835144,0.980471301232369,0.0765283595009682,0.221333539458849,0.0192220399973243,0.202111499461525,6.59343837471339,1.886,3.76583295966274,23.7696,0.263850700059923,0.135235420579375,0.267550765410037,0.205357657837136,0.128615279480548,0.0621931075729015,True,0.80323186776311,0.0682276954276743,0.213002767823073,229.021029302879
16404,1012:1594,Breast,DU-4475,SIDM01001,906844,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.959711178790678,0.064712549751161,0.536447335983805,9.1362342007948,4.3961,0.899310331124621,0.941908109627337,0.0969132630771563,0.514834505176136,0.299406000632586,0.21542850454355,8.26224558085987,2.3987,0.873988619934925,1.9974,0.863078177982245,0.781868888303939,0.90395974220295,0.855437427650833,0.0812092896783059,0.0485223145521171,True,0.80323186776311,0.0682276954276743,0.213002767823073,229.021029302879
16404,1058:1594,Breast,DU-4475,SIDM01001,906844,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.92767558247378,0.064712549751161,0.536447335983805,9.1362342007948,4.3961,0.899310331124621,0.941908109627337,0.0277322500892724,0.497649094875284,0.381774586610339,0.115874508264945,8.66642328982453,3.1743,0.469810910970271,1.2218,0.834268235250721,0.834732717526078,0.873785154235317,0.850849181934911,-0.0004644822753568,0.0229359723004062,True,0.80323186776311,0.0682276954276743,0.213002767823073,229.021029302879
16404,1561:1594,Breast,DU-4475,SIDM01001,906844,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.944528512608173,0.064712549751161,0.536447335983805,9.1362342007948,4.3961,0.899310331124621,0.941908109627337,0.0590439830568706,0.5066898043494,0.332212621267334,0.174477183082067,8.42961678788229,2.6938,0.706617412912513,1.7023,0.849424249430302,0.837200457949637,0.889659065799885,0.852469421437232,0.0122237914806643,0.0371896443626529,True,0.80323186776311,0.0682276954276743,0.213002767823073,229.021029302879
16404,1510:1594,Breast,DU-4475,SIDM01001,906844,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.278597091903812,0.064712549751161,0.536447335983805,9.1362342007948,4.3961,0.899310331124621,0.941908109627337,0.0232243639343107,0.149452667764635,0.062154900423443,0.0872977673411923,7.83614897976494,1.7853,1.30008522102986,2.6108,0.250545242970374,0.227220998929573,0.262412860182793,0.239614152468157,0.0233242440408007,0.0227987077146358,True,0.80323186776311,0.0682276954276743,0.213002767823073,229.021029302879
16404,1053:1594,Breast,DU-4475,SIDM01001,906844,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.968808317800857,0.064712549751161,0.536447335983805,9.1362342007948,4.3961,0.899310331124621,0.941908109627337,0.0833242985852974,0.519714641163221,0.25911725656293,0.260597384600291,8.06015644834778,2.0852,1.07607775244701,2.3109,0.871259329077776,0.787840976716198,0.912528411211045,0.849634279639248,0.0834183523615771,0.0628941315717978,True,0.80323186776311,0.0682276954276743,0.213002767823073,229.021029302879
17487,1021:1011,Breast,HCC1395,SIDM00884,749712,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,4.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.569602317271619,0.100355651434196,0.621966133006576,10.0567402991484,20.8023,0.901079389980407,0.900370808255033,0.085691775023172,0.354273350625014,0.144605796797969,0.209667553827045,6.71191940421525,2.0475,3.3448208949331,18.7548,0.513256908578537,0.34263900939811,0.512853298785787,0.40702127664074,0.170617899180427,0.105832022145047,True,0.854313068386799,0.0677982433116498,0.142503867884044,321.370818987034
17489,1179:1047,Breast,HCC1395,SIDM00884,749712,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.39569150464081,0.0813305958757443,0.842177224218544,12.5539742573329,117.45,0.928823720498907,0.96390211323181,0.0514692374281009,0.333242373025257,0.156266807479367,0.17697556554589,8.09443254612817,5.3382,4.45954171120476,112.1118,0.367527655510288,0.285583048824747,0.381407877511152,0.318816063478448,0.0819446066855412,0.0625918140327033,True,0.854313068386799,0.0677982433116498,0.142503867884044,321.370818987034
16916,1022:1190,Breast,HCC1395,SIDM00884,749712,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.239140392294725,0.0832647416017771,0.848284776761441,12.6530757696746,125.8014,0.917937960501919,0.965419450206001,0.0256278488460451,0.202859154292374,0.183202232307301,0.0196569219850733,11.5178804463681,57.274,1.1351953233065,68.5274,0.219516043976648,0.237935112177073,0.23087078605122,0.225755374396894,-0.0184190682004241,0.0051154116543265,True,0.694918836741811,0.0830058374282289,0.348259380045647,138.939630838179
16916,1005:1190,Breast,HCC1395,SIDM00884,749712,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.758254616377933,0.0832647416017771,0.848284776761441,12.6530757696746,125.8014,0.917937960501919,0.965419450206001,0.0510737114225471,0.643215847982487,0.0687003849286597,0.574515463053827,4.10515951722647,0.3361,8.5479162524481,125.4653,0.696030696099125,0.360988251587623,0.732033754859747,0.385719548458471,0.335042444511502,0.346314206401276,True,0.694918836741811,0.0830058374282289,0.348259380045647,138.939630838179
16919,1049:1549,Breast,HCC1395,SIDM00884,749712,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.560068316024163,0.0962343840250969,0.840940875525046,12.5342946996473,57.9294,0.915233627615453,0.963593634851575,0.0768994338971124,0.470984340031198,0.307187417558294,0.163796922472904,9.41288788874981,6.6567,3.12140681089747,51.2727,0.512593356587273,0.456094748061601,0.539678264402924,0.489552451925977,0.0564986085256713,0.0501258124769476,True,0.694918836741811,0.0830058374282289,0.348259380045647,138.939630838179
16919,1021:1549,Breast,HCC1395,SIDM00884,749712,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.816216790495037,0.0962343840250969,0.840940875525046,12.5342946996473,57.9294,0.915233627615453,0.963593634851575,0.0983747190041992,0.68639006241714,0.63576332961957,0.0506267327975696,11.672835092229,31.8841,0.861459607418325,26.0453,0.747029054085415,0.719271450419532,0.78650130398,0.773375415067564,0.0277576036658833,0.0131258889124352,True,0.694918836741811,0.0830058374282289,0.348259380045647,138.939630838179
14989,1179:1005,Breast,COLO-824,SIDM00954,906812,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.230932294582764,0.0793459248232825,0.87133588454749,12.9131331381913,60.2602,0.946424860427485,0.972051999604962,0.0344222155449234,0.201219595170855,0.132341729334462,0.0688778658363924,9.60228952812999,6.0725,3.31084361006133,54.1877,0.218560064668692,0.194437945378905,0.224478198722538,0.204894975467711,0.024122119289787,0.0195832232548275,True,0.416264290666616,0.0583336833950407,0.858240951911148,57.6385354725307
14989,1011:1005,Breast,COLO-824,SIDM00954,906812,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.110084375701999,0.0793459248232825,0.87133588454749,12.9131331381913,60.2602,0.946424860427485,0.972051999604962,0.0291063611511814,0.0959204668771597,0.0621844731109286,0.0337359937662312,9.53392097258176,5.7914,3.37921216560957,54.4688,0.104186589909011,0.0837576135163713,0.107007737526392,0.097352377540031,0.0204289763926402,0.0096553599863612,True,0.416264290666616,0.0583336833950407,0.858240951911148,57.6385354725307
14991,1011:1021,Breast,COLO-824,SIDM00954,906812,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.137114388264169,0.0692058603780359,0.481857354975116,8.85147440305354,9.0217,0.848947850081698,0.852290045186461,0.0432031389606786,0.0660695764580037,0.04124605349115,0.0248235229668538,7.27458307746752,3.0241,1.57689132558603,5.9976,0.116402965132134,0.0666374708320035,0.116861228169383,0.103906027451964,0.0497654943001304,0.012955200717419,True,0.416264290666616,0.0583336833950407,0.858240951911148,57.6385354725307
14991,1190:1022,Breast,COLO-824,SIDM00954,906812,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.01,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.843082372189447,0.138197801530832,0.501002168843264,9.0082007103352,1.0057,0.818575073802251,0.860139416296283,0.0571111702746406,0.422386096980436,0.311551346500391,0.110834750480046,7.90717208584489,0.4688,1.10102862449031,0.5369,0.690126215036353,0.670550143716823,0.725168379504716,0.673588874016127,0.0195760713195304,0.0515795054885889,True,0.416264290666616,0.0583336833950407,0.858240951911148,57.6385354725307
14992,1011:1049,Breast,COLO-824,SIDM00954,906812,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.321328813029092,0.12886230503302,0.69627811897489,10.6972194056741,32.4275,0.86710908218035,0.926614323238453,0.0403706177506897,0.22373422150833,0.0964545807312303,0.1272796407771,7.26834614458328,3.0111,3.4288732610908,29.4164,0.278627132143757,0.210763432091633,0.297747880621967,0.243367984421243,0.0678637000521241,0.0543798962007241,True,0.416264290666616,0.0583336833950407,0.858240951911148,57.6385354725307
15940,1179:1190,Breast,COLO-824,SIDM00954,906812,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.358076631372845,0.162452737641856,0.644847102743634,10.2202107721634,23.2981,0.802186329181649,0.9110920751715,0.0750417633410536,0.230904678300979,0.0635532262987941,0.167351452002185,5.86290031151363,1.1367,4.35731046064981,22.1614,0.287244178486713,0.184705542519782,0.326240781147906,0.233945868187203,0.10253863596693,0.0922949129607027,True,0.516993645390728,0.0654517838992969,0.646325689503053,76.3944339921565
15940,1011:1190,Breast,COLO-824,SIDM00954,906812,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.162529600849215,0.162452737641856,0.644847102743634,10.2202107721634,23.2981,0.802186329181649,0.9110920751715,0.0761873384020996,0.104806742217695,0.0215620082762831,0.0832447339414121,5.15892828162166,0.6978,5.06128249054178,22.6003,0.13037902388859,0.0276272505681115,0.148079431314507,0.0969672809797973,0.102751773320479,0.0511121503347093,True,0.516993645390728,0.0654517838992969,0.646325689503053,76.3944339921565
15182,1083:1372,Breast,COLO-824,SIDM00954,906812,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.777652947683145,0.0916999473613258,0.825109966008777,12.1736745387088,9.0234,0.911564918879673,0.960999480588129,0.120365075282958,0.641649197229465,0.347965990935347,0.293683206294118,8.56844710225838,0.7415,3.60522743645045,8.2819,0.708881146171324,0.561258754371658,0.747324078801329,0.65119211274839,0.147622391799667,0.0961319660529393,True,0.92594235044823,0.1134648770623,0.0658912910840268,655.553106639892
15182,1012:1372,Breast,COLO-824,SIDM00954,906812,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.941061954909031,0.0916999473613258,0.825109966008777,12.1736745387088,9.0234,0.911564918879673,0.960999480588129,0.0832856857474682,0.776479597627144,0.691580805021638,0.0848987926055063,11.0858275398787,4.2452,1.08784699883017,4.7782,0.857839064587398,0.849334284890434,0.904360049868828,0.882283835336929,0.0085047796969635,0.0220762145318989,True,0.92594235044823,0.1134648770623,0.0658912910840268,655.553106639892
15182,1049:1372,Breast,COLO-824,SIDM00954,906812,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.76002151112086,0.0916999473613258,0.825109966008777,12.1736745387088,9.0234,0.911564918879673,0.960999480588129,0.103473811477681,0.627101323206872,0.321219302188186,0.305882021018686,8.36188382682269,0.6426,3.81179071188614,8.3808,0.692808947131694,0.547502200517915,0.730380277422951,0.627710381058665,0.145306746613779,0.102669896364287,True,0.92594235044823,0.1134648770623,0.0658912910840268,655.553106639892
15182,1058:1372,Breast,COLO-824,SIDM00954,906812,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.833047925170008,0.0916999473613258,0.825109966008777,12.1736745387088,9.0234,0.911564918879673,0.960999480588129,0.106871165551097,0.687356145220707,0.463848165089366,0.223507980131342,9.46687711992672,1.3821,2.70679741878211,7.6413,0.759377264330478,0.659609903707914,0.800558623393396,0.734280389361239,0.0997673606225645,0.0662782340321567,True,0.92594235044823,0.1134648770623,0.0658912910840268,655.553106639892
15182,1559:1372,Breast,COLO-824,SIDM00954,906812,1559,Luminespib,HSP90,Protein stability and degradation,Targeted,Early clinical trials,0.01,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.81220265841265,0.0916999473613258,0.825109966008777,12.1736745387088,9.0234,0.911564918879673,0.960999480588129,0.164692759123354,0.6701565078751,0.319762658331926,0.350393849543175,8.11666344843904,0.5421,4.05701109026979,8.4813,0.740375450429782,0.532368550801954,0.780526332866854,0.659234396665225,0.208006899627828,0.121291936201629,True,0.92594235044823,0.1134648770623,0.0658912910840268,655.553106639892
15182,1191:1372,Breast,COLO-824,SIDM00954,906812,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.000625,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.922335755945821,0.0916999473613258,0.825109966008777,12.1736745387088,9.0234,0.911564918879673,0.960999480588129,0.0319763404166981,0.761028424237136,0.803546947085384,-0.0425185228482479,12.9108135368488,15.0408,-0.737138998139965,-6.0174,0.840768918548574,0.911016802277874,0.886364182391793,0.896531013122671,-0.0702478837292999,-0.0101668307308779,True,0.92594235044823,0.1134648770623,0.0658912910840268,655.553106639892
15182,1011:1372,Breast,COLO-824,SIDM00954,906812,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.101527688871154,0.0916999473613258,0.825109966008777,12.1736745387088,9.0234,0.911564918879673,0.960999480588129,0.0490793796690224,0.0837715079134275,0.050864540792271,0.0329069671211565,9.00811595855797,1.0056,3.16555858015086,8.0178,0.0925490794698741,0.0381294220427832,0.097568056270492,0.0873275440784161,0.0544196574270909,0.0102405121920759,True,0.92594235044823,0.1134648770623,0.0658912910840268,655.553106639892
15182,1558:1372,Breast,COLO-824,SIDM00954,906812,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.800769720064806,0.0916999473613258,0.825109966008777,12.1736745387088,9.0234,0.911564918879673,0.960999480588129,0.0667070749111615,0.66072307650353,0.41967601077499,0.24104706572854,9.19728628276916,1.1465,2.97638825593967,7.8769,0.729953584912174,0.661411075952806,0.76953928505298,0.696046495124047,0.0685425089593679,0.0734927899289326,True,0.92594235044823,0.1134648770623,0.0658912910840268,655.553106639892
15182,1179:1372,Breast,COLO-824,SIDM00954,906812,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.722546065564946,0.0916999473613258,0.825109966008777,12.1736745387088,9.0234,0.911564918879673,0.960999480588129,0.106302793400049,0.596179959598068,0.447392598722662,0.148787360875406,9.99444856790379,1.9923,2.17922597080504,7.0311,0.658647645643537,0.560705611263821,0.694366393708909,0.652375615369294,0.0979420343797158,0.0419907783396153,True,0.92594235044823,0.1134648770623,0.0658912910840268,655.553106639892
15182,1510:1372,Breast,COLO-824,SIDM00954,906812,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.601465344022514,0.0916999473613258,0.825109966008777,12.1736745387088,9.0234,0.911564918879673,0.960999480588129,0.0495112869717405,0.496275049561874,0.425728442761921,0.0705466067999531,10.8100969417989,3.5067,1.36357759690988,5.5167,0.548274707532818,0.540343030606595,0.578007883197396,0.559327466830358,0.0079316769262226,0.0186804163670374,True,0.92594235044823,0.1134648770623,0.0658912910840268,655.553106639892
15182,1053:1372,Breast,COLO-824,SIDM00954,906812,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.826248874469519,0.0916999473613258,0.825109966008777,12.1736745387088,9.0234,0.911564918879673,0.960999480588129,0.140357262671875,0.681746180728335,0.447586323894806,0.234159856833529,9.34209644480412,1.2676,2.83157809390471,7.7558,0.753179488230229,0.603937202285658,0.794024739201734,0.72370375079349,0.149242285944571,0.0703209884082442,True,0.92594235044823,0.1134648770623,0.0658912910840268,655.553106639892
15182,1022:1372,Breast,COLO-824,SIDM00954,906812,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.881587547001875,0.0916999473613258,0.825109966008777,12.1736745387088,9.0234,0.911564918879673,0.960999480588129,0.0546890377585521,0.727406670940478,0.675311190935134,0.0520954800053441,11.4261568454182,5.3746,0.747517693290602,3.6488,0.803624280768094,0.799467923234209,0.847205174761764,0.83392981323804,0.0041563575338848,0.0132753615237242,True,0.92594235044823,0.1134648770623,0.0658912910840268,655.553106639892
15184,1011:1549,Breast,COLO-824,SIDM00954,906812,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.203831047834353,0.104528899331708,0.890319512594862,13.283793526625,97.3913,0.913806854619326,0.97642346977885,0.0770924618136429,0.181474759159581,0.0885875597991048,0.0928871993604764,8.46185689257698,3.4433,4.82193663404803,93.948,0.186262208695272,0.0936800642988534,0.199025418975078,0.169490438294823,0.0925821443964181,0.0295349806802542,True,0.92594235044823,0.1134648770623,0.0658912910840268,655.553106639892
15184,1054:1549,Breast,COLO-824,SIDM00954,906812,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,1.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.966491602112128,0.104528899331708,0.890319512594862,13.283793526625,97.3913,0.913806854619326,0.97642346977885,0.0998839544316949,0.860486332119497,0.786079737887764,0.0744065942317329,12.0109495719382,40.3047,1.27284395468685,57.0866,0.883186650942076,0.852590456650527,0.943705083646443,0.925981668196422,0.0305961942915497,0.017723415450021,True,0.92594235044823,0.1134648770623,0.0658912910840268,655.553106639892
15185,1011:1558,Breast,COLO-824,SIDM00954,906812,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.0986498311633639,0.17507237385281,0.395465958270997,8.13180257740266,5.4783,0.818907210294227,0.812561694416585,0.0505876568235007,0.0390126500142918,0.021543187386534,0.0174694626277577,6.39141854862535,1.6396,1.74038402877732,3.8387,0.0807850580339868,0.016994915012337,0.080159073964013,0.0684808881336418,0.0637901430216499,0.0116781858303712,True,0.92594235044823,0.1134648770623,0.0658912910840268,655.553106639892
15186,1372:1561,Breast,COLO-824,SIDM00954,906812,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.901728541544577,0.156728091815081,0.471446546103332,8.76609396978377,8.5033,0.724536644713229,0.847891724218391,0.136037221239911,0.425116806433986,0.179045607226366,0.24607119920762,6.14552041678608,1.3827,2.62057355299768,7.1206,0.653335371932862,0.522672919020275,0.764568167867167,0.609027516561739,0.130662452912587,0.155540651305428,True,0.92594235044823,0.1134648770623,0.0658912910840268,655.553106639892
18113,1011:1007,Breast,UACC-812,SIDM01187,910910,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1007,Docetaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.0125,0.957858374408995,0.0548091087036485,0.636739335750589,10.3071938436272,0.0309,0.880376636905156,0.896672492857716,0.0910586120591434,0.609906105064322,0.306655132805088,0.303250972259234,7.2459453810842,0.0037,3.06124846254296,0.0272,0.84327613429363,0.71006283355242,0.858885256385952,0.710135007979677,0.13321330074121,0.148750248406276,True,0.889992549414813,0.106887110580996,0.104046112539975,433.310474375846
18114,1558:1011,Breast,UACC-812,SIDM01187,910910,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.530812266379988,0.173470746555833,0.447566870208465,8.50970554045911,7.1188,0.847698024572825,0.816648896848215,0.0605075655146596,0.237573984731953,0.117327544312844,0.12024644041911,6.06612337081684,1.3086,2.44358216964227,5.8102,0.44996850962934,0.321040791495723,0.433487251772718,0.350008451827571,0.128927718133617,0.0834787999451467,True,0.889992549414813,0.106887110580996,0.104046112539975,433.310474375846
18114,1561:1011,Breast,UACC-812,SIDM01187,910910,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.808919594611042,0.173470746555833,0.447566870208465,8.50970554045911,7.1188,0.847698024572825,0.816648896848215,0.130744097124833,0.362045611210365,0.28924306331204,0.0728025478983245,7.63527815464088,3.8831,0.874427385818224,3.2357,0.685719542390031,0.678427814882964,0.660603294578012,0.619723141961224,0.0072917275070665,0.0408801526167882,True,0.889992549414813,0.106887110580996,0.104046112539975,433.310474375846
18115,1011:1021,Breast,UACC-812,SIDM01187,910910,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.907760203473727,0.065394550466273,0.674855010785898,10.7007845160145,32.5078,0.92331245244571,0.909933261629142,0.0940002566583653,0.61260652190627,0.333522923235812,0.279083598670458,7.73451744044552,4.1596,2.96626707556901,28.3482,0.838146299701943,0.678760243815714,0.826001202723982,0.700977928224951,0.159386055886229,0.12502327449903,True,0.889992549414813,0.106887110580996,0.104046112539975,433.310474375846
18115,1073:1022,Breast,UACC-812,SIDM01187,910910,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,10.0,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.569480742330097,0.0448182680064879,0.936712422432786,15.2762462432451,77.5065,0.983999720420645,0.984987284788689,0.0666597576909694,0.533439685676846,0.483324944749101,0.0501147409277454,13.0166394205934,16.1856,2.25960682265169,61.3209,0.560368891237757,0.512122609619969,0.560931290127169,0.548045751349889,0.0482462816177875,0.0128855387772805,True,0.889992549414813,0.106887110580996,0.104046112539975,433.310474375846
18115,1559:1022,Breast,UACC-812,SIDM01187,910910,1559,Luminespib,HSP90,Protein stability and degradation,Targeted,Early clinical trials,0.01,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.75880497651252,0.0448182680064879,0.936712422432786,15.2762462432451,77.5065,0.983999720420645,0.984987284788689,0.0988043497617869,0.710782047703096,0.430210414393011,0.280571633310085,9.62758046902033,1.545,5.64866577422481,75.9615,0.746663884742113,0.586387900405953,0.747413253499212,0.660347351386717,0.16027598433616,0.0870659021124948,True,0.889992549414813,0.106887110580996,0.104046112539975,433.310474375846
18115,1179:1022,Breast,UACC-812,SIDM01187,910910,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.936064291993429,0.0448182680064879,0.936712422432786,15.2762462432451,77.5065,0.983999720420645,0.984987284788689,0.0916806005461154,0.876823050505996,0.531008928264727,0.345814122241269,9.63062068818835,1.5482,5.64562555505678,75.9583,0.921087001617283,0.843500896436489,0.922011425358254,0.814726899954802,0.077586105180794,0.107284525403453,True,0.889992549414813,0.106887110580996,0.104046112539975,433.310474375846
18116,1011:1047,Breast,UACC-812,SIDM01187,910910,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.942472949545485,0.0623765202463752,0.565842500447718,9.61700308730691,15.3369,0.849116967997553,0.869798778371714,0.085978480386075,0.533291250375153,0.209449980033728,0.323841270341425,6.08233155078519,1.3234,3.53467153652172,14.0135,0.800269773337773,0.570983341273547,0.819761820163049,0.622569503568769,0.229286432064226,0.19719231659428,True,0.889992549414813,0.106887110580996,0.104046112539975,433.310474375846
18116,1054:1049,Breast,UACC-812,SIDM01187,910910,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,1.0,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.896855734059133,0.120160878808387,0.75434471298321,11.6130851273147,61.1811,0.95472192235617,0.93537438987796,0.135455327936431,0.676538381296183,0.432227377168179,0.244311004128005,8.83163717442507,8.8985,2.78144795288964,52.2826,0.85624783049709,0.703092267787646,0.838895885054112,0.747423555227091,0.153155562709444,0.0914723298270208,True,0.889992549414813,0.106887110580996,0.104046112539975,433.310474375846
18116,1558:1049,Breast,UACC-812,SIDM01187,910910,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.504946673460378,0.120160878808387,0.75434471298321,11.6130851273147,61.1811,0.95472192235617,0.93537438987796,0.0764633095029289,0.380903853463296,0.333930562916346,0.04697329054695,10.5585886681581,29.4566,1.05449645915663,31.7245,0.482083658773446,0.40591502826072,0.472314186608907,0.457133148773098,0.0761686305127255,0.0151810378358092,True,0.889992549414813,0.106887110580996,0.104046112539975,433.310474375846
18116,1058:1049,Breast,UACC-812,SIDM01187,910910,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.66789065535987,0.120160878808387,0.75434471298321,11.6130851273147,61.1811,0.95472192235617,0.93537438987796,0.128919161968615,0.503819784721609,0.287820914887275,0.215998869834335,8.3524670617363,6.3837,3.26061806557841,54.7974,0.637649850408897,0.483574345358889,0.624727814262429,0.539723199786393,0.154075505050008,0.085004614476036,True,0.889992549414813,0.106887110580996,0.104046112539975,433.310474375846
18116,1559:1049,Breast,UACC-812,SIDM01187,910910,1559,Luminespib,HSP90,Protein stability and degradation,Targeted,Early clinical trials,0.01,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.626916645823084,0.120160878808387,0.75434471298321,11.6130851273147,61.1811,0.95472192235617,0.93537438987796,0.151024573126158,0.472911257257811,0.2808230223975,0.192088234860311,8.51324991822258,7.1363,3.09983520909214,54.0448,0.598531065257297,0.406275385999318,0.586401775091105,0.512089816768424,0.19225567925798,0.0743119583226802,True,0.889992549414813,0.106887110580996,0.104046112539975,433.310474375846
18117,1191:1053,Breast,UACC-812,SIDM01187,910910,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.0025,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.90918810874211,0.101524715053144,0.308144627281433,7.11619095044769,2.7097,0.706469224660999,0.732854133484483,0.130763854902702,0.280161430897049,0.0767695591131452,0.203391871783903,3.44848248089415,0.2132,3.66770846955354,2.4965,0.642313418254038,0.394005714347472,0.666302263606595,0.41501380732307,0.248307703906566,0.251288456283525,True,0.889992549414813,0.106887110580996,0.104046112539975,433.310474375846
18117,1012:1053,Breast,UACC-812,SIDM01187,910910,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.650663953024719,0.101524715053144,0.308144627281433,7.11619095044769,2.7097,0.706469224660999,0.732854133484483,0.112108269037305,0.200498601290266,0.0657470671701976,0.134751534120068,3.90935096934217,0.2935,3.20683998110552,2.4162,0.459674058408234,0.286304849004369,0.476841767483519,0.32066832946137,0.173369209403865,0.156173438022149,True,0.889992549414813,0.106887110580996,0.104046112539975,433.310474375846
18117,1011:1053,Breast,UACC-812,SIDM01187,910910,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.933363404854636,0.101524715053144,0.308144627281433,7.11619095044769,2.7097,0.706469224660999,0.732854133484483,0.163999184524531,0.287610918507061,0.0375098468649654,0.250101071642096,1.60930259902733,0.0596,5.50688835142036,2.6501,0.659392520954604,0.323153823794916,0.684019229290871,0.295996555216085,0.336238697159688,0.388022674074786,True,0.889992549414813,0.106887110580996,0.104046112539975,433.310474375846
18117,1058:1054,Breast,UACC-812,SIDM01187,910910,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.863778261020426,0.0885488242668098,0.782689916125494,11.9845589193216,31.6593,0.909852021949556,0.943813757390106,0.198663139716807,0.676070534669102,0.336185762925629,0.339884771743473,7.95035864147006,1.9324,4.03420027785157,29.7269,0.785910397305506,0.536036315628109,0.81524580608558,0.678196823247896,0.249874081677397,0.137048982837684,True,0.889992549414813,0.106887110580996,0.104046112539975,433.310474375846
18117,1559:1054,Breast,UACC-812,SIDM01187,910910,1559,Luminespib,HSP90,Protein stability and degradation,Targeted,Early clinical trials,0.01,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.544474630993424,0.0885488242668098,0.782689916125494,11.9845589193216,31.6593,0.909852021949556,0.943813757390106,0.135365455139996,0.426154803264702,0.265785312712946,0.160369490551757,8.88957947037779,3.7053,3.09497944894384,27.954,0.495391343909605,0.362070390112575,0.513882647281495,0.455334937028766,0.13332095379703,0.0585477102527291,True,0.889992549414813,0.106887110580996,0.104046112539975,433.310474375846
18118,1191:1058,Breast,UACC-812,SIDM01187,910910,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.0025,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.870233920980039,0.0968547667184357,0.242813524522416,6.35105660947342,0.6377,0.688497613798397,0.68003634023029,0.12306557773264,0.211304565512125,0.0512241150867612,0.160080450425363,2.5439495761983,0.0456,3.80710703327512,0.5921,0.59915397804118,0.331573496555379,0.591790690767521,0.336143203694469,0.267580481485801,0.255647487073052,True,0.889992549414813,0.106887110580996,0.104046112539975,433.310474375846
18118,1011:1058,Breast,UACC-812,SIDM01187,910910,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.955764234345367,0.0968547667184357,0.242813524522416,6.35105660947342,0.6377,0.688497613798397,0.68003634023029,0.0796117514508795,0.232072482353867,0.0206975901113482,0.211374892242518,0.124659389828722,0.0085,6.2263972196447,0.6292,0.658041394700637,0.2246042350725,0.649954412047229,0.209598400229805,0.433437159628137,0.440356011817424,True,0.889992549414813,0.106887110580996,0.104046112539975,433.310474375846
18118,1058:1073,Breast,UACC-812,SIDM01187,910910,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,20.0,0.916384831943145,0.128361167786737,0.418643744747146,8.23524918837804,11.7711,0.760680123096097,0.801571454045477,0.198603414747215,0.383638777674163,0.0618082559903829,0.32183052168378,2.88240887545388,0.288,5.35284031292416,11.4831,0.697075726765908,0.376118225667004,0.734547922205887,0.377792062653217,0.320957501098904,0.35675585955267,True,0.889992549414813,0.106887110580996,0.104046112539975,433.310474375846
18118,1559:1073,Breast,UACC-812,SIDM01187,910910,1559,Luminespib,HSP90,Protein stability and degradation,Targeted,Early clinical trials,0.01,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,20.0,0.567065847815535,0.128361167786737,0.418643744747146,8.23524918837804,11.7711,0.760680123096097,0.801571454045477,0.157159348163442,0.237398570047711,0.12242684139302,0.114971728654691,5.99602138539073,2.4931,2.2392278029873,9.278,0.431355718919914,0.285471938877358,0.45454379617303,0.370991808420737,0.145883780042556,0.0835519877522929,True,0.889992549414813,0.106887110580996,0.104046112539975,433.310474375846
17744,1049:1083,Breast,UACC-812,SIDM01187,910910,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.982957288703319,0.102029906813588,0.736548380226209,11.3945789034826,52.5824,0.941586512772855,0.92991514537718,0.116583081432711,0.723995598825976,0.681250155631808,0.0427454431941678,10.8970037222873,37.2439,0.497575181195327,15.3385,0.925539325674818,0.940067357603362,0.914066870024106,0.900399327708386,-0.0145280319285434,0.0136675423157202,True,0.886992079529511,0.0949916432117754,0.104887287626076,422.108145690102
17746,1012:1372,Breast,UACC-812,SIDM01187,910910,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.902850265990181,0.100549914792418,0.830289414727201,12.6978945357161,12.9771,0.888066340275973,0.957332116666162,0.109266938641383,0.749627018935285,0.577133048608333,0.172493970326952,10.3323565866975,2.5181,2.36553794901864,10.459,0.801790931535089,0.720411635190022,0.864327556172987,0.810365954999066,0.0813792963450669,0.0539616011739206,True,0.886992079529511,0.0949916432117754,0.104887287626076,422.108145690102
17748,1011:1510,Breast,UACC-812,SIDM01187,910910,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.880069204764945,0.054574217820575,0.938306750386608,15.3396335418327,809.8785,0.973269372222453,0.985377609670565,0.194800157375851,0.825774875638322,0.485775293971919,0.339999581666403,9.48596957598695,14.0053,5.85366396584577,795.8732,0.856544402433891,0.63173142458871,0.867200489335957,0.760519581595388,0.224812977845182,0.106680907740569,True,0.886992079529511,0.0949916432117754,0.104887287626076,422.108145690102
17750,1011:1561,Breast,UACC-812,SIDM01187,910910,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.841242970015571,0.103864953499225,0.273493697026343,6.72452429246643,2.0654,0.66612413942607,0.706335465302069,0.0925491611741777,0.23007464996698,0.0694215755997808,0.160653074367199,3.39018865014216,0.2048,3.33433564232427,1.8606,0.560372249449853,0.360748492672057,0.594199744658042,0.380144053888655,0.199623756777797,0.214055690769388,True,0.886992079529511,0.0949916432117754,0.104887287626076,422.108145690102
17750,1011:1594,Breast,UACC-812,SIDM01187,910910,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.841242970015571,0.0655616496016224,0.698826470293689,10.9604560456544,15.5674,0.917437526556707,0.917902268417998,0.0374185605653056,0.587882855395361,0.373675084841732,0.214207770553629,8.4779096998812,2.7854,2.48254634577322,12.782,0.771787869644303,0.69857242984589,0.772178830467987,0.685562623600939,0.0732154397984128,0.0866162068670479,True,0.886992079529511,0.0949916432117754,0.104887287626076,422.108145690102
17750,1558:1594,Breast,UACC-812,SIDM01187,910910,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.570900270656393,0.0655616496016224,0.698826470293689,10.9604560456544,15.5674,0.917437526556707,0.917902268417998,0.0784240246814466,0.398960221032519,0.198565227807495,0.200394993225024,7.53573797591474,1.4497,3.42471806973969,14.1177,0.523765332221556,0.389608306505272,0.524030653475952,0.433834057667889,0.134157025716284,0.0901965958080634,True,0.886992079529511,0.0949916432117754,0.104887287626076,422.108145690102
17750,1549:1594,Breast,UACC-812,SIDM01187,910910,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.759147052085985,0.0655616496016224,0.698826470293689,10.9604560456544,15.5674,0.917437526556707,0.917902268417998,0.0826653815585286,0.530512054843108,0.39293052255489,0.137581532288218,9.16398867541464,4.4815,1.79646737023979,11.0859,0.696469993758582,0.606143749832064,0.696822801172562,0.644940169873295,0.0903262439265179,0.0518826312992667,True,0.886992079529511,0.0949916432117754,0.104887287626076,422.108145690102
17750,1510:1594,Breast,UACC-812,SIDM01187,910910,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.947819742751186,0.0655616496016224,0.698826470293689,10.9604560456544,15.5674,0.917437526556707,0.917902268417998,0.0540468736980343,0.662361525301484,0.352702377762288,0.309659147539196,7.78155872684247,1.719,3.17889731881195,13.8484,0.869565400411262,0.709313758753751,0.870005891922678,0.734620727323654,0.160251641657511,0.135385164599024,True,0.886992079529511,0.0949916432117754,0.104887287626076,422.108145690102
18291,1021:1011,Breast,MCF7,SIDM00148,905946,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.875849905810844,0.120548440720718,0.329476297869696,7.45884378947093,3.4361,0.772048428968422,0.76353896631992,0.131400913509548,0.288571784456079,0.277363725792307,0.0112080586637725,7.33191896737787,3.1467,0.126924822093056,0.2894,0.676198543793402,0.596137607489259,0.668745531734211,0.661447150076693,0.0800609363041433,0.0072983816575182,True,0.350628263852705,0.0515394924053418,0.972163356290435,49.9353619849959
18292,1011:1021,Breast,MCF7,SIDM00148,905946,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.805342697898786,0.0907651192101595,0.553180290418293,9.46313289340098,13.7853,0.85016813159932,0.873318394209136,0.0524282597791019,0.445499707509902,0.244248112018115,0.201251595491787,7.1960750658227,2.8639,2.26705782757828,10.9214,0.684676696769766,0.609151541921778,0.703320591717021,0.600887588235535,0.0755251548479881,0.102433003481486,True,0.350628263852705,0.0515394924053418,0.972163356290435,49.9353619849959
18294,1054:1053,Breast,MCF7,SIDM00148,905946,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,1.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.883805733623088,0.110172502219912,0.496439999558418,8.96911365156234,9.7882,0.775398354802027,0.850287480943907,0.130349818334264,0.438756518009573,0.243263508346161,0.195493009663412,6.90008985050365,2.3327,2.06902380105869,7.4555,0.685301511815941,0.562764428199279,0.751488950886157,0.641460174731903,0.122537083616663,0.110028776154254,True,0.350628263852705,0.0515394924053418,0.972163356290435,49.9353619849959
18294,1558:1053,Breast,MCF7,SIDM00148,905946,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.924379017072381,0.110172502219912,0.496439999558418,8.96911365156234,9.7882,0.775398354802027,0.850287480943907,0.102781046553129,0.458898718827224,0.32561814128205,0.133280577545173,7.67881346583343,4.0021,1.29030018572891,5.7861,0.71676196905144,0.705683156390906,0.78598790586388,0.718819148203673,0.0110788126605337,0.0671687576602064,True,0.350628263852705,0.0515394924053418,0.972163356290435,49.9353619849959
18294,1011:1053,Breast,MCF7,SIDM00148,905946,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.874993179015602,0.110172502219912,0.496439999558418,8.96911365156234,9.7882,0.775398354802027,0.850287480943907,0.105436633832038,0.434381613404124,0.224834961872638,0.209546651531486,6.6969042524462,2.0263,2.27220939911615,7.7619,0.678468271471693,0.559341891782939,0.743995746028277,0.622490278358884,0.119126379688755,0.121505467669393,True,0.350628263852705,0.0515394924053418,0.972163356290435,49.9353619849959
18294,1058:1054,Breast,MCF7,SIDM00148,905946,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.963537512608147,0.0737522529442339,0.798684274731689,11.9890086072775,31.7571,0.931731932422435,0.951787408626514,0.190275394571325,0.769562259434214,0.454367165540961,0.315195093893253,8.7530066296252,3.3706,3.23600197765229,28.3865,0.897758668583896,0.649032421682774,0.917082872239745,0.80875782366578,0.248726246901121,0.108325048573965,True,0.350628263852705,0.0515394924053418,0.972163356290435,49.9353619849959
18294,1561:1054,Breast,MCF7,SIDM00148,905946,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.741079926745809,0.0737522529442339,0.798684274731689,11.9890086072775,31.7571,0.931731932422435,0.951787408626514,0.0816406176908485,0.591888883811189,0.421167692900777,0.170721190910412,9.59642689472615,6.0479,2.39258171255133,25.7092,0.690487832226349,0.591578208273809,0.70535054306252,0.651461256464378,0.09890962395254,0.0538892865981415,True,0.350628263852705,0.0515394924053418,0.972163356290435,49.9353619849959
18294,1594:1054,Breast,MCF7,SIDM00148,905946,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.79587911669903,0.0737522529442339,0.798684274731689,11.9890086072775,31.7571,0.931731932422435,0.951787408626514,0.118353198453638,0.635656135094862,0.420359417776086,0.215296717318777,9.24465556264443,4.7392,2.74435304463306,27.0179,0.741545987376648,0.606711880578841,0.757507722062928,0.687215100775917,0.134834106797807,0.0702926212870115,True,0.350628263852705,0.0515394924053418,0.972163356290435,49.9353619849959
18294,1053:1054,Breast,MCF7,SIDM00148,905946,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.85693268792069,0.0737522529442339,0.798684274731689,11.9890086072775,31.7571,0.931731932422435,0.951787408626514,0.116632660370584,0.684418662345813,0.54489257233396,0.139526090011854,10.209095163036,9.2477,1.77991344424153,22.5094,0.798431549272296,0.682616904802619,0.815617742403387,0.773834477297696,0.115814644469677,0.0417832651056907,True,0.350628263852705,0.0515394924053418,0.972163356290435,49.9353619849959
18878,1011:1083,Breast,MCF7,SIDM00148,905946,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.337243953546803,0.0625660574863289,0.916655056219922,14.200581047495,367.7315,0.949275854708542,0.981321000013448,0.0541101472613678,0.309136375198274,0.142622777646623,0.166513597551651,8.32577863845958,6.2667,5.87480240903539,361.4648,0.32013754224843,0.244729858237109,0.330944573743038,0.27527999405754,0.0754076840113207,0.055664579685498,True,0.945997151039455,0.0827786566226168,0.0300811730583094,921.490072695551
18878,1011:1179,Breast,MCF7,SIDM00148,905946,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,10.0,0.337243953546803,0.0688526116375248,0.874144699564647,13.2036669277778,184.2595,0.95317975702308,0.971136000735681,0.0981812477696192,0.294800014453164,0.137141323621029,0.157658690832135,8.18053138561911,5.6665,5.02313554215864,178.593,0.321454109699245,0.180496940101989,0.327509744319732,0.272481100654613,0.140957169597256,0.0550286436651193,True,0.945997151039455,0.0827786566226168,0.0300811730583094,921.490072695551
18878,1510:1179,Breast,MCF7,SIDM00148,905946,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,10.0,0.922685809233944,0.0688526116375248,0.874144699564647,13.2036669277778,184.2595,0.95317975702308,0.971136000735681,0.0500233039888229,0.80656090950537,0.485741125334519,0.320819784170851,9.22962484007376,11.7253,3.97404208770399,172.5342,0.879485435454255,0.794193954631366,0.896053406715018,0.796065149912557,0.0852914808228895,0.099988256802461,True,0.945997151039455,0.0827786566226168,0.0300811730583094,921.490072695551
18197,1510:1549,Breast,MCF7,SIDM00148,905946,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.708070611221762,0.0679740642955194,0.889835604853881,13.5310694367982,115.6,0.954593250887942,0.974951274408766,0.116632857576753,0.630066440615774,0.419820084873991,0.210246355741783,9.81551643034568,8.7996,3.71555300645252,106.8004,0.675919426624394,0.529561444031292,0.690334344782051,0.628838558209942,0.146357982593102,0.061495786572109,True,0.18756449216252,0.0412732476444996,1.56103222293323,31.5237892745064
18199,1054:1561,Breast,MCF7,SIDM00148,905946,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.84669487370765,0.11620749451476,0.213128464184655,6.16698511768507,1.4034,0.619855819848228,0.67253313610085,0.183046942550527,0.180454778066332,0.0237261543890201,0.156728623677312,1.30817174801798,0.0484,4.85881336966709,1.355,0.524828745103347,0.297914861377017,0.569430358735118,0.244644074169964,0.226913883726329,0.324786284565154,True,0.18756449216252,0.0412732476444996,1.56103222293323,31.5237892745064
20573,1191:1047,Breast,BT-549,SIDM00122,905951,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.0025,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.897338614712283,0.0516841698949216,0.904159728568202,12.8474269029368,143.9431,0.968275633918166,0.982781833920238,0.0751705748783758,0.811337438312024,0.557213487142822,0.254123951169202,9.84623471684939,17.978,3.00119218608742,125.9651,0.868871115999785,0.780248118732553,0.881888089414383,0.824315621504907,0.0886229972672316,0.0575724679094755,True,0.602976036124412,0.0629630511061314,0.388783343819554,108.253571561522
20573,1022:1047,Breast,BT-549,SIDM00122,905951,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.594274014825759,0.0516841698949216,0.904159728568202,12.8474269029368,143.9431,0.968275633918166,0.982781833920238,0.0451282325248611,0.537318631939993,0.352094204296796,0.185224427643197,9.64151973569946,15.5997,3.20590716723736,128.3434,0.575421048426505,0.505319182499024,0.584041706141601,0.541152873487029,0.0701018659274811,0.0428888326545728,True,0.602976036124412,0.0629630511061314,0.388783343819554,108.253571561522
20573,1179:1047,Breast,BT-549,SIDM00122,905951,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.168577857612277,0.0516841698949216,0.904159728568202,12.8474269029368,143.9431,0.968275633918166,0.982781833920238,0.0574251262745873,0.152421309981326,0.0732751016765929,0.0791462083047327,8.54941895546454,7.3175,4.29800794747228,136.6256,0.163229831944094,0.0934439924013638,0.165675256062539,0.144609588391018,0.0697858395427304,0.0210656676715211,True,0.602976036124412,0.0629630511061314,0.388783343819554,108.253571561522
20573,1011:1047,Breast,BT-549,SIDM00122,905951,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.659328771254209,0.0516841698949216,0.904159728568202,12.8474269029368,143.9431,0.968275633918166,0.982781833920238,0.09318976688108,0.596138522854412,0.373175442113286,0.222963080741125,9.45518053610811,13.7095,3.39224636682871,130.2336,0.638411983946655,0.559881180524788,0.647976338969588,0.595249586190554,0.0785308034218669,0.0527267527790345,True,0.602976036124412,0.0629630511061314,0.388783343819554,108.253571561522
20575,1011:1073,Breast,BT-549,SIDM00122,905951,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,20.0,0.743230883682644,0.0926506752845954,0.684723881306031,10.3295486614213,50.2648,0.89556835754375,0.935303930514603,0.0502801764393001,0.508907935381691,0.287078385405453,0.221829549976238,8.20615920292893,11.5361,2.12338945849233,38.7287,0.665614061775456,0.615898086954115,0.695146766788218,0.622621950405732,0.049715974821341,0.0725248163824865,True,0.602976036124412,0.0629630511061314,0.388783343819554,108.253571561522
20575,1022:1073,Breast,BT-549,SIDM00122,905951,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,20.0,0.92145876433446,0.0926506752845954,0.684723881306031,10.3295486614213,50.2648,0.89556835754375,0.935303930514603,0.0810129345477188,0.630944821578551,0.232206391923345,0.398738429655206,7.134882172623,5.49,3.19466648879827,44.7748,0.825229312119306,0.719823374544148,0.86184400408915,0.705097752792046,0.105405937575159,0.156746251297103,True,0.602976036124412,0.0629630511061314,0.388783343819554,108.253571561522
20576,1022:1179,Breast,BT-549,SIDM00122,905951,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,10.0,0.919537203202128,0.0987604513190599,0.201956232793175,6.64436892698688,1.9538,0.743748997783731,0.727736177007632,0.0964255962574977,0.185706269471874,0.0886137454433523,0.097092524028522,5.16298292275582,0.6997,1.48138600423106,1.2541,0.683904873306438,0.550763703891979,0.669180488874607,0.555005713159788,0.133141169414459,0.114174775714819,True,0.602976036124412,0.0629630511061314,0.388783343819554,108.253571561522
20132,1022:1190,Breast,BT-549,SIDM00122,905951,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.901277638662766,0.0626314359262244,0.639485736115234,9.98251742698778,19.7591,0.901533639891349,0.923638294819893,0.116563279897274,0.576354194204459,0.427751564006573,0.148602630197885,8.82571743298044,8.8621,1.15679999400734,10.897,0.812532110136324,0.728985859653674,0.832454541333777,0.786629350719406,0.0835462504826496,0.0458251906143712,True,0.734777339760551,0.0851040454572893,0.263473235917942,168.306608577002
20132,1005:1190,Breast,BT-549,SIDM00122,905951,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.99170912091641,0.0626314359262244,0.639485736115234,9.98251742698778,19.7591,0.901533639891349,0.923638294819893,0.0368936462749846,0.634183837201422,0.407998832717529,0.226185004483893,8.38604237644313,6.534,1.59647505054465,13.2251,0.894059133493221,0.846284119614397,0.915980521400568,0.841424656741501,0.0477750138788242,0.0745558646590665,True,0.734777339760551,0.0851040454572893,0.263473235917942,168.306608577002
20132,1011:1190,Breast,BT-549,SIDM00122,905951,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.799338852358843,0.0626314359262244,0.639485736115234,9.98251742698778,19.7591,0.901533639891349,0.923638294819893,0.0872788341715922,0.511165794406201,0.277847127436708,0.233318666969493,7.92064293976627,4.7324,2.06187448722151,15.0267,0.720630865073641,0.621058911801802,0.738299974576012,0.655288349548077,0.09957195327184,0.0830116250279345,True,0.734777339760551,0.0851040454572893,0.263473235917942,168.306608577002
20577,1083:1372,Breast,BT-549,SIDM00122,905951,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.862647735405231,0.0495430992667939,0.806957527738512,11.4520572516598,5.472,0.938984380858873,0.963351170317562,0.0883304399351573,0.696120083871831,0.46140211975336,0.234717964118472,9.23948017808403,1.1806,2.21257707357578,4.2914,0.810012749728789,0.709055391624544,0.831032705474424,0.770488013389214,0.100957358104245,0.0605446920852095,True,0.602976036124412,0.0629630511061314,0.388783343819554,108.253571561522
20577,1561:1372,Breast,BT-549,SIDM00122,905951,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.878171361324445,0.0495430992667939,0.806957527738512,11.4520572516598,5.472,0.938984380858873,0.963351170317562,0.0942493261867427,0.708646990665138,0.634542524308067,0.0741044663570705,10.64102118941,3.1189,0.811036062249842,2.3531,0.824589192001227,0.77151995874739,0.845987408671271,0.829423052864099,0.0530692332538376,0.0165643558071719,True,0.602976036124412,0.0629630511061314,0.388783343819554,108.253571561522
20579,1011:1558,Breast,BT-549,SIDM00122,905951,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.828524845395076,0.115330587500642,0.515792175502107,9.10832568217838,10.7798,0.906110052183766,0.886975633655509,0.137871234696653,0.427346632463873,0.1943243581143,0.233022274349573,6.97227203126058,2.4524,2.1360536509178,8.3274,0.750734690896479,0.637249407413146,0.734881349743631,0.623910592063468,0.113485283483333,0.110970757680163,True,0.602976036124412,0.0629630511061314,0.388783343819554,108.253571561522
20580,1047:1561,Breast,BT-549,SIDM00122,905951,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.482893142499507,0.0994013522500998,0.526482445492769,9.1817647580272,11.3427,0.830506225614766,0.890472635728411,0.0796754948770743,0.254234762574829,0.0672286075550749,0.187006155019754,5.87693621896047,1.1478,3.30482853906673,10.1949,0.401045761152518,0.272570080943093,0.430003129376711,0.321157530607755,0.128475680209426,0.108845598768956,True,0.602976036124412,0.0629630511061314,0.388783343819554,108.253571561522
20580,1047:1594,Breast,BT-549,SIDM00122,905951,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.482893142499507,0.130028036375379,0.387073788937789,8.21206094741033,2.3167,0.804428635785179,0.838082709608443,0.0741791541444077,0.18691527831936,0.0620434181896651,0.124871860129695,5.71808689287255,0.4112,2.49397405453778,1.9055,0.388453071850896,0.262508222790957,0.404704393317322,0.314655889081436,0.125944849059939,0.0900485042358869,True,0.602976036124412,0.0629630511061314,0.388783343819554,108.253571561522
22535,1594:1049,Breast,HCC1143,SIDM00866,749710,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.964101214558535,0.0562144114998495,0.855148541965469,13.0622593999132,167.0559,0.948138189494584,0.964688763719776,0.0727531751843945,0.824449747936869,0.726243319267539,0.09820642866933,11.5537436657874,58.7156,1.50851573412581,108.3403,0.914101180061059,0.871290721852709,0.930057608773207,0.902521529390202,0.0428104582083502,0.0275360793830055,True,0.547198197199656,0.0707303266507497,0.55368836934093,85.9064596474616
22535,1179:1049,Breast,HCC1143,SIDM00866,749710,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.392294172019208,0.0562144114998495,0.855148541965469,13.0622593999132,167.0559,0.948138189494584,0.964688763719776,0.0658585963048685,0.335469789223776,0.273638559484678,0.0618312297390982,10.9117021976338,37.6253,2.15055720227932,129.4306,0.371949086007568,0.305473818759051,0.378441779819682,0.360455853875339,0.0664752672485171,0.0179859259443432,True,0.547198197199656,0.0707303266507497,0.55368836934093,85.9064596474616
22535,1372:1049,Breast,HCC1143,SIDM00866,749710,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.879147225625228,0.0562144114998495,0.855148541965469,13.0622593999132,167.0559,0.948138189494584,0.964688763719776,0.0594467102385503,0.751801468166401,0.482525164538423,0.269276303627977,9.44853453199484,13.6465,3.61372486791833,153.4094,0.83355305880349,0.728153684905311,0.848103450216072,0.760560140945337,0.105399373898179,0.0875433092707348,True,0.547198197199656,0.0707303266507497,0.55368836934093,85.9064596474616
22535,1011:1049,Breast,HCC1143,SIDM00866,749710,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.713624493187249,0.0562144114998495,0.855148541965469,13.0622593999132,167.0559,0.948138189494584,0.964688763719776,0.0760177379709088,0.610254944859923,0.429888252498259,0.180366692361664,9.95056339953722,19.3263,3.11169600037594,147.7296,0.676614634949549,0.581416931552454,0.688425530092959,0.632231672373869,0.0951977033970945,0.0561938577190901,True,0.547198197199656,0.0707303266507497,0.55368836934093,85.9064596474616
22537,1022:1073,Breast,HCC1143,SIDM00866,749710,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,20.0,0.912827440769868,0.0635896312312667,0.825530191867069,12.5559721687255,235.2254,0.938374340376964,0.956745220128553,0.145455393073747,0.753566612320275,0.465102032450339,0.288464579869937,9.08711439352256,21.2449,3.46885777520299,213.9805,0.856573847610417,0.690705839453689,0.873343290758752,0.774532670639394,0.165868008156728,0.0988106201193579,True,0.547198197199656,0.0707303266507497,0.55368836934093,85.9064596474616
22539,1005:1190,Breast,HCC1143,SIDM00866,749710,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.974442125746217,0.133594949456211,0.638535199635092,10.3018239729159,24.654,0.807878201878344,0.899002438009114,0.0785783164559697,0.622215597296204,0.0647367033989983,0.557478893897205,2.95364277664407,0.1513,7.34818119627185,24.5027,0.787230552382365,0.382457719803691,0.876025846744632,0.406383960506769,0.404772832578674,0.469641886237863,True,0.547198197199656,0.0707303266507497,0.55368836934093,85.9064596474616
22540,1012:1372,Breast,HCC1143,SIDM00866,749710,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.867381671880672,0.095804563677992,0.534842299420461,9.31937578746172,1.2478,0.799993162930966,0.859330478424197,0.0658826315104261,0.463912407863822,0.378057239932738,0.0858551679310834,8.4097758570159,0.6642,0.909599930445825,0.5836,0.693899407156168,0.660498879565366,0.745367507073597,0.705806323490674,0.0334005275908024,0.0395611835829227,True,0.547198197199656,0.0707303266507497,0.55368836934093,85.9064596474616
22544,1012:1594,Breast,HCC1143,SIDM00866,749710,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.915008651391543,0.0447550188450055,0.686121602176234,10.7892244685058,13.8252,0.910160085720031,0.915135095735867,0.0255784156936043,0.627807201897881,0.57298071704609,0.0548264848517908,10.1804469510539,9.0659,0.608777517451893,4.7593,0.832804352585097,0.831928385088762,0.837356529790346,0.818593237785552,0.0008759674963345,0.0187632920047938,True,0.547198197199656,0.0707303266507497,0.55368836934093,85.9064596474616
22544,1021:1594,Breast,HCC1143,SIDM00866,749710,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.931584574428972,0.0447550188450055,0.686121602176234,10.7892244685058,13.8252,0.910160085720031,0.915135095735867,0.0592695095361224,0.639180300769872,0.647034308310903,-0.0078540075410311,10.8794583186058,14.7175,-0.0902338500999669,-0.892299999999999,0.847891096117732,0.815162173734518,0.852525738706114,0.855081299025313,0.0327289223832133,-0.0025555603191993,True,0.547198197199656,0.0707303266507497,0.55368836934093,85.9064596474616
22546,1022:1005,Breast,Hs-578-T,SIDM00135,905957,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.376215343600172,0.0779212284440683,0.902410704350084,14.432656581052,172.7637,0.948771020856415,0.975359816328993,0.11541676277561,0.33950075320554,0.183473614222756,0.156027138982784,8.87963747055019,3.6798,5.55301911050177,169.0839,0.356942215609382,0.249268692481873,0.366945328434013,0.311826923096917,0.107673523127509,0.0551184053370954,True,0.318718779162082,0.0714583106679093,1.05410383529536,46.0624684467724
22546,1179:1005,Breast,Hs-578-T,SIDM00135,905957,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.292046000919708,0.0779212284440683,0.902410704350084,14.432656581052,172.7637,0.948771020856415,0.975359816328993,0.052175589200146,0.263545437392579,0.0907106956681958,0.172834741724383,7.05267547731332,1.0372,7.37998110373864,171.7265,0.277084782429625,0.176883470675093,0.284849933816663,0.211235938263526,0.100201311754532,0.073613995553137,True,0.318718779162082,0.0714583106679093,1.05410383529536,46.0624684467724
22546,1559:1005,Breast,Hs-578-T,SIDM00135,905957,1559,Luminespib,HSP90,Protein stability and degradation,Targeted,Early clinical trials,0.01,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.552708772733182,0.0779212284440683,0.902410704350084,14.432656581052,172.7637,0.948771020856415,0.975359816328993,0.101279594715386,0.498770312902621,0.323280629744503,0.175489683158119,9.83757772913559,7.1482,4.59507885191636,165.6155,0.524394066542357,0.436875282557952,0.53908992705646,0.481897411273088,0.0875187839844048,0.0571925157833719,True,0.318718779162082,0.0714583106679093,1.05410383529536,46.0624684467724
22555,1191:1017,Breast,Hs-578-T,SIDM00135,905957,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.000625,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.971889077980445,0.102348781396711,0.815023823129046,12.6220698742612,123.1265,0.931079914263482,0.950965612822474,0.159519011151018,0.792112751992986,0.798898707187789,-0.0067859551948021,12.7368824976279,133.3257,-0.114812623366722,-10.1992,0.904906399399648,0.852499062690162,0.924233092637143,0.926216920544757,0.0524073367094861,-0.0019838279076132,True,0.318718779162082,0.0714583106679093,1.05410383529536,46.0624684467724
22549,1058:1049,Breast,Hs-578-T,SIDM00135,905957,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.876862920246258,0.109241990906066,0.58552376126909,9.84383085128734,17.9481,0.852350737891486,0.872135121921867,0.122944432441997,0.513424075179987,0.214631725186473,0.298792349993515,6.248158795762,1.4846,3.59567205552533,16.4635,0.747394757101582,0.535457722006339,0.764742949857735,0.586179810257336,0.211937035095243,0.178563139600399,True,0.318718779162082,0.0714583106679093,1.05410383529536,46.0624684467724
22549,1561:1049,Breast,Hs-578-T,SIDM00135,905957,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.847493191112979,0.109241990906066,0.58552376126909,9.84383085128734,17.9481,0.852350737891486,0.872135121921867,0.154118517447257,0.496227400910415,0.349828021016601,0.146399379893815,8.13908517876894,5.506,1.70474567251839,12.4421,0.722361446803158,0.590224930119841,0.73912857755927,0.66918830499811,0.132136516683317,0.0699402725611604,True,0.318718779162082,0.0714583106679093,1.05410383529536,46.0624684467724
22549,1594:1049,Breast,Hs-578-T,SIDM00135,905957,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.610392578810728,0.109241990906066,0.58552376126909,9.84383085128734,17.9481,0.852350737891486,0.872135121921867,0.0878876161717366,0.357399358595997,0.257323236861464,0.100076121734533,8.22738900701172,5.8536,1.61644184427561,12.0945,0.520268564952811,0.42316238071013,0.532344806141297,0.484990302612872,0.0971061842426803,0.0473545035284251,True,0.318718779162082,0.0714583106679093,1.05410383529536,46.0624684467724
22549,1053:1049,Breast,Hs-578-T,SIDM00135,905957,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.723117813449632,0.109241990906066,0.58552376126909,9.84383085128734,17.9481,0.852350737891486,0.872135121921867,0.0898890256612729,0.423402661971709,0.273433244052899,0.149969417918809,7.7849283694875,4.3075,2.05890248179983,13.6406,0.616350001876272,0.531602446979847,0.630656442396769,0.55613309214154,0.084747554896424,0.0745233502552285,True,0.318718779162082,0.0714583106679093,1.05410383529536,46.0624684467724
22553,1022:1190,Breast,Hs-578-T,SIDM00135,905957,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.370475602625742,0.103059573822766,0.4832446489039,8.83624495721697,8.927,0.771964882955781,0.826694841544184,0.0424872681134121,0.179030352518337,0.160896627900806,0.0181337246175315,8.35437698966128,6.3922,0.48186796755569,2.5348,0.285994155218953,0.276917984581366,0.306270269608674,0.296951961658776,0.0090761706375872,0.0093183079498978,True,0.318718779162082,0.0714583106679093,1.05410383529536,46.0624684467724
22553,1005:1190,Breast,Hs-578-T,SIDM00135,905957,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.950829139030346,0.103059573822766,0.4832446489039,8.83624495721697,8.927,0.771964882955781,0.826694841544184,0.127590019308705,0.459483093458317,0.180667546284903,0.278815547173415,5.45864817182584,0.8589,3.37759678539113,8.0681,0.734006705022507,0.568288174454791,0.786045544426285,0.581108205158865,0.165718530567716,0.20493733926742,True,0.318718779162082,0.0714583106679093,1.05410383529536,46.0624684467724
22553,1011:1190,Breast,Hs-578-T,SIDM00135,905957,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,10.0,0.829847888962768,0.103059573822766,0.4832446489039,8.83624495721697,8.927,0.771964882955781,0.826694841544184,0.11527946224725,0.401019551745456,0.132607148300268,0.268412403445188,4.94623553009001,0.6021,3.89000942712696,8.3249,0.640613428474245,0.443450359143794,0.686030969071851,0.475184104698282,0.197163069330451,0.210846864373569,True,0.318718779162082,0.0714583106679093,1.05410383529536,46.0624684467724
22554,1561:1372,Breast,Hs-578-T,SIDM00135,905957,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.833148437906827,0.122640888172241,0.565398927246368,9.64260534427146,1.5611,0.803520555554178,0.863837196998474,0.0886742081128547,0.471061233029507,0.410706329185801,0.0603549038437061,8.93118758599848,0.9534,0.711417758272972,0.6077,0.66945189568599,0.655521101090329,0.719704611285091,0.692672810505375,0.0139307945956612,0.0270318007797161,True,0.318718779162082,0.0714583106679093,1.05410383529536,46.0624684467724
23695,1021:1561,Breast,Hs-578-T,SIDM00135,905957,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.758010121097612,0.107014090093794,0.389160272237563,7.89885585035935,4.6615,0.72949815046161,0.775801675501661,0.0850629846968581,0.294987425085175,0.14931685345436,0.145670571630815,5.56781870236432,0.9264,2.33103714799503,3.7351,0.552966981371889,0.429913291137527,0.588065521994744,0.469401526726954,0.123053690234362,0.118663995267791,True,0.478860993256958,0.0861055951145148,0.702045567791944,69.4481115725415
23695,1049:1561,Breast,Hs-578-T,SIDM00135,905957,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.962750029103495,0.107014090093794,0.389160272237563,7.89885585035935,4.6615,0.72949815046161,0.775801675501661,0.142266767173565,0.374664063422638,0.177827858850978,0.19683620457166,5.3735868645429,0.8097,2.52526898581645,3.8518,0.702324365587861,0.521779443336623,0.746903085667764,0.5822909212238,0.180544922251238,0.164612164443964,True,0.478860993256958,0.0861055951145148,0.702045567791944,69.4481115725415
23695,1022:1561,Breast,Hs-578-T,SIDM00135,905957,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.545155262257836,0.107014090093794,0.389160272237563,7.89885585035935,4.6615,0.72949815046161,0.775801675501661,0.174309831449203,0.212152770271999,0.0656928308242068,0.146459939447792,4.14528151478969,0.3456,3.75357433556966,4.3159,0.397689755531505,0.229334457966582,0.422932365868176,0.278685834820402,0.168355297564924,0.144246531047774,True,0.478860993256958,0.0861055951145148,0.702045567791944,69.4481115725415
24165,1012:1005,Breast,HCC1599,SIDM00877,749713,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,0.365551273207795,0.0693542513369836,0.678242716304002,10.3582973319072,10.2553,0.929049587648832,0.929637070535117,0.0816372407940277,0.247932488488841,0.105557317505088,0.142375170983753,7.35810333287721,1.2817,3.00019399903,8.9736,0.339615259638208,0.217751944055105,0.339830014755277,0.283516458475459,0.121863315583103,0.0563135562798182,True,0.619539293835135,0.0799572866297131,0.461903022975487,105.646582477042
24165,1012:1007,Breast,HCC1599,SIDM00877,749713,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1007,Docetaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.0125,0.836684009159087,0.0743809372805651,0.660717721148179,10.2140109837849,0.029,0.907636686428824,0.924898030817934,0.0806425184549143,0.552811951852714,0.419997595190588,0.132814356662126,9.01441716763216,0.0126,1.19959381615276,0.0164,0.759405101661137,0.702393192677045,0.773847392488094,0.732272499910069,0.0570119089840925,0.0415748925780252,True,0.619539293835135,0.0799572866297131,0.461903022975487,105.646582477042
24165,1011:1007,Breast,HCC1599,SIDM00877,749713,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1007,Docetaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.0125,0.900480659799384,0.0743809372805651,0.660717721148179,10.2140109837849,0.029,0.907636686428824,0.924898030817934,0.100875727409481,0.594963529480657,0.303262603080804,0.291700926399853,7.76560851011197,0.0053,2.44840247367295,0.0237,0.817309282253553,0.673353969258068,0.832852789038084,0.723299202619659,0.143955312995485,0.109553586418425,True,0.619539293835135,0.0799572866297131,0.461903022975487,105.646582477042
24166,1058:1011,Breast,HCC1599,SIDM00877,749713,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.891519864028058,0.0911614751648814,0.539012624969909,9.28482297665438,12.1826,0.89004929529413,0.888071002211044,0.126411264542473,0.48054046212258,0.228034899860235,0.252505562262345,7.05463764235887,2.5965,2.23018533429551,9.5861,0.793496626718892,0.591872352385163,0.791732939138451,0.672052356117377,0.201624274333729,0.119680583021074,True,0.619539293835135,0.0799572866297131,0.461903022975487,105.646582477042
24166,1190:1011,Breast,HCC1599,SIDM00877,749713,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.465970853120582,0.0911614751648814,0.539012624969909,9.28482297665438,12.1826,0.89004929529413,0.888071002211044,0.111637616897244,0.251164172699993,0.0690661899103659,0.182097982789627,5.81489081375639,1.0995,3.46993216289799,11.0831,0.414737029447579,0.243621063081276,0.413815202531931,0.30592749631247,0.171115966366303,0.107887706219461,True,0.619539293835135,0.0799572866297131,0.461903022975487,105.646582477042
24166,1510:1011,Breast,HCC1599,SIDM00877,749713,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.489510844506604,0.0911614751648814,0.539012624969909,9.28482297665438,12.1826,0.89004929529413,0.888071002211044,0.0600388280665587,0.263852525248741,0.0890672161657675,0.174785309082974,6.26197330624218,1.4989,3.02284967041219,10.6837,0.435688782191937,0.319619371147449,0.434720386274154,0.339213946163298,0.116069411044488,0.0955064401108565,True,0.619539293835135,0.0799572866297131,0.461903022975487,105.646582477042
24166,1012:1011,Breast,HCC1599,SIDM00877,749713,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.304669578230923,0.0911614751648814,0.539012624969909,9.28482297665438,12.1826,0.89004929529413,0.888071002211044,0.0676491899088679,0.164220749110725,0.0397752071807446,0.12444554192998,5.5463005028252,0.9127,3.73852247382918,11.2699,0.271170943401993,0.15036924454576,0.270568217682752,0.193187241866237,0.120801698856233,0.0773809758165147,True,0.619539293835135,0.0799572866297131,0.461903022975487,105.646582477042
24166,1594:1011,Breast,HCC1599,SIDM00877,749713,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.914174751881987,0.0911614751648814,0.539012624969909,9.28482297665438,12.1826,0.89004929529413,0.888071002211044,0.0940139349359935,0.492751732693125,0.408603549367371,0.0841481833257541,8.61212604159908,7.6426,0.672696935055299,4.54,0.813660593688249,0.765314321393648,0.811852088099869,0.780931808107782,0.0483462722946008,0.030920279992087,True,0.619539293835135,0.0799572866297131,0.461903022975487,105.646582477042
24167,1191:1021,Breast,HCC1599,SIDM00877,749713,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.0025,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.918231599857763,0.0777482624929642,0.679368459601445,10.3677021958523,25.8059,0.917889107417295,0.929937316006977,0.0629003207149663,0.623817587552739,0.419781505581542,0.204036081971197,8.68712468638524,8.0504,1.68057750946707,17.7555,0.842834783595797,0.773479837969122,0.853897829444521,0.788136523457841,0.0693549456266752,0.0657613059866795,True,0.619539293835135,0.0799572866297131,0.461903022975487,105.646582477042
24168,1012:1049,Breast,HCC1599,SIDM00877,749713,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.867905750083072,0.10578905253269,0.821102438196426,11.7756455691488,68.4782,0.920327753680936,0.964260871386517,0.0414098717572296,0.712639527517908,0.774242176088496,-0.0616026485705878,12.8473010731128,143.9306,-1.07165550396405,-75.4524,0.798757749380722,0.832715631175289,0.836887554856471,0.849931279412832,-0.0339578817945672,-0.0130437245563604,True,0.619539293835135,0.0799572866297131,0.461903022975487,105.646582477042
24168,1594:1049,Breast,HCC1599,SIDM00877,749713,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.791176923907422,0.10578905253269,0.821102438196426,11.7756455691488,68.4782,0.920327753680936,0.964260871386517,0.1342115624033,0.649637301265133,0.518328007644015,0.131309293621118,10.1688304080005,22.4829,1.60681516114825,45.9953,0.728142081143911,0.606242539942145,0.762900950067875,0.730542877227932,0.121899541201767,0.0323580728399427,True,0.619539293835135,0.0799572866297131,0.461903022975487,105.646582477042
28078,1179:1003,Breast,CAL-85-1,SIDM00928,910852,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.706768192794581,0.0729090305373515,0.753285101391486,12.7909835592402,1.3842,0.919987060567421,0.909583877941457,0.0472512214715708,0.532397949769544,0.400211556248784,0.132186393520759,9.90542184279548,0.1873,2.88556171644476,1.1969,0.650217592191635,0.576749245399587,0.642864953607771,0.579743185982176,0.0734683467920479,0.063121767625595,True,0.424602712266287,0.0632372708380026,0.822796213546795,59.6049269528945
28078,1022:1003,Breast,CAL-85-1,SIDM00928,910852,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.969732737923388,0.0729090305373515,0.753285101391486,12.7909835592402,1.3842,0.919987060567421,0.909583877941457,0.141010995698738,0.730485223809263,0.410197591970339,0.320287631838923,7.94556015300066,0.0481,4.84542340623959,1.3361,0.892141571098135,0.727324505469593,0.882053264327142,0.709201927534925,0.164817065628542,0.172851336792217,True,0.424602712266287,0.0632372708380026,0.822796213546795,59.6049269528945
28078,1011:1003,Breast,CAL-85-1,SIDM00928,910852,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.786007915124143,0.0729090305373515,0.753285101391486,12.7909835592402,1.3842,0.919987060567421,0.909583877941457,0.0760843965810437,0.592088052038801,0.409095735390577,0.182992316648223,9.2782824581717,0.1213,3.51270110106855,1.2629,0.723117111417787,0.598581627977309,0.714940127531297,0.624325121743979,0.124535483440478,0.0906150057873183,True,0.424602712266287,0.0632372708380026,0.822796213546795,59.6049269528945
28081,1372:1059,Breast,CAL-85-1,SIDM00928,910852,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.711815411922167,0.0858820997386448,0.445912416317142,8.26232325462957,0.5997,0.768491617573802,0.747220548221983,0.0425054248754036,0.317407330301995,0.225944754184545,0.0914625761174502,6.39961750408661,0.1649,1.86270575054295,0.4348,0.547024177322028,0.433627439289924,0.531883102329338,0.460318330382373,0.113396738032104,0.0715647719469656,True,0.424602712266287,0.0632372708380026,0.822796213546795,59.6049269528945
28083,1021:1085,Breast,CAL-85-1,SIDM00928,910852,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.929030463544276,0.0856421766733781,0.702608034202195,11.9199613535783,75.6826,0.913622421912265,0.887608985044418,0.0814017018166148,0.652744267704798,0.502723560464285,0.150020707240514,9.55998482040623,14.7425,2.35997653317209,60.9401,0.848783062133596,0.795596094362176,0.824615786821881,0.749043226776372,0.0531869677714201,0.0755725600455084,True,0.424602712266287,0.0632372708380026,0.822796213546795,59.6049269528945
28083,1022:1085,Breast,CAL-85-1,SIDM00928,910852,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.92792590588994,0.0856421766733781,0.702608034202195,11.9199613535783,75.6826,0.913622421912265,0.887608985044418,0.129053010098122,0.651968196622622,0.453466536773381,0.198501659849241,8.84630218494795,8.9894,3.07365916863036,66.6932,0.847773913494299,0.78690557131102,0.823635371523391,0.71916269481699,0.0608683421832791,0.104472676706402,True,0.424602712266287,0.0632372708380026,0.822796213546795,59.6049269528945
28083,1549:1086,Breast,CAL-85-1,SIDM00928,910852,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1086,BI-2536,"PLK1, PLK2, PLK3",Cell cycle,Targeted,Early clinical trials,10.0,0.818614428486274,0.16040173092194,0.206927363245356,4.43691341791812,0.423,0.494540870913653,0.527361960321065,0.092860908047293,0.169393725201268,0.146575695176927,0.022818030024341,3.82820500778469,0.2774,0.608708410133434,0.1456,0.404838292406084,0.370642026907954,0.43170610975363,0.400493701230403,0.0341962654981299,0.0312124085232265,True,0.424602712266287,0.0632372708380026,0.822796213546795,59.6049269528945
28084,1372:1096,Breast,CAL-85-1,SIDM00928,910852,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.916128653670643,0.0731588645349595,0.919577988677209,17.2755123872902,1549.3426,0.952881728581536,0.973085078697659,0.137813050646072,0.842451744712009,0.719513749199189,0.12293799551282,13.4061152165275,106.009,3.86939717076267,1443.3336,0.872962255112757,0.740313672875567,0.891471123054278,0.845405273628196,0.13264858223719,0.0460658494260819,True,0.424602712266287,0.0632372708380026,0.822796213546795,59.6049269528945
28084,1011:1096,Breast,CAL-85-1,SIDM00928,910852,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.860130627357678,0.0731588645349595,0.919577988677209,17.2755123872902,1549.3426,0.952881728581536,0.973085078697659,0.103844978661852,0.79095719230524,0.374086825613124,0.416870366692115,8.11081230235908,2.6996,9.16470008493111,1546.643,0.819602759002505,0.561591177232516,0.836980279212613,0.636231732065198,0.25801158176999,0.200748547147415,True,0.424602712266287,0.0632372708380026,0.822796213546795,59.6049269528945
28677,1372:1553,Breast,CAL-85-1,SIDM00928,910852,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.880273636039796,0.0615546340263253,0.870015034381329,15.4566748402586,878.3201,0.93803727815426,0.955368679907951,0.091507257689008,0.765851297724141,0.399737450665564,0.366113847058577,8.37475987483825,6.4831,7.0819149654203,871.837,0.825729485581723,0.62748148326269,0.840985861621112,0.662603863212362,0.198248002319033,0.17838199840875,True,0.455257189340288,0.0487339867599479,0.746828593354963,65.2145900521926
28677,1594:1553,Breast,CAL-85-1,SIDM00928,910852,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.932945611104918,0.0615546340263253,0.870015034381329,15.4566748402586,878.3201,0.93803727815426,0.955368679907951,0.0452584263318661,0.811676707921355,0.833649718384091,-0.021973010462736,16.2263351935116,1497.4201,-0.769660353253062,-619.1,0.87513776170682,0.923424441521019,0.891307016907222,0.899268911842456,-0.0482866798141994,-0.0079618949352339,True,0.455257189340288,0.0487339867599479,0.746828593354963,65.2145900521926
28677,1372:1560,Breast,CAL-85-1,SIDM00928,910852,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.880273636039796,0.0822675040139687,0.765740903961525,13.022630653256,162.5296,0.909001442351291,0.914774149688664,0.0435772152598673,0.674061529794611,0.469028467022315,0.205033062772296,9.44652463688036,13.6275,3.57610601637568,148.9021,0.80017000482399,0.701582255862908,0.805251566901652,0.705541514284432,0.0985877489610819,0.0997100526172209,True,0.455257189340288,0.0487339867599479,0.746828593354963,65.2145900521926
28677,1011:1560,Breast,CAL-85-1,SIDM00928,910852,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.598341326925462,0.0822675040139687,0.765740903961525,13.022630653256,162.5296,0.909001442351291,0.914774149688664,0.0788728000482578,0.458174428557441,0.29453945230446,0.163634976252981,8.89484107956595,9.297,4.12778957369008,153.2326,0.54389312919363,0.457265123594525,0.547347178561826,0.465056736403627,0.0866280055991054,0.0822904421581988,True,0.455257189340288,0.0487339867599479,0.746828593354963,65.2145900521926
28677,1053:1560,Breast,CAL-85-1,SIDM00928,910852,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.966994777161219,0.0822675040139687,0.765740903961525,13.022630653256,162.5296,0.909001442351291,0.914774149688664,0.0615496570677089,0.740467454789505,0.581969217521571,0.158498237267934,10.4030375104677,26.4458,2.61959314278834,136.0838,0.878999647185714,0.785630425669183,0.884581825031033,0.811472805602778,0.0933692215165303,0.0731090194282554,True,0.455257189340288,0.0487339867599479,0.746828593354963,65.2145900521926
28082,1510:2169,Breast,CAL-85-1,SIDM00928,910852,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.869397299596211,0.0784591464038889,0.815362245064451,14.0443070181476,329.9801,0.920636607852356,0.934697932543095,0.0549892320535004,0.708873734051738,0.422310300802568,0.28656343324917,8.80636734408209,8.744,5.23793967406551,321.2361,0.800398980776254,0.650425105995593,0.812623858491128,0.672203657024841,0.149973874780661,0.140420201466287,True,0.424602712266287,0.0632372708380026,0.822796213546795,59.6049269528945
28082,1179:2169,Breast,CAL-85-1,SIDM00928,910852,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.544216182710278,0.0784591464038889,0.815362245064451,14.0443070181476,329.9801,0.920636607852356,0.934697932543095,0.0353575729848434,0.443733328535058,0.297345079240052,0.146388249295006,9.63180320068217,15.495,4.41250381746543,314.4851,0.501025340388748,0.440099613100338,0.508677740835792,0.440399490147796,0.0609257272884102,0.0682782506879955,True,0.424602712266287,0.0632372708380026,0.822796213546795,59.6049269528945
27061,1011:1032,Breast,EFM-192A,SIDM01002,1290798,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.913144779323201,0.118653503654282,0.436844030950184,8.19839638185224,5.7371,0.693938635965094,0.755282649863362,0.177914464005759,0.398901846240663,0.224877735554331,0.174024110686332,5.46945243261254,0.8654,2.7289439492397,4.8717,0.633666442602189,0.459170429483818,0.689682408636122,0.544182319887615,0.17449601311837,0.145500088748507,True,1.08530245217838,0.111643370898239,-0.0955361593230134,-618.416685395444
27061,1558:1038,Breast,EFM-192A,SIDM01002,1290798,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.623715923980498,0.0861271505214384,0.816301065425769,13.7073703910975,261.252,0.966911866665927,0.938912755348186,0.0548877883834753,0.509139973268298,0.327663882508943,0.181476090759355,9.32020248888361,12.4851,4.3871679022139,248.7669,0.603078328325247,0.529185256042943,0.585614836739069,0.504343198674073,0.0738930722823041,0.0812716380649958,True,1.08530245217838,0.111643370898239,-0.0955361593230134,-618.416685395444
27063,1053:1050,Breast,EFM-192A,SIDM01002,1290798,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.804384828233701,0.0728850141103056,0.766542301717467,12.7523278093295,134.7607,0.929829578518117,0.920106851703141,0.0725963912685537,0.61659499770087,0.406745319283591,0.209849678417279,9.07145995608204,10.5078,3.68086785324745,124.2529,0.74794080580291,0.607363250459549,0.740119991863882,0.641501162287546,0.140577555343361,0.0986188295763368,True,1.08530245217838,0.111643370898239,-0.0955361593230134,-618.416685395444
25835,1012:1059,Breast,EFM-192A,SIDM01002,1290798,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.954744353327142,0.0771951398817445,0.439446369321136,8.23176069100806,0.5871,0.771269355821251,0.756986455195753,0.0554865080207921,0.419558939699469,0.399969969631994,0.0195889700674747,7.96739158798225,0.4888,0.26436910302581,0.0982999999999999,0.736365062364602,0.711118533266774,0.722728543643275,0.709658389652943,0.0252465290978277,0.0130701539903321,True,0.543369948356915,0.0638512167263975,0.581057158949269,83.6140811297661
25836,1011:1080,Breast,EFM-192A,SIDM01002,1290798,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.913668189312358,0.0854706361131964,0.753514424486718,12.5268379264925,1.1526,0.871721353232857,0.914992208377845,0.163805945028793,0.688462159841524,0.481139252532227,0.207322907309297,9.33615507856624,0.1262,3.1906828479263,1.0264,0.796464070393183,0.699013355570187,0.835999274263502,0.739439292242686,0.0974507148229957,0.0965599820208156,True,0.543369948356915,0.0638512167263975,0.581057158949269,83.6140811297661
25836,1053:1080,Breast,EFM-192A,SIDM01002,1290798,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.838078824804164,0.0854706361131964,0.753514424486718,12.5268379264925,1.1526,0.871721353232857,0.914992208377845,0.0923965811501823,0.631504483346815,0.440306462881455,0.19119802046536,9.3206381166071,0.1249,3.20619980988544,1.0277,0.730571207274088,0.606810073170105,0.766835594702271,0.677695266945753,0.123761134103983,0.0891403277565178,True,0.543369948356915,0.0638512167263975,0.581057158949269,83.6140811297661
25837,1012:1086,Breast,EFM-192A,SIDM01002,1290798,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1086,BI-2536,"PLK1, PLK2, PLK3",Cell cycle,Targeted,Early clinical trials,10.0,0.946641119438758,0.0818079497844882,0.687776614748048,11.4925647885664,56.2778,0.862996051832983,0.887838529397012,0.0589506060036753,0.651077624508891,0.577894732610264,0.0731828918986275,10.4180093214398,26.7217,1.07455546712658,29.5561,0.816947548578403,0.780664387995519,0.840464459349248,0.807101770671852,0.0362831605828838,0.0333626886773966,True,0.543369948356915,0.0638512167263975,0.581057158949269,83.6140811297661
25837,1558:1086,Breast,EFM-192A,SIDM01002,1290798,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1086,BI-2536,"PLK1, PLK2, PLK3",Cell cycle,Targeted,Early clinical trials,10.0,0.650455293623816,0.0818079497844882,0.687776614748048,11.4925647885664,56.2778,0.862996051832983,0.887838529397012,0.0649259542560789,0.447367939893536,0.239649218043935,0.207718721849601,7.29900154675628,3.0757,4.19356324181012,53.2021,0.561340350291217,0.420599098225785,0.577499271329471,0.459765481596339,0.140741252065432,0.117733789733132,True,0.543369948356915,0.0638512167263975,0.581057158949269,83.6140811297661
25837,1549:1086,Breast,EFM-192A,SIDM01002,1290798,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1086,BI-2536,"PLK1, PLK2, PLK3",Cell cycle,Targeted,Early clinical trials,10.0,0.821644692755541,0.0818079497844882,0.687776614748048,11.4925647885664,56.2778,0.862996051832983,0.887838529397012,0.105148513047829,0.565108005309106,0.429713855532065,0.13539414977704,9.29047479645958,12.2304,2.20208999210682,44.0474,0.709076125857556,0.644214425911959,0.72948781570294,0.663318067201153,0.0648616999455964,0.0661697485017863,True,0.543369948356915,0.0638512167263975,0.581057158949269,83.6140811297661
25837,1053:1086,Breast,EFM-192A,SIDM01002,1290798,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1086,BI-2536,"PLK1, PLK2, PLK3",Cell cycle,Targeted,Early clinical trials,10.0,0.89718339386447,0.0818079497844882,0.687776614748048,11.4925647885664,56.2778,0.862996051832983,0.887838529397012,0.124978728629496,0.617061757440269,0.396132323555276,0.220929433884993,8.25842872974676,5.9809,3.23413605881964,50.2969,0.774265726675153,0.629510879988078,0.796553985008051,0.680373001076538,0.144754846687075,0.116180983931514,True,0.543369948356915,0.0638512167263975,0.581057158949269,83.6140811297661
27065,1054:1553,Breast,EFM-192A,SIDM01002,1290798,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.959627873413921,0.0675608512260923,0.662100709848895,11.1230556862398,43.5616,0.864351947439171,0.876564247833887,0.113891150812161,0.635370296178143,0.414279707939152,0.221090588238991,8.13242417738311,5.4807,2.9906315088567,38.0809,0.829456221202233,0.654744328209654,0.841175485059507,0.721537691118783,0.174711892992579,0.119637793940724,True,1.08530245217838,0.111643370898239,-0.0955361593230134,-618.416685395444
27065,1510:1553,Breast,EFM-192A,SIDM01002,1290798,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.995871815761233,0.0675608512260923,0.662100709848895,11.1230556862398,43.5616,0.864351947439171,0.876564247833887,0.0857216807001149,0.65936743613402,0.427184685993765,0.232182750140255,8.09697754142817,5.3477,3.02607814481165,38.2139,0.860783743353005,0.749625302538218,0.872945629121713,0.746964545755766,0.111158440814787,0.125981083365947,True,1.08530245217838,0.111643370898239,-0.0955361593230134,-618.416685395444
27065,1549:1553,Breast,EFM-192A,SIDM01002,1290798,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.938842170109476,0.0675608512260923,0.662100709848895,11.1230556862398,43.5616,0.864351947439171,0.876564247833887,0.116192405499448,0.621608067265561,0.219817819393749,0.401790247871812,5.25964311703768,0.7482,5.86341256920214,42.8134,0.811490058072143,0.493539888616505,0.822955480676748,0.546843799884409,0.317950169455638,0.276111680792339,True,1.08530245217838,0.111643370898239,-0.0955361593230134,-618.416685395444
27065,1594:1553,Breast,EFM-192A,SIDM01002,1290798,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.98535427779231,0.0675608512260923,0.662100709848895,11.1230556862398,43.5616,0.864351947439171,0.876564247833887,0.0780907594215516,0.652403766778933,0.546480660701167,0.105923106077767,9.69210696090198,16.1564,1.43094872533784,27.4052,0.8516928889273,0.860692076043672,0.863726331362919,0.812356465887715,-0.0089991871163718,0.0513698654752047,True,1.08530245217838,0.111643370898239,-0.0955361593230134,-618.416685395444
27065,1012:1560,Breast,EFM-192A,SIDM01002,1290798,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.78384954830166,0.0903626189935603,0.589744043429257,10.1453949243006,22.1207,0.855477968228781,0.842437941494083,0.0475492216508072,0.462270602055617,0.27159412055834,0.190676481497277,6.99736818637265,2.4954,3.14802673792798,19.6253,0.670566018978151,0.545852926704898,0.660344599912317,0.540523608144969,0.124713092273253,0.119820991767348,True,1.08530245217838,0.111643370898239,-0.0955361593230134,-618.416685395444
27065,1594:1560,Breast,EFM-192A,SIDM01002,1290798,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.971719720497535,0.0903626189935603,0.589744043429257,10.1453949243006,22.1207,0.855477968228781,0.842437941494083,0.0857796910720377,0.573065917046163,0.362157779307385,0.210908137738778,7.35671011884105,3.2013,2.78868480545958,18.9194,0.83128481217907,0.717051766864108,0.818613561045149,0.690002529048163,0.114233045314962,0.128611031996986,True,1.08530245217838,0.111643370898239,-0.0955361593230134,-618.416685395444
26110,1058:1593,Breast,EFM-192A,SIDM01002,1290798,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.919354058360613,0.0830583615289816,0.622065599964945,10.5727948241636,5.9496,0.861100261094579,0.858139620206321,0.101848870511669,0.571898533894301,0.319872076150017,0.252026457744285,7.01747253463327,0.5061,3.55532228953036,5.4435,0.791656019692685,0.57077074172858,0.788934142476716,0.63503530084049,0.220885277964105,0.153898841636226,True,0.510534656232309,0.0657864659366518,0.638914664808906,76.0659313853116
26110,1053:1593,Breast,EFM-192A,SIDM01002,1290798,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.886796364836223,0.0830583615289816,0.622065599964945,10.5727948241636,5.9496,0.861100261094579,0.858139620206321,0.0708752166810057,0.551645512738577,0.341171671958724,0.210473840779853,7.51803747739635,0.716,3.05475734676728,5.2336,0.763620581298195,0.597739856741245,0.760995095720902,0.63766463200525,0.16588072455695,0.123330463715653,True,0.510534656232309,0.0657864659366518,0.638914664808906,76.0659313853116
25836,1012:2169,Breast,EFM-192A,SIDM01002,1290798,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.809388878082839,0.0885423856529342,0.803095999679482,13.4368016910018,216.576,0.940165529058692,0.934030216702033,0.0896446361026017,0.650016970173392,0.368133494735662,0.28188347543773,8.42817207930559,6.7276,5.00862961169618,209.8484,0.760959522776973,0.577725703989372,0.755993669191929,0.620699373339855,0.183233818787602,0.135294295852075,True,0.543369948356915,0.0638512167263975,0.581057158949269,83.6140811297661
27064,1191:2172,Breast,EFM-192A,SIDM01002,1290798,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.0025,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.786725637170673,0.0967182888800621,0.725635046130241,12.0696466565001,83.9568,0.860251251462887,0.903760308998267,0.0551417519007141,0.570875694020185,0.347877035867469,0.222998658152716,8.26680618794799,6.0157,3.80284046855207,77.9411,0.676781713934009,0.564311353694461,0.711011404946226,0.596942704661709,0.112470360239548,0.114068700284518,True,1.08530245217838,0.111643370898239,-0.0955361593230134,-618.416685395444
27064,1549:2172,Breast,EFM-192A,SIDM01002,1290798,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.731503221021778,0.0967182888800621,0.725635046130241,12.0696466565001,83.9568,0.860251251462887,0.903760308998267,0.077103137501959,0.530804373530558,0.365188733033053,0.165615640497505,8.99028556759353,9.9329,3.07936108890654,74.0239,0.629276561333118,0.53381897608181,0.66110357706387,0.580660741620114,0.095457585251308,0.0804428354437557,True,1.08530245217838,0.111643370898239,-0.0955361593230134,-618.416685395444
27064,1558:2172,Breast,EFM-192A,SIDM01002,1290798,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.688362509136415,0.0967182888800621,0.725635046130241,12.0696466565001,83.9568,0.860251251462887,0.903760308998267,0.0524157708991956,0.499499961071531,0.380136695642694,0.119363265428837,9.66184188718692,15.821,2.40780476931314,68.1358,0.592164709944734,0.522483974923595,0.622114713959949,0.56664531570688,0.0696807350211391,0.055469398253069,True,1.08530245217838,0.111643370898239,-0.0955361593230134,-618.416685395444
27064,1561:2172,Breast,EFM-192A,SIDM01002,1290798,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.78015657062357,0.0967182888800621,0.725635046130241,12.0696466565001,83.9568,0.860251251462887,0.903760308998267,0.0975032527530597,0.566108949113245,0.504197235189605,0.0619117139236403,10.9022638532025,37.3799,1.16738280329758,46.5769,0.67113066621592,0.600801365895804,0.705074543333786,0.678275914881317,0.070329300320116,0.0267986284524691,True,1.08530245217838,0.111643370898239,-0.0955361593230134,-618.416685395444
27064,1012:2172,Breast,EFM-192A,SIDM01002,1290798,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.629625066150912,0.0967182888800621,0.725635046130241,12.0696466565001,83.9568,0.860251251462887,0.903760308998267,0.100649183093245,0.456878013921174,0.213967528462358,0.242910485458816,6.90418943256736,2.3394,5.1654572239327,81.6174,0.541635751108725,0.363719048300599,0.569030144337603,0.430757847361972,0.177916702808127,0.138272296975631,True,1.08530245217838,0.111643370898239,-0.0955361593230134,-618.416685395444
25848,1011:1059,Breast,HCC1419,SIDM00882,907045,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.967959770106553,0.149201214239067,0.607719232618595,10.6874431393234,3.2209,0.781437659085823,0.826164967202139,0.139503492017403,0.588247768694826,0.370468431368449,0.217779337326376,7.15744795004018,0.2788,3.52999518928326,2.9421,0.756400216841316,0.686469913149717,0.799694451723071,0.652039607484669,0.0699303036915994,0.147654844238402,True,0.689569102390084,0.0932041537937058,0.351015700715072,136.611923586837
25850,1510:1085,Breast,HCC1419,SIDM00882,907045,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.963617526263217,0.10283755994789,0.562408379748713,9.96736709549515,19.5527,0.839109365941929,0.799920603575941,0.11934202835641,0.541946571643158,0.443058405488654,0.0988881661545042,8.37857635339299,6.5003,1.58879074210216,13.0524,0.808580491473258,0.759326658815844,0.770817513224827,0.706245365418004,0.0492538326574138,0.0645721478068236,True,0.689569102390084,0.0932041537937058,0.351015700715072,136.611923586837
25850,1011:1085,Breast,HCC1419,SIDM00882,907045,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.952310047919545,0.10283755994789,0.562408379748713,9.96736709549515,19.5527,0.839109365941929,0.799920603575941,0.146973316362877,0.53558715106885,0.346099818143244,0.189487332925607,6.83930715349174,2.2365,3.1280599420034,17.3162,0.799092280489897,0.665977716106551,0.761772428323236,0.625883694643419,0.133114564383347,0.135888733679817,True,0.689569102390084,0.0932041537937058,0.351015700715072,136.611923586837
25850,1012:1086,Breast,HCC1419,SIDM00882,907045,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1086,BI-2536,"PLK1, PLK2, PLK3",Cell cycle,Targeted,Early clinical trials,10.0,0.967918184830724,0.0799321681092697,0.815383240956943,14.7260370970537,529.3086,0.91256595462235,0.927788568366613,0.122809012692007,0.789224266528437,0.44818426937874,0.341039997149697,8.42903501485723,6.7317,6.29700208219648,522.5769,0.883289182336381,0.739003164319197,0.898023427000107,0.711636039806362,0.144286018017184,0.186387387193745,True,0.689569102390084,0.0932041537937058,0.351015700715072,136.611923586837
25850,1011:1086,Breast,HCC1419,SIDM00882,907045,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1086,BI-2536,"PLK1, PLK2, PLK3",Cell cycle,Targeted,Early clinical trials,10.0,0.952310047919545,0.0799321681092697,0.815383240956943,14.7260370970537,529.3086,0.91256595462235,0.927788568366613,0.0693410672558119,0.7764976532685,0.490620952228722,0.285876701039778,9.23430379204302,11.7634,5.49173330501069,517.5452,0.869045727976155,0.762350335452634,0.883542376000415,0.733780062316954,0.106695392523522,0.149762313683461,True,0.689569102390084,0.0932041537937058,0.351015700715072,136.611923586837
25850,1558:1086,Breast,HCC1419,SIDM00882,907045,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1086,BI-2536,"PLK1, PLK2, PLK3",Cell cycle,Targeted,Early clinical trials,10.0,0.61866821785005,0.0799321681092697,0.815383240956943,14.7260370970537,529.3086,0.91256595462235,0.927788568366613,0.0664958394394719,0.50445169654763,0.258042118469463,0.246409578078167,7.70967858500961,4.0886,7.0163585120441,525.22,0.564575552816839,0.415561277148016,0.573993300133022,0.433805676400846,0.149014275668823,0.140187623732176,True,0.689569102390084,0.0932041537937058,0.351015700715072,136.611923586837
25850,1549:1086,Breast,HCC1419,SIDM00882,907045,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1086,BI-2536,"PLK1, PLK2, PLK3",Cell cycle,Targeted,Early clinical trials,10.0,0.701372496759361,0.0799321681092697,0.815383240956943,14.7260370970537,529.3086,0.91256595462235,0.927788568366613,0.0754500028710603,0.57188737952571,0.421671924196631,0.150215455329079,10.5824837922506,29.9485,4.1435533048031,499.3601,0.640048662051067,0.610128209893776,0.650725384660084,0.576880785839085,0.0299204521572904,0.0738445988209987,True,0.689569102390084,0.0932041537937058,0.351015700715072,136.611923586837
25850,1053:1086,Breast,HCC1419,SIDM00882,907045,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1086,BI-2536,"PLK1, PLK2, PLK3",Cell cycle,Targeted,Early clinical trials,10.0,0.822872863333204,0.0799321681092697,0.815383240956943,14.7260370970537,529.3086,0.91256595462235,0.927788568366613,0.0882784791390133,0.670956742200147,0.442370436546154,0.228586305653993,9.58076637073802,14.9564,5.14527072631569,514.3522,0.750925760060492,0.610531227583436,0.763452035819649,0.645751179312929,0.140394532477056,0.11770085650672,True,0.689569102390084,0.0932041537937058,0.351015700715072,136.611923586837
25852,1049:1192,Breast,HCC1419,SIDM00882,907045,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.96196775123838,0.0814134985385179,0.755591880255038,13.3509249884956,204.0605,0.923955170234783,0.901169516849212,0.127012799217104,0.726855021902918,0.700046065008152,0.0268089568947656,12.7897945936487,138.3063,0.561130394846929,65.7542,0.888815077355829,0.904937190405103,0.866896013608013,0.8543283909906,-0.0161221130492744,0.0125676226174132,True,0.689569102390084,0.0932041537937058,0.351015700715072,136.611923586837
25852,1558:1192,Breast,HCC1419,SIDM00882,907045,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.633490958132591,0.0814134985385179,0.755591880255038,13.3509249884956,204.0605,0.923955170234783,0.901169516849212,0.0517908295169002,0.47866062417997,0.408532822838401,0.0701278013415696,11.3000810561523,49.2485,2.05084393234334,154.812,0.585317246063594,0.543933784861234,0.570882740668692,0.536209749388214,0.0413834612023609,0.0346729912804781,True,0.689569102390084,0.0932041537937058,0.351015700715072,136.611923586837
25852,1012:1192,Breast,HCC1419,SIDM00882,907045,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.975585261586483,0.0814134985385179,0.755591880255038,13.3509249884956,204.0605,0.923955170234783,0.901169516849212,0.115486177129778,0.737144302151234,0.404373179981569,0.332771122169664,7.66841709742832,3.9733,5.68250789106731,200.0872,0.901397046447684,0.638527388545837,0.879167698829103,0.682104083845689,0.262869657901847,0.197063614983413,True,0.689569102390084,0.0932041537937058,0.351015700715072,136.611923586837
25852,1011:1192,Breast,HCC1419,SIDM00882,907045,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.946785726402931,0.0814134985385179,0.755591880255038,13.3509249884956,204.0605,0.923955170234783,0.901169516849212,0.153547640934547,0.715383607211423,0.488661310495107,0.226722296716316,9.24875484141146,11.8818,4.10217014708418,192.1787,0.874787567014483,0.789875610707742,0.853214435622259,0.73009638410747,0.0849119563067409,0.12311805151479,True,0.689569102390084,0.0932041537937058,0.351015700715072,136.611923586837
26744,1510:1564,Breast,HCC1419,SIDM00882,907045,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.957353645864588,0.076971698224195,0.787800792831991,14.056602080857,166.4021,0.903456784432979,0.91573682605707,0.047624019047003,0.75420396123272,0.786501271149235,-0.0322973099165146,14.8857022985264,295.6262,-0.829100217669403,-129.2241,0.86492764645801,0.912563745360826,0.876683989078203,0.890747338618918,-0.0476360989028157,-0.0140633495407154,True,1.08146630533899,0.138387256744588,-0.101267020320404,-652.619349433064
26742,1191:2172,Breast,HCC1419,SIDM00882,907045,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.0025,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.927117984974564,0.0965489266393264,0.892275591086609,17.1501114475692,2840.7173,0.92664130021852,0.959522994875671,0.112924647062861,0.827244748050205,0.511357939129543,0.315886808920662,9.7978244588726,17.3848,7.35228698869662,2823.3325,0.859105815052804,0.720526652628234,0.889591025545891,0.735538988079196,0.13857916242457,0.154052037466695,True,1.08146630533899,0.138387256744588,-0.101267020320404,-652.619349433064
26742,1558:2172,Breast,HCC1419,SIDM00882,907045,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.64878494099438,0.0965489266393264,0.892275591086609,17.1501114475692,2840.7173,0.92664130021852,0.959522994875671,0.0813260138534694,0.578894966713851,0.32377118280157,0.255123783912281,8.98523374955829,9.8982,8.16487769801093,2830.8191,0.601190921285228,0.450529734079117,0.622524069613163,0.493035473596137,0.150661187206111,0.129488596017026,True,1.08146630533899,0.138387256744588,-0.101267020320404,-652.619349433064
26742,1012:2172,Breast,HCC1419,SIDM00882,907045,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.93974814103948,0.0965489266393264,0.892275591086609,17.1501114475692,2840.7173,0.92664130021852,0.959522994875671,0.151585458302139,0.838514328018545,0.261349391359044,0.577164936659501,5.32286035959986,0.7818,11.8272510879694,2839.9355,0.870809439290762,0.513441726945014,0.901709950719047,0.540350800988832,0.357367712345748,0.361359149730215,True,1.08146630533899,0.138387256744588,-0.101267020320404,-652.619349433064
27314,1012:1003,Breast,HCC1500,SIDM00879,1303900,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.697617840780651,0.0764242761090389,0.717994452482093,10.4084484391251,0.2655,0.937131407076371,0.950148111166368,0.103548056558466,0.500885739633043,0.281947624848349,0.218938114784695,8.41498328383697,0.0667,1.9934651552881,0.1988,0.653759588732351,0.528492312377292,0.662840273733696,0.602570725236841,0.12526727635506,0.0602695484968555,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
27314,1011:1003,Breast,HCC1500,SIDM00879,1303900,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.0903453556158277,0.0764242761090389,0.717994452482093,10.4084484391251,0.2655,0.937131407076371,0.950148111166368,0.0658886674183225,0.0648674641396862,0.0258318870545818,0.0390355770851044,7.62059471769883,0.0384,2.78785372142624,0.2271,0.0846654702310758,0.0044747760646958,0.0858414689910326,0.0733422381203304,0.0801906941663799,0.0124992308707022,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
27314,1047:1003,Breast,HCC1500,SIDM00879,1303900,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.807061629342058,0.0764242761090389,0.717994452482093,10.4084484391251,0.2655,0.937131407076371,0.950148111166368,0.0861981538706472,0.579465772678757,0.34081387246997,0.238651900208787,8.52770045577395,0.0721,1.88074798335112,0.1934,0.756322800302672,0.649300616637734,0.766828082714208,0.702424443259649,0.107022183664938,0.0644036394545593,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
27314,1191:1013,Breast,HCC1500,SIDM00879,1303900,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.0025,1013,Nilotinib,ABL,ABL signaling,Targeted,FDA approved,10.0,0.735972988314266,0.0988106035524395,0.48531094826537,8.91142236584608,9.4045,0.909391743197959,0.891250820730335,0.0468433089104273,0.357175748856494,0.0964198394548645,0.26075590940163,6.14845833381495,1.3855,2.76296403203113,8.019,0.669287758789721,0.515718665143239,0.655936529870446,0.511493573552864,0.153569093646482,0.144442956317583,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
27314,1011:1013,Breast,HCC1500,SIDM00879,1303900,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1013,Nilotinib,ABL,ABL signaling,Targeted,FDA approved,10.0,0.166133580443784,0.0988106035524395,0.48531094826537,8.91142236584608,9.4045,0.909391743197959,0.891250820730335,0.0573019314731004,0.0806264454638939,0.0140272581501243,0.0665991873137696,5.40768361389092,0.8291,3.50373875195516,8.5754,0.151080506323491,0.0458301043278791,0.148066689921392,0.104598516898417,0.105250401995612,0.0434681730229746,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
27314,1047:1013,Breast,HCC1500,SIDM00879,1303900,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,1013,Nilotinib,ABL,ABL signaling,Targeted,FDA approved,10.0,0.356035433432044,0.0988106035524395,0.48531094826537,8.91142236584608,9.4045,0.909391743197959,0.891250820730335,0.0382040716501249,0.172787893814977,0.0490220504219048,0.123765843393073,6.23502169911094,1.4712,2.67640066673514,7.9333,0.323775683449008,0.22847742629912,0.31731687225539,0.25008302687548,0.0952982571498875,0.0672338453799095,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
27314,1049:1013,Breast,HCC1500,SIDM00879,1303900,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1013,Nilotinib,ABL,ABL signaling,Targeted,FDA approved,10.0,0.764408444725383,0.0988106035524395,0.48531094826537,8.91142236584608,9.4045,0.909391743197959,0.891250820730335,0.0828598081246425,0.370975787171732,0.150591834254108,0.220383952917623,6.88232303656672,2.3042,2.02909932927936,7.1003,0.695146728064057,0.595653975232827,0.681279653734696,0.577869838568429,0.0994927528312292,0.103409815166267,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
27315,1012:1030,Breast,HCC1500,SIDM00879,1303900,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1030,KU-55933,ATM,Genome integrity,Targeted,Experimental only,10.0,0.892138109099545,0.0849349965792016,0.912396304722273,12.5315405271668,115.6377,0.952664061227188,0.986201679900854,0.0608085067163535,0.813983514044341,0.758771112397748,0.0552124016465935,11.6202569275528,61.486,0.911283599613995,54.1517,0.849907914190316,0.843659992644832,0.879828101897542,0.870398059953532,0.0062479215454842,0.0094300419440098,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
27315,1049:1030,Breast,HCC1500,SIDM00879,1303900,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1030,KU-55933,ATM,Genome integrity,Targeted,Experimental only,10.0,0.752065864429341,0.0849349965792016,0.912396304722273,12.5315405271668,115.6377,0.952664061227188,0.986201679900854,0.0795081675414564,0.686182115613093,0.300106325498905,0.386075790114188,8.38290447869023,6.5198,4.14863604847661,109.1179,0.716466120717591,0.575032878100071,0.741688618896304,0.648161510035314,0.14143324261752,0.0935271088609894,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
27315,1047:1030,Breast,HCC1500,SIDM00879,1303900,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1030,KU-55933,ATM,Genome integrity,Targeted,Experimental only,10.0,0.889978365204207,0.0849349965792016,0.912396304722273,12.5315405271668,115.6377,0.952664061227188,0.986201679900854,0.165441983932734,0.812012971695088,0.305408705400325,0.506604266294763,8.02154556267175,5.0752,4.50999496449509,110.5625,0.847850403799773,0.620346762700953,0.877698158839805,0.74685724596303,0.22750364109882,0.130840912876775,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
27315,1191:1030,Breast,HCC1500,SIDM00879,1303900,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.000625,1030,KU-55933,ATM,Genome integrity,Targeted,Experimental only,10.0,0.990434690041228,0.0849349965792016,0.912396304722273,12.5315405271668,115.6377,0.952664061227188,0.986201679900854,0.0813000551894178,0.903668951262367,0.893455562239275,0.0102133890230918,12.346692660801,101.7314,0.184847866365851,13.9063,0.943551534194967,0.919101175237524,0.976768355150741,0.975074140256449,0.024450358957443,0.0016942148942917,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
27506,1049:1038,Breast,HCC1500,SIDM00879,1303900,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.860053215402476,0.101835273712556,0.598655505657011,9.60264283647529,15.185,0.923637957381325,0.922807430736586,0.0869027180599444,0.514875592558708,0.255355851196853,0.259519741361855,7.70076447201638,4.0634,1.90187836445892,11.1216,0.794377795113584,0.694015376506686,0.793663498002299,0.703053937988912,0.100362418606898,0.0906095600133864,True,1.18990599600383,0.10938205659987,-0.190979286348821,-292.434997055326
27506,1047:1038,Breast,HCC1500,SIDM00879,1303900,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.862853702826493,0.101835273712556,0.598655505657011,9.60264283647529,15.185,0.923637957381325,0.922807430736586,0.120201651294524,0.516552119773619,0.249171765213769,0.26738035455985,7.64158886526759,3.9001,1.9610539712077,11.2849,0.796964431597575,0.645774063453588,0.796247808606866,0.701748552940473,0.151190368143987,0.0944992556663932,True,1.18990599600383,0.10938205659987,-0.190979286348821,-292.434997055326
27322,1047:1042,Breast,HCC1500,SIDM00879,1303900,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.83031551179663,0.0812778815988277,0.737617571625607,10.5577840393335,29.4401,0.938206610036748,0.95420450356751,0.0595235788965098,0.612455311494503,0.397899635334964,0.214555676159539,8.87462642070351,9.1677,1.68315761863004,20.2724,0.779007501583644,0.690150965665912,0.792290800738307,0.738441878824377,0.0888565359177319,0.0538489219139301,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
27322,1179:1042,Breast,HCC1500,SIDM00879,1303900,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.815235775022534,0.0812778815988277,0.737617571625607,10.5577840393335,29.4401,0.938206610036748,0.95420450356751,0.06144938596085,0.601332232674441,0.596634756588819,0.0046974760856224,10.5132255221666,28.5448,0.0445585171669709,0.895300000000002,0.764859592864573,0.763689860192755,0.777901647995852,0.776939805633739,0.0011697326718181,0.0009618423621128,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
27322,1012:1042,Breast,HCC1500,SIDM00879,1303900,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.75502625325408,0.0812778815988277,0.737617571625607,10.5577840393335,29.4401,0.938206610036748,0.95420450356751,0.109910378812595,0.556920631438855,0.374586835091686,0.182333796347169,8.97663479674459,9.8393,1.58114924258895,19.6008,0.708370621554258,0.592644140765347,0.720449451166746,0.675418627789022,0.115726480788911,0.0450308233777246,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
27322,1011:1042,Breast,HCC1500,SIDM00879,1303900,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.133942652555674,0.0812778815988277,0.737617571625607,10.5577840393335,29.4401,0.938206610036748,0.95420450356751,0.0814643244214834,0.0987984541152086,0.0157301183663802,0.0830683357488284,5.96029675607601,1.2161,4.59748728325754,28.224,0.125665881993589,0.008520071290349,0.127808682288402,0.0909044473921599,0.11714581070324,0.0369042348962424,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
27322,1012:1046,Breast,HCC1500,SIDM00879,1303900,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1046,Wee1 Inhibitor,"WEE1, CHEK1",Cell cycle,Targeted,Experimental only,10.0,0.955429475502216,0.0879482927788898,0.460132823006387,8.75915163168527,8.4625,0.824455755151374,0.883244026040552,0.0206971890285941,0.439624461746346,0.278051959769205,0.161572501977141,7.6580368035742,3.9448,1.10111482811107,4.5177,0.78770932971906,0.775237034107169,0.84387737654039,0.77815019078292,0.0124722956118913,0.0657271857574698,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
27322,1049:1046,Breast,HCC1500,SIDM00879,1303900,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1046,Wee1 Inhibitor,"WEE1, CHEK1",Cell cycle,Targeted,Experimental only,10.0,0.85676092204706,0.0879482927788898,0.460132823006387,8.75915163168527,8.4625,0.824455755151374,0.883244026040552,0.0851390480504336,0.394223821703069,0.174654591723688,0.219569229979381,6.9467487570355,2.4094,1.81240287464977,6.0531,0.706361472970497,0.623843375544448,0.756728966143061,0.652070270480088,0.0825180974260489,0.104658695662973,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
27322,1047:1046,Breast,HCC1500,SIDM00879,1303900,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1046,Wee1 Inhibitor,"WEE1, CHEK1",Cell cycle,Targeted,Experimental only,10.0,0.83031551179663,0.0879482927788898,0.460132823006387,8.75915163168527,8.4625,0.824455755151374,0.883244026040552,0.0528531708278763,0.382055420428977,0.170814294212953,0.211241126216023,6.96403297682502,2.4384,1.79511865486025,6.0241,0.68455840229219,0.605928905053358,0.733371215523177,0.633076948189446,0.0786294972388328,0.100294267333731,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
27322,1011:1046,Breast,HCC1500,SIDM00879,1303900,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1046,Wee1 Inhibitor,"WEE1, CHEK1",Cell cycle,Targeted,Experimental only,10.0,0.133942652555674,0.0879482927788898,0.460132823006387,8.75915163168527,8.4625,0.824455755151374,0.883244026040552,0.0591294714930998,0.0616314108414059,0.0326160486182506,0.0290153622231553,7.29162216963995,3.06,1.46752946204531,5.4025,0.110429790759766,0.0484729225891444,0.118304047701824,0.105509038553272,0.0619568681706218,0.0127950091485524,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
26765,1049:1050,Breast,HCC1500,SIDM00879,1303900,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.968377292927658,0.0744754708370595,0.755501245400971,10.7002796223813,32.4964,0.95393699073725,0.957808580729746,0.13670493953446,0.731610250824867,0.571228774168341,0.160381476656525,9.54780403013299,14.6186,1.15247559224835,17.8778,0.923770920713694,0.919334877022874,0.927520080549953,0.891475925173785,0.0044360436908205,0.0360441553761685,True,1.1120462227238,0.132945306621086,-0.12825704405729,-480.978366743755
26765,1558:1050,Breast,HCC1500,SIDM00879,1303900,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.997758646163429,0.0744754708370595,0.755501245400971,10.7002796223813,32.4964,0.95393699073725,0.957808580729746,0.0566881029935193,0.753807899786057,0.584175911390497,0.16963198839556,9.520472725516,14.3443,1.17980689686534,18.1521,0.951798880403214,0.924006211541869,0.955661792792626,0.917402158033392,0.0277926688613449,0.0382596347592343,True,1.1120462227238,0.132945306621086,-0.12825704405729,-480.978366743755
26765,1012:1051,Breast,HCC1500,SIDM00879,1303900,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.965693553716779,0.0713173962961293,0.932613612927114,12.9600072992806,155.6256,0.946390108370929,0.989500044389763,0.0391274888217558,0.900618954112229,0.696102225502379,0.20451672860985,10.4296297016697,26.9378,2.53037759761098,128.6878,0.91392282695513,0.894748328946876,0.95555381426966,0.918124785756879,0.019174498008254,0.0374290285127811,True,1.1120462227238,0.132945306621086,-0.12825704405729,-480.978366743755
26765,1047:1051,Breast,HCC1500,SIDM00879,1303900,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.766801601562572,0.0713173962961293,0.932613612927114,12.9600072992806,155.6256,0.946390108370929,0.989500044389763,0.0500549991010353,0.715129612031568,0.618378923610138,0.0967506884214301,11.1507040544595,44.4044,1.8093032448211,111.2212,0.725693450801805,0.714838167018871,0.758750218784306,0.741976792937568,0.0108552837829339,0.0167734258467382,True,1.1120462227238,0.132945306621086,-0.12825704405729,-480.978366743755
26765,1011:1051,Breast,HCC1500,SIDM00879,1303900,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.123887645395262,0.0713173962961293,0.932613612927114,12.9600072992806,155.6256,0.946390108370929,0.989500044389763,0.0628167225439156,0.115539304569109,0.0824657748064066,0.0330735297627023,10.0377581906991,20.5303,2.92224910858152,135.0953,0.117246042151442,0.0513218531386004,0.122586830617955,0.116300915059607,0.0659241890128413,0.0062859155583487,True,1.1120462227238,0.132945306621086,-0.12825704405729,-480.978366743755
26765,1594:1051,Breast,HCC1500,SIDM00879,1303900,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.773920965302543,0.0713173962961293,0.932613612927114,12.9600072992806,155.6256,0.946390108370929,0.989500044389763,0.153211885946778,0.721769227570844,0.405118794966794,0.31665043260405,9.14154784879011,11.0309,3.81845945049053,144.5947,0.732431146223208,0.566036010022334,0.765794829521034,0.698561462150461,0.166395136200874,0.0672333673705736,True,1.1120462227238,0.132945306621086,-0.12825704405729,-480.978366743755
27316,1191:1052,Breast,HCC1500,SIDM00879,1303900,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.0025,1052,RO-3306,CDK1,Cell cycle,Targeted,Experimental only,10.0,0.760121083284194,0.0876314938678719,0.48553801670961,8.91279239980283,9.4134,0.871449631828259,0.891321128856712,0.0580416804287131,0.369067683236968,0.100225729663526,0.268841953573442,6.15961309038472,1.3962,2.75317930941811,8.0172,0.662407238172908,0.534429325062211,0.677511982020655,0.529005408613332,0.127977913110698,0.148506573407323,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
27316,1049:1052,Breast,HCC1500,SIDM00879,1303900,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1052,RO-3306,CDK1,Cell cycle,Targeted,Experimental only,10.0,0.959879316493093,0.0876314938678719,0.48553801670961,8.91279239980283,9.4134,0.871449631828259,0.891321128856712,0.0574329526181124,0.466057899610632,0.375974295334453,0.0900836042761793,8.33654313129566,6.3136,0.576249268507167,3.0998,0.836486476957466,0.830575502543928,0.855560715942833,0.824581952491706,0.0059109744135386,0.0309787634511268,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
27316,1047:1052,Breast,HCC1500,SIDM00879,1303900,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1052,RO-3306,CDK1,Cell cycle,Targeted,Experimental only,10.0,0.794412048972324,0.0876314938678719,0.48553801670961,8.91279239980283,9.4134,0.871449631828259,0.891321128856712,0.135593864303631,0.38571725070824,0.114465708901211,0.271251541807029,6.31472157918577,1.5547,2.59807082061706,7.8587,0.692290087596864,0.531741208801461,0.708076244267386,0.563392598037391,0.160548878795403,0.144683646229995,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
27316,1012:1059,Breast,HCC1500,SIDM00879,1303900,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.848724412592019,0.155715497026605,0.489687315728261,8.93782172868503,0.9578,0.777464903911412,0.892600150918609,0.097604892124522,0.415609579395231,0.387829986200052,0.0277795931951789,8.73986965567351,0.835,0.197952073011514,0.1228,0.659853443883124,0.692398783357587,0.757571538767945,0.748747204307463,-0.0325453394744626,0.0088243344604815,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
27316,1047:1059,Breast,HCC1500,SIDM00879,1303900,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.794412048972324,0.155715497026605,0.489687315728261,8.93782172868503,0.9578,0.777464903911412,0.892600150918609,0.107509550520307,0.389013503843445,0.035022506423795,0.35399099741965,4.36333584444799,0.0402,4.57448588423704,0.9176,0.617627487320336,0.418028626318471,0.709092314804258,0.424033418443581,0.199598861001865,0.285058896360677,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
27316,1011:1059,Breast,HCC1500,SIDM00879,1303900,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.0975291055834954,0.155715497026605,0.489687315728261,8.93782172868503,0.9578,0.777464903911412,0.892600150918609,0.0597044531288114,0.04775876591856,0.0197620008464541,0.0279967650721059,6.93532140859,0.239,2.00250032009502,0.7188,0.0758254567010382,0.0153780354579806,0.087054494362785,0.0741399827736374,0.0604474212430576,0.0129145115891476,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
27316,1558:1059,Breast,HCC1500,SIDM00879,1303900,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.971508562052795,0.155715497026605,0.489687315728261,8.93782172868503,0.9578,0.777464903911412,0.892600150918609,0.171550891313677,0.475735419958656,0.25951455957653,0.216220860382126,7.47893781984333,0.3484,1.45888390884169,0.6094,0.755313810845491,0.691066091309034,0.867168689107046,0.7787590695401,0.0642477195364569,0.0884096195669462,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
27318,1011:1085,Breast,HCC1500,SIDM00879,1303900,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.119895213070979,0.119148756063688,0.379903193989743,8.26157703248185,5.9939,0.873140428574535,0.854458640369874,0.0687350490349439,0.0455485743897458,0.008866117121461,0.0366824572682848,5.19069269559308,0.7133,3.07088433688878,5.2806,0.10468535772483,0.0058718866220362,0.102445500747485,0.073129993981258,0.098813471102794,0.0293155067662274,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
27318,1047:1086,Breast,HCC1500,SIDM00879,1303900,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1086,BI-2536,"PLK1, PLK2, PLK3",Cell cycle,Targeted,Early clinical trials,10.0,0.731557029620746,0.11189613138776,0.28509458003659,7.6144684406292,3.8275,0.819039942273119,0.811362944304768,0.0395841932949574,0.208562944132542,0.0619292631072352,0.146633681025307,5.41197609027396,0.8316,2.20249235035525,2.9959,0.59917442731007,0.461500565697778,0.593558265479939,0.460874960906592,0.137673861612292,0.132683304573346,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
27319,1011:1096,Breast,HCC1500,SIDM00879,1303900,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.150717339641952,0.0854903981411471,0.873170437556691,11.9076497150362,37.5197,0.945866133358224,0.9795886232384,0.0971231624656346,0.131601925402543,0.0231475114154905,0.108454413987053,6.42769762915135,0.8407,5.47995208588489,36.679,0.142558427277171,0.0097992225464824,0.147640991238014,0.108324582120611,0.132759204730689,0.039316409117403,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
27319,1012:1129,Breast,HCC1500,SIDM00879,1303900,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.914835922779999,0.0770650837083649,0.650914936196669,9.93902581869177,19.1723,0.936429430677612,0.935394321483566,0.11909070688183,0.595480366306764,0.491962440305475,0.103517926001289,9.22807015447746,11.7127,0.710955664214309,7.4596,0.856679282332303,0.866063967069739,0.855732327257589,0.82946118171222,-0.0093846847374362,0.0262711455453686,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
27319,1049:1129,Breast,HCC1500,SIDM00879,1303900,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.760100679900117,0.0770650837083649,0.650914936196669,9.93902581869177,19.1723,0.936429430677612,0.935394321483566,0.0981541310954057,0.494760885560229,0.27442060419314,0.220340281367089,8.1396080066428,5.508,1.79941781204896,13.6643,0.711780646936533,0.586325328199871,0.710993859734367,0.643658625382186,0.125455318736661,0.0673352343521808,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
27319,1047:1129,Breast,HCC1500,SIDM00879,1303900,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.850966840104112,0.0770650837083649,0.650914936196669,9.93902581869177,19.1723,0.936429430677612,0.935394321483566,0.113324719291859,0.553907026431849,0.25604541514669,0.297861611285159,7.72939285792906,4.1449,2.2096329607627,15.0274,0.79687039360422,0.606473589130849,0.7959895500042,0.697326781217001,0.190396804473371,0.098662768787199,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
27319,1011:1129,Breast,HCC1500,SIDM00879,1303900,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.194799127553756,0.0770650837083649,0.650914936196669,9.93902581869177,19.1723,0.936429430677612,0.935394321483566,0.0806455274830798,0.126797661682819,0.0188265642809298,0.10797109740189,5.63151691258645,0.9682,4.30750890610531,18.2041,0.182415636111659,0.0485523521438206,0.182213997743736,0.126555554004837,0.133863283967838,0.0556584437388983,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
27319,1510:1129,Breast,HCC1500,SIDM00879,1303900,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.89016660072244,0.0770650837083649,0.650914936196669,9.93902581869177,19.1723,0.936429430677612,0.935394321483566,0.0486308592638173,0.579422736113653,0.346175101731377,0.233247634382276,8.31880240920842,6.2365,1.62022340948335,12.9358,0.83357820312274,0.760644463699975,0.832656783490099,0.763735780509101,0.072933739422765,0.0689210029809987,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
27319,1558:1129,Breast,HCC1500,SIDM00879,1303900,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.969225288881143,0.0770650837083649,0.650914936196669,9.93902581869177,19.1723,0.936429430677612,0.935394321483566,0.120435003194504,0.630883217072267,0.536326252148045,0.0945569649242217,9.32288070740634,12.5083,0.616145111285425,6.664,0.907611085465312,0.861640118608745,0.906607831457689,0.88294068136425,0.0459709668565674,0.0236671500934389,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
27319,1058:1129,Breast,HCC1500,SIDM00879,1303900,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.984979378318034,0.0770650837083649,0.650914936196669,9.93902581869177,19.1723,0.936429430677612,0.935394321483566,0.114011326968223,0.641137789192918,0.519761704490327,0.12137608470259,9.16708594925784,11.2279,0.771939869433924,7.9444,0.922363678467545,0.844486405301751,0.921344117257102,0.890258761129826,0.0778772731657942,0.031085356127276,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
27320,1049:1192,Breast,HCC1500,SIDM00879,1303900,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.929103725735448,0.0799466233525721,0.53473220339937,9.2097189436579,11.5646,0.855541153087267,0.905828575570764,0.071681982927136,0.496821682449081,0.604450116989611,-0.107628434540531,9.93676065073855,19.1423,-0.727041707080655,-7.5777,0.794886472853382,0.85374520538702,0.841608704440431,0.869004993812393,-0.0588587325336389,-0.0273962893719626,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
27320,1012:1192,Breast,HCC1500,SIDM00879,1303900,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.741846855986438,0.0799466233525721,0.53473220339937,9.2097189436579,11.5646,0.855541153087267,0.905828575570764,0.0819326740325678,0.396689403886524,0.189551109104979,0.207138294781544,7.38825748954531,3.272,1.82146145411258,8.2926,0.634680514584801,0.544067756955084,0.671986080849845,0.589718292137809,0.0906127576297177,0.0822677887120355,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
27320,1011:1192,Breast,HCC1500,SIDM00879,1303900,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.0975080572506768,0.0799466233525721,0.53473220339937,9.2097189436579,11.5646,0.855541153087267,0.905828575570764,0.0729077134866175,0.0521406983028464,0.0609299070955897,-0.0087892087927432,9.76903832263752,17.0413,-0.559319378979625,-5.4767,0.0834221557355433,0.0190980192298553,0.088325584606053,0.0906096316015659,0.064324136505688,-0.0022840469955128,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
27323,1011:1373,Breast,HCC1500,SIDM00879,1303900,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10.0,0.103340227980314,0.0300003134775365,0.963908580482341,13.9507722670407,309.2651,0.98429724977842,0.994467447067369,0.0446238719450546,0.0996105324592257,0.0724548196816248,0.0271557127776009,10.2850826985014,24.3696,3.66568956853925,284.8955,0.101717502192498,0.053300578471248,0.102768492698942,0.0978189993293603,0.0484169237212498,0.0049494933695821,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
27507,1012:1553,Breast,HCC1500,SIDM00879,1303900,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.732415995569166,0.0691064667366821,0.884814965066622,12.0727569229409,84.138,0.95022190284591,0.981582227820063,0.0559784738271208,0.648052633533767,0.424090311499973,0.223962322033794,9.48045170691559,13.9518,2.59230521602535,70.1862,0.695957720984515,0.648473111098032,0.718926524621831,0.67220769009645,0.0474846098864832,0.0467188345253818,True,1.18990599600383,0.10938205659987,-0.190979286348821,-292.434997055326
27507,1011:1553,Breast,HCC1500,SIDM00879,1303900,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.190934447721706,0.0691064667366821,0.884814965066622,12.0727569229409,84.138,0.95022190284591,0.981582227820063,0.121278165832157,0.168941656690896,0.0457970071173736,0.123144649573522,7.26160371959205,2.997,4.81115320334888,81.141,0.181430094232952,0.034580376255143,0.187417860562265,0.149970217947568,0.146849717977809,0.0374476426146977,True,1.18990599600383,0.10938205659987,-0.190979286348821,-292.434997055326
27507,1049:1553,Breast,HCC1500,SIDM00879,1303900,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.830082323581513,0.0691064667366821,0.884814965066622,12.0727569229409,84.138,0.95022190284591,0.981582227820063,0.106314903743857,0.734469262142197,0.452642630002576,0.281826632139621,9.27383024405598,12.0901,2.79892667888496,72.0479,0.78876240503238,0.763214490819067,0.814794056455196,0.754354256416895,0.0255479142133134,0.0604398000383013,True,1.18990599600383,0.10938205659987,-0.190979286348821,-292.434997055326
27507,1047:1553,Breast,HCC1500,SIDM00879,1303900,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.873445977003369,0.0691064667366821,0.884814965066622,12.0727569229409,84.138,0.95022190284591,0.981582227820063,0.0776709911563012,0.772838071629817,0.611855798570734,0.160982273059083,10.2806189588639,24.2943,1.792137964077,59.8437,0.829967498301246,0.798024369280022,0.857359047987438,0.826663357189279,0.0319431290212245,0.0306956907981594,True,1.18990599600383,0.10938205659987,-0.190979286348821,-292.434997055326
27507,1011:1560,Breast,HCC1500,SIDM00879,1303900,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.206668488259104,0.0574753300400311,0.909264543754812,12.473421221345,111.0718,0.962976079919756,0.985684227661507,0.0859793200767024,0.187916328685411,0.05546607129856,0.132450257386851,7.48859650096865,3.5077,4.98482472037638,107.5641,0.199016810666694,0.0790486185377971,0.203709869231646,0.165810446195114,0.119968192128897,0.037899423036532,True,1.18990599600383,0.10938205659987,-0.190979286348821,-292.434997055326
27507,1047:1560,Breast,HCC1500,SIDM00879,1303900,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.404686845669371,0.0574753300400311,0.909264543754812,12.473421221345,111.0718,0.962976079919756,0.985684227661507,0.0580576262333699,0.367967400091135,0.255864757408349,0.112102642682786,9.81669980198634,17.6137,2.65672141935869,93.4581,0.389703752237782,0.315635610001157,0.398893440918386,0.376771292495348,0.0740681422366253,0.0221221484230382,True,1.18990599600383,0.10938205659987,-0.190979286348821,-292.434997055326
27507,1049:1560,Breast,HCC1500,SIDM00879,1303900,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.830082323581513,0.0574753300400311,0.909264543754812,12.473421221345,111.0718,0.962976079919756,0.985684227661507,0.0641376732585608,0.754764425230278,0.547545113599278,0.207219311631,9.99715700161015,19.9606,2.47626421973488,91.1112,0.799349421973208,0.753613414952559,0.818199054014913,0.778114361109994,0.0457360070206487,0.0400846929049191,True,1.18990599600383,0.10938205659987,-0.190979286348821,-292.434997055326
27326,1012:1632,Breast,HCC1500,SIDM00879,1303900,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.648691201945032,0.0816611743779965,0.8927669212255,12.1940523464547,36.6071,0.946892751700164,0.982928647606842,0.0842140708832753,0.579130047186535,0.522527817032434,0.0566022301541013,11.1417565892422,17.652,1.0522957572125,18.9551,0.614240997213418,0.570552305838607,0.637617165842287,0.627577725722473,0.0436886913748116,0.0100394401198139,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
27326,1011:1632,Breast,HCC1500,SIDM00879,1303900,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.11850866123078,0.0816611743779965,0.8927669212255,12.1940523464547,36.6071,0.946892751700164,0.982928647606842,0.0709502242252739,0.105800612625559,0.0106565154752406,0.0951440971503184,5.51165551138764,0.3564,6.68239683506711,36.2507,0.112214992333116,0.0152571632736053,0.116485558113268,0.0757216814456482,0.0969578290595103,0.0407638766676195,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
27323,1021:2172,Breast,HCC1500,SIDM00879,1303900,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.910263572685901,0.128954959229072,0.597107645383685,9.59293978434093,15.0832,0.836317763865428,0.922418109596662,0.162489731173171,0.543525338565019,0.404513872597777,0.139011465967242,8.66337786520088,7.9189,0.929561919140054,7.1643,0.761269595636828,0.670098551775065,0.839643603951632,0.799223498848907,0.0911710438617631,0.0404201051027258,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
27323,1191:2172,Breast,HCC1500,SIDM00879,1303900,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.0025,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.981722955144281,0.128954959229072,0.597107645383685,9.59293978434093,15.0832,0.836317763865428,0.922418109596662,0.0662709539365547,0.586194282165315,0.0619426869704111,0.524251595194904,4.93392628485387,0.597,4.65901349948706,14.4862,0.821032346581625,0.56143143628994,0.905559032431837,0.575761734451489,0.259600910291686,0.329797297980348,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
27323,1049:2172,Breast,HCC1500,SIDM00879,1303900,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.932054348816036,0.128954959229072,0.597107645383685,9.59293978434093,15.0832,0.836317763865428,0.922418109596662,0.121672072161878,0.556536777591168,0.489561052501578,0.0669757250895897,9.15234463637381,11.1137,0.440595147967125,3.9695,0.779493608802875,0.764619344720819,0.859743810476236,0.84177427432543,0.0148742640820561,0.0179695361508059,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
27323,1558:2172,Breast,HCC1500,SIDM00879,1303900,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.992612012362129,0.128954959229072,0.597107645383685,9.59293978434093,15.0832,0.836317763865428,0.922418109596662,0.0881076759489619,0.592696221481113,0.599587050225316,-0.0068908287442028,9.63655566219856,15.5461,-0.0436158778576221,-0.462899999999999,0.830139058564659,0.867802691451008,0.915603296006014,0.917328743644044,-0.0376636328863492,-0.0017254476380306,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
27323,1047:2172,Breast,HCC1500,SIDM00879,1303900,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.807317777114194,0.128954959229072,0.597107645383685,9.59293978434093,15.0832,0.836317763865428,0.922418109596662,0.150252717716714,0.482055616969047,0.227377685031671,0.254677931937376,7.58887302733242,3.7602,2.00406675700852,11.323,0.67517419808495,0.543360699306336,0.744684537809454,0.653553747253048,0.131813498778614,0.0911307905564057,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
27323,1007:2172,Breast,HCC1500,SIDM00879,1303900,1007,Docetaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.001,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.942895980213484,0.128954959229072,0.597107645383685,9.59293978434093,15.0832,0.836317763865428,0.922418109596662,0.128141611043442,0.563010398587016,0.477438279900487,0.0855721186865287,9.03830123243224,10.269,0.554638551908692,4.8142,0.788560657729842,0.752506867937892,0.869744327614814,0.846372413583076,0.0360537897919498,0.0233719140317374,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
27323,1012:2172,Breast,HCC1500,SIDM00879,1303900,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.815835876514524,0.128954959229072,0.597107645383685,9.59293978434093,15.0832,0.836317763865428,0.922418109596662,0.114193132248562,0.487141839245123,0.235807272948381,0.251334566296741,7.64350547495788,3.9053,1.94943430938305,11.1779,0.682298035927818,0.578631748421334,0.752541786955663,0.663620204983083,0.103666287506484,0.0889215819725806,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
25054,1022:1003,Breast,HDQ-P1,SIDM01062,1290922,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.995945222908746,0.0635834986334884,0.789552262006192,12.8547266079234,1.4467,0.930479785411356,0.933619462299764,0.102580659637534,0.786350803581861,0.381392180380631,0.40495862320123,7.60919439356122,0.0381,5.24553221436221,1.4086,0.926706897293596,0.76405844858715,0.929833843492083,0.732016354167106,0.162648448706446,0.197817489324977,True,0.703183336265105,0.0984298166640172,0.326794914173339,144.790142859417
25054,1179:1003,Breast,HDQ-P1,SIDM01062,1290922,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.503971857289864,0.0635834986334884,0.789552262006192,12.8547266079234,1.4467,0.930479785411356,0.933619462299764,0.0679049675236157,0.397912119910674,0.191873159815312,0.206038960095361,7.58173816636557,0.0374,5.27298844155786,1.4093,0.468935625624435,0.324943279098191,0.470517934417176,0.369631162446849,0.143992346526245,0.100886771970328,True,0.703183336265105,0.0984298166640172,0.326794914173339,144.790142859417
25054,1011:1003,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.63415362386099,0.0635834986334884,0.789552262006192,12.8547266079234,1.4467,0.930479785411356,0.933619462299764,0.07987202798637,0.500697428178868,0.18404807015028,0.316649358028588,6.39286797222448,0.0164,6.46185863569896,1.4303,0.590067127848008,0.398437914920622,0.592058165324544,0.41953421703463,0.191629212927386,0.172523948289914,True,0.703183336265105,0.0984298166640172,0.326794914173339,144.790142859417
25055,1011:1025,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.580816559227808,0.0993084995674416,0.859156530788213,14.2717884189179,386.3371,0.936468772272849,0.957287653012845,0.0832907582942534,0.49901234005051,0.277102790112765,0.221909549937744,8.73267287576869,8.3086,5.53911554314925,378.0285,0.543916570135806,0.434701801953936,0.556008520814184,0.461412313099142,0.10921476818187,0.0945962077150422,True,0.703183336265105,0.0984298166640172,0.326794914173339,144.790142859417
28375,1561:1032,Breast,HDQ-P1,SIDM01062,1290922,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.868128292157876,0.106340929501804,0.326782181173185,6.89287554560527,2.3211,0.655133353217163,0.69275951934501,0.147847615644733,0.283688856849503,0.123992558017438,0.159696298832065,3.77573165839681,0.2675,3.11714388720845,2.0536,0.568739799064078,0.38549044008467,0.601404138405095,0.420536643979753,0.183249358979408,0.180867494425341,True,0.349622540569322,0.0472529798870771,1.00813396186302,48.7704804755436
28375,1510:1032,Breast,HDQ-P1,SIDM01062,1290922,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.85332644204046,0.106340929501804,0.326782181173185,6.89287554560527,2.3211,0.655133353217163,0.69275951934501,0.0953755016990628,0.278851875982735,0.142345615043019,0.136506260939717,4.31102750730149,0.3877,2.58184803830378,1.9334,0.559042613362838,0.412639305672581,0.591150015832337,0.445099679578704,0.146403307690256,0.146050336253633,True,0.349622540569322,0.0472529798870771,1.00813396186302,48.7704804755436
28375,1011:1032,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.632175655105099,0.106340929501804,0.326782181173185,6.89287554560527,2.3211,0.655133353217163,0.69275951934501,0.0668248074076183,0.206583739459832,0.0892746851850585,0.117309054274773,3.73722880790854,0.2605,3.15564673769673,2.0606,0.41415935675126,0.275533252957017,0.437945702972225,0.30454691986006,0.138626103794243,0.133398783112166,True,0.349622540569322,0.0472529798870771,1.00813396186302,48.7704804755436
28375,1011:1038,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.632175655105099,0.098059597730463,0.695673698778236,11.4103332822443,53.1597,0.927750724823693,0.898311061991772,0.100448106828852,0.439787976264519,0.261543443176865,0.178244533087654,7.9836889798766,4.9438,3.42664430236768,48.2159,0.586501422239649,0.514756132663529,0.567890384102806,0.477787732933608,0.0717452895761191,0.0901026511691984,True,0.349622540569322,0.0472529798870771,1.00813396186302,48.7704804755436
28376,1549:1050,Breast,HDQ-P1,SIDM01062,1290922,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.694549634320389,0.0942469384990128,0.701035974569456,11.4845449641691,55.9658,0.927028363870126,0.900447220334404,0.0687362594143818,0.486904279782653,0.288460496219903,0.19844378356275,8.00291639189222,5.0101,3.4816285722769,50.9557,0.643867211130625,0.531820577468353,0.625405287608071,0.525652402885399,0.112046633662272,0.0997528847226715,True,0.349622540569322,0.0472529798870771,1.00813396186302,48.7704804755436
28376,1558:1050,Breast,HDQ-P1,SIDM01062,1290922,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.788818308020119,0.0942469384990128,0.701035974569456,11.4845449641691,55.9658,0.927028363870126,0.900447220334404,0.0864964192912859,0.552990011321114,0.413798511498653,0.139191499822461,9.28686902938137,12.1999,2.19767593478776,43.7659,0.731256945474692,0.661142974701209,0.710289252805604,0.647105833226871,0.0701139707734837,0.0631834195787331,True,0.349622540569322,0.0472529798870771,1.00813396186302,48.7704804755436
28376,1011:1050,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.618312879095209,0.0942469384990128,0.701035974569456,11.4845449641691,55.9658,0.927028363870126,0.900447220334404,0.0757467271945601,0.433459571785356,0.191178288756269,0.242281283029087,6.65639128174731,1.9702,4.82815368242181,53.9956,0.573193576667459,0.433646560816416,0.556758113278243,0.419319098817257,0.139547015851043,0.137439014460987,True,0.349622540569322,0.0472529798870771,1.00813396186302,48.7704804755436
28376,1011:1051,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.618312879095209,0.0742340124171544,0.525535501899465,9.29803646787782,12.2947,0.806201094962749,0.820847004029234,0.081334105827405,0.324945369246204,0.0600846694989013,0.264860699747303,2.50170182563104,0.1106,6.79633464224678,12.1841,0.498484520156128,0.207271780300104,0.507540274357992,0.245498989720219,0.291212739856024,0.262041284637774,True,0.349622540569322,0.0472529798870771,1.00813396186302,48.7704804755436
25056,1011:1052,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1052,RO-3306,CDK1,Cell cycle,Targeted,Experimental only,10.0,0.576561011261536,0.0641726631179209,0.657935739645508,10.9069394413413,37.5013,0.904425991612416,0.88281776581552,0.0887276147589158,0.379340095395121,0.166896990531413,0.212443104863707,6.38215293221705,1.6291,4.5247865091242,35.8722,0.521456764335272,0.386764310202035,0.508998303818246,0.381039614933225,0.134692454133238,0.127958688885021,True,0.703183336265105,0.0984298166640172,0.326794914173339,144.790142859417
25056,1011:1059,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.576561011261536,0.0754295684394439,0.495045335434445,8.94222027465969,0.9607,0.773527352037668,0.804495549449372,0.0447909972584298,0.28542383921839,0.149046077741505,0.136377761476885,5.92802353489489,0.1189,3.0141967397648,0.8418,0.445985712329296,0.339302847225201,0.463840767545935,0.364098844186161,0.106682865104095,0.0997419233597742,True,0.703183336265105,0.0984298166640172,0.326794914173339,144.790142859417
25057,1011:1080,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.72904818290787,0.0990405994675961,0.601731022280244,10.2031049735787,0.2302,0.827624989141054,0.858099934333233,0.106425656812056,0.438690908392706,0.0908519431189723,0.347838965273734,3.3168223571339,0.0019,6.88628261644484,0.2283,0.603378494462431,0.294584426538536,0.625596197879006,0.329990704723287,0.308794067923895,0.295605493155719,True,0.703183336265105,0.0984298166640172,0.326794914173339,144.790142859417
25058,1011:1085,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.583813364117093,0.0741829638337519,0.662002185961124,10.9597674040515,38.8999,0.900419357638892,0.884527378304345,0.107323576348432,0.386485723238833,0.181449984181876,0.205035739056957,6.67830624126509,2.0003,4.28146116278637,36.8996,0.525676854299314,0.430533892637047,0.516398904381532,0.396719471492926,0.0951429616622668,0.119679432888607,True,0.703183336265105,0.0984298166640172,0.326794914173339,144.790142859417
25058,1011:1086,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1086,BI-2536,"PLK1, PLK2, PLK3",Cell cycle,Targeted,Early clinical trials,10.0,0.583813364117093,0.104045327706364,0.470320182816559,8.65348735303329,7.8648,0.785225649046174,0.790527546027864,0.112827723438716,0.274579208142301,0.026402518572005,0.248176689570296,0.108715329901862,0.0211,8.54477202313143,7.8437,0.458425227760674,0.136877215974355,0.461520546073757,0.145520221601117,0.32154801178632,0.31600032447264,True,0.703183336265105,0.0984298166640172,0.326794914173339,144.790142859417
25059,1011:1096,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.609987876601182,0.0667916377143038,0.862837545791203,14.3614591746933,205.5559,0.94908473033563,0.958487408937265,0.0641835905049559,0.526320442408951,0.141209512428959,0.385110929979992,5.50194386007174,0.4425,8.85951531462157,205.1134,0.578930179372036,0.319337451078471,0.584665699326612,0.367943629055135,0.259592728293566,0.216722070271477,True,0.703183336265105,0.0984298166640172,0.326794914173339,144.790142859417
27664,1561:1553,Breast,HDQ-P1,SIDM01062,1290922,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.896682604200825,0.0851370668206366,0.632579472808116,10.5838927428969,29.9778,0.874071173629174,0.8719252045986,0.0860881094211469,0.567223009041566,0.397651551335964,0.169571457705603,8.33795238032235,6.3198,2.24594036257458,23.658,0.78376441622668,0.667406320448979,0.78184016312781,0.694534674385649,0.1163580957777,0.0873054887421613,True,,,,
27664,1372:1553,Breast,HDQ-P1,SIDM01062,1290922,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.847135488102248,0.0851370668206366,0.632579472808116,10.5838927428969,29.9778,0.874071173629174,0.8719252045986,0.0584562765459997,0.535880520460766,0.430531643900642,0.105348876560123,9.09587067308437,10.6871,1.48802206981255,19.2907,0.740456710308455,0.650923347936535,0.738638783786288,0.687597867488513,0.0895333623719204,0.0510409162977743,True,,,,
27664,1011:1553,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.69722006038452,0.0851370668206366,0.632579472808116,10.5838927428969,29.9778,0.874071173629174,0.8719252045986,0.0785630574310287,0.441047098229282,0.237687852674471,0.203359245554811,7.07806963116436,2.639,3.50582311173257,27.3388,0.609419956458101,0.446829209559661,0.607923743801021,0.490823702125602,0.16259074689844,0.117100041675419,True,,,,
27664,1011:1560,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.69722006038452,0.0754571335451481,0.639480278657482,10.6707994690361,31.8391,0.879684636526827,0.874930193561394,0.0547277933158686,0.445858478500279,0.18756439640319,0.258294082097089,6.0858027432364,1.3266,4.58499672579973,30.5125,0.613333775398569,0.43830845159901,0.610018882387115,0.447482376466203,0.175025323799558,0.162536505920912,True,,,,
27665,1058:1564,Breast,HDQ-P1,SIDM01062,1290922,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.873037899521778,0.108975027893338,0.603580547943841,10.2256220371483,11.6928,0.809777439118531,0.858947566712921,0.141896641870136,0.526948693769095,0.255486464218761,0.271462229550334,6.42695457935894,0.8402,3.79866745778933,10.8526,0.706966394528166,0.497205823496992,0.749893779442391,0.579463255374568,0.209760571031174,0.170430524067823,True,,,,
27665,1561:1564,Breast,HDQ-P1,SIDM01062,1290922,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.829763191882652,0.108975027893338,0.603580547943841,10.2256220371483,11.6928,0.809777439118531,0.858947566712921,0.0865704788451159,0.500828922020162,0.286667964539009,0.214160957481153,7.13722366023367,1.3747,3.0883983769146,10.3181,0.671923512597552,0.548170700539627,0.712723074615551,0.587067833135615,0.123752812057925,0.125655241479936,True,,,,
27665,1011:1564,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.65550830331431,0.108975027893338,0.603580547943841,10.2256220371483,11.6928,0.809777439118531,0.858947566712921,0.089586038349101,0.395652060896189,0.1938067355528,0.201845325343389,6.46933075348031,0.8653,3.75629128366797,10.8275,0.530815835178795,0.422788462374965,0.563047262091942,0.436842306980024,0.10802737280383,0.126204955111918,True,,,,
27665,1559:1564,Breast,HDQ-P1,SIDM01062,1290922,1559,Luminespib,HSP90,Protein stability and degradation,Targeted,Early clinical trials,0.01,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.920626967988599,0.108975027893338,0.603580547943841,10.2256220371483,11.6928,0.809777439118531,0.858947566712921,0.0751070201503969,0.555672529790436,0.463527533912764,0.0921449958776723,9.04071205105067,5.1431,1.18490998609761,6.5497,0.745502948521265,0.70789441662408,0.790770294004101,0.744895411019516,0.0376085318971852,0.0458748829845851,True,,,,
27665,1007:1593,Breast,HDQ-P1,SIDM01062,1290922,1007,Docetaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.001,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.935691476514034,0.0750469240107503,0.805698698940121,13.1464664562671,35.4194,0.920180730955112,0.939283532663772,0.0875663948564053,0.753885405236718,0.694090060642705,0.0597953445940128,12.0765788329717,16.8722,1.06988762329541,18.5472,0.861005266807152,0.812167273855,0.878879595543482,0.857272631697872,0.0488379929521517,0.0216069638456104,True,,,,
27665,1190:1593,Breast,HDQ-P1,SIDM01062,1290922,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.01,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.918821894952566,0.0750469240107503,0.805698698940121,13.1464664562671,35.4194,0.920180730955112,0.939283532663772,0.0531735658185494,0.740293605320979,0.690928990013909,0.04936461530707,12.2335657573491,18.8118,0.912900698918028,16.6076,0.845482202915014,0.880090815207511,0.863034275379867,0.845311003515221,-0.0346086122924971,0.0177232718646461,True,,,,
27665,1058:1593,Breast,HDQ-P1,SIDM01062,1290922,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.873037899521778,0.0750469240107503,0.805698698940121,13.1464664562671,35.4194,0.920180730955112,0.939283532663772,0.0616334225914287,0.703405499770112,0.577274253821658,0.126131245948454,10.9496436239567,7.7256,2.19682283231043,27.6938,0.803352652533465,0.760522467847668,0.820030122412174,0.771941243230321,0.042830184685797,0.0480888791818538,True,,,,
27665,1191:1593,Breast,HDQ-P1,SIDM01062,1290922,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.000625,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.925650979909112,0.0750469240107503,0.805698698940121,13.1464664562671,35.4194,0.920180730955112,0.939283532663772,0.0742708867648305,0.74579579018542,0.587355799973065,0.158439990212354,10.6084197311965,6.0984,2.53804672507067,29.321,0.851766195302083,0.791908251056772,0.869448722422713,0.807888631866128,0.0598579442453111,0.0615600905565845,True,,,,
27665,1011:1593,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.65550830331431,0.0750469240107503,0.805698698940121,13.1464664562671,35.4194,0.920180730955112,0.939283532663772,0.0751472369054198,0.528142187124786,0.193851530672008,0.334290656452777,6.4702873671213,0.3463,6.67617908914583,35.0731,0.603186109690907,0.420667632238809,0.6157081548275,0.436881981565194,0.182518477452099,0.178826173262306,True,,,,
27665,1561:1593,Breast,HDQ-P1,SIDM01062,1290922,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.829763191882652,0.0750469240107503,0.805698698940121,13.1464664562671,35.4194,0.920180730955112,0.939283532663772,0.0701776312000319,0.668539124128255,0.588524017455634,0.080015106672621,11.5999711904104,12.1255,1.54649526585677,23.2939,0.763532100426226,0.764046657065209,0.779382902145905,0.749853857231717,-0.0005145566389828,0.0295290449141876,True,,,,
27666,1558:1632,Breast,HDQ-P1,SIDM01062,1290922,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.783730349861893,0.0551958881792292,0.932641690602184,16.6614595380849,809.8212,0.976592673355849,0.980351237301847,0.161219383031363,0.730939598471437,0.44843327135565,0.282506327115787,9.84761024678634,7.1981,6.81384929129857,802.6231,0.765385317561741,0.541045357857272,0.768331018198117,0.661633382079814,0.224339959704469,0.106697636118302,True,,,,
25057,1561:2169,Breast,HDQ-P1,SIDM01062,1290922,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.773428889203662,0.101641508696446,0.547204262942882,9.55210733347463,14.6623,0.840704012738881,0.831934252563428,0.154644508548793,0.423223585255421,0.213029528225516,0.210194057029906,6.1802423921494,1.4163,3.37186494132524,13.246,0.650224770721693,0.426736209566742,0.643441984850611,0.501127800557638,0.223488561154951,0.142314184292972,True,0.703183336265105,0.0984298166640172,0.326794914173339,144.790142859417
24299,1022:1003,Breast,JIMT-1,SIDM01037,1298157,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.977521430890647,0.0610541557445718,0.810637614713025,11.582011060089,0.5988,0.947314472360257,0.962872490379962,0.12133095180034,0.792415641068058,0.42109787106562,0.371317770002438,8.50520190668981,0.071,3.07680915339923,0.5278,0.926020198525017,0.812760018736656,0.941228494561462,0.832168831518052,0.113260179788361,0.10905966304341,True,0.675969748037785,0.0750942135982808,0.372709379475618,129.451808920075
24299,1372:1003,Breast,JIMT-1,SIDM01037,1298157,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.969181863006949,0.0610541557445718,0.810637614713025,11.582011060089,0.5988,0.947314472360257,0.962872490379962,0.0365523484922053,0.785655273651079,0.706353949026147,0.0793013246249329,10.7553931171024,0.3376,0.826617942986601,0.2612,0.918120005175559,0.909395564753117,0.933198554064592,0.914973336339254,0.0087244404224414,0.018225217725338,True,0.675969748037785,0.0750942135982808,0.372709379475618,129.451808920075
24299,1179:1003,Breast,JIMT-1,SIDM01037,1298157,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.542136651297312,0.0610541557445718,0.810637614713025,11.582011060089,0.5988,0.947314472360257,0.962872490379962,0.0202399495841529,0.43947636185616,0.227043010292175,0.212433351563984,8.41808030286245,0.0668,3.16393075722659,0.532,0.513573895770869,0.438105299905433,0.522008467560895,0.45882954546209,0.0754685958654367,0.0631789220988057,True,0.675969748037785,0.0750942135982808,0.372709379475618,129.451808920075
24299,1011:1003,Breast,JIMT-1,SIDM01037,1298157,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.832725741268007,0.0610541557445718,0.810637614713025,11.582011060089,0.5988,0.947314472360257,0.962872490379962,0.0905212950767841,0.675038808611633,0.413803235854258,0.261235572757375,8.97816828712569,0.0985,2.60384277296335,0.5003,0.788853146210106,0.689792642611992,0.801808708298226,0.729860961946321,0.0990605035981137,0.071947746351905,True,0.675969748037785,0.0750942135982808,0.372709379475618,129.451808920075
24299,1058:1013,Breast,JIMT-1,SIDM01037,1298157,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1013,Nilotinib,ABL,ABL signaling,Targeted,FDA approved,10.0,1.0,0.0791179653385969,0.742124836256099,10.8768887193211,36.7282,0.95796412330224,0.947265606595329,0.152869859678515,0.742124836256099,0.563743216067776,0.178381620188323,9.45520798163825,13.7098,1.42168073768288,23.0184,0.95796412330224,0.867151076803475,0.947265606595329,0.898721549486037,0.090813046498765,0.0485440571092919,True,0.675969748037785,0.0750942135982808,0.372709379475618,129.451808920075
24299,1561:1013,Breast,JIMT-1,SIDM01037,1298157,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1013,Nilotinib,ABL,ABL signaling,Targeted,FDA approved,10.0,0.912901614747507,0.0791179653385969,0.742124836256099,10.8768887193211,36.7282,0.95796412330224,0.947265606595329,0.13427562260169,0.677486961362422,0.522773460308593,0.154713501053829,9.51967148892776,14.3363,1.35721723039337,22.3919,0.874526995032794,0.857855863505879,0.864760301855652,0.822969468048566,0.0166711315269148,0.0417908338070861,True,0.675969748037785,0.0750942135982808,0.372709379475618,129.451808920075
24299,1594:1013,Breast,JIMT-1,SIDM01037,1298157,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1013,Nilotinib,ABL,ABL signaling,Targeted,FDA approved,10.0,1.0,0.0791179653385969,0.742124836256099,10.8768887193211,36.7282,0.95796412330224,0.947265606595329,0.120677611031814,0.742124836256099,0.50199369367846,0.240131142577639,9.01416012412855,10.0986,1.86272859519258,26.6296,0.95796412330224,0.819904757409255,0.947265606595329,0.878260861514097,0.138059365892985,0.0690047450812328,True,0.675969748037785,0.0750942135982808,0.372709379475618,129.451808920075
24010,1012:1032,Breast,JIMT-1,SIDM01037,1298157,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.866545316444996,0.0893952952832265,0.430852878033625,8.50572081212278,7.0992,0.841943688185353,0.851334239451971,0.0652945028654979,0.373353543536884,0.160785630687404,0.21256791284948,6.37352025607704,1.6194,2.13220055604574,5.4798,0.729582359707444,0.56373651436872,0.737719697926368,0.609770179102053,0.165845845338724,0.127949518824316,True,0.429217451763087,0.0470851839379968,0.812888798923839,60.336039062316
24010,1011:1038,Breast,JIMT-1,SIDM01037,1298157,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.806825841195096,0.0609943079851531,0.684645434681104,10.3764551011569,25.963,0.931968785623448,0.93302316663461,0.0870783977269326,0.552389628756964,0.312414742308472,0.239974886448492,8.18493387558308,5.6838,2.19152122557387,20.2792,0.751936499428211,0.707506872955828,0.752787201274481,0.671713551794234,0.0444296264723827,0.0810736494802469,True,0.429217451763087,0.0470851839379968,0.812888798923839,60.336039062316
24011,1022:1046,Breast,JIMT-1,SIDM01037,1298157,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1046,Wee1 Inhibitor,"WEE1, CHEK1",Cell cycle,Targeted,Experimental only,10.0,0.922654975523108,0.0925522373342114,0.356037508132395,7.9477687275413,4.8222,0.779143071446688,0.81777647437526,0.0718503135227792,0.328499778351204,0.267962227389702,0.0605375509615019,7.41381660885234,3.3305,0.533952118688965,1.4917,0.718880231514643,0.735545912949245,0.754525532948079,0.72152510594857,-0.0166656814346016,0.0330004269995089,True,0.429217451763087,0.0470851839379968,0.812888798923839,60.336039062316
24012,1011:1050,Breast,JIMT-1,SIDM01037,1298157,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.903178859752463,0.156733737697006,0.530402018811742,9.21619459109391,11.6167,0.934206847241544,0.887967526669402,0.130380697710883,0.479047890560794,0.111153457787412,0.367894432773382,5.51327711805667,0.8921,3.70291747303724,10.7246,0.843755875064561,0.579572551887885,0.801993498234485,0.571246260339173,0.264183323176676,0.230747237895312,True,0.429217451763087,0.0470851839379968,0.812888798923839,60.336039062316
24012,1011:1051,Breast,JIMT-1,SIDM01037,1298157,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.903178859752463,0.0728622509225446,0.710526932278334,10.5943948176959,30.1968,0.915237003610452,0.939577899362885,0.09406060161503,0.641732904518561,0.007446873612248,0.634286030906313,0.495124269259332,0.0275,10.0992705484365,30.1693,0.826622713324149,0.195990884256702,0.848606895795185,0.191161863541072,0.630631829067447,0.657445032254113,True,0.429217451763087,0.0470851839379968,0.812888798923839,60.336039062316
24012,1561:1051,Breast,JIMT-1,SIDM01037,1298157,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.83918934306242,0.0728622509225446,0.710526932278334,10.5943948176959,30.1968,0.915237003610452,0.939577899362885,0.124001102127381,0.596266629526812,0.437247355246803,0.159019274280008,9.14949047794964,11.0918,1.44490433974622,19.105,0.768057139806273,0.651709618058797,0.788483760122308,0.742536022350569,0.116347521747476,0.0459477377717388,True,0.429217451763087,0.0470851839379968,0.812888798923839,60.336039062316
24301,1011:1052,Breast,JIMT-1,SIDM01037,1298157,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1052,RO-3306,CDK1,Cell cycle,Targeted,Experimental only,10.0,0.871794965312505,0.0862420492756775,0.648617279927192,10.0883869183484,21.2636,0.908821295078555,0.92347606250021,0.0956061083903534,0.565461279055218,0.126635804672059,0.438825474383159,5.85312641991401,1.129,4.2352604984344,20.1346,0.792305829418274,0.529218234766826,0.805081781874299,0.576384474677541,0.263087594651448,0.228697307196758,True,0.675969748037785,0.0750942135982808,0.372709379475618,129.451808920075
24301,1594:1052,Breast,JIMT-1,SIDM01037,1298157,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1052,RO-3306,CDK1,Cell cycle,Targeted,Experimental only,10.0,0.962573882715703,0.0862420492756775,0.648617279927192,10.0883869183484,21.2636,0.908821295078555,0.92347606250021,0.0398019546385027,0.624342053536016,0.69572111965115,-0.071379066115134,10.7014766526975,32.5234,-0.613089734349041,-11.2598,0.874807642698479,0.928425487341282,0.888913939075836,0.907318909985097,-0.0536178446428038,-0.0184049709092606,True,0.675969748037785,0.0750942135982808,0.372709379475618,129.451808920075
24301,1011:1059,Breast,JIMT-1,SIDM01037,1298157,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.871794965312505,0.0935921336501415,0.418820048664183,8.41827794407286,0.6682,0.826206588427247,0.846346984236678,0.0510548082816163,0.365125209797373,0.125404014296186,0.239721195501187,5.83283775570146,0.1113,2.5854401883714,0.5569,0.720282744098895,0.548998275333758,0.737841039764958,0.57490810956806,0.171284468765137,0.162932930196898,True,0.675969748037785,0.0750942135982808,0.372709379475618,129.451808920075
24302,1011:1080,Breast,JIMT-1,SIDM01037,1298157,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.83696484484311,0.0745579772156459,0.218037464427579,6.73230408237368,0.0208,0.713822156366858,0.731826050212694,0.0891594925193905,0.182489692584614,0.0332279060964059,0.149261786488208,3.34313237626318,0.002,3.38917170611049,0.0188,0.597444050349162,0.361311808555084,0.612512676568413,0.369832760291405,0.236132241794077,0.242679916277009,True,0.675969748037785,0.0750942135982808,0.372709379475618,129.451808920075
24304,1011:1096,Breast,JIMT-1,SIDM01037,1298157,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.812603893716409,0.0487367483364202,0.949918469458648,14.2251149339059,187.0193,0.966636806708046,0.990910625775832,0.171249561845694,0.771907446995229,0.0638339097650714,0.708073537230157,4.628199202097,0.2415,9.59691573180886,186.7778,0.785492832940553,0.423970055216294,0.805217832830404,0.451483566453805,0.36152277772426,0.3537342663766,True,0.675969748037785,0.0750942135982808,0.372709379475618,129.451808920075
24304,1561:1129,Breast,JIMT-1,SIDM01037,1298157,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.879666032478229,0.0498473788066508,0.899955493866432,12.9005248473916,149.3396,0.973475621917487,0.981354040821843,0.0551617330646508,0.79166027869647,0.703531549969145,0.0881287287273249,11.4589729319273,54.9825,1.44155191546434,94.3571,0.856333438046432,0.808619895442142,0.863263815546228,0.844907686110379,0.0477135426042907,0.0183561294358492,True,0.675969748037785,0.0750942135982808,0.372709379475618,129.451808920075
24014,1372:1553,Breast,JIMT-1,SIDM01037,1298157,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.988178822815977,0.0676266668058458,0.841267687157746,11.9611597645978,77.875,0.940093762535044,0.969429450301028,0.133844392781914,0.831322912768661,0.599223406844053,0.232099505924608,9.76736276219443,17.0216,2.19379700240341,60.8534,0.928980747598522,0.781571091116637,0.95796965300161,0.90081531936104,0.147409656481885,0.0571543336405692,True,0.429217451763087,0.0470851839379968,0.812888798923839,60.336039062316
24014,1179:1553,Breast,JIMT-1,SIDM01037,1298157,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.580739585955153,0.0676266668058458,0.841267687157746,11.9611597645978,77.875,0.940093762535044,0.969429450301028,0.0415764151078609,0.488557448317439,0.339188319266263,0.149369129051176,9.60277122338832,15.1863,2.35838854120952,62.6887,0.545949662413623,0.512998367306308,0.562986057580551,0.525551743107694,0.0329512951073152,0.0374343144728572,True,0.429217451763087,0.0470851839379968,0.812888798923839,60.336039062316
24014,1594:1553,Breast,JIMT-1,SIDM01037,1298157,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.943286710095527,0.0676266668058458,0.841267687157746,11.9611597645978,77.875,0.940093762535044,0.969429450301028,0.0263454943828948,0.793556628928704,0.675669413524653,0.117887215404051,10.6444693095218,31.2633,1.31669045507603,46.6117,0.886777952443007,0.891420822524312,0.914449916844173,0.887638228832951,-0.0046428700813041,0.0268116880112221,True,0.429217451763087,0.0470851839379968,0.812888798923839,60.336039062316
24014,1011:1560,Breast,JIMT-1,SIDM01037,1298157,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.862478699342904,0.0571104064192898,0.654592884702861,10.1351259731556,21.9638,0.909921556425082,0.925095474930382,0.0388087985737134,0.564572419797643,0.329276237956805,0.235296181840839,8.14415101995617,5.5254,1.99097495319939,16.4384,0.784787960489575,0.709317429917296,0.797875141985962,0.715901750535003,0.0754705305722793,0.0819733914509587,True,0.429217451763087,0.0470851839379968,0.812888798923839,60.336039062316
24014,1558:1560,Breast,JIMT-1,SIDM01037,1298157,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.932918692376918,0.0571104064192898,0.654592884702861,10.1351259731556,21.9638,0.909921556425082,0.925095474930382,0.0630173849003508,0.610681938036228,0.44696361852853,0.163718319507698,8.85149022056921,9.0218,1.28363575258636,12.942,0.848882828585657,0.770981799892591,0.863038860795856,0.811670857184853,0.0779010286930659,0.0513680036110032,True,0.429217451763087,0.0470851839379968,0.812888798923839,60.336039062316
24014,1594:1560,Breast,JIMT-1,SIDM01037,1298157,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.936097394845585,0.0571104064192898,0.654592884702861,10.1351259731556,21.9638,0.909921556425082,0.925095474930382,0.086796896156948,0.612762694054805,0.331139549601619,0.281623144453186,7.92998694103751,4.7631,2.20513903211806,17.2007,0.851775198483358,0.694656163377845,0.86597946406577,0.764455379080064,0.157119035105513,0.101524084985705,True,0.429217451763087,0.0470851839379968,0.812888798923839,60.336039062316
24015,1011:1564,Breast,JIMT-1,SIDM01037,1298157,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.856883268887092,0.049044883145653,0.935588199466041,13.7513031044031,134.665,0.969851284025684,0.988221828101397,0.0757669583892761,0.80168987469065,0.453507104078584,0.348182770612066,9.20799683782301,5.7754,4.54330626658014,128.8896,0.831049338590271,0.701908219505325,0.846790750449103,0.760556468756614,0.129141119084946,0.086234281692489,True,0.429217451763087,0.0470851839379968,0.812888798923839,60.336039062316
24016,1179:1909,Breast,JIMT-1,SIDM01037,1298157,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.595121861290206,0.0785036154103152,0.946183394277326,14.0904006173398,34.0693,0.936975746711286,0.990213724943183,0.0347838816818118,0.563094422724207,0.361749740091025,0.201344682633182,9.77828026600661,1.7151,4.31212035133323,32.3542,0.557614750366602,0.539805114285503,0.589297835063296,0.542761730374999,0.0178096360810992,0.0465361046882969,True,0.429217451763087,0.0470851839379968,0.812888798923839,60.336039062316
24302,1558:2169,Breast,JIMT-1,SIDM01037,1298157,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.976413179950263,0.0461979257740768,0.902424690089536,12.9497634174082,154.5245,0.963910655387709,0.981838611262205,0.0290306929260837,0.881139361315954,0.800782721450153,0.0803566398658015,11.693961131298,64.7088,1.25580228611019,89.8157,0.941175068215055,0.953785158576493,0.95868016062048,0.942170237761917,-0.0126100903614377,0.0165099228585625,True,0.675969748037785,0.0750942135982808,0.372709379475618,129.451808920075
24013,1058:2172,Breast,JIMT-1,SIDM01037,1298157,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.996779893830693,0.089658903848007,0.718949712739783,10.6677507605991,31.7719,0.896237304559915,0.941659900497198,0.0616625651452169,0.716634618334367,0.738180287146937,-0.0215456688125697,10.8624446622891,36.3623,-0.19469390169,-4.5904,0.893351325286338,0.922582564093916,0.938627655642218,0.943844708670368,-0.0292312388075781,-0.0052170530281504,True,0.429217451763087,0.0470851839379968,0.812888798923839,60.336039062316
24013,1190:2172,Breast,JIMT-1,SIDM01037,1298157,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.1,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.863032132189916,0.089658903848007,0.718949712739783,10.6677507605991,31.7719,0.896237304559915,0.941659900497198,0.0961240187713839,0.620476703523142,0.456134206397309,0.164342497125833,9.20281797480282,11.5094,1.46493278579632,20.2625,0.773481591902487,0.698468892910658,0.812682751723842,0.765804962705395,0.0750126989918293,0.046877789018447,True,0.429217451763087,0.0470851839379968,0.812888798923839,60.336039062316
24013,1012:2172,Breast,JIMT-1,SIDM01037,1298157,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.907630062846185,0.089658903848007,0.718949712739783,10.6677507605991,31.7719,0.896237304559915,0.941659900497198,0.10659863699164,0.652540372957255,0.418570953272623,0.233969419684632,8.72365028052409,8.2568,1.94410048007505,23.5151,0.813451921062811,0.692273376846766,0.854678834668004,0.783567394985557,0.121178544216045,0.0711114396824467,True,0.429217451763087,0.0470851839379968,0.812888798923839,60.336039062316
24013,1011:2172,Breast,JIMT-1,SIDM01037,1298157,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.858780021320804,0.089658903848007,0.718949712739783,10.6677507605991,31.7719,0.896237304559915,0.941659900497198,0.0540319923915299,0.617419649635256,0.426730648640779,0.190689000994477,8.97800583851583,9.8487,1.68974492208331,21.9232,0.769670691518464,0.726884802430896,0.80867870942593,0.752689846072382,0.0427858890875675,0.0559888633535486,True,0.429217451763087,0.0470851839379968,0.812888798923839,60.336039062316
23604,1179:1003,Breast,MDA-MB-157,SIDM00529,925338,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.637690986085681,0.0525066007942607,0.885370781260737,14.8949679303296,5.9506,0.964393862857686,0.96605429698683,0.0574453523691788,0.56459296655361,0.235493971387713,0.329098995165897,7.45653011735615,0.0343,7.43843781297348,5.9163,0.614985273380697,0.45504833421675,0.616044117257841,0.464051866975386,0.159936939163947,0.151992250282455,True,0.605611330841204,0.0751010466602057,0.466748670238479,102.278371455657
23604,1022:1003,Breast,MDA-MB-157,SIDM00529,925338,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.466502869298711,0.0525066007942607,0.885370781260737,14.8949679303296,5.9506,0.964393862857686,0.96605429698683,0.0868375008352078,0.413028009851376,0.147083840890174,0.265944168961201,6.7637600683342,0.0212,8.13120786199543,5.9294,0.449892504157178,0.247799537978247,0.450667101442706,0.320044909122179,0.202092966178932,0.130622192320527,True,0.605611330841204,0.0751010466602057,0.466748670238479,102.278371455657
23877,1022:1032,Breast,MDA-MB-157,SIDM00529,925338,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.457437801786058,0.0777118637247204,0.801742737834538,13.0290394461431,163.2532,0.917255075156771,0.938496698442601,0.121018845859577,0.366747435592967,0.266693444426685,0.100053991166283,9.96648621124082,19.5408,3.06255323490229,143.7124,0.419587145256819,0.29105427427309,0.429303866719057,0.389178085503694,0.128532870983729,0.0401257812153626,True,1.24182113227034,0.117184192801437,-0.231885685731512,-234.39969331049
23877,1179:1032,Breast,MDA-MB-157,SIDM00529,925338,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.245777980849761,0.0777118637247204,0.801742737834538,13.0290394461431,163.2532,0.917255075156771,0.938496698442601,0.0317585660443504,0.197050711265932,0.178461040574037,0.0185896706918945,11.8113964968087,70.1964,1.2176429493344,93.0568,0.225441100296227,0.199624021550219,0.230661823577389,0.223923361177318,0.0258170787460075,0.0067384624000712,True,1.24182113227034,0.117184192801437,-0.231885685731512,-234.39969331049
23879,1049:1050,Breast,MDA-MB-157,SIDM00529,925338,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.916325577831449,0.077269746752002,0.738428579202063,11.9926560334314,79.5938,0.895750814005985,0.915727877449131,0.0444595119558551,0.676640994524586,0.580365736570463,0.0962752579541236,10.5763721553912,29.8219,1.41628387804026,49.7719,0.820799382237025,0.81428128657932,0.839104876439941,0.8003743639611,0.0065180956577044,0.0387305124788411,True,1.24182113227034,0.117184192801437,-0.231885685731512,-234.39969331049
23606,1510:1059,Breast,MDA-MB-157,SIDM00529,925338,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.958857538882021,0.0468249596090049,0.720598039477177,11.7320154619728,6.6438,0.907003068070764,0.908977371325932,0.0597872252993501,0.690950862656295,0.47779557000547,0.213155292650826,8.98035360735577,0.9865,2.75166185461702,5.6573,0.869686729608775,0.762883334845867,0.871579805169032,0.774808535316522,0.106803394762908,0.0967712698525104,True,0.605611330841204,0.0751010466602057,0.466748670238479,102.278371455657
23607,1011:1080,Breast,MDA-MB-157,SIDM00529,925338,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.960770152991439,0.0621718724035621,0.597126648598311,10.1347193464403,0.2196,0.869720814950677,0.857317559870563,0.164865088348594,0.573701461529064,0.330111625880421,0.243589835648644,7.13334426450094,0.0274,3.00137508193932,0.1922,0.835601800440001,0.723941182842487,0.823685123159088,0.680830018798348,0.111660617597514,0.14285510436074,True,0.605611330841204,0.0751010466602057,0.466748670238479,102.278371455657
23608,1011:1085,Breast,MDA-MB-157,SIDM00529,925338,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.972500718026718,0.109937416416268,0.60340312156332,10.2101492192497,23.1362,0.892394169518476,0.860179284935611,0.1176335351045,0.586809968979892,0.290466157171158,0.296343811808734,6.53857281915252,1.8157,3.67157640009718,21.3205,0.867853970619575,0.671017442266023,0.836524972231591,0.653448751572465,0.196836528353552,0.183076220659126,True,0.605611330841204,0.0751010466602057,0.466748670238479,102.278371455657
23608,1011:1086,Breast,MDA-MB-157,SIDM00529,925338,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1086,BI-2536,"PLK1, PLK2, PLK3",Cell cycle,Targeted,Early clinical trials,10.0,0.972500718026718,0.108973203807502,0.333386971953321,7.00193219923103,2.5034,0.655742582709396,0.70069117953722,0.172781491376245,0.324219069605358,0.134523721701656,0.189695347903702,3.72516230886324,0.2583,3.27676989036779,2.2451,0.637710132525583,0.426916841857705,0.681422675214935,0.467552501107901,0.210793290667878,0.213870174107034,True,0.605611330841204,0.0751010466602057,0.466748670238479,102.278371455657
23609,1022:1096,Breast,MDA-MB-157,SIDM00529,925338,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.493824728397538,0.0556192261461169,0.882891420311575,14.8251757274219,283.4801,0.951480754265688,0.965274053990557,0.0980660088531144,0.43599361583988,0.275950476008508,0.160043139831372,9.68140588294631,8.0185,5.14376984447558,275.4616,0.469864725050738,0.320283313327526,0.476676197541077,0.414417413514365,0.149581411723212,0.0622587840267119,True,0.605611330841204,0.0751010466602057,0.466748670238479,102.278371455657
23610,1011:1192,Breast,MDA-MB-157,SIDM00529,925338,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.962441329791616,0.0754431421613492,0.721242989154623,11.7412591800958,66.8654,0.910512314900773,0.909224319046692,0.0966309036774251,0.694154061584855,0.468276811556938,0.225877250027917,8.84483631158223,8.9803,2.89642286851355,57.8851,0.876314683144743,0.718598339198076,0.875075062702175,0.771490444560511,0.157716343946667,0.103584618141664,True,0.605611330841204,0.0751010466602057,0.466748670238479,102.278371455657
23880,1073:2172,Breast,MDA-MB-157,SIDM00529,925338,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,2.5,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.785355452062534,0.0890964488628252,0.7803102609712,12.6549002755819,125.9606,0.876022340063233,0.93098876267289,0.0682524324518358,0.61282091775407,0.594991624187616,0.0178292935664544,12.2861875300653,97.5531,0.368712745516632,28.4075,0.687988920897239,0.66859986964526,0.731157100574106,0.724739279848132,0.0193890512519785,0.006417820725974,True,1.24182113227034,0.117184192801437,-0.231885685731512,-234.39969331049
23620,1022:1003,Breast,MDA-MB-415,SIDM00630,924240,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.939123253329006,0.0583648410069935,0.940021480666925,16.6270959909085,19.769,0.971618142467186,0.983336097751157,0.0970168402490105,0.882796031123072,0.524230408466954,0.358565622656118,9.64829799407521,0.1567,6.97879799683328,19.6123,0.912469190947269,0.790948660291226,0.923473795235916,0.792898239493781,0.121520530656043,0.130575555742135,True,0.463280570456549,0.0675161722674811,0.723880865528972,66.9673715613956
23973,1058:1032,Breast,MDA-MB-415,SIDM00630,924240,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.936230495938354,0.103765270484671,0.627441650479639,10.444694137178,27.2205,0.886710774119021,0.875241312001619,0.0680296550370603,0.587430007600932,0.539599739848216,0.0478302677527156,9.85314625167226,18.0644,0.591547885505747,9.1561,0.830165667807333,0.837964319848709,0.819427607601012,0.798365953728091,-0.0077986520413758,0.0210616538729212,True,0.520790102373951,0.0637165583821112,0.62227839021149,78.2133408496555
23973,1011:1032,Breast,MDA-MB-415,SIDM00630,924240,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.575988717374095,0.103765270484671,0.627441650479639,10.444694137178,27.2205,0.886710774119021,0.875241312001619,0.0917781683276855,0.361399311486852,0.102415849599433,0.258983461887419,4.75601185944697,0.5278,5.68868227773104,26.6927,0.510735401466605,0.28473733950564,0.504129120692633,0.31913475105234,0.225998061960965,0.184994369640293,True,0.520790102373951,0.0637165583821112,0.62227839021149,78.2133408496555
23973,1053:1032,Breast,MDA-MB-415,SIDM00630,924240,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.546837142861147,0.103765270484671,0.627441650479639,10.444694137178,27.2205,0.886710774119021,0.875241312001619,0.053752400104394,0.343108399460368,0.12463208069828,0.218476318762088,5.61835233520347,0.9595,4.82634180197453,26.261,0.484886386263442,0.306364615051172,0.478614458369008,0.336027328787595,0.17852177121227,0.142587129581412,True,0.520790102373951,0.0637165583821112,0.62227839021149,78.2133408496555
23975,1011:1050,Breast,MDA-MB-415,SIDM00630,924240,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.60889167473354,0.0762184874849695,0.807268850694964,12.9698706184313,156.6932,0.927818329790649,0.942449021348381,0.0673306317932385,0.491539282459877,0.266232828674201,0.225306453785676,8.3005581770071,6.1581,4.66931244142418,150.5351,0.564940856674705,0.430878476232842,0.573849362959802,0.475070160725347,0.134062380441863,0.0987792022344546,True,0.520790102373951,0.0637165583821112,0.62227839021149,78.2133408496555
23975,1011:1051,Breast,MDA-MB-415,SIDM00630,924240,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.60889167473354,0.0681975648074282,0.727004246242008,11.7146749431661,65.6445,0.90980321040513,0.914442916115344,0.104952463774454,0.442666833032691,0.176766455378639,0.265900377654052,6.52254292055855,1.7956,5.19213202260752,63.8489,0.553971600461531,0.344724390940501,0.556796678641695,0.410996870354382,0.20924720952103,0.145799808287313,True,0.520790102373951,0.0637165583821112,0.62227839021149,78.2133408496555
24221,1011:1052,Breast,MDA-MB-415,SIDM00630,924240,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1052,RO-3306,CDK1,Cell cycle,Targeted,Experimental only,10.0,0.51316256615377,0.0606092559101024,0.672545723958958,10.9947504885719,39.8547,0.915203661004829,0.893689970275134,0.0432684945352076,0.345125289562523,0.14463200036334,0.200493289199183,6.40767552196807,1.6582,4.58707496660382,38.1965,0.469648259234563,0.31425078978021,0.458608238492274,0.342545667607859,0.155397469454352,0.116062570884414,True,0.767826454468379,0.10201406665302,0.248123544766186,191.591849718129
24221,1011:1059,Breast,MDA-MB-415,SIDM00630,924240,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.51316256615377,0.0877301665302358,0.366013812450414,7.47742761218743,0.3481,0.717494272553472,0.734150670394557,0.0621988678981326,0.187824587244779,0.058304061973746,0.129520525271033,3.30634747417394,0.0193,4.17108013801349,0.3288,0.368191202104172,0.196024906685058,0.376738641963181,0.231113851727178,0.172166295419113,0.145624790236003,True,0.767826454468379,0.10201406665302,0.248123544766186,191.591849718129
24222,1011:1080,Breast,MDA-MB-415,SIDM00630,924240,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.695179184298889,0.0920246248307861,0.395659785484988,7.82601619272643,0.0443,0.767040137250642,0.754263821655426,0.0596158535807786,0.275054446933328,0.127310507258305,0.147743939675023,4.85579671968534,0.0057,2.97021947304109,0.0386,0.533230336938409,0.375792773501709,0.524348508284581,0.390098617357749,0.1574375634367,0.134249890926832,True,0.767826454468379,0.10201406665302,0.248123544766186,191.591849718129
23624,1011:1086,Breast,MDA-MB-415,SIDM00630,924240,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1086,BI-2536,"PLK1, PLK2, PLK3",Cell cycle,Targeted,Early clinical trials,10.0,0.68318999286705,0.120483039414123,0.564714023878997,9.72148154895552,16.4887,0.783672143884984,0.847353884345392,0.199057268408696,0.385806969945815,0.190361500965354,0.195445468980461,6.36359317114419,1.6083,3.35788837781133,14.8804,0.535396966390888,0.366930473634668,0.578903694201796,0.454070504891175,0.168466492756219,0.12483318931062,True,0.463280570456549,0.0675161722674811,0.723880865528972,66.9673715613956
23624,1594:1086,Breast,MDA-MB-415,SIDM00630,924240,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1086,BI-2536,"PLK1, PLK2, PLK3",Cell cycle,Targeted,Early clinical trials,10.0,0.748902318269001,0.120483039414123,0.564714023878997,9.72148154895552,16.4887,0.783672143884984,0.847353884345392,0.115488551951319,0.422915641641996,0.214096254044956,0.20881938759704,6.46269810698991,1.7226,3.25878344196561,14.7661,0.586893885318302,0.439614673816352,0.634585288380507,0.502593615446682,0.14727921150195,0.131991672933825,True,0.463280570456549,0.0675161722674811,0.723880865528972,66.9673715613956
23624,1053:1086,Breast,MDA-MB-415,SIDM00630,924240,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1086,BI-2536,"PLK1, PLK2, PLK3",Cell cycle,Targeted,Early clinical trials,10.0,0.763400085481394,0.120483039414123,0.564714023878997,9.72148154895552,16.4887,0.783672143884984,0.847353884345392,0.101608212700204,0.431102734101768,0.210678429537827,0.220424304563941,6.3267722611215,1.5678,3.39470928783401,14.9209,0.598255381631184,0.469082581187319,0.646870027742264,0.505534788905134,0.129172800443865,0.141335238837129,True,0.463280570456549,0.0675161722674811,0.723880865528972,66.9673715613956
23625,1011:1096,Breast,MDA-MB-415,SIDM00630,924240,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.728361362918823,0.0717508790813352,0.92692036261268,16.0406388337566,658.2843,0.962575588001202,0.979558926791765,0.0806231386297789,0.675132978629781,0.393653515633615,0.281479462996165,9.44958295366762,6.8282,6.59105588008897,651.4561,0.701102867188943,0.534642851066163,0.713472874977349,0.608745076287382,0.16646001612278,0.104727798689968,True,0.463280570456549,0.0675161722674811,0.723880865528972,66.9673715613956
23625,1011:1129,Breast,MDA-MB-415,SIDM00630,924240,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.728361362918823,0.0752334032334993,0.835050869570263,13.495066944882,225.5018,0.937259195051356,0.951519062209885,0.0690330822849958,0.608218789466744,0.399991672504996,0.208227116961748,9.54683854572552,14.6088,3.94822839915643,210.893,0.682663384715804,0.567956653993833,0.693049720994432,0.611812596922889,0.114706730721971,0.0812371240715433,True,0.463280570456549,0.0675161722674811,0.723880865528972,66.9673715613956
24223,1011:1192,Breast,MDA-MB-415,SIDM00630,924240,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.501562585404085,0.0616607855722289,0.622258968507365,10.3834163280847,26.0885,0.874340476791833,0.873040610885295,0.0908940301793947,0.312101817035433,0.09445543449913,0.217646382536303,4.95089680208324,0.6041,5.43251952600145,25.4844,0.438536470063152,0.224657074972167,0.437884505958391,0.284828343836745,0.213879395090985,0.153056162121646,True,0.767826454468379,0.10201406665302,0.248123544766186,191.591849718129
23977,1011:1553,Breast,MDA-MB-415,SIDM00630,924240,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.58584694876577,0.0791101486548409,0.247740884895037,5.92163738214628,1.1839,0.624265428445096,0.635184433032226,0.0526378656272523,0.145138241500289,0.0478735526201138,0.0972646888801756,2.29491922798645,0.0958,3.62671815415983,1.0881,0.365723996474516,0.180246792250857,0.372120861995445,0.222360737369367,0.185477204223658,0.149760124626078,True,0.520790102373951,0.0637165583821112,0.62227839021149,78.2133408496555
23977,1053:1560,Breast,MDA-MB-415,SIDM00630,924240,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.815544230560033,0.0474960411121681,0.841276491556349,13.6222845271593,246.2897,0.954022906850878,0.953511475241879,0.090138104315177,0.686098188994566,0.393969358783618,0.292128830210949,8.81229828168387,8.78,4.80998624547545,237.5097,0.778047877504345,0.610027956773096,0.7776307824063,0.657549067725964,0.168019920731249,0.120081714680337,True,0.520790102373951,0.0637165583821112,0.62227839021149,78.2133408496555
23978,1053:1564,Breast,MDA-MB-415,SIDM00630,924240,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.587464253556104,0.095061454947473,0.761538233004856,12.2181432051438,46.5294,0.883194268181695,0.926840943561057,0.102037432607995,0.447376489606632,0.303066151376085,0.144310338230547,9.17620480022229,5.6495,3.04193840492147,40.8799,0.518845061502389,0.40059176275319,0.544485923074331,0.483789490972166,0.118253298749198,0.0606964321021648,True,0.520790102373951,0.0637165583821112,0.62227839021149,78.2133408496555
24222,1012:2169,Breast,MDA-MB-415,SIDM00630,924240,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.825419962569476,0.0802070992622521,0.222651056787928,5.53476635533411,0.9054,0.589783017656319,0.60872961349445,0.0447662142777926,0.183780626959946,0.0658000183682858,0.11798060859166,2.22021957508246,0.091,3.31454678025165,0.8144,0.486818676357992,0.294524271280029,0.50245757478552,0.309077986399352,0.192294405077963,0.193379588386168,True,0.767826454468379,0.10201406665302,0.248123544766186,191.591849718129
24222,1011:2169,Breast,MDA-MB-415,SIDM00630,924240,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.491051810663257,0.0802070992622521,0.222651056787928,5.53476635533411,0.9054,0.589783017656319,0.60872961349445,0.070401660874373,0.1093332045818,0.0215855663492281,0.0877476382325717,0.464788300019638,0.027,5.06997805531447,0.8784,0.289614018718575,0.10225705901406,0.298917778910794,0.128879717822405,0.187356959704515,0.170038061088389,True,0.767826454468379,0.10201406665302,0.248123544766186,191.591849718129
23976,1053:2172,Breast,MDA-MB-415,SIDM00630,924240,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.598041350441761,0.0865175666594412,0.709351964373631,11.4728917293307,55.5155,0.86542080639302,0.907884715249181,0.0884272063313552,0.424221806712523,0.243071050958328,0.181150755754195,7.95046542697497,4.8312,3.52242630235575,50.6843,0.51755742775568,0.385306117903338,0.542952601153054,0.45524915187316,0.132251309852342,0.0877034492798942,True,0.520790102373951,0.0637165583821112,0.62227839021149,78.2133408496555
24244,1022:1003,Breast,MDA-MB-468,SIDM00628,908123,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.968221282837153,0.102450867107787,0.564275350931569,9.7374451656764,0.1667,0.856450665699369,0.843317487605923,0.136970175495099,0.546343404152348,0.353434053520829,0.192909350631519,7.42095117024919,0.0335,2.31649399542721,0.1332,0.829233762230177,0.730652463453811,0.816517939688812,0.703957683736288,0.0985812987763662,0.112560255952524,True,0.683659662240863,0.089327966891916,0.362151776606273,133.229524890384
24244,1011:1003,Breast,MDA-MB-468,SIDM00628,908123,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.719211866619677,0.102450867107787,0.564275350931569,9.7374451656764,0.1667,0.856450665699369,0.843317487605923,0.0743335495704129,0.405833528430967,0.231164995417869,0.174668533013098,6.86843343500134,0.0228,2.86901173067507,0.1439,0.615969481945308,0.479743134631224,0.606523944414072,0.498969443949761,0.136226347314085,0.107554500464312,True,0.683659662240863,0.089327966891916,0.362151776606273,133.229524890384
23901,1190:1032,Breast,MDA-MB-468,SIDM00628,908123,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.01,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.933983759216714,0.103530475064933,0.308288794556667,6.69485759792432,2.0234,0.688545278286492,0.682944390540914,0.0938454426382561,0.287936727264425,0.273655966720883,0.0142807605435415,6.48739118988292,1.7524,0.207466408041398,0.271,0.643090107404936,0.637714414626282,0.63785896921337,0.625572301186788,0.0053756927786539,0.0122866680265827,True,0.62272031493867,0.0718898044450808,0.445609142123599,107.750573305541
23901,1058:1032,Breast,MDA-MB-468,SIDM00628,908123,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,1.0,0.103530475064933,0.308288794556667,6.69485759792432,2.0234,0.688545278286492,0.682944390540914,0.0635783339841805,0.308288794556667,0.22422898070389,0.0840598138527773,5.45958771991465,0.8595,1.23526987800967,1.1639,0.688545278286492,0.586319369437915,0.682944390540914,0.601725187441989,0.102225908848577,0.0812192030989255,True,0.62272031493867,0.0718898044450808,0.445609142123599,107.750573305541
23657,1011:1096,Breast,MDA-MB-468,SIDM00628,908123,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.69614609091773,0.151393653332373,0.445243894468215,8.37273149079268,3.237,0.699714054466021,0.779675731589119,0.0902326591373672,0.309954796639034,0.112458917296114,0.19749587934292,4.3026756968831,0.1927,4.07005579390959,3.0443,0.487103203776716,0.335140534929708,0.542768212729187,0.362913119939383,0.151962668847008,0.179855092789804,True,0.311479619013044,0.0523649526502632,1.10505116450851,44.3782370688742
23905,1372:1553,Breast,MDA-MB-468,SIDM00628,908123,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.897687081484401,0.059543146191299,0.78010919243298,12.6120459638402,122.274,0.937453638047922,0.931571740126106,0.0800027709866267,0.700293944194315,0.439287182413537,0.261006761780777,8.87851888292007,9.1924,3.73352708092014,113.0816,0.841540020366173,0.680808027128311,0.836259916587149,0.722588760720455,0.160731993237862,0.113671155866694,True,0.62272031493867,0.0718898044450808,0.445609142123599,107.750573305541
23905,1049:1553,Breast,MDA-MB-468,SIDM00628,908123,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.986936046666113,0.059543146191299,0.78010919243298,12.6120459638402,122.274,0.937453638047922,0.931571740126106,0.0799704850178915,0.769917882347699,0.561690938668055,0.208226943679644,9.79379273484497,17.3363,2.81825322899524,104.9377,0.925206787467782,0.838179265352499,0.919401730385931,0.834585264236186,0.087027522115283,0.0848164661497455,True,0.62272031493867,0.0718898044450808,0.445609142123599,107.750573305541
23905,1594:1553,Breast,MDA-MB-468,SIDM00628,908123,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.947047214238366,0.059543146191299,0.78010919243298,12.6120459638402,122.274,0.937453638047922,0.931571740126106,0.102630196075114,0.738800237495395,0.370870419378611,0.367929818116784,7.74332620835837,4.1851,4.86871975548184,118.0889,0.887812856390906,0.663122836216888,0.882242421349616,0.706108175167085,0.224690020174018,0.176134246182531,True,0.62272031493867,0.0718898044450808,0.445609142123599,107.750573305541
23905,1179:1553,Breast,MDA-MB-468,SIDM00628,908123,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.828311518456954,0.059543146191299,0.78010919243298,12.6120459638402,122.274,0.937453638047922,0.931571740126106,0.062454631550288,0.64617342974639,0.410957443911092,0.235215985835298,8.95594330637587,9.6992,3.65610265746434,112.5748,0.77650364641447,0.633320078943179,0.771631602615442,0.669806064625349,0.143183567471291,0.101825537990093,True,0.62272031493867,0.0718898044450808,0.445609142123599,107.750573305541
23905,1549:1553,Breast,MDA-MB-468,SIDM00628,908123,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.785999930867108,0.059543146191299,0.78010919243298,12.6120459638402,122.274,0.937453638047922,0.931571740126106,0.0971020184717824,0.613165771321117,0.277693093428915,0.335472677892203,7.27550716013186,3.026,5.33653880370835,119.248,0.736838494696785,0.526969056446536,0.732215323336871,0.564726571777111,0.209869438250249,0.16748875155976,True,0.62272031493867,0.0718898044450808,0.445609142123599,107.750573305541
23905,1558:1553,Breast,MDA-MB-468,SIDM00628,908123,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.890688951599686,0.059543146191299,0.78010919243298,12.6120459638402,122.274,0.937453638047922,0.931571740126106,0.0505923512400462,0.694834638741408,0.478484518518882,0.216350120222526,9.42531064692916,13.4286,3.18673531691105,108.8454,0.834979598046215,0.741232216210064,0.829740656552816,0.739309032338153,0.0937473818361508,0.0904316242146636,True,0.62272031493867,0.0718898044450808,0.445609142123599,107.750573305541
23905,1510:1553,Breast,MDA-MB-468,SIDM00628,908123,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.953191294240642,0.059543146191299,0.78010919243298,12.6120459638402,122.274,0.937453638047922,0.931571740126106,0.0552457716883982,0.743593290784214,0.529103934356762,0.214489356427452,9.63108807937997,15.4873,2.98095788446024,106.7867,0.893572646541498,0.772677034876133,0.88796607264881,0.799612970985101,0.120895611665364,0.088353101663709,True,0.62272031493867,0.0718898044450808,0.445609142123599,107.750573305541
23905,1083:1560,Breast,MDA-MB-468,SIDM00628,908123,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.754228710890241,0.076266514538229,0.846504030625748,13.8703628343395,292.4996,0.940206538043431,0.954015629357573,0.0829205482344831,0.638457643782252,0.438249680170966,0.200207963611286,9.93306827782504,19.0933,3.93729455651447,273.4063,0.709130765159074,0.605143628287016,0.719545978299504,0.642035788110973,0.103987136872057,0.0775101901885312,True,0.62272031493867,0.0718898044450808,0.445609142123599,107.750573305541
23906,1005:1593,Breast,MDA-MB-468,SIDM00628,908123,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,1.0,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.871864091153238,0.0768637850150567,0.80532947866782,13.050294538943,33.1352,0.907542573127378,0.940306385987332,0.10874464733537,0.70213785399763,0.454911972630809,0.247225881366821,9.248539879228,2.376,3.80175465971503,30.7592,0.791253780702572,0.751099004173934,0.819819372624431,0.716832698553531,0.0401547765286381,0.1029866740709,True,0.62272031493867,0.0718898044450808,0.445609142123599,107.750573305541
23906,1190:1593,Breast,MDA-MB-468,SIDM00628,908123,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.01,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.909769710001887,0.0768637850150567,0.80532947866782,13.050294538943,33.1352,0.907542573127378,0.940306385987332,0.0783619595936449,0.732664366263593,0.724857702864289,0.0078066633993042,12.8966974958971,29.7888,0.153597043045965,3.3464,0.825654743568461,0.887663996449792,0.855462268092618,0.852785775911573,-0.0620092528813306,0.002676492181045,True,0.62272031493867,0.0718898044450808,0.445609142123599,107.750573305541
23655,1021:2169,Breast,MDA-MB-468,SIDM00628,908123,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.707736483045406,0.105451421506384,0.502124733998069,9.02424280518217,10.1695,0.761576342502145,0.811861434793262,0.0870849358944028,0.355371993289903,0.338203738552647,0.017168254737256,8.74730035202202,8.3932,0.276942453160142,1.7763,0.538995362213052,0.509475798558071,0.574583956580781,0.565181841579435,0.0295195636549814,0.0094021150013462,True,0.311479619013044,0.0523649526502632,1.10505116450851,44.3782370688742
23655,1549:2169,Breast,MDA-MB-468,SIDM00628,908123,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.687165145038961,0.105451421506384,0.502124733998069,9.02424280518217,10.1695,0.761576342502145,0.811861434793262,0.113591013287976,0.345042615665432,0.167417807459804,0.177624808205629,5.76861865615103,1.0648,3.25562414903114,9.1047,0.523328717853728,0.373968179309657,0.557882880591251,0.427851407246332,0.149360538544071,0.130031473344919,True,0.311479619013044,0.0523649526502632,1.10505116450851,44.3782370688742
23655,1558:2169,Breast,MDA-MB-468,SIDM00628,908123,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.852674887842608,0.105451421506384,0.502124733998069,9.02424280518217,10.1695,0.761576342502145,0.811861434793262,0.077435728939865,0.428149151244803,0.213190215501232,0.214958935743571,5.86666373778303,1.1397,3.15757906739913,9.0298,0.649377022426601,0.510261570696514,0.692253857856084,0.536498101059958,0.139115451730086,0.155755756796126,True,0.311479619013044,0.0523649526502632,1.10505116450851,44.3782370688742
23655,1561:2169,Breast,MDA-MB-468,SIDM00628,908123,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.908474506653726,0.105451421506384,0.502124733998069,9.02424280518217,10.1695,0.761576342502145,0.811861434793262,0.0920614170094842,0.456167519997529,0.356840348610403,0.0993271713871259,7.75748920524475,4.2264,1.26675359993742,5.9431,0.691872692033785,0.63338610528284,0.737555416444995,0.678073616957856,0.0584865867509456,0.0594817994871392,True,0.311479619013044,0.0523649526502632,1.10505116450851,44.3782370688742
23655,1510:2169,Breast,MDA-MB-468,SIDM00628,908123,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.879029155631982,0.105451421506384,0.502124733998069,9.02424280518217,10.1695,0.761576342502145,0.811861434793262,0.0941284477659744,0.441382280948256,0.236066612270693,0.205315668677562,6.14193909829551,1.3792,2.88230370688665,8.7903,0.669447809298954,0.522379236539367,0.713649871516491,0.569092148364712,0.147068572759587,0.144557723151779,True,0.311479619013044,0.0523649526502632,1.10505116450851,44.3782370688742
23655,1179:2169,Breast,MDA-MB-468,SIDM00628,908123,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.454115282012077,0.105451421506384,0.502124733998069,9.02424280518217,10.1695,0.761576342502145,0.811861434793262,0.0505756975787748,0.228022515184772,0.133494738690618,0.0945277764941542,6.50070748458619,1.7686,2.52353532059598,8.4009,0.345843455549088,0.279928801777563,0.368678684415871,0.304548023288995,0.0659146537715245,0.0641306611268767,True,0.311479619013044,0.0523649526502632,1.10505116450851,44.3782370688742
23904,1191:2172,Breast,MDA-MB-468,SIDM00628,908123,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.0025,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.883392041760781,0.0775698161441285,0.777153430436921,12.5631309430205,118.1978,0.913786792362812,0.930530325439991,0.0897949694348247,0.686531155675067,0.304534870035692,0.381996285639375,7.16796633216572,2.8087,5.39516461085476,115.3891,0.807231980239419,0.637654788278105,0.822023084110757,0.629020392345562,0.169577191961314,0.193002691765195,True,0.62272031493867,0.0718898044450808,0.445609142123599,107.750573305541
23904,1190:2172,Breast,MDA-MB-468,SIDM00628,908123,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.1,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.745214285679863,0.0775698161441285,0.777153430436921,12.5631309430205,118.1978,0.913786792362812,0.930530325439991,0.149538628924737,0.579145838526705,0.369250920664449,0.209894917862256,8.9486125618952,9.6501,3.61451838112528,108.5477,0.680966971734347,0.501536777062028,0.693444491776213,0.602351045089224,0.179430194672319,0.0910934466869892,True,0.62272031493867,0.0718898044450808,0.445609142123599,107.750573305541
23904,1510:2172,Breast,MDA-MB-468,SIDM00628,908123,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.981989815219534,0.0775698161441285,0.777153430436921,12.5631309430205,118.1978,0.913786792362812,0.930530325439991,0.044642970947482,0.763156753551979,0.504889656368379,0.2582670971836,9.16148618665185,11.1844,3.40164475636863,107.0134,0.897329323382408,0.787903842641431,0.913771302334989,0.803487922070616,0.109425480740977,0.110283380264373,True,0.62272031493867,0.0718898044450808,0.445609142123599,107.750573305541
23904,1005:2172,Breast,MDA-MB-468,SIDM00628,908123,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.615845694841154,0.0775698161441285,0.777153430436921,12.5631309430205,118.1978,0.913786792362812,0.930530325439991,0.0715824320265767,0.478606594365612,0.154436663013729,0.324169931351883,5.87800786626623,1.1486,6.68512307675426,117.0492,0.562751662079345,0.34710462411394,0.573063094841356,0.387952620092052,0.215647037965405,0.185110474749304,True,0.62272031493867,0.0718898044450808,0.445609142123599,107.750573305541
23904,1594:2172,Breast,MDA-MB-468,SIDM00628,908123,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.992560165817132,0.0775698161441285,0.777153430436921,12.5631309430205,118.1978,0.913786792362812,0.930530325439991,0.0533663364100833,0.771371537779823,0.76416776798954,0.0072037697902837,12.4449485114739,108.9012,0.118182431546543,9.2966,0.906988370149138,0.937735107999443,0.923607334116587,0.921053076583796,-0.0307467378503051,0.0025542575327907,True,0.62272031493867,0.0718898044450808,0.445609142123599,107.750573305541
26086,1011:1046,Breast,HCC1937,SIDM00874,749714,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1046,Wee1 Inhibitor,"WEE1, CHEK1",Cell cycle,Targeted,Experimental only,10.0,0.858747487672213,0.0773841051118238,0.592731057931148,10.213155673602,23.1844,0.85725835083067,0.84084089415544,0.103043355445051,0.509006306863666,0.225546394054533,0.283459912809134,5.66292350081208,0.9896,4.55023217278991,22.1948,0.736168455061862,0.518802670626352,0.722070005388041,0.520861673712397,0.21736578443551,0.201208331675644,True,0.386846446648174,0.0578389475654448,0.906641154990306,54.0389675162405
26087,1011:1051,Breast,HCC1937,SIDM00874,749714,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.764765251436569,0.0696084453216742,0.693738653442282,11.6433035533902,62.4761,0.870224860921856,0.888198613077962,0.0920379226154936,0.530547215731053,0.30406159565837,0.226485620072684,7.65670004212339,3.9412,3.98660351126678,58.5349,0.665517734569256,0.50914810277969,0.679263435656179,0.553164105297554,0.156369631789566,0.126099330358625,True,0.386846446648174,0.0578389475654448,0.906641154990306,54.0389675162405
30673,1011:1080,Breast,HCC1937,SIDM00874,749714,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.957999809555538,0.0804148535750553,0.729445172688397,12.2063016994725,0.923,0.879150457284873,0.903407800264132,0.116388467353414,0.698808336516691,0.428471222318571,0.27033711419812,8.31541495221455,0.0622,3.89088674725799,0.8608,0.842225970649572,0.697422018511099,0.865464500604026,0.725696587645181,0.144803952138473,0.139767912958845,True,0.69197906623469,0.0712368666314907,0.343857256467682,138.335633225288
30674,1011:1086,Breast,HCC1937,SIDM00874,749714,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1086,BI-2536,"PLK1, PLK2, PLK3",Cell cycle,Targeted,Early clinical trials,10.0,0.87475843476233,0.0889906304081464,0.383906215626444,7.47089214127337,3.4649,0.720095882915978,0.713218978252479,0.154103795314226,0.335825200276918,0.168730273685081,0.167094926591836,4.37274842750016,0.4046,3.09814371377321,3.0603,0.629909947418379,0.423563389972977,0.623894317058927,0.458522714712033,0.206346557445403,0.165371602346894,True,0.69197906623469,0.0712368666314907,0.343857256467682,138.335633225288
26089,1510:1553,Breast,HCC1937,SIDM00874,749714,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.975435178715359,0.0704717667759149,0.588335052823353,10.154383120137,22.2589,0.81941190571612,0.838613542227179,0.0615701812800439,0.573882707395257,0.451860434693765,0.122022272701492,8.52379069635137,7.1886,1.63059242378565,15.0703,0.799283198693697,0.737632182024323,0.818013150435488,0.748930264521529,0.0616510166693736,0.0690828859139595,True,0.386846446648174,0.0578389475654448,0.906641154990306,54.0389675162405
26089,1049:1553,Breast,HCC1937,SIDM00874,749714,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.966342448752769,0.0704717667759149,0.588335052823353,10.154383120137,22.2589,0.81941190571612,0.838613542227179,0.123046293999625,0.568533135632408,0.209902469662194,0.358630665970214,4.85564009179815,0.5655,5.29874302833886,21.6934,0.791832507506889,0.491179978754691,0.810387863953046,0.536640831877122,0.300652528752198,0.273747032075924,True,0.386846446648174,0.0578389475654448,0.906641154990306,54.0389675162405
26089,1047:1560,Breast,HCC1937,SIDM00874,749714,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.985875081755703,0.0732307862845722,0.74723693155509,12.5041063910931,113.4596,0.926294517935599,0.9107272022063,0.0907638455374402,0.736682270987755,0.48428347493697,0.252398796050786,8.88647825099725,9.2433,3.61762814009589,104.2163,0.913210683599618,0.748104289734761,0.897863254932279,0.773945572098121,0.165106393864857,0.123917682834158,True,0.386846446648174,0.0578389475654448,0.906641154990306,54.0389675162405
26089,1022:1560,Breast,HCC1937,SIDM00874,749714,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.976348256201142,0.0732307862845722,0.74723693155509,12.5041063910931,113.4596,0.926294517935599,0.9107272022063,0.0905573283920565,0.729563475092905,0.492255380895091,0.237308094197814,9.05405489124819,10.3818,3.45005149984495,103.0778,0.9043860373151,0.706583042191157,0.889186915749066,0.773968805568832,0.197802995123943,0.115218110180234,True,0.386846446648174,0.0578389475654448,0.906641154990306,54.0389675162405
30638,1011:1564,Breast,HCC1937,SIDM00874,749714,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.894979576840012,0.0990392614864018,0.755579654649644,12.6485017043161,62.7016,0.866953356928974,0.914103088212793,0.107605374618002,0.676228359587261,0.471790523303042,0.204437836284219,9.35145512176167,6.3792,3.29704658255444,56.3224,0.775905548524321,0.643400652864947,0.818103595076834,0.72126987392905,0.132504895659374,0.0968337211477838,True,0.612839905572013,0.0675552753270525,0.464699801293498,103.958011598677
30638,1191:1593,Breast,HCC1937,SIDM00874,749714,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.000625,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.954515491508825,0.0644511575191836,0.7537349986421,12.6162932229167,24.5269,0.907355839936356,0.913359677239058,0.0293481731178846,0.719451732696268,0.728015636639958,-0.0085639039436895,12.7745234961997,27.37,-0.158230273283015,-2.8431,0.866085205530253,0.865718817768342,0.871815961244181,0.875252051394206,0.0003663877619108,-0.0034360901500248,True,0.612839905572013,0.0675552753270525,0.464699801293498,103.958011598677
30638,1011:1593,Breast,HCC1937,SIDM00874,749714,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.894979576840012,0.0644511575191836,0.7537349986421,12.6162932229167,24.5269,0.907355839936356,0.913359677239058,0.0801501858397101,0.674577430134214,0.421909232061858,0.252668198072356,8.62999573419242,1.5476,3.98629748872424,22.9793,0.812064945669553,0.711922772249831,0.817438257438142,0.691753093772213,0.100142173419722,0.125685163665929,True,0.612839905572013,0.0675552753270525,0.464699801293498,103.958011598677
24248,1011:1003,Breast,T47D,SIDM00097,905945,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.865439483586336,0.0791785992383029,0.784610862265291,13.6471302973855,2.5057,0.900032936756011,0.918861929653268,0.130582215484341,0.679033219455103,0.35540332069316,0.323629898761943,7.70146100026062,0.0407,5.94566929712491,2.465,0.778924039996816,0.649747069549644,0.795219393886268,0.615047000932017,0.129176970447172,0.180172392954251,True,0.745636717036724,0.0938338308748129,0.275198452104281,172.753544531843
23911,1011:1050,Breast,T47D,SIDM00097,905945,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.933428419220513,0.0681116117440316,0.782157010794588,13.5951474804651,241.7003,0.902855773047261,0.917823420807698,0.0531671267290724,0.730087582168234,0.425060597307961,0.305026984860274,8.35662840226593,6.4022,5.23851907819916,235.2981,0.842751237019619,0.655961381464968,0.856722464808093,0.693450320688288,0.186789855554651,0.163272144119805,True,0.807245427473284,0.0769782491270564,0.185379655430023,239.187907591984
23582,1011:1052,Breast,T47D,SIDM00097,905945,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1052,RO-3306,CDK1,Cell cycle,Targeted,Experimental only,10.0,0.873793766364733,0.0909442394429283,0.754749479953114,13.0409202455492,164.6032,0.907559013361837,0.906015525739551,0.129775771965987,0.659495390750054,0.356352991215908,0.303142399534146,7.65924053479037,3.9481,5.38167971075878,160.6551,0.7930194084837,0.64335458014222,0.791670718620886,0.619107495596019,0.14966482834148,0.172563223024867,True,0.459169007859143,0.0662863316954957,0.733347304738049,66.1665895326004
23583,1011:1080,Breast,T47D,SIDM00097,905945,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.882412651957954,0.0649841199980097,0.562667582537733,9.90586984911351,0.1874,0.816586257393142,0.810174967695958,0.0765669824868843,0.496504993677892,0.292375966551163,0.204129027126729,6.47594132546208,0.0174,3.42992852365143,0.17,0.720566044938702,0.566612946837672,0.71490864179454,0.569372002926176,0.153953098101031,0.145536638868364,True,0.459169007859143,0.0662863316954957,0.733347304738049,66.1665895326004
23584,1179:1085,Breast,T47D,SIDM00097,905945,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.8316158715204,0.0688313938417665,0.798461517131786,13.9489661599809,308.8782,0.93829091101937,0.92466814357099,0.0394287865222561,0.664013270445051,0.468761130216587,0.195252140228464,9.92059158465785,18.9289,4.02837457532303,289.9493,0.780297613707043,0.67248138646159,0.768968704082939,0.674233051869314,0.107816227245453,0.0947356522136246,True,0.459169007859143,0.0662863316954957,0.733347304738049,66.1665895326004
23584,1011:1085,Breast,T47D,SIDM00097,905945,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.914813562351521,0.0688313938417665,0.798461517131786,13.9489661599809,308.8782,0.93829091101937,0.92466814357099,0.156839191956645,0.730443424887929,0.425123504616968,0.305319920270962,8.49172255498105,7.0306,5.45724360499983,301.8476,0.858361250831684,0.750914578887346,0.845898958413145,0.685456900478341,0.107446671944337,0.160442057934804,True,0.459169007859143,0.0662863316954957,0.733347304738049,66.1665895326004
23584,1011:1086,Breast,T47D,SIDM00097,905945,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1086,BI-2536,"PLK1, PLK2, PLK3",Cell cycle,Targeted,Early clinical trials,10.0,0.914813562351521,0.074560912472091,0.503615960178959,9.05199533086513,10.367,0.762346512169197,0.774716766308606,0.166363162289887,0.460714710588395,0.275410393523741,0.185304317064653,5.97220857374187,1.2262,3.07978675712325,9.1408,0.69740492854376,0.532789170162076,0.708721404800227,0.564211251863027,0.164615758381684,0.144510152937199,True,0.459169007859143,0.0662863316954957,0.733347304738049,66.1665895326004
23585,1053:1129,Breast,T47D,SIDM00097,905945,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.939708477862126,0.0664945621643243,0.834653528656646,14.8198650214556,564.8771,0.943779860132502,0.939411505311559,0.101158114418664,0.784330996956189,0.502693434588527,0.281637562367662,9.50331650227421,14.1747,5.31654851918138,550.7024,0.886877935802044,0.66457546883582,0.882772955742494,0.746094547873917,0.222302466966224,0.136678407868577,True,0.459169007859143,0.0662863316954957,0.733347304738049,66.1665895326004
23586,1011:1192,Breast,T47D,SIDM00097,905945,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.925787207886312,0.0759154628244572,0.787025689162359,13.6987075615159,259.688,0.91402161903964,0.919881002037255,0.0952447849357613,0.728618315304421,0.441818269896652,0.286800045407769,8.67243553259906,7.9688,5.02627202891687,251.7192,0.846189522638434,0.704626135673035,0.851614064463733,0.701441890470192,0.141563386965399,0.150172173993541,True,0.459169007859143,0.0662863316954957,0.733347304738049,66.1665895326004
27115,1011:1032,Breast,ZR-75-30,SIDM00971,909907,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.972672296242396,0.167077852274876,0.138103797273688,3.66445551001911,0.2477,0.450993272861877,0.476685636609134,0.106787937694663,0.134329737613993,0.0346299704811119,0.0996997671328806,-0.612846306631463,0.0128,4.27730181665057,0.2349,0.438668662304435,0.214530964262252,0.463658912746374,0.205629043297726,0.224137698042182,0.258029869448648,True,0.749516774496127,0.0791148097907352,0.262908017978766,176.96116610254
27115,1558:1038,Breast,ZR-75-30,SIDM00971,909907,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.448791107242893,0.0964178074635899,0.797167223192242,12.9880673068166,158.6821,0.969398083131626,0.93633351225574,0.0426207501280401,0.357761560754188,0.15189213413814,0.205869426616048,7.04710919747208,2.583,5.94095810934454,156.0991,0.43505723908778,0.318663452531224,0.42021815371388,0.315129767688704,0.116393786556556,0.105088386025176,True,0.749516774496127,0.0791148097907352,0.262908017978766,176.96116610254
27115,1549:1038,Breast,ZR-75-30,SIDM00971,909907,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.6542246927757,0.0964178074635899,0.797167223192242,12.9880673068166,158.6821,0.969398083131626,0.93633351225574,0.0722649498690997,0.521526481683802,0.333085646059041,0.188440835624761,9.10642787169411,10.7656,3.88163943512251,147.9165,0.634204163114141,0.568221683924886,0.612572504391104,0.531391204783629,0.0659824791892554,0.081181299607475,True,0.749516774496127,0.0791148097907352,0.262908017978766,176.96116610254
27115,1053:1038,Breast,ZR-75-30,SIDM00971,909907,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.91614306217746,0.0964178074635899,0.797167223192242,12.9880673068166,158.6821,0.969398083131626,0.93633351225574,0.0594494452480059,0.730319220922843,0.495711884653434,0.234607336269409,9.47994388954762,13.9469,3.508123417269,144.7352,0.888107328349168,0.762804890139265,0.85781545113735,0.759410783418113,0.125302438209903,0.0984046677192372,True,0.749516774496127,0.0791148097907352,0.262908017978766,176.96116610254
27115,1058:1038,Breast,ZR-75-30,SIDM00971,909907,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.755985200975607,0.0964178074635899,0.797167223192242,12.9880673068166,158.6821,0.969398083131626,0.93633351225574,0.0688418336184742,0.602646623436153,0.433989075546161,0.168657547889992,9.8697105788665,18.273,3.11835672795012,140.4091,0.73285060470163,0.686461834200646,0.707854278442851,0.638950358415994,0.0463887705009847,0.0689039200268567,True,0.749516774496127,0.0791148097907352,0.262908017978766,176.96116610254
27116,1558:1042,Breast,ZR-75-30,SIDM00971,909907,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.596975883678825,0.050890200577764,0.841733635021542,13.869496333128,292.324,0.94547989047768,0.951563216465692,0.0742745763018776,0.502494680589174,0.391124093370732,0.111370587218442,10.8702762418036,36.5603,2.99922009132447,255.7637,0.564428693118471,0.464613383331199,0.568060292025871,0.526356509477031,0.0998153097872725,0.0417037825488406,True,0.749516774496127,0.0791148097907352,0.262908017978766,176.96116610254
27117,1011:1050,Breast,ZR-75-30,SIDM00971,909907,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.94285758620196,0.0664288648956713,0.756966473848106,12.3104251558317,99.2058,0.93342335327568,0.921877594252835,0.07664469950066,0.713711582368235,0.427487251099833,0.286224331268402,8.45523224534089,6.855,3.85519291049077,92.3508,0.880085289774048,0.763998668810353,0.869199283290898,0.736051483653934,0.116086620963694,0.133147799636964,True,0.749516774496127,0.0791148097907352,0.262908017978766,176.96116610254
27110,1011:1059,Breast,ZR-75-30,SIDM00971,909907,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.941556955469916,0.0627335147531979,0.636933966674102,10.6377923610046,3.1119,0.857457095987892,0.873881530752634,0.136652595289673,0.599709606497044,0.474286256767961,0.125423349729083,9.04342235723825,1.0306,1.59437000376639,2.0813,0.807344692744435,0.677606618629324,0.82280923353684,0.762028758019205,0.129738074115111,0.0607804755176354,True,0.749516774496127,0.0791148097907352,0.262908017978766,176.96116610254
27110,1558:1059,Breast,ZR-75-30,SIDM00971,909907,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.46777508223775,0.0627335147531979,0.636933966674102,10.6377923610046,3.1119,0.857457095987892,0.873881530752634,0.0959495908533109,0.297941838640994,0.154880696245131,0.143061142395864,6.95098499973742,0.2416,3.68680736126722,2.8703,0.401097063591078,0.263141555936362,0.408780004913864,0.3257400503389,0.137955507654716,0.0830399545749637,True,0.749516774496127,0.0791148097907352,0.262908017978766,176.96116610254
25884,1047:1086,Breast,ZR-75-30,SIDM00971,909907,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,1086,BI-2536,"PLK1, PLK2, PLK3",Cell cycle,Targeted,Early clinical trials,10.0,0.82706353772922,0.0745573585402754,0.683002384694224,11.2366448086774,47.13,0.899437486950529,0.893248274668836,0.106297609459452,0.564886368562699,0.311122334880346,0.253764033682353,7.52618069262878,3.6003,3.71046411604857,43.5297,0.743891949923584,0.638324159498192,0.73877307811813,0.60403256900652,0.105567790425392,0.13474050911161,True,0.747578387495238,0.106151532224113,0.270711652974984,174.587436019628
25884,1558:1086,Breast,ZR-75-30,SIDM00971,909907,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1086,BI-2536,"PLK1, PLK2, PLK3",Cell cycle,Targeted,Early clinical trials,10.0,0.486461480700688,0.0745573585402754,0.683002384694224,11.2366448086774,47.13,0.899437486950529,0.893248274668836,0.0493039794186173,0.332254351380454,0.161315011103462,0.170939340276992,6.95766889942642,2.4277,4.27897590925093,44.7023,0.43754169169966,0.319381800077997,0.434530878328737,0.338950016129261,0.118159891621664,0.0955808621994761,True,0.747578387495238,0.106151532224113,0.270711652974984,174.587436019628
25884,1549:1086,Breast,ZR-75-30,SIDM00971,909907,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1086,BI-2536,"PLK1, PLK2, PLK3",Cell cycle,Targeted,Early clinical trials,10.0,0.702392666718777,0.0745573585402754,0.683002384694224,11.2366448086774,47.13,0.899437486950529,0.893248274668836,0.0260387768723717,0.47973586636066,0.250772500136767,0.228963366223893,7.28582507234275,3.0478,3.9508197363346,44.0822,0.631758295006017,0.500298481299674,0.62741103768659,0.503180705480675,0.131459813706343,0.124230332205916,True,0.747578387495238,0.106151532224113,0.270711652974984,174.587436019628
27119,1054:1553,Breast,ZR-75-30,SIDM00971,909907,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,1.0,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.994549112484859,0.060544630124711,0.711677914008007,11.6327559030029,62.021,0.892490488172701,0.904683947188573,0.123121383635917,0.707798637751739,0.401150991504256,0.306647646247483,7.85916674980077,4.535,3.77358915320218,57.486,0.887625622913338,0.670527696311458,0.899752616755694,0.744967562717375,0.217097926601879,0.15478505403832,True,0.749516774496127,0.0791148097907352,0.262908017978766,176.96116610254
27119,1558:1553,Breast,ZR-75-30,SIDM00971,909907,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.563434235987266,0.060544630124711,0.711677914008007,11.6327559030029,62.021,0.892490488172701,0.904683947188573,0.0770289520381498,0.400983701748113,0.220051494485288,0.180932207262824,7.70340532599867,4.0709,3.92935057700428,57.9501,0.502859696329488,0.368782034263365,0.509729908594138,0.417159056673601,0.134077662066123,0.0925708519205373,True,0.749516774496127,0.0791148097907352,0.262908017978766,176.96116610254
27119,1372:1553,Breast,ZR-75-30,SIDM00971,909907,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.952997618830361,0.060544630124711,0.711677914008007,11.6327559030029,62.021,0.892490488172701,0.904683947188573,0.0331068309509193,0.678227357423789,0.625770077322034,0.0524572801017542,10.8890958984987,37.0403,0.743660004504278,24.9807,0.85054131005733,0.855497229423596,0.862161647464762,0.840849818000578,-0.0049559193662662,0.0213118294641838,True,0.749516774496127,0.0791148097907352,0.262908017978766,176.96116610254
27119,1011:1553,Breast,ZR-75-30,SIDM00971,909907,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.951256560172578,0.060544630124711,0.711677914008007,11.6327559030029,62.021,0.892490488172701,0.904683947188573,0.0830866104095949,0.676988284430052,0.461692853197928,0.215295431232124,8.8292083414387,8.8836,2.80354756156425,53.1374,0.848987431765908,0.733243660787123,0.860586539645952,0.76023080474878,0.115743770978785,0.100355734897173,True,0.749516774496127,0.0791148097907352,0.262908017978766,176.96116610254
27119,1012:1560,Breast,ZR-75-30,SIDM00971,909907,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.925445202009482,0.0745610253608665,0.54667783867532,9.54562834356361,14.5966,0.818891452026133,0.831744232360987,0.0762394723356226,0.505920382846988,0.269815390316799,0.236104992530189,6.41295841075204,1.6643,3.13266993281157,12.9323,0.757839165244163,0.568713235275152,0.769733709137534,0.613473389309878,0.189125929969011,0.156260319827657,True,0.749516774496127,0.0791148097907352,0.262908017978766,176.96116610254
27119,1011:1560,Breast,ZR-75-30,SIDM00971,909907,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.951256560172578,0.0745610253608665,0.54667783867532,9.54562834356361,14.5966,0.818891452026133,0.831744232360987,0.038488365184366,0.520030880340865,0.259835157226216,0.260195723114648,6.14825794932731,1.3853,3.3973703942363,13.2113,0.778975865809107,0.604808998295896,0.791202157419093,0.61442479217269,0.174166867513211,0.176777365246403,True,0.749516774496127,0.0791148097907352,0.262908017978766,176.96116610254
27120,1549:1564,Breast,ZR-75-30,SIDM00971,909907,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.595315691339634,0.0419817877870224,0.923978216941182,16.2777066457916,775.8504,0.983649782980494,0.977735420699524,0.0708143198706228,0.550058731001102,0.344905629955865,0.205153101045236,9.93291432117826,9.5456,6.34479232461336,766.3048,0.585582150591113,0.469116283256074,0.582061237920985,0.50465970426895,0.116465867335039,0.0774015336520341,True,0.749516774496127,0.0791148097907352,0.262908017978766,176.96116610254
27120,1558:1564,Breast,ZR-75-30,SIDM00971,909907,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.615045153955357,0.0419817877870224,0.923978216941182,16.2777066457916,775.8504,0.983649782980494,0.977735420699524,0.10393552903502,0.568288324689985,0.279713970829566,0.28857435386042,8.47157916454768,3.4666,7.80612748124394,772.3838,0.604989032211391,0.422470720526951,0.601351432351744,0.480652586331322,0.18251831168444,0.120698846020423,True,0.749516774496127,0.0791148097907352,0.262908017978766,176.96116610254
27120,1561:1564,Breast,ZR-75-30,SIDM00971,909907,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.842326886860441,0.0419817877870224,0.923978216941182,16.2777066457916,775.8504,0.983649782980494,0.977735420699524,0.0758586039561798,0.778291695002926,0.7166785027181,0.0616131922848262,14.07333352829,168.3432,2.20437311750167,607.5072,0.828554659458907,0.771035736258399,0.823572833091013,0.804065741260956,0.057518923200508,0.0195070918300574,True,0.749516774496127,0.0791148097907352,0.262908017978766,176.96116610254
27120,1012:1593,Breast,ZR-75-30,SIDM00971,909907,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.930748999836631,0.0572456651076658,0.868707986603547,14.5058671427927,90.8785,0.952977767141085,0.96040878556337,0.0734511464294205,0.808549089681345,0.560952599560702,0.247596490120643,10.2141333183437,4.64,4.291733824449,86.2385,0.88698310363311,0.743697909713622,0.89389951659742,0.79914348210128,0.143285193919488,0.0947560344961408,True,0.749516774496127,0.0791148097907352,0.262908017978766,176.96116610254
27120,1021:1593,Breast,ZR-75-30,SIDM00971,909907,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.85634601643019,0.0572456651076658,0.868707986603547,14.5058671427927,90.8785,0.952977767141085,0.96040878556337,0.0619119576888722,0.743914623769038,0.651395506705754,0.0925191170632838,12.3693681187975,20.6686,2.13649902399516,70.2099,0.816078714637805,0.78662232605508,0.822442237661749,0.790612241435414,0.0294563885827247,0.0318299962263349,True,0.749516774496127,0.0791148097907352,0.262908017978766,176.96116610254
27120,1011:1593,Breast,ZR-75-30,SIDM00971,909907,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.98238500579013,0.0572456651076658,0.868707986603547,14.5058671427927,90.8785,0.952977767141085,0.96040878556337,0.0316600752764199,0.853405700449458,0.570820217734742,0.282585482714716,9.95312685634615,3.8721,4.55274028644653,87.0064,0.93619106929076,0.80927506008333,0.943491190366563,0.83357342651838,0.12691600920743,0.109917763848183,True,0.749516774496127,0.0791148097907352,0.262908017978766,176.96116610254
27120,1558:1593,Breast,ZR-75-30,SIDM00971,909907,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.482879757548169,0.0572456651076658,0.868707986603547,14.5058671427927,90.8785,0.952977767141085,0.96040878556337,0.047919083583923,0.419481501951279,0.222557168063996,0.196924333887283,8.54329802257311,1.4573,5.96256912021957,89.4212,0.460173673145882,0.347526528426783,0.463761961519972,0.379116357491811,0.112647144719099,0.0846456040281607,True,0.749516774496127,0.0791148097907352,0.262908017978766,176.96116610254
27120,1549:1593,Breast,ZR-75-30,SIDM00971,909907,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.720178148053163,0.0572456651076658,0.868707986603547,14.5058671427927,90.8785,0.952977767141085,0.96040878556337,0.049508743390584,0.625624508991134,0.40819904275914,0.217425466231995,9.78328389271079,3.4421,4.72258325008189,87.4364,0.686313763475505,0.614602996057118,0.691665420561015,0.606160844189077,0.0717107674183863,0.0855045763719384,True,0.749516774496127,0.0791148097907352,0.262908017978766,176.96116610254
27338,1558:1909,Breast,ZR-75-30,SIDM00971,909907,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.355026517537719,0.0579931767469136,0.941125900740288,17.0761085100685,269.8677,0.969063254028999,0.9829081451137,0.0982836359130222,0.334124651104374,0.221140075847077,0.112984575257296,10.4621574670874,2.7552,6.61395104298115,267.1125,0.344043152351686,0.210776365885516,0.348958455819176,0.308059741492758,0.13326678646617,0.0408987143264175,True,0.805964566386773,0.0966423949694635,0.189734085577825,236.830927586112
27338,1549:1909,Breast,ZR-75-30,SIDM00971,909907,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.612590565201575,0.0579931767469136,0.941125900740288,17.0761085100685,269.8677,0.969063254028999,0.9829081451137,0.0633927318728225,0.576524847460334,0.412107858801296,0.164416988659039,11.0995593128076,4.2858,5.9765491972609,265.5819,0.593639006501702,0.504938482207776,0.602120256156433,0.54461743671984,0.0887005242939257,0.0575028194365927,True,0.805964566386773,0.0966423949694635,0.189734085577825,236.830927586112
27118,1058:2172,Breast,ZR-75-30,SIDM00971,909907,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.900477973316099,0.0743949838312329,0.75024044548249,12.2048742471849,92.2069,0.895668788139157,0.919387347669498,0.122716840690945,0.67557499584784,0.594186848773947,0.0813881470738927,10.9308522621941,38.128,1.2740219849908,54.0789,0.806530015106035,0.711872078204866,0.827888055521893,0.795733586905183,0.0946579369011682,0.0321544686167106,True,0.749516774496127,0.0791148097907352,0.262908017978766,176.96116610254
27118,1191:2172,Breast,ZR-75-30,SIDM00971,909907,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.0025,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.957809947023822,0.0743949838312329,0.75024044548249,12.2048742471849,92.2069,0.895668788139157,0.919387347669498,0.122796912103091,0.718587761342712,0.389227780479837,0.329359980862875,7.89572485404875,4.6514,4.30914939313616,87.5555,0.857880474518456,0.631839956514807,0.880598346765694,0.719373159726983,0.226040518003649,0.161225187038711,True,0.749516774496127,0.0791148097907352,0.262908017978766,176.96116610254
27118,1549:2172,Breast,ZR-75-30,SIDM00971,909907,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.526492904230925,0.0743949838312329,0.75024044548249,12.2048742471849,92.2069,0.895668788139157,0.919387347669498,0.118676278489203,0.394996271013579,0.236472333409588,0.158523937603991,8.40523329344069,6.6215,3.79964095374421,85.5854,0.471563261496378,0.310617170873053,0.484050914787681,0.409667180789189,0.160946090623325,0.0743837339984925,True,0.749516774496127,0.0791148097907352,0.262908017978766,176.96116610254
27118,1054:2172,Breast,ZR-75-30,SIDM00971,909907,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,1.0,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.998819565340675,0.0743949838312329,0.75024044548249,12.2048742471849,92.2069,0.895668788139157,0.919387347669498,0.12763004066145,0.749354835657815,0.526198238100002,0.223156597557814,9.31289412448638,12.422,2.89198012269852,79.7849,0.894611509658362,0.73491751830519,0.918302070978964,0.820624957821541,0.159693991353171,0.0976771131574227,True,0.749516774496127,0.0791148097907352,0.262908017978766,176.96116610254
27118,1558:2172,Breast,ZR-75-30,SIDM00971,909907,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.576655385198128,0.0743949838312329,0.75024044548249,12.2048742471849,92.2069,0.895668788139157,0.919387347669498,0.11943512224506,0.432630193080921,0.187247463569495,0.245382729511426,6.86652626515277,2.2791,5.33834798203214,89.9278,0.516492230034326,0.310563242386079,0.53016966511664,0.39858926710688,0.205928987648248,0.13158039800976,True,0.749516774496127,0.0791148097907352,0.262908017978766,176.96116610254
23628,1022:1003,Breast,HCC1806,SIDM00875,907047,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.233400648718806,0.0818270742558212,0.470345322463138,8.68103625123309,0.0802,0.834547410142687,0.804619428204745,0.0424949581077705,0.109778903384753,0.0949900730822061,0.0147888303025465,7.98891467529562,0.0496,0.692121575937474,0.0306,0.194783906913903,0.13970937365751,0.187798696514742,0.179214146476736,0.0550745332563925,0.0085845500380066,True,0.285248527500019,0.0413207482711035,1.19133050935561,41.254379487671
23628,1011:1003,Breast,HCC1806,SIDM00875,907047,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.945074453513708,0.0818270742558212,0.470345322463138,8.68103625123309,0.0802,0.834547410142687,0.804619428204745,0.111282238565419,0.444511348589579,0.231139020779463,0.213372327810116,5.97099571190897,0.0123,2.71004053932412,0.0679,0.788709437571881,0.629396870806424,0.760425266397112,0.605884017154279,0.159312566765457,0.154541249242833,True,0.285248527500019,0.0413207482711035,1.19133050935561,41.254379487671
23628,1083:1013,Breast,HCC1806,SIDM00875,907047,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1013,Nilotinib,ABL,ABL signaling,Targeted,FDA approved,10.0,0.921979365870822,0.103331100621423,0.701913971641104,11.300219861299,49.2533,0.935470120814655,0.907677774588202,0.123664918280017,0.647150198469535,0.417505487079651,0.229644711389885,8.49179207187392,7.031,2.80842778942503,42.2223,0.862484148779797,0.762936632699569,0.83686017902987,0.732926491618838,0.0995475160802277,0.103933687411031,True,0.285248527500019,0.0413207482711035,1.19133050935561,41.254379487671
23628,1022:1013,Breast,HCC1806,SIDM00875,907047,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1013,Nilotinib,ABL,ABL signaling,Targeted,FDA approved,10.0,0.906423442731743,0.103331100621423,0.701913971641104,11.300219861299,49.2533,0.935470120814655,0.907677774588202,0.087106432186471,0.636231278676441,0.488727111545689,0.147504167130752,9.42180812232261,13.3961,1.87841173897635,35.8572,0.847932047481499,0.804915919235818,0.822740413333326,0.761018769389286,0.0430161282456816,0.0617216439440398,True,0.285248527500019,0.0413207482711035,1.19133050935561,41.254379487671
23869,1510:1032,Breast,HCC1806,SIDM00875,907047,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.848248267606175,0.113279732820429,0.245306867272447,5.98166355906569,1.2342,0.610845511718583,0.641828154780956,0.108848792263025,0.208081125195751,0.0858675432001329,0.122213581995618,3.13511907280242,0.1716,2.84654448626327,1.0626,0.518148647090296,0.351828791874782,0.544429620393814,0.370712897558765,0.166319855215514,0.173716722835048,True,0.345212458207546,0.04165304208536,1.02883802425932,47.9422281805696
23869,1012:1038,Breast,HCC1806,SIDM00875,907047,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.903675012045334,0.0641377441436597,0.768917288269366,12.2289225832146,93.7568,0.955862678825753,0.931366718907734,0.0723391111934113,0.694851339738686,0.487380522306987,0.207470817431699,9.42342678627201,13.4111,2.80549579694255,80.3457,0.863789217801548,0.756427880933845,0.84165283092757,0.758775667705762,0.107361336867702,0.0828771632218085,True,0.345212458207546,0.04165304208536,1.02883802425932,47.9422281805696
23869,1561:1038,Breast,HCC1806,SIDM00875,907047,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.972788322145657,0.0641377441436597,0.768917288269366,12.2289225832146,93.7568,0.955862678825753,0.931366718907734,0.062358339647621,0.747993758724345,0.522581258177209,0.225412500547137,9.40038402568533,13.1986,2.82853855752922,80.5582,0.929852051536557,0.826489028545851,0.90602266778856,0.815817530134312,0.103363022990706,0.0902051376542484,True,0.345212458207546,0.04165304208536,1.02883802425932,47.9422281805696
23869,1179:1038,Breast,HCC1806,SIDM00875,907047,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.280785881712577,0.0641377441436597,0.768917288269366,12.2289225832146,93.7568,0.955862678825753,0.931366718907734,0.0979267483552417,0.215901118750757,0.151803271795744,0.064097846955013,9.43754233976315,13.543,2.79138024345141,80.2138,0.268392745070234,0.164650899915594,0.261514625366258,0.23593773491,0.10374184515464,0.0255768904562576,True,0.345212458207546,0.04165304208536,1.02883802425932,47.9422281805696
23869,1022:1038,Breast,HCC1806,SIDM00875,907047,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.765180623414149,0.0641377441436597,0.768917288269366,12.2289225832146,93.7568,0.955862678825753,0.931366718907734,0.0412454875350815,0.588360609991871,0.580720938702491,0.0076396712893801,12.0802128781561,84.5739,0.148709705058407,9.1829,0.731407600482208,0.728609497925939,0.71266376660101,0.710062058482412,0.0027981025562693,0.0026017081185987,True,0.345212458207546,0.04165304208536,1.02883802425932,47.9422281805696
23870,1190:1042,Breast,HCC1806,SIDM00875,907047,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.1,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.256068794886387,0.0325259896974488,0.939617759775447,16.3720007633295,1656.5073,0.987041993814516,0.983688689707545,0.0880957704780844,0.240606787399545,0.0932480792015243,0.147358708198021,7.50295669308839,3.5428,8.86904407024111,1652.9645,0.25275065385834,0.118324188348008,0.25189197731678,0.189434111216703,0.134426465510331,0.0624578661000766,True,0.345212458207546,0.04165304208536,1.02883802425932,47.9422281805696
23870,1179:1042,Breast,HCC1806,SIDM00875,907047,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.200199815107978,0.0325259896974488,0.939617759775447,16.3720007633295,1656.5073,0.987041993814516,0.983688689707545,0.0365927889420711,0.188111301779217,0.102131220808483,0.085980080970734,9.10902120389584,10.785,7.26297955943365,1645.7223,0.197605624665476,0.135080881969033,0.19693429380326,0.165242298935538,0.0625247426964431,0.0316919948677216,True,0.345212458207546,0.04165304208536,1.02883802425932,47.9422281805696
23630,1011:1052,Breast,HCC1806,SIDM00875,907047,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1052,RO-3306,CDK1,Cell cycle,Targeted,Experimental only,10.0,0.968992140187672,0.0663552393372143,0.620215642812883,10.3173007060012,24.9199,0.903911560927989,0.875644841286819,0.136381203407426,0.600984083107128,0.328467065033864,0.272517018073264,7.20626550489304,2.8842,3.1110352011082,22.0357,0.875883197963991,0.748687188067309,0.848492968802809,0.699422635943716,0.127196009896682,0.149070332859092,True,0.285248527500019,0.0413207482711035,1.19133050935561,41.254379487671
23630,1053:1059,Breast,HCC1806,SIDM00875,907047,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.956538899417537,0.0545780550949181,0.656936662333808,10.7449083678191,3.3517,0.885734817717435,0.890517016904029,0.0746303845271651,0.628385471975811,0.523342226762046,0.105043245213764,9.50773896647186,1.4218,1.2371694013472,1.9299,0.847239807715228,0.785551334294434,0.851814167261968,0.806686340967009,0.0616884734207942,0.0451278262949585,True,0.285248527500019,0.0413207482711035,1.19133050935561,41.254379487671
23632,1179:1085,Breast,HCC1806,SIDM00875,907047,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.171228251939765,0.109452998860999,0.706765193485866,11.3627891692687,51.4364,0.945019552247699,0.909464871023438,0.0393684839296355,0.121018168612455,0.0739813170486769,0.0470368515637777,8.26558495945794,6.0106,3.09720420981077,45.4258,0.161814045980273,0.111490919629396,0.155726080065967,0.13407254357099,0.0503231263508767,0.0216535364949773,True,0.285248527500019,0.0413207482711035,1.19133050935561,41.254379487671
23632,1011:1085,Breast,HCC1806,SIDM00875,907047,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.975340740049306,0.109452998860999,0.706765193485866,11.3627891692687,51.4364,0.945019552247699,0.909464871023438,0.156133457171981,0.689336886855595,0.46077544271385,0.228561444141746,8.70345335703765,8.142,2.65933581223106,43.2944,0.921716069450334,0.864281429357072,0.887038140352847,0.785876224527391,0.057434640093262,0.101161915825456,True,0.285248527500019,0.0413207482711035,1.19133050935561,41.254379487671
23634,1049:1192,Breast,HCC1806,SIDM00875,907047,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.970517015481635,0.0740250174430981,0.839705145499742,13.4478267466012,218.2374,0.937651372378984,0.954313015379957,0.0393536449667504,0.814948131694982,0.795763308198166,0.0191848234968154,13.0715109914353,168.1307,0.376315755165871,50.1067,0.91000661148351,0.921064785153271,0.926177019521835,0.9201471864312,-0.0110581736697603,0.0060298330906352,True,0.285248527500019,0.0413207482711035,1.19133050935561,41.254379487671
23634,1510:1192,Breast,HCC1806,SIDM00875,907047,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.914350841490371,0.0740250174430981,0.839705145499742,13.4478267466012,218.2374,0.937651372378984,0.954313015379957,0.100256987397963,0.767785106391483,0.613603739876983,0.154181366514501,10.9152089209722,37.7168,2.53261782562899,180.5206,0.857342321359325,0.770283989157441,0.872576908657877,0.819288440866278,0.0870583322018842,0.0532884677915996,True,0.285248527500019,0.0413207482711035,1.19133050935561,41.254379487671
23634,1011:1192,Breast,HCC1806,SIDM00875,907047,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.944018125811057,0.0740250174430981,0.839705145499742,13.4478267466012,218.2374,0.937651372378984,0.954313015379957,0.128824946241456,0.792696877688568,0.496934105745032,0.295762771943536,9.28392122787096,12.175,4.16390551873021,206.0624,0.885159891217374,0.688272837841332,0.900888784216086,0.78677120665019,0.196887053376042,0.114117577565895,True,0.285248527500019,0.0413207482711035,1.19133050935561,41.254379487671
23873,1179:1553,Breast,HCC1806,SIDM00875,907047,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.17173247051357,0.0651282121967328,0.684751863534222,11.0833869524944,42.3801,0.889245089549185,0.901258398426799,0.0287450901607482,0.117594129213503,0.0972623659375951,0.0203317632759076,9.71715454667429,16.4394,1.36623240582008,25.9407,0.152712256120342,0.119048011649253,0.154775331332937,0.146354845394629,0.0336642444710887,0.0084204859383086,True,0.345212458207546,0.04165304208536,1.02883802425932,47.9422281805696
23873,1012:1553,Breast,HCC1806,SIDM00875,907047,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.853461411849141,0.0651282121967328,0.684751863534222,11.0833869524944,42.3801,0.889245089549185,0.901258398426799,0.0676833242447096,0.584409292218248,0.344394441630902,0.240014850587346,7.95040021593929,4.831,3.13298673655508,37.5491,0.758936369606563,0.611059821049916,0.769189265162232,0.653478623631344,0.147876548556647,0.115710641530888,True,0.345212458207546,0.04165304208536,1.02883802425932,47.9422281805696
23873,1594:1553,Breast,HCC1806,SIDM00875,907047,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.956776763180294,0.0651282121967328,0.684751863534222,11.0833869524944,42.3801,0.889245089549185,0.901258398426799,0.052877298481225,0.655154671573947,0.651681483582587,0.0034731879913596,11.0383599515176,41.0778,0.0450270009767415,1.3023,0.850809038452839,0.894622822808573,0.862303093235849,0.860984945095508,-0.0438137843557341,0.0013181481403403,True,0.345212458207546,0.04165304208536,1.02883802425932,47.9422281805696
23873,1372:1553,Breast,HCC1806,SIDM00875,907047,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.733372085091744,0.0651282121967328,0.684751863534222,11.0833869524944,42.3801,0.889245089549185,0.901258398426799,0.0640250463185051,0.50217790193055,0.285212270623401,0.216965631307149,7.78623105143304,4.3114,3.29715590106133,38.0687,0.65214752548028,0.508220093182162,0.660957750860708,0.554686562574029,0.143927432298118,0.106271188286678,True,0.345212458207546,0.04165304208536,1.02883802425932,47.9422281805696
23873,1049:1553,Breast,HCC1806,SIDM00875,907047,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.871349599186213,0.0651282121967328,0.684751863534222,11.0833869524944,42.3801,0.889245089549185,0.901258398426799,0.0726927137097833,0.596658261832557,0.371376630424581,0.225281631407976,8.20140325473285,5.7491,2.88198369776151,36.631,0.77484335235699,0.625531452686772,0.7853111442324,0.679252483264963,0.149311899670218,0.106058660967437,True,0.345212458207546,0.04165304208536,1.02883802425932,47.9422281805696
23873,1179:1560,Breast,HCC1806,SIDM00875,907047,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.320970731548182,0.060605776888379,0.740369149376938,11.8144467343327,70.3449,0.92639152300342,0.921527830993836,0.1317027952233,0.237636827491221,0.112322255682141,0.12531457180908,7.33672371341969,3.1572,4.47772302091303,67.1877,0.297344564838442,0.130809575638588,0.295783462056101,0.234238983627228,0.166534989199854,0.0615444784288729,True,0.345212458207546,0.04165304208536,1.02883802425932,47.9422281805696
23874,1190:1593,Breast,HCC1806,SIDM00875,907047,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.01,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.294512659187529,0.0570922782697539,0.695365594208002,11.2166815877831,9.2965,0.923247325991573,0.905246464082582,0.050613314538279,0.204793970257715,0.11321594984444,0.0915780204132747,7.73541055694011,0.8324,3.48127103084294,8.4641,0.271908025065553,0.183319658172424,0.266606543357069,0.221892116039927,0.0885883668931288,0.0447144273171419,True,0.345212458207546,0.04165304208536,1.02883802425932,47.9422281805696
23631,1190:2169,Breast,HCC1806,SIDM00875,907047,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.1,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.269219735868392,0.0440610505616164,0.796770358744724,12.6694580034705,127.238,0.938592951125051,0.940630738827109,0.0628083843269328,0.214506305529019,0.12055738331697,0.0939489222120486,8.43718001343763,6.7698,4.23227799003285,120.4682,0.252687746389821,0.167946091756508,0.253236359056725,0.213249868833693,0.0847416546333126,0.0399864902230314,True,0.285248527500019,0.0413207482711035,1.19133050935561,41.254379487671
23631,1510:2169,Breast,HCC1806,SIDM00875,907047,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.945077995503384,0.0440610505616164,0.796770358744724,12.6694580034705,127.238,0.938592951125051,0.940630738827109,0.0415413979218689,0.753010133518977,0.535770547012509,0.217239586506468,9.72313061356106,16.5076,2.94632738990942,110.7304,0.887043544842869,0.77955644908886,0.888969413159592,0.805654383484712,0.10748709575401,0.0833150296748794,True,0.285248527500019,0.0413207482711035,1.19133050935561,41.254379487671
23631,1179:2169,Breast,HCC1806,SIDM00875,907047,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.161414051373283,0.0440610505616164,0.796770358744724,12.6694580034705,127.238,0.938592951125051,0.940630738827109,0.0352722592909325,0.12860993161913,0.0747825792111337,0.0538273524079966,8.60497328949681,7.6048,4.06448471397367,119.6332,0.151502090831501,0.100489980900666,0.151831018400328,0.129255227453643,0.0510121099308348,0.0225757909466852,True,0.285248527500019,0.0413207482711035,1.19133050935561,41.254379487671
29168,1022:1003,Breast,EVSA-T,SIDM01042,906862,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.893485710277953,0.0832897031819765,0.689520992506775,10.5995136269037,0.303,0.913637455699367,0.926088013682849,0.0713178022928632,0.616077153741475,0.173271611357497,0.442805542383978,6.14392429245884,0.0138,4.45558933444486,0.2892,0.816322011042091,0.625905374144301,0.827446406685319,0.604690075926334,0.19041663689779,0.222756330758985,True,0.379782597692322,0.0723047189736789,0.909994462495103,53.5200840238903
29168,1558:1003,Breast,EVSA-T,SIDM01042,906862,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.938662383568415,0.0832897031819765,0.689520992506775,10.5995136269037,0.303,0.913637455699367,0.926088013682849,0.0870135548423434,0.647227418346869,0.600963874926971,0.0462635434198971,10.1554729783944,0.2228,0.444040648509283,0.0802,0.85759711188415,0.796329230430849,0.869283982317682,0.855471195582344,0.0612678814533008,0.0138127867353385,True,0.379782597692322,0.0723047189736789,0.909994462495103,53.5200840238903
29168,1179:1003,Breast,EVSA-T,SIDM01042,906862,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.497930490503365,0.0832897031819765,0.689520992506775,10.5995136269037,0.303,0.913637455699367,0.926088013682849,0.051291023895423,0.343333526011265,0.0920059196766998,0.251327606334566,6.0243913469655,0.0127,4.5751222799382,0.2903,0.454927946458632,0.322113973543583,0.461127458902388,0.33233141013685,0.13281397291505,0.128796048765538,True,0.379782597692322,0.0723047189736789,0.909994462495103,53.5200840238903
29168,1012:1003,Breast,EVSA-T,SIDM01042,906862,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.231175294554327,0.0832897031819765,0.689520992506775,10.5995136269037,0.303,0.913637455699367,0.926088013682849,0.0837945247145473,0.159400218544146,0.0681443851138485,0.0912558334302974,7.25127598705279,0.0298,3.3482376398509,0.2732,0.211210407937167,0.115334114024083,0.214088669346365,0.175313963859086,0.0958762939130848,0.0387747054872791,True,0.379782597692322,0.0723047189736789,0.909994462495103,53.5200840238903
29168,1011:1003,Breast,EVSA-T,SIDM01042,906862,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.54839806048673,0.0832897031819765,0.689520992506775,10.5995136269037,0.303,0.913637455699367,0.926088013682849,0.0716439725913769,0.3781319749556,0.142037179635973,0.236094795319627,6.8927515380911,0.0232,3.7067620888126,0.2798,0.501037008693563,0.382962444202378,0.507864870543682,0.402005740141219,0.118074564491185,0.105859130402463,True,0.379782597692322,0.0723047189736789,0.909994462495103,53.5200840238903
29168,1053:1003,Breast,EVSA-T,SIDM01042,906862,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.223301311088589,0.0832897031819765,0.689520992506775,10.5995136269037,0.303,0.913637455699367,0.926088013682849,0.0737130915181604,0.153970941649868,0.0621229215132498,0.0918480201366182,7.0887233182749,0.0266,3.51079030862879,0.2764,0.204016441717311,0.110915286630527,0.206796667638807,0.166813197656966,0.0931011550867845,0.0399834699818414,True,0.379782597692322,0.0723047189736789,0.909994462495103,53.5200840238903
29169,1012:1030,Breast,EVSA-T,SIDM01042,906862,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1030,KU-55933,ATM,Genome integrity,Targeted,Experimental only,10.0,0.83171700805557,0.0936652399414415,0.734564705087957,11.0406005342356,41.1417,0.925112975113456,0.938652752232128,0.0492984265098317,0.610949958738978,0.535800933540867,0.0751490251981105,10.1901653632218,22.8179,0.850435171013727,18.3238,0.769432195774751,0.763604213150892,0.780693458689632,0.759025526677362,0.0058279826238587,0.0216679320122699,True,0.379782597692322,0.0723047189736789,0.909994462495103,53.5200840238903
29169,1047:1030,Breast,EVSA-T,SIDM01042,906862,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1030,KU-55933,ATM,Genome integrity,Targeted,Experimental only,10.0,0.957398218853034,0.0936652399414415,0.734564705087957,11.0406005342356,41.1417,0.925112975113456,0.938652752232128,0.0535645517331572,0.703270940283514,0.700501466735887,0.0027694735476268,11.0109614369577,40.3051,0.0296390972779008,0.836599999999997,0.885701514611454,0.91638028237763,0.898664473108537,0.897914188258623,-0.0306787677661768,0.0007502848499137,True,0.379782597692322,0.0723047189736789,0.909994462495103,53.5200840238903
29169,1053:1030,Breast,EVSA-T,SIDM01042,906862,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1030,KU-55933,ATM,Genome integrity,Targeted,Experimental only,10.0,0.601066414892363,0.0936652399414415,0.734564705087957,11.0406005342356,41.1417,0.925112975113456,0.938652752232128,0.0695607102536409,0.441522173793684,0.200088873666241,0.241433300127443,7.60644361915292,3.8063,3.43415691508263,37.3354,0.556054339321853,0.413725144143525,0.564192644613015,0.470162754489409,0.142329195178328,0.0940298901236052,True,0.379782597692322,0.0723047189736789,0.909994462495103,53.5200840238903
28316,1053:1032,Breast,EVSA-T,SIDM01042,906862,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.228061167716026,0.121895396377605,0.422038717472636,8.36970188458593,6.4604,0.821535091139735,0.828925639159499,0.0765077779014859,0.0962506427281835,0.0168276221808803,0.0794230205473032,3.92821798443378,0.2973,4.44148390015215,6.1631,0.18736025220502,0.068542267459476,0.189045749216469,0.112643276105361,0.118817984745544,0.0764024731111077,True,0.20306154483193,0.0395421221533299,1.53144034569159,32.3121073664987
30189,1558:1050,Breast,EVSA-T,SIDM01042,906862,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.949935489945758,0.101571841796186,0.576118379663522,9.61516084267289,15.3173,0.899594912767545,0.890455305309168,0.0774225414741743,0.547275295252424,0.437803013357555,0.109472281894869,8.68563406925941,8.042,0.929526773413476,7.2753,0.854557134212549,0.816385695415393,0.845875096723664,0.803933377184042,0.0381714387971562,0.0419417195396216,True,0.365571125475349,0.0608608985546088,0.97322700985884,50.6438358533132
30189,1047:1050,Breast,EVSA-T,SIDM01042,906862,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.951769392839449,0.101571841796186,0.576118379663522,9.61516084267289,15.3173,0.899594912767545,0.890455305309168,0.0925681999266367,0.548331840415998,0.328251869640528,0.22007997077547,7.71379166623966,4.1003,1.90136917643323,11.217,0.856206903926223,0.789012454854183,0.847508105284773,0.751108311622776,0.0671944490720394,0.0963997936619967,True,0.365571125475349,0.0608608985546088,0.97322700985884,50.6438358533132
30189,1005:1050,Breast,EVSA-T,SIDM01042,906862,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.954201861260942,0.101571841796186,0.576118379663522,9.61516084267289,15.3173,0.899594912767545,0.890455305309168,0.0812817010353337,0.549733230181571,0.296701955923584,0.253031274257987,7.40482525433836,3.3098,2.21033558833453,12.0075,0.858395140143666,0.771214358008009,0.849674109695688,0.733616394181689,0.0871807821356565,0.116057715513999,True,0.365571125475349,0.0608608985546088,0.97322700985884,50.6438358533132
30189,1012:1050,Breast,EVSA-T,SIDM01042,906862,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.667256607580079,0.101571841796186,0.576118379663522,9.61516084267289,15.3173,0.899594912767545,0.890455305309168,0.11036410634625,0.384418795578814,0.1682767675783,0.216142028000514,6.8209774560617,2.2083,2.79418338661119,13.109,0.600260649689568,0.43539842975496,0.594162186222279,0.485663680893902,0.164862219934609,0.108498505328377,True,0.365571125475349,0.0608608985546088,0.97322700985884,50.6438358533132
30189,1011:1050,Breast,EVSA-T,SIDM01042,906862,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.928937994442011,0.101571841796186,0.576118379663522,9.61516084267289,15.3173,0.899594912767545,0.890455305309168,0.0768106674912789,0.535178252165813,0.19763251954439,0.337545732621424,6.37700350173356,1.6233,3.23815734093933,13.694,0.835667894076519,0.660812794964555,0.827177765454147,0.645370565961378,0.174855099111964,0.18180719949277,True,0.365571125475349,0.0608608985546088,0.97322700985884,50.6438358533132
30189,1012:1051,Breast,EVSA-T,SIDM01042,906862,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.667256607580079,0.134901814491384,0.496757771201163,8.97400082070517,9.8214,0.763948414299478,0.86112022168102,0.187542902511383,0.331464905200729,0.0374433560378827,0.294021549162847,3.34153902173063,0.198,5.63246179897454,9.6234,0.50974962729165,0.277923162266401,0.574588157837482,0.296488534819754,0.231826465025249,0.278099623017728,True,0.365571125475349,0.0608608985546088,0.97322700985884,50.6438358533132
30189,1011:1051,Breast,EVSA-T,SIDM01042,906862,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.928937994442011,0.134901814491384,0.496757771201163,8.97400082070517,9.8214,0.763948414299478,0.86112022168102,0.175544263203413,0.461457167703092,0.0163984436105804,0.445058724092512,0.943011009218527,0.0375,8.03098981148664,9.7839,0.709660707836511,0.272176296427664,0.799927291701826,0.237072541721723,0.437484411408847,0.562854749980104,True,0.365571125475349,0.0608608985546088,0.97322700985884,50.6438358533132
29170,1011:1052,Breast,EVSA-T,SIDM01042,906862,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1052,RO-3306,CDK1,Cell cycle,Targeted,Experimental only,10.0,0.804950782324097,0.150556784713499,0.409617939686164,8.26719104343732,6.0173,0.787960261161887,0.823034417809747,0.108438708104012,0.329722281004362,0.105142695750044,0.224579585254319,5.20011133506215,0.718,3.06707970837517,5.2993,0.634269228662561,0.465855985893324,0.662502198495614,0.483651780442269,0.168413242769237,0.178850418053345,True,0.379782597692322,0.0723047189736789,0.909994462495103,53.5200840238903
29170,1053:1052,Breast,EVSA-T,SIDM01042,906862,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1052,RO-3306,CDK1,Cell cycle,Targeted,Experimental only,10.0,0.281398041639681,0.150556784713499,0.409617939686164,8.26719104343732,6.0173,0.787960261161887,0.823034417809747,0.0718695495439942,0.115265686048168,0.0348166991940058,0.0804489868541619,5.0756050964639,0.6586,3.19158594697342,5.3587,0.221730474380847,0.120477154496503,0.231600273373718,0.166175570005613,0.101253319884344,0.0654247033681047,True,0.379782597692322,0.0723047189736789,0.909994462495103,53.5200840238903
29170,1053:1059,Breast,EVSA-T,SIDM01042,906862,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.556192315219582,0.15931821385637,0.28960736427739,7.20119714037181,0.2874,0.692701964753809,0.754896140882602,0.0734510197641346,0.161077390442083,0.0413576607597165,0.119719729682366,3.94496634915222,0.0301,3.2562307912196,0.2573,0.385275509533575,0.25752539460282,0.419867432347822,0.275502190175101,0.127750114930754,0.144365242172722,True,0.379782597692322,0.0723047189736789,0.909994462495103,53.5200840238903
29170,1022:1059,Breast,EVSA-T,SIDM01042,906862,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.933364235204316,0.15931821385637,0.28960736427739,7.20119714037181,0.2874,0.692701964753809,0.754896140882602,0.105205272711389,0.270309156068304,0.23951231136849,0.0307968446998136,6.86769081526731,0.2281,0.333506325104504,0.0593,0.646543239556966,0.658333360989654,0.704593059193579,0.682515955281504,-0.0117901214326877,0.0220771039120757,True,0.379782597692322,0.0723047189736789,0.909994462495103,53.5200840238903
29170,1012:1059,Breast,EVSA-T,SIDM01042,906862,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.771504359042811,0.15931821385637,0.28960736427739,7.20119714037181,0.2874,0.692701964753809,0.754896140882602,0.136945993913836,0.223433343950906,0.138684107646706,0.0847492363041994,5.95688651952006,0.1213,1.24431062085176,0.1661,0.534422585325084,0.457097543191445,0.582405663315524,0.510817298526703,0.0773250421336386,0.071588364788821,True,0.379782597692322,0.0723047189736789,0.909994462495103,53.5200840238903
25029,1011:1080,Breast,EVSA-T,SIDM01042,906862,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.908938231268576,0.173967947366644,0.29565486605097,7.2597665921709,0.0299,0.673984178428372,0.758944234808883,0.0913102088014417,0.268732011014316,0.0415749701227982,0.227157040891518,2.90979528593043,0.0015,4.34997130624047,0.0284,0.612609987043689,0.370830443377401,0.689833430418669,0.37107642697269,0.241779543666288,0.318757003445979,True,0.346698982789548,0.0755860240500048,1.01425062392302,48.4483271087789
25029,1053:1080,Breast,EVSA-T,SIDM01042,906862,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.531567451971044,0.173967947366644,0.29565486605097,7.2597665921709,0.0299,0.673984178428372,0.758944234808883,0.0812491163184903,0.157160503809555,0.041756896157761,0.115403607651794,4.06411390688349,0.0033,3.19565268528741,0.0266,0.358268052395967,0.253139856412604,0.403430053085472,0.268671871620571,0.105128195983363,0.134758181464901,True,0.346698982789548,0.0755860240500048,1.01425062392302,48.4483271087789
23536,1058:1096,Breast,EVSA-T,SIDM01042,906862,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.868076555411494,0.100095291587771,0.761660501948393,11.3290728256843,25.1241,0.901060460632658,0.945848315971672,0.0765532606606685,0.66117962492435,0.60477707770452,0.0564025472198302,10.6670460117806,15.8782,0.662026813903667,9.2459,0.782189460883492,0.740821211990614,0.821068748070451,0.805696731358812,0.0413682488928779,0.0153720167116392,True,0.283328311617201,0.0607107122635458,1.18237937471801,41.4047847216399
23536,1191:1096,Breast,EVSA-T,SIDM01042,906862,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.0025,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.748636540415697,0.100095291587771,0.761660501948393,11.3290728256843,25.1241,0.901060460632658,0.945848315971672,0.107796551518108,0.570206883149928,0.34426889396556,0.225937989184368,8.67744046442983,3.9982,2.65163236125444,21.1259,0.674566785953408,0.558398778112575,0.708096611027046,0.633247297900821,0.116168007840832,0.0748493131262252,True,0.283328311617201,0.0607107122635458,1.18237937471801,41.4047847216399
23536,1049:1096,Breast,EVSA-T,SIDM01042,906862,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.884794428293039,0.100095291587771,0.761660501948393,11.3290728256843,25.1241,0.901060460632658,0.945848315971672,0.178234648682114,0.673912968374817,0.486976808910466,0.186936159464351,9.4053966126725,6.6223,1.92367621301177,18.5018,0.797253275122935,0.649915856341514,0.836881319982089,0.779862064344872,0.147337418781422,0.0570192556372179,True,0.283328311617201,0.0607107122635458,1.18237937471801,41.4047847216399
23536,1558:1096,Breast,EVSA-T,SIDM01042,906862,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.932307426294465,0.100095291587771,0.761660501948393,11.3290728256843,25.1241,0.901060460632658,0.945848315971672,0.0519979508659961,0.710101742281656,0.528674463652198,0.181427278629459,9.54100282126177,7.2749,1.7880700044225,17.8492,0.840065358988139,0.820779641232833,0.881821409128504,0.827251321688249,0.0192857177553057,0.0545700874402545,True,0.283328311617201,0.0607107122635458,1.18237937471801,41.4047847216399
23536,1190:1096,Breast,EVSA-T,SIDM01042,906862,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.1,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.883255853319508,0.100095291587771,0.761660501948393,11.3290728256843,25.1241,0.901060460632658,0.945848315971672,0.193259342619649,0.672741096588192,0.427225950621684,0.245515145966508,8.86920248930305,4.5666,2.45987033638122,20.5575,0.795866926048567,0.598895467146587,0.835426061434379,0.755935974953159,0.19697145890198,0.0794900864812195,True,0.283328311617201,0.0607107122635458,1.18237937471801,41.4047847216399
23536,1047:1096,Breast,EVSA-T,SIDM01042,906862,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.996364557787559,0.100095291587771,0.761660501948393,11.3290728256843,25.1241,0.901060460632658,0.945848315971672,0.120387871885385,0.758891529208061,0.488752315325369,0.270139213882692,8.92409794856532,4.7437,2.40497487711894,20.3804,0.897784707398113,0.7668441013504,0.942409739077223,0.855506535141074,0.130940606047713,0.0869032039361487,True,0.283328311617201,0.0607107122635458,1.18237937471801,41.4047847216399
23536,1510:1096,Breast,EVSA-T,SIDM01042,906862,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.926923686037449,0.100095291587771,0.761660501948393,11.3290728256843,25.1241,0.901060460632658,0.945848315971672,0.0675093527205737,0.706001159975138,0.607182332746222,0.0988188272289162,10.2856491642226,12.1896,1.04342366146169,12.9345,0.835214283512225,0.81113161667462,0.876729207472776,0.848979654412896,0.0240826668376058,0.0277495530598807,True,0.283328311617201,0.0607107122635458,1.18237937471801,41.4047847216399
23536,1005:1096,Breast,EVSA-T,SIDM01042,906862,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.958594414065725,0.100095291587771,0.761660501948393,11.3290728256843,25.1241,0.901060460632658,0.945848315971672,0.134605167243622,0.730123502582225,0.508232389907897,0.221891112674329,9.2423425462101,5.9146,2.08673027947416,19.2095,0.863751524297955,0.760636225753204,0.906684912243918,0.837814585640531,0.103115298544752,0.0688703266033864,True,0.283328311617201,0.0607107122635458,1.18237937471801,41.4047847216399
23536,1011:1096,Breast,EVSA-T,SIDM01042,906862,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.866916354297506,0.100095291587771,0.761660501948393,11.3290728256843,25.1241,0.901060460632658,0.945848315971672,0.159723086983811,0.660295945561509,0.045564110408265,0.614731835153244,3.20273815790615,0.0899,8.12633466777811,25.0342,0.781144049533295,0.378100762615188,0.819971373800597,0.375103046798229,0.403043286918107,0.444868327002369,True,0.283328311617201,0.0607107122635458,1.18237937471801,41.4047847216399
23537,1083:1192,Breast,EVSA-T,SIDM01042,906862,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.813298763673943,0.0706583274570305,0.495612143446053,8.96481371117557,9.7591,0.859406056742207,0.86066367713279,0.192284324088513,0.403080743526468,0.190202266445286,0.212878477081182,6.6211934545186,1.9227,2.34362025665697,7.8364,0.698953883442336,0.445109772580689,0.699976704551168,0.579998018437296,0.253844110861647,0.119978686113872,True,0.283328311617201,0.0607107122635458,1.18237937471801,41.4047847216399
23537,1053:1192,Breast,EVSA-T,SIDM01042,906862,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.311759164556051,0.0706583274570305,0.495612143446053,8.96481371117557,9.7591,0.859406056742207,0.86066367713279,0.0850639627207967,0.154511627784575,0.0508585556099383,0.103653072174637,5.72212888268273,1.031,3.24268482849284,8.7281,0.267927714264361,0.129131060497636,0.268319788946657,0.20058649307383,0.138796653766724,0.0677332958728275,True,0.283328311617201,0.0607107122635458,1.18237937471801,41.4047847216399
23857,1012:1553,Breast,EVSA-T,SIDM01042,906862,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.945209338180909,0.075602995955883,0.0940040387218249,4.4579516754284,0.4292,0.540843811527924,0.538761964262674,0.070900604096146,0.0888534952265887,0.0658397328176455,0.0230137624089432,3.80384798147767,0.2728,0.654103693950723,0.1564,0.511210621153549,0.451448751471461,0.509242839677769,0.456895904914409,0.0597618696820879,0.0523469347633594,True,0.559777370681233,0.0870550572179395,0.549877491747011,88.0227815914027
23857,1053:1560,Breast,EVSA-T,SIDM01042,906862,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.480591293115123,0.101680639183628,0.755623207316091,11.2629713360699,47.9979,0.91263180648589,0.944267264989579,0.0384236253946384,0.363145934311837,0.107013566683043,0.256132367628794,6.49378031383266,1.7602,4.76919102223722,46.2377,0.438602900017044,0.328986488598127,0.453806625927622,0.338142357379696,0.109616411418917,0.115664268547926,True,0.559777370681233,0.0870550572179395,0.549877491747011,88.0227815914027
23857,1179:1560,Breast,EVSA-T,SIDM01042,906862,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.991558551144354,0.101680639183628,0.755623207316091,11.2629713360699,47.9979,0.91263180648589,0.944267264989579,0.0850817272077364,0.749244652657393,0.276164434664007,0.473080217993386,7.09184984693468,2.6643,4.1711214891352,45.3336,0.904927871767403,0.741553404935777,0.936296281166109,0.740944180583824,0.163374466831627,0.195352100582284,True,0.559777370681233,0.0870550572179395,0.549877491747011,88.0227815914027
23857,1012:1560,Breast,EVSA-T,SIDM01042,906862,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.945209338180909,0.101680639183628,0.755623207316091,11.2629713360699,47.9979,0.91263180648589,0.944267264989579,0.113110034609192,0.714222111701378,0.56173541456465,0.152486697136728,9.76531381683005,16.9974,1.49765751923983,31.0005,0.862628105811375,0.82565345389768,0.892530236606697,0.84748511508744,0.0369746519136951,0.0450451215192567,True,0.559777370681233,0.0870550572179395,0.549877491747011,88.0227815914027
23857,1007:1560,Breast,EVSA-T,SIDM01042,906862,1007,Docetaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.001,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.924516996030961,0.101680639183628,0.755623207316091,11.2629713360699,47.9979,0.91263180648589,0.944267264989579,0.150134414177992,0.698586497759152,0.383648084277353,0.314938413481799,8.31148245493818,6.2049,2.9514888811317,41.793,0.843743616214644,0.674050399508298,0.872991135278536,0.763276448786871,0.169693216706346,0.109714686491666,True,0.559777370681233,0.0870550572179395,0.549877491747011,88.0227815914027
23858,1561:1564,Breast,EVSA-T,SIDM01042,906862,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.930266596910428,0.101107332943536,0.886520480186876,13.1210302520179,87.0009,0.923835418608606,0.976028017297806,0.0972361076829348,0.824700390194844,0.659292232700223,0.165408157494621,10.7824663989824,17.2007,2.33856385303554,69.8002,0.859413230974349,0.796823383891893,0.907966262140862,0.866578840829836,0.0625898470824562,0.0413874213110268,True,0.559777370681233,0.0870550572179395,0.549877491747011,88.0227815914027
23858,1179:1593,Breast,EVSA-T,SIDM01042,906862,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.979152404322518,0.12538802253223,0.316506292040592,7.45663111648807,0.6862,0.752983938593029,0.772306455928065,0.102876833574537,0.30990789683475,0.221582392320527,0.0883255045142236,6.53557636222633,0.3624,0.921054754261738,0.3238,0.737286033889603,0.704743299875425,0.756205723195768,0.692007829226793,0.032542734014178,0.0641978939689747,True,0.559777370681233,0.0870550572179395,0.549877491747011,88.0227815914027
23858,1053:1593,Breast,EVSA-T,SIDM01042,906862,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.728541884585942,0.12538802253223,0.316506292040592,7.45663111648807,0.6862,0.752983938593029,0.772306455928065,0.0811795754318384,0.230588090486561,0.0976794435452383,0.132908646941323,5.26043482682871,0.1497,2.19619628965936,0.5365,0.548580337685511,0.396888468625087,0.562657600879723,0.441366931806376,0.151691869060424,0.121290669073347,True,0.559777370681233,0.0870550572179395,0.549877491747011,88.0227815914027
28319,1012:1909,Breast,EVSA-T,SIDM01042,906862,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.838355287399067,0.0755220825088165,0.875520227091923,12.9105228117128,15.0378,0.941354340901263,0.973544303116051,0.0610998626553663,0.733997011607345,0.73090952528726,0.0030874863200856,12.8436228530485,14.3564,0.0668999586643366,0.6814,0.789189389010638,0.787438739354035,0.816176014034581,0.81547309553206,0.0017506496566025,0.0007029185025213,True,0.20306154483193,0.0395421221533299,1.53144034569159,32.3121073664987
25029,1549:2169,Breast,EVSA-T,SIDM01042,906862,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.912230105769152,0.125091027476556,0.127908669818762,5.15181813154314,0.6944,0.569038004103388,0.59685337403406,0.118877496808752,0.116682139397561,0.0207157907183427,0.0959663486792183,1.45825911036948,0.0537,3.69355902117366,0.6407,0.519093598669901,0.301175715130425,0.544467616523766,0.267096908629868,0.217917883539476,0.277370707893898,True,0.346698982789548,0.0755860240500048,1.01425062392302,48.4483271087789
25029,1561:2169,Breast,EVSA-T,SIDM01042,906862,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.915910688697841,0.125091027476556,0.127908669818762,5.15181813154314,0.6944,0.569038004103388,0.59685337403406,0.114595849356563,0.117152917864127,0.0220744431009529,0.0950784747631744,1.58039195102982,0.0584,3.57142618051332,0.636,0.521187990233579,0.307549925994549,0.546664384863166,0.276620718182562,0.213638064239031,0.270043666680604,True,0.346698982789548,0.0755860240500048,1.01425062392302,48.4483271087789
25029,1179:2169,Breast,EVSA-T,SIDM01042,906862,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.665052355612499,0.125091027476556,0.127908669818762,5.15181813154314,0.6944,0.569038004103388,0.59685337403406,0.087490679932841,0.0850659621662292,0.0204988223469468,0.0645671398192824,2.08740448570044,0.083,3.0644136458427,0.6114,0.378440065061993,0.235620646086197,0.396938742356619,0.227048557221188,0.142819418975796,0.169890185135431,True,0.346698982789548,0.0755860240500048,1.01425062392302,48.4483271087789
25029,1012:2169,Breast,EVSA-T,SIDM01042,906862,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.475326201278539,0.125091027476556,0.127908669818762,5.15181813154314,0.6944,0.569038004103388,0.59685337403406,0.0775086547615296,0.0607983421355432,0.004423739778113,0.0563746023574302,-0.357280123588196,0.0152,5.50909825513133,0.6792,0.270478672873586,0.0791897980477356,0.283700046999889,0.0816523446910968,0.19128887482585,0.202047702308792,True,0.346698982789548,0.0755860240500048,1.01425062392302,48.4483271087789
25029,1559:2169,Breast,EVSA-T,SIDM01042,906862,1559,Luminespib,HSP90,Protein stability and degradation,Targeted,Early clinical trials,0.01,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.941573223383972,0.125091027476556,0.127908669818762,5.15181813154314,0.6944,0.569038004103388,0.59685337403406,0.075401923669751,0.120435378540008,0.0150409833679377,0.10539439517207,0.739282844298467,0.0326,4.41253528724467,0.6618,0.535790947751609,0.247409443882542,0.561981155276849,0.226910047677878,0.288381503869067,0.335071107598971,True,0.346698982789548,0.0755860240500048,1.01425062392302,48.4483271087789
27497,1022:1003,Breast,HCC1187,SIDM00885,749711,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.934161025426281,0.0337559543426187,0.960691487382097,15.781490447655,11.001,0.984110422096,0.991569374229464,0.0582903429688973,0.897440544971159,0.535314808404265,0.362125736566894,9.62437993006668,0.1542,6.1571105175883,10.8468,0.91931760103789,0.838738590675825,0.926285463411493,0.825123745853532,0.0805790103620646,0.10116171755796,True,1.7093364876793,0.175958369561553,-0.547274162650752,-94.4739551731581
27497,1179:1003,Breast,HCC1187,SIDM00885,749711,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.302256927258266,0.0337559543426187,0.960691487382097,15.781490447655,11.001,0.984110422096,0.991569374229464,0.0632817317951591,0.290375657019286,0.131322540139317,0.159053116879969,8.44066317267473,0.0679,7.34082727498025,10.9331,0.297454192265572,0.189062255679333,0.299708712218,0.249541223578612,0.108391936586239,0.0501674886393883,True,1.7093364876793,0.175958369561553,-0.547274162650752,-94.4739551731581
27497,1012:1013,Breast,HCC1187,SIDM00885,749711,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1013,Nilotinib,ABL,ABL signaling,Targeted,FDA approved,10.0,0.957330029268741,0.0554227293061785,0.836553113090968,12.4643602774993,110.3764,0.954944730279237,0.962506331574331,0.0582325396602316,0.800857416240233,0.776918585916782,0.0239388303234508,12.0979244090627,85.6186,0.366435868436632,24.7578,0.914197266588252,0.933503273567828,0.921436214577403,0.915339108461046,-0.0193060069795755,0.0060971061163567,True,1.7093364876793,0.175958369561553,-0.547274162650752,-94.4739551731581
27497,1021:1013,Breast,HCC1187,SIDM00885,749711,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1013,Nilotinib,ABL,ABL signaling,Targeted,FDA approved,10.0,0.956180721716407,0.0554227293061785,0.836553113090968,12.4643602774993,110.3764,0.954944730279237,0.962506331574331,0.0218548844471881,0.799895959429428,0.831275791499065,-0.0313798320696369,13.0215402777903,162.4068,-0.55718000029097,-52.0304,0.91309974139768,0.93164504128454,0.920329998781355,0.928054586916063,-0.0185452998868596,-0.0077245881347083,True,1.7093364876793,0.175958369561553,-0.547274162650752,-94.4739551731581
27524,1191:1032,Breast,HCC1187,SIDM00885,749711,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.0025,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.96750891688092,0.0647532578300015,0.776985877498132,11.6483124831624,62.6934,0.926158747280073,0.947007755893421,0.15309644517106,0.751740764769989,0.513457902199702,0.238282862570287,9.26088436363796,11.9821,2.3874281195244,50.7113,0.896066846440733,0.892602651693412,0.916238448182274,0.839076114218416,0.0034641947473212,0.0771623339638575,True,1.7093364876793,0.175958369561553,-0.547274162650752,-94.4739551731581
27524,1558:1032,Breast,HCC1187,SIDM00885,749711,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.957630152069058,0.0647532578300015,0.776985877498132,11.6483124831624,62.6934,0.926158747280073,0.947007755893421,0.101844458046022,0.744065104024047,0.664345393481798,0.0797197105422489,10.7348476013155,33.2844,0.913464881846837,29.409,0.886917541997905,0.908675379909156,0.906883181286794,0.884137955056802,-0.0217578379112507,0.0227452262299922,True,1.7093364876793,0.175958369561553,-0.547274162650752,-94.4739551731581
27524,1561:1032,Breast,HCC1187,SIDM00885,749711,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.988041106926783,0.0647532578300015,0.776985877498132,11.6483124831624,62.6934,0.926158747280073,0.947007755893421,0.10013086325659,0.767693986469732,0.606997082186931,0.160696904282801,9.98789542350557,19.8329,1.6604170596568,42.8605,0.915082913852526,0.905824648970728,0.935682591401184,0.887084676328675,0.0092582648817977,0.048597915072509,True,1.7093364876793,0.175958369561553,-0.547274162650752,-94.4739551731581
27524,1510:1032,Breast,HCC1187,SIDM00885,749711,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.736479939436144,0.0647532578300015,0.776985877498132,11.6483124831624,62.6934,0.926158747280073,0.947007755893421,0.0797481076923007,0.572234512002564,0.429533576897696,0.142700935104868,9.71295741249665,16.3916,1.93535507066572,46.3018,0.682097338105083,0.667320470262976,0.697452214705945,0.653225994251503,0.0147768678421072,0.044226220454442,True,1.7093364876793,0.175958369561553,-0.547274162650752,-94.4739551731581
27524,1179:1032,Breast,HCC1187,SIDM00885,749711,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.328986424235583,0.0647532578300015,0.776985877498132,11.6483124831624,62.6934,0.926158747280073,0.947007755893421,0.061316821911155,0.255617805519657,0.24681827717973,0.0087995283399272,11.3336551371381,50.4081,0.314657346024219,12.2853,0.304693654542178,0.265500789325717,0.31155269533474,0.309136131621425,0.0391928652164605,0.0024165637133153,True,1.7093364876793,0.175958369561553,-0.547274162650752,-94.4739551731581
27524,1012:1038,Breast,HCC1187,SIDM00885,749711,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.934294817367842,0.0498851179752172,0.845022164332187,12.598620671811,121.1414,0.946568112877426,0.964620735374921,0.0571480590355571,0.789499828696519,0.721596805143636,0.0679030235528831,11.5918874587285,60.2887,1.00673321308249,60.8527,0.884373682147038,0.853512684925734,0.901240153786346,0.883610284045781,0.0308609972213041,0.0176298697405647,True,1.7093364876793,0.175958369561553,-0.547274162650752,-94.4739551731581
27524,1191:1038,Breast,HCC1187,SIDM00885,749711,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.000625,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.97910319534943,0.0498851179752172,0.845022164332187,12.598620671811,121.1414,0.946568112877426,0.964620735374921,0.0306102748138627,0.827363901238735,0.87303843555434,-0.0456745343156048,13.4724518742441,221.9945,-0.873831202433086,-100.8531,0.926787863934168,0.952682052306497,0.944463244305903,0.955510796456483,-0.0258941883723294,-0.0110475521505802,True,1.7093364876793,0.175958369561553,-0.547274162650752,-94.4739551731581
27499,1012:1059,Breast,HCC1187,SIDM00885,749711,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.9783411869518,0.0622368556315191,0.932611558763289,14.5748706476767,47.6654,0.953993993984789,0.985335027556026,0.0905722180129261,0.912412299365445,0.84742480507144,0.0649874942940044,12.9626296039279,15.5909,1.61224104374881,32.0745,0.933331616419968,0.88510608291118,0.963993840404347,0.948809046318197,0.0482255335087872,0.0151847940861499,True,1.7093364876793,0.175958369561553,-0.547274162650752,-94.4739551731581
27502,1179:1096,Breast,HCC1187,SIDM00885,749711,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.910251820783617,0.117581714702943,0.723645675882837,11.0424129094229,20.5967,0.845393965764941,0.932098109093472,0.165021692548701,0.658699794074544,0.454599268351098,0.204100525723445,8.99508974891677,4.983,2.04732316050617,15.6137,0.769521396617021,0.65221266869696,0.848444000951299,0.77789016837645,0.117308727920061,0.0705538325748489,True,1.7093364876793,0.175958369561553,-0.547274162650752,-94.4739551731581
27503,1594:1192,Breast,HCC1187,SIDM00885,749711,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.946733050114891,0.11288682698522,0.813068126774597,12.1190889363514,86.8839,0.907437441356708,0.956530325671424,0.0672771131023202,0.769758467612515,0.536054425090468,0.233704042522047,9.5652805801404,14.7968,2.55380835621096,72.0871,0.859101016644089,0.841173323477603,0.905578872750297,0.833858059573425,0.0179276931664863,0.0717208131768726,True,1.7093364876793,0.175958369561553,-0.547274162650752,-94.4739551731581
27528,1083:1560,Breast,HCC1187,SIDM00885,749711,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.956881300685363,0.0990398632386903,0.866189394410151,12.9627036081692,155.9167,0.928365724009361,0.969815047928462,0.170143006203512,0.828840434363052,0.528411493198909,0.300428941164143,9.4448308219626,13.6115,3.51787278620656,142.3052,0.888335801501786,0.695291533531592,0.927997884486024,0.837797176163126,0.193044267970194,0.0902007083228984,True,1.7093364876793,0.175958369561553,-0.547274162650752,-94.4739551731581
27529,1549:1593,Breast,HCC1187,SIDM00885,749711,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.896006379141279,0.0945519034133623,0.702281880803191,10.8208402655853,7.0657,0.874372343299136,0.925819702538033,0.0332693737644444,0.629249045154994,0.601243117019189,0.0280059281358053,10.512424105034,5.7058,0.308416160551239,1.3599,0.783443197340735,0.797631059870722,0.829540359408759,0.820997890966653,-0.0141878625299876,0.0085424684421062,True,1.7093364876793,0.175958369561553,-0.547274162650752,-94.4739551731581
27529,1561:1593,Breast,HCC1187,SIDM00885,749711,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.926400639319545,0.0945519034133623,0.702281880803191,10.8208402655853,7.0657,0.874372343299136,0.925819702538033,0.0776186966108794,0.650594383358609,0.496753045917066,0.153841337441542,9.30792137042214,2.4758,1.51291889516312,4.5899,0.810019097835649,0.749026314078933,0.857679964325865,0.805423799467825,0.060992783756716,0.0522561648580401,True,1.7093364876793,0.175958369561553,-0.547274162650752,-94.4739551731581
28349,1179:2169,Breast,HCC1187,SIDM00885,749711,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.912234090251107,0.0433525257661233,0.932410720040496,14.5680996732785,474.4222,0.968558534092045,0.985289770650537,0.0523467581017706,0.850576844936521,0.703803223460946,0.146773621475575,11.5819115817532,59.8732,2.98618809152531,414.549,0.883552113202403,0.867823223019592,0.898814917563115,0.862541184600537,0.0157288901828105,0.0362737329625777,True,0.743495060530745,0.0670818472733293,0.280544989373736,170.707271015068
27527,1021:2172,Breast,HCC1187,SIDM00885,749711,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,4.0,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.795664696351773,0.104732875502703,0.509329976001175,9.07919184808451,10.5643,0.797754385823545,0.858682635445257,0.133452404699867,0.405255880697831,0.227049674611976,0.178206206085855,7.05218059796989,2.5921,2.02701125011462,7.9722,0.634745001159586,0.501083060229483,0.683223458394091,0.587718061218035,0.133661940930104,0.0955053971760557,True,1.7093364876793,0.175958369561553,-0.547274162650752,-94.4739551731581
27527,1191:2172,Breast,HCC1187,SIDM00885,749711,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.0025,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.954873489361318,0.104732875502703,0.509329976001175,9.07919184808451,10.5643,0.797754385823545,0.858682635445257,0.109980030752985,0.486345691420558,0.160622864483616,0.325722826936942,5.60875874211524,0.9531,3.47043310596927,9.6112,0.761754514044623,0.559273851961487,0.819933284361585,0.602537294426635,0.202480662083136,0.21739598993495,True,1.7093364876793,0.175958369561553,-0.547274162650752,-94.4739551731581
23563,1022:1003,Breast,MDA-MB-231,SIDM00146,905960,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,1.0,0.0844805729375393,0.570244644043119,9.79418993936111,0.1734,0.877338030845052,0.848233176353949,0.0611262807178053,0.570244644043119,0.308594287448225,0.261650356594894,6.73493384276257,0.0208,3.05925609659853,0.1526,0.877338030845052,0.705841644662007,0.848233176353949,0.687195710107252,0.171496386183045,0.161037466246697,True,0.376266276838739,0.0644337284002749,0.930287674904495,52.6275214634323
23563,1011:1003,Breast,MDA-MB-231,SIDM00146,905960,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.625579075245792,0.0844805729375393,0.570244644043119,9.79418993936111,0.1734,0.877338030845052,0.848233176353949,0.0977508468951464,0.356733117084361,0.234313941943438,0.122419175140922,7.56036478149301,0.0369,2.2338251578681,0.1365,0.548844314014012,0.428192665082855,0.530636926056304,0.461224242420287,0.120651648931157,0.0694126836360172,True,0.376266276838739,0.0644337284002749,0.930287674904495,52.6275214634323
23564,1011:1025,Breast,MDA-MB-231,SIDM00146,905960,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.58595988605768,0.0955764658809689,0.890376745555033,14.881245018168,589.4285,0.938546618807749,0.968378199601497,0.0896587738723358,0.521725056373835,0.201744742239574,0.319980314134261,7.19120433830882,2.8543,7.69004067985918,586.5742,0.549950669816409,0.405076913003732,0.567430779499235,0.419198761492689,0.144873756812677,0.148232018006546,True,0.376266276838739,0.0644337284002749,0.930287674904495,52.6275214634323
23886,1190:1042,Breast,MDA-MB-231,SIDM00146,905960,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.1,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.649956008183833,0.0700790582664297,0.846162203283339,13.7868051123062,276.0399,0.944982628748156,0.954542867258987,0.0956917617101823,0.549968207922076,0.478199377568843,0.0717688303532331,11.8750645276794,73.3636,1.91174058462684,202.6763,0.614197137184216,0.559096160335154,0.620410871644001,0.59580413398166,0.0551009768490626,0.0246067376623412,True,0.293398464868655,0.0560186288213278,1.17469798892598,41.9350509489362
23886,1179:1042,Breast,MDA-MB-231,SIDM00146,905960,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.407445418435918,0.0700790582664297,0.846162203283339,13.7868051123062,276.0399,0.944982628748156,0.954542867258987,0.0571489649494433,0.344764912981438,0.264155377870399,0.0806095351110389,10.7174495192992,32.8855,3.06935559300699,243.1544,0.385028842584966,0.334054149821242,0.388924117965359,0.35961530705746,0.0509746927637236,0.0293088109078982,True,0.293398464868655,0.0560186288213278,1.17469798892598,41.9350509489362
23887,1012:1050,Breast,MDA-MB-231,SIDM00146,905960,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.651104794431786,0.0934337594013969,0.707201476820101,11.4760218446332,55.6361,0.901524242609012,0.906007868569096,0.139721438850397,0.460462272186808,0.284636921997092,0.175825350189715,8.29047400148825,6.1152,3.18554784314498,49.5209,0.586986756659212,0.432731643475103,0.589906067018262,0.506395172835444,0.154255113184109,0.0835108941828178,True,0.293398464868655,0.0560186288213278,1.17469798892598,41.9350509489362
23887,1011:1050,Breast,MDA-MB-231,SIDM00146,905960,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.576370768406324,0.0934337594013969,0.707201476820101,11.4760218446332,55.6361,0.901524242609012,0.906007868569096,0.0922752965340101,0.407610258612889,0.148325477923601,0.259284780689288,6.02421686102954,1.2712,5.45180498360369,54.3649,0.519612220449486,0.368926345001763,0.522196451389346,0.369452664746294,0.150685875447722,0.152743786643052,True,0.293398464868655,0.0560186288213278,1.17469798892598,41.9350509489362
23887,1011:1051,Breast,MDA-MB-231,SIDM00146,905960,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.576370768406324,0.115953127610083,0.418633497643519,8.07795269026018,5.2776,0.731249341843232,0.766366402761778,0.118093164604697,0.241288110717422,0.0291585841929427,0.21212952652448,0.767228304915395,0.0332,7.31072438534479,5.2444,0.421470745054803,0.0935484634364402,0.441711192440597,0.162587236656263,0.327922281618362,0.279123955784334,True,0.293398464868655,0.0560186288213278,1.17469798892598,41.9350509489362
23566,1011:1080,Breast,MDA-MB-231,SIDM00146,905960,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.567280732667102,0.10422505765766,0.515861425695443,9.17820387224206,0.1131,0.782174780328433,0.821530615561966,0.0671465678662313,0.292638247523206,0.0902228969051997,0.202415350618007,4.32398526576614,0.0039,4.85421860647591,0.1092,0.443712682458443,0.267392798149026,0.466038489504447,0.296711317199062,0.176319884309417,0.169327172305385,True,0.376266276838739,0.0644337284002749,0.930287674904495,52.6275214634323
23567,1012:1086,Breast,MDA-MB-231,SIDM00146,905960,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1086,BI-2536,"PLK1, PLK2, PLK3",Cell cycle,Targeted,Early clinical trials,10.0,0.64892884109886,0.116092613472836,0.133360372766893,3.74497439932747,0.2619,0.471309848456153,0.481859128556365,0.151097962864211,0.0865413921481317,0.0279660054112658,0.0585753867368659,0.29496914949087,0.024,3.4500052498366,0.2379,0.30584655375713,0.189159941326744,0.312692285866989,0.165089433250653,0.116686612430386,0.147602852616336,True,0.376266276838739,0.0644337284002749,0.930287674904495,52.6275214634323
23567,1011:1086,Breast,MDA-MB-231,SIDM00146,905960,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1086,BI-2536,"PLK1, PLK2, PLK3",Cell cycle,Targeted,Early clinical trials,10.0,0.582030986501386,0.116092613472836,0.133360372766893,3.74497439932747,0.2619,0.471309848456153,0.481859128556365,0.0919427240716247,0.0776198693217072,0.0124837922347626,0.0651360770869446,-1.72702282016869,0.0059,5.47199721949616,0.256,0.274316936044753,0.0823242847354044,0.28045694394836,0.0899416468982085,0.191992651309349,0.190515297050151,True,0.376266276838739,0.0644337284002749,0.930287674904495,52.6275214634323
24219,1012:1096,Breast,MDA-MB-231,SIDM00146,905960,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.601054403913829,0.0593454104940789,0.755293664577199,12.1645466579763,44.8326,0.91756648375838,0.923770365915781,0.102199073639538,0.45397258334234,0.305377515456254,0.148595067886086,9.09064062854188,5.3242,3.07390602943443,39.5084,0.551507375946701,0.457333029640809,0.55523624663877,0.491354774922654,0.0941743463058927,0.063881471716116,True,0.322611572785931,0.0597851502404528,1.09672195107888,45.0416296631018
24219,1011:1096,Breast,MDA-MB-231,SIDM00146,905960,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.728910431676192,0.0593454104940789,0.755293664577199,12.1645466579763,44.8326,0.91756648375838,0.923770365915781,0.0856811635337124,0.550541431089259,0.065796027350442,0.484745403738817,2.51284744117956,0.0557,9.65169921679675,44.7769,0.668823781767926,0.231898374411317,0.673345856189346,0.288204307698005,0.436925407356609,0.385141548491341,True,0.322611572785931,0.0597851502404528,1.09672195107888,45.0416296631018
23569,1011:1192,Breast,MDA-MB-231,SIDM00146,905960,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.669385641819792,0.115759392477219,0.72199137693784,11.6796735588466,64.0711,0.879907631135921,0.911591015919864,0.15755667046459,0.483290661239891,0.116488745058537,0.366801916181354,4.62716690058908,0.4827,7.05250665825753,63.5884,0.588997534410051,0.291649021169436,0.610205937268674,0.364504748702003,0.297348513240615,0.245701188566671,True,0.376266276838739,0.0644337284002749,0.930287674904495,52.6275214634323
23890,1561:1564,Breast,MDA-MB-231,SIDM00146,905960,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.980364012287718,0.0832876367747304,0.42522670231601,8.15385447120639,2.7813,0.752016503042765,0.770469823243845,0.095862389650325,0.416876956014398,0.212775206185356,0.204101749829042,5.39751726493566,0.4116,2.75633720627073,2.3697,0.737249916229584,0.54373632121463,0.755340887261945,0.586685841178966,0.193513595014955,0.168655046082979,True,0.293398464868655,0.0560186288213278,1.17469798892598,41.9350509489362
23890,1594:1564,Breast,MDA-MB-231,SIDM00146,905960,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.951108146048704,0.0832876367747304,0.42522670231601,8.15385447120639,2.7813,0.752016503042765,0.770469823243845,0.0868032380603738,0.404436580490184,0.309697881229058,0.0947386992611264,6.9557051496075,1.2122,1.19814932159888,1.5691,0.715249022007034,0.618133235469854,0.732800125171926,0.666726868374288,0.0971157865371803,0.0660732567976381,True,0.293398464868655,0.0560186288213278,1.17469798892598,41.9350509489362
23890,1011:1593,Breast,MDA-MB-231,SIDM00146,905960,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.669235172501736,0.0670339831110604,0.748077743187643,12.055992425578,16.6332,0.928598898296954,0.921175817510121,0.0887484298432956,0.500639937506891,0.187539662567673,0.313100274939219,6.35132260175922,0.3189,5.7046698238188,16.3143,0.621451043886684,0.447439732177093,0.616483257135813,0.443416188455834,0.17401131170959,0.17306706867998,True,0.293398464868655,0.0560186288213278,1.17469798892598,41.9350509489362
23890,1179:1593,Breast,MDA-MB-231,SIDM00146,905960,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.890935003371521,0.0670339831110604,0.748077743187643,12.055992425578,16.6332,0.928598898296954,0.921175817510121,0.0448030752606214,0.666488646649042,0.557732281485698,0.108756365163345,10.4463863781115,5.4505,1.60960604746655,11.1827,0.827321262584987,0.790933406895143,0.820707780079143,0.7779709866284,0.0363878556898437,0.0427367934507428,True,0.293398464868655,0.0560186288213278,1.17469798892598,41.9350509489362
23566,1372:2169,Breast,MDA-MB-231,SIDM00146,905960,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.808781082585372,0.100837792210497,0.737176025983328,11.8958226814662,74.4268,0.890371880629683,0.91720996624739,0.0328374522884524,0.596214024350778,0.396142487888073,0.200071536462705,8.88544609895109,9.2367,3.01037658251507,65.1901,0.720115933519249,0.635220206106972,0.741822069459656,0.653313554875233,0.0848957274122769,0.0885085145844231,True,0.376266276838739,0.0644337284002749,0.930287674904495,52.6275214634323
23888,1011:2172,Breast,MDA-MB-231,SIDM00146,905960,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.634531603458299,0.126047235973704,0.321797527054945,6.90670510364026,2.3434,0.657451750834789,0.697960642565118,0.0780688136693826,0.204190700831089,0.0991579671228759,0.105032733708214,4.26531253386345,0.3756,2.64139256977681,1.9678,0.417173913653665,0.297026930273818,0.442878085677629,0.329240739410427,0.120146983379847,0.113637346267202,True,0.293398464868655,0.0560186288213278,1.17469798892598,41.9350509489362
25869,1191:1013,Breast,MDA-MB-436,SIDM00629,1240172,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.000625,1013,Nilotinib,ABL,ABL signaling,Targeted,FDA approved,10.0,0.947069513673492,0.104903814958335,0.755248412339752,13.2674588073914,192.5897,0.917501665979963,0.902343961710433,0.0896226824341461,0.715272746577286,0.776623433154523,-0.0613506865772371,14.7434686497516,535.7428,-1.47600984236027,-343.1531,0.868937856594263,0.925344214588534,0.854582456983312,0.881473427413904,-0.056406357994271,-0.0268909704305921,True,0.376837940993752,0.0494250502290587,0.937651088689218,52.4089960388764
27328,1012:1003,Breast,HCC2218,SIDM00772,749716,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.831136230307751,0.0341461809670703,0.947398942516016,18.2310819863419,60.0942,0.984824202199772,0.983519025772662,0.13470349924051,0.787417585680311,0.403775905501641,0.38364168017867,8.8187381169297,0.0882,9.41234386941221,60.006,0.818523074932156,0.605248972430986,0.817438295516642,0.651527782285535,0.21327410250117,0.165910513231107,True,0.82953097681057,0.0864563625863353,0.166626733246997,272.017013557198
27328,1012:1013,Breast,HCC2218,SIDM00772,749716,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1013,Nilotinib,ABL,ABL signaling,Targeted,FDA approved,10.0,0.930944481890809,0.067140864366526,0.922139323804735,16.8925237937974,2376.2187,0.961163575526371,0.97529178004915,0.103430012887965,0.85846051503054,0.770114256854185,0.088346258176355,14.0009353909255,320.2075,2.89158840287189,2056.0112,0.894789926830715,0.836246643103961,0.90794250087022,0.877263491408073,0.0585432837267537,0.0306790094621471,True,0.82953097681057,0.0864563625863353,0.166626733246997,272.017013557198
27328,1558:1013,Breast,HCC2218,SIDM00772,749716,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1013,Nilotinib,ABL,ABL signaling,Targeted,FDA approved,10.0,0.244835382830618,0.067140864366526,0.922139323804735,16.8925237937974,2376.2187,0.961163575526371,0.97529178004915,0.0979501203658413,0.225772334366899,0.14245538401018,0.0833169503567193,10.0547870095042,20.7741,6.83773678429317,2355.4446,0.235326851976844,0.123174050824248,0.238785936339888,0.20491206299345,0.112152801152596,0.0338738733464375,True,0.82953097681057,0.0864563625863353,0.166626733246997,272.017013557198
27328,1549:1013,Breast,HCC2218,SIDM00772,749716,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1013,Nilotinib,ABL,ABL signaling,Targeted,FDA approved,10.0,0.695617967839172,0.067140864366526,0.922139323804735,16.8925237937974,2376.2187,0.961163575526371,0.97529178004915,0.0824591477996483,0.641456682489638,0.329785119195529,0.311671563294109,8.66876727230722,7.9486,8.2237565214902,2368.2701,0.668602653168687,0.476614025242361,0.678430486088039,0.540340765430769,0.191988627926325,0.13808972065727,True,0.82953097681057,0.0864563625863353,0.166626733246997,272.017013557198
27329,1012:1025,Breast,HCC2218,SIDM00772,749716,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.760630991320418,0.0571804736954813,0.931035092559032,17.3105714595337,3174.9091,0.97008459388451,0.978213440748931,0.107809935594176,0.708174145407274,0.480177477778328,0.227996667628946,10.7170603205691,32.8766,6.59351113896464,3142.0325,0.73787640631104,0.611182839338395,0.744059459159816,0.655023618607668,0.126693566972645,0.089035840552148,True,0.82953097681057,0.0864563625863353,0.166626733246997,272.017013557198
27329,1011:1025,Breast,HCC2218,SIDM00772,749716,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,1.0,0.0571804736954813,0.931035092559032,17.3105714595337,3174.9091,0.97008459388451,0.978213440748931,0.0659219337261308,0.931035092559032,0.847244648393339,0.0837904441656928,14.4701945816773,443.2948,2.84037687785641,2731.6143,0.97008459388451,0.942441282574336,0.978213440748931,0.949572492951843,0.0276433113101744,0.028640947797088,True,0.82953097681057,0.0864563625863353,0.166626733246997,272.017013557198
27329,1047:1030,Breast,HCC2218,SIDM00772,749716,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1030,KU-55933,ATM,Genome integrity,Targeted,Experimental only,10.0,0.915639991747243,0.0547545956045816,0.902335917559566,16.0996161234918,1371.505,0.957585115145693,0.968690070146479,0.178873305857446,0.826214852107481,0.521541433281331,0.30467341882615,9.89465577799544,18.5917,6.20496034549638,1352.9133,0.876803226929284,0.627330979024801,0.886971367834558,0.760570050314342,0.249472247904483,0.126401317520216,True,0.82953097681057,0.0864563625863353,0.166626733246997,272.017013557198
25459,1558:1038,Breast,HCC2218,SIDM00772,749716,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.33870390740259,0.084599087273691,0.727483110516954,12.135233089116,87.8616,0.89442894771143,0.903585836605178,0.0561786693659786,0.246401372101482,0.132467820876754,0.113933551224729,7.58649096577271,3.754,4.54874212334334,84.1076,0.302946579483848,0.219952596293075,0.306048053531812,0.244283011250154,0.0829939831907733,0.0617650422816579,True,0.774547172121859,0.0905464416393621,0.228806107069878,200.005956048462
25459,1549:1038,Breast,HCC2218,SIDM00772,749716,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.833588572337255,0.084599087273691,0.727483110516954,12.135233089116,87.8616,0.89442894771143,0.903585836605178,0.0520035343794457,0.606421607495293,0.425438833617219,0.180982773878074,9.13247065974153,10.9617,3.00276242937452,76.8999,0.745585749579885,0.668627286181487,0.753218827519874,0.665474332133862,0.0769584633983971,0.0877444953860129,True,0.774547172121859,0.0905464416393621,0.228806107069878,200.005956048462
25461,1549:1050,Breast,HCC2218,SIDM00772,749716,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.461698781305262,0.0710263739814044,0.835884613349321,14.198046868543,367.0862,0.937968171661327,0.945483906035097,0.0595040852942255,0.385926907295201,0.315087189307796,0.0708397179874052,11.4428896344,54.373,2.75515723414298,312.7132,0.433058761759159,0.348867066726132,0.436528767160143,0.408337348360656,0.084191695033027,0.0281914187994866,True,0.774547172121859,0.0905464416393621,0.228806107069878,200.005956048462
27657,1510:1052,Breast,HCC2218,SIDM00772,749716,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1052,RO-3306,CDK1,Cell cycle,Targeted,Experimental only,10.0,0.934803510292235,0.056702377306467,0.86902848317501,15.0425317494458,659.1486,0.951474166169194,0.957269211975642,0.104170036991515,0.812370876615936,0.477531641351083,0.334839235264853,9.13842647094802,11.007,5.9041052784978,648.1416,0.88944139048734,0.74085598996794,0.894858619649512,0.74652683524147,0.1485854005194,0.148331784408041,True,,,,
27658,1011:1080,Breast,HCC2218,SIDM00772,749716,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.931862255302105,0.096655261574625,0.699896999202238,11.7039058889894,0.6516,0.892187899117195,0.891984183940071,0.0648574278866468,0.652207596155773,0.554336600832656,0.0978709953231169,10.2265610330885,0.234,1.47734485590085,0.4176,0.831396227824596,0.78535047481039,0.831206393340202,0.786025777163233,0.0460457530142063,0.045180616176969,True,,,,
27332,1011:1086,Breast,HCC2218,SIDM00772,749716,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1086,BI-2536,"PLK1, PLK2, PLK3",Cell cycle,Targeted,Early clinical trials,10.0,0.937492664367629,0.0757371199553256,0.641293362198475,10.8551100747465,36.1779,0.86779626151458,0.86584308122778,0.0983050751747452,0.601207822768723,0.604493541401192,-0.0032857186324691,10.9038649004084,37.4214,-0.0487548256618187,-1.2435,0.813552629335572,0.808701923201526,0.811721537144509,0.813244968664893,0.0048507061340457,-0.0015234315203843,True,0.82953097681057,0.0864563625863353,0.166626733246997,272.017013557198
27332,1549:1086,Breast,HCC2218,SIDM00772,749716,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1086,BI-2536,"PLK1, PLK2, PLK3",Cell cycle,Targeted,Early clinical trials,10.0,0.709437063608759,0.0757371199553256,0.641293362198475,10.8551100747465,36.1779,0.86779626151458,0.86584308122778,0.0677623751422281,0.454957279789874,0.216945572900516,0.238011706889358,6.3822324648285,1.6292,4.47287760991804,34.5487,0.615646831579562,0.445761233460442,0.614261173092196,0.462439720478599,0.169885598119121,0.151821452613597,True,0.82953097681057,0.0864563625863353,0.166626733246997,272.017013557198
27332,1510:1086,Breast,HCC2218,SIDM00772,749716,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1086,BI-2536,"PLK1, PLK2, PLK3",Cell cycle,Targeted,Early clinical trials,10.0,0.752842582170408,0.0757371199553256,0.641293362198475,10.8551100747465,36.1779,0.86779626151458,0.86584308122778,0.0670684368111348,0.482792950726243,0.273808789340551,0.208984161385692,7.21399089758993,2.8997,3.64111917715661,33.2782,0.653313978316463,0.537556153632347,0.651843541025904,0.527395043971323,0.115757824684116,0.124448497054581,True,0.82953097681057,0.0864563625863353,0.166626733246997,272.017013557198
27332,1053:1086,Breast,HCC2218,SIDM00772,749716,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1086,BI-2536,"PLK1, PLK2, PLK3",Cell cycle,Targeted,Early clinical trials,10.0,0.823891500637284,0.0757371199553256,0.641293362198475,10.8551100747465,36.1779,0.86779626151458,0.86584308122778,0.107712347154621,0.528356150530431,0.333495940438478,0.194860210091952,7.76881516640243,4.2597,3.08629490834412,31.9182,0.714969964146673,0.560048364023604,0.713360755509165,0.602327788178543,0.154921600123069,0.111032967330623,True,0.82953097681057,0.0864563625863353,0.166626733246997,272.017013557198
27332,1017:1086,Breast,HCC2218,SIDM00772,749716,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,1086,BI-2536,"PLK1, PLK2, PLK3",Cell cycle,Targeted,Early clinical trials,10.0,0.900724682831288,0.0757371199553256,0.641293362198475,10.8551100747465,36.1779,0.86779626151458,0.86584308122778,0.0891457110591335,0.577628760268031,0.526436870051582,0.0511918902164488,10.0891726717703,21.2752,0.76593740297629,14.9027,0.781645512414898,0.798545664091577,0.779886234720557,0.755048188126179,-0.0169001516766796,0.0248380465943782,True,0.82953097681057,0.0864563625863353,0.166626733246997,272.017013557198
27332,1058:1086,Breast,HCC2218,SIDM00772,749716,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1086,BI-2536,"PLK1, PLK2, PLK3",Cell cycle,Targeted,Early clinical trials,10.0,0.881872933098464,0.0757371199553256,0.641293362198475,10.8551100747465,36.1779,0.86779626151458,0.86584308122778,0.188619743799799,0.565539258298544,0.201805283296783,0.363733975001761,5.12078805237473,0.6796,5.73432202237181,35.4983,0.765286034473744,0.469648224887063,0.763563577645354,0.505238432013566,0.295637809586682,0.258325145631788,True,0.82953097681057,0.0864563625863353,0.166626733246997,272.017013557198
27332,1047:1086,Breast,HCC2218,SIDM00772,749716,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,1086,BI-2536,"PLK1, PLK2, PLK3",Cell cycle,Targeted,Early clinical trials,10.0,0.959144212500809,0.0757371199553256,0.641293362198475,10.8551100747465,36.1779,0.86779626151458,0.86584308122778,0.120918094715678,0.615092816867852,0.36380254573635,0.251290271131502,7.42734125998963,3.3619,3.42776881475691,32.816,0.832341761861548,0.715288586216434,0.830468380293493,0.683371614271885,0.117053175645114,0.147096766021608,True,0.82953097681057,0.0864563625863353,0.166626733246997,272.017013557198
27332,1049:1086,Breast,HCC2218,SIDM00772,749716,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1086,BI-2536,"PLK1, PLK2, PLK3",Cell cycle,Targeted,Early clinical trials,10.0,0.96815781697902,0.0757371199553256,0.641293362198475,10.8551100747465,36.1779,0.86779626151458,0.86584308122778,0.0901199645090568,0.620873181589211,0.347321523989604,0.273551657599607,7.14541879242063,2.7651,3.70969128232592,33.4128,0.84016373413051,0.689601578999148,0.838272747367875,0.674466472169709,0.150562155131363,0.163806275198166,True,0.82953097681057,0.0864563625863353,0.166626733246997,272.017013557198
27333,1012:1096,Breast,HCC2218,SIDM00772,749716,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.734579470509779,0.0717748387981218,0.912174162400963,16.4732748846427,888.4846,0.949415638889021,0.971986831696831,0.126229611796979,0.670064413229201,0.506505983718109,0.163558429511091,11.5476402156002,29.2339,4.92563466904253,859.2507,0.697421237308801,0.615190273866759,0.714001572170336,0.651945013109787,0.0822309634420417,0.0620565590605487,True,0.82953097681057,0.0864563625863353,0.166626733246997,272.017013557198
27333,1011:1096,Breast,HCC2218,SIDM00772,749716,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.983680091384374,0.0717748387981218,0.912174162400963,16.4732748846427,888.4846,0.949415638889021,0.971986831696831,0.0980358566303436,0.897287563429044,0.721723020859401,0.175564542569643,12.236039899926,47.1102,4.23723498471671,841.3744,0.933921262424107,0.865893158706333,0.956124095427947,0.89135379319212,0.0680281037177738,0.0647703022358267,True,0.82953097681057,0.0864563625863353,0.166626733246997,272.017013557198
25462,1021:1373,Breast,HCC2218,SIDM00772,749716,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10.0,0.756837814560231,0.134017986428306,0.741231089564857,12.3603016534523,102.6955,0.854972709826095,0.909214032020985,0.0675010893630215,0.560991717910365,0.478715749821491,0.0822759680888731,10.7339806619802,33.2644,1.62632099147209,69.4311,0.64707567721342,0.60207317301249,0.688127560962258,0.652196727709385,0.0450025042009294,0.0359308332528731,True,0.774547172121859,0.0905464416393621,0.228806107069878,200.005956048462
25463,1549:1553,Breast,HCC2218,SIDM00772,749716,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.483975385365221,0.0984393116698119,0.699438338064535,11.6969363343523,64.8423,0.903598060661833,0.891787681178756,0.0519070758886126,0.338510939203993,0.270511286313571,0.0679996528904226,9.75626050684948,16.8911,1.94067582750279,47.9512,0.437319219624077,0.368016556431729,0.431603286662445,0.399310665577078,0.0693026631923487,0.0322926210853676,True,0.774547172121859,0.0905464416393621,0.228806107069878,200.005956048462
25463,1558:1553,Breast,HCC2218,SIDM00772,749716,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.434856340357954,0.0984393116698119,0.699438338064535,11.6969363343523,64.8423,0.903598060661833,0.891787681178756,0.0545481860621874,0.304155195996793,0.249956022730942,0.0541991732658508,9.9626054800496,19.4883,1.73433085430267,45.354,0.392935345813949,0.351085386163002,0.3877995274137,0.362381144825621,0.0418499596509479,0.0254183825880785,True,0.774547172121859,0.0905464416393621,0.228806107069878,200.005956048462
25463,1372:1553,Breast,HCC2218,SIDM00772,749716,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.883586451947456,0.0984393116698119,0.699438338064535,11.6969363343523,64.8423,0.903598060661833,0.891787681178756,0.0626860303871218,0.618014239486468,0.395106126237149,0.222908113249318,8.32260920767058,6.253,3.37432712668169,58.5893,0.798407004406792,0.652141073712395,0.787971513103186,0.671340390565996,0.146265930694397,0.11663112253719,True,0.774547172121859,0.0905464416393621,0.228806107069878,200.005956048462
25463,1510:1553,Breast,HCC2218,SIDM00772,749716,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.904583589911072,0.0984393116698119,0.699438338064535,11.6969363343523,64.8423,0.903598060661833,0.891787681178756,0.112245048517833,0.632700442767851,0.378277297914464,0.254423144853387,7.94547372963701,4.8146,3.75146260471526,60.0277,0.817379977550164,0.650064570333048,0.80669650207915,0.669785778450048,0.167315407217116,0.136910723629102,True,0.774547172121859,0.0905464416393621,0.228806107069878,200.005956048462
25463,1179:1553,Breast,HCC2218,SIDM00772,749716,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.740284704684216,0.0984393116698119,0.699438338064535,11.6969363343523,64.8423,0.903598060661833,0.891787681178756,0.0677512041902758,0.517783503538923,0.337394819682746,0.180388683856177,8.43352113518239,6.7526,3.26341519916988,58.0897,0.668919823490276,0.54270499366762,0.660176780202437,0.566551524913099,0.126214829822656,0.0936252552893384,True,0.774547172121859,0.0905464416393621,0.228806107069878,200.005956048462
25463,1372:1560,Breast,HCC2218,SIDM00772,749716,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.916076891050652,0.0803290554594401,0.750725679346842,12.5203036542896,114.7406,0.886152004703163,0.913043844549285,0.0952430850252089,0.687722446367943,0.271272241829321,0.416450204538622,6.23537147609553,1.4715,6.28493217819403,113.2691,0.811783373466776,0.558754375325656,0.836418366507643,0.588969488560757,0.25302899814112,0.247448877946887,True,0.774547172121859,0.0905464416393621,0.228806107069878,200.005956048462
25463,1549:1560,Breast,HCC2218,SIDM00772,749716,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.7981283796586,0.0803290554594401,0.750725679346842,12.5203036542896,114.7406,0.886152004703163,0.913043844549285,0.0420240182010234,0.599175470025196,0.430239133175739,0.168936336849457,9.49990287255552,14.1412,3.02040078173403,100.5994,0.707263063644956,0.635127630804786,0.728726204207379,0.649987713920504,0.0721354328401702,0.0787384902868754,True,0.774547172121859,0.0905464416393621,0.228806107069878,200.005956048462
25464,1053:1564,Breast,HCC2218,SIDM00772,749716,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.777214170806529,0.16546272796359,0.681354974817537,11.4267429197065,26.8839,0.815308538036136,0.883942301479261,0.0818169416100619,0.529558741777716,0.162957479898974,0.366601261878742,4.76305496725153,0.2652,6.66368795245497,26.6187,0.633669349341239,0.378376609546398,0.687012482885019,0.42731110355619,0.255292739794841,0.259701379328829,True,0.774547172121859,0.0905464416393621,0.228806107069878,200.005956048462
25464,1058:1564,Breast,HCC2218,SIDM00772,749716,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.877081886955466,0.16546272796359,0.681354974817537,11.4267429197065,26.8839,0.815308538036136,0.883942301479261,0.0641289553283695,0.59760410699946,0.690136948430251,-0.0925328414307919,13.1703771967883,90.0282,-1.7436342770818,-63.1443,0.715092350991636,0.779860457561411,0.775289781741187,0.8132404136473,-0.0647681065697747,-0.0379506319061124,True,0.774547172121859,0.0905464416393621,0.228806107069878,200.005956048462
25464,1561:1564,Breast,HCC2218,SIDM00772,749716,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.866418197668052,0.16546272796359,0.681354974817537,11.4267429197065,26.8839,0.815308538036136,0.883942301479261,0.0579505467249927,0.590338349253572,0.422620748467575,0.167717600785997,8.84388158039731,4.4872,2.58286133930919,22.3967,0.706398154068644,0.666014566275458,0.765863695690212,0.680207506754942,0.040383587793186,0.0856561889352692,True,0.774547172121859,0.0905464416393621,0.228806107069878,200.005956048462
25464,1510:1593,Breast,HCC2218,SIDM00772,749716,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.781105895139684,0.130562219436262,0.747540169594403,12.466179909762,22.1031,0.896487378112164,0.911764025966163,0.100101621788425,0.583908033323907,0.408858106760948,0.175049926562959,9.29953585691864,2.4615,3.16664405284337,19.6416,0.70025157596173,0.656094540574727,0.712184255658462,0.629368877658757,0.0441570353870036,0.0828153779997048,True,0.774547172121859,0.0905464416393621,0.228806107069878,200.005956048462
25462,1179:2172,Breast,HCC2218,SIDM00772,749716,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.734184397195804,0.110839250464087,0.682395306344762,11.4420564914652,54.3416,0.840220620982604,0.884398908115529,0.0749556164760729,0.501003986637975,0.571346052756063,-0.070342066118088,13.0080458864873,160.8948,-1.56598939502213,-106.5532,0.616876870127597,0.660521768370396,0.649311879235427,0.678295433827801,-0.0436448982427985,-0.0289835545923737,True,0.774547172121859,0.0905464416393621,0.228806107069878,200.005956048462
26057,1011:1051,Breast,AU565,SIDM00898,910704,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.879952441971244,0.109530183868802,0.587411280990701,9.91162402949182,18.8116,0.799947100680758,0.866443339186816,0.110767422461368,0.516893991149224,0.314409652245582,0.202484338903642,7.48501538414634,3.499,2.42660864534548,15.3126,0.70391540469185,0.578891630865469,0.762428932147158,0.654577468828195,0.125023773826381,0.107851463318963,True,0.63530559289618,0.0841374855165565,0.428292058796561,112.281903075714
30662,1510:1085,Breast,AU565,SIDM00898,910704,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.981226520132083,0.0802863777712111,0.695127807562511,11.1268573558403,43.6765,0.923433336322385,0.908495374908341,0.100942896031684,0.682077839661608,0.433205195046278,0.24887264461533,8.39331712461593,6.567,2.73354023122441,37.1095,0.906097279173573,0.797574833624796,0.891439755277404,0.780768395976349,0.108522445548778,0.110671359301055,True,0.720620746220792,0.0749083539691857,0.305702222387214,155.201030412959
30662,1011:1085,Breast,AU565,SIDM00898,910704,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.964437310095032,0.0802863777712111,0.695127807562511,11.1268573558403,43.6765,0.923433336322385,0.908495374908341,0.105468797058284,0.670407192897845,0.3730390961737,0.297368096724145,7.81088845815565,4.3857,3.31596889768469,39.2908,0.890593562934841,0.756798759205561,0.876186835610378,0.736097328128975,0.133794803729281,0.140089507481403,True,0.720620746220792,0.0749083539691857,0.305702222387214,155.201030412959
30663,1179:1192,Breast,AU565,SIDM00898,910704,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.870876863793315,0.0551385672264643,0.773588531700979,12.1706264929634,90.0438,0.936502026289208,0.935317012610579,0.0624035375833287,0.673700354354224,0.419532104412172,0.254168249942052,8.81138745455567,8.7745,3.35923903840774,81.2693,0.81557794759083,0.688065748465762,0.814545946594833,0.711704541379324,0.127512199125068,0.102841405215509,True,0.720620746220792,0.0749083539691857,0.305702222387214,155.201030412959
26060,1179:1564,Breast,AU565,SIDM00898,910704,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.322261349985517,0.0682293572745559,0.72724442567955,11.5306632609564,28.8919,0.926178794070565,0.919813373855697,0.0864912461166264,0.234362770388934,0.239396015611937,-0.0050332452230029,11.7376601747359,33.3494,-0.206996913779506,-4.4575,0.298471628505139,0.244441646481483,0.29642029959347,0.298137836824828,0.0540299820236563,-0.0017175372313573,True,0.63530559289618,0.0841374855165565,0.428292058796561,112.281903075714
26060,1005:1564,Breast,AU565,SIDM00898,910704,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.831301719647541,0.0682293572745559,0.72724442567955,11.5306632609564,28.8919,0.926178794070565,0.919813373855697,0.0620665554179462,0.604559541671499,0.502993083503055,0.101566458168444,10.1008994998014,10.7244,1.42976376115505,18.1675,0.769934024211947,0.732420941824599,0.764642439441048,0.726410441630887,0.0375130823873474,0.0382319978101611,True,0.63530559289618,0.0841374855165565,0.428292058796561,112.281903075714
26060,1012:1564,Breast,AU565,SIDM00898,910704,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.517428225440081,0.0682293572745559,0.72724442567955,11.5306632609564,28.8919,0.926178794070565,0.919813373855697,0.162180110415874,0.376296792640561,0.0439308937061815,0.332365898934379,2.86478397191388,0.0711,8.66587928904256,28.8208,0.479231049856167,0.183801348127159,0.475937401770208,0.215077696116855,0.295429701729008,0.260859705653353,True,0.63530559289618,0.0841374855165565,0.428292058796561,112.281903075714
26061,1558:1632,Breast,AU565,SIDM00898,910704,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.46693041883765,0.114083638737749,0.841422290151851,13.306467267811,79.1472,0.897210042871126,0.956451805213103,0.0746492601880735,0.392885662359938,0.273490998289678,0.11939466407026,9.89363884286963,7.4314,3.4128284249414,71.7158,0.41893466110316,0.339298760028552,0.44659644200618,0.404233661728317,0.0796359010746082,0.0423627802778629,True,0.63530559289618,0.0841374855165565,0.428292058796561,112.281903075714
26058,1549:2172,Breast,AU565,SIDM00898,910704,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.496392256098176,0.0771953240321958,0.800502840368703,12.5854523499221,120.0408,0.934674656198547,0.943910901236044,0.100902026770619,0.397363410943619,0.162505038566394,0.234858372377225,7.14179562245779,2.7582,5.44365672746433,117.2826,0.463965261308184,0.287797380374321,0.468550061820223,0.358702884547029,0.176167880933863,0.109847177273194,True,0.63530559289618,0.0841374855165565,0.428292058796561,112.281903075714
26058,1558:2172,Breast,AU565,SIDM00898,910704,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.507063319354078,0.0771953240321958,0.800502840368703,12.5854523499221,120.0408,0.934674656198547,0.943910901236044,0.0536537596874466,0.405905627389722,0.136258912269391,0.269646715120331,6.41661372137018,1.6685,6.16883862855194,118.3723,0.473939233688167,0.296121507169039,0.478622594755248,0.342306524658289,0.177817726519128,0.136316070096959,True,0.63530559289618,0.0841374855165565,0.428292058796561,112.281903075714
26058,1510:2172,Breast,AU565,SIDM00898,910704,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.848272310599312,0.0771953240321958,0.800502840368703,12.5854523499221,120.0408,0.934674656198547,0.943910901236044,0.0880018849999302,0.679044394040872,0.332239002350124,0.346805391690747,7.86376200675991,4.5494,4.72169034316221,115.4914,0.792858630272159,0.605355668677881,0.800693481191378,0.650033478282477,0.187502961594278,0.150660002908901,True,0.63530559289618,0.0841374855165565,0.428292058796561,112.281903075714
26058,1179:2172,Breast,AU565,SIDM00898,910704,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.265841493361525,0.0771953240321958,0.800502840368703,12.5854523499221,120.0408,0.934674656198547,0.943910901236044,0.0256039367691059,0.212806870523759,0.22321107328846,-0.0104042027647016,13.2721487892225,193.2168,-0.686696439300359,-73.176,0.248475306410992,0.257425999946773,0.250930683584813,0.254122666982046,-0.0089506935357812,-0.003191983397233,True,0.63530559289618,0.0841374855165565,0.428292058796561,112.281903075714
26058,1012:2172,Breast,AU565,SIDM00898,910704,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.504399040815676,0.0771953240321958,0.800502840368703,12.5854523499221,120.0408,0.934674656198547,0.943910901236044,0.0780428774400777,0.403772864852198,0.0821383529525652,0.321634511899633,4.77515682587697,0.5348,7.81029552404515,119.506,0.471449000061269,0.226159784606982,0.476107753198921,0.281355722129747,0.245289215454287,0.194752031069174,True,0.63530559289618,0.0841374855165565,0.428292058796561,112.281903075714
23761,1011:1003,Breast,CAMA-1,SIDM00920,946382,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.800365759240622,0.0779314728941996,0.845409584017514,13.7738891009917,2.7358,0.928794533103949,0.954273447785015,0.110384072630456,0.676636883581476,0.338972169700889,0.337664713880587,8.13365908953733,0.0549,5.64023001145435,2.6809,0.743375341666282,0.547641367589132,0.76376779255962,0.615706321066578,0.19573397407715,0.148061471493042,True,0.742135738456837,0.0721676234634531,0.280835956229916,169.884136835809
23917,1012:1032,Breast,CAMA-1,SIDM00920,946382,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.821337441882371,0.0721547564994715,0.782626981216227,12.599410097959,121.2078,0.931745254649161,0.933345990840392,0.115359120258358,0.642800842700258,0.431546242312209,0.211254600388049,9.28593022095314,12.192,3.3134798770059,109.0158,0.76527726393958,0.658487168605946,0.766592008508014,0.678678385245142,0.106790095333634,0.0879136232628714,True,0.613321143377006,0.0657438572075255,0.463511229988519,104.159065207725
23919,1011:1050,Breast,CAMA-1,SIDM00920,946382,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.758508141061842,0.0767135619118661,0.797529672331713,12.8519629967268,144.3964,0.887278378897878,0.938456452612187,0.127765394918797,0.604932749201988,0.305810343027444,0.299122406174544,7.89784708445018,4.6582,4.9541159122766,139.7382,0.673007873782194,0.602662208871138,0.71182685933836,0.573707286786895,0.0703456649110564,0.138119572551466,True,0.613321143377006,0.0657438572075255,0.463511229988519,104.159065207725
23919,1058:1051,Breast,CAMA-1,SIDM00920,946382,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.910473494771077,0.17661015601947,0.77041498440161,12.4016444430079,105.681,0.809166646821482,0.929087807442241,0.156515008111188,0.701442423272139,0.610640790134261,0.0908016331378777,10.9985331669897,39.9594,1.40311127601819,65.7216,0.736724784783748,0.698279507521892,0.845909822991135,0.811835389342888,0.0384452772618563,0.0340744336482468,True,0.613321143377006,0.0657438572075255,0.463511229988519,104.159065207725
23919,1011:1051,Breast,CAMA-1,SIDM00920,946382,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.758508141061842,0.17661015601947,0.77041498440161,12.4016444430079,105.681,0.809166646821482,0.929087807442241,0.188763238686564,0.584366037664653,0.229866744262188,0.354499293402465,6.66000782230813,1.9751,5.74163662069975,103.7059,0.613759489089806,0.392197950616108,0.704720665706237,0.517586149120376,0.221561538473698,0.187134516585861,True,0.613321143377006,0.0657438572075255,0.463511229988519,104.159065207725
23919,1053:1051,Breast,CAMA-1,SIDM00920,946382,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.900456212450075,0.17661015601947,0.77041498440161,12.4016444430079,105.681,0.809166646821482,0.929087807442241,0.158211737773653,0.693724958869057,0.503051863258669,0.190673095610389,9.66236842917928,15.8268,2.73927601382861,89.8542,0.728619134037799,0.655194647243334,0.836602888122985,0.758780624184309,0.0734244867944654,0.0778222639386761,True,0.613321143377006,0.0657438572075255,0.463511229988519,104.159065207725
23763,1011:1052,Breast,CAMA-1,SIDM00920,946382,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1052,RO-3306,CDK1,Cell cycle,Targeted,Experimental only,10.0,0.785756499973267,0.0803701061960329,0.694699254138231,11.3101276930424,49.5927,0.913549755999566,0.901140604168945,0.0801568117289224,0.545864454465695,0.238800606073685,0.30706384839201,6.67144716518351,1.9908,4.63868052785889,47.6019,0.717827658825651,0.524095085679165,0.708077087115585,0.536750662653942,0.193732573146486,0.171326424461644,True,0.742135738456837,0.0721676234634531,0.280835956229916,169.884136835809
23763,1011:1059,Breast,CAMA-1,SIDM00920,946382,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.785756499973267,0.0694396564282331,0.377522090359816,7.59490121962805,0.3776,0.741998501373784,0.739182519316711,0.116394869695869,0.29664043638372,0.115988865945337,0.180651570438384,4.07327562914761,0.0329,3.52162559048045,0.3447,0.583030145424874,0.386943113976052,0.58081746921972,0.396973424095641,0.196087031448822,0.18384404512408,True,0.742135738456837,0.0721676234634531,0.280835956229916,169.884136835809
23765,1058:1086,Breast,CAMA-1,SIDM00920,946382,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1086,BI-2536,"PLK1, PLK2, PLK3",Cell cycle,Targeted,Early clinical trials,10.0,0.988612720969458,0.155795910574752,0.579855834006654,9.90525083056362,18.7287,0.78702336355474,0.852611635004298,0.178909292180906,0.573252853827332,0.362746647133781,0.210506206693551,7.4674713122634,3.4567,2.43777951830021,15.272,0.778061308910386,0.653968309186759,0.842902708411817,0.723433656528999,0.124092999723627,0.119469051882818,True,0.742135738456837,0.0721676234634531,0.280835956229916,169.884136835809
23765,1053:1086,Breast,CAMA-1,SIDM00920,946382,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1086,BI-2536,"PLK1, PLK2, PLK3",Cell cycle,Targeted,Early clinical trials,10.0,0.903012484829645,0.155795910574752,0.579855834006654,9.90525083056362,18.7287,0.78702336355474,0.852611635004298,0.186028693472167,0.523617057509314,0.248915168812827,0.274701888696487,6.28537373275241,1.5234,3.61987709781121,17.2053,0.71069192314255,0.527541143653181,0.769918951119897,0.594360472819614,0.183150779489369,0.175558478300283,True,0.742135738456837,0.0721676234634531,0.280835956229916,169.884136835809
23766,1011:1096,Breast,CAMA-1,SIDM00920,946382,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.721883648949978,0.0965683136122539,0.855999268220476,14.0082479743487,160.9173,0.899064037175092,0.957654651631728,0.154022924321879,0.617931875241509,0.257229279718826,0.360702595522683,7.33851978836569,1.5806,6.66972818598303,159.3367,0.649019627795655,0.422221519619263,0.691315234353832,0.522753136814425,0.226798108176392,0.168562097539407,True,0.742135738456837,0.0721676234634531,0.280835956229916,169.884136835809
23767,1190:1192,Breast,CAMA-1,SIDM00920,946382,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.1,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.854736061111011,0.0764176455485304,0.602467090252272,10.1681698811289,22.4726,0.855935854222995,0.862852244745323,0.0673300014958909,0.514950347671239,0.524416576803413,-0.0094662291321745,10.2987411473433,24.6014,-0.130571266214377,-2.1288,0.731599240602252,0.6930472086663,0.737510928994411,0.741684509146932,0.0385520319359519,-0.0041735801525206,True,0.742135738456837,0.0721676234634531,0.280835956229916,169.884136835809
23767,1011:1192,Breast,CAMA-1,SIDM00920,946382,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.756249389645221,0.0764176455485304,0.602467090252272,10.1681698811289,22.4726,0.855935854222995,0.862852244745323,0.073841180291724,0.455615369284613,0.162071512035398,0.293543857249215,5.34973411346646,0.7965,4.81843576766245,21.6761,0.647300967331601,0.40090973661681,0.652531483442659,0.45004103375305,0.246391230714791,0.202490449689609,True,0.742135738456837,0.0721676234634531,0.280835956229916,169.884136835809
23921,1012:1553,Breast,CAMA-1,SIDM00920,946382,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.803921459365236,0.0677481523912517,0.304675171070764,6.68158005437185,2.0049,0.686603217482915,0.683743539842979,0.0499498340220659,0.244934908159562,0.0774575328729865,0.167477375286575,2.71048242217732,0.1278,3.97109763219452,1.8771,0.551975060603731,0.300846791398872,0.54967610438212,0.328861208894714,0.251128269204859,0.220814895487406,True,0.613321143377006,0.0657438572075255,0.463511229988519,104.159065207725
23921,1011:1553,Breast,CAMA-1,SIDM00920,946382,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.855800251620109,0.0677481523912517,0.304675171070764,6.68158005437185,2.0049,0.686603217482915,0.683743539842979,0.0992752377935488,0.26074108806476,0.0847680799045865,0.175973008160173,2.79659563027788,0.1357,3.88498442409397,1.8692,0.587595206285055,0.328291055242622,0.585147893441245,0.355198668762321,0.259304151042433,0.229949224678924,True,0.613321143377006,0.0657438572075255,0.463511229988519,104.159065207725
23921,1053:1560,Breast,CAMA-1,SIDM00920,946382,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.931866255723782,0.0831093096359998,0.833544817516148,13.5264040331743,230.4535,0.928972876278408,0.950436150127567,0.0817118345959068,0.776752288076736,0.653713982551483,0.123038305525253,11.4009375992162,52.8146,2.12546643395802,177.6389,0.865678475886512,0.810990281310653,0.885679376523902,0.842194271639545,0.0546881945758592,0.043485104884357,True,0.613321143377006,0.0657438572075255,0.463511229988519,104.159065207725
23922,1011:1593,Breast,CAMA-1,SIDM00920,946382,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.897296779951799,0.0816043340836982,0.714471319226218,11.5771067769814,11.9348,0.906253590470995,0.908710990402453,0.072578229195131,0.6410928141096,0.536205306786509,0.10488750732309,10.1109365800082,4.3197,1.46617019697327,7.6151,0.81317842854938,0.808385088843566,0.815383445594931,0.77227609268631,0.0047933397058144,0.043107352908621,True,0.613321143377006,0.0657438572075255,0.463511229988519,104.159065207725
23764,1561:2169,Breast,CAMA-1,SIDM00920,946382,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.909327629718881,0.0799895661302008,0.500501912996218,9.00564100868668,10.0392,0.798572235062935,0.813395678284902,0.0548002188675772,0.455120218214616,0.321994629846545,0.133125588368072,7.31117787924715,3.1018,1.69446312943954,6.9374,0.726163797669088,0.644034316661245,0.739643164158392,0.657010026960036,0.0821294810078427,0.0826331371983553,True,0.742135738456837,0.0721676234634531,0.280835956229916,169.884136835809
23764,1011:2169,Breast,CAMA-1,SIDM00920,946382,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.76734080827908,0.0799895661302008,0.500501912996218,9.00564100868668,10.0392,0.798572235062935,0.813395678284902,0.0751605202675627,0.384055542463743,0.180913036212661,0.203142506251082,5.69563723636616,1.0122,3.31000377232052,9.027,0.612777064322423,0.459261539255156,0.624151697225847,0.474841155025622,0.153515525067267,0.149310542200225,True,0.742135738456837,0.0721676234634531,0.280835956229916,169.884136835809
23764,1053:2169,Breast,CAMA-1,SIDM00920,946382,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.827641691939977,0.0799895661302008,0.500501912996218,9.00564100868668,10.0392,0.798572235062935,0.813395678284902,0.126152570960448,0.414236250091385,0.159940845438436,0.254295404652948,4.98476079778923,0.6184,4.02088021089746,9.4208,0.660931675763776,0.419552749494664,0.673200175392381,0.471499430676008,0.241378926269112,0.201700744716373,True,0.742135738456837,0.0721676234634531,0.280835956229916,169.884136835809
23920,1012:2172,Breast,CAMA-1,SIDM00920,946382,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.818044555031524,0.0762999946236035,0.647373039101288,10.7069587507174,32.6472,0.867711735680644,0.882146077140778,0.0861433596987054,0.529579989711018,0.249345067315691,0.280234922395328,6.68331793187826,2.0073,4.02364081883912,30.6399,0.709826860710504,0.502543741782443,0.721634795147432,0.559422852159457,0.207283118928061,0.162211942987976,True,0.613321143377006,0.0657438572075255,0.463511229988519,104.159065207725
23920,1011:2172,Breast,CAMA-1,SIDM00920,946382,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.871968050992087,0.0762999946236035,0.647373039101288,10.7069587507174,32.6472,0.867711735680644,0.882146077140778,0.0565653217568623,0.564488607169974,0.276199221187757,0.288289385982217,6.84005749872978,2.2377,3.8669012519876,30.4095,0.756616910984413,0.594354068705333,0.76920319557476,0.604906848515788,0.16226284227908,0.164296347058972,True,0.613321143377006,0.0657438572075255,0.463511229988519,104.159065207725
23920,1053:2172,Breast,CAMA-1,SIDM00920,946382,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.902785315499694,0.0762999946236035,0.647373039101288,10.7069587507174,32.6472,0.867711735680644,0.882146077140778,0.0880391816853315,0.584438873351052,0.187858508705947,0.396580364645105,5.24478971111528,0.7406,5.4621690396021,31.9066,0.783357413059237,0.488161120242139,0.796388524568355,0.530681203303172,0.295196292817098,0.265707321265183,True,0.613321143377006,0.0657438572075255,0.463511229988519,104.159065207725
26723,1558:1032,Breast,BT-483,SIDM00892,949093,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.921602834096143,0.0630821939149173,0.729908877032725,12.7836707311145,137.7204,0.870663783932738,0.890219459223571,0.0615069868318543,0.672686089705292,0.698097494474771,-0.0254114047694783,13.3346242603068,201.7678,-0.550953529192304,-64.0474,0.802406210817283,0.848984197493279,0.820428776587978,0.832201457589858,-0.0465779866759962,-0.0117726810018799,True,0.904449885774196,0.0916894707354232,0.0771800291015912,508.057536634891
26723,1510:1032,Breast,BT-483,SIDM00892,949093,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.91014696087561,0.0630821939149173,0.729908877032725,12.7836707311145,137.7204,0.870663783932738,0.890219459223571,0.0594094429121777,0.664324346147463,0.611566991218843,0.0527573549286207,11.7287768111582,66.2893,1.05489391995632,71.4311,0.79243199689084,0.770770201706681,0.810230535324661,0.784437200421196,0.0216617951841594,0.0257933349034654,True,0.904449885774196,0.0916894707354232,0.0771800291015912,508.057536634891
26723,1011:1032,Breast,BT-483,SIDM00892,949093,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.86964507851938,0.0630821939149173,0.729908877032725,12.7836707311145,137.7204,0.870663783932738,0.890219459223571,0.0581534005631825,0.634761662679117,0.399611075105711,0.235150587573406,8.38225254490889,6.5169,4.40141818620563,131.2035,0.757168474742167,0.638400028965546,0.774174971515962,0.639277835709397,0.118768445776621,0.134897135806566,True,0.904449885774196,0.0916894707354232,0.0771800291015912,508.057536634891
26723,1011:1038,Breast,BT-483,SIDM00892,949093,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.86964507851938,0.102954126696743,0.75588973920573,13.3017110277159,197.2169,0.916709852720365,0.902267509885627,0.119303683136265,0.657355791603561,0.422764015626092,0.234591775977469,8.78885520780115,8.6385,4.51285581991478,188.5784,0.797212211848491,0.701781974676398,0.784652499479971,0.655281724437276,0.0954302371720926,0.129370775042696,True,0.904449885774196,0.0916894707354232,0.0771800291015912,508.057536634891
26724,1011:1046,Breast,BT-483,SIDM00892,949093,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1046,Wee1 Inhibitor,"WEE1, CHEK1",Cell cycle,Targeted,Experimental only,10.0,0.927194643978609,0.0879014981743316,0.567254283325637,10.0300938344564,20.4216,0.820071215821179,0.80464763682358,0.0979773670634786,0.525955133273455,0.332350411457291,0.193604721816164,6.78455098831091,2.1532,3.24554284614551,18.2684,0.760365638990423,0.622357041422978,0.746064979152868,0.608067172083368,0.138008597567445,0.1379978070695,True,0.904449885774196,0.0916894707354232,0.0771800291015912,508.057536634891
26725,1011:1050,Breast,BT-483,SIDM00892,949093,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.848633616260123,0.0885448433264196,0.78344254969162,13.8937803999007,297.2862,0.897432464089861,0.91464105870343,0.0536561557836369,0.664855684076851,0.426122108253344,0.238733575823507,9.03238535850535,10.227,4.86139504139538,287.0592,0.761591357349812,0.606189157178616,0.776195149227479,0.648480472889763,0.155402200171196,0.127714676337716,True,0.904449885774196,0.0916894707354232,0.0771800291015912,508.057536634891
26725,1011:1051,Breast,BT-483,SIDM00892,949093,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.848633616260123,0.0967882754855253,0.79521695987464,14.1633217293657,358.356,0.872678856968296,0.919808496155191,0.0957447586798631,0.674847844369797,0.453591813508584,0.221256030861213,9.52599810166037,14.3993,4.63732362770537,343.9567,0.740584614222756,0.592834127700626,0.780580410358966,0.666020352689765,0.14775048652213,0.1145600576692,True,0.904449885774196,0.0916894707354232,0.0771800291015912,508.057536634891
28115,1011:1052,Breast,BT-483,SIDM00892,949093,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1052,RO-3306,CDK1,Cell cycle,Targeted,Experimental only,10.0,0.848887514889206,0.0933358489402461,0.789323252263664,14.0270214539065,326.05,0.914233730335532,0.917230693713204,0.0551160142599122,0.670046654058368,0.431943343599753,0.238103310458615,9.13450835523507,10.9772,4.89251309867142,315.0728,0.776081599372418,0.652053469948159,0.778625684166304,0.652389134566966,0.124028129424259,0.126236549599338,True,0.844134862729705,0.101581365267409,0.151887762912825,299.33131508176
28115,1011:1059,Breast,BT-483,SIDM00892,949093,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.848887514889206,0.122308863664881,0.62017827165673,10.8660497047185,3.6453,0.776737000440344,0.834654579377709,0.128361812550824,0.526461591814965,0.171300076681363,0.355161515133602,3.76642962662273,0.0266,7.09962007809573,3.6187,0.6593623420263,0.379236399676302,0.708527851678839,0.413019955280551,0.280125942349998,0.295507896398288,True,0.844134862729705,0.101581365267409,0.151887762912825,299.33131508176
28117,1510:1085,Breast,BT-483,SIDM00892,949093,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.918625777275176,0.08857800536739,0.683866670063341,11.9366252317721,76.5618,0.886105458977799,0.867884107873493,0.0773361685672905,0.628217551339523,0.568206126043364,0.0600114252961592,10.8395905301715,35.7908,1.09703470160054,40.771,0.813999316001258,0.806470904121228,0.79726071318006,0.765913372247116,0.0075284118800296,0.0313473409329434,True,0.844134862729705,0.101581365267409,0.151887762912825,299.33131508176
28117,1011:1085,Breast,BT-483,SIDM00892,949093,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.79643011687415,0.08857800536739,0.683866670063341,11.9366252317721,76.5618,0.886105458977799,0.867884107873493,0.103227877280022,0.544652011964883,0.324498366032399,0.220153645932484,7.57448689149319,3.7229,4.36213834027889,72.8389,0.705721074256511,0.552501758144681,0.691209041466903,0.554566214146063,0.15321931611183,0.136642827320841,True,0.844134862729705,0.101581365267409,0.151887762912825,299.33131508176
28118,1011:1096,Breast,BT-483,SIDM00892,949093,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.868384191695435,0.0761992553660783,0.894712262607417,17.1438761040395,1414.2331,0.932956198367633,0.960880789573277,0.128966567672899,0.776953984964336,0.470409847171392,0.306544137792944,9.6364097036536,7.7723,7.50746640038594,1406.4608,0.810164414206722,0.586044948638165,0.834413687769261,0.685389571428134,0.224119465568557,0.149024116341127,True,0.844134862729705,0.101581365267409,0.151887762912825,299.33131508176
28119,1011:1192,Breast,BT-483,SIDM00892,949093,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.787046988544597,0.0705171526673789,0.728849729138698,12.7632486731349,135.7847,0.906562511490268,0.889720118586901,0.0847365082498642,0.573638984420157,0.393772057656647,0.17986692676351,9.00480787820681,10.0334,3.75844079492814,125.7513,0.713507294595842,0.618450073670839,0.700251539981362,0.600482276868852,0.0950572209250029,0.0997692631125102,True,0.844134862729705,0.101581365267409,0.151887762912825,299.33131508176
26727,1011:1560,Breast,BT-483,SIDM00892,949093,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.788315254806039,0.0822075566831192,0.630146385761954,11.027952123411,40.7826,0.822920731106328,0.840050823224183,0.0586880533459744,0.49675400865704,0.304732736780538,0.192021271876502,7.24248727931286,2.9576,3.78546484409818,37.825,0.648720965827257,0.526835797515478,0.662224878759994,0.535722615252531,0.121885168311778,0.126502263507463,True,0.904449885774196,0.0916894707354232,0.0771800291015912,508.057536634891
28116,1011:2169,Breast,BT-483,SIDM00892,949093,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.83685052524808,0.0918533529852687,0.793764416371843,14.1294632687034,350.0437,0.911312914917852,0.919174799005623,0.0593619617131359,0.664262168764013,0.408169016823074,0.256093151940939,8.81338590843515,8.7867,5.31607736026828,341.257,0.762632691514364,0.616533880040812,0.769211913342654,0.631478873716302,0.146098811473552,0.137733039626352,True,0.844134862729705,0.101581365267409,0.151887762912825,299.33131508176
23793,1022:1003,Breast,MDA-MB-453,SIDM00272,908122,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.968602805528531,0.0824106134116205,0.579979876515869,9.66198523964775,0.1582,0.898819411333616,0.889376268202895,0.0690643227534808,0.561770135543362,0.226952322138993,0.334817813404369,6.57079532809103,0.0186,3.09118991155672,0.1396,0.870599003481243,0.702084383514331,0.86145234855182,0.685158855166137,0.168514619966912,0.176293493385683,True,0.360663278296778,0.0481931615832932,0.991843027077493,49.8059749745999
23793,1011:1003,Breast,MDA-MB-453,SIDM00272,908122,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.956380229950337,0.0824106134116205,0.579979876515869,9.66198523964775,0.1582,0.898819411333616,0.889376268202895,0.0790257777913111,0.554681287668815,0.316097271366892,0.238584016301923,7.55196037120396,0.0367,2.11002486844379,0.1215,0.859613115295071,0.739276455599167,0.850581879896258,0.74218174283773,0.120336659695903,0.108400137058528,True,0.360663278296778,0.0481931615832932,0.991843027077493,49.8059749745999
30208,1058:1032,Breast,MDA-MB-453,SIDM00272,908122,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.927704978884557,0.113841906553368,0.367012955926237,7.88184934504986,4.6068,0.770154322902781,0.797055720259998,0.164080493302425,0.340479746527908,0.100018072060379,0.240461674467529,4.66469535424633,0.4954,3.21715399080352,4.1114,0.714475999866374,0.474300850141482,0.739432560133616,0.515470467612466,0.240175149724893,0.22396209252115,True,0.291107788233059,0.0460544685915318,1.19742347326714,41.3056000890627
30208,1049:1032,Breast,MDA-MB-453,SIDM00272,908122,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.789188885631924,0.113841906553368,0.367012955926237,7.88184934504986,4.6068,0.770154322902781,0.797055720259998,0.0936669931904403,0.289642545699905,0.0596955620282281,0.229946983671677,3.86502127080069,0.2846,4.01682807424917,4.3222,0.607797231856255,0.367356634830244,0.629027515658538,0.385655341637214,0.24044059702601,0.243372174021324,True,0.291107788233059,0.0460544685915318,1.19742347326714,41.3056000890627
30208,1179:1032,Breast,MDA-MB-453,SIDM00272,908122,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.384783955209041,0.113841906553368,0.367012955926237,7.88184934504986,4.6068,0.770154322902781,0.797055720259998,0.0747694527329389,0.141220696794259,0.0812375696991692,0.0599831270950896,6.29586258944172,1.5345,1.58598675560814,3.0723,0.296343026487873,0.21148417372847,0.306694252563633,0.264234782146905,0.0848588527594024,0.0424594704167275,True,0.291107788233059,0.0460544685915318,1.19742347326714,41.3056000890627
23982,1022:1046,Breast,MDA-MB-453,SIDM00272,908122,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1046,Wee1 Inhibitor,"WEE1, CHEK1",Cell cycle,Targeted,Experimental only,10.0,0.962378112871205,0.0986593337304506,0.33528934440033,7.59607123676521,3.779,0.784567309434827,0.778908223167004,0.132984789943549,0.322675126529813,0.325548174839304,-0.0028730483094906,7.62349050594367,3.8515,-0.0274192691784556,-0.0725000000000002,0.755050406674328,0.786390516625717,0.749604225911325,0.751315204609585,-0.0313401099513893,-0.0017109786982606,True,0.451678433853324,0.0631209094206473,0.762993308765472,64.1903562824848
30211,1558:1051,Breast,MDA-MB-453,SIDM00272,908122,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.628387532557607,0.161761236988908,0.741191645029456,11.158480982965,44.6445,0.837007828661079,0.939106182279086,0.0902512819055956,0.465755588972374,0.306466683726708,0.159288905245665,8.89907533679398,9.3244,2.25940564617099,35.3201,0.525965284183736,0.476952673289404,0.590122616691949,0.536853561825233,0.0490126108943312,0.0532690548667167,True,0.291107788233059,0.0460544685915318,1.19742347326714,41.3056000890627
30211,1549:1051,Breast,MDA-MB-453,SIDM00272,908122,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.93607413753412,0.161761236988908,0.741191645029456,11.158480982965,44.6445,0.837007828661079,0.939106182279086,0.188540537401762,0.693810329868444,0.461100309377783,0.232710020490661,8.93918651086546,9.5872,2.21929447209951,35.0573,0.783501381323226,0.662786356018332,0.879073009629856,0.801605797916791,0.120715025304895,0.0774672117130654,True,0.291107788233059,0.0460544685915318,1.19742347326714,41.3056000890627
23796,1011:1080,Breast,MDA-MB-453,SIDM00272,908122,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.935007862672247,0.123372723759078,0.331475713107706,7.56086784815047,0.0369,0.747430084903016,0.776614456099039,0.139862976907224,0.309932398040595,0.100095491714093,0.209836906326502,4.64845180726446,0.0049,2.91241604088601,0.032,0.698853006182105,0.527163757792006,0.726140622717532,0.518263258395563,0.171689248390099,0.20787736432197,True,0.360663278296778,0.0481931615832932,0.991843027077493,49.8059749745999
23797,1011:1086,Breast,MDA-MB-453,SIDM00272,908122,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1086,BI-2536,"PLK1, PLK2, PLK3",Cell cycle,Targeted,Early clinical trials,10.0,0.961991035169957,0.11848543612294,0.100230520850206,4.4977443627717,0.4413,0.51930611767909,0.541712831369873,0.100987179577652,0.0964208625083136,0.0136743302252799,0.0827465322830337,0.3035423230927,0.0241,4.194202039679,0.4172,0.499567829716199,0.2475928542435,0.521122887414352,0.206462714790732,0.251974975472699,0.31466017262362,True,0.360663278296778,0.0481931615832932,0.991843027077493,49.8059749745999
23798,1179:1096,Breast,MDA-MB-453,SIDM00272,908122,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.427610140118818,0.0828279439788429,0.852707418814189,12.6023437251766,60.7272,0.930650792521106,0.967582870500645,0.0310942562106771,0.364626338839491,0.364041176547302,0.000585162292189,12.5800774451195,59.7972,0.0222662800571207,0.930000000000007,0.397955715791639,0.411824320752998,0.413748246831349,0.413608616091829,-0.0138686049613597,0.0001396307395193,True,0.360663278296778,0.0481931615832932,0.991843027077493,49.8059749745999
23798,1594:1096,Breast,MDA-MB-453,SIDM00272,908122,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.93178571847423,0.0828279439788429,0.852707418814189,12.6023437251766,60.7272,0.930650792521106,0.967582870500645,0.100547696149897,0.794540594888086,0.589356848326695,0.20518374656139,10.1138735630027,10.8213,2.48847016217397,49.9059,0.86716711735789,0.777128165895333,0.901579900172802,0.845071186220315,0.0900389514625565,0.0565087139524869,True,0.360663278296778,0.0481931615832932,0.991843027077493,49.8059749745999
23798,1005:1129,Breast,MDA-MB-453,SIDM00272,908122,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,1.0,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.920791748353242,0.0662958299355325,0.564447793583113,9.53180499966571,14.4574,0.888156933975291,0.883881413874859,0.114921261672735,0.519738870707525,0.239749213102439,0.279989657605086,6.85821794120183,2.266,2.67358705846387,12.1914,0.817807576047163,0.606918528274466,0.813870712418766,0.670660146683877,0.210889047772697,0.143210565734889,True,0.360663278296778,0.0481931615832932,0.991843027077493,49.8059749745999
23798,1179:1129,Breast,MDA-MB-453,SIDM00272,908122,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.954195604050637,0.0662958299355325,0.564447793583113,9.53180499966571,14.4574,0.888156933975291,0.883881413874859,0.0786416671880885,0.538593603353088,0.299080712683566,0.239512890669522,7.39146091572968,3.2793,2.14034408393603,11.1781,0.847475442106314,0.690666226685086,0.843395759621451,0.730344559029153,0.156809215421228,0.113051200592299,True,0.360663278296778,0.0481931615832932,0.991843027077493,49.8059749745999
30213,1053:1373,Breast,MDA-MB-453,SIDM00272,908122,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10.0,0.582114772565189,0.0765482823097253,0.676748160468186,10.5157525546112,28.5948,0.917992893108377,0.920646836672343,0.108702396818847,0.393945101514848,0.191686225481523,0.202258876033325,7.54062615622617,3.6365,2.97512639838506,24.9583,0.534377224188243,0.41857246337356,0.535922123942382,0.451307702623174,0.115804760814683,0.0846144213192077,True,0.291107788233059,0.0460544685915318,1.19742347326714,41.3056000890627
24242,1549:1632,Breast,MDA-MB-453,SIDM00272,908122,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.885578814917208,0.0714938315068195,0.765571213442361,11.427834823825,21.5234,0.912856792840736,0.94567815091888,0.111452990061214,0.677973647935015,0.474447646257241,0.203526001677774,9.29384812855479,4.9036,2.13398669527021,16.6198,0.808406636793022,0.704076550324407,0.837472536183839,0.773397355222319,0.104330086468615,0.0640751809615197,True,0.62601923486366,0.0932155040377651,0.447763587028834,108.324027509349
24242,1372:1632,Breast,MDA-MB-453,SIDM00272,908122,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.963008517810542,0.0714938315068195,0.765571213442361,11.427834823825,21.5234,0.912856792840736,0.94567815091888,0.0719354678491283,0.737251599535546,0.753096575264283,-0.0158449757287371,11.6207432263316,24.6027,-0.192908402506591,-3.0793,0.879088867046841,0.855704355187504,0.910696114442205,0.914855633775651,0.0233845118593372,-0.0041595193334461,True,0.62601923486366,0.0932155040377651,0.447763587028834,108.324027509349
24242,1179:1909,Breast,MDA-MB-453,SIDM00272,908122,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.895959483275905,0.057146543477347,0.924460036290243,14.1379645166031,35.2112,0.961509076699614,0.98401476136979,0.0655434978609546,0.82827873642383,0.763927385681458,0.0643513507423725,12.6011788150908,12.1356,1.53678570151239,23.0756,0.861473175524879,0.840263095140093,0.88163735713274,0.866899809414719,0.0212100803847866,0.0147375477180217,True,0.62601923486366,0.0932155040377651,0.447763587028834,108.324027509349
23785,1022:1003,Breast,HCC1954,SIDM00872,749709,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.854894956721381,0.0431444173627217,0.942938835642652,16.7901267034029,22.1341,0.972864184063738,0.984140591034403,0.0833610158184753,0.806113655087635,0.31385378445023,0.492259870637405,7.48754368450393,0.0351,9.30258301889896,22.099,0.831696684530951,0.63280772140394,0.84133682798011,0.627896040776487,0.198888963127011,0.213440787203623,True,0.507194069671923,0.0473566635770073,0.656318258815952,74.731104431609
23941,1179:1032,Breast,HCC1954,SIDM00872,749709,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.574457436792669,0.096376783111984,0.624134285435478,10.4084874764034,26.5459,0.843859494824754,0.873608985751586,0.0605897472670656,0.358538581825689,0.172974198209686,0.185564383616003,6.66140654763669,1.977,3.74708092876673,24.5689,0.484761362410184,0.357895278631729,0.501851178713899,0.392761157588174,0.126866083778455,0.109090021125725,True,0.773479354934262,0.0653707820826554,0.238516190249404,197.469035322096
23941,1053:1032,Breast,HCC1954,SIDM00872,749709,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.916592906923839,0.096376783111984,0.624134285435478,10.4084874764034,26.5459,0.843859494824754,0.873608985751586,0.0955090314986126,0.572077058998138,0.327610591082989,0.244466467915149,7.3708885418243,3.2329,3.03759893457913,23.313,0.773475627396703,0.62913580854419,0.800743799764832,0.666882925553958,0.144339818852513,0.133860874210874,True,0.773479354934262,0.0653707820826554,0.238516190249404,197.469035322096
23941,1561:1038,Breast,HCC1954,SIDM00872,749709,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.656885477854771,0.0747416453991395,0.808112556138238,12.9932525215812,159.2534,0.952209058307284,0.942622616429399,0.0973985833865196,0.530837402599307,0.384811928828265,0.146025473771042,9.96285801658816,19.4917,3.03039450499306,139.7617,0.625492302283821,0.583246975160559,0.61919510782994,0.562813710698237,0.0422453271232626,0.0563813971317035,True,0.773479354934262,0.0653707820826554,0.238516190249404,197.469035322096
23941,1053:1038,Breast,HCC1954,SIDM00872,749709,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.987100963685379,0.0747416453991395,0.808112556138238,12.9932525215812,159.2534,0.952209058307284,0.942622616429399,0.126024559463421,0.79768868293031,0.57225676936533,0.22543191356498,9.89343117356997,18.5759,3.09982134801125,140.6775,0.939926479085067,0.871719423534601,0.930463693069094,0.843011567121021,0.0682070555504666,0.0874521259480729,True,0.773479354934262,0.0653707820826554,0.238516190249404,197.469035322096
23942,1022:1046,Breast,HCC1954,SIDM00872,749709,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1046,Wee1 Inhibitor,"WEE1, CHEK1",Cell cycle,Targeted,Experimental only,10.0,0.921480055102408,0.0911202946416995,0.627731849493291,10.4511615852989,27.3428,0.887699954172413,0.875136752115164,0.0878279290499376,0.578442379260614,0.513009354701325,0.0654330245592891,9.63288553454836,15.5066,0.818276050750514,11.8362,0.8179978026852,0.820487004086826,0.806421062561224,0.777091959579598,-0.002489201401626,0.0293291029816257,True,0.773479354934262,0.0653707820826554,0.238516190249404,197.469035322096
23943,1561:1051,Breast,HCC1954,SIDM00872,749709,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.548065380843925,0.0759916997958374,0.891557786654482,14.8511897279942,577.2762,0.927948445222386,0.969041179421507,0.0724078216911925,0.488631957887156,0.211306019576665,0.277325938310491,7.70558497035236,4.077,7.1456047576418,573.1992,0.508576418034335,0.352043859666875,0.531097923053095,0.409474018631995,0.15653255836746,0.1216239044211,True,0.773479354934262,0.0653707820826554,0.238516190249404,197.469035322096
23787,1053:1059,Breast,HCC1954,SIDM00872,749709,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.939502626796382,0.0639436786036317,0.483016395578454,8.81124973809523,0.8774,0.786968228427829,0.805892485857814,0.0490833732975604,0.453795172431678,0.268308312768578,0.1854868596631,6.4533869334302,0.1712,2.35786280466503,0.7062,0.73935871781324,0.609525330650246,0.757138107378882,0.629741093682975,0.129833387162994,0.127397013695908,True,0.507194069671923,0.0473566635770073,0.656318258815952,74.731104431609
23791,1558:1192,Breast,HCC1954,SIDM00872,749709,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.772340443190982,0.0761474662921759,0.655964818911772,10.792399514864,34.6391,0.896504974567741,0.886843227778371,0.0556795958343687,0.50662815895601,0.381023330040262,0.125604828915748,8.92596236350122,9.4998,1.86643715136273,25.1393,0.692407049380569,0.608597820417576,0.684944891583268,0.626711359795763,0.0838092289629931,0.0582335317875048,True,0.507194069671923,0.0473566635770073,0.656318258815952,74.731104431609
23791,1011:1192,Breast,HCC1954,SIDM00872,749709,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.942339344693157,0.0761474662921759,0.655964818911772,10.792399514864,34.6391,0.896504974567741,0.886843227778371,0.0744856234832959,0.618141457595085,0.414017983847537,0.204123473747548,8.3228950807115,6.2542,2.46950443415245,28.3849,0.844811910248321,0.728143506128397,0.835707266110234,0.736050775998099,0.116668404119923,0.0996564901121348,True,0.507194069671923,0.0473566635770073,0.656318258815952,74.731104431609
23945,1372:1553,Breast,HCC1954,SIDM00872,749709,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.950048217917799,0.0677436340451969,0.622473826936761,10.3888462654456,26.1869,0.857444720250265,0.872900999395819,0.0602096718740884,0.591380149981742,0.456483761968891,0.134896388012851,8.78308805234451,8.6041,1.60575821310106,17.5828,0.81461382843679,0.732310258633443,0.829298038894663,0.76432650236927,0.0823035698033464,0.0649715365253937,True,0.773479354934262,0.0653707820826554,0.238516190249404,197.469035322096
23945,1179:1553,Breast,HCC1954,SIDM00872,749709,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.490112051219196,0.0677436340451969,0.622473826936761,10.3888462654456,26.1869,0.857444720250265,0.872900999395819,0.0445898432078643,0.305081924150239,0.145674527856821,0.159407396293418,6.60998529719649,1.9078,3.77886096824909,24.2791,0.420243990648927,0.304416982106437,0.427819299325171,0.33347882211511,0.11582700854249,0.0943404772100614,True,0.773479354934262,0.0653707820826554,0.238516190249404,197.469035322096
23946,1561:1564,Breast,HCC1954,SIDM00872,749709,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.635770018994864,0.0768879286836624,0.808355750540589,12.9976104065091,79.8676,0.917850926817119,0.942703380311295,0.0439684791736487,0.513928350875798,0.410499171651292,0.103429179224505,10.6666056494835,15.8733,2.3310047570256,63.9943,0.583542101176974,0.554901013840158,0.599342546007035,0.561151305130904,0.0286410873368153,0.0381912408761302,True,0.773479354934262,0.0653707820826554,0.238516190249404,197.469035322096
23946,1561:1593,Breast,HCC1954,SIDM00872,749709,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.635770018994864,0.0740268529865303,0.804199051724274,12.9236961858316,30.3515,0.915739750435602,0.94131971710283,0.0476009126495713,0.511285646390394,0.397523052667068,0.113762593723326,10.421850719004,5.3586,2.50184546682759,24.9929,0.582199878528795,0.528034248428344,0.598462854422706,0.555719542092557,0.0541656301004507,0.0427433123301494,True,0.773479354934262,0.0653707820826554,0.238516190249404,197.469035322096
23788,1179:2169,Breast,HCC1954,SIDM00872,749709,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.623530832842011,0.077237282857129,0.663235310270633,10.8823361403438,36.8672,0.914505745138073,0.889779626042832,0.0380981634949382,0.413547665383278,0.192136502624652,0.221411162758626,6.75363351943128,2.1075,4.12870262091253,34.7597,0.570222528904747,0.414533280326112,0.55480503127234,0.429974443978615,0.155689248578635,0.124830587293725,True,0.507194069671923,0.0473566635770073,0.656318258815952,74.731104431609
23944,1561:2172,Breast,HCC1954,SIDM00872,749709,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.692831562533733,0.047312437971042,0.927422943915166,16.0760233964675,1349.2589,0.967293608699025,0.979666807842092,0.0719024258027177,0.642547887362379,0.543641286028948,0.0989066013334307,12.5912998165725,120.5283,3.484723579895,1228.7306,0.670171542343838,0.586020012287909,0.678744085239671,0.647606059840924,0.0841515300559292,0.0311380253987464,True,0.773479354934262,0.0653707820826554,0.238516190249404,197.469035322096
26065,1558:1038,Breast,BT-474,SIDM00963,946359,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.467179313380897,0.105665500050856,0.740258236678591,12.4923889827339,112.5418,0.934703491094076,0.905490824086841,0.0629864939323945,0.345833334736058,0.146350524777128,0.199482809958929,6.38264357088852,1.6297,6.10974541184538,110.9121,0.436674135184058,0.313223311927439,0.423026581469593,0.302511697796656,0.123450823256619,0.120514883672936,True,0.539982048897851,0.0705590164079511,0.581456360127077,83.1253322750216
26065,1549:1038,Breast,BT-474,SIDM00963,946359,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.618156204797809,0.105665500050856,0.740258236678591,12.4923889827339,112.5418,0.934703491094076,0.905490824086841,0.102765613961348,0.457595222155556,0.334900504364204,0.122694717791352,9.55849436953273,14.7273,2.93389461320118,97.8145,0.577792762665976,0.556880218996974,0.559734771296762,0.500328395509743,0.0209125436690023,0.0594063757870182,True,0.539982048897851,0.0705590164079511,0.581456360127077,83.1253322750216
26065,1561:1038,Breast,BT-474,SIDM00963,946359,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.661678813754743,0.105665500050856,0.740258236678591,12.4923889827339,112.5418,0.934703491094076,0.905490824086841,0.0784665786761538,0.489813191917668,0.332774250487864,0.157038941429804,9.03900411725272,10.274,3.45338486548119,102.2678,0.618473497199545,0.569311532629431,0.599144094347585,0.520636847696392,0.0491619645701143,0.0785072466511938,True,0.539982048897851,0.0705590164079511,0.581456360127077,83.1253322750216
26065,1053:1038,Breast,BT-474,SIDM00963,946359,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.80378017846786,0.105665500050856,0.740258236678591,12.4923889827339,112.5418,0.934703491094076,0.905490824086841,0.131933928681309,0.595004897589821,0.386279360704584,0.208725536885238,8.74081413864943,8.3556,3.75157484408447,104.1862,0.751296138886128,0.677039515886714,0.72781557618553,0.621441092404157,0.0742566229994139,0.106374483781373,True,0.539982048897851,0.0705590164079511,0.581456360127077,83.1253322750216
26067,1558:1050,Breast,BT-474,SIDM00963,946359,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.556402446299615,0.077953497947596,0.767480194397334,12.9819987958201,158.016,0.938637108648028,0.916749704665557,0.0565963068978591,0.427027857649181,0.370102590497189,0.056925267151992,11.2889617304594,48.8704,1.69303706536071,109.1456,0.522259983439361,0.499923379701667,0.510081778320365,0.485353771005863,0.022336603737694,0.024728007314502,True,0.539982048897851,0.0705590164079511,0.581456360127077,83.1253322750216
26415,1558:1086,Breast,BT-474,SIDM00963,946359,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1086,BI-2536,"PLK1, PLK2, PLK3",Cell cycle,Targeted,Early clinical trials,10.0,0.558855627298478,0.189411200477049,0.560181521998901,9.80664149804555,17.4913,0.786838643499503,0.819561578197786,0.0733102467149235,0.313060595877712,0.141952158752383,0.171108437125329,5.40739409577712,0.8289,4.39924740226843,16.6624,0.439729203695598,0.321360039975281,0.458016599893455,0.328931233034739,0.118369163720318,0.129085366858716,True,0.84845831477802,0.0845432462884306,0.141316079402979,310.210112723747
26415,1549:1086,Breast,BT-474,SIDM00963,946359,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1086,BI-2536,"PLK1, PLK2, PLK3",Cell cycle,Targeted,Early clinical trials,10.0,0.65709857665556,0.189411200477049,0.560181521998901,9.80664149804555,17.4913,0.786838643499503,0.819561578197786,0.096467026539669,0.368094480774223,0.224989880746859,0.143104600027364,6.82375187705812,2.2125,2.98288962098743,15.2788,0.517030552701115,0.438873836330094,0.53853274651535,0.442284981479555,0.0781567163710206,0.0962477650357944,True,0.84845831477802,0.0845432462884306,0.141316079402979,310.210112723747
26415,1561:1086,Breast,BT-474,SIDM00963,946359,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1086,BI-2536,"PLK1, PLK2, PLK3",Cell cycle,Targeted,Early clinical trials,10.0,0.689143391245641,0.189411200477049,0.560181521998901,9.80664149804555,17.4913,0.786838643499503,0.819561578197786,0.0818072313092721,0.386045393783467,0.307649656314082,0.0783957374693858,8.28261309309098,6.082,1.52402840495457,11.4093,0.542244651144368,0.525888434646027,0.564795445333852,0.517592011937383,0.0163562164983402,0.047203433396469,True,0.84845831477802,0.0845432462884306,0.141316079402979,310.210112723747
26070,1012:1564,Breast,BT-474,SIDM00963,946359,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.627345585851217,0.0862695491765778,0.873225814137631,15.4351132117091,432.6454,0.9440186625271,0.957199865070788,0.180335926060873,0.547814359950578,0.32491298745139,0.222901372499188,9.23908913360113,5.9012,6.19602407810799,426.7442,0.592225940897546,0.43471624191621,0.600495110129539,0.49919450853577,0.157509698981335,0.101300601593769,True,0.539982048897851,0.0705590164079511,0.581456360127077,83.1253322750216
26068,1558:2172,Breast,BT-474,SIDM00963,946359,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.472512166778094,0.0789168444093876,0.674100139231656,11.4235664313054,53.6496,0.835269165806483,0.87643070519122,0.100871027723286,0.318520517413764,0.157131756930434,0.16138876048333,6.67678449231977,1.9982,4.74678193898564,51.6514,0.394674843378152,0.259956532952193,0.414124171540756,0.314060264949683,0.134718310425959,0.100063906591074,True,0.539982048897851,0.0705590164079511,0.581456360127077,83.1253322750216
26068,1012:2172,Breast,BT-474,SIDM00963,946359,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.925770352334061,0.0789168444093876,0.674100139231656,11.4235664313054,53.6496,0.835269165806483,0.87643070519122,0.0537434142796363,0.624061923404929,0.45051075790851,0.173551165496419,8.82166693377187,8.8372,2.60189949753355,44.8124,0.773267429922445,0.696409753708169,0.811373562741265,0.719244563970915,0.0768576762142757,0.0921289987703501,True,0.539982048897851,0.0705590164079511,0.581456360127077,83.1253322750216
26068,1549:2172,Breast,BT-474,SIDM00963,946359,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.496675694212949,0.0789168444093876,0.674100139231656,11.4235664313054,53.6496,0.835269165806483,0.87643070519122,0.106715793171146,0.334809154621928,0.218975267741458,0.11583388688047,8.20774622591939,5.7744,3.21582020538603,47.8752,0.414857892781606,0.298555004227217,0.435301828930394,0.371186114074102,0.116302888554389,0.0641157148562924,True,0.539982048897851,0.0705590164079511,0.581456360127077,83.1253322750216
26068,1561:2172,Breast,BT-474,SIDM00963,946359,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.678602971235751,0.0789168444093876,0.674100139231656,11.4235664313054,53.6496,0.835269165806483,0.87643070519122,0.062728592122346,0.457446357393035,0.339308856797041,0.118137500595994,9.00014488655096,10.001,2.42342154475446,43.6486,0.566816137697887,0.519034360131684,0.594748480625007,0.532763363032178,0.0477817775662029,0.0619851175928289,True,0.539982048897851,0.0705590164079511,0.581456360127077,83.1253322750216
27340,1011:1003,Breast,DU-4475,SIDM01001,906844,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.31654884564831,0.0677769676878739,0.0847005197812484,6.39605953855049,0.0164,0.704868078596995,0.73005003146306,0.0317068103138329,0.026811851762566,0.000420935987266,0.0263909157753,1.75594601121519,0.0007,4.64011352733529,0.0157,0.223125176614221,0.070232452896367,0.231096494725144,0.0898754798235808,0.152892723717854,0.141221014901563,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27340,1012:1013,Breast,DU-4475,SIDM01001,906844,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1013,Nilotinib,ABL,ABL signaling,Targeted,FDA approved,10.0,0.878662759219003,0.0905251198609632,0.0679907688749274,6.13585339958292,1.3734,0.703389497638324,0.706042673377589,0.0662557889291278,0.0597409565810653,0.0583914100189891,0.0013495465620762,6.10905436625704,1.3482,0.0267990333258865,0.0251999999999999,0.618042156800559,0.614692832031702,0.620373403516314,0.618180456424842,0.0033493247688568,0.0021929470914716,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27341,1011:1025,Breast,DU-4475,SIDM01001,906844,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.276950923956035,0.0439195395703778,0.920339623461739,11.6770665935799,63.9554,0.979104742522236,0.990919171126891,0.0867860238454836,0.254888909071078,0.115986035279943,0.138902873791135,8.64146735555279,7.7996,3.03559923802706,56.1558,0.271163963091269,0.183442268012447,0.27443598000934,0.250583774358832,0.0877216950788214,0.0238522056505084,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27341,1005:1030,Breast,DU-4475,SIDM01001,906844,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,1.0,1030,KU-55933,ATM,Genome integrity,Targeted,Experimental only,10.0,0.918463580523668,0.0631404313828805,0.769704923210837,10.3201104023396,24.9685,0.964995980555228,0.971367407404488,0.0154751525034955,0.706945939718921,0.7188717586155,-0.0119258188965795,10.401903372196,26.425,-0.0817929698564885,-1.4565,0.886313663491703,0.898368101065902,0.892165587008719,0.893846312230106,-0.0120544375741996,-0.0016807252213872,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27341,1047:1030,Breast,DU-4475,SIDM01001,906844,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1030,KU-55933,ATM,Genome integrity,Targeted,Experimental only,10.0,0.216708290821511,0.0631404313828805,0.769704923210837,10.3201104023396,24.9685,0.964995980555228,0.971367407404488,0.0539828627885054,0.166801438345923,0.0309166713530992,0.135884766992824,7.03803750675332,2.5668,3.28207289558623,22.4017,0.209122629595752,0.116266818463951,0.210503370618349,0.170556829197771,0.0928558111318008,0.0399465414205777,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27341,1011:1030,Breast,DU-4475,SIDM01001,906844,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1030,KU-55933,ATM,Genome integrity,Targeted,Experimental only,10.0,0.276950923956035,0.0631404313828805,0.769704923210837,10.3201104023396,24.9685,0.964995980555228,0.971367407404488,0.0214710837627447,0.21317048965675,0.0790620739355734,0.134108415721176,7.99625505233013,4.987,2.32385535000943,19.9815,0.26725652842863,0.226413121287073,0.269021100981451,0.238975580993895,0.0408434071415573,0.030045519987556,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27341,1558:1030,Breast,DU-4475,SIDM01001,906844,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1030,KU-55933,ATM,Genome integrity,Targeted,Experimental only,10.0,0.77401754396589,0.0631404313828805,0.769704923210837,10.3201104023396,24.9685,0.964995980555228,0.971367407404488,0.0885159712379479,0.595765114242106,0.240883802399676,0.35488131184243,8.13083706434331,5.4746,2.18927333799625,19.4939,0.746923818806313,0.613795827105322,0.751855414967736,0.675192287714479,0.133127991700992,0.076663127253257,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27341,1510:1030,Breast,DU-4475,SIDM01001,906844,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1030,KU-55933,ATM,Genome integrity,Targeted,Experimental only,10.0,0.169310558919349,0.0631404313828805,0.769704923210837,10.3201104023396,24.9685,0.964995980555228,0.971367407404488,0.0403898878907536,0.130319170751801,0.0340909014909563,0.0962282692608449,7.4925646362188,3.5174,2.82754576612075,21.4511,0.163384008822731,0.100739367847552,0.164462758663693,0.13963133095358,0.0626446409751782,0.0248314277101128,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27341,1053:1030,Breast,DU-4475,SIDM01001,906844,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1030,KU-55933,ATM,Genome integrity,Targeted,Experimental only,10.0,0.986616163805488,0.0631404313828805,0.769704923210837,10.3201104023396,24.9685,0.964995980555228,0.971367407404488,0.0819764498653516,0.759403318600473,0.681716738681293,0.0776865799191808,9.88029430464733,18.4075,0.439816097692226,6.561,0.952080632423114,0.922038031894072,0.958366785139098,0.946719845323971,0.0300426005290422,0.0116469398151269,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27341,1017:1030,Breast,DU-4475,SIDM01001,906844,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,1030,KU-55933,ATM,Genome integrity,Targeted,Experimental only,10.0,0.606982837720167,0.0631404313828805,0.769704923210837,10.3201104023396,24.9685,0.964995980555228,0.971367407404488,0.0438314349543319,0.467197678497697,0.189767290383181,0.277430388114516,8.13811587547257,5.5023,2.18199452686699,19.4662,0.585735998665967,0.50708719254417,0.589603345415258,0.529788185815697,0.0786488061217978,0.0598151595995605,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27341,1022:1030,Breast,DU-4475,SIDM01001,906844,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1030,KU-55933,ATM,Genome integrity,Targeted,Experimental only,10.0,0.898786599068313,0.0631404313828805,0.769704923210837,10.3201104023396,24.9685,0.964995980555228,0.971367407404488,0.0961461575135276,0.691800470218805,0.597883095738096,0.0939173744807089,9.75116924931894,16.8316,0.568941153020615,8.1369,0.867325455477825,0.801470510340965,0.873052008546884,0.858707550945884,0.0658549451368603,0.0143444576009998,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27347,1179:1032,Breast,DU-4475,SIDM01001,906844,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.0692852710070354,0.133754160799205,0.274003263069962,7.93396815550364,4.7763,0.871496172896769,0.85839588917458,0.0227187150440224,0.0189843903386143,0.0104857370419599,0.0084986532966544,7.11375792425339,2.7051,0.820210231250251,2.0712,0.0603818485207468,0.0348881846258637,0.0594741918127859,0.0549770761875135,0.0254936638948831,0.0044971156252723,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27347,1047:1038,Breast,DU-4475,SIDM01001,906844,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.432465051878162,0.0982444626591162,0.491905420873472,8.96457395589958,9.7574,0.943773090137241,0.92239388279185,0.107598305304255,0.212731903357195,0.017808411786756,0.194923491570439,5.55622471173584,0.919,3.40834924416374,8.8384,0.408148878387415,0.212992529991435,0.398903118373677,0.281662244209471,0.195156348395981,0.117240874164206,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27347,1191:1038,Breast,DU-4475,SIDM01001,906844,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.000625,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.929393481393171,0.0982444626591162,0.491905420873472,8.96457395589958,9.7574,0.943773090137241,0.92239388279185,0.094472011200771,0.457173691621769,0.444818268828115,0.0123554227936545,8.90634328322103,9.3714,0.0582306726785564,0.386000000000001,0.877136557887842,0.880561190639533,0.857266861943682,0.854481727318864,-0.0034246327516914,0.0027851346248181,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27347,1510:1038,Breast,DU-4475,SIDM01001,906844,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.30881421035831,0.0982444626591162,0.491905420873472,8.96457395589958,9.7574,0.943773090137241,0.92239388279185,0.0274876048012622,0.151907384118013,0.0426207905100657,0.109286593607948,6.99586159478629,2.4928,1.9687123611133,7.2646,0.291450541588154,0.2288258391243,0.284848338553701,0.241928509584376,0.0626247024638546,0.0429198289693247,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27347,1022:1038,Breast,DU-4475,SIDM01001,906844,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.976340932280427,0.0982444626591162,0.491905420873472,8.96457395589958,9.7574,0.943773090137241,0.92239388279185,0.0643889433363446,0.480267397209401,0.365027677998831,0.115239719210571,8.43587679481316,6.7637,0.528697161086424,2.9937,0.921444298685773,0.88057197758194,0.900570903454758,0.871271458739577,0.0408723211038332,0.0292994447151812,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27348,1022:1042,Breast,DU-4475,SIDM01001,906844,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.853287277338043,0.0591024408476848,0.953879375294383,12.3141291919147,99.4609,0.969493592436399,0.994834755712599,0.048978596316894,0.813933135053857,0.594053934711529,0.219879200342329,9.90721764634415,18.7543,2.40691154557059,80.7066,0.827256547886734,0.804357841920166,0.848879840103261,0.819486281384387,0.0228987059665674,0.0293935587188746,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27348,1558:1042,Breast,DU-4475,SIDM01001,906844,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.987670212180441,0.0591024408476848,0.953879375294383,12.3141291919147,99.4609,0.969493592436399,0.994834755712599,0.0643295538410842,0.94211824499155,0.845009635199671,0.0971086097918782,10.9461533355235,38.5346,1.3679758563912,60.9263,0.957539942149237,0.949208474054406,0.98256865425914,0.9708155955003,0.0083314680948309,0.0117530587588399,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27348,1047:1042,Breast,DU-4475,SIDM01001,906844,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.42756926134906,0.0591024408476848,0.953879375294383,12.3141291919147,99.4609,0.969493592436399,0.994834755712599,0.0247396536790839,0.407849499910722,0.252101839404479,0.155747660506244,9.39645541319341,13.1627,2.91767377872133,86.2982,0.414525659200678,0.396333244569833,0.425360761664409,0.402860991763954,0.0181924146308453,0.0224997699004549,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27348,1372:1042,Breast,DU-4475,SIDM01001,906844,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.0757921629772883,0.0591024408476848,0.953879375294383,12.3141291919147,99.4609,0.969493592436399,0.994834755712599,0.0308938994847187,0.0722965810729859,0.0336016074208642,0.0386949736521217,8.75097347068199,8.4146,3.56315572123276,91.0463,0.0734800163633763,0.0486902045730699,0.0754006779404401,0.0690484630647315,0.0247898117903065,0.0063522148757086,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27348,1179:1042,Breast,DU-4475,SIDM01001,906844,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.078226661803137,0.0591024408476848,0.953879375294383,12.3141291919147,99.4609,0.969493592436399,0.994834755712599,0.0242338009579833,0.0746187992921412,0.0214700394049527,0.0531487598871885,7.93647525080813,4.7846,4.37765394110662,94.6763,0.0758402473758306,0.0444819139387811,0.0778226019851359,0.067163673250689,0.0313583334370495,0.0106589287344469,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27348,1011:1042,Breast,DU-4475,SIDM01001,906844,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.350906494224917,0.0591024408476848,0.953879375294383,12.3141291919147,99.4609,0.969493592436399,0.994834755712599,0.08282020300124,0.334722467498006,0.108765474179815,0.225956993318191,8.12441652638063,5.4503,4.18971266553411,94.0106,0.340201597695377,0.248413095911267,0.34909397646021,0.30594807167299,0.0917885017841107,0.0431459047872196,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27348,1190:1046,Breast,DU-4475,SIDM01001,906844,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.01,1046,Wee1 Inhibitor,"WEE1, CHEK1",Cell cycle,Targeted,Experimental only,10.0,0.749134628390218,0.0962419026012827,0.0693277523980385,6.15872842409361,1.3954,0.719970284690777,0.708169799407493,0.0567637183091912,0.0519358200298335,0.0024308945629963,0.0495049254668372,2.73402496462598,0.1299,3.42470345946763,1.2655,0.539354671673825,0.284532477876246,0.530514519516308,0.28211850055067,0.254822193797579,0.248396018965637,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27349,1558:1050,Breast,DU-4475,SIDM01001,906844,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.980594195119848,0.133671566922419,0.302484405513844,8.08594068058994,5.3069,0.864073459123727,0.869210719924494,0.121587328811521,0.296614452161153,0.26943879869424,0.0271756534669132,7.93818654037102,4.7903,0.147754140218916,0.5166,0.847305418173854,0.809463490527479,0.852342986293902,0.842038060308794,0.0378419276463744,0.0103049259851083,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27349,1510:1050,Breast,DU-4475,SIDM01001,906844,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.924018595447581,0.133671566922419,0.302484405513844,8.08594068058994,5.3069,0.864073459123727,0.869210719924494,0.0455937007719388,0.279501215527699,0.0750480936328349,0.204453121894864,6.34599033787696,1.5888,1.73995034271298,3.7181,0.798419944063039,0.665857905004395,0.803166868572612,0.670342558330613,0.132562039058644,0.132824310241999,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27349,1011:1050,Breast,DU-4475,SIDM01001,906844,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.30375046885946,0.133671566922419,0.302484405513844,8.08594068058994,5.3069,0.864073459123727,0.869210719924494,0.0232506130082451,0.0918797799975051,0.0054438020902071,0.086435977907298,4.61988073019422,0.4802,3.46605995039571,4.8267,0.262462718337847,0.15081821569515,0.264023163714734,0.170297871067222,0.111644502642697,0.0937252926475116,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27342,1011:1052,Breast,DU-4475,SIDM01001,906844,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1052,RO-3306,CDK1,Cell cycle,Targeted,Experimental only,10.0,0.315190114936581,0.104568140705085,0.0943727756045208,6.52598082557406,1.7999,0.74037930937446,0.741865729100117,0.0532463087427832,0.0297453659896731,0.0014615661843837,0.0282837998052894,3.12611509109111,0.1705,3.39986573448295,1.6294,0.233360239618402,0.0982519750263445,0.233828744422576,0.130675531002509,0.135108264592058,0.103153213420068,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27342,1012:1059,Breast,DU-4475,SIDM01001,906844,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.823277195969226,0.101608906879404,0.274223567137501,7.9351794616536,0.478,0.812185052606037,0.85848378187636,0.0647687980144562,0.22576200942164,0.121389084216368,0.104372925205272,7.0802202581731,0.2643,0.854959203480495,0.2137,0.668653432717616,0.612684797845394,0.706770120728226,0.650914185626082,0.0559686348722224,0.0558559351021436,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27342,1047:1059,Breast,DU-4475,SIDM01001,906844,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.360102617566393,0.101608906879404,0.274223567137501,7.9351794616536,0.478,0.812185052606037,0.85848378187636,0.0583599684861706,0.0987486243246075,0.0054331292624527,0.0933154950621548,4.42839565871134,0.0421,3.50678380294226,0.4359,0.292469963391733,0.159111823893446,0.309142256991974,0.195153837517941,0.133358139498287,0.113988419474032,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27342,1011:1059,Breast,DU-4475,SIDM01001,906844,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.315190114936581,0.101608906879404,0.274223567137501,7.9351794616536,0.478,0.812185052606037,0.85848378187636,0.036995575319463,0.0864325576443881,0.0042990261269713,0.0821335315174168,4.31638520368852,0.0389,3.61879425796508,0.4391,0.25599270008067,0.15380334704873,0.270585601880801,0.167360019265156,0.10218935303194,0.103225582615644,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27342,1510:1059,Breast,DU-4475,SIDM01001,906844,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.22805374929017,0.101608906879404,0.274223567137501,7.9351794616536,0.478,0.812185052606037,0.85848378187636,0.0378287908264756,0.0625377126294316,0.0387752233229945,0.0237624893064371,7.26547824225617,0.3005,0.669701219397424,0.1775,0.18522184636424,0.171456005264469,0.195780445161708,0.183860692748611,0.0137658410997713,0.0119197524130968,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
28107,1049:1080,Breast,DU-4475,SIDM01001,906844,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.908629916818014,0.132141056070688,0.268556190294282,7.90382236908377,0.0468,0.784092491475582,0.85619995553995,0.168668887995796,0.244018188848056,0.0252079992083388,0.218810189639717,5.10891654642327,0.0067,2.7949058226605,0.0401,0.712449895307087,0.545647178687227,0.777968894381852,0.552650495702313,0.16680271661986,0.225318398679539,True,0.612291922929542,0.0845053357199909,0.47545893654772,102.958859121377
28107,1047:1080,Breast,DU-4475,SIDM01001,906844,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.502742419537235,0.132141056070688,0.268556190294282,7.90382236908377,0.0468,0.784092491475582,0.85619995553995,0.1065699047211,0.135014588890249,0.0101977138386156,0.124816875051634,4.75797247487962,0.0053,3.14584989420415,0.0415,0.394196556305413,0.244178036017899,0.430448037255827,0.28863470664774,0.150018520287514,0.141813330608087,True,0.612291922929542,0.0845053357199909,0.47545893654772,102.958859121377
28107,1011:1080,Breast,DU-4475,SIDM01001,906844,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.379027343942161,0.132141056070688,0.268556190294282,7.90382236908377,0.0468,0.784092491475582,0.85619995553995,0.0504730465258335,0.101790139506467,0.0030381305535482,0.0987520089529188,3.72860068760812,0.0026,4.17522168147566,0.0442,0.297192494448981,0.159781801929107,0.324523195031703,0.179439862373873,0.137410692519874,0.14508333265783,True,0.612291922929542,0.0845053357199909,0.47545893654772,102.958859121377
28107,1558:1080,Breast,DU-4475,SIDM01001,906844,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.903868772194298,0.132141056070688,0.268556190294282,7.90382236908377,0.0468,0.784092491475582,0.85619995553995,0.136667153585218,0.242739553986471,0.0918611275027506,0.15087842648372,6.61584834488186,0.0192,1.28797402420192,0.0276,0.708716717556802,0.654534982064986,0.773892402566707,0.677868363528111,0.0541817354918159,0.0960240390385961,True,0.612291922929542,0.0845053357199909,0.47545893654772,102.958859121377
28107,1053:1080,Breast,DU-4475,SIDM01001,906844,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.92195637208454,0.132141056070688,0.268556190294282,7.90382236908377,0.0468,0.784092491475582,0.85619995553995,0.0880894019085967,0.247597090904562,0.0986267230060205,0.148970367898541,6.67844605610713,0.02,1.22537631297665,0.0268,0.722899068819556,0.667939774293106,0.789379004788557,0.696597480193396,0.0549592945264498,0.0927815245951609,True,0.612291922929542,0.0845053357199909,0.47545893654772,102.958859121377
27344,1047:1085,Breast,DU-4475,SIDM01001,906844,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.074116169659995,0.133531215107738,0.137366618485782,6.9898932387417,2.4825,0.794779039385551,0.782896938449072,0.0106010859412,0.010181087601312,0.000540659913546,0.0096404276877659,3.62471243717593,0.2409,3.36518080156577,2.2416,0.0589059781253074,0.0278435634009818,0.0580253223163821,0.0343347033025589,0.0310624147243255,0.0236906190138232,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27344,1372:1085,Breast,DU-4475,SIDM01001,906844,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.0518148166369143,0.133531215107738,0.137366618485782,6.9898932387417,2.4825,0.794779039385551,0.782896938449072,0.0242569659704741,0.0071176261488736,0.0005437989529014,0.0065738271959722,4.0261960302776,0.3182,2.9636972084641,2.1643,0.0411813301926252,0.038201432162286,0.0405656613113402,0.0260403599548742,0.0029798980303392,0.0145253013564661,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27344,1179:1085,Breast,DU-4475,SIDM01001,906844,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.075352943767108,0.133531215107738,0.137366618485782,6.9898932387417,2.4825,0.794779039385551,0.782896938449072,0.0143232717762991,0.0103509790782369,0.0004691263626604,0.0098818527155764,3.45016615411905,0.2135,3.53972708462264,2.269,0.0598889402620955,0.0320848996477922,0.0589935889783939,0.0336217454200655,0.0278040406143034,0.0253718435583284,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27344,1049:1086,Breast,DU-4475,SIDM01001,906844,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1086,BI-2536,"PLK1, PLK2, PLK3",Cell cycle,Targeted,Early clinical trials,10.0,0.885302017093432,0.0904464698583276,0.0007985305538461,1.19742346309122,0.0448,0.271021324578845,0.233430170846041,0.166757866037981,0.0007069407100307,4.2345466221172e-05,0.0006645952438095,-1.88319473682655,0.0053,3.08061819991778,0.0395,0.239935725324985,0.18500199603935,0.206656201100465,0.0357201569658592,0.0549337292856346,0.170936044134606,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27345,1047:1096,Breast,DU-4475,SIDM01001,906844,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.367524863269502,0.0807953708212986,0.102812730606955,6.62993552215301,0.9672,0.710727619060941,0.751226643571413,0.0386547701331778,0.0377862347586854,0.0007770616534082,0.0370091731052771,2.26413685301539,0.0469,4.36579866913762,0.9203,0.261210071017231,0.102642530428406,0.276094469462991,0.121865218098315,0.158567540588826,0.154229251364676,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27345,1012:1096,Breast,DU-4475,SIDM01001,906844,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.209481153471866,0.0807953708212986,0.102812730606955,6.62993552215301,0.9672,0.710727619060941,0.751226643571413,0.0755152450291026,0.0215373293991371,0.0005498223464226,0.0209875070527145,2.50126229372364,0.0553,4.12867322842937,0.9119,0.148884041445199,0.0346963553853932,0.157367823814138,0.0741999702339475,0.114187686059805,0.0831678535801902,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27345,1011:1096,Breast,DU-4475,SIDM01001,906844,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.27375289996543,0.0807953708212986,0.102812730606955,6.62993552215301,0.9672,0.710727619060941,0.751226643571413,0.0448581348647275,0.0281452831570184,0.0001981117297458,0.0279471714272725,1.08967481258148,0.0208,5.54026070957153,0.9464,0.194563746803458,0.0308100719970746,0.205650472208971,0.0613192812326237,0.163753674806384,0.144331190976347,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27345,1053:1096,Breast,DU-4475,SIDM01001,906844,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.957642940070379,0.0807953708212986,0.102812730606955,6.62993552215301,0.9672,0.710727619060941,0.751226643571413,0.149887218429365,0.0984578856151082,0.0066340170488682,0.0918238685662399,3.56778345378255,0.1158,3.06215206837046,0.8514,0.680623286706739,0.459732973381265,0.71940689160893,0.438300555402245,0.220890313325474,0.281106336206685,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27345,1049:1129,Breast,DU-4475,SIDM01001,906844,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.839109178577923,0.0619823399701994,0.651107409132852,9.68257872679013,16.0501,0.921577501263895,0.953063443212007,0.0593642973874152,0.546350203243467,0.121247402288387,0.42510280095508,7.05432352656193,2.5959,2.6282552002282,13.4542,0.773304140081442,0.620083167311769,0.799724282966274,0.661577084062579,0.153220972769672,0.138147198903695,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27345,1011:1129,Breast,DU-4475,SIDM01001,906844,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.27375289996543,0.0619823399701994,0.651107409132852,9.68257872679013,16.0501,0.921577501263895,0.953063443212007,0.0373069013735815,0.178242541439096,0.0300457190922901,0.148196822346806,6.70991830445766,2.0446,2.97266042233247,14.0055,0.252284513513886,0.184559734791792,0.260903881430325,0.207605409036993,0.0677247787220944,0.0532984723933319,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27345,1558:1129,Breast,DU-4475,SIDM01001,906844,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.853970909425162,0.0619823399701994,0.651107409132852,9.68257872679013,16.0501,0.921577501263895,0.953063443212007,0.0546337147088993,0.556026786310643,0.0229028541805888,0.533123932130054,5.0708347746117,0.6565,4.61174395217843,15.3936,0.787000376860097,0.488309457534115,0.813888455339634,0.516254605732379,0.298690919325982,0.297633849607254,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27345,1510:1129,Breast,DU-4475,SIDM01001,906844,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.21035590893559,0.0619823399701994,0.651107409132852,9.68257872679013,16.0501,0.921577501263895,0.953063443212007,0.0449385000276854,0.136964290862838,0.0163822891337091,0.120582001729129,6.29607391466022,1.5347,3.38650481212991,14.5154,0.193859272932957,0.116293955083257,0.200482526870145,0.151640511914208,0.0775653178496996,0.0488420149559371,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27346,1558:1192,Breast,DU-4475,SIDM01001,906844,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,1.0,0.0803381545859461,0.489120508077503,8.95238238841736,9.6753,0.858677623736665,0.921772873953083,0.100992153024573,0.489120508077503,0.414806113317575,0.0743143947599284,8.62350820297312,7.7031,0.328874185444242,1.9722,0.858677623736665,0.829023033740054,0.921772873953083,0.903747759061068,0.0296545899966111,0.0180251148920154,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27346,1047:1192,Breast,DU-4475,SIDM01001,906844,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.436083567764,0.0803381545859461,0.489120508077503,8.95238238841736,9.6753,0.858677623736665,0.921772873953083,0.0729763531614852,0.213297416228978,0.0244645970583275,0.18883281917065,5.91168573566094,1.1758,3.04069665275642,8.4995,0.374455201718198,0.251071426107137,0.401970003541536,0.298738741550703,0.123383775611062,0.103231261990833,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27346,1510:1192,Breast,DU-4475,SIDM01001,906844,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.951657793532415,0.0803381545859461,0.489120508077503,8.95238238841736,9.6753,0.858677623736665,0.921772873953083,0.0857588272643072,0.465475343488491,0.163287271794639,0.302188071693852,7.27749183334571,3.0302,1.67489055507165,6.6451,0.817167252760892,0.706257003203815,0.877212339364224,0.768189615086141,0.110910249557077,0.109022724278083,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27346,1012:1192,Breast,DU-4475,SIDM01001,906844,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.379844388675043,0.0803381545859461,0.489120508077503,8.95238238841736,9.6753,0.858677623736665,0.921772873953083,0.132400560652398,0.185789680379125,0.0039834379705061,0.181806242408619,4.0253506736416,0.318,4.92703171477576,9.3573,0.326163877057192,0.151689832522041,0.350130253803946,0.190865385039224,0.174474044535151,0.159264868764722,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27346,1011:1192,Breast,DU-4475,SIDM01001,906844,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.349161177125162,0.0803381545859461,0.489120508077503,8.95238238841736,9.6753,0.858677623736665,0.921772873953083,0.0670612582632928,0.170781892356398,0.0172017935441275,0.153580098812271,5.76166324557304,1.0597,3.19071914284432,8.6156,0.29981688987493,0.178108514596848,0.321847301711502,0.234240126311073,0.121708375278082,0.0876071754004283,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27351,1017:1553,Breast,DU-4475,SIDM01001,906844,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.662115278954156,0.0977885484946193,0.525182983546551,9.11029739515626,10.7945,0.908613792387216,0.929553942613152,0.0698688302635784,0.3477316776529,0.13904110865344,0.208690568999461,7.55045690806576,3.6614,1.5598404870905,7.1331,0.601607074608055,0.501772470509232,0.615471868016242,0.549093301751374,0.0998346040988227,0.0663785662648686,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27351,1021:1553,Breast,DU-4475,SIDM01001,906844,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.768814705819215,0.0977885484946193,0.525182983546551,9.11029739515626,10.7945,0.908613792387216,0.929553942613152,0.0541814968672573,0.403768400996599,0.251267266009422,0.152501134987178,8.20946919322745,5.7813,0.900828201928814,5.0132,0.698555645497459,0.669800124607886,0.714654740933221,0.674769335102929,0.0287555208895726,0.039885405830292,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27351,1558:1553,Breast,DU-4475,SIDM01001,906844,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.959526244696768,0.0977885484946193,0.525182983546551,9.11029739515626,10.7945,0.908613792387216,0.929553942613152,0.113064127895936,0.503926855981066,0.417407529228857,0.0865193267522096,8.7139957125428,8.2017,0.396301682613462,2.5928,0.871838780088994,0.851634414685662,0.891931403798672,0.872161840271018,0.0202043654033317,0.0197695635276537,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27351,1047:1553,Breast,DU-4475,SIDM01001,906844,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.438599425265397,0.0977885484946193,0.525182983546551,9.11029739515626,10.7945,0.908613792387216,0.929553942613152,0.0516090322970701,0.230344954742684,0.0176825750458171,0.212662379696867,5.53207313503753,0.9038,3.57822426011873,9.8907,0.398517487129245,0.247150706499527,0.407701824983312,0.284644072253069,0.151366780629718,0.123057752730243,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27351,1083:1553,Breast,DU-4475,SIDM01001,906844,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.613054178736312,0.0977885484946193,0.525182983546551,9.11029739515626,10.7945,0.908613792387216,0.929553942613152,0.0611774965601258,0.321965622664417,0.115802687234175,0.206162935430242,7.40576609998118,3.312,1.70453129517507,7.4825,0.55702948228043,0.490683190873604,0.569866928879806,0.501308246361716,0.0663462914068264,0.0685586825180899,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27351,1012:1553,Breast,DU-4475,SIDM01001,906844,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.348080848752599,0.0977885484946193,0.525182983546551,9.11029739515626,10.7945,0.908613792387216,0.929553942613152,0.0517050357974986,0.182806138663306,0.0016422864747158,0.18116385218859,3.14515509242363,0.1728,5.96514230273263,10.6217,0.31627106004246,0.112155011911682,0.323559925306111,0.144956650399426,0.204116048130778,0.178603274906685,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27351,1011:1553,Breast,DU-4475,SIDM01001,906844,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.308136689397066,0.0977885484946193,0.525182983546551,9.11029739515626,10.7945,0.908613792387216,0.929553942613152,0.0506789207663306,0.161828145877708,0.0113455033321737,0.150482642545534,5.42884923733551,0.8413,3.68144815782075,9.9532,0.279977245926709,0.153743920765497,0.286429674492807,0.196926202478337,0.126233325161212,0.0895034720144699,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27351,1594:1553,Breast,DU-4475,SIDM01001,906844,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.97620930610548,0.0977885484946193,0.525182983546551,9.11029739515626,10.7945,0.908613792387216,0.929553942613152,0.0642650218804561,0.512688515946384,0.496164011865366,0.0165245040810185,9.03613162222007,10.2536,0.0741657729361904,0.540899999999999,0.886997239784192,0.922234131039854,0.907439209305998,0.903940943264241,-0.0352368912556619,0.0034982660417568,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27351,1012:1560,Breast,DU-4475,SIDM01001,906844,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.903812101187836,0.0730558740138767,0.865265700223327,11.0346082391435,40.9711,0.947950889043366,0.984169127779389,0.0629956311116498,0.78203761060461,0.524628639926892,0.257408970677718,9.35520026902423,12.7916,1.67940797011929,28.1795,0.856769484849162,0.800677435239166,0.88950396730249,0.850035866770797,0.0560920496099959,0.039468100531693,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27351,1047:1560,Breast,DU-4475,SIDM01001,906844,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.438599425265397,0.0730558740138767,0.865265700223327,11.0346082391435,40.9711,0.947950889043366,0.984169127779389,0.108409857219229,0.379505038819813,0.0201837542957586,0.359321284524054,5.68333227218826,1.0037,5.35127596695526,39.9674,0.415770715114242,0.225467783092764,0.431656013807987,0.290976527687465,0.190302932021479,0.140679486120522,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27351,1375:1560,Breast,DU-4475,SIDM01001,906844,1375,Temozolomide,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved,30.0,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.951424772733998,0.0730558740138767,0.865265700223327,11.0346082391435,40.9711,0.947950889043366,0.984169127779389,0.139026341520783,0.823235222189503,0.613898051906936,0.209337170282567,9.65443329052455,15.74,1.38017494861896,25.2311,0.901903959171076,0.787781435082681,0.936362888729322,0.905826206939892,0.114122524088394,0.0305366817894299,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27351,1021:1560,Breast,DU-4475,SIDM01001,906844,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.768814705819215,0.0730558740138767,0.865265700223327,11.0346082391435,40.9711,0.947950889043366,0.984169127779389,0.0204927834893669,0.665228994772654,0.585644094594154,0.0795849001785005,10.2715883313446,24.1427,0.763019907798872,16.8284,0.728798583890939,0.74201285747167,0.756643698450064,0.74592778544766,-0.0132142735807312,0.0107159130024039,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27351,1011:1560,Breast,DU-4475,SIDM01001,906844,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.308136689397066,0.0730558740138767,0.865265700223327,11.0346082391435,40.9711,0.947950889043366,0.984169127779389,0.0509144846400054,0.26662010831565,0.0784634545275876,0.188156653788062,7.82498155827413,4.4288,3.20962668086939,36.5423,0.292098448660828,0.216846109592445,0.303258616840739,0.26203340171685,0.0752523390683831,0.0412252151238885,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27351,1558:1560,Breast,DU-4475,SIDM01001,906844,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.907913336765286,0.0730558740138767,0.865265700223327,11.0346082391435,40.9711,0.947950889043366,0.984169127779389,0.110208511336227,0.785586269078313,0.269558799257969,0.516027469820344,8.05682612181772,5.2009,2.97778211732579,35.7702,0.860657254760982,0.694605294119451,0.893540276743566,0.787317494888156,0.166051960641531,0.10622278185541,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27351,1594:1560,Breast,DU-4475,SIDM01001,906844,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.961028050698849,0.0730558740138767,0.865265700223327,11.0346082391435,40.9711,0.947950889043366,0.984169127779389,0.111911718419475,0.831544609222199,0.629419363108277,0.202125246113923,9.70110247822252,16.2575,1.333505760921,24.7136,0.911007395055588,0.840590389743198,0.945814138427813,0.916538277080282,0.0704170053123898,0.0292758613475312,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27351,1017:1560,Breast,DU-4475,SIDM01001,906844,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.662115278954156,0.0730558740138767,0.865265700223327,11.0346082391435,40.9711,0.947950889043366,0.984169127779389,0.0679299088523516,0.572905640472831,0.325666291715881,0.24723934875695,8.96436370261995,9.756,2.07024453652356,31.2151,0.627652767333788,0.553634000762699,0.651633416577718,0.610724010936312,0.0740187665710894,0.0409094056414068,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27353,1021:1632,Breast,DU-4475,SIDM01001,906844,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.733753736827922,0.0801122459085411,0.910144119481131,11.5331196821283,23.1529,0.965124372510321,0.989700583201028,0.17142577354424,0.667821648721239,0.446016051184768,0.221805597536471,9.47952091812559,5.5771,2.05359876400275,17.5758,0.708163614833152,0.58386525435966,0.726196501264528,0.693796865688317,0.124298360473491,0.0323996355762112,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27353,1558:1632,Breast,DU-4475,SIDM01001,906844,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.932653562086251,0.0801122459085411,0.910144119481131,11.5331196821283,23.1529,0.965124372510321,0.989700583201028,0.0659942937808153,0.848849155045931,0.859154728116984,-0.0103055730710532,11.6898766668198,25.8103,-0.156756984691416,-2.6574,0.900126683878009,0.913755648216264,0.923047774321279,0.924278945662436,-0.0136289643382554,-0.0012311713411571,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27353,1047:1632,Breast,DU-4475,SIDM01001,906844,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.358812211294348,0.0801122459085411,0.910144119481131,11.5331196821283,23.1529,0.965124372510321,0.989700583201028,0.10325578462436,0.326570824107572,0.152216966871508,0.174353857236063,8.66582254320409,3.1729,2.86729713892426,19.98,0.346298410274498,0.232706831205092,0.355116654777667,0.325156858172355,0.113591579069407,0.0299597966053118,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27353,1372:1632,Breast,DU-4475,SIDM01001,906844,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.0641672639118107,0.0801122459085411,0.910144119481131,11.5331196821283,23.1529,0.965124372510321,0.989700583201028,0.0280968077942213,0.0584014579125283,0.0404489256679224,0.0179525322446059,9.58398562833247,5.9959,1.94913405379588,17.157,0.0619293903185905,0.0416005955784134,0.0635063785159333,0.0609282534784715,0.020328794740177,0.0025781250374618,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27353,1510:1632,Breast,DU-4475,SIDM01001,906844,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.904770942534135,0.0801122459085411,0.910144119481131,11.5331196821283,23.1529,0.965124372510321,0.989700583201028,0.111945681101814,0.823471952824843,0.459923164438024,0.36354878838682,9.03646115706907,4.1024,2.49665852505928,19.0505,0.873216488178829,0.750133894537339,0.895452329489377,0.837805788905856,0.12308259364149,0.0576465405835208,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27353,1179:1632,Breast,DU-4475,SIDM01001,906844,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.0771233982629405,0.0801122459085411,0.910144119481131,11.5331196821283,23.1529,0.965124372510321,0.989700583201028,0.0453347820464715,0.0701934074034165,0.0225267328579623,0.0476666745454543,8.03148526147132,2.0441,3.50163442065702,21.1088,0.074433671354384,0.0199600626874212,0.0763290722392773,0.0667414585755238,0.0544736086669628,0.0095876136637535,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27353,1012:1632,Breast,DU-4475,SIDM01001,906844,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.232060109136706,0.0801122459085411,0.910144119481131,11.5331196821283,23.1529,0.965124372510321,0.989700583201028,0.0881875705472133,0.211208143696923,0.0381315410974522,0.173076602599471,7.2206119995293,1.1652,4.31250768259905,21.9877,0.22396686721524,0.117750288785293,0.229670025350293,0.186224116106613,0.106216578429947,0.0434459092436792,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27353,1011:1632,Breast,DU-4475,SIDM01001,906844,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.274041455311715,0.0801122459085411,0.910144119481131,11.5331196821283,23.1529,0.965124372510321,0.989700583201028,0.0908437558641312,0.249417219046009,0.0491251792290966,0.200292039816912,7.33558567120451,1.2619,4.19753401092383,21.891,0.264484087599534,0.141369880301726,0.271218988143263,0.222521529227717,0.123114207297808,0.0486974589155457,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27353,1073:1909,Breast,DU-4475,SIDM01001,906844,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,10.0,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.607809698302896,0.0978457626949642,0.621898750408175,9.54440757497592,1.4584,0.87458704709717,0.948042970751617,0.120638040849454,0.377996091860541,0.014250849265153,0.363745242595388,4.92000074730284,0.0591,4.62440682767308,1.3993,0.531582489235751,0.300989563972562,0.576229712030721,0.35854206702905,0.230592925263189,0.217687645001671,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27353,1083:1909,Breast,DU-4475,SIDM01001,906844,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.619724569449582,0.0978457626949642,0.621898750408175,9.54440757497592,1.4584,0.87458704709717,0.948042970751617,0.147317836108828,0.385405935337939,0.110619080207151,0.274786855130788,7.32988997596694,0.3142,2.21451759900898,1.1442,0.542003081208475,0.381833889955104,0.587525521868748,0.502926388364705,0.160169191253371,0.0845991335040435,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27353,1012:1909,Breast,DU-4475,SIDM01001,906844,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.881445562105416,0.0978457626949642,0.621898750408175,9.54440757497592,1.4584,0.87458704709717,0.948042970751617,0.0959329975911331,0.548169893626189,0.404292130049413,0.143877763576776,8.81871829515996,0.8819,0.725689279815962,0.5765,0.770900871338681,0.723437424484232,0.835648269254248,0.806295377278868,0.0474634468544484,0.0293528919753798,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27353,1007:1909,Breast,DU-4475,SIDM01001,906844,1007,Docetaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.001,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.955743459471202,0.0978457626949642,0.621898750408175,9.54440757497592,1.4584,0.87458704709717,0.948042970751617,0.136382868423198,0.594375663155926,0.388819012810357,0.205556650345569,8.58742692361813,0.7513,0.956980651357796,0.7071,0.835880850001352,0.736482985305196,0.906085868593506,0.861719754208442,0.0993978646961563,0.0443661143850638,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27353,1005:1909,Breast,DU-4475,SIDM01001,906844,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,1.0,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.928058931109843,0.0978457626949642,0.621898750408175,9.54440757497592,1.4584,0.87458704709717,0.948042970751617,0.0660286688099356,0.577158689562358,0.405426767866695,0.171731921695662,8.72218382916403,0.8248,0.82222374581189,0.6336,0.811668320091513,0.799459414522892,0.879839746081946,0.843988141743917,0.0122089055686215,0.0358516043380289,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27353,1190:1909,Breast,DU-4475,SIDM01001,906844,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.01,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.688664870777151,0.0978457626949642,0.621898750408175,9.54440757497592,1.4584,0.87458704709717,0.948042970751617,0.100673283909309,0.428279822586317,0.123549679719563,0.304730142866754,7.33664716752907,0.3157,2.20776040744685,1.1427,0.602297375772542,0.486007663800756,0.652883889943848,0.55925549827016,0.116289711971786,0.0936283916736884,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27353,1047:1909,Breast,DU-4475,SIDM01001,906844,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.358812211294348,0.0978457626949642,0.621898750408175,9.54440757497592,1.4584,0.87458704709717,0.948042970751617,0.0996746193298703,0.223144865835149,0.0027302723145465,0.220414593520602,3.67122801974253,0.0249,5.8731795552334,1.4335,0.313812512338329,0.110989486497621,0.34016939473745,0.167854724217482,0.202823025840708,0.172314670519969,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27353,1021:1909,Breast,DU-4475,SIDM01001,906844,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.733753736827922,0.0978457626949642,0.621898750408175,9.54440757497592,1.4584,0.87458704709717,0.948042970751617,0.124348011004059,0.456320532040613,0.308696683687755,0.147623848352859,8.65005797247346,0.7846,0.894349602502462,0.6738,0.641731513988846,0.550451823151011,0.695630072462443,0.664262274290476,0.091279690837835,0.0313677981719671,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27353,1510:1909,Breast,DU-4475,SIDM01001,906844,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.334678767233014,0.0978457626949642,0.621898750408175,9.54440757497592,1.4584,0.87458704709717,0.948042970751617,0.0895620022876509,0.208136307130359,0.0163729272391793,0.19176337989118,5.75358433621485,0.1054,3.79082323876108,1.353,0.292705714760442,0.156329090509947,0.317289852735075,0.224267830295021,0.136376624250496,0.0930220224400544,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27353,1017:1909,Breast,DU-4475,SIDM01001,906844,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.588627677708528,0.0978457626949642,0.621898750408175,9.54440757497592,1.4584,0.87458704709717,0.948042970751617,0.0997195387702557,0.366066817222599,0.0246893436061461,0.341377473616453,5.57723747153323,0.0932,3.96717010344269,1.3652,0.514806142486766,0.329495500005683,0.558044332241418,0.384552565378255,0.185310642481082,0.173491766863163,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27353,1022:1909,Breast,DU-4475,SIDM01001,906844,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.902178631014738,0.0978457626949642,0.621898750408175,9.54440757497592,1.4584,0.87458704709717,0.948042970751617,0.117804564177573,0.561063763273023,0.518719313847143,0.0423444494258798,9.33053953661703,1.2575,0.213868038358894,0.2009,0.789033744853346,0.748497487186945,0.855304109495839,0.84756024349754,0.0405362576664018,0.0077438659982983,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
28107,1021:2169,Breast,DU-4475,SIDM01001,906844,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.76384608018922,0.0654225613076436,0.893077679841337,11.3221628353947,50.0081,0.962335089739995,0.987629891066685,0.129430084482937,0.682173885051289,0.594177842839864,0.0879960422114249,10.3711885005196,25.8684,0.950974334875106,24.1397,0.735075886126436,0.618411783090075,0.754397220968993,0.74285757028076,0.116664103036361,0.0115396506882334,True,0.612291922929542,0.0845053357199909,0.47545893654772,102.958859121377
28107,1047:2169,Breast,DU-4475,SIDM01001,906844,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.502742419537235,0.0654225613076436,0.893077679841337,11.3221628353947,50.0081,0.962335089739995,0.987629891066685,0.0456840779244985,0.448988033598134,0.243165498742271,0.205822534855863,8.92854782328943,9.5168,2.39361501210525,40.4913,0.483806671421467,0.452593563282962,0.496523441042161,0.462799030681589,0.031213108138505,0.0337244103605723,True,0.612291922929542,0.0845053357199909,0.47545893654772,102.958859121377
28107,1375:2169,Breast,DU-4475,SIDM01001,906844,1375,Temozolomide,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved,30.0,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.961806841399122,0.0654225613076436,0.893077679841337,11.3221628353947,50.0081,0.962335089739995,0.987629891066685,0.0645327168745634,0.858968222372253,0.644308514462543,0.214659707909711,9.77425280653872,17.103,1.54791002885596,32.9051,0.925580473030366,0.89114765543927,0.949909185998207,0.919655542051602,0.0344328175910963,0.0302536439466051,True,0.612291922929542,0.0845053357199909,0.47545893654772,102.958859121377
28107,1372:2169,Breast,DU-4475,SIDM01001,906844,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.0935640492284432,0.0654225613076436,0.893077679841337,11.3221628353947,50.0081,0.962335089739995,0.987629891066685,0.0278093690644617,0.0835599640014988,0.0563826255299578,0.027177338471541,9.4555026148552,13.7126,1.86666022053948,36.2955,0.0900399677106912,0.0678233720399098,0.0924066517472453,0.0883802812950552,0.0222165956707814,0.00402637045219,True,0.612291922929542,0.0845053357199909,0.47545893654772,102.958859121377
28107,1510:2169,Breast,DU-4475,SIDM01001,906844,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.89697436617657,0.0654225613076436,0.893077679841337,11.3221628353947,50.0081,0.962335089739995,0.987629891066685,0.030025699673065,0.801067785822126,0.660302194534978,0.140765591287148,10.1225016241555,21.7724,1.19966121123918,28.2357,0.863189907169005,0.858429452835123,0.885878695556575,0.866917405096501,0.0047604543338821,0.0189612904600734,True,0.612291922929542,0.0845053357199909,0.47545893654772,102.958859121377
28107,1083:2169,Breast,DU-4475,SIDM01001,906844,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.610985331034847,0.0654225613076436,0.893077679841337,11.3221628353947,50.0081,0.962335089739995,0.987629891066685,0.0406972644710141,0.545657361857693,0.343625864312417,0.202031497545276,9.27455787317655,12.0962,2.04760496221813,37.9119,0.58797262337124,0.572430328718208,0.603427375933288,0.572520989242857,0.015542294653032,0.0309063866904312,True,0.612291922929542,0.0845053357199909,0.47545893654772,102.958859121377
28107,1179:2169,Breast,DU-4475,SIDM01001,906844,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.126275913466682,0.0654225613076436,0.893077679841337,11.3221628353947,50.0081,0.962335089739995,0.987629891066685,0.0515037466645976,0.11277419981867,0.0389782806417064,0.0737959191769635,8.117860609851,5.4256,3.20430222554368,44.5825,0.121519742517959,0.0574446991320545,0.124713866661445,0.110040182959984,0.0640750433859047,0.0146736837014608,True,0.612291922929542,0.0845053357199909,0.47545893654772,102.958859121377
28107,1012:2169,Breast,DU-4475,SIDM01001,906844,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.665710487474503,0.0654225613076436,0.893077679841337,11.3221628353947,50.0081,0.962335089739995,0.987629891066685,0.0927442912126917,0.594531177599775,0.208656979055988,0.385874198543787,8.14215902687057,5.5178,3.18000380852411,44.4903,0.640636561704632,0.506300830568097,0.657475576226393,0.581231828292387,0.134335731136535,0.0762437479340063,True,0.612291922929542,0.0845053357199909,0.47545893654772,102.958859121377
28107,1011:2169,Breast,DU-4475,SIDM01001,906844,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.379027343942161,0.0654225613076436,0.893077679841337,11.3221628353947,50.0081,0.962335089739995,0.987629891066685,0.0662550487277335,0.338500860924289,0.0625706461808713,0.275930214743418,7.22669256560741,2.9254,4.09547026978727,47.0827,0.364751313046491,0.257552806993541,0.374338734408891,0.304355098321625,0.10719850605295,0.069983636087266,True,0.612291922929542,0.0845053357199909,0.47545893654772,102.958859121377
27350,1021:2172,Breast,DU-4475,SIDM01001,906844,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,4.0,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.55161770468208,0.102911134631246,0.0621637256373628,6.03100896078753,1.2772,0.654798672095494,0.696256253279059,0.0636770834982641,0.0342906116505686,0.0010552329659046,0.033235378684664,2.15443940261458,0.087,3.87656955817295,1.1902,0.36119854053019,0.186741838471991,0.384067276304339,0.177174294313209,0.174456702058199,0.20689298199113,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27350,1510:2172,Breast,DU-4475,SIDM01001,906844,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.208838540362909,0.102911134631246,0.0621637256373628,6.03100896078753,1.2772,0.654798672095494,0.696256253279059,0.0510348652653821,0.0129821817256273,0.0001310138148552,0.012851167910772,0.933271471373228,0.0373,5.09773748941431,1.2399,0.136747198911994,0.0727914775274297,0.145405139653346,0.0439631242416012,0.0639557213845642,0.101442015411745,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27350,1372:2172,Breast,DU-4475,SIDM01001,906844,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.0622476796120199,0.102911134631246,0.0621637256373628,6.03100896078753,1.2772,0.654798672095494,0.696256253279059,0.0149520924521575,0.0038695476769641,5.12566514049295e-05,0.0038182910255592,1.2310443050693,0.0458,4.79996465571823,1.2314,0.0407596979509764,0.0168006556093715,0.0433403361819802,0.0147151718481615,0.0239590423416049,0.0286251643338187,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27350,1012:2172,Breast,DU-4475,SIDM01001,906844,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.903413344033187,0.102911134631246,0.0621637256373628,6.03100896078753,1.2772,0.654798672095494,0.696256253279059,0.0514932248423607,0.0561595392556115,0.0248493506936474,0.0313101885619641,5.0992720001557,0.6695,0.931736960631834,0.6077,0.591553858026281,0.565158745691149,0.629007190078852,0.548633695517796,0.0263951123351315,0.0803734945610559,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27350,1179:2172,Breast,DU-4475,SIDM01001,906844,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.250235095865567,0.102911134631246,0.0621637256373628,6.03100896078753,1.2772,0.654798672095494,0.696256253279059,0.0200272908452016,0.0155555458442262,0.0014209369134473,0.0141346089307789,3.34889272957261,0.199,2.68211623121492,1.0782,0.163853608484462,0.12331280055607,0.174227750286286,0.109177954028328,0.0405408079283917,0.0650497962579581,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27350,1083:2172,Breast,DU-4475,SIDM01001,906844,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.936662768876287,0.102911134631246,0.0621637256373628,6.03100896078753,1.2772,0.654798672095494,0.696256253279059,0.0390178339600348,0.0582264473791581,0.0208334812218459,0.0373929661573121,4.86097902985812,0.5676,1.17002993092941,0.7096,0.613325537261481,0.558677850222362,0.652157310043792,0.547153028129324,0.0546476870391193,0.105004281914468,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27350,1191:2172,Breast,DU-4475,SIDM01001,906844,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.0025,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.595518219631245,0.102911134631246,0.0621637256373628,6.03100896078753,1.2772,0.654798672095494,0.696256253279059,0.0527862733886541,0.0370196312172075,0.000758457213917,0.0362611740032904,1.70867827008549,0.0638,4.32233069070204,1.2134,0.389944539423212,0.162792574702306,0.414633284359866,0.166484113870871,0.227151964720906,0.248149170488995,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27350,1047:2172,Breast,DU-4475,SIDM01001,906844,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.423669298154851,0.102911134631246,0.0621637256373628,6.03100896078753,1.2772,0.654798672095494,0.696256253279059,0.011428556028122,0.0263368620114722,0.0008365487854771,0.0255003132259951,2.18915495316067,0.0891,3.84185400762686,1.1881,0.277418093839427,0.141323543182711,0.294982398162665,0.13746966154564,0.136094550656715,0.157512736617025,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
27350,1011:2172,Breast,DU-4475,SIDM01001,906844,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.330529849123362,0.102911134631246,0.0621637256373628,6.03100896078753,1.2772,0.654798672095494,0.696256253279059,0.0272296567877074,0.0205469668558635,0.0001868508217721,0.0203601160340914,0.819284333713678,0.0345,5.21172462707385,1.2427,0.216430506293902,0.0707752660140149,0.230133474347525,0.0663900668981495,0.145655240279887,0.163743407449375,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
23927,1011:1050,Breast,HCC1395,SIDM00884,749712,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.974971312503205,0.157311208978657,0.583596468751329,10.0144612825222,20.2015,0.90268878732431,0.845747862787408,0.116679998075009,0.568989815110719,0.3463652590133,0.222624556097419,7.20879546196454,2.8893,2.80566582055764,17.3122,0.880095671759509,0.729600835443753,0.82457990382862,0.690217975135787,0.150494836315756,0.134361928692833,True,0.667495015167967,0.0674649706669935,0.381649384184428,125.780977438173
23927,1011:1051,Breast,HCC1395,SIDM00884,749712,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.974971312503205,0.0910025477718484,0.609922774171275,10.3433416719256,25.3738,0.805319871170036,0.858229381651777,0.162169780441036,0.594657207659364,0.350895461352486,0.243761746306878,7.26958502540147,3.0137,3.07375664652415,22.3601,0.785163771779562,0.598686693857051,0.836749026657848,0.693666516002322,0.186477077922511,0.143082510655526,True,0.667495015167967,0.0674649706669935,0.381649384184428,125.780977438173
25841,1011:1080,Breast,HCC1395,SIDM00884,749712,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.945315547877528,0.0731624691857767,0.465303309446532,8.58222965681262,0.0749,0.765102369324519,0.782217418867008,0.147496009190406,0.439858452898675,0.208480384246942,0.231378068651733,5.20572323210951,0.0072,3.37650642470311,0.0677,0.723263165440403,0.555378229435477,0.739442287875611,0.5497759464626,0.167884936004925,0.189666341413012,True,0.44479748562928,0.0532231221514717,0.774592842687433,63.1282686288344
23928,1005:2172,Breast,HCC1395,SIDM00884,749712,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.914744813029508,0.0604142990394161,0.85348996790285,14.2960981292912,392.9021,0.945900701781852,0.954234856740557,0.0433031462825934,0.780725521111853,0.500700750707821,0.280024770404032,9.57112001458617,14.8568,4.72497811470505,378.0453,0.865257760595921,0.737038112762319,0.872881385615379,0.757112980923761,0.128219647833601,0.115768404691619,True,0.667495015167967,0.0674649706669935,0.381649384184428,125.780977438173
27481,1017:1003,Breast,BT-20,SIDM00893,906801,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.950349068119836,0.0899366282330497,0.513960104803216,9.15128034994134,0.1111,0.85921557651983,0.826031264361221,0.137866678057755,0.48844150665051,0.268919140973311,0.219522365677199,6.48172928561988,0.0175,2.66955106432146,0.0936,0.816554722459668,0.642013699542092,0.785018042323537,0.641165995702268,0.174541022917576,0.143852046621269,True,1.25334280311119,0.110750657810219,-0.239897217854411,-224.523668877531
27481,1179:1003,Breast,BT-20,SIDM00893,906801,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.381727777788107,0.0899366282330497,0.513960104803216,9.15128034994134,0.1111,0.85921557651983,0.826031264361221,0.0307909655372737,0.196192848678274,0.165115048640274,0.0310778000380002,8.26474061863814,0.0601,0.886539731303198,0.051,0.327986452665842,0.290321334035487,0.315319078928109,0.298406718503084,0.0376651186303548,0.0169123604250252,True,1.25334280311119,0.110750657810219,-0.239897217854411,-224.523668877531
28308,1561:1032,Breast,BT-20,SIDM00893,906801,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.622162961229422,0.11301136651222,0.615303904397837,10.2720581839246,24.1506,0.845671502148206,0.872654122040504,0.0743063328180199,0.382819299216184,0.228622813031536,0.154196486184647,7.52901446463819,3.6074,2.74304371928638,20.5432,0.526145486003861,0.457926599374387,0.542933072697781,0.460540246592014,0.0682188866294747,0.0823928261057673,True,0.526253313397235,0.0544055226357989,0.619330977615164,79.0524314471407
28308,1058:1032,Breast,BT-20,SIDM00893,906801,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.805902256720571,0.11301136651222,0.615303904397837,10.2720581839246,24.1506,0.845671502148206,0.872654122040504,0.111040919938788,0.495874805123195,0.277204805757698,0.218669999365497,7.2512623190803,2.9756,3.02079586484427,21.175,0.681528572025514,0.564823166139349,0.703273926288951,0.583092913098176,0.116705405886165,0.120181013190775,True,0.526253313397235,0.0544055226357989,0.619330977615164,79.0524314471407
28308,1179:1032,Breast,BT-20,SIDM00893,906801,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.368838564553892,0.11301136651222,0.615303904397837,10.2720581839246,24.1506,0.845671502148206,0.872654122040504,0.0576040809963621,0.226947808862503,0.0972170081408665,0.129730800721637,6.21716400539055,1.4531,4.05489417853401,22.6975,0.311916262936478,0.202534352008576,0.321868493725456,0.242356701463041,0.109381910927901,0.0795117922624148,True,0.526253313397235,0.0544055226357989,0.619330977615164,79.0524314471407
28308,1012:1032,Breast,BT-20,SIDM00893,906801,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.89491506440465,0.11301136651222,0.615303904397837,10.2720581839246,24.1506,0.845671502148206,0.872654122040504,0.107913676681518,0.550644733232623,0.32392282607617,0.226721907156454,7.46465958650592,3.45,2.80739859741865,20.7006,0.756804166810139,0.646674469844821,0.780951319828861,0.659018839219376,0.110129696965317,0.121932480609485,True,0.526253313397235,0.0544055226357989,0.619330977615164,79.0524314471407
28308,1011:1032,Breast,BT-20,SIDM00893,906801,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.807036634174456,0.11301136651222,0.615303904397837,10.2720581839246,24.1506,0.845671502148206,0.872654122040504,0.0947963095234148,0.496572791999632,0.0624157435939663,0.434157048405666,2.28559408285064,0.0952,7.98646410107393,24.0554,0.682487882710944,0.292250175193682,0.704263845450034,0.304454793565358,0.390237707517262,0.399809051884676,True,0.526253313397235,0.0544055226357989,0.619330977615164,79.0524314471407
28308,1021:1032,Breast,BT-20,SIDM00893,906801,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,4.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.793340519020705,0.11301136651222,0.615303904397837,10.2720581839246,24.1506,0.845671502148206,0.872654122040504,0.0366386665165634,0.488145518870446,0.277595275879971,0.210550242990476,7.32225357905476,3.1257,2.94980460486981,21.0249,0.670905468435277,0.552530096783824,0.692311874105171,0.577429879303478,0.118375371651452,0.114881994801693,True,0.526253313397235,0.0544055226357989,0.619330977615164,79.0524314471407
28308,1011:1038,Breast,BT-20,SIDM00893,906801,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.807036634174456,0.131642796824512,0.569663431634062,9.75966114386885,16.9309,0.881781162638132,0.852643860263548,0.116455954848566,0.459739258478224,0.244209948328478,0.215529310149746,6.73859670818907,2.0857,3.02106443567979,14.8452,0.711629701573917,0.601920294085223,0.688114831136609,0.557962512795877,0.109709407488694,0.130152318340732,True,0.526253313397235,0.0544055226357989,0.619330977615164,79.0524314471407
28309,1179:1042,Breast,BT-20,SIDM00893,906801,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.421807619081945,0.0517098981095347,0.884821701543462,14.522273508512,459.5894,0.965997463049187,0.967734032847541,0.0587920158351228,0.373224535240082,0.1888238503573,0.184400684882783,8.43080762685858,6.7399,6.09146588165346,452.8495,0.407465089927977,0.281539568083982,0.40819758829999,0.333444978788567,0.125925521843995,0.0747526095114228,True,0.526253313397235,0.0544055226357989,0.619330977615164,79.0524314471407
28309,1011:1046,Breast,BT-20,SIDM00893,906801,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1046,Wee1 Inhibitor,"WEE1, CHEK1",Cell cycle,Targeted,Experimental only,10.0,0.795178124783689,0.0693678346242988,0.567185626817112,9.7323047110267,16.6129,0.871615422038031,0.851514020020353,0.146848524982312,0.451013603136692,0.262417008706857,0.188596594429835,7.08204230744112,2.6463,2.65026240358559,13.9666,0.693089516828745,0.605055980300988,0.677105321666804,0.567040953786392,0.0880335365277568,0.110064367880412,True,0.526253313397235,0.0544055226357989,0.619330977615164,79.0524314471407
28310,1549:1050,Breast,BT-20,SIDM00893,906801,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.877426827978906,0.065322094454503,0.640469625761041,10.5638677506799,29.5645,0.885854274730533,0.883086348177509,0.0610279630328271,0.561965232148347,0.284010258767244,0.277954973381103,7.00417973859148,2.5073,3.55968801208841,27.0572,0.777272306328366,0.604127588752012,0.774843653312868,0.621427040243161,0.173144717576354,0.153416613069707,True,0.526253313397235,0.0544055226357989,0.619330977615164,79.0524314471407
28310,1558:1050,Breast,BT-20,SIDM00893,906801,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.881253754294711,0.065322094454503,0.640469625761041,10.5638677506799,29.5645,0.885854274730533,0.883086348177509,0.0677598832834849,0.564416262213646,0.42843104525936,0.135985216954286,8.85003070737574,9.0127,1.71383704330415,20.5518,0.780662405364301,0.723406636623817,0.778223159697836,0.715316490851402,0.0572557687404832,0.0629066688464344,True,0.526253313397235,0.0544055226357989,0.619330977615164,79.0524314471407
28310,1011:1050,Breast,BT-20,SIDM00893,906801,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.764187259652383,0.065322094454503,0.640469625761041,10.5638677506799,29.5645,0.885854274730533,0.883086348177509,0.13623641458825,0.489438728200917,0.181597078171632,0.307841650029285,5.84277611137881,1.1209,4.72109163930108,28.4436,0.676958550657675,0.511218152551525,0.674843336450201,0.482675570711907,0.16574039810615,0.192167765738294,True,0.526253313397235,0.0544055226357989,0.619330977615164,79.0524314471407
28310,1011:1051,Breast,BT-20,SIDM00893,906801,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.764187259652383,0.151943083976931,0.579178194733823,9.86508114395179,18.2144,0.755821813330187,0.856939166525253,0.141374518097598,0.442600597484055,0.0948627353262952,0.347737862157759,3.70812555796987,0.2553,6.15695558598192,17.9591,0.57758940031429,0.325585876642967,0.65486199335573,0.365878144464357,0.252003523671323,0.288983848891373,True,0.526253313397235,0.0544055226357989,0.619330977615164,79.0524314471407
28310,1558:1051,Breast,BT-20,SIDM00893,906801,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.881248369114554,0.151943083976931,0.579178194733823,9.86508114395179,18.2144,0.755821813330187,0.856939166525253,0.177423963828188,0.510399839535894,0.297403394532426,0.212996445003468,7.1730251752084,2.8186,2.69205596874339,15.3958,0.666066740338432,0.517525814068591,0.755176242930764,0.63337959492704,0.148540926269841,0.121796648003724,True,0.526253313397235,0.0544055226357989,0.619330977615164,79.0524314471407
28310,1549:1051,Breast,BT-20,SIDM00893,906801,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.856029570442636,0.151943083976931,0.579178194733823,9.86508114395179,18.2144,0.755821813330187,0.856939166525253,0.179521022913022,0.495793661247736,0.312451949341416,0.18334171190632,7.50027165799714,3.5362,2.36480948595465,14.6782,0.647005822196214,0.512385659609409,0.733565266616082,0.63219638072447,0.134620162586804,0.101368885891612,True,0.526253313397235,0.0544055226357989,0.619330977615164,79.0524314471407
28310,1561:1051,Breast,BT-20,SIDM00893,906801,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.665369203784412,0.151943083976931,0.579178194733823,9.86508114395179,18.2144,0.755821813330187,0.856939166525253,0.0778075199115515,0.385367334279337,0.20177184656552,0.183595487713817,6.74689707215855,2.0977,3.11818407179324,16.1167,0.502900558138397,0.417692651741158,0.570180930922585,0.460372651863384,0.0852079063972382,0.109808279059201,True,0.526253313397235,0.0544055226357989,0.619330977615164,79.0524314471407
27483,1011:1052,Breast,BT-20,SIDM00893,906801,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1052,RO-3306,CDK1,Cell cycle,Targeted,Experimental only,10.0,0.821024780027314,0.0857942394945984,0.616481803199327,10.2855438266818,24.3774,0.868381562354903,0.873151478259395,0.117393609785374,0.506146836862569,0.290011402018092,0.216135434844477,7.36174751240034,3.2125,2.92379631428141,21.1649,0.71296278121221,0.623746344362113,0.716879000368444,0.599539857777979,0.0892164368500965,0.117339142590466,True,1.25334280311119,0.110750657810219,-0.239897217854411,-224.523668877531
27486,1549:1096,Breast,BT-20,SIDM00893,906801,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.886195416605757,0.0631606370966427,0.824459774901272,13.1895946805515,91.2355,0.92046686924406,0.949152780896984,0.100478938064312,0.730632473693322,0.591999150876633,0.138633322816689,10.8939061719637,18.582,2.29568850858788,72.6535,0.815713520661537,0.738973010925768,0.841134844089516,0.792316934046416,0.0767405097357685,0.0488179100430994,True,1.25334280311119,0.110750657810219,-0.239897217854411,-224.523668877531
27486,1561:1096,Breast,BT-20,SIDM00893,906801,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.588041744513053,0.0631606370966427,0.824459774901272,13.1895946805515,91.2355,0.92046686924406,0.949152780896984,0.0288928686715492,0.484816764313783,0.4567182927158,0.0280984715979838,12.3758223655825,51.9032,0.81377231496907,39.3323,0.541272943556746,0.538719485404489,0.558141457088078,0.548926786065308,0.0025534581522568,0.0092146710227701,True,1.25334280311119,0.110750657810219,-0.239897217854411,-224.523668877531
27486,1011:1096,Breast,BT-20,SIDM00893,906801,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.847085942206233,0.0631606370966427,0.824459774901272,13.1895946805515,91.2355,0.92046686924406,0.949152780896984,0.176490631055877,0.698388285233383,0.30807099926482,0.390317285968563,7.48485731630821,1.7493,5.70473736424334,89.4862,0.779714545203226,0.520513775578801,0.804013977703788,0.624815722673665,0.259200769624426,0.179198255030123,True,1.25334280311119,0.110750657810219,-0.239897217854411,-224.523668877531
27487,1011:1192,Breast,BT-20,SIDM00893,906801,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.888701923520543,0.0673101737212491,0.657187740084802,10.7626240253927,33.9315,0.914410440861386,0.889800996857055,0.153345622736023,0.584044008727482,0.27737098470209,0.306673024025392,6.85955855868613,2.2681,3.90306546670658,31.6634,0.812638317680781,0.617373138625245,0.790767857457361,0.62129796300814,0.195265179055537,0.169469894449221,True,1.25334280311119,0.110750657810219,-0.239897217854411,-224.523668877531
28701,1561:1564,Breast,BT-20,SIDM00893,906801,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.620705159634988,0.0665946380658255,0.730711262690471,11.7036683321721,32.5728,0.899390535015731,0.917501773999729,0.0586581270187275,0.453556250955372,0.375164761807007,0.0783914891483655,10.1481226370395,11.0813,1.55554569513263,21.4915,0.558256345611136,0.492007689518264,0.569498085095886,0.538780450559334,0.0662486560928724,0.0307176345365519,True,1.02859151306523,0.0847988514123996,-0.0368532270813195,-1785.96185254479
28701,1011:1564,Breast,BT-20,SIDM00893,906801,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.760464948989309,0.0665946380658255,0.730711262690471,11.7036683321721,32.5728,0.899390535015731,0.917501773999729,0.12737783987551,0.555680303107823,0.207379004871031,0.348301298236792,6.34310355973343,0.7928,5.36056477243868,31.78,0.683954977332205,0.430261016697023,0.697727939762304,0.506086216024971,0.253693960635182,0.191641723737333,True,1.02859151306523,0.0847988514123996,-0.0368532270813195,-1785.96185254479
29177,1022:1003,Breast,HCC1428,SIDM00881,1290905,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.946989584263052,0.0397118731510543,0.931334316133299,13.9920840727918,3.1825,0.977274654600534,0.986456157829578,0.0484988866176844,0.881963896844986,0.589726561558694,0.292237335286293,9.95957512016074,0.1945,4.03250895263106,2.988,0.925468918870977,0.84683433454847,0.934163706796759,0.861706514058658,0.0786345843225074,0.0724571927381009,True,1.09371466975938,0.117913895939682,-0.102377456500339,-564.625261646695
29177,1012:1003,Breast,HCC1428,SIDM00881,1290905,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.155430343938016,0.0397118731510543,0.931334316133299,13.9920840727918,3.1825,0.977274654600534,0.986456157829578,0.0499208560578322,0.144757613077875,0.0710706114018115,0.0736870016760638,8.67180535461887,0.0797,5.32027871817293,3.1028,0.151898135686466,0.0876561326691543,0.153325219891225,0.132333208835912,0.0642420030173121,0.0209920110553126,True,1.09371466975938,0.117913895939682,-0.102377456500339,-564.625261646695
29177,1011:1003,Breast,HCC1428,SIDM00881,1290905,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.169822127740898,0.0397118731510543,0.931334316133299,13.9920840727918,3.1825,0.977274654600534,0.986456157829578,0.0359667400155258,0.158161175203871,0.0705002316821317,0.0876609435217395,8.34376865696244,0.0635,5.64831541582936,3.119,0.165962861231514,0.105002358827987,0.16752208364573,0.141483710042994,0.060960502403527,0.026038373602736,True,1.09371466975938,0.117913895939682,-0.102377456500339,-564.625261646695
29178,1011:1030,Breast,HCC1428,SIDM00881,1290905,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1030,KU-55933,ATM,Genome integrity,Targeted,Experimental only,10.0,0.278289561642279,0.0411179332367868,0.881811728479941,12.8477832877844,143.9787,0.968391819287551,0.976057007695686,0.0627353896709102,0.245398999369703,0.196334820407075,0.0490641789626288,10.6727038654196,31.8812,2.17507942236481,112.0975,0.269493334887502,0.19667066187045,0.271626476809507,0.259822578528555,0.0728226730170518,0.0118038982809522,True,1.09371466975938,0.117913895939682,-0.102377456500339,-564.625261646695
28367,1011:1038,Breast,HCC1428,SIDM00881,1290905,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.782040745129411,0.0988773376850667,0.515318515840604,9.11735242095803,10.8474,0.868906906943032,0.874035705922819,0.0549146741276196,0.403000076106968,0.167526886232475,0.235473189874494,6.51161014794874,1.7821,2.60574227300928,9.0653,0.679520604953821,0.523281985888976,0.683531534729592,0.554274373582862,0.156238619064845,0.12925716114673,True,0.529839606693131,0.0464284488132228,0.610266617538589,80.0369465272855
28367,1012:1038,Breast,HCC1428,SIDM00881,1290905,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.877298454764726,0.0988773376850667,0.515318515840604,9.11735242095803,10.8474,0.868906906943032,0.874035705922819,0.0691414574145752,0.452088137658614,0.346645497565443,0.105442640093171,8.18474999240805,5.6831,0.932602428549973,5.1643,0.76229068679552,0.720093291549626,0.766790174215286,0.722713104763132,0.0421973952458939,0.0440770694521532,True,0.529839606693131,0.0464284488132228,0.610266617538589,80.0369465272855
30193,1011:1050,Breast,HCC1428,SIDM00881,1290905,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.600669241425642,0.05904479652145,0.826919694234219,11.9943518424807,79.6874,0.943019972611937,0.963829274334037,0.0434902957728735,0.496705225455592,0.276995215079633,0.219710010375959,8.70182559244448,8.1328,3.29252625003625,71.5546,0.566443091598042,0.480340892907032,0.578942599078052,0.512372885047852,0.0861021986910092,0.0665697140302007,True,0.768000060532699,0.0777395877736317,0.250621367036338,191.296964465036
30193,1049:1050,Breast,HCC1428,SIDM00881,1290905,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.973145742819465,0.05904479652145,0.826919694234219,11.9943518424807,79.6874,0.943019972611937,0.963829274334037,0.0874404668509302,0.804713380097603,0.521307716777129,0.283405663320474,9.27382069963569,12.0901,2.72053114284504,67.5973,0.917695871741035,0.862902265341175,0.937946355122942,0.857715192695999,0.0547936063998599,0.0802311624269423,True,0.768000060532699,0.0777395877736317,0.250621367036338,191.296964465036
30193,1011:1051,Breast,HCC1428,SIDM00881,1290905,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.600669241425642,0.150776537283023,0.732472712744762,10.9283999072153,38.0633,0.808870881794366,0.940769345657739,0.150939556526597,0.439973828729378,0.250679472591456,0.189294356137923,8.36104080495581,6.4218,2.56735910225953,31.6415,0.485863858978712,0.367564741299501,0.565091209212731,0.501032719802652,0.11829911767921,0.0640584894100793,True,0.768000060532699,0.0777395877736317,0.250621367036338,191.296964465036
29179,1012:1059,Breast,HCC1428,SIDM00881,1290905,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.813892235591866,0.0597387620994028,0.874357048319131,12.7144213002157,13.1266,0.959256260689695,0.974441525556568,0.052891093021792,0.711632412761962,0.505341272786343,0.206291139975619,9.944565102065,1.9246,2.76985619815067,11.202,0.78073122251823,0.700512946887196,0.793090391688783,0.740137500841978,0.0802182756310332,0.0529528908468054,True,1.09371466975938,0.117913895939682,-0.102377456500339,-564.625261646695
29179,1011:1059,Breast,HCC1428,SIDM00881,1290905,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.242414491353753,0.0597387620994028,0.874357048319131,12.7144213002157,13.1266,0.959256260689695,0.974441525556568,0.051057521371302,0.211956819129851,0.155843330260268,0.0561134888695827,10.1255671727058,2.1819,2.58885412750989,10.9447,0.232537618512995,0.180423154439128,0.23621874677177,0.222048193244239,0.0521144640738672,0.0141705535275309,True,1.09371466975938,0.117913895939682,-0.102377456500339,-564.625261646695
29180,1011:1080,Breast,HCC1428,SIDM00881,1290905,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.266661434775163,0.077717319645014,0.821194649047461,11.9187449599461,0.7562,0.922522183400384,0.962507809912885,0.0747152457780849,0.218980943344683,0.148806434966373,0.0701745083783095,9.44646950957881,0.1363,2.47227545036733,0.6199,0.246001089037463,0.160733232635659,0.25666371357367,0.237096780793011,0.085267856401804,0.0195669327806593,True,1.09371466975938,0.117913895939682,-0.102377456500339,-564.625261646695
29181,1011:1085,Breast,HCC1428,SIDM00881,1290905,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.740411991324534,0.0713295178826422,0.540103194902976,9.30778842885722,12.3781,0.864259663968979,0.882938101619011,0.186914860670442,0.399898882058855,0.345771874958834,0.0541270071000215,8.74689861869003,8.3909,0.560889810167186,3.9872,0.639908218820744,0.597377348489538,0.653737958036035,0.633341806804271,0.0425308703312062,0.0203961512317641,True,1.09371466975938,0.117913895939682,-0.102377456500339,-564.625261646695
29181,1011:1086,Breast,HCC1428,SIDM00881,1290905,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1086,BI-2536,"PLK1, PLK2, PLK3",Cell cycle,Targeted,Early clinical trials,10.0,0.419992281381791,0.0925857008920336,0.274749100079187,7.14156970255826,2.7578,0.732591876433194,0.755358052224385,0.0647413535864744,0.115392501349852,0.0261268603296594,0.0892656410201922,3.8055868181877,0.2731,3.33598288437056,2.4847,0.307682933504944,0.166516525976839,0.317244551613825,0.202949509379836,0.141166407528105,0.114295042233989,True,1.09371466975938,0.117913895939682,-0.102377456500339,-564.625261646695
29182,1011:1096,Breast,HCC1428,SIDM00881,1290905,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.24579587206276,0.0704266525776884,0.869613292051256,12.633049129781,62.0336,0.933980865838574,0.973406377395633,0.0784669354739724,0.213747357477106,0.117013166695566,0.0967341907815403,8.81650402721749,4.4028,3.81654510256346,57.6308,0.229568641408724,0.129928467444566,0.239259269403412,0.211145467919959,0.0996401739641578,0.0281138014834528,True,1.09371466975938,0.117913895939682,-0.102377456500339,-564.625261646695
29182,1011:1129,Breast,HCC1428,SIDM00881,1290905,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.24579587206276,0.0553058697797603,0.768819249995061,11.300697944975,49.2696,0.919622805125108,0.94997524576123,0.0620097463425607,0.188972598011173,0.107950242991804,0.0810223550193696,8.53194769568366,7.2294,2.76875024929137,42.0402,0.226039489354528,0.14388639635863,0.233499993969917,0.207396115092861,0.0821530929958983,0.0261038788770558,True,1.09371466975938,0.117913895939682,-0.102377456500339,-564.625261646695
29183,1011:1192,Breast,HCC1428,SIDM00881,1290905,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.260377733563885,0.0832303328683097,0.81971358520452,11.8994951915649,74.6165,0.922980874438072,0.962164458127663,0.0800374647402247,0.213435165487079,0.104241342674859,0.10919382281222,8.2264587165617,5.8498,3.6730364750032,68.7667,0.240323668208998,0.140232822001943,0.250526200923004,0.215142852134232,0.100090846207055,0.0353833487887724,True,1.09371466975938,0.117913895939682,-0.102377456500339,-564.625261646695
28371,1191:1560,Breast,HCC1428,SIDM00881,1290905,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.000625,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.982896962140347,0.046803043998758,0.949907191500604,14.6337032149189,496.4936,0.975809475933723,0.99021507312249,0.0697150279091217,0.933660892841212,0.835600679892599,0.0980602129486137,12.3231909071359,100.0876,2.31051230778297,396.406,0.95912016952302,0.916457787809901,0.973279387237677,0.952523059348695,0.0426623817131199,0.0207563278889822,True,0.529839606693131,0.0464284488132228,0.610266617538589,80.0369465272855
28371,1011:1560,Breast,HCC1428,SIDM00881,1290905,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.568281796452205,0.046803043998758,0.949907191500604,14.6337032149189,496.4936,0.975809475933723,0.99021507312249,0.115964014729536,0.539814965248832,0.271035232010287,0.268779733238544,8.82325666557403,8.847,5.81044654934487,487.6466,0.554534761978701,0.386274261898325,0.5627212006281,0.488368445939792,0.168260500080375,0.0743527546883074,True,0.529839606693131,0.0464284488132228,0.610266617538589,80.0369465272855
28372,1011:1564,Breast,HCC1428,SIDM00881,1290905,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.597390796080047,0.0470437447968922,0.850512275168808,12.3287811812742,50.2381,0.956872377130198,0.969180713401667,0.0427846160037174,0.508088205138946,0.313470830716229,0.194617374422717,9.18957266486114,5.7021,3.13920851641302,44.536,0.571626751120816,0.495536592473523,0.578979637924449,0.524190304754122,0.0760901586472934,0.0547893331703275,True,0.529839606693131,0.0464284488132228,0.610266617538589,80.0369465272855
28373,1559:1909,Breast,HCC1428,SIDM00881,1290905,1559,Luminespib,HSP90,Protein stability and degradation,Targeted,Early clinical trials,0.01,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.977153889351445,0.0633653837642667,0.906308775253849,13.344960210496,20.3219,0.952740957113031,0.981271694476122,0.0384011014188352,0.885603144692644,0.88534187063436,0.0002612740582832,13.3389390150037,20.2372,0.0060211954923232,0.084699999999998,0.930974531787416,0.936457608225303,0.958853452767826,0.958798577885144,-0.0054830764378867,5.48748826824097e-05,True,0.529839606693131,0.0464284488132228,0.610266617538589,80.0369465272855
28373,1549:1909,Breast,HCC1428,SIDM00881,1290905,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.999855549861155,0.0633653837642667,0.906308775253849,13.344960210496,20.3219,0.952740957113031,0.981271694476122,0.0962479025497422,0.906177858825428,0.563174330327072,0.343003528498356,9.48704854774022,1.4016,3.85791166275578,18.9203,0.952603333549493,0.805041240640468,0.981129949643611,0.890767464677728,0.147562092909025,0.0903624849658825,True,0.529839606693131,0.0464284488132228,0.610266617538589,80.0369465272855
28373,1561:1909,Breast,HCC1428,SIDM00881,1290905,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.968851089145239,0.0633653837642667,0.906308775253849,13.344960210496,20.3219,0.952740957113031,0.981271694476122,0.0297595758118982,0.878078244006579,0.524149839677276,0.353928404329303,9.31471316549636,1.2438,4.03024704499963,19.0781,0.923064113972237,0.857648105117423,0.950706149940585,0.855740726405814,0.0654160088548142,0.094965423534771,True,0.529839606693131,0.0464284488132228,0.610266617538589,80.0369465272855
28373,1510:1909,Breast,HCC1428,SIDM00881,1290905,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.944808948962922,0.0633653837642667,0.906308775253849,13.344960210496,20.3219,0.952740957113031,0.981271694476122,0.0802334451310969,0.856288641383462,0.404352644391096,0.451935996992367,8.44452220435234,0.6804,4.90043800614365,19.6415,0.900158182323891,0.731987608744971,0.927114278305051,0.792584103817091,0.16817057357892,0.134530174487959,True,0.529839606693131,0.0464284488132228,0.610266617538589,80.0369465272855
29180,1012:2169,Breast,HCC1428,SIDM00881,1290905,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.283718671163062,0.0438758973198862,0.921591943624623,13.7179261261406,263.1705,0.968199421446613,0.984454515275012,0.077926518918168,0.261472841599762,0.131617139338022,0.12985570226174,8.72305027230995,8.2533,4.99487585383061,254.9172,0.274696253273679,0.167748755333011,0.279308126894303,0.242332893051173,0.106947497940667,0.0369752338431299,True,1.09371466975938,0.117913895939682,-0.102377456500339,-564.625261646695
29180,1011:2169,Breast,HCC1428,SIDM00881,1290905,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.266661434775163,0.0438758973198862,0.921591943624623,13.7179261261406,263.1705,0.968199421446613,0.984454515275012,0.0752471241721918,0.245753029964173,0.150854627771118,0.094898402193055,9.50620901773857,14.2031,4.21171710840199,248.9674,0.258181446871437,0.160186157194453,0.262516053514122,0.237788050161116,0.0979952896769833,0.0247280033530068,True,1.09371466975938,0.117913895939682,-0.102377456500339,-564.625261646695
28370,1012:2172,Breast,HCC1428,SIDM00881,1290905,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.351145257206495,0.110221461221455,0.310336860886479,7.47110103367152,3.4654,0.729223168461444,0.77825272274756,0.0852211517001143,0.108973316836639,0.0149132797703584,0.0940600370662806,3.0349504152564,0.1601,4.43615061841511,3.3053,0.256063257050329,0.101136335122734,0.273279752500847,0.146479577168207,0.154926921927596,0.12680017533264,True,0.529839606693131,0.0464284488132228,0.610266617538589,80.0369465272855
28370,1011:2172,Breast,HCC1428,SIDM00881,1290905,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.580509832608419,0.110221461221455,0.310336860886479,7.47110103367152,3.4654,0.729223168461444,0.77825272274756,0.0584572482491218,0.180153599165432,0.0367811062768082,0.143372492888624,3.84307327908718,0.2803,3.62802775458434,3.1851,0.423321219457734,0.261008044213668,0.451783357809232,0.282392533794668,0.162313175244066,0.169390824014565,True,0.529839606693131,0.0464284488132228,0.610266617538589,80.0369465272855
23769,1022:1003,Breast,COLO-824,SIDM00954,906812,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.774957626005965,0.0519541565047034,0.880060487343712,16.2381175596378,15.097,0.957077286781025,0.956738438281706,0.0842034858978255,0.682009586013536,0.367641161917475,0.314368424096061,8.62780561298414,0.0773,7.61031194665363,15.0197,0.741694342068053,0.593430114434154,0.741431748839446,0.584277768391485,0.1482642276339,0.15715398044796,True,0.62116469445567,0.0716828660669558,0.459323519276856,106.226187185512
23769,1179:1003,Breast,COLO-824,SIDM00954,906812,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.389503370604188,0.0519541565047034,0.880060487343712,16.2381175596378,15.097,0.957077286781025,0.956738438281706,0.0553873811243765,0.34278652615594,0.221165621722655,0.121620904433286,9.9912518340287,0.1988,6.24686572560907,14.8982,0.37278482912992,0.259938543778742,0.372652846497311,0.316141496805481,0.112846285351178,0.0565113496918304,True,0.62116469445567,0.0716828660669558,0.459323519276856,106.226187185512
23769,1011:1003,Breast,COLO-824,SIDM00954,906812,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.154586092347423,0.0519541565047034,0.880060487343712,16.2381175596378,15.097,0.957077286781025,0.956738438281706,0.0730778022435953,0.136045111767833,0.10334547791867,0.0326996338491639,11.5478463466704,0.5848,4.69027121296741,14.5122,0.147950837837953,0.0605465784911794,0.147898456572545,0.133725074021159,0.0874042593467733,0.0141733825513861,True,0.62116469445567,0.0716828660669558,0.459323519276856,106.226187185512
24002,1011:1038,Breast,COLO-824,SIDM00954,906812,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.128492178804365,0.101127236617676,0.642887971896542,11.1351903294162,43.9295,0.860582674090317,0.852183820190114,0.0402002399405824,0.0826060762361062,0.0571426395616851,0.0254634366744211,8.19360196919002,5.7181,2.94158836022618,38.2114,0.110578142835152,0.055895811489991,0.109498955798055,0.094250160827422,0.0546823313451608,0.0152487949706331,True,0.565928555038378,0.0610135507893322,0.548003044388525,89.1023628595486
24003,1011:1042,Breast,COLO-824,SIDM00954,906812,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.154588698479263,0.0710959058628726,0.746202177925533,12.9167075172778,151.0242,0.909250621897217,0.901462028989748,0.0511113006497757,0.1153544234879,0.0896127009320546,0.0257417225558453,10.1675364373827,22.4628,2.74917107989503,128.5614,0.140559870230552,0.0742501736250377,0.139355841790001,0.126510775872298,0.0663096966055139,0.012845065917703,True,0.565928555038378,0.0610135507893322,0.548003044388525,89.1023628595486
24004,1011:1051,Breast,COLO-824,SIDM00954,906812,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.118110956081537,0.132813878126938,0.569808823119777,10.0207843614992,20.2902,0.737829071141921,0.812790147113907,0.0436620525559202,0.0673006648823724,0.0593587192502535,0.0079419456321189,9.03729748129136,10.2619,0.983486880207799,10.0283,0.0871456970173248,0.0466156452471685,0.0959994213692768,0.0912209132246808,0.0405300517701563,0.0047785081445959,True,0.565928555038378,0.0610135507893322,0.548003044388525,89.1023628595486
23773,1012:1085,Breast,COLO-824,SIDM00954,906812,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.771316082736451,0.0959892504412896,0.684929087986472,11.8201288674562,70.6225,0.911771983685902,0.8730494118571,0.116618721772238,0.528296821097975,0.37528745094734,0.153009370150636,8.804631986185,8.7335,3.01549688127117,61.889,0.703264394805452,0.625451436417437,0.67339705238898,0.587738951571789,0.0778129583880154,0.0856581008171908,True,0.62116469445567,0.0716828660669558,0.459323519276856,106.226187185512
23773,1011:1085,Breast,COLO-824,SIDM00954,906812,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.17702265278358,0.0959892504412896,0.684929087986472,11.8201288674562,70.6225,0.911771983685902,0.8730494118571,0.0347540345101908,0.121247964124003,0.0517885106864218,0.0694594534375815,5.79309106928985,1.083,6.02703779816631,69.5395,0.161404295285825,0.080037292979603,0.154549522898088,0.10721413061068,0.0813670023062222,0.0473353922874082,True,0.62116469445567,0.0716828660669558,0.459323519276856,106.226187185512
23774,1372:1096,Breast,COLO-824,SIDM00954,906812,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.942350728400443,0.142665676861343,0.691555882540549,11.9322984387556,38.1663,0.8084724207238,0.876231702316605,0.117072328686686,0.651688189641697,0.460383086173328,0.191305103468369,8.83359967367558,4.4553,3.09869876508004,33.711,0.761864574560742,0.665030568589544,0.825717582925613,0.719294042813139,0.0968340059711986,0.106423540112473,True,0.62116469445567,0.0716828660669558,0.459323519276856,106.226187185512
23774,1011:1096,Breast,COLO-824,SIDM00954,906812,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.218589896319167,0.142665676861343,0.691555882540549,11.9322984387556,38.1663,0.8084724207238,0.876231702316605,0.0980015095497688,0.151167128663449,0.0947131392851647,0.0564539893782843,8.02510937209786,2.5439,3.90718906665776,35.6224,0.176723902622922,0.0539167213024407,0.191535396960954,0.15854871982029,0.122807181320481,0.032986677140664,True,0.62116469445567,0.0716828660669558,0.459323519276856,106.226187185512
24006,1011:1560,Breast,COLO-824,SIDM00954,906812,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.16466952826961,0.106188831566647,0.607978878564591,10.5937068942997,30.1824,0.795153198315271,0.833897848271777,0.0543415076210134,0.100115595131118,0.0753513721249118,0.0247642230062058,8.38244517076328,6.5177,2.21126172353641,23.6647,0.130937502068647,0.0671016140624645,0.137317565299956,0.122269624248779,0.0638358880061829,0.0150479410511777,True,0.565928555038378,0.0610135507893322,0.548003044388525,89.1023628595486
24007,1011:1564,Breast,COLO-824,SIDM00954,906812,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.200011797311372,0.0871932194805664,0.676263791191845,11.6753544978617,31.9398,0.850619023988854,0.868845681007224,0.0816421215050176,0.135260736332883,0.0778652764355653,0.057395459897318,7.36483003596265,1.6097,4.31052446189908,30.3301,0.170133839815256,0.0546252866096266,0.173779386244478,0.138402856304446,0.115508553205629,0.0353765299400319,True,0.565928555038378,0.0610135507893322,0.548003044388525,89.1023628595486
24008,1011:1632,Breast,COLO-824,SIDM00954,906812,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.201782176861376,0.0974260018113913,0.877332948138366,16.1451795797957,566.2046,0.92565175664426,0.955692129975677,0.0625222698695959,0.177030152107568,0.0958730961651052,0.0811570559424628,8.63843754005925,3.1133,7.50674203973642,563.0913,0.186780026471235,0.0930466668226238,0.192841638395777,0.152231828652264,0.0937333596486114,0.0406098097435132,True,0.565928555038378,0.0610135507893322,0.548003044388525,89.1023628595486
24008,1179:1909,Breast,COLO-824,SIDM00954,906812,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.8365241696347,0.100492686673153,0.353333157737576,6.80488959590683,0.2184,0.652166813770467,0.662223597363319,0.0589018551434867,0.295571726380832,0.186643518955382,0.10892820742545,4.46905346944814,0.0433,2.33583612645869,0.1751,0.545553302352647,0.410768334197776,0.553966044896854,0.441663326601622,0.134784968154872,0.112302718295231,True,0.565928555038378,0.0610135507893322,0.548003044388525,89.1023628595486
24008,1510:1909,Breast,COLO-824,SIDM00954,906812,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.601272067670247,0.100492686673153,0.353333157737576,6.80488959590683,0.2184,0.652166813770467,0.662223597363319,0.0708074157014995,0.21244935832933,0.122413374844757,0.090035983484573,4.04626647561022,0.0323,2.75862312029661,0.1861,0.392129688581685,0.260979909054567,0.398176551646672,0.302296615244198,0.131149779527118,0.0958799364024736,True,0.565928555038378,0.0610135507893322,0.548003044388525,89.1023628595486
24008,1021:1909,Breast,COLO-824,SIDM00954,906812,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,4.0,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.639385190987864,0.100492686673153,0.353333157737576,6.80488959590683,0.2184,0.652166813770467,0.662223597363319,0.0516518281183317,0.225915988542385,0.0988337712577758,0.127082217284609,2.82908613064498,0.0139,3.97580346526186,0.2045,0.416985802778577,0.228723678834902,0.423415961276816,0.275250192221614,0.188262123943675,0.148165769055202,True,0.565928555038378,0.0610135507893322,0.548003044388525,89.1023628595486
24008,1190:1909,Breast,COLO-824,SIDM00954,906812,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.1,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1.0,0.100492686673153,0.353333157737576,6.80488959590683,0.2184,0.652166813770467,0.662223597363319,0.0878492546290454,0.353333157737576,0.149899305311832,0.203433852425744,2.69746870051928,0.0127,4.10742089538756,0.2057,0.652166813770467,0.388464627944569,0.662223597363319,0.422780699275754,0.263702185825897,0.239442898087564,True,0.565928555038378,0.0610135507893322,0.548003044388525,89.1023628595486
24008,1083:1909,Breast,COLO-824,SIDM00954,906812,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.653185125770195,0.100492686673153,0.353333157737576,6.80488959590683,0.2184,0.652166813770467,0.662223597363319,0.0743303524494679,0.230791963075599,0.107658472647809,0.123133490427789,3.10641734473563,0.0168,3.69847225117121,0.2016,0.425985662275809,0.248598472800186,0.43255460373175,0.291863829248435,0.177387189475623,0.140690774483316,True,0.565928555038378,0.0610135507893322,0.548003044388525,89.1023628595486
23772,1179:2169,Breast,COLO-824,SIDM00954,906812,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.412340065956925,0.0950957469157578,0.743383041401528,12.862842278938,145.4894,0.870117409311307,0.900202427965327,0.06532340654993,0.306526612322766,0.208697948143728,0.0978286641790378,9.08906485746173,10.6368,3.77377742147624,134.8526,0.358784269945693,0.2824199427494,0.371189528521807,0.319395813846104,0.0763643271962923,0.051793714675703,True,0.62116469445567,0.0716828660669558,0.459323519276856,106.226187185512
23772,1011:2169,Breast,COLO-824,SIDM00954,906812,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.169032360679055,0.0950957469157578,0.743383041401528,12.862842278938,145.4894,0.870117409311307,0.900202427965327,0.0660009715037335,0.125655790376876,0.0843557711959149,0.0413000191809608,8.98621402655667,9.9049,3.8766282523813,135.5845,0.147077999763833,0.0612133630175979,0.152163341487996,0.130169679611605,0.0858646367462355,0.0219936618763907,True,0.62116469445567,0.0716828660669558,0.459323519276856,106.226187185512
24005,1372:2172,Breast,COLO-824,SIDM00954,906812,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.939381906452109,0.114751885564767,0.50964868091366,9.1401843442245,11.0205,0.719528050544556,0.776811649788683,0.0772653891296911,0.478754749497476,0.405891728729445,0.0728630207680316,8.00724191217107,5.0252,1.13294243205343,5.9953,0.675911631866315,0.635614777560024,0.729722808532701,0.680534384496025,0.0402968543062904,0.0491884240366761,True,0.565928555038378,0.0610135507893322,0.548003044388525,89.1023628595486
24005,1510:2172,Breast,COLO-824,SIDM00954,906812,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.74179815876797,0.114751885564767,0.50964868091366,9.1401843442245,11.0205,0.719528050544556,0.776811649788683,0.0594078976990637,0.378056453120277,0.230479184946613,0.147577268173665,6.10609011388702,1.3454,3.03409423033748,9.6751,0.533744583075858,0.419692574963195,0.576237451522754,0.462501677811502,0.114052008112664,0.113735773711252,True,0.565928555038378,0.0610135507893322,0.548003044388525,89.1023628595486
25003,1049:1013,Breast,CAL-148,SIDM00938,924106,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1013,Nilotinib,ABL,ABL signaling,Targeted,FDA approved,10.0,0.99483026580583,0.113204002582084,0.7213806560262,11.3278742980883,50.2065,0.899565730020046,0.921666288193826,0.121772332816166,0.717651309781729,0.385409772985588,0.332241536796141,7.87878453271989,4.5971,3.44908976536844,45.6094,0.894915214305658,0.798996927016981,0.916901518468136,0.7703707049564,0.0959182872886769,0.146530813511736,True,0.532529058290825,0.0951136991230921,0.58840538390151,81.7022787053045
25003,1559:1013,Breast,CAL-148,SIDM00938,924106,1559,Luminespib,HSP90,Protein stability and degradation,Targeted,Early clinical trials,0.01,1013,Nilotinib,ABL,ABL signaling,Targeted,FDA approved,10.0,0.831100892566052,0.113204002582084,0.7213806560262,11.3278742980883,50.2065,0.899565730020046,0.921666288193826,0.0869906226398837,0.599540107103259,0.395305009543045,0.204235097560215,8.76137823871676,8.4755,2.56649605937157,41.731,0.747629881141492,0.710049662652716,0.765997674765929,0.683709225500759,0.037580218488776,0.0822884492651692,True,0.532529058290825,0.0951136991230921,0.58840538390151,81.7022787053045
25003,1561:1013,Breast,CAL-148,SIDM00938,924106,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1013,Nilotinib,ABL,ABL signaling,Targeted,FDA approved,10.0,0.566736366338332,0.113204002582084,0.7213806560262,11.3278742980883,50.2065,0.899565730020046,0.921666288193826,0.0386812235048584,0.408832651743051,0.285996518624013,0.122836133119038,9.04539466814852,10.3197,2.28247962993982,39.8868,0.50981661311405,0.486060257701115,0.522341803147507,0.47415883975524,0.0237563554129342,0.0481829633922666,True,0.532529058290825,0.0951136991230921,0.58840538390151,81.7022787053045
25003,1179:1013,Breast,CAL-148,SIDM00938,924106,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1013,Nilotinib,ABL,ABL signaling,Targeted,FDA approved,10.0,0.263414218994884,0.113204002582084,0.7213806560262,11.3278742980883,50.2065,0.899565730020046,0.921666288193826,0.0768811308070243,0.190021922105159,0.180200906603086,0.0098210155020729,10.8907057627588,37.0817,0.437168535329558,13.1248,0.236958404207793,0.212072751269062,0.242780005478491,0.239440658375905,0.0248856529387313,0.0033393471025856,True,0.532529058290825,0.0951136991230921,0.58840538390151,81.7022787053045
30178,1047:1038,Breast,CAL-148,SIDM00938,924106,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.426232184193511,0.134875275824861,0.520119033620014,9.19703090339164,11.4634,0.868112899063429,0.843803473007244,0.0689481172639029,0.221691471740477,0.0921248987765707,0.129566572963906,5.84749784378129,1.1246,3.34953305961035,10.3388,0.370017657094367,0.248835325755492,0.359656197329948,0.272630387318522,0.121182331338875,0.0870258100114264,True,0.416826554677282,0.055635466803918,0.851046772990502,57.9543124271105
25441,1047:1042,Breast,CAL-148,SIDM00938,924106,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.642934490828464,0.121393626577099,0.792373171744402,12.2772331603269,96.9495,0.885626181372593,0.944127435868645,0.0915849066274685,0.509444041721623,0.411345545408456,0.0980984963131666,10.4057229396567,26.4951,1.87151022067022,70.4544,0.569399617985145,0.530162558192907,0.607012092257391,0.574152085429615,0.0392370597922385,0.0328600068277756,True,0.392728619687363,0.0747674562514498,0.88826692499863,55.0399055266655
25441,1054:1042,Breast,CAL-148,SIDM00938,924106,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.90544692475043,0.121393626577099,0.792373171744402,12.2772331603269,96.9495,0.885626181372593,0.944127435868645,0.0638671687143236,0.717451851610713,0.772338826168838,-0.0548869745581244,13.3024538702311,197.3184,-1.02522070990413,-100.3689,0.80188750240228,0.860331760501,0.854857283379773,0.870857762478829,-0.0584442580987199,-0.0160004790990563,True,0.392728619687363,0.0747674562514498,0.88826692499863,55.0399055266655
25441,1179:1042,Breast,CAL-148,SIDM00938,924106,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.129231863978046,0.121393626577099,0.792373171744402,12.2772331603269,96.9495,0.885626181372593,0.944127435868645,0.0368013100780265,0.102399861950725,0.0670691111849864,0.0353307507657389,9.18589218626659,11.3752,3.09134097406034,85.5743,0.114451122206539,0.0777704607174138,0.122011348370118,0.108979337616286,0.036680661489125,0.0130320107538319,True,0.392728619687363,0.0747674562514498,0.88826692499863,55.0399055266655
25441,1012:1042,Breast,CAL-148,SIDM00938,924106,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.374571726442875,0.121393626577099,0.792373171744402,12.2772331603269,96.9495,0.885626181372593,0.944127435868645,0.0975501749084984,0.296800586927317,0.123877245580772,0.172923341346545,7.27500744316645,3.025,5.00222571716048,93.9245,0.331730527739743,0.207497182168512,0.353643443635403,0.276217106101488,0.12423334557123,0.0774263375339145,True,0.392728619687363,0.0747674562514498,0.88826692499863,55.0399055266655
30172,1053:1059,Breast,CAL-148,SIDM00938,924106,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.684493206459214,0.0757934473921403,0.231471196793849,6.06355337595322,0.1306,0.658375576696517,0.655210122712724,0.0781466753178133,0.158440461696373,0.0508241723078029,0.10761628938857,2.82585863743248,0.0138,3.23769473852074,0.1168,0.450653609547433,0.266420828189128,0.448486877800168,0.280800175613022,0.184232781358305,0.167686702187145,True,0.416826554677282,0.055635466803918,0.851046772990502,57.9543124271105
29162,1007:1096,Breast,CAL-148,SIDM00938,924106,1007,Docetaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.001,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.88218855976277,0.198386166315835,0.414774399477503,8.15759176250337,2.7886,0.685964130509473,0.790390731342839,0.173009701749223,0.365909230101526,0.0995772976882695,0.266331932413256,3.95503035263011,0.1515,4.20256140987325,2.6371,0.605149708343073,0.405761768402437,0.697273660933181,0.438037440341732,0.199387939940636,0.259236220591449,True,0.506210556802888,0.0758872663076725,0.653588914111242,74.7712202968833
29162,1011:1096,Breast,CAL-148,SIDM00938,924106,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.281871340001267,0.198386166315835,0.414774399477503,8.15759176250337,2.7886,0.685964130509473,0.790390731342839,0.081794376013192,0.116913015778945,0.0868081409657726,0.0301048748131719,7.01885788680247,1.2664,1.13873387570089,1.5222,0.193353628659509,0.139198578455669,0.222788494568187,0.203192700175412,0.05415505020384,0.0195957943927755,True,0.506210556802888,0.0758872663076725,0.653588914111242,74.7712202968833
29162,1011:1129,Breast,CAL-148,SIDM00938,924106,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.281871340001267,0.0779069631230616,0.574235201748533,9.73202276956406,16.6097,0.865992937954338,0.867289746106231,0.0466484806781943,0.161860445792757,0.0736384649702367,0.0882219808225201,6.45637661982046,1.7151,3.2756461497436,14.8946,0.244098589852823,0.155509703427802,0.244464122904322,0.192489484249026,0.0885888864250213,0.0519746386552953,True,0.506210556802888,0.0758872663076725,0.653588914111242,74.7712202968833
29162,1558:1129,Breast,CAL-148,SIDM00938,924106,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.994794952077488,0.0779069631230616,0.574235201748533,9.73202276956406,16.6097,0.865992937954338,0.867289746106231,0.104554327247811,0.571246280004639,0.346566561164334,0.224679718840305,7.46777095390448,3.4574,2.26425181565958,13.1523,0.861485403211729,0.765101688527219,0.862775461415045,0.745641438189812,0.0963837146845101,0.117134023225233,True,0.506210556802888,0.0758872663076725,0.653588914111242,74.7712202968833
30181,1561:1373,Breast,CAL-148,SIDM00938,924106,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10.0,0.403857576964974,0.0632288567401222,0.934914678566169,15.5206392344671,918.1381,0.965234762273841,0.983817680966896,0.0654985023086401,0.37757237675472,0.311298760702547,0.0662736160521732,11.9679790777821,78.2439,3.55266015668504,839.8942,0.389817372294276,0.363023770869514,0.39732222481059,0.378625148765077,0.0267936014247619,0.018697076045513,True,0.416826554677282,0.055635466803918,0.851046772990502,57.9543124271105
30667,1053:1560,Breast,CAL-148,SIDM00938,924106,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.78900785800848,0.0749572925297236,0.327659966652019,7.24113137009836,2.9548,0.760341817949629,0.73526078745793,0.0732583330128498,0.25852628844324,0.0548730702008311,0.203653218242409,2.65330838625799,0.1229,4.58782298384038,2.8319,0.599915669134711,0.310202581678016,0.580126538989809,0.313466534591967,0.289713087456695,0.266660004397843,True,0.474910258884972,0.0624969254260594,0.715510620813386,68.4171977900929
30668,1047:1564,Breast,CAL-148,SIDM00938,924106,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.354152299334857,0.0497128065074787,0.93141347613742,15.3832430448604,417.3665,0.969621459940451,0.982916080426342,0.0701735886062604,0.329862224205539,0.245426443377776,0.0844357808277635,10.9922623619698,19.893,4.39098068289065,397.4735,0.343393669522332,0.290319159062026,0.348101989936194,0.323013613749467,0.0530745104603061,0.0250883761867269,True,0.474910258884972,0.0624969254260594,0.715510620813386,68.4171977900929
30668,1012:1564,Breast,CAL-148,SIDM00938,924106,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.277263127431314,0.0497128065074787,0.93141347613742,15.3832430448604,417.3665,0.969621459940451,0.982916080426342,0.105780522396379,0.258246613325533,0.0730550760469428,0.18519153727859,6.48467321125923,0.8745,8.89856983360122,416.492,0.268840278407606,0.109799260336074,0.272526386461537,0.18988588467948,0.159041018071532,0.0826405017820565,True,0.474910258884972,0.0624969254260594,0.715510620813386,68.4171977900929
30668,1011:1564,Breast,CAL-148,SIDM00938,924106,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.327813322180072,0.0497128065074787,0.93141347613742,15.3832430448604,417.3665,0.969621459940451,0.982916080426342,0.0752626204546044,0.305329745935897,0.145641660593189,0.159688085342707,8.45236249598093,3.4207,6.93088054887952,413.9458,0.317854832040171,0.208588097088121,0.322212985748774,0.264402452739332,0.10926673495205,0.0578105330094419,True,0.474910258884972,0.0624969254260594,0.715510620813386,68.4171977900929
30665,1047:2169,Breast,CAL-148,SIDM00938,924106,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.457446649728034,0.105117684136206,0.299431598321144,6.92004145165694,2.3652,0.743332528595408,0.714356146819754,0.0595976989014488,0.136973981474718,0.0914148212312272,0.0455591602434905,5.60525591939333,0.9508,1.31478553226361,1.4144,0.340034974839838,0.292628295832913,0.326779826075324,0.28448547127933,0.0474066790069246,0.0422943547959939,True,0.474910258884972,0.0624969254260594,0.715510620813386,68.4171977900929
23753,1011:1003,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.407010449058274,0.0798452510625699,0.552232563966474,9.6504522053314,0.157,0.860037844372493,0.825666472925276,0.0545977688874651,0.224764423844597,0.111352056678121,0.113412367166476,5.97097780088507,0.0123,3.67947440444633,0.1447,0.350044389245159,0.21718958303603,0.336054881917678,0.256055462060586,0.132854806209129,0.0799994198570916,True,0.736730507296901,0.0706013932544102,0.288990505344406,165.690121335531
23753,1011:1013,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1013,Nilotinib,ABL,ABL signaling,Targeted,FDA approved,10.0,0.407010449058274,0.110632761923569,0.76636826980744,12.6847898678446,128.5974,0.946132800513818,0.921202126898849,0.0579481830668074,0.311919893638339,0.161892401302006,0.150027492336333,7.71331025258835,4.0989,4.97147961525629,124.4985,0.385085936005892,0.254005547435426,0.374938891342538,0.298007291094076,0.131080388570465,0.0769316002484615,True,0.736730507296901,0.0706013932544102,0.288990505344406,165.690121335531
24308,1011:1032,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.295931781289953,0.0763222254830528,0.706161646176403,11.7197837838716,65.8774,0.863009823706813,0.897176952809321,0.0740066132654221,0.208975673831629,0.139242962851875,0.0697327109797535,8.63384813426269,7.7585,3.08593564960895,58.1189,0.255392034400286,0.165903323266957,0.265503173777155,0.230748820748718,0.0894887111333292,0.0347543530284364,True,0.835536134961899,0.0932482516360093,0.163052550286689,282.012793113546
24309,1011:1042,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.348106724597721,0.0809494601213323,0.858538978700826,14.5933566786154,482.801,0.940239575670921,0.95471657328842,0.123043657959683,0.298863191815017,0.180034393807343,0.118828798007674,9.21326589953702,11.5931,5.38009077907839,471.2079,0.327303719023955,0.186002368759304,0.332343259246592,0.280849062206824,0.141301350264651,0.0514941970397676,True,0.835536134961899,0.0932482516360093,0.163052550286689,282.012793113546
24309,1011:1046,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1046,Wee1 Inhibitor,"WEE1, CHEK1",Cell cycle,Targeted,Experimental only,10.0,0.348106724597721,0.0932180642152398,0.49854993489699,8.98200816623141,9.8761,0.842131583597639,0.796268150676507,0.069668998907061,0.173548584885398,0.0828875157353064,0.0906610691500919,5.39227515959553,0.8203,3.58973300663588,9.0558,0.293151667246466,0.153108986068638,0.277186297833484,0.20609827489427,0.140042681177828,0.0710880229392132,True,0.835536134961899,0.0932482516360093,0.163052550286689,282.012793113546
24310,1191:1050,Breast,HCC38,SIDM00675,749717,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.000625,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.92569759525208,0.0609012460063724,0.728330097988092,12.0589827532316,83.3385,0.902982664247901,0.906241042730268,0.0502370098756205,0.674213420257289,0.688990918390485,-0.0147774981331962,12.3140815193634,99.4576,-0.255098766131887,-16.1191,0.835888880848598,0.838051208258286,0.838905153974147,0.844798950985462,-0.0021623274096879,-0.005893797011315,True,0.835536134961899,0.0932482516360093,0.163052550286689,282.012793113546
24310,1011:1050,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.298540555291034,0.0609012460063724,0.728330097988092,12.0589827532316,83.3385,0.902982664247901,0.906241042730268,0.0759095422086109,0.217436071888538,0.0902968637045855,0.127139208183953,6.40803934436883,1.6586,5.65094340886273,81.6799,0.269576946002746,0.119322431230983,0.27054970412422,0.195936837739682,0.150254514771763,0.0746128663845376,True,0.835536134961899,0.0932482516360093,0.163052550286689,282.012793113546
24310,1011:1051,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.298540555291034,0.0802521925062826,0.785138277904344,13.0196342854202,162.1924,0.884822982152515,0.928327033783249,0.0911353149423648,0.234395617465809,0.112468057456746,0.121927560009062,7.43829918761115,3.3875,5.58133509780903,158.8049,0.26415554442608,0.126715516560543,0.277143268157329,0.214042710082704,0.137440027865537,0.0631005580746258,True,0.835536134961899,0.0932482516360093,0.163052550286689,282.012793113546
23755,1011:1052,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1052,RO-3306,CDK1,Cell cycle,Targeted,Experimental only,10.0,0.395741822361924,0.0678252690901843,0.791442095099262,13.1368076787598,175.9151,0.958746814057039,0.930683652521357,0.0760500210448162,0.313206737008521,0.146147030936923,0.167059706071598,7.33978783612565,3.1639,5.79701984263419,172.7512,0.379416211378621,0.262015103155996,0.368310444691254,0.281532625342974,0.117401108222626,0.0867778193482802,True,0.736730507296901,0.0706013932544102,0.288990505344406,165.690121335531
23755,1011:1059,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.395741822361924,0.0483780092249765,0.667671510341312,11.1641046565449,4.4819,0.878101082243384,0.880781396900497,0.0533932937011439,0.264225540241609,0.138325587847809,0.125899952393801,7.07346390935199,0.2631,4.09064074719292,4.2188,0.347501322504975,0.250646883383046,0.348562035111884,0.2754792253013,0.0968544391219286,0.073082809810584,True,0.736730507296901,0.0706013932544102,0.288990505344406,165.690121335531
23757,1011:1085,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.463170168384529,0.0596497443915987,0.891103659809969,15.5203772669614,917.9714,0.981752015511787,0.965741971907444,0.07442296872491,0.412732632162253,0.236535590929821,0.176197041232432,9.13263616373888,10.963,6.38774110322255,907.0084,0.454718246336445,0.356624667823247,0.447302871744378,0.372001372238078,0.0980935785131979,0.0753014995063005,True,0.736730507296901,0.0706013932544102,0.288990505344406,165.690121335531
23757,1191:1086,Breast,HCC38,SIDM00675,749717,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.000625,1086,BI-2536,"PLK1, PLK2, PLK3",Cell cycle,Targeted,Early clinical trials,10.0,0.952417544647413,0.144121253774198,0.466858727747362,8.58819358459081,7.5168,0.696017756913971,0.777507964553784,0.109111794691902,0.444644443178357,0.363732689913948,0.0809117532644095,7.50652643828129,3.5516,1.08166714630952,3.9652,0.662899523071004,0.623624092254312,0.740512226544123,0.686484634189108,0.0392754308166922,0.0540275923550148,True,0.736730507296901,0.0706013932544102,0.288990505344406,165.690121335531
23757,1011:1086,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1086,BI-2536,"PLK1, PLK2, PLK3",Cell cycle,Targeted,Early clinical trials,10.0,0.463170168384529,0.144121253774198,0.466858727747362,8.58819358459081,7.5168,0.696017756913971,0.777507964553784,0.148595037308459,0.216235035542533,0.0624818799309906,0.153753155611542,3.23573114858356,0.184,5.35246243600725,7.3328,0.322374661668466,0.143898503928972,0.360118494862689,0.20802775375133,0.178476157739494,0.152090741111359,True,0.736730507296901,0.0706013932544102,0.288990505344406,165.690121335531
23758,1011:1096,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.491714502384009,0.0785340274392974,0.840201042810825,14.1482873051648,177.3205,0.938351076956946,0.948330974307928,0.128444548193573,0.41313903766825,0.16467224292616,0.24846679474209,6.87169146227451,1.1436,7.27659584289027,176.1769,0.461400832867383,0.233739552794092,0.466308093127165,0.336465494144248,0.227661280073291,0.129842598982918,True,0.736730507296901,0.0706013932544102,0.288990505344406,165.690121335531
23759,1011:1192,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.4498949048784,0.0860335555767862,0.797411618985631,13.2501966427028,190.2991,0.890069299789595,0.932898914012007,0.058721588180743,0.358751424472471,0.188235387663324,0.170516036809148,7.97838907771307,4.9257,5.27180756498976,185.3734,0.400437642964024,0.280749846017238,0.419706468180594,0.335814911671418,0.119687796946786,0.0838915565091764,True,0.736730507296901,0.0706013932544102,0.288990505344406,165.690121335531
24312,1011:1553,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.239777185595395,0.069451516281356,0.767117934433524,12.6977918528253,129.7616,0.907999954783926,0.921489851923651,0.0855718106498387,0.183937379338223,0.11922100931749,0.0647163700207327,8.96545470362978,9.7634,3.73233714919547,119.9982,0.217717673678836,0.103349268475483,0.22095224324897,0.190742956191764,0.114368405203352,0.0302092870572061,True,0.835536134961899,0.0932482516360093,0.163052550286689,282.012793113546
24312,1191:1553,Breast,HCC38,SIDM00675,749717,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.0025,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.479873290897451,0.069451516281356,0.767117934433524,12.6977918528253,129.7616,0.907999954783926,0.921489851923651,0.0906947200143584,0.36811940770307,0.258213953117505,0.109905454585565,9.47349402646082,13.8847,3.22429782636444,115.8769,0.435724926436899,0.335971898372482,0.442198367771208,0.392625905016272,0.0997530280644179,0.0495724627549352,True,0.835536134961899,0.0932482516360093,0.163052550286689,282.012793113546
24313,1191:1593,Breast,HCC38,SIDM00675,749717,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.000625,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.961027193106501,0.0692104547180282,0.802212955293859,13.3432174856456,40.5946,0.92435938168602,0.93466925795938,0.0392788402132744,0.770948464699728,0.770827813405326,0.0001206512944025,13.3407637277991,40.5257,0.0024537578465739,0.0688999999999993,0.888334502003376,0.910051954682441,0.898242573459638,0.898198210441104,-0.0217174526790646,4.43630185342769e-05,True,0.835536134961899,0.0932482516360093,0.163052550286689,282.012793113546
24313,1011:1593,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.342100555909593,0.0692104547180282,0.802212955293859,13.3432174856456,40.5946,0.92435938168602,0.93466925795938,0.073100833372295,0.274437497963906,0.176210238944224,0.0982272590196828,9.18720228212172,2.2771,4.15601520352392,38.3175,0.316223858335035,0.218712721275709,0.31975087273951,0.275603983836004,0.0975111370593261,0.0441468889035066,True,0.835536134961899,0.0932482516360093,0.163052550286689,282.012793113546
23756,1011:2169,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.430251450309792,0.0661336601115262,0.798720713277555,13.2753937620208,193.6519,0.915489962835865,0.933382604689106,0.0413664863922079,0.343650745280139,0.217959074344245,0.125691670935894,9.08171270423559,10.5827,4.19368105778518,183.0692,0.393890884254188,0.312725443381391,0.401589219361419,0.34456681393362,0.0811654408727973,0.0570224054277986,True,0.736730507296901,0.0706013932544102,0.288990505344406,165.690121335531
24311,1191:2172,Breast,HCC38,SIDM00675,749717,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.0025,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.664278266444321,0.103966172621982,0.525465147419471,9.31623419808369,12.4508,0.776354526606421,0.811355897406366,0.0690031342827618,0.349055077204716,0.0966609051985112,0.252394172006204,3.50891075908809,0.2223,5.80732343899561,12.2285,0.515715439080315,0.271119182978361,0.538966088998477,0.310393872723268,0.244596256101954,0.228572216275209,True,0.835536134961899,0.0932482516360093,0.163052550286689,282.012793113546
25068,1011:1003,Breast,MRK-nu-1,SIDM00562,908151,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.914750686446493,0.10416822498347,0.54136660662427,9.34070305982504,0.1266,0.822265665477023,0.87526780591132,0.0498568421595408,0.495215475028759,0.18687716547651,0.308338309552249,6.2067637612489,0.0144,3.13393929857614,0.1122,0.752168081936489,0.603117484818742,0.800651826281896,0.621841186939704,0.149050597117747,0.178810639342191,True,0.467811078910659,0.0676782117312176,0.737813918168036,66.7104404815887
25068,1049:1013,Breast,MRK-nu-1,SIDM00562,908151,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1013,Nilotinib,ABL,ABL signaling,Targeted,FDA approved,10.0,0.824880359062618,0.111320857656754,0.729031706914571,11.033211901723,40.9315,0.945262268088293,0.935661435077829,0.159979966010548,0.601363936167725,0.319830578764538,0.281533357403186,8.06144277920773,5.2175,2.97176912251527,35.714,0.779728279109016,0.681882490779185,0.771808740528044,0.666373046418186,0.0978457883298315,0.105435694109859,True,0.467811078910659,0.0676782117312176,0.737813918168036,66.7104404815887
25069,1012:1030,Breast,MRK-nu-1,SIDM00562,908151,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1030,KU-55933,ATM,Genome integrity,Targeted,Experimental only,10.0,0.861696424885913,0.197991976433969,0.593777831729,9.7798377277611,17.1694,0.817478646507104,0.893995567257894,0.0444877295927004,0.511656234777388,0.46951538952926,0.0421408452481279,9.36973500562409,12.9212,0.41010272213701,4.2482,0.704418427115747,0.717130475814056,0.770352784169981,0.755342021767327,-0.0127120486983091,0.0150107624026538,True,0.467811078910659,0.0676782117312176,0.737813918168036,66.7104404815887
25496,1047:1038,Breast,MRK-nu-1,SIDM00562,908151,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.704481858832282,0.123051342161273,0.286581199753291,7.12634601229304,2.7288,0.739448320919187,0.747158206800768,0.0320827214614434,0.201891256308584,0.0851206602984668,0.116770596010117,4.92291824338854,0.5925,2.20342776890449,2.1363,0.520927927631559,0.398790467041751,0.5263594023688,0.406502339806073,0.122137460589807,0.119857062562726,True,0.320451994521816,0.0452146751194436,1.09103231884115,45.1099532283496
25496,1021:1038,Breast,MRK-nu-1,SIDM00562,908151,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.787473764015529,0.123051342161273,0.286581199753291,7.12634601229304,2.7288,0.739448320919187,0.747158206800768,0.0746711764964982,0.22567517606581,0.18022271067164,0.0454524653941706,6.50449274000695,1.7733,0.621853272286086,0.9555,0.582296152569195,0.56446730362895,0.588367485424494,0.553054781962525,0.0178288489402444,0.0353127034619688,True,0.320451994521816,0.0452146751194436,1.09103231884115,45.1099532283496
25496,1594:1038,Breast,MRK-nu-1,SIDM00562,908151,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.26665006173926,0.123051342161273,0.286581199753291,7.12634601229304,2.7288,0.739448320919187,0.747158206800768,0.0341128158176896,0.0764168946075262,0.0172351286103177,0.0591817659972085,3.51045803360652,0.2226,3.61588797868651,2.5062,0.197173940426093,0.0880430899573365,0.199229781972419,0.122391683519936,0.109130850468757,0.0768380984524833,True,0.320451994521816,0.0452146751194436,1.09103231884115,45.1099532283496
25497,1022:1046,Breast,MRK-nu-1,SIDM00562,908151,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1046,Wee1 Inhibitor,"WEE1, CHEK1",Cell cycle,Targeted,Experimental only,10.0,0.933729723919139,0.0983208572703684,0.452754308064114,8.61060345417766,7.6345,0.867475937667658,0.83911378546332,0.0670941718361268,0.422750155071906,0.347256617544284,0.0754935375276223,7.92339690941801,4.7414,0.687206544759649,2.8931,0.809988067784919,0.754270131553569,0.78350548323741,0.746471759917842,0.05571793623135,0.0370337233195678,True,0.320451994521816,0.0452146751194436,1.09103231884115,45.1099532283496
25498,1011:1050,Breast,MRK-nu-1,SIDM00562,908151,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.954254952507654,0.12742948910122,0.352255544853968,7.74862066568078,4.2005,0.734703796917381,0.788535403450693,0.107838816882482,0.336141598225181,0.119099711270968,0.217041886954212,4.99885130288067,0.6245,2.74976936280011,3.576,0.701094736834588,0.559776499158912,0.752463813970444,0.556605933218282,0.141318237675676,0.195857880752162,True,0.320451994521816,0.0452146751194436,1.09103231884115,45.1099532283496
25073,1594:1096,Breast,MRK-nu-1,SIDM00562,908151,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.833681870067712,0.18011428802034,0.677075933976539,10.5209639061711,14.3491,0.789283359037132,0.92063867763658,0.181511089747212,0.564465930815404,0.259494908042477,0.304971022772927,7.36840627692902,1.6137,3.15255762924203,12.7354,0.658011226775401,0.534566411849754,0.767519774428729,0.636684062813596,0.123444814925647,0.130835711615134,True,0.467811078910659,0.0676782117312176,0.737813918168036,66.7104404815887
25073,1049:1096,Breast,MRK-nu-1,SIDM00562,908151,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.861577939926596,0.18011428802034,0.677075933976539,10.5209639061711,14.3491,0.789283359037132,0.92063867763658,0.130720830814511,0.583353688369382,0.345773212188245,0.237580476181138,8.17837669191572,2.829,2.34258721425534,11.5201,0.680029130497556,0.611636344218087,0.79320197529487,0.702001478772411,0.0683927862794693,0.091200496522459,True,0.467811078910659,0.0676782117312176,0.737813918168036,66.7104404815887
25500,1073:1560,Breast,MRK-nu-1,SIDM00562,908151,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,10.0,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.626388556926997,0.0673814432828828,0.896916832895422,13.4444145672121,217.7219,0.957716849317771,0.977831898673976,0.0857075017775866,0.561818440640896,0.339702436254867,0.222116004386028,9.34858468687182,12.7331,4.09582988034031,204.9888,0.599902875188829,0.491616897052882,0.612502711927578,0.548480738554677,0.108285978135947,0.0640219733729005,True,0.320451994521816,0.0452146751194436,1.09103231884115,45.1099532283496
25500,1047:1560,Breast,MRK-nu-1,SIDM00562,908151,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.771954478739241,0.0673814432828828,0.896916832895422,13.4444145672121,217.7219,0.957716849317771,0.977831898673976,0.0571077433399186,0.692378966210236,0.581693633521534,0.110685332688703,11.2958233037374,49.1034,2.14859126347471,168.6185,0.739313811194889,0.711322260445876,0.754841713635472,0.72747605199911,0.0279915507490122,0.0273656616363624,True,0.320451994521816,0.0452146751194436,1.09103231884115,45.1099532283496
25500,1021:1560,Breast,MRK-nu-1,SIDM00562,908151,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.831225365004297,0.0673814432828828,0.896916832895422,13.4444145672121,217.7219,0.957716849317771,0.977831898673976,0.0117413147743976,0.745540021801995,0.65252588171658,0.0930141400854151,11.6606686692389,63.2326,1.78374589797318,154.4893,0.79607853764493,0.795232539266685,0.812798676888121,0.790251683636905,0.0008459983782455,0.0225469932512159,True,0.320451994521816,0.0452146751194436,1.09103231884115,45.1099532283496
25501,1510:1564,Breast,MRK-nu-1,SIDM00562,908151,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.990717095832567,0.0895730410607589,0.832277139658594,12.2907495960848,48.931,0.914817538104433,0.962602561203812,0.0717142140149137,0.824551190730398,0.624768718253883,0.199782472476515,10.0988443562193,10.7092,2.19190523986553,38.2218,0.906325374567522,0.83179253827274,0.953666813876832,0.89779626723415,0.0745328362947824,0.0558705466426819,True,0.320451994521816,0.0452146751194436,1.09103231884115,45.1099532283496
25501,1011:1593,Breast,MRK-nu-1,SIDM00562,908151,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.931085626679195,0.0811587180969542,0.607180802143666,9.89461812260902,3.7182,0.863948657838742,0.898522701549497,0.0399068169316303,0.565337317671511,0.284633713614758,0.280703604056753,7.31483382461575,0.6219,2.57978429799326,3.0963,0.804410177502434,0.700405495080082,0.836601572657697,0.70770664531288,0.104004682422352,0.128894927344817,True,0.320451994521816,0.0452146751194436,1.09103231884115,45.1099532283496
25501,1594:1593,Breast,MRK-nu-1,SIDM00562,908151,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.290338997213492,0.0811587180969542,0.607180802143666,9.89461812260902,3.7182,0.863948657838742,0.898522701549497,0.0431711443431166,0.176288265221676,0.0680439451330674,0.108244320088608,6.567965928677,0.3706,3.32665219393202,3.3476,0.250837986960843,0.166931500003102,0.260876180141439,0.205279689740605,0.0839064869577404,0.0555964904008334,True,0.320451994521816,0.0452146751194436,1.09103231884115,45.1099532283496
25502,1594:1909,Breast,MRK-nu-1,SIDM00562,908151,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.367798484916436,0.060269048410773,0.920321481277445,14.0264008390461,32.591,0.953307711941635,0.98307909645064,0.0380166558089478,0.338492846449894,0.20458401712114,0.133908829328754,9.46410342188319,1.3795,4.56229741716288,31.2115,0.350625132111287,0.294595159103835,0.361575002227564,0.323941443590339,0.0560299730074517,0.037633558637225,True,0.320451994521816,0.0452146751194436,1.09103231884115,45.1099532283496
25071,1021:2169,Breast,MRK-nu-1,SIDM00562,908151,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.84917104799255,0.0868135699596218,0.7824948129935,11.6300986977245,61.9068,0.938429356782616,0.950052312873689,0.0623105430312031,0.664471940398425,0.627243641835733,0.0372282985626918,11.1344278114618,43.9063,0.495670886262674,18.0005,0.796887040366068,0.792105807088688,0.806756918170697,0.796800146316822,0.00478123327738,0.0099567718538742,True,0.467811078910659,0.0676782117312176,0.737813918168036,66.7104404815887
25071,1047:2169,Breast,MRK-nu-1,SIDM00562,908151,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.679885588048146,0.0868135699596218,0.7824948129935,11.6300986977245,61.9068,0.938429356782616,0.950052312873689,0.0307857646625306,0.53200694607671,0.496306987562788,0.0356999585139215,11.0431473780673,41.2144,0.586951319657183,20.6924,0.638024595077792,0.648663637078729,0.645926875414629,0.636323520519251,-0.0106390420009373,0.009603354895378,True,0.467811078910659,0.0676782117312176,0.737813918168036,66.7104404815887
25071,1012:2169,Breast,MRK-nu-1,SIDM00562,908151,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.896496706806776,0.0868135699596218,0.7824948129935,11.6300986977245,61.9068,0.938429356782616,0.950052312873689,0.0403255299474602,0.701504022942057,0.443299709409197,0.25820431353286,8.95463849446604,9.6905,2.67546020325848,52.2163,0.841298827926415,0.791278006891195,0.851718769785423,0.768236984318688,0.0500208210352208,0.083481785466735,True,0.467811078910659,0.0676782117312176,0.737813918168036,66.7104404815887
25499,1049:2172,Breast,MRK-nu-1,SIDM00562,908151,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.886143862093008,0.114001837239727,0.616921815192234,9.97889954114168,19.7096,0.837235000207777,0.901751438567635,0.0718255308789728,0.546681479923876,0.65062738903515,-0.103945909111274,11.0875303766361,42.502,-1.10863083549445,-22.7924,0.74191065656356,0.79015815493878,0.799081502420251,0.830408855547582,-0.0482474983752197,-0.0313273531273314,True,0.320451994521816,0.0452146751194436,1.09103231884115,45.1099532283496
25499,1007:2172,Breast,MRK-nu-1,SIDM00562,908151,1007,Docetaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.001,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.814956886567501,0.114001837239727,0.616921815192234,9.97889954114168,19.7096,0.837235000207777,0.901751438567635,0.0989503981328844,0.502764681764635,0.25712965931829,0.245635022446345,7.40897777271472,3.3194,2.56992176842696,16.3902,0.682310429094671,0.560179181613739,0.734888544832845,0.624599197194956,0.122131247480932,0.110289347637889,True,0.320451994521816,0.0452146751194436,1.09103231884115,45.1099532283496
25499,1083:2172,Breast,MRK-nu-1,SIDM00562,908151,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.805011529581823,0.114001837239727,0.616921815192234,9.97889954114168,19.7096,0.837235000207777,0.901751438567635,0.0552066115276968,0.496629174080295,0.278507868914229,0.218121305166066,7.69177173101563,4.0382,2.28712781012605,15.6714,0.6739838281367,0.606257734140621,0.725920304863941,0.631866037894061,0.0677260939960797,0.0940542669698801,True,0.320451994521816,0.0452146751194436,1.09103231884115,45.1099532283496
25499,1179:2172,Breast,MRK-nu-1,SIDM00562,908151,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.39860516638204,0.114001837239727,0.616921815192234,9.97889954114168,19.7096,0.837235000207777,0.901751438567635,0.0285774567984308,0.245908222789411,0.14164960459818,0.104258618191231,7.77654457639263,4.2826,2.20235496474905,15.427,0.333726196558688,0.285260527257217,0.359442782205496,0.315018118872459,0.0484656693014709,0.0444246633330376,True,0.320451994521816,0.0452146751194436,1.09103231884115,45.1099532283496
25499,1012:2172,Breast,MRK-nu-1,SIDM00562,908151,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.901834624583698,0.114001837239727,0.616921815192234,9.97889954114168,19.7096,0.837235000207777,0.901751438567635,0.108917841465214,0.556361453601382,0.246890595768043,0.309470857833339,6.99577675985745,2.4927,2.98312278128423,17.2169,0.755047512100713,0.598741462534657,0.813230670068453,0.665564936913274,0.156306049566056,0.14766573315518,True,0.320451994521816,0.0452146751194436,1.09103231884115,45.1099532283496
25499,1594:2172,Breast,MRK-nu-1,SIDM00562,908151,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.791610921759333,0.114001837239727,0.616921815192234,9.97889954114168,19.7096,0.837235000207777,0.901751438567635,0.0326652522451532,0.488362046777765,0.222800357440988,0.265561689336777,7.07452604918894,2.6325,2.90437349195274,17.0771,0.662764370243654,0.58324388179701,0.71383628748233,0.588599546621249,0.0795204884466432,0.125236740861081,True,0.320451994521816,0.0452146751194436,1.09103231884115,45.1099532283496
29204,1053:1003,Breast,MCF7,SIDM00148,905946,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.910169043527204,0.0739441288440031,0.609669419477163,10.2315439471418,0.2348,0.858104939666896,0.868027780086637,0.0790318997574429,0.554902232393315,0.294903675319183,0.259998557074132,6.96896832110969,0.0245,3.26257562603211,0.2103,0.781020552182588,0.638856903152535,0.790052014356497,0.640536721457442,0.142163649030053,0.149515292899055,True,0.315129368312542,0.0607799338606985,1.10129995646435,44.6207699056795
29204,1049:1013,Breast,MCF7,SIDM00148,905946,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1013,Nilotinib,ABL,ABL signaling,Targeted,FDA approved,10.0,0.979922067457235,0.135216813849994,0.523505959361381,9.25986537161124,11.9737,0.855161278935771,0.827901507690351,0.197032565935981,0.512995042023588,0.31294622785329,0.200048814170297,6.91009377737944,2.349,2.34977159423179,9.6247,0.837991408464115,0.739090924522374,0.811278957066891,0.686020591915049,0.0989004839417406,0.125258365151842,True,0.315129368312542,0.0607799338606985,1.10129995646435,44.6207699056795
28334,1047:1025,Breast,MCF7,SIDM00148,905946,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.824182795928906,0.0743482756706858,0.791774644365921,12.688797069251,128.9551,0.957497800679013,0.937455024909103,0.054321481749756,0.65256704013912,0.439903489568896,0.212663550570224,9.37335414629455,12.9536,3.31544292295649,116.0015,0.789153214459407,0.680811493309096,0.772634303487187,0.686533181621296,0.108341721150311,0.0861011218658911,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
28334,1007:1025,Breast,MCF7,SIDM00148,905946,1007,Docetaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.001,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.758432701334911,0.0743482756706858,0.791774644365921,12.688797069251,128.9551,0.957497800679013,0.937455024909103,0.132375001320898,0.600507782374934,0.423371925441614,0.17713585693332,9.64609000671188,15.6492,3.04270706253915,113.3059,0.72619764349122,0.529018250095018,0.710996546921797,0.640704890280785,0.197179393396202,0.0702916566410117,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
28334,1053:1025,Breast,MCF7,SIDM00148,905946,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.763612971535716,0.0743482756706858,0.791774644365921,12.688797069251,128.9551,0.957497800679013,0.937455024909103,0.0695771077952042,0.604609388970896,0.496242216280798,0.108367172690098,10.7079660246507,32.67,1.98083104460035,96.2851,0.731157740815413,0.626728197352734,0.715852817251928,0.675737430616269,0.104429543462679,0.0401153866356591,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
28334,1073:1030,Breast,MCF7,SIDM00148,905946,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in breast,10.0,1030,KU-55933,ATM,Genome integrity,Targeted,Experimental only,10.0,0.642441039316295,0.041970143800195,0.878862531372301,14.4730402144876,444.1701,0.976737455101915,0.965354731712416,0.0306826774840428,0.564617358070971,0.552876117045,0.0117412410259708,14.0269224529487,326.0277,0.446117761538957,118.1424,0.627496225794827,0.635199485480364,0.620183497150227,0.616569231592604,-0.0077032596855368,0.0036142655576227,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
28334,1561:1030,Breast,MCF7,SIDM00148,905946,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1030,KU-55933,ATM,Genome integrity,Targeted,Experimental only,10.0,0.668535683984527,0.041970143800195,0.878862531372301,14.4730402144876,444.1701,0.976737455101915,0.965354731712416,0.105797158043032,0.587550963539355,0.355610542805682,0.231940420733672,9.35315565755101,12.7735,5.11988455693663,431.3966,0.652983842619865,0.475522295588498,0.64537408585306,0.556281354478303,0.177461547031367,0.0890927313747569,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
28334,1022:1030,Breast,MCF7,SIDM00148,905946,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1030,KU-55933,ATM,Genome integrity,Targeted,Experimental only,10.0,0.951562642419341,0.041970143800195,0.878862531372301,14.4730402144876,444.1701,0.976737455101915,0.965354731712416,0.0380753387089636,0.836292752675978,0.827477360356028,0.0088153923199498,14.24024966057,377.9831,0.232790553917628,66.187,0.929426873726721,0.932308863994484,0.91859549938028,0.915895517236576,-0.0028819902677639,0.0026999821437041,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
29212,1510:1032,Breast,MCF7,SIDM00148,905946,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.824569698353262,0.121817457753569,0.701592311571629,11.3610292143226,51.3737,0.910517294986086,0.9052471640299,0.10416002603554,0.578511760719586,0.392875916871031,0.185635843848555,8.73977705588433,8.3496,2.62125215843828,43.0241,0.750784971272105,0.587950552887208,0.746439380979281,0.662338639315366,0.162834418384897,0.084100741663915,True,0.315129368312542,0.0607799338606985,1.10129995646435,44.6207699056795
29212,1053:1032,Breast,MCF7,SIDM00148,905946,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.913929144537864,0.121817457753569,0.701592311571629,11.3610292143226,51.3737,0.910517294986086,0.9052471640299,0.0847298342507952,0.641205661129001,0.431426104508043,0.209779556620958,8.69098094884243,8.0719,2.67004826548018,43.3018,0.832148292493563,0.738160699246024,0.827331766217174,0.73190082199644,0.0939875932475389,0.0954309442207338,True,0.315129368312542,0.0607799338606985,1.10129995646435,44.6207699056795
29213,1017:1042,Breast,MCF7,SIDM00148,905946,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,2.5,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.966766252781838,0.0827396154882723,0.778781272568477,12.4759252093628,111.2648,0.914841588725094,0.933039812644713,0.0712416801237168,0.752899452617698,0.692140752886777,0.0607586997309211,11.5529434055813,58.683,0.922981803781489,52.5818,0.884437974620742,0.834020580018098,0.902031403366797,0.88036347795291,0.0504173946026443,0.0216679254138866,True,0.315129368312542,0.0607799338606985,1.10129995646435,44.6207699056795
29213,1021:1042,Breast,MCF7,SIDM00148,905946,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,4.0,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.818589412369067,0.0827396154882723,0.778781272568477,12.4759252093628,111.2648,0.914841588725094,0.933039812644713,0.0573207530564334,0.637502104275864,0.442593645538917,0.194908458736946,9.4503761691997,13.664,3.02554904016311,97.6008,0.748879638525258,0.654218272763126,0.763776511949779,0.684649738672367,0.0946613657621321,0.0791267732774127,True,0.315129368312542,0.0607799338606985,1.10129995646435,44.6207699056795
29213,1053:1042,Breast,MCF7,SIDM00148,905946,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.914066417385372,0.0827396154882723,0.778781272568477,12.4759252093628,111.2648,0.914841588725094,0.933039812644713,0.0679266767785399,0.711857807743489,0.501057276199127,0.210800531544362,9.53371725313331,14.4765,2.9422079562295,96.7883,0.836225973481088,0.75289576509867,0.852860358822071,0.767808254436657,0.0833302083824183,0.0850521043854142,True,0.315129368312542,0.0607799338606985,1.10129995646435,44.6207699056795
29214,1058:1050,Breast,MCF7,SIDM00148,905946,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.944840232049887,0.085495506073784,0.770291103544719,12.3416398401727,101.3757,0.922101625273148,0.930116206627368,0.0983548789966695,0.727802025019156,0.695400562490065,0.0324014625290909,11.8315799982712,71.1853,0.510059841901487,30.1904,0.871238713596659,0.805351981241098,0.878811212503163,0.867346224487031,0.0658867323555611,0.0114649880161316,True,0.315129368312542,0.0607799338606985,1.10129995646435,44.6207699056795
29214,1549:1050,Breast,MCF7,SIDM00148,905946,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.987144547255066,0.085495506073784,0.770291103544719,12.3416398401727,101.3757,0.922101625273148,0.930116206627368,0.0648223365597307,0.760388662663257,0.600034021872303,0.160354640790954,10.2104252705377,23.1406,2.13121456963496,78.2351,0.910247591403422,0.835531102860037,0.918159141685772,0.856088510231049,0.0747164885433848,0.0620706314547235,True,0.315129368312542,0.0607799338606985,1.10129995646435,44.6207699056795
29214,1558:1050,Breast,MCF7,SIDM00148,905946,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.998225366934004,0.085495506073784,0.770291103544719,12.3416398401727,101.3757,0.922101625273148,0.930116206627368,0.110175548021968,0.768924119481926,0.487507805036234,0.281416314445693,8.87154812476305,9.1481,3.47009171540964,92.2276,0.920465233238729,0.822770564737429,0.928465591651868,0.808269196016215,0.0976946685013005,0.120196395635653,True,0.315129368312542,0.0607799338606985,1.10129995646435,44.6207699056795
29214,1561:1050,Breast,MCF7,SIDM00148,905946,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.932435588185803,0.085495506073784,0.770291103544719,12.3416398401727,101.3757,0.922101625273148,0.930116206627368,0.092791614954528,0.718246838208011,0.525368569942697,0.192878268265314,9.7045932318767,16.2969,2.63704660829599,85.0788,0.859800371328652,0.733879178808608,0.867273452207737,0.789981888230003,0.125921192520044,0.0772915639777338,True,0.315129368312542,0.0607799338606985,1.10129995646435,44.6207699056795
29214,1510:1050,Breast,MCF7,SIDM00148,905946,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.816958929605378,0.085495506073784,0.770291103544719,12.3416398401727,101.3757,0.922101625273148,0.930116206627368,0.105327543845797,0.629296195436439,0.206778798166566,0.422517397269873,6.01145756708437,1.26,6.33018227308832,100.1157,0.75331915677053,0.477607564018454,0.759866740574909,0.524109936122778,0.275711592752076,0.235756804452131,True,0.315129368312542,0.0607799338606985,1.10129995646435,44.6207699056795
29214,1083:1050,Breast,MCF7,SIDM00148,905946,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.855942086833869,0.085495506073784,0.770291103544719,12.3416398401727,101.3757,0.922101625273148,0.930116206627368,0.0774153188505538,0.659324574637631,0.456741126045522,0.202583448592109,9.37187963625728,12.9404,2.96976020391541,88.4353,0.789265589409201,0.733633439586279,0.796125606898631,0.712932273182796,0.0556321498229218,0.0831933337158354,True,0.315129368312542,0.0607799338606985,1.10129995646435,44.6207699056795
29214,1594:1050,Breast,MCF7,SIDM00148,905946,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.990990225918248,0.085495506073784,0.770291103544719,12.3416398401727,101.3757,0.922101625273148,0.930116206627368,0.0642701654970925,0.763350954724598,0.676372399526241,0.0869785551983567,11.1138307980031,43.2839,1.22780904216959,58.0918,0.91379369794902,0.893538522931085,0.921736069735879,0.88983696130538,0.0202551750179352,0.0318991084304988,True,0.315129368312542,0.0607799338606985,1.10129995646435,44.6207699056795
29214,1053:1050,Breast,MCF7,SIDM00148,905946,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.877430216585349,0.085495506073784,0.770291103544719,12.3416398401727,101.3757,0.922101625273148,0.930116206627368,0.127728129545639,0.675876689817011,0.264903712549881,0.41097297726713,6.68499885739391,2.0096,5.65664098277879,99.3661,0.809079828777121,0.535811786072524,0.816112064630595,0.601759962687794,0.273268042704596,0.214352101942801,True,0.315129368312542,0.0607799338606985,1.10129995646435,44.6207699056795
29214,1012:1051,Breast,MCF7,SIDM00148,905946,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.947944096730787,0.0716021704055906,0.79466107903826,12.7373988411699,133.3734,0.928100928456706,0.938426341179264,0.103411213300204,0.753294278776036,0.507675136347511,0.245619142428526,9.39343294944464,13.1352,3.34396589172528,120.2382,0.879787796300897,0.717212128438044,0.889575710337555,0.790467085751662,0.162575667862852,0.0991086245858931,True,0.315129368312542,0.0607799338606985,1.10129995646435,44.6207699056795
29214,1372:1051,Breast,MCF7,SIDM00148,905946,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.955538120321512,0.0716021704055906,0.79466107903826,12.7373988411699,133.3734,0.928100928456706,0.938426341179264,0.0840779806830192,0.759328953756884,0.48616464294605,0.273164310810834,9.09707283534992,10.696,3.64032600582,122.6774,0.886835816646171,0.729092251615635,0.896702142110628,0.783945641090982,0.157743565030536,0.112756501019646,True,0.315129368312542,0.0607799338606985,1.10129995646435,44.6207699056795
29214,1375:1051,Breast,MCF7,SIDM00148,905946,1375,Temozolomide,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved,30.0,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.99719254785029,0.0716021704055906,0.79466107903826,12.7373988411699,133.3734,0.928100928456706,0.938426341179264,0.140350620024388,0.792430106083624,0.548511982906214,0.24391812317741,9.55483729109729,14.69,3.18256155007263,118.6834,0.925495329509962,0.740722281166934,0.935791754130376,0.838537844371123,0.184773048343029,0.0972539097592526,True,0.315129368312542,0.0607799338606985,1.10129995646435,44.6207699056795
29214,1021:1051,Breast,MCF7,SIDM00148,905946,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.881265080389016,0.0716021704055906,0.79466107903826,12.7373988411699,133.3734,0.928100928456706,0.938426341179264,0.0710946340639349,0.700307059700675,0.486346965076507,0.213960094624168,9.57512515880039,14.8981,3.16227368236953,118.4753,0.817902939325519,0.69408319950707,0.827002364998514,0.741819264459634,0.123819739818449,0.0851831005388807,True,0.315129368312542,0.0607799338606985,1.10129995646435,44.6207699056795
29214,1011:1051,Breast,MCF7,SIDM00148,905946,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.947424983474051,0.0716021704055906,0.79466107903826,12.7373988411699,133.3734,0.928100928456706,0.938426341179264,0.114615204181008,0.752881759675296,0.330351669760273,0.422530089915022,7.27435237523046,3.0236,5.46304646593946,130.3498,0.879306006805346,0.606355762833587,0.889088560783379,0.684506951831038,0.272950243971759,0.204581608952341,True,0.315129368312542,0.0607799338606985,1.10129995646435,44.6207699056795
29214,1561:1051,Breast,MCF7,SIDM00148,905946,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.932435588185803,0.0716021704055906,0.79466107903826,12.7373988411699,133.3734,0.928100928456706,0.938426341179264,0.0990619061627171,0.740970270641405,0.528962112263119,0.212008158378286,9.74790865471114,16.7936,2.98949018645878,116.5798,0.865394335121318,0.7236618402815,0.875022117406538,0.791655915609682,0.141732494839819,0.0833662017968558,True,0.315129368312542,0.0607799338606985,1.10129995646435,44.6207699056795
28335,1054:1052,Breast,MCF7,SIDM00148,905946,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,1.0,1052,RO-3306,CDK1,Cell cycle,Targeted,Experimental only,10.0,0.953338809384337,0.0953646165818928,0.649374806462114,10.7020678981821,32.5367,0.89189440821015,0.88472309387032,0.102457483623329,0.619074204836776,0.360791853523121,0.258282351313655,7.62979761143521,3.8684,3.07227028674692,28.6683,0.850277553219612,0.709858920781614,0.843440860945157,0.708830682485191,0.140418632437998,0.134610178459967,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
28335,1558:1052,Breast,MCF7,SIDM00148,905946,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1052,RO-3306,CDK1,Cell cycle,Targeted,Experimental only,10.0,0.985197645079899,0.0953646165818928,0.649374806462114,10.7020678981821,32.5367,0.89189440821015,0.88472309387032,0.0560604112710226,0.63976253010069,0.366877598341932,0.272884931758758,7.5584081394599,3.6816,3.14365975872223,28.8551,0.878692270628569,0.709160167946775,0.871627108628841,0.728425432100513,0.169532102681794,0.143201676528328,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
28335,1047:1052,Breast,MCF7,SIDM00148,905946,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1052,RO-3306,CDK1,Cell cycle,Targeted,Experimental only,10.0,0.685558606290477,0.0953646165818928,0.649374806462114,10.7020678981821,32.5367,0.89189440821015,0.88472309387032,0.0628572842116784,0.445184487278315,0.379865584263304,0.0653189030150112,9.59995973709941,15.1567,1.10210816108272,17.38,0.61144588745082,0.618084843883458,0.606529531186735,0.577805163545811,-0.006638956432638,0.0287243676409239,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
28335,1510:1052,Breast,MCF7,SIDM00148,905946,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1052,RO-3306,CDK1,Cell cycle,Targeted,Experimental only,10.0,0.753355172086539,0.0953646165818928,0.649374806462114,10.7020678981821,32.5367,0.89189440821015,0.88472309387032,0.0852826629720616,0.489209869070929,0.270878146421389,0.218331722649539,7.40571914416083,3.3119,3.2963487540213,29.2248,0.671913265380179,0.507547460017737,0.66651071863161,0.550224550016101,0.164365805362442,0.116286168615509,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
28335,1053:1052,Breast,MCF7,SIDM00148,905946,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1052,RO-3306,CDK1,Cell cycle,Targeted,Experimental only,10.0,0.76911049078289,0.0953646165818928,0.649374806462114,10.7020678981821,32.5367,0.89189440821015,0.88472309387032,0.100403729157152,0.49944097610012,0.199601276454662,0.299839699645458,6.10439554892113,1.3438,4.597672349261,31.1929,0.685965346025023,0.441875427475595,0.680449812933558,0.498214195905321,0.244089918549428,0.182235617028238,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
28338,1058:1096,Breast,MCF7,SIDM00148,905946,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.852874745137688,0.0981430458388702,0.754351160746687,12.0986006389356,42.8294,0.889934379698219,0.924542229213482,0.0915005475466975,0.643367053966149,0.457653925773776,0.185713128192374,9.40506752678606,6.6208,2.69353311214958,36.2086,0.759002557274385,0.649297642995921,0.788518718109478,0.711628993017814,0.109704914278464,0.0768897250916648,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
28338,1054:1096,Breast,MCF7,SIDM00148,905946,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,1.0,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.966126732036028,0.0981430458388702,0.754351160746687,12.0986006389356,42.8294,0.889934379698219,0.924542229213482,0.111413541822863,0.728798821739781,0.501365138428062,0.227433683311719,9.20937130243176,5.7809,2.88922933650388,37.0485,0.85978939398435,0.731829372528146,0.893224962539325,0.797639176026382,0.127960021456204,0.0955857865129431,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
28338,1558:1096,Breast,MCF7,SIDM00148,905946,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.942034137867742,0.0981430458388702,0.754351160746687,12.0986006389356,42.8294,0.889934379698219,0.924542229213482,0.0606359463093301,0.710624545363535,0.567460766642454,0.143163778721081,10.1472018966617,11.0742,1.95139874227392,31.7552,0.838348566137876,0.772780947109337,0.870950341819443,0.814717430513587,0.0655676190285387,0.0562329113058559,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
28338,1561:1096,Breast,MCF7,SIDM00148,905946,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.754315594640164,0.0981430458388702,0.754351160746687,12.0986006389356,42.8294,0.889934379698219,0.924542229213482,0.111034844542746,0.569018844386135,0.382795952179705,0.18622289220643,9.08257839622098,5.2945,3.01602224271466,37.5349,0.671291380812788,0.535007326791474,0.697396621399111,0.618347839580426,0.136284054021314,0.0790487818186851,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
28338,1011:1096,Breast,MCF7,SIDM00148,905946,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.937869792917525,0.0981430458388702,0.754351160746687,12.0986006389356,42.8294,0.889934379698219,0.924542229213482,0.0771381066337831,0.70748316691659,0.383175691908767,0.324307475007823,7.9783509543581,2.4628,4.12024968457753,40.3666,0.834642572397755,0.676433544864916,0.867100229055956,0.71586132041881,0.158209027532839,0.151238908637145,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
28338,1510:1096,Breast,MCF7,SIDM00148,905946,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.731899214791462,0.0981430458388702,0.754351160746687,12.0986006389356,42.8294,0.889934379698219,0.924542229213482,0.118532097029937,0.552109022227528,0.323880997621251,0.228228024606277,8.36220487379387,3.2135,3.73639576514176,39.6159,0.651342273717054,0.48120477576014,0.676671731602896,0.573807291555177,0.170137497956914,0.102864440047719,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
28338,1053:1096,Breast,MCF7,SIDM00148,905946,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.773612506556943,0.0981430458388702,0.754351160746687,12.0986006389356,42.8294,0.889934379698219,0.924542229213482,0.165313456692484,0.583575492289384,0.237365495051316,0.346209997238067,6.74916078029976,1.0505,5.34943985863588,41.7789,0.688464366149538,0.427795087459958,0.715237431359586,0.533726406718509,0.26066927868958,0.181511024641077,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
28338,1011:1129,Breast,MCF7,SIDM00148,905946,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.995221778314322,0.0612291970727675,0.792704550160268,12.7044001515571,130.3574,0.926386484209224,0.937768321347239,0.0755655552381933,0.788916832088356,0.574500197754278,0.214416634334078,9.86037717858759,18.1551,2.84402297296955,112.2023,0.921960004221056,0.824091002368582,0.933287456418036,0.849530643858299,0.0978690018524747,0.0837568125597369,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
28338,1053:1129,Breast,MCF7,SIDM00148,905946,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.891145318759122,0.0612291970727675,0.792704550160268,12.7044001515571,130.3574,0.926386484209224,0.937768321347239,0.0329749445972512,0.706414949034378,0.483884762899722,0.222530186134656,9.47611445745858,13.9099,3.22828569409856,116.4475,0.825544978764771,0.737731043778348,0.835687849649192,0.746333983622984,0.0878139349864226,0.0893538660262079,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
28338,1021:1129,Breast,MCF7,SIDM00148,905946,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,4.0,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.791134184366344,0.0612291970727675,0.792704550160268,12.7044001515571,130.3574,0.926386484209224,0.937768321347239,0.105802634717772,0.627135667734533,0.405713868454747,0.221421799279786,9.141717469907,11.0322,3.56268268165014,119.3252,0.73289601559287,0.600709253435272,0.741900576033644,0.650704409661554,0.132186762157598,0.0911961663720903,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
28339,1558:1192,Breast,MCF7,SIDM00148,905946,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.972242069066553,0.076379374585718,0.578425487206261,9.87358967149196,18.3222,0.873772370480352,0.854141819082696,0.11658049479767,0.562369592482244,0.307027519591904,0.25534207289034,6.86466295397203,2.2761,3.00892671751993,16.0461,0.849518257369003,0.639427118738182,0.83043260946123,0.677869930546852,0.210091138630821,0.152562678914377,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
28344,1047:1553,Breast,MCF7,SIDM00148,905946,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.763433835465249,0.0971932640446121,0.360839947087168,7.42103002737784,3.3472,0.734553631914192,0.73127551312428,0.0571458476058527,0.275477424793835,0.128624685110622,0.146852739683212,4.59101233807531,0.4707,2.83001768930252,2.8765,0.560783096567181,0.392579955300085,0.558280469766288,0.414090493952601,0.168203141267096,0.144189975813687,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
28344,1047:1560,Breast,MCF7,SIDM00148,905946,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.763433835465249,0.0766489956398326,0.450501426130637,8.45138499420947,6.8368,0.808248932404122,0.788647385688406,0.0582848807701474,0.343928031633477,0.136892805402479,0.207035226230998,4.79927751316123,0.5438,3.65210748104825,6.293,0.617044582475972,0.402277220547221,0.602080098485742,0.425431664310912,0.214767361928751,0.17664843417483,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
28345,1021:1564,Breast,MCF7,SIDM00148,905946,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.875194210605137,0.0551438904142998,0.895912446481613,14.9450511535411,308.0411,0.963699995282971,0.970501791890064,0.0616442172214864,0.784097386369792,0.729004730027109,0.0550926563426838,13.4375748388728,108.3461,1.50747631466823,199.695,0.843424656631853,0.796651704515816,0.849377549644096,0.83231155339122,0.0467729521160369,0.017065996252876,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
28345,1053:1593,Breast,MCF7,SIDM00148,905946,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.866512210908563,0.0847016975345742,0.76368893328274,12.2396080329423,18.8907,0.940303297390206,0.927821151009894,0.0994884755084751,0.661745786025229,0.572387434568602,0.0893583514566275,10.8388309648086,7.1544,1.40077706813374,11.7363,0.8147842891462,0.768684823401953,0.803968356889311,0.770547303211574,0.0460994657442469,0.0334210536777373,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
28346,1058:1632,Breast,MCF7,SIDM00148,905946,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.819071106723066,0.116798087564922,0.736032326021154,11.8320672949439,28.4838,0.873572905992545,0.917994293301499,0.126783718914682,0.602862811858099,0.376091222163242,0.226771589694857,8.54791580333714,2.9239,3.28415149160674,25.5599,0.715518326914599,0.567022529283193,0.751902601779917,0.65002295350198,0.148495797631406,0.101879648277937,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
28346,1012:1632,Breast,MCF7,SIDM00148,905946,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.822977648035081,0.116798087564922,0.736032326021154,11.8320672949439,28.4838,0.873572905992545,0.917994293301499,0.186967554181454,0.605738152546679,0.358823650135075,0.246914502411604,8.28915648988788,2.4439,3.542910805056,26.0399,0.718930975560916,0.530896401108449,0.755488784410894,0.642040159857768,0.188034574452467,0.113448624553126,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
28346,1011:1632,Breast,MCF7,SIDM00148,905946,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.926050216024247,0.116798087564922,0.736032326021154,11.8320672949439,28.4838,0.873572905992545,0.917994293301499,0.150999925102031,0.681602894512719,0.439841308249035,0.241761586263684,8.72320159654516,3.3017,3.10886569839873,25.1821,0.808972378307326,0.65131207091341,0.850108813620879,0.743092446369358,0.157660307393915,0.107016367251521,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
28346,1053:1632,Breast,MCF7,SIDM00148,905946,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.740361231561774,0.116798087564922,0.736032326021154,11.8320672949439,28.4838,0.873572905992545,0.917994293301499,0.105135015892812,0.544929799362298,0.186940742779527,0.357989056582772,6.0025596140055,0.5009,5.82950768093838,27.9829,0.646759512539638,0.414262899431769,0.679647385555378,0.474525681301521,0.232496613107869,0.205121704253857,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
28346,1054:1909,Breast,MCF7,SIDM00148,905946,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.839053302333125,0.084789087286831,0.881376185349345,14.5388391831043,46.4897,0.94014765438328,0.966119613253681,0.17479453809482,0.73952159891514,0.264378813091826,0.475142785823314,6.85569110484942,0.2262,7.68314807825491,46.2635,0.788833994091032,0.486091471394704,0.810625851949303,0.584533596576023,0.302742522696328,0.226092255373279,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
28346,1058:1909,Breast,MCF7,SIDM00148,905946,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.819071106723066,0.084789087286831,0.881376185349345,14.5388391831043,46.4897,0.94014765438328,0.966119613253681,0.0813413433702043,0.721909767573442,0.58937157141645,0.132538196156992,11.6023897923139,6.0729,2.93644939079041,40.4168,0.770047779758807,0.679365360011541,0.791320660854553,0.746969227041299,0.0906824197472667,0.0443514338132532,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
28346,1558:1909,Breast,MCF7,SIDM00148,905946,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.8133223256329,0.084789087286831,0.881376185349345,14.5388391831043,46.4897,0.94014765438328,0.966119613253681,0.114180695969523,0.716842928825783,0.400004674689318,0.316838254136464,8.90957855659506,0.9392,5.62926062650926,45.5505,0.764643076701325,0.608650029988251,0.785766650691041,0.660045472409141,0.155993046713074,0.125721178281901,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
28346,1053:1909,Breast,MCF7,SIDM00148,905946,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.855421628874283,0.084789087286831,0.881376185349345,14.5388391831043,46.4897,0.94014765438328,0.966119613253681,0.0740829787224894,0.753948252122538,0.578158850175497,0.175789401947042,11.0295901726241,4.0829,3.50924901048019,42.4068,0.804222637894881,0.732953890963365,0.826439613256856,0.765884500707941,0.0712687469315164,0.060555112548915,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
28336,1054:2169,Breast,MCF7,SIDM00148,905946,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,1.0,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.899350697623081,0.100542325897339,0.538509319796986,9.42626234040903,13.4375,0.867172532546611,0.835321081128846,0.0807912544577774,0.484308732435951,0.261794316438438,0.222514415997513,6.54177874610086,1.8197,2.88448359430817,11.6178,0.779892222105369,0.597347984034273,0.751246597052494,0.608500975726362,0.182544238071095,0.142745621326132,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
23745,1022:1003,Breast,HCC1569,SIDM00878,907046,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.304815766042515,0.0448580158767267,0.921047248935044,15.3313272998315,8.0523,0.981731837386693,0.979259766444194,0.0562248600417882,0.280749722745487,0.188287562767454,0.0924621599780325,10.2366396889364,0.2356,5.09468761089514,7.8167,0.299247342061351,0.223449439209051,0.298493815863302,0.267969241823708,0.0757979028522998,0.0305245740395937,True,0.651986154406439,0.0772730352432496,0.407258196959781,118.640417855539
24316,1049:1032,Breast,HCC1569,SIDM00878,907046,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.834374458426088,0.139760203552006,0.450724923123093,8.49037745695939,7.0241,0.73553879997657,0.801027318877183,0.146506363892007,0.376073363629971,0.125253557507731,0.25081980612224,4.53193156722213,0.4518,3.95844588973726,6.5723,0.613714787881825,0.401414940606132,0.668356735372651,0.450366000080151,0.212299847275693,0.217990735292499,True,0.769620794974068,0.10024655109279,0.246634271457924,193.158839126199
24316,1011:1032,Breast,HCC1569,SIDM00878,907046,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.163703599136669,0.139760203552006,0.450724923123093,8.49037745695939,7.0241,0.73553879997657,0.801027318877183,0.0588577536760813,0.0737852921358486,0.045046239477062,0.0287390526587866,6.50384429629333,1.7725,1.98653316066606,5.2516,0.120410348860831,0.058432201174075,0.131131055106991,0.11149759249688,0.0619781476867556,0.0196334626101109,True,0.769620794974068,0.10024655109279,0.246634271457924,193.158839126199
24317,1191:1042,Breast,HCC1569,SIDM00878,907046,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.0025,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.577762355706932,0.0802899601877595,0.803863337928067,12.6354543927635,124.2742,0.926057539729396,0.945027942791654,0.0567076486062125,0.464441975787758,0.264412475289044,0.200029500498714,8.56236410982659,7.3834,4.07309028293695,116.8908,0.535041185674222,0.476103704369567,0.546001570436182,0.464972833174341,0.0589374813046548,0.0810287372618415,True,0.769620794974068,0.10024655109279,0.246634271457924,193.158839126199
24317,1372:1042,Breast,HCC1569,SIDM00878,907046,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.947892462289355,0.0802899601877595,0.803863337928067,12.6354543927635,124.2742,0.926057539729396,0.945027942791654,0.0726792555034867,0.761975998732775,0.689753799552363,0.072222199180412,11.5329771074425,57.8765,1.10247728532103,66.3977,0.877802961555719,0.86071274852536,0.895784863625025,0.872111063789353,0.0170902130303593,0.0236737998356717,True,0.769620794974068,0.10024655109279,0.246634271457924,193.158839126199
24317,1011:1042,Breast,HCC1569,SIDM00878,907046,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.147297654516326,0.0802899601877595,0.803863337928067,12.6354543927635,124.2742,0.926057539729396,0.945027942791654,0.0472690180927376,0.118407184228469,0.0687784607306696,0.0496287234977998,8.65864247263173,7.893,3.97681192013181,116.3812,0.1364061035493,0.0784789741394218,0.1392003994256,0.119271819809425,0.0579271294098779,0.0199285796161747,True,0.769620794974068,0.10024655109279,0.246634271457924,193.158839126199
23747,1191:1052,Breast,HCC1569,SIDM00878,907046,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.0025,1052,RO-3306,CDK1,Cell cycle,Targeted,Experimental only,10.0,0.746839445461072,0.0758310008784319,0.74356123084113,11.7435951947957,66.9737,0.924489944632178,0.925464951377062,0.0990816499921512,0.555320857307742,0.277136413125163,0.278184444182578,7.64028899384157,3.8966,4.10330620095408,63.0771,0.690445557583433,0.571389343958238,0.691173731080103,0.562650526254419,0.119056213625194,0.128523204825683,True,0.651986154406439,0.0772730352432496,0.407258196959781,118.640417855539
23747,1011:1052,Breast,HCC1569,SIDM00878,907046,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1052,RO-3306,CDK1,Cell cycle,Targeted,Experimental only,10.0,0.166862420559413,0.0758310008784319,0.74356123084113,11.7435951947957,66.9737,0.924489944632178,0.925464951377062,0.0366516336191584,0.124072426812287,0.0846826842194688,0.0393897425928185,9.0773223845833,10.5506,2.66627281021236,56.4231,0.154262629944163,0.112564939239551,0.154425321929676,0.138547806791814,0.0416976907046115,0.0158775151378623,True,0.651986154406439,0.0772730352432496,0.407258196959781,118.640417855539
23750,1558:1096,Breast,HCC1569,SIDM00878,907046,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.805369717385001,0.0985476844823735,0.624072178611078,10.3063063017211,12.3654,0.822540048293046,0.881673071183442,0.0528673986745531,0.502608834115846,0.414731665279025,0.087877168836821,9.15424661646242,5.5642,1.1520596852587,6.8012,0.662448846231615,0.669760525287926,0.710072792164975,0.671615955416815,-0.0073116790563102,0.0384568367481596,True,0.651986154406439,0.0772730352432496,0.407258196959781,118.640417855539
23750,1011:1096,Breast,HCC1569,SIDM00878,907046,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.218051038452907,0.0985476844823735,0.624072178611078,10.3063063017211,12.3654,0.822540048293046,0.881673071183442,0.0716509246448562,0.136079586615714,0.0938097614852584,0.0422698251304553,8.27591667539275,3.0269,2.03038962632837,9.3385,0.179355711699403,0.0993748771954917,0.192249728747514,0.172167777938392,0.0799808345039114,0.0200819508091217,True,0.651986154406439,0.0772730352432496,0.407258196959781,118.640417855539
23750,1011:1129,Breast,HCC1569,SIDM00878,907046,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.218051038452907,0.0725602532828324,0.812604019450179,12.7808150951185,137.4481,0.959590330036905,0.947744247612733,0.0763564718332443,0.177189150292118,0.0965052801901135,0.0806838701020045,8.40545604620363,6.6225,4.3753590489149,130.8256,0.209239667953915,0.100309916998487,0.206656617379726,0.173686377773781,0.108929750955428,0.0329702396059445,True,0.651986154406439,0.0772730352432496,0.407258196959781,118.640417855539
23751,1372:1192,Breast,HCC1569,SIDM00878,907046,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.958823736949957,0.0626031000963483,0.589701853132735,9.93483822006569,19.1168,0.841949919345631,0.86756385670135,0.0555495656315054,0.565420134507044,0.531146685168159,0.034273449338885,9.55840322608173,14.7264,0.376434993983967,4.3904,0.807281567991693,0.812809684397187,0.831840819125105,0.816938677615978,-0.0055281164054944,0.0149021415091266,True,0.651986154406439,0.0772730352432496,0.407258196959781,118.640417855539
23751,1049:1192,Breast,HCC1569,SIDM00878,907046,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.721573800007407,0.0626031000963483,0.589701853132735,9.93483822006569,19.1168,0.841949919345631,0.86756385670135,0.0538127114701969,0.425513407036398,0.208811313771859,0.216702093264538,6.68468384507679,2.0092,3.2501543749889,17.1076,0.607529002718157,0.490420198194333,0.626011348829074,0.50017464514083,0.117108804523824,0.125836703688245,True,0.651986154406439,0.0772730352432496,0.407258196959781,118.640417855539
24320,1083:1560,Breast,HCC1569,SIDM00878,907046,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.84628587039552,0.0549774825989829,0.529481664914374,9.30427443035751,12.348,0.858388418934675,0.840812332857722,0.0978220860882127,0.44809285165053,0.241134865267247,0.206957986383283,6.62865553421621,1.9327,2.6756188961413,10.4153,0.726441990255566,0.590431400443329,0.711567596951785,0.583472707407586,0.136010589812237,0.1280948895442,True,0.769620794974068,0.10024655109279,0.246634271457924,193.158839126199
24320,1011:1560,Breast,HCC1569,SIDM00878,907046,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.146633439834351,0.0549774825989829,0.529481664914374,9.30427443035751,12.348,0.858388418934675,0.840812332857722,0.0352714057596092,0.0776397178556141,0.0377869460315898,0.0398527718240242,6.27337912423189,1.5108,3.03089530612562,10.8372,0.125868446582362,0.0672936546739701,0.123291204622073,0.0975738990766902,0.0585747919083915,0.0257173055453831,True,0.769620794974068,0.10024655109279,0.246634271457924,193.158839126199
24320,1053:1560,Breast,HCC1569,SIDM00878,907046,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.949292709437247,0.0549774825989829,0.529481664914374,9.30427443035751,12.348,0.858388418934675,0.840812332857722,0.090172838536069,0.502633084283911,0.270841866673298,0.231791217610612,6.63340982303451,1.939,2.670864607323,10.409,0.814861867960053,0.632544454178774,0.79817701758676,0.654791309516797,0.182317413781279,0.143385708069963,True,0.769620794974068,0.10024655109279,0.246634271457924,193.158839126199
24321,1011:1593,Breast,HCC1569,SIDM00878,907046,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.242848369990767,0.0664153028374324,0.821112643398044,12.9274169168097,30.4299,0.937092730338881,0.950361219362066,0.0348504901705118,0.199405867028025,0.133884897301841,0.0655209697261842,9.53082162794855,2.8895,3.39659528886113,27.5404,0.227571442092995,0.18629093832384,0.230793673024515,0.206623452148667,0.0412805037691548,0.0241702208758485,True,0.769620794974068,0.10024655109279,0.246634271457924,193.158839126199
24321,1191:1593,Breast,HCC1569,SIDM00878,907046,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.000625,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.929678233209176,0.0664153028374324,0.821112643398044,12.9274169168097,30.4299,0.937092730338881,0.950361219362066,0.028759777514664,0.763370551580009,0.800895220319429,-0.0375246687394192,13.7101077017519,52.3496,-0.782690784942233,-21.9197,0.871194713894613,0.915621192872289,0.883530139327043,0.894746410313251,-0.0444264789776755,-0.0112162709862075,True,0.769620794974068,0.10024655109279,0.246634271457924,193.158839126199
24322,1179:1909,Breast,HCC1569,SIDM00878,907046,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.416961378923253,0.0731427324419453,0.896014237268051,14.5505379296758,46.8682,0.941353217923404,0.972319336430007,0.106420593201509,0.373603331906154,0.243141159662881,0.130462172243272,9.86496404953327,1.8213,4.68557388014249,45.0469,0.392507935799184,0.268266700865491,0.405419611271598,0.360577472140341,0.124241234933693,0.0448421391312571,True,0.769620794974068,0.10024655109279,0.246634271457924,193.158839126199
23748,1510:2169,Breast,HCC1569,SIDM00878,907046,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.82958439088036,0.0790902289099556,0.753561566935814,11.8805411166134,73.6426,0.903522487347066,0.928813681857749,0.0645411260292303,0.625142913497297,0.404487645704186,0.220655267793111,8.87192416178888,9.1505,3.00861695482453,64.4921,0.749548152312524,0.631947922379398,0.770529332505306,0.680599993738759,0.117600229933125,0.0899293387665473,True,0.651986154406439,0.0772730352432496,0.407258196959781,118.640417855539
23748,1179:2169,Breast,HCC1569,SIDM00878,907046,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.434527635290907,0.0790902289099556,0.753561566935814,11.8805411166134,73.6426,0.903522487347066,0.928813681857749,0.084386775172721,0.32744332572673,0.174773815526757,0.152669510199973,7.9788029361374,4.9271,3.90173818047601,68.7155,0.392605489859079,0.264094969656155,0.403595212803489,0.335918601941126,0.128510520202924,0.0676766108623632,True,0.651986154406439,0.0772730352432496,0.407258196959781,118.640417855539
23748,1011:2169,Breast,HCC1569,SIDM00878,907046,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.219553665424202,0.0790902289099556,0.753561566935814,11.8805411166134,73.6426,0.903522487347066,0.928813681857749,0.0744142643470538,0.165447204143563,0.0836330899559681,0.081814114187595,7.74842692629091,4.1999,4.1321141903225,69.4427,0.19837167389024,0.0921163590077684,0.203924448348018,0.166809203815299,0.106255314882472,0.0371152445327189,True,0.651986154406439,0.0772730352432496,0.407258196959781,118.640417855539
24319,1191:2172,Breast,HCC1569,SIDM00878,907046,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.0025,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.732663739241301,0.0964234876136598,0.48448068593282,8.83996261789311,8.95,0.782680068442284,0.818836366236163,0.1239240490233,0.35496143094573,0.0959589197140966,0.259002511231634,4.1229285069996,0.3403,4.71703411089352,8.6097,0.573441305574561,0.349747292986812,0.599931713913346,0.373074699280494,0.223694012587749,0.226857014632853,True,0.769620794974068,0.10024655109279,0.246634271457924,193.158839126199
27093,1022:1003,Breast,UACC-893,SIDM01186,909778,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.99751164271116,0.0601726760094501,0.805009020614721,12.1924219812073,0.9141,0.956519239789594,0.951805719341573,0.0622339140787057,0.803005870550693,0.553103574568853,0.24990229598184,9.49263589612391,0.1407,2.69978608508337,0.7734,0.954139078167348,0.838160970951855,0.94943728664229,0.867181627129262,0.115978107215493,0.0822556595130284,True,0.759942519724141,0.0720124927544811,0.256498819929855,184.690351758114
26755,1058:1032,Breast,UACC-893,SIDM01186,909778,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.960757140061125,0.0979958685195143,0.0344988638953333,1.49858410209854,0.0552,0.315342474518601,0.306102338811245,0.0691519994444594,0.0331450298114384,0.0071739423400941,0.0259710874713442,-2.00938814664655,0.0049,3.5079722487451,0.0503,0.302967533958289,0.0827769079056322,0.294090007602313,0.105218225666332,0.220190626052657,0.188871781935981,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
26755,1012:1032,Breast,UACC-893,SIDM01186,909778,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.740937354150043,0.0979958685195143,0.0344988638953333,1.49858410209854,0.0552,0.315342474518601,0.306102338811245,0.0752769919080021,0.0255614969357907,0.0056285770444076,0.019932919891383,-1.97035256110752,0.005,3.46893666320607,0.0502,0.23364901872094,0.0912870176600774,0.226802657017944,0.0822559455136572,0.142362001060862,0.144546711504287,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
26755,1011:1032,Breast,UACC-893,SIDM01186,909778,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.77989077249665,0.0979958685195143,0.0344988638953333,1.49858410209854,0.0552,0.315342474518601,0.306102338811245,0.0521869700438494,0.0269053456135883,0.0045778772659288,0.0223274683476594,-2.55483976415086,0.0033,4.05342386624941,0.0519,0.245932686053317,0.0357585515123229,0.238726389478533,0.070313949229542,0.210174134540994,0.168412440248991,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
26755,1053:1032,Breast,UACC-893,SIDM01186,909778,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.544790051339185,0.0979958685195143,0.0344988638953333,1.49858410209854,0.0552,0.315342474518601,0.306102338811245,0.0839069565146364,0.0187946378326822,0.0035938917863599,0.0152007460463223,-2.29032031474224,0.004,3.78890441684079,0.0512,0.171795442882414,0.0256036306288674,0.166761508876023,0.0540303214194246,0.146191812253547,0.112731187456598,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
26755,1012:1038,Breast,UACC-893,SIDM01186,909778,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.962802426943286,0.0847867577776621,0.809029966538313,12.2505543811307,95.1731,0.978441659076196,0.952911203092049,0.124880701099415,0.778936015252933,0.680350873950762,0.0985851413021708,10.9793095071861,39.4304,1.27124487394457,55.7427,0.942046003980976,0.929718104966803,0.917465218998472,0.888586574272104,0.0123278990141739,0.0288786447263681,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
26755,1372:1038,Breast,UACC-893,SIDM01186,909778,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.755969497598651,0.0847867577776621,0.809029966538313,12.2505543811307,95.1731,0.978441659076196,0.952911203092049,0.103252632518742,0.611601977346222,0.238497372448423,0.373104604897799,7.25598326061504,2.9854,4.99457112051568,92.1877,0.739672049441422,0.607839952725794,0.720371803457623,0.563906031495953,0.131832096715628,0.15646577196167,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
26755,1011:1038,Breast,UACC-893,SIDM01186,909778,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.77989077249665,0.0847867577776621,0.809029966538313,12.2505543811307,95.1731,0.978441659076196,0.952911203092049,0.132657886630238,0.630955005576504,0.38933072898709,0.241624276589414,8.99290202902887,9.9509,3.25765235210184,85.2222,0.763077621339838,0.713603096159347,0.743166654300171,0.659964283256629,0.0494745251804911,0.083202371043542,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
26755,1558:1038,Breast,UACC-893,SIDM01186,909778,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.277586907755077,0.0847867577776621,0.809029966538313,12.2505543811307,95.1731,0.978441659076196,0.952911203092049,0.0457410624828784,0.224576126692564,0.0603117456760756,0.164264381016488,6.11437488476601,1.3531,6.1361794963647,93.82,0.271602594561709,0.1899824791858,0.264515674231493,0.184772691759531,0.0816201153759092,0.0797429824719611,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
26755,1549:1038,Breast,UACC-893,SIDM01186,909778,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.710851613194622,0.0847867577776621,0.809029966538313,12.2505543811307,95.1731,0.978441659076196,0.952911203092049,0.136652317425742,0.575100256836551,0.294066238600756,0.281034018235794,8.21474769856391,5.8025,4.0358066825668,89.3706,0.695526831771136,0.627612012767046,0.677378465949212,0.572232622229961,0.0679148190040898,0.10514584371925,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
26755,1561:1038,Breast,UACC-893,SIDM01186,909778,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.367107541289652,0.0847867577776621,0.809029966538313,12.2505543811307,95.1731,0.978441659076196,0.952911203092049,0.0511681116042051,0.29700100184553,0.255144541369202,0.0418564604763281,10.8544858926023,36.1623,1.39606848852842,59.0108,0.359193311758831,0.363350220562774,0.349820888834487,0.337461824172195,-0.0041569088039433,0.0123590646622923,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
26756,1558:1042,Breast,UACC-893,SIDM01186,909778,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.236995726311291,0.083491380811227,0.819763193402743,12.4104670227232,106.3293,0.933169133854744,0.955835793278371,0.0767328599078204,0.194280373423747,0.118076755933022,0.076203617490725,8.98399747079297,9.8897,3.42646955193023,96.4396,0.221157096649184,0.137103727396098,0.226528998062337,0.200448759016979,0.0840533692530861,0.0260802390453578,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
26756,1053:1042,Breast,UACC-893,SIDM01186,909778,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.443748697939561,0.083491380811227,0.819763193402743,12.4104670227232,106.3293,0.933169133854744,0.955835793278371,0.0706091532552391,0.363768849691244,0.231155599074259,0.132613250616984,9.18847663373639,11.3956,3.22199038898681,94.9337,0.41409258810543,0.317995367728509,0.424150888711304,0.379666746632452,0.0960972203769218,0.0444841420788522,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
26756,1049:1042,Breast,UACC-893,SIDM01186,909778,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.93269385182379,0.083491380811227,0.819763193402743,12.4104670227232,106.3293,0.933169133854744,0.955835793278371,0.137118232455952,0.764588090438175,0.549827118640717,0.214760971797458,9.81486098998635,17.5913,2.59560603273685,88.738,0.870361113858051,0.828226102162526,0.891502167743852,0.823431295489061,0.042135011695525,0.0680708722547911,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
26756,1561:1042,Breast,UACC-893,SIDM01186,909778,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.399642909092072,0.083491380811227,0.819763193402743,12.4104670227232,106.3293,0.933169133854744,0.955835793278371,0.0575116780925956,0.327612547378079,0.244309597904531,0.0833029494735472,10.019627480592,20.274,2.39083954213116,86.0553,0.372934427328638,0.317169295296918,0.381992997040096,0.356031861900014,0.0557651320317207,0.0259611351400824,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
26757,1058:1050,Breast,UACC-893,SIDM01186,909778,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.992294822840439,0.0649149197172569,0.791115273428704,11.998253563223,79.9032,0.942455802447936,0.947943564574353,0.027181404421037,0.785019590093302,0.755224726891969,0.0297948632013323,11.6087379641497,60.997,0.389515599073388,18.9062,0.935194013525019,0.939398205527754,0.940639491472042,0.932125551032907,-0.0042041920027354,0.0085139404391344,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
26757,1549:1050,Breast,UACC-893,SIDM01186,909778,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.454972638919991,0.0649149197172569,0.791115273428704,11.998253563223,79.9032,0.942455802447936,0.947943564574353,0.0537974312502359,0.359935803641767,0.196401084117097,0.16353471952467,8.38080317394975,6.5103,3.61745038927328,73.3929,0.428791603505195,0.320570165535598,0.431288385121616,0.370493268932134,0.108221437969597,0.0607951161894814,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
26757,1558:1050,Breast,UACC-893,SIDM01186,909778,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.459688529617997,0.0649149197172569,0.791115273428704,11.998253563223,79.9032,0.942455802447936,0.947943564574353,0.0485929580414175,0.363666616800781,0.210700882192277,0.152965734608503,8.62407873071746,7.7061,3.37417483250557,72.1971,0.433236122057241,0.384579945830902,0.435758783360027,0.380378250123076,0.0486561762263393,0.0553805332369508,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
26757,1561:1050,Breast,UACC-893,SIDM01186,909778,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.392044715225477,0.0649149197172569,0.791115273428704,11.998253563223,79.9032,0.942455802447936,0.947943564574353,0.0501803620512096,0.310152562081882,0.199629108994261,0.110523453087621,9.08286368535202,10.5912,2.91538987787102,69.312,0.369484816683299,0.342496176719819,0.371636264823376,0.333466880224796,0.0269886399634808,0.03816938459858,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
26757,1011:1050,Breast,UACC-893,SIDM01186,909778,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.809513882040078,0.0649149197172569,0.791115273428704,11.998253563223,79.9032,0.942455802447936,0.947943564574353,0.0709429833145795,0.640418796134468,0.416087773272628,0.22433102286184,9.12609144472592,10.9133,2.87216211849712,68.9899,0.762931055290825,0.698341989327844,0.767373474913494,0.690229560659002,0.064589065962981,0.0771439142544917,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
26757,1053:1050,Breast,UACC-893,SIDM01186,909778,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.443952433606499,0.0649149197172569,0.791115273428704,11.998253563223,79.9032,0.942455802447936,0.947943564574353,0.0446248886185746,0.351217550901944,0.162484854061535,0.188732696840409,7.76294513441642,4.2424,4.23530842880662,75.6608,0.418405547063327,0.30671013808363,0.420841852414404,0.345501871576261,0.111695408979697,0.0753399808381431,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
27095,1012:1059,Breast,UACC-893,SIDM01186,909778,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.914327379625484,0.109480728719444,0.220359478633873,6.15504841456646,0.1392,0.632290876359756,0.668652296340546,0.0594685165327201,0.201480704674947,0.19720530862858,0.0042753960463666,6.09329393638587,0.1334,0.0617544781805917,0.0058,0.578120860143117,0.598145544098403,0.611367101993614,0.607180610600424,-0.0200246839552861,0.0041864913931897,True,0.759942519724141,0.0720124927544811,0.256498819929855,184.690351758114
27095,1011:1059,Breast,UACC-893,SIDM01186,909778,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.691429673632824,0.109480728719444,0.220359478633873,6.15504841456646,0.1392,0.632290876359756,0.668652296340546,0.0540254802375465,0.152363082393718,0.0492327919142768,0.103130290479441,3.21735798764414,0.0182,2.93769042692232,0.121,0.437184674282439,0.280941041525201,0.462326039032582,0.302351433775099,0.156243632757237,0.159974605257483,True,0.759942519724141,0.0720124927544811,0.256498819929855,184.690351758114
27095,1549:1059,Breast,UACC-893,SIDM01186,909778,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.49024062376134,0.109480728719444,0.220359478633873,6.15504841456646,0.1392,0.632290876359756,0.668652296340546,0.0529199556956273,0.108029168257193,0.0275505371995355,0.0804786310576578,2.64839949247818,0.0122,3.50664892208828,0.127,0.309974673625211,0.160321170021476,0.327800518837441,0.192398439606654,0.149653503603735,0.135402079230787,True,0.759942519724141,0.0720124927544811,0.256498819929855,184.690351758114
27095,1053:1059,Breast,UACC-893,SIDM01186,909778,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.671829398421324,0.109480728719444,0.220359478633873,6.15504841456646,0.1392,0.632290876359756,0.668652296340546,0.0741683975775947,0.148043975967031,0.0464867045537745,0.101557271413257,3.14801487332047,0.0173,3.00703354124599,0.1219,0.424791599092067,0.274001057418601,0.449220270003506,0.290077670580189,0.150790541673466,0.159142599423317,True,0.759942519724141,0.0720124927544811,0.256498819929855,184.690351758114
27096,1011:1080,Breast,UACC-893,SIDM01186,909778,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.805906192690569,0.0994855009616376,0.617970776481281,10.0828522427073,0.2118,0.850813222775624,0.893264988612287,0.0848475011486485,0.498026475668064,0.2947403741369,0.203286101531164,7.76031834806185,0.0423,2.32253389464541,0.1695,0.685675645057896,0.586074449135227,0.719887786036313,0.627059025579509,0.0996011959226688,0.092828760456804,True,0.759942519724141,0.0720124927544811,0.256498819929855,184.690351758114
27096,1558:1080,Breast,UACC-893,SIDM01186,909778,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.254839404025676,0.0994855009616376,0.617970776481281,10.0828522427073,0.2118,0.850813222775624,0.893264988612287,0.02432748356091,0.157483304383774,0.141069246798657,0.0164140575851169,9.48423452129677,0.1399,0.598617721410502,0.0719,0.216820734629305,0.227084137352419,0.227639117334957,0.221449855090114,-0.010263402723114,0.0061892622448432,True,0.759942519724141,0.0720124927544811,0.256498819929855,184.690351758114
27096,1058:1080,Breast,UACC-893,SIDM01186,909778,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.611692832681841,0.0994855009616376,0.617970776481281,10.0828522427073,0.2118,0.850813222775624,0.893264988612287,0.114875819884657,0.378008294780432,0.212906471237294,0.165101823543138,7.58701095430882,0.0376,2.49584128839845,0.1742,0.520436350322788,0.393328196461324,0.546403791219763,0.469348057627728,0.127108153861464,0.0770557335920344,True,0.759942519724141,0.0720124927544811,0.256498819929855,184.690351758114
27096,1561:1080,Breast,UACC-893,SIDM01186,909778,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.231559398453341,0.0994855009616376,0.617970776481281,10.0828522427073,0.2118,0.850813222775624,0.893264988612287,0.0528692578112351,0.14309694126375,0.0579242483431768,0.0851726929205728,6.52824263347659,0.018,3.55460960923068,0.1938,0.197013798062072,0.117120270020912,0.206843903422492,0.161123716410331,0.0798935280411603,0.0457201870121608,True,0.759942519724141,0.0720124927544811,0.256498819929855,184.690351758114
27096,1559:1080,Breast,UACC-893,SIDM01186,909778,1559,Luminespib,HSP90,Protein stability and degradation,Targeted,Early clinical trials,0.01,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.910813838040716,0.0994855009616376,0.617970776481281,10.0828522427073,0.2118,0.850813222775624,0.893264988612287,0.147263785212383,0.562856334723917,0.329611402891441,0.233244931832477,7.72297569891646,0.0413,2.35987654379081,0.1705,0.774932456892057,0.62223888275445,0.813598112665354,0.706590310108374,0.152693574137607,0.107007802556979,True,0.759942519724141,0.0720124927544811,0.256498819929855,184.690351758114
27098,1011:1129,Breast,UACC-893,SIDM01186,909778,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.657008404768725,0.074221812427024,0.525289764478902,9.22795555023535,11.7117,0.854100346459755,0.857430339075302,0.0468168436938438,0.345119790201623,0.194842775729331,0.150277014472292,7.05529904874536,2.5977,2.17265650148999,9.114,0.561151106139939,0.482348034686639,0.563338939276171,0.481279606269315,0.0788030714532997,0.0820593330068568,True,0.759942519724141,0.0720124927544811,0.256498819929855,184.690351758114
27098,1058:1129,Breast,UACC-893,SIDM01186,909778,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.543372893320658,0.074221812427024,0.525289764478902,9.22795555023535,11.7117,0.854100346459755,0.857430339075302,0.142435516663771,0.285428219156628,0.289752480142079,-0.004324260985451,9.29987537423293,12.3104,-0.0719198239975825,-0.598699999999999,0.464094976442013,0.364005116198751,0.46590440416426,0.467703466362779,0.100089860243262,-0.0017990621985193,True,0.759942519724141,0.0720124927544811,0.256498819929855,184.690351758114
27099,1011:1192,Breast,UACC-893,SIDM01186,909778,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.793163712106229,0.0996808592207224,0.56729212175613,9.60973590877211,15.2598,0.885443058890093,0.874379789863137,0.0580984123575731,0.449955525140711,0.124036500895401,0.325919024245309,5.20530227371983,0.7206,4.40443363505227,14.5392,0.702301303447961,0.439306727685579,0.693526319918511,0.472814704086404,0.262994575762382,0.220711615832106,True,0.759942519724141,0.0720124927544811,0.256498819929855,184.690351758114
26759,1549:1553,Breast,UACC-893,SIDM01186,909778,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.369182846781486,0.0744263110590437,0.126642659458093,4.65238208074764,0.4912,0.556894528226654,0.552334342458035,0.0505060419788098,0.0467542975427169,0.0110396482095672,0.0357146493331497,1.16599307653861,0.0438,3.48638900420903,0.4474,0.205595907287748,0.0768196235160635,0.203912364923837,0.104341165587029,0.128776283771685,0.0995711993368082,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
26759,1558:1560,Breast,UACC-893,SIDM01186,909778,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.256374448871674,0.104780975545705,0.224943228419579,6.21467865411682,1.4506,0.698945582215939,0.673052126585912,0.0556110651457669,0.0576696962134845,0.0179041774857636,0.0397655187277209,3.17035635748619,0.1758,3.04432229663063,1.2748,0.179191788431903,0.0857839058936308,0.172553368015371,0.111150471429792,0.0934078825382717,0.0614028965855791,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
26759,1549:1560,Breast,UACC-893,SIDM01186,909778,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.639927886655244,0.104780975545705,0.224943228419579,6.21467865411682,1.4506,0.698945582215939,0.673052126585912,0.0770566223751939,0.143947444779949,0.0583674793248492,0.0855799654550996,3.82386865871805,0.2766,2.39080999539877,1.174,0.447274769314465,0.308119683789059,0.43070482497494,0.310901430129184,0.139155085525406,0.119803394845756,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
26760,1053:1564,Breast,UACC-893,SIDM01186,909778,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.797533886406168,0.111302175414479,0.590750102315213,9.82645673113497,8.8666,0.840380770101823,0.883318579149196,0.0914930874059945,0.471143224994293,0.276781627144892,0.1943615978494,7.57694060452525,1.8646,2.24951612660972,7.002,0.670232141640315,0.562804719805563,0.704476499363632,0.611436093788501,0.107427421834752,0.0930404055751313,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
26760,1561:1564,Breast,UACC-893,SIDM01186,909778,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.40771003046301,0.111302175414479,0.590750102315213,9.82645673113497,8.8666,0.840380770101823,0.883318579149196,0.0573644717515499,0.240854742210962,0.151049239195697,0.0898055030152642,7.80636111133475,2.186,2.02009561980022,6.6806,0.342631669378742,0.28779142092343,0.360137844813461,0.318379785592094,0.0548402484553123,0.0417580592213677,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
26760,1510:1564,Breast,UACC-893,SIDM01186,909778,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.927341924214814,0.111302175414479,0.590750102315213,9.82645673113497,8.8666,0.840380770101823,0.883318579149196,0.120189539761645,0.547827336611087,0.294729874515031,0.253097462096056,7.28029795505095,1.5181,2.54615877608402,7.3485,0.779320320419352,0.619891696347226,0.81913835088291,0.693224077533545,0.159428624072126,0.125914273349365,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
26760,1011:1564,Breast,UACC-893,SIDM01186,909778,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.798256867612161,0.111302175414479,0.590750102315213,9.82645673113497,8.8666,0.840380770101823,0.883318579149196,0.0701571756053538,0.471570326215705,0.143271565297827,0.328298760917878,5.57798951669219,0.4665,4.24846721444278,8.4001,0.670839721142977,0.474260450474703,0.705115122095262,0.498965528493527,0.196579270668274,0.206149593601735,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
26760,1594:1564,Breast,UACC-893,SIDM01186,909778,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.876777566620832,0.111302175414479,0.590750102315213,9.82645673113497,8.8666,0.840380770101823,0.883318579149196,0.0492510678556574,0.51795643718894,0.507656776083751,0.0102996611051887,9.7175161557539,8.2217,0.108940575381068,0.6449,0.736827006644818,0.789490563609913,0.774473914377403,0.770588065395555,-0.0526635569650949,0.0038858489818482,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
26760,1058:1593,Breast,UACC-893,SIDM01186,909778,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.978944891375078,0.0864145022716783,0.687850524925748,10.7788972563245,6.8633,0.895315342138506,0.916952301321503,0.119357589838935,0.673367757405727,0.443353034809859,0.230014722595868,8.57445027662681,1.4891,2.20444697969772,5.3742,0.87646438035622,0.753900068042345,0.897645771013306,0.807469708545645,0.122564312313875,0.0901760624676611,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
26760,1558:1593,Breast,UACC-893,SIDM01186,909778,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.289186774650997,0.0864145022716783,0.687850524925748,10.7788972563245,6.8633,0.895315342138506,0.916952301321503,0.0662237431369778,0.198917274745273,0.0773161252471283,0.121601149498144,6.73030871417855,0.4147,4.04858854214598,6.4486,0.258913356088589,0.147558561561132,0.265170478527975,0.205362954382131,0.111354794527456,0.059807524145844,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
26760,1549:1593,Breast,UACC-893,SIDM01186,909778,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.710471728547594,0.0864145022716783,0.687850524925748,10.7788972563245,6.8633,0.895315342138506,0.916952301321503,0.0693006664561652,0.488698351426366,0.261301897301847,0.227396454124519,7.7802994724253,0.8587,2.99859778389923,6.0046,0.636096238724325,0.552882754044364,0.651468686515582,0.553674092476516,0.0832134846799606,0.0977945940390668,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
26760,1561:1593,Breast,UACC-893,SIDM01186,909778,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.40771003046301,0.0864145022716783,0.687850524925748,10.7788972563245,6.8633,0.895315342138506,0.916952301321503,0.0512504183090273,0.280443558471474,0.0850594428190787,0.195384115652396,5.99823747438907,0.2497,4.78065978193546,6.6136,0.36502904541729,0.234848648757806,0.373850650704917,0.267858500603356,0.130180396659485,0.105992150101561,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
26760,1053:1593,Breast,UACC-893,SIDM01186,909778,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.797533886406168,0.0864145022716783,0.687850524925748,10.7788972563245,6.8633,0.895315342138506,0.916952301321503,0.0907378066006822,0.548584102410555,0.236516794848496,0.312067307562058,7.05529505115776,0.5195,3.72360220516677,6.3438,0.71404432437479,0.555864100228026,0.731300532522017,0.584218786845197,0.158180224146764,0.14708174567682,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
27523,1053:1909,Breast,UACC-893,SIDM01186,909778,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.769898880423952,0.0664687716040618,0.918271730829021,14.4466224158972,43.6111,0.954383289390446,0.981039069196327,0.126191961834174,0.706976377490228,0.590106166429179,0.116870211061049,11.6759194687526,6.3905,2.77070294714467,37.2206,0.734778625997033,0.608545896287829,0.755300881026409,0.724417903728483,0.126232729709205,0.030882977297926,True,1.18067733215172,0.113658977316676,-0.180505218992649,-305.228865526021
27096,1012:2169,Breast,UACC-893,SIDM01186,909778,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.726259516865457,0.105392649496166,0.259281020256053,6.6365660080599,1.9433,0.731669124792043,0.703532645167825,0.0724620675757767,0.188305308503544,0.0611547966113313,0.127150511892212,3.62668055640686,0.2413,3.00988545165305,1.702,0.531381665076841,0.321419182220849,0.510947278978661,0.341343630427678,0.209962482855992,0.169603648550983,True,0.759942519724141,0.0720124927544811,0.256498819929855,184.690351758114
26758,1191:2172,Breast,UACC-893,SIDM01186,909778,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.0025,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.933433165432669,0.0813897730409069,0.745777662463978,11.4231204377691,53.633,0.896861193403971,0.934859058568814,0.0730884639899356,0.696133604182728,0.486154554844842,0.209979049337886,9.1876521945803,11.3891,2.23546824318879,42.2439,0.83715998271279,0.752736965310887,0.872628450273294,0.798599610430704,0.0844230174019029,0.0740288398425893,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
26758,1549:2172,Breast,UACC-893,SIDM01186,909778,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.426420696048626,0.0813897730409069,0.745777662463978,11.4231204377691,53.633,0.896861193403971,0.934859058568814,0.072423126497095,0.318015029925407,0.109200047095041,0.208814982830366,6.59894934458996,1.8933,4.82417109317913,51.7397,0.382440174350323,0.24101869140095,0.398643250462277,0.298862804802119,0.141421482949374,0.0997804456601583,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
26758,1558:2172,Breast,UACC-893,SIDM01186,909778,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.470313032916617,0.0813897730409069,0.745777662463978,11.4231204377691,53.633,0.896861193403971,0.934859058568814,0.0523202052717843,0.350748954314898,0.236065499509453,0.114683454805446,9.0174062637266,10.1214,2.40571417404248,43.5116,0.421805507975038,0.360918677170482,0.439676399185072,0.398553565708174,0.0608868308045559,0.0411228334768981,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
26758,1372:2172,Breast,UACC-893,SIDM01186,909778,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.837699790865656,0.0813897730409069,0.745777662463978,11.4231204377691,53.633,0.896861193403971,0.934859058568814,0.0364535169983101,0.624737791878352,0.659138695305609,-0.0344009034272563,11.9404842753814,76.7669,-0.517363837612315,-23.1339,0.751300434150029,0.779738291703577,0.78313123785196,0.793086150122753,-0.0284378575535477,-0.009954912270793,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
26758,1510:2172,Breast,UACC-893,SIDM01186,909778,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.935746257735481,0.0813897730409069,0.745777662463978,11.4231204377691,53.633,0.896861193403971,0.934859058568814,0.103434642119914,0.697858656753382,0.489719218256483,0.208139438496899,9.21040988697503,11.5702,2.21271055079406,42.0628,0.839234505435944,0.744470074659961,0.874790865565883,0.801573602058766,0.0947644307759825,0.073217263507117,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
26758,1005:2172,Breast,UACC-893,SIDM01186,909778,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.939387197083693,0.0813897730409069,0.745777662463978,11.4231204377691,53.633,0.896861193403971,0.934859058568814,0.0944831328705115,0.700573987989665,0.443414143480514,0.257159844509152,8.74779125883106,8.3961,2.67532917893802,45.2369,0.842499922644893,0.712587287859735,0.878194630697259,0.783374273436659,0.129912634785158,0.0948203572606001,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
26758,1012:2172,Breast,UACC-893,SIDM01186,909778,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.809982981007224,0.0813897730409069,0.745777662463978,11.4231204377691,53.633,0.896861193403971,0.934859058568814,0.111780189963121,0.604067214211172,0.283294450593229,0.320772763617944,7.60378549767981,3.7992,3.81933494008928,49.8338,0.726442302983045,0.53995363331913,0.757219927081176,0.622350263064126,0.186488669663916,0.134869664017049,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
29164,1012:1003,Breast,CAL-51,SIDM00933,910927,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.535300755984178,0.0630426422163651,0.323100193441623,7.32649710275413,0.0313,0.751860807841944,0.749985247955916,0.0850832186986344,0.172955777807935,0.0382883102325805,0.134667467575354,3.199293375759,0.0018,4.12720372699513,0.0295,0.402471658832668,0.213835650117174,0.401467670207783,0.233393541277672,0.188636008715493,0.168074128930111,True,0.350958335207378,0.0449826280107119,0.991316499570475,49.3515852834387
29164,1011:1003,Breast,CAL-51,SIDM00933,910927,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.399791982835201,0.0630426422163651,0.323100193441623,7.32649710275413,0.0313,0.751860807841944,0.749985247955916,0.0349319458891197,0.129172866990463,0.023323434977272,0.105849432013191,2.7062096961001,0.0013,4.62028740665403,0.03,0.300587923183207,0.12683160918049,0.299838089377445,0.158803796378788,0.173756314002717,0.141034292998657,True,0.350958335207378,0.0449826280107119,0.991316499570475,49.3515852834387
29164,1191:1013,Breast,CAL-51,SIDM00933,910927,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.000625,1013,Nilotinib,ABL,ABL signaling,Targeted,FDA approved,10.0,0.987954316115118,0.167189577673611,0.374046243423469,7.83487370955993,4.4593,0.832169599538118,0.781993642776085,0.154297287120717,0.369540600616863,0.37121845753775,-0.0016778569208869,7.85127237127229,4.5102,-0.0163986617123584,-0.0509000000000004,0.822145547603473,0.826449091692759,0.772573994555217,0.773554841346759,-0.0043035440892863,-0.0009808467915427,True,0.350958335207378,0.0449826280107119,0.991316499570475,49.3515852834387
29164,1011:1013,Breast,CAL-51,SIDM00933,910927,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1013,Nilotinib,ABL,ABL signaling,Targeted,FDA approved,10.0,0.399791982835201,0.167189577673611,0.374046243423469,7.83487370955993,4.4593,0.832169599538118,0.781993642776085,0.0471101032841535,0.149540689330327,0.0524800488699581,0.0970606404603688,4.72371943495095,0.5161,3.11115427460898,3.9432,0.332694734254519,0.205079187072901,0.312634789009972,0.223036703414401,0.127615547181618,0.0895980855955709,True,0.350958335207378,0.0449826280107119,0.991316499570475,49.3515852834387
28726,1559:1030,Breast,CAL-51,SIDM00933,910927,1559,Luminespib,HSP90,Protein stability and degradation,Targeted,Early clinical trials,0.01,1030,KU-55933,ATM,Genome integrity,Targeted,Experimental only,10.0,0.682337799986262,0.0819917949551204,0.8896983617352,13.7240352509153,264.2873,0.93607985489056,0.973891244834089,0.0927436719651634,0.607074822797778,0.390370808929929,0.216704013867848,9.65725429229803,15.7708,4.06678095861725,248.5165,0.638722668797484,0.575634685656508,0.664522809425974,0.597500166737466,0.0630879831409763,0.0670226426885079,True,0.209215131890064,0.0424920144814723,1.50958538614663,32.8051673366155
28726,1561:1030,Breast,CAL-51,SIDM00933,910927,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1030,KU-55933,ATM,Genome integrity,Targeted,Experimental only,10.0,0.801044395541848,0.0819917949551204,0.8896983617352,13.7240352509153,264.2873,0.93607985489056,0.973891244834089,0.0657612610423667,0.712687886390746,0.57533898739624,0.137348898994506,11.1173983421746,43.3911,2.60663690874071,220.8962,0.74984152153971,0.746562868490066,0.780130123541621,0.741908525596961,0.003278653049644,0.0382215979446602,True,0.209215131890064,0.0424920144814723,1.50958538614663,32.8051673366155
28726,1017:1030,Breast,CAL-51,SIDM00933,910927,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,1030,KU-55933,ATM,Genome integrity,Targeted,Experimental only,10.0,0.7463977654862,0.0819917949551204,0.8896983617352,13.7240352509153,264.2873,0.93607985489056,0.973891244834089,0.102313937231252,0.664068869155886,0.417749938384254,0.246318930771632,9.54284531784886,14.5684,4.18118993306642,249.7189,0.69868791200696,0.572236274423204,0.726910248970738,0.649966551575302,0.126451637583757,0.0769436973954361,True,0.209215131890064,0.0424920144814723,1.50958538614663,32.8051673366155
29166,1049:1032,Breast,CAL-51,SIDM00933,910927,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.925823373202073,0.0971714834035144,0.707494171684332,10.9986358688766,39.9622,0.938593638039068,0.922824022684189,0.0648584360529591,0.655014640549595,0.621307426651366,0.0337072138982291,10.6136323087724,30.6021,0.385003560104217,9.3601,0.868971928035336,0.84981330308696,0.854372049553382,0.843496345611385,0.0191586249483765,0.0108757039419968,True,0.350958335207378,0.0449826280107119,0.991316499570475,49.3515852834387
29166,1022:1032,Breast,CAL-51,SIDM00933,910927,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.915416762841497,0.0971714834035144,0.707494171684332,10.9986358688766,39.9622,0.938593638039068,0.922824022684189,0.106161774082891,0.647652024372497,0.358284419844051,0.289367604528447,8.00101408680294,5.0035,2.9976217820737,34.9587,0.859204349757347,0.733985206059389,0.844768579517928,0.724948666555557,0.125219143697959,0.119819912962371,True,0.350958335207378,0.0449826280107119,0.991316499570475,49.3515852834387
29166,1047:1032,Breast,CAL-51,SIDM00933,910927,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.897089491913664,0.0971714834035144,0.707494171684332,10.9986358688766,39.9622,0.938593638039068,0.922824022684189,0.147349124107853,0.634685587008176,0.411535933882422,0.223149653125754,8.62574260837721,7.715,2.37289326049943,32.2472,0.842002489861865,0.786524784782706,0.827855733635482,0.741766829355629,0.0554777050791594,0.0860889042798533,True,0.350958335207378,0.0449826280107119,0.991316499570475,49.3515852834387
29166,1561:1032,Breast,CAL-51,SIDM00933,910927,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.948056801804104,0.0971714834035144,0.707494171684332,10.9986358688766,39.9622,0.938593638039068,0.922824022684189,0.127130791197283,0.670744661702092,0.450478752932974,0.220265908769118,8.7749804170602,8.5558,2.22365545181644,31.4064,0.889840082672998,0.825409232718563,0.87488959157397,0.791259658215005,0.064430849954435,0.0836299333589651,True,0.350958335207378,0.0449826280107119,0.991316499570475,49.3515852834387
29166,1179:1032,Breast,CAL-51,SIDM00933,910927,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.278376827145426,0.0971714834035144,0.707494171684332,10.9986358688766,39.9622,0.938593638039068,0.922824022684189,0.0242235973427969,0.196949982737366,0.181775520811837,0.0151744619255284,10.4305186321767,26.9544,0.568117236699974,13.0078,0.261282718936198,0.249886318909333,0.256892823448403,0.25193130056451,0.0113964000268646,0.0049615228838926,True,0.350958335207378,0.0449826280107119,0.991316499570475,49.3515852834387
29166,1005:1032,Breast,CAL-51,SIDM00933,910927,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.79480795907624,0.0971714834035144,0.707494171684332,10.9986358688766,39.9622,0.938593638039068,0.922824022684189,0.0716404681406899,0.562321998654759,0.298297302661958,0.264024695992801,7.84705400927723,4.4971,3.15158185959941,35.4651,0.746001693851775,0.652168366126102,0.733467878056146,0.622121071213159,0.0938333277256732,0.111346806842987,True,0.350958335207378,0.0449826280107119,0.991316499570475,49.3515852834387
29166,1012:1032,Breast,CAL-51,SIDM00933,910927,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.832173776875914,0.0971714834035144,0.707494171684332,10.9986358688766,39.9622,0.938593638039068,0.922824022684189,0.119929820517846,0.588758096968247,0.359421477199952,0.229336619768295,8.37981202157254,6.5059,2.6188238473041,33.4563,0.781073012718676,0.720867087307429,0.767949952348925,0.677040984375234,0.0602059254112468,0.0909089679736911,True,0.350958335207378,0.0449826280107119,0.991316499570475,49.3515852834387
29166,1011:1032,Breast,CAL-51,SIDM00933,910927,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.762167920113632,0.0971714834035144,0.707494171684332,10.9986358688766,39.9622,0.938593638039068,0.922824022684189,0.110357310759336,0.539229361325165,0.320287481453764,0.218941879871401,8.27177409849822,6.0365,2.72686177037842,33.9257,0.715365960936124,0.648782630125766,0.703346866000103,0.615491025687552,0.0665833308103584,0.0878558403125512,True,0.350958335207378,0.0449826280107119,0.991316499570475,49.3515852834387
29166,1011:1038,Breast,CAL-51,SIDM00933,910927,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.762167920113632,0.0697585741724306,0.627018746064749,10.1754249332583,22.5859,0.896431786299474,0.895991038131437,0.104852298545238,0.477893573560428,0.27047953521877,0.207414038341658,7.64762050868657,3.9165,2.52780442457172,18.6694,0.683231550087618,0.580919456333589,0.682895625973091,0.5872333900769,0.102312093754029,0.0956622358961909,True,0.350958335207378,0.0449826280107119,0.991316499570475,49.3515852834387
29166,1561:1038,Breast,CAL-51,SIDM00933,910927,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.948056801804104,0.0697585741724306,0.627018746064749,10.1754249332583,22.5859,0.896431786299474,0.895991038131437,0.0887138991495479,0.594449387065366,0.422604458862465,0.171844928202901,8.50710319086101,7.106,1.66832174239728,15.4799,0.849868252354619,0.825655418579447,0.849450398056029,0.777910394329552,0.024212833775172,0.0715400037264775,True,0.350958335207378,0.0449826280107119,0.991316499570475,49.3515852834387
23846,1190:1042,Breast,CAL-51,SIDM00933,910927,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.1,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.374334326004058,0.038988708524592,0.941453080506697,15.2852371990416,779.9108,0.981718240086335,0.986517564467557,0.0360628205382498,0.352418204355919,0.160293378211313,0.192124826144605,8.3456754807018,6.3537,6.93956171833979,773.5571,0.367490835728608,0.277455536396857,0.369287387586128,0.303843165268398,0.0900352993317509,0.0654442223177293,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
23847,1058:1050,Breast,CAL-51,SIDM00933,910927,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.942691125648322,0.0568679101556498,0.785099858035723,11.9318117571702,76.3068,0.9345939063717,0.945996750614978,0.0544590800978844,0.740106668918033,0.640514039667743,0.0995926292502903,10.6999713138844,32.4894,1.23184044328576,43.8174,0.881033381621601,0.856200284085534,0.891782741696889,0.861460238146798,0.0248330975360669,0.030322503550091,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
23847,1049:1050,Breast,CAL-51,SIDM00933,910927,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.942412873421143,0.0568679101556498,0.785099858035723,11.9318117571702,76.3068,0.9345939063717,0.945996750614978,0.0301186694345347,0.739888213133977,0.611097237876584,0.128790975257392,10.3852717610262,26.1221,1.54653999614401,50.1847,0.880773328785645,0.858534057400787,0.891519515994125,0.851422560034333,0.0222392713848579,0.0400969559597926,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
23847,1022:1050,Breast,CAL-51,SIDM00933,910927,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.856959935486654,0.0568679101556498,0.785099858035723,11.9318117571702,76.3068,0.9345939063717,0.945996750614978,0.0454923545902965,0.672799123692874,0.426614729126483,0.246184394566391,8.98029895772176,9.8644,2.95151279944844,66.4424,0.800909533710512,0.714253838848554,0.810681314377596,0.724043417694352,0.086655694861958,0.0866378966832435,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
23847,1558:1050,Breast,CAL-51,SIDM00933,910927,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.96310427629708,0.0568679101556498,0.785099858035723,11.9318117571702,76.3068,0.9345939063717,0.945996750614978,0.0821449900337695,0.756133030594435,0.616047712566398,0.140085318028037,10.2984967423474,24.5972,1.63331501482284,51.7096,0.900111387827777,0.861140239157428,0.911093515880427,0.867196679854341,0.0389711486703486,0.0438968360260857,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
23847,1047:1050,Breast,CAL-51,SIDM00933,910927,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.894255514323301,0.0568679101556498,0.785099858035723,11.9318117571702,76.3068,0.9345939063717,0.945996750614978,0.0447947294711927,0.702079877342885,0.430979952451704,0.271099924891182,8.83648659630727,8.9285,3.09532516086293,67.3783,0.835765754425847,0.75433402644118,0.845962810769368,0.74915329475635,0.081431727984667,0.0968095160130182,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
23847,1561:1050,Breast,CAL-51,SIDM00933,910927,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.874037645553958,0.0568679101556498,0.785099858035723,11.9318117571702,76.3068,0.9345939063717,0.945996750614978,0.0511196058028679,0.686206831442289,0.429930663774982,0.256276167667307,8.92659021035998,9.5039,3.00522154681022,66.8029,0.816870257474197,0.736756187744222,0.82683677260921,0.73615802845595,0.0801140697299744,0.0906787441532597,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
23847,1179:1050,Breast,CAL-51,SIDM00933,910927,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.256151923527094,0.0568679101556498,0.785099858035723,11.9318117571702,76.3068,0.9345939063717,0.945996750614978,0.0601584192498268,0.201104838796699,0.128186401760031,0.0729184370366676,9.00390248686543,10.0271,2.92790927030477,66.2797,0.239398026833812,0.196584919062286,0.242318887320408,0.216717765200104,0.0428131077715261,0.0256011221203033,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
23847,1011:1050,Breast,CAL-51,SIDM00933,910927,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.923551219373611,0.0568679101556498,0.785099858035723,11.9318117571702,76.3068,0.9345939063717,0.945996750614978,0.109979952734548,0.725079931218941,0.142405697991783,0.582674233227158,5.14847318063556,0.6927,6.78333857653464,75.6141,0.86314534184873,0.56088482997337,0.873676452553936,0.546214579027702,0.30226051187536,0.327461873526234,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
23847,1510:1050,Breast,CAL-51,SIDM00933,910927,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.977524653143835,0.0568679101556498,0.785099858035723,11.9318117571702,76.3068,0.9345939063717,0.945996750614978,0.0549794270315867,0.767454466409644,0.560957361010387,0.206497105399257,9.67341217898327,15.9484,2.25839957818693,60.3584,0.913588584156338,0.845138617009119,0.924735145520101,0.856645738506968,0.0684499671472188,0.0680894070131332,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
23847,1053:1050,Breast,CAL-51,SIDM00933,910927,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.95176896192929,0.0568679101556498,0.785099858035723,11.9318117571702,76.3068,0.9345939063717,0.945996750614978,0.045633031003746,0.747233676893493,0.528651452692907,0.218582224200586,9.50388638182326,14.1803,2.42792537534694,62.1265,0.889517472092833,0.814682419234171,0.900370345321299,0.827199275379338,0.0748350528586624,0.0731710699419609,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
23847,1058:1051,Breast,CAL-51,SIDM00933,910927,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.942691125648322,0.118792547279117,0.575330176590918,9.68706890436125,16.1001,0.79328916912695,0.876910722681429,0.16384220880391,0.54235865178994,0.420629165867962,0.121729485921978,8.51114951649836,7.1259,1.17591938786289,8.9742,0.747826659808907,0.644954151780431,0.82665595625764,0.773713393337336,0.102872508028476,0.0529425629203045,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
23847,1594:1051,Breast,CAL-51,SIDM00933,910927,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.884685561185945,0.118792547279117,0.575330176590918,9.68706890436125,16.1001,0.79328916912695,0.876910722681429,0.125187675889002,0.508986300144545,0.306950437783776,0.202035862360769,7.56891804428987,3.7085,2.11815086007139,12.3916,0.701811473771808,0.59576700678183,0.775790254805393,0.677262849616078,0.106044466989977,0.0985274051893145,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
23847,1011:1051,Breast,CAL-51,SIDM00933,910927,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.916248035697975,0.118792547279117,0.575330176590918,9.68706890436125,16.1001,0.79328916912695,0.876910722681429,0.123339547498862,0.527145144179197,0.0535717505719586,0.473573393607238,2.71154597420571,0.1279,6.97552293015555,15.9722,0.726849642953046,0.356875073098262,0.803467727139351,0.364329316081959,0.369974569854784,0.439138411057392,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
23847,1179:1051,Breast,CAL-51,SIDM00933,910927,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.765709505629578,0.118792547279117,0.575330176590918,9.68706890436125,16.1001,0.79328916912695,0.876910722681429,0.143875687295609,0.440535785091209,0.17789235800545,0.262643427085759,6.29537709165807,1.534,3.39169181270319,14.5661,0.607429057513495,0.440876070698514,0.671458875945673,0.519565943144451,0.166552986814981,0.151892932801222,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
23847,1561:1051,Breast,CAL-51,SIDM00933,910927,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.874037645553958,0.118792547279117,0.575330176590918,9.68706890436125,16.1001,0.79328916912695,0.876910722681429,0.0897851906728452,0.502860232963668,0.273528672130067,0.229331560833601,7.22057310003783,2.913,2.46649580432342,13.1871,0.693364597627175,0.587633801765722,0.766452983413496,0.649434493277082,0.105730795861453,0.117018490136414,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
29165,1011:1052,Breast,CAL-51,SIDM00933,910927,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1052,RO-3306,CDK1,Cell cycle,Targeted,Experimental only,10.0,0.754375239865387,0.0902340031975195,0.523838938782359,9.21593791277763,11.6146,0.836287337807625,0.856155470477951,0.150572094767076,0.395171125094772,0.149068314460873,0.246102810633899,5.82902144787977,1.1103,3.38691646489786,10.5043,0.630874461055013,0.519529920560767,0.645862488403868,0.485733816966305,0.111344540494246,0.160128671437563,True,0.350958335207378,0.0449826280107119,0.991316499570475,49.3515852834387
29165,1012:1059,Breast,CAL-51,SIDM00933,910927,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.899732965262927,0.102878888600539,0.792419951845075,12.0312338720599,8.1751,0.894692901263778,0.948064828008386,0.0717717393367863,0.712966353007075,0.675514804021278,0.0374515489857974,11.495578444286,5.6395,0.535655427773829,2.5356,0.80498469705375,0.82452657365487,0.853005178965472,0.842190327459102,-0.0195418766011197,0.0108148515063698,True,0.350958335207378,0.0449826280107119,0.991316499570475,49.3515852834387
29165,1049:1059,Breast,CAL-51,SIDM00933,910927,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.959684364045645,0.102878888600539,0.792419951845075,12.0312338720599,8.1751,0.894692901263778,0.948064828008386,0.108948054428178,0.760473037543522,0.528006936161552,0.23246610138197,9.45580436325373,1.3715,2.57542950880614,6.8036,0.858622787965482,0.749046435758017,0.909842991541273,0.832059744039681,0.109576352207465,0.0777832475015914,True,0.350958335207378,0.0449826280107119,0.991316499570475,49.3515852834387
29165,1047:1059,Breast,CAL-51,SIDM00933,910927,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.914128399025072,0.102878888600539,0.792419951845075,12.0312338720599,8.1751,0.894692901263778,0.948064828008386,0.0965253177933132,0.724373581935663,0.461987565924765,0.262386016010898,9.0487510905116,1.0344,2.98248278154827,7.1407,0.817864189451354,0.706716015998941,0.866652983399287,0.775389582100698,0.111148173452413,0.0912634012985888,True,0.350958335207378,0.0449826280107119,0.991316499570475,49.3515852834387
29165,1561:1059,Breast,CAL-51,SIDM00933,910927,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.930384383382167,0.102878888600539,0.792419951845075,12.0312338720599,8.1751,0.894692901263778,0.948064828008386,0.12313576665775,0.737255148277107,0.416412044000073,0.320843104277034,8.52368670954119,0.7188,3.50754716251867,7.4563,0.832408303258702,0.712926676793833,0.882064710412902,0.764240683078983,0.119481626464869,0.11782402733392,True,0.350958335207378,0.0449826280107119,0.991316499570475,49.3515852834387
29165,1179:1059,Breast,CAL-51,SIDM00933,910927,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.721153010017347,0.102878888600539,0.792419951845075,12.0312338720599,8.1751,0.894692901263778,0.948064828008386,0.0820454912972523,0.571456033470877,0.255652501991518,0.315803531479359,7.64389731483439,0.3906,4.38733655722547,7.7845,0.645210478787526,0.50623453483151,0.683699804409826,0.555464808903283,0.138975943956016,0.128234995506543,True,0.350958335207378,0.0449826280107119,0.991316499570475,49.3515852834387
29165,1053:1059,Breast,CAL-51,SIDM00933,910927,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.990834505240008,0.102878888600539,0.792419951845075,12.0312338720599,8.1751,0.894692901263778,0.948064828008386,0.103399915493919,0.785157030928727,0.57998925118625,0.205167779742476,9.78020899088808,1.7174,2.25102488117179,6.4577,0.886492598165443,0.80666193851481,0.939375344795143,0.872666542232315,0.0798306596506325,0.0667088025628281,True,0.350958335207378,0.0449826280107119,0.991316499570475,49.3515852834387
23550,1011:1080,Breast,CAL-51,SIDM00933,910927,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.71174886085315,0.0709368848961427,0.688688180856109,10.7966751734383,0.3474,0.898350363420463,0.91683240982217,0.0794233389551666,0.490173028207364,0.174760141880623,0.315412886326741,6.45982764807907,0.0172,4.33684752535922,0.3302,0.639399847811528,0.483330754184854,0.652554423284179,0.491427352218671,0.156069093626674,0.161127071065508,True,0.712052186993795,0.0594619573924292,0.310434235108037,150.6425287284
23550,1561:1080,Breast,CAL-51,SIDM00933,910927,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.924786910587501,0.0709368848961427,0.688688180856109,10.7966751734383,0.3474,0.898350363420463,0.91683240982217,0.064476298640437,0.636889815132047,0.59962873063306,0.0372610844989867,10.3848515996454,0.2611,0.411823573792923,0.0863,0.830782657212769,0.826428966617506,0.847874611805938,0.835484981486314,0.0043536905952625,0.0123896303196239,True,0.712052186993795,0.0594619573924292,0.310434235108037,150.6425287284
25015,1047:1096,Breast,CAL-51,SIDM00933,910927,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.7824280829382,0.140966738287399,0.502059753863198,9.01864362515612,5.065,0.757131628623728,0.846769444866781,0.119171927293205,0.392825650735606,0.164489610448953,0.228336040286654,6.0050460695709,0.6272,3.01359755558522,4.4378,0.592401048715941,0.44622520587932,0.662536193437759,0.514142705632195,0.146175842836621,0.148393487805563,True,0.135415023081001,0.0304704527633978,1.89014286052259,26.1886554136554
25015,1011:1096,Breast,CAL-51,SIDM00933,910927,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.874186728695784,0.140966738287399,0.502059753863198,9.01864362515612,5.065,0.757131628623728,0.846769444866781,0.0859436244805392,0.43889397383948,0.0388291952218841,0.400064778617595,2.05607153126065,0.0406,6.96257209389546,5.0244,0.661874421618688,0.282726162081925,0.740234610967636,0.303745576920174,0.379148259536763,0.436489034047462,True,0.135415023081001,0.0304704527633978,1.89014286052259,26.1886554136554
25015,1049:1096,Breast,CAL-51,SIDM00933,910927,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.861919687457297,0.140966738287399,0.502059753863198,9.01864362515612,5.065,0.757131628623728,0.846769444866781,0.16031354693578,0.432735186134655,0.19158289891379,0.241152287220865,6.1658924239645,0.7012,2.85275120119161,4.3638,0.652586656707398,0.485082455867449,0.729847255267964,0.576663631978838,0.167504200839949,0.153183623289127,True,0.135415023081001,0.0304704527633978,1.89014286052259,26.1886554136554
25016,1011:1192,Breast,CAL-51,SIDM00933,910927,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.909719520769137,0.0858121757060902,0.584394694113401,9.77126545064595,17.0677,0.870873542440895,0.880375261527799,0.112461210976293,0.53163526106887,0.196001974887355,0.335633286181515,6.07559879198038,1.3172,3.69566665866557,15.7505,0.792250661679852,0.609499648804428,0.800894561014074,0.602565979680184,0.182751012875424,0.19832858133389,True,0.135415023081001,0.0304704527633978,1.89014286052259,26.1886554136554
23849,1047:1553,Breast,CAL-51,SIDM00933,910927,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.92636099792078,0.0867283176812034,0.59233420258821,9.84544728027052,17.9682,0.818383973608264,0.883366837158531,0.06944075072799,0.548715303012224,0.281667176746812,0.267048126265412,7.12626222000145,2.7287,2.71918506026907,15.2395,0.758118994474125,0.638794961058675,0.8183165848003,0.682500459144943,0.11932403341545,0.135816125655356,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
23849,1190:1553,Breast,CAL-51,SIDM00933,910927,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.1,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.391971525257471,0.0867283176812034,0.59233420258821,9.84544728027052,17.9682,0.818383973608264,0.883366837158531,0.0586084351461535,0.232178140850668,0.0901122621842296,0.142065878666439,6.26445014875691,1.5015,3.58099713151362,16.4667,0.320783214381501,0.217241199138255,0.346254646522897,0.265083696938396,0.103542015243246,0.0811709495845007,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
23849,1179:1553,Breast,CAL-51,SIDM00933,910927,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.236113375888561,0.0867283176812034,0.59233420258821,9.84544728027052,17.9682,0.818383973608264,0.883366837158531,0.0567266161550905,0.139858028227361,0.0898834729563101,0.0499745552710514,7.89875595838511,4.6611,1.94669132188542,13.3071,0.193231402781743,0.135279707377227,0.208574726069502,0.18554892631541,0.057951695404516,0.0230257997540923,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
23849,1005:1553,Breast,CAL-51,SIDM00933,910927,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.667849281447293,0.0867283176812034,0.59233420258821,9.84544728027052,17.9682,0.818383973608264,0.883366837158531,0.0553781725654713,0.395589971575192,0.233708630528179,0.161881341047012,7.59864220409925,3.7857,2.24680507617127,14.1825,0.54655714872226,0.490845927143127,0.589955907450693,0.51251552999335,0.0557112215791325,0.0774403774573432,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
23849,1011:1553,Breast,CAL-51,SIDM00933,910927,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.860689541485231,0.0867283176812034,0.59233420258821,9.84544728027052,17.9682,0.818383973608264,0.883366837158531,0.0533367405560844,0.509815853231667,0.304682078298492,0.205133774933175,7.63887660648082,3.8928,2.20657067378971,14.0754,0.704374527003758,0.647791807715686,0.760304598037235,0.662672421693966,0.0565827192880723,0.0976321763432687,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
23849,1594:1553,Breast,CAL-51,SIDM00933,910927,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.999135331042764,0.0867283176812034,0.59233420258821,9.84544728027052,17.9682,0.818383973608264,0.883366837158531,0.0935623392858224,0.591822029590923,0.338252802152483,0.253569227438441,7.48439363475504,3.4975,2.36105364551548,14.4707,0.817676342391185,0.723748673874668,0.882603017276588,0.759518851866266,0.093927668516517,0.123084165410322,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
23849,1083:1560,Breast,CAL-51,SIDM00933,910927,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.910101176671378,0.0551639691087999,0.713686951429103,11.0667784639075,41.895,0.909590442577674,0.924762828375212,0.0613385092413264,0.649527334270635,0.361574762085224,0.287952572185411,8.05692658782699,5.2012,3.00985187608051,36.6938,0.82781933207898,0.741899358060101,0.841627738246232,0.723728635678435,0.085919974018879,0.117899102567797,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
23849,1190:1560,Breast,CAL-51,SIDM00933,910927,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.01,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.634976366674346,0.0551639691087999,0.713686951429103,11.0667784639075,41.895,0.909590442577674,0.924762828375212,0.053071515324525,0.453174347361342,0.316621522264696,0.136552825096646,8.98764606286861,9.9147,2.07913240103889,31.9803,0.577568434389681,0.494608741694697,0.587202540797184,0.536718524041141,0.0829596926949845,0.050484016756043,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
23849,1021:1560,Breast,CAL-51,SIDM00933,910927,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.812672320568609,0.0551639691087999,0.713686951429103,11.0667784639075,41.895,0.909590442577674,0.924762828375212,0.0824941233402252,0.579993630977425,0.480037068614505,0.0999565623629203,9.8300452699933,17.7774,1.23673319391419,24.1176,0.739198975736627,0.666575641932617,0.751529153711274,0.717386806112849,0.0726233338040091,0.0341423475984258,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
23849,1510:1560,Breast,CAL-51,SIDM00933,910927,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.911253959881742,0.0551639691087999,0.713686951429103,11.0667784639075,41.895,0.909590442577674,0.924762828375212,0.0472224830623939,0.650350060605698,0.42339160732115,0.226958453284548,8.67927557053865,8.0067,2.38750289336885,33.8883,0.828867892669491,0.746482576520337,0.842693789308351,0.756037314252307,0.082385316149154,0.0866564750560448,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
23849,1053:1560,Breast,CAL-51,SIDM00933,910927,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.952958844607207,0.0551639691087999,0.713686951429103,11.0667784639075,41.895,0.909590442577674,0.924762828375212,0.057249465950778,0.680114292645117,0.559188690680705,0.120925601964412,9.79362002414173,17.3342,1.27315843976577,24.5608,0.866802257224578,0.822996286878196,0.881260916464135,0.839826198664562,0.0438059703463813,0.0414347177995725,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
23850,1005:1593,Breast,CAL-51,SIDM00933,910927,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,1.0,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.892130978566456,0.0577543422374084,0.768126203541981,11.7103332030623,13.0895,0.912425436302389,0.941127344288258,0.072235689654501,0.685269181628444,0.648304598069317,0.0369645835591277,11.2128343897905,9.2717,0.497498813271838,3.8178,0.814002997357376,0.851569087285549,0.839608858615534,0.82859444173938,-0.0375660899281729,0.0110144168761541,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
23848,1005:2172,Breast,CAL-51,SIDM00933,910927,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.680642974385752,0.0699724794061583,0.737892806210652,11.3421344584372,50.7052,0.889819184653119,0.932185620619789,0.0713489773062452,0.502241554397068,0.327808023239313,0.174433531157755,8.83351826347698,8.9101,2.5086161949602,41.7951,0.605649176507804,0.527378461466467,0.634485593498282,0.570099485668448,0.0782707150413369,0.0643861078298342,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
23848,1012:2172,Breast,CAL-51,SIDM00933,910927,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.875305357040044,0.0699724794061583,0.737892806210652,11.3421344584372,50.7052,0.889819184653119,0.932185620619789,0.110375915937427,0.645881526197495,0.412694173155019,0.233187353042476,8.7416294336298,8.3603,2.60050502480738,42.3449,0.778863499123879,0.643515272113383,0.815947067484199,0.729041535550807,0.135348227010496,0.086905531933392,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
23848,1017:2172,Breast,CAL-51,SIDM00933,910927,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,2.5,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.891509998521667,0.0699724794061583,0.737892806210652,11.3421344584372,50.7052,0.889819184653119,0.932185620619789,0.0236611399435594,0.657838814574008,0.546884581362657,0.110954233211351,10.0449305418294,20.6327,1.29720391660779,30.0725,0.793282699994654,0.791997058396842,0.831052801260668,0.794452156149508,0.0012856415978118,0.0366006451111598,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
23848,1190:2172,Breast,CAL-51,SIDM00933,910927,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.01,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.695635354346966,0.0699724794061583,0.737892806210652,11.3421344584372,50.7052,0.889819184653119,0.932185620619789,0.0814808664030363,0.513304323718424,0.282205389338758,0.231098934379667,8.13593027969868,5.494,3.2062041787385,45.2112,0.618989683820901,0.510547358773168,0.648461274516994,0.55637399279435,0.108442325047733,0.0920872817226436,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
23848,1021:2172,Breast,CAL-51,SIDM00933,910927,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,4.0,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.829410690842987,0.0699724794061583,0.737892806210652,11.3421344584372,50.7052,0.889819184653119,0.932185620619789,0.0727754354646578,0.612016182167247,0.355169490097778,0.25684669206947,8.34576746338876,6.3541,2.99636699504842,44.3511,0.738025544668487,0.630890110040782,0.773164719592157,0.673228020628092,0.107135434627705,0.0999366989640652,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
23848,1047:2172,Breast,CAL-51,SIDM00933,910927,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.962535710443183,0.0699724794061583,0.737892806210652,11.3421344584372,50.7052,0.889819184653119,0.932185620619789,0.0520097027520166,0.710248176456884,0.389469711593978,0.320778464862906,8.12606025457578,5.4565,3.2160742038614,45.2487,0.856482741066064,0.73518991371832,0.897261948608188,0.76929414145907,0.121292827347743,0.127967807149117,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
25815,1022:1003,Breast,BT-549,SIDM00122,905951,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.739817673741611,0.080962586707361,0.630058620647371,10.6450453270129,0.3128,0.871170670614237,0.864330350656585,0.0486113127791339,0.466128503048186,0.227916481858339,0.238212021189846,6.50014731549094,0.0177,4.14489801152194,0.2951,0.644507458965744,0.473155548293518,0.639446869367025,0.490028887919387,0.171351910672226,0.149417981447639,True,0.439260134971284,0.057859028021508,0.790167407202078,62.0287632637178
25433,1179:1042,Breast,BT-549,SIDM00122,905951,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.415678355110078,0.0670019927523412,0.841869528759539,14.1662273971659,359.0785,0.948050682307439,0.949092471283843,0.0622525583671672,0.349946940932062,0.290323353624417,0.0596235873076448,11.5946785026445,60.4054,2.57154889452139,298.6731,0.394084148182544,0.368583780722452,0.394517197310627,0.371745686942594,0.0255003674600916,0.0227715103680334,True,0.48007583420443,0.0691850781264327,0.685633043817425,70.3849554459059
25433,1022:1046,Breast,BT-549,SIDM00122,905951,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1046,Wee1 Inhibitor,"WEE1, CHEK1",Cell cycle,Targeted,Experimental only,10.0,0.953231743571269,0.123965823072987,0.373964391480678,7.40816041494391,3.3175,0.763537142526469,0.715801175678638,0.0929234218027176,0.356474728924695,0.26370853562048,0.0927661933042154,6.03053684487135,1.2767,1.37762357007256,2.0408,0.727827841651931,0.58878007143838,0.682324402742512,0.603596436719388,0.139047770213551,0.0787279660231236,True,0.48007583420443,0.0691850781264327,0.685633043817425,70.3849554459059
25434,1011:1051,Breast,BT-549,SIDM00122,905951,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.767133698976271,0.143589212112984,0.550191767345068,9.62236014105678,15.3939,0.740578900682727,0.825175338253242,0.146748969905273,0.422070645629714,0.301249757922028,0.120820887707686,7.6530003675246,3.9311,1.96935977353217,11.4628,0.56812303146452,0.462555696886195,0.633019809538205,0.559581332193417,0.105567334578325,0.0734384773447875,True,0.48007583420443,0.0691850781264327,0.685633043817425,70.3849554459059
25819,1011:1086,Breast,BT-549,SIDM00122,905951,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1086,BI-2536,"PLK1, PLK2, PLK3",Cell cycle,Targeted,Early clinical trials,10.0,0.704490493516209,0.166130332891714,0.147404339047529,3.57765111023388,0.2332,0.46011264068026,0.471762868762943,0.114714832481862,0.103844955562024,0.036480883697068,0.0673640718649562,0.0173196113143703,0.0198,3.56033149891951,0.2134,0.324144981305883,0.182361855248378,0.332352456237428,0.178062047339765,0.141783126057505,0.154290408897663,True,0.439260134971284,0.057859028021508,0.790167407202078,62.0287632637178
25820,1011:1096,Breast,BT-549,SIDM00122,905951,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.749244494442054,0.0661670683798372,0.699713739450885,11.6134918229426,30.5992,0.86685078354703,0.89484576084017,0.105634479035463,0.524256666969038,0.32504709591389,0.199209571055148,8.17749378878301,2.8273,3.4359980341596,27.7719,0.649483177075393,0.493553145149478,0.670458259684309,0.567513710037465,0.155930031925915,0.102944549646844,True,0.439260134971284,0.057859028021508,0.790167407202078,62.0287632637178
25820,1011:1129,Breast,BT-549,SIDM00122,905951,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.749244494442054,0.0697770664749921,0.772494938626431,12.7767328667245,137.0597,0.91739212941428,0.923805846142441,0.0490895023181182,0.578787579750206,0.417200920481529,0.161586659268677,9.70533152490853,16.3052,3.07140134181602,120.7545,0.687351002208122,0.602268903083157,0.692156444155608,0.620842738221404,0.0850820991249646,0.0713137059342035,True,0.439260134971284,0.057859028021508,0.790167407202078,62.0287632637178
25821,1011:1192,Breast,BT-549,SIDM00122,905951,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.61508693601468,0.0795748210144357,0.355175542755858,7.15754470713406,2.7885,0.667832522206211,0.701482350502756,0.0747212078072444,0.218463836341051,0.0734082202487035,0.145055616092348,2.82526877374702,0.1384,4.33227593338705,2.6501,0.410775059854774,0.217641993562136,0.431472629639116,0.259513505738899,0.193133066292638,0.171959123900217,True,0.439260134971284,0.057859028021508,0.790167407202078,62.0287632637178
25435,1021:2172,Breast,BT-549,SIDM00122,905951,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.837075307325313,0.135121387998807,0.627649124180997,10.613150747254,30.5919,0.78941953407234,0.863218879747409,0.106406137313852,0.525389583516272,0.409146185494656,0.116243398021616,8.86132889913786,9.0836,1.75182184811617,21.5083,0.66080359909221,0.593641195456598,0.722579209053574,0.662364732280805,0.0671624036356117,0.0602144767727691,True,0.48007583420443,0.0691850781264327,0.685633043817425,70.3849554459059
25435,1191:2172,Breast,BT-549,SIDM00122,905951,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.0025,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.910995128830714,0.135121387998807,0.627649124180997,10.613150747254,30.5919,0.78941953407234,0.863218879747409,0.0835089731719543,0.571785294743752,0.229198925325034,0.342586369418718,5.63204267472462,0.9686,4.98110807252941,29.6233,0.719157350143714,0.538456337999702,0.786388194564595,0.553719559345945,0.180701012144012,0.23266863521865,True,0.48007583420443,0.0691850781264327,0.685633043817425,70.3849554459059
25435,1011:2172,Breast,BT-549,SIDM00122,905951,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.857794714140498,0.135121387998807,0.627649124180997,10.613150747254,30.5919,0.78941953407234,0.863218879747409,0.0501705255120873,0.538394101057373,0.213457160376698,0.324936940680674,5.58679401621751,0.9387,5.02635673103652,29.6532,0.677159903566508,0.500956985825136,0.740464592193609,0.518881994269147,0.176202917741373,0.221582597924462,True,0.48007583420443,0.0691850781264327,0.685633043817425,70.3849554459059
23588,1022:1013,Breast,HCC1143,SIDM00866,749710,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1013,Nilotinib,ABL,ABL signaling,Targeted,FDA approved,10.0,0.979644613206543,0.0770892397970328,0.769413271607271,13.2183886485467,186.1493,0.928639895899214,0.914214067037077,0.0613344921066153,0.753751566859686,0.75371143071314,4.01361465455219e-05,13.2175802877617,186.0451,0.0008083607850366,0.10420000000002,0.90973707162635,0.846424839276554,0.895604886090518,0.89558796507332,0.0633122323497962,1.69210171987455e-05,True,0.546227915609089,0.072899034644264,0.567374022417454,84.883032110697
23863,1049:1050,Breast,HCC1143,SIDM00866,749710,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.90284298145202,0.076894057780015,0.730528569218744,12.4913029159708,112.4571,0.923128566530212,0.897424810866889,0.0752404861685796,0.659552591469329,0.608476568223646,0.0510760232456831,11.5419988811323,58.2395,0.949304034838484,54.2176,0.833440147269667,0.810994375094243,0.810233691872077,0.786795220572671,0.0224457721754231,0.0234384712994056,True,0.847673427917615,0.0918835434609086,0.141300080327203,308.738200919289
23866,1049:1564,Breast,HCC1143,SIDM00866,749710,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.850816990713152,0.0791645367192591,0.650238779557799,11.1707664992594,22.5131,0.842609765409259,0.859980287078269,0.0472375003691937,0.553234201668359,0.548489110275371,0.0047450913929876,11.0852307767354,21.2171,0.0855357225240105,1.296,0.716906704951021,0.710340332167927,0.731685839924565,0.729340993173095,0.0065663727830932,0.0023448467514696,True,0.847673427917615,0.0918835434609086,0.141300080327203,308.738200919289
23866,1012:1564,Breast,HCC1143,SIDM00866,749710,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.640994602744477,0.0791645367192591,0.650238779557799,11.1707664992594,22.5131,0.842609765409259,0.859980287078269,0.113735018024015,0.416799548191705,0.230944872405538,0.185854675786167,6.99023065804686,1.2416,4.18053584121257,21.2715,0.540108311847125,0.374934503635062,0.551242722483816,0.433724384036652,0.165173808212063,0.117518338447164,True,0.847673427917615,0.0918835434609086,0.141300080327203,308.738200919289
23866,1372:1593,Breast,HCC1143,SIDM00866,749710,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.789874507307431,0.0576265298023521,0.645320783728049,11.0953075234572,8.5463,0.863024029057701,0.857551130244632,0.119139047225901,0.509722436102438,0.324137761789499,0.185584674312939,7.7311521809961,0.83,3.36415534246111,7.7163,0.681680679746425,0.583810709626002,0.677357776492909,0.565520314173046,0.0978699701204233,0.111837462319863,True,0.847673427917615,0.0918835434609086,0.141300080327203,308.738200919289
23864,1190:2172,Breast,HCC1143,SIDM00866,749710,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.1,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.880575066727662,0.0777373978666512,0.661735566299122,11.3491258779081,50.9515,0.841194746273307,0.86559401252058,0.0754940612857688,0.582707840449916,0.278975940209686,0.30373190024023,6.30980570420739,1.5494,5.03932017370069,49.4021,0.740735119830576,0.542002546370684,0.762220505334374,0.562252742480067,0.198732573459892,0.199967762854307,True,0.847673427917615,0.0918835434609086,0.141300080327203,308.738200919289
27075,1594:1003,Breast,Hs-578-T,SIDM00135,905957,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.712890458503318,0.0986502930784291,0.863433425454244,13.100325878843,1.7152,0.942305303537721,0.967742118379063,0.0828303794195378,0.615533450559167,0.360028307569638,0.255505142989529,9.04470344041071,0.1031,4.05562243843231,1.6121,0.671760459889115,0.554116114058118,0.689894122484223,0.606326234714982,0.117644345830997,0.0835678877692408,True,0.365803862566113,0.0690380380611123,0.965328189521898,50.911055800263
27075,1012:1003,Breast,Hs-578-T,SIDM00135,905957,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.838222177648993,0.0986502930784291,0.863433425454244,13.100325878843,1.7152,0.942305303537721,0.967742118379063,0.0455190243380374,0.723749046139185,0.7400303707972,-0.0162813246580142,13.4909106302117,2.2485,-0.390584751368721,-0.5333,0.789861203541584,0.829689283680348,0.811182905870348,0.815276336050551,-0.0398280801387639,-0.0040934301802033,True,0.365803862566113,0.0690380380611123,0.965328189521898,50.911055800263
27075,1179:1003,Breast,Hs-578-T,SIDM00135,905957,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.514794101529061,0.0986502930784291,0.863433425454244,13.100325878843,1.7152,0.942305303537721,0.967742118379063,0.0597276553813103,0.444490434486877,0.228882640719852,0.215607793767025,8.50533663450483,0.071,4.5949892443382,1.6442,0.48509321210077,0.388786830521041,0.49818793434278,0.423596439299658,0.0963063815797289,0.0745914950431222,True,0.365803862566113,0.0690380380611123,0.965328189521898,50.911055800263
27075,1191:1003,Breast,Hs-578-T,SIDM00135,905957,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.0025,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.372033625725758,0.0986502930784291,0.863433425454244,13.100325878843,1.7152,0.942305303537721,0.967742118379063,0.0927255591099732,0.321226267844553,0.171930153641333,0.14929611420322,8.66259548566338,0.0791,4.43773039317965,1.6361,0.350569258615749,0.253408283218299,0.360032609068088,0.309247093329934,0.0971609753974506,0.0507855157381537,True,0.365803862566113,0.0690380380611123,0.965328189521898,50.911055800263
27075,1022:1003,Breast,Hs-578-T,SIDM00135,905957,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.522050266663324,0.0986502930784291,0.863433425454244,13.100325878843,1.7152,0.942305303537721,0.967742118379063,0.0285191552745922,0.450755650004415,0.227765877945183,0.222989772059232,8.43028189292142,0.0674,4.6700439859216,1.6478,0.491930734990132,0.412716931419709,0.50521003096112,0.427429359555533,0.0792138035704225,0.0777806714055864,True,0.365803862566113,0.0690380380611123,0.965328189521898,50.911055800263
27075,1047:1003,Breast,Hs-578-T,SIDM00135,905957,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.923403490800205,0.0986502930784291,0.863433425454244,13.100325878843,1.7152,0.942305303537721,0.967742118379063,0.079186498894979,0.797297439138027,0.656534355424096,0.140763083713931,11.0016118030786,0.4004,2.09871407576446,1.3148,0.870128006686279,0.850377417610166,0.893616450305612,0.854299137301924,0.019750589076112,0.0393173130036877,True,0.365803862566113,0.0690380380611123,0.965328189521898,50.911055800263
27075,1011:1003,Breast,Hs-578-T,SIDM00135,905957,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.818196317216529,0.0986502930784291,0.863433425454244,13.100325878843,1.7152,0.942305303537721,0.967742118379063,0.05552677313724,0.706458048868315,0.20493508002623,0.501522968842084,6.562850786384,0.0185,6.53747509245902,1.6967,0.770990729048167,0.544414041999921,0.791803037273072,0.572303180596846,0.226576687048246,0.219499856676226,True,0.365803862566113,0.0690380380611123,0.965328189521898,50.911055800263
27075,1559:1003,Breast,Hs-578-T,SIDM00135,905957,1559,Luminespib,HSP90,Protein stability and degradation,Targeted,Early clinical trials,0.01,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.660450945768309,0.0986502930784291,0.863433425454244,13.100325878843,1.7152,0.942305303537721,0.967742118379063,0.0402695097489691,0.570255422449226,0.382643203687705,0.187612218761521,9.71189910484647,0.1638,3.38842677399655,1.5514,0.622346428923982,0.583247482905968,0.639146197343279,0.581480038185984,0.0390989460180141,0.0576661591572948,True,0.365803862566113,0.0690380380611123,0.965328189521898,50.911055800263
25085,1007:1025,Breast,Hs-578-T,SIDM00135,905957,1007,Docetaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.00025,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.770005004196641,0.120724013973701,0.736487785830934,11.2852749304554,48.7457,0.892152545918138,0.932876384514609,0.187107496426453,0.567099280619523,0.453205029745705,0.113894250873818,9.79616975414552,17.3648,1.48910517630987,31.3809,0.68696192486374,0.551467500522925,0.718319484373119,0.680583041466551,0.135494424340814,0.0377364429065672,True,0.532116710634315,0.107457460561628,0.588859162781535,81.6206801907577
25085,1011:1025,Breast,Hs-578-T,SIDM00135,905957,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.752739731467924,0.120724013973701,0.736487785830934,11.2852749304554,48.7457,0.892152545918138,0.932876384514609,0.113459423899151,0.554383618135783,0.359427106624668,0.194956511511115,8.79967934337061,8.7036,2.48559558708478,40.0421,0.671558667842844,0.616695217947326,0.702213119172294,0.631045901574551,0.0548634498955176,0.0711672175977436,True,0.532116710634315,0.107457460561628,0.588859162781535,81.6206801907577
25085,1053:1025,Breast,Hs-578-T,SIDM00135,905957,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.705853850980849,0.120724013973701,0.736487785830934,11.2852749304554,48.7457,0.892152545918138,0.932876384514609,0.0421286665058914,0.519852739829123,0.384800811727737,0.135051928101386,9.40271518860077,13.2199,1.88255974185463,35.5258,0.629729310198686,0.594122584283645,0.658474388498728,0.612089689486709,0.035606725915041,0.0463846990120192,True,0.532116710634315,0.107457460561628,0.588859162781535,81.6206801907577
26772,1011:1042,Breast,Hs-578-T,SIDM00135,905957,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.827332173834478,0.130569947883041,0.625039145652219,10.1361808923523,21.9798,0.898774871501426,0.896990273767775,0.171849234768403,0.517114995104095,0.274217333457263,0.242897661646832,7.43990854432666,3.3913,2.69627234802563,18.5885,0.743585368227078,0.640108201070152,0.742108913104677,0.628279591498086,0.103477167156926,0.113829321606591,True,0.475170786745362,0.083764377779771,0.702567472245077,69.0740616224605
26773,1011:1050,Breast,Hs-578-T,SIDM00135,905957,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.82383710854052,0.136034089430592,0.390497115499369,8.01005625207837,5.035,0.826545292755736,0.794750618403388,0.0526864051623423,0.321706014526414,0.0565179678451702,0.265188046681244,3.20040415390562,0.1795,4.80965209817274,4.8555,0.680938684061664,0.347134687237726,0.654745051476238,0.35881969897011,0.333803996823937,0.295925352506128,True,0.475170786745362,0.083764377779771,0.702567472245077,69.0740616224605
26773,1011:1051,Breast,Hs-578-T,SIDM00135,905957,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.82383710854052,0.199978364511154,0.310274077516982,7.22380069713128,2.9195,0.648555188145882,0.745224313340452,0.148109626331529,0.255615298876668,0.0156742089308408,0.239941089945827,0.233388878839388,0.023,6.9904118182919,2.8965,0.534303830931056,0.223743389192578,0.613943443516493,0.181213526354666,0.310560441738478,0.432729917161827,True,0.475170786745362,0.083764377779771,0.702567472245077,69.0740616224605
26773,1561:1051,Breast,Hs-578-T,SIDM00135,905957,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.914132727498124,0.199978364511154,0.310274077516982,7.22380069713128,2.9195,0.648555188145882,0.745224313340452,0.179594020079659,0.283631688752563,0.0864770098191281,0.197154678933435,3.97778881426932,0.3077,3.24601188286196,2.6118,0.592865523072854,0.423328976824076,0.681233934151824,0.455423611187393,0.169536546248778,0.225810322964431,True,0.475170786745362,0.083764377779771,0.702567472245077,69.0740616224605
27076,1011:1052,Breast,Hs-578-T,SIDM00135,905957,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1052,RO-3306,CDK1,Cell cycle,Targeted,Experimental only,10.0,0.79307899409099,0.12027032165192,0.379281278271661,7.90471487585208,4.6804,0.773267937840175,0.788455095644487,0.108703365959611,0.300800014649234,0.104916621883751,0.195883392765482,4.8179517807291,0.5509,3.08676309512298,4.1295,0.6132625583051,0.435509030810942,0.625307174139645,0.448820283603268,0.177753527494158,0.176486890536377,True,0.365803862566113,0.0690380380611123,0.965328189521898,50.911055800263
25856,1022:1085,Breast,Hs-578-T,SIDM00135,905957,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.642566880621002,0.123511045505695,0.479465923505854,8.81726895668408,8.8103,0.891341016719987,0.839228368192228,0.0988597325567822,0.308088922831224,0.117222784781148,0.190866138050077,5.66483375259097,0.9909,3.15243520409311,7.8194,0.572746216683315,0.393089817477266,0.539260354677933,0.406441886703008,0.179656399206048,0.132818467974925,True,0.267097541031162,0.0635120476940969,1.2666714972128,38.9519367860063
25856,1011:1085,Breast,Hs-578-T,SIDM00135,905957,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.964679061781894,0.123511045505695,0.479465923505854,8.81726895668408,8.8103,0.891341016719987,0.839228368192228,0.161022768062437,0.462530737244016,0.25350752106203,0.209023216181986,6.70643762274455,2.0397,2.11083133393953,6.7706,0.859858015737157,0.698023080012068,0.809586034848428,0.684627532728869,0.161834935725089,0.124958502119559,True,0.267097541031162,0.0635120476940969,1.2666714972128,38.9519367860063
25089,1047:1096,Breast,Hs-578-T,SIDM00135,905957,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.895281337307851,0.118549345391759,0.649553003543763,10.3720525892893,12.9419,0.83862247642194,0.905395450807786,0.17201441920668,0.581532681664991,0.352847441545951,0.22868524011904,8.04383679373866,2.5771,2.32821579555067,10.3648,0.750803052187456,0.59065493732458,0.810583649991639,0.713311956733263,0.160148114862876,0.0972716932583761,True,0.532116710634315,0.107457460561628,0.588859162781535,81.6206801907577
25089,1022:1096,Breast,Hs-578-T,SIDM00135,905957,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.971509406845898,0.118549345391759,0.649553003543763,10.3720525892893,12.9419,0.83862247642194,0.905395450807786,0.152552771044475,0.631046853187772,0.491910516446213,0.139136336741559,9.05635785828935,5.1992,1.31569473099998,7.7427,0.814729624636317,0.719966142532285,0.879600197375246,0.826833822362456,0.0947634821040323,0.0527663750127898,True,0.532116710634315,0.107457460561628,0.588859162781535,81.6206801907577
25089,1011:1096,Breast,Hs-578-T,SIDM00135,905957,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.869035276830005,0.118549345391759,0.649553003543763,10.3720525892893,12.9419,0.83862247642194,0.905395450807786,0.121050705226093,0.564484474250415,0.103401596902737,0.461082877347678,4.54841162987612,0.2285,5.8236409594132,12.7134,0.728792515953205,0.427155719224635,0.786820586233371,0.473010079927624,0.30163679672857,0.313810506305746,True,0.532116710634315,0.107457460561628,0.588859162781535,81.6206801907577
25089,1058:1129,Breast,Hs-578-T,SIDM00135,905957,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.69141589500502,0.0978982500476824,0.835258516359628,12.6095136265453,122.0596,0.937571042302476,0.960462167837388,0.0513672005318098,0.577511014649357,0.481708170072214,0.0958028445771432,10.8490969664782,36.0275,1.76041666006711,86.0321,0.648251521344356,0.63398615937338,0.664078809393749,0.636599255114424,0.0142653619709762,0.0274795542793246,True,0.532116710634315,0.107457460561628,0.588859162781535,81.6206801907577
27077,1049:1192,Breast,Hs-578-T,SIDM00135,905957,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.844154652572654,0.120953862935701,0.526751459751899,9.2381525405697,11.7948,0.790504930851237,0.859682943628311,0.0893780562844754,0.444659695499002,0.282929720909501,0.161729974589501,7.47708826662957,3.4798,1.76106427394012,8.315,0.667308415259696,0.640847377181946,0.725705356601193,0.643078712652425,0.02646103807775,0.0826266439487675,True,0.365803862566113,0.0690380380611123,0.965328189521898,50.911055800263
27077,1011:1192,Breast,Hs-578-T,SIDM00135,905957,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.785325700143283,0.120953862935701,0.526751459751899,9.2381525405697,11.7948,0.790504930851237,0.859682943628311,0.115860052787428,0.413671458931156,0.161885087185222,0.251786371745934,6.00193620972098,1.2517,3.23621633084872,10.5431,0.620803838287465,0.453954418440929,0.675131109606142,0.516904217064483,0.166849419846536,0.158226892541659,True,0.365803862566113,0.0690380380611123,0.965328189521898,50.911055800263
26775,1049:1560,Breast,Hs-578-T,SIDM00135,905957,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.619971365136852,0.1072228457132,0.498925823273003,8.99044635218944,9.934,0.825513955462705,0.847875259956889,0.0703623858964001,0.309319723756592,0.126930336934019,0.182389386822573,5.98284272275435,1.2352,3.00760362943509,8.6988,0.511795013907736,0.428923278732161,0.525658382381236,0.407175722004226,0.0828717351755749,0.11848266037701,True,0.475170786745362,0.083764377779771,0.702567472245077,69.0740616224605
26776,1561:1564,Breast,Hs-578-T,SIDM00135,905957,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.867436187164528,0.137681426396964,0.622424420457146,10.1114086796666,10.8028,0.817057276219375,0.896074708010054,0.116086045659964,0.539913466079438,0.327759156478795,0.212154309600643,7.89116975214062,2.3183,2.22023892752603,8.4845,0.708745048378769,0.627769420496103,0.777287628130809,0.683225419822306,0.0809756278826655,0.0940622083085025,True,0.475170786745362,0.083764377779771,0.702567472245077,69.0740616224605
26776,1011:1564,Breast,Hs-578-T,SIDM00135,905957,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.703616027524183,0.137681426396964,0.622424420457146,10.1114086796666,10.8028,0.817057276219375,0.896074708010054,0.0541270293403209,0.437947798156099,0.223934737068161,0.214013061087938,7.30622731278806,1.5456,2.80518136687859,9.2572,0.574894594953206,0.523620856578812,0.630492526414927,0.528191227939739,0.051273738374394,0.102301298475188,True,0.475170786745362,0.083764377779771,0.702567472245077,69.0740616224605
26776,1559:1564,Breast,Hs-578-T,SIDM00135,905957,1559,Luminespib,HSP90,Protein stability and degradation,Targeted,Early clinical trials,0.01,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.7969519219362,0.137681426396964,0.622424420457146,10.1114086796666,10.8028,0.817057276219375,0.896074708010054,0.104941382201542,0.496042338143348,0.280178667779589,0.21586367036376,7.63883860085425,1.9463,2.4725700788124,8.8565,0.651155366614987,0.539260683365294,0.714128460747032,0.615315565688994,0.111894683249693,0.0988128950580381,True,0.475170786745362,0.083764377779771,0.702567472245077,69.0740616224605
26776,1053:1564,Breast,Hs-578-T,SIDM00135,905957,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.652641897853152,0.137681426396964,0.622424420457146,10.1114086796666,10.8028,0.817057276219375,0.896074708010054,0.0725840686130515,0.4062202550373,0.205894523470173,0.200325731567127,7.27762891018891,1.5153,2.83377976947774,9.2875,0.533245811406539,0.44808195030154,0.58481589805389,0.488694648216962,0.0851638611049989,0.0961212498369288,True,0.475170786745362,0.083764377779771,0.702567472245077,69.0740616224605
26776,1049:1593,Breast,Hs-578-T,SIDM00135,905957,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.742510053644942,0.0857205130224845,0.700805864120838,10.8924871641236,7.4255,0.895116660585295,0.922004657348037,0.077939311618856,0.520355399763053,0.313095367749234,0.207260032013819,8.29756939890954,1.2291,2.59491776521409,6.1964,0.664633119669668,0.613869975204937,0.684597727588377,0.602448146886933,0.0507631444647318,0.0821495807014436,True,0.475170786745362,0.083764377779771,0.702567472245077,69.0740616224605
26776,1047:1593,Breast,Hs-578-T,SIDM00135,905957,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.923424699441333,0.0857205130224845,0.700805864120838,10.8924871641236,7.4255,0.895116660585295,0.922004657348037,0.101250054887113,0.647141444442508,0.515126976724334,0.132014467718174,9.51677364619437,2.8615,1.37571351792925,4.564,0.826572833265906,0.770090586087487,0.85140187359512,0.805388069888409,0.0564822471784183,0.0460138037067107,True,0.475170786745362,0.083764377779771,0.702567472245077,69.0740616224605
26776,1011:1593,Breast,Hs-578-T,SIDM00135,905957,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.703616027524183,0.0857205130224845,0.700805864120838,10.8924871641236,7.4255,0.895116660585295,0.922004657348037,0.0779853145137781,0.493098238178356,0.274966575207405,0.218131662970952,8.0127982163277,1.0089,2.87968894779593,6.4166,0.629818428891738,0.593192973164472,0.648737254362021,0.559313540984637,0.0366254557272658,0.0894237133773846,True,0.475170786745362,0.083764377779771,0.702567472245077,69.0740616224605
26776,1549:1593,Breast,Hs-578-T,SIDM00135,905957,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.878789810755939,0.0857205130224845,0.700805864120838,10.8924871641236,7.4255,0.895116660585295,0.922004657348037,0.0521269723291058,0.615861052707403,0.60297789210933,0.012883160598073,10.7391185313568,6.6766,0.153368632766805,0.748900000000001,0.786619400760239,0.816790094541955,0.810248298346975,0.806183463459269,-0.0301706937817152,0.0040648348877068,True,0.475170786745362,0.083764377779771,0.702567472245077,69.0740616224605
26776,1561:1593,Breast,Hs-578-T,SIDM00135,905957,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.867436187164528,0.0857205130224845,0.700805864120838,10.8924871641236,7.4255,0.895116660585295,0.922004657348037,0.0901094922556321,0.607904366715522,0.375667318503641,0.232237048211881,8.40120656480249,1.3206,2.49128059932114,6.1049,0.776456583125553,0.702243384557287,0.799780204517918,0.708824773886425,0.0742131985682659,0.0909554306314929,True,0.475170786745362,0.083764377779771,0.702567472245077,69.0740616224605
27078,1049:1632,Breast,Hs-578-T,SIDM00135,905957,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.665472666647804,0.0850842804174838,0.894714726016267,13.7578678779333,108.2233,0.935440857359884,0.975554941607511,0.152268974986235,0.595408194611105,0.361131262396283,0.234276932214822,9.38041793137842,5.2069,4.3774499465549,103.0164,0.62251032183859,0.487191842762217,0.649205148452993,0.576409635114761,0.135318479076373,0.0727955133382319,True,0.365803862566113,0.0690380380611123,0.965328189521898,50.911055800263
27078,1561:1632,Breast,Hs-578-T,SIDM00135,905957,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.92131080819315,0.0850842804174838,0.894714726016267,13.7578678779333,108.2233,0.935440857359884,0.975554941607511,0.168347832350096,0.82431034732836,0.706143381332236,0.118166965996124,11.64238532592,24.9745,2.11548255201332,83.2488,0.861831772311127,0.719459220340532,0.898789311689237,0.867518610785224,0.142372551970595,0.031270700904013,True,0.365803862566113,0.0690380380611123,0.965328189521898,50.911055800263
27078,1007:1909,Breast,Hs-578-T,SIDM00135,905957,1007,Docetaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.00025,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.925409505133233,0.0494370429395774,0.936895109123058,14.9984389327792,63.9308,0.979821030586105,0.98567322582756,0.17523652596996,0.867011639295316,0.724650440798094,0.142361198497222,11.8540204760359,7.2301,3.14441845674327,56.7007,0.906735695033822,0.735374665093796,0.91215137213616,0.875724749764013,0.171361029940027,0.0364266223721471,True,0.365803862566113,0.0690380380611123,0.965328189521898,50.911055800263
27078,1191:1909,Breast,Hs-578-T,SIDM00135,905957,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.000625,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.971018506628477,0.0494370429395774,0.936895109123058,14.9984389327792,63.9308,0.979821030586105,0.98567322582756,0.0652231625035169,0.909742489728196,0.897129681529852,0.012612808198344,14.5512214006666,46.8904,0.447217532112601,17.0404,0.951424353882895,0.930811969346424,0.95710694376675,0.954128729658671,0.0206123845364704,0.0029782141080788,True,0.365803862566113,0.0690380380611123,0.965328189521898,50.911055800263
25087,1021:2169,Breast,Hs-578-T,SIDM00135,905957,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.734826726995058,0.108455492900088,0.389047070466104,7.99650086578741,4.9879,0.760134773759731,0.793946661556034,0.0739651982911166,0.285882185437623,0.204924836307555,0.0809573491300674,6.88758783705137,2.3126,1.10891302873604,2.6753,0.558567347876992,0.53469947414091,0.583413226719874,0.530821715232423,0.0238678737360822,0.0525915114874509,True,0.532116710634315,0.107457460561628,0.588859162781535,81.6206801907577
25087,1049:2169,Breast,Hs-578-T,SIDM00135,905957,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.806271985844106,0.108455492900088,0.389047070466104,7.99650086578741,4.9879,0.760134773759731,0.793946661556034,0.0695988310126715,0.313677754091537,0.227526241203434,0.0861515128881033,6.92416614566556,2.372,1.07233472012185,2.6159,0.612875373548418,0.579837333941937,0.640136951467081,0.584472062205392,0.0330380396064817,0.0556648892616891,True,0.532116710634315,0.107457460561628,0.588859162781535,81.6206801907577
25087,1022:2169,Breast,Hs-578-T,SIDM00135,905957,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.609577476357462,0.108455492900088,0.389047070466104,7.99650086578741,4.9879,0.760134773759731,0.793946661556034,0.19510472971388,0.237154331398991,0.0421605383714587,0.194993793027533,3.21982512625773,0.182,4.77667573952968,4.8059,0.463361037080007,0.261944323356111,0.483972002313759,0.266446985333653,0.201416713723896,0.217525016980106,True,0.532116710634315,0.107457460561628,0.588859162781535,81.6206801907577
25087,1012:2169,Breast,Hs-578-T,SIDM00135,905957,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.69370122544001,0.108455492900088,0.389047070466104,7.99650086578741,4.9879,0.760134773759731,0.793946661556034,0.162070426276191,0.269882429536182,0.0862046586454926,0.183677770890689,4.65838734413599,0.4932,3.33811352165142,4.4947,0.52730642405669,0.345515612376786,0.550761772055426,0.383710088144755,0.181790811679905,0.167051683910671,True,0.532116710634315,0.107457460561628,0.588859162781535,81.6206801907577
26774,1561:2172,Breast,Hs-578-T,SIDM00135,905957,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.916539955620043,0.135654273671593,0.128274178159412,4.73913815583762,0.5216,0.530493268467518,0.559612152875377,0.0880844040248573,0.117568409557425,0.0280968707789263,0.0894715387784988,1.32052429791145,0.0488,3.41861385792617,0.4728,0.48621827673795,0.272829897385985,0.512906897760835,0.267825844030753,0.213388379351966,0.245081053730082,True,0.475170786745362,0.083764377779771,0.702567472245077,69.0740616224605
23596,1011:1003,Breast,MDA-MB-361,SIDM00528,908121,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.708261980385283,0.0663046954535147,0.75583792062498,11.9670330430899,0.7819,0.92987354951715,0.928373781288798,0.0438503507889945,0.535331262512143,0.294842849980663,0.24048841253148,8.11246062605557,0.0541,3.85457241703435,0.7278,0.658594081688909,0.526579475503508,0.657531852873378,0.550980169038645,0.132014606185401,0.106551683834733,True,0.616140688182289,0.0701054918648606,0.453927077406696,105.569384254758
23596,1053:1013,Breast,MDA-MB-361,SIDM00528,908121,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1013,Nilotinib,ABL,ABL signaling,Targeted,FDA approved,10.0,0.573462894007447,0.0765745949788281,0.858795524032739,13.7402430584615,267.2732,0.956327594097672,0.96098623188681,0.0275778566443876,0.492487366572457,0.447366145142811,0.045121221429646,12.3250038920346,100.2134,1.41523916642693,167.0598,0.54841838973043,0.523824735199838,0.551089945639122,0.537011353815456,0.0245936545305925,0.014078591823666,True,0.616140688182289,0.0701054918648606,0.453927077406696,105.569384254758
25483,1561:1032,Breast,MDA-MB-361,SIDM00528,908121,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.431051333916104,0.192065937036644,0.305262358113954,6.84071796190257,2.2387,0.613562431287046,0.701369467516364,0.0648964299119472,0.131583746659395,0.0198907185607511,0.111693028098644,1.0474457856398,0.0404,5.79327217626278,2.1983,0.264476904447089,0.0846987648492333,0.302326244540956,0.125624876161799,0.179778139597856,0.176701368379158,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
25483,1058:1032,Breast,MDA-MB-361,SIDM00528,908121,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.479467096061974,0.192065937036644,0.305262358113954,6.84071796190257,2.2387,0.613562431287046,0.701369467516364,0.0500887023280757,0.146363256381928,0.0241709422363392,0.122192314145588,1.29146253843882,0.0478,5.54925542346375,2.1909,0.294182997181924,0.107458247454853,0.336283581856604,0.147308134754793,0.186724749727071,0.188975447101812,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
25483,1510:1032,Breast,MDA-MB-361,SIDM00528,908121,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.928146430029684,0.192065937036644,0.305262358113954,6.84071796190257,2.2387,0.613562431287046,0.701369467516364,0.101280419013336,0.283328167905909,0.0594747299401007,0.223853437965808,1.95939776829128,0.076,4.88132019361129,2.1627,0.569475780199405,0.298659267082742,0.650973567407134,0.326929181353281,0.270816513116662,0.324044386053853,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
25483,1012:1032,Breast,MDA-MB-361,SIDM00528,908121,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.382412970564966,0.192065937036644,0.305262358113954,6.84071796190257,2.2387,0.613562431287046,0.701369467516364,0.159541527518239,0.116736285168023,0.0320063232967124,0.0847299618713109,2.71626494215493,0.1284,4.12445301974764,2.1103,0.234634231975542,0.120403700047665,0.268212781536501,0.155167619344197,0.114230531927876,0.113045162192304,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
25483,1011:1032,Breast,MDA-MB-361,SIDM00528,908121,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.673575347055991,0.192065937036644,0.305262358113954,6.84071796190257,2.2387,0.613562431287046,0.701369467516364,0.0621149069439039,0.205617198809736,0.016215561879125,0.189401636930611,-0.721043875803908,0.0118,7.56176183770648,2.2269,0.413280527594689,0.107280862119405,0.472425182496811,0.127925221773432,0.305999665475285,0.344499960723378,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
25483,1021:1032,Breast,MDA-MB-361,SIDM00528,908121,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,4.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.990011991314927,0.192065937036644,0.305262358113954,6.84071796190257,2.2387,0.613562431287046,0.701369467516364,0.176539376821766,0.302213395029885,0.112073844550778,0.190139550479107,3.59520056447174,0.236,3.24551739743083,2.0027,0.607434164394516,0.435068590042432,0.694364183183366,0.465346752019701,0.172365574352084,0.229017431163665,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
25483,1594:1032,Breast,MDA-MB-361,SIDM00528,908121,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.89625880737499,0.192065937036644,0.305262358113954,6.84071796190257,2.2387,0.613562431287046,0.701369467516364,0.124857490821305,0.273594077019689,0.174903673762895,0.0986904032567945,5.27964820464164,0.7587,1.56106975726094,1.48,0.549910732915427,0.495748287341056,0.628608562485448,0.532329376970215,0.054162445574371,0.0962791855152332,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
25483,1053:1032,Breast,MDA-MB-361,SIDM00528,908121,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.599392274998963,0.192065937036644,0.305262358113954,6.84071796190257,2.2387,0.613562431287046,0.701369467516364,0.0682360592366487,0.182971899301471,0.015547299947652,0.167424599353819,-0.52014699352653,0.0136,7.3608649554291,2.2251,0.367764581543037,0.0952097155104991,0.420395440749445,0.119990403124494,0.272554866032538,0.300405037624951,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
25483,1058:1038,Breast,MDA-MB-361,SIDM00528,908121,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.813883669251709,0.102421690264968,0.54814127755713,9.50719039391484,14.2128,0.876245781334066,0.84689454836738,0.0738023480231237,0.446123234246517,0.243803219326556,0.202320014919961,6.76968374314146,2.1311,2.73750665077337,12.0817,0.713162131678501,0.551722056034553,0.689273642494512,0.567081537655791,0.161440075643947,0.122192104838721,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
25483,1011:1038,Breast,MDA-MB-361,SIDM00528,908121,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.673575347055991,0.102421690264968,0.54814127755713,9.50719039391484,14.2128,0.876245781334066,0.84689454836738,0.0766672557485883,0.369214451266258,0.142162976169402,0.227051475096856,5.53783903618536,0.9074,3.96935135772948,13.3054,0.590217556268442,0.406328687555986,0.570447289336384,0.412533935781197,0.183888868712456,0.157913353555188,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
25483,1561:1038,Breast,MDA-MB-361,SIDM00528,908121,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.431051333916104,0.102421690264968,0.54814127755713,9.50719039391484,14.2128,0.876245781334066,0.84689454836738,0.0386332368238506,0.236277028865478,0.0924261478398498,0.143850881025628,5.59056390150536,0.9411,3.91662649240947,13.2717,0.377706912882408,0.250271330087531,0.365055024760035,0.265615942388972,0.127435582794877,0.0994390823710638,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
25483,1053:1038,Breast,MDA-MB-361,SIDM00528,908121,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.637653077555808,0.102421690264968,0.54814127755713,9.50719039391484,14.2128,0.876245781334066,0.84689454836738,0.0579849599999652,0.349523972569676,0.153508852476988,0.196015120092688,5.98405029385434,1.2363,3.5231401000605,12.9765,0.558740819162961,0.420641249425976,0.540024915131696,0.410549536020227,0.138099569736985,0.129475379111469,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
25484,1561:1042,Breast,MDA-MB-361,SIDM00528,908121,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.400239231752748,0.0844929428788114,0.813320804152199,12.8643397620389,145.6405,0.909878255113932,0.947078559766717,0.0848478512325568,0.325522893822403,0.218618695399637,0.106904198422766,9.48683083409499,14.0136,3.37750892794387,131.6269,0.364168973815331,0.270780571665667,0.37905799517053,0.338606123196975,0.0933884021496637,0.0404518719735548,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
25484,1011:1042,Breast,MDA-MB-361,SIDM00528,908121,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.591263363164089,0.0844929428788114,0.813320804152199,12.8643397620389,145.6405,0.909878255113932,0.947078559766717,0.0968281092592387,0.480886793994351,0.320838037953847,0.160048756040504,9.44883922357007,13.6494,3.41550053846879,131.9911,0.537977677188537,0.432860169675464,0.559972854428271,0.499231897178333,0.105117507513072,0.0607409572499381,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
25484,1053:1042,Breast,MDA-MB-361,SIDM00528,908121,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.412110164783795,0.0844929428788114,0.813320804152199,12.8643397620389,145.6405,0.909878255113932,0.947078559766717,0.138043944992874,0.335177770621252,0.192566648414657,0.142611122206595,8.65574864957849,7.8772,4.20859111246037,137.7633,0.374970077648195,0.213830425349702,0.390300701328661,0.332482720501035,0.161139652298492,0.0578179808276266,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
25485,1058:1050,Breast,MDA-MB-361,SIDM00528,908121,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.777018189324341,0.0750848822973631,0.758381254330325,12.0033478140406,80.1859,0.913583532342182,0.929230167607891,0.111817513909132,0.589276029057272,0.442288278738347,0.146987750318925,9.73162104217476,16.605,2.2717267718658,63.5809,0.709871022097058,0.610813766881579,0.722028742300237,0.665447896498291,0.0990572552154786,0.0565808458019464,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
25485,1561:1050,Breast,MDA-MB-361,SIDM00528,908121,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.405995118734907,0.0750848822973631,0.758381254330325,12.0033478140406,80.1859,0.913583532342182,0.929230167607891,0.0553488843702358,0.307899087398168,0.184377688450666,0.123521398947502,8.51695871534661,7.1547,3.48638909869395,73.0312,0.37091045468752,0.294046220429159,0.377262912230023,0.32465298873501,0.0768642342583615,0.0526099234950137,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
25485,1012:1050,Breast,MDA-MB-361,SIDM00528,908121,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.321442392179286,0.0750848822973631,0.758381254330325,12.0033478140406,80.1859,0.913583532342182,0.929230167607891,0.0778678447292041,0.243775884575868,0.138103045835442,0.105672838740426,8.25603615387583,5.971,3.74731166016474,74.2149,0.293664476091674,0.227202649908609,0.29869396796104,0.252588114627302,0.0664618261830647,0.0461058533337381,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
25485,1011:1050,Breast,MDA-MB-361,SIDM00528,908121,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.613986884076635,0.0750848822973631,0.758381254330325,12.0033478140406,80.1859,0.913583532342182,0.929230167607891,0.0938277606967598,0.465636143288407,0.179104449623239,0.286531693665168,6.67071958132208,1.9898,5.33262823271848,78.1961,0.560928306366502,0.385078283162216,0.570535135199578,0.423826513418752,0.175850023204287,0.146708621780826,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
25485,1559:1050,Breast,MDA-MB-361,SIDM00528,908121,1559,Luminespib,HSP90,Protein stability and degradation,Targeted,Early clinical trials,0.01,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.848701958541961,0.0750848822973631,0.758381254330325,12.0033478140406,80.1859,0.913583532342182,0.929230167607891,0.0698257044284466,0.643639655871656,0.394394748161331,0.249244907710325,8.62866924783155,7.7307,3.37467856620902,72.4552,0.775360133190493,0.656855219391994,0.788639463185091,0.683546442364736,0.118504913798499,0.105093020820355,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
25485,1053:1050,Breast,MDA-MB-361,SIDM00528,908121,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.391934863631903,0.0750848822973631,0.758381254330325,12.0033478140406,80.1859,0.913583532342182,0.929230167607891,0.0451840940738006,0.297236053496947,0.170145277377795,0.127090776119152,8.30398729297679,6.1728,3.69936052106377,74.0131,0.358065237164885,0.269056176016742,0.364197699024049,0.308995243630196,0.0890090611481432,0.0552024553938524,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
25485,1559:1051,Breast,MDA-MB-361,SIDM00528,908121,1559,Luminespib,HSP90,Protein stability and degradation,Targeted,Early clinical trials,0.01,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.848701958541961,0.126672608075352,0.775445126397463,12.2540814982586,95.4061,0.878824317307112,0.934904758385257,0.102272757534606,0.658121797515345,0.344367210715237,0.313754586800108,7.99821028345642,4.9938,4.25587121480222,90.4123,0.745859919312847,0.584748613004696,0.793455499491766,0.654820721607364,0.161111306308151,0.138634777884403,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
25485,1011:1051,Breast,MDA-MB-361,SIDM00528,908121,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.613986884076635,0.126672608075352,0.775445126397463,12.2540814982586,95.4061,0.878824317307112,0.934904758385257,0.178529403348992,0.476113136929191,0.128096324914378,0.348016812014813,5.49940737979009,0.8835,6.75467411846856,94.5226,0.53958660423417,0.278816728630873,0.574019259509384,0.374356139725404,0.260769875603297,0.19966311978398,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
25485,1558:1051,Breast,MDA-MB-361,SIDM00528,908121,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.698304292555218,0.126672608075352,0.775445126397463,12.2540814982586,95.4061,0.878824317307112,0.934904758385257,0.106862653343804,0.541496660404372,0.281046985751918,0.260449674652454,7.96237061159058,4.8713,4.29171088666807,90.5348,0.613686793177466,0.45484568078996,0.652848005910725,0.537368505338474,0.158841112387506,0.115479500572251,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
25485,1561:1051,Breast,MDA-MB-361,SIDM00528,908121,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.405995118734907,0.126672608075352,0.775445126397463,12.2540814982586,95.4061,0.878824317307112,0.934904758385257,0.0687956326102861,0.314826936164143,0.302149874826542,0.0126770613376009,11.8043094719945,69.8524,0.449772026264151,25.5537,0.356798383052225,0.319203193602474,0.379566768386452,0.375312467432061,0.0375951894497507,0.0042543009543913,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
23598,1510:1052,Breast,MDA-MB-361,SIDM00528,908121,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1052,RO-3306,CDK1,Cell cycle,Targeted,Experimental only,10.0,0.922050186734006,0.0856742043472116,0.783239153163071,12.3730950186438,103.6103,0.931172960248493,0.937456416267722,0.0664685467299409,0.722185807431394,0.521973152564379,0.200212654867015,9.69833005701474,16.2263,2.67476496162909,87.384,0.85858820187878,0.782511462680701,0.864381863674645,0.788378953575328,0.076076739198079,0.0760029100993168,True,0.616140688182289,0.0701054918648606,0.453927077406696,105.569384254758
23598,1011:1052,Breast,MDA-MB-361,SIDM00528,908121,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1052,RO-3306,CDK1,Cell cycle,Targeted,Experimental only,10.0,0.742601619082405,0.0856742043472116,0.783239153163071,12.3730950186438,103.6103,0.931172960248493,0.937456416267722,0.050620270715135,0.581634663267628,0.343025535746721,0.238609127520907,8.59931921031315,7.575,3.77377580833068,96.0353,0.691490547926286,0.580517490823984,0.696156652539599,0.596977863427923,0.110973057102302,0.0991787891116759,True,0.616140688182289,0.0701054918648606,0.453927077406696,105.569384254758
23598,1053:1052,Breast,MDA-MB-361,SIDM00528,908121,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1052,RO-3306,CDK1,Cell cycle,Targeted,Experimental only,10.0,0.380787440894346,0.0856742043472116,0.783239153163071,12.3730950186438,103.6103,0.931172960248493,0.937456416267722,0.0381657994710298,0.29824763274122,0.181368403709929,0.116879229031291,8.75087837920499,8.4141,3.62221663943883,95.1962,0.354578968563036,0.313246946838747,0.35697162970057,0.309037775940732,0.0413320217242882,0.0479338537598377,True,0.616140688182289,0.0701054918648606,0.453927077406696,105.569384254758
23598,1012:1059,Breast,MDA-MB-361,SIDM00528,908121,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.885235622284972,0.0821867236593739,0.338646271762235,7.24252954068919,0.2958,0.693318148641876,0.7268236324974,0.0619967589729665,0.299781743117928,0.298747432011756,0.0010343111061718,7.2288199372272,0.293,0.0137096034619946,0.0028,0.613749922754455,0.6556012352935,0.64341017060526,0.642657343538784,-0.0418513125390444,0.0007528270664759,True,0.616140688182289,0.0701054918648606,0.453927077406696,105.569384254758
23598,1011:1059,Breast,MDA-MB-361,SIDM00528,908121,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.742601619082405,0.0821867236593739,0.338646271762235,7.24252954068919,0.2958,0.693318148641876,0.7268236324974,0.0694522611202599,0.251479269706856,0.0769281772275066,0.174551092479349,3.33391968704056,0.0197,3.90860985364863,0.2761,0.514859179720672,0.308926707443465,0.539740406279924,0.33474980757055,0.205932472277207,0.204990598709374,True,0.616140688182289,0.0701054918648606,0.453927077406696,105.569384254758
23598,1053:1059,Breast,MDA-MB-361,SIDM00528,908121,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.610993543570547,0.0821867236593739,0.338646271762235,7.24252954068919,0.2958,0.693318148641876,0.7268236324974,0.0525742041520158,0.206910685600962,0.0744259947506373,0.132484690850325,3.81321543356135,0.0275,3.42931410712785,0.2683,0.423612912460471,0.265217044677107,0.444084546770404,0.297044705692894,0.158395867783363,0.147039841077509,True,0.616140688182289,0.0701054918648606,0.453927077406696,105.569384254758
25867,1011:1080,Breast,MDA-MB-361,SIDM00528,908121,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.641774037367772,0.0772825835907859,0.644021673654293,10.5566822805304,0.2942,0.853819504321094,0.887662656393671,0.102406793410606,0.413316389653465,0.146106483173135,0.26720990648033,5.79251784451355,0.0108,4.7641644360169,0.2834,0.547959190471499,0.360765973294417,0.569678846814368,0.404620696109258,0.187193217177082,0.16505815070511,True,0.515683554896602,0.0592523699019833,0.644583472804719,76.3402472101585
23600,1011:1085,Breast,MDA-MB-361,SIDM00528,908121,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.715514304829782,0.1325631550124,0.562118156187598,9.65580392012805,15.7549,0.904264480288444,0.853246234912593,0.165568190712213,0.402203581756768,0.170735259293594,0.231468322463173,5.9534831089139,1.2103,3.70232081121415,14.5446,0.64701417099585,0.48938975577354,0.610509886622113,0.459160934950436,0.157624415222311,0.151348951671677,True,0.616140688182289,0.0701054918648606,0.453927077406696,105.569384254758
23601,1011:1129,Breast,MDA-MB-361,SIDM00528,908121,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.767381284341832,0.0725007104491622,0.743306792400865,11.7917213835743,69.2456,0.916718523785211,0.924113052829429,0.128799878561181,0.570399721012584,0.318450450538227,0.251949270474357,8.09832771537289,5.3527,3.69339366820136,63.8929,0.703472638162244,0.633261142997749,0.709147061357299,0.596370048136985,0.0702114951644955,0.112777013220314,True,0.616140688182289,0.0701054918648606,0.453927077406696,105.569384254758
23602,1510:1192,Breast,MDA-MB-361,SIDM00528,908121,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.83129944565825,0.0639266096098773,0.697225885014939,11.1901596086667,45.6356,0.915949005023611,0.907822112425253,0.0712923767533552,0.579603491711501,0.452502392626191,0.12710109908531,9.4668306247447,13.8207,1.72332898392203,31.8149,0.761427900127353,0.724840750939229,0.754672018815414,0.70256124927443,0.0365871491881239,0.052110769540984,True,0.616140688182289,0.0701054918648606,0.453927077406696,105.569384254758
23602,1011:1192,Breast,MDA-MB-361,SIDM00528,908121,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.730673659301597,0.0639266096098773,0.697225885014939,11.1901596086667,45.6356,0.915949005023611,0.907822112425253,0.0495786019929643,0.50944458876366,0.17327120629921,0.336173382464449,5.93204854066679,1.1925,5.25811106799994,44.4431,0.669259811234258,0.462129085570064,0.663321704880665,0.467799325055519,0.207130725664194,0.195522379825146,True,0.616140688182289,0.0701054918648606,0.453927077406696,105.569384254758
25487,1012:1560,Breast,MDA-MB-361,SIDM00528,908121,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.471022816357278,0.0895599087498145,0.203873760412817,5.42311516924246,0.838,0.624269019761853,0.604257935818701,0.0632601972759985,0.096029192810994,0.0232878937688282,0.0727412990421658,1.23771223831535,0.0461,4.18540293092711,0.7919,0.294044951852825,0.122891051077297,0.28461927473556,0.143059900936636,0.171153900775529,0.141559373798924,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
25487,1011:1560,Breast,MDA-MB-361,SIDM00528,908121,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.679278760853154,0.0895599087498145,0.203873760412817,5.42311516924246,0.838,0.624269019761853,0.604257935818701,0.0313209095305953,0.138487115343691,0.0462332837107674,0.0922538316329239,2.12894336520675,0.0854,3.29417180403571,0.7526,0.424052686182845,0.231014163314801,0.410459581878612,0.247274288165121,0.193038522868044,0.163185293713491,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
26114,1561:1564,Breast,MDA-MB-361,SIDM00528,908121,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.425740291318785,0.0756200311246341,0.902602436899929,14.84608290464,287.6182,0.943835509913962,0.973721308519064,0.037391411201031,0.384274224430821,0.338932142723586,0.0453420817072351,12.5764716455089,59.6479,2.26961125913113,227.9703,0.401828804947784,0.416765130011351,0.414552393552215,0.400882861980346,-0.0149363250635671,0.0136695315718683,True,0.565658653598617,0.0705282839333344,0.540834861214288,89.5503927675915
26114,1510:1564,Breast,MDA-MB-361,SIDM00528,908121,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.925114547904223,0.0756200311246341,0.902602436899929,14.84608290464,287.6182,0.943835509913962,0.973721308519064,0.075396852898397,0.835010645349928,0.767595391888043,0.0674152534618847,13.1583706322526,89.2821,1.68771227238745,198.3361,0.873155961050007,0.849235840061107,0.900803748115322,0.880877814073556,0.0239201209889004,0.0199259340417665,True,0.565658653598617,0.0705282839333344,0.540834861214288,89.5503927675915
26114,1012:1564,Breast,MDA-MB-361,SIDM00528,908121,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.453345752750342,0.0756200311246341,0.902602436899929,14.84608290464,287.6182,0.943835509913962,0.973721308519064,0.107945075271608,0.409190981190692,0.109943438292936,0.299247542897756,6.00948802089186,0.6291,8.83659488374819,286.9891,0.427883819714448,0.231587748909942,0.441432419579623,0.292683749263249,0.196296070804507,0.148748670316374,True,0.565658653598617,0.0705282839333344,0.540834861214288,89.5503927675915
26114,1011:1564,Breast,MDA-MB-361,SIDM00528,908121,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.55084531672696,0.0756200311246341,0.902602436899929,14.84608290464,287.6182,0.943835509913962,0.973721308519064,0.121163957359256,0.497194325232668,0.222071480657425,0.275122844575243,7.9697499954094,2.4481,6.87633290923065,285.1701,0.519907370396709,0.334166826152916,0.536369822594974,0.424123702458269,0.185740544243793,0.112246120136705,True,0.565658653598617,0.0705282839333344,0.540834861214288,89.5503927675915
26114,1053:1564,Breast,MDA-MB-361,SIDM00528,908121,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.424873387721327,0.0756200311246341,0.902602436899929,14.84608290464,287.6182,0.943835509913962,0.973721308519064,0.0669616991817864,0.383491755131198,0.222816522935087,0.160675232196111,9.25679266092649,5.9741,5.58929024371356,281.6441,0.401010590548831,0.303644595325745,0.413708271046938,0.355090033936079,0.0973659952230868,0.0586182371108587,True,0.565658653598617,0.0705282839333344,0.540834861214288,89.5503927675915
25867,1558:2169,Breast,MDA-MB-361,SIDM00528,908121,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.664589885396157,0.0716319542871653,0.60919850604338,10.1656672219288,22.4337,0.891178495938423,0.873577017851271,0.0682274948824452,0.40486716531488,0.216349924151018,0.188517241163862,7.08735330103955,2.656,3.07831392088926,19.7777,0.592268214483236,0.467828908205107,0.580570450178493,0.476591919954025,0.124439306278129,0.103978530224467,True,0.515683554896602,0.0592523699019833,0.644583472804719,76.3402472101585
25867,1012:2169,Breast,MDA-MB-361,SIDM00528,908121,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.469589669646893,0.0716319542871653,0.60919850604338,10.1656672219288,22.4337,0.891178495938423,0.873577017851271,0.0528790053178888,0.286073325202292,0.129122516264724,0.156950808937568,6.45422916460076,1.7126,3.71143805732805,20.7211,0.41848821550414,0.308971612191395,0.410222743223897,0.317405321703357,0.109516603312744,0.0928174215205398,True,0.515683554896602,0.0592523699019833,0.644583472804719,76.3402472101585
25867,1011:2169,Breast,MDA-MB-361,SIDM00528,908121,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.641774037367772,0.0716319542871653,0.60919850604338,10.1656672219288,22.4337,0.891178495938423,0.873577017851271,0.080447113284643,0.390967784781875,0.169510384948717,0.221457399833159,6.30964139709365,1.5492,3.85602582483516,20.8845,0.571935221353741,0.432517824832941,0.560639049698109,0.427536299239663,0.1394173965208,0.133102750458446,True,0.515683554896602,0.0592523699019833,0.644583472804719,76.3402472101585
26113,1012:2172,Breast,MDA-MB-361,SIDM00528,908121,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.500238854376863,0.0992921486128002,0.286201168869068,6.60035160808728,1.8951,0.661146659513634,0.685646650947638,0.0809530883021602,0.143168944836382,0.0343815576416405,0.108787387194741,2.15646928100659,0.0871,4.44388232708069,1.808,0.330731247530191,0.135231935037462,0.34298709517738,0.183062613384678,0.195499312492729,0.159924481792702,True,0.565658653598617,0.0705282839333344,0.540834861214288,89.5503927675915
26113,1011:2172,Breast,MDA-MB-361,SIDM00528,908121,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.59231935037462,0.0992921486128002,0.286201168869068,6.60035160808728,1.8951,0.661146659513634,0.685646650947638,0.09107540995311,0.169522490420983,0.065246267281691,0.104276223139292,3.51445430998591,0.2232,3.08589729810137,1.6719,0.391609959865466,0.241547981198905,0.406121778875839,0.27488340895429,0.150061978666561,0.131238369921549,True,0.565658653598617,0.0705282839333344,0.540834861214288,89.5503927675915
28099,1022:1003,Breast,MFM-223,SIDM00332,910948,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.825397772591746,0.0532466437754609,0.921634903160014,16.5043900568953,18.1571,0.962569593523323,0.976121980383264,0.0743720385777433,0.760715396211085,0.447573319479355,0.313142076731731,9.51579807293836,0.143,6.98859198395695,18.0141,0.794502798458694,0.680194046831219,0.80568890838619,0.679416575789587,0.114308751627474,0.126272332596603,True,0.510180859930454,0.0724218129580126,0.647018430485456,75.5756476517284
26095,1191:1038,Breast,MFM-223,SIDM00332,910948,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.000625,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.910022854347657,0.0751806187498558,0.71730912574788,11.8350446837967,71.3565,0.922643901311504,0.903303790818542,0.0723222764029784,0.652767698062708,0.622945382258531,0.0298223158041766,11.3587191634228,51.2915,0.476325520373987,20.065,0.839627036617953,0.854004635374158,0.822027094063749,0.809752374794567,-0.0143775987562051,0.0122747192691818,True,0.653753468716616,0.103293154734791,0.398371306841104,120.003434048815
26095,1011:1038,Breast,MFM-223,SIDM00332,910948,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.81633346741934,0.0751806187498558,0.71730912574788,11.8350446837967,71.3565,0.922643901311504,0.903303790818542,0.112284516150889,0.585563445833302,0.353184763765492,0.23237868206781,8.17472386067776,5.6437,3.66032082311899,65.7128,0.753185095150928,0.664543723834191,0.737397115691935,0.620013356086253,0.0886413713167369,0.117383759605682,True,0.653753468716616,0.103293154734791,0.398371306841104,120.003434048815
26096,1012:1042,Breast,MFM-223,SIDM00332,910948,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.941733359249244,0.178502689021711,0.585191427330546,10.047734368143,20.6728,0.892877897376769,0.844841557436985,0.186272110569171,0.551094288663854,0.530558102656575,0.0205361860072795,9.77611427969848,17.1251,0.271620088444532,3.5477,0.840852901696026,0.841333071658121,0.795615477918495,0.785417902892638,-0.0004801699620952,0.0101975750258566,True,0.653753468716616,0.103293154734791,0.398371306841104,120.003434048815
30690,1012:1050,Breast,MFM-223,SIDM00332,910948,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.666743491235853,0.126288528376136,0.700582869409301,11.5881898948993,60.1344,0.91468639889222,0.896494024744262,0.150909109910257,0.467109068249989,0.276730706615643,0.190378361634346,7.95527135791202,4.8474,3.63291853698732,55.287,0.609861202983349,0.497322024413992,0.597731555930071,0.498677071367998,0.112539178569356,0.0990544845620723,True,0.6071989498949,0.0824661982717897,0.477339150063199,101.749386895928
30690,1011:1050,Breast,MFM-223,SIDM00332,910948,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.694471084022068,0.126288528376136,0.700582869409301,11.5881898948993,60.1344,0.91468639889222,0.896494024744262,0.0623356250730777,0.486534544765968,0.123016563654428,0.36351798111154,4.3238094206206,0.3911,7.26438047427874,59.7433,0.635223254978921,0.355698938084834,0.622589177183454,0.362422051723822,0.279524316894087,0.260167125459632,True,0.6071989498949,0.0824661982717897,0.477339150063199,101.749386895928
30690,1011:1051,Breast,MFM-223,SIDM00332,910948,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.694471084022068,0.0768811856693239,0.206706851091338,4.9052625240862,0.5853,0.551213259144612,0.560921966383347,0.0681188505415534,0.14355193095219,0.0241061543326581,0.119445776619532,-1.12457800191933,0.009,6.02984052600553,0.5763,0.382801669605495,0.101364005713054,0.389544086046033,0.134809578987954,0.281437663892441,0.254734507058079,True,0.6071989498949,0.0824661982717897,0.477339150063199,101.749386895928
30580,1011:1052,Breast,MFM-223,SIDM00332,910948,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1052,RO-3306,CDK1,Cell cycle,Targeted,Experimental only,10.0,0.678418930754676,0.0637608323878115,0.806602879124292,13.3480366348863,203.6524,0.939859045617538,0.937285515621308,0.121205968425134,0.547214662799145,0.317536406442806,0.22967825635634,8.61040518049436,7.6334,4.73763145439191,196.019,0.637618168787961,0.513113946900998,0.635872237319653,0.530219767061083,0.124504221886963,0.10565247025857,True,,,,
30580,1053:1052,Breast,MFM-223,SIDM00332,910948,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1052,RO-3306,CDK1,Cell cycle,Targeted,Experimental only,10.0,0.868788279263398,0.0637608323878115,0.806602879124292,13.3480366348863,203.6524,0.939859045617538,0.937285515621308,0.133127927599241,0.700767127403296,0.351326347472759,0.349440779930537,7.82104523714542,4.4167,5.52699139774085,199.2357,0.816538522992201,0.656701831253663,0.814302670295143,0.64350592095439,0.159836691738537,0.170796749340752,True,,,,
30580,1053:1059,Breast,MFM-223,SIDM00332,910948,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.965896471878211,0.0820412074997968,0.484985319417603,8.81708657128203,0.8809,0.804867447499382,0.791554496083682,0.0505927233438647,0.468445608938189,0.302454523560876,0.165991085377313,6.60838724476453,0.1906,2.2086993265175,0.6903,0.777418627869274,0.636782792411117,0.764559695066563,0.647653514218898,0.140635835458156,0.116906180847665,True,,,,
30687,1012:1080,Breast,MFM-223,SIDM00332,910948,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.966190246705211,0.0839682302831792,0.405824082660128,7.839205857209,0.0447,0.737009779282835,0.741679272731787,0.0586723871858596,0.392103270544305,0.34597408269794,0.046129187846365,7.22281873170004,0.0292,0.616387125508966,0.0155,0.712091660469435,0.680514125945957,0.716603279496867,0.683196774164401,0.0315775345234782,0.0334065053324663,True,0.6071989498949,0.0824661982717897,0.477339150063199,101.749386895928
30687,1011:1080,Breast,MFM-223,SIDM00332,910948,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.899606868842057,0.0839682302831792,0.405824082660128,7.839205857209,0.0447,0.737009779282835,0.741679272731787,0.122506913325405,0.365082132302578,0.184316314051635,0.180765818250943,4.87133210052355,0.0057,2.96787375668545,0.039,0.663019059846607,0.496051464041892,0.667219768227297,0.502570573930301,0.166967595804714,0.164649194296996,True,0.6071989498949,0.0824661982717897,0.477339150063199,101.749386895928
28104,1011:1096,Breast,MFM-223,SIDM00332,910948,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.71770786622787,0.0898038939700817,0.507337760099629,9.08937037668701,5.3195,0.800196272682543,0.804275089397844,0.0502170496988794,0.364120301257932,0.0688060561798678,0.295314245078064,2.16781282865376,0.0439,6.92155754803325,5.2756,0.574307159430483,0.22459222245465,0.577234558271956,0.271444991795973,0.349714936975833,0.305789566475983,True,0.510180859930454,0.0724218129580126,0.647018430485456,75.5756476517284
30689,1021:1192,Breast,MFM-223,SIDM00332,910948,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.444329778233951,0.0943020185728289,0.788566837907504,13.0077120165038,160.8576,0.96532563280022,0.930720607041845,0.056081271896425,0.350383728210089,0.265198864283314,0.0851848639267758,10.1946124487268,22.8883,2.813099567777,137.9693,0.42892292434567,0.323952762913859,0.413546880924671,0.37789238413596,0.104970161431812,0.0356544967887111,True,0.6071989498949,0.0824661982717897,0.477339150063199,101.749386895928
30689,1561:1192,Breast,MFM-223,SIDM00332,910948,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.78829907618994,0.0943020185728289,0.788566837907504,13.0077120165038,160.8576,0.96532563280022,0.930720607041845,0.122246016993233,0.621626509836508,0.577550506494187,0.0440760033423208,12.0694140928254,83.9432,0.938297923678398,76.9144,0.760965304558883,0.758971344173843,0.733686194722026,0.716894930127643,0.0019939603850397,0.0167912645943831,True,0.6071989498949,0.0824661982717897,0.477339150063199,101.749386895928
30689,1510:1192,Breast,MFM-223,SIDM00332,910948,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.909318577502408,0.0943020185728289,0.788566837907504,13.0077120165038,160.8576,0.96532563280022,0.930720607041845,0.0596946537085063,0.717058475311624,0.703882699449001,0.0131757758626224,12.7494320064634,134.4905,0.258280010040419,26.3671,0.877788531244508,0.870889946709722,0.846321538447467,0.841430685426194,0.0068985845347862,0.0048908530212733,True,0.6071989498949,0.0824661982717897,0.477339150063199,101.749386895928
30689,1011:1192,Breast,MFM-223,SIDM00332,910948,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.652292449903449,0.0943020185728289,0.788566837907504,13.0077120165038,160.8576,0.96532563280022,0.930720607041845,0.0728803081185338,0.514376194611302,0.183819949714401,0.330556244896901,6.15165698066473,1.3886,6.85605503583904,159.469,0.629674621973853,0.372466658322176,0.60710202494295,0.418866752516274,0.257207963651677,0.188235272426676,True,0.6071989498949,0.0824661982717897,0.477339150063199,101.749386895928
26098,1372:1373,Breast,MFM-223,SIDM00332,910948,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10.0,0.802333018230676,0.0899431324233328,0.850437384509366,14.2917289068896,391.714,0.926968775368028,0.95267443561903,0.0863138258235349,0.682333993529602,0.506227927100991,0.17610606642861,10.6327680941553,31.0107,3.65896081273433,360.7033,0.743737655346624,0.635577404514916,0.764362155321423,0.695126621236966,0.108160250831708,0.0692355340844562,True,0.653753468716616,0.103293154734791,0.398371306841104,120.003434048815
26099,1049:1560,Breast,MFM-223,SIDM00332,910948,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.549875345486925,0.0938347748102038,0.605433217288,10.3035893164632,24.6842,0.850621963088872,0.854559550395842,0.0599526778131493,0.3329127995255,0.134588193922949,0.198324605602551,5.5694269537167,0.9275,4.7341623627465,23.7567,0.46773604583226,0.333290939894084,0.469901228013065,0.332551777758858,0.134445105938177,0.137349450254207,True,0.653753468716616,0.103293154734791,0.398371306841104,120.003434048815
26099,1021:1560,Breast,MFM-223,SIDM00332,910948,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.523790789574281,0.0938347748102038,0.605433217288,10.3035893164632,24.6842,0.850621963088872,0.854559550395842,0.0465781157780618,0.317120342917779,0.0955521539918852,0.221568188925894,4.432983355419,0.4219,5.87060596104419,24.2623,0.445547949675546,0.260986016005943,0.447610421640081,0.277205145843905,0.184561933669603,0.170405275796176,True,0.653753468716616,0.103293154734791,0.398371306841104,120.003434048815
26099,1510:1560,Breast,MFM-223,SIDM00332,910948,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.957485842916549,0.0938347748102038,0.605433217288,10.3035893164632,24.6842,0.850621963088872,0.854559550395842,0.0773567210752791,0.579693734384679,0.37287277816048,0.206820956224199,7.63077673872704,3.871,2.67281257773615,20.8132,0.814458487331479,0.679928258687398,0.81822867143315,0.699197631268539,0.134530228644081,0.119031040164611,True,0.653753468716616,0.103293154734791,0.398371306841104,120.003434048815
26099,1053:1560,Breast,MFM-223,SIDM00332,910948,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.901225584506886,0.0938347748102038,0.605433217288,10.3035893164632,24.6842,0.850621963088872,0.854559550395842,0.0336185284718073,0.545631905130262,0.309939012597154,0.235692892533108,7.03337675443402,2.5585,3.27021256202918,22.1257,0.766602275879164,0.623651116580713,0.770150930301435,0.627285475462157,0.142951159298451,0.142865454839277,True,0.653753468716616,0.103293154734791,0.398371306841104,120.003434048815
26099,1022:1560,Breast,MFM-223,SIDM00332,910948,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.912229471042142,0.0938347748102038,0.605433217288,10.3035893164632,24.6842,0.850621963088872,0.854559550395842,0.0703236363444657,0.552294023557975,0.50250557614247,0.0497884474155049,9.62148598734009,15.3846,0.682103329123111,9.2996,0.775962423445391,0.798911035741464,0.77955440663161,0.754972188103332,-0.022948612296073,0.0245822185282778,True,0.653753468716616,0.103293154734791,0.398371306841104,120.003434048815
30691,1372:1564,Breast,MFM-223,SIDM00332,910948,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.924797835533682,0.0888645498102905,0.724963816660842,11.9509432840948,38.6627,0.879504541243187,0.90637016108196,0.12468513413818,0.670444968488183,0.427564141742582,0.242880826745602,8.5403907774376,3.6359,3.41055250665723,35.0268,0.813363896083743,0.649528473079996,0.838209163160911,0.719582243351412,0.163835423003748,0.118626919809499,True,0.6071989498949,0.0824661982717897,0.477339150063199,101.749386895928
30691,1012:1564,Breast,MFM-223,SIDM00332,910948,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.41422286864219,0.0888645498102905,0.724963816660842,11.9509432840948,38.6627,0.879504541243187,0.90637016108196,0.103730628513035,0.300296591799045,0.17238760403396,0.127908987765085,7.96934788503582,2.4474,3.98159539905901,36.2153,0.364310894057586,0.2183323423848,0.375439248175053,0.310121039613107,0.145978551672786,0.0653182085619465,True,0.6071989498949,0.0824661982717897,0.477339150063199,101.749386895928
30691,1011:1564,Breast,MFM-223,SIDM00332,910948,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.596526473973953,0.0888645498102905,0.724963816660842,11.9509432840948,38.6627,0.879504541243187,0.90637016108196,0.120127759561619,0.432460109311392,0.180457804556845,0.252002304754546,6.45663249142256,0.8577,5.49431079267227,37.805,0.524647742831878,0.393604804825025,0.540673796305426,0.394420628705813,0.131042938006853,0.146253167599613,True,0.6071989498949,0.0824661982717897,0.477339150063199,101.749386895928
30691,1011:1593,Breast,MFM-223,SIDM00332,910948,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.596526473973953,0.0414759663156049,0.929090417710321,16.8333046311613,456.1311,0.985424301914743,0.978476024011747,0.0731532365913709,0.554227030879725,0.33229202163018,0.221935009249545,9.6977673697615,3.244,7.13553726139981,452.8871,0.587831684189446,0.51102843861265,0.583686852471781,0.495589004854148,0.0768032455767959,0.0880978476176328,True,0.6071989498949,0.0824661982717897,0.477339150063199,101.749386895928
30691,1179:1593,Breast,MFM-223,SIDM00332,910948,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.651243097565823,0.0414759663156049,0.929090417710321,16.8333046311613,456.1311,0.985424301914743,0.978476024011747,0.057892961753084,0.605063721548394,0.530438496940729,0.0746252246076646,13.5046658329079,45.4014,3.32863879825337,410.7297,0.641750774795596,0.637540291674948,0.637225756771301,0.612244416767762,0.0042104831206479,0.0249813400035389,True,0.6071989498949,0.0824661982717897,0.477339150063199,101.749386895928
26101,1047:1632,Breast,MFM-223,SIDM00332,910948,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.950997886771837,0.127765425543167,0.741291673173733,12.2050927230613,36.8883,0.842203907459229,0.912809485811077,0.122034265386902,0.704966814669779,0.702419895537075,0.0025469191327043,12.1627166163003,35.8206,0.0423761067609902,1.0677,0.80093413622471,0.762229041200005,0.868079892031622,0.867084284254698,0.0387050950247056,0.0009956077769234,True,0.653753468716616,0.103293154734791,0.398371306841104,120.003434048815
30687,1021:2169,Breast,MFM-223,SIDM00332,910948,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.453000916962686,0.0706104374614104,0.610480596011694,10.3680660193612,25.8124,0.88516103389457,0.856935217656835,0.0253447080938047,0.276548269781225,0.152871532865321,0.123676736915904,6.94602391780047,2.4082,3.42204210156076,23.4042,0.400978760013879,0.29964356277267,0.388192439376165,0.312963477508005,0.101335197241209,0.0752289618681598,True,0.6071989498949,0.0824661982717897,0.477339150063199,101.749386895928
30687,1011:2169,Breast,MFM-223,SIDM00332,910948,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.722662440570523,0.0706104374614104,0.610480596011694,10.3680660193612,25.8124,0.88516103389457,0.856935217656835,0.0522152325775503,0.441171397434758,0.187604243363548,0.25356715407121,5.80907112309813,1.0951,4.55899489626309,24.7173,0.639672633052177,0.449214103984461,0.619274895802721,0.448268652850492,0.190458529067716,0.171006242952229,True,0.6071989498949,0.0824661982717897,0.477339150063199,101.749386895928
26098,1021:2172,Breast,MFM-223,SIDM00332,910948,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.611219760389984,0.0669191773295909,0.854643007627881,14.3935894463034,420.3705,0.942120216882105,0.954110812127318,0.0534450655277041,0.522374694341289,0.255421102244522,0.266953592096767,7.99084281517757,4.9684,6.40274663112587,415.4021,0.57584249322124,0.427944012719526,0.583171381973953,0.458309523645931,0.147898480501714,0.124861858328022,True,0.653753468716616,0.103293154734791,0.398371306841104,120.003434048815
26098,1191:2172,Breast,MFM-223,SIDM00332,910948,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.0025,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.487642103547368,0.0669191773295909,0.854643007627881,14.3935894463034,420.3705,0.942120216882105,0.954110812127318,0.0715433759692608,0.416759914021709,0.131856844500421,0.284903069521289,5.97783771552508,1.2309,8.41575173077836,419.1396,0.459417484354892,0.266428103411995,0.465264603443053,0.307759431626619,0.192989380942897,0.157505171816434,True,0.653753468716616,0.103293154734791,0.398371306841104,120.003434048815
26098,1049:2172,Breast,MFM-223,SIDM00332,910948,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.611205062761911,0.0669191773295909,0.854643007627881,14.3935894463034,420.3705,0.942120216882105,0.954110812127318,0.128504827385438,0.522362133116227,0.265309369721712,0.257052763394515,8.192432095265,5.7134,6.20115735103844,414.6571,0.575828646288692,0.386646617358396,0.583157358808095,0.464779053552859,0.189182028930296,0.118378305255236,True,0.653753468716616,0.103293154734791,0.398371306841104,120.003434048815
26098,1012:2172,Breast,MFM-223,SIDM00332,910948,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.655988735502093,0.0669191773295909,0.854643007627881,14.3935894463034,420.3705,0.942120216882105,0.954110812127318,0.0972507624123841,0.560636185879519,0.406623575039854,0.154012610839665,10.4887463932392,28.0645,3.90484305306424,392.306,0.618020249763449,0.506230928653422,0.625885945176274,0.565005007356407,0.111789321110027,0.0608809378198668,True,0.653753468716616,0.103293154734791,0.398371306841104,120.003434048815
26098,1011:2172,Breast,MFM-223,SIDM00332,910948,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.775524544624476,0.0669191773295909,0.854643007627881,14.3935894463034,420.3705,0.942120216882105,0.954110812127318,0.0618954493541972,0.662796629307105,0.428370879800465,0.23442574950664,9.64005418884323,15.5839,4.75353525746021,404.7866,0.730637352179007,0.639653056779718,0.739936353096327,0.642436663714293,0.0909842953992884,0.0974996893820343,True,0.653753468716616,0.103293154734791,0.398371306841104,120.003434048815
28353,1012:1030,Breast,HCC1599,SIDM00877,749713,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1030,KU-55933,ATM,Genome integrity,Targeted,Experimental only,10.0,0.877497912262984,0.0606045591338237,0.859846569149973,12.6713879325311,127.4084,0.944844744790839,0.969674501746649,0.0815026668822023,0.754513569295591,0.709324988860258,0.045188580435333,11.9130422762202,75.3205,0.75834565631083,52.0879,0.829099290966613,0.836957488545062,0.850887350857334,0.840012983595038,-0.0078581975784485,0.010874367262296,True,0.429713227651758,0.0557296793840869,0.813583656083833,60.3431862324098
27649,1021:1032,Breast,HCC1599,SIDM00877,749713,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.937646449678319,0.0856589440838811,0.526214035934185,9.21241314292572,11.5862,0.86000050950297,0.871354372879339,0.0700843788810662,0.493402722564588,0.433390330845333,0.0600123917192548,8.69348934277025,8.086,0.518923800155473,3.5002,0.806376424457006,0.79008404983174,0.81702233414199,0.792765933925177,0.0162923746252652,0.0242564002168129,True,,,,
27649,1083:1038,Breast,HCC1599,SIDM00877,749713,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.839424445668703,0.0575121565212725,0.619568731387298,9.98709283484889,19.8219,0.889679714439073,0.903995819194103,0.0514804021256624,0.520081138898444,0.302674349427763,0.217406789470681,7.84055783135097,4.4769,2.14653500349792,15.345,0.746818901115709,0.670211485085037,0.758836189413835,0.668265392285525,0.076607416030672,0.0905707971283096,True,,,,
27649,1012:1038,Breast,HCC1599,SIDM00877,749713,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.868288333697315,0.0575121565212725,0.619568731387298,9.98709283484889,19.8219,0.889679714439073,0.903995819194103,0.0927385567822607,0.537964301387236,0.406325263039198,0.131639038348038,8.74027090250368,8.3524,1.24682193234521,11.4695,0.772498516774606,0.727863764978838,0.784929023517387,0.7362643882872,0.0446347517957677,0.0486646352301874,True,,,,
27649,1011:1038,Breast,HCC1599,SIDM00877,749713,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.831036595466666,0.0575121565212725,0.619568731387298,9.98709283484889,19.8219,0.889679714439073,0.903995819194103,0.0736377324609857,0.514884289189701,0.276912028839005,0.237972260350696,7.59604133409206,3.7789,2.39105150075683,16.043,0.739356400943203,0.664091771205059,0.751253607899167,0.64858497492526,0.0752646297381437,0.102668632973907,True,,,,
27649,1561:1038,Breast,HCC1599,SIDM00877,749713,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.627611435425664,0.0575121565212725,0.619568731387298,9.98709283484889,19.8219,0.889679714439073,0.903995819194103,0.0455958655239472,0.388848420850839,0.182494180835131,0.206354240015709,7.19545112668195,2.8627,2.79164170816694,16.9592,0.558373162648201,0.4776078647849,0.56735811370321,0.472908538176674,0.0807652978633009,0.0944495755265354,True,,,,
27649,1510:1038,Breast,HCC1599,SIDM00877,749713,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.5191453668281,0.0575121565212725,0.619568731387298,9.98709283484889,19.8219,0.889679714439073,0.903995819194103,0.0380696260650812,0.32164623633128,0.156901754833119,0.16474448149816,7.30660848993325,3.092,2.68048434491564,16.7299,0.461873101711992,0.395056219586228,0.469305241166592,0.395142301371398,0.0668168821257641,0.0741629397951939,True,,,,
27649,1053:1038,Breast,HCC1599,SIDM00877,749713,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.801252611298093,0.0575121565212725,0.619568731387298,9.98709283484889,19.8219,0.889679714439073,0.903995819194103,0.0727184234278036,0.496431063902719,0.255560067129139,0.24087099677358,7.46467281549726,3.45,2.52242001935163,16.3719,0.712858194413249,0.620516013743976,0.724329010731834,0.618399355909919,0.0923421806692732,0.105929654821915,True,,,,
27650,1017:1042,Breast,HCC1599,SIDM00877,749713,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.762895287202126,0.0605065310777451,0.76032851117277,11.3365552466094,50.5095,0.931621507682,0.944999680774806,0.0695709383496882,0.580051037899115,0.373039533112539,0.207011504786577,8.91076136163604,9.4002,2.42579388497335,41.1093,0.710729657666738,0.60893154636037,0.720935802870613,0.653579289954044,0.101798111306368,0.0673565129165693,True,,,,
27650,1372:1042,Breast,HCC1599,SIDM00877,749713,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.984961932012572,0.0605065310777451,0.76032851117277,11.3365552466094,50.5095,0.931621507682,0.944999680774806,0.0675397864069106,0.748894639328974,0.699197336701048,0.0496973026279253,10.810914408998,35.0865,0.525640837611359,15.423,0.917611720110928,0.901730151252042,0.930788711327217,0.917233386208206,0.015881568858886,0.0135553251190101,True,,,,
27650,1012:1042,Breast,HCC1599,SIDM00877,749713,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.416691532023641,0.0605065310777451,0.76032851117277,11.3365552466094,50.5095,0.931621507682,0.944999680774806,0.093056077281378,0.316822452161836,0.159764757894698,0.157057694267138,8.03846794572606,5.1351,3.29808730088333,45.3744,0.388198793302187,0.264536981016109,0.393773364743906,0.336808937933642,0.123661812286078,0.0569644268102643,True,,,,
27650,1011:1042,Breast,HCC1599,SIDM00877,749713,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.845055634050981,0.0605065310777451,0.76032851117277,11.3365552466094,50.5095,0.931621507682,0.944999680774806,0.0549198852655565,0.642519892096143,0.396822688517594,0.245697203578549,8.75344135756917,8.429,2.58311388904022,42.0805,0.787272003869743,0.72081707927537,0.798577304415128,0.717146541701698,0.0664549245943732,0.0814307627134301,True,,,,
27651,1012:1050,Breast,HCC1599,SIDM00877,749713,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.457109322609258,0.0839849233668799,0.713937351823938,10.8510275923411,36.0757,0.917791673680275,0.932381457733558,0.0578844089954997,0.326347419277688,0.144334961900056,0.182012457377632,7.43482619029618,3.3794,3.41620140204492,32.6963,0.419531130252407,0.323445530949726,0.426200256558019,0.351882059132862,0.0960855993026813,0.0743181974251576,True,,,,
27651,1011:1050,Breast,HCC1599,SIDM00877,749713,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.847891267262059,0.0839849233668799,0.713937351823938,10.8510275923411,36.0757,0.917791673680275,0.932381457733558,0.0589160367470532,0.605341245983718,0.358068186129332,0.247273059854386,8.36586987136484,6.4433,2.48515772097626,29.6324,0.778187545279334,0.678671181176218,0.790558095769353,0.701632788918064,0.0995163641031162,0.0889253068512887,True,,,,
27651,1012:1051,Breast,HCC1599,SIDM00877,749713,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.457109322609258,0.0834002264379571,0.768496232013754,11.4283555342785,53.828,0.896248080317378,0.947142054858696,0.131370449364987,0.351286792043574,0.0671710000059715,0.284115792037603,5.44047148955133,0.8482,5.98788404472719,52.9798,0.409683352883724,0.200618792696748,0.432947463111199,0.283457556419719,0.209064560186976,0.14948990669148,True,,,,
27651,1011:1051,Breast,HCC1599,SIDM00877,749713,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.847891267262059,0.0834002264379571,0.768496232013754,11.4283555342785,53.828,0.896248080317378,0.947142054858696,0.110843908202979,0.651601244048259,0.417670206130138,0.233931037918121,8.94007831996247,9.5932,2.48827721431605,44.2348,0.759920920601489,0.655322701223624,0.80307347717133,0.727643592336492,0.104598219377865,0.0754298848348379,True,,,,
28357,1047:1096,Breast,HCC1599,SIDM00877,749713,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.986497991152438,0.096329030221859,0.690114881749921,10.6204487952348,15.3735,0.875359730828409,0.925582654169875,0.194093326371922,0.680796944510699,0.450209674301365,0.230587270209334,8.64590143298932,3.9118,1.97454736224544,11.4617,0.863540615997964,0.812821906499377,0.913085428984124,0.83156996863575,0.0507187094985871,0.0815154603483741,True,0.429713227651758,0.0557296793840869,0.813583656083833,60.3431862324098
28357,1012:1096,Breast,HCC1599,SIDM00877,749713,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.46804548159757,0.096329030221859,0.690114881749921,10.6204487952348,15.3735,0.875359730828409,0.925582654169875,0.0838027311908078,0.323005152186292,0.0887962346789025,0.234208917507389,6.06160160515115,0.6523,4.55884719008361,14.7212,0.409708166786702,0.262732962790271,0.433214779129296,0.313435624530437,0.146975203996431,0.119779154598859,True,0.429713227651758,0.0557296793840869,0.813583656083833,60.3431862324098
28357,1011:1096,Breast,HCC1599,SIDM00877,749713,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.864060492178291,0.096329030221859,0.690114881749921,10.6204487952348,15.3735,0.875359730828409,0.925582654169875,0.127514278645507,0.5963010043844,0.372383445623494,0.223917558760906,8.43756215615745,3.3858,2.18288663907731,11.9877,0.756363759852651,0.626611250154258,0.799759403713711,0.718505737461681,0.129752509698393,0.0812536662520302,True,0.429713227651758,0.0557296793840869,0.813583656083833,60.3431862324098
27654,1017:1564,Breast,HCC1599,SIDM00877,749713,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.832101636606213,0.0387166424275039,0.93690061426802,14.4602121357647,220.1191,0.977286786209788,0.986906014673295,0.132999065063118,0.779596534469786,0.459525557821635,0.32007097664815,9.42451977689658,6.7106,5.03569235886816,213.4085,0.813201934238791,0.624969307395171,0.821206109986164,0.733080223025838,0.18823262684362,0.0881258869603259,True,,,,
27654,1190:1564,Breast,HCC1599,SIDM00877,749713,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.313470809586074,0.0387166424275039,0.93690061426802,14.4602121357647,220.1191,0.977286786209788,0.986906014673295,0.0714780744927112,0.293690994056286,0.192315373000311,0.101375621055976,9.93516796518148,9.5606,4.52504417058327,210.5585,0.306350880070955,0.225229321169413,0.309366227405004,0.2827593487459,0.0811215589015414,0.0266068786591041,True,,,,
27654,1179:1564,Breast,HCC1599,SIDM00877,749713,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.217330591793346,0.0387166424275039,0.93690061426802,14.4602121357647,220.1191,0.977286786209788,0.986906014673295,0.0279786298754321,0.203617164950418,0.109602564119398,0.0940146008310201,9.03491426506949,5.1225,5.42529787069525,214.9966,0.212394315598791,0.165657087912271,0.21448486821336,0.187527837021657,0.0467372276865201,0.0269570311917035,True,,,,
27655,1179:1632,Breast,HCC1599,SIDM00877,749713,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.222397783604193,0.0415867384276086,0.954352677846394,15.1528356803969,284.6086,0.985694362062697,0.990613116361546,0.0420785158084085,0.212245920329765,0.159536347113958,0.0527095732158068,10.8849370601025,14.7735,4.26789862029441,269.8351,0.219216241433893,0.179277251894939,0.220310161488051,0.207571877736224,0.0399389895389542,0.0127382837518267,True,,,,
27655,1510:1909,Breast,HCC1599,SIDM00877,749713,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.535851505771859,0.0700379860807973,0.887147286480269,13.1731356081909,18.0401,0.952633123275911,0.975948896684319,0.100830647580864,0.475379209301871,0.222977859266184,0.252401350035687,8.31445044128722,0.6218,4.85868516690364,17.4183,0.510469893555546,0.352572381150491,0.522963685844677,0.44184562469646,0.157897512405054,0.0811180611482171,True,,,,
27655,1561:1909,Breast,HCC1599,SIDM00877,749713,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.476263895033107,0.0700379860807973,0.887147286480269,13.1731356081909,18.0401,0.952633123275911,0.975948896684319,0.0529290157812809,0.422516222127144,0.27610684212551,0.146409380001634,9.6510595331189,1.5703,3.52207607507196,16.4698,0.453704761828939,0.375110808713256,0.464809222888137,0.424211180803963,0.0785939531156828,0.0405980420841737,True,,,,
27652,1017:2172,Breast,HCC1599,SIDM00877,749713,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.740242211161201,0.131589906852395,0.387323697058735,8.07188795537576,5.2555,0.736622694088668,0.810309648595301,0.0816779655993825,0.286713349945889,0.0526923387703961,0.234021011175493,3.80127957865828,0.2723,4.27060837671748,4.9832,0.545279211863716,0.340230092678959,0.599825406001441,0.357707272856867,0.205049119184757,0.242118133144574,True,,,,
27652,1021:2172,Breast,HCC1599,SIDM00877,749713,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.956107310132627,0.131589906852395,0.387323697058735,8.07188795537576,5.2555,0.736622694088668,0.810309648595301,0.143602266986837,0.370323018145452,0.227454198567728,0.142868819577723,6.64367634404496,1.9529,1.42821161133081,3.3026,0.704290342627766,0.623647349089992,0.774742978492968,0.682628032725299,0.0806429935377738,0.0921149457676688,True,,,,
27652,1022:2172,Breast,HCC1599,SIDM00877,749713,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.394400222062842,0.131589906852395,0.387323697058735,8.07188795537576,5.2555,0.736622694088668,0.810309648595301,0.064506489133281,0.152760552130166,0.0674180265114435,0.0853425256187225,5.80427503280463,1.0914,2.26761292257114,4.1641,0.2905241541251,0.205867371440827,0.31958630534565,0.256117505391771,0.0846567826842725,0.0634687999538787,True,,,,
27652,1005:2172,Breast,HCC1599,SIDM00877,749713,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,4.0,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.525507384886973,0.131589906852395,0.387323697058735,8.07188795537576,5.2555,0.736622694088668,0.810309648595301,0.0719639271821546,0.20354146314609,0.0323423807449157,0.171199082401174,3.48595379516885,0.2188,4.58593416020691,5.0367,0.387100665618932,0.209187786230205,0.425823704381998,0.239987059777002,0.177912879388727,0.185836644604997,True,,,,
23737,1191:1013,Breast,HCC70,SIDM00673,907048,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.0025,1013,Nilotinib,ABL,ABL signaling,Targeted,FDA approved,10.0,0.776609832451305,0.0700527592455283,0.777199786442905,12.6458407245701,125.1721,0.933235144862349,0.929153794698739,0.105005311223921,0.603580995930614,0.288495578450883,0.315085417479731,7.46550055054196,3.452,5.1803401740281,121.7201,0.724759589489218,0.597577942341911,0.721589972822482,0.564326108254235,0.127181647147307,0.157263864568247,True,0.680872585130312,0.0825361768624602,0.368612997774341,131.54939790493
27072,1011:1032,Breast,HCC70,SIDM00673,907048,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.947299909255044,0.119141426607221,0.644329729205051,10.7339075998351,33.2628,0.909212884039212,0.876926044939287,0.140475951310128,0.610373494006272,0.358665336315264,0.251708157691008,7.55436574785883,3.6713,3.17954185197626,29.5915,0.861297282543862,0.748515294296827,0.830711962794371,0.693187308335404,0.112781988247035,0.137524654458968,True,0.897710429713034,0.0931134865295216,0.0924821916336861,469.308377553025
27072,1053:1032,Breast,HCC70,SIDM00673,907048,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.654069310776944,0.119141426607221,0.644329729205051,10.7339075998351,33.2628,0.909212884039212,0.876926044939287,0.080838218429711,0.421436301894242,0.214992236644179,0.206444065250063,6.91631919217393,2.3591,3.81758840766116,30.9037,0.594688244413044,0.456396833245895,0.573570413815791,0.453977523911979,0.138291411167149,0.119592889903812,True,0.897710429713034,0.0931134865295216,0.0924821916336861,469.308377553025
27072,1191:1032,Breast,HCC70,SIDM00673,907048,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.0025,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.817558391109954,0.119141426607221,0.644329729205051,10.7339075998351,33.2628,0.909212884039212,0.876926044939287,0.119517005308889,0.526777176753194,0.295678100936736,0.231099075816458,7.34207662390091,3.1689,3.39183097593417,30.0939,0.743334622651539,0.605178624589183,0.716938246422979,0.588226100474132,0.138155998062356,0.128712145948847,True,0.897710429713034,0.0931134865295216,0.0924821916336861,469.308377553025
27072,1011:1038,Breast,HCC70,SIDM00673,907048,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.964693126067321,0.0682499902255591,0.653108371432981,10.846321921141,35.9582,0.908422338570266,0.880680525906149,0.144972704858209,0.630049156498419,0.481682788294575,0.148366368203844,8.99196880162334,9.9445,1.85435311951764,26.0137,0.876348785584736,0.839677782303415,0.849586449603015,0.778208357687803,0.0366710032813208,0.0713780919152118,True,0.897710429713034,0.0931134865295216,0.0924821916336861,469.308377553025
27072,1558:1038,Breast,HCC70,SIDM00673,907048,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.97495011359489,0.0682499902255591,0.653108371432981,10.846321921141,35.9582,0.908422338570266,0.880680525906149,0.0706366421364454,0.636748080918358,0.528171568722774,0.108576512195584,9.48835467921168,14.0284,1.3579672419293,21.9298,0.885666462181216,0.837548981153088,0.858619578773008,0.808278140866677,0.0481174810281283,0.0503414379063302,True,0.897710429713034,0.0931134865295216,0.0924821916336861,469.308377553025
27072,1561:1038,Breast,HCC70,SIDM00673,907048,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.913010433651821,0.0682499902255591,0.653108371432981,10.846321921141,35.9582,0.908422338570266,0.880680525906149,0.101795238595425,0.59629475742366,0.384869130634982,0.211425626788679,8.07656128882553,5.2725,2.76976063231545,30.6857,0.82939907327704,0.742670006867986,0.804070508866288,0.694485728802156,0.0867290664090543,0.109584780064131,True,0.897710429713034,0.0931134865295216,0.0924821916336861,469.308377553025
27072,1191:1038,Breast,HCC70,SIDM00673,907048,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.000625,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.982162001049617,0.0682499902255591,0.653108371432981,10.846321921141,35.9582,0.908422338570266,0.880680525906149,0.0660167457793727,0.641458224988873,0.608347554188436,0.0331106708004372,10.4210381931997,26.7778,0.42528372794124,9.1804,0.892217901848345,0.860986978094291,0.864970947609413,0.850543651705219,0.0312309237540538,0.0144272959041933,True,0.897710429713034,0.0931134865295216,0.0924821916336861,469.308377553025
25469,1053:1051,Breast,HCC70,SIDM00673,907048,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.6227583331486,0.124976989208274,0.758022589210398,12.3319982222992,100.7004,0.841559312687763,0.922168887711551,0.108251250839808,0.472064884145654,0.402937685398561,0.0691271987470924,10.7682335929322,34.0637,1.56376462936705,66.6367,0.524088074815113,0.461031111124032,0.574288359392744,0.546832992879808,0.0630569636910803,0.0274553665129366,True,0.61999503388235,0.0705374589707875,0.442922827892318,107.362367348008
25469,1594:1051,Breast,HCC70,SIDM00673,907048,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.962175466878676,0.124976989208274,0.758022589210398,12.3319982222992,100.7004,0.841559312687763,0.922168887711551,0.095335811525116,0.729350738678098,0.618702651214264,0.110648087463834,10.7173049814527,32.8822,1.61469324084654,67.8182,0.809727724591446,0.77537538773847,0.887288280074852,0.84321573390251,0.0343523368529759,0.0440725461723411,True,0.61999503388235,0.0705374589707875,0.442922827892318,107.362367348008
23740,1011:1080,Breast,HCC70,SIDM00673,907048,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.967549826488848,0.0785843578458385,0.529929873306479,9.34976226123641,0.1274,0.809186600756098,0.822992073401422,0.0932266140627241,0.512733556968941,0.287924559876636,0.224808997092306,6.49387709777869,0.0176,2.85588516345771,0.1098,0.782928355158663,0.661941200808063,0.796285837821244,0.646201686786175,0.120987154350601,0.150084151035069,True,0.680872585130312,0.0825361768624602,0.368612997774341,131.54939790493
23741,1191:1086,Breast,HCC70,SIDM00673,907048,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.000625,1086,BI-2536,"PLK1, PLK2, PLK3",Cell cycle,Targeted,Early clinical trials,10.0,0.846646029448285,0.149727819016446,0.419539033573836,8.05261752709607,5.1857,0.796755745222345,0.759369891030366,0.113657873442256,0.35520105697386,0.48177496006011,-0.12657390308625,9.81101476539672,17.5445,-1.75839723830065,-12.3588,0.674570088132608,0.753008790065637,0.642917503123436,0.713360607140643,-0.0784387019330289,-0.0704431040172062,True,0.680872585130312,0.0825361768624602,0.368612997774341,131.54939790493
23743,1561:1192,Breast,HCC70,SIDM00673,907048,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.945344937737361,0.0782485077275298,0.613736899447901,10.3511830183092,25.5121,0.859292589936037,0.863451066669609,0.0793430492366384,0.580193070995697,0.372353850931183,0.207839220064514,7.74225800220931,4.182,2.6089250160999,21.3301,0.812327899931258,0.668924921818151,0.816259094860039,0.701786613273396,0.143402978113107,0.114472481586643,True,0.680872585130312,0.0825361768624602,0.368612997774341,131.54939790493
25471,1191:1553,Breast,HCC70,SIDM00673,907048,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.0025,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.583929257139547,0.0780073479392853,0.294724890840987,6.45389279188445,1.7122,0.657777395059971,0.665346613195364,0.0530712028339983,0.172098486569312,0.0756093636832245,0.0964891228860874,3.43961926061758,0.2119,3.01427353126687,1.5003,0.384095465660555,0.240064191647662,0.388515353583482,0.269272617397053,0.144031274012893,0.119242736186429,True,0.61999503388235,0.0705374589707875,0.442922827892318,107.362367348008
25471,1372:1553,Breast,HCC70,SIDM00673,907048,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.871512595113719,0.0780073479392853,0.294724890840987,6.45389279188445,1.7122,0.657777395059971,0.665346613195364,0.0834535443678346,0.256856454461436,0.156736850502682,0.100119603958754,4.57219188570149,0.4646,1.88170090618297,1.2476,0.573261284575858,0.461723057411191,0.579857953516016,0.470335542212184,0.111538227164666,0.109522411303832,True,0.61999503388235,0.0705374589707875,0.442922827892318,107.362367348008
25472,1191:1593,Breast,HCC70,SIDM00673,907048,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.000625,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.845840149236594,0.132126558482862,0.456182396865481,8.48724174455752,1.4018,0.799734111924463,0.782062248192732,0.177922509667123,0.385857386643806,0.384723315782655,0.0011340708611512,8.47146735432935,1.3865,0.0157743902281737,0.0152999999999999,0.676447220579783,0.737165846770045,0.661499648723647,0.660823032631841,-0.0607186261902619,0.0006766160918055,True,0.61999503388235,0.0705374589707875,0.442922827892318,107.362367348008
25470,1191:2172,Breast,HCC70,SIDM00673,907048,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.0025,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.519745800335893,0.06900332403831,0.696539015076705,11.424499085353,53.6843,0.888446832233881,0.898575981774162,0.0824395601638739,0.362023227856216,0.0342370830294885,0.327786144826728,1.2617329930022,0.0468,10.1627660923508,53.6375,0.461766509875287,0.0868074419101734,0.467031092809822,0.164681434800026,0.374959067965114,0.302349658009796,True,0.61999503388235,0.0705374589707875,0.442922827892318,107.362367348008
25470,1190:2172,Breast,HCC70,SIDM00673,907048,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.1,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.934155754829039,0.06900332403831,0.696539015076705,11.424499085353,53.6843,0.888446832233881,0.898575981774162,0.0967484837058896,0.650675929396855,0.313832842786156,0.336843086610699,7.01171917540691,2.5204,4.41277990994612,51.1639,0.82994772119091,0.608944021739002,0.839409924525487,0.653784613381113,0.221003699451908,0.185625311144374,True,0.61999503388235,0.0705374589707875,0.442922827892318,107.362367348008
25470,1372:2172,Breast,HCC70,SIDM00673,907048,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.838862469743999,0.06900332403831,0.696539015076705,11.424499085353,53.6843,0.888446832233881,0.898575981774162,0.050689969906254,0.584300438460297,0.446680321098151,0.137620117362146,9.37968360755699,13.0106,2.04481547779605,40.6737,0.745284703923946,0.691082537258298,0.753781667323712,0.691483877716447,0.054202166665648,0.062297789607265,True,0.61999503388235,0.0705374589707875,0.442922827892318,107.362367348008
25470,1012:2172,Breast,HCC70,SIDM00673,907048,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.770240729433742,0.06900332403831,0.696539015076705,11.424499085353,53.6843,0.888446832233881,0.898575981774162,0.127288762543672,0.536502719051741,0.068936676120872,0.467566042930869,2.23090932427069,0.0917,9.19358976108235,53.5926,0.684317936122922,0.23207831601865,0.692119819653371,0.291960537007801,0.452239620104271,0.40015928264557,True,0.61999503388235,0.0705374589707875,0.442922827892318,107.362367348008
28762,1561:1030,Breast,MDA-MB-330,SIDM00631,1330941,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1030,KU-55933,ATM,Genome integrity,Targeted,Experimental only,10.0,0.6049237405524,0.0408631593142973,0.904552345409361,14.3627182975435,411.4708,0.980346655262921,0.976457977019034,0.0632122967160616,0.547185188310477,0.451262814055379,0.095922374255098,11.5689722163412,59.3387,2.79374608120236,352.1321,0.59303496573968,0.522940272264418,0.590682611950583,0.563389717814879,0.0700946934752623,0.0272928941357039,True,0.955223667874901,0.115953398274562,0.0291781763160902,1107.28982924016
28762,1053:1030,Breast,MDA-MB-330,SIDM00631,1330941,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1030,KU-55933,ATM,Genome integrity,Targeted,Experimental only,10.0,0.703126646648136,0.0408631593142973,0.904552345409361,14.3627182975435,411.4708,0.980346655262921,0.976457977019034,0.0566742333036408,0.63601485734539,0.618900881529876,0.0171139758155138,13.7560240622267,270.2128,0.606694235316802,141.258,0.689307856267734,0.651225236984081,0.686573622974216,0.682077342109342,0.0380826192836526,0.0044962808648735,True,0.955223667874901,0.115953398274562,0.0291781763160902,1107.28982924016
28763,1011:1052,Breast,MDA-MB-330,SIDM00631,1330941,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1052,RO-3306,CDK1,Cell cycle,Targeted,Experimental only,10.0,0.509919806712545,0.0590200122352283,0.812704807998909,12.4998877226758,113.1283,0.946757007000653,0.951373690458967,0.112193971642174,0.414414278609159,0.161527156987602,0.252887121621557,7.16703298452357,2.8069,5.33285473815221,110.3214,0.482770150013521,0.302302087814745,0.485124288350237,0.374029343742542,0.180468062198775,0.111094944607695,True,0.955223667874901,0.115953398274562,0.0291781763160902,1107.28982924016
28763,1011:1059,Breast,MDA-MB-330,SIDM00631,1330941,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.509919806712545,0.107433066058186,0.705282803552765,11.0807921431096,4.2304,0.881150212690628,0.918238163785674,0.0659087466571548,0.359637670865307,0.0712930169348021,0.288344653930505,4.66747237946423,0.0496,6.41331976364541,4.1808,0.449315946139923,0.231703876078452,0.468227826993673,0.281480155295137,0.217612070061471,0.186747671698536,True,0.955223667874901,0.115953398274562,0.0291781763160902,1107.28982924016
28763,1053:1059,Breast,MDA-MB-330,SIDM00631,1330941,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.793464427922901,0.107433066058186,0.705282803552765,11.0807921431096,4.2304,0.881150212690628,0.918238163785674,0.0783003549989879,0.559616816244854,0.301310747107071,0.258306069137783,7.82998082168508,0.4444,3.25081132142457,3.786,0.699161349426711,0.551692439022948,0.728589319325174,0.614864433222771,0.147468910403763,0.113724886102403,True,0.955223667874901,0.115953398274562,0.0291781763160902,1107.28982924016
30697,1011:1085,Breast,MDA-MB-330,SIDM00631,1330941,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.215887300843363,0.105131731080599,0.598214601226299,9.94916020242389,19.3075,0.890738506337769,0.879881208608409,0.0471975554375133,0.129146935583834,0.0553827993198635,0.0737641362639707,6.46262083242799,1.7226,3.4865393699959,17.5849,0.192299131890509,0.11266618512763,0.189955179189265,0.148051688242995,0.0796329467628795,0.0419034909462695,True,0.945378612019343,0.0939934088263652,0.0386979291183321,903.723751361501
28767,1011:1192,Breast,MDA-MB-330,SIDM00631,1330941,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.400397176903575,0.074855495876019,0.569847561545968,9.67062942648722,15.9177,0.877775435668953,0.868592800456875,0.0682739024156576,0.228165354908392,0.0893895827445679,0.138775772163824,6.02680410727196,1.2734,3.64382531921526,14.6443,0.351458806397154,0.203962501994223,0.347782105181703,0.262115892986221,0.147496304402931,0.0856662121954814,True,0.955223667874901,0.115953398274562,0.0291781763160902,1107.28982924016
23612,1022:1003,Breast,CAL-120,SIDM00940,906826,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.948621418116258,0.0612090330534724,0.596485213589918,10.0217812620804,0.203,0.876542019398594,0.868748395495372,0.0589037199363843,0.565838649201047,0.275636407588061,0.290202241612987,6.66635918150924,0.0198,3.35542208057119,0.1832,0.831506533480382,0.647359710033574,0.824113334921043,0.654982514763644,0.184146823446808,0.169130820157399,True,0.236419811525149,0.0428531842744916,1.36363887219313,36.0919245180187
23612,1011:1003,Breast,CAL-120,SIDM00940,906826,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.271835341946983,0.0612090330534724,0.596485213589918,10.0217812620804,0.203,0.876542019398594,0.868748395495372,0.0446628456055264,0.162145762002535,0.0974815403608114,0.0646642216417235,7.47997728303714,0.0349,2.54180397904329,0.1681,0.238275099574116,0.171253775776696,0.236156517155378,0.201674814343592,0.0670213237974197,0.0344817028117855,True,0.236419811525149,0.0428531842744916,1.36363887219313,36.0919245180187
23837,1179:1032,Breast,CAL-120,SIDM00940,906826,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.649774866215681,0.0898052009465085,0.68326699610348,11.0099526628012,40.2769,0.901482003539022,0.903059397381104,0.0890127188996394,0.443969720982728,0.482903877770003,-0.038934156787275,11.7779594251751,68.5882,-0.768006762373847,-28.3113,0.585760348245411,0.563813854727443,0.58678529911812,0.600631430201586,0.0219464935179683,-0.0138461310834661,True,0.59639014242596,0.0746576032925633,0.487314599745485,98.8170824196229
23837,1011:1032,Breast,CAL-120,SIDM00940,906826,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.346759232320249,0.0898052009465085,0.68326699610348,11.0099526628012,40.2769,0.901482003539022,0.903059397381104,0.0776306375529191,0.236929139038605,0.201504992950425,0.0354241460881802,9.85573912028365,18.0969,1.15421354251755,22.18,0.312597207497711,0.242807655251679,0.313144183375459,0.298965455905231,0.0697895522460325,0.0141787274702276,True,0.59639014242596,0.0746576032925633,0.487314599745485,98.8170824196229
23837,1083:1038,Breast,CAL-120,SIDM00940,906826,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.969520889470456,0.080238878311414,0.76194838185917,12.0414681071109,82.3328,0.915413555660241,0.930698860073665,0.0624873085918138,0.738724872910677,0.517870659268504,0.220854213642173,9.35768357925958,12.8137,2.6837845278513,69.5191,0.88751256471703,0.803675845240611,0.902331986647759,0.815357420107836,0.0838367194764184,0.0869745665399233,True,0.59639014242596,0.0746576032925633,0.487314599745485,98.8170824196229
23837,1561:1038,Breast,CAL-120,SIDM00940,906826,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.972112382755851,0.080238878311414,0.76194838185917,12.0414681071109,82.3328,0.915413555660241,0.930698860073665,0.0607568787901686,0.740699457026082,0.575254826110895,0.165444630915187,9.97052605253349,19.5955,2.0709420545774,62.7373,0.889884852799882,0.867179842028276,0.904743886494364,0.84257192654948,0.0227050107716066,0.0621719599448842,True,0.59639014242596,0.0746576032925633,0.487314599745485,98.8170824196229
23837,1510:1038,Breast,CAL-120,SIDM00940,906826,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.938936980660275,0.080238878311414,0.76194838185917,12.0414681071109,82.3328,0.915413555660241,0.930698860073665,0.0493972554765123,0.715421513081831,0.502774025673403,0.212647487408428,9.37155885152645,12.9375,2.66990925558444,69.3953,0.859515640007113,0.778639739308666,0.873867577581526,0.79021844333946,0.0808759006984467,0.0836491342420658,True,0.59639014242596,0.0746576032925633,0.487314599745485,98.8170824196229
23838,1011:1042,Breast,CAL-120,SIDM00940,906826,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.375966371225263,0.0556923658428604,0.942626199199798,16.317674548151,1595.2896,0.966976952973076,0.984900129139156,0.0792680149570045,0.35439575153501,0.214115127054005,0.140280624481005,9.73157916043295,16.6046,6.58609538771801,1578.685,0.36355081606775,0.250856511266417,0.370289327571742,0.322238537819438,0.112694304801333,0.0480507897523033,True,0.59639014242596,0.0746576032925633,0.487314599745485,98.8170824196229
23839,1011:1050,Breast,CAL-120,SIDM00940,906826,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.313699373478003,0.0584041639967337,0.878531163035453,14.1726616354882,360.6835,0.951966665842333,0.96693103075728,0.0654070144731869,0.275594675425123,0.120579955639922,0.1550147197852,7.76867021707064,4.2592,6.40399141841758,356.4243,0.298631346646683,0.198841282515343,0.303325658544998,0.238103619655758,0.09979006413134,0.0652220388892398,True,0.59639014242596,0.0746576032925633,0.487314599745485,98.8170824196229
23839,1011:1051,Breast,CAL-120,SIDM00940,906826,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.313699373478003,0.0732000200319805,0.684318488348691,11.0226662327421,40.6334,0.889110599897915,0.903448711455643,0.0909405404634801,0.214670281054398,0.108143821078197,0.106526459976201,7.32094667839115,3.1229,3.70171955435098,37.5105,0.278913438140627,0.146568171113473,0.283411294753144,0.229692233409639,0.132345267027154,0.0537190613435049,True,0.59639014242596,0.0746576032925633,0.487314599745485,98.8170824196229
23615,1011:1080,Breast,CAL-120,SIDM00940,906826,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.315388508073791,0.0782171909511638,0.4585895622191,8.56596652630948,0.074,0.786958871969453,0.80283655037492,0.0644862176177697,0.144633877846495,0.0720956074496429,0.072538270396852,5.82028269244513,0.011,2.74568383386435,0.063,0.24819778454588,0.162268482311267,0.253205421849855,0.199561426108904,0.085929302234613,0.0536439957409511,True,0.236419811525149,0.0428531842744916,1.36363887219313,36.0919245180187
23616,1011:1086,Breast,CAL-120,SIDM00940,906826,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1086,BI-2536,"PLK1, PLK2, PLK3",Cell cycle,Targeted,Early clinical trials,10.0,0.297446863148924,0.17433270603793,0.290265363468316,6.66255490114024,1.9786,0.59904899886015,0.690206534450488,0.0906973035188434,0.0863385218444328,0.0568992055600738,0.029439316284359,5.2311110792686,0.7336,1.43144382187164,1.245,0.178185245583455,0.115557636210416,0.205299768597187,0.175692571084559,0.0626276093730383,0.0296071975126285,True,0.236419811525149,0.0428531842744916,1.36363887219313,36.0919245180187
23618,1011:1192,Breast,CAL-120,SIDM00940,906826,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.362112554401572,0.0726327692157239,0.727688842520796,11.5696811802431,59.3678,0.899592212490559,0.919021436424602,0.0816119456813924,0.263505265574729,0.118931177910679,0.14457408766405,7.13008025180845,2.7359,4.4396009284347,56.6319,0.325753633984718,0.181451098045925,0.332789199893515,0.260840250246589,0.144302535938794,0.0719489496469258,True,0.236419811525149,0.0428531842744916,1.36363887219313,36.0919245180187
23618,1594:1192,Breast,CAL-120,SIDM00940,906826,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.927716656999912,0.0726327692157239,0.727688842520796,11.5696811802431,59.3678,0.899592212490559,0.919021436424602,0.0310024755002355,0.675089060319529,0.623743807319866,0.0513452529996625,10.8791711468402,36.7864,0.690510033402948,22.5814,0.834566680034896,0.828836642979641,0.852591494711089,0.833998837623086,0.0057300370552551,0.0185926570880033,True,0.236419811525149,0.0428531842744916,1.36363887219313,36.0919245180187
24186,1049:1553,Breast,CAL-120,SIDM00940,906826,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.92431333983968,0.0504246204827619,0.840930451273343,13.3532676802947,204.3921,0.958560754389887,0.955784643077465,0.0407254414483687,0.777283233989353,0.609525470757747,0.167757763231606,10.7274898607191,33.1151,2.62577781957553,171.277,0.88601049232936,0.821421962351218,0.883444495610408,0.826407156303622,0.064588529978142,0.0570373393067851,True,0.565411235593296,0.0827652068016045,0.549244766441732,88.9365855972975
24186,1179:1553,Breast,CAL-120,SIDM00940,906826,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.685045281932598,0.0504246204827619,0.840930451273343,13.3532676802947,204.3921,0.958560754389887,0.955784643077465,0.0764820948222199,0.576075438078254,0.41084257204146,0.165232866036795,10.0570774438926,20.8071,3.29619023640208,183.585,0.656657522240545,0.530624802087208,0.65475576028385,0.596068808900868,0.126032720153337,0.0586869513829816,True,0.565411235593296,0.0827652068016045,0.549244766441732,88.9365855972975
24186,1011:1553,Breast,CAL-120,SIDM00940,906826,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.334955420043103,0.0504246204827619,0.840930451273343,13.3532676802947,204.3921,0.958560754389887,0.955784643077465,0.100218183611895,0.281674212533299,0.147639460490411,0.134034752042888,8.37773200522111,6.4965,4.97553567507356,197.8956,0.321075120123499,0.186031544936666,0.32014524659276,0.26560861998243,0.135043575186833,0.05453662661033,True,0.565411235593296,0.0827652068016045,0.549244766441732,88.9365855972975
24186,1594:1553,Breast,CAL-120,SIDM00940,906826,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.969718028188824,0.0504246204827619,0.840930451273343,13.3532676802947,204.3921,0.958560754389887,0.955784643077465,0.0741712629783575,0.815465419052724,0.53670953292584,0.278755886126884,9.56129204550572,14.7559,3.79197563478895,189.6362,0.929533644646154,0.841442498354664,0.926841599458238,0.824175218942193,0.0880911462914893,0.102666380516045,True,0.565411235593296,0.0827652068016045,0.549244766441732,88.9365855972975
24186,1372:1560,Breast,CAL-120,SIDM00940,906826,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.990742920427197,0.0598055000083392,0.840006334749982,13.3352492439437,201.8553,0.946661085038442,0.955504623388566,0.0808462389902428,0.832230329267543,0.572575185433611,0.259655143833932,9.82157749699818,17.6734,3.51367174694552,184.1819,0.937897768045766,0.804429074547891,0.946659441057677,0.852818564331695,0.133468693497874,0.0938408767259821,True,0.565411235593296,0.0827652068016045,0.549244766441732,88.9365855972975
24186,1011:1560,Breast,CAL-120,SIDM00940,906826,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.334955420043103,0.0598055000083392,0.840006334749982,13.3352492439437,201.8553,0.946661085038442,0.955504623388566,0.0714053627178011,0.281364674695048,0.183081093314615,0.0982835813804328,9.48855171544969,14.0304,3.84669752849401,187.8249,0.317089261377511,0.231627971648924,0.320051452480245,0.283629088654141,0.0854612897285872,0.0364223638261032,True,0.565411235593296,0.0827652068016045,0.549244766441732,88.9365855972975
24186,1594:1560,Breast,CAL-120,SIDM00940,906826,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.821334404381974,0.0598055000083392,0.840006334749982,13.3352492439437,201.8553,0.946661085038442,0.955504623388566,0.086998339770969,0.689926102628962,0.332669211339853,0.357256891289109,7.99472126773201,4.9817,5.34052797621169,196.8736,0.777525318431642,0.596819517804405,0.784788820735071,0.634045308321705,0.180705800627237,0.150743512413366,True,0.565411235593296,0.0827652068016045,0.549244766441732,88.9365855972975
24186,1179:1560,Breast,CAL-120,SIDM00940,906826,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.895480857855449,0.0598055000083392,0.840006334749982,13.3352492439437,201.8553,0.946661085038442,0.955504623388566,0.0728416244912126,0.752209593245925,0.455041249764338,0.297168343481587,9.08526510536904,10.6088,4.24998413857465,191.2465,0.847716880528594,0.678743295071372,0.855636099836841,0.74188900731103,0.168973585457222,0.113747092525811,True,0.565411235593296,0.0827652068016045,0.549244766441732,88.9365855972975
27638,1011:1593,Breast,CAL-120,SIDM00940,906826,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.337781175290056,0.0725816271316629,0.864386337079106,13.8422545306422,57.3712,0.941358249810235,0.962793488571781,0.0475783843692769,0.291973432843247,0.190214321160047,0.1017591116832,9.66369577460193,3.1683,4.17855875604027,54.2029,0.317973095989891,0.249850715054394,0.325213516131389,0.288553494942526,0.068122380935497,0.0366600211888632,True,,,,
23615,1510:2169,Breast,CAL-120,SIDM00940,906826,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.957280213460919,0.0834361191819881,0.736193578310993,11.683009908329,64.2194,0.924194346045913,0.921969324433488,0.0843452969097454,0.704743545794106,0.59837903096938,0.106364514824725,10.3363770688092,25.2516,1.34663283951984,38.9678,0.884712960862206,0.782925426691816,0.882582991698108,0.842942217862461,0.10178753417039,0.0396407738356475,True,0.236419811525149,0.0428531842744916,1.36363887219313,36.0919245180187
23615,1011:2169,Breast,CAL-120,SIDM00940,906826,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.315388508073791,0.0834361191819881,0.736193578310993,11.683009908329,64.2194,0.924194346045913,0.921969324433488,0.0717074880259454,0.23218699431701,0.110200875743231,0.121986118573779,7.37489121061335,3.2419,4.30811869771565,60.9775,0.291480275969654,0.179074849335235,0.290778529722879,0.231972808241336,0.112405426634419,0.0588057214815431,True,0.236419811525149,0.0428531842744916,1.36363887219313,36.0919245180187
23840,1011:2172,Breast,CAL-120,SIDM00940,906826,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.375999088047153,0.0505558812849678,0.893559379130591,14.5622774935308,472.5115,0.969690013199479,0.971256392843259,0.09084634383539,0.335977511669082,0.101732831309286,0.234244680359796,6.40725763251886,1.6577,8.1550198610119,470.8538,0.364602560651435,0.169410650472373,0.365191517969032,0.253118281595183,0.195191910179063,0.11207323637385,True,0.59639014242596,0.0746576032925633,0.487314599745485,98.8170824196229
30681,1011:1025,Breast,MDA-MB-175-VII,SIDM00633,908120,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.823071475142499,0.0516539669639515,0.899567513011257,14.1947576393097,366.2502,0.970356175489744,0.975310236092495,0.120398125768356,0.740408359924445,0.443060055310821,0.297348304613624,9.36371367779336,12.8673,4.83104396151636,353.3829,0.798672488773978,0.736384344874971,0.802750034742229,0.704730824915029,0.0622881438990066,0.0980192098271997,True,1.05980494238137,0.109157373625576,-0.0731324150120437,-872.61358169783
30201,1372:1038,Breast,MDA-MB-175-VII,SIDM00633,908120,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.800085629591559,0.0746777910878659,0.813499364199284,12.4899261197128,112.3498,0.96480238213816,0.951889740337198,0.106571618823827,0.650869150977718,0.444355539643805,0.206513611333912,9.52708132793104,14.4101,2.96284479178175,97.9397,0.771924521344446,0.709628447498916,0.761593302199433,0.690815637011504,0.0622960738455303,0.0707776651879288,True,0.837711561026985,0.0973970778679042,0.161464736200137,285.893578219592
30201,1191:1038,Breast,MDA-MB-175-VII,SIDM00633,908120,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.000625,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.971757010401089,0.0746777910878659,0.813499364199284,12.4899261197128,112.3498,0.96480238213816,0.951889740337198,0.0600991560696251,0.790523710117483,0.79717692045108,-0.006653210333597,12.5984036324646,121.1232,-0.108477512751771,-8.7734,0.937553478494427,0.953238755230354,0.925005528301544,0.92690065017394,-0.0156852767359272,-0.0018951218723962,True,0.837711561026985,0.0973970778679042,0.161464736200137,285.893578219592
30201,1011:1038,Breast,MDA-MB-175-VII,SIDM00633,908120,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.880141175109815,0.0746777910878659,0.813499364199284,12.4899261197128,112.3498,0.96480238213816,0.951889740337198,0.113475138853497,0.715994286357446,0.444638369499366,0.27135591685808,9.04918905615008,10.3468,3.44073706356271,102.003,0.849162302363829,0.78160344871668,0.837797354635358,0.740724265214849,0.0675588536471498,0.0970730894205096,True,0.837711561026985,0.0973970778679042,0.161464736200137,285.893578219592
30201,1558:1038,Breast,MDA-MB-175-VII,SIDM00633,908120,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.276346056216469,0.0746777910878659,0.813499364199284,12.4899261197128,112.3498,0.96480238213816,0.951889740337198,0.0466223965725343,0.224807341031077,0.0770153638392583,0.147791977191819,6.74678696319236,2.0976,5.74313915652043,110.2522,0.266619333332135,0.201607204102363,0.263050975695103,0.195132229691767,0.0650121292297726,0.0679187460033364,True,0.837711561026985,0.0973970778679042,0.161464736200137,285.893578219592
30201,1549:1038,Breast,MDA-MB-175-VII,SIDM00633,908120,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.367945236449714,0.0746777910878659,0.813499364199284,12.4899261197128,112.3498,0.96480238213816,0.951889740337198,0.0570747111213563,0.299323215911998,0.115185116751528,0.18413809916047,7.13788131309138,2.7507,5.35204480662141,109.5991,0.354994440623073,0.278331689029573,0.350243295582428,0.26945982362781,0.0766627515935003,0.0807834719546179,True,0.837711561026985,0.0973970778679042,0.161464736200137,285.893578219592
30201,1561:1038,Breast,MDA-MB-175-VII,SIDM00633,908120,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.729180428937224,0.0746777910878659,0.813499364199284,12.4899261197128,112.3498,0.96480238213816,0.951889740337198,0.0531620211261503,0.593187815326993,0.427690884200627,0.165496931126366,9.82849995803356,17.7584,2.66142616167923,94.5914,0.703515014847159,0.661328268369568,0.69409936916002,0.638782841583005,0.0421867464775906,0.0553165275770154,True,0.837711561026985,0.0973970778679042,0.161464736200137,285.893578219592
30201,1053:1038,Breast,MDA-MB-175-VII,SIDM00633,908120,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.845063523525982,0.0746777910878659,0.813499364199284,12.4899261197128,112.3498,0.96480238213816,0.951889740337198,0.093363645859587,0.687458639096393,0.420696049673405,0.266762589422988,8.97941182686644,9.8583,3.51051429284635,102.4915,0.815319300555934,0.69716020513813,0.804407297977584,0.708348477015199,0.118159095417804,0.0960588209623847,True,0.837711561026985,0.0973970778679042,0.161464736200137,285.893578219592
30202,1191:1042,Breast,MDA-MB-175-VII,SIDM00633,908120,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.0025,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.626625614796245,0.13118927231565,0.660644927837398,10.5784275575722,29.8644,0.925543369945201,0.903560278588523,0.0435387901157617,0.413977034068131,0.196166323396459,0.217810710671671,7.13790614536872,2.7508,3.44052141220351,27.1136,0.5799691832125,0.474699208526918,0.566194015076,0.458901995032688,0.105269974685582,0.107292020043312,True,0.837711561026985,0.0973970778679042,0.161464736200137,285.893578219592
30202,1558:1042,Breast,MDA-MB-175-VII,SIDM00633,908120,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.340242588184392,0.13118927231565,0.660644927837398,10.5784275575722,29.8644,0.925543369945201,0.903560278588523,0.0674586845150197,0.224779540118287,0.107278334253815,0.117501205864473,7.16262276053389,2.7983,3.41580479703835,27.0661,0.314909271667059,0.208090418376597,0.307429687767569,0.249723331430708,0.106818853290462,0.0577063563368616,True,0.837711561026985,0.0973970778679042,0.161464736200137,285.893578219592
30202,1372:1042,Breast,MDA-MB-175-VII,SIDM00633,908120,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.890234406216632,0.13118927231565,0.660644927837398,10.5784275575722,29.8644,0.925543369945201,0.903560278588523,0.139439475927162,0.588128845053356,0.487670676757437,0.100458168295919,9.45442148201682,13.7023,1.12400607555542,16.1621,0.823950552370906,0.788741603397224,0.804380448090188,0.765828403451875,0.0352089489736825,0.0385520446383139,True,0.837711561026985,0.0973970778679042,0.161464736200137,285.893578219592
30202,1011:1042,Breast,MDA-MB-175-VII,SIDM00633,908120,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.73753971728369,0.13118927231565,0.660644927837398,10.5784275575722,29.8644,0.925543369945201,0.903560278588523,0.0893801286576209,0.487251873302099,0.259850590906312,0.227401282395787,7.55737793537922,3.679,3.02104962219301,26.1854,0.682624995403177,0.563032636949218,0.666411592418952,0.559892003661076,0.119592358453959,0.106519588757876,True,0.837711561026985,0.0973970778679042,0.161464736200137,285.893578219592
28755,1011:1050,Breast,MDA-MB-175-VII,SIDM00633,908120,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.879850239067369,0.108237767244637,0.589217888379342,9.85472397332696,18.0841,0.873754204760199,0.877082522038059,0.0895227399335796,0.518423499953334,0.23775689746318,0.280666602490154,6.64602861968971,1.9561,3.20869535363724,16.128,0.768772845944379,0.635212756648616,0.771701266696997,0.615175160116205,0.133560089295763,0.156526106580792,True,0.550432533300249,0.0756485778333503,0.577003870657841,84.8624514962054
28755,1011:1051,Breast,MDA-MB-175-VII,SIDM00633,908120,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.879850239067369,0.119115428231446,0.680456330626569,10.7909638258194,34.6046,0.849837654277023,0.910408885655056,0.171964657978488,0.598699665176691,0.21898955312257,0.379710112054121,6.38294362267711,1.63,4.40802020314233,32.9746,0.747729863284091,0.500397392381612,0.801023475692657,0.59896578152802,0.247332470902479,0.202057694164637,True,0.550432533300249,0.0756485778333503,0.577003870657841,84.8624514962054
28755,1549:1051,Breast,MDA-MB-175-VII,SIDM00633,908120,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.314040983491784,0.119115428231446,0.680456330626569,10.7909638258194,34.6046,0.849837654277023,0.910408885655056,0.0482851618233263,0.213691175293178,0.135192331112371,0.0784988441808069,8.33694129282542,6.3154,2.45402253299402,28.2892,0.266883852757507,0.228922994371818,0.285905701830772,0.252759457470149,0.0379608583856883,0.0331462443606239,True,0.550432533300249,0.0756485778333503,0.577003870657841,84.8624514962054
28755,1510:1051,Breast,MDA-MB-175-VII,SIDM00633,908120,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.942693719248,0.119115428231446,0.680456330626569,10.7909638258194,34.6046,0.849837654277023,0.910408885655056,0.11098115557812,0.641461909104208,0.372739911622696,0.268721997481511,7.99377294965039,4.9785,2.79719087616905,29.6261,0.801136619067403,0.667161958450869,0.858236738454592,0.740406706327212,0.133974660616534,0.11783003212738,True,0.550432533300249,0.0756485778333503,0.577003870657841,84.8624514962054
28748,1510:1052,Breast,MDA-MB-175-VII,SIDM00633,908120,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1052,RO-3306,CDK1,Cell cycle,Targeted,Experimental only,10.0,0.938024768603487,0.0650578289104046,0.572240319674753,9.68949184291086,16.1272,0.845502270176085,0.870328524219336,0.101701326654418,0.536775593448495,0.242441635379498,0.294333958068998,6.50266862465377,1.771,3.18682321825709,14.3562,0.793102071335646,0.627874035003815,0.816389712539857,0.64648498401137,0.16522803633183,0.169904728528488,True,0.550432533300249,0.0756485778333503,0.577003870657841,84.8624514962054
28748,1011:1052,Breast,MDA-MB-175-VII,SIDM00633,908120,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1052,RO-3306,CDK1,Cell cycle,Targeted,Experimental only,10.0,0.867799274091968,0.0650578289104046,0.572240319674753,9.68949184291086,16.1272,0.845502270176085,0.870328524219336,0.068547235676472,0.496589734019906,0.259864190938041,0.236725543081865,6.98621880883376,2.4762,2.7032730340771,13.651,0.733726256301917,0.644466183438757,0.755270461539073,0.626814390779755,0.0892600728631604,0.128456070759318,True,0.550432533300249,0.0756485778333503,0.577003870657841,84.8624514962054
28748,1372:1059,Breast,MDA-MB-175-VII,SIDM00633,908120,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.657156907930309,0.133819217729732,0.517392564274948,9.16490686761648,1.1211,0.773381875450265,0.847092058026552,0.0899291383162771,0.340008097725058,0.131870833104247,0.208137264620811,5.72519335676222,0.1033,3.43971351085427,1.0178,0.50823324192024,0.38568625115565,0.556672397585051,0.415931153801421,0.12254699076459,0.14074124378363,True,0.550432533300249,0.0756485778333503,0.577003870657841,84.8624514962054
28748,1011:1059,Breast,MDA-MB-175-VII,SIDM00633,908120,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.867799274091968,0.133819217729732,0.517392564274948,9.16490686761648,1.1211,0.773381875450265,0.847092058026552,0.0939061773001228,0.448992891698381,0.20433066012083,0.244662231577551,6.20944855638849,0.1445,2.95545831122799,0.9766,0.671140230111625,0.581465025580414,0.735105873044512,0.580013738765552,0.0896752045312106,0.15509213427896,True,0.550432533300249,0.0756485778333503,0.577003870657841,84.8624514962054
28748,1558:1059,Breast,MDA-MB-175-VII,SIDM00633,908120,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.267518768362838,0.133819217729732,0.517392564274948,9.16490686761648,1.1211,0.773381875450265,0.847092058026552,0.0759926093548014,0.138412221554925,0.038974012644392,0.0994382089105326,4.80890326958544,0.0547,4.35600359803104,1.0664,0.206894166794597,0.089492098934289,0.226613024053205,0.150656817575832,0.117402067860308,0.075956206477373,True,0.550432533300249,0.0756485778333503,0.577003870657841,84.8624514962054
28748,1561:1059,Breast,MDA-MB-175-VII,SIDM00633,908120,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.704244341313854,0.133819217729732,0.517392564274948,9.16490686761648,1.1211,0.773381875450265,0.847092058026552,0.0711523247561109,0.364370785628496,0.287532636563923,0.0768381490645732,8.12081155069035,0.5437,1.04409531692614,0.5774,0.544649809460545,0.517006322375666,0.596559788437106,0.558284845303965,0.0276434870848794,0.0382749431331406,True,0.550432533300249,0.0756485778333503,0.577003870657841,84.8624514962054
28748,1053:1059,Breast,MDA-MB-175-VII,SIDM00633,908120,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.692472482967968,0.133819217729732,0.517392564274948,9.16490686761648,1.1211,0.773381875450265,0.847092058026552,0.0687221022335647,0.358280113652637,0.245480932540219,0.112799181112418,7.57996533014417,0.3737,1.58494153747231,0.7474,0.535545667575469,0.483423790470591,0.586587940724092,0.526650300553734,0.0521218771048776,0.059937640170358,True,0.550432533300249,0.0756485778333503,0.577003870657841,84.8624514962054
28749,1011:1080,Breast,MDA-MB-175-VII,SIDM00633,908120,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.858270244033976,0.0735042046850449,0.825903087834182,12.6888493820389,1.2896,0.919434041034507,0.955411139509982,0.108530186617503,0.708848044743858,0.220137381197409,0.488710663546449,6.4782514772282,0.0174,6.21059790481073,1.2722,0.789122878771831,0.543527620014434,0.820000951860012,0.590047416624785,0.245595258757397,0.229953535235226,True,0.550432533300249,0.0756485778333503,0.577003870657841,84.8624514962054
28749,1558:1080,Breast,MDA-MB-175-VII,SIDM00633,908120,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.242679466091412,0.0735042046850449,0.825903087834182,12.6888493820389,1.2896,0.919434041034507,0.955411139509982,0.0637448839496555,0.200429720398847,0.121646139319124,0.0787835810797232,9.01196645225884,0.1008,3.67688292978009,1.1888,0.223127762184523,0.157009952018019,0.23185866523407,0.203802506447623,0.0661178101665043,0.0280561587864462,True,0.550432533300249,0.0756485778333503,0.577003870657841,84.8624514962054
28749,1549:1080,Breast,MDA-MB-175-VII,SIDM00633,908120,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.331330802845609,0.0735042046850449,0.825903087834182,12.6888493820389,1.2896,0.919434041034507,0.955411139509982,0.0461313391404966,0.273647133164767,0.167200984753388,0.106446148411379,9.04392622500363,0.1031,3.6449231570353,1.1865,0.304636818979546,0.258269733918105,0.316557139901481,0.278763190574033,0.0463670850614406,0.0377939493274472,True,0.550432533300249,0.0756485778333503,0.577003870657841,84.8624514962054
28750,1191:1086,Breast,MDA-MB-175-VII,SIDM00633,908120,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.000625,1086,BI-2536,"PLK1, PLK2, PLK3",Cell cycle,Targeted,Early clinical trials,10.0,0.971750567271764,0.0967837880245216,0.557097855091036,9.54352339767825,14.5753,0.852516373458408,0.864137710114407,0.0584096399338828,0.541360156710597,0.538690886740832,0.0026692699697652,9.51716209838885,14.3114,0.0263612992893982,0.2639,0.828433269516675,0.82122154936316,0.839726310004599,0.838617966039848,0.0072117201535144,0.0011083439647511,True,0.550432533300249,0.0756485778333503,0.577003870657841,84.8624514962054
28750,1558:1086,Breast,MDA-MB-175-VII,SIDM00633,908120,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1086,BI-2536,"PLK1, PLK2, PLK3",Cell cycle,Targeted,Early clinical trials,10.0,0.257823335398733,0.0967837880245216,0.557097855091036,9.54352339767825,14.5753,0.852516373458408,0.864137710114407,0.0545001335730913,0.143632827143051,0.0585298639303332,0.0851029632127175,6.09690317075401,1.3368,3.44662022692424,13.2385,0.219798614887078,0.13086792639383,0.22279486666552,0.170226597571271,0.0889306884932486,0.0525682690942488,True,0.550432533300249,0.0756485778333503,0.577003870657841,84.8624514962054
30682,1011:1096,Breast,MDA-MB-175-VII,SIDM00633,908120,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.889753771505829,0.0546724883029285,0.938007113404726,15.4370608602791,433.2299,0.958755848162811,0.985066275857956,0.186579728450566,0.834595366851151,0.193952757966047,0.640642608885103,5.97320169173542,0.6135,9.46385916854367,432.6164,0.853056631856131,0.498666145954425,0.876466434127818,0.579435488232871,0.354390485901706,0.297030945894947,True,1.05980494238137,0.109157373625576,-0.0731324150120437,-872.61358169783
30682,1011:1129,Breast,MDA-MB-175-VII,SIDM00633,908120,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.889753771505829,0.0718195582234152,0.683011771068559,10.8188701239181,35.2805,0.917938684841784,0.911278035444764,0.0556327716805134,0.607712299291127,0.230904276545513,0.376808022745613,6.51569478889916,1.7871,4.30317533501894,33.4934,0.816739406849078,0.585550224966652,0.810813068927402,0.614028784447523,0.231189181882426,0.196784284479879,True,1.05980494238137,0.109157373625576,-0.0731324150120437,-872.61358169783
30683,1021:1192,Breast,MDA-MB-175-VII,SIDM00633,908120,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.933982384127976,0.0795553921713483,0.652379317126875,10.4915762444314,28.1196,0.925909639088542,0.900643361559403,0.057693558773269,0.609310789965939,0.593464022014959,0.0158467679509797,10.3162240893834,24.9014,0.175352155048,3.2182,0.86478329220299,0.857833451970028,0.841185034078286,0.835485405973991,0.0069498402329625,0.0056996281042944,True,1.05980494238137,0.109157373625576,-0.0731324150120437,-872.61358169783
30683,1011:1192,Breast,MDA-MB-175-VII,SIDM00633,908120,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.802961440217169,0.0795553921713483,0.652379317126875,10.4915762444314,28.1196,0.925909639088542,0.900643361559403,0.157766011450121,0.523835436048088,0.254635093867306,0.269200342180782,7.18257127454227,2.8373,3.30900496988918,25.2823,0.743469737313495,0.63741278190501,0.72318189071977,0.590384904223002,0.106056955408485,0.132796986496768,True,1.05980494238137,0.109157373625576,-0.0731324150120437,-872.61358169783
30204,1372:1553,Breast,MDA-MB-175-VII,SIDM00633,908120,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.918084528160435,0.0772092263849426,0.230477484017915,6.1434011751388,1.3806,0.663744260144316,0.663611835009392,0.064911784334342,0.211597812166192,0.0782310677839269,0.133366744382265,3.37606626697523,0.2028,2.76733490816357,1.1778,0.609373335893792,0.399162215350014,0.609251758426278,0.414245056055828,0.210211120543777,0.195006702370449,True,0.837711561026985,0.0973970778679042,0.161464736200137,285.893578219592
30204,1372:1560,Breast,MDA-MB-175-VII,SIDM00633,908120,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.918084528160435,0.0762036427389428,0.410999227890163,8.1474012769013,5.5379,0.792062599568925,0.794257718430205,0.0468528501208515,0.377332032211843,0.184234878506573,0.19309715370527,5.72525827553722,1.0332,2.42214300136409,4.5047,0.727180417998764,0.569607347015275,0.729195722662778,0.581083249192087,0.157573070983489,0.148112473470691,True,0.837711561026985,0.0973970778679042,0.161464736200137,285.893578219592
30204,1558:1560,Breast,MDA-MB-175-VII,SIDM00633,908120,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.257602848842658,0.0762036427389428,0.410999227890163,8.1474012769013,5.5379,0.792062599568925,0.794257718430205,0.068290694974237,0.105874571976639,0.0281556415941895,0.0777189303824491,4.02915890139716,0.3189,4.11824237550414,5.219,0.204037582110676,0.0925386561709306,0.20460305098289,0.129390156836035,0.111498925939746,0.0752128941468557,True,0.837711561026985,0.0973970778679042,0.161464736200137,285.893578219592
30204,1549:1560,Breast,MDA-MB-175-VII,SIDM00633,908120,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.328531534064286,0.0762036427389428,0.410999227890163,8.1474012769013,5.5379,0.792062599568925,0.794257718430205,0.0224022500047506,0.135026206837992,0.0555400328810725,0.07948617395692,5.22710472420671,0.7316,2.92029655269459,4.8063,0.260217540911326,0.183107487583169,0.260938706678275,0.195591794924632,0.0771100533281562,0.0653469117536432,True,0.837711561026985,0.0973970778679042,0.161464736200137,285.893578219592
30684,1058:1564,Breast,MDA-MB-175-VII,SIDM00633,908120,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.908389944143887,0.0911246495770854,0.571012392854978,9.67761016937584,7.9974,0.836872312295478,0.869832483975334,0.0711074777858327,0.518701915651,0.271585881731079,0.247116033919922,6.98082923863395,1.2335,2.69678093074189,6.7639,0.760206393021654,0.644589174749578,0.790147081532891,0.655806363646518,0.115617218272077,0.134340717886373,True,1.05980494238137,0.109157373625576,-0.0731324150120437,-872.61358169783
30684,1191:1564,Breast,MDA-MB-175-VII,SIDM00633,908120,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.0025,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.664748621128417,0.0911246495770854,0.571012392854978,9.67761016937584,7.9974,0.836872312295478,0.869832483975334,0.0572258451506381,0.379579700797585,0.129076816769588,0.250502884027996,5.62806219475318,0.483,4.04954797462267,7.5144,0.556309715658969,0.414379320510573,0.578219944335309,0.415917952105321,0.141930395148397,0.162301992229988,True,1.05980494238137,0.109157373625576,-0.0731324150120437,-872.61358169783
30684,1549:1564,Breast,MDA-MB-175-VII,SIDM00633,908120,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.254118313141124,0.0911246495770854,0.571012392854978,9.67761016937584,7.9974,0.836872312295478,0.869832483975334,0.0677337570458289,0.145104706054984,0.054209313931246,0.0908953921237378,5.90789981770033,0.5863,3.76971035167551,7.4111,0.212664580315039,0.107201463268579,0.221040363543166,0.164272390087669,0.10546311704646,0.0567679734554962,True,1.05980494238137,0.109157373625576,-0.0731324150120437,-872.61358169783
30684,1558:1564,Breast,MDA-MB-175-VII,SIDM00633,908120,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.404784875763419,0.0911246495770854,0.571012392854978,9.67761016937584,7.9974,0.836872312295478,0.869832483975334,0.068979182214522,0.231137180501175,0.0574616965780517,0.173675483923123,4.73710986601763,0.2604,4.94050030335821,7.737,0.33875325496237,0.176387339690431,0.352095033960941,0.225705688132875,0.162365915271939,0.126389345828067,True,1.05980494238137,0.109157373625576,-0.0731324150120437,-872.61358169783
30684,1561:1564,Breast,MDA-MB-175-VII,SIDM00633,908120,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.752176564151993,0.0911246495770854,0.571012392854978,9.67761016937584,7.9974,0.836872312295478,0.869832483975334,0.0663664307185092,0.429502139745865,0.119095963438581,0.310406176307284,5.04150525958226,0.3216,4.63610490979358,7.6758,0.629475740496346,0.432201076173353,0.65426760918436,0.437109160259693,0.197274664322993,0.217158448924666,True,1.05980494238137,0.109157373625576,-0.0731324150120437,-872.61358169783
30684,1510:1564,Breast,MDA-MB-175-VII,SIDM00633,908120,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.914312549719343,0.0911246495770854,0.571012392854978,9.67761016937584,7.9974,0.836872312295478,0.869832483975334,0.0707933329517519,0.522083796832578,0.245737876128129,0.276345920704449,6.62850045560719,0.9662,3.04910971376865,7.0312,0.7651628576444,0.634582194238984,0.795298756252196,0.638161232702823,0.130580663405416,0.157137523549373,True,1.05980494238137,0.109157373625576,-0.0731324150120437,-872.61358169783
30684,1012:1564,Breast,MDA-MB-175-VII,SIDM00633,908120,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.69596355014104,0.0911246495770854,0.571012392854978,9.67761016937584,7.9974,0.836872312295478,0.869832483975334,0.0731894032684426,0.39740381210588,0.0409044837368426,0.356499328369038,2.42848034812967,0.0526,7.24912982124618,7.9448,0.582432625479901,0.226863894221988,0.605371703575472,0.263464790173718,0.355568731257914,0.341906913401754,True,1.05980494238137,0.109157373625576,-0.0731324150120437,-872.61358169783
30684,1011:1564,Breast,MDA-MB-175-VII,SIDM00633,908120,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.834939831837644,0.0911246495770854,0.571012392854978,9.67761016937584,7.9974,0.836872312295478,0.869832483975334,0.0776933286559305,0.476760991267546,0.0447000629931804,0.432060928274366,2.19420329868314,0.0447,7.4834068706927,7.9527,0.698738027697567,0.264536224217634,0.726257787897285,0.301490616611323,0.434201803479932,0.424767171285962,True,1.05980494238137,0.109157373625576,-0.0731324150120437,-872.61358169783
30684,1053:1564,Breast,MDA-MB-175-VII,SIDM00633,908120,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.702997325037629,0.0911246495770854,0.571012392854978,9.67761016937584,7.9974,0.836872312295478,0.869832483975334,0.0517647820629875,0.401420184740385,0.0420472652014401,0.359372919538945,2.4725555768488,0.0542,7.20505459252704,7.9432,0.588318996941776,0.232524787594771,0.611489909465496,0.268456537044935,0.355794209347004,0.343033372420561,True,1.05980494238137,0.109157373625576,-0.0731324150120437,-872.61358169783
30684,1372:1593,Breast,MDA-MB-175-VII,SIDM00633,908120,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.763466548945357,0.0483638815362796,0.78944083823585,12.1313108219039,17.5246,0.936701051130532,0.944906653660232,0.126106547764109,0.602711672364454,0.242036356961547,0.360675315402908,7.18150897693927,0.567,4.94980184496468,16.9576,0.715139918900115,0.60327007911561,0.721404621945482,0.561293016502665,0.111869839784505,0.160111605442818,True,1.05980494238137,0.109157373625576,-0.0731324150120437,-872.61358169783
30684,1058:1593,Breast,MDA-MB-175-VII,SIDM00633,908120,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.908389944143887,0.0483638815362796,0.78944083823585,12.1313108219039,17.5246,0.936701051130532,0.944906653660232,0.0854844287418772,0.717120118949967,0.550022465712445,0.167097653237522,10.0150548926326,4.042,2.11625592927133,13.4826,0.850889815515984,0.776085651619979,0.858343702339604,0.802454102636335,0.0748041638960046,0.0558895997032699,True,1.05980494238137,0.109157373625576,-0.0731324150120437,-872.61358169783
30684,1191:1593,Breast,MDA-MB-175-VII,SIDM00633,908120,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.000625,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.954881337334281,0.0483638815362796,0.78944083823585,12.1313108219039,17.5246,0.936701051130532,0.944906653660232,0.0685626390079732,0.753822323360945,0.770103083785287,-0.0162807604243419,12.3820171300084,20.8506,-0.250706308104448,-3.326,0.894438352385949,0.919210996278691,0.902273729103143,0.907019489158447,-0.0247726438927414,-0.0047457600553042,True,1.05980494238137,0.109157373625576,-0.0731324150120437,-872.61358169783
30684,1011:1593,Breast,MDA-MB-175-VII,SIDM00633,908120,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.834939831837644,0.0483638815362796,0.78944083823585,12.1313108219039,17.5246,0.936701051130532,0.944906653660232,0.0597979770006423,0.65913560072241,0.385625197623832,0.273510403098578,8.63781824380995,1.556,3.493492578094,15.9686,0.782089018113071,0.681367037601573,0.788940202509345,0.685474250980166,0.100721980511498,0.103465951529179,True,1.05980494238137,0.109157373625576,-0.0731324150120437,-872.61358169783
30684,1561:1593,Breast,MDA-MB-175-VII,SIDM00633,908120,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.752176564151993,0.0483638815362796,0.78944083823585,12.1313108219039,17.5246,0.936701051130532,0.944906653660232,0.0536408370883826,0.593798897305511,0.52688679110147,0.0669121062040413,11.0130450180991,8.0727,1.1182658038048,9.4519,0.704564578276924,0.715132016363289,0.71073664019451,0.689848467367898,-0.0105674380863658,0.020888172826612,True,1.05980494238137,0.109157373625576,-0.0731324150120437,-872.61358169783
28749,1558:2169,Breast,MDA-MB-175-VII,SIDM00633,908120,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.34164600559922,0.0605117976924761,0.553792864587961,9.51180981683708,14.2584,0.848891824029059,0.862764727333725,0.0753906012762041,0.189201120115827,0.0932534615536502,0.0959476585621764,6.67871654309017,2.0009,2.83309327374691,12.2575,0.290020500865364,0.180710615517611,0.294760122865467,0.239643756434364,0.109309885347753,0.0551163664311032,True,0.550432533300249,0.0756485778333503,0.577003870657841,84.8624514962054
28749,1372:2169,Breast,MDA-MB-175-VII,SIDM00633,908120,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.919882724107575,0.0605117976924761,0.553792864587961,9.51180981683708,14.2584,0.848891824029059,0.862764727333725,0.0365659966474949,0.509424488868511,0.328225242230009,0.181199246638502,7.60387884838836,3.7995,1.90793096844872,10.4589,0.780880923560499,0.687922568979054,0.793642367643676,0.700964363701987,0.0929583545814442,0.0926780039416891,True,0.550432533300249,0.0756485778333503,0.577003870657841,84.8624514962054
28749,1011:2169,Breast,MDA-MB-175-VII,SIDM00633,908120,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.858270244033976,0.0605117976924761,0.553792864587961,9.51180981683708,14.2584,0.848891824029059,0.862764727333725,0.110804618131432,0.475303937034184,0.251900943985631,0.223402993048553,6.91858565870776,2.3628,2.59322415812932,11.8956,0.728578592967867,0.577920180190183,0.740485293072623,0.616043287467574,0.150658412777684,0.124442005605049,True,0.550432533300249,0.0756485778333503,0.577003870657841,84.8624514962054
28756,1191:2172,Breast,MDA-MB-175-VII,SIDM00633,908120,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.000625,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.970858433571882,0.0736024045972455,0.686279808915967,10.854734666762,36.1685,0.876817044148953,0.912384926367061,0.0518787664295778,0.666280540276166,0.695050178934399,-0.0287696386582328,11.1899921671584,45.6303,-0.335257500396411,-9.4618,0.851265222011581,0.873884753905118,0.885796600427322,0.895318395437121,-0.0226195318935375,-0.0095217950097989,True,0.550432533300249,0.0756485778333503,0.577003870657841,84.8624514962054
28756,1021:2172,Breast,MDA-MB-175-VII,SIDM00633,908120,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.885556634081802,0.0736024045972455,0.686279808915967,10.854734666762,36.1685,0.876817044148953,0.912384926367061,0.0591613043237576,0.607739637621926,0.613698418587805,-0.0059587809658786,10.9292265292332,38.0851,-0.0744918624712501,-1.9166,0.776471150322102,0.784701007565374,0.807968524380587,0.809972468517137,-0.0082298572432717,-0.0020039441365492,True,0.550432533300249,0.0756485778333503,0.577003870657841,84.8624514962054
28756,1012:2172,Breast,MDA-MB-175-VII,SIDM00633,908120,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.907001990695802,0.0736024045972455,0.686279808915967,10.854734666762,36.1685,0.876817044148953,0.912384926367061,0.0562703950417804,0.622457152861117,0.574275205304266,0.0481819475568506,10.2931922649167,24.507,0.561542401845289,11.6615,0.79527480451911,0.781694595329848,0.827534944495768,0.810603914504396,0.0135802091892615,0.016931029991372,True,0.550432533300249,0.0756485778333503,0.577003870657841,84.8624514962054
25076,1053:1003,Breast,OCUB-M,SIDM00241,909256,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.227590570771538,0.138478660601526,0.562331824919921,9.53444483170902,0.1448,0.800149593062125,0.878765712419011,0.0615279192475133,0.127981420996525,0.048542792429231,0.0794386285672942,6.21678126826952,0.0145,3.3176635634395,0.1303,0.182106502587623,0.107908146143033,0.1999987900639,0.154222605345895,0.0741983564445891,0.0457761847180043,True,0.696813824939661,0.0921391971612566,0.336642508283271,141.041246137303
25076,1179:1003,Breast,OCUB-M,SIDM00241,909256,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.625,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.860495920276695,0.138478660601526,0.562331824919921,9.53444483170902,0.1448,0.800149593062125,0.878765712419011,0.0904645555133974,0.483884241185341,0.100453207073712,0.383431034111628,4.68470631130915,0.005,4.84973852039987,0.1398,0.688525460441016,0.482250600645644,0.756174310415602,0.478724664595353,0.206274859795372,0.277449645820249,True,0.696813824939661,0.0921391971612566,0.336642508283271,141.041246137303
25076,1022:1003,Breast,OCUB-M,SIDM00241,909256,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.849495715069632,0.138478660601526,0.562331824919921,9.53444483170902,0.1448,0.800149593062125,0.878765712419011,0.101414599478619,0.477698475716759,0.128686542880486,0.349011932836273,5.32589177186031,0.0078,4.2085530598487,0.137,0.679723650720985,0.510793061547444,0.746507707250062,0.51671847033504,0.168930589173541,0.229789236915023,True,0.696813824939661,0.0921391971612566,0.336642508283271,141.041246137303
25077,1053:1030,Breast,OCUB-M,SIDM00241,909256,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1030,KU-55933,ATM,Genome integrity,Targeted,Experimental only,10.0,0.706977985141752,0.0880865073678181,0.738845575887891,11.2176433805601,46.5133,0.898885815541852,0.936151139293417,0.125508816976523,0.522347556572119,0.318145947723068,0.204201608849051,8.57216186100897,7.4337,2.64548151955113,39.0796,0.635492482744279,0.506637232750308,0.661838246245816,0.588285103723879,0.128855249993971,0.0735531425219367,True,0.696813824939661,0.0921391971612566,0.336642508283271,141.041246137303
27336,1058:1032,Breast,OCUB-M,SIDM00241,909256,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.892714149570672,0.0718010772084429,0.095175294380483,4.19779869715214,0.3584,0.514696522541966,0.516315383845192,0.0518050861522311,0.0849643319830112,0.0085795419303087,0.0763847900527025,-0.884145579618229,0.0106,5.08194427677037,0.3478,0.459476868408033,0.0991988241508913,0.460922048799616,0.135352047087687,0.360278044257142,0.325570001711929,True,0.49621423654552,0.0626877082544931,0.663764931189795,73.1460280545743
27336,1561:1032,Breast,OCUB-M,SIDM00241,909256,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.25648335096175,0.0718010772084429,0.095175294380483,4.19779869715214,0.3584,0.514696522541966,0.516315383845192,0.059462080731132,0.0244108784314774,0.0040561322198609,0.0203547462116165,0.191298088063042,0.0223,4.0065006090891,0.3361,0.132011088829923,0.0094977507409289,0.132426299801717,0.0544220211548487,0.122513338088995,0.0780042786468685,True,0.49621423654552,0.0626877082544931,0.663764931189795,73.1460280545743
27336,1012:1032,Breast,OCUB-M,SIDM00241,909256,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.430364640529019,0.0718010772084429,0.095175294380483,4.19779869715214,0.3584,0.514696522541966,0.516315383845192,0.0932901363950849,0.0409600813533002,0.0049247554987549,0.0360353258545453,-0.50803398007784,0.0137,4.70583267722998,0.3447,0.221507183905309,0.0693712752781383,0.222203884568139,0.0737499448910197,0.152135908627171,0.148453939677119,True,0.49621423654552,0.0626877082544931,0.663764931189795,73.1460280545743
27336,1594:1032,Breast,OCUB-M,SIDM00241,909256,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.949021533636566,0.0718010772084429,0.095175294380483,4.19779869715214,0.3584,0.514696522541966,0.516315383845192,0.0551508631009017,0.0903234038372777,0.0250640964347248,0.0652593074025528,1.30795628106956,0.0484,2.88984241608258,0.31,0.488458083180184,0.266185399982629,0.489994417416916,0.272660265797416,0.222272683197555,0.217334151619501,True,0.49621423654552,0.0626877082544931,0.663764931189795,73.1460280545743
27336,1053:1032,Breast,OCUB-M,SIDM00241,909256,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.273873853508452,0.0718010772084429,0.095175294380483,4.19779869715214,0.3584,0.514696522541966,0.516315383845192,0.0680895174183412,0.0260660246307842,0.0033966685835341,0.0226693560472501,-0.334336637094061,0.0155,4.5321353342462,0.3429,0.140961920015968,0.0120547287980116,0.141405283799378,0.0495753917630488,0.128907191217956,0.0918298920363292,True,0.49621423654552,0.0626877082544931,0.663764931189795,73.1460280545743
27336,1561:1038,Breast,OCUB-M,SIDM00241,909256,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.25648335096175,0.164805236334982,0.465222557040134,8.70288305336718,8.1388,0.895495179797953,0.83906164935354,0.0319833576809445,0.119321840372647,0.0751987408628443,0.0441230995098031,7.12363238724303,2.7237,1.57925066612415,5.4151,0.229679604484674,0.214308613097696,0.215205343489689,0.190578182339746,0.0153709913869784,0.0246271611499425,True,0.49621423654552,0.0626877082544931,0.663764931189795,73.1460280545743
25505,1058:1042,Breast,OCUB-M,SIDM00241,909256,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.922893471466843,0.120728503139718,0.659321586828633,10.4079626388902,26.5362,0.900233654533887,0.912186598778399,0.0608949988308106,0.608483588081304,0.534602343194125,0.0738812448871796,9.68187172712497,16.0422,0.726090911765231,10.494,0.830819762564062,0.847277814069621,0.84185105677213,0.816753227911949,-0.0164580515055588,0.0250978288601805,True,0.580978458229836,0.0841587442812999,0.506517911403239,94.5380765593994
25505,1561:1042,Breast,OCUB-M,SIDM00241,909256,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.0761397800895721,0.120728503139718,0.659321586828633,10.4079626388902,26.5362,0.900233654533887,0.912186598778399,0.0315828812970812,0.0502006006294398,0.0283353466851985,0.0218652539442412,7.88473881453085,4.6161,2.52322382435935,21.9201,0.068543592485442,0.0299334899074633,0.0694536870316421,0.0603409283884965,0.0386101025779787,0.0091127586431456,True,0.580978458229836,0.0841587442812999,0.506517911403239,94.5380765593994
25505,1011:1042,Breast,OCUB-M,SIDM00241,909256,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.582189647368686,0.120728503139718,0.659321586828633,10.4079626388902,26.5362,0.900233654533887,0.912186598778399,0.0895580963231353,0.383850202138324,0.0958880281331598,0.287962174005165,5.53773890969095,0.9073,4.87022372919926,25.6289,0.524106713882508,0.335031890158827,0.531065594277238,0.363933993649804,0.18907482372368,0.167131600627434,True,0.580978458229836,0.0841587442812999,0.506517911403239,94.5380765593994
27080,1558:1059,Breast,OCUB-M,SIDM00241,909256,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.54693771665781,0.0919118899105576,0.125665855065287,4.86350015728769,0.0569,0.582813292490779,0.570930989711913,0.0603632974350647,0.0687313958312592,0.0176515707346523,0.0510798250966069,1.7483498364191,0.0066,3.11515032086859,0.0503,0.318762571432727,0.149213569700998,0.312263691882217,0.174879653435655,0.16954900173173,0.137384038446562,True,0.597231696755248,0.0818589810846161,0.483725397765941,99.2586921991921
27080,1561:1059,Breast,OCUB-M,SIDM00241,909256,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.248198995206108,0.0919118899105576,0.125665855065287,4.86350015728769,0.0569,0.582813292490779,0.570930989711913,0.0590518790628139,0.0311901389589205,0.0059713148159769,0.0252188241429436,1.10392567327817,0.0042,3.75957448400952,0.0527,0.144653673588975,0.019697644318611,0.141704497978525,0.0677009564880346,0.124956029270364,0.0740035414904908,True,0.597231696755248,0.0818589810846161,0.483725397765941,99.2586921991921
27080,1053:1059,Breast,OCUB-M,SIDM00241,909256,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.583290259870607,0.0919118899105576,0.125665855065287,4.86350015728769,0.0569,0.582813292490779,0.570930989711913,0.0442955084142413,0.0732996692578932,0.0138944282279787,0.0594052410299145,1.08222433877131,0.0041,3.78127581851638,0.0528,0.339949316832991,0.127786225837837,0.333018485357245,0.158212943483214,0.212163090995154,0.174805541874031,True,0.597231696755248,0.0818589810846161,0.483725397765941,99.2586921991921
27081,1011:1096,Breast,OCUB-M,SIDM00241,909256,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.199600514645895,0.179774188281564,0.471368926752728,8.75552135518398,4.2206,0.718098594452588,0.841806091131047,0.077839977485462,0.094085480367928,0.0177319631672221,0.0763535172007058,4.0359615161048,0.1602,4.71955983907917,4.0604,0.143332849019231,0.0402970753830347,0.168024929021807,0.100392459062165,0.103035773636196,0.0676324699596419,True,0.597231696755248,0.0818589810846161,0.483725397765941,99.2586921991921
25508,1012:1560,Breast,OCUB-M,SIDM00241,909256,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.910193989452031,0.120768641086762,0.153407907563388,5.35761401116479,0.8008,0.632535294996408,0.610799369059789,0.1303685554218,0.139630955398608,0.138009950884762,0.0016210045138463,5.32823263332307,0.7847,0.0293813778417196,0.0161,0.575729823621998,0.593959092754532,0.555945914479313,0.553809449872357,-0.018229269132534,0.0021364646069553,True,0.580978458229836,0.0841587442812999,0.506517911403239,94.5380765593994
25508,1558:1560,Breast,OCUB-M,SIDM00241,909256,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.470280830271115,0.120768641086762,0.153407907563388,5.35761401116479,0.8008,0.632535294996408,0.610799369059789,0.0632264224156738,0.0721447981390646,0.0166093117151348,0.0555354864239298,1.94729071557444,0.0753,3.41032329559035,0.7255,0.297469223706696,0.137822244068135,0.287247234410511,0.157460279064713,0.159646979638561,0.129786955345798,True,0.580978458229836,0.0841587442812999,0.506517911403239,94.5380765593994
25508,1549:1560,Breast,OCUB-M,SIDM00241,909256,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.832083958856039,0.120768641086762,0.153407907563388,5.35761401116479,0.8008,0.632535294996408,0.610799369059789,0.112719974500357,0.127648259045165,0.0583446265872054,0.0693036324579597,3.48803705875232,0.2191,1.86957695241246,0.5817,0.526322472376784,0.381714453717022,0.50823635707404,0.380949644402952,0.144608018659762,0.127286712671088,True,0.580978458229836,0.0841587442812999,0.506517911403239,94.5380765593994
25508,1053:1560,Breast,OCUB-M,SIDM00241,909256,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.694790286861547,0.120768641086762,0.153407907563388,5.35761401116479,0.8008,0.632535294996408,0.610799369059789,0.0643809171059178,0.106586324102796,0.0289606907924974,0.0776256333102985,2.31473582752317,0.0972,3.04287818364161,0.7036,0.439479379060608,0.232772562629684,0.424377468843902,0.252397751523925,0.206706816430924,0.171979717319977,True,0.580978458229836,0.0841587442812999,0.506517911403239,94.5380765593994
25509,1058:1593,Breast,OCUB-M,SIDM00241,909256,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.908332565508787,0.167119970362956,0.557466052036652,9.49233714231608,2.8134,0.813046028410844,0.876942754363477,0.0677845772592959,0.506364569230508,0.224719945994454,0.281644623236054,6.62763114812608,0.3863,2.86470599419,2.4271,0.738516184863152,0.608643093785428,0.79655566187532,0.643132542271297,0.129873091077723,0.153423119604023,True,0.580978458229836,0.0841587442812999,0.506517911403239,94.5380765593994
25509,1011:1593,Breast,OCUB-M,SIDM00241,909256,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.581089162456985,0.167119970362956,0.557466052036652,9.49233714231608,2.8134,0.813046028410844,0.876942754363477,0.0392280826379615,0.32393748127618,0.113453664279306,0.210483816996875,5.97989830780289,0.2465,3.51243883451319,2.5669,0.472452235688235,0.379982493600349,0.509581930655795,0.38328628155049,0.0924697420878859,0.126295649105305,True,0.580978458229836,0.0841587442812999,0.506517911403239,94.5380765593994
25509,1558:1593,Breast,OCUB-M,SIDM00241,909256,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.532199116267331,0.167119970362956,0.557466052036652,9.49233714231608,2.8134,0.813046028410844,0.876942754363477,0.0558804792148131,0.296682940242945,0.0590302312773173,0.237652708965627,4.56162427379375,0.0922,4.93071286852232,2.7212,0.432702377804914,0.254192922927775,0.466708158889282,0.290714048460141,0.178509454877139,0.175994110429141,True,0.580978458229836,0.0841587442812999,0.506517911403239,94.5380765593994
25509,1549:1593,Breast,OCUB-M,SIDM00241,909256,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.819369529250109,0.167119970362956,0.557466052036652,9.49233714231608,2.8134,0.813046028410844,0.876942754363477,0.0836206931052253,0.456770696630189,0.242460566105249,0.21431013052494,7.15154193036961,0.5554,2.34079521194647,2.258,0.666185141557664,0.635109040432973,0.718540171822097,0.610390854523658,0.0310761011246908,0.108149317298439,True,0.580978458229836,0.0841587442812999,0.506517911403239,94.5380765593994
25509,1561:1593,Breast,OCUB-M,SIDM00241,909256,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.325545963312676,0.167119970362956,0.557466052036652,9.49233714231608,2.8134,0.813046028410844,0.876942754363477,0.0488331675099664,0.181480822924386,0.0333485169397325,0.148132305984654,4.3718115814354,0.0809,5.12052556088068,2.7325,0.264683852536553,0.124035124968452,0.285485173739329,0.172751292671784,0.140648727568101,0.112733881067546,True,0.580978458229836,0.0841587442812999,0.506517911403239,94.5380765593994
25509,1594:1593,Breast,OCUB-M,SIDM00241,909256,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.531186789678836,0.167119970362956,0.557466052036652,9.49233714231608,2.8134,0.813046028410844,0.876942754363477,0.0442718054479177,0.296118602536284,0.0918013467517884,0.204317255784496,5.66120007714576,0.1977,3.83113706517032,2.6157,0.431879309692683,0.316850610720967,0.465820406422451,0.337218845272944,0.115028698971716,0.128601561149508,True,0.580978458229836,0.0841587442812999,0.506517911403239,94.5380765593994
25509,1053:1593,Breast,OCUB-M,SIDM00241,909256,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.698178052503175,0.167119970362956,0.557466052036652,9.49233714231608,2.8134,0.813046028410844,0.876942754363477,0.0869914335526979,0.389210562547584,0.0965692215811679,0.292641340966416,5.09910608723535,0.1339,4.39323105508073,2.6795,0.567650892711324,0.363942445207373,0.612262184398263,0.411952255945093,0.203708447503951,0.20030992845317,True,0.580978458229836,0.0841587442812999,0.506517911403239,94.5380765593994
27083,1011:1632,Breast,OCUB-M,SIDM00241,909256,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.34831358287374,0.0895791588034211,0.895806084959749,13.5877875607154,96.1882,0.939220811278269,0.976764793529109,0.13074840024599,0.312021427012428,0.0642955312751217,0.247725895737306,5.83222338122697,0.4451,7.75556417948841,95.7431,0.327143365885914,0.13172258590869,0.340220444859052,0.225774671245066,0.195420779977224,0.114445773613986,True,0.597231696755248,0.0818589810846161,0.483725397765941,99.2586921991921
27083,1558:1632,Breast,OCUB-M,SIDM00241,909256,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.532264783474203,0.0895791588034211,0.895806084959749,13.5877875607154,96.1882,0.939220811278269,0.976764793529109,0.143471010848254,0.476806031845974,0.244269609040619,0.232536422805355,8.64885581021207,3.1358,4.93893175050331,93.0524,0.499914161749493,0.336761424142545,0.519897501332996,0.445086504039009,0.163152737606948,0.0748109972939872,True,0.597231696755248,0.0818589810846161,0.483725397765941,99.2586921991921
27083,1594:1909,Breast,OCUB-M,SIDM00241,909256,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.393697212413928,0.0619333709568286,0.829564448001762,12.3746103413754,10.3719,0.939329127043697,0.960557487814257,0.0454705918762729,0.326597210695993,0.207770588013749,0.118826622682244,9.23687177298911,1.1784,3.13773856838634,9.1935,0.369811258856312,0.312120429984009,0.378168805315799,0.340727222061413,0.0576908288723026,0.0374415832543856,True,0.597231696755248,0.0818589810846161,0.483725397765941,99.2586921991921
27083,1011:1909,Breast,OCUB-M,SIDM00241,909256,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.575265064125575,0.0619333709568286,0.829564448001762,12.3746103413754,10.3719,0.939329127043697,0.960557487814257,0.0719020154830563,0.477219445376031,0.317164842401363,0.160054602974668,9.43943079122434,1.3561,2.9351795501511,9.0158,0.540363230503813,0.434901648010965,0.55257516482377,0.503140665110471,0.105461582492848,0.0494344997132985,True,0.597231696755248,0.0818589810846161,0.483725397765941,99.2586921991921
27083,1053:1909,Breast,OCUB-M,SIDM00241,909256,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.556148272688705,0.0619333709568286,0.829564448001762,12.3746103413754,10.3719,0.939329127043697,0.960557487814257,0.0794842624643461,0.46136083484014,0.239129155779667,0.222231679060473,8.39875317491942,0.6592,3.97585716645603,9.7127,0.522406271491542,0.387332587540384,0.534212387666101,0.457488452744865,0.135073683951157,0.0767239349212357,True,0.597231696755248,0.0818589810846161,0.483725397765941,99.2586921991921
27083,1021:1909,Breast,OCUB-M,SIDM00241,909256,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,4,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.64214883399145,0.0619333709568286,0.829564448001762,12.3746103413754,10.3719,0.939329127043697,0.960557487814257,0.0988757522772345,0.532703843005093,0.347834707776915,0.184869135228177,9.35628024079059,1.2801,3.01833010058486,9.0918,0.603189103665317,0.486674902587867,0.616820870781681,0.559257812457762,0.11651420107745,0.0575630583239193,True,0.597231696755248,0.0818589810846161,0.483725397765941,99.2586921991921
27083,1561:1909,Breast,OCUB-M,SIDM00241,909256,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.140120557386679,0.0619333709568286,0.829564448001762,12.3746103413754,10.3719,0.939329127043697,0.960557487814257,0.0674919831214728,0.11623903284218,0.0775287001703387,0.0387103326718408,9.45636056679926,1.3721,2.91824977457619,8.9998,0.131619320850905,0.0525949861306008,0.134593850594482,0.122657255880111,0.0790243347203045,0.0119365947143712,True,0.597231696755248,0.0818589810846161,0.483725397765941,99.2586921991921
25079,1058:2169,Breast,OCUB-M,SIDM00241,909256,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.898478178654717,0.125546794289599,0.138276602184987,5.09840044761176,0.6691,0.604638403201402,0.589981982481955,0.101482190565804,0.12423850968173,0.0816400917032042,0.0425984179785259,4.08883409023713,0.3323,1.00956635737463,0.3368,0.543254411253092,0.462000659011322,0.530085937059486,0.455823856930039,0.0812537522417709,0.0742620801294471,True,0.696813824939661,0.0921391971612566,0.336642508283271,141.041246137303
25079,1549:2169,Breast,OCUB-M,SIDM00241,909256,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.555253909400608,0.125546794289599,0.138276602184987,5.09840044761176,0.6691,0.604638403201402,0.589981982481955,0.0705815705723885,0.0767786239418468,0.0172571896676914,0.0595214342741553,1.66535870812925,0.062,3.43304173948251,0.6071,0.33572783715132,0.146001992995486,0.327589802249027,0.174087405680442,0.189725844155834,0.153502396568585,True,0.696813824939661,0.0921391971612566,0.336642508283271,141.041246137303
25079,1558:2169,Breast,OCUB-M,SIDM00241,909256,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.586014474905346,0.125546794289599,0.138276602184987,5.09840044761176,0.6691,0.604638403201402,0.589981982481955,0.050761040021261,0.0810320904211306,0.0291987959690208,0.0518332944521098,2.71346744750608,0.1281,2.38493300010568,0.541,0.354326856359677,0.212587809567476,0.345737981667778,0.231408315017408,0.141739046792201,0.11432966665037,True,0.696813824939661,0.0921391971612566,0.336642508283271,141.041246137303
25507,1017:2172,Breast,OCUB-M,SIDM00241,909256,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.698114816079755,0.100172450696018,0.376465969711023,7.92404458295256,4.7436,0.773470052437243,0.794901869957126,0.0435597001091341,0.262816471205097,0.188638439609361,0.0741780315957363,6.88135466003248,2.3026,1.04268992292008,2.441,0.539970903400424,0.509191400997009,0.554932772746572,0.506966408908408,0.0307795024034152,0.0479663638381645,True,0.580978458229836,0.0841587442812999,0.506517911403239,94.5380765593994
25507,1058:2172,Breast,OCUB-M,SIDM00241,909256,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.916689004449686,0.100172450696018,0.376465969711023,7.92404458295256,4.7436,0.773470052437243,0.794901869957126,0.0706247288973725,0.345102214983583,0.178735628064008,0.166366586919575,5.97631963900459,1.2296,1.94772494394797,3.514,0.709031492340343,0.61289188750455,0.728677803806192,0.604395799950394,0.0961396048357923,0.124282003855798,True,0.580978458229836,0.0841587442812999,0.506517911403239,94.5380765593994
25507,1549:2172,Breast,OCUB-M,SIDM00241,909256,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.539016165306842,0.100172450696018,0.376465969711023,7.92404458295256,4.7436,0.773470052437243,0.794901869957126,0.0705900291064894,0.202921243362157,0.0420043578542345,0.160916885507923,3.73118859950356,0.2594,4.19285598344901,4.4842,0.416912861644405,0.23601072063625,0.428464957739529,0.257558875270346,0.180902141008155,0.170906082469183,True,0.580978458229836,0.0841587442812999,0.506517911403239,94.5380765593994
25507,1558:2172,Breast,OCUB-M,SIDM00241,909256,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.653887505300147,0.100172450696018,0.376465969711023,7.92404458295256,4.7436,0.773470052437243,0.794901869957126,0.0337127254751647,0.246166393764741,0.0738426220195446,0.172323771745197,4.60476965271347,0.4752,3.31927493023909,4.2684,0.505762403012562,0.345231236355988,0.519776400704687,0.35950009952793,0.160531166656574,0.160276301176757,True,0.580978458229836,0.0841587442812999,0.506517911403239,94.5380765593994
25507,1561:2172,Breast,OCUB-M,SIDM00241,909256,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.288341551762985,0.100172450696018,0.376465969711023,7.92404458295256,4.7436,0.773470052437243,0.794901869957126,0.048213708964825,0.108550781892433,0.0244819236924096,0.0840688582000235,3.93026529415314,0.2978,3.99377928879943,4.4458,0.223023555161952,0.103479228111191,0.229203238682737,0.142511887516708,0.119544327050761,0.0866913511660288,True,0.580978458229836,0.0841587442812999,0.506517911403239,94.5380765593994
25507,1012:2172,Breast,OCUB-M,SIDM00241,909256,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.470366603321088,0.100172450696018,0.376465969711023,7.92404458295256,4.7436,0.773470052437243,0.794901869957126,0.122566537970867,0.177077019438953,0.03555087770708,0.141526141731873,3.66056988701697,0.247,4.26347469593559,4.4966,0.363814481335489,0.189662792576533,0.373895292545315,0.222019927115852,0.174151688758956,0.151875365429462,True,0.580978458229836,0.0841587442812999,0.506517911403239,94.5380765593994
25507,1053:2172,Breast,OCUB-M,SIDM00241,909256,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.228328032874218,0.100172450696018,0.376465969711023,7.92404458295256,4.7436,0.773470052437243,0.794901869957126,0.0387978534227428,0.085957734308203,0.034936909991935,0.051020824316268,5.35110536771974,0.7972,2.57293921523283,3.9464,0.176604895560114,0.105872731246666,0.181498380295349,0.139343960513779,0.0707321643134485,0.0421544197815696,True,0.580978458229836,0.0841587442812999,0.506517911403239,94.5380765593994
25018,1022:1003,Breast,EFM-19,SIDM01056,906851,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.97129518096845,0.0604437164926979,0.883391153345335,14.1813732284529,3.6287,0.965669781697809,0.968951735718205,0.0428004144123176,0.858033570154485,0.44406320217675,0.413970367977735,8.56072553948029,0.0738,5.62064768897261,3.5549,0.937950405369937,0.771882555162531,0.941138151494107,0.782632969619096,0.166067850207406,0.158505181875011,True,0.904416820919878,0.0974601943778396,0.0802773793942531,506.394160987749
25018,1179:1003,Breast,EFM-19,SIDM01056,906851,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.5,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.555314715758436,0.0604437164926979,0.883391153345335,14.1813732284529,3.6287,0.965669781697809,0.968951735718205,0.0865900526152056,0.490560107223481,0.359026917089481,0.131533190134,10.545027759405,0.2918,3.63634546904791,3.3369,0.536250640340029,0.427477183486606,0.538073157703998,0.494894089460852,0.108773456853423,0.0431790682431453,True,0.904416820919878,0.0974601943778396,0.0802773793942531,506.394160987749
25018,1011:1003,Breast,EFM-19,SIDM01056,906851,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved,0.1,0.808684150712418,0.0604437164926979,0.883391153345335,14.1813732284529,3.6287,0.965669781697809,0.968951735718205,0.087763592647326,0.714384424589935,0.268704210706547,0.445680213883388,7.21417774421356,0.029,6.96719548423934,3.5997,0.780921847280938,0.547328285498034,0.783575911480599,0.588880830154273,0.233593561782905,0.194695081326327,True,0.904416820919878,0.0974601943778396,0.0802773793942531,506.394160987749
26731,1011:1038,Breast,EFM-19,SIDM01056,906851,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.625151271151149,0.0937078651033825,0.538548063598659,9.39532777125929,13.1524,0.877120878603092,0.846007566542399,0.129783928965525,0.336674006534692,0.185577157347285,0.151096849187407,6.79347729607713,2.1666,2.60185047518216,10.9858,0.548333232211935,0.487693388872173,0.528882705627471,0.438305856121602,0.0606398433397622,0.0905768495058688,True,1.00344554167563,0.0904766268881112,-0.0272216516846095,-14859.1356151873
26732,1011:1042,Breast,EFM-19,SIDM01056,906851,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.694837195121466,0.14063140813819,0.625572291175824,10.3133376632727,24.8516,0.924832719310745,0.883027527526416,0.0746249889660712,0.434670896146319,0.222680113270798,0.211990782875521,7.07688756034557,2.6369,3.23645010292709,22.2147,0.642608172642436,0.517055485723975,0.613560370441498,0.499931401216908,0.125552686918461,0.11362896922459,True,1.00344554167563,0.0904766268881112,-0.0272216516846095,-14859.1356151873
26733,1561:1050,Breast,EFM-19,SIDM01056,906851,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.540937808170589,0.0694012423300404,0.737157298075507,11.6387252260689,62.2781,0.906655695661718,0.923794476419454,0.0311174310228662,0.398756253097918,0.256982540989819,0.141773712108099,8.74461234091916,8.3776,2.89411288514971,53.9005,0.49044434477663,0.437521756330278,0.499715359274436,0.440954165899937,0.0529225884463522,0.0587611933744992,True,1.00344554167563,0.0904766268881112,-0.0272216516846095,-14859.1356151873
26733,1510:1050,Breast,EFM-19,SIDM01056,906851,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.997285569050969,0.0694012423300404,0.737157298075507,11.6387252260689,62.2781,0.906655695661718,0.923794476419454,0.0510628871515345,0.735156335491307,0.561429910300633,0.173726425190673,9.64781991460189,15.668,1.99090531146698,46.6101,0.904194641381298,0.833743046895062,0.921286900102116,0.854617102876395,0.0704515944862366,0.066669797225721,True,1.00344554167563,0.0904766268881112,-0.0272216516846095,-14859.1356151873
26733,1011:1050,Breast,EFM-19,SIDM01056,906851,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.673466396828793,0.0694012423300404,0.737157298075507,11.6387252260689,62.2781,0.906655695661718,0.923794476419454,0.132435503056131,0.49645066943096,0.100122145649016,0.396328523781944,4.53469357713499,0.4527,7.10403164893387,61.8254,0.6106021445216,0.351564279200966,0.622144537444551,0.363761756584169,0.259037865320633,0.258382780860382,True,1.00344554167563,0.0904766268881112,-0.0272216516846095,-14859.1356151873
26733,1594:1050,Breast,EFM-19,SIDM01056,906851,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.863294005320047,0.0694012423300404,0.737157298075507,11.6387252260689,62.2781,0.906655695661718,0.923794476419454,0.0503177183239781,0.636383476406508,0.611827421746862,0.0245560546596463,11.2751094966384,48.4034,0.363615729430499,13.8747,0.782710426954038,0.798383449545089,0.797506233640686,0.78905331399422,-0.0156730225910514,0.0084529196464654,True,1.00344554167563,0.0904766268881112,-0.0272216516846095,-14859.1356151873
26733,1011:1051,Breast,EFM-19,SIDM01056,906851,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.673466396828793,0.0846378760086382,0.63693116825082,10.438208469203,27.0984,0.833994839111004,0.887487202575958,0.112500240173555,0.428951738909833,0.0551639121020826,0.373787826807751,2.81628841139384,0.1376,7.62192005780914,26.9608,0.561667499269897,0.24447532797879,0.597692808550495,0.277265463028163,0.317192171291107,0.320427345522333,True,1.00344554167563,0.0904766268881112,-0.0272216516846095,-14859.1356151873
25829,1011:1052,Breast,EFM-19,SIDM01056,906851,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1052,RO-3306,CDK1,Cell cycle,Targeted,Experimental only,10.0,0.666338888816862,0.0627605518455719,0.82607763401081,12.9867753470114,158.54,0.953936249184995,0.952189759713883,0.118644459925394,0.550447652723226,0.205024464391983,0.345423188331242,6.92496006909477,2.3733,6.06181527791661,156.1667,0.635644820284055,0.470525841132772,0.634481066430544,0.472908273713159,0.165118979151284,0.161572792717384,True,0.69726247590643,0.079796795175027,0.337729563413539,141.08803728045
25829,1011:1059,Breast,EFM-19,SIDM01056,906851,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.666338888816862,0.0930718937495509,0.590128303796698,9.9326627209184,1.9088,0.826686244898249,0.868589920395696,0.0698716787992384,0.393225438211271,0.0657376143411511,0.32748782387012,3.33932458178968,0.0198,6.59333813912872,1.889,0.550853193825684,0.263447104271648,0.578775242393995,0.300153538975916,0.287406089554036,0.278621703418079,True,0.69726247590643,0.079796795175027,0.337729563413539,141.08803728045
25021,1011:1080,Breast,EFM-19,SIDM01056,906851,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.794088730360431,0.0921743822562348,0.274731170307792,6.5160709573547,0.0179,0.701668731671322,0.682631478166938,0.1005466626779,0.21816092622015,0.0677915859335951,0.150369340286555,2.93181118095123,0.0015,3.58425977640347,0.0164,0.557187232266494,0.304870295859489,0.542069963801648,0.333677459448311,0.252316936407005,0.208392504353337,True,0.904416820919878,0.0974601943778396,0.0802773793942531,506.394160987749
25022,1011:1085,Breast,EFM-19,SIDM01056,906851,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.785558979550154,0.0548139785909962,0.566339734503023,9.6830207168784,16.055,0.874348161662092,0.858422022902349,0.131268910075633,0.4448932639149,0.165941266997963,0.278951996916937,5.62889391162512,0.9665,4.05412680525327,15.0885,0.686852049646826,0.510749005825492,0.674341128334548,0.487572784960119,0.176103043821334,0.186768343374429,True,0.904416820919878,0.0974601943778396,0.0802773793942531,506.394160987749
25830,1011:1096,Breast,EFM-19,SIDM01056,906851,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.683766773426401,0.0686423864607738,0.886877048324554,14.2691088113923,192.8101,0.952916935226828,0.969936651599522,0.196075907004657,0.606417057758811,0.123529259061952,0.482887798696859,5.13143224196673,0.3423,9.13767656942552,192.4678,0.651572938143423,0.314896375372945,0.663210454692212,0.399632765259213,0.336676562770477,0.263577689433,True,0.69726247590643,0.079796795175027,0.337729563413539,141.08803728045
25830,1011:1129,Breast,EFM-19,SIDM01056,906851,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.793896605144426,0.0887035717415753,0.804979529349321,12.6276067303854,123.6,0.895175382361551,0.945731985511707,0.0312848225408143,0.639070515561184,0.363774471817888,0.275296043743296,8.57131536970161,7.4294,4.05629136068382,116.1706,0.710676697065699,0.624506874442089,0.750813412674242,0.64012828613832,0.0861698226236096,0.110685126535921,True,0.69726247590643,0.079796795175027,0.337729563413539,141.08803728045
25831,1011:1192,Breast,EFM-19,SIDM01056,906851,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.643443866084715,0.063451419619327,0.653996826074724,10.6290557000705,30.931,0.88322335154813,0.894044651505737,0.0685935262918921,0.420810246176653,0.0726139578105509,0.348196288366103,3.72397466834342,0.2581,6.90508103172711,30.6729,0.568304647936428,0.273431328823133,0.575267547017213,0.308375484587499,0.294873319113295,0.266892062429714,True,0.69726247590643,0.079796795175027,0.337729563413539,141.08803728045
26735,1011:1553,Breast,EFM-19,SIDM01056,906851,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.706927207428837,0.074777855308618,0.406155626839414,8.02797032005424,5.0979,0.739239880227854,0.776853084541154,0.0837231520386543,0.287122463063096,0.0648046715976093,0.222317791465486,3.13170185181517,0.1712,4.89626846823907,4.9267,0.522588784149505,0.28182666018952,0.549178581637156,0.307509945695324,0.240762123959986,0.241668635941833,True,1.00344554167563,0.0904766268881112,-0.0272216516846095,-14859.1356151873
26735,1011:1560,Breast,EFM-19,SIDM01056,906851,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.817987301508881,0.0738976921601839,0.363332705781581,7.56471083575723,3.6977,0.728278685608096,0.749788124701042,0.0769431095621019,0.297201539552196,0.0664119908573,0.230789548694896,2.79166027798395,0.1352,4.77305055777328,3.5625,0.595722716787001,0.31042963558195,0.61331716482761,0.335285852569728,0.285293081205052,0.278031312257882,True,1.00344554167563,0.0904766268881112,-0.0272216516846095,-14859.1356151873
26736,1510:1564,Breast,EFM-19,SIDM01056,906851,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.941637030580712,0.0724750994642436,0.79367930115802,12.4473037071278,54.5396,0.908670827371159,0.942204963359737,0.0503185180014539,0.747357820375813,0.782948371844363,-0.0355905514685504,13.0841184791924,84.8032,-0.636814772064652,-30.2636,0.855638099661096,0.881942014259502,0.887215083896472,0.898148636934303,-0.0263039145984053,-0.0109335530378313,True,1.00344554167563,0.0904766268881112,-0.0272216516846095,-14859.1356151873
26736,1058:1593,Breast,EFM-19,SIDM01056,906851,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.794833455295732,0.0539738237442674,0.879846671851164,14.0944671301074,68.3309,0.958645425011769,0.967946364203824,0.054425645980937,0.699331570317911,0.705629548706066,-0.0062979783881551,14.2919701459809,78.3559,-0.197503015873526,-10.025,0.76196345556555,0.752476799955254,0.769356153201066,0.77113822178455,0.0094866556102951,-0.0017820685834837,True,1.00344554167563,0.0904766268881112,-0.0272216516846095,-14859.1356151873
26736,1011:1593,Breast,EFM-19,SIDM01056,906851,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.650161503073919,0.0539738237442674,0.879846671851164,14.0944671301074,68.3309,0.958645425011769,0.967946364203824,0.0672223638344339,0.572042434645338,0.386180582360546,0.185861852284792,9.97343029195675,3.927,4.12103683815062,64.4039,0.623274350440587,0.53396194462441,0.629321463045693,0.565768842270242,0.0893124058161771,0.0635526207754511,True,1.00344554167563,0.0904766268881112,-0.0272216516846095,-14859.1356151873
26736,1561:1593,Breast,EFM-19,SIDM01056,906851,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.639355479219006,0.0539738237442674,0.879846671851164,14.0944671301074,68.3309,0.958645425011769,0.967946364203824,0.0737798727313016,0.562534790520648,0.282818077684009,0.27971671283664,8.40729742365114,1.3262,5.68716970645623,67.0047,0.612915205109507,0.493147018291252,0.61886181154383,0.510006131271739,0.119768186818254,0.108855680272091,True,1.00344554167563,0.0904766268881112,-0.0272216516846095,-14859.1356151873
25021,1011:2169,Breast,EFM-19,SIDM01056,906851,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.794088730360431,0.0758870117279521,0.729944309044146,11.5442923676973,58.3322,0.915525318155197,0.921346788462576,0.0957290572112679,0.579640549602688,0.287597128279946,0.292043421322743,7.55186874390276,3.665,3.99242362379452,54.6672,0.72700833750669,0.615354289254294,0.731631101471908,0.594783193757878,0.111654048252396,0.13684790771403,True,0.904416820919878,0.0974601943778396,0.0802773793942531,506.394160987749
26734,1049:2172,Breast,EFM-19,SIDM01056,906851,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.913856495773969,0.0775881899163281,0.657605297320682,10.6699607266701,31.8206,0.857147494588215,0.895409935419421,0.104787432032282,0.600956872611877,0.409442408995148,0.19151446361673,8.46623628659339,6.9075,2.20372444007668,24.9131,0.783309805765824,0.663714071036386,0.818276185863589,0.731829073666054,0.119595734729438,0.0864471121975344,True,1.00344554167563,0.0904766268881112,-0.0272216516846095,-14859.1356151873
26734,1561:2172,Breast,EFM-19,SIDM01056,906851,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.630393662947351,0.0775881899163281,0.657605297320682,10.6699607266701,31.8206,0.857147494588215,0.895409935419421,0.087764175080538,0.414550212151567,0.201993974285565,0.212556237866002,7.0762650452689,2.6357,3.59369568140117,29.1849,0.54034034879961,0.408830843362435,0.5644607490285,0.453539582308646,0.131509505437175,0.110921166719854,True,1.00344554167563,0.0904766268881112,-0.0272216516846095,-14859.1356151873
26734,1190:2172,Breast,EFM-19,SIDM01056,906851,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in breast,0.1,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.886962264819647,0.0775881899163281,0.657605297320682,10.6699607266701,31.8206,0.857147494588215,0.895409935419421,0.134574367899014,0.583271083868949,0.294961371737713,0.288309712131236,7.21739429217397,2.9066,3.4525664344961,28.914,0.760257483084449,0.57816470830529,0.794194824261624,0.64606206709903,0.182092774779159,0.148132757162593,True,1.00344554167563,0.0904766268881112,-0.0272216516846095,-14859.1356151873
26734,1012:2172,Breast,EFM-19,SIDM01056,906851,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.599913088774121,0.0775881899163281,0.657605297320682,10.6699607266701,31.8206,0.857147494588215,0.895409935419421,0.053628406421068,0.394506025109874,0.148989229161957,0.245516795947917,6.16634999746548,1.4028,4.50361072920458,30.4178,0.514214001013416,0.375011256611277,0.537168140076501,0.395151025028912,0.139202744402138,0.142017115047589,True,1.00344554167563,0.0904766268881112,-0.0272216516846095,-14859.1356151873
26734,1011:2172,Breast,EFM-19,SIDM01056,906851,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.641957503835274,0.0775881899163281,0.657605297320682,10.6699607266701,31.8206,0.857147494588215,0.895409935419421,0.0833399050448952,0.422154655176838,0.148512555838872,0.273642099337966,5.92757200709369,1.1888,4.74238871957638,30.6318,0.55025226604451,0.421927079081848,0.574815127051156,0.412109606451206,0.128325186962662,0.162705520599949,True,1.00344554167563,0.0904766268881112,-0.0272216516846095,-14859.1356151873
26734,1053:2172,Breast,EFM-19,SIDM01056,906851,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.641055821708161,0.0775881899163281,0.657605297320682,10.6699607266701,31.8206,0.857147494588215,0.895409935419421,0.0825314472138331,0.421561704233549,0.232222563254293,0.189339140979256,7.55272835636064,3.6671,3.11723237030943,28.1535,0.54947939146834,0.417271331727574,0.574007751915949,0.480192740693868,0.132208059740765,0.093815011222081,True,1.00344554167563,0.0904766268881112,-0.0272216516846095,-14859.1356151873
26074,1012:1032,Breast,CAL-85-1,SIDM00928,910852,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.778661433386566,0.0937083846695414,0.578263564388448,9.63381065110113,15.5166,0.886673964018918,0.891022926453466,0.0824707576835494,0.450271535921934,0.246697503106334,0.2035740328156,7.45705863448588,3.4319,2.17675201661525,12.0847,0.690418819769519,0.60665716564412,0.693805189092549,0.601248473241788,0.0837616541253994,0.0925567158507613,True,0.283149477858129,0.0547067666777218,1.2001884730147,40.9736599459934
26074,1011:1032,Breast,CAL-85-1,SIDM00928,910852,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.817170892155919,0.0937083846695414,0.578263564388448,9.63381065110113,15.5166,0.886673964018918,0.891022926453466,0.0959598233323414,0.47254015281257,0.236710786947991,0.235829365864579,7.19889694900635,2.8696,2.43491370209478,12.647,0.724564154228765,0.588411072656903,0.728117999741357,0.616610962024003,0.136153081571862,0.111507037717354,True,0.283149477858129,0.0547067666777218,1.2001884730147,40.9736599459934
26074,1510:1032,Breast,CAL-85-1,SIDM00928,910852,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.789785871687268,0.0937083846695414,0.578263564388448,9.63381065110113,15.5166,0.886673964018918,0.891022926453466,0.107854284861077,0.456704393265517,0.237330859390131,0.219373533875387,7.303441696886,3.0852,2.33036895421513,12.4314,0.700282569575087,0.536524786703888,0.703717318662392,0.60163419268666,0.163757782871198,0.102083125975731,True,0.283149477858129,0.0547067666777218,1.2001884730147,40.9736599459934
26074,1372:1032,Breast,CAL-85-1,SIDM00928,910852,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.589879095677782,0.0937083846695414,0.578263564388448,9.63381065110113,15.5166,0.886673964018918,0.891022926453466,0.126912631099189,0.341105588424869,0.153952352216805,0.187153236208064,6.91005391418429,2.3489,2.72375673691683,13.1677,0.523030436056514,0.362254185796491,0.525595798084542,0.433057450986491,0.160776250260023,0.0925383470980509,True,0.283149477858129,0.0547067666777218,1.2001884730147,40.9736599459934
26077,1049:1050,Breast,CAL-85-1,SIDM00928,910852,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.972899760817548,0.126105962267638,0.639743732111963,10.1530745596688,22.2387,0.928016045511206,0.911082593601509,0.113617668379444,0.622406523956254,0.627448509878285,-0.0050419859220307,10.198370161833,22.948,-0.0452956021641882,-0.709299999999999,0.902866588712698,0.92109872231958,0.886392037399939,0.887951386141953,-0.0182321336068814,-0.0015593487420131,True,0.283149477858129,0.0547067666777218,1.2001884730147,40.9736599459934
26077,1372:1050,Breast,CAL-85-1,SIDM00928,910852,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.90246862315611,0.126105962267638,0.639743732111963,10.1530745596688,22.2387,0.928016045511206,0.911082593601509,0.170106632421541,0.577348645091835,0.419228794586156,0.158119850505678,8.71467655635164,8.2056,1.43839800331718,14.0331,0.837505362859276,0.742962265043984,0.822223453829052,0.764960226757241,0.0945430978152912,0.0572632270718108,True,0.283149477858129,0.0547067666777218,1.2001884730147,40.9736599459934
26077,1011:1050,Breast,CAL-85-1,SIDM00928,910852,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.843414557913867,0.126105962267638,0.639743732111963,10.1530745596688,22.2387,0.928016045511206,0.911082593601509,0.0904560891053783,0.539569176997379,0.207236847844077,0.332332329153302,6.7478418405998,2.0991,3.40523271906902,20.1396,0.782702242761808,0.603528146799701,0.768420322905436,0.609245559257266,0.179174095962107,0.15917476364817,True,0.283149477858129,0.0547067666777218,1.2001884730147,40.9736599459934
26078,1058:1373,Breast,CAL-85-1,SIDM00928,910852,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10.0,0.959440474652738,0.0434845078423605,0.897976927925375,13.367201169394,206.3757,0.975317608928908,0.978548902153734,0.0645426305021539,0.86155540995593,0.697041309394714,0.164514100561216,10.9617313663189,38.9529,2.4054698030751,167.4228,0.935759189647925,0.848351995418427,0.938859423153295,0.898384968240193,0.0874071942294982,0.0404744549131022,True,0.283149477858129,0.0547067666777218,1.2001884730147,40.9736599459934
26078,1561:1373,Breast,CAL-85-1,SIDM00928,910852,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10.0,0.887030319200981,0.0434845078423605,0.897976927925375,13.367201169394,206.3757,0.975317608928908,0.978548902153734,0.0508759740596745,0.796532761012762,0.779053557887214,0.0174792031255486,12.9680558145242,156.4962,0.3991453548698,49.8795,0.865136289970547,0.859895094064685,0.868002545031197,0.864081071300732,0.0052411959058623,0.0039214737304647,True,0.283149477858129,0.0547067666777218,1.2001884730147,40.9736599459934
26080,1058:1564,Breast,CAL-85-1,SIDM00928,910852,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.959269445036784,0.105494849345881,0.546557058544957,9.37502502823281,6.4843,0.832907209590575,0.879837542069893,0.0559223506320084,0.524295486231358,0.416777505310868,0.10751798092049,8.47066042575883,3.4644,0.904364602473985,3.0199,0.798982436711087,0.769729018951914,0.844001270703915,0.80041532450545,0.0292534177591733,0.0435859461984653,True,0.283149477858129,0.0547067666777218,1.2001884730147,40.9736599459934
26080,1049:1564,Breast,CAL-85-1,SIDM00928,910852,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.978930123147457,0.105494849345881,0.546557058544957,9.37502502823281,6.4843,0.832907209590575,0.879837542069893,0.0657839489034657,0.535041168628526,0.606370025881332,-0.071328857252806,9.9780608525191,9.8491,-0.603035824286286,-3.3648,0.815357957254906,0.845856724464229,0.861299473408237,0.885609632222044,-0.0304987672093223,-0.0243101588138075,True,0.283149477858129,0.0547067666777218,1.2001884730147,40.9736599459934
26080,1561:1564,Breast,CAL-85-1,SIDM00928,910852,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.870330392365924,0.105494849345881,0.546557058544957,9.37502502823281,6.4843,0.832907209590575,0.879837542069893,0.049802524204894,0.475685219213797,0.179007767667963,0.296677451545834,6.28689115953205,0.7625,3.08813386870077,5.7218,0.724904458527372,0.577805176458045,0.76574935320796,0.598537291641655,0.147099282069327,0.167212061566305,True,0.283149477858129,0.0547067666777218,1.2001884730147,40.9736599459934
26080,1510:1564,Breast,CAL-85-1,SIDM00928,910852,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.864409985073035,0.105494849345881,0.546557058544957,9.37502502823281,6.4843,0.832907209590575,0.879837542069893,0.0888046589056307,0.472449378818408,0.366055339543491,0.106394039274917,8.38048954988373,3.2545,0.994535478349082,3.2298,0.719973308609412,0.656573625253225,0.760540356607333,0.716884288287135,0.0633996833561871,0.043656068320198,True,0.283149477858129,0.0547067666777218,1.2001884730147,40.9736599459934
26080,1083:1564,Breast,CAL-85-1,SIDM00928,910852,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.96077310347585,0.105494849345881,0.546557058544957,9.37502502823281,6.4843,0.832907209590575,0.879837542069893,0.122947881301092,0.52511732136487,0.254248145457403,0.270869175907467,6.94776994869785,1.2056,2.42725507953496,5.2787,0.800234844665747,0.684990227502932,0.845324245849056,0.707950644005487,0.115244617162815,0.137373601843568,True,0.283149477858129,0.0547067666777218,1.2001884730147,40.9736599459934
26080,1012:1564,Breast,CAL-85-1,SIDM00928,910852,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.856135082364858,0.105494849345881,0.546557058544957,9.37502502823281,6.4843,0.832907209590575,0.879837542069893,0.113985109498801,0.467926672334481,0.117860642252748,0.350066030081733,5.3157713340556,0.389,4.05925369417721,6.0953,0.71308108248511,0.47204422779614,0.753259786547702,0.522499508648385,0.24103685468897,0.230760277899317,True,0.283149477858129,0.0547067666777218,1.2001884730147,40.9736599459934
26080,1011:1564,Breast,CAL-85-1,SIDM00928,910852,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.843425705032519,0.105494849345881,0.546557058544957,9.37502502823281,6.4843,0.832907209590575,0.879837542069893,0.0562734300477876,0.46098027244378,0.030079198027787,0.430901074415993,2.37910982839139,0.0508,6.99591519984142,6.4335,0.702495350475599,0.284822425765007,0.742077599234379,0.307720033796241,0.417672924710592,0.434357565438138,True,0.283149477858129,0.0547067666777218,1.2001884730147,40.9736599459934
26080,1053:1564,Breast,CAL-85-1,SIDM00928,910852,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.932781313306323,0.105494849345881,0.546557058544957,9.37502502823281,6.4843,0.832907209590575,0.879837542069893,0.118840293650085,0.509818210866405,0.201614305938208,0.308203904928198,6.41317573344909,0.8323,2.96184929478372,5.652,0.776920280824201,0.613283608993496,0.820696017988162,0.650485678471102,0.163636671830705,0.17021033951706,True,0.283149477858129,0.0547067666777218,1.2001884730147,40.9736599459934
26080,1058:1593,Breast,CAL-85-1,SIDM00928,910852,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.959269445036784,0.0687835873705425,0.730497281017077,11.0022303517231,8.0124,0.922055254341481,0.937452601716531,0.0817884287428184,0.700743721362131,0.455052639679594,0.245691081682537,8.79399697836459,1.7339,2.20823337335854,6.2785,0.884499432125403,0.759509692531187,0.899269636996906,0.817084620085968,0.124989739594217,0.082185016910938,True,0.283149477858129,0.0547067666777218,1.2001884730147,40.9736599459934
26080,1011:1593,Breast,CAL-85-1,SIDM00928,910852,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.843425705032519,0.0687835873705425,0.730497281017077,11.0022303517231,8.0124,0.922055254341481,0.937452601716531,0.0911509660639512,0.616120184266167,0.322867163207117,0.29325302105905,8.04087554403689,1.0287,2.96135480768624,6.9837,0.777685102971903,0.723501562666596,0.790671621537335,0.68267076779834,0.0541835403053069,0.108000853738995,True,0.283149477858129,0.0547067666777218,1.2001884730147,40.9736599459934
26080,1053:1593,Breast,CAL-85-1,SIDM00928,910852,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1593,Entinostat,"HDAC1, HDAC3",Chromatin histone acetylation,Targeted,Advanced clinical trials,2.0,0.927939145964389,0.0687835873705425,0.730497281017077,11.0022303517231,8.0124,0.922055254341481,0.937452601716531,0.0414682987384151,0.677857023076294,0.555157764407807,0.122699258668488,9.7996901407601,3.4815,1.20254021096303,4.5309,0.855611165245611,0.822469692931016,0.869898966618932,0.833078631032443,0.0331414723145946,0.0368203355864888,True,0.283149477858129,0.0547067666777218,1.2001884730147,40.9736599459934
26081,1372:1632,Breast,CAL-85-1,SIDM00928,910852,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.785858225627208,0.0690909658518501,0.944249792898121,14.6815392980939,205.2928,0.964976843829371,0.988562899347757,0.0651121240267085,0.742046466795776,0.687301983366899,0.0547444834288774,12.8997503234078,59.7038,1.78178897468607,145.589,0.758334990263093,0.726960884508269,0.776870286002316,0.764868434412367,0.031374105754824,0.0120018515899493,True,0.283149477858129,0.0547067666777218,1.2001884730147,40.9736599459934
26081,1083:1632,Breast,CAL-85-1,SIDM00928,910852,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.908926619819609,0.0690909658518501,0.944249792898121,14.6815392980939,205.2928,0.964976843829371,0.988562899347757,0.183528449550996,0.858253772524255,0.410660778600348,0.447592993923908,8.61172852874148,3.0562,6.0698107693524,202.2366,0.877093140866025,0.604069338782098,0.898531134583229,0.76543962738309,0.273023802083927,0.13309150720014,True,0.283149477858129,0.0547067666777218,1.2001884730147,40.9736599459934
26081,1594:1632,Breast,CAL-85-1,SIDM00928,910852,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.89265512895499,0.0690909658518501,0.944249792898121,14.6815392980939,205.2928,0.964976843829371,0.988562899347757,0.0227756858326045,0.842889420645195,0.844339747847678,-0.0014503272024833,14.7443791419059,214.4324,-0.0628398438120108,-9.1396,0.861391528967086,0.89265512895499,0.882445742397391,0.882751651187434,-0.0312635999879035,-0.0003059087900428,True,0.283149477858129,0.0547067666777218,1.2001884730147,40.9736599459934
26081,1191:1632,Breast,CAL-85-1,SIDM00928,910852,1191,Bortezomib,Proteasome,Protein stability and degradation,Targeted,FDA approved,0.0025,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.88519646732659,0.0690909658518501,0.944249792898121,14.6815392980939,205.2928,0.964976843829371,0.988562899347757,0.131637330720722,0.835846580947281,0.472466230890314,0.363380350056967,9.2714199871267,4.828,5.41011931096718,200.4648,0.854194093209721,0.673178545181851,0.875072386232766,0.774665150051241,0.18101554802787,0.100407236181525,True,0.283149477858129,0.0547067666777218,1.2001884730147,40.9736599459934
26078,1012:2172,Breast,CAL-85-1,SIDM00928,910852,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.94819793117948,0.0893721112809236,0.553135400884097,9.42839239192012,13.4573,0.833161005329506,0.882210025472077,0.0585531298561347,0.524481842780434,0.405793223590827,0.118688619189607,8.41735317292357,6.6774,1.01103921899655,6.7799,0.790001541592854,0.756813072224453,0.83650972101842,0.788347690013857,0.0331884693684009,0.0481620310045634,True,0.283149477858129,0.0547067666777218,1.2001884730147,40.9736599459934
26078,1011:2172,Breast,CAL-85-1,SIDM00928,910852,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,2172,JQ1,"BRD2, BRD3, BRD4, BRDT",Chromatin other,Targeted,Experimental only,10.0,0.785707165175622,0.0893721112809236,0.553135400884097,9.42839239192012,13.4573,0.833161005329506,0.882210025472077,0.0789398303642832,0.434602447786926,0.223141649062525,0.2114607987244,7.1432386411203,2.761,2.28515375079981,10.6963,0.654620571632318,0.568149664720026,0.693158738203179,0.589824148487431,0.0864709069122913,0.103334589715748,True,0.283149477858129,0.0547067666777218,1.2001884730147,40.9736599459934
25062,1011:1086,Breast,JIMT-1,SIDM01037,1298157,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1086,BI-2536,"PLK1, PLK2, PLK3",Cell cycle,Targeted,Early clinical trials,10.0,0.727442395760568,0.0961273989128804,0.0366427210146097,0.451512916264543,0.0267,0.268429595927561,0.254006689259062,0.0729250932723276,0.0266554687620538,0.0070404459971582,0.0196150227648956,-3.10187833302752,0.0023,3.55339124929206,0.0244,0.195267068354586,0.0559893051031392,0.184775234573822,0.0685138120914959,0.139277763251447,0.116261422482326,True,0.419830927171027,0.0621161558904039,0.827490334639781,59.0850993592943
25063,1011:1192,Breast,JIMT-1,SIDM01037,1298157,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.814711339772979,0.0567803555264476,0.649995092101866,10.6186372213777,30.7085,0.883626109038289,0.890411097507956,0.0576795550337116,0.529558372332172,0.125945422692438,0.403612949639734,4.55723461947766,0.4598,6.06140260190004,30.2487,0.719900211152969,0.408491649292263,0.725428018199435,0.44100791436851,0.311408561860706,0.284420103830926,True,0.419830927171027,0.0621161558904039,0.827490334639781,59.0850993592943
19427,1786:1053,Colon,RCM-1,SIDM00359,909263,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.752442903220769,0.0474385095104469,0.778465983069311,12.4033318151364,105.8047,0.939368437430411,0.934094962943243,0.0918177015648556,0.585751204359283,0.304021086617906,0.281730117741377,7.94755319057013,4.8215,4.45577862456624,100.9832,0.706821114254096,0.572147414860235,0.702853125800911,0.57513629394694,0.134673699393861,0.127716831853971,True,0.499774390407091,0.0575571633222263,0.650242614740972,74.2496679568235
19427,1373:1053,Colon,RCM-1,SIDM00359,909263,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.898306712315383,0.0474385095104469,0.778465983069311,12.4033318151364,105.8047,0.939368437430411,0.934094962943243,0.061228613775093,0.699301217900356,0.47541537338287,0.223885844517485,9.31704052141679,12.4577,3.08629129371957,93.347,0.843840972680951,0.74263186683165,0.839103775151904,0.74884169177205,0.101209105849301,0.0902620833798545,True,0.499774390407091,0.0575571633222263,0.650242614740972,74.2496679568235
22240,1022:1059,Colon,RCM-1,SIDM00359,909263,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.740980667125588,0.0736573840967194,0.663636655561515,10.8402318151315,3.5807,0.877385755652177,0.892361587112027,0.111299790460975,0.491741931766966,0.290438736878393,0.201303194888573,7.81101036702267,0.4386,3.02922144810886,3.1421,0.650125882549638,0.492445845214199,0.661222684135519,0.56065155301795,0.15768003733544,0.100571131117568,True,0.28242804704129,0.0411664461900904,1.19869563139657,40.9851976717341
19424,2171:1372,Colon,RCM-1,SIDM00359,909263,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.858190812139455,0.157721531067687,0.110318131055021,3.34697017609804,0.0199,0.439948221619536,0.452607118615724,0.103177396827575,0.0946740064838149,0.0299931446180753,0.0646808618657395,0.0139440161216431,0.002,3.3330261599764,0.0179,0.377559521610978,0.226340594293053,0.388423270704927,0.200377923493353,0.151218927317926,0.188045347211574,True,0.499774390407091,0.0575571633222263,0.650242614740972,74.2496679568235
20642,1053:1373,Colon,RCM-1,SIDM00359,909263,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10.0,0.906907455897928,0.0741090909409619,0.81590621167859,13.0318821299814,163.5752,0.942852725186429,0.946420717524414,0.0412166505773597,0.739951426684746,0.618323159130995,0.12162826755375,11.0635944223206,41.8027,1.96828770766082,121.7725,0.855080166285252,0.824648612976112,0.858316005139158,0.815675793851253,0.0304315533091403,0.0426402112879041,True,0.301789315323562,0.0468918373025813,0.999273940067492,46.9257595822263
20642,2171:1373,Colon,RCM-1,SIDM00359,909263,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10.0,0.782197527523043,0.0741090909409619,0.81590621167859,13.0318821299814,163.5752,0.942852725186429,0.946420717524414,0.0528903608861537,0.638199821465686,0.443422670383024,0.194777151082662,9.72897203670375,16.5746,3.30291009327766,147.0006,0.737497070459188,0.634517677659151,0.740287945244181,0.665962987645337,0.102979392800037,0.0743249575988447,True,0.301789315323562,0.0468918373025813,0.999273940067492,46.9257595822263
22241,1373:1510,Colon,RCM-1,SIDM00359,909263,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.936440676919319,0.0842583941612386,0.644640018765427,10.6128046224565,30.5846,0.85462602822167,0.884792267912244,0.129484021347256,0.603667135541979,0.265991175369995,0.337675960171984,6.49645337548973,1.7634,4.11635124696679,28.8212,0.800306576380769,0.571861212462661,0.828555470296721,0.632702916094135,0.228445363918108,0.195852554202586,True,0.28242804704129,0.0411664461900904,1.19869563139657,40.9851976717341
21248,1083:1549,Colon,RCM-1,SIDM00359,909263,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.968599398179118,0.0809576777141758,0.625235418608138,10.3860586451506,13.0682,0.842019051282056,0.876835567413566,0.0633236363439867,0.605602650184111,0.362197988769745,0.243404661414366,7.60440643196361,1.9004,2.78165221318694,11.1678,0.815579146327151,0.691485456419626,0.849302402898826,0.721299422070875,0.124093689907526,0.128002980827951,True,0.607094293335371,0.0800870938872699,0.465526030274622,102.683196581919
20646,1011:1598,Colon,RCM-1,SIDM00359,909263,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1598,LGK974,PORCN,WNT signaling,Targeted,Early clinical trials,10.0,0.665200726996241,0.0464829252631404,0.875114980893009,14.2724580237781,386.5165,0.959289518056099,0.964835445442277,0.0819441457365108,0.582127121495331,0.364236777436593,0.217890344058738,9.51673174943694,14.3071,4.75572627434115,372.2094,0.63812008481079,0.513098127102857,0.641809239739944,0.560374939852323,0.125021957707933,0.0814342998876207,True,0.301789315323562,0.0468918373025813,0.999273940067492,46.9257595822263
20646,2171:1786,Colon,RCM-1,SIDM00359,909263,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10.0,0.796998005307206,0.116339645347597,0.724689428771654,11.6209623327813,61.516,0.949609345202854,0.915347829352754,0.102832261434701,0.577576029198227,0.344889801100516,0.232686228097711,8.26694175192134,6.0163,3.35402058086,55.4997,0.756836753947756,0.558932399986168,0.729530394156425,0.62314607588849,0.197904353961588,0.106384318267935,True,0.301789315323562,0.0468918373025813,0.999273940067492,46.9257595822263
20646,1053:1786,Colon,RCM-1,SIDM00359,909263,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10.0,0.935226065807825,0.116339645347597,0.724689428771654,11.6209623327813,61.516,0.949609345202854,0.915347829352754,0.135326891024317,0.677748443402634,0.552767843328835,0.1249806000738,9.99742313218891,19.9643,1.62353920059243,41.5517,0.88809941196841,0.848678158258265,0.856057149291308,0.806374414515556,0.0394212537101453,0.0496827347757519,True,0.301789315323562,0.0468918373025813,0.999273940067492,46.9257595822263
20646,1083:1786,Colon,RCM-1,SIDM00359,909263,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10.0,0.977437523609052,0.116339645347597,0.724689428771654,11.6209623327813,61.516,0.949609345202854,0.915347829352754,0.135504950748905,0.708338640644224,0.491674469413358,0.216664171230866,9.0327561947735,10.2296,2.58820613800783,51.2864,0.92818380677109,0.751330818222971,0.894695315563476,0.801995401701135,0.176852988548119,0.0926999138623412,True,0.301789315323562,0.0468918373025813,0.999273940067492,46.9257595822263
20647,1089:2048,Colon,RCM-1,SIDM00359,909263,1089,Oxaliplatin,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved in colon,5,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.893233414446383,0.114484750563863,0.784385786302074,12.4971955100251,1.1292,0.891207614479293,0.936081558083885,0.155827316549328,0.700639594141813,0.530196926415085,0.170442667726727,10.0256584823181,0.2036,2.471537027707,0.9256,0.796056420461955,0.674254550692938,0.836139326327559,0.77115305587692,0.121801869769017,0.0649862704506395,True,0.301789315323562,0.0468918373025813,0.999273940067492,46.9257595822263
20647,2171:2048,Colon,RCM-1,SIDM00359,909263,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.812643534084649,0.114484750563863,0.784385786302074,12.4971955100251,1.1292,0.891207614479293,0.936081558083885,0.181326150587483,0.637426037466283,0.338850911348265,0.298575126118019,8.09223796670208,0.0533,4.40495754332305,1.0759,0.724234105433601,0.508367880109397,0.760700625552753,0.62767631308908,0.215866225324204,0.133024312463672,True,0.301789315323562,0.0468918373025813,0.999273940067492,46.9257595822263
20647,1011:2048,Colon,RCM-1,SIDM00359,909263,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.754403272190948,0.114484750563863,0.784385786302074,12.4971955100251,1.1292,0.891207614479293,0.936081558083885,0.179613620736749,0.591743203846354,0.330378270777466,0.261364933068888,8.32419642355654,0.0626,4.17299908646859,1.0666,0.672329940564667,0.5068949199363,0.706182990456084,0.592146484231394,0.165435020628367,0.114036506224691,True,0.301789315323562,0.0468918373025813,0.999273940067492,46.9257595822263
20647,1083:2048,Colon,RCM-1,SIDM00359,909263,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.987236519938329,0.114484750563863,0.784385786302074,12.4971955100251,1.1292,0.891207614479293,0.936081558083885,0.12255056708802,0.774374293957949,0.558668657904266,0.215705636053683,9.71792263308254,0.1645,2.77927287694259,0.9647,0.879832703861077,0.751272483445749,0.924133899781184,0.840080602568262,0.128560220415328,0.0840532972129211,True,0.301789315323562,0.0468918373025813,0.999273940067492,46.9257595822263
20647,1786:2048,Colon,RCM-1,SIDM00359,909263,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.600289345169118,0.114484750563863,0.784385786302074,12.4971955100251,1.1292,0.891207614479293,0.936081558083885,0.117023004461774,0.470858430019236,0.2009239815564,0.269934448462835,7.13970909571014,0.0275,5.35748641431499,1.1017,0.534982435305506,0.364994895339905,0.561919785527063,0.430222939403625,0.169987539965601,0.131696846123438,True,0.301789315323562,0.0468918373025813,0.999273940067492,46.9257595822263
19402,1011:1003,Colon,LS-513,SIDM00677,907795,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.1,0.915927925628808,0.0562730905571993,0.407797407088916,8.09904618783174,0.0536,0.786429491525356,0.788900869387918,0.0656037317356391,0.373513033151758,0.13739428608832,0.236118747063437,4.8111845870866,0.0055,3.28786160074514,0.0481,0.720312732826138,0.516142001386122,0.722576336825239,0.515404147683289,0.204170731440016,0.20717218914195,True,0.358157203394903,0.0352757689158785,0.96933213054103,50.3959381371787
19405,1549:1011,Colon,LS-513,SIDM00677,907795,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.708127890725862,0.0664950446263123,0.569916866415261,9.67982858702327,16.0195,0.84354758821518,0.867099447692602,0.0761019129462971,0.403574028503732,0.178854823298025,0.224719205205707,6.37998192625988,1.6267,3.29984666076339,14.3928,0.597339574369704,0.478362612967169,0.614017302944122,0.480680025637376,0.118976961402535,0.133337277306746,True,0.358157203394903,0.0352757689158785,0.96933213054103,50.3959381371787
19405,1032:1011,Colon,LS-513,SIDM00677,907795,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.686569398478188,0.0664950446263123,0.569916866415261,9.67982858702327,16.0195,0.84354758821518,0.867099447692602,0.197107147193943,0.391287480157299,0.229952945430548,0.161334534726751,7.34344036340125,3.1719,2.33638822362202,12.8476,0.579153960228622,0.421604610687364,0.595323946223079,0.510367335577604,0.157549349541258,0.0849566106454744,True,0.358157203394903,0.0352757689158785,0.96933213054103,50.3959381371787
19405,1372:1011,Colon,LS-513,SIDM00677,907795,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.230464339553583,0.0664950446263123,0.569916866415261,9.67982858702327,16.0195,0.84354758821518,0.867099447692602,0.0764668514736289,0.131345514218841,0.0346691630292373,0.0966763511896033,4.81924783540287,0.5514,4.8605807516204,15.4681,0.194407637800029,0.0842185217112405,0.199835501539752,0.129827750203793,0.110189116088789,0.0700077513359594,True,0.358157203394903,0.0352757689158785,0.96933213054103,50.3959381371787
19405,1564:1011,Colon,LS-513,SIDM00677,907795,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.612761765429763,0.0664950446263123,0.569916866415261,9.67982858702327,16.0195,0.84354758821518,0.867099447692602,0.0725017994648285,0.349223265212814,0.0724069413417812,0.276816323871032,4.14619700528872,0.3458,5.53363158173455,15.6737,0.516893709378752,0.306827963351003,0.531325388371291,0.313331733745385,0.210065746027749,0.217993654625907,True,0.358157203394903,0.0352757689158785,0.96933213054103,50.3959381371787
19405,1073:1011,Colon,LS-513,SIDM00677,907795,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.637884575052183,0.0664950446263123,0.569916866415261,9.67982858702327,16.0195,0.84354758821518,0.867099447692602,0.0693685883321726,0.363541178148371,0.0880264321724801,0.275514745975891,4.57581263631111,0.4658,5.10401595071216,15.5537,0.538085994844934,0.347871828303809,0.553109362719378,0.347391157588778,0.190214166541125,0.205718205130601,True,0.358157203394903,0.0352757689158785,0.96933213054103,50.3959381371787
19405,1089:1011,Colon,LS-513,SIDM00677,907795,1089,Oxaliplatin,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved in colon,1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.657567110786833,0.0664950446263123,0.569916866415261,9.67982858702327,16.0195,0.84354758821518,0.867099447692602,0.053765553563023,0.374758587237369,0.0995572744396098,0.275201312797759,4.83754081618497,0.5584,4.8422877708383,15.4611,0.554689150393857,0.370787762684308,0.570176078584083,0.371350595793154,0.18390138770955,0.198825482790929,True,0.358157203394903,0.0352757689158785,0.96933213054103,50.3959381371787
19405,1047:1011,Colon,LS-513,SIDM00677,907795,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.463825825947744,0.0664950446263123,0.569916866415261,9.67982858702327,16.0195,0.84354758821518,0.867099447692602,0.0659286260084327,0.264342161286608,0.0374037448233024,0.226938416463306,3.1229113769898,0.1701,6.55691721003347,15.8494,0.391259156830133,0.173200766993518,0.402183117504854,0.20048191967608,0.218058389836615,0.201701197828774,True,0.358157203394903,0.0352757689158785,0.96933213054103,50.3959381371787
19405,1053:1011,Colon,LS-513,SIDM00677,907795,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.64721183083494,0.0664950446263123,0.569916866415261,9.67982858702327,16.0195,0.84354758821518,0.867099447692602,0.153027244340561,0.368856938536333,0.315120014866412,0.053736923669921,8.87331838170139,9.1594,0.806510205321878,6.8601,0.545953978965145,0.483338962809268,0.561197021057094,0.537320740268151,0.0626150161558765,0.0238762807889427,True,0.358157203394903,0.0352757689158785,0.96933213054103,50.3959381371787
19405,2048:1011,Colon,LS-513,SIDM00677,907795,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.932962595272526,0.0664950446263123,0.569916866415261,9.67982858702327,16.0195,0.84354758821518,0.867099447692602,0.117723119292372,0.531711118780367,0.401928128375384,0.129782990404984,8.32731555640948,6.2734,1.35251303061379,9.7461,0.786998347137115,0.799281275924065,0.808971351078664,0.747923224021766,-0.01228292878695,0.0610481270568977,True,0.358157203394903,0.0352757689158785,0.96933213054103,50.3959381371787
19405,1510:1011,Colon,LS-513,SIDM00677,907795,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.438395359457188,0.0664950446263123,0.569916866415261,9.67982858702327,16.0195,0.84354758821518,0.867099447692602,0.130352562738449,0.249848909512832,0.0857655312167481,0.164083378296084,5.58578367159896,0.938,4.09404491542431,15.0815,0.369807348154838,0.240383459616198,0.380132374056327,0.272377330168717,0.129423888538639,0.10775504388761,True,0.358157203394903,0.0352757689158785,0.96933213054103,50.3959381371787
19405,1017:1011,Colon,LS-513,SIDM00677,907795,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.909332388804118,0.0664950446263123,0.569916866415261,9.67982858702327,16.0195,0.84354758821518,0.867099447692602,0.136640218300215,0.518243865557146,0.524149578154069,-0.005905712596923,9.74393759700785,16.7474,-0.0641090099845822,-0.727899999999998,0.767065143461662,0.746491267240243,0.788481612101045,0.790901644194675,0.0205738762214186,-0.0024200320936306,True,0.358157203394903,0.0352757689158785,0.96933213054103,50.3959381371787
19405,1561:1011,Colon,LS-513,SIDM00677,907795,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.821968435762224,0.0664950446263123,0.569916866415261,9.67982858702327,16.0195,0.84354758821518,0.867099447692602,0.0826608490510419,0.46845367520186,0.30735693199328,0.161096743208581,7.75534468814107,4.2201,1.92448389888219,11.7994,0.693369491576228,0.638578678962002,0.712728376670177,0.631924648109523,0.0547908126142259,0.0808037285606539,True,0.358157203394903,0.0352757689158785,0.96933213054103,50.3959381371787
19405,2171:1011,Colon,LS-513,SIDM00677,907795,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.578559326284305,0.0664950446263123,0.569916866415261,9.67982858702327,16.0195,0.84354758821518,0.867099447692602,0.0706048595150753,0.329730718271276,0.0948322574512162,0.234898460820059,5.06510409959429,0.6539,4.61472448742897,15.3656,0.488042324326525,0.342283729042812,0.501668472278525,0.336790886997084,0.145758595283713,0.164877585281441,True,0.358157203394903,0.0352757689158785,0.96933213054103,50.3959381371787
19405,1179:1011,Colon,LS-513,SIDM00677,907795,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.38513695405243,0.0664950446263123,0.569916866415261,9.67982858702327,16.0195,0.84354758821518,0.867099447692602,0.0461519530672744,0.219496045994279,0.0498493333777049,0.169646712616574,4.3972042202761,0.4115,5.28262436674716,15.608,0.324881348723468,0.188210670245528,0.333952040144873,0.204428897251851,0.13667067847794,0.129523142893022,True,0.358157203394903,0.0352757689158785,0.96933213054103,50.3959381371787
19405,1003:1011,Colon,LS-513,SIDM00677,907795,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.669070476124698,0.0664950446263123,0.569916866415261,9.67982858702327,16.0195,0.84354758821518,0.867099447692602,0.0692916673990282,0.381314549163954,0.10528965041485,0.276024898749104,4.94788581898246,0.6028,4.73194276804081,15.4167,0.564392786480971,0.392653536608815,0.580150640315152,0.383498237547234,0.171739249872156,0.196652402767918,True,0.358157203394903,0.0352757689158785,0.96933213054103,50.3959381371787
19405,1025:1011,Colon,LS-513,SIDM00677,907795,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.73506662625289,0.0664950446263123,0.569916866415261,9.67982858702327,16.0195,0.84354758821518,0.867099447692602,0.0516147471698864,0.418926868240485,0.148045686812694,0.270881181427791,5.67335369978599,0.9967,4.00647488723727,15.0228,0.620063679753095,0.456502091720897,0.637375865641145,0.461471397688655,0.163561588032197,0.17590446795249,True,0.358157203394903,0.0352757689158785,0.96933213054103,50.3959381371787
19405,1022:1011,Colon,LS-513,SIDM00677,907795,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.979895275315366,0.0664950446263123,0.569916866415261,9.67982858702327,16.0195,0.84354758821518,0.867099447692602,0.0767270927768372,0.558458844722853,0.343597152314028,0.214861692408825,7.51193351826823,3.5649,2.16789506875504,12.4546,0.826588296195727,0.749117540535441,0.849666652022544,0.738776237436784,0.0774707556602855,0.11089041458576,True,0.358157203394903,0.0352757689158785,0.96933213054103,50.3959381371787
19405,1786:1011,Colon,LS-513,SIDM00677,907795,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.715327811822849,0.0664950446263123,0.569916866415261,9.67982858702327,16.0195,0.84354758821518,0.867099447692602,0.0637597424835125,0.407677384973764,0.169147892754485,0.238529492219278,6.1692924604419,1.4056,3.51053612658137,14.6139,0.603413050446407,0.493693492378556,0.62026035055075,0.474887018346347,0.10971955806785,0.145373332204403,True,0.358157203394903,0.0352757689158785,0.96933213054103,50.3959381371787
19405,1059:1011,Colon,LS-513,SIDM00677,907795,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.604890251901113,0.0664950446263123,0.569916866415261,9.67982858702327,16.0195,0.84354758821518,0.867099447692602,0.0433448122362252,0.34473715688862,0.148423342118334,0.196313814770286,6.28696519238402,1.5251,3.39286339463925,14.4944,0.510253713126057,0.409243745627396,0.524500003338094,0.40663386612839,0.101009967498661,0.117866137209705,True,0.358157203394903,0.0352757689158785,0.96933213054103,50.3959381371787
19722,1011:1017,Colon,LS-513,SIDM00677,907795,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.788320019513338,0.061377200146618,0.804900741223327,12.4224484215924,107.216,0.936841317631845,0.94851688283561,0.0384100348617945,0.634519368027473,0.291838917886429,0.342680450141045,7.71684874807666,4.109,4.70559967351574,103.107,0.738530765796437,0.577996226790556,0.747734847585698,0.604229681362019,0.160534539005881,0.14350516622368,True,0.241984047229246,0.0274981859161809,1.32862384943808,36.9343636406378
19403,1179:1022,Colon,LS-513,SIDM00677,907795,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.421435307964761,0.0797236812037292,0.634843807381487,10.3355800784709,2.5238,0.897400964163286,0.892471464527839,0.0379885620333578,0.267545595473338,0.105207762643117,0.162337832830221,6.34232153898574,0.1585,3.99325853948513,2.3653,0.378196451700028,0.28032618105487,0.376118986503051,0.284955251203275,0.097870270645158,0.091163735299776,True,0.358157203394903,0.0352757689158785,0.96933213054103,50.3959381371787
19721,1011:1025,Colon,LS-513,SIDM00677,907795,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.794447737576824,0.0466427786243916,0.633711848655504,10.3237958113642,25.0324,0.885933202861952,0.892051198840852,0.0461562605471812,0.503450944439992,0.253994819109551,0.249456125330441,7.17651008205781,2.8254,3.14728572930642,22.207,0.703827628657867,0.587628490172393,0.708688056721808,0.58205834560039,0.116199138485474,0.126629711121418,True,0.241984047229246,0.0274981859161809,1.32862384943808,36.9343636406378
19402,1011:1032,Colon,LS-513,SIDM00677,907795,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.915927925628808,0.0721101658480534,0.1930972521607,5.5466438226602,0.9129,0.608598265697773,0.618394106859768,0.0716354607793551,0.176863165616173,0.0553628978007714,0.121500267815402,2.37423653932184,0.1013,3.17240728333836,0.8116,0.557432147041851,0.325159279812804,0.566404431517147,0.344139497481012,0.232272867229047,0.222264934036135,True,0.358157203394903,0.0352757689158785,0.96933213054103,50.3959381371787
19406,1194:1053,Colon,LS-513,SIDM00677,907795,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,0.625,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.929482097228895,0.063918002847933,0.320201529238136,7.18193844543321,2.836,0.746219028221477,0.733009215867958,0.0747053902038199,0.297621588932162,0.256242171964895,0.0413794169672673,6.66723960408089,1.985,0.514698841352321,0.851,0.693597227343406,0.680380811670666,0.681318943253057,0.649452226847379,0.0132164156727408,0.0318667164056777,True,0.358157203394903,0.0352757689158785,0.96933213054103,50.3959381371787
19406,1059:1053,Colon,LS-513,SIDM00677,907795,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.83744258983022,0.063918002847933,0.320201529238136,7.18193844543321,2.836,0.746219028221477,0.733009215867958,0.100172308693566,0.268150397912782,0.0791942260424827,0.188956171870299,3.54443844089427,0.2279,3.63750000453894,2.6081,0.624915595574384,0.37606685009206,0.613853136105881,0.389151369349173,0.248848745482325,0.224701766756708,True,0.358157203394903,0.0352757689158785,0.96933213054103,50.3959381371787
19407,1194:1054,Colon,LS-513,SIDM00677,907795,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,2.5,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.606560944943108,0.112584031412609,0.506743603974924,9.06514497616925,4.1848,0.75881595626918,0.839556638362106,0.0514249463287895,0.307370879270906,0.118523971754861,0.188846907516045,5.58222344243103,0.3743,3.48292153373822,3.8105,0.460268123472542,0.366419310359214,0.509242267898178,0.376699027510274,0.0938488131133279,0.132543240387905,True,0.358157203394903,0.0352757689158785,0.96933213054103,50.3959381371787
19723,1011:1073,Colon,LS-513,SIDM00677,907795,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,20.0,0.801252680918599,0.0680729363788907,0.316118810124157,7.1364890253484,5.4961,0.727579115351313,0.730060125959213,0.0826082216642539,0.253291044100778,0.0534513101150383,0.19983973398574,2.62855956762712,0.2416,4.50792945772128,5.2545,0.582974716755622,0.296091735394208,0.584962633156589,0.316262955933172,0.286882981361414,0.268699677223418,True,0.241984047229246,0.0274981859161809,1.32862384943808,36.9343636406378
19722,1372:1373,Colon,LS-513,SIDM00677,907795,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10.0,0.204559342820189,0.0451382629517079,0.820869570644301,12.6761103299702,127.8261,0.974252509848109,0.953168544348713,0.0305644596515039,0.167916539912089,0.140881633945217,0.0270349059668717,10.9176520571859,37.7808,1.75845827278432,90.0453,0.199292453155449,0.169096532371061,0.194979531028849,0.186490348184152,0.0301959207843878,0.0084891828446963,True,0.241984047229246,0.0274981859161809,1.32862384943808,36.9343636406378
19722,1564:1373,Colon,LS-513,SIDM00677,907795,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.5,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10.0,0.679352887619042,0.0451382629517079,0.820869570644301,12.6761103299702,127.8261,0.974252509848109,0.953168544348713,0.0590999847099005,0.557660113175809,0.340464325646701,0.217195787529107,9.01120286179072,10.078,3.66490746817947,117.7481,0.661861255835412,0.59100328810669,0.647537802990937,0.568593920172753,0.0708579677287213,0.0789438828181843,True,0.241984047229246,0.0274981859161809,1.32862384943808,36.9343636406378
19722,2171:1373,Colon,LS-513,SIDM00677,907795,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10.0,0.548934437360996,0.0451382629517079,0.820869570644301,12.6761103299702,127.8261,0.974252509848109,0.953168544348713,0.0337760948094072,0.450603575908392,0.246685736074803,0.203917839833589,8.50944548053699,7.1175,4.16666484943319,120.7086,0.53480075334101,0.416465794332971,0.523227038602261,0.445460881900745,0.11833495900804,0.0777661567015155,True,0.241984047229246,0.0274981859161809,1.32862384943808,36.9343636406378
19405,1194:1510,Colon,LS-513,SIDM00677,907795,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,0.625,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.928178247933959,0.0788038890358887,0.413904443728125,8.15997600990017,5.5863,0.795938016986316,0.792354660925284,0.0445894381127398,0.384177101391651,0.339617351963288,0.0445597494283629,7.6721306596119,3.9836,0.487845350288269,1.6027,0.738772354070388,0.723784877202249,0.735446360919936,0.708915248789352,0.0149874768681392,0.0265311121305839,True,0.358157203394903,0.0352757689158785,0.96933213054103,50.3959381371787
19405,1059:1510,Colon,LS-513,SIDM00677,907795,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.867981897113682,0.0788038890358887,0.413904443728125,8.15997600990017,5.5863,0.795938016986316,0.792354660925284,0.0908508734999798,0.359261564290921,0.13509257306075,0.224168991230172,4.91628904737713,0.5898,3.24368696252304,4.9965,0.690859789968685,0.466052211137401,0.687749501776796,0.495413660579092,0.224807578831284,0.192335841197704,True,0.358157203394903,0.0352757689158785,0.96933213054103,50.3959381371787
19724,1083:1549,Colon,LS-513,SIDM00677,907795,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.94994514033772,0.107421383082734,0.463006440391146,8.64200002144262,3.9012,0.742757506319527,0.818462756519107,0.124148028727314,0.439830717994636,0.322360236414275,0.117470481580361,7.39115859104617,1.6393,1.25084143039645,2.2619,0.705578883577598,0.62709957314857,0.77749471810274,0.709017243077405,0.0784793104290282,0.0684774750253354,True,0.241984047229246,0.0274981859161809,1.32862384943808,36.9343636406378
19725,1011:1561,Colon,LS-513,SIDM00677,907795,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.716192672258855,0.0915591756126658,0.287437643559889,6.80758817884553,2.1879,0.658823360711808,0.708260744506956,0.0478707333703624,0.205860734048945,0.0517421865929477,0.154118547455998,2.8354681808185,0.1394,3.97211999802703,2.0485,0.471844463254749,0.277172495294928,0.507251155264483,0.293873616449514,0.19467196795982,0.213377538814968,True,0.241984047229246,0.0274981859161809,1.32862384943808,36.9343636406378
19726,1194:1786,Colon,LS-513,SIDM00677,907795,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,0.625,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10.0,0.950080956687709,0.0803880754967132,0.776515213072961,12.0077159818678,80.429,0.947590751613705,0.940020403573757,0.0767938396798924,0.737752316518919,0.740414240155337,-0.0026619236364181,12.0468804544709,82.6423,-0.0391644726031544,-2.2133,0.900287927841574,0.88117632701553,0.893095484333322,0.893905015501929,0.0191116008260442,-0.000809531168607,True,0.241984047229246,0.0274981859161809,1.32862384943808,36.9343636406378
19727,1011:2048,Colon,LS-513,SIDM00677,907795,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.739133611968459,0.0674810822544332,0.32270853367909,7.20969467291638,0.0289,0.73577499047608,0.734802425586033,0.12331692114478,0.238524724111271,0.0881431095200936,0.150381614591177,4.17128927033007,0.0035,3.03840540258631,0.0254,0.543836026306643,0.392586305656888,0.54311717090659,0.379389741386245,0.151249720649756,0.163727429520345,True,0.241984047229246,0.0274981859161809,1.32862384943808,36.9343636406378
19406,1194:2171,Colon,LS-513,SIDM00677,907795,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,2.5,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.6010226992753,0.157570981272325,0.10514369791545,3.82884926343641,0.2775,0.465851275599139,0.48672094816622,0.0407641423096621,0.0631937491329306,0.0107425065442235,0.0524512425887071,-0.675104102959119,0.0122,4.50395336639553,0.2653,0.279987191121436,0.0882719894619174,0.292530338060695,0.108078779617693,0.191715201659518,0.184451558443002,True,0.358157203394903,0.0352757689158785,0.96933213054103,50.3959381371787
19406,1011:2171,Colon,LS-513,SIDM00677,907795,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.851981721985101,0.157570981272325,0.10514369791545,3.82884926343641,0.2775,0.465851275599139,0.48672094816622,0.0414961975148943,0.0895805088058866,0.0212589511180732,0.0683215576878135,0.148071191919841,0.0216,3.68077807151657,0.2559,0.39689677197391,0.182934422471845,0.414677351544877,0.192079247332364,0.213962349502065,0.222598104212513,True,0.358157203394903,0.0352757689158785,0.96933213054103,50.3959381371787
22250,1017:1011,Colon,SW48,SIDM00837,909751,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.693506530531892,0.127908944544848,0.212512963737615,5.35882101061205,0.8015,0.63620661539698,0.596348644197086,0.105351327911983,0.147379128174723,0.0553997448142773,0.0919793833604461,2.20622186292344,0.0901,3.15259914768861,0.7114,0.441213442545397,0.241105042726241,0.413571679224519,0.259178313556857,0.200108399819156,0.154393365667662,True,0.180694267683178,0.0410040507259235,1.61572689118342,30.5497392311884
22250,1003:1011,Colon,SW48,SIDM00837,909751,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.0025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.884428743433893,0.127908944544848,0.212512963737615,5.35882101061205,0.8015,0.63620661539698,0.596348644197086,0.106289055488104,0.187952573481871,0.157093548601898,0.0308590248799735,4.73974114500846,0.5218,0.61907986560359,0.2797,0.56267941741988,0.516587720589627,0.527427882035734,0.488922081004897,0.0460916968302537,0.0385058010308372,True,0.180694267683178,0.0410040507259235,1.61572689118342,30.5497392311884
22250,1089:1011,Colon,SW48,SIDM00837,909751,1089,Oxaliplatin,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved in colon,1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.637309867673873,0.127908944544848,0.212512963737615,5.35882101061205,0.8015,0.63620661539698,0.596348644197086,0.0783559801098002,0.135436608798602,0.0630770230422403,0.0723595857563619,2.86018953798532,0.1418,2.49863147262673,0.6597,0.405460753871892,0.259149343628888,0.380058875520739,0.266999729856603,0.146311410243004,0.113059145664136,True,0.180694267683178,0.0410040507259235,1.61572689118342,30.5497392311884
22639,1011:1017,Colon,SW48,SIDM00837,909751,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.781221060422407,0.0669601743608332,0.796343484127135,12.7906014825928,138.3836,0.942022849521825,0.938636736134493,0.126289045276314,0.622120301130275,0.253879556681409,0.368240744448866,6.96795670378699,2.4451,5.82264477880577,135.9385,0.735928089445578,0.535999923646366,0.733282786354416,0.549144054035429,0.199928165799212,0.184138732318986,True,0.206902700647126,0.0392166777439462,1.47333149252402,33.3746269959984
22639,1372:1017,Colon,SW48,SIDM00837,909751,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.780326691844324,0.0669601743608332,0.796343484127135,12.7906014825928,138.3836,0.942022849521825,0.938636736134493,0.0336359411195256,0.621408076540711,0.718287557348584,-0.0968794808078735,15.8081609554988,1120.6259,-3.01755947290604,-982.2423,0.735085573809129,0.769038482719521,0.732443299151383,0.762869183311347,-0.0339529089103923,-0.0304258841599645,True,0.206902700647126,0.0392166777439462,1.47333149252402,33.3746269959984
22248,1179:1022,Colon,SW48,SIDM00837,909751,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.707455163500831,0.162544314276569,0.428126271691477,8.19523126066178,0.5725,0.838922249682138,0.774165931650714,0.0819942477692353,0.302880141538495,0.118710981120105,0.18416916041839,4.5486148544616,0.0457,3.64661640620018,0.5268,0.593499877313362,0.386447979545173,0.547687685752729,0.381471916431664,0.207051897768189,0.166215769321065,True,0.180694267683178,0.0410040507259235,1.61572689118342,30.5497392311884
22638,1372:1025,Colon,SW48,SIDM00837,909751,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.491398715717472,0.0877148835945572,0.787979366653781,12.6493639776738,125.4781,0.916352525749916,0.93580236013754,0.0297569480749001,0.387212048785536,0.41343206879238,-0.0262200200068446,13.6373913111654,248.8822,-0.988027333491582,-123.4041,0.450294454297971,0.478486812725138,0.459852077936967,0.468502990432843,-0.0281923584271671,-0.008650912495876,True,0.206902700647126,0.0392166777439462,1.47333149252402,33.3746269959984
22638,1011:1025,Colon,SW48,SIDM00837,909751,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.762517524118791,0.0877148835945572,0.787979366653781,12.6493639776738,125.4781,0.916352525749916,0.93580236013754,0.0942339090352165,0.600848075717535,0.322788800260145,0.278059275457389,8.1405800278549,5.5117,4.5087839498189,119.9664,0.698734859154827,0.5301242189304,0.713565698716598,0.588070453404247,0.168610640224427,0.125495245312351,True,0.206902700647126,0.0392166777439462,1.47333149252402,33.3746269959984
22637,1011:1032,Colon,SW48,SIDM00837,909751,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.698335782455466,0.141060094881863,0.244328039907473,5.86127546033281,1.1354,0.59247925669448,0.6308609219496,0.0757142904662361,0.170623012924595,0.0615908173578285,0.109032195566767,2.50665281694858,0.111,3.35462264338423,1.0244,0.413749465312372,0.263177977777416,0.440552755550251,0.275371658988889,0.150571487534957,0.165181096561362,True,0.206902700647126,0.0392166777439462,1.47333149252402,33.3746269959984
22637,1022:1032,Colon,SW48,SIDM00837,909751,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.908286945154178,0.141060094881863,0.244328039907473,5.86127546033281,1.1354,0.59247925669448,0.6308609219496,0.147190796041536,0.221919968983067,0.0824370241870853,0.139482944795981,2.59415719251516,0.1179,3.26711826781765,1.0175,0.538141174130247,0.369299083515342,0.57300273961475,0.363664649107299,0.168842090614905,0.209338090507452,True,0.206902700647126,0.0392166777439462,1.47333149252402,33.3746269959984
22637,1564:1032,Colon,SW48,SIDM00837,909751,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.717168041465671,0.141060094881863,0.244328039907473,5.86127546033281,1.1354,0.59247925669448,0.6308609219496,0.0831493319558481,0.175224261855589,0.105834632264519,0.0693896295910694,4.1247846825629,0.3407,1.73649077776991,0.7947,0.424907188132616,0.350055697723929,0.452433291831822,0.364990824695966,0.0748514904086879,0.0874424671358554,True,0.206902700647126,0.0392166777439462,1.47333149252402,33.3746269959984
22251,2171:1053,Colon,SW48,SIDM00837,909751,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.137431700850319,0.125876477997761,0.469388303173597,8.6591891742666,7.896,0.744958655819447,0.798231315508605,0.0438108868346505,0.0645088328643926,0.0296854864959847,0.0348233463684079,5.41642959669898,0.8341,3.24275957756762,7.0619,0.102380935132434,0.0749071444357947,0.109702287362335,0.0825070149872752,0.0274737906966392,0.02719527237506,True,0.180694267683178,0.0410040507259235,1.61572689118342,30.5497392311884
22251,1011:1053,Colon,SW48,SIDM00837,909751,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.569152858568797,0.125876477997761,0.469388303173597,8.6591891742666,7.896,0.744958655819447,0.798231315508605,0.0719543628349542,0.26715369453001,0.0906389445081515,0.176514750021858,4.37486999552089,0.4052,4.2843191787457,7.4908,0.423995348475207,0.30191650982311,0.454315635020854,0.299840965750778,0.122078838652097,0.154474669270077,True,0.180694267683178,0.0410040507259235,1.61572689118342,30.5497392311884
22251,1054:1053,Colon,SW48,SIDM00837,909751,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.736249558672805,0.125876477997761,0.469388303173597,8.6591891742666,7.896,0.744958655819447,0.798231315508605,0.159372407584313,0.345586931057738,0.128830527502717,0.216756403555021,4.68921689156867,0.5039,3.96997228269793,7.3921,0.548475481576554,0.370407886494294,0.587697453762023,0.404365067183264,0.17806759508226,0.18333238657876,True,0.180694267683178,0.0410040507259235,1.61572689118342,30.5497392311884
22251,1047:1053,Colon,SW48,SIDM00837,909751,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.527645662562366,0.125876477997761,0.469388303173597,8.6591891742666,7.896,0.744958655819447,0.798231315508605,0.0812647004538839,0.247670702227057,0.125967350877616,0.121703351349441,5.77639759060313,1.0705,2.88279158366346,6.8255,0.393074203531421,0.299147004571906,0.421183291349567,0.329828977596973,0.0939271989595154,0.0913543137525941,True,0.180694267683178,0.0410040507259235,1.61572689118342,30.5497392311884
22640,1011:1073,Colon,SW48,SIDM00837,909751,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,20.0,0.699594242864299,0.0732708033249467,0.586697983692722,9.97387174874734,39.2821,0.88159334837908,0.85707954702584,0.11046370940978,0.41045053169152,0.202762951769997,0.207687579921523,6.50865603492515,3.5568,3.46521571382219,35.7253,0.616757631073465,0.502765904011178,0.599607916776018,0.471377526038098,0.113991727062286,0.128230390737921,True,0.206902700647126,0.0392166777439462,1.47333149252402,33.3746269959984
22640,1011:1089,Colon,SW48,SIDM00837,909751,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,1089,Oxaliplatin,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved in colon,10.0,0.940295908495626,0.105121217696147,0.403214364165962,7.91004681125397,4.6978,0.796515552597431,0.758558997872863,0.154687281355889,0.379140816871919,0.203184189143559,0.175956627728361,5.41780221946637,0.8349,2.4922445917876,3.8629,0.748960315160497,0.590611252898423,0.713269922052395,0.564595431080798,0.158349062262074,0.148674490971597,True,0.206902700647126,0.0392166777439462,1.47333149252402,33.3746269959984
22641,1022:1179,Colon,SW48,SIDM00837,909751,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,10.0,0.752150812995169,0.187328848063709,0.237965007632602,5.7646108710438,1.0618,0.680476027343827,0.624292740209611,0.0396126256348837,0.178985573955263,0.0678012962671151,0.111184277688148,2.57328308352498,0.1162,3.19132778751881,0.9456,0.511820597190382,0.278155322813589,0.469562292095641,0.300061137711988,0.233665274376793,0.169501154383653,True,0.206902700647126,0.0392166777439462,1.47333149252402,33.3746269959984
22638,1011:1194,Colon,SW48,SIDM00837,909751,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,10.0,0.762517524118791,0.0800358643879309,0.68429328461312,11.1504222695113,44.3958,0.896645046897748,0.898032675947866,0.183861019742211,0.521785621154312,0.270050559404303,0.251735061750009,7.32981127177522,3.1421,3.82061099773605,41.2537,0.683707561173848,0.559933107213934,0.684765652641539,0.552824635880559,0.123774453959913,0.13194101676098,True,0.206902700647126,0.0392166777439462,1.47333149252402,33.3746269959984
22248,2171:1372,Colon,SW48,SIDM00837,909751,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.12584462493961,0.179607274694157,0.223170044731739,5.53271900890979,0.0904,0.542615472625449,0.608392754907515,0.0460775205567511,0.0280847505770218,0.0199607924688013,0.0081239581082204,4.36160651050321,0.0402,1.17111249840658,0.0502,0.0682852406389791,0.018769326828996,0.0765629580573126,0.0661781837360914,0.049515913809983,0.0103847743212212,True,0.180694267683178,0.0410040507259235,1.61572689118342,30.5497392311884
22248,1032:1372,Colon,SW48,SIDM00837,909751,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.701039659132728,0.179607274694157,0.223170044731739,5.53271900890979,0.0904,0.542615472625449,0.608392754907515,0.161890470697879,0.156451052087374,0.0751927561321656,0.0812582959552079,3.10934124151392,0.0169,2.42337776739588,0.0735,0.380394965969489,0.294281438744526,0.426507449519186,0.306001535161877,0.086113527224963,0.120505914357309,True,0.180694267683178,0.0410040507259235,1.61572689118342,30.5497392311884
22248,1561:1372,Colon,SW48,SIDM00837,909751,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.366399528394851,0.179607274694157,0.223170044731739,5.53271900890979,0.0904,0.542615472625449,0.608392754907515,0.0642390212612208,0.0817693991415667,0.0292561485094711,0.0525132506320956,2.20486561269932,0.009,3.32785339621048,0.0814,0.198814053269713,0.105981746229688,0.222914818476957,0.136897586077558,0.0928323070400257,0.0860172323993996,True,0.180694267683178,0.0410040507259235,1.61572689118342,30.5497392311884
22248,1549:1372,Colon,SW48,SIDM00837,909751,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.624066861889804,0.179607274694157,0.223170044731739,5.53271900890979,0.0904,0.542615472625449,0.608392754907515,0.104648887428312,0.139273029483543,0.0494541425994861,0.0898188868840571,2.18198207397747,0.0089,3.35073693493232,0.0815,0.338628335214217,0.223677752759605,0.379677757351626,0.232198914536266,0.114950582454612,0.147478842815359,True,0.180694267683178,0.0410040507259235,1.61572689118342,30.5497392311884
22250,1011:1510,Colon,SW48,SIDM00837,909751,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.832026604332322,0.0852583515543169,0.276242603149647,6.32250615268692,1.5631,0.649111841272549,0.661648654362816,0.0475725216722615,0.229841195070522,0.222470389080481,0.007370805990041,6.19807865096953,1.434,0.124427501717393,0.1291,0.5400783211259,0.546652818231174,0.550509283150544,0.543678455263381,-0.0065744971052736,0.0068308278871623,True,0.180694267683178,0.0410040507259235,1.61572689118342,30.5497392311884
22641,1011:1549,Colon,SW48,SIDM00837,909751,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.656073608811241,0.156294998692666,0.436014936580533,8.28460023813578,3.0452,0.693245466608146,0.778930817276946,0.10871067976924,0.286057892937994,0.0890519795894373,0.197005913348557,3.85399177773557,0.1412,4.43060846040021,2.904,0.454820055069639,0.292343870941045,0.511035952305175,0.321179143733364,0.162476184128594,0.189856808571812,True,0.206902700647126,0.0392166777439462,1.47333149252402,33.3746269959984
22641,1372:1549,Colon,SW48,SIDM00837,909751,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.670051033940997,0.156294998692666,0.436014936580533,8.28460023813578,3.0452,0.693245466608146,0.778930817276946,0.1034931881066,0.292152259069504,0.0800653924984369,0.212086866571067,3.44791779706514,0.1066,4.83668244107063,2.9386,0.464509841675697,0.287285039111549,0.521923399484923,0.30858251539316,0.177224802564147,0.213340884091763,True,0.206902700647126,0.0392166777439462,1.47333149252402,33.3746269959984
22641,1564:1549,Colon,SW48,SIDM00837,909751,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.764259851829943,0.156294998692666,0.436014936580533,8.28460023813578,3.0452,0.693245466608146,0.778930817276946,0.107737876033876,0.33322871082668,0.202178546748,0.13105016407868,6.15760909526897,0.6971,2.1269911428668,2.3481,0.529819677591721,0.446033293151086,0.595305550997855,0.497344136917627,0.0837863844406347,0.0979614140802277,True,0.206902700647126,0.0392166777439462,1.47333149252402,33.3746269959984
22642,1372:1561,Colon,SW48,SIDM00837,909751,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.617049734726854,0.179653513571102,0.172381613765074,4.63884483971986,0.4866,0.502312319483829,0.545641374896892,0.0613731929729481,0.106368029045526,0.0242304070160254,0.0821376220295006,0.112014560887577,0.0211,4.52683027883228,0.4655,0.309951683487528,0.14669680039486,0.336687865636123,0.149741555293017,0.163254883092668,0.186946310343106,True,0.206902700647126,0.0392166777439462,1.47333149252402,33.3746269959984
22642,1047:1561,Colon,SW48,SIDM00837,909751,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.404773415258038,0.179653513571102,0.172381613765074,4.63884483971986,0.4866,0.502312319483829,0.545641374896892,0.0873548683610132,0.0697754945313812,0.0224888773070402,0.047286617224341,1.12426339322208,0.0426,3.51458144649778,0.444,0.203322673083657,0.117471900939669,0.220861122823106,0.122574958628963,0.0858507721439871,0.0982861641941437,True,0.206902700647126,0.0392166777439462,1.47333149252402,33.3746269959984
22642,1011:1561,Colon,SW48,SIDM00837,909751,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.709388436080151,0.179653513571102,0.172381613765074,4.63884483971986,0.4866,0.502312319483829,0.545641374896892,0.0819447287311861,0.122285523397778,0.0279846940280506,0.0943008293697278,0.125313583172253,0.0213,4.51353125654761,0.4653,0.356334550742427,0.122718904300859,0.387071681598729,0.172677930250277,0.233615646441567,0.214393751348452,True,0.206902700647126,0.0392166777439462,1.47333149252402,33.3746269959984
22642,1011:1564,Colon,SW48,SIDM00837,909751,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.709388436080151,0.152712097437308,0.237801910465863,5.7621100461818,0.53,0.566383525664966,0.624122327740713,0.0645956983995738,0.16869392536225,0.0553389978658734,0.113354927496377,2.13457265941124,0.0429,3.62753738677056,0.4871,0.401785923493032,0.260256180479575,0.442745161998687,0.261663458061428,0.141529743013457,0.18108170393726,True,0.206902700647126,0.0392166777439462,1.47333149252402,33.3746269959984
22642,1054:1564,Colon,SW48,SIDM00837,909751,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.783584593701381,0.152712097437308,0.237801910465863,5.7621100461818,0.53,0.566383525664966,0.624122327740713,0.148673090688627,0.186337913393805,0.0576058704824151,0.12873204291139,1.95613043078535,0.0379,3.80597961539644,0.4921,0.443809404837338,0.289368758761896,0.489052640602667,0.27961188238485,0.154440646075442,0.209440758217817,True,0.206902700647126,0.0392166777439462,1.47333149252402,33.3746269959984
22642,1053:1564,Colon,SW48,SIDM00837,909751,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.674857698363695,0.152712097437308,0.237801910465863,5.7621100461818,0.53,0.566383525664966,0.624122327740713,0.0545881770841811,0.160482449963482,0.0525899381640125,0.107892511799469,2.13140197024844,0.0428,3.63070807593336,0.4872,0.382228282521374,0.241709815387907,0.421193757596489,0.248781595127674,0.140518467133467,0.172412162468815,True,0.206902700647126,0.0392166777439462,1.47333149252402,33.3746269959984
22642,1083:1564,Colon,SW48,SIDM00837,909751,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.857791448577171,0.152712097437308,0.237801910465863,5.7621100461818,0.53,0.566383525664966,0.624122327740713,0.105722134711013,0.203984445252931,0.074023831499602,0.129960613753329,2.44030022599423,0.053,3.32180982018756,0.477,0.485838944930396,0.335872398643513,0.535366795602062,0.334322021488879,0.149966546286883,0.201044774113183,True,0.206902700647126,0.0392166777439462,1.47333149252402,33.3746269959984
22642,1561:1564,Colon,SW48,SIDM00837,909751,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.453970088974884,0.152712097437308,0.237801910465863,5.7621100461818,0.53,0.566383525664966,0.624122327740713,0.046360147931788,0.107954954452585,0.0452312747572516,0.0627236796953334,2.88073493434235,0.0719,2.88137511183945,0.4581,0.257121179540033,0.171314392311489,0.283332868655663,0.190844322839982,0.085806787228544,0.0924885458156807,True,0.206902700647126,0.0392166777439462,1.47333149252402,33.3746269959984
22643,1053:1598,Colon,SW48,SIDM00837,909751,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1598,LGK974,PORCN,WNT signaling,Targeted,Early clinical trials,10.0,0.689824682727951,0.0557281998708448,0.878792483154985,14.5070212799002,454.7562,0.965556410128578,0.965130910288871,0.0757834133658858,0.606212745876096,0.524156111103194,0.0820566347729023,12.2018403826078,92.0132,2.30518089729242,362.743,0.666064644272886,0.618132378701833,0.665771123980959,0.638811204974666,0.0479322655710529,0.0269599190062929,True,0.206902700647126,0.0392166777439462,1.47333149252402,33.3746269959984
22643,1510:1598,Colon,SW48,SIDM00837,909751,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1598,LGK974,PORCN,WNT signaling,Targeted,Early clinical trials,10.0,0.459536165771475,0.0557281998708448,0.878792483154985,14.5070212799002,454.7562,0.965556410128578,0.965130910288871,0.0503164074346599,0.403836928217835,0.308418889825417,0.0954180383924179,10.9831575858068,39.5357,3.52386369409343,415.2205,0.443708090546556,0.376757711772382,0.443512557981681,0.410300368194994,0.0669503787741745,0.0332121897866866,True,0.206902700647126,0.0392166777439462,1.47333149252402,33.3746269959984
18369,1032:1011,Colon,CW-2,SIDM00282,910554,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.624005686737914,0.112356009725444,0.678656334983462,11.3754508208472,51.8898,0.91156950575377,0.883230635680943,0.0628914103342492,0.423485412370392,0.250611772643474,0.172873639726917,7.73307085735443,4.1554,3.6423799634928,47.7344,0.568824555447222,0.457597212091483,0.551140939366051,0.455435061782982,0.11122734335574,0.0957058775830691,True,0.561548075640563,0.06189365507892,0.529368520167496,89.691056552523
18369,1003:1011,Colon,CW-2,SIDM00282,910554,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.0025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.945704095487189,0.112356009725444,0.678656334983462,11.3754508208472,51.8898,0.91156950575377,0.883230635680943,0.121269204305983,0.641808075422186,0.518923917543759,0.122884157878427,9.62114808699944,15.381,1.75430273384779,36.5088,0.862075014912573,0.794161970075765,0.835274829423221,0.77579476906731,0.0679130448368083,0.059480060355911,True,0.561548075640563,0.06189365507892,0.529368520167496,89.691056552523
18369,2171:1011,Colon,CW-2,SIDM00282,910554,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.05,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.873699165851879,0.112356009725444,0.678656334983462,11.3754508208472,51.8898,0.91156950575377,0.883230635680943,0.0975721782809439,0.592941473775145,0.552657353940924,0.0402841198342208,10.7258690281297,33.0779,0.649581792717536,18.8119,0.796437516793079,0.788518134146926,0.771677869649265,0.753398773734202,0.0079193826461522,0.0182790959150624,True,0.561548075640563,0.06189365507892,0.529368520167496,89.691056552523
18369,1549:1011,Colon,CW-2,SIDM00282,910554,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.602493468996483,0.112356009725444,0.678656334983462,11.3754508208472,51.8898,0.91156950575377,0.883230635680943,0.0891104601159191,0.408886009520625,0.266471884876899,0.142414124643726,8.26313520012046,6.0004,3.11231562072677,45.8894,0.549214673752998,0.487767667703715,0.53214068961538,0.456419492408407,0.0614470060492835,0.0757211972069733,True,0.561548075640563,0.06189365507892,0.529368520167496,89.691056552523
18369,1047:1011,Colon,CW-2,SIDM00282,910554,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.492021799162006,0.112356009725444,0.678656334983462,11.3754508208472,51.8898,0.91156950575377,0.883230635680943,0.067943419856644,0.333913710951256,0.146846817188874,0.187066893762382,6.28438163248319,1.5224,5.09106918836404,50.3674,0.44851206828219,0.317106543564943,0.43456872644274,0.3180345397087,0.131405524717248,0.11653418673404,True,0.561548075640563,0.06189365507892,0.529368520167496,89.691056552523
18369,2048:1011,Colon,CW-2,SIDM00282,910554,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.917001378952603,0.112356009725444,0.678656334983462,11.3754508208472,51.8898,0.91156950575377,0.883230635680943,0.160834768797555,0.622328795014755,0.5801233618661,0.0422054331486551,10.726990814724,33.1037,0.648460006123267,18.7861,0.83591049378735,0.850612684280284,0.809923710852609,0.790773957602688,-0.0147021904929338,0.0191497532499205,True,0.561548075640563,0.06189365507892,0.529368520167496,89.691056552523
18988,1032:1564,Colon,CW-2,SIDM00282,910554,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.512584924028395,0.085771330527585,0.712284698868183,11.8803508610102,36.8165,0.880249032471207,0.89766524546352,0.078522154892884,0.365106398255936,0.318311615781065,0.046794782474871,10.5688982218553,14.8339,1.31145263915487,21.9826,0.451202383435322,0.393113135989953,0.460129671648849,0.439204483809655,0.0580892474453694,0.0209251878391946,True,0.337310389856464,0.0492710106596731,1.01905549149413,47.8763510471682
18988,1047:1564,Colon,CW-2,SIDM00282,910554,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.766914859613315,0.085771330527585,0.712284698868183,11.8803508610102,36.8165,0.880249032471207,0.89766524546352,0.036250797474566,0.546261719837205,0.470394779301016,0.0758669405361889,10.4662437434272,13.8151,1.41410711758298,23.0014,0.675076063162412,0.662048500042298,0.688432815704407,0.654315722412315,0.0130275631201135,0.0341170932920923,True,0.337310389856464,0.0492710106596731,1.01905549149413,47.8763510471682
18370,1549:2171,Colon,CW-2,SIDM00282,910554,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.616186940829543,0.100504973154953,0.698139206783558,11.6641157574185,63.3839,0.846314107528984,0.891673151703198,0.0792394037747693,0.430184262101124,0.290087188964657,0.140097073136468,8.62817263979674,7.728,3.03594311762179,55.6559,0.521487700899169,0.425087520923421,0.549437351567831,0.47792255908818,0.0964001799757478,0.0715147924796505,True,0.561548075640563,0.06189365507892,0.529368520167496,89.691056552523
18370,1047:2171,Colon,CW-2,SIDM00282,910554,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.494597832817699,0.100504973154953,0.698139206783558,11.6641157574185,63.3839,0.846314107528984,0.891673151703198,0.0603953054206431,0.345298138680215,0.229396199004217,0.115901939675998,8.53914771976734,7.2656,3.1249680376512,56.1183,0.41858512346688,0.353573382698759,0.441019608414129,0.381476503999173,0.0650117407681208,0.0595431044149555,True,0.561548075640563,0.06189365507892,0.529368520167496,89.691056552523
18370,1011:2171,Colon,CW-2,SIDM00282,910554,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.961022710524327,0.100504973154953,0.698139206783558,11.6641157574185,63.3839,0.846314107528984,0.891673151703198,0.125169295260474,0.670927632826439,0.461135467406184,0.209792165420255,8.7436117600835,8.3718,2.92050399733504,55.0121,0.813327077572481,0.66411622047534,0.856918149151577,0.75070011305637,0.149210857097141,0.106218036095207,True,0.561548075640563,0.06189365507892,0.529368520167496,89.691056552523
19430,1083:1003,Colon,SNU-C1,SIDM01197,910905,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.1,0.936415948141131,0.123174403909527,0.731743229768247,11.9814372012028,0.7898,0.895325182442024,0.910943429198091,0.108513123125319,0.685216030299287,0.474908650403537,0.210307379895749,9.08504606822342,0.1061,2.8963911329794,0.6837,0.838396779611078,0.697496929972777,0.853021954955463,0.756707977620275,0.140899849638301,0.0963139773351883,True,0.455853436322891,0.0447323888560769,0.74813690467937,65.2048763158901
19430,1179:1003,Colon,SNU-C1,SIDM01197,910905,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,1,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.1,0.899634412108913,0.123174403909527,0.731743229768247,11.9814372012028,0.7898,0.895325182442024,0.910943429198091,0.092375517368046,0.658301390327235,0.383796466466988,0.274504923860246,8.12150939900199,0.0544,3.85992780220083,0.7354,0.805465344152535,0.719513961246617,0.819516056391101,0.684064781904398,0.0859513829059183,0.135451274486704,True,0.455853436322891,0.0447323888560769,0.74813690467937,65.2048763158901
19430,1022:1003,Colon,SNU-C1,SIDM01197,910905,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.1,0.805268966735288,0.123174403909527,0.731743229768247,11.9814372012028,0.7898,0.895325182442024,0.910943429198091,0.0859597703052138,0.589250114551019,0.260004539553795,0.329245574997224,6.7996999273614,0.0218,5.18173727384143,0.768,0.720977584557171,0.56791903958969,0.733554473984646,0.551529010972561,0.153058544967482,0.182025463012085,True,0.455853436322891,0.0447323888560769,0.74813690467937,65.2048763158901
19433,1372:1011,Colon,SNU-C1,SIDM01197,910905,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.434088624863765,0.13237869829638,0.484063022544713,8.81053550096528,8.7693,0.735578155765446,0.7951758610703,0.0742009654846761,0.210126251803832,0.0777062689702661,0.132419982833566,4.4748380856827,0.4343,4.33569741528258,8.335,0.319306110116047,0.210237905662386,0.345176796056867,0.231180171768974,0.109068204453661,0.113996624287892,True,0.455853436322891,0.0447323888560769,0.74813690467937,65.2048763158901
19433,1053:1011,Colon,SNU-C1,SIDM01197,910905,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.649974478007745,0.13237869829638,0.484063022544713,8.81053550096528,8.7693,0.735578155765446,0.7951758610703,0.050600788022557,0.314628610401351,0.138231699560372,0.17639691084098,5.11117687484463,0.6751,3.69935862612065,8.0942,0.478107027827545,0.360241126179334,0.516844015223527,0.374269786947688,0.117865901648211,0.142574228275839,True,0.455853436322891,0.0447323888560769,0.74813690467937,65.2048763158901
19433,1510:1011,Colon,SNU-C1,SIDM01197,910905,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.381283089703728,0.13237869829638,0.484063022544713,8.81053550096528,8.7693,0.735578155765446,0.7951758610703,0.0485678672953193,0.184565044847174,0.059414881525644,0.12515016332153,3.98006606281994,0.3082,4.83046943814534,8.4611,0.280463511948819,0.151860908780218,0.303187109166706,0.190119717786885,0.128602603168601,0.113067391379821,True,0.455853436322891,0.0447323888560769,0.74813690467937,65.2048763158901
19433,1561:1011,Colon,SNU-C1,SIDM01197,910905,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.8502692835177,0.13237869829638,0.484063022544713,8.81053550096528,8.7693,0.735578155765446,0.7951758610703,0.189945426714931,0.411583919356506,0.456207037991638,-0.0446231186351325,9.43507900015,13.5198,-0.624543499184723,-4.7505,0.625439511473957,0.659844699302993,0.676113609662814,0.70041089065102,-0.0344051878290359,-0.0242972809882062,True,0.455853436322891,0.0447323888560769,0.74813690467937,65.2048763158901
19433,2171:1011,Colon,SNU-C1,SIDM01197,910905,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.518919566047193,0.13237869829638,0.484063022544713,8.81053550096528,8.7693,0.735578155765446,0.7951758610703,0.0461286897980123,0.251189773598395,0.0612747846350385,0.189914988963357,3.02596985113775,0.1591,5.78456564982753,8.6102,0.3817058973836,0.188335374116186,0.412632312757803,0.224921181908394,0.193370523267413,0.187711130849409,True,0.455853436322891,0.0447323888560769,0.74813690467937,65.2048763158901
19431,1073:1022,Colon,SNU-C1,SIDM01197,910905,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,2.5,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.88694023357323,0.132288344215176,0.383381301467333,7.58807970253905,0.3758,0.762326316431208,0.731215743856628,0.0448157163242805,0.340036301071045,0.110575268975087,0.229461032095958,3.20957864993069,0.0181,4.37850105260836,0.3577,0.676137881154516,0.387562699202716,0.648544662648621,0.395487214400837,0.2885751819518,0.253057448247784,True,0.455853436322891,0.0447323888560769,0.74813690467937,65.2048763158901
19431,1179:1022,Colon,SNU-C1,SIDM01197,910905,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.891919432089237,0.132288344215176,0.383381301467333,7.58807970253905,0.3758,0.762326316431208,0.731215743856628,0.0904330224321047,0.341945232678376,0.143514569167127,0.198430663511249,4.09323433957389,0.0333,3.49484536296516,0.3425,0.679933655218003,0.451119951816114,0.652185530995313,0.451668840592626,0.228813703401889,0.200516690402686,True,0.455853436322891,0.0447323888560769,0.74813690467937,65.2048763158901
19431,1003:1022,Colon,SNU-C1,SIDM01197,910905,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.025,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.99655742564657,0.132288344215176,0.383381301467333,7.58807970253905,0.3758,0.762326316431208,0.731215743856628,0.0868831358937088,0.382061482831317,0.155766354890681,0.226295127940636,3.9907958448988,0.0311,3.59728385764025,0.3447,0.759701951405317,0.494173078157944,0.728698479290003,0.497648955964184,0.265528873247373,0.231049523325819,True,0.455853436322891,0.0447323888560769,0.74813690467937,65.2048763158901
19430,1179:1032,Colon,SNU-C1,SIDM01197,910905,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.25,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.937487119875109,0.0934168223201453,0.608396660542473,10.3089926357181,24.7768,0.892251640371612,0.858890622815553,0.133664972463489,0.570364033033597,0.464507604504694,0.105856428528904,8.94630020297365,9.6346,1.36269243274446,15.1422,0.836474420535824,0.751156852707329,0.805198896271092,0.75151914946958,0.0853175678284952,0.0536797468015118,True,0.455853436322891,0.0447323888560769,0.74813690467937,65.2048763158901
20291,1022:1073,Colon,SNU-C1,SIDM01197,910905,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,20.0,0.746954687785024,0.0636212866264949,0.546588630939514,9.55528545763833,29.3892,0.842566487899911,0.828921033837027,0.083802299517872,0.408276940170268,0.090178666498938,0.31809827367133,3.10076602554658,0.3351,6.45451943209175,29.0541,0.629358987907403,0.285863542256321,0.619166452028176,0.327546706322522,0.343495445651082,0.291619745705654,True,0.21036747512769,0.0289222261476665,1.36945750665856,35.3346173802413
20292,1022:1179,Colon,SNU-C1,SIDM01197,910905,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,10.0,0.583075607873129,0.147959674176519,0.358388811909008,7.26974823558647,3.014,0.767295181716691,0.712950129711659,0.0942903450571245,0.208967774358773,0.0485018425978856,0.160465931760888,1.86979359796066,0.0714,5.39995463762581,2.9426,0.447391104497583,0.166801262823712,0.415703830264852,0.208162195150547,0.28058984167387,0.207541635114305,True,0.21036747512769,0.0289222261476665,1.36945750665856,35.3346173802413
20289,1011:1194,Colon,SNU-C1,SIDM01197,910905,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,10.0,0.979339632657395,0.0953936333137623,0.616677011696618,10.412653200026,26.6226,0.908004185170224,0.862685418985531,0.12859185957137,0.603936238103226,0.402494599812176,0.20144163829105,7.93073113270701,4.7656,2.481922067319,21.857,0.889244485155984,0.790564068221667,0.84486202132818,0.734666593622728,0.0986804169343174,0.110195427705452,True,0.21036747512769,0.0289222261476665,1.36945750665856,35.3346173802413
20289,1053:1194,Colon,SNU-C1,SIDM01197,910905,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,10.0,0.450637544281325,0.0953936333137623,0.616677011696618,10.412653200026,26.6226,0.908004185170224,0.862685418985531,0.0586214470575143,0.27789781416571,0.199108620711635,0.0787891934540748,8.30563572575404,6.1798,2.10701747427196,20.4428,0.409180776202275,0.350271137716726,0.388758438698945,0.346993356245689,0.0589096384855488,0.0417650824532562,True,0.21036747512769,0.0289222261476665,1.36945750665856,35.3346173802413
20292,1053:1549,Colon,SNU-C1,SIDM01197,910905,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.431391709882768,0.0542745432699108,0.935419790140257,16.9419640065587,1229.5308,0.972134162380534,0.980872629888713,0.0282633901549464,0.403532342726786,0.330006850270294,0.0735254924564914,12.5064411795638,56.8217,4.43552282699484,1172.7091,0.419370618544791,0.401791813122465,0.423140320984899,0.398407266156099,0.0175788054223264,0.0247330548288,True,0.21036747512769,0.0289222261476665,1.36945750665856,35.3346173802413
20292,1510:1549,Colon,SNU-C1,SIDM01197,910905,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.357692592779835,0.0542745432699108,0.935419790140257,16.9419640065587,1229.5308,0.972134162380534,0.980872629888713,0.0942447582638407,0.334592730072838,0.199239092155122,0.135353637917716,9.68050986010538,8.0135,7.26145414645328,1221.5173,0.347725189071747,0.231459969339787,0.350850874171669,0.298384241842078,0.11626521973196,0.0524666323295917,True,0.21036747512769,0.0289222261476665,1.36945750665856,35.3346173802413
20292,2171:1549,Colon,SNU-C1,SIDM01197,910905,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.05,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.436936206154013,0.0542745432699108,0.935419790140257,16.9419640065587,1229.5308,0.972134162380534,0.980872629888713,0.0412842228505176,0.408718774265267,0.340532687435486,0.0681860868297812,12.7494126810383,67.2443,4.19255132552039,1162.2865,0.42476061278326,0.395367109109839,0.428578765623884,0.405838873855969,0.0293935036734213,0.0227398917679147,True,0.21036747512769,0.0289222261476665,1.36945750665856,35.3346173802413
20292,1022:1549,Colon,SNU-C1,SIDM01197,910905,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.583075607873129,0.0542745432699108,0.935419790140257,16.9419640065587,1229.5308,0.972134162380534,0.980872629888713,0.0732385791090498,0.545420462752585,0.335239615910027,0.210180846842558,9.89749977412737,9.3142,7.04446423243129,1220.2166,0.566827717664265,0.442765077234012,0.571922904918476,0.491561540181943,0.124062640430253,0.0803613647365334,True,0.21036747512769,0.0289222261476665,1.36945750665856,35.3346173802413
20293,1011:1564,Colon,SNU-C1,SIDM01197,910905,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.934422454373305,0.159650447563463,0.131181782330276,3.38301966052003,0.1019,0.444839041151052,0.457720152615689,0.10717533313537,0.122579203014121,0.030271799538257,0.0923074034758639,-1.09211299880628,0.0046,4.47513265932631,0.0973,0.415667588633434,0.157926879799375,0.427703988423276,0.179021562420424,0.257740708834059,0.248682426002851,True,0.21036747512769,0.0289222261476665,1.36945750665856,35.3346173802413
20294,1053:1598,Colon,SNU-C1,SIDM01197,910905,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1598,LGK974,PORCN,WNT signaling,Targeted,Early clinical trials,10.0,0.430672667283365,0.0594828231412595,0.763398362237318,12.4803327157476,111.6052,0.91781834373059,0.922951326343388,0.0262396861092421,0.328774808864499,0.229673338000839,0.0991014708636595,9.39621308303045,13.1605,3.08411963271719,98.4447,0.395279274176054,0.357115954822442,0.397489909489027,0.354037720910351,0.0381633193536122,0.0434521885786756,True,0.21036747512769,0.0289222261476665,1.36945750665856,35.3346173802413
20294,1510:1598,Colon,SNU-C1,SIDM01197,910905,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1598,LGK974,PORCN,WNT signaling,Targeted,Early clinical trials,10.0,0.352879162367197,0.0594828231412595,0.763398362237318,12.4803327157476,111.6052,0.91781834373059,0.922951326343388,0.0308402587254446,0.269387374618795,0.141810210444919,0.127577164173876,7.81841447892397,4.4087,4.66191823682368,107.1965,0.323878968340899,0.249367706607031,0.325690290945748,0.26255541514358,0.0745112617338683,0.0631348758021679,True,0.21036747512769,0.0289222261476665,1.36945750665856,35.3346173802413
20294,1561:1598,Colon,SNU-C1,SIDM01197,910905,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1598,LGK974,PORCN,WNT signaling,Targeted,Early clinical trials,10.0,0.673583573259144,0.0594828231412595,0.763398362237318,12.4803327157476,111.6052,0.91781834373059,0.922951326343388,0.0218088918241775,0.514212596655991,0.412978855231388,0.101233741424603,10.367861645566,25.8088,2.11247107018163,85.7964,0.61822735957284,0.584480302784504,0.621684852342645,0.579992703049259,0.0337470567883361,0.0416921492933857,True,0.21036747512769,0.0289222261476665,1.36945750665856,35.3346173802413
20294,1786:1598,Colon,SNU-C1,SIDM01197,910905,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1598,LGK974,PORCN,WNT signaling,Targeted,Early clinical trials,10.0,0.376829023255711,0.0594828231412595,0.763398362237318,12.4803327157476,111.6052,0.91781834373059,0.922951326343388,0.0423708596906508,0.287670659196898,0.169116164523344,0.118554494673554,8.38923213938524,6.5485,4.09110057636241,105.0567,0.345860589994173,0.26564664513578,0.347794846818542,0.291777823486506,0.0802139448583929,0.0560170233320355,True,0.21036747512769,0.0289222261476665,1.36945750665856,35.3346173802413
20295,1011:2048,Colon,SNU-C1,SIDM01197,910905,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.925460263070712,0.0909027382626263,0.467889580258233,8.61786320446855,0.0767,0.785658801089597,0.785785155959856,0.116775813227976,0.433013214033829,0.263983399905224,0.169029814128606,6.2707966452579,0.0151,2.34706655921065,0.0616,0.727096000740198,0.636865023982966,0.727212937151669,0.603367205651235,0.0902309767572319,0.123845731500434,True,0.21036747512769,0.0289222261476665,1.36945750665856,35.3346173802413
20295,1053:2048,Colon,SNU-C1,SIDM01197,910905,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.244969459827175,0.0909027382626263,0.467889580258233,8.61786320446855,0.0767,0.785658801089597,0.785785155959856,0.0274602431578441,0.114618657734623,0.0592445358778744,0.0553741218567488,5.60526120944083,0.0095,3.01260199502773,0.0672,0.192462412111385,0.142349005041182,0.192493365195699,0.149139332252528,0.0501134070702024,0.0433540329431704,True,0.21036747512769,0.0289222261476665,1.36945750665856,35.3346173802413
19641,1022:1003,Colon,COLO-320-HSR,SIDM00842,910569,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.1,0.786148782880852,0.0576163205236174,0.683768939778373,10.8166922543053,0.3523,0.902877703289528,0.912003641462914,0.0449792918520419,0.537544119778499,0.2939164182943,0.243627701484198,7.78520257651619,0.0431,3.03148967778912,0.3092,0.709796207531322,0.618532653644473,0.716970552718975,0.608331148218714,0.0912635538868486,0.108639404500261,True,0.23045812477545,0.0284234415112103,1.38021306343624,35.6205725130981
19644,1089:1011,Colon,COLO-320-HSR,SIDM00842,910569,1089,Oxaliplatin,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved in colon,1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.946582353543685,0.115260297087967,0.715475841394468,11.1723822233704,45.0767,0.925863245893509,0.922464514366493,0.082515804603324,0.677256805850824,0.491737896597516,0.185518909253308,9.18373210007463,11.3582,1.98865012329582,33.7185,0.876405810357473,0.832846009951536,0.873188631069567,0.803475888220426,0.0435598004059371,0.0697127428491412,True,0.23045812477545,0.0284234415112103,1.38021306343624,35.6205725130981
19644,2048:1011,Colon,COLO-320-HSR,SIDM00842,910569,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.968431959201936,0.115260297087967,0.715475841394468,11.1723822233704,45.0767,0.925863245893509,0.922464514366493,0.107850998330562,0.692889670843299,0.492611230476004,0.200278440367295,9.08169816917793,10.5826,2.09068405419252,34.4941,0.896635557173715,0.864815141860603,0.893344116942205,0.817352841583338,0.0318204153131121,0.0759912753588676,True,0.23045812477545,0.0284234415112103,1.38021306343624,35.6205725130981
19644,2171:1011,Colon,COLO-320-HSR,SIDM00842,910569,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.468680801513755,0.115260297087967,0.715475841394468,11.1723822233704,45.0767,0.925863245893509,0.922464514366493,0.0373968814536269,0.335329790808487,0.191619431735372,0.143710359073116,8.13133949895472,5.4766,3.04104272441573,39.6001,0.433934328177496,0.357211143995385,0.432341407961284,0.372191689812395,0.076723184182111,0.0601497181488893,True,0.23045812477545,0.0284234415112103,1.38021306343624,35.6205725130981
19644,1786:1011,Colon,COLO-320-HSR,SIDM00842,910569,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.622390093747136,0.115260297087967,0.715475841394468,11.1723822233704,45.0767,0.925863245893509,0.922464514366493,0.0670895886977342,0.445305075999314,0.255823664620971,0.189481411378343,8.15262772159059,5.558,3.01975450177986,39.5187,0.576248112408689,0.45976048388401,0.574132775574968,0.495011271719248,0.116487628524679,0.0791215038557201,True,0.23045812477545,0.0284234415112103,1.38021306343624,35.6205725130981
19642,1179:1022,Colon,COLO-320-HSR,SIDM00842,910569,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.292472637436455,0.0639805451463482,0.467314146871462,8.69155065169181,0.8075,0.848707382798279,0.824598664642248,0.0447051175585141,0.136676601046863,0.115796463151599,0.0208801378952639,8.00469763221318,0.5016,0.686853019478626,0.3059,0.248223686658803,0.203245580164308,0.241172546274497,0.230123859185835,0.044978106494495,0.0110486870886618,True,0.23045812477545,0.0284234415112103,1.38021306343624,35.6205725130981
19641,1053:1032,Colon,COLO-320-HSR,SIDM00842,910569,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.939343201384596,0.164218664960135,0.529013520018838,9.27371135498524,12.0891,0.890887125384794,0.85298289308733,0.103437212334052,0.496925253470229,0.343359531599358,0.153565721870871,7.70091158952432,4.0638,1.57279976546092,8.0253,0.836848764431272,0.753858312547936,0.801243681518947,0.722073094055391,0.082990451883336,0.0791705874635559,True,0.23045812477545,0.0284234415112103,1.38021306343624,35.6205725130981
19641,2048:1032,Colon,COLO-320-HSR,SIDM00842,910569,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.953254447333269,0.164218664960135,0.529013520018838,9.27371135498524,12.0891,0.890887125384794,0.85298289308733,0.168228639641484,0.504284490657384,0.349706446445931,0.154578044211453,7.71434848730838,4.1019,1.55936286767686,7.9872,0.849242114345006,0.804272132362707,0.813109736334695,0.733547479197843,0.0449699819822991,0.0795622571368519,True,0.23045812477545,0.0284234415112103,1.38021306343624,35.6205725130981
19646,2048:1047,Colon,COLO-320-HSR,SIDM00842,910569,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.949910197888784,0.0483005948743831,0.952842777688873,16.0815420506278,1354.43,0.974040569140384,0.988787190061664,0.0227845717279336,0.905115071511336,0.87829005306536,0.0268250184459758,14.9051287220129,599.2677,1.1764133286149,755.1623,0.925251069783846,0.945958125681576,0.93925903538137,0.93262924306013,-0.02070705589773,0.0066297923212408,True,0.23045812477545,0.0284234415112103,1.38021306343624,35.6205725130981
19645,1194:1053,Colon,COLO-320-HSR,SIDM00842,910569,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,0.625,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,1.0,0.0773018639766423,0.684460480977838,10.8242310869722,35.4118,0.913798248993331,0.912236823530067,0.0417804182841801,0.684460480977838,0.603983643765829,0.0804768372120088,9.99437674385474,19.9222,0.82985434311745,15.4896,0.913798248993331,0.891283665785484,0.912236823530067,0.883421555346464,0.0225145832078474,0.0288152681836028,True,0.23045812477545,0.0284234415112103,1.38021306343624,35.6205725130981
19645,1022:1053,Colon,COLO-320-HSR,SIDM00842,910569,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.83636727565817,0.0773018639766423,0.684460480977838,10.8242310869722,35.4118,0.913798248993331,0.912236823530067,0.111518014446992,0.572460347771115,0.284444920229354,0.288015427541761,7.43839521505902,3.3877,3.38583587191317,32.0241,0.764270952011758,0.552821489586606,0.762965026850905,0.629267561836663,0.211449462425152,0.133697465014241,True,0.23045812477545,0.0284234415112103,1.38021306343624,35.6205725130981
19645,2048:1053,Colon,COLO-320-HSR,SIDM00842,910569,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.93705273775662,0.0773018639766423,0.684460480977838,10.8242310869722,35.4118,0.913798248993331,0.912236823530067,0.0405794655308893,0.641375567586496,0.615630666336245,0.0257449012502515,10.531036336773,28.8993,0.293194750199198,6.5125,0.856277150976407,0.876308412501774,0.854814012971252,0.845962215097033,-0.0200312615253677,0.008851797874219,True,0.23045812477545,0.0284234415112103,1.38021306343624,35.6205725130981
19645,1373:1053,Colon,COLO-320-HSR,SIDM00842,910569,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.911924168000345,0.0773018639766423,0.684460480977838,10.8242310869722,35.4118,0.913798248993331,0.912236823530067,0.034053106980109,0.624176054644831,0.615456462413464,0.008719592231367,10.7207604598381,32.961,0.103470627134106,2.4508,0.833314707933416,0.845829414199107,0.831890806316933,0.828931800745484,-0.012514706265691,0.0029590055714496,True,0.23045812477545,0.0284234415112103,1.38021306343624,35.6205725130981
19645,1179:1053,Colon,COLO-320-HSR,SIDM00842,910569,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.810236518140959,0.0773018639766423,0.684460480977838,10.8242310869722,35.4118,0.913798248993331,0.912236823530067,0.0881037022445397,0.554574876912569,0.277206485073335,0.277368391839235,7.45972169944263,3.4382,3.36450938752956,31.9736,0.740392711547662,0.552713887129518,0.73912758761697,0.61069920965541,0.187678824418144,0.12842837796156,True,0.23045812477545,0.0284234415112103,1.38021306343624,35.6205725130981
19643,2171:1059,Colon,COLO-320-HSR,SIDM00842,910569,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.545548342959394,0.0728582761275529,0.877712295940948,13.6432083212524,24.9888,0.946006150021834,0.969741545281281,0.0733608304650063,0.478834488645669,0.461749019264534,0.017085469381135,13.0204541235327,16.2285,0.622754197719729,8.7603,0.516092087573807,0.474173017523834,0.529040893127085,0.52444874865509,0.0419190700499735,0.004592144471995,True,0.23045812477545,0.0284234415112103,1.38021306343624,35.6205725130981
19498,1022:1073,Colon,COLO-320-HSR,SIDM00842,910569,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,20.0,0.646379320343948,0.0704274384397602,0.607047546673113,10.0245947468439,40.6878,0.875731634087252,0.884585639329054,0.0413729733249259,0.392382980635028,0.148516000873913,0.243866979761115,6.15030862493918,2.7745,3.87428612190474,37.9133,0.566054818445013,0.422245221103755,0.57177786433553,0.429576857017421,0.143809597341259,0.142201007318109,True,0.262882368562616,0.0363525112258181,1.26901169982246,38.7752195755996
19499,1022:1179,Colon,COLO-320-HSR,SIDM00842,910569,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,10.0,0.665027369246216,0.1126445821619,0.123121753384866,4.37504451526073,0.4053,0.541622794876302,0.529459266178605,0.0671436453276455,0.0818793357505188,0.0226356037302649,0.0592437320202539,1.11815473536026,0.0424,3.25688977990047,0.3629,0.36019398240037,0.174107349743071,0.35210490290979,0.18892623534564,0.186086632657299,0.16317866756415,True,0.262882368562616,0.0363525112258181,1.26901169982246,38.7752195755996
19642,2048:1372,Colon,COLO-320-HSR,SIDM00842,910569,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.950468500796917,0.0454428727826166,0.940179043382936,15.4896429973718,89.8622,0.971092930918482,0.985682897954008,0.038639427330528,0.893610565844858,0.872113628639483,0.0214969372053755,14.6767804682522,51.1542,0.812862529119549,38.708,0.922993242184574,0.950468500796916,0.936860546279506,0.93149223674739,-0.0274752586123429,0.0053683095321166,True,0.23045812477545,0.0284234415112103,1.38021306343624,35.6205725130981
19499,2048:1549,Colon,COLO-320-HSR,SIDM00842,910569,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.01,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.869480343586352,0.0418115774838794,0.95410762279357,16.1487179028978,709.4937,0.980058336851687,0.989095009580064,0.0922245256452858,0.829577823684911,0.445107599776583,0.384470223908328,9.11238228125305,5.4051,7.03633562164478,704.0886,0.852141459460474,0.751324100960703,0.85999866876922,0.735108337957009,0.100817358499771,0.124890330812211,True,0.262882368562616,0.0363525112258181,1.26901169982246,38.7752195755996
19502,1047:2048,Colon,COLO-320-HSR,SIDM00842,910569,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.976851596126218,0.0873799192215445,0.422905697966118,8.26767449998413,0.0602,0.822527152500898,0.80182075775398,0.0617442408270096,0.413116106069074,0.274312229976125,0.13880387609295,6.78449478314674,0.0215,1.48317971683739,0.0387,0.803486961777655,0.703284174935903,0.783259887019109,0.692870759710354,0.100202786841752,0.090389127308755,True,0.262882368562616,0.0363525112258181,1.26901169982246,38.7752195755996
18408,1011:1003,Colon,HCT-116,SIDM00783,905936,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.1,0.94900054478848,0.0808205732744525,0.348570231820329,7.88872605272618,0.0463,0.818340159867278,0.813899853649169,0.112927872494131,0.330793339894539,0.0957644700520881,0.235028869842451,5.113224541792,0.0068,2.77550151093418,0.0395,0.776605257536338,0.589458299797753,0.772391404516325,0.567528571214216,0.187146957738586,0.204862833302108,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
18411,1073:1011,Colon,HCT-116,SIDM00783,905936,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.918801329587001,0.1509399829445,0.442407103581435,8.58878142802463,7.5199,0.872292479615788,0.855877299925651,0.0964025016175112,0.406484234989357,0.245859089668884,0.160625145320472,7.21063592456806,2.893,1.37814550345656,4.6269,0.801463490059728,0.715298652698294,0.786381201135021,0.705147663964228,0.086164837361434,0.0812335371707924,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
18411,1089:1011,Colon,HCT-116,SIDM00783,905936,1089,Oxaliplatin,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved in colon,1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.924258319760261,0.1509399829445,0.442407103581435,8.58878142802463,7.5199,0.872292479615788,0.855877299925651,0.0797615768889726,0.408898446206181,0.143794536015723,0.265103910190458,5.99402950377442,1.2448,2.59475192425021,6.2751,0.806223581549199,0.617734092441234,0.791051715150231,0.621831178551648,0.188489489107966,0.169220536598583,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
18411,1047:1011,Colon,HCT-116,SIDM00783,905936,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.464492473710886,0.1509399829445,0.442407103581435,8.58878142802463,7.5199,0.872292479615788,0.855877299925651,0.0588535179706934,0.205494769929809,0.0315263767469994,0.17396839318281,4.34429034453309,0.3967,4.24449108349154,7.1232,0.40517329165614,0.235279603239823,0.39754856423546,0.246418641514787,0.169893688416317,0.151129922720673,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
18411,2048:1011,Colon,HCT-116,SIDM00783,905936,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.780043770082816,0.1509399829445,0.442407103581435,8.58878142802463,7.5199,0.872292479615788,0.855877299925651,0.141960512511925,0.345096904989082,0.134077823022683,0.211019081966398,6.20581811446049,1.4417,2.38296331356414,6.0782,0.680426314414387,0.576288092766004,0.667621755762306,0.538323778643226,0.104138221648383,0.12929797711908,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
18411,1083:1011,Colon,HCT-116,SIDM00783,905936,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.590102277815777,0.1509399829445,0.442407103581435,8.58878142802463,7.5199,0.872292479615788,0.855877299925651,0.0852067125273722,0.261065439545285,0.0527067393284055,0.20835870021688,4.87358870202885,0.5726,3.71519272599578,6.9473,0.514741779142848,0.327178342789377,0.505055144216943,0.340569320626644,0.187563436353471,0.164485823590299,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
18411,1017:1011,Colon,HCT-116,SIDM00783,905936,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.950526274351568,0.1509399829445,0.442407103581435,8.58878142802463,7.5199,0.872292479615788,0.855877299925651,0.139002916400091,0.42051957591393,0.409104277115547,0.0114152987983828,8.50200505647762,7.0809,0.0867763715470105,0.439,0.829136920794086,0.841319991536308,0.813533861200408,0.808923239309889,-0.0121830707422221,0.0046106218905196,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
18411,2171:1011,Colon,HCT-116,SIDM00783,905936,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.813813902106574,0.1509399829445,0.442407103581435,8.58878142802463,7.5199,0.872292479615788,0.855877299925651,0.0907698591597043,0.360037051285275,0.120407768861939,0.239629282423336,5.88877374368249,1.1573,2.70000768434214,6.3626,0.709883746614343,0.545437713130041,0.696524845176932,0.540428246164489,0.164446033484302,0.156096599012443,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
18411,1564:1011,Colon,HCT-116,SIDM00783,905936,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.915468750768867,0.1509399829445,0.442407103581435,8.58878142802463,7.5199,0.872292479615788,0.855877299925651,0.0982459738350943,0.405009878446969,0.270400879817555,0.134608998629415,7.45490014721957,3.4267,1.13388128080505,4.0932,0.798556506618943,0.714471363687808,0.783528922574367,0.718456540481903,0.084085142931135,0.0650723820924634,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
18411,1003:1011,Colon,HCT-116,SIDM00783,905936,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.563699986713971,0.1509399829445,0.442407103581435,8.58878142802463,7.5199,0.872292479615788,0.855877299925651,0.0592156995415973,0.249384878411022,0.0324733362110484,0.216911542199973,4.03341405648655,0.3198,4.55536737153808,7.2001,0.491711259170117,0.271451424803539,0.482458022596879,0.283520333498872,0.220259834366578,0.198937689098007,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
22209,1011:1017,Colon,HCT-116,SIDM00783,905936,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.953810674312922,0.0790091378759592,0.720273285816417,10.6808128502988,32.0609,0.924201208533985,0.941937171314498,0.0526877058644167,0.687004348434141,0.466185119286633,0.220819229147508,8.92009268118316,9.4612,1.76072016911563,22.5997,0.881512977912618,0.848527587707406,0.898429728531887,0.833104233709764,0.0329853902052117,0.0653254948221234,True,0.0870109011674361,0.0253393311293597,2.23759213652962,22.1108907544919
22209,1003:1017,Colon,HCT-116,SIDM00783,905936,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.0025,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.904225793003624,0.0790091378759592,0.720273285816417,10.6808128502988,32.0609,0.924201208533985,0.941937171314498,0.048326631504021,0.651289683046675,0.371733265910666,0.27955641713601,8.36132380361081,6.423,2.31948904668798,25.6379,0.835686570681551,0.772281585190429,0.851723885691442,0.762214301392267,0.0634049854911218,0.0895095842991751,True,0.0870109011674361,0.0253393311293597,2.23759213652962,22.1108907544919
18409,1083:1022,Colon,HCT-116,SIDM00783,905936,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.962187087892145,0.0619374599067511,0.706823611755461,10.5638602954691,2.9564,0.946112138599697,0.938604287095568,0.0707709305346737,0.680096552648395,0.415640241739822,0.264456310908573,8.51343000869508,0.7137,2.05043028677401,2.2427,0.910336883458651,0.791439537680783,0.903112925683567,0.819467002671419,0.118897345777869,0.0836459230121483,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
18409,1372:1022,Colon,HCT-116,SIDM00783,905936,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.373711552619575,0.0619374599067511,0.706823611755461,10.5638602954691,2.9564,0.946112138599697,0.938604287095568,0.0505447665917006,0.264148149377309,0.155898323373721,0.108249826003587,8.40567732703262,0.6624,2.15818296843648,2.294,0.353573036268319,0.302436821609213,0.350767265425874,0.315981687497688,0.0511362146591056,0.0347855779281859,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
18409,1073:1022,Colon,HCT-116,SIDM00783,905936,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,2.5,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.90747833702865,0.0619374599067511,0.706823611755461,10.5638602954691,2.9564,0.946112138599697,0.938604287095568,0.103968669852261,0.64142711576843,0.258884193669315,0.382542922099115,7.36786418125624,0.3226,3.19599611421286,2.6338,0.858576270179073,0.671258002463446,0.851763057581448,0.706649194076928,0.187318267715627,0.145113863504521,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
18409,1053:1022,Colon,HCT-116,SIDM00783,905936,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.944475265031906,0.0619374599067511,0.706823611755461,10.5638602954691,2.9564,0.946112138599697,0.938604287095568,0.067973865683745,0.667577418043548,0.458687573378161,0.208889844665387,8.89799022465625,0.9317,1.66587007081284,2.0247,0.893579512853852,0.804572614102862,0.88648853281467,0.823887647485058,0.0890068987509904,0.0626008853296122,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
18409,2048:1022,Colon,HCT-116,SIDM00783,905936,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.71497253365498,0.0619374599067511,0.706823611755461,10.5638602954691,2.9564,0.946112138599697,0.938604287095568,0.103482760641024,0.505359468543966,0.25816354745572,0.247195921088246,7.98585847585001,0.4951,2.57800181961908,2.4613,0.676444192856357,0.530813461030223,0.671076285244145,0.586351537218259,0.145630731826134,0.084724748025886,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
18409,1510:1022,Colon,HCT-116,SIDM00783,905936,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.797384966076101,0.0619374599067511,0.706823611755461,10.5638602954691,2.9564,0.946112138599697,0.938604287095568,0.0540565503649089,0.563610521681415,0.346569211151584,0.217041310529831,8.53266490570083,0.7233,2.03119538976826,2.2331,0.754415595541506,0.700380942503496,0.748428947624582,0.679971779699602,0.0540346530380105,0.0684571679249802,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
18409,1373:1022,Colon,HCT-116,SIDM00783,905936,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.831018958605749,0.0619374599067511,0.706823611755461,10.5638602954691,2.9564,0.946112138599697,0.938604287095568,0.0579961165083257,0.587383821758977,0.474766847180265,0.112616974578712,9.51035689884173,1.4244,1.05350339662736,1.532,0.786237124143378,0.726344341074807,0.779997957205051,0.748741482689447,0.0598927830685715,0.0312564745156039,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
18409,1017:1022,Colon,HCT-116,SIDM00783,905936,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,2.5,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.975890251711468,0.0619374599067511,0.706823611755461,10.5638602954691,2.9564,0.946112138599697,0.938604287095568,0.0722575829459127,0.689782272391646,0.590705403715548,0.0990768686760978,9.75987761650398,1.6933,0.803982678965118,1.2631,0.923301613085334,0.910752307135077,0.915974773991157,0.889231482736122,0.0125493059502572,0.0267432912550356,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
18409,1011:1022,Colon,HCT-116,SIDM00783,905936,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.968025624064339,0.0619374599067511,0.706823611755461,10.5638602954691,2.9564,0.946112138599697,0.938604287095568,0.103854813098258,0.68422336787299,0.48024190619758,0.203981461675409,8.97230893990326,0.981,1.59155135556584,1.9754,0.915860793402817,0.872145614359373,0.908593000765151,0.84806716074108,0.043715179043444,0.0605258400240716,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
18409,2171:1022,Colon,HCT-116,SIDM00783,905936,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.811329651914799,0.0619374599067511,0.706823611755461,10.5638602954691,2.9564,0.946112138599697,0.938604287095568,0.0830688086834943,0.573466954890719,0.251800866100023,0.321666088790695,7.58106277074775,0.374,2.98279752472135,2.5824,0.767608832082458,0.591693224352404,0.761517489534985,0.64378064311318,0.175915607730053,0.117736846421805,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
18409,1179:1022,Colon,HCT-116,SIDM00783,905936,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.695669590844359,0.0619374599067511,0.706823611755461,10.5638602954691,2.9564,0.946112138599697,0.938604287095568,0.0677019138647607,0.491715692789053,0.124706398078886,0.367009294710167,6.29638590703624,0.1535,4.26747438843286,2.8029,0.658181444352532,0.468064154063425,0.652958460368535,0.485185190261328,0.190117290289107,0.167773270107207,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
18413,1073:1047,Colon,HCT-116,SIDM00783,905936,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,10,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.549910338840343,0.0677643911740543,0.462186410025099,8.73069159425539,8.2972,0.854225991666866,0.863588347503356,0.0771735637876996,0.254161085344304,0.265452050223914,-0.0112909648796105,8.87710922796392,9.1835,-0.146417633708532,-0.8863,0.469747704523754,0.426346636999009,0.474896160794142,0.479111617398419,0.0434010675247448,-0.0042154566042761,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
18413,1011:1047,Colon,HCT-116,SIDM00783,905936,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.977400784964645,0.0677643911740543,0.462186410025099,8.73069159425539,8.2972,0.854225991666866,0.863588347503356,0.132939633829761,0.451741359958523,0.150465299218792,0.301276060739731,5.9718312016567,1.2258,2.75886039259869,7.0714,0.834921154792397,0.679825974770587,0.844071928736101,0.655792802366527,0.155095180021811,0.188279126369574,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
18412,1003:1053,Colon,HCT-116,SIDM00783,905936,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.0025,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.965405113798602,0.0522753789515214,0.73492832545634,10.8122385265803,35.1187,0.931375107780982,0.945498973640669,0.056956477536051,0.709503563670994,0.620221596594128,0.0892819670768658,10.0413819452274,20.582,0.770856581352817,14.5367,0.899154291916484,0.893207456619857,0.912789544244031,0.889837107528617,0.0059468352966275,0.0229524367154138,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
18412,1054:1053,Colon,HCT-116,SIDM00783,905936,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.75216016691743,0.0522753789515214,0.73492832545634,10.8122385265803,35.1187,0.931375107780982,0.945498973640669,0.0545632180926884,0.552783811947588,0.321597805585166,0.231186006362422,8.48145905555863,6.9808,2.33077947102162,28.1379,0.700543256531283,0.612358411362494,0.711166665833824,0.639233307422558,0.0881848451687891,0.0719333584112661,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
18412,1510:1053,Colon,HCT-116,SIDM00783,905936,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.790144439796714,0.0522753789515214,0.73492832545634,10.8122385265803,35.1187,0.931375107780982,0.945498973640669,0.0472578907219444,0.580699530008437,0.363020564007749,0.217678966000688,8.71101753392816,8.1848,2.10122099265209,26.9339,0.735920862778209,0.666406966610096,0.747080756855674,0.681527861357161,0.069513896168113,0.0655528954985138,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
18412,1786:1053,Colon,HCT-116,SIDM00783,905936,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.502146516712548,0.0522753789515214,0.73492832545634,10.8122385265803,35.1187,0.931375107780982,0.945498973640669,0.0744654100368269,0.369041698661287,0.149123890848011,0.219917807813276,7.46857534627596,3.4594,3.34366318030429,31.6593,0.467686766124994,0.352912347753628,0.474779016168951,0.394560250361752,0.114774418371366,0.0802187658071994,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
18412,1372:1053,Colon,HCT-116,SIDM00783,905936,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.872591456079446,0.0522753789515214,0.73492832545634,10.8122385265803,35.1187,0.931375107780982,0.945498973640669,0.0998238262540726,0.641292177623977,0.355052030956862,0.286240146667114,8.33035060071221,6.2866,2.48188792586804,28.8321,0.812709961454758,0.683435497909552,0.825034326130732,0.733964923163162,0.129274463545206,0.0910694029675702,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
18412,1564:1053,Colon,HCT-116,SIDM00783,905936,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.82984578796036,0.0522753789515214,0.73492832545634,10.8122385265803,35.1187,0.931375107780982,0.945498973640669,0.123490349050999,0.609877175332705,0.275601932183838,0.334275243148867,7.75843374469255,4.2291,3.0538047818877,30.8896,0.772897710203175,0.601201701329495,0.784618340796552,0.668353550493781,0.171696008873679,0.116264790302771,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
18412,2048:1053,Colon,HCT-116,SIDM00783,905936,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.763827307303993,0.0522753789515214,0.73492832545634,10.8122385265803,35.1187,0.931375107780982,0.945498973640669,0.145136757280737,0.561358323894749,0.282698800819525,0.278659523075224,8.05502262778468,5.1944,2.75721589879557,29.9243,0.711409740666314,0.547278583513103,0.722197935094641,0.62973629086204,0.164131157153211,0.0924616442326017,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
18412,1179:1053,Colon,HCT-116,SIDM00783,905936,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.805245073839556,0.0522753789515214,0.73492832545634,10.8122385265803,35.1187,0.931375107780982,0.945498973640669,0.086491996931644,0.591797413698872,0.391761586547581,0.200035827151291,8.90410033526619,9.3569,1.90813819131406,25.7618,0.749985217437422,0.62462988304428,0.761358390844505,0.702684916478812,0.125355334393141,0.0586734743656924,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
18412,1059:1053,Colon,HCT-116,SIDM00783,905936,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.790465388447997,0.0522753789515214,0.73492832545634,10.8122385265803,35.1187,0.931375107780982,0.945498973640669,0.099022454939721,0.580935404263282,0.358220477724486,0.222714926538795,8.66618289220845,7.9343,2.1460556343718,27.1844,0.736219786362889,0.595933061761484,0.747384213476053,0.679892956056563,0.140286724601405,0.0674912574194904,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
18413,1372:1054,Colon,HCT-116,SIDM00783,905936,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.371459444642961,0.0513208846983554,0.783525962197783,11.2859439361876,19.5073,0.946089312339486,0.956824051300593,0.0446680029089402,0.29104811878133,0.195010948625271,0.0960371701560588,9.17775745016059,4.5245,2.10818648602703,14.9828,0.351433810544266,0.306765915492431,0.355421330717146,0.329136925861411,0.0446678950518351,0.0262844048557354,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
18413,1053:1054,Colon,HCT-116,SIDM00783,905936,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.953111168427668,0.0513208846983554,0.783525962197783,11.2859439361876,19.5073,0.946089312339486,0.956824051300593,0.0869675320586447,0.746787345323742,0.425676443215342,0.3211109021084,8.61908638101445,3.0718,2.66685755517317,16.4355,0.901728289920817,0.774657431323329,0.911959689514803,0.817337752795453,0.127070858597487,0.0946219367193507,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
18413,1561:1054,Colon,HCT-116,SIDM00783,905936,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.826115175379317,0.0513208846983554,0.783525962197783,11.2859439361876,19.5073,0.946089312339486,0.956824051300593,0.0903259730089374,0.64728268767527,0.379411667464597,0.267871020210673,8.70984700004768,3.2713,2.57609693613993,16.236,0.781578738187832,0.64049388320526,0.790446868947338,0.712502035931051,0.141084854982572,0.0779448330162866,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
18413,2171:1054,Colon,HCT-116,SIDM00783,905936,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.808828496061607,0.0513208846983554,0.783525962197783,11.2859439361876,19.5073,0.946089312339486,0.956824051300593,0.10125606348966,0.633738125629656,0.381354029797805,0.252384095831852,8.79711483762484,3.4752,2.48882909856278,16.0321,0.765223995639506,0.653129589304378,0.773906558409032,0.701337295947006,0.112094406335128,0.0725692624620266,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
18413,1025:1054,Colon,HCT-116,SIDM00783,905936,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.941923833172031,0.0513208846983554,0.783525962197783,11.2859439361876,19.5073,0.946089312339486,0.956824051300593,0.176651893962137,0.73802177770314,0.383350062815053,0.354671714888087,8.33103165442196,2.5158,2.95491228176565,16.9915,0.8911440716019,0.671000914694032,0.901255378072247,0.79232034025669,0.220143156907868,0.108935037815557,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
18409,2171:1372,Colon,HCT-116,SIDM00783,905936,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.811329651914799,0.100503309005755,0.0563557051874511,3.99201406949641,0.0311,0.495971890734475,0.49929180020899,0.067265004829162,0.0457230546731477,0.0070557449770081,0.0386673096961396,0.583478759987784,0.0029,3.40853530950862,0.0282,0.402396701469126,0.197485140506193,0.405090242467473,0.176775359552415,0.204911560962933,0.228314882915058,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
18409,1561:1372,Colon,HCT-116,SIDM00783,905936,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.780018926402389,0.100503309005755,0.0563557051874511,3.99201406949641,0.0311,0.495971890734475,0.49929180020899,0.0331119608334571,0.0439585166569652,0.0057171835560626,0.0382413331009025,0.277128627952774,0.0024,3.71488544154363,0.0287,0.386867461736468,0.149921713343649,0.389457053960532,0.1536343623022,0.236945748392819,0.235822691658333,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
22209,1372:1373,Colon,HCT-116,SIDM00783,905936,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10.0,0.296104065070342,0.140361091337989,0.510098237157793,9.0717920883088,10.5102,0.796504526662957,0.880987307575662,0.0814009977844927,0.151042161607638,0.0427830957989304,0.108259065808707,5.83940154163459,1.1183,3.23239054667421,9.3919,0.23584822819183,0.14417362742961,0.260863923048529,0.195415323831523,0.0916746007622204,0.0654485992170062,True,0.0870109011674361,0.0253393311293597,2.23759213652962,22.1108907544919
22209,1564:1373,Colon,HCT-116,SIDM00783,905936,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.5,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10.0,0.28890001168981,0.140361091337989,0.510098237157793,9.0717920883088,10.5102,0.796504526662957,0.880987307575662,0.0934333196952099,0.147367386677838,0.0412233044087866,0.106144082269051,5.81344470229716,1.0984,3.25834738601164,9.4118,0.230110167063915,0.150360359185313,0.254517243457183,0.190034513868235,0.0797498078786018,0.0644827295889479,True,0.0870109011674361,0.0253393311293597,2.23759213652962,22.1108907544919
22209,1053:1373,Colon,HCT-116,SIDM00783,905936,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10.0,0.818061686003221,0.140361091337989,0.510098237157793,9.0717920883088,10.5102,0.796504526662957,0.880987307575662,0.110285342235189,0.417291823916575,0.205487724948396,0.21180409896818,7.05890273193592,2.6042,2.01288935637288,7.906,0.651589835991096,0.589186231066624,0.720701962182784,0.61876617296083,0.0624036049244722,0.101935789221955,True,0.0870109011674361,0.0253393311293597,2.23759213652962,22.1108907544919
22209,1510:1373,Colon,HCT-116,SIDM00783,905936,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10.0,0.666715067154454,0.140361091337989,0.510098237157793,9.0717920883088,10.5102,0.796504526662957,0.880987307575662,0.136057195389421,0.340090180442027,0.246926342058949,0.0931638383830782,8.05696128352571,5.2014,1.01483080478309,5.3088,0.53104156898292,0.466930459650835,0.587367511932529,0.549752861077807,0.0641111093320851,0.0376146508547225,True,0.0870109011674361,0.0253393311293597,2.23759213652962,22.1108907544919
22209,1561:1373,Colon,HCT-116,SIDM00783,905936,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10.0,0.707515732739963,0.140361091337989,0.510098237157793,9.0717920883088,10.5102,0.796504526662957,0.880987307575662,0.0874044189924092,0.360902528032059,0.118571966676368,0.242330561355691,6.15164458205366,1.3885,2.92014750625514,9.1217,0.563539483812639,0.454693605510808,0.623312380454001,0.485154733131807,0.108845878301831,0.138157647322194,True,0.0870109011674361,0.0253393311293597,2.23759213652962,22.1108907544919
18411,1786:1510,Colon,HCT-116,SIDM00783,905936,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.480096176084164,0.0473209471209297,0.784951548347036,11.3009161135202,49.2771,0.945652646933634,0.957145611055651,0.0616246213179356,0.376852236772756,0.187549127829884,0.189303108942872,8.20992838508514,5.7832,3.09098772843506,43.4939,0.454004219696706,0.37186874141944,0.459521947823559,0.400379581489311,0.0821354782772662,0.0591423663342476,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
18411,1564:1510,Colon,HCT-116,SIDM00783,905936,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.915468750768867,0.0473209471209297,0.784951548347036,11.3009161135202,49.2771,0.945652646933634,0.957145611055651,0.134548484735958,0.718598613379349,0.364993079759838,0.353605533619511,8.26978167687317,6.0281,3.03113443664703,43.249,0.865715447349606,0.672602979022837,0.876236896857021,0.766748368571003,0.193112468326769,0.109488528286017,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
18411,1373:1510,Colon,HCT-116,SIDM00783,905936,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.784631878595224,0.0473209471209297,0.784951548347036,11.3009161135202,49.2771,0.945652646933634,0.957145611055651,0.130052565603196,0.615898007985764,0.358120524422685,0.25777748356308,8.68941722911286,8.0632,2.61149888440734,41.2139,0.741989212862083,0.593961094079844,0.751006958891769,0.675861548475248,0.148028118782239,0.075145410416521,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
18411,1179:1510,Colon,HCT-116,SIDM00783,905936,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.25,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.831742659469248,0.0473209471209297,0.784951548347036,11.3009161135202,49.2771,0.945652646933634,0.957145611055651,0.0777367729168787,0.652877688376667,0.421513218627216,0.231364469749451,9.04822077201292,10.3399,2.25269534150728,38.9372,0.786539647494714,0.683043509282997,0.796098836038745,0.731797808840299,0.103496138211717,0.064301027198446,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
18411,1059:1510,Colon,HCT-116,SIDM00783,905936,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.756286874880057,0.0473209471209297,0.784951548347036,11.3009161135202,49.2771,0.945652646933634,0.957145611055651,0.0932286850754391,0.593648553431641,0.361687231113191,0.231961322318451,8.84522902807374,8.9827,2.45568708544646,40.2944,0.715184685071491,0.598822525723227,0.72387666299044,0.657674765064777,0.116362159348264,0.0662018979256633,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
18995,2171:1549,Colon,HCT-116,SIDM00783,905936,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.774676168171953,0.0419698602173015,0.911285533162634,13.1396368989795,88.1302,0.975296653802391,0.983553164201162,0.086101766127863,0.705951184940965,0.382194933167909,0.323756251773055,8.95280385151022,4.8391,4.18683304746929,83.2911,0.755539074598563,0.613020364609284,0.761935196436756,0.677919782879039,0.142518709989279,0.084015413557717,True,0.179796884489869,0.0327326016472857,1.59080944722518,30.9116686924603
18995,1372:1549,Colon,HCT-116,SIDM00783,905936,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.770026868977011,0.0419698602173015,0.911285533162634,13.1396368989795,88.1302,0.975296653802391,0.983553164201162,0.0700878289028539,0.701714345845269,0.446855729568678,0.254858616276591,9.57587607936788,7.4529,3.56376081961163,80.6773,0.75100462865121,0.648396219174591,0.757362363502253,0.695914838875851,0.102608409476619,0.0614475246264018,True,0.179796884489869,0.0327326016472857,1.59080944722518,30.9116686924603
18995,1564:1549,Colon,HCT-116,SIDM00783,905936,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.917110110942852,0.0419698602173015,0.911285533162634,13.1396368989795,88.1302,0.975296653802391,0.983553164201162,0.104148415306519,0.8357491764194,0.756008791897134,0.0797403845222654,11.7474319518864,33.576,1.39220494709314,54.5542,0.894454422370903,0.885734316806845,0.902026551538721,0.885751527496392,0.008720105564058,0.0162750240423288,True,0.179796884489869,0.0327326016472857,1.59080944722518,30.9116686924603
18995,2048:1549,Colon,HCT-116,SIDM00783,905936,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.77959635679445,0.0419698602173015,0.911285533162634,13.1396368989795,88.1302,0.975296653802391,0.983553164201162,0.0611968091166629,0.710434881653077,0.66402502861097,0.0464098530421074,12.1071391402284,43.0836,1.03249775875108,45.0466,0.760337718098161,0.744735300511718,0.766774463524879,0.757453133640339,0.0156024175864434,0.0093213298845399,True,0.179796884489869,0.0327326016472857,1.59080944722518,30.9116686924603
18996,1372:1561,Colon,HCT-116,SIDM00783,905936,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.323355127084174,0.0957718630068749,0.477746745975327,8.84171036153336,8.9609,0.799686186474646,0.869427880470666,0.0543197981004433,0.154481859758902,0.0054502483682439,0.149031611390658,1.77414791482413,0.0668,7.06756244670923,8.8941,0.258582628454967,0.0941714066363454,0.281133962780116,0.0996763390411838,0.164411221818622,0.181457623738932,True,0.179796884489869,0.0327326016472857,1.59080944722518,30.9116686924603
18996,1564:1561,Colon,HCT-116,SIDM00783,905936,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.401051759516892,0.0957718630068749,0.477746745975327,8.84171036153336,8.9609,0.799686186474646,0.869427880470666,0.0548723442964858,0.191601173076874,0.0049321419705534,0.186669031106321,1.20573910237263,0.045,7.63597125916073,8.9159,0.32071555214701,0.0973062445408173,0.348685581235803,0.105674982102795,0.223409307606193,0.243010599133008,True,0.179796884489869,0.0327326016472857,1.59080944722518,30.9116686924603
18996,2048:1561,Colon,HCT-116,SIDM00783,905936,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.798728893819998,0.0957718630068749,0.477746745975327,8.84171036153336,8.9609,0.799686186474646,0.869427880470666,0.129946317759396,0.381590129938977,0.172611682211417,0.208978447727559,6.71021831322105,2.0451,2.13149204831231,6.9158,0.638732463126027,0.505217251715725,0.694437169224601,0.583117715683075,0.133515211410302,0.111319453541526,True,0.179796884489869,0.0327326016472857,1.59080944722518,30.9116686924603
18996,1373:1561,Colon,HCT-116,SIDM00783,905936,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.73671906399932,0.0957718630068749,0.477746745975327,8.84171036153336,8.9609,0.799686186474646,0.869427880470666,0.173001298213062,0.351965135523664,0.156695225114698,0.195269910408966,6.67419045560227,1.9946,2.16751990593109,6.9663,0.589144058792787,0.437136838855524,0.640524094315262,0.53579636602097,0.152007219937264,0.104727728294292,True,0.179796884489869,0.0327326016472857,1.59080944722518,30.9116686924603
18996,1179:1561,Colon,HCT-116,SIDM00783,905936,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.636823393728683,0.0957718630068749,0.477746745975327,8.84171036153336,8.9609,0.799686186474646,0.869427880470666,0.151588179866564,0.304240304114843,0.0189335459078931,0.28530675820695,2.80613873542328,0.1366,6.03557162611008,8.8243,0.509258871188732,0.270884674012728,0.553672013443665,0.251535229863821,0.238374197176005,0.302136783579844,True,0.179796884489869,0.0327326016472857,1.59080944722518,30.9116686924603
18996,1786:1561,Colon,HCT-116,SIDM00783,905936,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.514701518965429,0.0957718630068749,0.477746745975327,8.84171036153336,8.9609,0.799686186474646,0.869427880470666,0.139211173589118,0.245896975834292,0.0574827431037004,0.188414232730591,5.31486734989633,0.7774,3.52684301163703,8.1835,0.411599694874172,0.26102997002148,0.447495850709145,0.316776620710674,0.150569724852692,0.130719229998471,True,0.179796884489869,0.0327326016472857,1.59080944722518,30.9116686924603
18996,1054:1561,Colon,HCT-116,SIDM00783,905936,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.770855906101128,0.0957718630068749,0.477746745975327,8.84171036153336,8.9609,0.799686186474646,0.869427880470666,0.150104132560651,0.368273900755676,0.0702459878726156,0.298027912883061,4.9127613137378,0.5883,3.92894904779556,8.3726,0.616442819871469,0.409508351028924,0.670203616589799,0.447530223415182,0.206934468842545,0.222673393174617,True,0.179796884489869,0.0327326016472857,1.59080944722518,30.9116686924603
18996,2171:1564,Colon,HCT-116,SIDM00783,905936,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.856353249382486,0.0587007476391837,0.0970114765150405,5.03550122374063,0.3203,0.586939338953733,0.591271056362451,0.102235586541832,0.0830760931410477,0.0091010989987717,0.0739749941422759,0.943331897138466,0.0188,4.09216932660216,0.3015,0.502627410103437,0.230744971460605,0.5063368903818,0.208765357200924,0.271882438642832,0.297571533180876,True,0.179796884489869,0.0327326016472857,1.59080944722518,30.9116686924603
18996,1561:1564,Colon,HCT-116,SIDM00783,905936,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.755824984152481,0.0587007476391837,0.0970114765150405,5.03550122374063,0.3203,0.586939338953733,0.591271056362451,0.0415264377002455,0.0733236976995892,0.0131073695510467,0.0602163281485425,1.82559453927498,0.0346,3.20990668446564,0.2857,0.443623416563173,0.221350160123867,0.44689743680497,0.236143379796124,0.222273256439306,0.210754057008846,True,0.179796884489869,0.0327326016472857,1.59080944722518,30.9116686924603
18997,1372:1598,Colon,HCT-116,SIDM00783,905936,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1598,LGK974,PORCN,WNT signaling,Targeted,Early clinical trials,10.0,0.321102640177264,0.0515925743000035,0.806479291805975,11.5364442243326,58.0157,0.928442616296152,0.961932045437071,0.0593733253257889,0.258962629847189,0.249186016691931,0.0097766131552579,11.2083888867499,46.2159,0.32805533758272,11.7998,0.298125375345781,0.274389551516705,0.308878919460959,0.306692876461467,0.023735823829076,0.0021860429994919,True,0.179796884489869,0.0327326016472857,1.59080944722518,30.9116686924603
18997,1059:1786,Colon,HCT-116,SIDM00783,905936,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10.0,0.588272629065146,0.0830752207822222,0.633618669446095,9.97344696716172,19.6353,0.939100390691448,0.919278917591767,0.0641452151177608,0.372740520499814,0.374031673319095,-0.0012911528192813,9.99026990757882,19.8656,-0.0168229404171036,-0.2303,0.552447055788164,0.544283875941934,0.540786625695871,0.54114608208448,0.0081631798462296,-0.0003594563886093,True,0.179796884489869,0.0327326016472857,1.59080944722518,30.9116686924603
18997,1073:1786,Colon,HCT-116,SIDM00783,905936,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,10,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10.0,0.530369218329913,0.0830752207822222,0.633618669446095,9.97344696716172,19.6353,0.939100390691448,0.919278917591767,0.060437227997262,0.336051838433365,0.317947211490631,0.0181046269427334,9.71672321100033,16.4345,0.256723756161387,3.2008,0.498069940144339,0.454446492834562,0.487557240950314,0.482367977813841,0.0436234473097767,0.0051892631364731,True,0.179796884489869,0.0327326016472857,1.59080944722518,30.9116686924603
18997,2171:1786,Colon,HCT-116,SIDM00783,905936,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10.0,0.831450164472594,0.0830752207822222,0.633618669446095,9.97344696716172,19.6353,0.939100390691448,0.919278917591767,0.1856913087118,0.526822346923862,0.236902545943554,0.289919800980308,7.36479757731142,3.2193,2.60864938985029,16.416,0.780815174296681,0.524355364634305,0.764334607227863,0.64726640784252,0.256459809662376,0.117068199385343,True,0.179796884489869,0.0327326016472857,1.59080944722518,30.9116686924603
18997,1053:1786,Colon,HCT-116,SIDM00783,905936,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10.0,0.923076974057734,0.0830752207822222,0.633618669446095,9.97344696716172,19.6353,0.939100390691448,0.919278917591767,0.0871426634965723,0.584878804098789,0.312226583844319,0.272652220254471,7.80734718744891,4.375,2.1660997797128,15.2603,0.866861946975898,0.703864465303904,0.848565201565678,0.746411213845313,0.162997481671993,0.102153987720365,True,0.179796884489869,0.0327326016472857,1.59080944722518,30.9116686924603
18997,1083:1786,Colon,HCT-116,SIDM00783,905936,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10.0,0.942898517427026,0.0830752207822222,0.633618669446095,9.97344696716172,19.6353,0.939100390691448,0.919278917591767,0.117685178584943,0.597438104034808,0.333656313630618,0.263781790404189,7.92999995760968,4.7632,2.04344700955203,14.8721,0.885476366098106,0.719262568511838,0.866786728499198,0.76992415332265,0.166213797586269,0.0968625751765476,True,0.179796884489869,0.0327326016472857,1.59080944722518,30.9116686924603
18997,1598:1786,Colon,HCT-116,SIDM00783,905936,1598,LGK974,PORCN,WNT signaling,Targeted,Early clinical trials,10,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10.0,0.874805317026724,0.0830752207822222,0.633618669446095,9.97344696716172,19.6353,0.939100390691448,0.919278917591767,0.0743158408926986,0.554292980998842,0.346222807558368,0.208070173440474,8.24807968045953,5.9381,1.72536728670218,13.6972,0.821530014998752,0.71654893639583,0.80419008493985,0.731556776226533,0.104981078602922,0.0726333087133162,True,0.179796884489869,0.0327326016472857,1.59080944722518,30.9116686924603
18998,2171:2048,Colon,HCT-116,SIDM00783,905936,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.862391913296365,0.128647277536441,0.0973102650650162,5.04155427647983,0.0064,0.603650458275944,0.591797962562243,0.143834764046195,0.0839195856727958,0.0137652622187796,0.0701543234540162,1.67573188846417,0.0006,3.36582238801567,0.0058,0.520583273674819,0.307176371046556,0.510361777218944,0.258996495908716,0.213406902628263,0.251365281310228,True,0.179796884489869,0.0327326016472857,1.59080944722518,30.9116686924603
18412,1011:2171,Colon,HCT-116,SIDM00783,905936,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.948993282517246,0.0971622248504556,0.29658626285767,7.46528339556575,3.4515,0.738323092230323,0.785518548221426,0.145774647959137,0.281458371138823,0.0712248323013348,0.210233538837488,4.5367388854421,0.4533,2.92854451012365,2.9982,0.700663654853937,0.520229430022712,0.745451825554833,0.519593865657451,0.180434224831225,0.225857959897381,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
19513,1073:1017,Colon,LoVo,SIDM00839,907790,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,10,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.512749199284606,0.0826314456364078,0.85860020712215,13.2310837164234,187.7946,0.963618177627276,0.964781680862593,0.0772342169490341,0.440246568707479,0.293331200846122,0.146915367861357,9.68103117373121,16.0329,3.55005254269222,171.7617,0.494094448994477,0.382051484732705,0.494691034346751,0.446835474877568,0.112042964261772,0.0478555594691827,True,0.355478053913173,0.0733685789284344,0.984059518889439,49.7967247983116
19512,1786:1025,Colon,LoVo,SIDM00839,907790,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.507141840607861,0.0738877942507815,0.745419503717525,11.5201252806947,57.3632,0.937905984784828,0.932204834052144,0.0814167554587801,0.378033419140304,0.369822934292953,0.0082104848473511,11.3239918270398,50.0716,0.196133453654872,7.2916,0.475651367440906,0.411162771226651,0.47276007536475,0.470197480567384,0.0644885962142551,0.0025625947973658,True,0.355478053913173,0.0733685789284344,0.984059518889439,49.7967247983116
21228,1083:1053,Colon,LoVo,SIDM00839,907790,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.751397082081143,0.0979860228766124,0.142539248454415,4.79085877685431,0.5407,0.560690424078551,0.56208452595919,0.127626617993685,0.107103575370686,0.0320272405097974,0.075076334860889,1.70047649586393,0.0635,3.09038228099038,0.4772,0.421301148603462,0.265972693208746,0.422348672688698,0.243669656724412,0.155328455394716,0.178679015964286,True,0.247728507760508,0.0639012483496555,1.30316855966593,37.6134756524681
22223,1073:1510,Colon,LoVo,SIDM00839,907790,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,10,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.401701501575306,0.0728624571611217,0.804681136345912,12.3211630179414,99.947,0.941665255760005,0.949824707235125,0.0763857073225525,0.323241620759476,0.199967454392864,0.123274166366612,8.97936757896973,9.858,3.34179543897166,90.089,0.378268347220089,0.280206552586583,0.381546011129675,0.337300183830388,0.0980617946335059,0.0442458272992876,True,0.244155980213523,0.0544773320729213,1.34695547496321,36.6231703743959
22223,1017:1510,Colon,LoVo,SIDM00839,907790,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.920474698561054,0.0728624571611217,0.804681136345912,12.3211630179414,99.947,0.941665255760005,0.949824707235125,0.115034607264983,0.740688626415769,0.677991291461521,0.0626973349542488,11.411917713399,53.2181,0.909245304542424,46.7289,0.866779042441108,0.803594962239699,0.874289611078093,0.855540136859518,0.0631840802014094,0.0187494742185752,True,0.244155980213523,0.0544773320729213,1.34695547496321,36.6231703743959
19515,1047:1549,Colon,LoVo,SIDM00839,907790,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.823815572098349,0.0951754775924349,0.409679845652179,8.1431179756506,2.7607,0.761934094485003,0.795380350415829,0.156788180574742,0.337500636423113,0.0815038533147022,0.255996783108411,3.81792730408098,0.1377,4.32519067156961,2.623,0.6276931719494,0.378011838512525,0.655246718413601,0.400092660018872,0.249681333436875,0.255154058394729,True,0.355478053913173,0.0733685789284344,0.984059518889439,49.7967247983116
21232,1083:1598,Colon,LoVo,SIDM00839,907790,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1598,LGK974,PORCN,WNT signaling,Targeted,Early clinical trials,10.0,0.774001114415391,0.0660551509628785,0.89059040292617,13.9185660428474,302.4377,0.972435952811191,0.973224876083576,0.121333833389193,0.689317964352507,0.599904400126391,0.0894135642261163,11.9020843704372,74.7506,2.01648167241014,227.6871,0.752666511173454,0.66976042432881,0.753277138665468,0.728478834527164,0.0829060868446445,0.0247983041383044,True,0.247728507760508,0.0639012483496555,1.30316855966593,37.6134756524681
21232,1089:1598,Colon,LoVo,SIDM00839,907790,1089,Oxaliplatin,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved in colon,1,1598,LGK974,PORCN,WNT signaling,Targeted,Early clinical trials,10.0,0.935861977526458,0.0660551509628785,0.89059040292617,13.9185660428474,302.4377,0.972435952811191,0.973224876083576,0.125189379268769,0.83346969564857,0.659567707263209,0.173901988385361,11.0410921810281,41.1557,2.87747386181929,261.282,0.910065833815706,0.824778194591196,0.910804157109517,0.86034268820934,0.0852876392245104,0.0504614689001762,True,0.247728507760508,0.0639012483496555,1.30316855966593,37.6134756524681
18380,1372:1003,Colon,LS-411N,SIDM00660,907794,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.1,0.481914848200283,0.0793960002551814,0.786793793760828,11.8861354392962,0.7393,0.94147345469313,0.947645613499237,0.0704250487220221,0.379167611685174,0.241526952993766,0.137640658691408,9.01044906498794,0.1007,2.87568637430826,0.6386,0.453710037003036,0.362927156426032,0.456684491977149,0.409474147515939,0.0907828805770043,0.0472103444612102,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18380,1089:1003,Colon,LS-411N,SIDM00660,907794,1089,Oxaliplatin,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved in colon,1,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.1,0.966982635481605,0.0793960002551814,0.786793793760828,11.8861354392962,0.7393,0.94147345469313,0.947645613499237,0.113038798121307,0.760815936271415,0.554361287792503,0.206454648478912,9.65270124901209,0.1572,2.23343419028411,0.5821,0.910388482455134,0.825522139336332,0.916356852844075,0.849782707367133,0.0848663431188021,0.066574145476942,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18380,1011:1003,Colon,LS-411N,SIDM00660,907794,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.1,0.91061779529176,0.0793960002551814,0.786793793760828,11.8861354392962,0.7393,0.94147345469313,0.947645613499237,0.0866073671697647,0.716468429823724,0.199836014430481,0.516632415393243,6.19529141031798,0.0143,5.69084402897822,0.725,0.857322481638374,0.597191691851984,0.862942959282582,0.612964722065147,0.26013078978639,0.249978237217435,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18380,1179:1003,Colon,LS-411N,SIDM00660,907794,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,1,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.1,0.422814799127742,0.0793960002551814,0.786793793760828,11.8861354392962,0.7393,0.94147345469313,0.947645613499237,0.0273510763881572,0.332668059863938,0.248629035447225,0.0840390244167133,9.78654847089361,0.1725,2.09958696840259,0.5668,0.398068909630177,0.378785262568699,0.400678589715966,0.373898027859319,0.0192836470614783,0.0267805618566471,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18380,1022:1003,Colon,LS-411N,SIDM00660,907794,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.1,0.657666671818238,0.0793960002551814,0.786793793760828,11.8861354392962,0.7393,0.94147345469313,0.947645613499237,0.106817551070678,0.517448055749929,0.131033818997259,0.38641423675267,5.92522494734838,0.0119,5.96091049194781,0.7274,0.619175713553249,0.378548373942251,0.623234936693196,0.42935031839129,0.240627339610998,0.193884618301905,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18383,1032:1011,Colon,LS-411N,SIDM00660,907794,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.897219874968032,0.185294466723005,0.410629591378298,8.2012420192324,5.7484,0.824524829476932,0.806674267119441,0.123702201144259,0.368425030634611,0.360943378931478,0.0074816517031333,8.12483841678383,5.4519,0.0764036024485719,0.2965,0.73978006441133,0.742545677626976,0.723764185084834,0.719802265099685,-0.0027656132156458,0.0039619199851482,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18383,1083:1011,Colon,LS-411N,SIDM00660,907794,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.998645134964774,0.185294466723005,0.410629591378298,8.2012420192324,5.7484,0.824524829476932,0.806674267119441,0.0909989558874854,0.410073243702511,0.267385970161318,0.142687273541193,6.7761708474447,2.1407,1.4250711717877,3.6077,0.823407709614797,0.740086499225474,0.805581332360104,0.714225491407425,0.0833212103893234,0.0913558409526792,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18383,1372:1011,Colon,LS-411N,SIDM00660,907794,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.535982142071991,0.185294466723005,0.410629591378298,8.2012420192324,5.7484,0.824524829476932,0.806674267119441,0.0464088879659497,0.220090127985087,0.0558971656352467,0.16419296234984,4.24664321376147,0.3708,3.95459880547093,5.3776,0.441930584294589,0.266753642746613,0.432363001645031,0.278713241795141,0.175176941547976,0.15364975984989,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18383,1564:1011,Colon,LS-411N,SIDM00660,907794,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.633646652105381,0.185294466723005,0.410629591378298,8.2012420192324,5.7484,0.824524829476932,0.806674267119441,0.0310286565681239,0.260194065832259,0.0771371928254723,0.183056873006787,4.63202858219689,0.4843,3.56921343703552,5.2641,0.522457397775817,0.336238445004764,0.511146448699795,0.349241533882585,0.186218952771054,0.16190491481721,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18383,1053:1011,Colon,LS-411N,SIDM00660,907794,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.992418721016472,0.185294466723005,0.410629591378298,8.2012420192324,5.7484,0.824524829476932,0.806674267119441,0.161372906172771,0.407516493887168,0.273574040662756,0.133942453224412,6.86459071973652,2.276,1.33665129949588,3.4724,0.818273876715821,0.773342223133625,0.800558644451576,0.715915332429305,0.0449316535821968,0.0846433120222705,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18383,2048:1011,Colon,LS-411N,SIDM00660,907794,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.979965893119869,0.185294466723005,0.410629591378298,8.2012420192324,5.7484,0.824524829476932,0.806674267119441,0.113672855122353,0.402402994256481,0.202731988848948,0.199671005407533,6.02953754568391,1.2759,2.17170447354849,4.4725,0.808006210917869,0.674541339883102,0.790513268634519,0.647489069131864,0.133464871034767,0.143024199502655,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18383,1510:1011,Colon,LS-411N,SIDM00660,907794,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.726647380351003,0.185294466723005,0.410629591378298,8.2012420192324,5.7484,0.824524829476932,0.806674267119441,0.0551531597102115,0.298382916869643,0.0808020637461196,0.217580853123524,4.40555324104793,0.4139,3.79568877818448,5.3345,0.59913880737377,0.385034769127644,0.586167742998907,0.387211280981379,0.214104038246126,0.198956462017528,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18383,1194:1011,Colon,LS-411N,SIDM00660,907794,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.879196933553774,0.185294466723005,0.410629591378298,8.2012420192324,5.7484,0.824524829476932,0.806674267119441,0.117338434477336,0.361024277566239,0.115558503090216,0.245465774476023,4.8260600842146,0.554,3.3751819350178,5.1944,0.724919701715067,0.495932217403212,0.70922554202815,0.498291273310636,0.228987484311855,0.210934268717515,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18383,2171:1011,Colon,LS-411N,SIDM00660,907794,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.768679291706114,0.185294466723005,0.410629591378298,8.2012420192324,5.7484,0.824524829476932,0.806674267119441,0.0618266938987215,0.315642463454241,0.104690008866729,0.210952454587513,4.91680850563266,0.59,3.28443351359974,5.1584,0.633795161916432,0.444245988371097,0.62007380428692,0.441239219464799,0.189549173545335,0.178834584822121,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18383,1179:1011,Colon,LS-411N,SIDM00660,907794,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.453881255439971,0.185294466723005,0.410629591378298,8.2012420192324,5.7484,0.824524829476932,0.806674267119441,0.0389574292900222,0.186377074455584,0.0374128302166717,0.148964244238913,3.67338109493415,0.2492,4.52786092429825,5.4992,0.374236364744418,0.189235753678012,0.36613432909129,0.214919901489721,0.185000611066406,0.15121442760157,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18383,1003:1011,Colon,LS-411N,SIDM00660,907794,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.956425509756071,0.185294466723005,0.410629591378298,8.2012420192324,5.7484,0.824524829476932,0.806674267119441,0.0843549615944456,0.392736616254916,0.165556154225589,0.227180462029327,5.54332465225126,0.9108,2.65791736698114,4.8376,0.788596580339012,0.618261134755901,0.771523847136816,0.596315867498834,0.170335445583111,0.175207979637982,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18383,1022:1011,Colon,LS-411N,SIDM00660,907794,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.695524956487029,0.185294466723005,0.410629591378298,8.2012420192324,5.7484,0.824524829476932,0.806674267119441,0.103157283322874,0.285603128675678,0.0381105288830678,0.24749259979261,2.70516539187297,0.1274,5.49607662735943,5.621,0.573477596144418,0.268792540110396,0.561062084537455,0.275405120252591,0.304685056034022,0.285656964284864,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18383,1059:1011,Colon,LS-411N,SIDM00660,907794,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.626547286240237,0.185294466723005,0.410629591378298,8.2012420192324,5.7484,0.824524829476932,0.806674267119441,0.069137185647425,0.25727885612801,0.0900331969187278,0.167245659209283,5.05462252339855,0.6491,3.14661949583385,5.0993,0.516603794346466,0.369204919506331,0.505419572943518,0.36653902111723,0.147398874840135,0.138880551826288,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
19682,1022:1017,Colon,LS-411N,SIDM00660,907794,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.444375831458889,0.0386869868893471,0.928661870278417,14.6725838559139,510.056,0.98164199034104,0.983824758247953,0.0259270681094691,0.412674890749139,0.34262557795963,0.0700493127895088,11.6836859309955,64.2495,2.98889792491837,445.8065,0.436217975652759,0.434004013820139,0.437187944956275,0.419150007985831,0.0022139618326193,0.0180379369704444,True,0.144492621214001,0.01982445528807,1.78284611409711,27.6301540347009
18381,1179:1022,Colon,LS-411N,SIDM00660,907794,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.41023823271207,0.116048155311286,0.323362696438046,7.36792615371348,0.3226,0.792916259073917,0.755409904465573,0.0735993103735683,0.132655741111753,0.194417432432556,-0.0617616913208023,8.76914373052874,0.8521,-1.40121757681526,-0.5295,0.32528456481115,0.304328875546434,0.30989802418115,0.343610512752022,0.0209556892647161,-0.0337124885708715,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18380,1011:1032,Colon,LS-411N,SIDM00660,907794,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.91061779529176,0.0795425216027764,0.430999553099844,8.38600755302356,6.5339,0.847566833603077,0.817104190589818,0.137716384547401,0.392475862815514,0.163218992249298,0.229256870566216,5.63686055009509,0.9718,2.74914700292847,5.5621,0.771809441378051,0.611662891993127,0.744069616558558,0.57436143542976,0.160146549384924,0.169708181128798,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18380,1373:1032,Colon,LS-411N,SIDM00660,907794,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.764066297355117,0.0795425216027764,0.430999553099844,8.38600755302356,6.5339,0.847566833603077,0.817104190589818,0.064679516437494,0.329312232698708,0.111431572696742,0.217880660001966,5.09287900080621,0.6666,3.29312855221735,5.8673,0.647597252312103,0.442542248979109,0.624321773457312,0.449313474901948,0.205055003332994,0.175008298555364,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18384,2171:1053,Colon,LS-411N,SIDM00660,907794,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.794618064779359,0.0578222623761846,0.860026441367492,13.0130052211804,161.4488,0.970098277159572,0.967058684778523,0.136530516152084,0.683392546498515,0.127879390185322,0.555513156313193,5.34994044782289,0.7966,7.66306477335755,160.6522,0.770857615642329,0.426367297473562,0.768442300626782,0.483419639087113,0.344490318168767,0.285022661539669,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18384,1054:1053,Colon,LS-411N,SIDM00660,907794,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.915821839318131,0.0578222623761846,0.860026441367492,13.0130052211804,161.4488,0.970098277159572,0.967058684778523,0.100115425909442,0.787630997395403,0.410665863384192,0.376965134011211,8.54225381125922,7.2812,4.47075140992123,154.1676,0.888437188507629,0.680471956734611,0.88565346342244,0.756144396671461,0.207965231773018,0.129509066750978,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18384,1083:1053,Colon,LS-411N,SIDM00660,907794,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.987600030117075,0.0578222623761846,0.860026441367492,13.0130052211804,161.4488,0.970098277159572,0.967058684778523,0.0501177772462687,0.849362139396016,0.730170352844555,0.119191786551461,11.3044127588841,49.3966,1.70859246229636,112.0522,0.958069087739316,0.937564996939954,0.955067186212249,0.922506739506655,0.0205040907993622,0.0325604467055938,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18384,1510:1053,Colon,LS-411N,SIDM00660,907794,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.710625431746139,0.0578222623761846,0.860026441367492,13.0130052211804,161.4488,0.970098277159572,0.967058684778523,0.125735044719038,0.611156661209869,0.29759988662794,0.313556774581929,8.2755198463329,6.0522,4.73748537484754,155.3966,0.689376507042706,0.493059133850112,0.687216495394592,0.576253082914485,0.196317373192594,0.110963412480107,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18384,1786:1053,Colon,LS-411N,SIDM00660,907794,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.858538319288847,0.0578222623761846,0.860026441367492,13.0130052211804,161.4488,0.970098277159572,0.967058684778523,0.101031140518599,0.738365655515614,0.408665229591961,0.329700425923654,8.78764847231949,8.6313,4.22535674886095,152.8175,0.832866544417585,0.684206856171254,0.830256937883436,0.719916483975086,0.14865968824633,0.11034045390835,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18384,1372:1053,Colon,LS-411N,SIDM00660,907794,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.856313684404275,0.0578222623761846,0.860026441367492,13.0130052211804,161.4488,0.970098277159572,0.967058684778523,0.140510617771027,0.736452410692494,0.41300796050818,0.323444450184314,8.84351951615457,8.9721,4.16948570502587,152.4767,0.830708429948753,0.614940799428272,0.82810558539785,0.720487188236353,0.215767630520481,0.107618397161497,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18384,1032:1053,Colon,LS-411N,SIDM00660,907794,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.903607397083856,0.0578222623761846,0.860026441367492,13.0130052211804,161.4488,0.970098277159572,0.967058684778523,0.0582645998364023,0.77712625410737,0.735574580407,0.0415516737003706,12.263641611602,96.0404,0.749363609578486,65.4084,0.876587979139693,0.892248830416538,0.873841380980058,0.863007818782527,-0.0156608512768445,0.0108335621975313,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18384,1564:1053,Colon,LS-411N,SIDM00660,907794,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.940394475392494,0.0578222623761846,0.860026441367492,13.0130052211804,161.4488,0.970098277159572,0.967058684778523,0.0762366087311923,0.808764114153456,0.618896751347898,0.189867362805557,10.4476980617768,27.2772,2.5653071594036,134.1716,0.912275060428638,0.827064074885894,0.909416644546055,0.854599629205438,0.0852109855427433,0.0548170153406169,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18384,1373:1053,Colon,LS-411N,SIDM00660,907794,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.806141949833599,0.0578222623761846,0.860026441367492,13.0130052211804,161.4488,0.970098277159572,0.967058684778523,0.0778904036787797,0.693303392352441,0.328391386468025,0.364912005884416,8.17135889033839,5.6306,4.84164633084206,155.8182,0.782036916679632,0.609092496851285,0.779586573750874,0.648907402287288,0.172944419828347,0.130679171463586,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18384,1561:1053,Colon,LS-411N,SIDM00660,907794,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.993219513913982,0.0578222623761846,0.860026441367492,13.0130052211804,161.4488,0.970098277159572,0.967058684778523,0.1320500881766,0.854195044048192,0.304505421770965,0.549689622277227,7.19600877917534,2.8638,5.8169964420051,158.585,0.963520539289221,0.660090160757826,0.96050155682202,0.738983884110645,0.303430378531395,0.221517672711375,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18384,1059:1053,Colon,LS-411N,SIDM00660,907794,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.809485810964445,0.0578222623761846,0.860026441367492,13.0130052211804,161.4488,0.970098277159572,0.967058684778523,0.0794697683281165,0.69617920134123,0.351514811946053,0.344664389395177,8.41522940353629,6.6676,4.59777581764415,154.7812,0.785280790601727,0.609989489902569,0.782820283698153,0.662743191218476,0.175291300699158,0.120077092479677,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18385,1372:1054,Colon,LS-411N,SIDM00660,907794,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.540765394510602,0.0834711517224884,0.900350014122985,13.8653583621689,116.5947,0.939402298174236,0.977062197318612,0.095052756658326,0.486878130584842,0.243716832565797,0.243161298019045,8.56258672230926,2.9538,5.30277163985969,113.6409,0.507996254376356,0.367125432413401,0.528361424594394,0.447071470689856,0.140870821962956,0.0812899539045387,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18385,1053:1054,Colon,LS-411N,SIDM00660,907794,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.9884358630575,0.0834711517224884,0.900350014122985,13.8653583621689,116.5947,0.939402298174236,0.977062197318612,0.12816192661692,0.889938243263485,0.495109828075968,0.394828415187517,9.00797806604015,4.0222,4.85738029612879,112.5725,0.92853892135405,0.78211199686953,0.96576331626748,0.839736443355058,0.146426924484519,0.126026872912422,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18385,1510:1054,Colon,LS-411N,SIDM00660,907794,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.717451671732315,0.0834711517224884,0.900350014122985,13.8653583621689,116.5947,0.939402298174236,0.977062197318612,0.0922204169606624,0.645957622776749,0.498358827978163,0.147598794798586,10.8165627465583,14.0896,3.0487956156106,102.5051,0.673975749254284,0.578156016279364,0.700994906852687,0.660419703730072,0.0958197329749202,0.0405752031226154,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18385,1373:1054,Colon,LS-411N,SIDM00660,907794,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,1,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.750072913483245,0.0834711517224884,0.900350014122985,13.8653583621689,116.5947,0.939402298174236,0.977062197318612,0.0903173225812786,0.675328158247908,0.365698732763615,0.309629425484293,8.88990731001428,3.7061,4.97545105215466,112.8886,0.704620218724405,0.55918867240754,0.732867888997112,0.632850606304286,0.145431546316865,0.100017282692826,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18385,1561:1054,Colon,LS-411N,SIDM00660,907794,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.948810691011271,0.0834711517224884,0.900350014122985,13.8653583621689,116.5947,0.939402298174236,0.977062197318612,0.0358989436937446,0.854261719052037,0.802456955671164,0.051804763380873,12.7613335051584,54.2418,1.10402485701055,62.3529,0.891314943668273,0.919783811767708,0.927047058598863,0.914089598472668,-0.0284688680994348,0.0129574601261946,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18385,2171:1054,Colon,LS-411N,SIDM00660,907794,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.812762035165602,0.0834711517224884,0.900350014122985,13.8653583621689,116.5947,0.939402298174236,0.977062197318612,0.12140394826746,0.731770309839976,0.436030597763618,0.295739712076358,9.32311617384418,5.0041,4.54224218832477,111.5906,0.763510523703336,0.597395961057184,0.79411905997605,0.702562929053731,0.166114562646152,0.0915561309223187,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
19681,1786:1194,Colon,LS-411N,SIDM00660,907794,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,10.0,0.84678055847817,0.0552753962181503,0.596028921762896,9.85972663114003,18.1469,0.903323817430838,0.887237991077726,0.0860881478115515,0.504705703239527,0.297147058132049,0.207558645107478,7.64054882385055,3.8973,2.21917780728948,14.2496,0.764917046610718,0.675367849982519,0.751295881587847,0.654488281684758,0.0895491966281987,0.0968075999030884,True,0.144492621214001,0.01982445528807,1.78284611409711,27.6301540347009
18381,2171:1372,Colon,LS-411N,SIDM00660,907794,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.76706862085781,0.179802644394344,0.200578432876149,5.94371520658365,0.1202,0.575487474081999,0.654241268334578,0.0955342876318703,0.153857421880129,0.0265305917549092,0.127326830125219,1.64139969948043,0.0061,4.30231550710322,0.1141,0.441438383065024,0.259009575490259,0.501847947409669,0.241482815565077,0.182428807574765,0.260365131844592,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18381,1011:1372,Colon,LS-411N,SIDM00660,907794,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.924538725346646,0.179802644394344,0.200578432876149,5.94371520658365,0.1202,0.575487474081999,0.654241268334578,0.0657939415782005,0.185442528663343,0.0224669855231645,0.162975543140178,0.837767072305232,0.0035,5.10594813427842,0.1167,0.532060455740732,0.227490944745946,0.604871388295223,0.238750399239709,0.304569510994786,0.366120989055514,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18381,1194:1372,Colon,LS-411N,SIDM00660,907794,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,0.625,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.941424937669217,0.179802644394344,0.200578432876149,5.94371520658365,0.1202,0.575487474081999,0.654241268334578,0.157352941154894,0.188829538668218,0.237561556248298,-0.0487320175800805,6.59915577560088,0.1894,-0.655440569017233,-0.0692,0.541778259417061,0.577006196463089,0.615919045262509,0.661469190690984,-0.0352279370460279,-0.0455501454284748,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18381,1053:1372,Colon,LS-411N,SIDM00660,907794,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.991061710812816,0.179802644394344,0.200578432876149,5.94371520658365,0.1202,0.575487474081999,0.654241268334578,0.134623890269643,0.19878560483839,0.0452214343032826,0.153564170535107,2.27926850566609,0.0095,3.66444670091756,0.1107,0.570343600615052,0.377143607390759,0.648393470680013,0.359548571768992,0.193199993224293,0.288844898911021,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18381,1083:1372,Colon,LS-411N,SIDM00660,907794,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.974787360412896,0.179802644394344,0.200578432876149,5.94371520658365,0.1202,0.575487474081999,0.654241268334578,0.161409444531989,0.195521321139097,0.117518848196341,0.0780024729427554,4.60759513906372,0.0476,1.33612006751993,0.0726,0.560977915811077,0.498755683474879,0.637746119033048,0.535345614613593,0.0622222323361978,0.102400504419455,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18381,1510:1372,Colon,LS-411N,SIDM00660,907794,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.723122327277117,0.179802644394344,0.200578432876149,5.94371520658365,0.1202,0.575487474081999,0.654241268334578,0.110938607176835,0.145042743182998,0.0322326722233998,0.112810070959598,2.22512032200816,0.0091,3.7185948845755,0.1111,0.416147841577005,0.268871519155286,0.473096468558832,0.25933472454433,0.147276322421719,0.213761744014503,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18381,2048:1372,Colon,LS-411N,SIDM00660,907794,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.99939645490487,0.179802644394344,0.200578432876149,5.94371520658365,0.1202,0.575487474081999,0.654241268334578,0.155936819587648,0.200457374746798,0.127315537433203,0.0731418373135948,4.74671514231082,0.0524,1.19700006427283,0.0678,0.575140141439708,0.515099868682918,0.653846404226043,0.560050926598108,0.0600402727567904,0.0937954776279348,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18381,1561:1372,Colon,LS-411N,SIDM00660,907794,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.980077659008966,0.179802644394344,0.200578432876149,5.94371520658365,0.1202,0.575487474081999,0.654241268334578,0.14596682226521,0.196582440940943,0.0289665079910657,0.167615932949877,1.28240362591008,0.0048,4.66131158067358,0.1154,0.564022416387268,0.328774442629176,0.641207250696409,0.283182543259902,0.235247973758092,0.358024707436508,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
19682,1053:1373,Colon,LS-411N,SIDM00660,907794,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10.0,0.879192122419877,0.179468643782524,0.535024521636807,9.31018103197939,12.3986,0.722984737166496,0.86382558966479,0.162082765920352,0.470389344724544,0.205670890622857,0.264718454101687,6.37792830202578,1.6243,2.93225272995361,10.7743,0.635642485546589,0.500017137377401,0.759468653577989,0.603656008243698,0.135625348169187,0.155812645334291,True,0.144492621214001,0.01982445528807,1.78284611409711,27.6301540347009
19682,1083:1373,Colon,LS-411N,SIDM00660,907794,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10.0,0.74644871348808,0.179468643782524,0.535024521636807,9.31018103197939,12.3986,0.722984737166496,0.86382558966479,0.198662934875428,0.39936836586037,0.107465397738109,0.291902968122261,5.05949631834036,0.6513,4.25068471363903,11.7473,0.539671026929449,0.351362826821184,0.644801500083365,0.436972467215702,0.188308200108265,0.207829032867663,True,0.144492621214001,0.01982445528807,1.78284611409711,27.6301540347009
19682,1561:1373,Colon,LS-411N,SIDM00660,907794,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10.0,0.894486769417394,0.179468643782524,0.535024521636807,9.31018103197939,12.3986,0.722984737166496,0.86382558966479,0.175738862653332,0.478572355917995,0.504680383647834,-0.0261080277298391,9.57089180467297,14.8544,-0.260710772693582,-2.4558,0.646700281886143,0.633110117647266,0.772680561039334,0.782977405005993,0.013590164238877,-0.010296843966659,True,0.144492621214001,0.01982445528807,1.78284611409711,27.6301540347009
19682,2171:1373,Colon,LS-411N,SIDM00660,907794,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10.0,0.646806466825886,0.179468643782524,0.535024521636807,9.31018103197939,12.3986,0.722984737166496,0.86382558966479,0.177755551408101,0.346057320505113,0.123004800719636,0.223052519785477,5.79737190369493,1.0862,3.51280912828446,11.3124,0.467631203415703,0.314004642457845,0.558727977604871,0.415955794402617,0.153626560957858,0.142772183202253,True,0.144492621214001,0.01982445528807,1.78284611409711,27.6301540347009
19682,1032:1373,Colon,LS-411N,SIDM00660,907794,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,1,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10.0,0.806066843855641,0.179468643782524,0.535024521636807,9.31018103197939,12.3986,0.722984737166496,0.86382558966479,0.157237909090564,0.431265527541155,0.18135195612177,0.249913571419385,6.26605221650668,1.5031,3.04412881547271,10.8955,0.582774025243597,0.451815934834566,0.696301166702835,0.546816024154545,0.130958090409031,0.14948514254829,True,0.144492621214001,0.01982445528807,1.78284611409711,27.6301540347009
18383,1073:1510,Colon,LS-411N,SIDM00660,907794,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,10,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.836388529057164,0.066184553173974,0.796221869450826,12.0124370633466,80.6926,0.946348843840948,0.950242599269077,0.066397310782751,0.665950838193122,0.459416494683336,0.206534343509785,9.43718689844233,13.5396,2.5752501649043,67.153,0.791515317475078,0.70638115050479,0.794772009850119,0.727260853589573,0.0851341669702879,0.067511156260546,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18383,1011:1510,Colon,LS-411N,SIDM00660,907794,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.916540186910635,0.066184553173974,0.796221869450826,12.0124370633466,80.6926,0.946348843840948,0.950242599269077,0.139501295552077,0.729769341048795,0.256178434399344,0.473590906649452,6.90694074973649,2.3438,5.10549631361014,78.3488,0.867366746216646,0.715573532183461,0.870935529544527,0.663875298268122,0.151793214033185,0.207060231276405,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18383,1054:1510,Colon,LS-411N,SIDM00660,907794,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.898063889252271,0.066184553173974,0.796221869450826,12.0124370633466,80.6926,0.946348843840948,0.950242599269077,0.064755794876917,0.715058108786723,0.45845304347367,0.256605065313054,9.09276608557329,10.6641,2.91967097777334,70.0285,0.849881723289193,0.729030077097214,0.853378564432775,0.766643948969093,0.120851646191978,0.0867346154636814,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18383,1053:1510,Colon,LS-411N,SIDM00660,907794,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.992418721016472,0.066184553173974,0.796221869450826,12.0124370633466,80.6926,0.946348843840948,0.950242599269077,0.121548001967115,0.790185489325734,0.292659373624696,0.497526115701038,7.07313306710257,2.63,4.93930399624406,78.0626,0.939174309240051,0.67569914979386,0.943038545021986,0.730160745640146,0.263475159446191,0.21287779938184,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18383,1083:1510,Colon,LS-411N,SIDM00660,907794,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.998645134964774,0.066184553173974,0.796221869450826,12.0124370633466,80.6926,0.946348843840948,0.950242599269077,0.043045102635175,0.795143096279625,0.669646892444145,0.12549620383548,10.5709282645646,29.7096,1.44150879878201,50.983,0.945066668881302,0.930275853059561,0.948955148796345,0.911599359723224,0.0147908158217409,0.0373557890731212,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18383,1786:1510,Colon,LS-411N,SIDM00660,907794,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.930753768215546,0.066184553173974,0.796221869450826,12.0124370633466,80.6926,0.946348843840948,0.950242599269077,0.0898374690879059,0.741086505326983,0.435505153117121,0.305581352209862,8.71584567447242,8.2122,3.29659138887421,72.4804,0.880817752451388,0.725192058578036,0.884441879988629,0.777022979931296,0.155625693873352,0.107418900057333,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18383,1372:1510,Colon,LS-411N,SIDM00660,907794,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.893593405773511,0.066184553173974,0.796221869450826,12.0124370633466,80.6926,0.946348843840948,0.950242599269077,0.0735123428419607,0.711498612073916,0.340238226610378,0.371260385463538,7.92496229181382,4.7466,4.08747477153281,75.946,0.845651086417658,0.659293593587087,0.849130520591928,0.706320568200971,0.186357492830571,0.142809952390957,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18383,1598:1510,Colon,LS-411N,SIDM00660,907794,1598,LGK974,PORCN,WNT signaling,Targeted,Early clinical trials,10,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.97977335632751,0.066184553173974,0.796221869450826,12.0124370633466,80.6926,0.946348843840948,0.950242599269077,0.0892620758644535,0.780116973413201,0.515494314335691,0.26462265907751,9.23129756487861,11.7389,2.78113949846801,68.9537,0.927207382986704,0.787195759367629,0.931022380811241,0.842798717523107,0.140011623619075,0.0882236632881337,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18383,1564:1510,Colon,LS-411N,SIDM00660,907794,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1.0,0.066184553173974,0.796221869450826,12.0124370633466,80.6926,0.946348843840948,0.950242599269077,0.0910165963001918,0.796221869450826,0.523065502149119,0.273156367301707,9.20408093492018,11.5195,2.80835612842645,69.1731,0.946348843840948,0.8132308078087,0.950242599269077,0.858930240285728,0.133118036032248,0.0913123589833489,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18383,1373:1510,Colon,LS-411N,SIDM00660,907794,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.825594792096436,0.066184553173974,0.796221869450826,12.0124370633466,80.6926,0.946348843840948,0.950242599269077,0.0644464561399221,0.657356628771891,0.432176400561942,0.225180228209949,9.20768973707981,11.5484,2.80474732626682,69.1442,0.781300676981571,0.675980720574249,0.784515341184731,0.709267455784522,0.105319956407322,0.075247885400209,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18383,1179:1510,Colon,LS-411N,SIDM00660,907794,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.25,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.909344743028474,0.066184553173974,0.796221869450826,12.0124370633466,80.6926,0.946348843840948,0.950242599269077,0.137468447321818,0.724040171269413,0.473519046292829,0.250521124976583,9.1833522579658,11.3552,2.82908480538083,69.3374,0.86055734621784,0.704745412746102,0.864098112247048,0.780181037730944,0.155811933471738,0.0839170745161042,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18383,1561:1510,Colon,LS-411N,SIDM00660,907794,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.991251569834839,0.066184553173974,0.796221869450826,12.0124370633466,80.6926,0.946348843840948,0.950242599269077,0.173842282113748,0.789256178029962,0.241933593958396,0.547322584071566,6.50114073291503,1.7692,5.5112963304316,78.9234,0.938069777068725,0.636232737256177,0.94192946824941,0.689483308776917,0.301837039812547,0.252446159472493,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18383,1059:1510,Colon,LS-411N,SIDM00660,907794,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.778402336260549,0.066184553173974,0.796221869450826,12.0124370633466,80.6926,0.946348843840948,0.950242599269077,0.103086977820932,0.619780963362265,0.235093311589416,0.384687651772849,7.14835599982725,2.7708,4.86408106351938,77.9218,0.736640150963264,0.517232967614963,0.739671059285346,0.576662905121935,0.2194071833483,0.163008154163411,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
19684,1372:1549,Colon,LS-411N,SIDM00660,907794,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.445370430542139,0.0351971497779642,0.952216897855415,15.6137883951589,489.6871,0.985471328384324,0.98929759381899,0.0413054585288309,0.424089249767366,0.259889901572821,0.164199348194545,9.74558651058869,8.3833,5.86820188457019,481.3038,0.43889978980946,0.36093397522976,0.440603895293466,0.393102350040988,0.0779658145796999,0.0475015452524782,True,0.144492621214001,0.01982445528807,1.78284611409711,27.6301540347009
19684,1564:1549,Colon,LS-411N,SIDM00660,907794,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.985586654365455,0.0351971497779642,0.952216897855415,15.6137883951589,489.6871,0.985471328384324,0.98929759381899,0.0486212623279011,0.93849226658757,0.888714951445812,0.049777315141758,13.8991098774303,149.1932,1.71467851772854,340.4939,0.971267389515386,0.975346383361472,0.975038505663853,0.963304721174699,-0.0040789938460865,0.0117337844891536,True,0.144492621214001,0.01982445528807,1.78284611409711,27.6301540347009
19684,1373:1549,Colon,LS-411N,SIDM00660,907794,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.681840171907433,0.0351971497779642,0.952216897855415,15.6137883951589,489.6871,0.985471328384324,0.98929759381899,0.0297717985843572,0.649259733326899,0.474365609153563,0.174894124173335,10.8279349023885,17.7514,4.78585349277042,471.9357,0.671933939955414,0.61927739586199,0.67454284143715,0.627871744043648,0.0526565440934235,0.0466710973935023,True,0.144492621214001,0.01982445528807,1.78284611409711,27.6301540347009
19685,1372:1561,Colon,LS-411N,SIDM00660,907794,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.379956423595879,0.0519679123863288,0.422288684668914,8.30729304060591,6.1869,0.82801268473618,0.812704097679142,0.0402139584685794,0.160451298351808,0.0593721117989412,0.101079186552867,5.27255414397469,0.755,3.03473889663121,5.4319,0.314608738384381,0.208541050286754,0.308792142395883,0.228839009813176,0.106067688097627,0.0799531325827073,True,0.144492621214001,0.01982445528807,1.78284611409711,27.6301540347009
19685,1053:1561,Colon,LS-411N,SIDM00660,907794,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.863180968089162,0.0519679123863288,0.422288684668914,8.30729304060591,6.1869,0.82801268473618,0.812704097679142,0.0997655465586219,0.364511555645612,0.0987847802892231,0.265726775356389,4.47720305922233,0.435,3.83008998138358,5.7519,0.714724790800682,0.436748148240512,0.701510709804711,0.464967352760107,0.27797664256017,0.236543357044605,True,0.144492621214001,0.01982445528807,1.78284611409711,27.6301540347009
19685,1011:1561,Colon,LS-411N,SIDM00660,907794,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.972100620479235,0.0519679123863288,0.422288684668914,8.30729304060591,6.1869,0.82801268473618,0.812704097679142,0.0910400795460505,0.410507092388011,0.179395582482506,0.231111509905506,5.71565746584378,1.0264,2.59163557476213,5.1605,0.804911644596718,0.626920228084093,0.790030157619911,0.619051363025436,0.177991416512625,0.170978794594475,True,0.144492621214001,0.01982445528807,1.78284611409711,27.6301540347009
19685,1011:1564,Colon,LS-411N,SIDM00660,907794,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.972100620479235,0.0755191076872956,0.185444965305594,5.72886247194637,0.5179,0.62631854549108,0.637834197216803,0.135087105506661,0.180271165838318,0.0533958738774412,0.126875291960877,2.71089629048633,0.0639,3.01796618146005,0.454,0.608844646689531,0.368262213138874,0.620039018877328,0.3853588696201,0.240582433550657,0.234680149257229,True,0.144492621214001,0.01982445528807,1.78284611409711,27.6301540347009
19687,1510:2048,Colon,LS-411N,SIDM00660,907794,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.609966183345264,0.0739605468714944,0.539896769205433,9.35350305193393,0.1278,0.848261179659222,0.865789341544592,0.0808591930255009,0.329318771712677,0.179539755769749,0.149779015942927,7.06726965828079,0.0262,2.28623339365314,0.1016,0.517410634236686,0.422455021307326,0.528102220242963,0.44853242992053,0.0949556129293602,0.0795697903224332,True,0.144492621214001,0.01982445528807,1.78284611409711,27.6301540347009
19687,2171:2048,Colon,LS-411N,SIDM00660,907794,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.05,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.880269822550588,0.0739605468714944,0.539896769205433,9.35350305193393,0.1278,0.848261179659222,0.865789341544592,0.106215031703503,0.475254833224102,0.254981175855109,0.220273657368993,7.01721752398166,0.0253,2.33628552795227,0.1025,0.746698718095176,0.584572178239079,0.762128230047648,0.644290945047268,0.162126539856096,0.11783728500038,True,0.144492621214001,0.01982445528807,1.78284611409711,27.6301540347009
19687,1011:2048,Colon,LS-411N,SIDM00660,907794,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.976664867685392,0.0739605468714944,0.539896769205433,9.35350305193393,0.1278,0.848261179659222,0.865789341544592,0.0683579583898605,0.527298206659795,0.220156162497932,0.307142044161863,6.27153135464973,0.0151,3.0819716972842,0.1127,0.828466892794528,0.675046208616163,0.845586032703071,0.662940918323169,0.153420684178365,0.182645114379902,True,0.144492621214001,0.01982445528807,1.78284611409711,27.6301540347009
18384,1032:2171,Colon,LS-411N,SIDM00660,907794,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.903607397083856,0.120612860556824,0.400232036209415,8.10589614632559,5.3808,0.765629702997327,0.801154510556001,0.196779290323626,0.361652628468761,0.343732979412167,0.0179196490565944,7.92166141619211,4.7357,0.184234730133482,0.6451,0.6918286630555,0.627171519774402,0.723929141945499,0.714056318049736,0.0646571432810977,0.0098728238957622,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18384,1372:2171,Colon,LS-411N,SIDM00660,907794,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.514056140641086,0.120612860556824,0.400232036209415,8.10589614632559,5.3808,0.765629702997327,0.801154510556001,0.084730677222934,0.205741735894735,0.0363097440751655,0.16943199181957,3.30380868898199,0.1929,4.8020874573436,5.1879,0.393576650282987,0.200975627592262,0.411838395753616,0.228072768503629,0.192601022690724,0.183765627249987,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18384,1564:2171,Colon,LS-411N,SIDM00660,907794,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.5,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.637424350544288,0.120612860556824,0.400232036209415,8.10589614632559,5.3808,0.765629702997327,0.801154510556001,0.100370055187633,0.255117645747804,0.0694229503534827,0.185694695394322,4.35394289860847,0.3994,3.75195324771712,4.9814,0.488031016190487,0.301435394934104,0.510675393576786,0.337004205055564,0.186595621256383,0.173671188521222,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18384,1053:2171,Colon,LS-411N,SIDM00660,907794,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.988761032406187,0.120612860556824,0.400232036209415,8.10589614632559,5.3808,0.765629702997327,0.801154510556001,0.18918538353584,0.395733841324452,0.0439152202324229,0.351818621092029,2.21680640200825,0.0908,5.88908974431734,5.29,0.757024815576479,0.380199214814715,0.792150360974225,0.353971046495972,0.376825600761764,0.438179314478253,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18384,1194:2171,Colon,LS-411N,SIDM00660,907794,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,2.5,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.861513710873595,0.120612860556824,0.400232036209415,8.10589614632559,5.3808,0.765629702997327,0.801154510556001,0.0830078030977985,0.344805386725268,0.105408391613905,0.239396995111364,4.64476089079077,0.4886,3.46113525553483,4.8922,0.659600486584275,0.460097230016912,0.690205595372219,0.475716698503841,0.199503256567363,0.214488896868378,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18384,1373:2171,Colon,LS-411N,SIDM00660,907794,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,1,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.750765582924276,0.120612860556824,0.400232036209415,8.10589614632559,5.3808,0.765629702997327,0.801154510556001,0.176807220588877,0.300480437969732,0.130838517271469,0.169641920698263,5.56141543587117,0.9223,2.54448071045443,4.4585,0.574808430274929,0.383171151997468,0.601479233129989,0.469145880017928,0.191637278277461,0.132333353112061,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18384,1011:2171,Colon,LS-411N,SIDM00660,907794,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.925158259661309,0.120612860556824,0.400232036209415,8.10589614632559,5.3808,0.765629702997327,0.801154510556001,0.0942853165214894,0.370277974080205,0.0948168860232484,0.275461088056956,4.20367312712633,0.3599,3.90222301919927,5.0209,0.708328643570012,0.459740275144129,0.741194712705798,0.477864007892777,0.248588368425883,0.26333070481302,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
18384,1059:2171,Colon,LS-411N,SIDM00660,907794,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.619958894059205,0.120612860556824,0.400232036209415,8.10589614632559,5.3808,0.765629702997327,0.801154510556001,0.122701972895843,0.248127410535453,0.132328549430828,0.115798861104625,6.11704004433976,1.3556,1.98885610198584,4.0252,0.4746589439291,0.357440463006457,0.496682864334842,0.413695338926849,0.117218480922643,0.0829875254079931,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
19591,2048:1011,Colon,SW620,SIDM00841,905962,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.965481488858102,0.155874429173341,0.205463057553927,5.85995974262785,1.1344,0.691980772481297,0.644388021268075,0.127071715256259,0.198370778712504,0.0889421306705814,0.109428648041922,3.68803368284209,0.2517,2.17192605978576,0.8827,0.668094626476422,0.449045364030779,0.622144706176227,0.458898844600104,0.219049262445643,0.163245861576123,True,0.150087880964705,0.0197658542426096,1.74107388358514,28.2596068597113
19589,1011:1022,Colon,SW620,SIDM00841,905962,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.727027885635276,0.0623969038857059,0.728538613851184,11.2919987610152,4.8973,0.941992236848099,0.927631768632568,0.0867236812501069,0.529667888031881,0.279758545791218,0.249909342240664,7.91059427977097,0.47,3.38140448124422,4.4273,0.684854624240518,0.603645019182588,0.674414163397047,0.569421936144948,0.0812096050579302,0.104992227252099,True,0.150087880964705,0.0197658542426096,1.74107388358514,28.2596068597113
19589,1179:1022,Colon,SW620,SIDM00841,905962,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.545515136126664,0.0623969038857059,0.728538613851184,11.2919987610152,4.8973,0.941992236848099,0.927631768632568,0.0239302447671351,0.39742884110856,0.164243403637867,0.233185437470693,7.04477750052564,0.2579,4.24722126048955,4.6394,0.513871023314452,0.39892659908649,0.506037170541013,0.397386015157563,0.114944424227962,0.10865115538345,True,0.150087880964705,0.0197658542426096,1.74107388358514,28.2596068597113
19589,1003:1022,Colon,SW620,SIDM00841,905962,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.025,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.502429875302407,0.0623969038857059,0.728538613851184,11.2919987610152,4.8973,0.941992236848099,0.927631768632568,0.114966880041,0.366039564910239,0.0683309876208845,0.297708577289355,4.70744714944625,0.051,6.58455161156894,4.8463,0.473285042095426,0.244018988917208,0.466069913840612,0.279285342983912,0.229266053178217,0.1867845708567,True,0.150087880964705,0.0197658542426096,1.74107388358514,28.2596068597113
19590,1510:1059,Colon,SW620,SIDM00841,905962,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,1,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.931127924265128,0.109129254358599,0.777778785389957,11.9085132276073,7.5084,0.908703544198043,0.942545262151154,0.143218729720572,0.724211545977603,0.477654828386432,0.246556717591171,9.1206162547041,1.0872,2.78789697290319,6.4212,0.846119244881489,0.689646968135854,0.877630213472736,0.789575059509509,0.156472276745635,0.0880551539632265,True,0.150087880964705,0.0197658542426096,1.74107388358514,28.2596068597113
20746,1011:1372,Colon,SW620,SIDM00841,905962,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.8149764080959,0.198318269553233,0.113888764838415,4.2368188863478,0.0368,0.487240471178381,0.518750323619543,0.0708558746206124,0.0928166564904898,0.0148339205472725,0.0779827359432173,-0.258517899118315,0.0016,4.49533678546612,0.0352,0.397089489079911,0.149207760236963,0.422769275442041,0.160291803762745,0.247881728842948,0.262477471679297,True,0.181862921892115,0.0276104221850542,1.57742485945792,31.1571674504069
20746,1083:1372,Colon,SW620,SIDM00841,905962,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.965451898920169,0.198318269553233,0.113888764838415,4.2368188863478,0.0368,0.487240471178381,0.518750323619543,0.195171539823313,0.10995412427892,0.114489456228065,-0.0045353319491451,4.34300038211002,0.0396,-0.106181495762222,-0.0028,0.470407238129925,0.461822631732105,0.50082848500394,0.508935740588293,0.00858460639782,-0.0081072555843525,True,0.181862921892115,0.0276104221850542,1.57742485945792,31.1571674504069
19591,1179:1510,Colon,SW620,SIDM00841,905962,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.25,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.931117893422705,0.0843519383583807,0.771720136918823,11.8279068259436,71.0043,0.9369584528269,0.940761121008411,0.12640034800147,0.718562428199736,0.336944522925007,0.381617905274729,7.68302721170387,4.0138,4.14487961423975,66.9905,0.87241878082078,0.627979466653789,0.875959513207334,0.716458372253284,0.24443931416699,0.15950114095405,True,0.150087880964705,0.0197658542426096,1.74107388358514,28.2596068597113
20074,1011:1561,Colon,SW620,SIDM00841,905962,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.754725960263175,0.0782463639355061,0.696158344495058,10.9248263207109,37.9691,0.872519494779171,0.91727524082125,0.10898645643293,0.525408775044255,0.214957487852265,0.31045128719199,6.86244023918522,2.2726,4.06238608152572,35.6965,0.65851311354555,0.471930615557194,0.692291436954453,0.540490630962561,0.186582497988356,0.151800805991892,True,0.14538764884658,0.0214106837134932,1.77119448894505,27.7932803207291
20074,1011:1564,Colon,SW620,SIDM00841,905962,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.754725960263175,0.12743228493421,0.216027145865594,6.00743885829065,0.6282,0.59790670867553,0.655319786077597,0.1017939558389,0.163041295106323,0.0391173881764099,0.123923906929913,2.2519181493519,0.0465,3.75552070893876,0.5817,0.451255714852934,0.256873710936178,0.494586854826873,0.274703551880919,0.194382003916756,0.219883302945954,True,0.14538764884658,0.0214106837134932,1.77119448894505,27.7932803207291
20076,1011:2048,Colon,SW620,SIDM00841,905962,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.940676658409686,0.128461931868478,0.343271854404372,7.49382383048798,0.0352,0.723730612235461,0.757667098677711,0.154147832033826,0.3229078209272,0.200344358347351,0.122563462579849,5.96543723284136,0.0122,1.52838659764662,0.023,0.680796493906449,0.623281824499296,0.712719754571111,0.613526262389505,0.0575146694071532,0.0991934921816054,True,0.14538764884658,0.0214106837134932,1.77119448894505,27.7932803207291
19592,1011:2171,Colon,SW620,SIDM00841,905962,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.6557672986741,0.0875086849227095,0.321319200732422,7.26405194903321,3.0021,0.710806578079307,0.742929743096626,0.076023660045925,0.210710624276421,0.0384068119387488,0.172303812337672,2.55222121382157,0.1146,4.71183073521164,2.8875,0.466123709586848,0.216413668779723,0.487189030735117,0.253595259563998,0.249710040807125,0.23359377117112,True,0.150087880964705,0.0197658542426096,1.74107388358514,28.2596068597113
18544,1022:1003,Colon,LS-123,SIDM00776,907792,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.1,0.87804194023543,0.111075504339489,0.678654627929595,10.956275635382,0.3881,0.887971580088379,0.901262162753366,0.0484200986199583,0.595887226257055,0.388878300698213,0.207008925558842,8.39963613114242,0.066,2.55663950423957,0.3221,0.779676289054721,0.718450273111956,0.791345978044745,0.697159472942094,0.0612260159427652,0.0941865051026508,True,0.4656830891927,0.0670148805380014,0.708840224043507,67.8977301029373
18545,1073:1022,Colon,LS-123,SIDM00776,907792,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,2.5,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.907707037852732,0.132063527044135,0.538312463914808,9.40180502200555,1.3212,0.875031468868396,0.842808258694982,0.069298570559332,0.488630012059316,0.357462762459782,0.131167249599535,7.8713119140469,0.4573,1.53049310795865,0.8639,0.794272222634456,0.731227772647832,0.765022987977841,0.694233137839569,0.0630444499866247,0.0707898501382715,True,0.4656830891927,0.0670148805380014,0.708840224043507,67.8977301029373
18545,1179:1022,Colon,LS-123,SIDM00776,907792,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.477759897169787,0.132063527044135,0.538312463914808,9.40180502200555,1.3212,0.875031468868396,0.842808258694982,0.0391225019639483,0.257184107405154,0.133061973625495,0.124122133779659,6.50923220976601,0.1779,2.89257281223954,1.1433,0.418054944586893,0.3112257971847,0.402659987007962,0.324847037101078,0.106829147402193,0.077812949906884,True,0.4656830891927,0.0670148805380014,0.708840224043507,67.8977301029373
20623,1022:1025,Colon,LS-123,SIDM00776,907792,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.960033138952398,0.0607530700255407,0.826873644512622,13.0916379078763,170.4927,0.938845001541347,0.951451404267968,0.0808523992606456,0.793826100458461,0.509821903736845,0.284004196721617,9.32537934391936,12.5299,3.76625856395694,157.9628,0.901322313819508,0.78560348858119,0.913424878200045,0.805846946789861,0.115718825238318,0.107577931410183,True,0.364550537533847,0.0579711384084306,0.830986080866088,55.473761892262
18548,1194:1053,Colon,LS-123,SIDM00776,907792,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.486701531565185,0.095065541881932,0.650468946268895,10.6252698517615,30.85,0.856314240141537,0.890524002561726,0.0583353118871508,0.316584232384663,0.13271681589989,0.183867416484773,6.43286843111702,1.6874,4.19240142064451,29.1626,0.416769452177964,0.325762058526278,0.433419395942351,0.32843669720255,0.0910073936516856,0.104982698739801,True,0.4656830891927,0.0670148805380014,0.708840224043507,67.8977301029373
18548,1372:1053,Colon,LS-123,SIDM00776,907792,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.818975778673591,0.095065541881932,0.650468946268895,10.6252698517615,30.85,0.856314240141537,0.890524002561726,0.0830968493427971,0.532718311773558,0.445080121364659,0.087638190408899,9.45604172984787,13.7177,1.16922812191365,17.1323,0.7013006216092,0.653235697867084,0.729317588425512,0.692197820901225,0.0480649237421159,0.0371197675242874,True,0.4656830891927,0.0670148805380014,0.708840224043507,67.8977301029373
20622,1194:1059,Colon,LS-123,SIDM00776,907792,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,2.5,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.406246716866895,0.0995912668067724,0.338316192651808,7.24466242894407,0.2962,0.709040261070037,0.727374766068179,0.0596165450989154,0.137439842527705,0.0145439019459057,0.122895940581799,0.382156317741783,0.0025,6.86250611120229,0.2937,0.288045278186149,0.0469015605519784,0.295493610647024,0.101549072473207,0.241143717634171,0.193944538173817,True,0.364550537533847,0.0579711384084306,0.830986080866088,55.473761892262
20625,1022:1073,Colon,LS-123,SIDM00776,907792,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,20.0,0.930040488975655,0.0764911577127002,0.867388459402095,13.9144312245113,603.1443,0.951187866520663,0.96364630496058,0.0927722492295988,0.806706386914165,0.318459515298206,0.488246871615959,7.29243093948012,6.1235,6.62200028503121,597.0208,0.884643228486587,0.684572577483731,0.896230080665121,0.679237686232194,0.200070651002856,0.216992394432927,True,0.364550537533847,0.0579711384084306,0.830986080866088,55.473761892262
20622,1194:1083,Colon,LS-123,SIDM00776,907792,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,0.625,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.95647819710583,0.0974038137217403,0.478541884406657,8.77525938762793,8.5575,0.841801732247298,0.813311812311513,0.0964107956375796,0.457714878836906,0.524788831888551,-0.0670739530516453,9.51102536936898,14.2506,-0.735765981741052,-5.6931,0.80516500318046,0.859244704106558,0.777915015924591,0.810708048341289,-0.0540797009260979,-0.0327930324166981,True,0.364550537533847,0.0579711384084306,0.830986080866088,55.473761892262
20626,1022:1179,Colon,LS-123,SIDM00776,907792,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,10.0,0.914650124379404,0.101416040327455,0.258047969712484,6.2363422070184,1.4725,0.68015612477492,0.661506947640847,0.126515143707989,0.236023607593376,0.0899901301083408,0.146033477485035,3.20317695560484,0.1799,3.03316525141356,1.2926,0.622104884122794,0.380953193792479,0.60504741193754,0.40341917909468,0.241151690330315,0.20162823284286,True,0.364550537533847,0.0579711384084306,0.830986080866088,55.473761892262
18545,1011:1372,Colon,LS-123,SIDM00776,907792,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.621379612557168,0.1503941213366,0.421731193619746,8.17396697219492,0.5641,0.683006622625577,0.781812862368835,0.0614504076650754,0.26205516569471,0.0392669215368894,0.222788244157821,1.94449032034553,0.0075,6.22947665184939,0.5566,0.424406390541061,0.192096404771672,0.485802573510957,0.21805563012391,0.232309985769389,0.267746943387047,True,0.4656830891927,0.0670148805380014,0.708840224043507,67.8977301029373
18545,1194:1372,Colon,LS-123,SIDM00776,907792,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,0.625,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.979136745525796,0.1503941213366,0.421731193619746,8.17396697219492,0.5641,0.683006622625577,0.781812862368835,0.119182840860889,0.412932508407548,0.439010054417143,-0.0260775460095952,8.45759523053613,0.6866,-0.28362825834121,-0.1225,0.668756881650173,0.694613829821811,0.765501701670028,0.780423659998506,-0.0258569481716375,-0.0149219583284779,True,0.4656830891927,0.0670148805380014,0.708840224043507,67.8977301029373
18545,1053:1372,Colon,LS-123,SIDM00776,907792,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.775104581657391,0.1503941213366,0.421731193619746,8.17396697219492,0.5641,0.683006622625577,0.781812862368835,0.123713336053464,0.326885780402506,0.123597086633992,0.203288693768513,4.65026694911358,0.049,3.52370002308134,0.5151,0.529401562499425,0.384377728811967,0.605986731620763,0.424875140137522,0.145023833687459,0.181111591483241,True,0.4656830891927,0.0670148805380014,0.708840224043507,67.8977301029373
20624,1194:1373,Colon,LS-123,SIDM00776,907792,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,2.5,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10.0,0.342775448093551,0.106371680413377,0.862781558986738,13.8111337685578,280.7344,0.926039737487902,0.962287930431565,0.093301756249457,0.295740335488532,0.19070505882528,0.105035276663252,9.59239298898666,15.0775,4.2187407795711,265.6569,0.31742368596985,0.201564350930982,0.329848676548696,0.291734919229468,0.115859335038868,0.0381137573192281,True,0.364550537533847,0.0579711384084306,0.830986080866088,55.473761892262
20626,1786:1549,Colon,LS-123,SIDM00776,907792,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.952925535421242,0.130469660680758,0.753589437623011,11.9251365052014,37.9773,0.855064132588098,0.927836685589732,0.126322610293181,0.718114618334701,0.445790595499693,0.272324022835008,8.66262747743098,3.9574,3.26250902777039,34.0199,0.814812446366013,0.684158470115983,0.884159270399066,0.769626621756881,0.13065397625003,0.114532648642185,True,0.364550537533847,0.0579711384084306,0.830986080866088,55.473761892262
20627,1011:1561,Colon,LS-123,SIDM00776,907792,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.700722289551856,0.120524109635957,0.438951134089575,8.35779609452999,6.4073,0.730902567718445,0.791767193717798,0.0395496265807164,0.307582843680631,0.113022541459482,0.194560302221148,4.68594123635663,0.5027,3.67185485817336,5.9046,0.512159720690999,0.363227268359511,0.554808920773983,0.385944138034409,0.148932452331488,0.168864782739574,True,0.364550537533847,0.0579711384084306,0.830986080866088,55.473761892262
20627,1011:1564,Colon,LS-123,SIDM00776,907792,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.700722289551856,0.0992516390258821,0.523361865186075,9.24470733537422,5.9243,0.797396145997432,0.835736148404159,0.069263763425226,0.366731324437316,0.114841234525544,0.251890089911772,4.7358237091205,0.2602,4.50888362625372,5.6641,0.558753253103146,0.380915162203921,0.585618947371012,0.388516979783296,0.177838090899225,0.197101967587717,True,0.364550537533847,0.0579711384084306,0.830986080866088,55.473761892262
20628,1011:1598,Colon,LS-123,SIDM00776,907792,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1598,LGK974,PORCN,WNT signaling,Targeted,Early clinical trials,10.0,0.670078492924334,0.0932369237789987,0.822034210538587,13.00413487529,160.4592,0.917587028099551,0.949956000861092,0.0904009321720165,0.550827444929941,0.35984986080547,0.190977584124471,9.38826722814675,13.0882,3.61586764714323,147.371,0.614855332915865,0.504787770507031,0.636545085401428,0.564345052694889,0.110067562408834,0.0722000327065386,True,0.364550537533847,0.0579711384084306,0.830986080866088,55.473761892262
22628,1011:2048,Colon,LS-123,SIDM00776,907792,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.722928023494129,0.0965730418036315,0.69521641217993,11.1578320788632,0.4462,0.867528187491823,0.907372255650611,0.0858442993535287,0.502591426757916,0.152587578470785,0.350003848287132,5.54982163314805,0.0091,5.60801044571518,0.4371,0.627160437908908,0.433274937391613,0.655964831350906,0.44353697267144,0.193885500517295,0.212427858679466,True,,,,
18548,1053:2171,Colon,LS-123,SIDM00776,907792,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.821986886703594,0.09972244795897,0.509708403963248,9.10163085144433,10.7299,0.847761177354928,0.829106275974229,0.101339893547406,0.418973624100409,0.213221792549437,0.205751831550971,6.25476293388633,1.4914,2.846867917558,9.2385,0.696848570842151,0.486494588072446,0.681514486534468,0.544783071167901,0.210353982769704,0.136731415366566,True,0.4656830891927,0.0670148805380014,0.708840224043507,67.8977301029373
19395,1022:1003,Colon,HCC2998,SIDM00118,905971,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.1,0.92788302997916,0.0687028101791826,0.76716410881109,11.4883470401388,0.5611,0.917997033940327,0.94521072668115,0.0866580100890997,0.711838557774896,0.0952261559668074,0.616612401808089,4.47484105714121,0.0043,7.01350598299761,0.5568,0.851793869364432,0.484774967234039,0.877044993041709,0.50059602127857,0.367018902130393,0.376448971763139,True,0.404070935266718,0.0499616027026634,0.848106670081728,57.2340703121238
19398,1372:1011,Colon,HCC2998,SIDM00118,905971,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.264425378410421,0.113774881282936,0.283230758239518,7.06233270109485,2.6104,0.774155837780705,0.741076083902624,0.0452072924890737,0.0748934004249551,0.0183953087494846,0.0564980916754705,3.58792833105103,0.2349,3.47440437004383,2.3755,0.204706450353799,0.0874048392263479,0.195959323916864,0.123144854847787,0.117301611127451,0.0728144690690774,True,0.404070935266718,0.0499616027026634,0.848106670081728,57.2340703121238
19398,1564:1011,Colon,HCC2998,SIDM00118,905971,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.332277199858641,0.113774881282936,0.283230758239518,7.06233270109485,2.6104,0.774155837780705,0.741076083902624,0.0382539274808884,0.0941111232616668,0.0212193331037857,0.0728917901578812,3.39654281731207,0.2057,3.66578988378279,2.4047,0.257234334031993,0.116882599279376,0.246242686041371,0.1494707588504,0.140351734752617,0.0967719271909715,True,0.404070935266718,0.0499616027026634,0.848106670081728,57.2340703121238
19398,1073:1011,Colon,HCC2998,SIDM00118,905971,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.544377342165111,0.113774881282936,0.283230758239518,7.06233270109485,2.6104,0.774155837780705,0.741076083902624,0.0553579437269344,0.154184407389838,0.0531038796404792,0.101080527749359,4.35717356234343,0.4003,2.70515913875142,2.2101,0.421432897392664,0.276293242045383,0.403425028897039,0.288373740403844,0.145139655347282,0.115051288493195,True,0.404070935266718,0.0499616027026634,0.848106670081728,57.2340703121238
19398,2048:1011,Colon,HCC2998,SIDM00118,905971,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.65933750381268,0.113774881282936,0.283230758239518,7.06233270109485,2.6104,0.774155837780705,0.741076083902624,0.0524915955479586,0.186744661140617,0.0497776866195886,0.136966974521028,3.77196726063655,0.2668,3.29036544045831,2.3436,0.510429977644344,0.308370257282598,0.488619255295633,0.317147938344496,0.202059720361746,0.171471316951137,True,0.404070935266718,0.0499616027026634,0.848106670081728,57.2340703121238
19398,1053:1011,Colon,HCC2998,SIDM00118,905971,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.583308715127204,0.113774881282936,0.283230758239518,7.06233270109485,2.6104,0.774155837780705,0.741076083902624,0.167220691136408,0.165210969673197,0.0500041814639856,0.115206788209212,4.06034363202141,0.3258,3.00198906907344,2.2846,0.451571847044087,0.269255028958228,0.43227613831274,0.294586469155324,0.182316818085859,0.137689669157416,True,0.404070935266718,0.0499616027026634,0.848106670081728,57.2340703121238
19398,2171:1011,Colon,HCC2998,SIDM00118,905971,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.538820313840297,0.113774881282936,0.283230758239518,7.06233270109485,2.6104,0.774155837780705,0.741076083902624,0.0445182319707795,0.152610486043842,0.0411864129516483,0.111424073092194,3.79996092663639,0.272,3.26237177445846,2.3384,0.417130891474297,0.247678223279839,0.39930684810795,0.260433454087316,0.169452668194459,0.138873394020634,True,0.404070935266718,0.0499616027026634,0.848106670081728,57.2340703121238
19398,1786:1011,Colon,HCC2998,SIDM00118,905971,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.646720429576441,0.113774881282936,0.283230758239518,7.06233270109485,2.6104,0.774155837780705,0.741076083902624,0.0396954095491901,0.183171117637922,0.0506709963071443,0.132500121330778,3.85586123313391,0.2828,3.20647146796094,2.3276,0.500662395968647,0.301662754028338,0.479269043330332,0.315595877704254,0.198999641940309,0.163673165626077,True,0.404070935266718,0.0499616027026634,0.848106670081728,57.2340703121238
20604,1011:1017,Colon,HCC2998,SIDM00118,905971,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.753530255086861,0.0461358060072519,0.867633798793482,12.923778644243,151.7662,0.977514111729888,0.970633082672674,0.0183848981741144,0.653788317726834,0.354714600531224,0.29907371719561,8.75544535299671,8.4408,4.16833329124627,143.3254,0.736586457962828,0.630381433775693,0.731401394382086,0.636506565887604,0.106205024187136,0.0948948284944817,True,0.208093821689184,0.0338009464970596,1.30869555843349,36.4568241004816
20604,1022:1017,Colon,HCC2998,SIDM00118,905971,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.917026729972421,0.0461358060072519,0.867633798793482,12.923778644243,151.7662,0.977514111729888,0.970633082672674,0.0460225689628791,0.795643385321136,0.493329999429404,0.302313385891732,9.31754306490178,12.4621,3.6062355793412,139.3041,0.896406569381554,0.787344061244671,0.890096481806373,0.799741751813138,0.109062508136883,0.0903547299932344,True,0.208093821689184,0.0338009464970596,1.30869555843349,36.4568241004816
19396,1073:1022,Colon,HCC2998,SIDM00118,905971,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,2.5,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.452410034615686,0.118838784909482,0.387626794556096,8.04566421287352,0.5161,0.804404455225538,0.804940002263673,0.0550100332134531,0.175366251543091,0.0395416181998733,0.135824633343217,4.10460837427807,0.0336,3.94105583859545,0.4825,0.363920647433597,0.226692070037451,0.364162934287658,0.230147145052547,0.137228577396146,0.134015789235111,True,0.404070935266718,0.0499616027026634,0.848106670081728,57.2340703121238
19396,1017:1022,Colon,HCC2998,SIDM00118,905971,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,2.5,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.906677920402358,0.118838784909482,0.387626794556096,8.04566421287352,0.5161,0.804404455225538,0.804940002263673,0.0850319745652806,0.351452655980353,0.265802770034282,0.0856498859460707,7.16336333275004,0.28,0.882300880123482,0.2361,0.729335758626282,0.671324834344966,0.729821327301097,0.67825376703604,0.0580109242813159,0.0515675602650564,True,0.404070935266718,0.0499616027026634,0.848106670081728,57.2340703121238
19396,1179:1022,Colon,HCC2998,SIDM00118,905971,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.500725802301543,0.118838784909482,0.387626794556096,8.04566421287352,0.5161,0.804404455225538,0.804940002263673,0.0375517002596471,0.194094737697677,0.0247370468747306,0.169357690822946,2.82885256665732,0.0139,5.2168116462162,0.5022,0.402786066217743,0.194590571805825,0.403054228438084,0.201904965801605,0.208195494411918,0.201149262636479,True,0.404070935266718,0.0499616027026634,0.848106670081728,57.2340703121238
19396,1003:1022,Colon,HCC2998,SIDM00118,905971,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.025,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.807310264496215,0.118838784909482,0.387626794556096,8.04566421287352,0.5161,0.804404455225538,0.804940002263673,0.0320737233209488,0.312935090038902,0.025445590438858,0.287489499600044,1.85208666202656,0.0071,6.19357755084696,0.509,0.649403973510063,0.264584464356388,0.64983632613107,0.26311747535594,0.384819509153675,0.386718850775131,True,0.404070935266718,0.0499616027026634,0.848106670081728,57.2340703121238
20603,1510:1025,Colon,HCC2998,SIDM00118,905971,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.774349963922381,0.0315080086991414,0.945788719148062,14.9667106971064,625.4015,0.98234935817708,0.988467683280922,0.0915625775574877,0.732371460550497,0.4465954427472,0.285776017803297,9.6456613975562,15.6446,5.32104929955019,609.7569,0.760682190063596,0.616075439968636,0.765419914887022,0.686391734420413,0.14460675009496,0.0790281804666082,True,0.208093821689184,0.0338009464970596,1.30869555843349,36.4568241004816
20603,1011:1025,Colon,HCC2998,SIDM00118,905971,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.812782134409303,0.0315080086991414,0.945788719148062,14.9667106971064,625.4015,0.98234935817708,0.988467683280922,0.0731286274984283,0.768720173849402,0.43136820217973,0.337351971669672,9.25684862842961,11.9487,5.70986206867677,613.4528,0.798436008074776,0.685008135450576,0.803408873411686,0.706568028354811,0.113427872624199,0.0968408450568755,True,0.208093821689184,0.0338009464970596,1.30869555843349,36.4568241004816
20603,2171:1025,Colon,HCC2998,SIDM00118,905971,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.629642231930706,0.0315080086991414,0.945788719148062,14.9667106971064,625.4015,0.98234935817708,0.988467683280922,0.0746246613415898,0.595508520059269,0.319186161219008,0.276322358840261,9.05787403669973,10.4093,5.90883666040666,614.9922,0.618528642418313,0.534785504884122,0.622380998292374,0.54142836645146,0.0837431375341918,0.0809526318409136,True,0.208093821689184,0.0338009464970596,1.30869555843349,36.4568241004816
19399,1510:1053,Colon,HCC2998,SIDM00118,905971,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,1,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.78662276679527,0.0645133781661023,0.482564379086157,8.85439557031027,9.04,0.823220728761649,0.849788646390852,0.13253232000812,0.379596127033595,0.155422436761271,0.224173690272324,6.07526268587752,1.3169,2.77913288443275,7.7231,0.647564167341707,0.44679257752844,0.66846309621518,0.525861099676403,0.200771589813266,0.142601996538777,True,0.404070935266718,0.0499616027026634,0.848106670081728,57.2340703121238
19399,1786:1053,Colon,HCC2998,SIDM00118,905971,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.629393151745248,0.0645133781661023,0.482564379086157,8.85439557031027,9.04,0.823220728761649,0.849788646390852,0.063220607390957,0.303722715473025,0.0511416159218944,0.252581099551131,3.93841791214902,0.2994,4.91597765816125,8.7406,0.518129489057314,0.29030659790204,0.534851154469266,0.311467883844925,0.227822891155274,0.223383270624341,True,0.404070935266718,0.0499616027026634,0.848106670081728,57.2340703121238
20610,1510:1059,Colon,HCC2998,SIDM00118,905971,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.743291031326075,0.106251196067584,0.431108926238685,8.42124457565695,0.6695,0.796818314795267,0.826682219923036,0.113854835533082,0.320439398397829,0.223692756285825,0.0967466421120042,7.2411996275933,0.2955,1.18004494806365,0.374,0.592267906983678,0.477992603462235,0.614465479825523,0.559985320431412,0.114275303521444,0.0544801593941103,True,0.208093821689184,0.0338009464970596,1.30869555843349,36.4568241004816
20610,1011:1059,Colon,HCC2998,SIDM00118,905971,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.768619337973665,0.106251196067584,0.431108926238685,8.42124457565695,0.6695,0.796818314795267,0.826682219923036,0.0727767222368765,0.331358657480116,0.105611585473673,0.225747072006443,5.16633106066169,0.0701,3.25491351499527,0.5994,0.612449965603229,0.459641849610343,0.635403940591844,0.458392136065895,0.152808115992886,0.177011804525949,True,0.208093821689184,0.0338009464970596,1.30869555843349,36.4568241004816
20605,1011:1073,Colon,HCC2998,SIDM00118,905971,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,20.0,0.788063297870814,0.106922674806208,0.222831664564174,6.39296383187029,3.2827,0.663669058286475,0.69263961083611,0.0638125233941325,0.175605456446486,0.0391278910851482,0.136477565361338,2.83986102570298,0.2797,3.55310280616731,3.003,0.523013226768057,0.300366000146339,0.545843855951462,0.318471915956101,0.222647226621718,0.227371939995361,True,0.208093821689184,0.0338009464970596,1.30869555843349,36.4568241004816
20605,1022:1073,Colon,HCC2998,SIDM00118,905971,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,20.0,0.942970009095978,0.106922674806208,0.222831664564174,6.39296383187029,3.2827,0.663669058286475,0.69263961083611,0.103283665465679,0.210123576760951,0.0272189013149927,0.182904675445959,1.66281809412143,0.1237,4.73014573774886,3.159,0.625820017929116,0.273433699547688,0.653138380130361,0.293781823620205,0.352386318381428,0.359356556510156,True,0.208093821689184,0.0338009464970596,1.30869555843349,36.4568241004816
20605,1011:1089,Colon,HCC2998,SIDM00118,905971,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,1089,Oxaliplatin,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved in colon,10.0,0.922015208743617,0.0734728058317242,0.597839125427428,9.82739108464355,17.7447,0.883807705900526,0.893804593426859,0.0506381056095075,0.551216766026071,0.489093293711099,0.0621234723149718,9.25459285515503,11.93,0.572798229488528,5.8147,0.81488414644509,0.818671166394234,0.824101428784469,0.801430446153278,-0.0037870199491433,0.0226709826311908,True,0.208093821689184,0.0338009464970596,1.30869555843349,36.4568241004816
20606,1022:1179,Colon,HCC2998,SIDM00118,905971,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,10.0,0.958083946737243,0.116188363736185,0.134638886728262,5.11722218913784,0.6779,0.616362976594161,0.592386779820395,0.125924427472758,0.128995355980922,0.0144845274538159,0.114510828527106,0.283822013495321,0.0238,4.83340017564252,0.6541,0.590527473238048,0.14674698949632,0.56755626400529,0.206357035593952,0.443780483741729,0.361199228411339,True,0.208093821689184,0.0338009464970596,1.30869555843349,36.4568241004816
19398,1011:1510,Colon,HCC2998,SIDM00118,905971,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.820289084333769,0.065574149217232,0.68473417815342,10.6186277915966,30.7083,0.904306741302805,0.921759820375461,0.0784666031243639,0.561679972009505,0.257112370706677,0.304567601302828,7.36370518806256,3.2168,3.254922603534,27.4915,0.741792948780132,0.592678444027231,0.756109519031447,0.62477218645414,0.149114504752902,0.131337332577307,True,0.404070935266718,0.0499616027026634,0.848106670081728,57.2340703121238
19398,1053:1510,Colon,HCC2998,SIDM00118,905971,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.847106525837222,0.065574149217232,0.68473417815342,10.6186277915966,30.7083,0.904306741302805,0.921759820375461,0.091831524555758,0.580042790777549,0.283919177285628,0.296123613491922,7.57063668949658,3.7129,3.04799110209998,26.9954,0.766044141916199,0.614095295540439,0.780828759094599,0.656745131358031,0.15194884637576,0.124083627736567,True,0.404070935266718,0.0499616027026634,0.848106670081728,57.2340703121238
19398,1032:1510,Colon,HCC2998,SIDM00118,905971,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.952804973610103,0.065574149217232,0.68473417815342,10.6186277915966,30.7083,0.904306741302805,0.921759820375461,0.082936444029896,0.652418130545405,0.43154037359334,0.220877756952064,8.60579198867234,7.6091,2.01283580292422,23.0992,0.861627960782457,0.749918444422359,0.878257341327695,0.797296433514144,0.111709516360098,0.0809609078135503,True,0.404070935266718,0.0499616027026634,0.848106670081728,57.2340703121238
19398,1598:1510,Colon,HCC2998,SIDM00118,905971,1598,LGK974,PORCN,WNT signaling,Targeted,Early clinical trials,10,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.983821050672917,0.065574149217232,0.68473417815342,10.6186277915966,30.7083,0.904306741302805,0.921759820375461,0.0365450663217798,0.673655898582554,0.442671802006611,0.230984096575943,8.5808123228316,7.4785,2.03781546876496,23.2298,0.889676008359127,0.820710657422021,0.906846714949865,0.821926737025658,0.0689653509371057,0.0849199779242074,True,0.404070935266718,0.0499616027026634,0.848106670081728,57.2340703121238
19398,2048:1510,Colon,HCC2998,SIDM00118,905971,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.65933750381268,0.065574149217232,0.68473417815342,10.6186277915966,30.7083,0.904306741302805,0.921759820375461,0.0918077592654715,0.451470923798903,0.338021461227452,0.113449462571452,9.10577269936337,10.7607,1.51285509223319,19.9476,0.596243349491571,0.503584433659966,0.607750819081181,0.568486403315368,0.0926589158316051,0.0392644157658132,True,0.404070935266718,0.0499616027026634,0.848106670081728,57.2340703121238
19398,1059:1510,Colon,HCC2998,SIDM00118,905971,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.699339834260036,0.065574149217232,0.68473417815342,10.6186277915966,30.7083,0.904306741302805,0.921759820375461,0.12026791447746,0.478861886661994,0.268767668841074,0.210094217820921,8.01651293640763,5.0576,2.60211485518893,25.6507,0.632417726582936,0.475680935146432,0.644623360008935,0.561701368180809,0.156736791436504,0.0829219918281263,True,0.404070935266718,0.0499616027026634,0.848106670081728,57.2340703121238
19398,1549:1510,Colon,HCC2998,SIDM00118,905971,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.952182002293757,0.065574149217232,0.68473417815342,10.6186277915966,30.7083,0.904306741302805,0.921759820375461,0.0742899697418031,0.651991560793094,0.421734775256877,0.230256785536217,8.5213829602273,7.1767,2.09724483136926,23.5316,0.861064603621447,0.790266326184814,0.87768311139904,0.792419223467379,0.0707982774366334,0.085263887931661,True,0.404070935266718,0.0499616027026634,0.848106670081728,57.2340703121238
19398,1047:1510,Colon,HCC2998,SIDM00118,905971,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.94603909627832,0.065574149217232,0.68473417815342,10.6186277915966,30.7083,0.904306741302805,0.921759820375461,0.087642254442699,0.64778530309114,0.382165457869289,0.26561984522185,8.18824597798008,5.6969,2.43038181361648,25.0114,0.855509532300498,0.73416089077923,0.872020827453668,0.769486194413946,0.121348641521268,0.102534633039722,True,0.404070935266718,0.0499616027026634,0.848106670081728,57.2340703121238
20606,1073:1549,Colon,HCC2998,SIDM00118,905971,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,10,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.472989215118683,0.0387992068398078,0.951901412165135,15.2298235015129,375.2613,0.978446284426433,0.98980036668647,0.0414273870232056,0.450239101810353,0.297277733872562,0.152961367937792,10.097339563446,10.698,5.1324839380669,364.5633,0.46279454010665,0.406153717641221,0.468164898563218,0.427631576887237,0.0566408224654297,0.0405333216759817,True,0.208093821689184,0.0338009464970596,1.30869555843349,36.4568241004816
20606,2171:1549,Colon,HCC2998,SIDM00118,905971,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.772613762302539,0.0387992068398078,0.951901412165135,15.2298235015129,375.2613,0.978446284426433,0.98980036668647,0.105242846399015,0.735452131394005,0.443612037421965,0.291840093972039,9.62374726477051,7.7044,5.60607623674241,367.5569,0.755961065021647,0.608151798858655,0.764733385234066,0.684144242602944,0.147809266162991,0.0805891426311227,True,0.208093821689184,0.0338009464970596,1.30869555843349,36.4568241004816
20606,1510:1549,Colon,HCC2998,SIDM00118,905971,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.786460458192044,0.0387992068398078,0.951901412165135,15.2298235015129,375.2613,0.978446284426433,0.98980036668647,0.100019647791858,0.748632820765045,0.406032010852476,0.342600809912569,9.13592773176178,5.494,6.09389576975114,369.7673,0.769509313166315,0.596789984285832,0.778438849902894,0.679225931821127,0.172719328880483,0.099212918081767,True,0.208093821689184,0.0338009464970596,1.30869555843349,36.4568241004816
20606,1786:1549,Colon,HCC2998,SIDM00118,905971,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.607531403523282,0.0387992068398078,0.951901412165135,15.2298235015129,375.2613,0.978446284426433,0.98980036668647,0.0990050573174244,0.578310000948478,0.295672947656364,0.282637053292114,8.88877781157073,4.629,6.34104568994219,370.6323,0.594436844449731,0.478298655198081,0.60133480598089,0.517331555340836,0.11613818925165,0.0840032506400543,True,0.208093821689184,0.0338009464970596,1.30869555843349,36.4568241004816
20606,1372:1549,Colon,HCC2998,SIDM00118,905971,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.271369531056157,0.0387992068398078,0.951901412165135,15.2298235015129,375.2613,0.978446284426433,0.98980036668647,0.0573466442956214,0.258317039830947,0.074193440871165,0.184123598959782,6.96022195918624,1.216,8.26960154232668,374.0453,0.265520509368441,0.150342941030519,0.26860166134692,0.199164032063984,0.115177568337922,0.0694376292829358,True,0.208093821689184,0.0338009464970596,1.30869555843349,36.4568241004816
20606,1564:1549,Colon,HCC2998,SIDM00118,905971,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.818413017947233,0.0387992068398078,0.951901412165135,15.2298235015129,375.2613,0.978446284426433,0.98980036668647,0.129048701145351,0.779048507518301,0.57343848400748,0.205610023510822,10.7748985432136,17.1107,4.45492495829927,358.1506,0.800773176536694,0.684582964188239,0.810065505265152,0.758262991970545,0.116190212348455,0.0518025132946071,True,0.208093821689184,0.0338009464970596,1.30869555843349,36.4568241004816
20606,2048:1549,Colon,HCC2998,SIDM00118,905971,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.568481697130097,0.0387992068398078,0.951901412165135,15.2298235015129,375.2613,0.978446284426433,0.98980036668647,0.0411217479817353,0.541138530288171,0.447657164365739,0.0934813659224324,11.7331848759443,33.2461,3.49663862556862,342.0152,0.556228804321376,0.542388793317344,0.562683392273917,0.540399964782216,0.0138400110040323,0.0222834274917004,True,0.208093821689184,0.0338009464970596,1.30869555843349,36.4568241004816
20607,1372:1561,Colon,HCC2998,SIDM00118,905971,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.233865919627986,0.0824129054334678,0.281913024915691,7.04876763756725,2.586,0.701705130318719,0.740130875270739,0.0365753638332038,0.0659298488270152,0.0138449035695898,0.0520849452574255,3.22804753023049,0.183,3.82072010733676,2.403,0.164104915609663,0.0840054346894726,0.173091387790257,0.1019465273676,0.08009948092019,0.0711448604226571,True,0.208093821689184,0.0338009464970596,1.30869555843349,36.4568241004816
20607,1564:1561,Colon,HCC2998,SIDM00118,905971,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.321136599691983,0.0824129054334678,0.281913024915691,7.04876763756725,2.586,0.701705130318719,0.740130875270739,0.0441356496928237,0.0905325902303062,0.0148540227347191,0.0756785674955871,2.6845537012301,0.1256,4.36421393633715,2.4604,0.225343199536973,0.11342026668328,0.237683112611496,0.125735109895399,0.111922932853693,0.111948002716097,True,0.208093821689184,0.0338009464970596,1.30869555843349,36.4568241004816
20607,2048:1561,Colon,HCC2998,SIDM00118,905971,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.720615458526306,0.0824129054334678,0.281913024915691,7.04876763756725,2.586,0.701705130318719,0.740130875270739,0.078949725605812,0.203150883714159,0.109271655603466,0.0938792281106932,5.40673358498451,0.8286,1.64203405258274,1.7574,0.505659564234885,0.416735968523433,0.5333497500527,0.443772873522911,0.0889235957114519,0.0895768765297889,True,0.208093821689184,0.0338009464970596,1.30869555843349,36.4568241004816
20607,1011:1561,Colon,HCC2998,SIDM00118,905971,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.729980865196281,0.0824129054334678,0.281913024915691,7.04876763756725,2.586,0.701705130318719,0.740130875270739,0.0536645043168354,0.205791113838057,0.051839442084295,0.153951671753762,3.63416045953568,0.2425,3.41460717803157,2.3435,0.512231318142728,0.336644351925192,0.540281376688615,0.34276135792532,0.175586966217536,0.197520018763295,True,0.208093821689184,0.0338009464970596,1.30869555843349,36.4568241004816
20608,2048:1598,Colon,HCC2998,SIDM00118,905971,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1598,LGK974,PORCN,WNT signaling,Targeted,Early clinical trials,10.0,0.679717508272906,0.0624904809927963,0.914800924124555,13.9537009722353,309.8936,0.95273992119972,0.981577638237324,0.0677006699522747,0.621806204711694,0.588955848288717,0.0328503564229766,12.9027361866231,149.5687,1.05096478561218,160.3249,0.647594005269998,0.61268463384827,0.667195506439078,0.659567965205712,0.0349093714217281,0.0076275412333655,True,0.208093821689184,0.0338009464970596,1.30869555843349,36.4568241004816
20608,1053:1786,Colon,HCC2998,SIDM00118,905971,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10.0,0.612898977491551,0.0726223151011612,0.725544878651326,11.0287461474908,40.805,0.904007511811475,0.933699581768855,0.086525671594832,0.444685714249629,0.204494581729398,0.240191132520231,7.55645906296631,3.6766,3.47228708452445,37.1284,0.554065279633934,0.501432532957218,0.57226351895042,0.474604350881748,0.0526327466767159,0.0976591680686721,True,0.208093821689184,0.0338009464970596,1.30869555843349,36.4568241004816
20608,1373:1786,Colon,HCC2998,SIDM00118,905971,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,1,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10.0,0.857695881586891,0.0726223151011612,0.725544878651326,11.0287461474908,40.805,0.904007511811475,0.933699581768855,0.0276164241854361,0.622296854325703,0.767256149442813,-0.144959295117111,13.4620721100154,220.403,-2.43332596252467,-179.598,0.775363519804315,0.85229864719272,0.80083028592255,0.837925948793552,-0.0769351273884054,-0.0370956628710024,True,0.208093821689184,0.0338009464970596,1.30869555843349,36.4568241004816
20608,1510:1786,Colon,HCC2998,SIDM00118,905971,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10.0,0.824085037762659,0.0726223151011612,0.725544878651326,11.0287461474908,40.805,0.904007511811475,0.933699581768855,0.0914191074813121,0.597910678721881,0.323088397418003,0.274822281303878,8.0845336520624,5.3017,2.94421249542836,35.5033,0.744979064508886,0.662082872166639,0.769447855100966,0.665252391966749,0.0828961923422477,0.104195463134217,True,0.208093821689184,0.0338009464970596,1.30869555843349,36.4568241004816
19374,1179:1003,Colon,COLO-205,SIDM00826,905961,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.25,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.1,0.938986957794575,0.0910943429069719,0.664943645964018,10.6019593954823,0.3036,0.853374931312996,0.906254801392049,0.0845111905533466,0.624373411228587,0.26645839248028,0.357915018748306,6.8361121439153,0.0223,3.76584725156701,0.2813,0.801307930611745,0.681902858221927,0.850961438945847,0.670100505009939,0.119405072389818,0.180860933935908,True,0.470030446985157,0.0401915957219674,0.714148009281862,68.0355140430849
19374,1022:1003,Colon,COLO-205,SIDM00826,905961,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.1,0.960297575026448,0.0910943429069719,0.664943645964018,10.6019593954823,0.3036,0.853374931312996,0.906254801392049,0.107035881844098,0.638543770748492,0.194553070710888,0.443990700037604,5.79763203298876,0.0109,4.80432736249355,0.2927,0.819493877128232,0.631348349642575,0.87027428813286,0.613885804363166,0.188145527485657,0.256388483769693,True,0.470030446985157,0.0401915957219674,0.714148009281862,68.0355140430849
21209,1047:1017,Colon,COLO-205,SIDM00826,905961,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,1.0,0.110885147762825,0.68515450933403,10.8173575555646,35.2435,0.878335591778762,0.913110228552935,0.0538514688723539,0.68515450933403,0.795121581211454,-0.109967071877424,12.1694939051105,89.9731,-1.35213634954588,-54.7296,0.878335591778762,0.9619339669184,0.913110228552935,0.947249545373428,-0.0835983751396376,-0.0341393168204931,True,0.275120103108335,0.034089133402475,1.2285655485732,40.053299014619
19375,1083:1022,Colon,COLO-205,SIDM00826,905961,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.942906199105916,0.166416642459092,0.769656510369565,11.8195944721121,7.0596,0.873734677858048,0.939775939260591,0.162330738638066,0.72571389480969,0.672554705127127,0.0531591896825627,11.1300772712597,4.3774,0.689517200852404,2.6822,0.823849844126163,0.78844427587187,0.886120558899396,0.869667899953658,0.0354055682542935,0.016452658945738,True,0.470030446985157,0.0401915957219674,0.714148009281862,68.0355140430849
19375,1073:1022,Colon,COLO-205,SIDM00826,905961,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,2.5,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.690800657147861,0.166416642459092,0.769656510369565,11.8195944721121,7.0596,0.873734677858048,0.939775939260591,0.0644902786655195,0.531679223141426,0.143260872735886,0.388418350405539,5.86629041859433,0.1139,5.95330405351782,6.9457,0.603576489637214,0.42141494020387,0.649197836412965,0.445134219653618,0.182161549433344,0.204063616759348,True,0.470030446985157,0.0401915957219674,0.714148009281862,68.0355140430849
19375,1089:1022,Colon,COLO-205,SIDM00826,905961,1089,Oxaliplatin,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved in colon,1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.959440640075135,0.166416642459092,0.769656510369565,11.8195944721121,7.0596,0.873734677858048,0.939775939260591,0.052748892993229,0.738439734946971,0.620562229030351,0.11787750591662,10.4139999997356,2.6647,1.40559447237654,4.3949,0.838296558579967,0.876313761724725,0.901659228691393,0.863422694780113,-0.0380172031447581,0.0382365339112799,True,0.470030446985157,0.0401915957219674,0.714148009281862,68.0355140430849
19375,2048:1022,Colon,COLO-205,SIDM00826,905961,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.653455931857389,0.166416642459092,0.769656510369565,11.8195944721121,7.0596,0.873734677858048,0.939775939260591,0.0344063302338571,0.50293661219365,0.338874275703956,0.164062336489694,9.17385747952957,1.1281,2.64573699258257,5.9315,0.570947108115846,0.583977270269763,0.614102162126682,0.555120028959115,-0.0130301621539171,0.0589821331675678,True,0.470030446985157,0.0401915957219674,0.714148009281862,68.0355140430849
19375,1510:1022,Colon,COLO-205,SIDM00826,905961,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.395747237148579,0.166416642459092,0.769656510369565,11.8195944721121,7.0596,0.873734677858048,0.939775939260591,0.0749734180553804,0.304589437532172,0.170592846273079,0.133996591259093,8.35139761513279,0.6379,3.46819685697935,6.4217,0.345778084763226,0.30324008687508,0.37191373150109,0.319589295485339,0.0425379978881458,0.0523244360157512,True,0.470030446985157,0.0401915957219674,0.714148009281862,68.0355140430849
19375,1017:1022,Colon,COLO-205,SIDM00826,905961,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,2.5,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.880819034568706,0.166416642459092,0.769656510369565,11.8195944721121,7.0596,0.873734677858048,0.939775939260591,0.133030693038972,0.67792810441324,0.49575716687788,0.18217093753536,9.5905814651083,1.5059,2.22901300700385,5.5537,0.769602135420125,0.729347220608187,0.827772535530413,0.764697164573219,0.0402549148119372,0.0630753709571937,True,0.470030446985157,0.0401915957219674,0.714148009281862,68.0355140430849
19375,1561:1022,Colon,COLO-205,SIDM00826,905961,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.761621367144175,0.166416642459092,0.769656510369565,11.8195944721121,7.0596,0.873734677858048,0.939775939260591,0.0480628284497773,0.586186843659084,0.507087448079057,0.0790993955800263,10.6109480152049,3.0545,1.2086464569072,4.0051,0.665454999871522,0.696560276300589,0.715753435668853,0.690447364809304,-0.0311052764290671,0.0253060708595488,True,0.470030446985157,0.0401915957219674,0.714148009281862,68.0355140430849
19375,1179:1022,Colon,COLO-205,SIDM00826,905961,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.514494815799211,0.166416642459092,0.769656510369565,11.8195944721121,7.0596,0.873734677858048,0.939775939260591,0.0377071523804945,0.395984284531253,0.167804281428633,0.22818000310262,7.30401143746927,0.3086,4.51558303464287,6.751,0.449531962141959,0.383911925265947,0.483509848762409,0.383163675600458,0.0656200368760119,0.100346173161951,True,0.470030446985157,0.0401915957219674,0.714148009281862,68.0355140430849
19375,1003:1022,Colon,COLO-205,SIDM00826,905961,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.025,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.874489977259338,0.166416642459092,0.769656510369565,11.8195944721121,7.0596,0.873734677858048,0.939775939260591,0.105630500869401,0.673056904250583,0.0693824694249404,0.603674434825642,3.27060211143224,0.0188,8.54899236067991,7.0408,0.764072218570779,0.382630562984077,0.821824639752867,0.387051866158349,0.381441655586702,0.434772773594519,True,0.470030446985157,0.0401915957219674,0.714148009281862,68.0355140430849
21208,1561:1025,Colon,COLO-205,SIDM00826,905961,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.839177924507033,0.101041192961635,0.651221828631918,10.4594120926987,27.4996,0.883378877803048,0.901483116761171,0.119207792809636,0.546490982545008,0.32017094660873,0.226320035936278,7.87096276274443,4.5722,2.58844932995428,22.9274,0.741312053228113,0.573445273240269,0.756504730901771,0.654545647842189,0.167866779987844,0.101959083059582,True,0.275120103108335,0.034089133402475,1.2285655485732,40.053299014619
19374,1011:1032,Colon,COLO-205,SIDM00826,905961,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.469371851716622,0.0967214006279397,0.564264815459688,9.6041533636666,15.2009,0.892586742567571,0.868743958128108,0.0517806577611564,0.264850021290851,0.104923233497153,0.159926787793698,6.08975784645125,1.3302,3.51439551721534,13.8707,0.418955092176648,0.284616283182672,0.407763960294217,0.310176421113793,0.134338808993976,0.0975875391804242,True,0.470030446985157,0.0401915957219674,0.714148009281862,68.0355140430849
19378,1011:1053,Colon,COLO-205,SIDM00826,905961,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.375284827028864,0.0460947359935408,0.26319616701365,6.59398340869491,1.8868,0.692819733035104,0.696909859511909,0.0632532257327996,0.0987735280123777,0.0318382961665481,0.0669352318458296,3.44117459174829,0.2121,3.15280881694662,1.6747,0.260004733674263,0.163633480596348,0.261539696081637,0.171118551214852,0.0963712530779144,0.0904211448667843,True,0.470030446985157,0.0401915957219674,0.714148009281862,68.0355140430849
22201,1179:1059,Colon,COLO-205,SIDM00826,905961,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,1,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.793282238419162,0.0641302406026197,0.315836141827685,7.19336680846,0.2859,0.74970150845145,0.737539966235965,0.072104814062986,0.250547201562738,0.0737840937881186,0.17676310777462,3.67712189093133,0.025,3.51624491752867,0.2609,0.594724890770589,0.358346826815503,0.58507735533926,0.376436034831473,0.236378063955086,0.208641320507787,True,0.217782615788915,0.0278847677864423,1.4588028315805,33.8710974050001
21210,1179:1073,Colon,COLO-205,SIDM00826,905961,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,1,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,20.0,0.603297564429691,0.127735510900919,0.287819991932306,6.88246223601482,4.6088,0.683826349057444,0.71679712556681,0.122004303769419,0.173641100126934,0.053199114309207,0.120441985817727,3.54005446863598,0.4544,3.34240776737883,4.1544,0.412550770879204,0.251686046970505,0.43244196004466,0.279772969571057,0.160864723908699,0.152668990473603,True,0.275120103108335,0.034089133402475,1.2285655485732,40.053299014619
21210,1022:1073,Colon,COLO-205,SIDM00826,905961,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,20.0,0.892271594108448,0.127735510900919,0.287819991932306,6.88246223601482,4.6088,0.683826349057444,0.71679712556681,0.170357328883754,0.256813603017719,0.0829241994626106,0.173889403555109,3.67504048647749,0.499,3.20742174953733,4.1098,0.610158826566845,0.415973726374088,0.639577713881851,0.423263104567626,0.194185100192757,0.216314609314225,True,0.275120103108335,0.034089133402475,1.2285655485732,40.053299014619
18963,1372:1549,Colon,COLO-205,SIDM00826,905961,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.258811845821125,0.0749813619697217,0.884227225473458,13.7518268885578,134.7139,0.945048747283963,0.971666043653668,0.0412519600863459,0.228848480350078,0.156252271726665,0.0725962086234124,9.98404762329951,9.89,3.76777926525828,124.8239,0.244589810675504,0.201597447350902,0.251478682279716,0.228834338405802,0.0429923633246022,0.0226443438739135,True,0.256454194040285,0.0329463405048502,1.27736688997614,38.4063021517707
18963,1373:1549,Colon,COLO-205,SIDM00826,905961,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.369777926818252,0.0749813619697217,0.884227225473458,13.7518268885578,134.7139,0.945048747283963,0.971666043653668,0.0640699882386707,0.326967710271831,0.19792433534242,0.129043374929411,9.33011764305873,6.2856,4.42170924549906,128.4283,0.34945816651285,0.267229879463035,0.359300655181947,0.316794021032585,0.0822282870498148,0.0425066341493618,True,0.256454194040285,0.0329463405048502,1.27736688997614,38.4063021517707
18963,1510:1549,Colon,COLO-205,SIDM00826,905961,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,1,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.473241957141997,0.0749813619697217,0.884227225473458,13.7518268885578,134.7139,0.945048747283963,0.971666043653668,0.0352970332334762,0.418453422741297,0.321055957709467,0.0973974650318298,10.7447850497714,16.7572,3.00704183878637,117.9567,0.447236718759255,0.423263073317429,0.459833140187083,0.431051288214306,0.0239736454418255,0.0287818519727761,True,0.256454194040285,0.0329463405048502,1.27736688997614,38.4063021517707
18963,1179:1549,Colon,COLO-205,SIDM00826,905961,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.25,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.936364500329061,0.0749813619697217,0.884227225473458,13.7518268885578,134.7139,0.945048747283963,0.971666043653668,0.0466942338255323,0.827958984157807,0.841822261447969,-0.0138632772901625,14.1104487922887,172.7302,-0.358621903730901,-38.0163,0.884910098037153,0.936364500329061,0.909833589452482,0.913411275347348,-0.0514544022919081,-0.0035776858948656,True,0.256454194040285,0.0329463405048502,1.27736688997614,38.4063021517707
18963,2171:1549,Colon,COLO-205,SIDM00826,905961,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.441011369541218,0.0749813619697217,0.884227225473458,13.7518268885578,134.7139,0.945048747283963,0.971666043653668,0.0468327621619652,0.389954259691681,0.250329715982821,0.13962454370886,9.63613774587096,7.7708,4.11568914268683,126.9431,0.416777242322913,0.352572463124173,0.428515772648401,0.383723376777208,0.06420477919874,0.044792395871193,True,0.256454194040285,0.0329463405048502,1.27736688997614,38.4063021517707
18964,1372:1561,Colon,COLO-205,SIDM00826,905961,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.222631138240908,0.127852485371114,0.308579085453673,7.11437546470349,2.7063,0.664568057417285,0.732341054811607,0.0298895110634548,0.0686993130318897,0.0181690483413258,0.0505302646905639,3.34230546043603,0.1981,3.77207000426746,2.5082,0.14795354306136,0.079979054877108,0.163041922613256,0.0997867770546661,0.0679744881842516,0.0632551455585896,True,0.256454194040285,0.0329463405048502,1.27736688997614,38.4063021517707
18964,1564:1561,Colon,COLO-205,SIDM00826,905961,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.238027532591834,0.127852485371114,0.308579085453673,7.11437546470349,2.7063,0.664568057417285,0.732341054811607,0.0288312373006915,0.0734503183199822,0.0195381046034762,0.053912213716506,3.35701163611753,0.2001,3.75736382858596,2.5062,0.158185494946384,0.0871727471574098,0.174317334292508,0.106961969244317,0.0710127477889747,0.0673553650481907,True,0.256454194040285,0.0329463405048502,1.27736688997614,38.4063021517707
18964,1373:1561,Colon,COLO-205,SIDM00826,905961,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.272261905074627,0.127852485371114,0.308579085453673,7.11437546470349,2.7063,0.664568057417285,0.732341054811607,0.0239337422661126,0.0840143296718029,0.0230980991313636,0.0609162305404393,3.44117782336822,0.2121,3.67319764133527,2.4942,0.180936565364174,0.108433913142314,0.19938857074737,0.124143278157016,0.0725026522218603,0.0752452925903537,True,0.256454194040285,0.0329463405048502,1.27736688997614,38.4063021517707
18964,1011:1561,Colon,COLO-205,SIDM00826,905961,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.781544344265962,0.127852485371114,0.308579085453673,7.11437546470349,2.7063,0.664568057417285,0.732341054811607,0.0579844885403411,0.241168238995081,0.0529663246241522,0.188201914370928,2.87304337212796,0.1431,4.24133209257553,2.5632,0.519389406654296,0.31143416810494,0.572357009461781,0.321758166422937,0.207955238549357,0.250598843038843,True,0.256454194040285,0.0329463405048502,1.27736688997614,38.4063021517707
18964,1179:1561,Colon,COLO-205,SIDM00826,905961,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.49751356353731,0.127852485371114,0.308579085453673,7.11437546470349,2.7063,0.664568057417285,0.732341054811607,0.092627340036668,0.153522280437141,0.0308494602123779,0.122672820224763,2.65088287907376,0.1227,4.46349258562973,2.5836,0.330631622458741,0.194241982938793,0.364349607903995,0.196330315848074,0.136389639519948,0.168019292055921,True,0.256454194040285,0.0329463405048502,1.27736688997614,38.4063021517707
18965,1011:1786,Colon,COLO-205,SIDM00826,905961,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10.0,0.82403731698876,0.0979559325955142,0.64396538247671,10.3850940376845,26.1189,0.877189363655059,0.898919788690184,0.149359530707011,0.530651506009749,0.323260452366362,0.207391053643387,7.97698041181001,4.9209,2.40811362587453,21.198,0.722836769717392,0.59693302503348,0.740743450860362,0.647904597086411,0.125903744683912,0.0928388537739513,True,0.256454194040285,0.0329463405048502,1.27736688997614,38.4063021517707
19097,1047:1025,Colon,GP5d,SIDM00537,907291,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.5048340324531,0.0509719329044523,0.885287252133022,13.796053271294,277.8151,0.976981153812548,0.971832169839917,0.0644991718188249,0.446923133373638,0.22502564575797,0.221897487615668,8.48861026805821,7.0155,5.30744300323578,270.7996,0.493213335509871,0.41457097475098,0.490613953167931,0.41115766800827,0.0786423607588904,0.0794562851596611,True,,,,
19097,2048:1025,Colon,GP5d,SIDM00537,907291,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.927589696586466,0.0509719329044523,0.885287252133022,13.796053271294,277.8151,0.976981153812548,0.971832169839917,0.0990151051412488,0.821183333597937,0.687169539346193,0.134013794251743,11.4648046760844,55.2052,2.3312485952096,222.6099,0.906237652035677,0.837855168515117,0.901461507554776,0.863348439918114,0.0683824835205595,0.0381130676366614,True,,,,
19100,1022:1179,Colon,GP5d,SIDM00537,907291,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,10.0,0.944963895459731,0.17322115222989,0.15416185809981,5.00464058082928,0.627,0.617618857740154,0.578671621445741,0.0608084065804697,0.145677389961307,0.0214047131023447,0.124272676858962,0.164421922081903,0.0219,4.84021865874738,0.6051,0.583627521719525,0.165056645318013,0.546823789593366,0.210418799295297,0.418570876401512,0.336404990298069,True,,,,
19097,1011:1194,Colon,GP5d,SIDM00537,907291,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,10.0,0.927022651620795,0.0673496028799784,0.725525652836271,11.2813762441499,48.6141,0.930162308484813,0.925944010686538,0.047831515855386,0.672578714511189,0.603704025017044,0.0688746894941442,10.4655752086152,27.6174,0.815801035534683,20.9967,0.862281529649312,0.862726310928516,0.858371072039028,0.835345323074658,-0.0004447812792042,0.0230257489643702,True,,,,
19097,1373:1194,Colon,GP5d,SIDM00537,907291,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,1,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,10.0,0.92162608333152,0.0673496028799784,0.725525652836271,11.2813762441499,48.6141,0.930162308484813,0.925944010686538,0.0761046654136843,0.668663365780037,0.680743357212025,-0.0120799914319885,11.43824172463,54.1981,-0.15686548048015,-5.584,0.857261845231464,0.865712649494311,0.853374151953313,0.85717275292011,-0.0084508042628469,-0.0037986009667967,True,,,,
19097,1025:1194,Colon,GP5d,SIDM00537,907291,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,2.5,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,10.0,0.923320217673401,0.0673496028799784,0.725525652836271,11.2813762441499,48.6141,0.930162308484813,0.925944010686538,0.0309819132155842,0.669892503704423,0.564152752483803,0.10573975122062,10.0597564237998,20.8458,1.22161982035008,27.7683,0.858837665141791,0.819458581627877,0.854942825500477,0.81849926202884,0.0393790835139148,0.0364435634716365,True,,,,
19097,1022:1194,Colon,GP5d,SIDM00537,907291,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,10.0,0.969943055133495,0.0673496028799784,0.725525652836271,11.2813762441499,48.6141,0.930162308484813,0.925944010686538,0.100455428029785,0.703718568289736,0.460703995229194,0.243014573060543,8.76492002587697,8.4964,2.5164562182729,40.1177,0.902204471261784,0.797612477340308,0.898112962607862,0.803988423313693,0.104591993921476,0.0941245392941686,True,,,,
19194,1073:1510,Colon,GP5d,SIDM00537,907291,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,10,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.452676776558812,0.0656760951991101,0.814628600878684,12.4744329881473,111.1498,0.937879800780202,0.952633524308635,0.0565824782658806,0.368763449138378,0.357478192451445,0.0112852566869323,12.1053396665131,86.0598,0.369093321634175,25.09,0.424556405016803,0.41631782494053,0.431235073025894,0.427990821509046,0.0082385800762723,0.0032442515168478,True,0.407105143114998,0.0495901856250191,0.846463078464426,57.4925995795047
19194,1025:1510,Colon,GP5d,SIDM00537,907291,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,2.5,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.963913824723184,0.0656760951991101,0.814628600878684,12.4744329881473,111.1498,0.937879800780202,0.952633524308635,0.0448186007425095,0.785231770401868,0.54865134479318,0.236580425608688,9.65376285413378,15.7327,2.82067013401349,95.4171,0.904035305900662,0.810152483948596,0.918256623975862,0.838827556728901,0.0938828219520658,0.0794290672469613,True,0.407105143114998,0.0495901856250191,0.846463078464426,57.4925995795047
19194,1032:1510,Colon,GP5d,SIDM00537,907291,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.686926366970584,0.0656760951991101,0.814628600878684,12.4744329881473,111.1498,0.937879800780202,0.952633524308635,0.0542479194086141,0.559589865231924,0.337760136683653,0.221829728548271,8.922051089404,9.474,3.55238189874328,101.6758,0.644254364205039,0.552684212605474,0.654389085907714,0.574811434869639,0.0915701515995652,0.0795776510380749,True,0.407105143114998,0.0495901856250191,0.846463078464426,57.4925995795047
19194,2048:1510,Colon,GP5d,SIDM00537,907291,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.900178242631775,0.0656760951991101,0.814628600878684,12.4744329881473,111.1498,0.937879800780202,0.952633524308635,0.0677298396309021,0.733310942336555,0.527331763699902,0.205979178636653,9.81361893863432,17.5761,2.66081404951295,93.5737,0.844258990866161,0.757770967884041,0.857539971784261,0.789295352101864,0.0864880229821204,0.0682446196823973,True,0.407105143114998,0.0495901856250191,0.846463078464426,57.4925995795047
19194,1549:1510,Colon,GP5d,SIDM00537,907291,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.697105642441553,0.0656760951991101,0.814628600878684,12.4744329881473,111.1498,0.937879800780202,0.952633524308635,0.0363766346381298,0.567882194166798,0.30867762774139,0.259204566425408,8.46063460219295,6.8807,4.01379838595432,104.2691,0.653801301055838,0.55830648684816,0.664086204974532,0.566701645054005,0.0954948142076778,0.0973845599205261,True,0.407105143114998,0.0495901856250191,0.846463078464426,57.4925995795047
19100,1073:1549,Colon,GP5d,SIDM00537,907291,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,10,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.797279338920259,0.0840046632613145,0.728684526972145,11.3187405403053,24.9448,0.884331182346213,0.926943971141444,0.0793446849025616,0.580965117945773,0.415543860923875,0.165421257021898,9.19916718694166,5.7402,2.11957335336365,19.2046,0.70505898044756,0.620622473288088,0.73903327652777,0.677757907978137,0.0844365071594716,0.061275368549633,True,,,,
19100,2171:1549,Colon,GP5d,SIDM00537,907291,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.781461363627102,0.0840046632613145,0.728684526972145,11.3187405403053,24.9448,0.884331182346213,0.926943971141444,0.156793084550806,0.569438804101622,0.15207729063741,0.417361513464212,5.66642966774619,0.496,5.65231087255913,24.4488,0.691070651654239,0.418361867076696,0.724370899694114,0.491671950334961,0.272708784577543,0.232698949359153,True,,,,
19100,1083:1549,Colon,GP5d,SIDM00537,907291,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.954249069101905,0.0840046632613145,0.728684526972145,11.3187405403053,24.9448,0.884331182346213,0.926943971141444,0.129244083123178,0.695346531532131,0.374986733103974,0.320359798428157,7.97937157486434,2.4645,3.33936896544097,22.4803,0.84387220753166,0.655649400216582,0.884535421571345,0.749890252867375,0.188222807315078,0.13464516870397,True,,,,
19100,1510:1549,Colon,GP5d,SIDM00537,907291,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.798730930825172,0.0840046632613145,0.728684526972145,11.3187405403053,24.9448,0.884331182346213,0.926943971141444,0.0788418375624045,0.582022870506362,0.408770223216409,0.173252647289953,9.11056070444801,5.3982,2.20817983585731,19.5466,0.706342668433116,0.631501530424137,0.740378820892587,0.675662233902146,0.0748411380089787,0.0647165869904412,True,,,,
19100,1786:1549,Colon,GP5d,SIDM00537,907291,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.880192283728259,0.0840046632613145,0.728684526972145,11.3187405403053,24.9448,0.884331182346213,0.926943971141444,0.140374282702172,0.641382497913059,0.402565337815646,0.238817160097412,8.59872710793092,3.7859,2.72001343237439,21.1589,0.778381482961425,0.644403642904895,0.815888930847129,0.722017398747229,0.13397784005653,0.0938715320999005,True,,,,
19100,2048:1549,Colon,GP5d,SIDM00537,907291,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.893930722436119,0.0840046632613145,0.728684526972145,11.3187405403053,24.9448,0.884331182346213,0.926943971141444,0.142750112746079,0.651393485624231,0.576609094312394,0.0747843913118373,10.4017436694343,13.211,0.916996870871017,11.7338,0.790530812707537,0.698686288896806,0.828623693780275,0.80356159013798,0.0918445238107314,0.0250621036422951,True,,,,
19100,1059:1549,Colon,GP5d,SIDM00537,907291,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.837386349573281,0.0840046632613145,0.728684526972145,11.3187405403053,24.9448,0.884331182346213,0.926943971141444,0.121652547084768,0.610190476031737,0.394851382641347,0.215339093390391,8.73241826170291,4.1536,2.5863222786024,20.7912,0.740526860598719,0.609505938208656,0.776210228253094,0.692720279199013,0.131020922390062,0.0834899490540807,True,,,,
19100,1047:1549,Colon,GP5d,SIDM00537,907291,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.751089860165283,0.0840046632613145,0.728684526972145,11.3187405403053,24.9448,0.884331182346213,0.926943971141444,0.121559542667349,0.547307559468114,0.371786221962903,0.17552133750521,8.9530176659518,4.8398,2.36572287435352,20.105,0.664212184088216,0.560733103296069,0.696218217665679,0.629647830532209,0.103479080792148,0.0665703871334695,True,,,,
19101,1786:1564,Colon,GP5d,SIDM00537,907291,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.915249955410674,0.101293513917967,0.698442615277495,10.9712295198815,19.6051,0.864601334793787,0.917191223092901,0.142271609435602,0.639249572489642,0.662232075201787,-0.0229825027121453,11.258181473313,23.9194,-0.286951953431483,-4.3143,0.791326333118023,0.749379424992487,0.839459226038839,0.846896769183622,0.0419469081255364,-0.0074375431447825,True,,,,
19101,1598:1564,Colon,GP5d,SIDM00537,907291,1598,LGK974,PORCN,WNT signaling,Targeted,Early clinical trials,10,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.889112031603548,0.101293513917967,0.698442615277495,10.9712295198815,19.6051,0.864601334793787,0.917191223092901,0.0806692919280395,0.620993732627868,0.415384964429938,0.205608768197931,8.69154382522986,4.0375,2.27968569465167,15.5676,0.768727449305644,0.690907158513705,0.815485751733073,0.733638499746638,0.0778202907919386,0.0818472519864343,True,,,,
19101,2048:1564,Colon,GP5d,SIDM00537,907291,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.777576630648854,0.101293513917967,0.698442615277495,10.9712295198815,19.6051,0.864601334793787,0.917191223092901,0.0870346953061653,0.543092655489048,0.447484621071667,0.095608034417381,9.7141239195059,8.2024,1.25710560037563,11.4027,0.672293792763455,0.642749507289804,0.713186460913279,0.678629439057081,0.0295442854736507,0.0345570218561989,True,,,,
19101,1510:1564,Colon,GP5d,SIDM00537,907291,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.938185368137049,0.101293513917967,0.698442615277495,10.9712295198815,19.6051,0.864601334793787,0.917191223092901,0.0906358785433379,0.65526864213672,0.533075295505631,0.122193346631089,9.64426102419168,7.8147,1.32696849568985,11.7904,0.811156321575294,0.747471432511116,0.860495385289484,0.816062813422221,0.0636848890641778,0.0444325718672637,True,,,,
19101,1059:1564,Colon,GP5d,SIDM00537,907291,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.834042147271453,0.101293513917967,0.698442615277495,10.9712295198815,19.6051,0.864601334793787,0.917191223092901,0.0989778870702075,0.582530578591931,0.365853476965154,0.216677101626777,8.42113918040314,3.3475,2.55009033947839,16.2576,0.721113953805175,0.6185673814638,0.764976137166933,0.676237786780292,0.102546572341374,0.0887383503866409,True,,,,
19101,1011:1564,Colon,GP5d,SIDM00537,907291,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.91588713106262,0.101293513917967,0.698442615277495,10.9712295198815,19.6051,0.864601334793787,0.917191223092901,0.0772084309857174,0.639694603118378,0.57178347203535,0.067911131083028,10.1918483323981,11.4223,0.779381187483409,8.1828,0.791877236037194,0.792813750075924,0.840043637954373,0.816430797904593,-0.0009365140387307,0.0236128400497799,True,,,,
19101,1053:1564,Colon,GP5d,SIDM00537,907291,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.580638624093443,0.101293513917967,0.698442615277495,10.9712295198815,19.6051,0.864601334793787,0.917191223092901,0.0585705162427026,0.405542759142951,0.195468735174356,0.210074023968595,7.40806619776864,1.6586,3.56316332211288,17.9465,0.502020929424019,0.400686886005724,0.532556649807245,0.436008813722497,0.101334043418296,0.0965478360847473,True,,,,
19101,1047:1564,Colon,GP5d,SIDM00537,907291,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.78586434954309,0.101293513917967,0.698442615277495,10.9712295198815,19.6051,0.864601334793787,0.917191223092901,0.171509003887719,0.548881151548223,0.296496375020309,0.252384776527914,7.82396508349548,2.2128,3.14726443638605,17.3923,0.679459365581807,0.509426656263893,0.720787883942534,0.610325817334942,0.170032709317914,0.110462066607593,True,,,,
19195,1032:2171,Colon,GP5d,SIDM00537,907291,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.748298141195386,0.127727570795384,0.17053357129252,5.28739438652582,0.7628,0.553971050986514,0.600437545301501,0.0783118400789877,0.127609954409604,0.0288873789681255,0.0987225754414782,1.45432472725483,0.0535,3.83306965927099,0.7093,0.414535507729262,0.233935863559474,0.449306299053033,0.229635244955745,0.180599644169788,0.219671054097288,True,0.407105143114998,0.0495901856250191,0.846463078464426,57.4925995795047
22194,1549:1011,Colon,CCK-81,SIDM00487,1240123,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.467306812054025,0.180956732844327,0.413452590890829,8.02596890371897,5.0908,0.830441770074366,0.7646966705389,0.0798926411670998,0.19320921218467,0.0914764740047754,0.101732738179895,5.06428772838981,0.6535,2.96168117532915,4.4373,0.388071096169953,0.271430741400283,0.35734796329786,0.26900911542981,0.11664035476967,0.0883388478680502,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
22194,1032:1011,Colon,CCK-81,SIDM00487,1240123,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.498396464804806,0.180956732844327,0.413452590890829,8.02596890371897,5.0908,0.830441770074366,0.7646966705389,0.0650362738302444,0.206063309664377,0.0617179233709511,0.144345386293426,3.55031861433331,0.2288,4.47565028938566,4.862,0.413889242431309,0.212418360692743,0.381122117244593,0.233187982113985,0.201470881738566,0.147934135130608,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
22194,1598:1011,Colon,CCK-81,SIDM00487,1240123,1598,LGK974,PORCN,WNT signaling,Targeted,Early clinical trials,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.940384651559424,0.180956732844327,0.413452590890829,8.02596890371897,5.0908,0.830441770074366,0.7646966705389,0.123098450141605,0.388804470621213,0.295714065707545,0.093090404913668,6.82932629372419,2.2211,1.19664260999478,2.8697,0.780934694591773,0.690709374725674,0.719109012073374,0.652667507726907,0.0902253198660991,0.0664415043464675,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
22194,2171:1011,Colon,CCK-81,SIDM00487,1240123,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.73385388319685,0.180956732844327,0.413452590890829,8.02596890371897,5.0908,0.830441770074366,0.7646966705389,0.0936613035030276,0.303413789343033,0.136853954591954,0.16655983475108,4.89732133883272,0.5821,3.12864756488624,4.5087,0.609422917737939,0.429609774143791,0.561175621142673,0.413819286926949,0.179813143594148,0.147356334215725,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
22194,1025:1011,Colon,CCK-81,SIDM00487,1240123,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.725781248040531,0.180956732844327,0.413452590890829,8.02596890371897,5.0908,0.830441770074366,0.7646966705389,0.0796987046000573,0.300076137422337,0.100638603890255,0.199437533532082,3.91289951535203,0.2942,4.11306938836694,4.7966,0.602719064309561,0.353272500971897,0.555002503916161,0.358370106259419,0.249446563337664,0.196632397656742,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
22197,1059:1017,Colon,CCK-81,SIDM00487,1240123,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.835579221318535,0.0730062092664514,0.88362593975577,14.646323358255,500.8558,0.940594316697301,0.966550676562725,0.140931491901662,0.738339474677984,0.395783266586877,0.342556208091108,8.70631189336019,8.1581,5.94001146489484,492.6977,0.78594106672257,0.564248476354293,0.807629661687185,0.668697652540856,0.221692590368277,0.138932009146329,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
21293,1032:1025,Colon,CCK-81,SIDM00487,1240123,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.347123155230949,0.110031484158372,0.701997748884093,11.3864822444811,52.2881,0.860231902344448,0.90469394373235,0.0516240458926058,0.24367967355767,0.183211831586556,0.0604678419711144,9.3100468068361,12.3975,2.07643543764504,39.8906,0.298606412172127,0.248059485987301,0.314040216266704,0.287696932520497,0.0505469261848252,0.0263432837462073,True,0.378102148325947,0.0598590154009765,0.908638786741109,53.4731209271498
21293,1089:1025,Colon,CCK-81,SIDM00487,1240123,1089,Oxaliplatin,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved in colon,1,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.567772624829313,0.110031484158372,0.701997748884093,11.3864822444811,52.2881,0.860231902344448,0.90469394373235,0.0413455822326811,0.39857510450819,0.442212158497611,-0.0436370539894209,12.5066344940575,113.6586,-1.1201522495764,-61.3705,0.48841612515602,0.529332348927291,0.513660455100099,0.529482749157134,-0.0409162237712707,-0.0158222940570346,True,0.378102148325947,0.0598590154009765,0.908638786741109,53.4731209271498
21293,1047:1025,Colon,CCK-81,SIDM00487,1240123,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.619031491954622,0.110031484158372,0.701997748884093,11.3864822444811,52.2881,0.860231902344448,0.90469394373235,0.0380421042697086,0.434558713840506,0.274932302875302,0.159626410965204,8.37497611113536,6.4841,3.01150613334578,45.804,0.532510637935246,0.458238276189886,0.560034041750947,0.48494651582826,0.0742723617453595,0.0750875259226877,True,0.378102148325947,0.0598590154009765,0.908638786741109,53.4731209271498
22196,1372:1047,Colon,CCK-81,SIDM00487,1240123,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.803205701576123,0.0945091863641577,0.718437040748219,11.6090036687765,61.0082,0.914649790820733,0.910893522524331,0.0592861492733263,0.577052727352448,0.486310990152013,0.0907417372004341,10.1928627746898,22.8606,1.41614089408673,38.1476,0.734651926932621,0.709534510182468,0.731634870820301,0.694941140966634,0.0251174167501538,0.0366937298536677,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
22196,1032:1047,Colon,CCK-81,SIDM00487,1240123,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.519429209769385,0.0945091863641577,0.718437040748219,11.6090036687765,61.0082,0.914649790820733,0.910893522524331,0.051666801424043,0.373177184344903,0.261478358359134,0.111698825985769,9.03783050623958,10.2657,2.57117316253693,50.7425,0.475095818061747,0.431913915794842,0.473144702588865,0.424012956897644,0.0431819022669045,0.0491317456912208,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
22196,1025:1047,Colon,CCK-81,SIDM00487,1240123,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.678362757004232,0.0945091863641577,0.718437040748219,11.6090036687765,61.0082,0.914649790820733,0.910893522524331,0.143449917943387,0.487360931695924,0.297305045401371,0.190055886294553,8.30872318747276,6.1931,3.30028048130374,54.8151,0.620464353794497,0.45552882125871,0.617916241276902,0.529066664184999,0.164935532535787,0.0888495770919029,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
22196,2048:1047,Colon,CCK-81,SIDM00487,1240123,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.997275381427304,0.0945091863641577,0.718437040748219,11.6090036687765,61.0082,0.914649790820733,0.910893522524331,0.0799982673211575,0.716479573843684,0.544170109079823,0.172309464763861,9.5100832243337,14.2413,2.09892044444281,46.7669,0.912157719013151,0.877516063375163,0.908411685115113,0.835323095665192,0.0346416556379879,0.0730885894499202,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
22196,1059:1047,Colon,CCK-81,SIDM00487,1240123,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.821859050203024,0.0945091863641577,0.718437040748219,11.6090036687765,61.0082,0.914649790820733,0.910893522524331,0.060042278330075,0.590453983940003,0.375742503115186,0.214711480824817,8.52183921539503,7.1789,3.08716445338147,53.8293,0.751713208352322,0.620816591745773,0.748626085257933,0.650078608754542,0.13089661660655,0.0985474765033912,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
22196,1011:1047,Colon,CCK-81,SIDM00487,1240123,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.904562777716986,0.0945091863641577,0.718437040748219,11.6090036687765,61.0082,0.914649790820733,0.910893522524331,0.0307698704629873,0.649871405193981,0.558583428334213,0.0912879768597673,10.334203444071,25.2136,1.2748002247055,35.7946,0.827358155423062,0.790570621695241,0.823960374939018,0.787382999222961,0.0367875337278212,0.0365773757160577,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
22196,1083:1047,Colon,CCK-81,SIDM00487,1240123,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.794551483404395,0.0945091863641577,0.718437040748219,11.6090036687765,61.0082,0.914649790820733,0.910893522524331,0.0604609197220415,0.570835216459162,0.365238487542754,0.205596728916408,8.54980434098151,7.3194,3.05919932779499,53.6888,0.726736348092133,0.616109398753718,0.723751799545162,0.62961193470791,0.110626949338416,0.0941398648372518,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
22195,1372:1053,Colon,CCK-81,SIDM00487,1240123,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.844024787488374,0.0954514559074277,0.50788163408382,9.08781651653605,10.6276,0.786741023744449,0.818645394352058,0.0635506892504241,0.428664688276845,0.282876032274182,0.145788656002663,7.09216796723103,2.6649,1.99564854930502,7.9627,0.664028925374294,0.570332204433057,0.690957004996332,0.599565598557425,0.0936967209412374,0.0913914064389074,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
22195,1032:1053,Colon,CCK-81,SIDM00487,1240123,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.465749943411885,0.0954514559074277,0.50788163408382,9.08781651653605,10.6276,0.786741023744449,0.818645394352058,0.0427335602414204,0.236545842334475,0.0964239488597478,0.140121893474727,5.25961967570336,0.7482,3.82819684083268,9.8794,0.366424587288786,0.257109373862293,0.381284046093871,0.274481082787155,0.109315213426493,0.106802963306716,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
22195,1022:1053,Colon,CCK-81,SIDM00487,1240123,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.511992109567049,0.0954514559074277,0.50788163408382,9.08781651653605,10.6276,0.786741023744449,0.818645394352058,0.150999770714639,0.260031389244935,0.0616733425156097,0.198358046729325,3.4626362705627,0.2153,5.62518024597335,10.4123,0.40280519642986,0.204219280566189,0.419139982441659,0.236351027611979,0.198585915863671,0.18278895482968,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
22195,1564:1053,Colon,CCK-81,SIDM00487,1240123,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.873232723073969,0.0954514559074277,0.50788163408382,9.08781651653605,10.6276,0.786741023744449,0.818645394352058,0.0558419170880239,0.443498862330272,0.451675485536809,-0.0081766232065371,9.19220557053305,11.4251,-0.104389053997,-0.797500000000001,0.687008006518367,0.727182980921324,0.714867946942011,0.719078156310998,-0.0401749744029571,-0.0042102093689874,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
22195,1549:1053,Colon,CCK-81,SIDM00487,1240123,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.480913218116648,0.0954514559074277,0.50788163408382,9.08781651653605,10.6276,0.786741023744449,0.818645394352058,0.0422846639033684,0.244246991069592,0.101374398731437,0.142872592338155,5.32309216104624,0.7819,3.76472435548981,9.8457,0.378354157553329,0.271632710009669,0.393697391094221,0.285543320947835,0.10672144754366,0.108154070146385,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
22196,1032:1054,Colon,CCK-81,SIDM00487,1240123,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,1,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.503680092015429,0.102344314789069,0.769760419759012,12.361680645174,41.1175,0.901774277520605,0.929405689147044,0.119421403573326,0.387712999054054,0.167122792329136,0.220590206724919,7.05021568229496,1.0354,5.31146496287908,40.0821,0.454205751078726,0.268642051871769,0.468123143029246,0.356498696889593,0.185563699206957,0.111624446139654,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
22884,1047:1059,Colon,CCK-81,SIDM00487,1240123,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.825669391633791,0.12879443124326,0.632234344360468,10.5090872460689,2.8463,0.843349979310418,0.876732037601746,0.116088039194621,0.522016546478096,0.256907152117439,0.265109394360658,6.78642991973809,0.2156,3.72265732633082,2.6307,0.696328264351603,0.530742052738438,0.723890808112488,0.570818646643157,0.165586211613165,0.153072161469331,True,0.412532572045341,0.0758581816042552,0.812890189154335,59.1689122387981
22884,1022:1059,Colon,CCK-81,SIDM00487,1240123,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.450177065278692,0.12879443124326,0.632234344360468,10.5090872460689,2.8463,0.843349979310418,0.876732037601746,0.0804242691637148,0.284617401712593,0.162681184346376,0.121936217366217,7.41403438152661,0.3331,3.0950528645423,2.5132,0.379656818688809,0.284066246926148,0.394684655723362,0.328522536965223,0.0955905717626609,0.0661621187581385,True,0.412532572045341,0.0758581816042552,0.812890189154335,59.1689122387981
22885,1022:1179,Colon,CCK-81,SIDM00487,1240123,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,10.0,0.436319008832842,0.136049365323296,0.140621046652547,3.95830634483734,0.3036,0.505003904809133,0.4970184289299,0.0414450508966206,0.0613556356964762,0.0240335743102946,0.0373220613861815,1.0835876960554,0.0414,2.87471864878194,0.2622,0.220342803203036,0.103697397713504,0.21685858828235,0.131115209598843,0.116645405489532,0.0857433786835072,True,0.412532572045341,0.0758581816042552,0.812890189154335,59.1689122387981
21293,1089:1194,Colon,CCK-81,SIDM00487,1240123,1089,Oxaliplatin,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved in colon,5,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,10.0,0.411500882831413,0.125455252402108,0.649037412973334,10.7124007615014,32.7706,0.886698177135748,0.883727951263878,0.0846384047111528,0.267079468429143,0.152608474931707,0.114470993497436,7.52789329615887,3.6046,3.18450746534249,29.166,0.364877082696365,0.24415017405008,0.363654832127882,0.303054454187354,0.120726908646285,0.060600377940528,True,0.378102148325947,0.0598590154009765,0.908638786741109,53.4731209271498
21293,1047:1194,Colon,CCK-81,SIDM00487,1240123,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,10.0,0.826244872645806,0.125455252402108,0.649037412973334,10.7124007615014,32.7706,0.886698177135748,0.883727951263878,0.069560699014098,0.536263834624516,0.463347367157011,0.0729164674675055,9.68059384758498,16.028,1.03180691391638,16.7426,0.732629822442794,0.707414582210014,0.730175688545562,0.698054210408305,0.0252152402327802,0.0321214781372575,True,0.378102148325947,0.0598590154009765,0.908638786741109,53.4731209271498
22192,1022:1372,Colon,CCK-81,SIDM00487,1240123,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.870060552901133,0.136184921487553,0.390938280185981,7.76510455398277,0.4249,0.678735498060136,0.750129310669473,0.162526193123648,0.340139976208833,0.315906809915095,0.0242331662937378,7.43470447431681,0.3379,0.330400079665957,0.087,0.590540982715828,0.539774739282533,0.652657922788428,0.636001614504774,0.0507662434332949,0.0166563082836534,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
22192,1510:1372,Colon,CCK-81,SIDM00487,1240123,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.671323642635989,0.136184921487553,0.390938280185981,7.76510455398277,0.4249,0.678735498060136,0.750129310669473,0.0801855529494629,0.262446110300302,0.147381422342496,0.115064687957806,5.46730906498459,0.0864,2.29779548899818,0.3385,0.455651186944083,0.374015309807454,0.503579541286654,0.405313182464739,0.0816358771366293,0.0982663588219156,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
22192,1561:1372,Colon,CCK-81,SIDM00487,1240123,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.489584515858273,0.136184921487553,0.390938280185981,7.76510455398277,0.4249,0.678735498060136,0.750129310669473,0.0626018139953876,0.191397328635319,0.0528459692984879,0.138551359336831,3.11768499169873,0.017,4.64741956228404,0.4079,0.332298390213596,0.190704119956855,0.367251695395214,0.214027284931979,0.141594270256741,0.153224410463235,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
22192,1053:1372,Colon,CCK-81,SIDM00487,1240123,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.535808273027482,0.136184921487553,0.390938280185981,7.76510455398277,0.4249,0.678735498060136,0.750129310669473,0.0448665559940484,0.209467964766784,0.0390804297028573,0.170387535063927,1.91872688376503,0.0074,5.84637767021774,0.4175,0.363672095058049,0.164569798011152,0.401925490497106,0.189945455970144,0.199102297046897,0.211980034526962,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
22192,1047:1372,Colon,CCK-81,SIDM00487,1240123,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.842835011144541,0.136184921487553,0.390938280185981,7.76510455398277,0.4249,0.678735498060136,0.750129310669473,0.118926717244331,0.329496469737379,0.207819628156326,0.121676841581052,5.88893661426171,0.1157,1.87616793972106,0.3092,0.57206204107171,0.480085408151964,0.632235245917952,0.53316025940618,0.0919766329197459,0.0990749865117719,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
22192,2171:1372,Colon,CCK-81,SIDM00487,1240123,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.697936845218125,0.136184921487553,0.390938280185981,7.76510455398277,0.4249,0.678735498060136,0.750129310669473,0.0854508119137753,0.272850229948003,0.107880358851333,0.16496987109667,4.26731818954923,0.0376,3.49778636443354,0.3873,0.473714512253645,0.335698971016079,0.523542884594299,0.362305507398813,0.138015541237566,0.161237377195487,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
22194,1032:1510,Colon,CCK-81,SIDM00487,1240123,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.498396464804806,0.107786485230125,0.493284106055415,8.92517376197826,9.4946,0.780829486242961,0.810958470572606,0.0469203755992071,0.245851054602418,0.0737010581488546,0.172149996453563,4.12204068470507,0.3401,4.80313307727319,9.1545,0.389162655558845,0.236392335812192,0.404178834836899,0.253547586804481,0.152770319746653,0.150631248032418,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
22194,1022:1510,Colon,CCK-81,SIDM00487,1240123,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.499071964234208,0.107786485230125,0.493284106055415,8.92517376197826,9.4946,0.780829486242961,0.810958470572606,0.0878000633090051,0.246184267734591,0.121757779026944,0.124426488707648,5.84975964971082,1.1264,3.07541411226744,8.3682,0.389690105431262,0.286172890984563,0.40472663682104,0.314380099407906,0.1035172144467,0.090346537413134,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
22194,1549:1510,Colon,CCK-81,SIDM00487,1240123,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.467306812054025,0.107786485230125,0.493284106055415,8.92517376197826,9.4946,0.780829486242961,0.810958470572606,0.0673702345634909,0.230515023037675,0.0925299545832799,0.137985068454396,5.10399872216018,0.6717,3.82117503981809,8.8229,0.36488693797398,0.26412534016378,0.378966417591492,0.270311762888943,0.1007615978102,0.108654654702549,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
22885,2171:1549,Colon,CCK-81,SIDM00487,1240123,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.604270588800342,0.131511919924888,0.225518243933573,5.56357960138259,0.4619,0.567545440691676,0.610390669829079,0.0629897281369188,0.136274042046959,0.0493231650167713,0.0869508770301878,2.25836268379651,0.0467,3.30521691758608,0.4152,0.342951017617709,0.208120741385535,0.368841129455853,0.228061673047679,0.134830276232174,0.140779456408174,True,0.412532572045341,0.0758581816042552,0.812890189154335,59.1689122387981
22885,1011:1549,Colon,CCK-81,SIDM00487,1240123,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.882720541867175,0.131511919924888,0.225518243933573,5.56357960138259,0.4619,0.567545440691676,0.610390669829079,0.103199554020189,0.199069586485977,0.071717724771682,0.127351861714295,2.24428582761506,0.0463,3.31929377376753,0.4156,0.500984018941601,0.31063339753049,0.538804382822193,0.332306782333993,0.190350621411111,0.206497600488201,True,0.412532572045341,0.0758581816042552,0.812890189154335,59.1689122387981
22885,1053:1549,Colon,CCK-81,SIDM00487,1240123,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.816923895128257,0.131511919924888,0.225518243933573,5.56357960138259,0.4619,0.567545440691676,0.610390669829079,0.0570721439124874,0.184231242256699,0.0480528455787091,0.136178396677989,1.27755857982612,0.0237,4.28602102155646,0.4382,0.463641432072127,0.254900334842224,0.498642723546717,0.255460891201992,0.208741097229903,0.243181832344725,True,0.412532572045341,0.0758581816042552,0.812890189154335,59.1689122387981
22885,1510:1549,Colon,CCK-81,SIDM00487,1240123,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.696383345459049,0.131511919924888,0.225518243933573,5.56357960138259,0.4619,0.567545440691676,0.610390669829079,0.0423299050947919,0.157047149172511,0.0430840603206689,0.113963088851842,1.42723691050658,0.0263,4.13634269087601,0.4356,0.3952291926889,0.207617358169152,0.425065896692564,0.224428005205827,0.187611834519748,0.200637891486737,True,0.412532572045341,0.0758581816042552,0.812890189154335,59.1689122387981
22885,1786:1549,Colon,CCK-81,SIDM00487,1240123,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.777600085661863,0.131511919924888,0.225518243933573,5.56357960138259,0.4619,0.567545440691676,0.610390669829079,0.039925284232512,0.175363005801059,0.0619745971547235,0.113388408646335,2.18607750575879,0.0444,3.3775020956238,0.4175,0.441323383298847,0.282860405139568,0.474639837146294,0.289656277680693,0.158462978159279,0.184983559465601,True,0.412532572045341,0.0758581816042552,0.812890189154335,59.1689122387981
22885,1561:1549,Colon,CCK-81,SIDM00487,1240123,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.543214665010654,0.131511919924888,0.225518243933573,5.56357960138259,0.4619,0.567545440691676,0.610390669829079,0.0638919201656074,0.122504817332167,0.0310559974252769,0.0914488199068898,1.19338664893003,0.0223,4.37019295245256,0.4396,0.308299006443653,0.16614877624228,0.331573163236832,0.166976893365211,0.142150230201374,0.164596269871621,True,0.412532572045341,0.0758581816042552,0.812890189154335,59.1689122387981
23240,1053:1564,Colon,CCK-81,SIDM00487,1240123,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.788004085580777,0.09934796561465,0.480527688074685,8.78294930184669,4.3016,0.773206245517348,0.804062844064558,0.070933950973604,0.378657781437537,0.144233043545948,0.234424737891589,4.83351093808033,0.2784,3.94943836376636,4.0232,0.609289680464244,0.44578711830755,0.633604806186571,0.440800952585211,0.163502562156694,0.19280385360136,True,0.269560506540268,0.0463355612699547,1.21074750620733,40.2873718252522
23240,1510:1564,Colon,CCK-81,SIDM00487,1240123,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.629135127663632,0.09934796561465,0.480527688074685,8.78294930184669,4.3016,0.773206245517348,0.804062844064558,0.0412759152888182,0.302316848382777,0.144966277335542,0.157350571047235,5.64117796229916,0.4874,3.14177133954753,3.8142,0.486451209983875,0.375649351759272,0.505864180050139,0.387370098580063,0.110801858224603,0.118494081470076,True,0.269560506540268,0.0463355612699547,1.21074750620733,40.2873718252522
23240,1561:1564,Colon,CCK-81,SIDM00487,1240123,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.543892351487537,0.09934796561465,0.480527688074685,8.78294930184669,4.3016,0.773206245517348,0.804062844064558,0.0387513459628151,0.26135533422181,0.114029907195644,0.147325427026166,5.30396251210917,0.3858,3.47898678973752,3.9158,0.420540963059281,0.312020143113765,0.437323631002029,0.322213317239356,0.108520819945515,0.115110313762673,True,0.269560506540268,0.0463355612699547,1.21074750620733,40.2873718252522
23240,1047:1564,Colon,CCK-81,SIDM00487,1240123,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.862867537735028,0.09934796561465,0.480527688074685,8.78294930184669,4.3016,0.773206245517348,0.804062844064558,0.0423759147391852,0.414631743022509,0.339398022104029,0.0752337209184795,7.79313708105114,2.166,0.989812220795552,2.1356,0.667174569230899,0.661657725611717,0.693799726442208,0.648633348737924,0.0055168436191828,0.0451663777042849,True,0.269560506540268,0.0463355612699547,1.21074750620733,40.2873718252522
21297,1549:1786,Colon,CCK-81,SIDM00487,1240123,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10.0,0.396765279651488,0.090282417397421,0.747360790921377,12.0208406664971,81.164,0.919833633049885,0.921477083674318,0.0691359729442365,0.296526813210477,0.165096462260571,0.131430350949906,8.05641647979443,5.1994,3.96442418670264,75.9646,0.364958048649882,0.272800202984595,0.365610112796478,0.304066804282472,0.092157845665287,0.0615433085140062,True,0.378102148325947,0.0598590154009765,0.908638786741109,53.4731209271498
21297,1047:1786,Colon,CCK-81,SIDM00487,1240123,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10.0,0.789607022379606,0.090282417397421,0.747360790921377,12.0208406664971,81.164,0.919833633049885,0.921477083674318,0.0624685682606729,0.590121328762696,0.551683633557694,0.0384376952050023,11.3424666022244,50.7169,0.67837406427263,30.4471,0.726307096077135,0.748852263541665,0.727604776231121,0.713351773805534,-0.0225451674645302,0.0142530024255871,True,0.378102148325947,0.0598590154009765,0.908638786741109,53.4731209271498
21298,1179:2048,Colon,CCK-81,SIDM00487,1240123,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.25,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.759116836582512,0.140614011670072,0.447169457339059,8.40921004883789,0.0664,0.837545708593302,0.785179718124838,0.187654329245445,0.339453863871545,0.281827085722748,0.0576267781487967,7.53264734994207,0.0362,0.876562698895818,0.0302,0.635795048800605,0.527529992185985,0.596043143771675,0.55927098936817,0.108265056614621,0.0367721544035057,True,0.378102148325947,0.0598590154009765,0.908638786741109,53.4731209271498
21298,1561:2048,Colon,CCK-81,SIDM00487,1240123,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.500120783770988,0.140614011670072,0.447169457339059,8.40921004883789,0.0664,0.837545708593302,0.785179718124838,0.0346508743252374,0.223638739482858,0.0963381059963817,0.127300633486476,5.00870286370297,0.0063,3.40050718513492,0.0601,0.41887401622571,0.284371218042931,0.392684696029678,0.285944236233645,0.134502798182778,0.106740459796032,True,0.378102148325947,0.0598590154009765,0.908638786741109,53.4731209271498
21298,1032:2048,Colon,CCK-81,SIDM00487,1240123,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,1,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.316477816680804,0.140614011670072,0.447169457339059,8.40921004883789,0.0664,0.837545708593302,0.785179718124838,0.0173437366293012,0.141519213545005,0.0615122811232364,0.0800069324217689,5.03967853877575,0.0064,3.36953151006214,0.06,0.265064637225985,0.191723773187234,0.248491962894198,0.181635826487701,0.0733408640387506,0.0668561364064964,True,0.378102148325947,0.0598590154009765,0.908638786741109,53.4731209271498
21298,1549:2048,Colon,CCK-81,SIDM00487,1240123,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.445446380707973,0.140614011670072,0.447169457339059,8.40921004883789,0.0664,0.837545708593302,0.785179718124838,0.0414286995522403,0.199190016334832,0.0678671639761148,0.131322852358717,4.21987810411915,0.0036,4.18933194471874,0.0628,0.373081704570381,0.236194377290008,0.349755463644015,0.229725581640885,0.136887327280373,0.12002988200313,True,0.378102148325947,0.0598590154009765,0.908638786741109,53.4731209271498
21298,1053:2048,Colon,CCK-81,SIDM00487,1240123,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.683950121618437,0.140614011670072,0.447169457339059,8.40921004883789,0.0664,0.837545708593302,0.785179718124838,0.0934430228951832,0.3058416047311,0.199072111391129,0.106769493339971,6.52048752816369,0.0179,1.8887225206742,0.0485,0.572839489253389,0.458537232126206,0.537023763703813,0.46122442839603,0.114302257127183,0.0757993353077832,True,0.378102148325947,0.0598590154009765,0.908638786741109,53.4731209271498
21298,1047:2048,Colon,CCK-81,SIDM00487,1240123,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.912264256875931,0.140614011670072,0.447169457339059,8.40921004883789,0.0664,0.837545708593302,0.785179718124838,0.0686045263941991,0.40793671269703,0.157881800920444,0.250054911776586,4.64372401461703,0.0049,3.76548603422085,0.0615,0.764063013449494,0.498415914911919,0.716291392069209,0.498036093455394,0.265647098537575,0.218255298613815,True,0.378102148325947,0.0598590154009765,0.908638786741109,53.4731209271498
22195,1549:2171,Colon,CCK-81,SIDM00487,1240123,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.480913218116648,0.1517939936738,0.320035221515976,6.90100892892641,2.3342,0.641440783494335,0.698535531842329,0.049776867955485,0.153909168289923,0.0292307850733541,0.124678383216568,1.3746662758933,0.0506,5.5263426530331,2.2836,0.308477351421525,0.10848375586494,0.335934970587119,0.153364552749862,0.199993595556584,0.182570417837257,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
22195,1032:2171,Colon,CCK-81,SIDM00487,1240123,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.465749943411885,0.1517939936738,0.320035221515976,6.90100892892641,2.3342,0.641440783494335,0.698535531842329,0.0570936266852206,0.149056386310876,0.0268364107045161,0.12221997560636,1.21650330884894,0.0454,5.68450562007747,2.2888,0.298751008614562,0.0960597163077225,0.325342884426756,0.14384442402576,0.202691292306839,0.181498460400995,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
22195,1011:2171,Colon,CCK-81,SIDM00487,1240123,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.864777831567001,0.1517939936738,0.320035221515976,6.90100892892641,2.3342,0.641440783494335,0.698535531842329,0.101199444766446,0.276759364887651,0.107943888430397,0.168815476457253,3.57563823255923,0.2329,3.32537069636718,2.1013,0.554703769828869,0.386827919856246,0.604078042499111,0.406170316070564,0.167875849972624,0.197907726428547,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
19210,2048:1047,Colon,KM12,SIDM00150,905989,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.67725361875101,0.0420394296253945,0.934409010824729,15.2025553564345,736.4703,0.982605059301308,0.984386044913348,0.0396830348515597,0.632831883974599,0.4177341970119,0.215097686962699,10.111435598913,21.6061,5.09111975752157,714.8642,0.665472832214861,0.610465093563451,0.666679011165559,0.602195017113975,0.0550077386514105,0.0644839940515843,True,0.343768098462956,0.0471873418052944,0.977647296068201,49.4340239490331
19209,1510:1053,Colon,KM12,SIDM00150,905989,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.598313554728652,0.0717215400216426,0.591995026383325,9.86908679043694,18.2651,0.877909688868367,0.879802897027902,0.0647219659337998,0.354198648617089,0.100781057029746,0.253417591587343,5.27187096346814,0.7546,4.5972158269688,17.5105,0.525265266677558,0.331502267776452,0.52639799878133,0.358695520918285,0.193762998901105,0.167702477863045,True,0.343768098462956,0.0471873418052944,0.977647296068201,49.4340239490331
19209,1561:1053,Colon,KM12,SIDM00150,905989,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.936392944736416,0.0717215400216426,0.591995026383325,9.86908679043694,18.2651,0.877909688868367,0.879802897027902,0.05012895893772,0.554339966024394,0.215584126320581,0.338755839703812,6.18174547885225,1.4178,3.68734131158469,16.8473,0.822068438772081,0.613440402693609,0.823841225535587,0.625149096479521,0.208628036078472,0.198692129056065,True,0.343768098462956,0.0471873418052944,0.977647296068201,49.4340239490331
19208,1054:1510,Colon,KM12,SIDM00150,905989,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.434235330889305,0.048946155468007,0.825583020136894,12.6299017450272,123.7968,0.960057248942979,0.955928276305266,0.0458570279030598,0.358497315925735,0.214098503688325,0.14439881223741,8.9350597470779,9.5598,3.6948419979493,114.237,0.41689077716743,0.34081919218447,0.41509783136786,0.363967027210755,0.0760715849829597,0.0511308041571046,True,0.343768098462956,0.0471873418052944,0.977647296068201,49.4340239490331
19208,1053:1510,Colon,KM12,SIDM00150,905989,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.816504631480979,0.048946155468007,0.825583020136894,12.6299017450272,123.7968,0.960057248942979,0.955928276305266,0.0487931924426132,0.674092359613828,0.265991437265691,0.408100922348138,7.30163831691788,3.0814,5.32826342810932,120.7154,0.78389119024883,0.611326008199228,0.780519864966879,0.608054075831055,0.172565182049602,0.172465789135824,True,0.343768098462956,0.0471873418052944,0.977647296068201,49.4340239490331
19208,1083:1510,Colon,KM12,SIDM00150,905989,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.481471438446249,0.048946155468007,0.825583020136894,12.6299017450272,123.7968,0.960057248942979,0.955928276305266,0.0781761162178078,0.397494644262109,0.179816900831618,0.217677743430491,7.79206484841206,4.3289,4.83783689661514,119.4679,0.462240144639325,0.317032805898292,0.46025216224414,0.373323609859212,0.145207338741033,0.0869285523849275,True,0.343768098462956,0.0471873418052944,0.977647296068201,49.4340239490331
19208,1786:1510,Colon,KM12,SIDM00150,905989,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.321807648286767,0.048946155468007,0.825583020136894,12.6299017450272,123.7968,0.960057248942979,0.955928276305266,0.0241549119463234,0.26567893017574,0.176661722548022,0.0890172076277185,9.45879738488813,13.744,3.17110436013907,110.0528,0.308953765503003,0.272487036729404,0.30762503052862,0.277593250701424,0.0364667287735991,0.0300317798271958,True,0.343768098462956,0.0471873418052944,0.977647296068201,49.4340239490331
19208,1372:1510,Colon,KM12,SIDM00150,905989,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.841871066378138,0.048946155468007,0.825583020136894,12.6299017450272,123.7968,0.960057248942979,0.955928276305266,0.0823625921127439,0.69503445754633,0.394933250623731,0.300101206922599,8.71116889492695,8.1857,3.91873285010025,115.6111,0.808244419951687,0.654380367613851,0.804768357354129,0.696134346475902,0.153864052337836,0.108634010878227,True,0.343768098462956,0.0471873418052944,0.977647296068201,49.4340239490331
19208,1022:1510,Colon,KM12,SIDM00150,905989,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.410175438161459,0.048946155468007,0.825583020136894,12.6299017450272,123.7968,0.960057248942979,0.955928276305266,0.0717908341940637,0.338633877023311,0.153291373379095,0.185342503644216,7.79453741746822,4.3363,4.83536432755898,119.4605,0.393791902745271,0.263788501830389,0.39209829958444,0.318103309696614,0.130003400914882,0.0739949898878267,True,0.343768098462956,0.0471873418052944,0.977647296068201,49.4340239490331
19208,1373:1510,Colon,KM12,SIDM00150,905989,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.663406080188874,0.048946155468007,0.825583020136894,12.6299017450272,123.7968,0.960057248942979,0.955928276305266,0.0627096680529857,0.547696795259509,0.188146855219464,0.359549940040045,6.83641143520213,2.232,5.79349030982508,121.5648,0.636907816278176,0.428591719278289,0.634168630725384,0.473518514985497,0.208316096999887,0.160650115739886,True,0.343768098462956,0.0471873418052944,0.977647296068201,49.4340239490331
19208,1179:1510,Colon,KM12,SIDM00150,905989,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.25,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.841650836459448,0.048946155468007,0.825583020136894,12.6299017450272,123.7968,0.960057248942979,0.955928276305266,0.0752329769833474,0.694852639464934,0.483618430768019,0.211234208696915,9.70203506193804,16.268,2.92786668308916,107.5288,0.808032986621815,0.734444638308942,0.804557833347565,0.734765630178931,0.0735883483128728,0.0697922031686344,True,0.343768098462956,0.0471873418052944,0.977647296068201,49.4340239490331
19208,1561:1510,Colon,KM12,SIDM00150,905989,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.855868958001233,0.048946155468007,0.825583020136894,12.6299017450272,123.7968,0.960057248942979,0.955928276305266,0.0674275713597659,0.706590879188075,0.332135771948363,0.374455107239711,7.93660519656821,4.785,4.693296548459,119.0118,0.821683197274358,0.618036267826063,0.818149337765303,0.671013073888483,0.203646929448296,0.147136263876819,True,0.343768098462956,0.0471873418052944,0.977647296068201,49.4340239490331
19208,1059:1510,Colon,KM12,SIDM00150,905989,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.523036827708167,0.048946155468007,0.825583020136894,12.6299017450272,123.7968,0.960057248942979,0.955928276305266,0.0693897799206482,0.431810323862129,0.246279384886396,0.185530938975733,8.72757807241546,8.2793,3.90232367261175,115.5175,0.502145297905366,0.386676653792634,0.499985693155242,0.432935394574695,0.115468644112732,0.0670502985805476,True,0.343768098462956,0.0471873418052944,0.977647296068201,49.4340239490331
19507,1083:1549,Colon,KM12,SIDM00150,905989,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.280021371083308,0.0423552189255571,0.927650099816353,14.9566097520719,310.519,0.977725390156176,0.982716109286377,0.0655631752230894,0.259761852836143,0.10429514103646,0.155466711799683,7.78188671301712,2.1492,7.17472303905479,308.3698,0.273784004294495,0.168264159908778,0.275181512308025,0.216950889606684,0.105519844385717,0.0582306227013414,True,0.157361806512615,0.0264679364226542,1.74523528479844,28.3185243573698
19507,1179:1549,Colon,KM12,SIDM00150,905989,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,1,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.206770587230971,0.0423552189255571,0.927650099816353,14.9566097520719,310.519,0.977725390156176,0.982716109286377,0.033972825238645,0.191810755883896,0.11464979375619,0.0771609621277064,9.5108288339054,7.1243,5.44578091816651,303.3947,0.202164853073223,0.161770449961954,0.203196786998479,0.178831925844133,0.0403944031112693,0.0243648611543462,True,0.157361806512615,0.0264679364226542,1.74523528479844,28.3185243573698
19507,2171:1549,Colon,KM12,SIDM00150,905989,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.199841398578313,0.0423552189255571,0.927650099816353,14.9566097520719,310.519,0.977725390156176,0.982716109286377,0.0377040620776898,0.185382893338612,0.0702725985182908,0.115110294820321,7.57144954973191,1.8575,7.38516020234,308.6615,0.195390009394337,0.117288324343019,0.196387361685228,0.152247099805311,0.0781016850513188,0.0441402618799173,True,0.157361806512615,0.0264679364226542,1.74523528479844,28.3185243573698
19507,1786:1549,Colon,KM12,SIDM00150,905989,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.21182097715276,0.0423552189255571,0.927650099816353,14.9566097520719,310.519,0.977725390156176,0.982716109286377,0.0443172963354672,0.196495750598955,0.0989459608905269,0.0975497897084281,8.69247910858075,4.0401,6.26413064349116,306.4789,0.207102747529944,0.139206524537247,0.208159886532799,0.174948088631507,0.0678962229926977,0.0332117979012918,True,0.157361806512615,0.0264679364226542,1.74523528479844,28.3185243573698
19508,1053:1561,Colon,KM12,SIDM00150,905989,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.746284516344393,0.0683294907244375,0.3766270326976,7.82347769238624,4.4242,0.785723323552345,0.777273115263623,0.0767648504403669,0.281070922938952,0.109978662500022,0.17109226043893,4.90136616203094,0.5837,2.9221115303553,3.8405,0.586373150497771,0.393126648272076,0.580066890892012,0.426017553721506,0.193246502225694,0.154049337170507,True,0.157361806512615,0.0264679364226542,1.74523528479844,28.3185243573698
19412,1053:1011,Colon,MDST8,SIDM00527,1240173,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.806145793474072,0.0710900341588613,0.220935906818678,6.41224378351938,1.6634,0.699396241295696,0.695441014708664,0.0516132910390862,0.178106551909257,0.137390586583435,0.0407159653258218,5.75028527953679,1.0513,0.661958503982595,0.6121,0.563815337892102,0.519051018908254,0.56062684861673,0.519312262646573,0.0447643189838486,0.0413145859701568,True,0.327948776758786,0.039588145106418,1.04487579419688,46.7122268991962
19412,2048:1011,Colon,MDST8,SIDM00527,1240173,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.494698028663165,0.0710900341588613,0.220935906818678,6.41224378351938,1.6634,0.699396241295696,0.695441014708664,0.0733609193922285,0.109296557564108,0.0189906536400488,0.0903059039240597,2.38624558913725,0.1021,4.02599819438213,1.5613,0.345989941823408,0.151048603268808,0.344033299027887,0.181400943170079,0.1949413385546,0.162632355857808,True,0.327948776758786,0.039588145106418,1.04487579419688,46.7122268991962
19412,1179:1011,Colon,MDST8,SIDM00527,1240173,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.539009000894814,0.0710900341588613,0.220935906818678,6.41224378351938,1.6634,0.699396241295696,0.695441014708664,0.0380226780704664,0.119086442396125,0.0305981970363373,0.0884882453597879,3.22918741250161,0.1832,3.18305637101777,1.4802,0.376980869250381,0.216167714585427,0.374848966519393,0.234771208543412,0.160813154664954,0.140077757975981,True,0.327948776758786,0.039588145106418,1.04487579419688,46.7122268991962
19412,1022:1011,Colon,MDST8,SIDM00527,1240173,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.434570675408321,0.0710900341588613,0.220935906818678,6.41224378351938,1.6634,0.699396241295696,0.695441014708664,0.0308693014996426,0.0960122662481426,0.0249882333770677,0.0710240328710749,3.2571457796958,0.1867,3.15509800382359,1.4767,0.303937096957911,0.166787615772125,0.302218271468592,0.19029096375895,0.137149481185786,0.111927307709642,True,0.327948776758786,0.039588145106418,1.04487579419688,46.7122268991962
21236,1011:1017,Colon,MDST8,SIDM00527,1240173,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.220038342688788,0.0467975043758876,0.750970422901213,11.2665485364316,48.1171,0.936053436885068,0.941714321768936,0.0600448485794084,0.165242287263481,0.0894961695291833,0.0757461177342981,8.22483472607762,5.8432,3.04171381035397,42.2739,0.205967646920335,0.12606213781945,0.207213258648333,0.179894379052935,0.0799055091008849,0.0273188795953982,True,0.258369000132148,0.0370443926243604,1.28939907431798,38.2038922759026
21235,1564:1025,Colon,MDST8,SIDM00527,1240173,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.5,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.409042263732551,0.0890604392796662,0.835881485782752,12.3427504581919,101.4538,0.925770748773466,0.963497902259636,0.0714466699292742,0.341910855156705,0.215207184342347,0.126703670814358,9.21477391989473,11.6052,3.12797653829718,89.8486,0.378679362775677,0.291697434360602,0.394111363041846,0.355678824262654,0.086981928415075,0.0384325387791913,True,0.258369000132148,0.0370443926243604,1.28939907431798,38.2038922759026
21235,1011:1025,Colon,MDST8,SIDM00527,1240173,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.182403793828576,0.0890604392796662,0.835881485782752,12.3427504581919,101.4538,0.925770748773466,0.963497902259636,0.0357426497147361,0.152467954197841,0.109978034887483,0.0424899193103588,9.85774978230457,18.1221,2.48500067588734,83.3317,0.168864096791802,0.142633488211778,0.175745672718033,0.163642498413635,0.0262306085800242,0.0121031743043974,True,0.258369000132148,0.0370443926243604,1.28939907431798,38.2038922759026
19414,1011:1047,Colon,MDST8,SIDM00527,1240173,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.603473659425656,0.06369679420412,0.514403357421412,9.11833702936024,10.8548,0.840842125815445,0.864981881883334,0.0369232249335505,0.310428876523943,0.0543516303292824,0.256077246194661,4.25076682859929,0.3718,4.86757020076095,10.483,0.507426074665094,0.287750687489135,0.521993781597026,0.314427485498005,0.219675387175959,0.20756629609902,True,0.327948776758786,0.039588145106418,1.04487579419688,46.7122268991962
18971,1022:1179,Colon,MDST8,SIDM00527,1240173,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,10.0,0.97420471602909,0.0665432061028693,0.249376030002179,6.73725375546729,2.0837,0.719468224922107,0.719512174414926,0.095087310345704,0.242943304492735,0.0732977922183775,0.169645512274357,3.84824534796981,0.2813,2.88900840749748,1.8024,0.700909337752195,0.465968811163604,0.700952153555366,0.474701570377858,0.234940526588591,0.226250583177508,True,0.221931874671536,0.0324110473483048,1.39733934166966,35.0875192801639
19412,1011:1510,Colon,MDST8,SIDM00527,1240173,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.537106484824315,0.0758863042593394,0.666712554085651,10.4237429490525,26.8281,0.886602429037135,0.91754152510339,0.0556813548580762,0.358095636313185,0.193795140052827,0.164300496260357,7.82578304262641,4.4312,2.59795990642611,22.3969,0.476199914096835,0.39141768821587,0.492817503228623,0.426166400538694,0.084782225880965,0.0666511026899289,True,0.327948776758786,0.039588145106418,1.04487579419688,46.7122268991962
19412,1564:1510,Colon,MDST8,SIDM00527,1240173,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.94054250169803,0.0758863042593394,0.666712554085651,10.4237429490525,26.8281,0.886602429037135,0.91754152510339,0.098459358881798,0.627071493533201,0.425212631551529,0.201858861981672,8.60529692124539,7.6065,1.81844602780713,19.2216,0.833887266618137,0.71889705682563,0.862986801432568,0.78900882354033,0.114990209792507,0.0739779778922384,True,0.327948776758786,0.039588145106418,1.04487579419688,46.7122268991962
18972,1011:1561,Colon,MDST8,SIDM00527,1240173,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.575547938175489,0.0470561056896502,0.439959559906889,8.50445716277136,7.0929,0.820281153295057,0.833395846801372,0.0668381163026039,0.253217817585005,0.0628504873339134,0.190367330251092,4.69003106407121,0.5042,3.81442609870015,6.5887,0.472111126503182,0.310300374406619,0.479659261310545,0.320998026506841,0.161810752096562,0.158661234803704,True,0.221931874671536,0.0324110473483048,1.39733934166966,35.0875192801639
18973,1372:1786,Colon,MDST8,SIDM00527,1240173,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10.0,0.368656221646161,0.0750836421038936,0.717006564274116,10.9089805795674,37.5544,0.927892157910516,0.93230997346791,0.0781858357266349,0.264328930880791,0.115292569198017,0.149036361682774,7.38323775335429,3.2607,3.5257428262131,34.2937,0.342073217030394,0.220817061398418,0.343701872221712,0.281928638556136,0.121256155631976,0.0617732336655762,True,0.221931874671536,0.0324110473483048,1.39733934166966,35.0875192801639
18973,1564:1786,Colon,MDST8,SIDM00527,1240173,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10.0,0.922675056557301,0.0750836421038936,0.717006564274116,10.9089805795674,37.5544,0.927892157910516,0.93230997346791,0.0558800467189661,0.661564072243576,0.56891188511118,0.0926521871323966,9.97557318366598,19.6642,0.933407395901403,17.8902,0.856142949279161,0.844822398756332,0.860219157498439,0.831961618941456,0.0113205505228294,0.0282575385569831,True,0.221931874671536,0.0324110473483048,1.39733934166966,35.0875192801639
19413,1011:2171,Colon,MDST8,SIDM00527,1240173,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.516896072319438,0.107258049612141,0.239287520118026,6.62504134677294,1.9278,0.653839209749814,0.711292601304541,0.0427653753090953,0.123686779304066,0.0282863499932455,0.0954004293108204,3.14944098583433,0.1733,3.47560036093862,1.7545,0.337966919448124,0.196512593761541,0.367664351884193,0.221721645092602,0.141454325686583,0.145942706791592,True,0.327948776758786,0.039588145106418,1.04487579419688,46.7122268991962
19570,1011:1003,Colon,HT-29,SIDM00136,905939,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.1,0.944417869957317,0.120540309675592,0.450902306210767,8.57506568289921,0.0745,0.872448322594153,0.830744430255009,0.125646991416287,0.425840195590415,0.219791715998228,0.206048479592187,6.42705492644683,0.0168,2.14801075645238,0.0577,0.823955786472204,0.695929609046207,0.784569885300341,0.653870695127893,0.128026177425998,0.130699190172448,True,0.134872289698204,0.0212679676449138,1.85260163319187,26.6265026142081
19570,1022:1003,Colon,HT-29,SIDM00136,905939,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.1,0.307180029215618,0.120540309675592,0.450902306210767,8.57506568289921,0.0745,0.872448322594153,0.830744430255009,0.0325898281202171,0.138508183595213,0.103997251853742,0.0345109317414708,7.55553780029677,0.0367,1.01952788260244,0.0378,0.267998701223588,0.215409488425501,0.255188098356445,0.236668241951333,0.0525892127980878,0.0185198564051118,True,0.134872289698204,0.0212679676449138,1.85260163319187,26.6265026142081
19573,1372:1011,Colon,HT-29,SIDM00136,905939,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.26229755254221,0.118836982054705,0.499599430344778,8.99654429139746,9.9761,0.884235018661549,0.852416151433905,0.0301649520302754,0.131043707830917,0.0409687416942202,0.0900749661366973,5.36191462153178,0.8032,3.63462966986569,9.1729,0.23193268126704,0.139677270823906,0.223586670268563,0.160150671756344,0.0922554104431336,0.0634359985122186,True,0.134872289698204,0.0212679676449138,1.85260163319187,26.6265026142081
19573,1564:1011,Colon,HT-29,SIDM00136,905939,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.322895140206696,0.118836982054705,0.499599430344778,8.99654429139746,9.9761,0.884235018661549,0.852416151433905,0.0337667244240885,0.161318228108362,0.0380552363507063,0.123262991757656,4.65871076697651,0.4933,4.33783352442095,9.4828,0.285515190326391,0.157021625843243,0.275241032731702,0.178860477587812,0.128493564483148,0.09638055514389,True,0.134872289698204,0.0212679676449138,1.85260163319187,26.6265026142081
19573,2048:1011,Colon,HT-29,SIDM00136,905939,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.733844679040182,0.118836982054705,0.499599430344778,8.99654429139746,9.9761,0.884235018661549,0.852416151433905,0.0969131640435602,0.366628383610021,0.0986995261697593,0.267928857440262,4.98462780238036,0.6184,4.0119164890171,9.3577,0.648891163465774,0.411760688110947,0.62554105705768,0.425891570993927,0.237130475354826,0.199649486063754,True,0.134872289698204,0.0212679676449138,1.85260163319187,26.6265026142081
19573,1179:1011,Colon,HT-29,SIDM00136,905939,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.225937342120178,0.118836982054705,0.499599430344778,8.99654429139746,9.9761,0.884235018661549,0.852416151433905,0.0736097731152974,0.112878167416854,0.0131411955476796,0.0997369718691745,2.99436274655791,0.1556,6.00218154483955,9.8205,0.199781709925976,0.0472561063094798,0.192592639635287,0.0944302910620714,0.152525603616497,0.0981623485732161,True,0.134872289698204,0.0212679676449138,1.85260163319187,26.6265026142081
19573,1003:1011,Colon,HT-29,SIDM00136,905939,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.912544801676001,0.118836982054705,0.499599430344778,8.99654429139746,9.9761,0.884235018661549,0.852416151433905,0.149954432838902,0.455906863081418,0.0504274381160827,0.405479424965336,2.87730897437803,0.1435,6.11923531701943,9.8326,0.806904069739479,0.368938409551701,0.777867927855673,0.372804414777544,0.437965660187778,0.405063513078129,True,0.134872289698204,0.0212679676449138,1.85260163319187,26.6265026142081
19573,1022:1011,Colon,HT-29,SIDM00136,905939,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.354654890858016,0.118836982054705,0.499599430344778,8.99654429139746,9.9761,0.884235018661549,0.852416151433905,0.070054318445678,0.177185381441654,0.0200039070405813,0.157181474401073,2.92410051969263,0.1482,6.07244377170484,9.8279,0.313598274036247,0.115732499401104,0.302313557152401,0.146221295423401,0.197865774635144,0.156092261729,True,0.134872289698204,0.0212679676449138,1.85260163319187,26.6265026142081
19571,1003:1022,Colon,HT-29,SIDM00136,905939,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.025,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.900568031966355,0.131845630897991,0.236520014321062,6.4726085075274,0.1735,0.739604939025077,0.695700142051791,0.115680057322665,0.213002363817773,0.0200489615359216,0.192953402281851,0.842466122063179,0.0035,5.63014238546422,0.17,0.666064564370409,0.260618944894339,0.626525307766295,0.230424664080141,0.405445619476071,0.396100643686154,True,0.134872289698204,0.0212679676449138,1.85260163319187,26.6265026142081
19570,1373:1032,Colon,HT-29,SIDM00136,905939,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,1,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.458524689942229,0.105373783963385,0.369987285476496,7.85202592208991,4.5126,0.813332436198953,0.789087407275105,0.0820336496504851,0.169648305355677,0.0456601174491559,0.123988187906521,4.25107322665178,0.3719,3.60095269543812,4.1407,0.372933003128082,0.201662678094724,0.361816058758134,0.238707765015303,0.171270325033358,0.123108293742832,True,0.134872289698204,0.0212679676449138,1.85260163319187,26.6265026142081
20043,2171:1549,Colon,HT-29,SIDM00136,905939,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.440492904937004,0.0444891826402372,0.905494640551462,13.8738679217006,146.6056,0.971650133065445,0.978807156527168,0.036897018780581,0.398863964621402,0.24913053526156,0.149733429359843,9.56896713375592,7.4173,4.30490078794468,139.1883,0.428004989696424,0.385686929488827,0.431157607751781,0.387053506014119,0.0423180602075972,0.0441041017376624,True,0.130024643598101,0.0255965750247918,1.86690335014021,26.3890862076322
20043,1053:1549,Colon,HT-29,SIDM00136,905939,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.67758859033446,0.0444891826402372,0.905494640551462,13.8738679217006,146.6056,0.971650133065445,0.978807156527168,0.055464127832342,0.613552837046674,0.47981568578628,0.133737151260393,10.911486408742,18.8098,2.96238151295857,127.7958,0.658379043962105,0.61134043001562,0.663228561400525,0.627733106089329,0.0470386139464845,0.0354954553111956,True,0.130024643598101,0.0255965750247918,1.86690335014021,26.3890862076322
20043,1083:1549,Colon,HT-29,SIDM00136,905939,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.920705052753331,0.0444891826402372,0.905494640551462,13.8738679217006,146.6056,0.971650133065445,0.978807156527168,0.0710373939598974,0.833693490796792,0.655380947662457,0.178312543134336,10.9502688687734,19.3223,2.9235990529272,127.2833,0.894603187021801,0.819221566618997,0.901192694685684,0.853983106939375,0.0753816204028035,0.0472095877463085,True,0.130024643598101,0.0255965750247918,1.86690335014021,26.3890862076322
20043,1786:1549,Colon,HT-29,SIDM00136,905939,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.315589045235123,0.0444891826402372,0.905494640551462,13.8738679217006,146.6056,0.971650133065445,0.978807156527168,0.0603656730383292,0.285764189077157,0.160600849518877,0.12516333955828,9.07672221086193,5.2731,4.79714571083867,141.3325,0.306642137796704,0.240592107392874,0.308900815997715,0.270243738055879,0.0660500304038303,0.0386570779418365,True,0.130024643598101,0.0255965750247918,1.86690335014021,26.3890862076322
20043,1372:1549,Colon,HT-29,SIDM00136,905939,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.31995429270817,0.0444891826402372,0.905494640551462,13.8738679217006,146.6056,0.971650133065445,0.978807156527168,0.0461983460439879,0.289716897268682,0.16454521648846,0.125171680780221,9.12320316752546,5.4458,4.75066475417514,141.1598,0.310883631084753,0.246398518522353,0.313173551464345,0.274694493633519,0.0644851125624008,0.0384790578308259,True,0.130024643598101,0.0255965750247918,1.86690335014021,26.3890862076322
20043,1564:1549,Colon,HT-29,SIDM00136,905939,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.758812890006148,0.0444891826402372,0.905494640551462,13.8738679217006,146.6056,0.971650133065445,0.978807156527168,0.0584327238398904,0.687101005081933,0.432532679999719,0.254568325082214,9.60798954527974,7.6207,4.26587837642085,138.9849,0.737300645546248,0.64043884464735,0.742731487203081,0.668013890610424,0.0968618008988981,0.0747175965926561,True,0.130024643598101,0.0255965750247918,1.86690335014021,26.3890862076322
20043,1373:1549,Colon,HT-29,SIDM00136,905939,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.459425529447817,0.0444891826402372,0.905494640551462,13.8738679217006,146.6056,0.971650133065445,0.978807156527168,0.0995517594438366,0.416007354647517,0.117816020566915,0.298191334080602,6.70404899975869,1.0182,7.1698189219419,145.5874,0.446400876821634,0.263425015064713,0.449688996114807,0.327329222237836,0.182975861756921,0.122359773876971,True,0.130024643598101,0.0255965750247918,1.86690335014021,26.3890862076322
18376,1073:1011,Colon,SK-CO-1,SIDM01096,909718,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.703261354209994,0.0645554909354787,0.075957850594236,3.8201500409425,0.2759,0.485533790976054,0.484977294337462,0.0408408389056085,0.0534182208717828,0.0099573897291519,0.0434608311426309,0.203440857587474,0.0225,3.61670918335503,0.2534,0.341457151356532,0.154842838757161,0.341065788776862,0.147351455866768,0.18661431259937,0.193714332910095,True,0.588175135124897,0.065263922363461,0.48951868011935,97.1014133864232
18376,1089:1011,Colon,SK-CO-1,SIDM01096,909718,1089,Oxaliplatin,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved in colon,1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.585611701947501,0.0645554909354787,0.075957850594236,3.8201500409425,0.2759,0.485533790976054,0.484977294337462,0.0476807522820423,0.0444818061627645,0.0069609790847208,0.0375208270780437,-0.1639682596633,0.0174,3.9841183006058,0.2585,0.284334269686509,0.103267403508309,0.284008378742855,0.109630193780409,0.1810668661782,0.174378184962446,True,0.588175135124897,0.065263922363461,0.48951868011935,97.1014133864232
18376,1047:1011,Colon,SK-CO-1,SIDM01096,909718,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.397658322923412,0.0645554909354787,0.075957850594236,3.8201500409425,0.2759,0.485533790976054,0.484977294337462,0.0510144372884125,0.0302052714801709,0.0041778854142653,0.0260273860659056,-0.422791269618208,0.0146,4.24294131056071,0.2613,0.193076553042184,0.0701395030154859,0.192855257522169,0.0685447121530427,0.122937050026698,0.124310545369126,True,0.588175135124897,0.065263922363461,0.48951868011935,97.1014133864232
18376,2048:1011,Colon,SK-CO-1,SIDM01096,909718,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.704613456401546,0.0645554909354787,0.075957850594236,3.8201500409425,0.2759,0.485533790976054,0.484977294337462,0.0642579756648368,0.0535209236480368,0.0156179742559339,0.0379029493921029,1.14949033110022,0.0433,2.67065970984228,0.2326,0.342113642659383,0.191140077961382,0.341721527639389,0.192513504340575,0.150973564698001,0.149208023298814,True,0.588175135124897,0.065263922363461,0.48951868011935,97.1014133864232
18376,1017:1011,Colon,SK-CO-1,SIDM01096,909718,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.769631692777983,0.0645554909354787,0.075957850594236,3.8201500409425,0.2759,0.485533790976054,0.484977294337462,0.0310657335530472,0.058459569132619,0.0139146757767619,0.0445448933558571,0.71846701002494,0.0321,3.10168303091756,0.2438,0.373682193449812,0.192605320935492,0.373253895999827,0.18714135276086,0.181076872514319,0.186112543238967,True,0.588175135124897,0.065263922363461,0.48951868011935,97.1014133864232
20060,1011:1025,Colon,SK-CO-1,SIDM01096,909718,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.151135957632208,0.0764678896766165,0.713294720569026,10.8895227035599,37.0513,0.890034257806839,0.930626163230876,0.0242303615607596,0.107804480667198,0.055446486168539,0.0523579944986593,7.86872023208025,4.5651,3.02080247147966,32.4862,0.134516179879108,0.100723627219989,0.140651076377486,0.120148783533192,0.0337925526591192,0.0205022928442948,True,0.448613352570212,0.0453060903290271,0.752646058675902,64.4037944142825
18378,1011:1047,Colon,SK-CO-1,SIDM01096,909718,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.396041827177951,0.0636996700348424,0.375902770246027,7.94897951498752,4.8263,0.81178528742492,0.799909085114541,0.0350768982587618,0.14887321996949,0.0465361900070165,0.102337029962474,4.81999361911726,0.5517,3.12898589587025,4.2746,0.321500928507943,0.202089171429321,0.316797455645006,0.225045370178045,0.119411757078622,0.0917520854669606,True,0.588175135124897,0.065263922363461,0.48951868011935,97.1014133864232
18377,1011:1053,Colon,SK-CO-1,SIDM01096,909718,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.425766276358491,0.0836587201308115,0.660406939739185,10.3788479586929,26.0061,0.870601982663275,0.914841565675552,0.0580370573641779,0.28117900361406,0.107289768153043,0.173889235461016,6.74441534799175,2.0941,3.63443261070114,23.912,0.370672964348862,0.283746359250561,0.389508686875652,0.306184794992589,0.0869266050983009,0.0833238918830631,True,0.588175135124897,0.065263922363461,0.48951868011935,97.1014133864232
18377,1372:1053,Colon,SK-CO-1,SIDM01096,909718,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.622006237510406,0.0836587201308115,0.660406939739185,10.3788479586929,26.0061,0.870601982663275,0.914841565675552,0.110361637967988,0.410777235812932,0.168115976291221,0.242661259521711,6.94097608628967,2.3998,3.43787187240322,23.6063,0.541519863605483,0.396261850868779,0.56903716018398,0.45607069601956,0.145258012736705,0.112966464164419,True,0.588175135124897,0.065263922363461,0.48951868011935,97.1014133864232
18377,1564:1053,Colon,SK-CO-1,SIDM01096,909718,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.778456296893858,0.0836587201308115,0.660406939739185,10.3788479586929,26.0061,0.870601982663275,0.914841565675552,0.110672148394971,0.514097940752371,0.186485124321248,0.327612816431124,6.60532769145657,1.9017,3.77352026723632,24.1044,0.677725595492503,0.485435891268551,0.71216417746037,0.551911753515209,0.192289704223952,0.160252423945161,True,0.588175135124897,0.065263922363461,0.48951868011935,97.1014133864232
19599,1011:1059,Colon,SK-CO-1,SIDM01096,909718,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.471447011889982,0.142809926766777,0.694259801149427,10.7001861084954,3.2494,0.888739154812654,0.925082531817087,0.0959118646925248,0.32730670872723,0.155568230569002,0.171738478158228,7.53166398792685,0.3614,3.1685221205685,2.888,0.418993418886054,0.354426948277445,0.436127395376785,0.364666493114354,0.0645664706086083,0.0714609022624307,True,0.543511544894465,0.0527850801357794,0.562073757134335,84.8401690513899
20062,1011:1073,Colon,SK-CO-1,SIDM01096,909718,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,20.0,0.215668117778195,0.0742931709767365,0.386624207526963,8.04320491235774,10.304,0.816089764398793,0.80561790718719,0.0239634133886033,0.0833825151248265,0.0658253227116772,0.0175571924131493,7.2946900180896,6.1331,0.748514894268142,4.1709,0.176004543425938,0.147774516583145,0.17374609769147,0.163419125001823,0.0282300268427935,0.0103269726896469,True,0.448613352570212,0.0453060903290271,0.752646058675902,64.4037944142825
18376,1011:1510,Colon,SK-CO-1,SIDM01096,909718,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.430566925850043,0.142961934346113,0.212301072704043,6.28191282921155,1.5198,0.620430832916438,0.684810393725872,0.0449284615025287,0.0914098202288464,0.0163997306214786,0.0750100896073678,2.30589110278929,0.0966,3.97602172642225,1.4232,0.267136996431412,0.150241780266485,0.294856706016707,0.155370164159938,0.116895216164927,0.139486541856769,True,0.588175135124897,0.065263922363461,0.48951868011935,97.1014133864232
18376,1372:1510,Colon,SK-CO-1,SIDM01096,909718,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.601389952315041,0.142961934346113,0.212301072704043,6.28191282921155,1.5198,0.620430832916438,0.684810393725872,0.0559721842385609,0.127675731989916,0.0264184476781087,0.101257284311808,2.61426100886517,0.1196,3.66765182034638,1.4002,0.373120869022397,0.234974448803638,0.411838090027647,0.231855499539418,0.138146420218759,0.179982590488229,True,0.588175135124897,0.065263922363461,0.48951868011935,97.1014133864232
20959,1372:1561,Colon,SK-CO-1,SIDM01096,909718,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.227191171109154,0.0780323727580437,0.143654388087933,5.29893718863852,0.7689,0.579586646295679,0.60744567292886,0.0693476510349654,0.0326370086646666,0.0189472486063507,0.0136897600583159,4.03062903135557,0.3192,1.26830815728296,0.4497,0.131676968931143,0.106446166005049,0.138006293817896,0.114176941901038,0.0252308029260936,0.0238293519168581,True,0.624425835146665,0.0706405710843436,0.432662411163343,109.270745254226
23802,1194:1025,Colon,C2BBe1,SIDM01233,910700,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,2.5,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.223147985666559,0.0641530317480637,0.875203479851225,14.4746100159605,444.6536,0.971904375911065,0.963673575258862,0.0739762488708603,0.195299893577164,0.0987613368169221,0.0965385567602415,8.35160249799554,6.3799,6.12300751796495,438.2737,0.216878503745068,0.122360502222216,0.215041817159106,0.174234778849667,0.0945180015228519,0.0408070383094388,True,0.345422582926677,0.0536287308165879,1.03134670320914,47.8771136297993
23437,2171:1032,Colon,C2BBe1,SIDM01233,910700,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.902211253785553,0.0727791682014609,0.660706086282306,10.8731721734436,36.6337,0.856204704197024,0.887595382713839,0.168571175554994,0.596096466488505,0.33964728436038,0.256449182128125,7.58172673257158,3.7416,3.29144544087201,32.8921,0.772477519670685,0.564388822721931,0.80079854309252,0.666170603681325,0.208088696948754,0.134627939411196,True,0.651853366495297,0.0775931991800355,0.400921185365453,119.218872096122
23437,1011:1032,Colon,C2BBe1,SIDM01233,910700,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.888671983269735,0.0727791682014609,0.660706086282306,10.8731721734436,36.6337,0.856204704197024,0.887595382713839,0.082325556123939,0.587150988054882,0.363434832734274,0.223716155320608,7.9649586250584,4.88,2.9082135483852,31.7537,0.760885132563646,0.61479817761856,0.788781149097366,0.675419182863405,0.146086954945085,0.113361966233961,True,0.651853366495297,0.0775931991800355,0.400921185365453,119.218872096122
23437,1053:1032,Colon,C2BBe1,SIDM01233,910700,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.846715703347774,0.0727791682014609,0.660706086282306,10.8731721734436,36.6337,0.856204704197024,0.887595382713839,0.113317507388146,0.559430218552678,0.537789059575462,0.0216411589772154,10.5581490180362,29.4476,0.315023155407374,7.1861,0.724961968323856,0.652796698271778,0.751540948762784,0.742558607272503,0.0721652700520777,0.0089823414902808,True,0.651853366495297,0.0775931991800355,0.400921185365453,119.218872096122
23441,1194:1053,Colon,C2BBe1,SIDM01233,910700,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,0.625,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.537058019939453,0.100709594650621,0.665527098870015,10.9338303589028,38.2068,0.828384142109533,0.889552264464874,0.0551445831657978,0.357426665935179,0.141383236421325,0.216043429513854,6.10745275684108,1.3467,4.82637760206169,36.8601,0.444890347110589,0.305960949077559,0.477741177786162,0.347177920503187,0.138929398033029,0.130563257282976,True,0.651853366495297,0.0775931991800355,0.400921185365453,119.218872096122
23441,1179:1053,Colon,C2BBe1,SIDM01233,910700,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.945881791446614,0.100709594650621,0.665527098870015,10.9338303589028,38.2068,0.828384142109533,0.889552264464874,0.0886053516321403,0.629509964535438,0.410756005350524,0.218753959184914,8.25656189833114,5.9731,2.67726846057163,32.2337,0.783553476344532,0.668813782645157,0.841411289497427,0.733816202038755,0.114739693699374,0.107595087458672,True,0.651853366495297,0.0775931991800355,0.400921185365453,119.218872096122
23804,1194:1073,Colon,C2BBe1,SIDM01233,910700,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,2.5,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,20.0,0.217255422195075,0.054525729622649,0.743590034235659,11.9925909717622,159.1804,0.925571611997871,0.919477378753436,0.0602510715120072,0.161548966827919,0.103234416117386,0.0583145507105327,8.72067109262379,16.4795,3.27191987913839,142.7009,0.201085451336374,0.114181327652222,0.199761446119899,0.173711971504949,0.0869041236841514,0.0260494746149496,True,0.345422582926677,0.0536287308165879,1.03134670320914,47.8771136297993
23439,1194:1083,Colon,C2BBe1,SIDM01233,910700,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.433474666301434,0.0738577382528677,0.720106038786311,11.6560805483849,63.0318,0.911638558062848,0.910805136090684,0.070318914489609,0.312147724864544,0.209525275368257,0.102622449496287,8.81287537473173,8.7835,2.84320517365316,54.2483,0.395172219743813,0.30013860549374,0.394810952432542,0.348556659887202,0.0950336142500735,0.0462542925453398,True,0.651853366495297,0.0775931991800355,0.400921185365453,119.218872096122
23438,1011:1372,Colon,C2BBe1,SIDM01233,910700,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.839515495409211,0.104643563140335,0.610345135702767,10.2613405308668,2.3972,0.802991523036191,0.866295116718191,0.0578997339234792,0.51239419897011,0.268493917678887,0.243900281291224,6.87904633833087,0.2299,3.38229419253594,2.1673,0.674123826271125,0.53806502641432,0.727268174082252,0.584404466214112,0.136058799856805,0.14286370786814,True,0.651853366495297,0.0775931991800355,0.400921185365453,119.218872096122
23438,1053:1372,Colon,C2BBe1,SIDM01233,910700,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.914466951040328,0.104643563140335,0.610345135702767,10.2613405308668,2.3972,0.802991523036191,0.866295116718191,0.110800151455717,0.558140455328405,0.467820740457783,0.0903197148706213,9.13018726348777,1.0944,1.13115326737905,1.3028,0.734309209782135,0.666482844545445,0.792198254086409,0.749091776719564,0.0678263652366908,0.0431064773668448,True,0.651853366495297,0.0775931991800355,0.400921185365453,119.218872096122
23803,1194:1373,Colon,C2BBe1,SIDM01233,910700,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,2.5,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10.0,0.228841904040978,0.0655295088158466,0.880786315136898,14.6211198119419,492.1819,0.965035720018855,0.965403014111959,0.0884314815574843,0.201560817409165,0.134800795856902,0.0667600215522627,10.0120391989573,20.1676,4.60908061298454,472.0143,0.220840611636671,0.104773705530364,0.22092466391628,0.196067592482456,0.116066906106307,0.0248570714338243,True,0.345422582926677,0.0536287308165879,1.03134670320914,47.8771136297993
23801,1194:1510,Colon,C2BBe1,SIDM01233,910700,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,0.625,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.398227614929942,0.089418775093272,0.731137319357945,11.8118297198021,70.2175,0.888706906517695,0.914912145531311,0.0408747847495467,0.291159070874186,0.124720552847376,0.16643851802681,6.79288969587639,2.1657,5.0189400239257,68.0518,0.353907631754309,0.256632529412573,0.36434328158537,0.27506850255166,0.0972751023417364,0.0892747790337098,True,0.345422582926677,0.0536287308165879,1.03134670320914,47.8771136297993
23801,1032:1510,Colon,C2BBe1,SIDM01233,910700,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.818868228316955,0.089418775093272,0.731137319357945,11.8118297198021,70.2175,0.888706906517695,0.914912145531311,0.0482307519896136,0.598705121359048,0.398046043284045,0.200659078075003,8.84360485420905,8.9726,2.96822486559304,61.2449,0.727733850033187,0.657969605354927,0.749192487676889,0.659673944595431,0.0697642446782595,0.0895185430814581,True,0.345422582926677,0.0536287308165879,1.03134670320914,47.8771136297993
23801,1059:1510,Colon,C2BBe1,SIDM01233,910700,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.542039643065897,0.089418775093272,0.731137319357945,11.8118297198021,70.2175,0.888706906517695,0.914912145531311,0.0830685658743896,0.396305411616937,0.293581810952662,0.102723600664275,9.46905927589977,13.8421,2.34277044390232,56.3754,0.481714374399049,0.404202094782578,0.495918652800446,0.452251555881557,0.0775122796164709,0.043667096918889,True,0.345422582926677,0.0536287308165879,1.03134670320914,47.8771136297993
23805,2171:1549,Colon,C2BBe1,SIDM01233,910700,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.872345918783438,0.101888105540869,0.546428861679369,9.52349925134675,7.1872,0.78712328022713,0.83670674105413,0.0988634618866352,0.476674987391477,0.211906568777897,0.26476841861358,5.80490463838118,0.5459,3.71859461296556,6.6413,0.686643781085569,0.508494384801469,0.729897710777161,0.546257149242306,0.1781493962841,0.183640561534855,True,0.345422582926677,0.0536287308165879,1.03134670320914,47.8771136297993
23805,1053:1549,Colon,C2BBe1,SIDM01233,910700,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.874006608743688,0.101888105540869,0.546428861679369,9.52349925134675,7.1872,0.78712328022713,0.83670674105413,0.127492884673547,0.477582436316059,0.330636752198224,0.146945684117835,7.60372694082204,1.8995,1.91977231052471,5.2877,0.687950948814521,0.581803847627899,0.731287221261703,0.646455826398904,0.106147101186622,0.0848313948627988,True,0.345422582926677,0.0536287308165879,1.03134670320914,47.8771136297993
23805,1561:1549,Colon,C2BBe1,SIDM01233,910700,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.784757984929711,0.101888105540869,0.546428861679369,9.52349925134675,7.1872,0.78712328022713,0.83670674105413,0.135292846238429,0.428814412398937,0.211941686192394,0.216872726206543,6.20544662926541,0.7207,3.31805262208134,6.4665,0.617701279282307,0.442227638560393,0.656612296086745,0.512382614672514,0.175473640721914,0.144229681414231,True,0.345422582926677,0.0536287308165879,1.03134670320914,47.8771136297993
23806,1372:1561,Colon,C2BBe1,SIDM01233,910700,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.62431012217361,0.103355552084834,0.411969221806678,7.99986538723176,4.9995,0.781001886216531,0.761952644905296,0.0726456682029666,0.257196555197894,0.105028269411792,0.152168285786103,4.50788441964006,0.4444,3.4919809675917,4.5551,0.487587383001663,0.314210489242304,0.475694748831331,0.334672935985122,0.173376893759358,0.141021812846209,True,0.345422582926677,0.0536287308165879,1.03134670320914,47.8771136297993
23806,1194:1561,Colon,C2BBe1,SIDM01233,910700,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.195766735280076,0.103355552084834,0.411969221806678,7.99986538723176,4.9995,0.781001886216531,0.761952644905296,0.0523507221499028,0.0806498695889667,0.0692638670726319,0.0113860025163348,7.30699605031674,3.0928,0.692869336915027,1.9067,0.152894189512192,0.105125969523124,0.149164981731129,0.141388672032998,0.0477682199890678,0.0077763096981304,True,0.345422582926677,0.0536287308165879,1.03134670320914,47.8771136297993
23806,1053:1564,Colon,C2BBe1,SIDM01233,910700,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.890357128881027,0.0932941813656033,0.560094687994046,9.67891528687945,8.0047,0.813359813413269,0.843300020831138,0.0638968009567862,0.498684298303893,0.33024764911179,0.168436649192103,7.51513477960143,1.7864,2.16378050727802,6.2183,0.724180708217847,0.665248690997034,0.750838185332523,0.653974669597009,0.0589320172208131,0.0968635157355136,True,0.345422582926677,0.0536287308165879,1.03134670320914,47.8771136297993
23807,1053:1598,Colon,C2BBe1,SIDM01233,910700,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1598,LGK974,PORCN,WNT signaling,Targeted,Early clinical trials,10.0,0.879839110758376,0.0840608140148168,0.699325362351781,11.3724796877865,51.783,0.887155977766747,0.902901478519028,0.127608126097072,0.61529380494237,0.412180214205706,0.203113590736665,8.64506849209139,7.8191,2.72741119569507,43.9639,0.780554526582272,0.641690461660826,0.794408033962604,0.700189558728809,0.138864064921446,0.094218475233795,True,0.345422582926677,0.0536287308165879,1.03134670320914,47.8771136297993
23808,2171:2048,Colon,C2BBe1,SIDM01233,910700,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.05,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.909686589469774,0.0856525373334129,0.708422887000273,11.4951650714214,0.5638,0.870604506159942,0.906388984781551,0.125269505645081,0.64444279997761,0.414579709848302,0.229863090129308,8.50107644243871,0.0708,2.99408862898266,0.493,0.791977243985654,0.679509018830209,0.8245299042989,0.717317488446889,0.112468225155445,0.107212415852011,True,0.345422582926677,0.0536287308165879,1.03134670320914,47.8771136297993
23808,1011:2048,Colon,C2BBe1,SIDM01233,910700,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,1.0,0.0856525373334129,0.708422887000273,11.4951650714214,0.5638,0.870604506159942,0.906388984781551,0.0501795833370751,0.708422887000273,0.645570463814204,0.0628524231860694,10.6853678273617,0.3216,0.809797244059647,0.2422,0.870604506159942,0.903758702122468,0.906388984781551,0.881361675450434,-0.0331541959625257,0.0250273093311171,True,0.345422582926677,0.0536287308165879,1.03134670320914,47.8771136297993
23808,1053:2048,Colon,C2BBe1,SIDM01233,910700,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.790267820854993,0.0856525373334129,0.708422887000273,11.4951650714214,0.5638,0.870604506159942,0.906388984781551,0.071665110393075,0.559843811153509,0.285409046451069,0.27443476470244,7.39690000412605,0.0329,4.09826506729532,0.5309,0.688010725909554,0.538082799445593,0.716290047850286,0.574974161439153,0.149927926463962,0.141315886411133,True,0.345422582926677,0.0536287308165879,1.03134670320914,47.8771136297993
23808,1047:2048,Colon,C2BBe1,SIDM01233,910700,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.964034400615827,0.0856525373334129,0.708422887000273,11.4951650714214,0.5638,0.870604506159942,0.906388984781551,0.0878374456109829,0.682944033251843,0.527085948260192,0.155858084991651,9.52714301632863,0.1441,1.96802205509274,0.4197,0.839292693269338,0.785690975891933,0.873790161668671,0.806765238801932,0.0536017173774055,0.0670249228667392,True,0.345422582926677,0.0536287308165879,1.03134670320914,47.8771136297993
23808,1194:2048,Colon,C2BBe1,SIDM01233,910700,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,2.5,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.248592950550383,0.0856525373334129,0.708422887000273,11.4951650714214,0.5638,0.870604506159942,0.906388984781551,0.0752385671557213,0.176108935716819,0.100686251362562,0.0754226843542565,7.91908081934822,0.0473,3.57608425207315,0.5165,0.216426142948759,0.14324182580835,0.225321912073212,0.188307762865372,0.0731843171404098,0.0370141492078405,True,0.345422582926677,0.0536287308165879,1.03134670320914,47.8771136297993
23441,1549:2171,Colon,C2BBe1,SIDM01233,910700,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.755298111238421,0.120807180022927,0.652772987233412,10.7742586790829,34.2062,0.813174292480076,0.8843453301415,0.133726023391518,0.493038204324859,0.323526452658863,0.169511751665995,8.18878586633115,5.699,2.58547281275171,28.5072,0.614189007217841,0.486359938608896,0.667944357538393,0.583235328021598,0.127829068608945,0.0847090295167958,True,0.651853366495297,0.0775931991800355,0.400921185365453,119.218872096122
23441,1032:2171,Colon,C2BBe1,SIDM01233,910700,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.846918229531413,0.120807180022927,0.652772987233412,10.7742586790829,34.2062,0.813174292480076,0.8843453301415,0.126175872989259,0.552845342633654,0.252127693801306,0.300717648832347,6.58764692943792,1.8785,4.18661174964494,32.3277,0.688692132087686,0.495365749178318,0.748968181297813,0.573978148580969,0.193326382909367,0.174990032716844,True,0.651853366495297,0.0775931991800355,0.400921185365453,119.218872096122
21266,1179:1003,Colon,SW948,SIDM00832,909757,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,1,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.1,0.287730001118365,0.113486829444833,0.531316202297884,9.32387913076869,0.1252,0.825270221700888,0.841399297072234,0.0348844028360806,0.152875611481375,0.113958164586798,0.0389174468945772,7.91055163562755,0.047,1.41332749514114,0.0782,0.23745500181295,0.191847035009942,0.242095820687585,0.221237064216527,0.0456079668030081,0.0208587564710583,True,0.297292024152372,0.0736474137455505,1.15305018714611,42.609188659605
21266,1022:1003,Colon,SW948,SIDM00832,909757,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.1,0.788767348527728,0.113486829444833,0.531316202297884,9.32387913076869,0.1252,0.825270221700888,0.841399297072234,0.0941975776500987,0.419084872116324,0.137612995125504,0.281471876990819,4.98652783480788,0.0062,4.3373512959608,0.119,0.6509462045899,0.450202628925695,0.66366829260476,0.45226982777575,0.200743575664204,0.21139846482901,True,0.297292024152372,0.0736474137455505,1.15305018714611,42.609188659605
21268,1510:1017,Colon,SW948,SIDM00832,909757,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,1,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.790652199889574,0.123617059046109,0.847551891016238,13.4297864396826,215.5255,0.915394923767947,0.958254405175966,0.0802187409979197,0.670118767152557,0.701747516237456,-0.031628749084899,14.3347885166623,403.5816,-0.905002076979747,-188.0561,0.723759010244876,0.738589695363211,0.757645953506253,0.766836420878653,-0.0148306851183349,-0.0091904673724001,True,0.297292024152372,0.0736474137455505,1.15305018714611,42.609188659605
21268,1598:1017,Colon,SW948,SIDM00832,909757,1598,LGK974,PORCN,WNT signaling,Targeted,Early clinical trials,2.5,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.910396194703636,0.123617059046109,0.847551891016238,13.4297864396826,215.5255,0.915394923767947,0.958254405175966,0.140004591645921,0.771608016395053,0.63677511589547,0.134832900499584,11.1810885540705,45.3496,2.2486978856121,170.1759,0.833372055249363,0.74657273523288,0.872391164030195,0.828455695027911,0.0867993200164831,0.0439354690022838,True,0.297292024152372,0.0736474137455505,1.15305018714611,42.609188659605
21268,1053:1017,Colon,SW948,SIDM00832,909757,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.421573613061073,0.123617059046109,0.847551891016238,13.4297864396826,215.5255,0.915394923767947,0.958254405175966,0.0874578616562551,0.35730551295246,0.246735598890251,0.110569914062209,9.88944797589019,18.5247,3.54033846379239,197.0008,0.385906345390618,0.292844835436238,0.403974771821721,0.364854016864479,0.0930615099543804,0.0391207549572416,True,0.297292024152372,0.0736474137455505,1.15305018714611,42.609188659605
21268,1047:1017,Colon,SW948,SIDM00832,909757,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.916458287444466,0.123617059046109,0.847551891016238,13.4297864396826,215.5255,0.915394923767947,0.958254405175966,0.042828057768154,0.77674595456106,0.754347155008324,0.0223987995527355,12.970270435867,156.7366,0.459516003815581,58.7889,0.83892126417173,0.868366565889515,0.878200191103682,0.871447550551542,-0.0294453017177853,0.0067526405521393,True,0.297292024152372,0.0736474137455505,1.15305018714611,42.609188659605
18388,1073:1022,Colon,SW948,SIDM00832,909757,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,2.5,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.748552942737014,0.124220131506814,0.49605871883436,8.95929090623715,0.9722,0.854564428842542,0.824373963477273,0.0898389290826057,0.371326213753813,0.137904000722134,0.233422213031679,5.15782111496639,0.0697,3.80146979127076,0.9025,0.639686717968461,0.435099996156439,0.617087556276688,0.438619473942387,0.204586721812021,0.178468082334301,True,0.301433607553238,0.0603330809606757,1.14193672100903,43.0397231053888
18388,1179:1022,Colon,SW948,SIDM00832,909757,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.278481623011427,0.124220131506814,0.49605871883436,8.95929090623715,0.9722,0.854564428842542,0.824373963477273,0.0338796926030853,0.138143237129962,0.0788389544213914,0.0593042827085701,6.60084822672835,0.1896,2.3584426795088,0.7826,0.237980489111904,0.196961429723671,0.229572999317514,0.191428277238927,0.0410190593882331,0.0381447220785871,True,0.301433607553238,0.0603330809606757,1.14193672100903,43.0397231053888
18388,1003:1022,Colon,SW948,SIDM00832,909757,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.025,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.70669656648652,0.124220131506814,0.49605871883436,8.95929090623715,0.9722,0.854564428842542,0.824373963477273,0.0982209521408531,0.350562993375944,0.0823239847168127,0.268239008659132,3.76830226492081,0.0266,5.19098864131634,0.9456,0.603917747704539,0.318008801465061,0.582582249490273,0.341105751489975,0.285908946239477,0.241476498000297,True,0.301433607553238,0.0603330809606757,1.14193672100903,43.0397231053888
22255,1083:1025,Colon,SW948,SIDM00832,909757,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.377455391656463,0.0810177419869619,0.923586839555166,15.4350543421654,865.2555,0.940137078719929,0.979918227874206,0.0850501932239413,0.34861283225305,0.12920508720982,0.21940774504323,7.31374780296985,3.1073,8.1213065391956,862.1482,0.354859809258994,0.200243939860984,0.369875418493565,0.276787099292561,0.15461586939801,0.0930883192010046,True,0.336435317390915,0.0653459167376983,1.04089679696544,47.1947233830346
21266,1083:1032,Colon,SW948,SIDM00832,909757,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.906111650373542,0.144889035153065,0.408619808920119,8.04543857741383,5.16,0.791518952869033,0.776562517189796,0.1106245856883,0.370255169435931,0.422718973511455,-0.0524638040755241,8.65367474441157,7.8659,-0.608236166997738,-2.7059,0.717204544686097,0.789581893758756,0.703652344069078,0.73321788732561,-0.0723773490726587,-0.0295655432565318,True,0.297292024152372,0.0736474137455505,1.15305018714611,42.609188659605
21266,1510:1032,Colon,SW948,SIDM00832,909757,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.712695660488341,0.144889035153065,0.408619808920119,8.04543857741383,5.16,0.791518952869033,0.776562517189796,0.116403189697266,0.291221564606944,0.097219533322245,0.194002031284699,4.23479801674566,0.3677,3.81064056066817,4.7923,0.564112122904035,0.3432010674835,0.55345273609907,0.368859392718515,0.220911055420536,0.184593343380556,True,0.297292024152372,0.0736474137455505,1.15305018714611,42.609188659605
18392,1011:1047,Colon,SW948,SIDM00832,909757,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.264122317842638,0.0684824795424348,0.913758550971392,15.094996780054,683.5603,0.960323891979962,0.977218141853796,0.0727461192903611,0.241344026431095,0.144682281424827,0.0966617450062677,9.4950686229785,14.0939,5.59992815707547,669.4664,0.253642972229411,0.14985047243114,0.258105120664301,0.224235343131942,0.103792499798271,0.033869777532359,True,0.301433607553238,0.0603330809606757,1.14193672100903,43.0397231053888
18392,2048:1047,Colon,SW948,SIDM00832,909757,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.928332853785183,0.0684824795424348,0.913758550971392,15.094996780054,683.5603,0.960323891979962,0.977218141853796,0.0274706375954256,0.848272083293886,0.848077226609709,0.0001948566841766,15.0881265542172,680.3129,0.006870225836721,3.24739999999997,0.891500219199851,0.925044837165849,0.907183706397788,0.907129887305119,-0.0335446179659981,5.3819092668439e-05,True,0.301433607553238,0.0603330809606757,1.14193672100903,43.0397231053888
18392,1053:1054,Colon,SW948,SIDM00832,909757,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.769553218237087,0.0951980616529011,0.821755922577043,12.9463053314292,61.6618,0.914502943065558,0.950471390216633,0.112005573331983,0.63238491482455,0.452221574394228,0.180163340430322,9.91466919082747,7.5405,3.03163614060169,54.1213,0.703758682923388,0.580878762020068,0.731438317183488,0.666790140996535,0.12287992090332,0.0646481761869537,True,0.301433607553238,0.0603330809606757,1.14193672100903,43.0397231053888
21269,1047:1089,Colon,SW948,SIDM00832,909757,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1089,Oxaliplatin,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved in colon,10.0,0.911536599300444,0.121080626035617,0.641706733248252,10.5048366002891,28.3793,0.848673678672569,0.888430533801047,0.12666475548858,0.584939173373308,0.654940052748991,-0.0700008793756823,11.4195943679791,53.5021,-0.914757767689988,-25.1228,0.773597118972991,0.789830371932247,0.809836947495684,0.835635158257953,-0.0162332529592566,-0.025798210762269,True,0.297292024152372,0.0736474137455505,1.15305018714611,42.609188659605
22255,1011:1194,Colon,SW948,SIDM00832,909757,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,10.0,0.918664297267616,0.0864400968817952,0.576276350471944,9.79403273930342,17.3391,0.863881200295268,0.861598582746567,0.0579807843983306,0.529404508538255,0.468238446783083,0.0611660617551717,9.10014743883222,10.7188,0.6938853004712,6.6203,0.793616815791957,0.787121142440435,0.791519856545649,0.763494926177781,0.0064956733515223,0.0280249303678676,True,0.336435317390915,0.0653459167376983,1.04089679696544,47.1947233830346
18390,1011:1510,Colon,SW948,SIDM00832,909757,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.214994964749006,0.0764319337266273,0.514152615194419,9.14621695781386,11.0666,0.824910733918018,0.833251361388838,0.0398471372633526,0.110540223379334,0.0449547705415245,0.065585452837809,5.56473636834567,0.9244,3.58148058946819,10.1422,0.177351654159781,0.123275548338198,0.179144847068855,0.132320508460519,0.0540761058215836,0.046824338608336,True,0.301433607553238,0.0603330809606757,1.14193672100903,43.0397231053888
18390,1053:1510,Colon,SW948,SIDM00832,909757,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.682475208220444,0.0764319337266273,0.514152615194419,9.14621695781386,11.0666,0.824910733918018,0.833251361388838,0.0546096503440908,0.350896413111897,0.134708488690746,0.216187924421151,5.37789448719271,0.8122,3.76832247062115,10.2544,0.562981124893979,0.41112040583657,0.568673396363816,0.410836825480012,0.151860719057409,0.157836570883804,True,0.301433607553238,0.0603330809606757,1.14193672100903,43.0397231053888
18390,1032:1510,Colon,SW948,SIDM00832,909757,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.906975845623483,0.0764319337266273,0.514152615194419,9.14621695781386,11.0666,0.824910733918018,0.833251361388838,0.0759112742076138,0.466324002945484,0.371239935920066,0.0950840670254172,8.05287832373103,5.1867,1.09333863408282,5.8799,0.748174110459183,0.707126911626579,0.75573885811256,0.704702561449138,0.0410471988326042,0.0510362966634225,True,0.301433607553238,0.0603330809606757,1.14193672100903,43.0397231053888
18390,1022:1510,Colon,SW948,SIDM00832,909757,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.929685314818636,0.0764319337266273,0.514152615194419,9.14621695781386,11.0666,0.824910733918018,0.833251361388838,0.131564233239356,0.478000135921848,0.270201913175064,0.207798222746784,6.69596145311208,2.025,2.45025550470178,9.0416,0.766907395359845,0.606775346462127,0.774661554235839,0.644936851104274,0.160132048897717,0.129724703131565,True,0.301433607553238,0.0603330809606757,1.14193672100903,43.0397231053888
18390,2048:1510,Colon,SW948,SIDM00832,909757,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.892417170438903,0.0764319337266273,0.514152615194419,9.14621695781386,11.0666,0.824910733918018,0.833251361388838,0.0411249785204394,0.458838622025566,0.424724864266333,0.0341137577592326,8.75115865964615,8.4157,0.395058298167713,2.6509,0.736164503027797,0.736011161861395,0.743607822194991,0.726538156572592,0.0001533411664023,0.0170696656223994,True,0.301433607553238,0.0603330809606757,1.14193672100903,43.0397231053888
18390,1561:1510,Colon,SW948,SIDM00832,909757,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.327227637829669,0.0764319337266273,0.514152615194419,9.14621695781386,11.0666,0.824910733918018,0.833251361388838,0.0635518423780602,0.168244945754016,0.117660731483451,0.0505842142705656,7.50947338322345,3.5588,1.63674357459041,7.5078,0.269933590880332,0.222761884950552,0.272662874705625,0.24387508188975,0.0471717059297799,0.0287877928158753,True,0.301433607553238,0.0603330809606757,1.14193672100903,43.0397231053888
21270,1053:1549,Colon,SW948,SIDM00832,909757,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.630524431079109,0.0915343923798871,0.884761740008972,14.2632823276248,192.033,0.947471031722409,0.969083367438033,0.0695371606013281,0.55786389275972,0.456464293562466,0.101399599197253,11.4894960824074,28.0791,2.77378624521733,163.9539,0.597403633240708,0.563054070077682,0.611030738922093,0.579215716189653,0.034349563163026,0.0318150227324402,True,0.297292024152372,0.0736474137455505,1.15305018714611,42.609188659605
21270,1083:1549,Colon,SW948,SIDM00832,909757,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.979221764330196,0.0915343923798871,0.884761740008972,14.2632823276248,192.033,0.947471031722409,0.969083367438033,0.173117946914292,0.86637795206344,0.75500380467682,0.11137414738662,12.1350248153107,43.9245,2.12825751231404,148.1085,0.927784255334968,0.883742870895908,0.948947524845719,0.915028582365258,0.04404138443906,0.0339189424804609,True,0.297292024152372,0.0736474137455505,1.15305018714611,42.609188659605
21270,2048:1549,Colon,SW948,SIDM00832,909757,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.902973125637892,0.0915343923798871,0.884761740008972,14.2632823276248,192.033,0.947471031722409,0.969083367438033,0.0472157005021746,0.798916073820722,0.714062916943112,0.0848531568776102,12.433511115042,54.0207,1.82977121258274,138.0123,0.855540878965742,0.882116806193691,0.875056237299215,0.849524325091535,-0.0265759272279491,0.0255319122076799,True,0.297292024152372,0.0736474137455505,1.15305018714611,42.609188659605
22256,2048:1561,Colon,SW948,SIDM00832,909757,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.97574460741733,0.125444749457754,0.216155154189727,5.67360926950291,0.9969,0.585925213649164,0.623252344440132,0.0799641408231951,0.210912226066088,0.101476196416918,0.10943602964917,3.43913121088094,0.2118,2.23447805862197,0.7851,0.571713367568019,0.439577934378936,0.608135114147668,0.447013105609271,0.132135433189083,0.161122008538396,True,0.336435317390915,0.0653459167376983,1.04089679696544,47.1947233830346
22256,1011:1561,Colon,SW948,SIDM00832,909757,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.673071476228346,0.125444749457754,0.216155154189727,5.67360926950291,0.9969,0.585925213649164,0.623252344440132,0.065359311308538,0.145487868724845,0.0452183121256828,0.100269556599162,2.20681324901229,0.0902,3.46679602049062,0.9067,0.394369548510252,0.217753874789748,0.419493375535097,0.24785378542014,0.176615673720504,0.171639590114957,True,0.336435317390915,0.0653459167376983,1.04089679696544,47.1947233830346
22256,1786:1561,Colon,SW948,SIDM00832,909757,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.910969771852294,0.125444749457754,0.216155154189727,5.67360926950291,0.9969,0.585925213649164,0.623252344440132,0.139945633354248,0.196910811496913,0.0602655612109915,0.136645250285922,2.16420874265094,0.0875,3.50940052685197,0.9094,0.533760158200486,0.345563277116545,0.567764046021035,0.332711110891796,0.188196881083941,0.235052935129238,True,0.336435317390915,0.0653459167376983,1.04089679696544,47.1947233830346
22256,1011:1564,Colon,SW948,SIDM00832,909757,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.673071476228346,0.118444566313591,0.450954457708327,8.49178987702767,3.5155,0.781998553992582,0.800817098504803,0.0422441639734503,0.303524582561497,0.123580397566472,0.179944184995025,5.14714082447018,0.3461,3.34464905255749,3.1694,0.526340921144219,0.397478541578957,0.539007146679528,0.393864713447301,0.128862379565262,0.145142433232227,True,0.336435317390915,0.0653459167376983,1.04089679696544,47.1947233830346
22256,1194:1564,Colon,SW948,SIDM00832,909757,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,0.625,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.976204354213939,0.118444566313591,0.450954457708327,8.49178987702767,3.5155,0.781998553992582,0.800817098504803,0.112111197718116,0.440223705167055,0.234566737050579,0.205656968116476,6.02760956655425,0.6371,2.46418031047342,2.8784,0.763390393396563,0.590039166596933,0.781761138489361,0.632822352978384,0.17335122679963,0.148938785510978,True,0.336435317390915,0.0653459167376983,1.04089679696544,47.1947233830346
22256,1022:1564,Colon,SW948,SIDM00832,909757,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.965827200397312,0.118444566313591,0.450954457708327,8.49178987702767,3.5155,0.781998553992582,0.800817098504803,0.0619006192450148,0.435544081395122,0.207189182697452,0.22835489869767,5.64861953868014,0.4899,2.84317033834754,3.0256,0.755275474117401,0.570773422816854,0.773450936279192,0.600230281797548,0.184502051300548,0.173220654481644,True,0.336435317390915,0.0653459167376983,1.04089679696544,47.1947233830346
22256,1373:1564,Colon,SW948,SIDM00832,909757,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.970877289871758,0.118444566313591,0.450954457708327,8.49178987702767,3.5155,0.781998553992582,0.800817098504803,0.189734645017872,0.437821441755449,0.169391898825796,0.268429542929653,4.9866558258069,0.3096,3.50513405122077,3.2059,0.759224636783951,0.495379877878241,0.777495134279307,0.556698649672528,0.263844758905711,0.220796484606779,True,0.336435317390915,0.0653459167376983,1.04089679696544,47.1947233830346
22256,1179:1564,Colon,SW948,SIDM00832,909757,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.25,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.947550836031849,0.118444566313591,0.450954457708327,8.49178987702767,3.5155,0.781998553992582,0.800817098504803,0.0712082879081315,0.427302273413815,0.3526459779103,0.074656295503515,7.64968758145429,1.961,0.842102295573381,1.5545,0.740983383611368,0.720963769803005,0.758814911196825,0.714150260447566,0.0200196138083631,0.0446646507492591,True,0.336435317390915,0.0653459167376983,1.04089679696544,47.1947233830346
18391,1025:2171,Colon,SW948,SIDM00832,909757,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.89413087940106,0.107503720041575,0.113977429828329,3.70463315648676,0.2546,0.47039672652348,0.477920057140366,0.0806998195830835,0.101910739564276,0.0325734557204808,0.0693372838437957,0.542759341158543,0.0285,3.16187381532822,0.2261,0.420596238753819,0.237462876717455,0.42732308097432,0.230589475840492,0.183133362036363,0.196733605133828,True,0.301433607553238,0.0603330809606757,1.14193672100903,43.0397231053888
22646,1179:1003,Colon,T84,SIDM00782,909761,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,1,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.1,0.476978898380468,0.0717259719276788,0.438501544597933,8.38748471478247,0.0654,0.812671337249847,0.801308031073788,0.044342113364211,0.209155983680456,0.0747739938234155,0.13438198985704,4.83187161279049,0.0056,3.55561310199198,0.0598,0.387627079186814,0.24341435531907,0.382207021924997,0.268741623471239,0.144212723867744,0.113465398453758,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
22646,1022:1003,Colon,T84,SIDM00782,909761,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.1,0.87293357217148,0.0717259719276788,0.438501544597933,8.38748471478247,0.0654,0.812671337249847,0.801308031073788,0.1267198471359,0.382782719728585,0.146343712863544,0.236439006865041,5.03027654556001,0.0064,3.35720816922246,0.059,0.709408093426882,0.500258984505406,0.699488681974937,0.50489458862007,0.209149108921476,0.194594093354867,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
22653,1179:1017,Colon,T84,SIDM00782,909761,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.25,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.934735511129633,0.0695367367248291,0.916246957395056,14.9268568106776,608.3614,0.957430655720739,0.978730287551599,0.0706228726220411,0.85644856804164,0.745242363735684,0.111206204305955,12.3923821523804,105.0047,2.53447465829716,503.3567,0.894944433346305,0.827696434555261,0.914853955592597,0.883310409180293,0.067247998791044,0.0315435464123036,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
22647,1179:1022,Colon,T84,SIDM00782,909761,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.448887149621015,0.111486572480998,0.446962563846143,8.47244518678647,0.6937,0.844223292397175,0.805857888595377,0.0436551860431717,0.200635751272196,0.101608494818793,0.0990272564534032,5.95533011697705,0.1212,2.51711506980941,0.5725,0.378960987367836,0.278369962808443,0.361739250611188,0.290192382252983,0.100591024559394,0.0715468683582052,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
22647,1003:1022,Colon,T84,SIDM00782,909761,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.025,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.722458014594117,0.111486572480998,0.446962563846143,8.47244518678647,0.6937,0.844223292397175,0.805857888595377,0.0593169218501389,0.32291168647418,0.0841432143540601,0.23876847212012,3.98010805376933,0.0308,4.49233713301714,0.6629,0.609915883699372,0.345363206816245,0.582198490239623,0.360129036787598,0.264552676883127,0.222069453452025,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
22646,2171:1032,Colon,T84,SIDM00782,909761,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.826618193212268,0.0982157347379647,0.468339742059285,8.68584492004188,8.0432,0.778628635700326,0.816994307491637,0.0960070589201674,0.387138151390546,0.183120987466385,0.204017163924161,5.88653332795515,1.1555,2.79931159208673,6.8877,0.643628596025937,0.480559229177829,0.675342358323446,0.530299013581316,0.163069366848108,0.14504334474213,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
22646,1179:1032,Colon,T84,SIDM00782,909761,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.25,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.948882894135726,0.0982157347379647,0.468339742059285,8.68584492004188,8.0432,0.778628635700326,0.816994307491637,0.0945127559261544,0.444399569883994,0.351171535146461,0.0932280347375322,7.6824606084101,4.0122,1.00338431163178,4.031,0.738827393300277,0.730568806010202,0.775231922985078,0.722179851138749,0.0082585872900744,0.0530520718463295,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
22651,1179:1047,Colon,T84,SIDM00782,909761,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.25,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.963332746226931,0.0435303225042132,0.934851084890287,15.5989586117905,969.3586,0.973295604916612,0.983615218263199,0.0267791387691363,0.900572662920586,0.908087124223085,-0.0075144613024991,15.9354815670668,1224.0185,-0.336522955276305,-254.6599,0.937607527974922,0.949519158641918,0.947548749440089,0.949494559871252,-0.011911630666996,-0.0019458104311627,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
22650,1510:1053,Colon,T84,SIDM00782,909761,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.800086864009393,0.0674344437412892,0.73278289446035,11.4991257879957,56.5343,0.929428070097551,0.924567704721679,0.092137342523446,0.586289968028508,0.321936899198184,0.264353068830324,8.02003561064802,5.0699,3.47909017734767,51.4644,0.743623189926652,0.580335960757442,0.739734475435131,0.624774863515332,0.16328722916921,0.1149596119198,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
22650,1372:1053,Colon,T84,SIDM00782,909761,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.89503649535688,0.0674344437412892,0.73278289446035,11.4991257879957,56.5343,0.929428070097551,0.924567704721679,0.0272280756435677,0.655867433715262,0.579785862862703,0.0760815708525595,10.509429594288,28.4697,0.989696193707701,28.0646,0.831872042546421,0.819779524451429,0.827521838154247,0.800877846736703,0.0120925180949921,0.0266439914175438,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
22650,1022:1053,Colon,T84,SIDM00782,909761,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.859793571423557,0.0674344437412892,0.73278289446035,11.4991257879957,56.5343,0.929428070097551,0.924567704721679,0.0635989609201932,0.630042021906156,0.380891704649941,0.249150317256215,8.43273379433478,6.7489,3.06639199366091,49.7854,0.799116279770477,0.663515565632466,0.794937368865534,0.691049982570249,0.135600714138012,0.103887386295285,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
22650,1564:1053,Colon,T84,SIDM00782,909761,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.955352603323722,0.0674344437412892,0.73278289446035,11.4991257879957,56.5343,0.929428070097551,0.924567704721679,0.0409062117202327,0.700066045893787,0.67536942751593,0.0246966183778573,11.1813859968167,45.3589,0.317739791179029,11.1754,0.887931526369838,0.892105986800543,0.883288163654894,0.874995155865439,-0.0041744604307054,0.0082930077894557,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
22650,2048:1053,Colon,T84,SIDM00782,909761,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.954197699711708,0.0674344437412892,0.73278289446035,11.4991257879957,56.5343,0.929428070097551,0.924567704721679,0.0489264547652766,0.699219752282153,0.618333680765108,0.0808860715170454,10.5119838052326,28.5202,0.987141982763058,28.0141,0.886858126534575,0.866083897941165,0.88222037707316,0.853898737696211,0.02077422859341,0.0283216393769491,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
22650,1179:1053,Colon,T84,SIDM00782,909761,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.939865726386271,0.0674344437412892,0.73278289446035,11.4991257879957,56.5343,0.929428070097551,0.924567704721679,0.0430154551690341,0.688717527385411,0.639260497686603,0.0494570296988075,10.8691992585774,36.533,0.62992652941824,20.0013,0.873537588226024,0.851081030990907,0.868969497391528,0.852049500777972,0.0224565572351173,0.0169199966135567,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
22648,1372:1059,Colon,T84,SIDM00782,909761,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.749628620730645,0.0774967987715048,0.610171728683343,10.1099394800472,2.1584,0.853872352330332,0.880394160673931,0.109962521524169,0.457402191381728,0.222053524398536,0.235348666983192,6.85616466156771,0.2263,3.25377481847949,1.9321,0.640087153757418,0.503886419463587,0.659968660365313,0.531315461261491,0.13620073429383,0.128653199103821,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
22648,1011:1083,Colon,T84,SIDM00782,909761,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.929321060282679,0.0987577601441875,0.601793083054216,10.0230036031321,20.3215,0.913381398425977,0.877067463362614,0.119182058187611,0.559258986014727,0.492092389087329,0.067166596927398,9.29284847376712,12.2506,0.730155129364983,8.0709,0.848824569627705,0.81694551559993,0.815077264991585,0.786530357642026,0.0318790540277748,0.0285469073495588,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
22648,1372:1083,Colon,T84,SIDM00782,909761,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.949861316139777,0.0987577601441875,0.601793083054216,10.0230036031321,20.3215,0.913381398425977,0.877067463362614,0.113783582323265,0.571619969913692,0.439410470636007,0.132209499277685,8.62874273108373,7.7311,1.39426087204838,12.5904,0.867585657246488,0.802623192161148,0.833092455092989,0.773239852193266,0.0649624650853404,0.0598526028997226,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
22647,1011:1372,Colon,T84,SIDM00782,909761,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.90381503617455,0.132510526617733,0.313502958252988,7.05826638223694,0.2603,0.654474692522039,0.722038718230971,0.0462350966071165,0.283348687554253,0.101377259740523,0.18197142781373,3.87483481363855,0.0287,3.18343156859838,0.2316,0.591524067897134,0.433109950297064,0.652589450237351,0.443249530291241,0.15841411760007,0.20933991994611,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
22647,1053:1372,Colon,T84,SIDM00782,909761,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.889549697641683,0.132510526617733,0.313502958252988,7.05826638223694,0.2603,0.654474692522039,0.722038718230971,0.0367126381649001,0.278876461723719,0.141601682080525,0.137274779643194,4.87690027520099,0.0574,2.18136610703594,0.2029,0.582187764847114,0.493772156431404,0.642289323487949,0.504222324037535,0.0884156084157094,0.138066999450414,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
22647,1561:1372,Colon,T84,SIDM00782,909761,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.536213333469903,0.132510526617733,0.313502958252988,7.05826638223694,0.2603,0.654474692522039,0.722038718230971,0.0553973611604133,0.168104466297511,0.0308334913124532,0.137270974985058,2.07156006246822,0.0082,4.98670631976872,0.2521,0.350938056548933,0.168462515728328,0.387166787996965,0.190601518905366,0.182475540820605,0.1965652690916,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
22647,1059:1372,Colon,T84,SIDM00782,909761,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.735823140126264,0.132510526617733,0.313502958252988,7.05826638223694,0.2603,0.654474692522039,0.722038718230971,0.0550144094115785,0.230682731180587,0.102729191338232,0.127953539842355,4.49487459008542,0.044,2.56339179215152,0.2163,0.481577623384738,0.389916846877903,0.531292796941456,0.395744728271408,0.0916607765068352,0.135548068670048,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
22649,1053:1510,Colon,T84,SIDM00782,909761,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.835900038397371,0.0467751417637643,0.867160080415339,13.6477127634451,250.6692,0.957921520520526,0.965359072954951,0.0412294211875939,0.724859144515849,0.435086336709439,0.289772807806409,9.20326138803232,11.513,4.44445137541277,239.1562,0.800726635784775,0.697333996934735,0.806943686150293,0.704024289874143,0.10339263885004,0.102919396276151,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
22649,1022:1510,Colon,T84,SIDM00782,909761,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.897577690711898,0.0467751417637643,0.867160080415339,13.6477127634451,250.6692,0.957921520520526,0.965359072954951,0.0641072193834881,0.778343542456744,0.477612296407344,0.3007312460494,9.31865469766334,12.4717,4.32905806578175,238.1975,0.859808986272044,0.724136326208914,0.866484767410683,0.760715553885902,0.135672660063129,0.105769213524781,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
22649,1179:1510,Colon,T84,SIDM00782,909761,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.25,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.93814396589766,0.0467751417637643,0.867160080415339,13.6477127634451,250.6692,0.957921520520526,0.965359072954951,0.0717091904607669,0.813520996908979,0.692013360297993,0.121507636610987,11.5609480202066,59.0095,2.08676474323849,191.6597,0.898668294279842,0.842596877563943,0.905645789217245,0.868876656879602,0.0560714167158999,0.0367691323376435,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
22649,1059:1510,Colon,T84,SIDM00782,909761,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.765324609375675,0.0467751417637643,0.867160080415339,13.6477127634451,250.6692,0.957921520520526,0.965359072954951,0.09231106272516,0.663658949810048,0.456488241715571,0.207170708094477,9.96802974273031,19.5617,3.67968302071479,231.1075,0.733120913504924,0.627410216642916,0.738813055416511,0.669603869069834,0.105710696862008,0.0692091863466772,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
22649,1549:1510,Colon,T84,SIDM00782,909761,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.836151850439203,0.0467751417637643,0.867160080415339,13.6477127634451,250.6692,0.957921520520526,0.965359072954951,0.0215739511416638,0.725077505866294,0.513558302680817,0.211519203185477,10.1518966296353,22.2206,3.49581613380976,228.4486,0.800967851958773,0.740855284640418,0.807186775189556,0.737464955158629,0.0601125673183542,0.0697218200309264,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
22655,1510:1549,Colon,T84,SIDM00782,909761,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.88081668171289,0.109238343188126,0.705469702511386,11.1639246687888,22.4066,0.840398820767639,0.915386854287413,0.135204187059905,0.621389482415059,0.327950365523678,0.293439116891381,7.70619167233523,2.0394,3.45773299645354,20.3672,0.740237300623978,0.594528916637339,0.806288011477041,0.671629368388524,0.145708383986638,0.134658643088517,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
22656,1372:1561,Colon,T84,SIDM00782,909761,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.639440694547451,0.10257975989545,0.346249614367895,7.42547838188152,3.3575,0.699838590265757,0.745377706117625,0.0793265203734522,0.221406093898194,0.0606110844395051,0.160795009458689,3.40977375866759,0.2076,4.01570462321393,3.1499,0.447505274230645,0.271780317750157,0.47662483810004,0.29088933662003,0.175724956480488,0.18573550148001,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
22656,1011:1564,Colon,T84,SIDM00782,909761,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.899036791953243,0.0649324173359291,0.613669202997485,10.1464257338879,11.0682,0.853423757614475,0.881769706466116,0.0940242014228341,0.551711191583362,0.312147260892617,0.239563930690745,7.4358934743103,1.6909,2.71053225957764,9.3773,0.7672593572224,0.688304701851398,0.79274340814285,0.670703529036281,0.0789546553710017,0.122039879106569,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
22656,1053:1564,Colon,T84,SIDM00782,909761,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.880225144691997,0.0649324173359291,0.613669202997485,10.1464257338879,11.0682,0.853423757614475,0.881769706466116,0.0572928985527012,0.540167063001483,0.326054593071402,0.214112469930082,7.68599204892103,2.011,2.46043368496691,9.0572,0.751205050529789,0.699699904497786,0.776155867459157,0.670112207681143,0.0515051460320035,0.106043659778013,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
22656,1561:1564,Colon,T84,SIDM00782,909761,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.561477057807613,0.0649324173359291,0.613669202997485,10.1464257338879,11.0682,0.853423757614475,0.881769706466116,0.0500924277797489,0.344561178566171,0.129730794250082,0.214830384316088,6.02128667127723,0.6343,4.12513906261071,10.4339,0.479177860488493,0.358047456259404,0.495093460450477,0.365626668334756,0.121130404229089,0.129466792115721,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
22656,1059:1564,Colon,T84,SIDM00782,909761,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.761277673496228,0.0649324173359291,0.613669202997485,10.1464257338879,11.0682,0.853423757614475,0.881769706466116,0.0411166016408638,0.467172663154209,0.325827969879548,0.141344693274662,8.28154294949319,3.0387,1.86488278439476,8.0295,0.649692452703156,0.62143965094167,0.671271590697977,0.605629092613963,0.0282528017614864,0.0656424980840139,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
22656,1549:1564,Colon,T84,SIDM00782,909761,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.883551027085256,0.0649324173359291,0.613669202997485,10.1464257338879,11.0682,0.853423757614475,0.881769706466116,0.0837020637123577,0.542208054599018,0.237379254825406,0.304828799773611,6.51916139260856,0.8957,3.62726434127938,10.1725,0.754043437579227,0.557666150898671,0.779088529800801,0.606146347286946,0.196377286680556,0.172942182513855,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
22658,1053:2048,Colon,T84,SIDM00782,909761,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.941254855072551,0.0855815623475856,0.589841283040469,9.90004599867347,0.1866,0.908605191334064,0.872243393769464,0.067074480513144,0.555190971384064,0.40498599699838,0.150204974385684,8.30440053862259,0.0617,1.59564546005089,0.1249,0.855229047687312,0.75642960159837,0.821003329190467,0.749987506253824,0.0987994460889419,0.0710158229366429,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
18394,1179:1003,Colon,HT55,SIDM00541,907287,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,1,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.1,0.639232182557979,0.0630544051293694,0.817678253057683,13.4316243838563,2.158,0.937238987340197,0.942778568445412,0.0614413920189146,0.522686254332258,0.340978180731521,0.181708073600737,9.39533317477531,0.1315,4.03629120908103,2.0265,0.599113323455904,0.51390408180471,0.602654401976247,0.526106154978326,0.0852092416511937,0.0765482469979214,True,0.306262632082908,0.0422742255336387,1.10886005457665,44.0771149292623
18394,1022:1003,Colon,HT55,SIDM00541,907287,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.1,0.971218200420039,0.0630544051293694,0.817678253057683,13.4316243838563,2.158,0.937238987340197,0.942778568445412,0.0823439720928302,0.794144001457284,0.31771642769866,0.476427573758624,6.87030448565928,0.0229,6.56131989819706,2.1351,0.910263562648046,0.66434395205298,0.915643704640134,0.670039057818417,0.245919610595066,0.245604646821717,True,0.306262632082908,0.0422742255336387,1.10886005457665,44.0771149292623
18397,2048:1011,Colon,HT55,SIDM00541,907287,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.891719822166366,0.141266708391865,0.444730433076544,8.34446695850879,6.3484,0.81582628529985,0.772936409826582,0.113108263134533,0.396574942694986,0.308855610536264,0.0877193321587226,7.12457841020757,2.7255,1.21988854830122,3.6229,0.727488470046229,0.660232230616846,0.68924271791647,0.628815917077943,0.0672562394293827,0.0604268008385263,True,0.306262632082908,0.0422742255336387,1.10886005457665,44.0771149292623
18397,1510:1011,Colon,HT55,SIDM00541,907287,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.434680990504502,0.141266708391865,0.444730433076544,8.34446695850879,6.3484,0.81582628529985,0.772936409826582,0.0429084450567986,0.193315865157208,0.0949230869610102,0.0983927781961981,5.23437491560363,0.7352,3.11009204290516,5.6132,0.354624177773747,0.250660420741224,0.335980764220413,0.254043246299097,0.103963757032524,0.0819375179213158,True,0.306262632082908,0.0422742255336387,1.10886005457665,44.0771149292623
18397,1194:1011,Colon,HT55,SIDM00541,907287,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.683679329545015,0.141266708391865,0.444730433076544,8.34446695850879,6.3484,0.81582628529985,0.772936409826582,0.0797991013325734,0.304053004314035,0.141009955675554,0.163043048638481,5.02026906602711,0.6338,3.32419789248167,5.7146,0.557763567759001,0.394001392288822,0.528440646451169,0.389669337045665,0.16376217547018,0.138771309405504,True,0.306262632082908,0.0422742255336387,1.10886005457665,44.0771149292623
18397,1179:1011,Colon,HT55,SIDM00541,907287,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.62239818161932,0.141266708391865,0.444730433076544,8.34446695850879,6.3484,0.81582628529985,0.772936409826582,0.0437256222820665,0.276799412857613,0.0633928317892707,0.213406581068343,2.57178483108381,0.1161,5.77268212742497,6.2323,0.507768796487871,0.223702128397852,0.48107421598343,0.250550335534851,0.284066668090019,0.230523880448579,True,0.306262632082908,0.0422742255336387,1.10886005457665,44.0771149292623
21219,1510:1017,Colon,HT55,SIDM00541,907287,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.382158683382317,0.0922089893585329,0.801194586268246,13.115888714127,173.3828,0.922855326960904,0.937014063134536,0.0873828583704649,0.306183468221313,0.216385577578348,0.0897978906429647,9.78681515143995,17.2526,3.32907356268707,156.1302,0.352677176703736,0.246405986338692,0.358088060678209,0.32085848947311,0.106271190365044,0.0372295712050993,True,0.241405951442356,0.0487509605429818,1.34398224312432,36.610006142732
21219,1022:1017,Colon,HT55,SIDM00541,907287,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.849461967920517,0.0922089893585329,0.801194586268246,13.115888714127,173.3828,0.922855326960904,0.937014063134536,0.122383836853318,0.680584329938689,0.388231570620754,0.292352759317935,8.49120284429378,7.0281,4.62468586983323,166.3547,0.783930502146141,0.637090881923303,0.795957810039462,0.662931394094351,0.146839620222838,0.13302641594511,True,0.241405951442356,0.0487509605429818,1.34398224312432,36.610006142732
18395,1003:1022,Colon,HT55,SIDM00541,907287,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.0025,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.957330032355698,0.102283673775401,0.61892092692695,10.432140629432,2.6985,0.893847025168669,0.864407762445846,0.0821283268330333,0.592511591000595,0.578333154311198,0.0141784366893972,10.248022632206,2.3752,0.184117997226053,0.3233,0.855706601525766,0.868666612181517,0.827523511190797,0.821047211778747,-0.0129600106557509,0.0064762994120504,True,0.306262632082908,0.0422742255336387,1.10886005457665,44.0771149292623
18395,1179:1022,Colon,HT55,SIDM00541,907287,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.25,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.912451257315499,0.102283673775401,0.61892092692695,10.432140629432,2.6985,0.893847025168669,0.864407762445846,0.0587449560478266,0.564735177953369,0.293501868383009,0.271233309570361,6.79661563733033,0.2171,3.63552499210171,2.4814,0.81559184196287,0.627002878589225,0.788729949676989,0.625395997682245,0.188588963373645,0.163333951994743,True,0.306262632082908,0.0422742255336387,1.10886005457665,44.0771149292623
18395,1011:1022,Colon,HT55,SIDM00541,907287,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.912721113008239,0.102283673775401,0.61892092692695,10.432140629432,2.6985,0.893847025168669,0.864407762445846,0.145212349393068,0.564902197288857,0.324350988473055,0.240551208815801,7.24137248302538,0.2955,3.19076814640666,2.403,0.815833051671052,0.706010179727746,0.788963215032534,0.649917343467663,0.109822871943305,0.139045871564871,True,0.306262632082908,0.0422742255336387,1.10886005457665,44.0771149292623
21218,1194:1025,Colon,HT55,SIDM00541,907287,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,2.5,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.284955187912149,0.0933873789113566,0.798740386645388,13.0705977450465,168.0243,0.936089443362923,0.936146098730007,0.0249086946557397,0.227605216969559,0.10082112553717,0.126784091432389,7.22133254034381,2.9145,5.84926520470267,165.1098,0.26674354323606,0.184610894701104,0.266759687476834,0.202571363531414,0.0821326485349564,0.0641883239454199,True,0.241405951442356,0.0487509605429818,1.34398224312432,36.610006142732
18394,1083:1032,Colon,HT55,SIDM00541,907287,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.992841494932777,0.120573219418433,0.327284392964259,6.87235043986921,2.2883,0.633818375003262,0.690019834750579,0.16561928771718,0.324941525978802,0.227836759727698,0.0971047662511039,5.42311515437691,0.838,1.4492352854923,1.4503,0.629281182954102,0.533515222377473,0.685080324267032,0.592828391026964,0.0957659605766297,0.0922519332400685,True,0.306262632082908,0.0422742255336387,1.10886005457665,44.0771149292623
22622,2171:1047,Colon,HT55,SIDM00541,907287,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.431121463754556,0.077783113504332,0.90371329276574,15.6124073753807,978.4372,0.961056230929862,0.971165010472219,0.0767735389690855,0.389610197591615,0.155123860555594,0.234486337036021,7.29854848415252,3.0748,8.31385889122816,975.3624,0.414331969028918,0.247335456078927,0.418690080861991,0.308429071492349,0.166996512949991,0.110261009369643,True,0.137834679944973,0.0449434440063534,1.85456844434429,26.6441096514902
22622,2048:1047,Colon,HT55,SIDM00541,907287,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.765859170750178,0.077783113504332,0.90371329276574,15.6124073753807,978.4372,0.961056230929862,0.971165010472219,0.0928300337084644,0.692117112993483,0.387734606892886,0.304382506100597,9.07411386064275,10.5271,6.53829351473793,967.9101,0.736033728064236,0.634058067595297,0.743775629581842,0.619257537506137,0.101975660468939,0.124518092075706,True,0.137834679944973,0.0449434440063534,1.85456844434429,26.6441096514902
22622,1179:1047,Colon,HT55,SIDM00541,907287,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.25,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.920459135542288,0.077783113504332,0.90371329276574,15.6124073753807,978.4372,0.961056230929862,0.971165010472219,0.100139420094984,0.831831156237228,0.692745514031093,0.139085642206134,12.2854820856474,97.5054,3.32692528973325,880.9318,0.88461298752923,0.830713972871435,0.893917706008176,0.84621260239706,0.0538990146577958,0.0477051036111168,True,0.137834679944973,0.0449434440063534,1.85456844434429,26.6441096514902
22622,1549:1054,Colon,HT55,SIDM00541,907287,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.61248878567062,0.127639479075977,0.568151517651558,9.81005996936796,7.0131,0.835964342284638,0.840542488509589,0.0898632074696877,0.347986433123323,0.246781665835577,0.101204767287746,7.83848193471651,1.7882,1.97157803465145,5.2249,0.512018784869856,0.409631187719303,0.514822848091799,0.456920679016004,0.102387597150553,0.0579021690757947,True,0.137834679944973,0.0449434440063534,1.85456844434429,26.6441096514902
21220,1022:1073,Colon,HT55,SIDM00541,907287,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,20.0,0.785585702494272,0.0945989433787016,0.516329093726881,9.19295088495288,22.862,0.823972081129701,0.814014135306022,0.134585510487089,0.405620753813663,0.192587701468973,0.21303305234469,5.67888802094591,2.0011,3.51406286400697,20.8609,0.647300686189943,0.442347075281064,0.639477866324649,0.482429499996446,0.204953610908879,0.157048366328203,True,0.241405951442356,0.0487509605429818,1.34398224312432,36.610006142732
21219,1003:1373,Colon,HT55,SIDM00541,907287,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.0025,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10.0,0.894437731334559,0.121622781628835,0.736651113587382,12.037605640747,82.1127,0.882755700065287,0.913293099615762,0.108595480252247,0.658888550822174,0.587588825762878,0.0712997250592959,10.9185112783046,37.8033,1.11909436244238,44.3094,0.789570005689045,0.827979398985651,0.81688380806383,0.788084032322613,-0.0384093932966055,0.0287997757412165,True,0.241405951442356,0.0487509605429818,1.34398224312432,36.610006142732
21219,1179:1373,Colon,HT55,SIDM00541,907287,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.25,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10.0,0.796025967103608,0.121622781628835,0.736651113587382,12.037605640747,82.1127,0.882755700065287,0.913293099615762,0.113686064808085,0.586393415111345,0.509409896932248,0.0769835181790975,10.6983246000189,32.4524,1.3392810407281,49.6603,0.702696459860692,0.638746779440464,0.727005022870689,0.695528286096018,0.0639496804202284,0.0314767367746712,True,0.241405951442356,0.0487509605429818,1.34398224312432,36.610006142732
21219,1510:1373,Colon,HT55,SIDM00541,907287,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10.0,0.382158683382317,0.121622781628835,0.736651113587382,12.037605640747,82.1127,0.882755700065287,0.913293099615762,0.0796302214194281,0.281517619680671,0.187118758773605,0.0943988609070658,8.87756437406923,9.1864,3.16004126667778,72.9263,0.337352756085185,0.251174343616415,0.349022888491315,0.305482220752329,0.0861784124687696,0.0435406677389855,True,0.241405951442356,0.0487509605429818,1.34398224312432,36.610006142732
21221,1083:1549,Colon,HT55,SIDM00541,907287,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.980325605302455,0.158304875346529,0.537739976340705,9.4466410604299,6.8143,0.740044662082104,0.82526487384718,0.0907191372471305,0.52716026780153,0.36134259081653,0.165817676984999,7.41051902987444,1.6615,2.03612203055546,5.1528,0.72548473130649,0.691741894693706,0.809028286989092,0.707702644399075,0.0337428366127844,0.101325642590017,True,0.241405951442356,0.0487509605429818,1.34398224312432,36.610006142732
22623,1053:1561,Colon,HT55,SIDM00541,907287,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.788716435773446,0.102413749283125,0.209860414517392,5.08494889012724,0.6629,0.562833225105538,0.574343573936984,0.161550856682714,0.165520358148095,0.0435911860365433,0.121929172111552,0.6171957954587,0.03,4.46775309466854,0.6329,0.443915815240114,0.248089986294049,0.452994216544961,0.220599848720071,0.195825828946064,0.23239436782489,True,0.137834679944973,0.0449434440063534,1.85456844434429,26.6441096514902
21222,1549:1786,Colon,HT55,SIDM00541,907287,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10.0,0.697357269142377,0.138465303399437,0.592743582514921,10.1083340014118,21.5597,0.889083737970531,0.852343516206215,0.0824048381255604,0.413354046004274,0.338406192405022,0.0749478535992527,8.8259498945914,8.8635,1.28238410682042,12.6962,0.620009007550026,0.545227197857356,0.594387946832778,0.55571804191538,0.0747818096926701,0.0386699049173977,True,0.241405951442356,0.0487509605429818,1.34398224312432,36.610006142732
19223,1032:1011,Colon,NCI-H508,SIDM00777,908442,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.393950272678685,0.159861016563322,0.408672474688757,7.80611242010364,4.3712,0.803264229499426,0.731348070187711,0.0668150903013885,0.160996632839909,0.127000516559437,0.0339961162804721,6.59943698306888,1.8939,1.20667543703475,2.4773,0.316446162244333,0.283253551788699,0.288114771673479,0.261415408366182,0.0331926104556331,0.026699363307297,True,0.303828065256482,0.0809112345920737,1.12097657803301,43.667840710893
19223,2048:1011,Colon,NCI-H508,SIDM00777,908442,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.794916917741126,0.159861016563322,0.408672474688757,7.80611242010364,4.3712,0.803264229499426,0.731348070187711,0.0845908066158348,0.324860663945225,0.164074160535469,0.160786503409755,4.64805051068131,0.4897,3.15806190942233,3.8815,0.638528325445385,0.439400169448091,0.581360953749536,0.430828834867049,0.199128155997293,0.150532118882487,True,0.303828065256482,0.0809112345920737,1.12097657803301,43.667840710893
19223,1510:1011,Colon,NCI-H508,SIDM00777,908442,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.640447944331287,0.159861016563322,0.408672474688757,7.80611242010364,4.3712,0.803264229499426,0.731348070187711,0.065950203069124,0.261733446319194,0.135960205721481,0.125773240597713,4.76295143777941,0.5303,3.04316098232423,3.8409,0.514448924537763,0.351444714087888,0.468390368142373,0.351853043546234,0.163004210449875,0.116537324596139,True,0.303828065256482,0.0809112345920737,1.12097657803301,43.667840710893
19223,2171:1011,Colon,NCI-H508,SIDM00777,908442,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.432424892096384,0.159861016563322,0.408672474688757,7.80611242010364,4.3712,0.803264229499426,0.731348070187711,0.0439363750341173,0.176720150770048,0.0900351356890077,0.0866850150810402,4.6835591618828,0.5019,3.12255325822084,3.8693,0.347351447766175,0.220010714819244,0.31625311033582,0.23535599963498,0.127340732946931,0.0808971107008395,True,0.303828065256482,0.0809112345920737,1.12097657803301,43.667840710893
19223,1179:1011,Colon,NCI-H508,SIDM00777,908442,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.306973846023191,0.159861016563322,0.408672474688757,7.80611242010364,4.3712,0.803264229499426,0.731348070187711,0.0417850190935111,0.125451761319023,0.0604479403416913,0.0650038209773316,4.45756652433331,0.4291,3.34854589577032,3.9421,0.246581109902294,0.126508638809762,0.224504729887161,0.162594612699419,0.120072471092532,0.0619101171877421,True,0.303828065256482,0.0809112345920737,1.12097657803301,43.667840710893
19223,1022:1011,Colon,NCI-H508,SIDM00777,908442,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.851091409198056,0.159861016563322,0.408672474688757,7.80611242010364,4.3712,0.803264229499426,0.731348070187711,0.0568524366429611,0.347817632383311,0.164047527141265,0.183770105242046,4.37174696445346,0.4043,3.43436545565017,3.9669,0.683651285043058,0.434615015569143,0.622444059670338,0.44606766943048,0.249036269473914,0.176376390239858,True,0.303828065256482,0.0809112345920737,1.12097657803301,43.667840710893
19223,1786:1011,Colon,NCI-H508,SIDM00777,908442,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.788012952356799,0.159861016563322,0.408672474688757,7.80611242010364,4.3712,0.803264229499426,0.731348070187711,0.0406334128163753,0.322039203326446,0.161856429980985,0.160182773345462,4.6281686823669,0.483,3.17794373773673,3.8882,0.632982617010452,0.409452769180677,0.576311751989066,0.426075887159753,0.223529847829775,0.150235864829313,True,0.303828065256482,0.0809112345920737,1.12097657803301,43.667840710893
19520,1011:1194,Colon,NCI-H508,SIDM00777,908442,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,10.0,0.427611612059372,0.0855870451910503,0.762263539054588,12.7650862488405,135.9577,0.957511770012617,0.916810499531412,0.0734015000954068,0.325952740749214,0.237821524187843,0.0881312165613711,9.72902650837639,16.5752,3.03605974046407,119.3825,0.409443151540918,0.370539646531507,0.392038815657585,0.351447863538473,0.0389035050094114,0.0405909521191121,True,0.313157782574321,0.0371845480838703,1.09873578111021,44.61243274509
19223,1032:1510,Colon,NCI-H508,SIDM00777,908442,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.393950272678685,0.110914712756356,0.527023083687239,9.34963828859668,12.7424,0.834142857400345,0.805896468378695,0.0251783615931014,0.207620887526549,0.201140647036416,0.0064802404901336,9.13669489283798,10.9938,0.212943395758698,1.7486,0.328610806125843,0.323998067388431,0.317483133468576,0.31378467995147,0.004612738737412,0.0036984535171059,True,0.303828065256482,0.0809112345920737,1.12097657803301,43.667840710893
19525,1053:1786,Colon,NCI-H508,SIDM00777,908442,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10.0,0.457487305450502,0.0878115623540637,0.755169007667929,12.6398467028524,124.6531,0.947964400363054,0.913966654373427,0.038289440347408,0.34548023447773,0.312254798701763,0.0332254357759673,11.4736404038328,55.5444,1.1662062990196,69.1087,0.433681679185094,0.393115089802728,0.418128141980909,0.404106526383912,0.0405665893823663,0.0140216155969968,True,0.313157782574321,0.0371845480838703,1.09873578111021,44.61243274509
19619,1179:1003,Colon,LS-1034,SIDM00681,917486,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,1,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.1,0.817307403372943,0.0637829200635285,0.67643411115448,10.8203236567816,0.3532,0.903965024671331,0.905549216327395,0.0906167331493011,0.552854606940553,0.200780784656813,0.35207382228374,6.23066242050142,0.0147,4.58966123628021,0.3385,0.738817307054084,0.565078399531843,0.740112078622946,0.544594546358934,0.173738907522241,0.195517532264012,True,0.271157623415435,0.0367741766136671,1.2270548595153,39.9632113096037
19619,1022:1003,Colon,LS-1034,SIDM00681,917486,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.1,0.976014137374332,0.0637829200635285,0.67643411115448,10.8203236567816,0.3532,0.903965024671331,0.905549216327395,0.135050907319591,0.660209255489013,0.250984698081986,0.409224557407027,6.38140528889775,0.0163,4.43891836788388,0.3369,0.882282643771156,0.708153631969206,0.883828837223785,0.66063439623862,0.17412901180195,0.223194440985165,True,0.271157623415435,0.0367741766136671,1.2270548595153,39.9632113096037
19622,1510:1011,Colon,LS-1034,SIDM00681,917486,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.71110341147596,0.111900881393037,0.401673033081966,8.01632039380557,5.0569,0.816955033580985,0.781164978157922,0.0635136248137615,0.285631064122482,0.0930839245774715,0.192547139545011,4.32715553790319,0.392,3.68916485590238,4.6649,0.580939511401895,0.367680977971445,0.555489080893642,0.37338240604551,0.21325853343045,0.182106674848132,True,0.271157623415435,0.0367741766136671,1.2270548595153,39.9632113096037
19622,1561:1011,Colon,LS-1034,SIDM00681,917486,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.990454168723508,0.111900881393037,0.401673033081966,8.01632039380557,5.0569,0.816955033580985,0.781164978157922,0.120944166078878,0.397838730079849,0.310667702539622,0.0871710275402273,7.06705870692639,2.6189,0.949261686879178,2.438,0.809156518669939,0.744877624591391,0.773708109077322,0.716120333004237,0.0642788940785484,0.0575877760730851,True,0.271157623415435,0.0367741766136671,1.2270548595153,39.9632113096037
19620,1032:1022,Colon,LS-1034,SIDM00681,917486,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.89013217351094,0.0777451367284477,0.791878446719369,12.2985704170744,9.8394,0.937533605169713,0.943525557528995,0.0956830630515573,0.704876482934779,0.607407846259071,0.097468636675708,10.8877024981545,3.7005,1.41086791891989,6.1389,0.834528825709264,0.807945567317017,0.839862455286406,0.807932404148725,0.026583258392247,0.0319300511376815,True,0.271157623415435,0.0367741766136671,1.2270548595153,39.9632113096037
19620,1073:1022,Colon,LS-1034,SIDM00681,917486,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,2.5,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.939406455503821,0.0777451367284477,0.791878446719369,12.2985704170744,9.8394,0.937533605169713,0.943525557528995,0.0932814328052275,0.743895724822514,0.245297054229058,0.498598670593456,6.43240530146656,0.1687,5.86616511560779,9.6707,0.880725120948198,0.662342054665335,0.88635399967558,0.639178155319212,0.218383066282863,0.247175844356368,True,0.271157623415435,0.0367741766136671,1.2270548595153,39.9632113096037
19620,1053:1022,Colon,LS-1034,SIDM00681,917486,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.975323167453506,0.0777451367284477,0.791878446719369,12.2985704170744,9.8394,0.937533605169713,0.943525557528995,0.0780135608661986,0.772337394892497,0.535373433984024,0.236963960908473,9.48456907170805,1.3992,2.8140013453663,8.4402,0.914398245388229,0.860738601168636,0.920242335342515,0.8343360740241,0.0536596442195932,0.0859062613184152,True,0.271157623415435,0.0367741766136671,1.2270548595153,39.9632113096037
19620,1011:1022,Colon,LS-1034,SIDM00681,917486,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.931735179738264,0.0777451367284477,0.791878446719369,12.2985704170744,9.8394,0.937533605169713,0.943525557528995,0.0773502502668864,0.737821006884929,0.464722120696524,0.273098886188405,8.98786113032541,0.9916,3.31070928674894,8.8478,0.873533042123465,0.806357864916352,0.879115954931925,0.775735980232287,0.0671751772071127,0.103379974699637,True,0.271157623415435,0.0367741766136671,1.2270548595153,39.9632113096037
19620,1179:1022,Colon,LS-1034,SIDM00681,917486,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.714638964340547,0.0777451367284477,0.791878446719369,12.2985704170744,9.8394,0.937533605169713,0.943525557528995,0.0641164728955323,0.565907193047131,0.234482714379135,0.331424478667996,7.2307798752833,0.2934,5.06779054179105,9.546,0.669998044632943,0.504372220459796,0.674280127261359,0.524230104832219,0.165625824173146,0.15005002242914,True,0.271157623415435,0.0367741766136671,1.2270548595153,39.9632113096037
19620,1003:1022,Colon,LS-1034,SIDM00681,917486,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.025,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.967674918846759,0.0777451367284477,0.791878446719369,12.2985704170744,9.8394,0.937533605169713,0.943525557528995,0.048830123556002,0.766280911665663,0.183143199129526,0.583137712536137,5.40883524998401,0.083,6.88973516709035,9.7564,0.907227755298711,0.575118954356341,0.913026017311714,0.587225418916674,0.33210880094237,0.32580059839504,True,0.271157623415435,0.0367741766136671,1.2270548595153,39.9632113096037
20297,1179:1025,Colon,LS-1034,SIDM00681,917486,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,1,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.590643512768985,0.0542848796035893,0.939113951581257,15.7535464454169,1078.9966,0.971974343235921,0.984771863750232,0.0705533971104595,0.554681563252316,0.335180771389212,0.219500791863105,9.67041809771454,15.9153,6.08312834770235,1063.0813,0.574090340410191,0.511681629902599,0.581649112881497,0.509963822717062,0.0624087105075929,0.0716852901644353,True,0.22619748666549,0.0368660011582517,1.24388228424017,38.269059378773
19619,1011:1032,Colon,LS-1034,SIDM00681,917486,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.907076504080284,0.10611655092412,0.666015155074711,10.7037740571299,32.5752,0.928634388931387,0.901816026454768,0.132645437810843,0.604126698529657,0.270530569302847,0.33359612922681,6.88780734793606,2.313,3.81596670919384,30.2622,0.842342435080613,0.68896309875869,0.818016128600163,0.645168804066527,0.153379336321923,0.172847324533636,True,0.271157623415435,0.0367741766136671,1.2270548595153,39.9632113096037
19619,1053:1032,Colon,LS-1034,SIDM00681,917486,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.980536209431523,0.10611655092412,0.666015155074711,10.7037740571299,32.5752,0.928634388931387,0.901816026454768,0.128690355201941,0.653051975580906,0.48985205107675,0.163199924504156,8.99581040295538,9.971,1.70796365417452,22.6042,0.910559643670541,0.875443365340351,0.884263268184557,0.816743313148124,0.0351162783301899,0.0675199550364323,True,0.271157623415435,0.0367741766136671,1.2270548595153,39.9632113096037
19619,1372:1032,Colon,LS-1034,SIDM00681,917486,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.984536101316133,0.10611655092412,0.666015155074711,10.7037740571299,32.5752,0.928634388931387,0.901816026454768,0.100004396511002,0.655715964194716,0.441401540445106,0.21431442374961,8.48803573059568,7.0127,2.21573832653422,25.5625,0.914274080826597,0.778558078772358,0.887870434790184,0.79472376439351,0.135716002054239,0.0931466703966742,True,0.271157623415435,0.0367741766136671,1.2270548595153,39.9632113096037
19619,1564:1032,Colon,LS-1034,SIDM00681,917486,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.959909268878256,0.10611655092412,0.666015155074711,10.7037740571299,32.5752,0.928634388931387,0.901816026454768,0.0861703607164252,0.639314120569604,0.584334341274396,0.0549797792952081,10.0910981035122,21.3036,0.612675953617742,11.2716,0.891404757334333,0.841621216014978,0.86566156261689,0.84493122515318,0.0497835413193548,0.0207303374637097,True,0.271157623415435,0.0367741766136671,1.2270548595153,39.9632113096037
19619,2048:1032,Colon,LS-1034,SIDM00681,917486,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.942857515499757,0.10611655092412,0.666015155074711,10.7037740571299,32.5752,0.928634388931387,0.901816026454768,0.076899678723658,0.627957394398928,0.502181442531278,0.125775951867649,9.3225080748932,12.505,1.38126598223669,20.0702,0.875569912755482,0.838960461944455,0.850284018141006,0.799769057567978,0.036609450811027,0.0505149605730282,True,0.271157623415435,0.0367741766136671,1.2270548595153,39.9632113096037
19619,1179:1032,Colon,LS-1034,SIDM00681,917486,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.25,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.94412133292547,0.10611655092412,0.666015155074711,10.7037740571299,32.5752,0.928634388931387,0.901816026454768,0.0795212181377898,0.6287991159577,0.601427397934089,0.0273717180236106,10.3884311967129,26.1794,0.31534286041704,6.3958,0.87674353707833,0.882507367506091,0.851423748950026,0.841326091355647,-0.0057638304277614,0.010097657594379,True,0.271157623415435,0.0367741766136671,1.2270548595153,39.9632113096037
19624,1053:1047,Colon,LS-1034,SIDM00681,917486,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.90080063550236,0.078939833846748,0.880804562349275,13.9371002403259,306.3482,0.919920242634227,0.969251060002742,0.0247207195322645,0.793429309517604,0.811900281064765,-0.0184709715471609,14.4598961092691,440.1417,-0.522795868943128,-133.7935,0.828664739176397,0.891239063066013,0.873101970811806,0.878119401626133,-0.0625743238896161,-0.0050174308143271,True,0.271157623415435,0.0367741766136671,1.2270548595153,39.9632113096037
19624,1510:1047,Colon,LS-1034,SIDM00681,917486,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.5980712216599,0.078939833846748,0.880804562349275,13.9371002403259,306.3482,0.919920242634227,0.969251060002742,0.0614477451058203,0.526783860647844,0.401327155995503,0.12545670465234,10.7597005518925,33.8628,3.17739968843347,272.4854,0.550177823341924,0.484125378124766,0.579681165550993,0.54043030366585,0.0660524452171574,0.0392508618851427,True,0.271157623415435,0.0367741766136671,1.2270548595153,39.9632113096037
19624,1786:1047,Colon,LS-1034,SIDM00681,917486,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.880051606886466,0.078939833846748,0.880804562349275,13.9371002403259,306.3482,0.919920242634227,0.969251060002742,0.0684428267049445,0.77515347044841,0.489190186350578,0.285963284097832,9.55391863063467,14.6807,4.38318160969127,291.6675,0.80957728773764,0.726934276954749,0.852990952831824,0.755483343810172,0.0826430107828908,0.0975076090216516,True,0.271157623415435,0.0367741766136671,1.2270548595153,39.9632113096037
19624,2048:1047,Colon,LS-1034,SIDM00681,917486,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.963680909458838,0.078939833846748,0.880804562349275,13.9371002403259,306.3482,0.919920242634227,0.969251060002742,0.0540938410562423,0.848814541700243,0.777237703583476,0.0715768381167668,12.5240248340574,115.0369,1.41307540626858,191.3113,0.886509576051347,0.911716355069428,0.934048742997385,0.91352416918411,-0.0252067790180807,0.0205245738132752,True,0.271157623415435,0.0367741766136671,1.2270548595153,39.9632113096037
19623,1194:1053,Colon,LS-1034,SIDM00681,917486,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,0.625,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.952958710836484,0.07277068369738,0.60167964190396,10.0181629884197,20.2534,0.863216169436832,0.877422371279174,0.0780772549372461,0.573375855885355,0.643277303756043,-0.0699014478706879,10.8045244348583,34.9314,-0.786361446438658,-14.678,0.822609367999731,0.888172861217907,0.836147291793292,0.862475267036481,-0.065563493218176,-0.0263279752431895,True,0.271157623415435,0.0367741766136671,1.2270548595153,39.9632113096037
19623,1510:1053,Colon,LS-1034,SIDM00681,917486,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.617995364669342,0.07277068369738,0.60167964190396,10.0181629884197,20.2534,0.863216169436832,0.877422371279174,0.0875699202509141,0.371835229712557,0.284925810912238,0.0869094188003188,8.61461750890157,7.6558,1.40354547951812,12.5976,0.533463591419587,0.495775560260368,0.542242958307712,0.502955631383911,0.0376880311592191,0.0392873269238011,True,0.271157623415435,0.0367741766136671,1.2270548595153,39.9632113096037
19624,1053:1054,Colon,LS-1034,SIDM00681,917486,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.90080063550236,0.0853508552548557,0.764171419962833,11.902138721608,29.9014,0.905170753936189,0.934929662365362,0.0659740745219573,0.68836610073526,0.477728312883037,0.210637787852223,9.29991579944026,4.9243,2.60222292216776,24.9771,0.815378390383869,0.735551641849805,0.842185234008724,0.76317200064002,0.0798267485340639,0.0790132333687039,True,0.271157623415435,0.0367741766136671,1.2270548595153,39.9632113096037
19624,1561:1054,Colon,LS-1034,SIDM00681,917486,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.926568030875192,0.0853508552548557,0.764171419962833,11.902138721608,29.9014,0.905170753936189,0.934929662365362,0.0951323917576128,0.708056807846061,0.546342637548946,0.161714170297115,9.8947733465211,7.4373,2.00736537508692,22.4641,0.838702283080468,0.740921765660864,0.866275936264681,0.808502348291881,0.0977805174196033,0.0577735879728004,True,0.271157623415435,0.0367741766136671,1.2270548595153,39.9632113096037
19621,1510:1059,Colon,LS-1034,SIDM00681,917486,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.705510066703575,0.0614497895356049,0.894747071837733,14.2829404199322,38.9335,0.957452187521333,0.973052023460117,0.116092904071938,0.631253066335067,0.494100591851126,0.137152474483941,11.0955817552552,4.274,3.18735866467692,34.6595,0.675492156683659,0.556227722891121,0.686497997977396,0.644772074676141,0.119264433792538,0.0417259233012544,True,0.271157623415435,0.0367741766136671,1.2270548595153,39.9632113096037
19621,1561:1059,Colon,LS-1034,SIDM00681,917486,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.966440867139159,0.0614497895356049,0.894747071837733,14.2829404199322,38.9335,0.957452187521333,0.973052023460117,0.13175123201155,0.864720135977082,0.785938516775695,0.0787816192013867,12.6314404712424,12.3929,1.65149994868978,26.5406,0.925320922352402,0.828782936785482,0.940397241324309,0.918071739841788,0.0965379855669204,0.022325501482521,True,0.271157623415435,0.0367741766136671,1.2270548595153,39.9632113096037
20299,1022:1073,Colon,LS-1034,SIDM00681,917486,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,20.0,0.991571292561372,0.0813357399317654,0.599739342123181,9.99819462426251,39.95,0.845629111096837,0.876647888911277,0.0920530468102854,0.59468431466899,0.252043507439253,0.342640807229736,6.34292234279262,3.1708,3.65527228146989,36.7792,0.838501550717815,0.633570378541062,0.869258880328953,0.668508310147014,0.204931172176753,0.200750570181939,True,0.22619748666549,0.0368660011582517,1.24388228424017,38.269059378773
20300,1022:1179,Colon,LS-1034,SIDM00681,917486,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,10.0,0.956726058103939,0.1436181080691,0.252895600642822,6.32609226293274,1.567,0.703643459921605,0.673016600341169,0.080244746577345,0.241951811114835,0.0813377885872212,0.160614022527614,3.13479372558805,0.1716,3.19129853734469,1.3954,0.673194033721414,0.393962520491643,0.643892519082921,0.415148322989206,0.279231513229771,0.228744196093714,True,0.22619748666549,0.0368660011582517,1.24388228424017,38.269059378773
19622,1194:1510,Colon,LS-1034,SIDM00681,917486,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,0.625,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.952755344785127,0.0865184938219761,0.556383609706455,9.55910124016394,14.7335,0.84383307642529,0.858676399568289,0.0647614423826371,0.530097457898667,0.521142418244236,0.0089550396544312,9.46529073827506,13.806,0.0938105018888731,0.9275,0.803966473670672,0.841291672177855,0.818108529129537,0.81422622214388,-0.0373251985071831,0.0038823069856566,True,0.271157623415435,0.0367741766136671,1.2270548595153,39.9632113096037
20300,1179:1549,Colon,LS-1034,SIDM00681,917486,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.25,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.943060044570049,0.0819891989133979,0.934129652790327,15.5461810664623,467.2689,0.938124513561566,0.983482630463951,0.0489406880712452,0.880940351994651,0.849472825938695,0.0314675260559557,14.4447415651088,217.7712,1.10143950135351,249.4977,0.884707745571626,0.939140574713801,0.927483173319203,0.919176053126458,-0.0544328291421753,0.0083071201927456,True,0.22619748666549,0.0368660011582517,1.24388228424017,38.269059378773
20300,2171:1549,Colon,LS-1034,SIDM00681,917486,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.705415044918266,0.0819891989133979,0.934129652790327,15.5461810664623,467.2689,0.938124513561566,0.983482630463951,0.065572921496668,0.658949110982573,0.399895204930535,0.259053906052039,9.66447990661152,7.925,5.88170115985075,459.3439,0.661767145872959,0.558787054868749,0.693763443945063,0.608882183865118,0.10298009100421,0.0848812600799447,True,0.22619748666549,0.0368660011582517,1.24388228424017,38.269059378773
20300,1054:1549,Colon,LS-1034,SIDM00681,917486,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.835507799758633,0.0819891989133979,0.934129652790327,15.5461810664623,467.2689,0.938124513561566,0.983482630463951,0.106017023011662,0.780472610892142,0.469913632265293,0.310558978626849,9.6196457830988,7.6825,5.92653528336346,459.5864,0.783810348225461,0.649087391782648,0.821707408679769,0.719591184608726,0.134722956442813,0.102116224071043,True,0.22619748666549,0.0368660011582517,1.24388228424017,38.269059378773
20301,1053:1564,Colon,LS-1034,SIDM00681,917486,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.940236993148713,0.0761231756944598,0.505187128250677,9.05121875626995,5.1807,0.836746839450525,0.835619115645597,0.096962897352555,0.47499562644385,0.212601588662618,0.262394037781232,5.96285314566354,0.6091,3.08836561060641,4.5716,0.786740332351651,0.561475095567476,0.785680004712203,0.608608238226014,0.225265236784175,0.177071766486189,True,0.22619748666549,0.0368660011582517,1.24388228424017,38.269059378773
20303,1011:2048,Colon,LS-1034,SIDM00681,917486,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.777852753974258,0.146594128616753,0.521755441174039,9.21494564458194,0.1161,0.784155281785964,0.84331921084033,0.0715676241938717,0.40584890681828,0.107677387995002,0.298171518823278,4.48666429841267,0.0044,4.72828134616927,0.1117,0.609957345480673,0.420296089148583,0.655978170631549,0.417919206652557,0.18966125633209,0.238058963978991,True,0.22619748666549,0.0368660011582517,1.24388228424017,38.269059378773
20303,1194:2048,Colon,LS-1034,SIDM00681,917486,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,0.625,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.928948304463639,0.146594128616753,0.521755441174039,9.21494564458194,0.1161,0.784155281785964,0.84331921084033,0.0606604517357877,0.484683832423301,0.358824981882013,0.125858850541288,7.85705774926892,0.0453,1.35788789531302,0.0708,0.728439719451278,0.690722039262812,0.783399951031738,0.717081464685256,0.0377176801884666,0.066318486346482,True,0.22619748666549,0.0368660011582517,1.24388228424017,38.269059378773
20303,1053:2048,Colon,LS-1034,SIDM00681,917486,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.912454761180186,0.146594128616753,0.521755441174039,9.21494564458194,0.1161,0.784155281785964,0.84331921084033,0.192510213099323,0.47607823647092,0.211147899985167,0.264930336485753,6.03689087342938,0.0128,3.17805477115256,0.1033,0.715506220370193,0.506264303278135,0.769490629125976,0.59546081499584,0.209241917092059,0.174029814130136,True,0.22619748666549,0.0368660011582517,1.24388228424017,38.269059378773
19623,1194:2171,Colon,LS-1034,SIDM00681,917486,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,2.5,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.81796769816986,0.14691969672836,0.325485457783184,7.20129223846674,2.8743,0.657394055370287,0.731676309007775,0.0760090841588812,0.266236590690675,0.0559454408586139,0.210291149832061,2.55336719920929,0.1146,4.64792503925744,2.7597,0.537727102261784,0.305163799919739,0.598487586284509,0.319300894870775,0.232563302342044,0.279186691413735,True,0.271157623415435,0.0367741766136671,1.2270548595153,39.9632113096037
23228,2048:1011,Colon,CaR-1,SIDM00488,924108,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.01,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.698364339464375,0.182676775668712,0.506884653646452,9.06655956231904,10.4722,0.88736383388261,0.839508661692955,0.0619429194416845,0.353990166328433,0.107906197198826,0.246083969129607,4.89231667369835,0.58,4.17424288862069,9.8922,0.619703257714005,0.3934296728572,0.586282911997822,0.397301002315564,0.226273584856805,0.188981909682258,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
23228,1003:1011,Colon,CaR-1,SIDM00488,924108,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.622508838446067,0.182676775668712,0.506884653646452,9.06655956231904,10.4722,0.88736383388261,0.839508661692955,0.0883809154963874,0.31554017696759,0.107302551200356,0.208237625767234,5.20824452258517,0.7221,3.85831503973387,9.7501,0.552391829509312,0.365393442446063,0.522601561855894,0.36911362507598,0.186998387063249,0.153487936779914,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
23226,1179:1022,Colon,CaR-1,SIDM00488,924108,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.828365493742851,0.0421247369145935,0.741327354305112,11.5445990808419,5.8345,0.926836994561008,0.929004134119642,0.0839652286190686,0.614089999874035,0.277352826161219,0.336737173712817,7.34094488136359,0.3166,4.20365419947833,5.5179,0.76775978461867,0.640324862810042,0.769554968249168,0.615563507499506,0.127434921808629,0.153991460749662,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
23225,2171:1032,Colon,CaR-1,SIDM00488,924108,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.895013599601372,0.0993825297604828,0.555364493176274,9.53742354687881,14.5138,0.868069911370172,0.860929021552807,0.126534207760002,0.497058774128488,0.169229223228669,0.327829550899819,5.48114035763337,0.8724,4.05628318924544,13.6414,0.776934376081061,0.520641831433606,0.770543182581265,0.549056744878146,0.256292544647455,0.221486437703118,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
23225,1053:1032,Colon,CaR-1,SIDM00488,924108,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.8635046878234,0.0993825297604828,0.555364493176274,9.53742354687881,14.5138,0.868069911370172,0.860929021552807,0.0950164330018618,0.479559843308379,0.304822515260732,0.174737328047647,7.53577846228699,3.6243,2.00164508459182,10.8895,0.749582437826587,0.649517512174241,0.743416245994062,0.652216957037369,0.100064925652346,0.0911992889566928,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
23225,1510:1032,Colon,CaR-1,SIDM00488,924108,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.832017476397892,0.0993825297604828,0.555364493176274,9.53742354687881,14.5138,0.868069911370172,0.860929021552807,0.0707972884746091,0.462072964093518,0.115908623269683,0.346164340823834,4.59893249961268,0.4733,4.93849104726613,14.0405,0.722249336995153,0.436856770569454,0.716307991870073,0.454583705090408,0.285392566425698,0.261724286779665,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
23225,1786:1032,Colon,CaR-1,SIDM00488,924108,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.775119152236844,0.0993825297604828,0.555364493176274,9.53742354687881,14.5138,0.868069911370172,0.860929021552807,0.0889865888457393,0.430473655133238,0.0716867422320129,0.358786912901225,3.48083343247842,0.2181,6.05659011440039,14.2957,0.67285761378356,0.33986162014274,0.667322573322108,0.356392885007091,0.33299599364082,0.310929688315017,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
23225,2048:1032,Colon,CaR-1,SIDM00488,924108,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.966067120780987,0.0993825297604828,0.555364493176274,9.53742354687881,14.5138,0.868069911370172,0.860929021552807,0.122925066725613,0.536519376906795,0.482091497648144,0.0544278792586508,8.99057298953099,9.9349,0.546850557347815,4.5789,0.838613799913989,0.865823598908959,0.831715221048313,0.807486986244459,-0.0272097989949701,0.0242282348038533,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
23230,2048:1047,Colon,CaR-1,SIDM00488,924108,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.93531813517907,0.0653502223010817,0.917852686724253,14.8330046230669,570.0453,0.957669102018164,0.97962853518309,0.0233724445585505,0.858484263316027,0.858324586421071,0.0001596768949556,14.8275376518411,567.8892,0.005466971225811,2.15610000000004,0.895725278618243,0.923249361216769,0.916264334695652,0.916223016362903,-0.0275240825985258,4.13183327488964e-05,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
23229,2171:1053,Colon,CaR-1,SIDM00488,924108,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.890288991384888,0.0575004564573172,0.641898231221562,10.4104755034732,26.5825,0.878585513920981,0.894999311029355,0.0439809060943776,0.571474928845989,0.33244089220232,0.239034036643669,7.74900420542223,4.2016,2.66147129805094,22.3809,0.782195011034084,0.657089514839252,0.796808033906494,0.684019690517204,0.125105496194832,0.11278834338929,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
23229,1083:1053,Colon,CaR-1,SIDM00488,924108,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.998315515607596,0.0575004564573172,0.641898231221562,10.4104755034732,26.5825,0.878585513920981,0.894999311029355,0.1009126740464,0.640816963669558,0.552265539449253,0.0885514242203049,9.51622384689628,14.3021,0.894251656576889,12.2804,0.877105550335389,0.782002715489957,0.893491698658713,0.858562298122056,0.0951028348454319,0.0349294005366577,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
23229,1510:1053,Colon,CaR-1,SIDM00488,924108,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.81934349226351,0.0575004564573172,0.641898231221562,10.4104755034732,26.5825,0.878585513920981,0.894999311029355,0.09754142983071,0.525935138446845,0.277625325941028,0.248309812505817,7.38443265912839,3.2634,3.02604284434478,23.3191,0.719863323228148,0.54925294919927,0.733311861072227,0.611113628982015,0.170610374028878,0.122198232090212,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
23229,1786:1053,Colon,CaR-1,SIDM00488,924108,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.73720959734868,0.0575004564573172,0.641898231221562,10.4104755034732,26.5825,0.878585513920981,0.894999311029355,0.0712439315707581,0.473213536577678,0.134119289273109,0.339094247304569,5.36673260223857,0.8059,5.0437429012346,25.7766,0.64770167295407,0.413709784170599,0.659802081711297,0.445932639363519,0.233991888783471,0.213869442347777,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
23229,1372:1053,Colon,CaR-1,SIDM00488,924108,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.887106426503712,0.0575004564573172,0.641898231221562,10.4104755034732,26.5825,0.878585513920981,0.894999311029355,0.0266309786143059,0.569432046078014,0.526489023610583,0.0429430224674308,9.91454876707941,18.8498,0.495926736393761,7.7327,0.779398855632369,0.790038197627834,0.793959640530535,0.777579586343743,-0.0106393419954649,0.0163800541867918,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
23229,1564:1053,Colon,CaR-1,SIDM00488,924108,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.948690634885193,0.0575004564573172,0.641898231221562,10.4104755034732,26.5825,0.878585513920981,0.894999311029355,0.0419436462458288,0.608962840509267,0.550561853936158,0.0584009865731088,9.78343941464691,17.2123,0.627036088826259,9.3702,0.833505849002629,0.838270857938829,0.849077464602249,0.826560533194946,-0.0047650089361999,0.0225169314073035,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
23229,2048:1053,Colon,CaR-1,SIDM00488,924108,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.930439611931844,0.0575004564573172,0.641898231221562,10.4104755034732,26.5825,0.878585513920981,0.894999311029355,0.0500441664728422,0.597247541157528,0.548283766800775,0.0489637743567521,9.87237937063537,18.3068,0.538096132837801,8.2757,0.817470764621577,0.824654963123146,0.832742811633421,0.814002171079411,-0.0071841985015687,0.01874064055401,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
23229,1561:1053,Colon,CaR-1,SIDM00488,924108,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.629407624805232,0.0575004564573172,0.641898231221562,10.4104755034732,26.5825,0.878585513920981,0.894999311029355,0.0581237974616621,0.404015641079843,0.349505464976886,0.0545101761029574,9.53672099072305,14.5067,0.873754512750116,12.0758,0.552988421505289,0.52459498998946,0.563319390557305,0.541856185434784,0.0283934315158286,0.021463205122521,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
23230,1053:1054,Colon,CaR-1,SIDM00488,924108,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.844383156719165,0.0730877120009981,0.804761869513906,12.4229793443425,42.9022,0.91953796480596,0.948438875853107,0.0469134938455258,0.679527367787369,0.475933227711078,0.203594140076291,9.61863521967421,6.1417,2.80434412466826,36.7605,0.776442369445973,0.695528460512946,0.800845811948023,0.729889489464894,0.0809139089330265,0.0709563224831289,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
23227,1510:1059,Colon,CaR-1,SIDM00488,924108,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.837346818171248,0.110685051809674,0.463128494979807,8.64290738057553,0.7807,0.779753420629433,0.818396947386066,0.114462243633477,0.38779917167578,0.166162080987958,0.221637090687822,5.62595051608171,0.0965,3.01695686449382,0.6842,0.652924045722202,0.471908526945881,0.685282079894785,0.522701512155712,0.181015518776322,0.162580567739073,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
23226,2171:1372,Colon,CaR-1,SIDM00488,924108,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.892102363755923,0.100259629347298,0.802708851336234,12.3915249151785,10.4942,0.873329849746674,0.947833751527349,0.118382466373159,0.716098463684856,0.507738312895841,0.208360150789015,9.67277951266357,1.5941,2.71874540251498,8.9001,0.779099623297613,0.678509540474975,0.845564730185192,0.773174327555645,0.100590082822638,0.0723904026295465,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
23226,1053:1372,Colon,CaR-1,SIDM00488,924108,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.873232641399618,0.100259629347298,0.802708851336234,12.3915249151785,10.4942,0.873329849746674,0.947833751527349,0.157758928459214,0.700951570527193,0.314860297871487,0.386091272655706,7.61542191283698,0.383,4.77610300234157,10.1112,0.76262013150742,0.567091230785761,0.827679370453936,0.663843504688072,0.195528900721658,0.163835865765864,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
23226,1786:1372,Colon,CaR-1,SIDM00488,924108,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.714425430101161,0.100259629347298,0.802708851336234,12.3915249151785,10.4942,0.873329849746674,0.947833751527349,0.144695297520135,0.573475616361898,0.34541020727899,0.228065409082907,8.84023692399218,0.8952,3.55128799118637,9.599,0.62392905352545,0.473388440242317,0.677156535599323,0.591862829015288,0.150540613283132,0.0852937065840346,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
23226,2048:1372,Colon,CaR-1,SIDM00488,924108,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.959114569110302,0.100259629347298,0.802708851336234,12.3915249151785,10.4942,0.873329849746674,0.947833751527349,0.0819236415601536,0.769889754070378,0.81149288808641,-0.0416031340160324,13.1187677155951,17.3729,-0.727242800416567,-6.8787,0.837623382530946,0.857480289375993,0.909081160184354,0.921044872753772,-0.0198569068450466,-0.011963712569418,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
23226,1561:1372,Colon,CaR-1,SIDM00488,924108,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.642150960499766,0.100259629347298,0.802708851336234,12.3915249151785,10.4942,0.873329849746674,0.947833751527349,0.134738376716286,0.515460259887227,0.230979648463283,0.284480611423944,7.60627828404041,0.3806,4.78524663113813,10.1136,0.560809601847943,0.392924199183976,0.608652353937384,0.487812508504692,0.167885402663967,0.120839845432692,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
23226,1059:1372,Colon,CaR-1,SIDM00488,924108,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.682973334827636,0.100259629347298,0.802708851336234,12.3915249151785,10.4942,0.873329849746674,0.947833751527349,0.118743622819898,0.548228741092769,0.443142682558433,0.105086058534336,10.4838161998804,2.7969,1.90770871529815,7.6973,0.596460999886004,0.529502077042729,0.647345178142822,0.612993421630179,0.0669589228432749,0.0343517565126432,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
23228,2048:1510,Colon,CaR-1,SIDM00488,924108,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.968436999953048,0.0696676416329101,0.838477997851896,12.9803433512159,157.8348,0.92256712470372,0.95816583386981,0.0587572703053469,0.812013116766328,0.648924945175631,0.163088171590697,10.7123569363338,32.7696,2.26798641488213,125.0652,0.893448138503381,0.88736351406642,0.92792324561039,0.876562456546762,0.0060846244369606,0.0513607890636276,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
23228,1059:1510,Colon,CaR-1,SIDM00488,924108,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.65668208297354,0.0696676416329101,0.838477997851896,12.9803433512159,157.8348,0.92256712470372,0.95816583386981,0.0581214536178868,0.550613478156866,0.299888758934435,0.250724719222431,8.58009267087226,7.4747,4.40025068034366,150.3601,0.605833301133349,0.492525876191862,0.629210335619706,0.535274627431052,0.113307424941487,0.0939357081886536,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
23228,1032:1510,Colon,CaR-1,SIDM00488,924108,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,1,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.90402438613032,0.0696676416329101,0.838477997851896,12.9803433512159,157.8348,0.92256712470372,0.95816583386981,0.103080307216034,0.75800455729184,0.422774328288636,0.335230229003204,8.68690710264341,8.0491,4.29343624857251,149.7857,0.834023178574296,0.682304259125381,0.866205279775202,0.741905684231374,0.151718919448914,0.124299595543827,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
23228,1549:1510,Colon,CaR-1,SIDM00488,924108,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.885848211347759,0.0696676416329101,0.838477997851896,12.9803433512159,157.8348,0.92256712470372,0.95816583386981,0.0822492979386725,0.742764234651552,0.453131203291968,0.289633031359584,9.11140912533932,10.8028,3.8689342258766,147.032,0.817254437267036,0.706698205014621,0.848789490108105,0.745566985787848,0.110556232252415,0.103222504320257,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
23228,1053:1510,Colon,CaR-1,SIDM00488,924108,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.695861335476588,0.0696676416329101,0.838477997851896,12.9803433512159,157.8348,0.92256712470372,0.95816583386981,0.0766076376078392,0.583464419352956,0.356602585598378,0.226861833754578,9.12049896491849,10.8711,3.85984438629743,146.9637,0.641978791463127,0.536509448332625,0.666750556764685,0.585965267797856,0.105469343130501,0.0807852889668287,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
23228,1786:1510,Colon,CaR-1,SIDM00488,924108,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.760091313840877,0.0696676416329101,0.838477997851896,12.9803433512159,157.8348,0.92256712470372,0.95816583386981,0.0927950742785071,0.637319843013915,0.374835114195962,0.262484728817954,8.93372567428478,9.551,4.04661767693115,148.2838,0.701235257922451,0.584257869446754,0.728293527543543,0.633213711469431,0.116977388475697,0.0950798160741126,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
22574,2171:1549,Colon,CaR-1,SIDM00488,924108,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.959958965804216,0.0733485064398624,0.727189963818082,11.3694609238179,25.8374,0.879101855661658,0.924451260121973,0.102778439092818,0.698072525610011,0.239165598142804,0.458906927467207,6.33379386937038,0.7877,5.03566705444757,25.0497,0.843901708197532,0.599798254743415,0.887435275603094,0.648435371020001,0.244103453454117,0.238999904583093,True,0.622280279032064,0.0753201733935228,0.438208211513741,108.289947944377
22574,1053:1549,Colon,CaR-1,SIDM00488,924108,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.899574279527772,0.0733485064398624,0.727189963818082,11.3694609238179,25.8374,0.879101855661658,0.924451260121973,0.07310234121022,0.654161387781477,0.472212155578837,0.18194923220264,9.24118865340269,5.9098,2.12827227041526,19.9276,0.790817418438363,0.712456224295446,0.831612576282765,0.762573234673359,0.0783611941429166,0.0690393416094055,True,0.622280279032064,0.0753201733935228,0.438208211513741,108.289947944377
22574,1510:1549,Colon,CaR-1,SIDM00488,924108,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.857651481159458,0.0733485064398624,0.727189963818082,11.3694609238179,25.8374,0.879101855661658,0.924451260121973,0.131601596511455,0.623675549552871,0.271017782158471,0.352657767394399,7.13370707088001,1.3714,4.23575385293793,24.466,0.753963008598249,0.549625460564164,0.792856992503338,0.62590479445957,0.204337548034085,0.166952198043767,True,0.622280279032064,0.0753201733935228,0.438208211513741,108.289947944377
22574,1786:1549,Colon,CaR-1,SIDM00488,924108,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.871999299961088,0.0733485064398624,0.727189963818082,11.3694609238179,25.8374,0.879101855661658,0.924451260121973,0.0912714479266989,0.634109139388096,0.204338905859404,0.429770233528692,6.13850807035324,0.688,5.23095285346471,25.1494,0.766576202731459,0.530281374682795,0.806120851674506,0.576919259197216,0.236294828048664,0.22920159247729,True,0.622280279032064,0.0753201733935228,0.438208211513741,108.289947944377
22575,2171:1564,Colon,CaR-1,SIDM00488,924108,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.937436109726689,0.0625642776464223,0.768189690671152,11.8956112581023,37.208,0.909015678574891,0.937425592351517,0.0976360527492465,0.720128755154913,0.481562891673751,0.238565863481162,9.13249411145419,5.4809,2.76311714664808,31.7271,0.852144121403812,0.743131544952704,0.878776600452243,0.789919340781846,0.109012576451108,0.0888572596703969,True,0.622280279032064,0.0753201733935228,0.438208211513741,108.289947944377
22575,1053:1564,Colon,CaR-1,SIDM00488,924108,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.881489241694715,0.0625642776464223,0.768189690671152,11.8956112581023,37.208,0.909015678574891,0.937425592351517,0.0437227986035178,0.677150947907411,0.493323431614373,0.183827516293038,9.57938557369124,7.4711,2.31622568441104,29.7369,0.801287541195587,0.75015379198175,0.826330574547158,0.760490143049116,0.0511337492138368,0.0658404314980418,True,0.622280279032064,0.0753201733935228,0.438208211513741,108.289947944377
22575,1510:1564,Colon,CaR-1,SIDM00488,924108,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.850794818620017,0.0625642776464223,0.768189690671152,11.8956112581023,37.208,0.909015678574891,0.937425592351517,0.0810228507937749,0.65357180854033,0.365742491386814,0.287829317153516,8.31767113602223,3.1158,3.57794012208004,34.0922,0.773385829375876,0.648573246080261,0.797556836814471,0.681508400839965,0.124812583295615,0.116048435974506,True,0.622280279032064,0.0753201733935228,0.438208211513741,108.289947944377
22575,1786:1564,Colon,CaR-1,SIDM00488,924108,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.898358683281252,0.0625642776464223,0.768189690671152,11.8956112581023,37.208,0.909015678574891,0.937425592351517,0.104376184790624,0.690109879021568,0.476186139048904,0.213923739972664,9.2909701065934,6.1173,2.60464115150888,31.0907,0.816622128086553,0.704399376886638,0.842144420819056,0.763592849443546,0.112222751199915,0.0785515713755104,True,0.622280279032064,0.0753201733935228,0.438208211513741,108.289947944377
22575,1561:1564,Colon,CaR-1,SIDM00488,924108,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.665849673047615,0.0625642776464223,0.768189690671152,11.8956112581023,37.208,0.909015678574891,0.937425592351517,0.0978970237951932,0.511498854371935,0.28897482904685,0.222524025325085,8.35816149769713,3.2045,3.53744976040514,34.0035,0.605267792374247,0.470414959273953,0.624184524173724,0.534838709377383,0.134852833100295,0.0893458147963417,True,0.622280279032064,0.0753201733935228,0.438208211513741,108.289947944377
22576,1053:1786,Colon,CaR-1,SIDM00488,924108,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10.0,0.880182949107014,0.0610131231825157,0.868353572920209,13.5592451861839,235.7597,0.965065105539106,0.966469374960426,0.0645456989897359,0.764310008680522,0.686111649698453,0.0781983589820693,12.0519721646027,82.9345,1.50727302158118,152.8252,0.849433850673682,0.854979950738502,0.85066986467428,0.828154095462317,-0.0055461000648203,0.0225157692119636,True,0.622280279032064,0.0753201733935228,0.438208211513741,108.289947944377
22576,1510:1786,Colon,CaR-1,SIDM00488,924108,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10.0,0.865146067648232,0.0610131231825157,0.868353572920209,13.5592451861839,235.7597,0.965065105539106,0.966469374960426,0.145225665414544,0.751252678940212,0.409254544818417,0.341998134121795,8.73918468859055,8.3462,4.8200604975933,227.4135,0.834922281081683,0.617815972287336,0.836137179249458,0.712315046658299,0.217106308794347,0.123822132591159,True,0.622280279032064,0.0753201733935228,0.438208211513741,108.289947944377
22576,1549:1786,Colon,CaR-1,SIDM00488,924108,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10.0,0.860513850835564,0.0610131231825157,0.868353572920209,13.5592451861839,235.7597,0.965065105539106,0.966469374960426,0.0850661758616982,0.74723027692039,0.495953696736255,0.251276580184135,9.74386964432237,16.7466,3.81537554186148,219.0131,0.830451890274485,0.738344796212723,0.831660283561837,0.748338634806338,0.0921070940617621,0.083321648755499,True,0.622280279032064,0.0753201733935228,0.438208211513741,108.289947944377
22577,1011:2048,Colon,CaR-1,SIDM00488,924108,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.912225598275418,0.105195914896838,0.443408108758016,8.45056032557358,0.0683,0.791683068390233,0.80824388715623,0.116199731178585,0.404488227291953,0.143607268399452,0.260880958892501,4.94578643524707,0.006,3.50477389032651,0.0623,0.722193560706798,0.534830247878194,0.737300763513541,0.522696254472213,0.187363312828605,0.214604509041328,True,0.622280279032064,0.0753201733935228,0.438208211513741,108.289947944377
23229,1549:2171,Colon,CaR-1,SIDM00488,924108,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.834465617320031,0.0775872986630299,0.312834577904927,7.09821794280641,2.6761,0.736679148193611,0.72747547789211,0.0708371569297124,0.261049699170486,0.0892140550208684,0.171835644149618,3.86989669695699,0.2856,3.22832124584942,2.3905,0.614733420164177,0.395783147359315,0.607053273744425,0.408812346243831,0.218950272804862,0.198240927500593,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
23229,1032:2171,Colon,CaR-1,SIDM00488,924108,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.923971396475808,0.0775872986630299,0.312834577904927,7.09821794280641,2.6761,0.736679148193611,0.72747547789211,0.08965380258227,0.289050201812735,0.0907552351987678,0.198294966613968,3.64164502426203,0.2438,3.45657291854438,2.4323,0.68067046131106,0.421695847599141,0.672166533209879,0.436321014199963,0.258974613711919,0.235845519009916,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
23229,1053:2171,Colon,CaR-1,SIDM00488,924108,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.850427860435248,0.0775872986630299,0.312834577904927,7.09821794280641,2.6761,0.736679148193611,0.72747547789211,0.106017921214546,0.266043240757851,0.120275458782501,0.14576778197535,4.64137480262402,0.4874,2.45684314018239,2.1887,0.626492471825554,0.45019314633719,0.618665414182897,0.467423854124954,0.176299325488364,0.151241560057942,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
19627,1011:1003,Colon,SW837,SIDM00833,909755,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.1,0.844473343697953,0.0525318303477057,0.690036613742014,11.3092661710481,0.4956,0.898742642601501,0.896966672508474,0.0705874192062572,0.582717526480731,0.353858317322363,0.228859209158368,8.05711346916081,0.052,3.25215270188728,0.4436,0.758964204521624,0.645054077334446,0.757464445118857,0.642857396537649,0.113910127187178,0.114607048581208,True,0.404449675748226,0.0406437254522698,0.848002849507577,57.2623260352616
19627,1022:1003,Colon,SW837,SIDM00833,909755,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.1,0.974353459159711,0.0525318303477057,0.690036613742014,11.3092661710481,0.4956,0.898742642601501,0.896966672508474,0.075138002876396,0.672339561546385,0.279107080910113,0.393232480636272,6.36645655577474,0.0161,4.94280961527334,0.4795,0.875693002713113,0.654980289022076,0.873962580109607,0.643941070005229,0.220712713691037,0.230021510104378,True,0.404449675748226,0.0406437254522698,0.848002849507577,57.2623260352616
19630,1083:1011,Colon,SW837,SIDM00833,909755,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,1.0,0.140754266749859,0.307680589181906,6.65987375144943,1.9749,0.731454232052169,0.679495731196738,0.131970160252692,0.307680589181906,0.235627188132292,0.0720534010496142,5.60428858327769,0.9501,1.05558516817173,1.0248,0.731454232052169,0.634901652961311,0.679495731196738,0.610761751681165,0.0965525790908582,0.0687339795155737,True,0.404449675748226,0.0406437254522698,0.848002849507577,57.2623260352616
19630,1089:1011,Colon,SW837,SIDM00833,909755,1089,Oxaliplatin,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved in colon,1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.819245490120302,0.140754266749859,0.307680589181906,6.65987375144943,1.9749,0.731454232052169,0.679495731196738,0.0685335968509594,0.252065935084834,0.183051124668536,0.0690148104162979,5.40537757647189,0.8278,1.25449617497753,1.1471,0.599240580838149,0.504894037163072,0.556673813338925,0.489355887846373,0.0943465436750761,0.0673179254925518,True,0.404449675748226,0.0406437254522698,0.848002849507577,57.2623260352616
19630,2048:1011,Colon,SW837,SIDM00833,909755,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.953341968175485,0.140754266749859,0.307680589181906,6.65987375144943,1.9749,0.731454232052169,0.679495731196738,0.117232769002046,0.293324818460071,0.244446724742257,0.0488780937178144,5.92774097251325,1.1889,0.732132778936172,0.786,0.697326017214903,0.643584723270283,0.647791797745939,0.602819081344205,0.0537412939446195,0.0449727164017342,True,0.404449675748226,0.0406437254522698,0.848002849507577,57.2623260352616
19628,1073:1022,Colon,SW837,SIDM00833,909755,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,2.5,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.904609524159834,0.113724669200842,0.587409613602079,10.0193645313918,2.027,0.891089350638005,0.852746271025172,0.0994597888555274,0.531376331047488,0.215411061915922,0.315965269131566,5.64417719259543,0.0977,4.37518733879632,1.9293,0.806087913464542,0.55285102939503,0.771402398461154,0.554924425027018,0.253236884069512,0.216477973434136,True,0.404449675748226,0.0406437254522698,0.848002849507577,57.2623260352616
19628,1179:1022,Colon,SW837,SIDM00833,909755,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.446147932646495,0.113724669200842,0.587409613602079,10.0193645313918,2.027,0.891089350638005,0.852746271025172,0.050916492293056,0.262071584725244,0.172731696492366,0.0893398882328778,7.67480130738437,0.3991,2.34456322400739,1.6279,0.397557671590454,0.307226604841277,0.380450985889888,0.330204078234508,0.0903310667491767,0.05024690765538,True,0.404449675748226,0.0406437254522698,0.848002849507577,57.2623260352616
19628,1003:1022,Colon,SW837,SIDM00833,909755,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.025,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.884657548417947,0.113724669200842,0.587409613602079,10.0193645313918,2.027,0.891089350638005,0.852746271025172,0.0515814002788901,0.519656348686348,0.232882806581877,0.286773542104471,6.03031224584245,0.1277,3.98905228554931,1.8993,0.788308920356758,0.556815547997246,0.754388425547675,0.56536289752205,0.231493372359512,0.189025528025625,True,0.404449675748226,0.0406437254522698,0.848002849507577,57.2623260352616
19631,1017:1053,Colon,SW837,SIDM00833,909755,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.967725740836667,0.0515275402932469,0.740196314996311,12.0211238295834,81.18,0.921937982664328,0.916339933090594,0.0681162270867377,0.716307027294376,0.480618159076308,0.235688868218068,8.96129949616922,9.7353,3.05982433341416,71.4447,0.892183117279299,0.735085488136677,0.886765740608316,0.781000441064118,0.157097629142622,0.105765299544198,True,0.404449675748226,0.0406437254522698,0.848002849507577,57.2623260352616
19631,1011:1053,Colon,SW837,SIDM00833,909755,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.791817243571859,0.0515275402932469,0.740196314996311,12.0211238295834,81.18,0.921937982664328,0.916339933090594,0.0628223539888833,0.586100205842426,0.280682933457311,0.305417272385115,7.27039096347522,3.0153,4.75073286610816,78.1647,0.730006392177468,0.589880469940307,0.725573759994615,0.567505757692119,0.140125922237161,0.158068002302496,True,0.404449675748226,0.0406437254522698,0.848002849507577,57.2623260352616
19631,1372:1053,Colon,SW837,SIDM00833,909755,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.87200978784089,0.0515275402932469,0.740196314996311,12.0211238295834,81.18,0.921937982664328,0.916339933090594,0.0514591385450326,0.645458431600542,0.359416810519235,0.286041621081306,7.97563690846505,4.9163,4.04548692111833,76.2637,0.803938944665579,0.626974029665859,0.799057390644464,0.65996661964564,0.17696491499972,0.139090770998824,True,0.404449675748226,0.0406437254522698,0.848002849507577,57.2623260352616
19631,1032:1053,Colon,SW837,SIDM00833,909755,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.793371065236243,0.0515275402932469,0.740196314996311,12.0211238295834,81.18,0.921937982664328,0.916339933090594,0.0344859267104915,0.587250338912565,0.414725500427613,0.172524838484951,9.26263064357906,11.9966,2.75849318600432,69.1834,0.731438919388151,0.655565882929208,0.726997588834592,0.65131142839549,0.0758730364589424,0.0756861604391019,True,0.404449675748226,0.0406437254522698,0.848002849507577,57.2623260352616
19631,1022:1053,Colon,SW837,SIDM00833,909755,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.958748104553558,0.0515275402932469,0.740196314996311,12.0211238295834,81.18,0.921937982664328,0.916339933090594,0.115967184163234,0.709661814000242,0.509224246532146,0.200437567468095,9.35982492307775,12.8327,2.66129890650562,68.3473,0.883906293395356,0.730294538004826,0.878539173977341,0.791230218183281,0.15361175539053,0.0873089557940602,True,0.404449675748226,0.0406437254522698,0.848002849507577,57.2623260352616
19631,2048:1053,Colon,SW837,SIDM00833,909755,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.937692861851977,0.0515275402932469,0.740196314996311,12.0211238295834,81.18,0.921937982664328,0.916339933090594,0.0305283143780095,0.694076800941179,0.660680086760591,0.0333967141805878,11.5081246509868,56.888,0.512999178596589,24.292,0.864494665414553,0.862223804190681,0.859245414288968,0.846473269338135,0.0022708612238714,0.0127721449508329,True,0.404449675748226,0.0406437254522698,0.848002849507577,57.2623260352616
19631,1059:1053,Colon,SW837,SIDM00833,909755,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.87758052625246,0.0515275402932469,0.740196314996311,12.0211238295834,81.18,0.921937982664328,0.916339933090594,0.0592217329505359,0.649581871644594,0.396651216223315,0.252930655421279,8.44406432140982,6.8022,3.57705950817356,74.3778,0.809074819998692,0.683625983889635,0.804162080707787,0.685907650802314,0.125448836109057,0.118254429905473,True,0.404449675748226,0.0406437254522698,0.848002849507577,57.2623260352616
19631,1549:1053,Colon,SW837,SIDM00833,909755,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.832070816171164,0.0515275402932469,0.740196314996311,12.0211238295834,81.18,0.921937982664328,0.916339933090594,0.0211553446710922,0.615895751945868,0.356640861562427,0.259254890383441,8.17043674884786,5.627,3.85068708073552,75.553,0.767117689694704,0.638732239408875,0.76245971601692,0.638464567052919,0.128385450285829,0.123995148964001,True,0.404449675748226,0.0406437254522698,0.848002849507577,57.2623260352616
19632,1083:1054,Colon,SW837,SIDM00833,909755,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.997746847530234,0.0547721104328635,0.91086997281535,15.7068601401678,417.8554,0.960801831572157,0.97394321608255,0.0931005609057432,0.908817643886466,0.873387062229856,0.0354305816566098,14.624484700738,197.3325,1.08237543942972,220.5229,0.958636998552395,0.897027620881227,0.971748773519822,0.960699378335591,0.0616093776711684,0.0110493951842308,True,0.404449675748226,0.0406437254522698,0.848002849507577,57.2623260352616
19632,1073:1054,Colon,SW837,SIDM00833,909755,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,2.5,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.933977355534511,0.0547721104328635,0.91086997281535,15.7068601401678,417.8554,0.960801831572157,0.97394321608255,0.138360846766307,0.850731928445872,0.525880482676473,0.3248514457694,9.73168333976653,6.6423,5.97517680040123,411.2131,0.897367153844478,0.67615472338008,0.909640909397557,0.785639799712538,0.221212430464397,0.124001109685019,True,0.404449675748226,0.0406437254522698,0.848002849507577,57.2623260352616
19632,1786:1054,Colon,SW837,SIDM00833,909755,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.802990164611088,0.0547721104328635,0.91086997281535,15.7068601401678,417.8554,0.960801831572157,0.97394321608255,0.14730083644108,0.731419629410295,0.411783338685321,0.319636290724974,9.14791525688755,4.4319,6.55894488328021,413.4235,0.771514420892761,0.546916274369244,0.782066823403979,0.655026703393314,0.224598146523517,0.127040120010665,True,0.404449675748226,0.0406437254522698,0.848002849507577,57.2623260352616
20315,1011:1073,Colon,SW837,SIDM00833,909755,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,20.0,0.856917384289225,0.0626009944435868,0.588690863300744,10.0346261891622,40.9717,0.845913878348883,0.853342274267756,0.0645208562420541,0.504459434734639,0.280975754732321,0.223483680002318,6.92894208106739,4.7597,3.10568410809486,36.212,0.724878307968678,0.574678589498878,0.731243829568944,0.596552017523429,0.1501997184698,0.134691812045515,True,0.459104106274789,0.054451687200939,0.623085128501194,71.5573788824219
20315,1179:1073,Colon,SW837,SIDM00833,909755,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,1,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,20.0,0.365342455555626,0.0626009944435868,0.588690863300744,10.0346261891622,40.9717,0.845913878348883,0.853342274267756,0.037178824740467,0.215073765561456,0.224699128057291,-0.0096253624958353,10.3519747261122,51.0523,-0.31734853694994,-10.0806,0.309048253504564,0.295861826016711,0.311762161910405,0.31614271687482,0.0131864274878534,-0.0043805549644149,True,0.459104106274789,0.054451687200939,0.623085128501194,71.5573788824219
20315,1022:1073,Colon,SW837,SIDM00833,909755,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,20.0,0.87471825014252,0.0626009944435868,0.588690863300744,10.0346261891622,40.9717,0.845913878348883,0.853342274267756,0.108305722383842,0.514938641821316,0.137638080375355,0.377300561445961,4.15787310718299,0.6973,5.87675308197926,40.2744,0.739936307440607,0.412702003199838,0.74643406092013,0.447018095323119,0.327234304240769,0.29941596559701,True,0.459104106274789,0.054451687200939,0.623085128501194,71.5573788824219
19629,1011:1083,Colon,SW837,SIDM00833,909755,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.896145161522676,0.109630281264841,0.680117502152102,11.1765932212709,45.2085,0.940559214261522,0.892976603235323,0.154845018964005,0.609484008820494,0.332188744272418,0.277295264548076,7.4727623384485,3.4694,3.7038308828224,41.7391,0.842877588986033,0.716812790150496,0.800236662342289,0.652894337460226,0.126064798835537,0.147342324882062,True,0.404449675748226,0.0406437254522698,0.848002849507577,57.2623260352616
19629,1549:1083,Colon,SW837,SIDM00833,909755,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.86087486801959,0.109630281264841,0.680117502152102,11.1765932212709,45.2085,0.940559214261522,0.892976603235323,0.117390250137631,0.585496064903004,0.421183309979967,0.164312754923037,8.87590663862264,9.1758,2.30068658264826,36.0327,0.809703789441998,0.747635634866802,0.768741115454791,0.691268253612526,0.0620681545751958,0.0774728618422649,True,0.404449675748226,0.0406437254522698,0.848002849507577,57.2623260352616
19630,1022:1510,Colon,SW837,SIDM00833,909755,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.962452743945772,0.0535766088385526,0.730917417489795,11.8834636043846,73.792,0.893487106071659,0.91285280278865,0.0500673047381701,0.703473474060811,0.531678910074541,0.171794563986269,9.60727973656953,15.2338,2.27618386781507,58.5582,0.859939116918835,0.784007570106937,0.878577684862525,0.80458694481972,0.075931546811898,0.0739907400428051,True,0.404449675748226,0.0406437254522698,0.848002849507577,57.2623260352616
19630,1179:1510,Colon,SW837,SIDM00833,909755,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.25,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.982721851760327,0.0535766088385526,0.730917417489795,11.8834636043846,73.792,0.893487106071659,0.91285280278865,0.142359839291504,0.718288517999448,0.420786294767911,0.297502223231536,8.16532413540944,5.6071,3.71813946897516,68.1849,0.878049303402716,0.663099596748105,0.897080396741067,0.753795044506263,0.214949706654612,0.143285352234804,True,0.404449675748226,0.0406437254522698,0.848002849507577,57.2623260352616
19630,1059:1510,Colon,SW837,SIDM00833,909755,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.88095754318918,0.0535766088385526,0.730917417489795,11.8834636043846,73.792,0.893487106071659,0.91285280278865,0.102917065146406,0.64390721238599,0.345355773448116,0.298551438937874,7.73378164343134,4.1575,4.14968196095326,69.6345,0.787124205836098,0.595403934997671,0.804184562438046,0.654945470973941,0.191720270838428,0.149239091464106,True,0.404449675748226,0.0406437254522698,0.848002849507577,57.2623260352616
19630,1011:1510,Colon,SW837,SIDM00833,909755,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.948883948105145,0.0535766088385526,0.730917417489795,11.8834636043846,73.792,0.893487106071659,0.91285280278865,0.0620966678220586,0.693555804846534,0.520153968560834,0.1734018362857,9.5577668678234,14.7199,2.3256967365612,59.0721,0.847815572790316,0.759896486530745,0.866191371548942,0.791247989290566,0.0879190862595712,0.0749433822583762,True,0.404449675748226,0.0406437254522698,0.848002849507577,57.2623260352616
19630,1017:1510,Colon,SW837,SIDM00833,909755,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.936067531046106,0.0535766088385526,0.730917417489795,11.8834636043846,73.792,0.893487106071659,0.91285280278865,0.0675475838327968,0.684188062388268,0.461778863802867,0.222409198585401,8.92286961458173,9.4794,2.96059398980287,64.3126,0.836364269402028,0.709253747689494,0.85449186931489,0.753745240871037,0.127110521712534,0.100746628443853,True,0.404449675748226,0.0406437254522698,0.848002849507577,57.2623260352616
19630,1003:1510,Colon,SW837,SIDM00833,909755,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.0025,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.975837742166078,0.0535766088385526,0.730917417489795,11.8834636043846,73.792,0.893487106071659,0.91285280278865,0.0782996694195171,0.713256802393103,0.633664753800974,0.0795920485921283,10.778077079353,34.2969,1.10538652503162,39.4951,0.871898440243471,0.830346934750205,0.890796218003253,0.858970343210616,0.0415515054932653,0.0318258747926371,True,0.404449675748226,0.0406437254522698,0.848002849507577,57.2623260352616
19630,1372:1510,Colon,SW837,SIDM00833,909755,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.881900165203702,0.0535766088385526,0.730917417489795,11.8834636043846,73.792,0.893487106071659,0.91285280278865,0.128532180971187,0.644596191234514,0.351666951653492,0.292929239581022,7.81510593762137,4.3986,4.06835766676323,69.3934,0.787966426451974,0.578656065354606,0.805045037585973,0.659655371179745,0.209310361097368,0.145389666406229,True,0.404449675748226,0.0406437254522698,0.848002849507577,57.2623260352616
20316,2171:1549,Colon,SW837,SIDM00833,909755,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.709197147814863,0.0731475812171591,0.744162846519344,12.0809398569755,42.3083,0.882235393300438,0.917817844825337,0.111227162593012,0.527758168261309,0.333132917793105,0.194625250468203,8.65022009369121,3.9235,3.43071976328432,38.3848,0.625678824629995,0.485784088753929,0.650913797763714,0.561667781417808,0.139894735876065,0.0892460163459062,True,0.459104106274789,0.054451687200939,0.623085128501194,71.5573788824219
20316,1053:1549,Colon,SW837,SIDM00833,909755,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.861890670079061,0.0731475812171591,0.744162846519344,12.0809398569755,42.3083,0.882235393300438,0.917817844825337,0.0838811129315609,0.641387014434498,0.404691140375294,0.236695874059204,8.64797701438238,3.9174,3.43296284259315,38.3909,0.760390454299178,0.627353265852294,0.791058637287029,0.682501585270243,0.133037188446884,0.108557052016786,True,0.459104106274789,0.054451687200939,0.623085128501194,71.5573788824219
20316,1083:1549,Colon,SW837,SIDM00833,909755,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.997055470295704,0.0731475812171591,0.744162846519344,12.0809398569755,42.3083,0.882235393300438,0.917817844825337,0.10264939148835,0.741971636912935,0.584208017786442,0.157763619126493,10.0017970170377,10.0125,2.07914283993779,32.2958,0.879637624978684,0.774084253496759,0.915115302918117,0.849549096618249,0.105553371481925,0.0655662062998678,True,0.459104106274789,0.054451687200939,0.623085128501194,71.5573788824219
20316,1510:1549,Colon,SW837,SIDM00833,909755,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.731764938581812,0.0731475812171591,0.744162846519344,12.0809398569755,42.3083,0.882235393300438,0.917817844825337,0.1154534714004,0.544552279678094,0.354284251521497,0.190268028156597,8.81699981585907,4.4043,3.26394004111646,37.904,0.645588928393196,0.511172180905758,0.671626918847904,0.58552005265404,0.134416747487437,0.0861068661938639,True,0.459104106274789,0.054451687200939,0.623085128501194,71.5573788824219
20316,1786:1549,Colon,SW837,SIDM00833,909755,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.746532181884619,0.0731475812171591,0.744162846519344,12.0809398569755,42.3083,0.882235393300438,0.917817844825337,0.117913431116722,0.555541513489554,0.227886656811311,0.327654856678243,6.62701605200604,0.9652,5.45392380496949,41.3431,0.658617113096411,0.441303484222624,0.685180558270098,0.505726283372428,0.217313628873786,0.179454274897669,True,0.459104106274789,0.054451687200939,0.623085128501194,71.5573788824219
20316,1564:1549,Colon,SW837,SIDM00833,909755,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.931347820637363,0.0731475812171591,0.744162846519344,12.0809398569755,42.3083,0.882235393300438,0.917817844825337,0.0946925095060555,0.693074445305087,0.555934444315728,0.137140000989359,10.1329263217704,10.9652,1.94801353520514,31.3431,0.821668010839509,0.740235257190289,0.854807649520159,0.79829395906239,0.0814327536492203,0.056513690457769,True,0.459104106274789,0.054451687200939,0.623085128501194,71.5573788824219
20316,2048:1549,Colon,SW837,SIDM00833,909755,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.865982772156212,0.0731475812171591,0.744162846519344,12.0809398569755,42.3083,0.882235393300438,0.917817844825337,0.0754747876250287,0.644432204764479,0.512693825373862,0.131738379390617,10.0745517800818,10.5303,2.00638807689374,31.778,0.764000651584639,0.692177160201291,0.794814441596285,0.740322625547159,0.0718234913833476,0.0544918160491261,True,0.459104106274789,0.054451687200939,0.623085128501194,71.5573788824219
21009,1011:2048,Colon,SW837,SIDM00833,909755,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.663303748966509,0.118639925684931,0.515942114611134,9.18406850954029,0.1136,0.788392679379476,0.817386463257389,0.100867702726972,0.342226338871274,0.125285934605702,0.216940404265572,4.79492986534743,0.0054,4.38913864419286,0.1082,0.522943819890158,0.370534338458387,0.542175505433102,0.36841810079102,0.152409481431771,0.173757404642082,True,0.50229362816937,0.0520374206622998,0.636959963706353,75.2493354432507
19631,1549:2171,Colon,SW837,SIDM00833,909755,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.832070816171164,0.127321812949172,0.430692382785745,8.19485837957514,5.7231,0.690349811440046,0.768615572045757,0.144445867462256,0.358366562463238,0.180960269369352,0.177406293093886,5.30535541596483,0.7723,2.88950296361031,4.9508,0.574419931048528,0.430484647861902,0.639542586353979,0.49135728490141,0.143935283186626,0.148185301452568,True,0.404449675748226,0.0406437254522698,0.848002849507577,57.2623260352616
19631,1073:2171,Colon,SW837,SIDM00833,909755,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,2.5,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.934907492646192,0.127321812949172,0.430692382785745,8.19485837957514,5.7231,0.690349811440046,0.768615572045757,0.193524821319301,0.402657535692035,0.180160181286364,0.222497354405671,4.86636536651464,0.5697,3.3284930130605,5.1534,0.645413211262186,0.455635457543063,0.718584457270117,0.523897299203197,0.189777753719122,0.19468715806692,True,0.404449675748226,0.0406437254522698,0.848002849507577,57.2623260352616
19631,1011:2171,Colon,SW837,SIDM00833,909755,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.791817243571859,0.127321812949172,0.430692382785745,8.19485837957514,5.7231,0.690349811440046,0.768615572045757,0.0709876680977701,0.341029655364804,0.0788841221506892,0.262145533214115,2.64776121360617,0.1224,5.54709716596897,5.6007,0.54663088479481,0.299181921475563,0.608603063623678,0.321703388474667,0.247448963319247,0.286899675149012,True,0.404449675748226,0.0406437254522698,0.848002849507577,57.2623260352616
19201,1073:1011,Colon,RKO,SIDM01090,909698,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.35125215810875,0.161830784957577,0.395775775869171,8.10746702682427,5.3867,0.824617450121843,0.807261547062049,0.0573703551843484,0.139017095401211,0.0429150213179332,0.0961020740832781,4.84008465613747,0.5594,3.2673823706868,4.8273,0.289648658969432,0.15537215128066,0.283552360563753,0.199988799097368,0.134276507688772,0.0835635614663854,True,0.220241614142168,0.0345711494421503,1.40037504091982,34.9902775156483
19201,1003:1011,Colon,RKO,SIDM01090,909698,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.394615420700079,0.161830784957577,0.395775775869171,8.10746702682427,5.3867,0.824617450121843,0.807261547062049,0.0507593832401942,0.156179224297513,0.0517962637905502,0.104382960506963,5.01324850187899,0.6308,3.09421852494528,4.7559,0.325406761996457,0.191098885520459,0.318557855008887,0.230257502528609,0.134307876475998,0.0883003524802785,True,0.220241614142168,0.0345711494421503,1.40037504091982,34.9902775156483
19529,2048:1017,Colon,RKO,SIDM01090,909698,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.734239138234772,0.0395931573999105,0.886324393933669,13.3323946298783,201.4562,0.974872405573799,0.974780137281402,0.037193517547969,0.650774059198314,0.597724684103241,0.0530493750950727,12.1151285920087,86.6457,1.21726603786959,114.8105,0.715789474957366,0.722144330536965,0.715721727965869,0.702686412275578,-0.0063548555795993,0.013035315690291,True,0.183090916035041,0.0312930230709679,1.57842086498348,31.1650292683018
19529,1373:1017,Colon,RKO,SIDM01090,909698,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.540320657273951,0.0395931573999105,0.886324393933669,13.3323946298783,201.4562,0.974872405573799,0.974780137281402,0.0461134627329486,0.478899379088176,0.319806676577009,0.159092702511167,9.78422606510011,17.2217,3.54816856477821,184.2345,0.526743698937873,0.4565245944582,0.526693844473479,0.481227823187772,0.0702191044796722,0.0454660212857066,True,0.183090916035041,0.0312930230709679,1.57842086498348,31.1650292683018
19199,1179:1022,Colon,RKO,SIDM01090,909698,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.398440680479469,0.133089451184119,0.300968421709064,7.22232685985191,0.2917,0.800172050286577,0.750936296432741,0.0271286245181733,0.119918062748591,0.0367181710402928,0.0831998917082986,4.17424876896275,0.0353,3.04807809088916,0.2564,0.318821096216836,0.197977312190509,0.299203568947394,0.204975256617221,0.120843784026326,0.0942283123301722,True,0.220241614142168,0.0345711494421503,1.40037504091982,34.9902775156483
19528,1073:1025,Colon,RKO,SIDM01090,909698,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,2.5,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.419101620501858,0.047461360819489,0.904700515000824,13.7476440073967,268.6478,0.973228389835752,0.979066888561242,0.0822201379813023,0.379161451905711,0.177660485767177,0.201500966138534,8.35290170083478,6.3856,5.3947423065619,262.2622,0.407881595298578,0.296840661637363,0.410328519575728,0.34426773545304,0.111040933661214,0.0660607841226881,True,0.183090916035041,0.0312930230709679,1.57842086498348,31.1650292683018
19528,2048:1025,Colon,RKO,SIDM01090,909698,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.738252062407544,0.047461360819489,0.904700515000824,13.7476440073967,268.6478,0.973228389835752,0.979066888561242,0.0424197319850174,0.667897021060526,0.44813693986782,0.219760081192706,9.91726394640993,18.8853,3.83038006098675,249.7625,0.718487865989818,0.673840360323681,0.722798149715274,0.661389050290772,0.0446475056661367,0.0614090994245019,True,0.183090916035041,0.0312930230709679,1.57842086498348,31.1650292683018
19203,1372:1047,Colon,RKO,SIDM01090,909698,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.716545368147304,0.0566960361200718,0.621399577358769,10.045252624072,20.6373,0.88684434590276,0.900752734164958,0.0525590801399632,0.445260988925118,0.218957067622291,0.226303921302827,7.26830009143292,3.011,2.77695253263907,17.6263,0.635464208324248,0.538889945224948,0.64543019951192,0.540310285501195,0.0965742630992998,0.105119914010725,True,0.220241614142168,0.0345711494421503,1.40037504091982,34.9902775156483
19203,1373:1047,Colon,RKO,SIDM01090,909698,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.523055013310085,0.0566960361200718,0.621399577358769,10.045252624072,20.6373,0.88684434590276,0.900752734164958,0.0396827981750009,0.325026164206273,0.188156074404838,0.136870089801434,7.78374109387295,4.304,2.26151153019904,16.3333,0.463868381150142,0.404402929126203,0.471143233357748,0.411944538595522,0.0594654520239395,0.0591986947622259,True,0.220241614142168,0.0345711494421503,1.40037504091982,34.9902775156483
19202,1510:1053,Colon,RKO,SIDM01090,909698,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.870422486290557,0.0833298410431048,0.622979022549906,10.0594266109574,20.841,0.841039431548635,0.901280763808577,0.0822987117834655,0.54225494971475,0.329952953697028,0.212301996017722,7.95897648992668,4.8598,2.10045012103071,15.9812,0.73205963307696,0.639872943224055,0.784495043280114,0.694916942147685,0.092186689852905,0.0895781011324281,True,0.220241614142168,0.0345711494421503,1.40037504091982,34.9902775156483
19202,1786:1053,Colon,RKO,SIDM01090,909698,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.913634710165211,0.0833298410431048,0.622979022549906,10.0594266109574,20.841,0.841039431548635,0.901280763808577,0.0397003639523315,0.56917525870639,0.2733068068954,0.295868451810989,7.20398494619376,2.8797,2.85544166476364,17.9613,0.768402817280451,0.682186849520816,0.823441389419729,0.684941975493453,0.0862159677596351,0.138499413926277,True,0.220241614142168,0.0345711494421503,1.40037504091982,34.9902775156483
19202,1564:1053,Colon,RKO,SIDM01090,909698,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.834813448204552,0.0833298410431048,0.622979022549906,10.0594266109574,20.841,0.841039431548635,0.901280763808577,0.105133736043814,0.520071265973989,0.297577961635293,0.222493304338695,7.75377901481701,4.2155,2.30564759614038,16.6255,0.702111027927112,0.574407277352668,0.75240130223547,0.655910355164676,0.127703750574444,0.0964909470707945,True,0.220241614142168,0.0345711494421503,1.40037504091982,34.9902775156483
19202,1373:1053,Colon,RKO,SIDM01090,909698,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.555172747360252,0.0833298410431048,0.622979022549906,10.0594266109574,20.841,0.841039431548635,0.901280763808577,0.0770763232326012,0.345860975496836,0.138819579868126,0.20704139562871,6.68298954456744,2.0068,3.37643706638995,18.8342,0.46692217185116,0.362583227459139,0.500366517786554,0.395868103927174,0.104338944392021,0.10449841385938,True,0.220241614142168,0.0345711494421503,1.40037504091982,34.9902775156483
19203,1561:1054,Colon,RKO,SIDM01090,909698,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.733517704165656,0.0928492445925934,0.749990713311307,11.3174408046346,19.9379,0.881834227899378,0.93992362360907,0.110637602940788,0.550131466173672,0.328701915186359,0.221429550987314,8.56062732546292,2.9498,2.7568134791717,16.9881,0.646841018303446,0.516349080208736,0.689450618480789,0.610965916169511,0.130491938094709,0.0784847023112786,True,0.220241614142168,0.0345711494421503,1.40037504091982,34.9902775156483
22245,1564:1083,Colon,RKO,SIDM01090,909698,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.816712511365745,0.104477500349338,0.397422539031496,8.12198338595251,5.4411,0.824237264067757,0.80811842668028,0.0524693850589331,0.324579959925763,0.284474571540178,0.0401053883855857,7.67849760632361,4.0012,0.443485779628902,1.4399,0.673164885898008,0.655346606537966,0.660000429734986,0.637803883354226,0.0178182793600424,0.0221965463807597,True,0.19037913541846,0.032440063069866,1.56738697633428,31.4782018961987
22245,1373:1083,Colon,RKO,SIDM01090,909698,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.556476470332258,0.104477500349338,0.397422539031496,8.12198338595251,5.4411,0.824237264067757,0.80811842668028,0.0497721966936415,0.221156291750731,0.0815431936230364,0.139613098127694,5.28293718927855,0.7604,2.83904619667396,4.6807,0.458668643424742,0.322150204182594,0.4496988896895,0.336855502330411,0.136518439242148,0.112843387359089,True,0.19037913541846,0.032440063069866,1.56738697633428,31.4782018961987
19531,1022:1179,Colon,RKO,SIDM01090,909698,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,10.0,0.530750666398545,0.101497800122045,0.124675184790303,4.88879068419326,0.5786,0.588605897910572,0.573344568153481,0.0563811892801175,0.066171437410815,0.0095408969050266,0.0566305405057883,0.560725410042394,0.0288,4.32806527415086,0.5498,0.31240297256215,0.0949552156571446,0.304303011623446,0.124485747645965,0.217447756905006,0.179817263977481,True,0.183090916035041,0.0312930230709679,1.57842086498348,31.1650292683018
19199,2171:1372,Colon,RKO,SIDM01090,909698,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.853465848860845,0.184428140513875,0.109966450306976,4.58881551128066,0.047,0.505461663824832,0.548716868961567,0.0989827775892122,0.0938526098574575,0.0079743743403644,0.0858782355170931,-0.838139484965642,0.0011,5.4269549962463,0.0459,0.431394267982875,0.176744773396215,0.468311108352549,0.130143945851433,0.25464949458666,0.338167162501116,True,0.220241614142168,0.0345711494421503,1.40037504091982,34.9902775156483
19199,1053:1372,Colon,RKO,SIDM01090,909698,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.816561787715127,0.184428140513875,0.109966450306976,4.58881551128066,0.047,0.505461663824832,0.548716868961567,0.134164807101406,0.0897944012513513,0.033973455096708,0.0558209461546433,2.38237616869168,0.0102,2.20643934258898,0.0368,0.412740679834267,0.319578099210976,0.448061227468704,0.3004518369427,0.0931625806232915,0.147609390526005,True,0.220241614142168,0.0345711494421503,1.40037504091982,34.9902775156483
19199,1786:1372,Colon,RKO,SIDM01090,909698,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.945198800851629,0.184428140513875,0.109966450306976,4.58881551128066,0.047,0.505461663824832,0.548716868961567,0.15782633138775,0.103940156964064,0.0256746518588307,0.0782655051052337,1.4513924060211,0.0053,3.13742310525955,0.0417,0.4777617585237,0.333585445311078,0.518646526549534,0.280487326977732,0.144176313212622,0.238159199571802,True,0.220241614142168,0.0345711494421503,1.40037504091982,34.9902775156483
19199,1561:1372,Colon,RKO,SIDM01090,909698,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.638742649716095,0.184428140513875,0.109966450306976,4.58881551128066,0.047,0.505461663824832,0.548716868961567,0.111530292568577,0.0702402618489514,0.0139288897315177,0.0563113721174336,0.976462463938615,0.0038,3.61235304734204,0.0432,0.322859922481379,0.193610437485229,0.350488866824431,0.167823344878369,0.129249484996151,0.182665521946062,True,0.220241614142168,0.0345711494421503,1.40037504091982,34.9902775156483
19199,1083:1372,Colon,RKO,SIDM01090,909698,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.737138658529919,0.184428140513875,0.109966450306976,4.58881551128066,0.047,0.505461663824832,0.548716868961567,0.130931018200284,0.0810605216625816,0.0079318350525603,0.0731286866100213,-0.537296725341399,0.0013,5.12611223662206,0.0457,0.372595332810137,0.190799758129466,0.404480416699067,0.124089823805417,0.181795574680671,0.28039059289365,True,0.220241614142168,0.0345711494421503,1.40037504091982,34.9902775156483
19199,1047:1372,Colon,RKO,SIDM01090,909698,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.759173114315547,0.184428140513875,0.109966450306976,4.58881551128066,0.047,0.505461663824832,0.548716868961567,0.136242040410303,0.083483572549773,0.0120272453755489,0.0714563271742241,0.289608085164065,0.0024,4.29920742611659,0.0446,0.383732905493015,0.220773986106513,0.416571094287029,0.16476894450116,0.162958919386502,0.251802149785869,True,0.220241614142168,0.0345711494421503,1.40037504091982,34.9902775156483
19529,1047:1373,Colon,RKO,SIDM01090,909698,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10.0,0.564498961182357,0.0939149355701062,0.360718578676365,7.79283383966202,4.3312,0.758260476653739,0.788141861300367,0.0661772150095829,0.203625262941984,0.0667175098375872,0.136907753104397,4.7605096969785,0.5294,3.03232414268352,3.8018,0.428037251376674,0.287896336598391,0.444905261968386,0.317720770125127,0.140140914778283,0.127184491843259,True,0.183090916035041,0.0312930230709679,1.57842086498348,31.1650292683018
19529,1083:1373,Colon,RKO,SIDM01090,909698,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10.0,0.66443029492683,0.0939149355701062,0.360718578676365,7.79283383966202,4.3312,0.758260476653739,0.788141861300367,0.0569489026731348,0.239672351615524,0.0702987711468204,0.169373580468704,4.49755224727637,0.4412,3.29528159238565,3.89,0.503811232134402,0.343226476279312,0.523665329347983,0.359583010923895,0.160584755855091,0.164082318424088,True,0.183090916035041,0.0312930230709679,1.57842086498348,31.1650292683018
19201,1073:1510,Colon,RKO,SIDM01090,909698,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,10,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.296018675847803,0.0345038277147173,0.910535949127861,13.8945023852626,297.435,0.979252085016264,0.98041014522578,0.0541953986908684,0.269535645972652,0.190627254484569,0.0789083914880829,10.2501836316167,23.7872,3.64431875364586,273.6478,0.289876905527714,0.225463263102345,0.290219712977487,0.268836984381905,0.0644136424253695,0.0213827285955825,True,0.220241614142168,0.0345711494421503,1.40037504091982,34.9902775156483
19201,1564:1510,Colon,RKO,SIDM01090,909698,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.765726261693721,0.0345038277147173,0.910535949127861,13.8945023852626,297.435,0.979252085016264,0.98041014522578,0.0688690257019401,0.697221288463421,0.672287066743138,0.0249342217202833,13.1628742760769,179.1225,0.731628109185687,118.3125,0.749839038315286,0.725602108967977,0.750725795430335,0.744900648207102,0.0242369293473089,0.0058251472232323,True,0.220241614142168,0.0345711494421503,1.40037504091982,34.9902775156483
19201,1373:1510,Colon,RKO,SIDM01090,909698,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.55971105443748,0.0345038277147173,0.910535949127861,13.8945023852626,297.435,0.979252085016264,0.98041014522578,0.0608372065481006,0.509637036189587,0.337937603166282,0.171699433023305,9.888540428328,18.513,4.00596195693459,278.922,0.548098217064555,0.457939041096638,0.548746396165525,0.500811521089559,0.0901591759679169,0.0479348750759659,True,0.220241614142168,0.0345711494421503,1.40037504091982,34.9902775156483
19531,1073:1549,Colon,RKO,SIDM01090,909698,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,10,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.295414863138029,0.0442777882768806,0.928137400865864,14.3970478517472,210.6897,0.977437743862773,0.984410769167418,0.0641230035273535,0.274185583250075,0.177302758611723,0.0968828246383523,9.8569390894709,9.056,4.54010876227631,201.6337,0.288749637329165,0.216850706567532,0.290809572645195,0.263961542878224,0.071898930761633,0.0268480297669704,True,0.183090916035041,0.0312930230709679,1.57842086498348,31.1650292683018
19531,1372:1549,Colon,RKO,SIDM01090,909698,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.572089035957272,0.0442777882768806,0.928137400865864,14.3970478517472,210.6897,0.977437743862773,0.984410769167418,0.0324935293478831,0.53097723089724,0.38756914099413,0.14340808990311,10.5655532512809,14.7995,3.83149460046627,195.8902,0.559181416594705,0.525837986376257,0.563170607918945,0.525595735739067,0.0333434302184477,0.0375748721798786,True,0.183090916035041,0.0312930230709679,1.57842086498348,31.1650292683018
19531,1564:1549,Colon,RKO,SIDM01090,909698,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.826245181577812,0.0442777882768806,0.928137400865864,14.3970478517472,210.6897,0.977437743862773,0.984410769167418,0.0660629172179932,0.766869055307574,0.725505313428015,0.0413637418795593,13.1648830375888,89.686,1.23216481415839,121.0037,0.807603226158904,0.781847050604148,0.813364654717887,0.803793666208833,0.0257561755547554,0.0095709885090542,True,0.183090916035041,0.0312930230709679,1.57842086498348,31.1650292683018
19531,1373:1549,Colon,RKO,SIDM01090,909698,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.542018414686492,0.0442777882768806,0.928137400865864,14.3970478517472,210.6897,0.977437743862773,0.984410769167418,0.0268426033540817,0.503067562628557,0.301910482039265,0.201157080589292,9.48316885490248,6.9891,4.91387899684473,203.7006,0.529789256383242,0.481494883940744,0.533568764504435,0.47590176512148,0.0482943724424976,0.0576669993829551,True,0.183090916035041,0.0312930230709679,1.57842086498348,31.1650292683018
19532,1372:1561,Colon,RKO,SIDM01090,909698,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.455600817702971,0.157471200148919,0.364991047336034,7.83181862569403,4.4498,0.682382754514355,0.790566871966061,0.0720608531019022,0.166290219620561,0.0464470088753379,0.119843210745223,4.41014915296779,0.4153,3.42166947272624,4.0345,0.310894140943146,0.213277629220502,0.360182913316617,0.243277207466395,0.0976165117226442,0.116905705850222,True,0.183090916035041,0.0312930230709679,1.57842086498348,31.1650292683018
19532,1564:1561,Colon,RKO,SIDM01090,909698,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.5477351183562,0.157471200148919,0.364991047336034,7.83181862569403,4.4498,0.682382754514355,0.790566871966061,0.103874306707208,0.199918414511556,0.0359300166003521,0.163988397911204,3.39633093939667,0.2056,4.43548768629736,4.2442,0.37376499880815,0.232632295940957,0.433021239184821,0.246513330356929,0.141132702867194,0.186507908827893,True,0.183090916035041,0.0312930230709679,1.57842086498348,31.1650292683018
19532,1373:1561,Colon,RKO,SIDM01090,909698,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.565952382679612,0.157471200148919,0.364991047336034,7.83181862569403,4.4498,0.682382754514355,0.790566871966061,0.0922568882519415,0.206567552896555,0.024315426421523,0.182252126475032,2.45313442774711,0.107,5.37868419794692,4.3428,0.386196145816876,0.211873525571737,0.44742320485676,0.21141449818876,0.174322620245139,0.236008706667999,True,0.183090916035041,0.0312930230709679,1.57842086498348,31.1650292683018
19532,1083:1564,Colon,RKO,SIDM01090,909698,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.725935481770568,0.165691532090022,0.341667675363755,7.61642596022189,1.9163,0.669522283915809,0.776976004998141,0.0908275156527225,0.248028688520618,0.0275188034391465,0.220509885081471,2.17792345739055,0.0442,5.43850250283133,1.8721,0.486029981730554,0.256627564441351,0.564034450512497,0.255442451820838,0.229402417289203,0.308591998691659,True,0.183090916035041,0.0312930230709679,1.57842086498348,31.1650292683018
19532,2048:1564,Colon,RKO,SIDM01090,909698,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.01,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.259710317145063,0.165691532090022,0.341667675363755,7.61642596022189,1.9163,0.669522283915809,0.776976004998141,0.072677524537921,0.0887346203269371,0.0288671014556012,0.0598675188713359,4.61423030884869,0.2392,3.00219565137319,1.6771,0.173881844691462,0.107625654065357,0.201788684672171,0.143051168135448,0.0662561906261046,0.0587375165367231,True,0.183090916035041,0.0312930230709679,1.57842086498348,31.1650292683018
19532,1053:1564,Colon,RKO,SIDM01090,909698,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.5477351183562,0.165691532090022,0.341667675363755,7.61642596022189,1.9163,0.669522283915809,0.776976004998141,0.102941635667254,0.187143384603854,0.0503648665080982,0.136778518095756,4.16911151613074,0.1757,3.44731444409115,1.7406,0.366720867422739,0.254258629793715,0.425577044057585,0.281545661264262,0.112462237629025,0.144031382793323,True,0.183090916035041,0.0312930230709679,1.57842086498348,31.1650292683018
19532,1059:1564,Colon,RKO,SIDM01090,909698,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.521912161866074,0.165691532090022,0.341667675363755,7.61642596022189,1.9163,0.669522283915809,0.776976004998141,0.100979795385285,0.178320515088853,0.0730203016314646,0.105300213457388,5.16901665229698,0.3513,2.44740930792491,1.565,0.349431822616011,0.268698149328048,0.405513226486645,0.31113359791565,0.0807336732879631,0.0943796285709953,True,0.183090916035041,0.0312930230709679,1.57842086498348,31.1650292683018
19532,1047:1564,Colon,RKO,SIDM01090,909698,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.640540878631409,0.165691532090022,0.341667675363755,7.61642596022189,1.9163,0.669522283915809,0.776976004998141,0.135510613362716,0.21885211297745,0.0244148033775992,0.194437309599851,2.18991478797345,0.0446,5.42651117224844,1.8717,0.42885639200274,0.242628886387803,0.497684892917031,0.225993606929074,0.186227505614937,0.271691285987957,True,0.183090916035041,0.0312930230709679,1.57842086498348,31.1650292683018
19532,1073:1564,Colon,RKO,SIDM01090,909698,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,10,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.298680076514124,0.165691532090022,0.341667675363755,7.61642596022189,1.9163,0.669522283915809,0.776976004998141,0.0738686796574077,0.102049327420049,0.0379221109974125,0.0641272164226366,4.93272125078011,0.2983,2.68370470944177,1.618,0.199972966987885,0.137473289327037,0.232067252622483,0.172318550972512,0.0624996776608478,0.0597487016499712,True,0.183090916035041,0.0312930230709679,1.57842086498348,31.1650292683018
19532,2171:1564,Colon,RKO,SIDM01090,909698,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.785180811593967,0.165691532090022,0.341667675363755,7.61642596022189,1.9163,0.669522283915809,0.776976004998141,0.122313042183329,0.268270902637537,0.0326585606610864,0.235612341976451,2.38175125398875,0.0509,5.23467470623314,1.8654,0.525696050265261,0.301218444898147,0.610066650193479,0.288866480696892,0.224477605367114,0.321200169496586,True,0.183090916035041,0.0312930230709679,1.57842086498348,31.1650292683018
19532,1510:1564,Colon,RKO,SIDM01090,909698,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.8771486510325,0.165691532090022,0.341667675363755,7.61642596022189,1.9163,0.669522283915809,0.776976004998141,0.140745928018979,0.299693340546728,0.0516338295854025,0.248059510961325,3.15276712393018,0.0869,4.46365883629171,1.8294,0.58727056817295,0.373218369877362,0.681523454668741,0.377222301381476,0.214052198295589,0.304301153287264,True,0.183090916035041,0.0312930230709679,1.57842086498348,31.1650292683018
19532,1561:1564,Colon,RKO,SIDM01090,909698,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.713278154130086,0.165691532090022,0.341667675363755,7.61642596022189,1.9163,0.669522283915809,0.776976004998141,0.141402987923036,0.243704088809376,0.0324599638374787,0.211244124971898,2.58012150607341,0.0584,5.03630445414847,1.8579,0.477555618820428,0.27845157098656,0.554200010648443,0.27366727832111,0.199104047833867,0.280532732327333,True,0.183090916035041,0.0312930230709679,1.57842086498348,31.1650292683018
19533,1053:1786,Colon,RKO,SIDM01090,909698,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10.0,0.796570391312729,0.0596680601715519,0.85384338654161,12.7234495658893,132.09,0.968893651828638,0.966983177989689,0.0563885108663123,0.680146360537236,0.581868838581293,0.0982775219559435,11.1031838862551,42.9657,1.6202656796342,89.1243,0.771791995377557,0.75146019404999,0.770270168484073,0.744335303798845,0.0203318013275667,0.0259348646852282,True,0.183090916035041,0.0312930230709679,1.57842086498348,31.1650292683018
19202,1372:2171,Colon,RKO,SIDM01090,909698,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.68763413197071,0.080388300681358,0.348342448059117,7.67873728956727,4.0018,0.767070996300363,0.780955741860954,0.078582614929647,0.239532156899683,0.0706886460963394,0.168843510803344,4.42973263079034,0.4209,3.24900465877693,3.5809,0.527464198700908,0.359627871497019,0.537011823662099,0.368289022815002,0.167836327203889,0.168722800847097,True,0.220241614142168,0.0345711494421503,1.40037504091982,34.9902775156483
19202,1373:2171,Colon,RKO,SIDM01090,909698,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,1,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.524318642801514,0.080388300681358,0.348342448059117,7.67873728956727,4.0018,0.767070996300363,0.780955741860954,0.0358264823513291,0.182642439596513,0.0444254557325682,0.138216983863945,3.97986634382837,0.3082,3.6988709457389,3.6936,0.402189623712612,0.23724982952554,0.409469654660585,0.261284136616086,0.164939794187071,0.148185518044499,True,0.220241614142168,0.0345711494421503,1.40037504091982,34.9902775156483
19202,1564:2171,Colon,RKO,SIDM01090,909698,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.834813448204552,0.080388300681358,0.348342448059117,7.67873728956727,4.0018,0.767070996300363,0.780955741860954,0.046503397752643,0.290800960220246,0.121664357077986,0.169136603142261,5.26947220436431,0.7534,2.40926508520296,3.2484,0.640361183439207,0.488485981604079,0.651952355758087,0.504437804143348,0.151875201835128,0.147514551614739,True,0.220241614142168,0.0345711494421503,1.40037504091982,34.9902775156483
22888,1011:1003,Colon,NCI-H716,SIDM00779,908458,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.1,0.385194137581973,0.0806848278345978,0.813953189735113,12.6351554030853,1.2425,0.931274778838959,0.950267593892405,0.0382701376386855,0.313529996952112,0.200165201802896,0.113364795149217,9.19366782359971,0.1144,3.44148757948555,1.1281,0.358721585286715,0.290461687425729,0.366037506301481,0.324590264665991,0.0682598978609857,0.0414472416354902,True,0.576479795863676,0.0679251441180702,0.505482167604042,93.8330460713588
22888,1022:1003,Colon,NCI-H716,SIDM00779,908458,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.1,0.697740240306325,0.0806848278345978,0.813953189735113,12.6351554030853,1.2425,0.931274778838959,0.950267593892405,0.0507062368813436,0.567927894203877,0.341606994712511,0.226320899491365,8.89743073727818,0.0931,3.73772466580708,1.1494,0.649787887978315,0.578240711236301,0.6630399393178,0.578067494293325,0.0715471767420135,0.0849724450244742,True,0.576479795863676,0.0679251441180702,0.505482167604042,93.8330460713588
22892,1011:1053,Colon,NCI-H716,SIDM00779,908458,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.343321406701428,0.109239031905041,0.333337153571312,7.29281966075075,3.0626,0.693967046174808,0.737767173791536,0.0741643862283673,0.114441780469953,0.064914999784539,0.0495267806854139,5.41386159335594,0.8327,1.87895806739481,2.2299,0.23825374249717,0.184052606600516,0.253291263924247,0.208513512720597,0.0542011358966537,0.0447777512036507,True,0.576479795863676,0.0679251441180702,0.505482167604042,93.8330460713588
22892,1022:1053,Colon,NCI-H716,SIDM00779,908458,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.607614019063228,0.109239031905041,0.333337153571312,7.29281966075075,3.0626,0.693967046174808,0.737767173791536,0.0805097308914983,0.202540327584561,0.072873514185854,0.129666813398707,4.09109886652073,0.3329,3.20172079423003,2.7297,0.421664106023712,0.297857366189944,0.448277677600394,0.308056981830666,0.123806739833767,0.140220695769729,True,0.576479795863676,0.0679251441180702,0.505482167604042,93.8330460713588
22892,1564:1053,Colon,NCI-H716,SIDM00779,908458,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.976604179703732,0.109239031905041,0.333337153571312,7.29281966075075,3.0626,0.693967046174808,0.737767173791536,0.0613059237145856,0.325538457428288,0.34433769891682,-0.0187992414885315,7.50326319588678,3.5435,-0.210443535136033,-0.4809,0.67773111787097,0.717153550279051,0.720506505573024,0.733353108803622,-0.0394224324080811,-0.0128466032305974,True,0.576479795863676,0.0679251441180702,0.505482167604042,93.8330460713588
22889,1564:1372,Colon,NCI-H716,SIDM00779,908458,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.945976532511309,0.0779120118698567,0.102051580599217,3.64387215668001,0.0244,0.469504527509259,0.472674947417058,0.10471469587948,0.0965384003525457,0.0661246976529279,0.0304137026996177,2.625231411988,0.0121,1.01864074469201,0.0123,0.444140264931569,0.362109511275725,0.447139407762554,0.3741919993232,0.0820307536558442,0.0729474084393542,True,0.576479795863676,0.0679251441180702,0.505482167604042,93.8330460713588
20634,1564:1373,Colon,NCI-H716,SIDM00779,908458,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.5,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10.0,0.583558394828172,0.0595235482672434,0.751988034698303,11.7320684247042,66.4408,0.922644694292903,0.931192942994208,0.0821163795119142,0.438828930458533,0.184331628825452,0.254497301633082,7.09660922217102,2.6731,4.63545920253314,63.7677,0.538417056798296,0.434993788607982,0.543405459089021,0.423193349667639,0.103423268190314,0.120212109421382,True,0.39070401389069,0.0461992653042968,0.79909013567362,58.2716513966522
22891,1011:1510,Colon,NCI-H716,SIDM00779,908458,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.326562239496936,0.0917852846447759,0.291014601040111,6.80679183773102,2.1866,0.689024713499007,0.706109385668072,0.0433256526754643,0.0950343798419658,0.0825626353231441,0.0124717445188217,6.33106825582117,1.5724,0.475723581909855,0.6142,0.22500945350897,0.2070916048936,0.230588662313571,0.219961420980755,0.0179178486153699,0.0106272413328157,True,0.576479795863676,0.0679251441180702,0.505482167604042,93.8330460713588
22891,1022:1510,Colon,NCI-H716,SIDM00779,908458,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.716874835779854,0.0917852846447759,0.291014601040111,6.80679183773102,2.1866,0.689024713499007,0.706109385668072,0.0752383332616222,0.208621044330169,0.0524394142953289,0.15618163003484,2.74575102567831,0.131,4.06104081205272,2.0556,0.493944478337862,0.284961363590428,0.506192049893413,0.290009134851395,0.208983114747434,0.216182915042018,True,0.576479795863676,0.0679251441180702,0.505482167604042,93.8330460713588
20636,2171:1549,Colon,NCI-H716,SIDM00779,908458,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.285163110045384,0.0565740293572084,0.895506584621146,14.2911816072089,195.7827,0.970033597846708,0.973312101872201,0.0573974606584385,0.255365442736685,0.160882143964678,0.094483298772007,9.6357677655297,7.7688,4.65541384167919,188.0139,0.27661779761048,0.207690008077186,0.277552706014686,0.24589055457708,0.0689277895332941,0.0316621514376056,True,0.39070401389069,0.0461992653042968,0.79909013567362,58.2716513966522
20636,1011:1549,Colon,NCI-H716,SIDM00779,908458,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.370160802009998,0.0565740293572084,0.895506584621146,14.2911816072089,195.7827,0.970033597846708,0.973312101872201,0.0543319726321422,0.331481435568597,0.200081489527747,0.13139994604085,9.40013890796866,6.5982,4.89104269924023,189.1845,0.359068414555581,0.284365388553402,0.360281988235051,0.315398414967793,0.0747030260021792,0.0448835732672575,True,0.39070401389069,0.0461992653042968,0.79909013567362,58.2716513966522
20636,1372:1549,Colon,NCI-H716,SIDM00779,908458,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.593498871356216,0.0565740293572084,0.895506584621146,14.2911816072089,195.7827,0.970033597846708,0.973312101872201,0.0632303774935181,0.53148214726471,0.481548695305456,0.0499334519592541,12.5934048034017,60.3521,1.69777680380715,135.4306,0.575713845499631,0.547074881196911,0.577659633938498,0.563528361527386,0.0286389643027195,0.0141312724111121,True,0.39070401389069,0.0461992653042968,0.79909013567362,58.2716513966522
20637,1011:1561,Colon,NCI-H716,SIDM00779,908458,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.285750393413262,0.144501044917956,0.235628559894008,6.10154654387357,1.3412,0.594873642895201,0.65738233160132,0.0384798987129296,0.0673309536891133,0.0993048502847654,-0.0319738965956521,7.44844491955608,3.4114,-1.34689837568251,-2.0702,0.169985377488484,0.193740892962184,0.187847259878005,0.213606630815855,-0.0237555154737001,-0.02575937093785,True,0.39070401389069,0.0461992653042968,0.79909013567362,58.2716513966522
20637,1564:1561,Colon,NCI-H716,SIDM00779,908458,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.953752060959692,0.144501044917956,0.235628559894008,6.10154654387357,1.3412,0.594873642895201,0.65738233160132,0.11518147633367,0.224731224619875,0.276046201663174,-0.0513149770432991,6.78786707415934,2.1582,-0.68632053028577,-0.817,0.567361962921898,0.609224503748684,0.626979753603247,0.672245220759481,-0.0418625408267861,-0.0452654671562344,True,0.39070401389069,0.0461992653042968,0.79909013567362,58.2716513966522
20637,1372:1561,Colon,NCI-H716,SIDM00779,908458,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.313116154047786,0.144501044917956,0.235628559894008,6.10154654387357,1.3412,0.594873642895201,0.65738233160132,0.0627807001647099,0.0737791084578303,0.0951925468663823,-0.021413438408552,6.9600362689801,2.4317,-0.858489725106528,-1.0905,0.186264547207742,0.186535845197382,0.205837027409972,0.224277313983617,-0.0002712979896403,-0.0184402865736448,True,0.39070401389069,0.0461992653042968,0.79909013567362,58.2716513966522
20637,1373:1564,Colon,NCI-H716,SIDM00779,908458,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.74656507190355,0.0692937318452257,0.353996980304231,7.51846557636857,1.7905,0.752934926360308,0.751858156659909,0.0893201226877372,0.264281781054468,0.0905255429325341,0.173756238121934,4.12180595643842,0.17,3.39665961993015,1.6205,0.562114917436878,0.371115242892253,0.561311038788076,0.380264305759009,0.190999674544624,0.181046733029067,True,0.39070401389069,0.0461992653042968,0.79909013567362,58.2716513966522
20637,1011:1564,Colon,NCI-H716,SIDM00779,908458,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.843306759026573,0.0692937318452257,0.353996980304231,7.51846557636857,1.7905,0.752934926360308,0.751858156659909,0.0395000445403475,0.298528046165555,0.109193348785285,0.189334697380269,4.30664344036494,0.1933,3.21182213600363,1.5972,0.634955112506823,0.433576960080999,0.634047065340561,0.441498542003127,0.201378152425823,0.192548523337434,True,0.39070401389069,0.0461992653042968,0.79909013567362,58.2716513966522
20637,1053:1564,Colon,NCI-H716,SIDM00779,908458,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.435687165965443,0.0692937318452257,0.353996980304231,7.51846557636857,1.7905,0.752934926360308,0.751858156659909,0.0711190166884419,0.154231941109075,0.0632816850032724,0.0909502561058028,4.63460704496254,0.2426,2.88385853140603,1.5479,0.328044084222322,0.223424581400281,0.327574949483158,0.239025187041852,0.104619502822041,0.088549762441306,True,0.39070401389069,0.0461992653042968,0.79909013567362,58.2716513966522
20638,1510:1598,Colon,NCI-H716,SIDM00779,908458,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1598,LGK974,PORCN,WNT signaling,Targeted,Early clinical trials,10.0,0.321009059403198,0.0891807106300847,0.873980587156458,13.7699037582915,272.825,0.92514081653497,0.967435847098817,0.0625215477123134,0.280555686219749,0.17515652813869,0.105399158081059,9.45093612658189,13.6693,4.31896763170957,259.1557,0.296978583331397,0.256850575898173,0.310555671310127,0.274240024849747,0.040128007433224,0.0363156464603801,True,0.39070401389069,0.0461992653042968,0.79909013567362,58.2716513966522
20638,1011:1598,Colon,NCI-H716,SIDM00779,908458,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1598,LGK974,PORCN,WNT signaling,Targeted,Early clinical trials,10.0,0.347690582766926,0.0891807106300847,0.873980587156458,13.7699037582915,272.825,0.92514081653497,0.967435847098817,0.0322930156825394,0.303874819675409,0.17035479280459,0.133520026870819,8.90108148010533,9.3373,4.86882227818613,263.4877,0.321662749642514,0.286884436878331,0.336368333467403,0.2881190416424,0.034778312764183,0.0482492918250028,True,0.39070401389069,0.0461992653042968,0.79909013567362,58.2716513966522
20638,2171:1598,Colon,NCI-H716,SIDM00779,908458,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1598,LGK974,PORCN,WNT signaling,Targeted,Early clinical trials,10.0,0.234290460131512,0.0891807106300847,0.873980587156458,13.7699037582915,272.825,0.92514081653497,0.967435847098817,0.0526312216524552,0.204765313910896,0.137019427348035,0.0677458865628612,9.8438773025944,17.9487,3.92602645569706,254.8763,0.216751667592421,0.212391180271682,0.226660989764501,0.204037101465105,0.0043604873207394,0.0226238882993964,True,0.39070401389069,0.0461992653042968,0.79909013567362,58.2716513966522
20638,1786:1598,Colon,NCI-H716,SIDM00779,908458,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1598,LGK974,PORCN,WNT signaling,Targeted,Early clinical trials,10.0,0.253115892295164,0.0891807106300847,0.873980587156458,13.7699037582915,272.825,0.92514081653497,0.967435847098817,0.0481985259720514,0.221218376166758,0.107772211314213,0.113446164852546,8.26336223549874,6.0014,5.50654152279272,266.8236,0.234167843275926,0.193086113066341,0.244873387676745,0.20131965531836,0.0410817302095848,0.0435537323583848,True,0.39070401389069,0.0461992653042968,0.79909013567362,58.2716513966522
20639,1011:2048,Colon,NCI-H716,SIDM00779,908458,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.358138774621046,0.0672288494895084,0.557373557701747,9.56774530489412,0.1482,0.846978827933909,0.859383342324988,0.0670601937165318,0.199617082961476,0.148181164213036,0.0514359187484402,8.14171768242847,0.0552,1.42602762246566,0.093,0.30333595956622,0.258405280063646,0.30777849715001,0.282424842244259,0.044930679502574,0.0253536549057511,True,0.39070401389069,0.0461992653042968,0.79909013567362,58.2716513966522
20639,1561:2048,Colon,NCI-H716,SIDM00779,908458,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.608635844952591,0.0672288494895084,0.557373557701747,9.56774530489412,0.1482,0.846978827933909,0.859383342324988,0.0375895355515411,0.339237526246035,0.156058833446829,0.183178692799206,6.37758084959006,0.0162,3.19016445530406,0.132,0.51550167459651,0.414580585477396,0.523051506694151,0.411930844333801,0.100921089119114,0.11112066236035,True,0.39070401389069,0.0461992653042968,0.79909013567362,58.2716513966522
18415,1022:1003,Colon,SNU-81,SIDM00193,1660036,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.1,0.971885578113017,0.0568266494287574,0.887874327086882,14.0926223138166,3.4122,0.950101113021169,0.971264679294475,0.075002448636599,0.862912253672541,0.342058450891561,0.52085380278098,7.49756115678374,0.0353,6.59506115703285,3.3769,0.9233895694944,0.723765894190762,0.943958134336865,0.729560277929751,0.199623675303638,0.214397856407115,True,0.925999351124554,0.0881708872528886,0.0443935543943987,669.766476452241
18418,2048:1011,Colon,SNU-81,SIDM00193,1660036,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.921539287788296,0.093538760051544,0.2201797133662,5.88759027721343,1.1563,0.666924742311082,0.642101953030592,0.0813605001822593,0.202904256240919,0.163980231607021,0.038924024633898,5.23357533796953,0.7348,0.654014939243893,0.4215,0.614597352037748,0.563124419103944,0.591722176483286,0.547344308315291,0.0514729329338034,0.0443778681679954,True,0.925999351124554,0.0881708872528886,0.0443935543943987,669.766476452241
18416,1073:1022,Colon,SNU-81,SIDM00193,1660036,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,2.5,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.894317197709501,0.0559832094308969,0.861143430499296,13.4911426413282,22.4889,0.947791176225453,0.963888763756653,0.0541374122091207,0.770135379590077,0.328388320554554,0.441747059035522,7.66046953087602,0.3951,5.83067311045219,22.0938,0.847625948735739,0.663165177801864,0.862022298106525,0.680230190774077,0.184460770933875,0.181792107332448,True,0.925999351124554,0.0881708872528886,0.0443935543943987,669.766476452241
18416,1179:1022,Colon,SNU-81,SIDM00193,1660036,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.88700201923212,0.0559832094308969,0.861143430499296,13.4911426413282,22.4889,0.947791176225453,0.963888763756653,0.0663259921362757,0.763835961701351,0.311126807630014,0.452709154071337,7.48469756967506,0.3498,6.00644507165315,22.1391,0.840692687122363,0.642031272954728,0.854971279767303,0.665136181647087,0.198661414167636,0.189835098120216,True,0.925999351124554,0.0881708872528886,0.0443935543943987,669.766476452241
18416,1003:1022,Colon,SNU-81,SIDM00193,1660036,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.025,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.945293547016334,0.0559832094308969,0.861143430499296,13.4911426413282,22.4889,0.947791176225453,0.963888763756653,0.125718807588159,0.814033327906494,0.331865839007106,0.482167488899388,7.48804173707438,0.3506,6.00310090425384,22.1383,0.895940882804942,0.675074194712106,0.911157828420715,0.709042693269815,0.220866688092836,0.202115135150901,True,0.925999351124554,0.0881708872528886,0.0443935543943987,669.766476452241
18415,1179:1032,Colon,SNU-81,SIDM00193,1660036,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.25,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.900305533217345,0.0863334928370201,0.703577691393708,11.1273955198713,43.6928,0.942903764235642,0.915248354856752,0.0791623959951073,0.633434888610041,0.63360214105707,-0.0001672524470288,11.1295882002433,43.7593,-0.0021926803720422,-0.0665000000000049,0.848901476232812,0.853157278599354,0.824003158145606,0.82406023684602,-0.0042558023665424,-5.70787004139373e-05,True,0.925999351124554,0.0881708872528886,0.0443935543943987,669.766476452241
18415,1011:1032,Colon,SNU-81,SIDM00193,1660036,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.919216570438613,0.0863334928370201,0.703577691393708,11.1273955198713,43.6928,0.942903764235642,0.915248354856752,0.130860085512971,0.646740272520041,0.47246503788942,0.174275234630621,9.13772845546359,11.0017,1.98966706440771,32.6911,0.866732764414346,0.822828880548416,0.841311453851006,0.772294511224783,0.0439038838659296,0.0690169426262229,True,0.925999351124554,0.0881708872528886,0.0443935543943987,669.766476452241
18415,2048:1032,Colon,SNU-81,SIDM00193,1660036,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.01,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.74764013689789,0.0863334928370201,0.703577691393708,11.1273955198713,43.6928,0.942903764235642,0.915248354856752,0.0667774221647434,0.526022921511893,0.182864506474077,0.343158415037817,6.22461024638835,1.4606,4.90278527348295,42.2322,0.704952699374672,0.500916816805405,0.684276405320671,0.498049813876298,0.204035882569267,0.186226591444373,True,0.925999351124554,0.0881708872528886,0.0443935543943987,669.766476452241
18419,1564:1053,Colon,SNU-81,SIDM00193,1660036,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.966437973193645,0.0965902962211319,0.715833443274474,11.2738183807841,48.3601,0.895128539093164,0.919396296295098,0.0600358265221325,0.691808622062411,0.692915894909354,-0.0011072728469436,11.2876975051643,48.8276,-0.0138791243802068,-0.467499999999994,0.865086211068985,0.859912982322372,0.888539493153178,0.888910817705538,0.0051732287466137,-0.0003713245523602,True,0.925999351124554,0.0881708872528886,0.0443935543943987,669.766476452241
18419,1372:1053,Colon,SNU-81,SIDM00193,1660036,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.903292772004561,0.0965902962211319,0.715833443274474,11.2738183807841,48.3601,0.895128539093164,0.919396296295098,0.0796298768376615,0.646607175268969,0.195815407311297,0.450791767957673,5.83857950988592,1.1177,5.43523887089819,47.2424,0.808563139377857,0.525848042913808,0.830484029051126,0.576802695288156,0.282715096464049,0.25368133376297,True,0.925999351124554,0.0881708872528886,0.0443935543943987,669.766476452241
18419,2048:1053,Colon,SNU-81,SIDM00193,1660036,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.95084877565547,0.0965902962211319,0.715833443274474,11.2738183807841,48.3601,0.895128539093164,0.919396296295098,0.0904079404152947,0.680649353110773,0.666429624255366,0.0142197288554067,11.0956279628688,42.7412,0.17819041791533,5.6189,0.851131875451004,0.841090608257367,0.874206842674367,0.869385191915937,0.0100412671936362,0.0048216507584298,True,0.925999351124554,0.0881708872528886,0.0443935543943987,669.766476452241
18419,1179:1053,Colon,SNU-81,SIDM00193,1660036,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.959650760954273,0.0965902962211319,0.715833443274474,11.2738183807841,48.3601,0.895128539093164,0.919396296295098,0.132065775382708,0.686950108554866,0.550793396200421,0.136156712354445,9.73340455558302,16.6256,1.5404138252011,31.7345,0.859010783692641,0.727844108429763,0.882299355358131,0.831514743514186,0.131166675262878,0.0507846118439442,True,0.925999351124554,0.0881708872528886,0.0443935543943987,669.766476452241
19706,1022:1073,Colon,SNU-81,SIDM00193,1660036,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,20.0,0.95353362918544,0.0633756900296681,0.56927553723586,9.68640300058578,32.1853,0.842871483996547,0.864522727673105,0.137983827183653,0.542823369027,0.208344750862021,0.33447861816498,5.86341163271843,2.2742,3.82299136786735,29.9111,0.803706305072144,0.56566783657558,0.824351494031432,0.610598936468694,0.238038468496565,0.213752557562738,True,0.50567577540225,0.0400445422033462,0.638339252090191,75.54931060814
18417,1011:1083,Colon,SNU-81,SIDM00193,1660036,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.618760000885752,0.0384284186463403,0.854271706359082,13.3525454778123,204.2898,0.961535910019386,0.961956368303263,0.0546040318731142,0.528589161783418,0.316126232546521,0.212462929236897,9.10735068263162,10.7725,4.24519479518069,193.5173,0.594959960535278,0.516610933833152,0.595220123303381,0.518974936319674,0.0783490267021254,0.0762451869837073,True,0.925999351124554,0.0881708872528886,0.0443935543943987,669.766476452241
19706,1022:1089,Colon,SNU-81,SIDM00193,1660036,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1089,Oxaliplatin,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved in colon,10.0,0.95353362918544,0.041711295974783,0.891572864581688,14.185404700222,363.8835,0.971583923131396,0.972268035950941,0.0371672576931996,0.850144709247835,0.553623813885911,0.296520895361924,9.80047794068592,17.4168,4.38492675953607,346.4667,0.926437944281707,0.844784026910395,0.927090268861301,0.828838446496793,0.0816539173713121,0.0982518223645075,True,0.50567577540225,0.0400445422033462,0.638339252090191,75.54931060814
19707,1022:1179,Colon,SNU-81,SIDM00193,1660036,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,10.0,0.945201895375947,0.088319530499126,0.356557274321588,7.54709318072048,3.6528,0.750437188420404,0.75371276509134,0.143602514456917,0.337018611498846,0.112991743989754,0.224026867509092,4.08566204697126,0.3316,3.46143113374922,3.3212,0.709314652855562,0.439662159831393,0.71241073413338,0.478820204530029,0.26965249302417,0.233590529603351,True,0.50567577540225,0.0400445422033462,0.638339252090191,75.54931060814
18416,1073:1372,Colon,SNU-81,SIDM00193,1660036,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,10,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.824180452713537,0.0880255387543442,0.758785631016573,11.8205522382887,7.0643,0.870402093178885,0.9334052151515,0.081622012398495,0.625376284883766,0.460521631458475,0.164854653425291,9.58118352637384,1.4961,2.23936871191487,5.5682,0.717368391198984,0.638315813075493,0.76929433278874,0.708855712888968,0.0790525781234908,0.0604386198997716,True,0.925999351124554,0.0881708872528886,0.0443935543943987,669.766476452241
18416,1011:1372,Colon,SNU-81,SIDM00193,1660036,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.611480105544664,0.0880255387543442,0.758785631016573,11.8205522382887,7.0643,0.870402093178885,0.9334052151515,0.095091762465885,0.463982317739789,0.268105783136312,0.195876534603477,8.39101576501649,0.6557,3.42953647327221,6.4086,0.532233563803321,0.426050010574055,0.570758719476779,0.490675878095407,0.106183553229267,0.0800828413813723,True,0.925999351124554,0.0881708872528886,0.0443935543943987,669.766476452241
18416,1053:1372,Colon,SNU-81,SIDM00193,1660036,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.760036717112049,0.0880255387543442,0.758785631016573,11.8205522382887,7.0643,0.870402093178885,0.9334052151515,0.0744962369351255,0.576704939989631,0.141935220539754,0.434769719449877,5.37896417891168,0.0813,6.44158805937702,6.983,0.661537549467135,0.411838752386227,0.709422235459011,0.459664711077216,0.249698797080908,0.249757524381795,True,0.925999351124554,0.0881708872528886,0.0443935543943987,669.766476452241
19707,1053:1549,Colon,SNU-81,SIDM00193,1660036,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.675645105924606,0.0377781829932963,0.92598144291577,15.2181732805931,372.2431,0.966804498995878,0.981411583501045,0.113532690856843,0.625634830083045,0.449412764712373,0.176222065370672,10.6892777391609,16.1248,4.52889554143221,356.1183,0.653216728132455,0.512888909058044,0.663085933290199,0.609279105959338,0.140327819074411,0.0538068273308614,True,0.50567577540225,0.0400445422033462,0.638339252090191,75.54931060814
19708,1053:1564,Colon,SNU-81,SIDM00193,1660036,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.593153025051197,0.0617650632565572,0.690156343031918,10.9710074964136,19.6021,0.884997012858274,0.910624255588604,0.0837461549060188,0.409368322627654,0.068394226672452,0.340974095955202,3.98505033399147,0.1546,6.98595716242216,19.4475,0.524938655338158,0.274847362382994,0.540139531887376,0.295895365088257,0.250091292955165,0.244244166799119,True,0.50567577540225,0.0400445422033462,0.638339252090191,75.54931060814
19710,1011:2048,Colon,SNU-81,SIDM00193,1660036,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.483949762874301,0.0486910208529425,0.492666127775566,8.92779597596977,0.0951,0.829457711002332,0.830089589074445,0.0701590926911142,0.238425655713185,0.10212432716741,0.136301328545775,5.75431157068798,0.0105,3.17348440528179,0.0846,0.401415862553839,0.312415110632828,0.401721659797004,0.306065404251165,0.0890007519210105,0.0956562555458387,True,0.50567577540225,0.0400445422033462,0.638339252090191,75.54931060814
19437,1022:1003,Colon,SNU-C5,SIDM00498,1674021,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.1,0.624095688363845,0.0775220658526664,0.531011420169022,9.37067295158392,0.1293,0.838768253086801,0.820198266295688,0.0600183836125666,0.331401937799448,0.141924390283318,0.18947754751613,5.3501109621064,0.008,4.02056198947752,0.1213,0.523471650287946,0.334702377281564,0.511882201598639,0.369211667680497,0.188769273006382,0.142670533918142,True,0.368404837033656,0.0472892109324904,0.927985743407709,52.2815632844293
19440,1083:1011,Colon,SNU-C5,SIDM00498,1674021,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.935774414215023,0.0775091154620713,0.652829075866472,10.8846186583766,36.9255,0.868704696562973,0.87824734778161,0.0555176517190601,0.610900746051483,0.64867099218141,-0.037770246129927,11.4325027550774,53.9829,-0.547884096700827,-17.0574,0.812911628552055,0.870413533494909,0.821841397406234,0.837736519937112,-0.057501904942854,-0.0158951225308784,True,0.368404837033656,0.0472892109324904,0.927985743407709,52.2815632844293
19440,2048:1011,Colon,SNU-C5,SIDM00498,1674021,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.707417770241577,0.0775091154620713,0.652829075866472,10.8846186583766,36.9255,0.868704696562973,0.87824734778161,0.183766147518559,0.461822889198329,0.409092263168161,0.0527306260301679,9.94232861770448,19.2163,0.942290040672127,17.7092,0.614537139440964,0.577500057009133,0.621287780488245,0.597121241418766,0.037037082431831,0.024166539069479,True,0.368404837033656,0.0472892109324904,0.927985743407709,52.2815632844293
19440,1025:1011,Colon,SNU-C5,SIDM00498,1674021,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.906807923107802,0.0775091154620713,0.652829075866472,10.8846186583766,36.9255,0.868704696562973,0.87824734778161,0.0533167029376053,0.591990578430862,0.329002940371939,0.262987638058923,7.31929794186257,3.1193,3.56532071651404,33.8062,0.787748301684263,0.645223172470053,0.796401653416777,0.648600455235016,0.14252512921421,0.147801198181761,True,0.368404837033656,0.0472892109324904,0.927985743407709,52.2815632844293
20650,1011:1025,Colon,SNU-C5,SIDM00498,1674021,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.921502394882354,0.063878540559143,0.848773718115468,14.1480694574814,354.5874,0.954549093012015,0.952925847419729,0.0477901875737491,0.782147013956604,0.475341781589271,0.306805232367333,9.18907445989995,11.4003,4.95899499758142,343.1871,0.879619275243351,0.74047074899385,0.878123450542577,0.74835719483583,0.139148526249501,0.129766255706747,True,0.229827004623137,0.0376189007246153,1.21435473073504,39.0116085621949
20652,1022:1073,Colon,SNU-C5,SIDM00498,1674021,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,20.0,0.466211425382609,0.0661002043736018,0.527563326261534,9.32936963869363,25.1293,0.819715490522263,0.818378945762275,0.0764062392066413,0.24595605031598,0.169938569108296,0.0760174812076845,7.34116106318568,6.3339,1.98820857550795,18.7954,0.382160727244589,0.276208608692982,0.381537614806947,0.334050550226524,0.105952118551607,0.0474870645804232,True,0.229827004623137,0.0376189007246153,1.21435473073504,39.0116085621949
19438,1053:1372,Colon,SNU-C5,SIDM00498,1674021,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.762583443026506,0.15961397986502,0.426767317862134,8.11945586484718,0.5432,0.661274126239955,0.759608533850988,0.128844439514927,0.325445690626493,0.155622556052745,0.169823134573748,4.93819207074201,0.0599,3.18126379410517,0.4833,0.504276699972409,0.38362809092994,0.579264891096402,0.430056923966993,0.120648609042469,0.149207967129409,True,0.368404837033656,0.0472892109324904,0.927985743407709,52.2815632844293
20651,1032:1373,Colon,SNU-C5,SIDM00498,1674021,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10.0,0.92881483915021,0.166780723685422,0.570826365210562,9.8512100239881,18.0401,0.725187162580285,0.840439728676707,0.150263613414874,0.530191998585747,0.338145541456509,0.192046457129238,7.33538313006692,3.1543,2.51582689392118,14.8858,0.673564597765804,0.562623133513063,0.780612891406301,0.665205656339461,0.110941464252741,0.11540723506684,True,0.229827004623137,0.0376189007246153,1.21435473073504,39.0116085621949
20654,1053:1564,Colon,SNU-C5,SIDM00498,1674021,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.788338618888672,0.113859719258281,0.529602395603236,9.35379075965104,6.3896,0.747999263041855,0.819456161118806,0.132528303360179,0.417506021109988,0.271049251639028,0.146456769470959,7.07120153911317,1.3132,2.28258922053787,5.0764,0.589676705956161,0.472660409524415,0.646008938296213,0.55239552215387,0.117016296431746,0.0936134161423428,True,0.229827004623137,0.0376189007246153,1.21435473073504,39.0116085621949
20656,1510:2048,Colon,SNU-C5,SIDM00498,1674021,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.895863488784562,0.121031345076032,0.240320931434858,5.56523617588222,0.0092,0.615973330053516,0.605859936247737,0.105098971668744,0.215294748063187,0.0840432924957939,0.131251455567393,2.23162672912425,0.0009,3.33360944675798,0.0083,0.551828016459987,0.339123897429303,0.54276779620169,0.341146082098515,0.212704119030684,0.201621714103175,True,0.229827004623137,0.0376189007246153,1.21435473073504,39.0116085621949
24109,1549:1022,Colon,SW1116,SIDM00835,909746,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.631557074090674,0.0619420982213659,0.850775436340311,13.7492857525364,26.8954,0.962509094718951,0.957129738356523,0.0457353188752382,0.537313245283303,0.487401524958014,0.0499117203252886,12.323703938812,10.0123,1.42558181372434,16.8831,0.607879427646364,0.612872311997938,0.604482057081618,0.588210518956404,-0.0049928843515744,0.0162715381252136,True,0.61090969612462,0.076405687476197,0.47199878234274,102.950812163568
24109,1054:1022,Colon,SW1116,SIDM00835,909746,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.947625001785872,0.0619420982213659,0.850775436340311,13.7492857525364,26.8954,0.962509094718951,0.957129738356523,0.0819402926252385,0.806216074381363,0.829296453930578,-0.023080379549215,14.3124697384672,39.7386,-0.563183985930833,-12.8432,0.912097682601964,0.918889129356933,0.907000070019411,0.914082193175902,-0.0067914467549682,-0.0070821231564903,True,0.61090969612462,0.076405687476197,0.47199878234274,102.950812163568
24109,1053:1022,Colon,SW1116,SIDM00835,909746,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.970090690553081,0.0619420982213659,0.850775436340311,13.7492857525364,26.8954,0.962509094718951,0.957129738356523,0.102601822884131,0.82532933054497,0.553893809258351,0.27143552128662,9.77981171375444,1.7169,3.96947403878191,25.1785,0.933721112359528,0.814935499591763,0.928502648831169,0.82680370208295,0.118785612767765,0.101698946748219,True,0.61090969612462,0.076405687476197,0.47199878234274,102.950812163568
24109,1561:1022,Colon,SW1116,SIDM00835,909746,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.903818168060352,0.0619420982213659,0.850775436340311,13.7492857525364,26.8954,0.962509094718951,0.957129738356523,0.0980678961006381,0.768946296303847,0.662723805942141,0.106222490361706,11.7588591957819,6.7686,1.99042655675446,20.1268,0.869933206730311,0.792546854669169,0.865071246717477,0.829592703908898,0.0773863520611416,0.0354785428085787,True,0.61090969612462,0.076405687476197,0.47199878234274,102.950812163568
24109,1003:1022,Colon,SW1116,SIDM00835,909746,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.025,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.858171171738455,0.0619420982213659,0.850775436340311,13.7492857525364,26.8954,0.962509094718951,0.957129738356523,0.0763238883152645,0.73011095309046,0.493481773836842,0.236629179253618,9.82517199149122,1.7717,3.92411376104513,25.1237,0.825997557623882,0.739339190288242,0.821381149071138,0.733004511977269,0.0866583673356398,0.0883766370938699,True,0.61090969612462,0.076405687476197,0.47199878234274,102.950812163568
24115,1059:1053,Colon,SW1116,SIDM00835,909746,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.765968881596955,0.0638386891477655,0.847804110386447,13.6859470609707,257.4012,0.954655299887989,0.95620382749774,0.112304719631154,0.649391566246008,0.437410389178297,0.211981177067711,9.78074594279736,17.1802,3.9052011181733,240.221,0.731236252365808,0.576149208727723,0.732422376327171,0.652860998454595,0.155087043638085,0.0795613778725768,True,0.61090969612462,0.076405687476197,0.47199878234274,102.950812163568
24115,1564:1053,Colon,SW1116,SIDM00835,909746,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.933179309038063,0.0638386891477655,0.847804110386447,13.6859470609707,257.4012,0.954655299887989,0.95620382749774,0.0597032621934226,0.791153253930054,0.65577352746812,0.135379726461934,11.3473213808605,50.8879,2.33862568011016,206.5133,0.890864573118998,0.816073901200624,0.892309627043892,0.846100914425619,0.074790671918374,0.0462087126182729,True,0.61090969612462,0.076405687476197,0.47199878234274,102.950812163568
24115,1549:1053,Colon,SW1116,SIDM00835,909746,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.632980204437619,0.0638386891477655,0.847804110386447,13.6859470609707,257.4012,0.954655299887989,0.95620382749774,0.0660813390304948,0.536643219115467,0.35924923689081,0.177393982224657,9.74176735245225,16.7222,3.94417970851841,240.679,0.604277906890556,0.49374753538989,0.605258094213553,0.538494517267947,0.110530371500666,0.0667635769456061,True,0.61090969612462,0.076405687476197,0.47199878234274,102.950812163568
24110,1053:1059,Colon,SW1116,SIDM00835,909746,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.95473450914494,0.0638197728056367,0.79445122555088,12.6886876725703,12.8945,0.929113714639284,0.939020059731282,0.0654947022255337,0.758490000865915,0.45637804686437,0.302111954001545,8.75991838125276,0.8467,3.92876929131758,12.0478,0.887056926285969,0.77300089105805,0.896514855804798,0.769646991097518,0.114056035227919,0.12686786470728,True,0.61090969612462,0.076405687476197,0.47199878234274,102.950812163568
24110,1561:1059,Colon,SW1116,SIDM00835,909746,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.90881066617539,0.0638197728056367,0.79445122555088,12.6886876725703,12.8945,0.929113714639284,0.939020059731282,0.0560419288533338,0.72200574753675,0.582343782021628,0.139661965515122,10.5790039856836,2.9876,2.10968368688672,9.9069,0.844388453954019,0.795653804871112,0.85339144603644,0.801983643009857,0.0487346490829069,0.0514078030265833,True,0.61090969612462,0.076405687476197,0.47199878234274,102.950812163568
23810,1089:1194,Colon,SW1116,SIDM00835,909746,1089,Oxaliplatin,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved in colon,5,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,10.0,0.855222741728888,0.095328805840041,0.600785481991526,10.115196756725,21.6625,0.905219342248753,0.86558627193768,0.0916700017364686,0.513805407099704,0.311017372741023,0.202788034358681,7.47352974479466,3.4713,2.64166701193038,18.1912,0.774164167743999,0.594113403541097,0.74026906468943,0.629423372971294,0.180050764202902,0.110845691718136,True,0.495135089373144,0.0895383579279863,0.68175884072653,72.0886523598128
24109,1053:1372,Colon,SW1116,SIDM00835,909746,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.970090690553081,0.112270461461592,0.190300173629465,5.04913469921417,0.0647,0.546218792877466,0.575528147420391,0.0721082274674436,0.184608426848579,0.119126497894684,0.0654819289538949,3.63549595610105,0.0243,1.41363874311312,0.0404,0.529881765975571,0.440653539228069,0.558314497963782,0.459457744790411,0.0892282267475017,0.0988567531733716,True,0.61090969612462,0.076405687476197,0.47199878234274,102.950812163568
24109,1510:1372,Colon,SW1116,SIDM00835,909746,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.799543769211354,0.112270461461592,0.190300173629465,5.04913469921417,0.0647,0.546218792877466,0.575528147420391,0.0626342737482633,0.152153318105278,0.0766237339291059,0.0755295841761716,2.87643888810226,0.0143,2.17269581111192,0.0504,0.436725832471325,0.314955765932757,0.460159944275727,0.335155474402984,0.121770066538568,0.125004469872743,True,0.61090969612462,0.076405687476197,0.47199878234274,102.950812163568
24109,1549:1372,Colon,SW1116,SIDM00835,909746,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.631557074090674,0.112270461461592,0.190300173629465,5.04913469921417,0.0647,0.546218792877466,0.575528147420391,0.121089567231649,0.120185420856372,0.0442009390499731,0.0759844818063989,1.94198514993741,0.0075,3.10714954927676,0.0572,0.344968342643032,0.217822738834595,0.363478872841648,0.22375419661048,0.127145603808437,0.139724676231168,True,0.61090969612462,0.076405687476197,0.47199878234274,102.950812163568
24109,1047:1372,Colon,SW1116,SIDM00835,909746,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.958634863503812,0.112270461461592,0.190300173629465,5.04913469921417,0.0647,0.546218792877466,0.575528147420391,0.115404741764134,0.182428380972034,0.0620306213986226,0.120397759573411,1.71252510387254,0.0064,3.33660959534163,0.0583,0.523624377953307,0.331050521395277,0.551721347044949,0.324879438258608,0.19257385655803,0.226841908786341,True,0.61090969612462,0.076405687476197,0.47199878234274,102.950812163568
24112,1089:1510,Colon,SW1116,SIDM00835,909746,1089,Oxaliplatin,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved in colon,5,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.971261489439334,0.0715456841114959,0.824083947581597,13.2133483015032,185.5001,0.919613631033515,0.948697383989602,0.0808556265469797,0.800401002351148,0.544157118029975,0.256243884321173,9.66084067821861,15.81,3.55250762328459,169.6901,0.893185304986326,0.794737078454052,0.921433234200941,0.823005026283208,0.0984482265322748,0.0984282079177329,True,0.61090969612462,0.076405687476197,0.47199878234274,102.950812163568
24112,1083:1510,Colon,SW1116,SIDM00835,909746,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.950487318430638,0.0715456841114959,0.824083947581597,13.2133483015032,185.5001,0.919613631033515,0.948697383989602,0.0887297481745123,0.783281341498566,0.752308096879857,0.0309732446187094,12.639592923266,124.6312,0.573755378237177,60.8689,0.874081094153308,0.84651493548373,0.901724832510438,0.891591587141969,0.0275661586695776,0.0101332453684698,True,0.61090969612462,0.076405687476197,0.47199878234274,102.950812163568
24112,1032:1510,Colon,SW1116,SIDM00835,909746,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.678037151428254,0.0715456841114959,0.824083947581597,13.2133483015032,185.5001,0.919613631033515,0.948697383989602,0.0281771071272282,0.558759532355977,0.402156262661761,0.156603269694215,10.0282499775074,20.3955,3.18509832399576,165.1046,0.623532206800558,0.591261244738323,0.643252071807747,0.584623744980088,0.0322709620622359,0.0586283268276588,True,0.61090969612462,0.076405687476197,0.47199878234274,102.950812163568
24112,2048:1510,Colon,SW1116,SIDM00835,909746,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.946505148654653,0.0715456841114959,0.824083947581597,13.2133483015032,185.5001,0.919613631033515,0.948697383989602,0.0648379138752443,0.779999699309633,0.740956344547695,0.0390433547619375,12.4984919887983,113.0189,0.714856312704882,72.4812,0.870419036546223,0.877404314636076,0.897946958461359,0.885105789368739,-0.0069852780898535,0.0128411690926207,True,0.61090969612462,0.076405687476197,0.47199878234274,102.950812163568
24112,1549:1510,Colon,SW1116,SIDM00835,909746,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.688206731652149,0.0715456841114959,0.824083947581597,13.2133483015032,185.5001,0.919613631033515,0.948697383989602,0.052927706188535,0.567140120172131,0.377655488490752,0.189484631681379,9.53376305685249,14.477,3.67958524465071,171.0231,0.63288429139634,0.543401382827222,0.652899925962428,0.579436848957977,0.089482908569118,0.0734630770044503,True,0.61090969612462,0.076405687476197,0.47199878234274,102.950812163568
24112,1047:1510,Colon,SW1116,SIDM00835,909746,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.912043238911047,0.0715456841114959,0.824083947581597,13.2133483015032,185.5001,0.919613631033515,0.948697383989602,0.0696656607367907,0.751600192686921,0.682982582327684,0.0686176103592369,11.9807111222706,78.9375,1.23263717923258,106.5626,0.838727394594555,0.829635915179361,0.865253034840314,0.842201467601818,0.0090914794151943,0.0230515672384958,True,0.61090969612462,0.076405687476197,0.47199878234274,102.950812163568
23813,2171:1549,Colon,SW1116,SIDM00835,909746,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.907008263832227,0.0791911632277995,0.532230218167759,9.35223396836281,6.3827,0.800572254823765,0.833997166643081,0.110971450478093,0.482737206139386,0.264561031099965,0.218176175039422,6.5793435699395,0.9339,2.77289039842331,5.4488,0.726125650919954,0.557501310600865,0.756442322157938,0.617034242263281,0.16862434031909,0.139408079894657,True,0.495135089373144,0.0895383579279863,0.68175884072653,72.0886523598128
23813,1083:1549,Colon,SW1116,SIDM00835,909746,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.982901263528878,0.0791911632277995,0.532230218167759,9.35223396836281,6.3827,0.800572254823765,0.833997166643081,0.0710788914125718,0.52312975392534,0.419885767572675,0.103243986352666,8.19969842272266,2.8711,1.15253554564016,3.5116,0.786883480812441,0.724816707881774,0.819736868872988,0.763863904265379,0.0620667729306671,0.0558729646076099,True,0.495135089373144,0.0895383579279863,0.68175884072653,72.0886523598128
23814,1032:1561,Colon,SW1116,SIDM00835,909746,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.756174145096373,0.0678795913907335,0.765256779533315,12.2241830125095,93.4492,0.905500730433554,0.929137941911486,0.142949146590678,0.578667391042808,0.3875025213622,0.191164869680608,9.13591719037686,10.9879,3.08826582213262,82.4613,0.684716240719734,0.516761715881089,0.702590088901521,0.62320821048023,0.167954524838645,0.0793818784212914,True,0.495135089373144,0.0895383579279863,0.68175884072653,72.0886523598128
23814,1372:1561,Colon,SW1116,SIDM00835,909746,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.490612194653244,0.0678795913907335,0.765256779533315,12.2241830125095,93.4492,0.905500730433554,0.929137941911486,0.0616783444408261,0.375444308080113,0.23022279529078,0.145221512789333,8.66405228596458,7.9226,3.56013072654491,85.5266,0.444249700618122,0.363182336164293,0.455846404816792,0.39315518884146,0.0810673644538284,0.0626912159753326,True,0.495135089373144,0.0895383579279863,0.68175884072653,72.0886523598128
23814,1564:1561,Colon,SW1116,SIDM00835,909746,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.775805040392288,0.0678795913907335,0.765256779533315,12.2241830125095,93.4492,0.905500730433554,0.929137941911486,0.0944039286536549,0.593690066756315,0.372491336946494,0.221198729809822,8.78309107035019,8.6041,3.4410919421593,84.8451,0.702492030749249,0.563369299050966,0.720829898554647,0.626293097263476,0.139122731698284,0.0945368012911714,True,0.495135089373144,0.0895383579279863,0.68175884072653,72.0886523598128
23814,1011:1561,Colon,SW1116,SIDM00835,909746,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.912392166672835,0.0678795913907335,0.765256779533315,12.2241830125095,93.4492,0.905500730433554,0.929137941911486,0.106519132953462,0.698214291139477,0.46221303532609,0.236001255813386,9.07197564554335,10.5116,3.15220736696614,82.9376,0.826171773364105,0.691552096343805,0.847738179958559,0.74923567980754,0.1346196770203,0.0985025001510186,True,0.495135089373144,0.0895383579279863,0.68175884072653,72.0886523598128
23814,1053:1564,Colon,SW1116,SIDM00835,909746,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.974465927053422,0.0533304902859758,0.482635153697568,8.81041191989617,4.3843,0.811358642528599,0.808625124507764,0.048849384948098,0.470311512476471,0.288061360262747,0.182250152213724,6.63096194165494,0.9679,2.17944997824124,3.4164,0.790641351764438,0.647949826443486,0.787977631592147,0.666186637946453,0.142691525320952,0.121790993645694,True,0.495135089373144,0.0895383579279863,0.68175884072653,72.0886523598128
23816,1059:2048,Colon,SW1116,SIDM00835,909746,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.926524956137125,0.076926321243905,0.828859002183103,13.3041947286974,1.9756,0.930701713022314,0.950225183352454,0.0902464503630939,0.76795855064156,0.537371787897208,0.230586762744352,9.88049619462071,0.1841,3.42369853407668,1.7915,0.862318363834746,0.7571863802348,0.880407346326024,0.793460105102159,0.105131983599946,0.0869472412238647,True,0.495135089373144,0.0895383579279863,0.68175884072653,72.0886523598128
23816,1011:2048,Colon,SW1116,SIDM00835,909746,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.956566397359876,0.076926321243905,0.828859002183103,13.3041947286974,1.9756,0.930701713022314,0.950225183352454,0.0621355138906802,0.792858669637592,0.76471962736937,0.0281390422682218,12.7728420468622,1.3669,0.531352681835221,0.6087,0.890277984642419,0.901190237610844,0.908953480320084,0.899817373621696,-0.010912252968425,0.009136106698388,True,0.495135089373144,0.0895383579279863,0.68175884072653,72.0886523598128
23816,1053:2048,Colon,SW1116,SIDM00835,909746,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.911302002225895,0.076926321243905,0.828859002183103,13.3041947286974,1.9756,0.930701713022314,0.950225183352454,0.10034013579855,0.755340868252419,0.51817500002732,0.237165868225099,9.75352574514862,0.1686,3.55066898354877,1.807,0.848150334552304,0.713409147022115,0.865942112154559,0.775713260932849,0.13474118753019,0.0902288512217099,True,0.495135089373144,0.0895383579279863,0.68175884072653,72.0886523598128
23816,2171:2048,Colon,SW1116,SIDM00835,909746,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.932666738284042,0.076926321243905,0.828859002183103,13.3041947286974,1.9756,0.930701713022314,0.950225183352454,0.161384967427834,0.77304922206348,0.464259177086342,0.308790044977138,8.97572882916734,0.0983,4.32846589953005,1.8773,0.868034530999892,0.644315392959392,0.886243422392689,0.761638176312076,0.2237191380405,0.124605246080613,True,0.495135089373144,0.0895383579279863,0.68175884072653,72.0886523598128
24115,1549:2171,Colon,SW1116,SIDM00835,909746,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.632980204437619,0.0948500240132041,0.494917728485403,8.94453254933134,9.6228,0.780493353069882,0.815131918895207,0.0707663421549178,0.313273124956492,0.15356056006228,0.159712564894212,5.89378660480714,1.1613,3.0507459445242,8.4615,0.494036842188377,0.35703148268648,0.515962368665917,0.401654719911434,0.137005359501897,0.114307648754483,True,0.61090969612462,0.076405687476197,0.47199878234274,102.950812163568
19248,1032:1003,Colon,SNU-407,SIDM00214,1660034,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.1,0.821465409131151,0.0747943976061963,0.642075759291232,10.6899477896708,0.3226,0.870161851153648,0.876910031872643,0.0387086095568501,0.527443026299366,0.479073533547313,0.048369492752053,9.97136380419264,0.1961,0.718583985478155,0.1265,0.714807861068251,0.683056759055503,0.720351258103471,0.698654944103236,0.0317511020127484,0.0216963140002355,True,0.461888619224743,0.0587461906520786,0.715713732915597,67.2313560949461
19251,1053:1011,Colon,SNU-407,SIDM00214,1660034,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.731836687127451,0.135920660817656,0.667640981409581,11.0171590636365,40.4786,0.92721631498239,0.887666761081692,0.0803042427698234,0.488604164025308,0.249029320265406,0.239574843759902,7.08546569824314,2.6526,3.9316933653934,37.826,0.678570916207236,0.513136476944524,0.64962710170318,0.516239025765843,0.165434439262712,0.133388075937337,True,0.461888619224743,0.0587461906520786,0.715713732915597,67.2313560949461
19251,1561:1011,Colon,SNU-407,SIDM00214,1660034,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.661516127129727,0.135920660817656,0.667640981409581,11.0171590636365,40.4786,0.92721631498239,0.887666761081692,0.104337988267201,0.441655276335156,0.239047866676451,0.202607409658705,7.35324023876202,3.1936,3.66391882487451,37.285,0.613368545698648,0.43795890689069,0.587205877972549,0.47715896894576,0.175409638807958,0.110046909026789,True,0.461888619224743,0.0587461906520786,0.715713732915597,67.2313560949461
19249,1017:1022,Colon,SNU-407,SIDM00214,1660034,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,2.5,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.878415923566754,0.0651255256560929,0.717254638081189,11.6919681913565,6.4619,0.936962634817119,0.907465085851544,0.0524203128803827,0.630047895342625,0.551169503212619,0.0788783921300061,10.5075998343515,2.8434,1.18436835700503,3.6185,0.823042898210419,0.75318368737206,0.797131781492867,0.764726949436459,0.0698592108383588,0.032404832056408,True,0.461888619224743,0.0587461906520786,0.715713732915597,67.2313560949461
19249,1179:1022,Colon,SNU-407,SIDM00214,1660034,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.561871350460657,0.0651255256560929,0.717254638081189,11.6919681913565,6.4619,0.936962634817119,0.907465085851544,0.0538262602086438,0.403004832122848,0.182483136837674,0.220521695285174,6.88345587630106,0.2306,4.80851231505546,6.2313,0.526452460955871,0.4052616499445,0.509878633283303,0.389443848824411,0.121190811011371,0.120434784458892,True,0.461888619224743,0.0587461906520786,0.715713732915597,67.2313560949461
19248,1510:1032,Colon,SNU-407,SIDM00214,1660034,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.572859310553189,0.122973707411221,0.388916394946819,7.69326603747145,4.0423,0.768626620080047,0.740864035592688,0.0669831493272819,0.222794377872066,0.108720492621209,0.114073885250857,4.80277364409127,0.5451,2.89049239338018,3.4972,0.440314915651884,0.300131092174238,0.424410860643281,0.318449814934997,0.140183823477646,0.105961045708283,True,0.461888619224743,0.0587461906520786,0.715713732915597,67.2313560949461
19248,2048:1032,Colon,SNU-407,SIDM00214,1660034,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.884291847924715,0.122973707411221,0.388916394946819,7.69326603747145,4.0423,0.768626620080047,0.740864035592688,0.122718471284948,0.343915597575741,0.256021190224428,0.0878944073513123,6.40396388129436,1.6539,1.28930215617709,2.3884,0.679690254234713,0.624690359061593,0.65514002709522,0.586352549096256,0.0549998951731191,0.0687874779989636,True,0.461888619224743,0.0587461906520786,0.715713732915597,67.2313560949461
19253,1017:1047,Colon,SNU-407,SIDM00214,1660034,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.837694025602873,0.11215196182657,0.512170870883832,9.14081266076104,11.0253,0.838647890878521,0.81505460342234,0.0862013837186268,0.429042478627206,0.192381748449643,0.236660730177563,5.50014289556703,0.884,3.64066976519401,10.1413,0.702530327773387,0.460030035737543,0.682766371827013,0.505632920600654,0.242500292035844,0.177133451226359,True,0.461888619224743,0.0587461906520786,0.715713732915597,67.2313560949461
19253,1032:1047,Colon,SNU-407,SIDM00214,1660034,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.802749934931492,0.11215196182657,0.512170870883832,9.14081266076104,11.0253,0.838647890878521,0.81505460342234,0.0848439749445726,0.411145133275801,0.155996088899084,0.255149044376718,4.88741361096927,0.5781,4.25339904979177,10.4472,0.673224539833165,0.421960699454759,0.654285029862896,0.450939623938767,0.251263840378407,0.20334540592413,True,0.461888619224743,0.0587461906520786,0.715713732915597,67.2313560949461
19253,1549:1047,Colon,SNU-407,SIDM00214,1660034,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.891345355205597,0.11215196182657,0.512170870883832,9.14081266076104,11.0253,0.838647890878521,0.81505460342234,0.0910821890163356,0.456521126833909,0.255340256874297,0.201180869959612,6.3608791052923,1.6053,2.77993355546873,9.42,0.74752490218754,0.563203505111416,0.726495134999443,0.588572616694468,0.184321397076124,0.137922518304975,True,0.461888619224743,0.0587461906520786,0.715713732915597,67.2313560949461
19252,1510:1053,Colon,SNU-407,SIDM00214,1660034,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,1,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.877873703142865,0.0828877213287835,0.556433313292166,9.65557774489461,15.7525,0.847979265285307,0.837648251925114,0.132760793303594,0.488478173291848,0.195094423390847,0.293383749901001,5.37742679331113,0.8119,4.27815095158348,14.9406,0.744418697804378,0.474856274446571,0.735349372848648,0.522595692304265,0.269562423357807,0.212753680544383,True,0.461888619224743,0.0587461906520786,0.715713732915597,67.2313560949461
19252,1032:1053,Colon,SNU-407,SIDM00214,1660034,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,1,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.802371088122537,0.0828877213287835,0.556433313292166,9.65557774489461,15.7525,0.847979265285307,0.837648251925114,0.0652035335481372,0.446466003053864,0.186049210805175,0.260416792248689,5.53627509689097,0.9064,4.11930264800364,14.8461,0.680394045792321,0.456720557925547,0.672104739361095,0.48626665251948,0.223673487866775,0.185838086841615,True,0.461888619224743,0.0587461906520786,0.715713732915597,67.2313560949461
19252,1549:1053,Colon,SNU-407,SIDM00214,1660034,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.824668856133997,0.0828877213287835,0.556433313292166,9.65557774489461,15.7525,0.847979265285307,0.837648251925114,0.0385726138083268,0.458873223987501,0.229090081931197,0.229783142056303,6.23708295648088,1.4733,3.41849478841372,14.2792,0.699302090728181,0.527961279563434,0.690782425757726,0.537973404015347,0.171340811164747,0.152809021742379,True,0.461888619224743,0.0587461906520786,0.715713732915597,67.2313560949461
19252,2048:1053,Colon,SNU-407,SIDM00214,1660034,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.01,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.676006760667858,0.0828877213287835,0.556433313292166,9.65557774489461,15.7525,0.847979265285307,0.837648251925114,0.0458387765530386,0.376152681646321,0.15266935389117,0.223483327755151,5.43739223181091,0.8463,4.21818551308369,14.9062,0.57323971623903,0.395420022512833,0.56625588136299,0.405171727893412,0.177819693726197,0.161084153469578,True,0.461888619224743,0.0587461906520786,0.715713732915597,67.2313560949461
19252,1047:1053,Colon,SNU-407,SIDM00214,1660034,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.667816671086964,0.0828877213287835,0.556433313292166,9.65557774489461,15.7525,0.847979265285307,0.837648251925114,0.0726742580325313,0.371595442964664,0.19464742474052,0.176948018224144,6.43128467396421,1.6855,3.2242930709304,14.067,0.566294690093603,0.420287717006461,0.559395467142444,0.443977290033706,0.146006973087141,0.115418177108738,True,0.461888619224743,0.0587461906520786,0.715713732915597,67.2313560949461
19253,1549:1054,Colon,SNU-407,SIDM00214,1660034,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.891345355205597,0.0986052168187083,0.692548803361897,11.3483543704029,20.3697,0.865670922475508,0.897775604249168,0.09356248976218,0.617300159129822,0.57929669399223,0.0380034651375913,10.7890530958622,13.8235,0.559301274540672,6.5462,0.771611755885088,0.727621995389494,0.800228114864394,0.784606942895729,0.043989760495594,0.0156211719686656,True,0.461888619224743,0.0587461906520786,0.715713732915597,67.2313560949461
19253,1564:1054,Colon,SNU-407,SIDM00214,1660034,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.5,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.753474895316608,0.0986052168187083,0.692548803361897,11.3483543704029,20.3697,0.865670922475508,0.897775604249168,0.158960028866043,0.521818137114748,0.200006376784055,0.321811760330693,6.05652439627378,0.52,5.2918299741291,19.8497,0.652261307690864,0.3955457418997,0.676451379429446,0.482680031431723,0.256715565791164,0.193771347997723,True,0.461888619224743,0.0587461906520786,0.715713732915597,67.2313560949461
19253,1053:1054,Colon,SNU-407,SIDM00214,1660034,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.725221431501917,0.0986052168187083,0.692548803361897,11.3483543704029,20.3697,0.865670922475508,0.897775604249168,0.111912122975522,0.502251234559055,0.307431854553268,0.194819380005787,8.11300196764775,2.163,3.23535240275513,18.2067,0.627803105607273,0.474781859773163,0.65108610888108,0.554021481385145,0.15302124583411,0.0970646274959358,True,0.461888619224743,0.0587461906520786,0.715713732915597,67.2313560949461
19253,1561:1054,Colon,SNU-407,SIDM00214,1660034,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.72070395897825,0.0986052168187083,0.692548803361897,11.3483543704029,20.3697,0.865670922475508,0.897775604249168,0.125194060851707,0.499122664368569,0.291776227261922,0.207346437106646,7.8857703366379,1.8478,3.46258403376498,18.5219,0.623892461000452,0.458683548772155,0.647030432256466,0.541677652827635,0.165208912228297,0.10535277942883,True,0.461888619224743,0.0587461906520786,0.715713732915597,67.2313560949461
19253,1059:1054,Colon,SNU-407,SIDM00214,1660034,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.689627950315438,0.0986052168187083,0.692548803361897,11.3483543704029,20.3697,0.865670922475508,0.897775604249168,0.100599506389735,0.477601011755875,0.357845392312806,0.119755619443068,9.21868446721814,4.6547,2.12966990318474,15.715,0.596990863914459,0.490887174607541,0.619131149801558,0.564531775761872,0.106103689306918,0.0545993740396856,True,0.461888619224743,0.0587461906520786,0.715713732915597,67.2313560949461
19701,1032:1089,Colon,SNU-407,SIDM00214,1660034,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1089,Oxaliplatin,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved in colon,10.0,0.702869487881404,0.0696590468109347,0.64607424319786,10.7403881424884,33.4125,0.871930831584045,0.878619040770333,0.0409464914381372,0.454105872449846,0.344271858547565,0.109834013902281,8.88210165403257,9.2153,1.85828648845587,24.1972,0.612853577063484,0.541832358716832,0.617554515229094,0.564356231232394,0.0710212183466525,0.0531982839966999,True,0.374026453100746,0.0401843071124103,0.925626323993473,52.6641472983473
19249,1053:1372,Colon,SNU-407,SIDM00214,1660034,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.675369384788636,0.186413734823482,0.264376887017802,6.04065802143181,0.1286,0.556742112370835,0.639566515867238,0.111495409509994,0.178552055537548,0.0782879748878356,0.100264080649712,3.12476592573314,0.017,2.91589209569867,0.1116,0.376006577917817,0.268268203496395,0.431943644352668,0.296552785763505,0.107738374421422,0.135390858589164,True,0.461888619224743,0.0587461906520786,0.715713732915597,67.2313560949461
19700,1510:1373,Colon,SNU-407,SIDM00214,1660034,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10.0,0.39035165233086,0.0658035456105734,0.850824533681235,14.0349325317311,327.8429,0.970076721193941,0.95487487443274,0.0331531280825864,0.332120762566104,0.333614879264588,-0.0014941166984835,14.1230817043532,348.4988,-0.0881491726220602,-20.6559,0.378671051005758,0.378453994300625,0.372736985004043,0.37322506514144,0.0002170567051334,-0.0004880801373965,True,0.374026453100746,0.0401843071124103,0.925626323993473,52.6641472983473
19251,1053:1510,Colon,SNU-407,SIDM00214,1660034,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.731836687127451,0.0939984503145765,0.639712479592156,10.6602528968472,31.6072,0.882352339249548,0.875895163180883,0.0495216193709473,0.468165061778811,0.351573412071549,0.116591649707262,8.77314874734724,8.545,1.88710414949993,23.0622,0.645737812835546,0.552680681604421,0.641012214493256,0.583767269908674,0.0930571312311249,0.0572449445845814,True,0.461888619224743,0.0587461906520786,0.715713732915597,67.2313560949461
19251,1032:1510,Colon,SNU-407,SIDM00214,1660034,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.885437479763761,0.0939984503145765,0.639712479592156,10.6602528968472,31.6072,0.882352339249548,0.875895163180883,0.0764209575401516,0.566425405703505,0.25244101308165,0.313984392621855,6.34156841788523,1.5839,4.31868447896194,30.0233,0.781267831528778,0.541583245109632,0.775550405824149,0.5835750903856,0.239684586419146,0.191975315438549,True,0.461888619224743,0.0587461906520786,0.715713732915597,67.2313560949461
19251,1373:1510,Colon,SNU-407,SIDM00214,1660034,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.925863268116809,0.0939984503145765,0.639712479592156,10.6602528968472,31.6072,0.882352339249548,0.875895163180883,0.0667954901930184,0.592286287010301,0.385735767965329,0.206550519044972,8.02645446805018,5.0925,2.63379842879698,26.5147,0.816937620448098,0.691282071660599,0.810959158310358,0.702986799987592,0.125655548787499,0.107972358322766,True,0.461888619224743,0.0587461906520786,0.715713732915597,67.2313560949461
19251,1179:1510,Colon,SNU-407,SIDM00214,1660034,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.25,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.880809844444657,0.0939984503145765,0.639712479592156,10.6602528968472,31.6072,0.882352339249548,0.875895163180883,0.0835715760488339,0.563465049638873,0.356507154704678,0.206957894934196,7.88457433797783,4.6155,2.77567855886934,26.9917,0.777184626679774,0.609953259687539,0.771497082431181,0.661954432391621,0.167231366992234,0.10954265003956,True,0.461888619224743,0.0587461906520786,0.715713732915597,67.2313560949461
19251,1549:1510,Colon,SNU-407,SIDM00214,1660034,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.809560316762057,0.0939984503145765,0.639712479592156,10.6602528968472,31.6072,0.882352339249548,0.875895163180883,0.059011128799957,0.517885837615267,0.240578167456915,0.277307670158352,6.51069255049089,1.7809,4.14956034635628,29.8263,0.714317439258605,0.508852903730931,0.709089965755069,0.542296349783407,0.205464535527675,0.166793615971662,True,0.461888619224743,0.0587461906520786,0.715713732915597,67.2313560949461
18955,1053:1549,Colon,SNU-407,SIDM00214,1660034,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.7894536845149,0.119404075697431,0.708236441874917,11.5645827657117,29.5792,0.833075111531794,0.903965712941637,0.056820095714324,0.559119868545876,0.331423615633187,0.227696252912689,8.06438139811916,2.6141,3.50020136759257,26.9651,0.657674216276437,0.58674395716253,0.713639062756914,0.601030402922452,0.0709302591139069,0.112608659834462,True,0.307879698043422,0.044967815678425,1.10100144627532,44.3472071688402
18955,1083:1549,Colon,SNU-407,SIDM00214,1660034,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.949458147986585,0.119404075697431,0.708236441874917,11.5645827657117,29.5792,0.833075111531794,0.903965712941637,0.115813932049924,0.672440860439167,0.51023975252774,0.162201107911427,9.43344038690534,6.7523,2.13114237880639,22.8269,0.790969952528695,0.714119203807643,0.85827761165294,0.786292568932198,0.0768507487210517,0.071985042720742,True,0.307879698043422,0.044967815678425,1.10100144627532,44.3472071688402
18955,1510:1549,Colon,SNU-407,SIDM00214,1660034,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.548366413517654,0.119404075697431,0.708236441874917,11.5645827657117,29.5792,0.833075111531794,0.903965712941637,0.0604366241824331,0.388373077553453,0.169719586461798,0.218653491091655,6.67942468236542,1.0009,4.88515808334631,28.5783,0.45683041110151,0.347290196977056,0.495704435948735,0.373153607366293,0.109540214124454,0.122550828582442,True,0.307879698043422,0.044967815678425,1.10100144627532,44.3472071688402
18955,2171:1549,Colon,SNU-407,SIDM00214,1660034,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.05,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.730383343848943,0.119404075697431,0.708236441874917,11.5645827657117,29.5792,0.833075111531794,0.903965712941637,0.0587189840123419,0.517284100652279,0.316983355826291,0.200300744825988,8.23202460401248,2.9362,3.33255816169926,26.643,0.608464185637923,0.54351443818726,0.660241500143107,0.562579277515129,0.0649497474506635,0.0976622226279781,True,0.307879698043422,0.044967815678425,1.10100144627532,44.3472071688402
18955,2048:1549,Colon,SNU-407,SIDM00214,1660034,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.921658495518906,0.119404075697431,0.708236441874917,11.5645827657117,29.5792,0.833075111531794,0.903965712941637,0.0832668525559301,0.652752133490099,0.566000550224218,0.0867515832658805,10.3436229205519,12.6894,1.22095984515981,16.8898,0.767810753948638,0.775903762133406,0.833147678990464,0.796927235299789,-0.0080930081847677,0.0362204436906759,True,0.307879698043422,0.044967815678425,1.10100144627532,44.3472071688402
18955,1047:1549,Colon,SNU-407,SIDM00214,1660034,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.637975438018335,0.119404075697431,0.708236441874917,11.5645827657117,29.5792,0.833075111531794,0.903965712941637,0.0560822555806886,0.451837454225697,0.364213405894385,0.0876240483313121,9.82556463010439,8.8611,1.73901813560735,20.7181,0.53148145918167,0.524223571939086,0.576707921667497,0.538872783603562,0.0072578872425836,0.0378351380639359,True,0.307879698043422,0.044967815678425,1.10100144627532,44.3472071688402
18956,1053:1564,Colon,SNU-407,SIDM00214,1660034,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.767639774840739,0.0740922411365162,0.416178965500004,8.02117255745255,2.537,0.751844872436527,0.758991200431823,0.0645474344039204,0.319475527369875,0.175664446421912,0.143811080947963,5.48673441913971,0.4379,2.53443813831284,2.0991,0.57714602859234,0.466069167639844,0.582631834205587,0.462653328278206,0.111076860952496,0.119978505927381,True,0.307879698043422,0.044967815678425,1.10100144627532,44.3472071688402
19702,1564:1598,Colon,SNU-407,SIDM00214,1660034,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.5,1598,LGK974,PORCN,WNT signaling,Targeted,Early clinical trials,10.0,0.558031970378638,0.0643942109609226,0.713937220756044,11.6448298340359,62.5422,0.914584593015022,0.906182731066057,0.0667728687231201,0.398399794025144,0.324964821589764,0.0734349724353799,9.96121965379972,19.4696,1.68361018023619,43.0726,0.510367442518117,0.421180453286407,0.505678934939887,0.474381545577767,0.0891869892317105,0.0312973893621195,True,0.374026453100746,0.0401843071124103,0.925626323993473,52.6641472983473
19702,1073:1598,Colon,SNU-407,SIDM00214,1660034,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,2.5,1598,LGK974,PORCN,WNT signaling,Targeted,Early clinical trials,10.0,0.674582316423453,0.0643942109609226,0.713937220756044,11.6448298340359,62.5422,0.914584593015022,0.906182731066057,0.0620630077901503,0.481609424158535,0.486121289667087,-0.0045118655085518,11.7402119458622,66.8168,-0.0953821118263143,-4.2746,0.616962593321275,0.576385893502357,0.611294845825472,0.61303500527971,0.0405766998189182,-0.0017401594542384,True,0.374026453100746,0.0401843071124103,0.925626323993473,52.6641472983473
19702,2048:1598,Colon,SNU-407,SIDM00214,1660034,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1598,LGK974,PORCN,WNT signaling,Targeted,Early clinical trials,10.0,0.911517041867869,0.0643942109609226,0.713937220756044,11.6448298340359,62.5422,0.914584593015022,0.906182731066057,0.0504958659675979,0.650765943542918,0.662785217363464,-0.0120192738205466,11.8342220403102,71.3158,-0.189392206274254,-8.77359999999999,0.833659442762982,0.853553784174974,0.826001002413079,0.830616745718556,-0.0198943414119921,-0.004615743305477,True,0.374026453100746,0.0401843071124103,0.925626323993473,52.6641472983473
19702,1786:1598,Colon,SNU-407,SIDM00214,1660034,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1598,LGK974,PORCN,WNT signaling,Targeted,Early clinical trials,10.0,0.767474044772507,0.0643942109609226,0.713937220756044,11.6448298340359,62.5422,0.914584593015022,0.906182731066057,0.09540787105031,0.547928286527284,0.302364515376878,0.245563771150406,7.75465909098193,4.2181,3.89017074305398,58.3241,0.701919936887856,0.564768203378604,0.695471725914263,0.571241366816447,0.137151733509253,0.124230359097816,True,0.374026453100746,0.0401843071124103,0.925626323993473,52.6641472983473
19702,1017:1786,Colon,SNU-407,SIDM00214,1660034,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10.0,0.830508969973571,0.0902661062561337,0.820739135480397,13.39953904035,211.0538,0.967259965831962,0.94485402586454,0.140279736944547,0.681631214024824,0.473213668155961,0.208417545868863,9.81256192774065,17.5633,3.58697711260935,193.4905,0.803318077919774,0.656292412409554,0.784709743796141,0.701059333348746,0.14702566551022,0.0836504104473954,True,0.374026453100746,0.0401843071124103,0.925626323993473,52.6641472983473
19702,1372:1786,Colon,SNU-407,SIDM00214,1660034,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10.0,0.588441047543214,0.0902661062561337,0.820739135480397,13.39953904035,211.0538,0.967259965831962,0.94485402586454,0.0619166606005021,0.482956596641797,0.425412484111968,0.0575441125298286,11.7736615664311,68.3841,1.62587747391889,142.6697,0.569175467540773,0.528789463659673,0.555990892755153,0.53527706609296,0.0403860038811001,0.020713826662193,True,0.374026453100746,0.0401843071124103,0.925626323993473,52.6641472983473
19702,1032:1786,Colon,SNU-407,SIDM00214,1660034,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10.0,0.719281881546775,0.0902661062561337,0.820739135480397,13.39953904035,211.0538,0.967259965831962,0.94485402586454,0.124639649859444,0.590342789627413,0.3862606617127,0.204082127914713,9.42887785828906,13.4619,3.97066118206094,197.5919,0.695732568168482,0.534648990516824,0.679616381510891,0.595529174706348,0.161083577651658,0.0840872068045435,True,0.374026453100746,0.0401843071124103,0.925626323993473,52.6641472983473
19702,1373:1786,Colon,SNU-407,SIDM00214,1660034,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10.0,0.867810771295452,0.0902661062561337,0.820739135480397,13.39953904035,211.0538,0.967259965831962,0.94485402586454,0.113363048449314,0.712246262193605,0.494468116874089,0.217778145319517,9.81256664317787,17.5633,3.58697239717213,193.4905,0.839398616991847,0.701196483022579,0.81995450094712,0.732547150131617,0.138202133969268,0.0874073508155027,True,0.374026453100746,0.0401843071124103,0.925626323993473,52.6641472983473
19252,1549:2171,Colon,SNU-407,SIDM00214,1660034,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.859192006103419,0.0937023084483355,0.315978549736992,6.7665887471173,2.1266,0.660860287485197,0.685908513897388,0.0840016136473938,0.271486244034175,0.0865011973539745,0.1849850466802,2.66767802743116,0.1241,4.09891071968614,2.0025,0.567805876158488,0.338073073301703,0.589327112058911,0.350349372647252,0.229732802856785,0.238977739411659,True,0.461888619224743,0.0587461906520786,0.715713732915597,67.2313560949461
19264,1047:1011,Colon,SNU-175,SIDM00216,1659928,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.614805896690176,0.196213702067916,0.558443157213142,9.56930891671963,14.8381,0.885866321044151,0.861844966218322,0.0492435875564911,0.343334146020919,0.0464339599289633,0.296900186091956,2.92804998851369,0.1486,6.64125892820595,14.6895,0.544635837857177,0.232151355108579,0.529867367263771,0.256697684331038,0.312484482748598,0.273169682932733,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
19264,1510:1011,Colon,SNU-175,SIDM00216,1659928,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.809984299963149,0.196213702067916,0.558443157213142,9.56930891671963,14.8381,0.885866321044151,0.861844966218322,0.0975437077945875,0.452330189764497,0.196514674355321,0.255815515409176,6.24033005889718,1.4766,3.32897885782245,13.3615,0.717537811911876,0.547386083504461,0.698080891639111,0.541556379086476,0.170151728407415,0.156524512552636,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
19264,1003:1011,Colon,SNU-175,SIDM00216,1659928,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.521140142436915,0.196213702067916,0.558443157213142,9.56930891671963,14.8381,0.885866321044151,0.861844966218322,0.0556490300997806,0.291027146492977,0.0363791939504365,0.254647952542541,2.72220343166296,0.1289,6.84710548505668,14.7092,0.461660500729015,0.178797518179745,0.449142008453555,0.209477119933946,0.282862982549269,0.239664888519609,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
19264,1549:1011,Colon,SNU-175,SIDM00216,1659928,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.833490040149239,0.196213702067916,0.558443157213142,9.56930891671963,14.8381,0.885866321044151,0.861844966218322,0.0702604099704086,0.465456809526649,0.191510371636752,0.273946437889897,6.06767755642636,1.31,3.50163136029327,13.5281,0.738360755493948,0.547307459249627,0.718339195495729,0.546995362679962,0.191053296244321,0.171343832815767,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
19264,1786:1011,Colon,SNU-175,SIDM00216,1659928,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.455045293545634,0.196213702067916,0.558443157213142,9.56930891671963,14.8381,0.885866321044151,0.861844966218322,0.025766320903231,0.254116930402605,0.0584971698008461,0.195619760601759,4.36056014222982,0.4012,5.20874877448981,14.4369,0.403109300101727,0.220788694280269,0.392178495643644,0.240219274415867,0.182320605821458,0.151959221227777,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
19264,1032:1011,Colon,SNU-175,SIDM00216,1659928,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.713499720573597,0.196213702067916,0.558443157213142,9.56930891671963,14.8381,0.885866321044151,0.861844966218322,0.126299560913598,0.398449036627814,0.273754246639713,0.124694789988101,7.85102329134828,4.5094,1.71828562537136,10.3287,0.632065372530562,0.609967495941432,0.614926142574534,0.552240709434191,0.0220978765891297,0.0626854331403432,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
19264,1598:1011,Colon,SNU-175,SIDM00216,1659928,1598,LGK974,PORCN,WNT signaling,Targeted,Early clinical trials,10,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.854798183879213,0.196213702067916,0.558443157213142,9.56930891671963,14.8381,0.885866321044151,0.861844966218322,0.0824893983513486,0.477356196585567,0.189883419997278,0.287472776588289,5.96190120769172,1.2174,3.60740770902792,13.6207,0.7572369223883,0.565764745739489,0.736703511908864,0.55445484086468,0.191472176648811,0.182248671044184,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
19264,1561:1011,Colon,SNU-175,SIDM00216,1659928,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.724464406778671,0.196213702067916,0.558443157213142,9.56930891671963,14.8381,0.885866321044151,0.861844966218322,0.168963430995823,0.404572190610027,0.233495312220078,0.171076878389949,7.19830368728236,2.8684,2.37100522943728,11.9697,0.641778618760455,0.4849710438734,0.624376002186541,0.531480553060225,0.156807574887055,0.0928954491263155,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
19264,1017:1011,Colon,SNU-175,SIDM00216,1659928,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.774585913230974,0.196213702067916,0.558443157213142,9.56930891671963,14.8381,0.885866321044151,0.861844966218322,0.0523630119333945,0.43256220291753,0.103239657948063,0.329322544969467,4.46137462000874,0.4303,5.1079342967109,14.4078,0.686179573286547,0.410974360304266,0.667572970221737,0.41493530862018,0.275205212982281,0.252637661601557,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
19264,1059:1011,Colon,SNU-175,SIDM00216,1659928,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.487624855141519,0.196213702067916,0.558443157213142,9.56930891671963,14.8381,0.885866321044151,0.861844966218322,0.0514694629019718,0.272310763640831,0.0989100246300232,0.173400739010807,5.68218284757849,1.0029,3.88712606914115,13.8352,0.431970436473904,0.31085442833192,0.420257026806657,0.306321113496383,0.121116008141984,0.113935913310274,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
19264,2171:1011,Colon,SNU-175,SIDM00216,1659928,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.05,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.86694681478715,0.196213702067916,0.558443157213142,9.56930891671963,14.8381,0.885866321044151,0.861844966218322,0.116236136650886,0.484140516385613,0.290186422669015,0.193954093716598,7.33482331193507,3.1531,2.23448560478457,11.685,0.767998985356437,0.669475546370332,0.747173748303313,0.6435773717616,0.0985234389861048,0.103596376541713,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
19264,1083:1011,Colon,SNU-175,SIDM00216,1659928,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.916932427465664,0.196213702067916,0.558443157213142,9.56930891671963,14.8381,0.885866321044151,0.861844966218322,0.122948286607857,0.512054639745036,0.239186574772198,0.272868064972838,6.47514857122256,1.7376,3.09416034549707,13.1005,0.812279556165091,0.648280916514709,0.79025359697363,0.628186852347887,0.163998639650382,0.162066744625743,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
19264,1073:1011,Colon,SNU-175,SIDM00216,1659928,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.751091821082637,0.196213702067916,0.558443157213142,9.56930891671963,14.8381,0.885866321044151,0.861844966218322,0.063395049943879,0.419442087922356,0.0891504734496681,0.330291614472688,4.13988163504483,0.3443,5.42942728167481,14.4938,0.665366948308827,0.381376308105292,0.647324705167823,0.383681369409099,0.283990640203535,0.263643335758725,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
19264,1089:1011,Colon,SNU-175,SIDM00216,1659928,1089,Oxaliplatin,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved in colon,1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.957457755914542,0.196213702067916,0.558443157213142,9.56930891671963,14.8381,0.885866321044151,0.861844966218322,0.124681350598155,0.534685732111126,0.316169384774663,0.218516347336463,7.28561787757713,3.0473,2.28369103914251,11.7908,0.848179579787203,0.743363501297,0.825180147301639,0.707771294697316,0.104816078490204,0.117408852604323,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
19264,1053:1011,Colon,SNU-175,SIDM00216,1659928,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.704724865466137,0.196213702067916,0.558443157213142,9.56930891671963,14.8381,0.885866321044151,0.861844966218322,0.122370094924528,0.393548778837516,0.232077501312629,0.161471277524887,7.27573432568263,3.0265,2.293574591037,11.8116,0.624292023918821,0.549953699293206,0.607363577870875,0.520501574899204,0.0743383246256144,0.086862002971671,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
19264,2048:1011,Colon,SNU-175,SIDM00216,1659928,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.545888339983354,0.196213702067916,0.558443157213142,9.56930891671963,14.8381,0.885866321044151,0.861844966218322,0.0538638710968274,0.304847608066145,0.0638511263153818,0.240996481750763,4.0996019687273,0.3348,5.46970694799234,14.5033,0.483584095441952,0.267072796294893,0.47047111793193,0.27715457468668,0.21651129914706,0.19331654324525,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
19537,1011:1017,Colon,SNU-175,SIDM00216,1659928,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.967322302344445,0.0356986406949311,0.807171622115131,12.4707837097771,110.869,0.956206967054328,0.949003648109627,0.0873918056448892,0.780795111891509,0.59682185303751,0.183973258853999,10.1557612836718,22.2802,2.3150224261053,88.5888,0.924960324888791,0.871626321284231,0.917992393822681,0.856421987682323,0.0533340036045599,0.0615704061403585,True,0.190411427660888,0.0327857386121546,1.54004486756684,31.9152539374976
19262,2171:1022,Colon,SNU-175,SIDM00216,1659928,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.559494750545075,0.0931554554098425,0.625434891089168,10.2428319314851,2.3666,0.898234385704044,0.888566427268852,0.054879079570884,0.34992753837212,0.162064339547225,0.187863198824896,6.82544736908993,0.2215,3.41738456239512,2.1451,0.502557423560492,0.375243726098447,0.497148251567514,0.396713501963153,0.127313697462045,0.100434749604362,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
19262,1179:1022,Colon,SNU-175,SIDM00216,1659928,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.561701846417248,0.0931554554098425,0.625434891089168,10.2428319314851,2.3666,0.898234385704044,0.888566427268852,0.0728577043823699,0.351307933138557,0.219288512843719,0.132019420294838,7.91971236713681,0.4729,2.32311956434825,1.8937,0.504539912965424,0.472039554932835,0.499109402861292,0.437019564181659,0.0325003580325894,0.0620898386796327,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
19261,1003:1032,Colon,SNU-175,SIDM00216,1659928,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.0025,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.922132845730102,0.135086713560717,0.289390461771383,6.82224790556652,2.2102,0.713778116048911,0.708841592255518,0.135544851223323,0.266856450040393,0.321234661846639,-0.0543782118062451,7.48184914350289,3.4913,-0.659601237936362,-1.2811,0.658198245372053,0.730398270061883,0.653646114638437,0.693062401041547,-0.0722000246898304,-0.0394162864031096,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
19261,1047:1032,Colon,SNU-175,SIDM00216,1659928,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.631008831910515,0.135086713560717,0.289390461771383,6.82224790556652,2.2102,0.713778116048911,0.708841592255518,0.0735538134504877,0.182607937248405,0.0416152263691723,0.140992710879233,2.57440308412226,0.1163,4.24784482144426,2.0939,0.450400295251311,0.235212527730978,0.447285305138744,0.246641031302776,0.215187767520333,0.200644273835968,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
19266,1011:1047,Colon,SNU-175,SIDM00216,1659928,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.904421567666773,0.075459054033854,0.413792743316443,8.1556386358713,5.5696,0.80805593470705,0.791580635403018,0.132309114152572,0.374243081599392,0.131179231644573,0.243063849954819,4.69943878755754,0.5075,3.45619984831376,5.0621,0.73082321523019,0.521234148763749,0.715922599205858,0.50106370905646,0.209589066466441,0.214858890149398,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
19266,1372:1047,Colon,SNU-175,SIDM00216,1659928,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.893437185345134,0.075459054033854,0.413792743316443,8.1556386358713,5.5696,0.80805593470705,0.791580635403018,0.0989422688749365,0.369697823904884,0.139384871774249,0.230312952130635,4.90744583570573,0.5862,3.24819280016558,4.9834,0.721947219906098,0.481776339805638,0.707227574868185,0.509211334626178,0.24017088010046,0.198016240242007,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
19265,1372:1053,Colon,SNU-175,SIDM00216,1659928,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.885191713442594,0.0772897242385361,0.511787372925544,9.11431998808705,10.8246,0.82027043413436,0.841326241726583,0.152072905467515,0.453029941558246,0.154025973364884,0.299003968193362,5.22429538543341,0.7301,3.89002460265364,10.0945,0.726096591077695,0.472232775435622,0.744735017478171,0.525810419969612,0.253863815642073,0.218924597508559,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
19265,1022:1053,Colon,SNU-175,SIDM00216,1659928,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.929735220514412,0.0772897242385361,0.511787372925544,9.11431998808705,10.8246,0.82027043413436,0.841326241726583,0.156420246628926,0.475826746023423,0.169884351904734,0.305942394118689,5.36856955443869,0.8069,3.74575043364836,10.0177,0.762634312961362,0.50059677579351,0.782210638876226,0.562361333331692,0.262037537167852,0.219849305544534,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
19265,2048:1053,Colon,SNU-175,SIDM00216,1659928,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.501089487489485,0.0772897242385361,0.511787372925544,9.11431998808705,10.8246,0.82027043413436,0.841326241726583,0.0383702932333877,0.256451272402851,0.20248844894755,0.0539628234553007,8.0583870200281,5.2065,1.05593296805895,5.6181,0.411028891443164,0.396739469630323,0.421579735278228,0.393883633439515,0.0142894218128415,0.0276961018387131,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
19265,1047:1053,Colon,SNU-175,SIDM00216,1659928,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.637303042365606,0.0772897242385361,0.511787372925544,9.11431998808705,10.8246,0.82027043413436,0.841326241726583,0.0689823055959954,0.32616364980975,0.234244056073163,0.0919195937365878,7.68435110746234,4.0174,1.42996888062471,6.8072,0.522760843236384,0.470364815542944,0.536179773474372,0.486910847391675,0.05239602769344,0.0492689260826977,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
19266,1083:1054,Colon,SNU-175,SIDM00216,1659928,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.97701295979866,0.114443283123161,0.495099816650789,8.95248279287076,3.8704,0.763588969057678,0.833544097735956,0.175061831647019,0.483718937261761,0.151155257739355,0.332563679522407,4.88346536954868,0.2306,4.06901742332209,3.6398,0.74603631872865,0.498211875379265,0.81438338605171,0.555055359614888,0.247824443349385,0.259328026436821,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
19266,1786:1054,Colon,SNU-175,SIDM00216,1659928,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.481840541116473,0.114443283123161,0.495099816650789,8.95248279287076,3.8704,0.763588969057678,0.833544097735956,0.11086361113807,0.238559163561683,0.161168578961906,0.0773905845997767,7.33224296174588,1.259,1.62023983112488,2.6114,0.367928122041321,0.282766233025457,0.401635339097535,0.35761513599386,0.0851618890158646,0.044020203103675,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
20804,1549:1059,Colon,SNU-175,SIDM00216,1659928,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.73684563947286,0.0592019655008602,0.794247778842453,12.2743939136487,9.6759,0.934136133973116,0.945169485120052,0.0833148430176048,0.585238012501066,0.328289336677005,0.256948675824061,8.46974869217031,0.6924,3.80464522147837,8.9835,0.688314136992126,0.538592465147106,0.696444013673518,0.595987773482045,0.14972167184502,0.100456240191473,True,0.419879314926118,0.041398689687404,0.811497878919208,59.7311866628631
20804,1372:1059,Colon,SNU-175,SIDM00216,1659928,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.593539220003359,0.0592019655008602,0.794247778842453,12.2743939136487,9.6759,0.934136133973116,0.945169485120052,0.0529117248787229,0.47141720714355,0.382567995027144,0.0888492121164063,10.4428341209592,2.7185,1.83155979268943,6.9574,0.554446432335357,0.499171193419374,0.560995158969132,0.531622281730909,0.0552752389159828,0.0293728772382229,True,0.419879314926118,0.041398689687404,0.811497878919208,59.7311866628631
20804,1564:1059,Colon,SNU-175,SIDM00216,1659928,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.5,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.690409954467662,0.0592019655008602,0.794247778842453,12.2743939136487,9.6759,0.934136133973116,0.945169485120052,0.0562743523743966,0.54835657282666,0.353712855973657,0.194643716853002,9.1195162270223,1.0864,3.15487768662638,8.5895,0.644936885722977,0.542765922018494,0.652554421185958,0.581029622886757,0.102170963704483,0.0715247982992017,True,0.419879314926118,0.041398689687404,0.811497878919208,59.7311866628631
20804,1054:1059,Colon,SNU-175,SIDM00216,1659928,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,1,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.9145730900705,0.0592019655008602,0.794247778842453,12.2743939136487,9.6759,0.934136133973116,0.945169485120052,0.0980481997675151,0.726397645377573,0.630882007945228,0.0955156374323447,10.9374837030808,3.8304,1.33691021056791,5.8455,0.854335770594304,0.767490873104143,0.864426576646589,0.833849483048367,0.0868448974901606,0.0305770935982221,True,0.419879314926118,0.041398689687404,0.811497878919208,59.7311866628631
20804,1053:1059,Colon,SNU-175,SIDM00216,1659928,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.957059092167802,0.0592019655008602,0.794247778842453,12.2743939136487,9.6759,0.934136133973116,0.945169485120052,0.0940704618564589,0.760142058175251,0.362125824549856,0.398016233625395,7.79649814010015,0.4342,4.47789577354853,9.2417,0.894023480341451,0.677553819405038,0.904583049373706,0.737656358886621,0.216469660936413,0.166926690487085,True,0.419879314926118,0.041398689687404,0.811497878919208,59.7311866628631
20804,1510:1059,Colon,SNU-175,SIDM00216,1659928,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.707777794927434,0.0592019655008602,0.794247778842453,12.2743939136487,9.6759,0.934136133973116,0.945169485120052,0.0859392287186937,0.562150941535124,0.371982856019326,0.190168085515798,9.24810767451827,1.1876,3.02628623913041,8.4883,0.661160813065531,0.572896744642119,0.668969974010969,0.599889827162743,0.0882640684234113,0.0690801468482255,True,0.419879314926118,0.041398689687404,0.811497878919208,59.7311866628631
20804,1561:1059,Colon,SNU-175,SIDM00216,1659928,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.909457343508124,0.0592019655008602,0.794247778842453,12.2743939136487,9.6759,0.934136133973116,0.945169485120052,0.0653219607439744,0.722334475033285,0.486456255839945,0.23587821919334,9.33883290406333,1.2647,2.93556100958535,8.4112,0.849556966878139,0.722975172845839,0.859591329102223,0.774586607943437,0.1265817940323,0.0850047211587861,True,0.419879314926118,0.041398689687404,0.811497878919208,59.7311866628631
19538,1011:1073,Colon,SNU-175,SIDM00216,1659928,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,20.0,0.825471563242593,0.073707436141849,0.472621664419371,8.73425425084442,16.6354,0.824978467487051,0.82265032542739,0.142217276274792,0.390135744150574,0.136547931650556,0.253587812500018,5.07657608446569,1.3181,3.65767816637872,15.3173,0.680996265198015,0.508504683645409,0.679074450132575,0.481105340110401,0.172491581552606,0.197969110022174,True,0.190411427660888,0.0327857386121546,1.54004486756684,31.9152539374976
19262,1003:1372,Colon,SNU-175,SIDM00216,1659928,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.0025,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.860732030772342,0.164339468394738,0.505690147275669,9.05517812370005,1.039,0.722722733691395,0.838511715998699,0.161953461783706,0.435263707406151,0.279314001545195,0.155949705860956,7.22275343777567,0.2917,1.83242468592439,0.7473,0.622070606255533,0.530395130660199,0.721733892137961,0.632804060881448,0.0916754755953343,0.0889298312565135,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
19262,1179:1372,Colon,SNU-175,SIDM00216,1659928,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.25,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.882517319283672,0.164339468394738,0.505690147275669,9.05517812370005,1.039,0.722722733691395,0.838511715998699,0.134226397175166,0.446280313161889,0.229562965085532,0.216717348076356,6.46593329378183,0.1727,2.58924482991822,0.8663,0.637815329522697,0.527207168510791,0.740001111791124,0.604043454624898,0.110608161011907,0.135957657166226,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
19262,1047:1372,Colon,SNU-175,SIDM00216,1659928,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.646005864811283,0.164339468394738,0.505690147275669,9.05517812370005,1.039,0.722722733691395,0.838511715998699,0.146936619007828,0.326678800917364,0.163637976190602,0.163040824726762,6.37933998161609,0.1626,2.67583814208396,0.8764,0.466883124597084,0.361851076172679,0.541683486248133,0.438254109410544,0.105032048424406,0.103429376837589,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
19264,1022:1510,Colon,SNU-175,SIDM00216,1659928,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.938972320000109,0.082412645099935,0.658445857132139,10.5911731062432,30.1294,0.865783151974586,0.900723960507353,0.0563391287631555,0.618262434065825,0.515137435310144,0.10312499875568,9.47293252653377,13.8793,1.11824057970938,16.2501,0.812946414826584,0.796658474764872,0.845754866877276,0.805324740279823,0.0162879400617121,0.0404301265974527,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
19264,1179:1510,Colon,SNU-175,SIDM00216,1659928,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.25,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.931248138333147,0.082412645099935,0.658445857132139,10.5911731062432,30.1294,0.865783151974586,0.900723960507353,0.0871317037925947,0.613176478647478,0.383015419651086,0.230161058996392,8.13062974269984,5.4739,2.46054336354331,24.6555,0.806258948476537,0.677544169368891,0.838797511374532,0.735842227683761,0.128714779107646,0.102955283690771,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
19264,1032:1510,Colon,SNU-175,SIDM00216,1659928,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,1,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.713499720573597,0.082412645099935,0.658445857132139,10.5911731062432,30.1294,0.865783151974586,0.900723960507353,0.0766676025647651,0.469800935076624,0.309642731653138,0.160158203423486,8.35603704111794,6.3995,2.23513606512521,23.7299,0.617736037011195,0.523414421808241,0.64266629413594,0.572722950368702,0.0943216152029546,0.0699433437672387,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
19264,1549:1510,Colon,SNU-175,SIDM00216,1659928,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.762363238948547,0.082412645099935,0.658445857132139,10.5911731062432,30.1294,0.865783151974586,0.900723960507353,0.0723114219303484,0.50197491631551,0.271161390866168,0.230813525449342,7.55969598312051,3.6849,3.03147712312264,26.4445,0.660041247966427,0.526777792709496,0.686678835930949,0.576655909153074,0.133263455256931,0.110022926777875,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
19264,1011:1510,Colon,SNU-175,SIDM00216,1659928,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.944646991959935,0.082412645099935,0.658445857132139,10.5911731062432,30.1294,0.865783151974586,0.900723960507353,0.0662245833091382,0.621998898308356,0.410646538433067,0.211352359875289,8.36325582321283,6.4316,2.22791728303032,23.6978,0.817859450202383,0.709188005265263,0.85086617987951,0.75863547967661,0.10867144493712,0.0922307002029003,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
19264,1047:1510,Colon,SNU-175,SIDM00216,1659928,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.614805896690176,0.082412645099935,0.658445857132139,10.5911731062432,30.1294,0.865783151974586,0.900723960507353,0.11816553207857,0.404816395616056,0.184563557713906,0.22025283790215,6.94828463757261,2.412,3.64288846867054,27.7174,0.532288587088983,0.37673941840968,0.55377040221005,0.440976145465205,0.155549168679303,0.112794256744846,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
19264,1003:1510,Colon,SNU-175,SIDM00216,1659928,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.0025,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.922129529877606,0.082412645099935,0.658445857132139,10.5911731062432,30.1294,0.865783151974586,0.900723960507353,0.0868938104998127,0.607172368687116,0.604239366093195,0.0029330025939216,10.5569640843297,29.4234,0.0342090219134867,0.706,0.798364210906277,0.812448428726416,0.830584162252141,0.829528122072394,-0.0140842178201394,0.0010560401797471,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
19264,1372:1510,Colon,SNU-175,SIDM00216,1659928,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.824404570701692,0.082412645099935,0.658445857132139,10.5911731062432,30.1294,0.865783151974586,0.900723960507353,0.146557973276357,0.542825774179328,0.209032538711554,0.333793235467774,6.3825240540858,1.6295,4.20864905215735,28.4999,0.713755587724366,0.482067770463398,0.742560949982792,0.559464863813152,0.231687817260968,0.18309608616964,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
19539,1003:1549,Colon,SNU-175,SIDM00216,1659928,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.0025,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.976055984012138,0.16380708852286,0.375627513917348,7.76815557458231,2.1289,0.662712231529867,0.769061186513349,0.113823245250496,0.36663348271863,0.332660642872135,0.0339728398464952,7.40092308045182,1.6504,0.367232494130485,0.4785,0.646844239262764,0.659018660676649,0.750646773167829,0.728648856328386,-0.0121744214138848,0.0219979168394429,True,0.190411427660888,0.0327857386121546,1.54004486756684,31.9152539374976
19539,1053:1549,Colon,SNU-175,SIDM00216,1659928,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.688898052623861,0.16380708852286,0.375627513917348,7.76815557458231,2.1289,0.662712231529867,0.769061186513349,0.102224889673123,0.258769062849604,0.12094600375103,0.137823059098574,5.25053983816849,0.3718,2.51761573641382,1.7571,0.456541165750939,0.368060377609161,0.529804753737642,0.410574327735943,0.0884807881417787,0.1192304260017,True,0.190411427660888,0.0327857386121546,1.54004486756684,31.9152539374976
19539,1047:1549,Colon,SNU-175,SIDM00216,1659928,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.596760845033775,0.16380708852286,0.375627513917348,7.76815557458231,2.1289,0.662712231529867,0.769061186513349,0.10487752440917,0.224159792623253,0.132628853770012,0.0915309388532407,5.96343869810754,0.6094,1.80471687647477,1.5195,0.395480711301982,0.334054834438533,0.458945603546384,0.387148391984879,0.0614258768634491,0.0717972115615042,True,0.190411427660888,0.0327857386121546,1.54004486756684,31.9152539374976
19540,1047:1561,Colon,SNU-175,SIDM00216,1659928,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.358108786205924,0.128709945514777,0.325319749698595,7.23173032679779,2.9356,0.658644066961447,0.735769732933014,0.0472871633982568,0.116499860693379,0.0425724160544496,0.0739274446389293,4.14420607507717,0.3454,3.08752425172062,2.5902,0.235866227361297,0.151612019983148,0.263485605987698,0.18305313916555,0.0842542073781488,0.0804324668221482,True,0.190411427660888,0.0327857386121546,1.54004486756684,31.9152539374976
19540,1047:1564,Colon,SNU-175,SIDM00216,1659928,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.65262627602023,0.126092023866061,0.272387933049444,6.61814535628235,0.9593,0.633197061363185,0.694974746911815,0.0741307625165526,0.177767522378906,0.0690557433632254,0.108711779015681,3.82619294485405,0.1385,2.7919524114283,0.8208,0.413241040144408,0.298146942431109,0.45355878100516,0.31753031678889,0.115094097713299,0.13602846421627,True,0.190411427660888,0.0327857386121546,1.54004486756684,31.9152539374976
18429,1022:1003,Colon,SW1417,SIDM00812,909747,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.1,0.944662225445795,0.0744340979607018,0.75730268723167,13.3483048595165,2.0369,0.92900940125907,0.902613378060035,0.128519516303524,0.71539524185635,0.419086110974091,0.296309130882259,8.1348135896086,0.0549,5.2134912699079,1.982,0.877600088453459,0.696445423707589,0.85266476243534,0.682911154668858,0.181154664745871,0.169753607766482,True,0.648520762392188,0.0715490348241926,0.390111103998348,119.34394816505
18430,1011:1022,Colon,SW1417,SIDM00812,909747,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.127662233113269,0.0798576464729548,0.703458657096934,12.3008217094902,9.8548,0.896095869998351,0.877176507654651,0.0358926143681508,0.0898051030678558,0.0639775877583389,0.0258275153095169,9.01753671061012,1.0122,3.2832849988801,8.8426,0.114397599847567,0.0679273146854669,0.111982311801691,0.0973838188039453,0.0464702851621001,0.0145984929977459,True,0.648520762392188,0.0715490348241926,0.390111103998348,119.34394816505
18430,1179:1022,Colon,SW1417,SIDM00812,909747,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.661724932709225,0.0798576464729548,0.703458657096934,12.3008217094902,9.8548,0.896095869998351,0.877176507654651,0.0614351025779586,0.46549613253119,0.327747059393468,0.137749073137722,8.92803726040257,0.9513,3.37278444908765,8.9035,0.592968979275673,0.473382361348936,0.580449565501887,0.502213659867805,0.119586617926738,0.0782359056340823,True,0.648520762392188,0.0715490348241926,0.390111103998348,119.34394816505
18430,1003:1022,Colon,SW1417,SIDM00812,909747,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.025,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.888424378427608,0.0798576464729548,0.703458657096934,12.3008217094902,9.8548,0.896095869998351,0.877176507654651,0.0723372951947135,0.624969820180863,0.39519505341684,0.229774766764023,8.15324631001416,0.556,4.14757539947606,9.2988,0.796113416314832,0.654267213341593,0.779304993584383,0.643028980286749,0.141846202973239,0.136276013297634,True,0.648520762392188,0.0715490348241926,0.390111103998348,119.34394816505
18429,1053:1032,Colon,SW1417,SIDM00812,909747,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.847529516824152,0.0772744107452297,0.781003761819114,13.858728355112,290.1503,0.921565265582842,0.913294947769374,0.0362382141536828,0.661923740892399,0.62784939435855,0.0340743465338486,13.0127281456864,161.4178,0.846000209425664,128.7325,0.781053764261348,0.773352890928884,0.774044425800917,0.758534978080866,0.0077008733324633,0.0155094477200511,True,0.648520762392188,0.0715490348241926,0.390111103998348,119.34394816505
18429,1372:1032,Colon,SW1417,SIDM00812,909747,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.749387223408249,0.0772744107452297,0.781003761819114,13.858728355112,290.1503,0.921565265582842,0.913294947769374,0.102881051097762,0.585274240541024,0.425172187258321,0.160102053282703,10.0358733484699,20.5035,3.82285500664211,269.6468,0.690609235564612,0.530707486924966,0.684411565061673,0.602609517726415,0.159901748639646,0.0818020473352585,True,0.648520762392188,0.0715490348241926,0.390111103998348,119.34394816505
18429,1564:1032,Colon,SW1417,SIDM00812,909747,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.881797267759904,0.0772744107452297,0.781003761819114,13.858728355112,290.1503,0.921565265582842,0.913294947769374,0.0888798462664321,0.688686983282302,0.512240706392019,0.176446276890283,10.2475804927733,23.7443,3.61114786233869,266.406,0.812633733253381,0.655276738509726,0.805340989601958,0.716076027734361,0.157356994743654,0.0892649618675974,True,0.648520762392188,0.0715490348241926,0.390111103998348,119.34394816505
18429,1373:1032,Colon,SW1417,SIDM00812,909747,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.791983037104298,0.0772744107452297,0.781003761819114,13.858728355112,290.1503,0.921565265582842,0.913294947769374,0.07373939074605,0.618541731275384,0.399878227780984,0.218663503494399,9.07501319850531,10.5337,4.78371515660672,279.6166,0.729864057926128,0.563487558189968,0.7233141065064,0.606099625402805,0.16637649973616,0.117214481103595,True,0.648520762392188,0.0715490348241926,0.390111103998348,119.34394816505
18434,1561:1054,Colon,SW1417,SIDM00812,909747,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.863151645411799,0.0596648316713478,0.81728359457219,14.7243231589595,211.472,0.921625674162389,0.929088166475339,0.073386253667262,0.705439679423056,0.622587769772626,0.0828519096504298,12.6335567585145,49.6443,2.09076640044493,161.8277,0.795502717107025,0.702903923765078,0.801943979625821,0.764572900450382,0.0925987933419472,0.0373710791754389,True,0.648520762392188,0.0715490348241926,0.390111103998348,119.34394816505
18430,1025:1372,Colon,SW1417,SIDM00812,909747,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,2.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,1.0,0.112124303315582,0.360051872725918,6.80228992290279,0.218,0.60874881572453,0.656293512977079,0.0934681040780607,0.360051872725918,0.281396182254503,0.0786556904714152,5.41746500162358,0.0835,1.38482492127921,0.1345,0.60874881572453,0.533039022716416,0.656293512977079,0.580815329538945,0.0757097930081142,0.0754781834381344,True,0.648520762392188,0.0715490348241926,0.390111103998348,119.34394816505
18430,1032:1372,Colon,SW1417,SIDM00812,909747,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.904409687282629,0.112124303315582,0.360051872725918,6.80228992290279,0.218,0.60874881572453,0.656293512977079,0.117050378315575,0.325634401617573,0.231687397492887,0.0939470041246855,4.92683705213441,0.0594,1.87545287076837,0.1586,0.550558326063093,0.447074946237498,0.593558210837218,0.500205960910627,0.103483379825596,0.0933522499265911,True,0.648520762392188,0.0715490348241926,0.390111103998348,119.34394816505
20660,1549:1373,Colon,SW1417,SIDM00812,909747,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10.0,0.896044063997106,0.174843712390631,0.454887583960524,8.30858898970291,6.1925,0.632618555668175,0.731058362986133,0.199826724043798,0.407599319393813,0.210015850488615,0.197583468905197,4.4767318212168,0.4349,3.83185716848611,5.7576,0.566854101580891,0.392649287144762,0.655060506589166,0.472542768520207,0.174204814436129,0.182517738068959,True,0.426577842368687,0.0480263881547785,0.701232238719629,64.9549614983255
20660,1032:1373,Colon,SW1417,SIDM00812,909747,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10.0,0.901938194041607,0.174843712390631,0.454887583960524,8.30858898970291,6.1925,0.632618555668175,0.731058362986133,0.164080926796273,0.410280485969305,0.258997848876144,0.151282637093161,5.5256595234733,0.8997,2.78292946622962,5.2928,0.570582837616564,0.448196878839073,0.659369459650726,0.529328410651693,0.12238595877749,0.130041048999033,True,0.426577842368687,0.0480263881547785,0.701232238719629,64.9549614983255
20660,1011:1373,Colon,SW1417,SIDM00812,909747,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10.0,0.109320838005501,0.174843712390631,0.454887583960524,8.30858898970291,6.1925,0.632618555668175,0.731058362986133,0.0789021388967495,0.049728691876862,0.0664598489886548,-0.0167311571117927,10.6761071267224,31.9564,-2.3675181370195,-25.7639,0.0691583906434744,0.0095703166996013,0.0799199128725736,0.0904529676154397,0.0595880739438731,-0.0105330547428662,True,0.426577842368687,0.0480263881547785,0.701232238719629,64.9549614983255
18432,1011:1510,Colon,SW1417,SIDM00812,909747,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.923663754900941,0.0729545058679176,0.742035699852052,13.0373683830906,164.1984,0.869934890040923,0.895571309624651,0.0511043295170543,0.685391480795894,0.607399557198582,0.0779919235973117,11.4937364889867,56.3235,1.54363189410387,107.8749,0.803527327054536,0.790075777776977,0.827206758629458,0.78889220073417,0.0134515492775598,0.0383145578952884,True,0.648520762392188,0.0715490348241926,0.390111103998348,119.34394816505
20662,1786:1549,Colon,SW1417,SIDM00812,909747,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.723831503494219,0.0540360328146828,0.735902526268779,12.9158673246862,75.4681,0.878496649407329,0.892705365418246,0.070794725538218,0.532669432014324,0.297659019866542,0.235010412147782,7.62859524532919,1.9326,5.28727207935701,73.5355,0.63588355055514,0.468986141497948,0.646168266828045,0.505554950144372,0.166897409057192,0.140613316683672,True,0.426577842368687,0.0480263881547785,0.701232238719629,64.9549614983255
20662,1372:1549,Colon,SW1417,SIDM00812,909747,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.545185332961694,0.0540360328146828,0.735902526268779,12.9158673246862,75.4681,0.878496649407329,0.892705365418246,0.0513125167463875,0.401203263811196,0.287384044083718,0.113819219727478,9.41509624866977,6.6669,3.50077107601643,68.8012,0.478943488312867,0.386979438102973,0.486689871882237,0.425011482851145,0.0919640502098939,0.0616783890310924,True,0.426577842368687,0.0480263881547785,0.701232238719629,64.9549614983255
20662,2171:1549,Colon,SW1417,SIDM00812,909747,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.05,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.809194749785902,0.0540360328146828,0.735902526268779,12.9158673246862,75.4681,0.878496649407329,0.892705365418246,0.0439975265157401,0.595488460610878,0.55136711692124,0.0441213436896373,11.9045160821875,37.4383,1.01135124249873,38.0298,0.710874876404917,0.695372050100586,0.72237249480215,0.700952639433386,0.0155028263043314,0.0214198553687642,True,0.426577842368687,0.0480263881547785,0.701232238719629,64.9549614983255
20662,1564:1549,Colon,SW1417,SIDM00812,909747,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.749031394780279,0.0540360328146828,0.735902526268779,12.9158673246862,75.4681,0.878496649407329,0.892705365418246,0.0520883354582689,0.551214095673434,0.504169115079497,0.0470449805939369,11.7597171765687,33.8632,1.15615014811752,41.6049,0.658021570615373,0.642132115846635,0.668664344987067,0.645701244730613,0.0158894547687383,0.0229631002564539,True,0.426577842368687,0.0480263881547785,0.701232238719629,64.9549614983255
20662,1373:1549,Colon,SW1417,SIDM00812,909747,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.689029254592959,0.0540360328146828,0.735902526268779,12.9158673246862,75.4681,0.878496649407329,0.892705365418246,0.0785616032500904,0.507058369128052,0.416398045607348,0.0906603235207039,10.6183527268881,15.3512,2.29751459779808,60.1169,0.605309891503544,0.526289192969453,0.615100112505269,0.568721409110427,0.0790206985340905,0.0463787033948421,True,0.426577842368687,0.0480263881547785,0.701232238719629,64.9549614983255
20662,1011:1549,Colon,SW1417,SIDM00812,909747,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.957716906248747,0.0540360328146828,0.735902526268779,12.9158673246862,75.4681,0.878496649407329,0.892705365418246,0.056247635601708,0.704786290758772,0.746925854295837,-0.0421395635370646,13.8341701634289,142.6265,-0.918302838742651,-67.1584,0.841351093220277,0.862849056502524,0.85495902076002,0.87420898395446,-0.0214979632822462,-0.0192499631944399,True,0.426577842368687,0.0480263881547785,0.701232238719629,64.9549614983255
21006,1011:2048,Colon,SW1417,SIDM00812,909747,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.779347310509503,0.0865652145052265,0.718657075386522,12.5835414589958,1.1988,0.872848723218031,0.884529675316182,0.0450868877963694,0.560083458881111,0.482684055703294,0.077399403177817,10.8600156310791,0.363,1.72352582791665,0.8358,0.680252304921626,0.687940119712175,0.68935582352351,0.649745913483353,-0.0076878147905488,0.0396099100401576,True,0.57409154378327,0.0519928564661112,0.509203079528235,93.1560991401707
21006,1053:2048,Colon,SW1417,SIDM00812,909747,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.833356700332355,0.0865652145052265,0.718657075386522,12.5835414589958,1.1988,0.872848723218031,0.884529675316182,0.0637076771787544,0.598897689014612,0.367123758212493,0.231773930802119,8.08678986806674,0.0531,4.49675159092904,1.1457,0.727394331870287,0.595892412313252,0.737128731567543,0.600551512368369,0.131501919557035,0.136577219199174,True,0.57409154378327,0.0519928564661112,0.509203079528235,93.1560991401707
21006,1047:2048,Colon,SW1417,SIDM00812,909747,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.938674276402827,0.0865652145052265,0.718657075386522,12.5835414589958,1.1988,0.872848723218031,0.884529675316182,0.168703281793737,0.674584910220215,0.440612538511732,0.233972371708483,8.53168316713043,0.0723,4.05185829186535,1.1265,0.819320643675816,0.616013967764835,0.830285252934244,0.695848667525377,0.203306675910982,0.134436585408868,True,0.57409154378327,0.0519928564661112,0.509203079528235,93.1560991401707
21006,1510:2048,Colon,SW1417,SIDM00812,909747,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.768957423122842,0.0865652145052265,0.718657075386522,12.5835414589958,1.1988,0.872848723218031,0.884529675316182,0.0733367346540454,0.552616692798218,0.480786118216538,0.0718305745816796,10.9559378174892,0.388,1.62760364150657,0.8108,0.6711835049818,0.62782972879223,0.680165659806816,0.643556708332347,0.0433537761895699,0.0366089514744682,True,0.57409154378327,0.0519928564661112,0.509203079528235,93.1560991401707
19447,1549:1011,Colon,SW1463,SIDM00834,909748,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.598639341111062,0.104350235456805,0.71566283561876,11.520464463433,57.3767,0.879104858862322,0.911420630805948,0.0757060222353606,0.428423928372489,0.162227491564012,0.266196436808477,6.29784671354245,1.5366,5.22261774989056,55.8401,0.526266753476874,0.391802274172322,0.545612245900701,0.396129024227091,0.134464479304551,0.14948322167361,True,0.32415918469777,0.04283158651987,1.05797121998219,46.1794138522287
19447,1032:1011,Colon,SW1463,SIDM00834,909748,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.572916056721229,0.104350235456805,0.71566283561876,11.520464463433,57.3767,0.879104858862322,0.911420630805948,0.069725656702795,0.410014729724633,0.25046936556481,0.159545364159823,8.31025031655344,6.1996,3.21021414687957,51.1771,0.503653289183874,0.438189267917609,0.522167513815719,0.44856473828423,0.065464021266265,0.0736027755314894,True,0.32415918469777,0.04283158651987,1.05797121998219,46.1794138522287
19447,1372:1011,Colon,SW1463,SIDM00834,909748,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.321392597850035,0.104350235456805,0.71566283561876,11.520464463433,57.3767,0.879104858862322,0.911420630805948,0.0509475047485316,0.230008737924236,0.142195097208035,0.087813640716201,8.36844647937665,6.4548,3.15201798405636,50.9219,0.28253779437235,0.227468659894424,0.292923844268841,0.252622938401966,0.055069134477926,0.0403009058668757,True,0.32415918469777,0.04283158651987,1.05797121998219,46.1794138522287
19447,1564:1011,Colon,SW1463,SIDM00834,909748,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.818444454302149,0.104350235456805,0.71566283561876,11.520464463433,57.3767,0.879104858862322,0.911420630805948,0.0725483281952968,0.585730278962324,0.232717983987183,0.353012294975141,6.47959798095476,1.7429,5.04086648247825,55.6338,0.719498496485941,0.515885345044286,0.745947160819694,0.551391213397536,0.203613151441655,0.194555947422158,True,0.32415918469777,0.04283158651987,1.05797121998219,46.1794138522287
19447,1047:1011,Colon,SW1463,SIDM00834,909748,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.97876059087078,0.104350235456805,0.71566283561876,11.520464463433,57.3767,0.879104858862322,0.911420630805948,0.06672521833613,0.700462579854476,0.332060438676242,0.368402141178233,7.17988391986332,2.832,4.34058054356969,54.5447,0.860433191097461,0.693013943722368,0.892062595139449,0.702902124703376,0.167419247375093,0.189160470436074,True,0.32415918469777,0.04283158651987,1.05797121998219,46.1794138522287
19447,1510:1011,Colon,SW1463,SIDM00834,909748,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.63509825666504,0.104350235456805,0.71566283561876,11.520464463433,57.3767,0.879104858862322,0.911420630805948,0.0829372579401162,0.454516219261434,0.35190656747011,0.102609651791323,9.59319744226968,15.0859,1.92726702116332,42.2908,0.558317963289227,0.47818622188706,0.578841653713409,0.536255845753643,0.0801317414021669,0.0425858079597665,True,0.32415918469777,0.04283158651987,1.05797121998219,46.1794138522287
19447,1561:1011,Colon,SW1463,SIDM00834,909748,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.956527525174112,0.104350235456805,0.71566283561876,11.520464463433,57.3767,0.879104858862322,0.911420630805948,0.06145139423249,0.6845512010135,0.472865873849212,0.211685327164288,8.93836023371374,9.5817,2.58210422971927,47.795,0.840887995016114,0.76165801653137,0.871798920377442,0.779291749846661,0.0792299784847443,0.0925071705307808,True,0.32415918469777,0.04283158651987,1.05797121998219,46.1794138522287
19445,1003:1022,Colon,SW1463,SIDM00834,909748,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.025,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.843176757837142,0.0921870870283224,0.769056561554531,12.2848740499991,9.7464,0.943892241077381,0.930394566805679,0.0440475781516602,0.64845061816493,0.401060209019924,0.247390409145006,8.7338715676697,0.8315,3.55100248232938,8.9149,0.79586799957926,0.70727451125542,0.784487074348505,0.678521940043282,0.0885934883238403,0.105965134305223,True,0.32415918469777,0.04283158651987,1.05797121998219,46.1794138522287
19445,1025:1022,Colon,SW1463,SIDM00834,909748,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.884870662634966,0.0921870870283224,0.769056561554531,12.2848740499991,9.7464,0.943892241077381,0.930394566805679,0.16137404723866,0.680515589226526,0.355310178876595,0.325205410349931,7.91034204244342,0.4699,4.37453200755566,9.2765,0.835222552818145,0.578720532219663,0.823278856841314,0.673476568239877,0.256502020598482,0.149802288601436,True,0.32415918469777,0.04283158651987,1.05797121998219,46.1794138522287
19445,1032:1022,Colon,SW1463,SIDM00834,909748,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.511508031448773,0.0921870870283224,0.769056561554531,12.2848740499991,9.7464,0.943892241077381,0.930394566805679,0.0909982995172827,0.39337860787352,0.241164232721375,0.152214375152145,8.68812236733194,0.8056,3.59675168266714,8.9408,0.482808462133261,0.374868833438754,0.475904293337407,0.410454215576393,0.107939628694508,0.0654500777610136,True,0.32415918469777,0.04283158651987,1.05797121998219,46.1794138522287
19445,1179:1022,Colon,SW1463,SIDM00834,909748,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.25,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.890643090732216,0.0921870870283224,0.769056561554531,12.2848740499991,9.7464,0.943892241077381,0.930394566805679,0.0648940858734275,0.684954912930818,0.293368358600632,0.391586554330186,7.0586938066186,0.2604,5.22618024338048,9.486,0.840671102911316,0.664408434070879,0.828649492580271,0.632959904616457,0.176262668840437,0.195689587963814,True,0.32415918469777,0.04283158651987,1.05797121998219,46.1794138522287
19445,1372:1022,Colon,SW1463,SIDM00834,909748,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.27425121010177,0.0921870870283224,0.769056561554531,12.2848740499991,9.7464,0.943892241077381,0.930394566805679,0.0492877983222805,0.210914692643037,0.125934160817356,0.0849805318256808,8.55329508476326,0.7337,3.73157896523582,9.0127,0.258863589321143,0.199558186815275,0.25516183581857,0.218198936469118,0.0593054025058683,0.0369628993494512,True,0.32415918469777,0.04283158651987,1.05797121998219,46.1794138522287
19445,1053:1022,Colon,SW1463,SIDM00834,909748,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.987896186675599,0.0921870870283224,0.769056561554531,12.2848740499991,9.7464,0.943892241077381,0.930394566805679,0.0570032564535949,0.759748044497569,0.557782673743643,0.201965370753926,9.70973499402935,1.6355,2.57513905596973,8.1109,0.93246754559303,0.87036925157814,0.919133244651026,0.838991367590849,0.0620982940148898,0.0801418770601768,True,0.32415918469777,0.04283158651987,1.05797121998219,46.1794138522287
19445,1373:1022,Colon,SW1463,SIDM00834,909748,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.934857956684173,0.0921870870283224,0.769056561554531,12.2848740499991,9.7464,0.943892241077381,0.930394566805679,0.0395658270252581,0.718958645709425,0.505056699538435,0.21390194617099,9.44057425471032,1.3571,2.84429979528876,8.3893,0.882405171823645,0.798385532785594,0.869786763634014,0.783198975541483,0.0840196390380517,0.0865877880925309,True,0.32415918469777,0.04283158651987,1.05797121998219,46.1794138522287
19445,1011:1022,Colon,SW1463,SIDM00834,909748,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.96940436366431,0.0921870870283224,0.769056561554531,12.2848740499991,9.7464,0.943892241077381,0.930394566805679,0.0860279721114269,0.745526786675633,0.530017499671912,0.21550928700372,9.51206641390048,1.4261,2.7728076360986,8.3203,0.915013257329298,0.809472032406614,0.901928552990991,0.815158494484015,0.105541224922684,0.0867700585069759,True,0.32415918469777,0.04283158651987,1.05797121998219,46.1794138522287
20668,1372:1025,Colon,SW1463,SIDM00834,909748,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.408273771008423,0.0525606475626456,0.896913705504967,14.9073343897504,600.1846,0.953097442906878,0.971097014580492,0.0557223682692994,0.366186340815651,0.191625022109188,0.174561318706463,8.664856101321,7.9271,6.2424782884294,592.2575,0.389124687154076,0.32432854161966,0.396473440157799,0.327138606988359,0.0647961455344158,0.0693348331694397,True,0.269741196153515,0.0416730931630788,1.10230436882875,42.9193037775805
20668,1564:1025,Colon,SW1463,SIDM00834,909748,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.5,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.88428207275026,0.0525606475626456,0.896913705504967,14.9073343897504,600.1846,0.953097442906878,0.971097014580492,0.0627237157089655,0.793124710582049,0.499078377681433,0.294046332900616,9.70719725406831,16.3263,5.20013713568209,583.8583,0.842806982346666,0.723041622457219,0.858723680894827,0.750901557648465,0.119765359889447,0.107822123246362,True,0.269741196153515,0.0416730931630788,1.10230436882875,42.9193037775805
19448,1194:1053,Colon,SW1463,SIDM00834,909748,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,0.625,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.980393775285872,0.0389265931115184,0.831579657950369,13.360377392921,205.4019,0.957209336194614,0.9510565212196,0.0605909502635849,0.815275520308896,0.75828030901576,0.056995211293136,12.3527921267514,102.1624,1.00758526616951,103.2395,0.938442074850721,0.952360161673306,0.932409893348732,0.913625847043519,-0.013918086822585,0.0187840463052129,True,0.32415918469777,0.04283158651987,1.05797121998219,46.1794138522287
19448,1510:1053,Colon,SW1463,SIDM00834,909748,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.621868966800694,0.0389265931115184,0.831579657950369,13.360377392921,205.4019,0.957209336194614,0.9510565212196,0.101982012145597,0.517133582702071,0.346056444322212,0.171077138379859,9.61951712544633,15.3636,3.74086026747463,190.0383,0.595258780911323,0.461558068265232,0.591432536219895,0.525780372978712,0.13370071264609,0.0656521632411831,True,0.32415918469777,0.04283158651987,1.05797121998219,46.1794138522287
19448,1786:1053,Colon,SW1463,SIDM00834,909748,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.919912575873928,0.0389265931115184,0.831579657950369,13.360377392921,205.4019,0.957209336194614,0.9510565212196,0.0917394669580309,0.764980585189484,0.442871368354239,0.322109216835245,8.79705314610483,8.6877,4.56332424681612,196.7142,0.88054890610936,0.774066074638912,0.87488885423682,0.743145466574928,0.106482831470447,0.131743387661892,True,0.32415918469777,0.04283158651987,1.05797121998219,46.1794138522287
19448,1372:1053,Colon,SW1463,SIDM00834,909748,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.886519493462864,0.0389265931115184,0.831579657950369,13.360377392921,205.4019,0.957209336194614,0.9510565212196,0.0665815839061837,0.737211577140183,0.527556695156843,0.20965488198334,10.0513787966322,20.7251,3.30899859628878,184.6768,0.848584735861173,0.792558548528642,0.843130145446154,0.765065404088598,0.0560261873325315,0.0780647413575558,True,0.32415918469777,0.04283158651987,1.05797121998219,46.1794138522287
19448,1564:1053,Colon,SW1463,SIDM00834,909748,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.977857724464131,0.0389265931115184,0.831579657950369,13.360377392921,205.4019,0.957209336194614,0.9510565212196,0.0598059564990302,0.813166592034008,0.65655682027972,0.156609771754289,10.9513628942948,38.674,2.40901449862613,166.7279,0.936014543327086,0.903095478489979,0.929997965676571,0.874826021669392,0.032919064837107,0.0551719440071793,True,0.32415918469777,0.04283158651987,1.05797121998219,46.1794138522287
19448,1059:1053,Colon,SW1463,SIDM00834,909748,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.905120692671914,0.0389265931115184,0.831579657950369,13.360377392921,205.4019,0.957209336194614,0.9510565212196,0.0848245382673287,0.752679956015912,0.415709503037402,0.33697045297851,8.55432359267237,7.3424,4.80605380024858,198.0595,0.866389977408492,0.680737832466519,0.860820937256426,0.720177056687857,0.185652144941973,0.140643880568569,True,0.32415918469777,0.04283158651987,1.05797121998219,46.1794138522287
19448,1549:1053,Colon,SW1463,SIDM00834,909748,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.701932720015986,0.0389265931115184,0.831579657950369,13.360377392921,205.4019,0.957209336194614,0.9510565212196,0.0705301186189052,0.583712971215066,0.441420326332857,0.142292644882209,10.4399674018443,27.1315,2.92040999107665,178.2704,0.671896552979781,0.620244636728918,0.667577690828615,0.615911584808936,0.0516519162508636,0.0516661060196791,True,0.32415918469777,0.04283158651987,1.05797121998219,46.1794138522287
19449,1025:1054,Colon,SW1463,SIDM00834,909748,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.9191303092481,0.0695535448195085,0.670330803499904,10.9378477156572,15.3253,0.884413583465511,0.894207279552568,0.109755797674425,0.616121358719394,0.410686330535394,0.205435028184,8.41695048315125,2.6702,2.52089723250596,12.6551,0.812891330473875,0.649041423820311,0.821893013387054,0.724797723456791,0.163849906653564,0.0970952899302625,True,0.32415918469777,0.04283158651987,1.05797121998219,46.1794138522287
20667,1510:1059,Colon,SW1463,SIDM00834,909748,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.624696324077918,0.0746570788705023,0.609835021141385,10.2195316765881,2.3287,0.862798784978202,0.869403273578855,0.0452669193410736,0.380961696001003,0.243036640032583,0.13792505596842,7.76763913049804,0.4256,2.4518925460901,1.9031,0.538987229394777,0.436757662081109,0.543113029146019,0.470403586276415,0.102229567313668,0.0727094428696047,True,0.269741196153515,0.0416730931630788,1.10230436882875,42.9193037775805
20667,1011:1083,Colon,SW1463,SIDM00834,909748,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.929463682157042,0.113611287573718,0.661327662301241,10.8273537541289,35.4886,0.939323705729005,0.890655578932198,0.109746386472389,0.61468004411482,0.386381651766031,0.228298392348789,8.07041310514823,5.2501,2.75694064898065,30.2385,0.873067270264279,0.764530954505474,0.827832013928032,0.715681969019766,0.108536315758805,0.112150044908266,True,0.269741196153515,0.0416730931630788,1.10230436882875,42.9193037775805
20668,1510:1194,Colon,SW1463,SIDM00834,909748,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,10.0,0.752420129299816,0.0978738961573146,0.487752572438638,8.86620254715844,9.1143,0.844001003220375,0.811223787126038,0.0966112611250313,0.366994853620598,0.157823473127703,0.209171380492895,5.37813201621565,0.8123,3.48807053094279,8.302,0.635043343972248,0.445350968629784,0.610381106800459,0.45050770812735,0.189692375342465,0.159873398673109,True,0.269741196153515,0.0416730931630788,1.10230436882875,42.9193037775805
19447,1194:1510,Colon,SW1463,SIDM00834,909748,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,0.625,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.95085126203256,0.0807229521562195,0.548549740697664,9.53195328616948,14.4589,0.815386372709932,0.841744222044077,0.0651055794262711,0.521589213230008,0.544635558314853,-0.0230463450848457,9.80069716131835,17.4194,-0.268743875148868,-2.9605,0.77531116153539,0.812119002203197,0.800373555839226,0.811095324764758,-0.0368078406678067,-0.010721768925532,True,0.32415918469777,0.04283158651987,1.05797121998219,46.1794138522287
20671,2171:1549,Colon,SW1463,SIDM00834,909748,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.954300763410355,0.0751533520542557,0.686396482564309,11.1389399425377,22.0219,0.876047985064718,0.900432575098,0.0933797352854013,0.655028687313302,0.28026562291433,0.374763064398972,6.60378814397829,0.9498,4.53515179855938,21.0721,0.836013260931363,0.632150139921313,0.859283493815573,0.650640654263682,0.203863121010051,0.208642839551891,True,0.269741196153515,0.0416730931630788,1.10230436882875,42.9193037775805
20671,1053:1549,Colon,SW1463,SIDM00834,909748,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.973222097106075,0.0751533520542557,0.686396482564309,11.1389399425377,22.0219,0.876047985064718,0.900432575098,0.0402209019617599,0.66801622420747,0.467738720816186,0.200277503391284,8.78809193694014,4.317,2.35084800559753,17.7049,0.852589257190236,0.768364847259244,0.876320879039499,0.785782112322444,0.0842244099309923,0.090538766717055,True,0.269741196153515,0.0416730931630788,1.10230436882875,42.9193037775805
20671,1510:1549,Colon,SW1463,SIDM00834,909748,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.777468973026861,0.0751533520542557,0.686396482564309,11.1389399425377,22.0219,0.876047985064718,0.900432575098,0.116924394121129,0.533651968388523,0.212787033207411,0.320864935181112,6.33502632330985,0.7884,4.80391361922782,21.2335,0.681100127270517,0.464470433630023,0.700058389441374,0.516381189674744,0.216629693640494,0.18367719976663,True,0.269741196153515,0.0416730931630788,1.10230436882875,42.9193037775805
20671,1786:1549,Colon,SW1463,SIDM00834,909748,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.931738460688995,0.0751533520542557,0.686396482564309,11.1389399425377,22.0219,0.876047985064718,0.900432575098,0.04728734610179,0.63954200208681,0.383604805650023,0.255937196436787,8.02543617534636,2.5445,3.11350376719131,19.4774,0.816247601093896,0.702819620357487,0.838967661476039,0.715123700152412,0.113427980736409,0.123843961323626,True,0.269741196153515,0.0416730931630788,1.10230436882875,42.9193037775805
20671,1564:1549,Colon,SW1463,SIDM00834,909748,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.975086190487514,0.0751533520542557,0.686396482564309,11.1389399425377,22.0219,0.876047985064718,0.900432575098,0.0780092025192824,0.669295731347662,0.593195979656886,0.0760997516907758,10.2025279826571,11.5071,0.936411959880616,10.5148,0.854222292441019,0.820959046059061,0.877999369443172,0.847121879023607,0.0332632463819579,0.0308774904195647,True,0.269741196153515,0.0416730931630788,1.10230436882875,42.9193037775805
20671,1561:1549,Colon,SW1463,SIDM00834,909748,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.906216184577129,0.0751533520542557,0.686396482564309,11.1389399425377,22.0219,0.876047985064718,0.900432575098,0.0853739654071722,0.62202360153659,0.315532417080345,0.306491184456244,7.28786876535475,1.526,3.85107117718292,20.4959,0.79388886253183,0.619053825129947,0.815986572674268,0.656768846441878,0.174835037401883,0.15921772623239,True,0.269741196153515,0.0416730931630788,1.10230436882875,42.9193037775805
20672,1549:1561,Colon,SW1463,SIDM00834,909748,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.749670702054161,0.0711943525633612,0.677846395756186,11.0312628428709,40.8762,0.871798685000127,0.897137174535124,0.0608739061450127,0.508161583391422,0.346709274150724,0.161452309240698,8.58944458778584,7.5233,2.4418182550851,33.3529,0.653561932233939,0.554341503961999,0.672557455472632,0.597832895541296,0.0992204282719399,0.0747245599313365,True,0.269741196153515,0.0416730931630788,1.10230436882875,42.9193037775805
20672,1372:1561,Colon,SW1463,SIDM00834,909748,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.440279488008791,0.0711943525633612,0.677846395756186,11.0312628428709,40.8762,0.871798685000127,0.897137174535124,0.065425403294928,0.298441864072138,0.15248834340435,0.145953520667788,7.26567591720721,3.0055,3.76558692566373,37.8707,0.383835078678593,0.290361312009134,0.394991095877978,0.318494246999312,0.0934737666694591,0.0764968488786659,True,0.269741196153515,0.0416730931630788,1.10230436882875,42.9193037775805
20672,1564:1561,Colon,SW1463,SIDM00834,909748,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.883260139775665,0.0711943525633612,0.677846395756186,11.0312628428709,40.8762,0.871798685000127,0.897137174535124,0.0476098201326737,0.598714702262039,0.257941640362134,0.340773061899905,6.58198899101534,1.8711,4.4492738518556,39.0051,0.770025028369453,0.590905112703141,0.792405506177839,0.600956127630294,0.179119915666312,0.191449378547545,True,0.269741196153515,0.0416730931630788,1.10230436882875,42.9193037775805
20672,1011:1561,Colon,SW1463,SIDM00834,909748,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.870413477031706,0.0711943525633612,0.677846395756186,11.0312628428709,40.8762,0.871798685000127,0.897137174535124,0.0749701091547871,0.590006638223551,0.308952522782335,0.281054115441216,7.36887096699729,3.2284,3.66239187587365,37.6478,0.758825324682629,0.651951847146912,0.780880287461518,0.635074304630984,0.106873477535717,0.145805982830533,True,0.269741196153515,0.0416730931630788,1.10230436882875,42.9193037775805
20672,1053:1564,Colon,SW1463,SIDM00834,909748,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.951645198937752,0.0752529597442804,0.498227804138526,8.98064337565785,4.9334,0.814612240161247,0.816731619447363,0.0525868098366097,0.474136097785727,0.329786957560449,0.144349140225277,7.26808312693822,1.5053,1.71256024871963,3.4281,0.775221827345377,0.693019195286517,0.777238724467738,0.688550766386667,0.0822026320588601,0.0886879580810709,True,0.269741196153515,0.0416730931630788,1.10230436882875,42.9193037775805
20672,1510:1564,Colon,SW1463,SIDM00834,909748,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.739227663462906,0.0752529597442804,0.498227804138526,8.98064337565785,4.9334,0.814612240161247,0.816731619447363,0.0870574495199868,0.368303775525577,0.163976159812349,0.204327615713228,5.57287709050218,0.4648,3.40776628515567,4.4686,0.602183902922682,0.43522089825446,0.60375060672035,0.452669713639734,0.166963004668222,0.151080893080615,True,0.269741196153515,0.0416730931630788,1.10230436882875,42.9193037775805
19448,1549:2171,Colon,SW1463,SIDM00834,909748,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.701932720015986,0.0709670077359729,0.417972794608051,8.09590017841424,5.3437,0.746580837892131,0.771392481894387,0.119847052437561,0.293388780611912,0.143733185856957,0.149655594754955,5.29525419584089,0.7669,2.80064598257335,4.5768,0.524049518253437,0.356522860083594,0.541465623016009,0.416187117556757,0.167526658169844,0.125278505459251,True,0.32415918469777,0.04283158651987,1.05797121998219,46.1794138522287
19448,1059:2171,Colon,SW1463,SIDM00834,909748,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.688235949668815,0.0709670077359729,0.417972794608051,8.09590017841424,5.3437,0.746580837892131,0.771392481894387,0.114247325143612,0.2876639032328,0.247181048109613,0.0404828551231872,7.41885795248316,3.3422,0.677042225931081,2.0015,0.51382377197123,0.428053640647635,0.530900037343967,0.50421316330338,0.085770131323595,0.0266868740405868,True,0.32415918469777,0.04283158651987,1.05797121998219,46.1794138522287
18423,1179:1022,Colon,LS-180,SIDM00680,998189,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.25,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.928273336089241,0.0997568958580332,0.563304669301321,9.74808705189383,1.6796,0.852829285710492,0.838834186095218,0.0732674466878888,0.522900704606984,0.242492656166484,0.2804080484405,5.94521844072989,0.1203,3.80286861116394,1.5593,0.791658686161083,0.606131083112501,0.778667408352311,0.586647137228263,0.185527603048581,0.192020271124048,True,0.322432072654076,0.0551020714213911,1.0561335627985,46.15924765546
19675,1510:1025,Colon,LS-180,SIDM00680,998189,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.943587125335813,0.0787752179033489,0.879598909334269,14.8435284411539,574.2187,0.927073625575034,0.963637826118179,0.161767804021944,0.829978206307239,0.474569925866291,0.355408280440948,9.03458428730394,10.2426,5.80894415384993,563.9761,0.874774737330996,0.66967005418673,0.909276246211704,0.761995384625374,0.205104683144266,0.14728086158633,True,0.160298885117818,0.034838527019102,1.69591137707902,29.0360425779815
18422,1053:1032,Colon,LS-180,SIDM00680,998189,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.898501442248502,0.0866143375443071,0.505938226987837,9.06980021485329,10.4957,0.809531754682363,0.809185403226326,0.0841875486089098,0.454586226637221,0.331488954470586,0.123097272166635,7.42267418129553,3.351,1.64712603355775,7.1447,0.727365449128063,0.663574710927691,0.72705425184529,0.64984964813824,0.0637907382003726,0.0772046037070504,True,0.322432072654076,0.0551020714213911,1.0561335627985,46.15924765546
18422,1510:1032,Colon,LS-180,SIDM00680,998189,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.846980945143613,0.0866143375443071,0.505938226987837,9.06980021485329,10.4957,0.809531754682363,0.809185403226326,0.0610091466313804,0.428520037678441,0.189979616417394,0.238540421261048,5.35405110046066,0.7988,3.71574911439262,9.6969,0.685657970704635,0.473122232957022,0.685364617621049,0.502065359669657,0.212535737747613,0.183299257951392,True,0.322432072654076,0.0551020714213911,1.0561335627985,46.15924765546
18422,1564:1032,Colon,LS-180,SIDM00680,998189,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.957654849557039,0.0866143375443071,0.505938226987837,9.06980021485329,10.4957,0.809531754682363,0.809185403226326,0.0867501326077111,0.484514196651192,0.41866828297239,0.0658459136788022,8.25771093232672,5.9779,0.812089282526562,4.5178,0.775252010741984,0.708980203096733,0.77492032559046,0.736621026156871,0.0662718076452511,0.0382992994335883,True,0.322432072654076,0.0551020714213911,1.0561335627985,46.15924765546
18422,1561:1032,Colon,LS-180,SIDM00680,998189,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.646480635407588,0.0866143375443071,0.505938226987837,9.06980021485329,10.4957,0.809531754682363,0.809185403226326,0.0954258035547154,0.327079266460085,0.236040764529994,0.0910385019300911,7.3743715643419,3.2407,1.69542865051138,7.255,0.523346603149674,0.413770948283291,0.523122693640301,0.465766091513839,0.109575654866382,0.0573566021264624,True,0.322432072654076,0.0551020714213911,1.0561335627985,46.15924765546
18426,1510:1053,Colon,LS-180,SIDM00680,998189,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.846582996911804,0.119998473435879,0.71941249532984,11.7667033866242,68.0551,0.874260664818728,0.907018840275414,0.0899475848162796,0.609042386312135,0.290644173870471,0.318398212441664,7.0942377726608,2.6688,4.67246561396338,65.3863,0.740134213704345,0.567601723766808,0.767866728055829,0.595973286566904,0.172532489937536,0.171893441488925,True,0.322432072654076,0.0551020714213911,1.0561335627985,46.15924765546
18426,1786:1053,Colon,LS-180,SIDM00680,998189,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.852515425604351,0.119998473435879,0.71941249532984,11.7667033866242,68.0551,0.874260664818728,0.907018840275414,0.0872416146952699,0.613310249641207,0.304202398102846,0.30910785153836,7.26879816036947,3.012,4.49790522625471,65.0431,0.74532070275708,0.581980363818468,0.773247552648559,0.608955899914448,0.163340338938612,0.164291652734111,True,0.322432072654076,0.0551020714213911,1.0561335627985,46.15924765546
18426,1032:1053,Colon,LS-180,SIDM00680,998189,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.817745590644919,0.119998473435879,0.71941249532984,11.7667033866242,68.0551,0.874260664818728,0.907018840275414,0.0414719584019761,0.588296395910835,0.394964230599179,0.193332165311656,8.80000863363238,8.7056,2.96669475299181,59.3495,0.71492280372981,0.649974224326901,0.741710657267088,0.651280551749562,0.0649485794029093,0.0904301055175262,True,0.322432072654076,0.0551020714213911,1.0561335627985,46.15924765546
18426,1564:1053,Colon,LS-180,SIDM00680,998189,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.948701964936018,0.119998473435879,0.71941249532984,11.7667033866242,68.0551,0.874260664818728,0.907018840275414,0.0426695068832552,0.682508047918943,0.577868754228553,0.10463929369039,10.3034836500639,24.6824,1.4632197365603,43.3727,0.829412810579796,0.793022662877074,0.860490556003273,0.816390191572625,0.0363901477027222,0.0441003644306482,True,0.322432072654076,0.0551020714213911,1.0561335627985,46.15924765546
18426,1373:1053,Colon,LS-180,SIDM00680,998189,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.884830307369938,0.119998473435879,0.71941249532984,11.7667033866242,68.0551,0.874260664818728,0.907018840275414,0.055084061744452,0.636557979368476,0.467714762166616,0.16884321720186,9.33643984958627,12.6264,2.43026353703791,55.4287,0.773572332773001,0.758262056483674,0.802557759231219,0.726670178223124,0.015310276289327,0.075887581008095,True,0.322432072654076,0.0551020714213911,1.0561335627985,46.15924765546
18426,1059:1053,Colon,LS-180,SIDM00680,998189,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.694279185208288,0.119998473435879,0.71941249532984,11.7667033866242,68.0551,0.874260664818728,0.907018840275414,0.120218866580058,0.499473121086263,0.307144327922564,0.192328793163699,8.31987810126237,6.2411,3.44682528536181,61.814,0.606980982030003,0.463118809001893,0.629724301394981,0.536276896211159,0.143862173028109,0.093447405183822,True,0.322432072654076,0.0551020714213911,1.0561335627985,46.15924765546
18426,1549:1053,Colon,LS-180,SIDM00680,998189,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.77573544308802,0.119998473435879,0.71941249532984,11.7667033866242,68.0551,0.874260664818728,0.907018840275414,0.0427114970086882,0.558073770827752,0.355530384791635,0.202543386036116,8.50888924002123,7.1148,3.25781414660296,60.9403,0.678194984197583,0.598462315663699,0.70360666195023,0.606682507792092,0.0797326685338842,0.0969241541581382,True,0.322432072654076,0.0551020714213911,1.0561335627985,46.15924765546
19674,1053:1059,Colon,LS-180,SIDM00680,998189,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.949882380937211,0.0821097354831744,0.464602040520656,8.58324106123403,0.7491,0.780840089098503,0.785800252635903,0.114746641643167,0.441317292438047,0.191855880352036,0.249461412086011,4.9626348519809,0.0609,3.62060620925313,0.6882,0.74170624296411,0.494521487621532,0.746417814914854,0.537875223612707,0.247184755342578,0.208542591302147,True,0.160298885117818,0.034838527019102,1.69591137707902,29.0360425779815
19677,1032:1073,Colon,LS-180,SIDM00680,998189,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,20.0,0.750442549399922,0.0929989989583854,0.707330639235257,11.5930564987149,120.6751,0.938853759300236,0.902271110920712,0.070730400853546,0.530811008176383,0.523674797085272,0.0071362110911104,11.4593266313885,109.992,0.133729867326428,10.6831,0.70455580864297,0.703162989001917,0.677102632729239,0.674257306499171,0.0013928196410523,0.0028453262300685,True,0.160298885117818,0.034838527019102,1.69591137707902,29.0360425779815
19677,1011:1073,Colon,LS-180,SIDM00680,998189,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,20.0,0.952318927713203,0.0929989989583854,0.707330639235257,11.5930564987149,120.6751,0.938853759300236,0.902271110920712,0.120852460851239,0.673604355895215,0.526659139923297,0.146945215971918,9.62563641118084,30.8578,1.96742008753411,89.8173,0.89408820533631,0.789172953330289,0.859249856858614,0.793984635226772,0.104915252006021,0.065265221631842,True,0.160298885117818,0.034838527019102,1.69591137707902,29.0360425779815
19003,1022:1179,Colon,LS-180,SIDM00680,998189,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,10.0,0.912888270700759,0.106860840013883,0.314393297925578,6.70900325386818,2.0433,0.705825632335384,0.680568419767478,0.113457120239977,0.287005954063189,0.0759534852088641,0.211052468854325,1.94880154717314,0.0754,4.76020170669504,1.9679,0.644339940918918,0.313343258759344,0.621282927815082,0.329668949921043,0.330996682159575,0.291613977894039,True,0.239014046932689,0.0413235566498211,1.32784096807399,36.8710923103673
18423,1561:1372,Colon,LS-180,SIDM00680,998189,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.616852877939831,0.14543686851332,0.346420679923749,7.13463711088156,0.2745,0.635446071221789,0.706381575394615,0.0843626420640411,0.213690593388837,0.126318726746912,0.0873718666419255,5.01343276970059,0.0631,2.12120434118097,0.2114,0.391976737808719,0.31012643118963,0.43573350770584,0.351430697290998,0.0818503066190887,0.0843028104148416,True,0.322432072654076,0.0551020714213911,1.0561335627985,46.15924765546
19676,1053:1373,Colon,LS-180,SIDM00680,998189,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10.0,0.884316575513412,0.077748082440474,0.885278088376084,15.0044188921718,641.9633,0.944020954927083,0.965457976762021,0.112752064055909,0.782866087489799,0.52930999655919,0.253556090930608,10.1737317981388,22.5594,4.83068709403298,619.4039,0.834813378074019,0.719638661135755,0.853770491812298,0.756683899599893,0.115174716938264,0.0970865922124049,True,0.160298885117818,0.034838527019102,1.69591137707902,29.0360425779815
19676,1561:1373,Colon,LS-180,SIDM00680,998189,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10.0,0.826242617508406,0.077748082440474,0.885278088376084,15.0044188921718,641.9633,0.944020954927083,0.965457976762021,0.0653219629521467,0.731454484962694,0.596601095213605,0.134853389749089,11.8054321197186,69.9068,3.19898677245322,572.0565,0.779990344781738,0.711544700752969,0.797702525814222,0.750270510183486,0.0684456440287693,0.047432015630736,True,0.160298885117818,0.034838527019102,1.69591137707902,29.0360425779815
18425,1053:1510,Colon,LS-180,SIDM00680,998189,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.867498607959704,0.0911254013413339,0.827586119741583,13.6093108954365,244.0849,0.930862883905097,0.946421595504567,0.0440769182926393,0.717929806842596,0.471367298044804,0.246562508797793,9.51097403126618,14.2501,4.09833686417035,229.8348,0.807522255989027,0.734470359224361,0.821019416643214,0.719038122110857,0.0730518967646663,0.101981294532357,True,0.322432072654076,0.0551020714213911,1.0561335627985,46.15924765546
18425,1032:1510,Colon,LS-180,SIDM00680,998189,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.794076261173418,0.0911254013413339,0.827586119741583,13.6093108954365,244.0849,0.930862883905097,0.946421595504567,0.0363923008207164,0.657166491763413,0.444019281909116,0.213147209854297,9.69868328844349,16.2302,3.91062760699304,227.8547,0.739176118516465,0.666809571402488,0.751530922052048,0.664476472495048,0.0723665471139775,0.0870544495569994,True,0.322432072654076,0.0551020714213911,1.0561335627985,46.15924765546
18425,1561:1510,Colon,LS-180,SIDM00680,998189,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.67508947537057,0.0911254013413339,0.827586119741583,13.6093108954365,244.0849,0.930862883905097,0.946421595504567,0.0599153597289741,0.558694679400311,0.367648462261883,0.191046217138428,9.52552558702025,14.3946,4.08378530841627,229.6903,0.628415735937427,0.522791892113482,0.638919258388555,0.559978496836869,0.105623843823945,0.0789407615516866,True,0.322432072654076,0.0551020714213911,1.0561335627985,46.15924765546
18425,1059:1510,Colon,LS-180,SIDM00680,998189,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.702929919133399,0.0911254013413339,0.827586119741583,13.6093108954365,244.0849,0.930862883905097,0.946421595504567,0.0863046685612743,0.581735044225875,0.391276155190149,0.190458889035725,9.66856026708111,15.8949,3.94075062835541,228.19,0.654331371707692,0.542320743186045,0.665268055594128,0.587324235146895,0.112010628521648,0.0779438204472324,True,0.322432072654076,0.0551020714213911,1.0561335627985,46.15924765546
18425,1549:1510,Colon,LS-180,SIDM00680,998189,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.717444198926708,0.0911254013413339,0.827586119741583,13.6093108954365,244.0849,0.930862883905097,0.946421595504567,0.0610709603333948,0.593746860720863,0.474598091733392,0.119148768987471,10.968885825203,39.1466,2.64042507023354,204.9383,0.667842176053897,0.610303847564168,0.679004683433711,0.633887109856883,0.057538328489729,0.0451175735768279,True,0.322432072654076,0.0551020714213911,1.0561335627985,46.15924765546
19003,2171:1549,Colon,LS-180,SIDM00680,998189,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.833620850738005,0.107919276344984,0.579946002786156,9.94780486291962,9.6447,0.795533609114664,0.84690346291282,0.110557525104103,0.483455080224701,0.151982219713103,0.331472860511598,4.59014929730248,0.2352,5.35765556561714,9.4095,0.663173404020842,0.420371004140722,0.705996385246347,0.450768924768504,0.24280239988012,0.255227460477843,True,0.239014046932689,0.0413235566498211,1.32784096807399,36.8710923103673
19003,1053:1549,Colon,LS-180,SIDM00680,998189,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.911337088855866,0.107919276344984,0.579946002786156,9.94780486291962,9.6447,0.795533609114664,0.84690346291282,0.0854498384436,0.528526301872731,0.306397831084271,0.22212847078846,7.00113217453437,1.251,2.94667268838525,8.3937,0.724999283417558,0.60439769276724,0.77181453643292,0.636471607121814,0.120601590650318,0.135342929311106,True,0.239014046932689,0.0413235566498211,1.32784096807399,36.8710923103673
19003,1083:1549,Colon,LS-180,SIDM00680,998189,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.940529313775073,0.107919276344984,0.579946002786156,9.94780486291962,9.6447,0.795533609114664,0.84690346291282,0.0842199826998005,0.54545621602706,0.436983147323853,0.108473068703207,8.58338310162963,3.7459,1.36442176128999,5.8988,0.748222679465622,0.683537114881682,0.796537532807127,0.739074831599522,0.0646855645839405,0.0574627012076058,True,0.239014046932689,0.0413235566498211,1.32784096807399,36.8710923103673
19003,1510:1549,Colon,LS-180,SIDM00680,998189,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.884460786790853,0.107919276344984,0.579946002786156,9.94780486291962,9.6447,0.795533609114664,0.84690346291282,0.0113381631325589,0.512939497920454,0.320022115034091,0.192917382886363,7.33259634143478,1.5741,2.61520852148484,8.0706,0.703618281836123,0.627708508825226,0.749052903143771,0.635073783666216,0.075909773010897,0.113979119477555,True,0.239014046932689,0.0413235566498211,1.32784096807399,36.8710923103673
19003,2048:1549,Colon,LS-180,SIDM00680,998189,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.851545618723443,0.107919276344984,0.579946002786156,9.94780486291962,9.6447,0.795533609114664,0.84690346291282,0.0705160809506155,0.493850477768725,0.439138654728953,0.0547118230397721,9.18454860999386,5.6823,0.763256252925764,3.9624,0.677433159388841,0.685628280006402,0.721176933325124,0.693536540646848,-0.0081951206175613,0.027640392678276,True,0.239014046932689,0.0413235566498211,1.32784096807399,36.8710923103673
19004,1372:1561,Colon,LS-180,SIDM00680,998189,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.457583011213722,0.0992565128514196,0.332246998287411,6.9488393953436,2.4129,0.65213506405741,0.695236671188781,0.0758160254344012,0.152030581943074,0.0868862475460346,0.0651443343970391,4.73692969347967,0.5208,2.21190970186393,1.8921,0.298405926329443,0.214738339309255,0.318128489508766,0.25204499865102,0.0836675870201878,0.0660834908577468,True,0.239014046932689,0.0413235566498211,1.32784096807399,36.8710923103673
19004,1564:1561,Colon,LS-180,SIDM00680,998189,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.679657112640142,0.0992565128514196,0.332246998287411,6.9488393953436,2.4129,0.65213506405741,0.695236671188781,0.104768139984437,0.225814035539376,0.0965979528087771,0.129216082730599,3.71744184609224,0.2569,3.23139754925136,2.156,0.443228234688653,0.295561873816918,0.472522548541711,0.326554529015655,0.147666360871735,0.145968019526056,True,0.239014046932689,0.0413235566498211,1.32784096807399,36.8710923103673
19678,1089:1786,Colon,LS-180,SIDM00680,998189,1089,Oxaliplatin,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved in colon,1,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10.0,0.791504884559321,0.0757693946875055,0.878641166380691,14.8170453895451,563.7741,0.97819868955202,0.963329759862376,0.125392264065601,0.695448774965216,0.476574318244677,0.218874456720539,10.2173195514859,23.2514,4.59972583805916,540.5227,0.774249040849951,0.642647029964542,0.762480210372429,0.678571734682321,0.131602010885409,0.0839084756901078,True,0.160298885117818,0.034838527019102,1.69591137707902,29.0360425779815
19678,1053:1786,Colon,LS-180,SIDM00680,998189,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10.0,0.914084401679293,0.0757693946875055,0.878641166380691,14.8170453895451,563.7741,0.97819868955202,0.963329759862376,0.0746797494346083,0.80315218486189,0.701562464234946,0.101589720626944,12.5092972554229,113.8685,2.30774813412218,449.9056,0.894156163862626,0.880905379765653,0.880564707163657,0.845702759118221,0.0132507840969738,0.0348619480454364,True,0.160298885117818,0.034838527019102,1.69591137707902,29.0360425779815
19678,1561:1786,Colon,LS-180,SIDM00680,998189,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10.0,0.72474029406952,0.0757693946875055,0.878641166380691,14.8170453895451,563.7741,0.97819868955202,0.963329759862376,0.036489356224015,0.636786657304328,0.405507152287644,0.231279505016684,9.70292869589127,16.2781,5.1141166936538,547.496,0.70894000592435,0.590780167607616,0.698163893448579,0.606584430599637,0.118159838316734,0.0915794628489417,True,0.160298885117818,0.034838527019102,1.69591137707902,29.0360425779815
18426,1549:2171,Colon,LS-180,SIDM00680,998189,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.77573544308802,0.105034321501531,0.537904774328535,9.44638286518155,13.6262,0.788093831954701,0.826074193485486,0.0860377891190439,0.417271798452908,0.202553878184659,0.214717920268248,5.94342546543605,1.2019,3.5029573997455,12.4243,0.611352317926315,0.446735412337848,0.640815030507043,0.490155942277328,0.164616905588468,0.150659088229715,True,0.322432072654076,0.0551020714213911,1.0561335627985,46.15924765546
18426,1032:2171,Colon,LS-180,SIDM00680,998189,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.817745590644919,0.105034321501531,0.537904774328535,9.44638286518155,13.6262,0.788093831954701,0.826074193485486,0.141948778968893,0.43986925739401,0.21844187333804,0.22142738405597,6.03436505512813,1.2801,3.41201781005342,12.3461,0.644460256095414,0.451735284944276,0.675518529268314,0.521542039801288,0.192724971151138,0.153976489467026,True,0.322432072654076,0.0551020714213911,1.0561335627985,46.15924765546
22212,1017:1003,Colon,HT-115,SIDM00534,907289,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,2.5,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.1,0.903127864919109,0.0728461093033572,0.601026521011738,10.0527734911317,0.2075,0.85956052934904,0.872647185135256,0.08554263705306,0.542803798681091,0.320258480695526,0.222545317985565,7.46138779784688,0.0344,2.59138569328479,0.1731,0.776293065639738,0.651414282881016,0.788111989138874,0.671019659015081,0.124878782758722,0.117092330123793,True,0.282784465500255,0.0479108274369462,1.18897457011574,41.2284136632928
22212,1179:1003,Colon,HT-115,SIDM00534,907289,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,1,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.1,0.623433495083722,0.0728461093033572,0.601026521011738,10.0527734911317,0.2075,0.85956052934904,0.872647185135256,0.0755053058882903,0.374700064632358,0.243376754349269,0.13132331028309,7.8548180779528,0.0452,2.19795541317888,0.1623,0.535878825048087,0.480770792408804,0.544037484603845,0.477785861578347,0.0551080326392827,0.0662516230254976,True,0.282784465500255,0.0479108274369462,1.18897457011574,41.2284136632928
22212,1022:1003,Colon,HT-115,SIDM00534,907289,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.1,0.94160467959215,0.0728461093033572,0.601026521011738,10.0527734911317,0.2075,0.85956052934904,0.872647185135256,0.126072443244821,0.565929384743642,0.208543800269025,0.357385584474617,5.77013020417987,0.0107,4.2826432869518,0.1968,0.809366216827762,0.621082383108391,0.821688673156274,0.593667283312818,0.188283833719371,0.228021389843456,True,0.282784465500255,0.0479108274369462,1.18897457011574,41.2284136632928
22215,1549:1011,Colon,HT-115,SIDM00534,907289,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.557770741750379,0.122261602650765,0.225466407693948,5.82919892665649,1.1104,0.655020108668296,0.634680427428408,0.0387438503851825,0.125758565459247,0.0397196800593034,0.0860388853999433,2.40134188536037,0.1032,3.42785704129612,1.0072,0.365351051873329,0.18943486983788,0.35400617278119,0.212944792508862,0.175916182035449,0.141061380272328,True,0.282784465500255,0.0479108274369462,1.18897457011574,41.2284136632928
22215,1032:1011,Colon,HT-115,SIDM00534,907289,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.560960542756697,0.122261602650765,0.225466407693948,5.82919892665649,1.1104,0.655020108668296,0.634680427428408,0.057025276163171,0.1264777584334,0.0599470016296009,0.0665307568037989,3.54484057231102,0.2279,2.28435835434547,0.8825,0.367440435675118,0.248119824555516,0.356030677047292,0.2613520574475,0.119320611119602,0.0946786195997927,True,0.282784465500255,0.0479108274369462,1.18897457011574,41.2284136632928
22215,1025:1011,Colon,HT-115,SIDM00534,907289,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.47836044879678,0.122261602650765,0.225466407693948,5.82919892665649,1.1104,0.655020108668296,0.634680427428408,0.0571361596833817,0.107854211973075,0.0325698510742618,0.075284360898813,2.27740893268785,0.0947,3.55178999396864,1.0157,0.313335713153482,0.154782702887293,0.303606014107185,0.17838207096067,0.158553010266188,0.125223943146515,True,0.282784465500255,0.0479108274369462,1.18897457011574,41.2284136632928
22213,1073:1022,Colon,HT-115,SIDM00534,907289,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,2.5,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.822810989708497,0.0735629455305448,0.889778125744613,14.366014757132,41.2412,0.944934008104724,0.970642980161331,0.0840093410083488,0.732119220264897,0.377025132840784,0.355094087424112,8.56956594553417,0.742,5.79644881159784,40.4992,0.777502086417865,0.670996138791606,0.79865571116015,0.662864376088186,0.106505947626259,0.135791335071963,True,0.282784465500255,0.0479108274369462,1.18897457011574,41.2284136632928
22213,1179:1022,Colon,HT-115,SIDM00534,907289,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.812940414146074,0.0735629455305448,0.889778125744613,14.366014757132,41.2412,0.944934008104724,0.970642980161331,0.0733906955394076,0.723336598040943,0.26654209372679,0.456794504314152,7.15568379597297,0.2785,7.21033096115904,40.9627,0.768175043889364,0.598562514190926,0.789074906280331,0.588580120641952,0.169612529698438,0.200494785638379,True,0.282784465500255,0.0479108274369462,1.18897457011574,41.2284136632928
22213,1003:1022,Colon,HT-115,SIDM00534,907289,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.025,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.896145579316088,0.0735629455305448,0.889778125744613,14.366014757132,41.2412,0.944934008104724,0.970642980161331,0.12401623691572,0.797370733958189,0.0965576500560781,0.700813083902111,3.5685196356292,0.0232,10.7974951215028,41.218,0.846798434108481,0.400260715734867,0.86983741576577,0.419101453479628,0.446537718373614,0.450735962286142,True,0.282784465500255,0.0479108274369462,1.18897457011574,41.2284136632928
19666,1083:1025,Colon,HT-115,SIDM00534,907289,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.975086109386184,0.0718529420925407,0.719772975529277,11.4237538946988,53.6565,0.918930758487486,0.917547922509237,0.0502890498981591,0.701840630350159,0.724881716801753,-0.0230410864515935,11.7330889175277,66.4878,-0.309335022828826,-12.8313,0.896036618088857,0.931460813869976,0.894688233934907,0.90255692673275,-0.0354241957811186,-0.0078686927978431,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
19666,1011:1025,Colon,HT-115,SIDM00534,907289,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.81578755002171,0.0718529420925407,0.719772975529277,11.4237538946988,53.6565,0.918930758487486,0.917547922509237,0.112406952507059,0.587181832278865,0.330593850711236,0.25658798156763,8.01425171907158,5.0496,3.40950217562726,48.6069,0.749652272106098,0.668271880034259,0.74852417173132,0.632644537274344,0.0813803920718384,0.115879634456975,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
19666,2171:1025,Colon,HT-115,SIDM00534,907289,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.865921593465468,0.0718529420925407,0.719772975529277,11.4237538946988,53.6565,0.918930758487486,0.917547922509237,0.145654664493489,0.623266961903693,0.393171444669761,0.230095517233932,8.52641532001461,7.2017,2.89733857468424,46.4548,0.795721986673915,0.745811887708567,0.794524559140128,0.695651269000935,0.0499100989653473,0.098873290139193,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
19666,1786:1025,Colon,HT-115,SIDM00534,907289,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.864713723888149,0.0718529420925407,0.719772975529277,11.4237538946988,53.6565,0.918930758487486,0.917547922509237,0.0657236479732285,0.622397570023975,0.397592362854628,0.224805207169347,8.58591985311677,7.505,2.83783404158207,46.1515,0.794612038167075,0.731977307457245,0.793416280918797,0.697353452855297,0.0626347307098305,0.0960628280634998,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
22212,1011:1032,Colon,HT-115,SIDM00534,907289,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.958019639894852,0.114654618800141,0.121625841458871,3.92009084207612,0.2957,0.486488540808474,0.494006828645052,0.104418561326543,0.116519944836336,0.075014003636805,0.0415059411995308,2.66488013222707,0.1239,1.25521070984906,0.1718,0.466065576678306,0.369791822545583,0.473268244084131,0.384016608439544,0.0962737541327232,0.0892516356445864,True,0.282784465500255,0.0479108274369462,1.18897457011574,41.2284136632928
22217,2171:1047,Colon,HT-115,SIDM00534,907289,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.763958659731447,0.043950310401049,0.933877238731067,15.8031905510944,1116.7718,0.977328241862941,0.982793962714899,0.0707681720207681,0.71344360365469,0.413977732522753,0.299465871131938,9.43147896114051,13.4862,6.37171158995388,1103.2856,0.746638373771303,0.669323858501264,0.750813958547832,0.647050140530038,0.0773145152700392,0.103763818017794,True,0.282784465500255,0.0479108274369462,1.18897457011574,41.2284136632928
22216,1786:1053,Colon,HT-115,SIDM00534,907289,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.774692250259543,0.0696352639896416,0.575202734383107,9.77879514464938,17.157,0.854992176143593,0.861749595323826,0.104342913178531,0.445605100654691,0.23514756440743,0.210457536247261,6.86612824475233,2.2785,2.91266689989705,14.8785,0.662355812890983,0.511463610070841,0.667590733161665,0.546487174933384,0.150892202820142,0.121103558228281,True,0.282784465500255,0.0479108274369462,1.18897457011574,41.2284136632928
22216,1564:1053,Colon,HT-115,SIDM00534,907289,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.935761742959326,0.0696352639896416,0.575202734383107,9.77879514464938,17.157,0.854992176143593,0.861749595323826,0.0756778412602746,0.538252713281307,0.368583077715869,0.169669635565438,7.8925917001717,4.6413,1.88620344447768,12.5157,0.800068968964716,0.672600704534284,0.806392303314718,0.719187696760815,0.127468264430432,0.0872046065539029,True,0.282784465500255,0.0479108274369462,1.18897457011574,41.2284136632928
22214,1510:1059,Colon,HT-115,SIDM00534,907289,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.457991800048136,0.0836901244519787,0.391697600384993,7.86902109068703,0.4566,0.756122059678245,0.76719940331724,0.0643347170322266,0.179394289074859,0.242158834452751,-0.0627645453778928,9.29570333486173,1.2275,-1.4266822441747,-0.7709,0.346297703168143,0.363955391849101,0.351371035721119,0.385123999213898,-0.017657688680958,-0.0337529634927793,True,0.282784465500255,0.0479108274369462,1.18897457011574,41.2284136632928
19666,1510:1194,Colon,HT-115,SIDM00534,907289,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,10.0,0.678229596594926,0.0511093112453615,0.776499273238017,12.1998120189478,91.8839,0.934941756034283,0.936510498037149,0.0771744237091721,0.526644788844473,0.347913393652151,0.178731395192322,9.13335714703372,10.9684,3.06645487191405,80.9155,0.634105170034883,0.535865018142352,0.635169137290649,0.565248510192228,0.0982401518925314,0.0699206270984203,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
22213,1011:1372,Colon,HT-115,SIDM00534,907289,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.689675362669411,0.124760801329486,0.275162448990374,6.51136981251689,0.1782,0.632094201741158,0.681904760378295,0.06812655013504,0.18977276180044,0.045325153913533,0.144447607886907,2.17998469649359,0.0089,4.3313851160233,0.1693,0.435939797827065,0.222585262435001,0.470292912919899,0.25240111854524,0.213354535392064,0.217891794374659,True,0.282784465500255,0.0479108274369462,1.18897457011574,41.2284136632928
22215,1011:1510,Colon,HT-115,SIDM00534,907289,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.751560997949068,0.0770956823403337,0.473899907441532,8.73151552086409,8.3019,0.795286655162663,0.813886803874161,0.0297012512091461,0.356164687364729,0.129234993554819,0.22692969380991,4.96142407630864,0.6085,3.77009144455545,7.6934,0.597706432209628,0.41563507947114,0.611685578537242,0.429698914965955,0.182071352738488,0.181986663571287,True,0.282784465500255,0.0479108274369462,1.18897457011574,41.2284136632928
22215,1549:1510,Colon,HT-115,SIDM00534,907289,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.557770741750379,0.0770956823403337,0.473899907441532,8.73151552086409,8.3019,0.795286655162663,0.813886803874161,0.0458165535896331,0.264327502889099,0.139975317853587,0.124352185035513,6.19035632336059,1.4263,2.5411591975035,6.8756,0.443587627554256,0.346263799129094,0.453962246297736,0.368118798641644,0.0973238284251619,0.0858434476560918,True,0.282784465500255,0.0479108274369462,1.18897457011574,41.2284136632928
19669,2171:1549,Colon,HT-115,SIDM00534,907289,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.917906644341671,0.0970408980118839,0.711860645993097,11.3238119845398,25.0327,0.87301325626723,0.914788156326027,0.0997008110680475,0.653421616802418,0.277754322980754,0.375667293821664,6.85467719687379,1.1302,4.46913478766598,23.9025,0.801344668526048,0.605381334087878,0.839690126856728,0.646828730112392,0.19596333443817,0.192861396744336,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
19669,1025:1549,Colon,HT-115,SIDM00534,907289,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,2.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.905636123637253,0.0970408980118839,0.711860645993097,11.3238119845398,25.0327,0.87301325626723,0.914788156326027,0.120347769917387,0.644686716007099,0.459533092645752,0.185153623361347,9.07620936077294,5.2712,2.24760262376684,19.7615,0.79063234128979,0.687741723795487,0.828465199844373,0.752337558953802,0.102890617494302,0.0761276408905711,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
19669,1011:1549,Colon,HT-115,SIDM00534,907289,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.857062633149871,0.0970408980118839,0.711860645993097,11.3238119845398,25.0327,0.87301325626723,0.914788156326027,0.0819988232282689,0.610109159690612,0.141293979280254,0.468815180410358,4.83120292348204,0.278,6.49260906105774,24.7547,0.748227040191135,0.483641867882363,0.784030746035101,0.481759014838242,0.264585172308773,0.302271731196859,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
19669,1053:1549,Colon,HT-115,SIDM00534,907289,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.943378258952548,0.0970408980118839,0.711860645993097,11.3238119845398,25.0327,0.87301325626723,0.914788156326027,0.105001018194621,0.671553856833804,0.457355790641854,0.21419806619195,8.84380129165861,4.4869,2.48001069288117,20.5458,0.823581725739873,0.728184275163351,0.862991258225259,0.7730885597495,0.0953974505765223,0.0899026984757589,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
19669,1083:1549,Colon,HT-115,SIDM00534,907289,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.943372413063694,0.0970408980118839,0.711860645993097,11.3238119845398,25.0327,0.87301325626723,0.914788156326027,0.0452149198788388,0.671549695375588,0.600421669657639,0.0711280257179486,10.4389490555469,13.5562,0.884862928992844,11.4765,0.823576622201409,0.837606592008879,0.862985910475372,0.836664409296815,-0.0140299698074695,0.0263215011785571,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
19669,1510:1549,Colon,HT-115,SIDM00534,907289,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.71517706477591,0.0970408980118839,0.711860645993097,11.3238119845398,25.0327,0.87301325626723,0.914788156326027,0.0795403757544901,0.509106407330826,0.133059478251111,0.376046929079715,5.20796659537699,0.361,6.11584538916278,24.6717,0.624359058127657,0.404082243524675,0.654235508533015,0.421863620859318,0.220276814602981,0.232371887673697,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
19669,1786:1549,Colon,HT-115,SIDM00534,907289,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.841969625003262,0.0970408980118839,0.711860645993097,11.3238119845398,25.0327,0.87301325626723,0.914788156326027,0.0561034466491325,0.599365041161388,0.248623054175736,0.350741986985652,6.76508007771238,1.0622,4.5587319068274,23.9705,0.735050644002196,0.589533637074144,0.770223840939251,0.588373377287407,0.145517006928053,0.181850463651844,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
19669,1372:1549,Colon,HT-115,SIDM00534,907289,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.880646025660925,0.0970408980118839,0.711860645993097,11.3238119845398,25.0327,0.87301325626723,0.914788156326027,0.0982593229522116,0.626897248718239,0.355504585012893,0.271392663705346,7.99762322388112,2.4959,3.32618876065866,22.5368,0.768815654481038,0.652464815193817,0.805604554190201,0.682113008127006,0.116350839287222,0.123491546063195,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
19669,1598:1549,Colon,HT-115,SIDM00534,907289,1598,LGK974,PORCN,WNT signaling,Targeted,Early clinical trials,10,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.864603829771453,0.0970408980118839,0.711860645993097,11.3238119845398,25.0327,0.87301325626723,0.914788156326027,0.0680912359348616,0.615477440789212,0.411019084942385,0.204458355846827,8.74681051418551,4.1952,2.57700147035427,20.8375,0.754810604809894,0.683737874519424,0.79092934338905,0.704355181283348,0.0710727302904692,0.0865741621057017,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
19669,1564:1549,Colon,HT-115,SIDM00534,907289,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.991971440855016,0.0970408980118839,0.711860645993097,11.3238119845398,25.0327,0.87301325626723,0.914788156326027,0.0269820001547521,0.706145430693755,0.553535575709032,0.152609854984723,9.59894610520322,7.573,1.72486587933656,17.4597,0.866004217704933,0.843172832000747,0.907443725507833,0.847373491474755,0.0228313857041861,0.0600702340330787,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
19669,1561:1549,Colon,HT-115,SIDM00534,907289,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.826868617219275,0.0970408980118839,0.711860645993097,11.3238119845398,25.0327,0.87301325626723,0.914788156326027,0.114765021742911,0.588615228005132,0.263791778465996,0.324823449539136,7.0517796040346,1.2957,4.27203238050518,23.737,0.72186726402378,0.53461217279986,0.756409617869872,0.593203353988349,0.187255091223921,0.163206263881523,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
19669,1059:1549,Colon,HT-115,SIDM00534,907289,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.804706852573991,0.0970408980118839,0.711860645993097,11.3238119845398,25.0327,0.87301325626723,0.914788156326027,0.113047066362316,0.572839139908393,0.306541810987712,0.266297328920681,7.75238506495409,2.1057,3.57142691958568,22.927,0.702519749706173,0.539584978153463,0.736136298049081,0.611905336177999,0.16293477155271,0.124230961871083,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
19669,1047:1549,Colon,HT-115,SIDM00534,907289,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.961302831052988,0.0970408980118839,0.711860645993097,11.3238119845398,25.0327,0.87301325626723,0.914788156326027,0.0831408810825584,0.684313654308373,0.686431651533431,-0.0021179972250583,11.3514739777282,25.5173,-0.0276619931884703,-0.4846,0.839230114796476,0.842630071988495,0.879388444489954,0.880130054598448,-0.0033999571920194,-0.0007416101084939,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
19670,1549:1561,Colon,HT-115,SIDM00534,907289,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.764181506204162,0.0855837226171287,0.567483687483722,9.69781311551377,16.2204,0.836428609211541,0.858400370217518,0.166196730547435,0.433660539047603,0.203740097454758,0.229920441592845,6.40013357254936,1.6495,3.29767954296441,14.5709,0.639183274419528,0.423430213728316,0.655973687839033,0.515343686230216,0.215753060691212,0.140630001608818,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
19670,1786:1561,Colon,HT-115,SIDM00534,907289,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.943843212077399,0.0855837226171287,0.567483687483722,9.69781311551377,16.2204,0.836428609211541,0.858400370217518,0.13951068111564,0.535615626396163,0.308028398470681,0.227587227925482,7.13795708962335,2.7509,2.55985602589042,13.4695,0.789457465191652,0.598879900666584,0.810195362674531,0.682297133283093,0.190577564525068,0.127898229391438,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
19670,1032:1561,Colon,HT-115,SIDM00534,907289,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.731472749662903,0.0855837226171287,0.567483687483722,9.69781311551377,16.2204,0.836428609211541,0.858400370217518,0.0882298728646807,0.415098853272562,0.28429697314858,0.130801880123982,7.83626100737678,4.4635,1.861552108137,11.7569,0.611824734676684,0.502138582364421,0.627896479114662,0.559798194181298,0.109686152312263,0.0680982849333633,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
19670,1372:1561,Colon,HT-115,SIDM00534,907289,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.687871467905488,0.0855837226171287,0.567483687483722,9.69781311551377,16.2204,0.836428609211541,0.858400370217518,0.130096175787211,0.390355837121847,0.277588405753001,0.112767431368846,7.99613720615047,4.9866,1.70167590936331,11.2338,0.575355375216489,0.448263196431273,0.590469122712139,0.532739615393562,0.127092178785216,0.0577295073185764,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
19670,1564:1561,Colon,HT-115,SIDM00534,907289,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.913174205606436,0.0855837226171287,0.567483687483722,9.69781311551377,16.2204,0.836428609211541,0.858400370217518,0.0887908830892264,0.518211465512559,0.300598945050873,0.217612520461686,7.17089742413281,2.8144,2.52691569138097,13.406,0.763805030763245,0.635195247141055,0.783869076165652,0.662028013952759,0.12860978362219,0.121841062212894,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
19670,1510:1561,Colon,HT-115,SIDM00534,907289,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.713860742049568,0.0855837226171287,0.567483687483722,9.69781311551377,16.2204,0.836428609211541,0.858400370217518,0.12916281674026,0.405104326248155,0.160233517456634,0.244870808791521,5.81437511555865,1.0991,3.88343799995512,15.1213,0.597093547643239,0.385909206065797,0.612778325259101,0.452322786929425,0.211184341577442,0.160455538329677,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
19670,1011:1561,Colon,HT-115,SIDM00534,907289,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.900031459293623,0.0855837226171287,0.567483687483722,9.69781311551377,16.2204,0.836428609211541,0.858400370217518,0.0407677331085673,0.510753171371301,0.287202556199027,0.223550615172274,7.05269937858153,2.593,2.64511373693224,13.6274,0.752812061743599,0.642976698778656,0.772587337865059,0.645743983094305,0.109835362964943,0.126843354770754,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
19670,1510:1564,Colon,HT-115,SIDM00534,907289,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.950757575054543,0.0747458884796307,0.660615535045511,10.7112817411893,16.3726,0.921631210774483,0.896158514515447,0.075024945492839,0.628085224143229,0.460077043337673,0.168008180805556,8.8345360422102,4.4582,1.87674569897907,11.9144,0.876247855050531,0.789445304909227,0.852029496125188,0.778700328380073,0.0868025501413032,0.073329167745115,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
19670,1561:1564,Colon,HT-115,SIDM00534,907289,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.804851784038909,0.0747458884796307,0.660615535045511,10.7112817411893,16.3726,0.921631210774483,0.896158514515447,0.0267804645636115,0.531697591945198,0.316061798192569,0.215635793752629,7.87977854649725,2.3001,2.83150319469201,14.0725,0.741776524217783,0.627161230271821,0.721274779189416,0.61798151604192,0.114615293945962,0.103293263147496,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
19670,1059:1564,Colon,HT-115,SIDM00534,907289,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.870469374516858,0.0747458884796307,0.660615535045511,10.7112817411893,16.3726,0.921631210774483,0.896158514515447,0.0484280728511852,0.575045591587185,0.35477259406199,0.220272997525195,8.03895763600613,2.5684,2.67232410518313,13.8042,0.802251743578079,0.666282597257009,0.780078541598218,0.676264714069925,0.13596914632107,0.103813827528294,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
19670,1549:1564,Colon,HT-115,SIDM00534,907289,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.805688471328891,0.0747458884796307,0.660615535045511,10.7112817411893,16.3726,0.921631210774483,0.896158514515447,0.0669943636251548,0.532250320566935,0.313043595797669,0.219206724769265,7.83494104585618,2.2297,2.87634069533309,14.1429,0.742547641337888,0.577536579548861,0.72202458362832,0.616533985918208,0.165011061789027,0.105490597710112,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
19670,1011:1564,Colon,HT-115,SIDM00534,907289,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.950973242896371,0.0747458884796307,0.660615535045511,10.7112817411893,16.3726,0.921631210774483,0.896158514515447,0.060292032056741,0.62822769766995,0.470141807367959,0.158085890301992,8.94223499641635,4.8038,1.76904674477291,11.5688,0.876446621264719,0.821181477436077,0.852222768697949,0.783895405706331,0.0552651438286422,0.0683273629916178,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
19670,1083:1564,Colon,HT-115,SIDM00534,907289,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.635456387118208,0.0747458884796307,0.660615535045511,10.7112817411893,16.3726,0.921631210774483,0.896158514515447,0.0372832861889615,0.419792361174182,0.166997773874601,0.252794587299581,6.3498059784299,0.7965,4.36147576275937,15.5761,0.585656439454133,0.405085455134314,0.569469651919206,0.426354877844963,0.180570984319818,0.143114774074243,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
19670,1053:1564,Colon,HT-115,SIDM00534,907289,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.819948532966834,0.0747458884796307,0.660615535045511,10.7112817411893,16.3726,0.921631210774483,0.896158514515447,0.0705436931006702,0.541670738815667,0.181088535096837,0.360582203718829,5.76083016170213,0.5295,4.95045157948713,15.8431,0.755690159210985,0.534418861470532,0.734803859282678,0.516422165003337,0.221271297740453,0.218381694279341,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
19670,1373:1564,Colon,HT-115,SIDM00534,907289,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.982403582833063,0.0747458884796307,0.660615535045511,10.7112817411893,16.3726,0.921631210774483,0.896158514515447,0.0808509854143907,0.64899106850389,0.412054500319761,0.236936568184129,8.16472438760361,2.8024,2.54655735358565,13.5702,0.905413803515626,0.811241528494789,0.88038933544633,0.770124994498061,0.094172275020837,0.110264340948269,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
19670,1047:1564,Colon,HT-115,SIDM00534,907289,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.976957320224985,0.0747458884796307,0.660615535045511,10.7112817411893,16.3726,0.921631210774483,0.896158514515447,0.0794143890856083,0.645393182817057,0.475105485775672,0.170287697041384,8.85928199814627,4.5353,1.851999743043,11.8373,0.900394357913948,0.838286795541504,0.875508620837815,0.801352285322287,0.0621075623724441,0.0741563355155272,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
19670,1025:1564,Colon,HT-115,SIDM00534,907289,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.96417575258704,0.0747458884796307,0.660615535045511,10.7112817411893,16.3726,0.921631210774483,0.896158514515447,0.0375528283246081,0.636949480673195,0.501761756295442,0.135187724377753,9.20982502809159,5.7827,1.50145671309767,10.5899,0.888614466256192,0.821222272437483,0.864054310170215,0.806986371897108,0.0673921938187094,0.0570679382731066,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
19670,1786:1564,Colon,HT-115,SIDM00534,907289,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.943843212077399,0.0747458884796307,0.660615535045511,10.7112817411893,16.3726,0.921631210774483,0.896158514515447,0.168597841667556,0.623517488545584,0.37032755254423,0.253189936001354,7.87617584302949,2.2944,2.83510589815978,14.0782,0.869875362328171,0.706100857196151,0.84583313087077,0.724505796840573,0.16377450513202,0.121327334030197,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
19671,1011:1598,Colon,HT-115,SIDM00534,907289,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1598,LGK974,PORCN,WNT signaling,Targeted,Early clinical trials,10.0,0.85246062315178,0.0613308298838972,0.764067640283852,12.0192645565021,81.0754,0.929549864183737,0.932472916129144,0.0230852087782917,0.651337576766483,0.430856608371728,0.220480968394755,9.05577742052839,10.3942,2.96348713597368,70.6812,0.792404656472721,0.707049744262119,0.794896443155607,0.707337439377533,0.0853549122106013,0.0875590037780741,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
19671,1053:1786,Colon,HT-115,SIDM00534,907289,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10.0,0.930296595004171,0.0627534425295928,0.862298721906577,13.713499862325,262.3644,0.974404839595259,0.962770067022696,0.0395189784772516,0.802193564866137,0.85215605018521,-0.0499624853190728,15.1388318525552,704.6485,-1.42533199023025,-442.2841,0.906485504431055,0.918909540582295,0.895661715123151,0.909772799186204,-0.0124240361512401,-0.0141110840630531,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
19671,1510:1786,Colon,HT-115,SIDM00534,907289,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10.0,0.7472731255163,0.0627534425295928,0.862298721906577,13.713499862325,262.3644,0.974404839595259,0.962770067022696,0.0825661453753672,0.644372661047839,0.40911846353667,0.235254197511169,9.48946354769391,14.0392,4.22403631463108,248.3252,0.728146550002558,0.594963703475294,0.719452197137587,0.63481822371581,0.133182846527264,0.0846339734217773,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
19671,1032:1786,Colon,HT-115,SIDM00534,907289,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10.0,0.786427597766825,0.0627534425295928,0.862298721906577,13.713499862325,262.3644,0.974404839595259,0.962770067022696,0.0677055914502528,0.678135512426393,0.500576498153628,0.177559014272765,10.4395760435119,27.1241,3.27392381881305,235.2403,0.766298857255268,0.698751603588293,0.757148951010464,0.697489502085836,0.0675472536669752,0.0596594489246282,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
19671,1549:1786,Colon,HT-115,SIDM00534,907289,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10.0,0.745783837654541,0.0627534425295928,0.862298721906577,13.713499862325,262.3644,0.974404839595259,0.962770067022696,0.108018299781193,0.643088450028093,0.325443648401499,0.317644801626594,8.34256907448364,6.3401,5.37093078784136,256.0243,0.72669538070251,0.535850156917698,0.718018355363106,0.591870020764516,0.190845223784813,0.12614833459859,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
19672,1025:2048,Colon,HT-115,SIDM00534,907289,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,2.5,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.889981270925071,0.103676721931554,0.638547017670256,10.4621193475962,0.2755,0.928254711736119,0.887699997825635,0.159553001338159,0.568294886331589,0.2706747913634,0.297620094968189,6.87339988998543,0.0229,3.58871945761079,0.2526,0.826129308093097,0.699354819679897,0.790036372265042,0.628236544591368,0.1267744884132,0.161799827673674,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
19672,1011:2048,Colon,HT-115,SIDM00534,907289,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.843214580270716,0.103676721931554,0.638547017670256,10.4621193475962,0.2755,0.928254711736119,0.887699997825635,0.194025035531539,0.538432155487943,0.210867231933461,0.327564923554482,6.17832061298526,0.0141,4.28379873461096,0.2614,0.782717907140886,0.621430285884047,0.748521581072858,0.555804428078138,0.161287621256839,0.19271715299472,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
19672,1053:2048,Colon,HT-115,SIDM00534,907289,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.945811509970401,0.103676721931554,0.638547017670256,10.4621193475962,0.2755,0.928254711736119,0.887699997825635,0.135257322067806,0.603945118969801,0.387761591722592,0.21618352724721,8.06461056212055,0.0523,2.39750878547566,0.2232,0.877953990544278,0.802421200655814,0.839596875344185,0.736162704182469,0.0755327898884633,0.103434171161716,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
19672,1510:2048,Colon,HT-115,SIDM00534,907289,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.714062951808947,0.103676721931554,0.638547017670256,10.4621193475962,0.2755,0.928254711736119,0.887699997825635,0.0581687480767953,0.455962768306423,0.249832943196174,0.206129825110249,7.40806627908578,0.0332,3.05405306851044,0.2423,0.662832299492857,0.526075668961476,0.633873680768169,0.528216697924683,0.136756630531381,0.105656982843486,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
19672,1032:2048,Colon,HT-115,SIDM00534,907289,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.762330151896837,0.103676721931554,0.638547017670256,10.4621193475962,0.2755,0.928254711736119,0.887699997825635,0.0964916715025852,0.486783644973839,0.272317008619544,0.214466636354295,7.49059955442078,0.0351,2.97151979317544,0.2404,0.707636555396751,0.617659492879464,0.676720474181238,0.567762655206594,0.0899770625172864,0.108957818974644,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
19672,1598:2048,Colon,HT-115,SIDM00534,907289,1598,LGK974,PORCN,WNT signaling,Targeted,Early clinical trials,10,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.867115098174942,0.103676721931554,0.638547017670256,10.4621193475962,0.2755,0.928254711736119,0.887699997825635,0.107920524742413,0.553693759916461,0.337858114252486,0.215835645663975,7.84675498498814,0.045,2.61536436260807,0.2305,0.804903675498418,0.713642018262726,0.769738070764471,0.664133276450212,0.0912616572356912,0.10560479431426,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
19672,1373:2048,Colon,HT-115,SIDM00534,907289,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.976324692016276,0.103676721931554,0.638547017670256,10.4621193475962,0.2755,0.928254711736119,0.887699997825635,0.154540726069421,0.623429220364825,0.32507914199395,0.298350078370874,7.21477345986282,0.029,3.2473458877334,0.2465,0.906277995548423,0.770424409127716,0.866683426979962,0.710506411462517,0.135853586420707,0.156177015517445,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
19672,1549:2048,Colon,HT-115,SIDM00534,907289,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.76152718553678,0.103676721931554,0.638547017670256,10.4621193475962,0.2755,0.928254711736119,0.887699997825635,0.114266884900659,0.486270913199335,0.216756167787435,0.2695147454119,6.63211209139557,0.0194,3.83000725620065,0.2561,0.706891198089662,0.546749166252572,0.676007680945161,0.525451714088969,0.16014203183709,0.150555966856192,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
19672,1047:2048,Colon,HT-115,SIDM00534,907289,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.955153670470712,0.103676721931554,0.638547017670256,10.4621193475962,0.2755,0.928254711736119,0.887699997825635,0.114145299547317,0.609910527695872,0.24074392030421,0.369166607391662,6.20526599370251,0.0144,4.25685335389371,0.2611,0.886625895046487,0.662431966260865,0.847889911199998,0.631368898033269,0.224193928785622,0.216521013166729,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
22216,1032:2171,Colon,HT-115,SIDM00534,907289,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.525644546829026,0.114848557584554,0.186890062515285,5.22217622519228,0.7291,0.561338469366698,0.590912817724965,0.0677327996288307,0.0982377422176954,0.0409604472300548,0.0572772949876407,2.65143304530403,0.1227,2.57074317988825,0.6064,0.295064505347957,0.191541579867794,0.310610100288502,0.210187114887704,0.103522925480163,0.100422985400799,True,0.282784465500255,0.0479108274369462,1.18897457011574,41.2284136632928
19258,1372:1011,Colon,NCI-H747,SIDM00778,908457,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.397111646441281,0.161848130538613,0.484357823480769,8.77472741239634,8.5543,0.837491430172689,0.762136184092885,0.0573190602237207,0.192344132749164,0.113661976821438,0.0786821559277262,5.71100458310377,1.0231,3.06372282929257,7.5312,0.33257760071634,0.220348747136911,0.302653154877601,0.238900053046956,0.112228853579429,0.0637531018306453,True,0.426136587833001,0.0420140301828437,0.790043916089502,61.058594957668
19256,1179:1022,Colon,NCI-H747,SIDM00778,908457,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.584971046168405,0.0705842593998401,0.786268859670735,13.6882829086814,25.7818,0.935726590617197,0.919483025739429,0.0298014318316615,0.459944517411229,0.380824278669097,0.0791202387421323,11.2441149781258,4.7375,2.44416793055564,21.0443,0.547372962640937,0.507815301797862,0.537870947500885,0.501499387356424,0.0395576608430749,0.0363715601444607,True,0.426136587833001,0.0420140301828437,0.790043916089502,61.058594957668
19255,2171:1032,Colon,NCI-H747,SIDM00778,908457,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.729316238196891,0.0728859978492952,0.369682191786166,7.07952197033817,2.6417,0.660728551409825,0.678082353423881,0.0572639836494651,0.269615225441868,0.146582639933335,0.123032585508533,4.03255788163604,0.3196,3.04696408870213,2.3221,0.481880061583495,0.336828319603966,0.494536471186799,0.366085008090142,0.145051741979529,0.128451463096657,True,0.426136587833001,0.0420140301828437,0.790043916089502,61.058594957668
19259,2171:1053,Colon,NCI-H747,SIDM00778,908457,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.784024802942897,0.0548760866110176,0.596704384632212,10.4100049750055,26.5738,0.838160044439606,0.828967139345594,0.0711207483217464,0.467831037576432,0.301189121400601,0.166641916175831,7.30138720343527,3.0808,3.10861777157023,23.493,0.657138263676372,0.502169990110007,0.649930798071566,0.540851308784822,0.154968273566365,0.109079489286745,True,0.426136587833001,0.0420140301828437,0.790043916089502,61.058594957668
19259,1786:1053,Colon,NCI-H747,SIDM00778,908457,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.575519361307523,0.0548760866110176,0.596704384632212,10.4100049750055,26.5738,0.838160044439606,0.828967139345594,0.0309018801035268,0.343414926332929,0.214059323066406,0.129355603266523,7.11437024238415,2.7063,3.29563473262135,23.8675,0.482377333449368,0.382359497209957,0.477086638581101,0.391320119500499,0.10001783623941,0.0857665190806022,True,0.426136587833001,0.0420140301828437,0.790043916089502,61.058594957668
19259,1564:1053,Colon,NCI-H747,SIDM00778,908457,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.877376177214606,0.0548760866110176,0.596704384632212,10.4100049750055,26.5738,0.838160044439606,0.828967139345594,0.0298769024840508,0.523534211915804,0.344756133406278,0.178778078509526,7.43443994101961,3.3785,2.9755650339859,23.1953,0.735381655684446,0.601629959287265,0.727316019755565,0.611346822955962,0.133751696397182,0.115969196799603,True,0.426136587833001,0.0420140301828437,0.790043916089502,61.058594957668
21241,1022:1073,Colon,NCI-H747,SIDM00778,908457,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,20.0,0.897038719107525,0.105013114134529,0.780959494844615,13.5755791640451,476.8882,0.88190947557695,0.917234486472411,0.149124958074613,0.700550904930274,0.365313857641173,0.3352370472891,7.64896004571474,7.8402,5.9266191183304,469.048,0.791106946340337,0.531776609550829,0.82279484886646,0.634951490589324,0.259330336789508,0.187843358277136,True,0.51985444688515,0.0578948867755601,0.615403056837906,78.4987485414859
21242,1022:1179,Colon,NCI-H747,SIDM00778,908457,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,10.0,0.886629421309191,0.108844643362927,0.346667041208907,6.71908927219676,2.0577,0.644065056289038,0.6585604433939,0.142265730362589,0.307365198134023,0.155483747316751,0.151881450817272,3.428136740355,0.2102,3.29095253184176,1.8475,0.571047028143021,0.372976011059344,0.583899064823458,0.412886881623049,0.198071017083677,0.17101218320041,True,0.51985444688515,0.0578948867755601,0.615403056837906,78.4987485414859
21242,1786:1549,Colon,NCI-H747,SIDM00778,908457,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.485068819671106,0.13720086063699,0.517492948382942,9.25194730941753,5.9541,0.712734935901774,0.78316908232113,0.0957632678165663,0.251019693660234,0.146115720984477,0.104903972675757,5.97138292409211,0.6127,3.28056438532542,5.3414,0.345725494096235,0.24759584910492,0.379890902364414,0.299092947057144,0.0981296449913153,0.0807979553072698,True,0.51985444688515,0.0578948867755601,0.615403056837906,78.4987485414859
21242,2171:1549,Colon,NCI-H747,SIDM00778,908457,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.05,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.649143069722519,0.13720086063699,0.517492948382942,9.25194730941753,5.9541,0.712734935901774,0.78316908232113,0.0819093204876805,0.33592696107306,0.380155890683893,-0.0442289296108331,10.2450368432155,11.8512,-0.99308953379796,-5.8971,0.46266694418976,0.484768702497347,0.508388782209706,0.534181487666197,-0.0221017583075873,-0.0257927054564905,True,0.51985444688515,0.0578948867755601,0.615403056837906,78.4987485414859
21242,1011:1549,Colon,NCI-H747,SIDM00778,908457,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.930593887585295,0.13720086063699,0.517492948382942,9.25194730941753,5.9541,0.712734935901774,0.78316908232113,0.0771245019754686,0.481575774633659,0.620611466198719,-0.13903569156506,11.4985471937141,28.2558,-2.24659988429661,-22.3017,0.663266774818688,0.762386089391972,0.728812360953828,0.805140594258518,-0.0991193145732845,-0.0763282333046902,True,0.51985444688515,0.0578948867755601,0.615403056837906,78.4987485414859
21243,1083:1786,Colon,NCI-H747,SIDM00778,908457,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10.0,0.993656035256361,0.11131115286917,0.690351932044704,11.8857359697533,73.9083,0.923672246402286,0.876523686666119,0.0906731817587171,0.68597236372711,0.465256850118085,0.220715513609025,8.54195348893281,7.2797,3.34378248082054,66.6286,0.917812502236432,0.736533710733786,0.870963051300944,0.746667438454458,0.181278791502647,0.124295612846486,True,0.51985444688515,0.0578948867755601,0.615403056837906,78.4987485414859
21244,1011:2048,Colon,NCI-H747,SIDM00778,908457,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.511495045383488,0.104765503539487,0.544175926233364,9.63765969709692,0.1556,0.776250381793508,0.799256095206003,0.0875309295604487,0.278343290085336,0.161784599255114,0.116558690830222,6.22557171159622,0.0146,3.4120879855007,0.141,0.397048224264421,0.303421600126126,0.408815532690424,0.32278661791108,0.0936266241382944,0.086028914779344,True,0.51985444688515,0.0578948867755601,0.615403056837906,78.4987485414859
19259,1032:2171,Colon,NCI-H747,SIDM00778,908457,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.731993278084693,0.110802614986979,0.429386400107322,7.97654113720297,4.9194,0.671492938554407,0.72427990688243,0.0841323556354088,0.314307958579544,0.218060161941365,0.096247796638179,5.91430165202133,1.1779,2.06223948518164,3.7415,0.491528317303163,0.404811813823791,0.530168023289746,0.448949747683967,0.0867165034793725,0.0812182756057788,True,0.426136587833001,0.0420140301828437,0.790043916089502,61.058594957668
24154,1179:1003,Colon,CL-11,SIDM00944,1290769,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.25,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.1,0.905973067294139,0.0848585631543278,0.580996855543165,9.94295909721743,0.1922,0.847361326488141,0.849775422302388,0.0642737729982834,0.526367503304691,0.266805113172522,0.259562390132169,6.4796621673613,0.0174,3.46329692985614,0.1748,0.767686540064892,0.611908497116927,0.769873645854466,0.605320710122491,0.155778042947965,0.164552935731976,True,0.493452263343676,0.0666688096947567,0.679037987672109,72.0570940142605
24154,1011:1003,Colon,CL-11,SIDM00944,1290769,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.1,0.790559297136171,0.0848585631543278,0.580996855543165,9.94295909721743,0.1922,0.847361326488141,0.849775422302388,0.0774988847046159,0.45931246575653,0.217578620803766,0.241733844952764,6.20663229740775,0.0144,3.73632679980969,0.1778,0.669889374688838,0.511573585642214,0.671797860578968,0.514340591688104,0.158315789046624,0.157457268890865,True,0.493452263343676,0.0666688096947567,0.679037987672109,72.0570940142605
24154,1022:1003,Colon,CL-11,SIDM00944,1290769,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.1,0.82031118663676,0.0848585631543278,0.580996855543165,9.94295909721743,0.1922,0.847361326488141,0.849775422302388,0.0705870254931918,0.47659822000284,0.21784333446437,0.25875488553847,6.06537196339464,0.0131,3.87758713382279,0.1791,0.695099975241586,0.512441349085981,0.697080285043626,0.526143312665211,0.182658626155605,0.170936972378415,True,0.493452263343676,0.0666688096947567,0.679037987672109,72.0570940142605
24157,1372:1011,Colon,CL-11,SIDM00944,1290769,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.451531378710925,0.152708339554006,0.253677987988611,5.88699269960425,1.1558,0.675407624187602,0.629646618735494,0.0662303522641666,0.114543571665111,0.0455757033789376,0.0689678682861734,2.69122996601676,0.1261,3.19576273358749,1.0297,0.304967735741299,0.144349071531019,0.28430520585831,0.184780314595979,0.16061866421028,0.0995248912623306,True,0.493452263343676,0.0666688096947567,0.679037987672109,72.0570940142605
24155,1003:1022,Colon,CL-11,SIDM00944,1290769,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.025,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.901724920931929,0.106929561804053,0.488486089497021,8.86711330261085,0.912,0.834574176478309,0.802600132745556,0.0784239589223365,0.440480080428049,0.156589009064245,0.283891071363804,4.49981523127959,0.0442,4.36729807133126,0.8678,0.752556333296733,0.484743666133545,0.723724541239942,0.4823547994734,0.267812667163187,0.241369741766542,True,0.493452263343676,0.0666688096947567,0.679037987672109,72.0570940142605
24154,1011:1032,Colon,CL-11,SIDM00944,1290769,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.984524856310005,0.0910210489296948,0.613397510659898,10.331689310578,25.1697,0.888557127045338,0.864628686027547,0.112169134453352,0.603905096043351,0.570510087122326,0.0333950089210253,9.92496427440127,18.9864,0.406725036176743,6.1833,0.874806577827542,0.879607420854768,0.851248432872778,0.835920500497793,-0.0048008430272266,0.0153279323749854,True,0.493452263343676,0.0666688096947567,0.679037987672109,72.0570940142605
24154,1564:1032,Colon,CL-11,SIDM00944,1290769,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.722099784603445,0.0910210489296948,0.613397510659898,10.331689310578,25.1697,0.888557127045338,0.864628686027547,0.02731459574252,0.442934210323802,0.214465845027316,0.228468365296486,6.51439184164412,1.7855,3.81729746893388,23.3842,0.641626910047294,0.475942021400966,0.624348187942451,0.484059385984298,0.165684888646328,0.140288801958153,True,0.493452263343676,0.0666688096947567,0.679037987672109,72.0570940142605
24154,1053:1032,Colon,CL-11,SIDM00944,1290769,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.837421351225978,0.0910210489296948,0.613397510659898,10.331689310578,25.1697,0.888557127045338,0.864628686027547,0.133256111081907,0.513672172215463,0.26776370654432,0.245908465671143,6.82214507693448,2.21,3.50954423364353,22.9597,0.744096709971779,0.625629565710421,0.72405852256193,0.577503198271481,0.118467144261359,0.146555324290449,True,0.493452263343676,0.0666688096947567,0.679037987672109,72.0570940142605
24100,2171:1047,Colon,CL-11,SIDM00944,1290769,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.739658166720728,0.0886359883584805,0.872205650172712,14.5406340272576,465.4757,0.925379474887468,0.961872557826015,0.130168793485436,0.645134032210209,0.325424916599488,0.319709115610721,8.30389519898421,6.1724,6.23673882827342,459.3033,0.684464485916255,0.50063067958625,0.711456892740568,0.572779455360313,0.183833806330005,0.138677437380255,True,0.493452263343676,0.0666688096947567,0.679037987672109,72.0570940142605
24099,1011:1053,Colon,CL-11,SIDM00944,1290769,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.707265748425344,0.0865085111965909,0.744488273820768,12.0851320576717,84.8628,0.871616534487182,0.917955946525348,0.0702298681423219,0.526551056177738,0.282219699639703,0.244331356538035,7.81862394227819,4.4093,4.26650811539351,80.4535,0.616464520603981,0.503235816890803,0.649238799540746,0.529192392019901,0.113228703713178,0.120046407520845,True,0.493452263343676,0.0666688096947567,0.679037987672109,72.0570940142605
24099,1564:1053,Colon,CL-11,SIDM00944,1290769,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.663817536688005,0.0865085111965909,0.744488273820768,12.0851320576717,84.8628,0.871616534487182,0.917955946525348,0.0724227003185504,0.494204372020807,0.189581643677491,0.304622728343316,6.35493227769177,1.5987,5.73019977997994,83.2641,0.578594340859817,0.390485775173945,0.609355255210563,0.438235551733297,0.188108565685872,0.171119703477266,True,0.493452263343676,0.0666688096947567,0.679037987672109,72.0570940142605
24099,1372:1053,Colon,CL-11,SIDM00944,1290769,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.689146684775796,0.0865085111965909,0.744488273820768,12.0851320576717,84.8628,0.871616534487182,0.917955946525348,0.0850105769802138,0.513061625758037,0.337386805090692,0.175674820667345,8.87964812231987,9.1996,3.20548393535183,75.6632,0.600671645137609,0.512476428937303,0.632606297318171,0.553523317594096,0.0881952162003058,0.0790829797240754,True,0.493452263343676,0.0666688096947567,0.679037987672109,72.0570940142605
24156,1372:1059,Colon,CL-11,SIDM00944,1290769,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.357554018542922,0.0834275553420851,0.658091855894528,10.8890008301064,3.7038,0.870376550766904,0.883938255574734,0.0620622771118438,0.235303387645458,0.14249068018628,0.0928127074591789,7.81243792693407,0.439,3.07656290317231,3.2648,0.311206633372234,0.228735291594863,0.316055675424567,0.267407050134621,0.0824713417773715,0.0486486252899462,True,0.493452263343676,0.0666688096947567,0.679037987672109,72.0570940142605
24156,1011:1059,Colon,CL-11,SIDM00944,1290769,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.811888368176041,0.0834275553420851,0.658091855894528,10.8890008301064,3.7038,0.870376550766904,0.883938255574734,0.0426000310154607,0.534297122992151,0.229402813010647,0.304894309981503,6.31183325303505,0.1552,4.57716757707133,3.5486,0.706648597500832,0.534165607479551,0.717659187886947,0.533738335829554,0.172482990021282,0.183920852057392,True,0.493452263343676,0.0666688096947567,0.679037987672109,72.0570940142605
24157,1564:1510,Colon,CL-11,SIDM00944,1290769,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.924694294361574,0.0619394528873582,0.751653673632833,12.1948213008034,91.5666,0.913031571746058,0.920605055448296,0.0717186128758904,0.695049863344197,0.600524861297643,0.0945250020465545,10.7786133040499,34.3096,1.41620799675352,57.257,0.844275084965559,0.819143084041296,0.85127824213346,0.814004605433688,0.0251320009242638,0.0372736366997717,True,0.493452263343676,0.0666688096947567,0.679037987672109,72.0570940142605
24157,1372:1510,Colon,CL-11,SIDM00944,1290769,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.451531378710925,0.0619394528873582,0.751653673632833,12.1948213008034,91.5666,0.913031571746058,0.920605055448296,0.0674480073094733,0.339395219568565,0.162249121066376,0.177146098502189,7.33178315108055,3.1464,4.86303814972284,88.4202,0.412262404397101,0.289223358651275,0.415682069934817,0.325267290939665,0.123039045745826,0.0904147789951524,True,0.493452263343676,0.0666688096947567,0.679037987672109,72.0570940142605
24157,1011:1510,Colon,CL-11,SIDM00944,1290769,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.972879864135273,0.0619394528873582,0.751653673632833,12.1948213008034,91.5666,0.913031571746058,0.920605055448296,0.0705841674051844,0.731268723880689,0.725147368058631,0.0061213558220584,12.0983924698588,85.6464,0.0964288309446157,5.92019999999999,0.888270031471519,0.876382701651701,0.895638121266783,0.893376273745291,0.0118873298198185,0.0022618475214922,True,0.493452263343676,0.0666688096947567,0.679037987672109,72.0570940142605
19012,1372:1561,Colon,CL-11,SIDM00944,1290769,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.283031840745605,0.0958978655508333,0.775117307795393,12.5698046376321,118.7458,0.891818663387625,0.92911334139699,0.0334576632274648,0.219382878419108,0.169997466818267,0.0493854116008408,10.1772792966753,22.615,2.3925253409568,96.1308,0.252413077909885,0.248948017309808,0.26296865927689,0.243086648004975,0.0034650606000763,0.0198820112719151,True,1.07377915509701,0.139743052593617,-0.0949087246180258,-718.534644018198
19012,1564:1561,Colon,CL-11,SIDM00944,1290769,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.625314568482482,0.0958978655508333,0.775117307795393,12.5698046376321,118.7458,0.891818663387625,0.92911334139699,0.109972630792732,0.484692144847379,0.211170819303051,0.273521325544329,7.05692757358231,2.6006,5.51287706404977,116.1452,0.557667202660856,0.372789480043184,0.580988108146976,0.440205168898926,0.184877722617673,0.14078293924805,True,1.07377915509701,0.139743052593617,-0.0949087246180258,-718.534644018198
19012,1011:1561,Colon,CL-11,SIDM00944,1290769,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.291961436178851,0.0958978655508333,0.775117307795393,12.5698046376321,118.7458,0.891818663387625,0.92911334139699,0.0450599800638421,0.226304362391027,0.115544724862652,0.110759637528375,7.77916069502517,4.2903,4.79064394260691,114.4555,0.260376657773754,0.178230044807512,0.271265265527196,0.217810002295387,0.0821466129662416,0.053455263231809,True,1.07377915509701,0.139743052593617,-0.0949087246180258,-718.534644018198
19012,1510:1564,Colon,CL-11,SIDM00944,1290769,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.976348648954123,0.0759758364181694,0.338448449220448,7.06653304402906,1.309,0.718755893246654,0.704554414708074,0.0903014109159187,0.330443686137003,0.123588665915055,0.206855020221948,3.42787394201924,0.1051,3.63865910200982,1.2039,0.701756345299185,0.436618117616796,0.687890750914891,0.44915803172298,0.265138227682389,0.238732719191911,True,1.07377915509701,0.139743052593617,-0.0949087246180258,-718.534644018198
19014,2171:2048,Colon,CL-11,SIDM00944,1290769,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.848041104508268,0.0869562521455316,0.612688381104043,10.3230656054904,0.2502,0.860886817077582,0.864311656329769,0.176919741730272,0.519584931430856,0.314086130965124,0.205498800465732,7.46917565927575,0.0346,2.85388994621468,0.2156,0.73006740721108,0.528787167048402,0.732971811673268,0.617698620156428,0.201280240162678,0.11527319151684,True,1.07377915509701,0.139743052593617,-0.0949087246180258,-718.534644018198
24099,1372:2171,Colon,CL-11,SIDM00944,1290769,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.344144696479761,0.180797062648639,0.31563725553414,6.76743747381685,2.1278,0.61034849454028,0.686231942643481,0.0763518655688347,0.108624887503502,0.0418046070684337,0.0668202804350678,3.2922094749661,0.1913,3.47522799885074,1.9365,0.210048197400444,0.0998934248419948,0.236163083615758,0.155073875821514,0.110154772558449,0.0810892077942441,True,0.493452263343676,0.0666688096947567,0.679037987672109,72.0570940142605
24099,1011:2171,Colon,CL-11,SIDM00944,1290769,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.707265748425344,0.180797062648639,0.31563725553414,6.76743747381685,2.1278,0.61034849454028,0.686231942643481,0.0899635488392268,0.223239419766275,0.0330948530253014,0.190144566740974,0.304783794705244,0.0241,6.4626536791116,2.1037,0.431678584791313,0.168643180974788,0.48534834850712,0.18296319428461,0.263035403816525,0.30238515422251,True,0.493452263343676,0.0666688096947567,0.679037987672109,72.0570940142605
24119,1022:1003,Colon,SNU-1040,SIDM00217,1659823,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.1,0.673436690427262,0.0924411843929065,0.862629158698363,14.7411453748917,5.3488,0.919354753875452,0.95584646627681,0.0699555121185974,0.580926125699879,0.409681925912412,0.171244199787467,10.3760285863776,0.2596,4.3651167885141,5.0892,0.619127222778454,0.542051992038111,0.643702080806049,0.574298379496542,0.0770752307403428,0.0694037013095067,True,1.05879986570871,0.140484699452236,-0.0693721155591084,-884.535851004785
24119,1032:1003,Colon,SNU-1040,SIDM00217,1659823,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,1,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.1,0.816063329061326,0.0924411843929065,0.862629158698363,14.7411453748917,5.3488,0.919354753875452,0.95584646627681,0.121905405273194,0.703960022992757,0.438446334096353,0.265513688896404,9.46670645777122,0.1382,5.27443891712047,5.2106,0.750251701035957,0.583924400346188,0.780031249341358,0.666439424155941,0.16632730068977,0.113591825185418,True,1.05879986570871,0.140484699452236,-0.0693721155591084,-884.535851004785
24123,2171:1053,Colon,SNU-1040,SIDM00217,1659823,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.861095905584462,0.0621108012128943,0.608455963019837,10.3774823215561,25.9815,0.844262957479189,0.852840694390851,0.119143750984395,0.523938938484832,0.280737012035644,0.243201926449188,6.73070216446439,2.0743,3.64678015709169,23.9072,0.726991375921958,0.516483379417332,0.734377630055771,0.581286534305417,0.210507996504625,0.153091095750353,True,1.05879986570871,0.140484699452236,-0.0693721155591084,-884.535851004785
24120,1053:1372,Colon,SNU-1040,SIDM00217,1659823,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.873905023352008,0.121151584948014,0.609033359653505,10.3850575748441,2.6118,0.781200432663985,0.853117744964791,0.139812927729338,0.532237312390148,0.417239712512762,0.114997599877386,8.71786481839961,0.8224,1.66719275644452,1.7894,0.682694982349819,0.591561967828196,0.745543882835468,0.683933740024768,0.0911330145216231,0.0616101428107004,True,1.05879986570871,0.140484699452236,-0.0693721155591084,-884.535851004785
24122,1053:1510,Colon,SNU-1040,SIDM00217,1659823,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.833422057991458,0.069570940578093,0.841195428586945,14.2094621162362,370.0022,0.927720613476083,0.948357759270136,0.0494469174889834,0.701070825265938,0.614439607990469,0.0866312172754693,12.2238865068412,93.43,1.98557560939504,276.5722,0.773182822924335,0.78898094170155,0.790382275443084,0.757791926526443,-0.0157981187772154,0.0325903489166415,True,1.05879986570871,0.140484699452236,-0.0693721155591084,-884.535851004785
24128,1053:1549,Colon,SNU-1040,SIDM00217,1659823,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.801619769768884,0.112741677731265,0.767032138011265,12.7235660381989,66.0503,0.850705742796324,0.92096674502305,0.091439007673705,0.614868125877925,0.479999525870126,0.134868600007799,10.2512011888427,11.902,2.47236484935623,54.1483,0.681942541681456,0.62684479069963,0.738265150110175,0.679905356284788,0.055097750981826,0.058359793825387,True,1.05879986570871,0.140484699452236,-0.0693721155591084,-884.535851004785
24129,1053:1564,Colon,SNU-1040,SIDM00217,1659823,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.8787691396191,0.0806113270988909,0.646106941391193,10.8810196339147,18.4168,0.833626572246705,0.870411279222222,0.0843489820453485,0.567778840988267,0.424738017132051,0.143040823856216,8.79159897981464,4.3275,2.08942065410009,14.0893,0.732565305656857,0.626766622088819,0.764890570956872,0.69083376368255,0.105798683568038,0.0740568072743224,True,1.05879986570871,0.140484699452236,-0.0693721155591084,-884.535851004785
19388,1032:1003,Colon,DiFi,SIDM00049,1789883,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.1,0.306452248327242,0.0708906468218052,0.669319484847788,11.2083692796762,0.4622,0.88987035195879,0.880542733203415,0.0399759558868028,0.205114460980836,0.164309578005813,0.0408048829750225,9.45388624131347,0.137,1.75448303836274,0.3252,0.272702770077526,0.271627013430122,0.269844300338402,0.249976846576877,0.0010757566474036,0.0198674537615244,True,0.685976473863846,0.0935507009277229,0.340878093723021,136.45536482418
19388,1022:1003,Colon,DiFi,SIDM00049,1789883,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.1,0.786486619553697,0.0708906468218052,0.669319484847788,11.2083692796762,0.4622,0.88987035195879,0.880542733203415,0.0502739541604369,0.526410819039358,0.319760895205613,0.206649923833746,7.8155939096331,0.044,3.39277537004311,0.4182,0.699871124953127,0.566017681151889,0.692535077609727,0.579129110413432,0.133853443801238,0.113405967196295,True,0.685976473863846,0.0935507009277229,0.340878093723021,136.45536482418
21212,1372:1025,Colon,DiFi,SIDM00049,1789883,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.373869533115314,0.0878388795557856,0.747895632924708,12.4057517576174,105.9823,0.920662550653561,0.913323638545855,0.0371683595438129,0.279615391100543,0.210049188875781,0.0695662022247621,9.77851443037324,17.1536,2.62723732724415,88.8287,0.344207677969601,0.297476647239276,0.341463882326319,0.310047385000496,0.0467310307303251,0.0314164973258227,True,0.476222046130431,0.076292859072651,0.703203720824386,69.1414293878976
21212,1011:1025,Colon,DiFi,SIDM00049,1789883,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.458159209868403,0.0878388795557856,0.747895632924708,12.4057517576174,105.9823,0.920662550653561,0.913323638545855,0.0534527407006808,0.342655272244813,0.177737793890838,0.164917478353975,7.57187806335544,3.7161,4.83387369426195,102.2662,0.421810026762864,0.337163914221731,0.418447636590304,0.331289743592224,0.0846461125411324,0.0871578929980795,True,0.476222046130431,0.076292859072651,0.703203720824386,69.1414293878976
22203,1510:1059,Colon,DiFi,SIDM00049,1789883,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.708332289225922,0.0948733153224613,0.342766131021941,6.96112357551637,0.2434,0.711867572667352,0.688390815939625,0.0714395041204264,0.242792318255884,0.176772028802336,0.0660202894535479,5.55185611006525,0.0916,1.40926746545112,0.1518,0.504238787373166,0.414590113720967,0.487609442536615,0.426221141907116,0.089648673652199,0.0613883006294991,True,0.331892179768896,0.0500699863387572,1.05250605167914,46.6621748946023
22203,1011:1059,Colon,DiFi,SIDM00049,1789883,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,0.766149496171132,0.0948733153224613,0.342766131021941,6.96112357551637,0.2434,0.711867572667352,0.688390815939625,0.0882510628884877,0.262610098586988,0.0809501596871938,0.181659938899794,2.31053131147161,0.0097,4.65059226404476,0.2337,0.545396982139658,0.259277176601383,0.527410276800978,0.298406102299176,0.286119805538275,0.229004174501803,True,0.331892179768896,0.0500699863387572,1.05250605167914,46.6621748946023
22205,1011:1073,Colon,DiFi,SIDM00049,1789883,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in colon,20.0,0.91427790503866,0.124078520178721,0.69292133952685,11.548824550784,117.0315,0.835418553383242,0.890754552047899,0.111347231164549,0.633522670659191,0.719711060835971,-0.0861883901767797,13.0968295029972,342.2146,-1.54800495221325,-225.1831,0.763804724817659,0.786007124520334,0.814397205750003,0.848919707487129,-0.0222023997026757,-0.0345225017371257,True,0.331892179768896,0.0500699863387572,1.05250605167914,46.6621748946023
22203,1011:1083,Colon,DiFi,SIDM00049,1789883,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.766149496171132,0.11430539695899,0.735106981122322,12.196755488032,91.6894,0.935863838939249,0.908216692766953,0.133116878400543,0.563201843218749,0.295629455222153,0.267572387996596,7.54448099926352,3.6462,4.65227448876853,88.0432,0.717011608688087,0.608111727845854,0.695829761577613,0.552835336967965,0.108899880842234,0.142994424609648,True,0.331892179768896,0.0500699863387572,1.05250605167914,46.6621748946023
22203,1510:1083,Colon,DiFi,SIDM00049,1789883,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.708332289225922,0.11430539695899,0.735106981122322,12.196755488032,91.6894,0.935863838939249,0.908216692766953,0.112216226610592,0.520700010764331,0.33237536688567,0.188324643878661,8.61411298836556,7.6531,3.58264249966649,84.0363,0.662902575439598,0.595224936534333,0.643319209100812,0.550542090753364,0.0676776389052658,0.0927771183474478,True,0.331892179768896,0.0500699863387572,1.05250605167914,46.6621748946023
22203,1372:1083,Colon,DiFi,SIDM00049,1789883,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.911893783205484,0.11430539695899,0.735106981122322,12.196755488032,91.6894,0.935863838939249,0.908216692766953,0.0316396603958157,0.670339486076397,0.665513287465052,0.004826198611345,12.1121661760463,86.468,0.0845893119857752,5.2214,0.85340841665552,0.853781142052489,0.82819715593763,0.826247451303936,-0.0003727253969685,0.001949704633694,True,0.331892179768896,0.0500699863387572,1.05250605167914,46.6621748946023
22203,1032:1083,Colon,DiFi,SIDM00049,1789883,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.226505953982354,0.11430539695899,0.735106981122322,12.196755488032,91.6894,0.935863838939249,0.908216692766953,0.0587827139586543,0.1665061080382,0.0851848890106777,0.0813212190275224,7.41457195247693,3.3323,4.78218353555512,88.3571,0.211978731636523,0.170349038452801,0.205716488417877,0.161803839080193,0.0416296931837222,0.0439126493376845,True,0.331892179768896,0.0500699863387572,1.05250605167914,46.6621748946023
22203,1549:1083,Colon,DiFi,SIDM00049,1789883,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.287956269201824,0.11430539695899,0.735106981122322,12.196755488032,91.6894,0.935863838939249,0.908216692766953,0.0537850190778576,0.211678663748199,0.101117640909937,0.110561022838263,7.07710253051081,2.6372,5.11965295752124,89.0522,0.269487859541843,0.202919072817933,0.261526690475991,0.200167856881533,0.0665687867239101,0.061358833594458,True,0.331892179768896,0.0500699863387572,1.05250605167914,46.6621748946023
22205,1011:1089,Colon,DiFi,SIDM00049,1789883,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,1089,Oxaliplatin,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved in colon,10.0,0.91427790503866,0.0792281068288541,0.704855054055245,11.7264473183954,66.1824,0.873873667199039,0.895793885722174,0.0885226481623793,0.644433402177541,0.657219983000102,-0.0127865808225609,11.940020827838,76.7422,-0.213573509442567,-10.5598,0.798963385715189,0.840496902390033,0.81900455718451,0.824311350042594,-0.0415335166748441,-0.0053067928580844,True,0.331892179768896,0.0500699863387572,1.05250605167914,46.6621748946023
22204,1564:1373,Colon,DiFi,SIDM00049,1789883,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.5,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10.0,0.757824386781627,0.0644946628250039,0.925240021475141,16.8792808119211,2354.5064,0.955959318466608,0.976701233673252,0.129379619233629,0.701169451900219,0.400189597096379,0.300979854803839,9.35211353119296,12.7643,7.52716728072811,2341.7421,0.72444928430514,0.574694581917243,0.740168013477291,0.614826788776181,0.149754702387896,0.125341224701109,True,0.331892179768896,0.0500699863387572,1.05250605167914,46.6621748946023
19391,1011:1510,Colon,DiFi,SIDM00049,1789883,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.419181973104197,0.0654564823760409,0.635304187681709,10.7383614435318,33.3656,0.859440157922198,0.865213680000621,0.0514240619617084,0.266308062913778,0.16676394200878,0.0995441209049974,7.70178172816958,4.0663,3.03657971536225,29.2993,0.36026182116281,0.301843722804468,0.362681977539404,0.306086855476651,0.0584180983583412,0.0565951220627526,True,0.685976473863846,0.0935507009277229,0.340878093723021,136.45536482418
19391,1372:1510,Colon,DiFi,SIDM00049,1789883,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.896190669429317,0.0654564823760409,0.635304187681709,10.7383614435318,33.3656,0.859440157922198,0.865213680000621,0.0776905491980939,0.569353685249719,0.382196759111018,0.187156926138701,8.07207722221979,5.2561,2.66628422131204,28.1095,0.770222250462733,0.682946467132461,0.77539642707916,0.672071486441864,0.0872757833302719,0.103324940637296,True,0.685976473863846,0.0935507009277229,0.340878093723021,136.45536482418
19391,1032:1510,Colon,DiFi,SIDM00049,1789883,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.33394787249896,0.0654564823760409,0.635304187681709,10.7383614435318,33.3656,0.859440157922198,0.865213680000621,0.0420895302514121,0.212158481865987,0.125050423071077,0.0871080587949098,7.39291097622602,3.2826,3.34545046730581,30.083,0.287008212278288,0.225708251694442,0.288936267693204,0.238149014686208,0.0612999605838463,0.0507872530069952,True,0.685976473863846,0.0935507009277229,0.340878093723021,136.45536482418
19391,1564:1510,Colon,DiFi,SIDM00049,1789883,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.977177739494252,0.0654564823760409,0.635304187681709,10.7383614435318,33.3656,0.859440157922198,0.865213680000621,0.0722204023493074,0.620805110010044,0.589522663674418,0.0312824463356266,10.3129069083566,24.8442,0.425454535175231,8.5214,0.839825790748996,0.795901879287381,0.84546754800251,0.830667196837699,0.043923911461615,0.0148003511648106,True,0.685976473863846,0.0935507009277229,0.340878093723021,136.45536482418
19391,1179:1510,Colon,DiFi,SIDM00049,1789883,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.25,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.852049255052897,0.0654564823760409,0.635304187681709,10.7383614435318,33.3656,0.859440157922198,0.865213680000621,0.0670666415887644,0.541310459846186,0.319704275718759,0.221606184127427,7.40303067461551,3.3057,3.33533076891632,30.0599,0.732285346320153,0.597330624071135,0.737204671506105,0.608107635592124,0.134954722249018,0.129097035913981,True,0.685976473863846,0.0935507009277229,0.340878093723021,136.45536482418
19391,1059:1510,Colon,DiFi,SIDM00049,1789883,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.718569682949465,0.0654564823760409,0.635304187681709,10.7383614435318,33.3656,0.859440157922198,0.865213680000621,0.0902964507251687,0.456510328718913,0.26820441964176,0.188305909077153,7.3766777957704,3.2459,3.36168364776143,30.1197,0.617567641792192,0.474762632410516,0.621716319721586,0.511779915951855,0.142805009381675,0.109936403769731,True,0.685976473863846,0.0935507009277229,0.340878093723021,136.45536482418
19391,1549:1510,Colon,DiFi,SIDM00049,1789883,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.383326845487931,0.0654564823760409,0.635304187681709,10.7383614435318,33.3656,0.859440157922198,0.865213680000621,0.051687090979207,0.243529150189302,0.117412866355388,0.126116283833914,6.43970050845119,1.6954,4.29866093508064,31.6702,0.329446484621965,0.231760107354964,0.331659630627642,0.251950780395722,0.0976863772670019,0.0797088502319201,True,0.685976473863846,0.0935507009277229,0.340878093723021,136.45536482418
19391,1047:1510,Colon,DiFi,SIDM00049,1789883,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.907061106442339,0.0654564823760409,0.635304187681709,10.7383614435318,33.3656,0.859440157922198,0.865213680000621,0.0724053885254646,0.576259719406022,0.373256043423622,0.2030036759824,7.87949257271478,4.5993,2.85886887081705,28.7663,0.779564740565887,0.669311260209785,0.784801677890411,0.671014795696001,0.110253480356102,0.11378688219441,True,0.685976473863846,0.0935507009277229,0.340878093723021,136.45536482418
18979,1510:1549,Colon,DiFi,SIDM00049,1789883,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.815382094953737,0.184803756355309,0.0727869426574603,1.03027989599884,0.0199,0.327891613682256,0.311107108133843,0.0774493552056524,0.0593491697893176,0.0236458097985733,0.0357033599907443,-1.99642809994406,0.0024,3.02670799594289,0.0175,0.267356950881999,0.126914738864854,0.253671165585172,0.132090584079486,0.140442212017145,0.121580581505686,True,0.701728345506927,0.0932668669161269,0.311947475710476,146.015648084567
18980,1372:1561,Colon,DiFi,SIDM00049,1789883,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.418719525511971,0.0940286196901874,0.219842335330908,5.0331110940171,0.6395,0.547711238451194,0.568152879049699,0.0880219038009933,0.0920522783372015,0.0660502296475221,0.0260020486896795,3.7536137897495,0.2634,1.27949730426761,0.3761,0.229337389881858,0.170927208422898,0.237896703933951,0.202521348715458,0.0584101814589597,0.0353753552184929,True,0.701728345506927,0.0932668669161269,0.311947475710476,146.015648084567
18980,1011:1564,Colon,DiFi,SIDM00049,1789883,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.336653064228521,0.0909388120208222,0.366099586950376,7.28059888693693,1.5184,0.717107672591101,0.706792730199077,0.0274208930969281,0.12324854775964,0.0555409925765377,0.0677075551831022,3.92112079227432,0.1479,3.35947809466261,1.3705,0.241416495359577,0.140506439491816,0.237943938395962,0.166565880082199,0.10091005586776,0.0713780583137626,True,0.701728345506927,0.0932668669161269,0.311947475710476,146.015648084567
18980,1053:1564,Colon,DiFi,SIDM00049,1789883,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.705459668277573,0.0909388120208222,0.366099586950376,7.28059888693693,1.5184,0.717107672591101,0.706792730199077,0.0783761280493686,0.258268493166569,0.137639501402949,0.12062899176362,4.56149687203101,0.2306,2.71910201490592,1.2878,0.50589054082542,0.381691731578909,0.498613764987241,0.378954453570213,0.124198809246511,0.119659311417028,True,0.701728345506927,0.0932668669161269,0.311947475710476,146.015648084567
18980,1510:1564,Colon,DiFi,SIDM00049,1789883,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.760373305728464,0.0909388120208222,0.366099586950376,7.28059888693693,1.5184,0.717107672591101,0.706792730199077,0.0553114312888235,0.278372353155283,0.135566492380605,0.142805860774678,4.21443405802855,0.1813,3.06616482890838,1.3371,0.54526953157134,0.387715086386549,0.537426324726318,0.390995188200128,0.157554445184791,0.146431136526191,True,0.701728345506927,0.0932668669161269,0.311947475710476,146.015648084567
18980,1561:1564,Colon,DiFi,SIDM00049,1789883,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.457436315069907,0.0909388120208222,0.366099586950376,7.28059888693693,1.5184,0.717107672591101,0.706792730199077,0.0538266154807007,0.167467246003195,0.097655025623,0.069812220380195,4.91575737204332,0.2948,2.36484151489362,1.2236,0.32803109125843,0.252312721146285,0.323312662020465,0.256382484011215,0.0757183701121455,0.0669301780092493,True,0.701728345506927,0.0932668669161269,0.311947475710476,146.015648084567
19578,1022:1003,Colon,HCT-15,SIDM00789,905937,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.1,0.962371856985548,0.0719395513583713,0.328360941968585,7.69076458456426,0.0404,0.807092059941875,0.797830051331869,0.0751917429554385,0.316005329483831,0.0657777075180308,0.2502276219658,4.22064231341451,0.0036,3.47012227114975,0.0368,0.776722684484554,0.494442076642229,0.767809188059126,0.499821712623697,0.282280607842326,0.267987475435429,True,0.122422380174148,0.0262902013554606,1.91411019602722,25.7402793695913
20031,1022:1017,Colon,HCT-15,SIDM00789,905937,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.935372939135964,0.142146484969202,0.863901486300578,12.3811425621806,104.1898,0.942891788190541,0.973356253300241,0.0819543711659763,0.8080700723649,0.387314165710318,0.420755906654583,8.36488056479936,6.4389,4.0162619973812,97.7509,0.881955463206951,0.800804960164725,0.910451099475816,0.785506518096559,0.0811505030422262,0.124944581379257,True,0.114299271286458,0.037342189154545,1.96644644918607,25.0563183075642
19580,1017:1022,Colon,HCT-15,SIDM00789,905937,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,2.5,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.965182732145718,0.073918036659033,0.679331901733932,10.3734442508706,2.5909,0.914574963537131,0.929626361366128,0.0769589166647341,0.655679420949303,0.584106915464105,0.0715725054851972,9.7813719111132,1.7188,0.592072339757429,0.8721,0.882731962058839,0.855338012234645,0.897259311338042,0.876982656309611,0.0273939498241935,0.0202766550284302,True,0.122422380174148,0.0262902013554606,1.91411019602722,25.7402793695913
19580,1179:1022,Colon,HCT-15,SIDM00789,905937,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.555283768082488,0.073918036659033,0.679331901733932,10.3734442508706,2.5909,0.914574963537131,0.929626361366128,0.0374545337365687,0.37722197817346,0.0313764402418149,0.345845537931645,3.84936351607154,0.0282,6.5240807347991,2.5627,0.507848631946803,0.243942850666475,0.516206428848196,0.270299694639067,0.263905781280327,0.24590673420913,True,0.122422380174148,0.0262902013554606,1.91411019602722,25.7402793695913
19580,1003:1022,Colon,HCT-15,SIDM00789,905937,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.025,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.513798738475943,0.073918036659033,0.679331901733932,10.3734442508706,2.5909,0.914574963537131,0.929626361366128,0.0677839449819858,0.349039874117357,0.0113597085272026,0.337680165590155,2.06712449737539,0.0082,8.30631975349524,2.5827,0.46990746250706,0.157269659562277,0.477640851723898,0.171604499692678,0.312637802944783,0.30603635203122,True,0.122422380174148,0.0262902013554606,1.91411019602722,25.7402793695913
19584,1510:1047,Colon,HCT-15,SIDM00789,905937,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.669039652017761,0.0624092412150786,0.886148253345124,12.7542000100361,134.9357,0.953374143352519,0.977985494451725,0.0710493673282233,0.592868319054168,0.3494379144813,0.243430404572868,9.16328723559591,11.1984,3.59091277444018,123.7373,0.6378451051113,0.539366652785463,0.6543110748864,0.590008808625694,0.0984784523258366,0.0643022662607059,True,0.122422380174148,0.0262902013554606,1.91411019602722,25.7402793695913
19584,2048:1047,Colon,HCT-15,SIDM00789,905937,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.994808589466566,0.0624092412150786,0.886148253345124,12.7542000100361,134.9357,0.953374143352519,0.977985494451725,0.0484326858329277,0.881547893968525,0.621329445211572,0.260218448756953,9.93123640487357,19.0691,2.82296360516252,115.8666,0.948424786782415,0.924146169900101,0.972908370254283,0.909603108213724,0.0242786168823143,0.063305262040559,True,0.122422380174148,0.0262902013554606,1.91411019602722,25.7402793695913
19583,1786:1053,Colon,HCT-15,SIDM00789,905937,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.537263248869939,0.0791605486921203,0.594885241679393,9.70290725518551,16.2778,0.879778726554135,0.905502035741293,0.0674584502647936,0.31960997764945,0.0916218146669471,0.227988162982503,6.10594503456309,1.3452,3.59696222062242,14.9326,0.472672776915132,0.339862229854789,0.486492965580711,0.365399066863713,0.132810547060343,0.121093898716998,True,0.122422380174148,0.0262902013554606,1.91411019602722,25.7402793695913
19583,1032:1053,Colon,HCT-15,SIDM00789,905937,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.93662430692898,0.0791605486921203,0.594885241679393,9.70290725518551,16.2778,0.879778726554135,0.905502035741293,0.0423052592808758,0.55718397719024,0.351207101643575,0.205976875546665,8.06519708764493,5.2311,1.63771016754058,11.0467,0.824022140009627,0.753641880821769,0.848115216648968,0.769740357163772,0.0703802591878586,0.0783748594851964,True,0.122422380174148,0.0262902013554606,1.91411019602722,25.7402793695913
19583,2048:1053,Colon,HCT-15,SIDM00789,905937,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.965078473343677,0.0791605486921203,0.594885241679393,9.70290725518551,16.2778,0.879778726554135,0.905502035741293,0.0626609868843671,0.574110940854633,0.472743491968083,0.101367448886551,8.92570881876461,9.4981,0.777198436420903,6.7797,0.849055510303109,0.819430656628819,0.873880522262799,0.839847380194238,0.0296248536742904,0.034033142068561,True,0.122422380174148,0.0262902013554606,1.91411019602722,25.7402793695913
20928,1022:1179,Colon,HCT-15,SIDM00789,905937,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,10.0,0.844329944887157,0.0950395864823879,0.0810947076267819,4.55866322891534,0.4603,0.553066124751014,0.548956586339311,0.0711273672501411,0.068470690021161,0.011374621884966,0.0570960681361951,1.14468004685167,0.0432,3.41398318206366,0.4171,0.466970290629978,0.19047849397924,0.463500484289313,0.220659768886409,0.276491796650738,0.242840715402904,True,0.0815614553839107,0.0215367248282488,2.23928402347549,22.044031053242
19580,1053:1372,Colon,HCT-15,SIDM00789,905937,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.874827143371527,0.0824473462997922,0.685552635183729,10.4259620104616,2.6869,0.897880318879849,0.931283761034069,0.110382474207433,0.599740053468604,0.136672614628451,0.463067438840154,5.91435609394159,0.1178,4.51160591652001,2.5691,0.785490074455174,0.531036133199754,0.814712312333726,0.581312225681291,0.254453941255419,0.233400086652435,True,0.122422380174148,0.0262902013554606,1.91411019602722,25.7402793695913
19580,1083:1372,Colon,HCT-15,SIDM00789,905937,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.972954136474514,0.0824473462997922,0.685552635183729,10.4259620104616,2.6869,0.897880318879849,0.931283761034069,0.065746643666735,0.667011272173013,0.671051074934758,-0.0040398027617454,10.4613283608021,2.7536,-0.0353663503404764,-0.0667,0.873596370313205,0.862073753131504,0.906096387529641,0.907164645988808,0.0115226171817007,-0.0010682584591679,True,0.122422380174148,0.0262902013554606,1.91411019602722,25.7402793695913
19580,2048:1372,Colon,HCT-15,SIDM00789,905937,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.996180683718996,0.0824473462997922,0.685552635183729,10.4259620104616,2.6869,0.897880318879849,0.931283761034069,0.107214666431775,0.682934292842687,0.571964722414682,0.110969570428005,9.54673102870949,1.4608,0.879230981752112,1.2261,0.894451029959558,0.834760334489236,0.927726893803317,0.895626651234104,0.059690695470322,0.0321002425692127,True,0.122422380174148,0.0262902013554606,1.91411019602722,25.7402793695913
19580,1179:1372,Colon,HCT-15,SIDM00789,905937,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.25,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.847719222686003,0.0824473462997922,0.685552635183729,10.4259620104616,2.6869,0.897880318879849,0.931283761034069,0.0815478043383957,0.581156147008292,0.400184042359982,0.18097210464831,8.79540103184855,0.8678,1.63056097861306,1.8191,0.761150405985886,0.701785139529096,0.789467146003898,0.732033582521481,0.0593652664567893,0.0574335634824171,True,0.122422380174148,0.0262902013554606,1.91411019602722,25.7402793695913
19580,1561:1372,Colon,HCT-15,SIDM00789,905937,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.729268764301221,0.0824473462997922,0.685552635183729,10.4259620104616,2.6869,0.897880318879849,0.931283761034069,0.144602135036581,0.499952123123884,0.0971705544757958,0.402781568648088,5.574038564908,0.093,4.85192344555361,2.5939,0.654796070639894,0.390516169860352,0.679156157623109,0.463965613776075,0.264279900779542,0.215190543847034,True,0.122422380174148,0.0262902013554606,1.91411019602722,25.7402793695913
20031,1372:1373,Colon,HCT-15,SIDM00789,905937,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10.0,0.612388691552192,0.14865654025996,0.656852815941284,10.1879236122339,22.7825,0.869856652997484,0.923508867835945,0.0890150257008178,0.402249236496655,0.196424108064387,0.205825128432268,7.62724952805728,3.8615,2.56067408417657,18.921,0.532690377567098,0.483109319789833,0.5655463872109,0.485988805795662,0.0495810577772647,0.0795575814152383,True,0.114299271286458,0.037342189154545,1.96644644918607,25.0563183075642
20031,2048:1373,Colon,HCT-15,SIDM00789,905937,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,10.0,0.972336383950192,0.14865654025996,0.656852815941284,10.1879236122339,22.7825,0.869856652997484,0.923508867835945,0.160953834036091,0.638681891839849,0.437402798405697,0.201279093434152,8.63173464740338,7.7471,1.55618896483047,15.0354,0.84579327253059,0.82869403878743,0.897961273097539,0.831144528750799,0.0170992337431604,0.06681674434674,True,0.114299271286458,0.037342189154545,1.96644644918607,25.0563183075642
19582,1032:1510,Colon,HCT-15,SIDM00789,905937,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.959476309611267,0.059342383760969,0.694438789263491,10.5019709899153,28.3229,0.922195409625779,0.933625569557762,0.0792220454378971,0.666297566773451,0.48784292150403,0.17845464526942,9.06182303899507,10.4378,1.44014795092019,17.8851,0.884824648368193,0.815087193426961,0.895791616037999,0.841458016183552,0.0697374549412321,0.0543335998544473,True,0.122422380174148,0.0262902013554606,1.91411019602722,25.7402793695913
20928,1083:1549,Colon,HCT-15,SIDM00789,905937,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.673606494251723,0.086610307718814,0.802929146233553,11.56996570973,29.6898,0.92236915607436,0.960033356705092,0.0427802644627728,0.540858287326913,0.174370626751361,0.366487660575552,7.07551110786048,1.3172,4.49445460186949,28.3726,0.62131385362917,0.497713273336767,0.646684703774831,0.50853633849887,0.123600580292403,0.138148365275961,True,0.0815614553839107,0.0215367248282488,2.23928402347549,22.044031053242
20928,2048:1549,Colon,HCT-15,SIDM00789,905937,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.01,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.738887379426844,0.086610307718814,0.802929146233553,11.56996570973,29.6898,0.92236915607436,0.960033356705092,0.0483614301191419,0.593274212725943,0.163014093186935,0.430260119539008,6.69102263693726,1.009,4.87894307279272,28.6808,0.681526928595934,0.511454833963364,0.709356531098182,0.536589144302603,0.17007209463257,0.172767386795579,True,0.0815614553839107,0.0215367248282488,2.23928402347549,22.044031053242
20928,1053:1549,Colon,HCT-15,SIDM00789,905937,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.376795977441097,0.086610307718814,0.802929146233553,11.56996570973,29.6898,0.92236915607436,0.960033356705092,0.033039745753789,0.302540472471017,0.140284355771774,0.162256116699243,8.04438202239016,2.5781,3.52558368733982,27.1117,0.347544987724558,0.296884123668882,0.361736707015752,0.309174250527956,0.0506608640556762,0.0525624564877963,True,0.0815614553839107,0.0215367248282488,2.23928402347549,22.044031053242
20928,2171:1549,Colon,HCT-15,SIDM00789,905937,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.609999300591845,0.086610307718814,0.802929146233553,11.56996570973,29.6898,0.92236915607436,0.960033356705092,0.0701042692938967,0.489786217627274,0.161826900591043,0.327959317036231,7.13633403195503,1.3739,4.43363167777495,28.3159,0.56264454009285,0.436908821356857,0.585619676134947,0.463210571642875,0.125735718735993,0.122409104492072,True,0.0815614553839107,0.0215367248282488,2.23928402347549,22.044031053242
20928,1510:1549,Colon,HCT-15,SIDM00789,905937,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.5865607032978,0.086610307718814,0.802929146233553,11.56996570973,29.6898,0.92236915607436,0.960033356705092,0.154570042243392,0.470966684713055,0.176702625715001,0.294264058998054,7.46072679657548,1.7203,4.10923891315449,27.9695,0.541025500887175,0.345965818961449,0.563117840898287,0.458852171040971,0.195059681925726,0.104265669857316,True,0.0815614553839107,0.0215367248282488,2.23928402347549,22.044031053242
20034,1053:1564,Colon,HCT-15,SIDM00789,905937,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.694295892004303,0.116997124436006,0.62103812705228,9.90371566078872,9.3544,0.879041452713687,0.913318838414532,0.0258908807768591,0.431184220390445,0.301323045925748,0.129861174464697,8.51415081051267,3.5704,1.38956485027605,5.784,0.610314869520608,0.590803152825766,0.634113517601351,0.588965242777424,0.0195117166948416,0.045148274823927,True,0.114299271286458,0.037342189154545,1.96644644918607,25.0563183075642
20034,1083:1564,Colon,HCT-15,SIDM00789,905937,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.842083839179664,0.116997124436006,0.62103812705228,9.90371566078872,9.3544,0.879041452713687,0.913318838414532,0.100153723636604,0.522966170305132,0.646348612130187,-0.123382441825055,11.1855291855977,22.7447,-1.28181352480894,-13.3903,0.740226601299211,0.774841859112627,0.76909103384722,0.801525115463608,-0.0346152578134159,-0.0324340816163873,True,0.114299271286458,0.037342189154545,1.96644644918607,25.0563183075642
20034,1561:1564,Colon,HCT-15,SIDM00789,905937,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.733722258161495,0.116997124436006,0.62103812705228,9.90371566078872,9.3544,0.879041452713687,0.913318838414532,0.141363725814466,0.455669496985185,0.0842897592421655,0.371379737743019,5.26436730769373,0.3753,4.63934835309499,8.9791,0.644972279702648,0.383651104967569,0.670122360542944,0.447553272690858,0.261321174735079,0.222569087852086,True,0.114299271286458,0.037342189154545,1.96644644918607,25.0563183075642
20036,1047:2048,Colon,HCT-15,SIDM00789,905937,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.974434646610681,0.129894729943261,0.211362915359533,6.59098570939834,0.0188,0.695115555178911,0.718520421357787,0.0827042719372589,0.205959347734969,0.0367624143972978,0.169196933337672,3.07424631000701,0.0016,3.51673939939133,0.0172,0.677344680364349,0.407385305211515,0.700151192868333,0.408413666473024,0.269959375152834,0.291737526395309,True,0.114299271286458,0.037342189154545,1.96644644918607,25.0563183075642
19634,1022:1003,Colon,SNU-C2B,SIDM00781,909740,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.1,0.828926494474451,0.0497367183714979,0.670721074044104,11.0596986511888,0.4169,0.904066960536851,0.888828821933832,0.0718627389245501,0.555978468677518,0.34953828631296,0.206440182364558,8.08545143144067,0.0531,2.97424721974812,0.3638,0.749405056367984,0.638306152017304,0.736773759553467,0.631884764379857,0.11109890435068,0.104888995173611,True,0.407045196922232,0.038164825261396,0.835125698178497,57.9266400930893
19637,2048:1011,Colon,SNU-C2B,SIDM00781,909740,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.941406275025143,0.0586431052503158,0.590988280261723,10.0655406995427,20.9295,0.858668272323203,0.853996772302184,0.0323744330744978,0.556360075504704,0.440202656995701,0.116157418509003,8.62428464956575,7.7072,1.44125604997695,13.2223,0.808355699730062,0.746347260715276,0.803957920296494,0.743872322810749,0.0620084390147858,0.0600855974857452,True,0.407045196922232,0.038164825261396,0.835125698178497,57.9266400930893
19637,1179:1011,Colon,SNU-C2B,SIDM00781,909740,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.485716754005672,0.0586431052503158,0.590988280261723,10.0655406995427,20.9295,0.858668272323203,0.853996772302184,0.0855976620395085,0.287052909144119,0.154491400421176,0.132561508722943,6.79203751183808,2.1644,3.27350318770463,18.7651,0.417069566000485,0.304896324478942,0.414800540173938,0.333861803710212,0.112173241521543,0.080938736463726,True,0.407045196922232,0.038164825261396,0.835125698178497,57.9266400930893
19639,2048:1047,Colon,SNU-C2B,SIDM00781,909740,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,10.0,0.933728591243715,0.0384954062607678,0.806343653629872,13.1296125817139,175.04,0.955535898942414,0.939874654479735,0.0262488506214765,0.752906123762131,0.546918592364466,0.205987531397664,10.0027579460491,20.0383,3.1268546356648,155.0017,0.892211188802297,0.793172052951281,0.877587837073037,0.795114966725301,0.0990391358510163,0.0824728703477356,True,0.407045196922232,0.038164825261396,0.835125698178497,57.9266400930893
19638,2048:1053,Colon,SNU-C2B,SIDM00781,909740,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.01,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.649848468766713,0.0459626660962103,0.706450870418455,11.5424833834262,58.2591,0.895820883001732,0.903173949714109,0.0447876216320658,0.459086016400345,0.284882445549063,0.174203570851282,8.28280891995241,6.0828,3.25967446347378,52.1763,0.58214782910792,0.475474521065223,0.586926208251698,0.502169117485088,0.106673308042697,0.0847570907666101,True,0.407045196922232,0.038164825261396,0.835125698178497,57.9266400930893
19638,1373:1053,Colon,SNU-C2B,SIDM00781,909740,1373,Dabrafenib,BRAF,ERK MAPK signaling,Targeted,FDA approved,1,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.886117199210951,0.0459626660962103,0.706450870418455,11.5424833834262,58.2591,0.895820883001732,0.903173949714109,0.0436033309847959,0.62599826667534,0.482995797545808,0.143002469129532,9.52334398178322,14.3728,2.01913940164297,43.8863,0.793802291840176,0.714789348014963,0.800317970720959,0.737120738934472,0.0790129438252134,0.0631972317864867,True,0.407045196922232,0.038164825261396,0.835125698178497,57.9266400930893
19553,1083:1549,Colon,SNU-C2B,SIDM00781,909740,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.941522488908826,0.0499771951125048,0.698412611589301,11.4311432767605,26.966,0.891680923822576,0.900008079868727,0.0377218367362193,0.657571180348872,0.557036751201836,0.100534429147036,10.0732767749658,10.521,1.35786650179467,16.445,0.839537642709953,0.791004500592106,0.847377847396058,0.804339267801849,0.048533142117847,0.0430385795942085,True,0.301437846817851,0.0313999186014628,1.12035622121367,43.5948771528688
19553,1786:1549,Colon,SNU-C2B,SIDM00781,909740,1786,AZD4547,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Advanced clinical trials,10,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.636749377739405,0.0499771951125048,0.698412611589301,11.4311432767605,26.966,0.891680923822576,0.900008079868727,0.0609105760357467,0.444713795834841,0.270111792241226,0.174602003593615,8.11544354333948,2.7083,3.31569973342101,24.2577,0.567777273386123,0.469188851759416,0.573079584816849,0.486412584285367,0.0985884216267073,0.0866670005314815,True,0.301437846817851,0.0313999186014628,1.12035622121367,43.5948771528688
22678,1083:1011,Colon,COLO-678,SIDM00957,910689,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.966307130285157,0.102973311239062,0.706487848055553,13.624377572692,246.6473,0.893108994664511,0.848834821331525,0.11173866557207,0.682684245035898,0.678768578572433,0.0039156664634649,13.5219087029062,229.7366,0.102468869785787,16.9107,0.863017589666125,0.875002497565409,0.82023514028698,0.817893761961884,-0.0119849078992834,0.0023413783250961,True,0.829645477106352,0.0754333092735834,0.147816011870294,276.906111506539
22678,2048:1011,Colon,COLO-678,SIDM00957,910689,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.946776423394244,0.102973311239062,0.706487848055553,13.624377572692,246.6473,0.893108994664511,0.848834821331525,0.177767777855238,0.668886037953533,0.429731330850808,0.239154707102725,8.02620297779556,5.0916,5.59817459489645,241.5557,0.845574539669695,0.669346738622697,0.803656796192753,0.635577534583842,0.176227801046998,0.168079261608911,True,0.829645477106352,0.0754333092735834,0.147816011870294,276.906111506539
22684,1011:1179,Colon,COLO-678,SIDM00957,910689,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,10.0,0.866506608977627,0.12995301635073,0.669842275993344,12.7245733377969,132.193,0.813864206255571,0.826506006005311,0.117142372118393,0.580422759120848,0.46088150348665,0.119541255634198,9.67235373335879,15.9367,3.05221960443815,116.2563,0.705218713530783,0.662431120671536,0.716172916563304,0.634946902017481,0.0427875928592469,0.0812260145458229,True,0.829645477106352,0.0754333092735834,0.147816011870294,276.906111506539
22684,1003:1179,Colon,COLO-678,SIDM00957,910689,1003,Camptothecin,TOP1,DNA replication,Chemotherapeutic,FDA approved in colon,0.025,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,10.0,0.974406889825112,0.12995301635073,0.669842275993344,12.7245733377969,132.193,0.813864206255571,0.826506006005311,0.0597856110439504,0.652698928824048,0.70842953156864,-0.0557306027445911,14.1574336938081,356.8965,-1.43286035601112,-224.7035,0.793034889957474,0.825577960900943,0.80535314673341,0.838918759515664,-0.0325430709434688,-0.033565612782254,True,0.829645477106352,0.0754333092735834,0.147816011870294,276.906111506539
22684,1059:1179,Colon,COLO-678,SIDM00957,910689,1059,AZD8055,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,10.0,0.915135964199316,0.12995301635073,0.669842275993344,12.7245733377969,132.193,0.813864206255571,0.826506006005311,0.0448211744489907,0.612996757102633,0.464426657166435,0.148570099936198,9.15783907691416,11.1561,3.56673426088279,121.0369,0.744796405119003,0.625835840536468,0.756365370722196,0.653688046502675,0.118960564582536,0.102677324219521,True,0.829645477106352,0.0754333092735834,0.147816011870294,276.906111506539
22684,1089:1549,Colon,COLO-678,SIDM00957,910689,1089,Oxaliplatin,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved in colon,5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.987863444749466,0.118149855637094,0.675998467495314,12.8718289903068,73.1993,0.785878279551916,0.830323892417335,0.067463157757881,0.66779417474528,0.658066149966214,0.0097280247790662,12.6369461190436,62.2014,0.234882871263187,10.9979,0.77634042439194,0.801421752204222,0.820246620621173,0.814200402600601,-0.0250813278122825,0.006046218020572,True,0.829645477106352,0.0754333092735834,0.147816011870294,276.906111506539
22684,2171:1549,Colon,COLO-678,SIDM00957,910689,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.783420786812047,0.118149855637094,0.675998467495314,12.8718289903068,73.1993,0.785878279551916,0.830323892417335,0.109557853909218,0.529591251288916,0.272140151734297,0.25745109955462,5.6801202154028,0.5007,7.19170877490396,72.6986,0.61567338010506,0.383717866657535,0.65049299710643,0.449510041144869,0.231955513447525,0.200982955961561,True,0.829645477106352,0.0754333092735834,0.147816011870294,276.906111506539
22684,1510:1549,Colon,COLO-678,SIDM00957,910689,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.855130881451565,0.118149855637094,0.675998467495314,12.8718289903068,73.1993,0.785878279551916,0.830323892417335,0.115272722006801,0.578067165369174,0.447255890885951,0.130811274483223,9.48524129901881,6.9991,3.38658769128795,66.2002,0.672028785906869,0.554948891760961,0.71003560201313,0.620941821808769,0.117079894145909,0.0890937802043613,True,0.829645477106352,0.0754333092735834,0.147816011870294,276.906111506539
22684,2048:1549,Colon,COLO-678,SIDM00957,910689,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.930526593157871,0.118149855637094,0.675998467495314,12.8718289903068,73.1993,0.785878279551916,0.830323892417335,0.0993858116806022,0.629034550938356,0.502354895657067,0.126679655281289,9.84119516976725,8.9577,3.03063382053952,64.2416,0.731280638108213,0.624944099183789,0.772638462828685,0.687347798803221,0.106336538924424,0.0852906640254637,True,0.829645477106352,0.0754333092735834,0.147816011870294,276.906111506539
22684,1047:1549,Colon,COLO-678,SIDM00957,910689,1047,Nutlin-3a (-),MDM2,p53 pathway,Targeted,Experimental only,2.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.825048263219889,0.118149855637094,0.675998467495314,12.8718289903068,73.1993,0.785878279551916,0.830323892417335,0.0522970924429649,0.557731361546315,0.466897776250441,0.0908335852958742,10.3959525127754,13.1581,2.47587647753137,60.0412,0.648387509646543,0.584856524820027,0.685057285348901,0.624956043263081,0.0635309848265156,0.0601012420858197,True,0.829645477106352,0.0754333092735834,0.147816011870294,276.906111506539
22685,1179:1561,Colon,COLO-678,SIDM00957,910689,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.923017411560363,0.0545072388471142,0.777232399952715,15.5787292434932,955.8612,0.88892338552655,0.889433036092157,0.117132559485425,0.717399037985203,0.504534147330038,0.212864890655165,9.9844775496369,19.786,5.59425169385631,936.0752,0.82049176238419,0.611504037592557,0.820962178730057,0.686363674867865,0.208987724791633,0.134598503862192,True,0.829645477106352,0.0754333092735834,0.147816011870294,276.906111506539
22685,1561:1564,Colon,COLO-678,SIDM00957,910689,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.915410292367614,0.10473100269563,0.551473735730449,10.0878134456794,10.6276,0.728233506827914,0.747137464278122,0.0767864487913443,0.50482473365807,0.332900359704435,0.171924373953635,6.0544266947815,0.649,4.03338675089791,9.9786,0.666632447397233,0.483426983718059,0.683937324613633,0.540013039165442,0.183205463679174,0.14392428544819,True,0.829645477106352,0.0754333092735834,0.147816011870294,276.906111506539
38107,1089:1005,Pancreas,PL4,SIDM00042,1298533,1089,Oxaliplatin,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved in pancreas,2.5,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,8.0,0.841315498459702,0.0912568457595062,0.690513830838563,10.6854980637446,25.7321,0.930378440427444,0.923027380133856,0.116635329253427,0.580939987785264,0.292394955113727,0.288545032671538,7.67716128157415,3.198,3.00833678217046,22.5341,0.782741801364375,0.593375134455843,0.776557240409268,0.657386010312579,0.189366666908532,0.119171230096689,True,0.369015225346918,0.0622468248261796,0.923654642499215,52.4604517987161
38107,1053:1005,Pancreas,PL4,SIDM00042,1298533,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,8.0,0.838632611658974,0.0912568457595062,0.690513830838563,10.6854980637446,25.7321,0.930378440427444,0.923027380133856,0.0679599708124222,0.579087417342788,0.524711341727677,0.0543760756151106,10.0789111452215,16.8995,0.606586918523126,8.8326,0.780245701326871,0.756616907073248,0.774080862434397,0.756938270141637,0.0236287942536226,0.0171425922927602,True,0.369015225346918,0.0622468248261796,0.923654642499215,52.4604517987161
38107,1179:1005,Pancreas,PL4,SIDM00042,1298533,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,8.0,0.578488926918843,0.0912568457595062,0.690513830838563,10.6854980637446,25.7321,0.930378440427444,0.923027380133856,0.0702809028657929,0.39945460502442,0.194724040401328,0.204730564623092,7.57509231572027,2.9795,3.11040574802434,22.7526,0.538213625631298,0.412179520188509,0.533961118650345,0.448229673085224,0.12603410544279,0.0857314455651214,True,0.369015225346918,0.0622468248261796,0.923654642499215,52.4604517987161
38107,1190:1005,Pancreas,PL4,SIDM00042,1298533,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.01,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,8.0,0.867090697468672,0.0912568457595062,0.690513830838563,10.6854980637446,25.7321,0.930378440427444,0.923027380133856,0.0973324901005271,0.598738119193575,0.624186967745796,-0.025448848552221,10.9821839129554,31.6073,-0.296685849210844,-5.8752,0.806722490820048,0.776439382068514,0.800348454822947,0.807837279293102,0.0302831087515342,-0.0074888244701547,True,0.369015225346918,0.0622468248261796,0.923654642499215,52.4604517987161
38107,1011:1005,Pancreas,PL4,SIDM00042,1298533,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,8.0,0.281637532370145,0.0912568457595062,0.690513830838563,10.6854980637446,25.7321,0.930378440427444,0.923027380133856,0.0928040961590716,0.194474611384828,0.0650813456755501,0.129393265709278,6.47505412319006,1.39,4.21044394055455,24.3421,0.262029488132369,0.164945354111593,0.259959153650979,0.196642578458907,0.0970841340207753,0.0633165751920713,True,0.369015225346918,0.0622468248261796,0.923654642499215,52.4604517987161
38107,1022:1005,Pancreas,PL4,SIDM00042,1298533,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,8.0,0.927689470034843,0.0912568457595062,0.690513830838563,10.6854980637446,25.7321,0.930378440427444,0.923027380133856,0.184535074669543,0.640582409782356,0.32034133020624,0.320241079576116,7.65643841491168,3.1524,3.02905964883292,22.5797,0.863102282331979,0.653143348629004,0.856282781104027,0.72365087112954,0.209958933702975,0.132631909974487,True,0.369015225346918,0.0622468248261796,0.923654642499215,52.4604517987161
38107,1564:1011,Pancreas,PL4,SIDM00042,1298533,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.658917565930479,0.10156612677526,0.185289021347006,5.88970508543465,1.158,0.668657259808303,0.653686403489876,0.0792432289955204,0.12209019093961,0.0459427712873242,0.0761474196522857,3.55840502602194,0.2301,2.33130005941271,0.9279,0.440590014074631,0.292929557734914,0.430725453869399,0.305315628189177,0.147660456339717,0.125409825680222,True,0.369015225346918,0.0622468248261796,0.923654642499215,52.4604517987161
38107,1561:1011,Pancreas,PL4,SIDM00042,1298533,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.771118686287883,0.10156612677526,0.185289021347006,5.88970508543465,1.158,0.668657259808303,0.653686403489876,0.0647489454191569,0.142879826724671,0.0436597642013355,0.0992200625233353,3.09172258358259,0.1665,2.79798250185206,0.9915,0.515614107760234,0.311058544334802,0.504069800703365,0.327660421395395,0.204555563425432,0.176409379307969,True,0.369015225346918,0.0622468248261796,0.923654642499215,52.4604517987161
38112,1011:1083,Pancreas,PL4,SIDM00042,1298533,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.331590318189735,0.0756269295275551,0.53579208383472,9.30120448333484,9.8574,0.854559251698018,0.87049330660716,0.068125009761096,0.177663467562296,0.0591416038396921,0.118521863722604,5.79183507646319,0.8656,3.50936940687165,8.9918,0.283363574182528,0.178820790157866,0.288647152519903,0.214221136483351,0.104542784024661,0.0744260160365512,True,0.369015225346918,0.0622468248261796,0.923654642499215,52.4604517987161
38112,1372:1085,Pancreas,PL4,SIDM00042,1298533,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.683639229212901,0.116697392446392,0.613972375599047,9.9746021028812,19.651,0.902452436337357,0.898675239548746,0.0494448758394862,0.419735601612547,0.526497388533444,-0.106761786920898,11.5394070492163,58.135,-1.56480494633511,-38.484,0.616951887978976,0.642817543414248,0.614369648077824,0.646504203552839,-0.0258656554352727,-0.032134555475015,True,0.369015225346918,0.0622468248261796,0.923654642499215,52.4604517987161
38112,1558:1085,Pancreas,PL4,SIDM00042,1298533,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.811799384518815,0.116697392446392,0.613972375599047,9.9746021028812,19.651,0.902452436337357,0.898675239548746,0.0938038506837399,0.498422396622861,0.199790955084115,0.298631441538747,6.64882379972716,1.9599,3.32577830315404,17.6911,0.732610332376172,0.578895240893211,0.72954400634797,0.577174200254071,0.153715091482961,0.1523698060939,True,0.369015225346918,0.0622468248261796,0.923654642499215,52.4604517987161
39388,1011:1088,Pancreas,PL4,SIDM00042,1298533,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,0.626601121099324,0.0642488831437009,0.580803173095179,9.68483137024058,8.0376,0.893863846743981,0.887177020717361,0.0566637357972975,0.363931919399484,0.192175044851276,0.171756874548207,7.28699591382864,1.5251,2.39783545641194,6.5125,0.560096088479933,0.484570277684778,0.555906115795057,0.473580908583317,0.0755258107951549,0.08232520721174,True,0.402353562218538,0.0548116384564468,0.845815971871477,57.2116572655736
39388,1022:1088,Pancreas,PL4,SIDM00042,1298533,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,0.902260474747396,0.0642488831437009,0.580803173095179,9.68483137024058,8.0376,0.893863846743981,0.887177020717361,0.0812799646884872,0.52403574669165,0.247645396607768,0.276390350083882,6.95845301537812,1.2145,2.72637835486246,6.8231,0.806498018722758,0.649531123790786,0.800464759897427,0.661495582340567,0.156966894931972,0.13896917755686,True,0.402353562218538,0.0548116384564468,0.845815971871477,57.2116572655736
38415,1179:1168,Pancreas,PL4,SIDM00042,1298533,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.44441431889254,0.0350050810239685,0.925352937945857,14.2871777805654,390.4803,0.982202899213153,0.983851126618838,0.10067026505628,0.411240095652419,0.217552583927911,0.193687511724508,8.91199921478587,9.4083,5.37517856577951,381.072,0.436505032468092,0.307923357207173,0.437237528327969,0.378570247108289,0.128581675260919,0.0586672812196804,True,0.460000596625353,0.0739947369785051,0.724395516121771,66.6564022500615
38415,1594:1168,Pancreas,PL4,SIDM00042,1298533,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.382238404571905,0.0350050810239685,0.925352937945857,14.2871777805654,390.4803,0.982202899213153,0.983851126618838,0.0471218505170678,0.35370543066635,0.271838271935577,0.0818671587307732,10.8925267732557,37.1285,3.39465100730969,353.3518,0.375435669161136,0.343067142380742,0.376065684975056,0.355154535230072,0.0323685267803941,0.020911149744984,True,0.460000596625353,0.0739947369785051,0.724395516121771,66.6564022500615
38415,1079:1168,Pancreas,PL4,SIDM00042,1298533,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.5,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.68094885650096,0.0350050810239685,0.925352937945857,14.2871777805654,390.4803,0.982202899213153,0.983851126618838,0.0913365376825192,0.630118024954035,0.404723728397788,0.225394296556247,9.80227126660557,17.4384,4.48490651395981,373.0419,0.668829941071124,0.546543328630714,0.669952299638279,0.607372520114722,0.122286612440411,0.0625797795235564,True,0.460000596625353,0.0739947369785051,0.724395516121771,66.6564022500615
38416,1053:1190,Pancreas,PL4,SIDM00042,1298533,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.2,0.975724923692976,0.0798108821753341,0.567784603868316,9.57298612625444,0.2975,0.848525961100827,0.882486274234179,0.0849838224126604,0.554001589283459,0.342443656988539,0.211557932294921,7.70875051815628,0.0817,1.86423560809816,0.2158,0.827927928646613,0.72533677316132,0.861063852587243,0.764368075141798,0.102591155485294,0.0966957774454456,True,0.460000596625353,0.0739947369785051,0.724395516121771,66.6564022500615
38416,1011:1190,Pancreas,PL4,SIDM00042,1298533,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.2,0.645874211930469,0.0798108821753341,0.567784603868316,9.57298612625444,0.2975,0.848525961100827,0.882486274234179,0.081874050382341,0.366717433569702,0.143487259990897,0.223230173578805,6.36812553433448,0.0323,3.20486059191996,0.2652,0.54804103642854,0.42024778961712,0.569975126910456,0.44581149359716,0.127793246811421,0.124163633313296,True,0.460000596625353,0.0739947369785051,0.724395516121771,66.6564022500615
38416,1022:1190,Pancreas,PL4,SIDM00042,1298533,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.2,0.884079003883455,0.0798108821753341,0.567784603868316,9.57298612625444,0.2975,0.848525961100827,0.882486274234179,0.120489253141157,0.501966447008263,0.142559498091602,0.359406948916661,5.53680956661875,0.0181,4.03617655963569,0.2794,0.75016398645927,0.534118487441304,0.780187586265775,0.553338054147321,0.216045499017966,0.226849532118454,True,0.460000596625353,0.0739947369785051,0.724395516121771,66.6564022500615
38416,1011:1372,Pancreas,PL4,SIDM00042,1298533,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.645874211930469,0.102333639391726,0.301516587966998,7.23560857016401,0.2944,0.727391209915484,0.752315892361432,0.0993168572255812,0.194741788637149,0.0359555932264471,0.158786195410701,3.05410648057082,0.0162,4.18150208959319,0.2782,0.469803224469314,0.257892189414117,0.485901434101708,0.272454421202948,0.211911035055197,0.21344701289876,True,0.460000596625353,0.0739947369785051,0.724395516121771,66.6564022500615
38416,1561:1372,Pancreas,PL4,SIDM00042,1298533,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.794566951022561,0.102333639391726,0.301516587966998,7.23560857016401,0.2944,0.727391209915484,0.752315892361432,0.0647130412308425,0.239575115983663,0.079957866707601,0.159617249276062,4.39995727179144,0.0412,2.83565129837257,0.2532,0.577961015863158,0.41543047384169,0.597765344799441,0.423657240768939,0.162530542021468,0.174108104030502,True,0.460000596625353,0.0739947369785051,0.724395516121771,66.6564022500615
38417,1080:1510,Pancreas,PL4,SIDM00042,1298533,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.025,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.617099122737561,0.0716094509016992,0.865344605555427,12.9073238049859,150.045,0.94757532105539,0.969903996567565,0.0959851279279997,0.534003396953935,0.337872223348273,0.196131173605662,9.40039811389034,13.1987,3.50692569109555,136.8463,0.584747899351044,0.455106449640003,0.598526905421499,0.539942277575897,0.129641449711041,0.0585846278456019,True,0.460000596625353,0.0739947369785051,0.724395516121771,66.6564022500615
38417,1085:1510,Pancreas,PL4,SIDM00042,1298533,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,5,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.724329834840943,0.0716094509016992,0.865344605555427,12.9073238049859,150.045,0.94757532105539,0.969903996567565,0.0758207944104475,0.626794915222464,0.438533125854364,0.188261789368099,9.89923168958129,18.6507,3.00809211540461,131.3943,0.686357075799405,0.597053962697916,0.702530401645355,0.648836298830201,0.0893031131014883,0.0536941028151546,True,0.460000596625353,0.0739947369785051,0.724395516121771,66.6564022500615
38417,1088:1510,Pancreas,PL4,SIDM00042,1298533,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.73472281455715,0.0716094509016992,0.865344605555427,12.9073238049859,150.045,0.94757532105539,0.969903996567565,0.116144042659056,0.63578842415553,0.382318642099707,0.253469782055823,9.17111926999103,11.2593,3.73620453499487,138.7857,0.696205206890712,0.539646367401769,0.71261059420835,0.635133355879004,0.156558839488943,0.0774772383293462,True,0.460000596625353,0.0739947369785051,0.724395516121771,66.6564022500615
38417,1011:1510,Pancreas,PL4,SIDM00042,1298533,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.643125148462948,0.0716094509016992,0.865344605555427,12.9073238049859,150.045,0.94757532105539,0.969903996567565,0.0628396098821465,0.556524877919445,0.314610263456821,0.241914614462624,8.90916936595604,9.3898,3.99815443902985,140.6552,0.609409519033573,0.507687410068996,0.623769651787322,0.54774891436162,0.101722108964577,0.0760207374257015,True,0.460000596625353,0.0739947369785051,0.724395516121771,66.6564022500615
38417,1057:1510,Pancreas,PL4,SIDM00042,1298533,1057,Dactolisib,"PI3K (class 1), MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.0125,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.903721020715189,0.0716094509016992,0.865344605555427,12.9073238049859,150.045,0.94757532105539,0.969903996567565,0.117635781791402,0.782030110202933,0.373780741654218,0.408249368548715,8.26681335093277,6.0157,4.64051045405313,144.0293,0.8563437363487,0.650846348016262,0.876522629773781,0.738440387469611,0.205497388332438,0.13808224230417,True,0.460000596625353,0.0739947369785051,0.724395516121771,66.6564022500615
38417,1594:1510,Pancreas,PL4,SIDM00042,1298533,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.416179075666274,0.0716094509016992,0.865344605555427,12.9073238049859,150.045,0.94757532105539,0.969903996567565,0.061155230230738,0.360138318072854,0.138602083444311,0.221536234628543,7.5413948259292,3.6384,5.3659289790567,146.4066,0.394361021241006,0.273470609114465,0.403653748776515,0.321557958125992,0.120890412126541,0.0820957906505228,True,0.460000596625353,0.0739947369785051,0.724395516121771,66.6564022500615
38417,1079:1510,Pancreas,PL4,SIDM00042,1298533,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.05,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.87439513123442,0.0716094509016992,0.865344605555427,12.9073238049859,150.045,0.94757532105539,0.969903996567565,0.074628597452647,0.756653109937635,0.488254165076798,0.268398944860837,9.49278921143022,14.0716,3.41453459355568,135.9734,0.828555247208726,0.725536147144187,0.848079332363484,0.768624171686781,0.103019100064538,0.0794551606767039,True,0.460000596625353,0.0739947369785051,0.724395516121771,66.6564022500615
38418,1510:1558,Pancreas,PL4,SIDM00042,1298533,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.848400738502939,0.0666817269002284,0.892185551649691,13.4383793926811,216.813,0.946376895153224,0.976257099656311,0.0806369916385812,0.756930880901249,0.501632053867514,0.255298827033736,9.77543108071538,17.117,3.66294831196567,199.696,0.802906856750114,0.719313329876113,0.828257244317152,0.75581735394327,0.0835935268740001,0.0724398903738815,True,0.460000596625353,0.0739947369785051,0.724395516121771,66.6564022500615
38418,1053:1558,Pancreas,PL4,SIDM00042,1298533,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.87229989641082,0.0666817269002284,0.892185551649691,13.4383793926811,216.813,0.946376895153224,0.976257099656311,0.0788743918913566,0.778253364283255,0.696188063803197,0.0820653004800578,11.8867948930594,73.9625,1.55158449962163,142.8505,0.82552446760775,0.811189033052976,0.851588966900528,0.831380763641157,0.0143354345547745,0.0202082032593709,True,0.460000596625353,0.0739947369785051,0.724395516121771,66.6564022500615
38418,1083:1558,Pancreas,PL4,SIDM00042,1298533,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,1,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.886132428510087,0.0666817269002284,0.892185551649691,13.4383793926811,216.813,0.946376895153224,0.976257099656311,0.0565340540736958,0.790594549564952,0.722435727089804,0.0681588224751483,12.1180586641087,86.8219,1.32032072857238,129.9911,0.838615256387962,0.846285531534815,0.865093074568661,0.848482096858286,-0.0076702751468523,0.0166109777103749,True,0.460000596625353,0.0739947369785051,0.724395516121771,66.6564022500615
38418,1085:1558,Pancreas,PL4,SIDM00042,1298533,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,1.25,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.958797244247488,0.0666817269002284,0.892185551649691,13.4383793926811,216.813,0.946376895153224,0.976257099656311,0.0607822641095338,0.855425048279148,0.806295473033286,0.0491295752458624,12.4974917843881,112.9406,0.940887608292943,103.8724,0.907383559092405,0.919271091483389,0.936032616827516,0.924239347428209,-0.0118875323909846,0.0117932693993068,True,0.460000596625353,0.0739947369785051,0.724395516121771,66.6564022500615
38418,1372:1558,Pancreas,PL4,SIDM00042,1298533,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.50694684588147,0.0666817269002284,0.892185551649691,13.4383793926811,216.813,0.946376895153224,0.976257099656311,0.116581823306077,0.45229065134983,0.231345920639104,0.220944730710727,8.63237263626806,7.7506,4.806006756413,209.0624,0.479762782013026,0.344857682736793,0.494910457440159,0.424500298402324,0.134905099276233,0.0704101590378353,True,0.460000596625353,0.0739947369785051,0.724395516121771,66.6564022500615
38418,1594:1558,Pancreas,PL4,SIDM00042,1298533,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.380168979054089,0.0666817269002284,0.892185551649691,13.4383793926811,216.813,0.946376895153224,0.976257099656311,0.0392253166365668,0.339181270297472,0.298856964945184,0.0403243053522883,11.7338351066275,66.5222,1.70454428605353,150.2908,0.35978313803078,0.349303913836227,0.371142664870646,0.36113983651467,0.010479224194553,0.0100028283559759,True,0.460000596625353,0.0739947369785051,0.724395516121771,66.6564022500615
38418,1372:1561,Pancreas,PL4,SIDM00042,1298533,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.470846335070862,0.107440613815064,0.420006283108773,8.3221493642692,6.251,0.763147225326217,0.820272735787967,0.0949788046368031,0.197758419108501,0.0668993746069633,0.130859044501538,5.22355320856442,0.7298,3.09859615570478,5.5212,0.359325074164347,0.242763346503897,0.386222411404314,0.282859296515159,0.11656172766045,0.103363114889156,True,0.460000596625353,0.0739947369785051,0.724395516121771,66.6564022500615
38418,1011:1561,Pancreas,PL4,SIDM00042,1298533,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.604596403556944,0.107440613815064,0.420006283108773,8.3221493642692,6.251,0.763147225326217,0.820272735787967,0.0547269456224836,0.253934288238884,0.0634299695342866,0.190504318704597,4.49750424378368,0.4412,3.82464512048552,5.8098,0.461396067816691,0.321382182915812,0.49593394599322,0.327248021638361,0.140013884900879,0.16868592435486,True,0.460000596625353,0.0739947369785051,0.724395516121771,66.6564022500615
38418,1057:1561,Pancreas,PL4,SIDM00042,1298533,1057,Dactolisib,"PI3K (class 1), MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.0125,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.924291216835217,0.107440613815064,0.420006283108773,8.3221493642692,6.251,0.763147225326217,0.820272735787967,0.0974871430279543,0.388208118493044,0.185735112479194,0.20247300601385,6.10086632131867,1.3405,2.22128304295053,4.9105,0.705370277521188,0.563741238559639,0.758170885098213,0.619272179473155,0.141629038961549,0.138898705625057,True,0.460000596625353,0.0739947369785051,0.724395516121771,66.6564022500615
38418,1594:1561,Pancreas,PL4,SIDM00042,1298533,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.380168979054089,0.107440613815064,0.420006283108773,8.3221493642692,6.251,0.763147225326217,0.820272735787967,0.100948613590143,0.159673359845765,0.0586721073660721,0.101001252479693,5.42742571725129,0.8405,2.89472364701791,5.4105,0.290124901520229,0.177943659208161,0.311842248510416,0.234624034898689,0.112181242312068,0.0772182136117274,True,0.460000596625353,0.0739947369785051,0.724395516121771,66.6564022500615
38418,1564:1561,Pancreas,PL4,SIDM00042,1298533,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.502298711442336,0.107440613815064,0.420006283108773,8.3221493642692,6.251,0.763147225326217,0.820272735787967,0.100127719430245,0.210968614803222,0.0711831503515041,0.139785464451718,5.21719769495201,0.7265,3.10495166931719,5.5245,0.383327867922153,0.256637543624041,0.412021938217576,0.301495966483886,0.126690324298111,0.110525971733689,True,0.460000596625353,0.0739947369785051,0.724395516121771,66.6564022500615
38419,1053:1564,Pancreas,PL4,SIDM00042,1298533,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.906703438361959,0.105670953286101,0.362451719185826,7.81390749655602,4.3949,0.739245131131135,0.789989826613243,0.132172373946463,0.328636220025992,0.126302910684086,0.202333309341906,5.17518393602777,0.7057,2.63872356052825,3.6892,0.670276102188938,0.512947998045198,0.716286492061195,0.541148055125096,0.15732810414374,0.175138436936099,True,0.460000596625353,0.0739947369785051,0.724395516121771,66.6564022500615
38419,1561:1564,Pancreas,PL4,SIDM00042,1298533,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,2,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.733438970954211,0.105670953286101,0.362451719185826,7.81390749655602,4.3949,0.739245131131135,0.789989826613243,0.123776042343588,0.265836215940237,0.0421803756972022,0.223655840243035,3.12652724879552,0.1706,4.6873802477605,4.2243,0.542191188259731,0.305810196485582,0.579409325495513,0.313740614805554,0.236380991774149,0.265668710689959,True,0.460000596625353,0.0739947369785051,0.724395516121771,66.6564022500615
38419,1057:1564,Pancreas,PL4,SIDM00042,1298533,1057,Dactolisib,"PI3K (class 1), MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.0125,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.906858205500539,0.105670953286101,0.362451719185826,7.81390749655602,4.3949,0.739245131131135,0.789989826613243,0.119802202747663,0.328692315641443,0.14768121392586,0.181011101715584,5.56151496253147,0.9224,2.25239253402455,3.4725,0.670390513042592,0.53838745724198,0.716408756526168,0.569377840589018,0.132003055800612,0.14703091593715,True,0.460000596625353,0.0739947369785051,0.724395516121771,66.6564022500615
38419,1011:1564,Pancreas,PL4,SIDM00042,1298533,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.609506757914302,0.105670953286101,0.362451719185826,7.81390749655602,4.3949,0.739245131131135,0.789989826613243,0.0844432985945066,0.220916772261418,0.0192956334981349,0.201621138763283,1.81588184201812,0.0688,5.9980256545379,4.3261,0.450574903179671,0.161855236077777,0.481504138004319,0.197264612529914,0.288719667101894,0.284239525474405,True,0.460000596625353,0.0739947369785051,0.724395516121771,66.6564022500615
38419,1558:1564,Pancreas,PL4,SIDM00042,1298533,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.986351369941016,0.105670953286101,0.362451719185826,7.81390749655602,4.3949,0.739245131131135,0.789989826613243,0.131337318866303,0.357504749756416,0.252884120106538,0.104620629649878,6.76354548858633,2.1221,1.05036200796969,2.2728,0.729155447813422,0.674920178815571,0.779207547719438,0.709468878915032,0.0542352689978506,0.069738668804406,True,0.460000596625353,0.0739947369785051,0.724395516121771,66.6564022500615
38419,1594:1564,Pancreas,PL4,SIDM00042,1298533,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.42217295024956,0.105670953286101,0.362451719185826,7.81390749655602,4.3949,0.739245131131135,0.789989826613243,0.0970977598789671,0.153017311611705,0.197075127758566,-0.0440578161468606,8.72077164256067,8.2403,-0.906864146004644,-3.8454,0.312089297967255,0.293477526679833,0.333512335768451,0.355485976944523,0.0186117712874211,-0.0219736411760712,True,0.460000596625353,0.0739947369785051,0.724395516121771,66.6564022500615
38419,1561:1594,Pancreas,PL4,SIDM00042,1298533,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.695510765245005,0.0967699247927042,0.367462631668522,7.85931713454396,1.8142,0.805335919261529,0.792806942590156,0.0776421566673456,0.255574216150717,0.116497774021745,0.139076442128973,5.63234841519454,0.3875,2.22696871934942,1.4267,0.560119801484876,0.432150897567637,0.551405763332432,0.440590388957603,0.127968903917238,0.110815374374829,True,0.460000596625353,0.0739947369785051,0.724395516121771,66.6564022500615
38419,1510:1594,Pancreas,PL4,SIDM00042,1298533,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.901030902209343,0.0967699247927042,0.367462631668522,7.85931713454396,1.8142,0.805335919261529,0.792806942590156,0.102478567080478,0.331095186540508,0.13073312254669,0.200362063993819,5.27495642806945,0.3025,2.58436070647451,1.5117,0.725632549913807,0.53804763805788,0.714343554759839,0.545032896414295,0.187584911855926,0.169310658345545,True,0.460000596625353,0.0739947369785051,0.724395516121771,66.6564022500615
38420,1558:1598,Pancreas,PL4,SIDM00042,1298533,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,2.5,1598,LGK974,PORCN,WNT signaling,Targeted,Early clinical trials,10.0,0.954919935743905,0.0900773505171267,0.853259515800646,12.6972761103589,129.7152,0.919600938520918,0.966979553487235,0.0346642813796802,0.814794522001229,0.878284356647936,-0.0634898346467073,14.1223184692756,348.3145,-1.42504235891669,-218.5993,0.87814526912243,0.928036658824351,0.9233880530817,0.938291556214191,-0.0498913897019214,-0.0149035031324902,True,0.460000596625353,0.0739947369785051,0.724395516121771,66.6564022500615
38420,1088:2265,Pancreas,PL4,SIDM00042,1298533,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.5,2265,Galunisertib,TGFBR1,RTK signaling,Targeted,Early clinical trials,10.0,0.897477567746581,0.0582633891332316,0.906740990832638,13.7769685150598,274.1642,0.971946976710479,0.979623580259837,0.0224023048017617,0.813779699028601,0.848582167210592,-0.0348024681819908,14.9938689076565,637.2859,-1.21690039259667,-363.1217,0.872300608636764,0.896969905970604,0.879190188118797,0.887010861304833,-0.02466929733384,-0.0078206731860364,True,0.460000596625353,0.0739947369785051,0.724395516121771,66.6564022500615
35944,1564:1053,Pancreas,SUIT-2,SIDM00371,1240219,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,1,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.77655191184996,0.0707279289896904,0.896725689943733,13.7302828929806,265.4343,0.945359306055312,0.976404600791612,0.109309108314429,0.69635404893078,0.352748321418582,0.343605727512198,8.59836460735163,7.57,5.13191828562899,257.8643,0.734120576502404,0.552258488828523,0.758228859483824,0.644543685643741,0.181862087673881,0.113685173840083,True,0.424190196426818,0.0692014474387167,0.816391018500765,59.8351871830716
35944,1372:1053,Pancreas,SUIT-2,SIDM00371,1240219,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.588888286818773,0.0707279289896904,0.896725689943733,13.7302828929806,265.4343,0.945359306055312,0.976404600791612,0.110475154257324,0.528071255297347,0.318616773632602,0.209454481664746,9.3601548372484,12.8356,4.37012805573222,252.5987,0.556711022171097,0.412553219713037,0.574993232602141,0.510851124475747,0.14415780245806,0.0641421081263942,True,0.424190196426818,0.0692014474387167,0.816391018500765,59.8351871830716
35944,1558:1053,Pancreas,SUIT-2,SIDM00371,1240219,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.942100073757064,0.0707279289896904,0.896725689943733,13.7302828929806,265.4343,0.945359306055312,0.976404600791612,0.0294652726834468,0.844805338635845,0.734650124034321,0.110155214601523,11.7674515674374,68.0904,1.96283132554321,197.3439,0.890623071961636,0.880405649067848,0.919870846422514,0.891421030141928,0.010217422893788,0.0284498162805858,True,0.424190196426818,0.0692014474387167,0.816391018500765,59.8351871830716
35944,1594:1053,Pancreas,SUIT-2,SIDM00371,1240219,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.655577840994508,0.0707279289896904,0.896725689943733,13.7302828929806,265.4343,0.945359306055312,0.976404600791612,0.0790497598231048,0.587873491777623,0.40907184974471,0.178801642032913,10.1085187733595,21.5624,3.62176411962111,243.8719,0.619756612827808,0.540227553505712,0.640109220124069,0.588803527568587,0.0795290593220954,0.0513056925554821,True,0.424190196426818,0.0692014474387167,0.816391018500765,59.8351871830716
35944,1561:1054,Pancreas,SUIT-2,SIDM00371,1240219,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.5,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,8.0,0.90140965146319,0.0971666873862165,0.778950678209214,11.7566348355872,54.0654,0.885676523334683,0.94597082698413,0.123835377794645,0.702153659351583,0.535066411884339,0.167087247467244,9.82907309775813,14.2123,1.92756173782902,39.8531,0.798357366208246,0.68994351546226,0.85270723344611,0.799910030057109,0.108413850745987,0.052797203389001,True,0.424190196426818,0.0692014474387167,0.816391018500765,59.8351871830716
38077,1561:1079,Pancreas,SUIT-2,SIDM00371,1240219,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.5,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.899780012950623,0.0569400947772104,0.862540972553397,13.0194264666962,32.4338,0.962342055482922,0.96799835013588,0.0780204764354099,0.776097127454539,0.470019438721719,0.306077688732819,9.19597693870148,2.291,3.82344952799467,30.1428,0.865896147145353,0.710395227391067,0.870985568021444,0.773760712215342,0.155500919754287,0.0972248558061021,True,0.25422191395617,0.0468775435389465,1.26936020626965,38.5142066827039
38077,1510:1079,Pancreas,SUIT-2,SIDM00371,1240219,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.886190847219646,0.0569400947772104,0.862540972553397,13.0194264666962,32.4338,0.962342055482922,0.96799835013588,0.104729801835882,0.764375915228752,0.381040096708394,0.383335818520358,8.38292868393185,1.304,4.6364977827643,31.1298,0.852818721463506,0.636519036336885,0.857831278014135,0.725139950558281,0.216299685126621,0.132691327455854,True,0.25422191395617,0.0468775435389465,1.26936020626965,38.5142066827039
38077,1053:1079,Pancreas,SUIT-2,SIDM00371,1240219,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,5,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.902742732646605,0.0569400947772104,0.862540972553397,13.0194264666962,32.4338,0.962342055482922,0.96799835013588,0.128241910734126,0.778652594582513,0.372404523157379,0.406248071425134,8.22626682593588,1.1698,4.79315964076027,31.264,0.868747296907404,0.629791342690418,0.873853475799069,0.730697229795451,0.238955954216986,0.143156246003618,True,0.25422191395617,0.0468775435389465,1.26936020626965,38.5142066827039
38077,1564:1079,Pancreas,SUIT-2,SIDM00371,1240219,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.605693662667245,0.0569400947772104,0.862540972553397,13.0194264666962,32.4338,0.962342055482922,0.96799835013588,0.133497946322957,0.522435600866435,0.279566772953135,0.2428688279133,8.66286147003985,1.5832,4.35656499665631,30.8506,0.582884484324176,0.405829925352058,0.586310466149651,0.504800455283044,0.177054558972118,0.081510010866607,True,0.25422191395617,0.0468775435389465,1.26936020626965,38.5142066827039
38077,1372:1079,Pancreas,SUIT-2,SIDM00371,1240219,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.438655876941472,0.0569400947772104,0.862540972553397,13.0194264666962,32.4338,0.962342055482922,0.96799835013588,0.062709765514692,0.37835866671336,0.246981275511585,0.131377391201775,9.55483086322177,2.938,3.46459560347438,29.4958,0.42213699826552,0.332390706306871,0.424618165156752,0.384280881066542,0.0897462919586486,0.0403372840902103,True,0.25422191395617,0.0468775435389465,1.26936020626965,38.5142066827039
38077,1179:1079,Pancreas,SUIT-2,SIDM00371,1240219,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.434964650130669,0.0569400947772104,0.862540972553397,13.0194264666962,32.4338,0.962342055482922,0.96799835013588,0.0747705501711153,0.375174832350055,0.312819326622777,0.0623555057272779,11.0581591201254,8.3291,1.96126734657079,24.1047,0.418584775469158,0.346065277642656,0.421045063693917,0.403969239545504,0.0725194978265024,0.0170758241484134,True,0.25422191395617,0.0468775435389465,1.26936020626965,38.5142066827039
38077,1190:1079,Pancreas,SUIT-2,SIDM00371,1240219,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.01,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.666534685517014,0.0569400947772104,0.862540972553397,13.0194264666962,32.4338,0.962342055482922,0.96799835013588,0.0795162410860107,0.574913475886418,0.340548355634286,0.234365120252133,9.09564403286725,2.1371,3.9237824338289,30.2967,0.641434359311107,0.528499555713459,0.645204475888807,0.570014529482876,0.112934803597648,0.0751899464059316,True,0.25422191395617,0.0468775435389465,1.26936020626965,38.5142066827039
38077,1510:1080,Pancreas,SUIT-2,SIDM00371,1240219,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.1,0.761534913210477,0.0740105730286569,0.70678980447993,10.9255961028356,0.3799,0.894795915016577,0.924991093813352,0.0410947806118604,0.538245112412673,0.27166843122434,0.266576681188334,7.70972946384155,0.0409,3.215866638994,0.339,0.681418329483239,0.573596463118391,0.704413012347616,0.592828921855583,0.107821866364847,0.111584090492032,True,0.25422191395617,0.0468775435389465,1.26936020626965,38.5142066827039
38077,1011:1080,Pancreas,SUIT-2,SIDM00371,1240219,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.1,0.950011342685869,0.0740105730286569,0.70678980447993,10.9255961028356,0.3799,0.894795915016577,0.924991093813352,0.079880880400961,0.671458331150661,0.479067864951797,0.192390466198864,9.03743364689279,0.1026,1.88816245594276,0.2773,0.850066268654729,0.843113504377689,0.878752031006094,0.809773302548704,0.0069527642770405,0.0689787284573893,True,0.25422191395617,0.0468775435389465,1.26936020626965,38.5142066827039
38077,1561:1080,Pancreas,SUIT-2,SIDM00371,1240219,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,2,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.1,0.87018622386146,0.0740105730286569,0.70678980447993,10.9255961028356,0.3799,0.894795915016577,0.924991093813352,0.0514917424898353,0.615038751024169,0.407123317433147,0.207915433591022,8.71822911755534,0.0823,2.20736698528021,0.2976,0.778639078414935,0.681213036004451,0.804914507030922,0.727757443704171,0.097426042410484,0.0771570633267512,True,0.25422191395617,0.0468775435389465,1.26936020626965,38.5142066827039
35947,1558:1083,Pancreas,SUIT-2,SIDM00371,1240219,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.95345028394039,0.0944521401708753,0.761082937393934,11.5357296639484,46.3896,0.89435196871662,0.940960338199184,0.0545755880880296,0.725654742760432,0.521918970968388,0.203735771792044,9.41620464993003,10.6753,2.11952501401838,35.7143,0.852720138515508,0.832060659222103,0.897158901632657,0.82949249410949,0.0206594792934051,0.0676664075231674,True,0.424190196426818,0.0692014474387167,0.816391018500765,59.8351871830716
37958,1564:1168,Pancreas,SUIT-2,SIDM00371,1240219,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.550708917039812,0.0659368164056466,0.672113864161134,10.570868426098,29.7083,0.902858492391703,0.914146225135205,0.0415570315106679,0.370139098259621,0.293114672105196,0.0770244261544256,9.28271518505731,12.1648,1.28815324104069,17.5435,0.497212222585232,0.454554156785857,0.503428477660241,0.475792935980164,0.0426580657993752,0.0276355416800764,True,0.226934173653881,0.0382289244364478,1.33674838290432,36.3780405043498
37958,1080:1168,Pancreas,SUIT-2,SIDM00371,1240219,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.0025,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.967609271081451,0.0659368164056466,0.672113864161134,10.570868426098,29.7083,0.902858492391703,0.914146225135205,0.101966197336577,0.650343606184692,0.619913333050226,0.0304302731344664,10.2655414381261,24.0417,0.305326987971942,5.6666,0.873614247712833,0.896670373981713,0.884536362564936,0.874547669388117,-0.0230561262688802,0.0099886931768188,True,0.226934173653881,0.0382289244364478,1.33674838290432,36.3780405043498
37960,1594:1510,Pancreas,SUIT-2,SIDM00371,1240219,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.638742875282002,0.0656224248541906,0.835545150836799,12.5574016360082,117.7293,0.94013660362033,0.961123914165742,0.0796901364758912,0.533698512073431,0.205971599674151,0.32772691239928,7.37505275988869,3.2422,5.18234887611955,114.4871,0.600505557354305,0.424894292156418,0.613911052436518,0.48354220620259,0.175611265197887,0.130368846233928,True,0.226934173653881,0.0382289244364478,1.33674838290432,36.3780405043498
37960,1564:1510,Pancreas,SUIT-2,SIDM00371,1240219,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.51314285332889,0.0656224248541906,0.835545150836799,12.5574016360082,117.7293,0.94013660362033,0.961123914165742,0.0827026851232565,0.428754022785513,0.296501477195901,0.132252545589612,9.68679153202466,16.097,2.87061010398358,101.6323,0.482424379300668,0.399448636637201,0.49319386771764,0.452390891793069,0.0829757426634666,0.0408029759245712,True,0.226934173653881,0.0382289244364478,1.33674838290432,36.3780405043498
37961,1510:1558,Pancreas,SUIT-2,SIDM00371,1240219,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.79528568799247,0.065484857567791,0.801256860743659,12.0512300140997,82.8918,0.936869751455779,0.952069131540499,0.046325786525797,0.637228113755208,0.418151689343907,0.219076424411301,9.22595569868773,11.6955,2.82527431541193,71.1963,0.745079104845843,0.672721044043957,0.757166954293579,0.685013849635351,0.0723580608018857,0.0721531046582278,True,0.226934173653881,0.0382289244364478,1.33674838290432,36.3780405043498
37961,1080:1558,Pancreas,SUIT-2,SIDM00371,1240219,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.0025,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.994968554647889,0.065484857567791,0.801256860743659,12.0512300140997,82.8918,0.936869751455779,0.952069131540499,0.0496755619548473,0.797225380635823,0.70446228269102,0.0927630979448031,10.9386532064791,38.3348,1.11257680762054,44.557,0.932155942499283,0.926398756169342,0.947278847733721,0.92071162409918,0.005757186329941,0.0265672236345414,True,0.226934173653881,0.0382289244364478,1.33674838290432,36.3780405043498
37961,1564:1558,Pancreas,SUIT-2,SIDM00371,1240219,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,1,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.78696664356754,0.065484857567791,0.801256860743659,12.0512300140997,82.8918,0.936869751455779,0.952069131540499,0.0837732415338334,0.630562422334901,0.241807485716155,0.388754936618746,7.22083580792521,2.9135,4.83039420617445,79.9783,0.737285243763109,0.523379403336623,0.749246648892689,0.587703190492022,0.213905840426486,0.161543458400667,True,0.226934173653881,0.0382289244364478,1.33674838290432,36.3780405043498
37961,1372:1561,Pancreas,SUIT-2,SIDM00371,1240219,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.448299157208695,0.0862128822586796,0.72625074270117,11.1353465362544,43.9343,0.87110291374507,0.930850019109827,0.0898623162018754,0.325577595875123,0.184814756738883,0.140762839136241,8.22384646049922,5.8392,2.91150007575514,38.0951,0.390514702073954,0.291042241596636,0.417299279054633,0.362799731136487,0.0994724604773175,0.0544995479181461,True,0.226934173653881,0.0382289244364478,1.33674838290432,36.3780405043498
37961,1594:1561,Pancreas,SUIT-2,SIDM00371,1240219,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.666096845385236,0.0862128822586796,0.72625074270117,11.1353465362544,43.9343,0.87110291374507,0.930850019109827,0.152756324889215,0.483753328671934,0.192613670008463,0.291139658663471,7.03153790472483,2.5553,4.10380863152953,41.379,0.580238902851478,0.388888185133583,0.620036261255842,0.488889123694613,0.191350717717896,0.131147137561229,True,0.226934173653881,0.0382289244364478,1.33674838290432,36.3780405043498
37961,1564:1561,Pancreas,SUIT-2,SIDM00371,1240219,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.541902910204686,0.0862128822586796,0.72625074270117,11.1353465362544,43.9343,0.87110291374507,0.930850019109827,0.0998523229514183,0.393557391008079,0.226457689528345,0.167099701479734,8.27465018443799,6.0485,2.86069635181637,37.8858,0.472053204046235,0.35826029458866,0.504430334319703,0.440122118688571,0.113792909457575,0.0643082156311319,True,0.226934173653881,0.0382289244364478,1.33674838290432,36.3780405043498
38227,1510:1564,Pancreas,SUIT-2,SIDM00371,1240219,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.897237982732244,0.0717053328517269,0.602781428496435,9.9127809570988,18.8267,0.892244747850788,0.890704580753406,0.11248714748074,0.540838392932602,0.285093491792349,0.255744901140253,7.32760437685302,3.1373,2.58517658024578,15.6894,0.800555877665081,0.623751912726749,0.799173981245555,0.676425830127152,0.176803964938332,0.122748151118403,True,0.525132045984711,0.071803460598143,0.606304264252823,79.6806170205275
38227,1053:1564,Pancreas,SUIT-2,SIDM00371,1240219,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.934228043804635,0.0717053328517269,0.602781428496435,9.9127809570988,18.8267,0.892244747850788,0.890704580753406,0.0964802123509769,0.563135314785988,0.391931059688628,0.171204255097361,8.28931155998798,6.1103,1.62346939711082,12.7164,0.833560065379601,0.737608025940387,0.832121198085082,0.759537087217365,0.0959520394392139,0.0725841108677171,True,0.525132045984711,0.071803460598143,0.606304264252823,79.6806170205275
38227,1558:1564,Pancreas,SUIT-2,SIDM00371,1240219,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.962684564143345,0.0717053328517269,0.602781428496435,9.9127809570988,18.8267,0.892244747850788,0.890704580753406,0.128219193137265,0.580288376765794,0.499670821398119,0.0806175553676747,9.16675297942503,11.2253,0.746027977673764,7.6014,0.858950246193925,0.777310971700675,0.857467551103074,0.826533293412038,0.0816392744932501,0.030934257691036,True,0.525132045984711,0.071803460598143,0.606304264252823,79.6806170205275
38227,1053:1594,Pancreas,SUIT-2,SIDM00371,1240219,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.934228043804635,0.0903681058020536,0.73030082321416,11.1801390395455,18.1279,0.899319686334323,0.93204986820086,0.0346663391871167,0.682267509460279,0.540838509288837,0.141429000171442,9.69666539955174,6.483,1.4834736399938,11.6449,0.840169671319112,0.825930660443688,0.870747125097658,0.824005019340189,0.0142390108754238,0.0467421057574692,True,0.525132045984711,0.071803460598143,0.606304264252823,79.6806170205275
38227,1564:1594,Pancreas,SUIT-2,SIDM00371,1240219,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.705415875772236,0.0903681058020536,0.73030082321416,11.1801390395455,18.1279,0.899319686334323,0.93204986820086,0.070548923427507,0.515165794784801,0.274775109872634,0.240390684912167,8.01663055006853,2.0232,3.163508489477,16.1047,0.634394384134738,0.526731144200352,0.657482774040307,0.562344465212807,0.107663239934387,0.0951383088274995,True,0.525132045984711,0.071803460598143,0.606304264252823,79.6806170205275
38227,1561:1594,Pancreas,SUIT-2,SIDM00371,1240219,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.954159155238075,0.0903681058020536,0.73030082321416,11.1801390395455,18.1279,0.899319686334323,0.93204986820086,0.0603575898086898,0.696823216547693,0.334873651071582,0.361949565476111,7.65444068899014,1.574,3.5256983505554,16.5539,0.858094112201728,0.699606014728665,0.889323914882292,0.739469588468148,0.158488097473062,0.149854326414144,True,0.525132045984711,0.071803460598143,0.606304264252823,79.6806170205275
38227,1510:1594,Pancreas,SUIT-2,SIDM00371,1240219,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.897237982732244,0.0903681058020536,0.73030082321416,11.1801390395455,18.1279,0.899319686334323,0.93204986820086,0.0766246886213266,0.65525363740837,0.373635684981297,0.281617952427073,8.26146562463935,2.3974,2.91867341490618,15.7305,0.806903781198002,0.704795818773564,0.836270543550394,0.728045181343234,0.102107962424438,0.10822536220716,True,0.525132045984711,0.071803460598143,0.606304264252823,79.6806170205275
34817,1080:1011,Pancreas,YAPC,SIDM00411,909904,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.874819091619307,0.173552914148548,0.620477122505218,10.7426614465886,33.4652,0.874376280920454,0.843490465338752,0.150930590435762,0.542805232680576,0.327021017521364,0.215784215159213,7.1711635368742,2.8149,3.57149790971439,30.6503,0.7649210638083,0.600622236326562,0.737901562677194,0.599146476932571,0.164298827481737,0.138755085744623,True,0.481711914238674,0.0535966179242956,0.701861854839167,69.7296936504019
34817,1088:1011,Pancreas,YAPC,SIDM00411,909904,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.788368122505437,0.173552914148548,0.620477122505218,10.7426614465886,33.4652,0.874376280920454,0.843490465338752,0.0913326582098312,0.489164384127015,0.26506296639533,0.224101417731684,6.58865590675553,1.8798,4.15400553983306,31.5854,0.689330386952545,0.515293953853261,0.664980994510349,0.514802839961801,0.174036433099284,0.150178154548549,True,0.481711914238674,0.0535966179242956,0.701861854839167,69.7296936504019
34817,1564:1011,Pancreas,YAPC,SIDM00411,909904,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.800778279709989,0.173552914148548,0.620477122505218,10.7426614465886,33.4652,0.874376280920454,0.843490465338752,0.140936301472055,0.496864602759133,0.272097765977265,0.224766836781868,6.64528651579622,1.9551,4.09737493079237,31.5101,0.7001815340547,0.559259348324287,0.675448843785744,0.525434990894512,0.140922185730413,0.150013852891233,True,0.481711914238674,0.0535966179242956,0.701861854839167,69.7296936504019
34817,1190:1011,Pancreas,YAPC,SIDM00411,909904,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.644517251253263,0.173552914148548,0.620477122505218,10.7426614465886,33.4652,0.874376280920454,0.843490465338752,0.0877615224606445,0.399908209462598,0.247128926770958,0.152779282691639,7.31608056106157,3.1124,3.42658088552702,30.3528,0.563550597139903,0.465086293335141,0.543644156178469,0.446389356767596,0.0984643038047616,0.0972547994108725,True,0.481711914238674,0.0535966179242956,0.701861854839167,69.7296936504019
34817,1558:1011,Pancreas,YAPC,SIDM00411,909904,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.702677185611596,0.173552914148548,0.620477122505218,10.7426614465886,33.4652,0.874376280920454,0.843490465338752,0.152435891464138,0.435995118178348,0.282020011407601,0.153975106770748,7.58254050869222,3.7437,3.16012093789637,29.7215,0.614404264242719,0.524371071065655,0.59270150627445,0.496466222305197,0.0900331931770648,0.0962352839692533,True,0.481711914238674,0.0535966179242956,0.701861854839167,69.7296936504019
34819,1564:1053,Pancreas,YAPC,SIDM00411,909904,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,1,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.868663457798773,0.101908412375341,0.635280745803085,10.9672954815359,39.1034,0.805018129294409,0.851083238260269,0.0803189597922527,0.551845169322291,0.368064876935282,0.183780292387009,7.9097317219487,4.6967,3.05756375958719,34.4067,0.699289831783581,0.57042875523025,0.739304908621742,0.628216123330756,0.128861076553331,0.111088785290987,True,0.481711914238674,0.0535966179242956,0.701861854839167,69.7296936504019
34819,1372:1053,Pancreas,YAPC,SIDM00411,909904,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.848697929283356,0.101908412375341,0.635280745803085,10.9672954815359,39.1034,0.805018129294409,0.851083238260269,0.0457713564133366,0.539161453476664,0.347484115165395,0.191677338311269,7.70139352370768,4.0652,3.2659019578282,35.0382,0.683217219367726,0.569579684446976,0.722312581959263,0.604822493250508,0.113637534920749,0.117490088708755,True,0.481711914238674,0.0535966179242956,0.701861854839167,69.7296936504019
34819,1558:1053,Pancreas,YAPC,SIDM00411,909904,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.876939113978512,0.101908412375341,0.635280745803085,10.9672954815359,39.1034,0.805018129294409,0.851083238260269,0.0660654926613621,0.557102534352166,0.576895846533822,-0.0197933121816564,11.3175334853007,49.8479,-0.350238003764833,-10.7445,0.705951885040078,0.705825319341581,0.746348180881923,0.75623337762916,0.0001265656984972,-0.009885196747237,True,0.481711914238674,0.0535966179242956,0.701861854839167,69.7296936504019
34821,1372:1079,Pancreas,YAPC,SIDM00411,909904,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.892074495910115,0.0811651471590103,0.638886214431699,11.0225777151559,8.1262,0.834008575485133,0.852908114012048,0.0760697874861598,0.56993409768308,0.446170349705109,0.123763747977971,9.00211576238893,2.0029,2.02046195276701,6.1233,0.743997779560613,0.643420797360744,0.760857575864944,0.691248167953101,0.100576982199869,0.0696094079118434,True,0.481711914238674,0.0535966179242956,0.701861854839167,69.7296936504019
34821,1011:1080,Pancreas,YAPC,SIDM00411,909904,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.1,0.924858879689777,0.0839892202572684,0.814740253325887,14.2506334422879,3.8071,0.905202541249868,0.932135238067918,0.0931073561902169,0.753519757929145,0.446489359943333,0.307030397985812,8.75550422485126,0.0844,5.49512921743661,3.7227,0.837184608192692,0.708081775563149,0.862093551998859,0.706377352012481,0.129102832629542,0.155716199986378,True,0.481711914238674,0.0535966179242956,0.701861854839167,69.7296936504019
34822,1011:1083,Pancreas,YAPC,SIDM00411,909904,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.973868357463014,0.0907643686871727,0.648652472484703,11.1735549054242,36.0907,0.853811028338152,0.857804546531478,0.0553620976679542,0.631702117943001,0.545483448889301,0.0862186690536997,9.85666629452089,14.4868,1.31688861090336,21.6039,0.831499543751483,0.798807265463248,0.835388704754916,0.789545824838526,0.0326922782882348,0.0458428799163899,True,0.481711914238674,0.0535966179242956,0.701861854839167,69.7296936504019
34822,1558:1083,Pancreas,YAPC,SIDM00411,909904,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.796726484031142,0.0907643686871727,0.648652472484703,11.1735549054242,36.0907,0.853811028338152,0.857804546531478,0.1182398930679,0.516798603760845,0.325262563666593,0.191536040094252,7.68403687917011,3.2133,3.48951802625414,32.8774,0.680253858634869,0.596261078699224,0.683435600343953,0.567077328885657,0.0839927799356457,0.116358271458296,True,0.481711914238674,0.0535966179242956,0.701861854839167,69.7296936504019
34870,1011:1088,Pancreas,YAPC,SIDM00411,909904,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,0.898969685497483,0.0816330629604502,0.763530384866409,13.1552887911002,89.0916,0.925815501925355,0.91083264077993,0.108674881597649,0.686390669951129,0.484776444341031,0.201614225610098,9.55783451798131,7.3603,3.59745427311894,81.7313,0.832280070594531,0.764766791997201,0.818810932622776,0.717976243767056,0.0675132785973301,0.10083468885572,True,0.360438605834855,0.0411792027929915,0.9861399348987,49.9747279774248
34871,1510:1168,Pancreas,YAPC,SIDM00411,909904,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.717002868006612,0.0626850102799574,0.771974488757258,13.3231858921013,200.1744,0.924844363998201,0.914434594919748,0.039538515552293,0.553507922466892,0.339146119341655,0.214361803125237,8.61683477702868,7.6675,4.70635111507262,192.5069,0.663116061446461,0.522517308557304,0.655652227161924,0.543039897155157,0.140598752889157,0.112612330006767,True,0.360438605834855,0.0411792027929915,0.9861399348987,49.9747279774248
34872,1011:1190,Pancreas,YAPC,SIDM00411,909904,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.2,0.886418328952781,0.065955979755205,0.583441918626606,10.1943998887605,0.4577,0.816450662571779,0.823750726133688,0.153399954719741,0.517173610550001,0.321467006132268,0.195706604417732,7.00113383266344,0.05,3.19326605609703,0.4077,0.723716831989268,0.643177029338307,0.730187742133064,0.598966053830409,0.0805398026509605,0.131221688302655,True,0.360438605834855,0.0411792027929915,0.9861399348987,49.9747279774248
34872,1053:1372,Pancreas,YAPC,SIDM00411,909904,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.790103401707958,0.0874809385111934,0.864855803248615,15.5804228385698,95.6984,0.916111537003101,0.951812269537518,0.0432194832861475,0.683325512133599,0.523791689940312,0.159533822193287,11.3979764882543,5.2706,4.18244635031549,90.4278,0.723822841730056,0.66494467753516,0.752030111948965,0.683319683480742,0.0588781641948961,0.0687104284682228,True,0.360438605834855,0.0411792027929915,0.9861399348987,49.9747279774248
34872,1561:1372,Pancreas,YAPC,SIDM00411,909904,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.700641131401582,0.0874809385111934,0.864855803248615,15.5804228385698,95.6984,0.916111537003101,0.951812269537518,0.0409743124481061,0.605953548487333,0.279654424160402,0.326299124326931,7.54990300841347,0.366,8.03051983015628,95.3324,0.641865423775895,0.456492203549191,0.666878825410674,0.49384356516213,0.185373220226704,0.173035260248543,True,0.360438605834855,0.0411792027929915,0.9861399348987,49.9747279774248
34872,1011:1372,Pancreas,YAPC,SIDM00411,909904,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.933560196807334,0.0874809385111934,0.864855803248615,15.5804228385698,95.6984,0.916111537003101,0.951812269537518,0.0357743752425018,0.807394953890742,0.822406820034478,-0.0150118661437361,16.0948249669815,136.6958,-0.514402128411746,-40.9974,0.855245266782084,0.91168053283083,0.88857404967308,0.894258514668027,-0.0564352660487454,-0.0056844649949469,True,0.360438605834855,0.0411792027929915,0.9861399348987,49.9747279774248
34873,1168:1510,Pancreas,YAPC,SIDM00411,909904,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,2.5,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.874621764290702,0.0954991780124467,0.688141546963134,11.8057247627313,69.9209,0.845006313750922,0.876940864831486,0.0578472470854358,0.60186357388663,0.426945808479735,0.174917765406895,8.83191935909783,8.9003,2.97380540363347,61.0206,0.739060912969614,0.636740953068802,0.766991566377529,0.671049931672528,0.102319959900812,0.0959416347050007,True,0.360438605834855,0.0411792027929915,0.9861399348987,49.9747279774248
34873,1594:1510,Pancreas,YAPC,SIDM00411,909904,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.669444366438927,0.0954991780124467,0.688141546963134,11.8057247627313,69.9209,0.845006313750922,0.876940864831486,0.0687513599840537,0.460672481927039,0.389429334613944,0.0712431473130949,10.1693012938498,22.4903,1.63642346888155,47.4306,0.565684716345879,0.491902404297014,0.587063121661519,0.550822695781527,0.0737823120488657,0.0362404258799921,True,0.360438605834855,0.0411792027929915,0.9861399348987,49.9747279774248
34873,1558:1510,Pancreas,YAPC,SIDM00411,909904,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.814038156751017,0.0954991780124467,0.688141546963134,11.8057247627313,69.9209,0.845006313750922,0.876940864831486,0.0741867241238968,0.560173476473664,0.321521858787345,0.238651617686319,7.4881642646352,3.5066,4.3175604980961,66.4143,0.687867382088773,0.518490710638612,0.713863325187066,0.571157491849699,0.169376671450161,0.142705833337367,True,0.360438605834855,0.0411792027929915,0.9861399348987,49.9747279774248
34874,1083:1558,Pancreas,YAPC,SIDM00411,909904,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,1,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.914518566480768,0.0506148720249126,0.846460370732415,15.0517976571025,663.3957,0.952785705123115,0.944715845912998,0.0369914933677355,0.774103724824987,0.75686447464734,0.0172392501776476,14.5614306994755,472.2342,0.490366957626982,191.1615,0.871340217212558,0.850550623362185,0.863960181136021,0.857172201530763,0.0207895938503728,0.0067879796052575,True,0.360438605834855,0.0411792027929915,0.9861399348987,49.9747279774248
34874,1564:1561,Pancreas,YAPC,SIDM00411,909904,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.81275233493577,0.0852419726996426,0.558700542776515,9.83624525940847,17.854,0.764282715061481,0.809923339970299,0.0891343801129848,0.454085170671495,0.282354566562037,0.171730604109458,6.76496525673193,2.1242,3.07128000267654,15.7298,0.621172561217269,0.48518434539335,0.658267085679838,0.538682949023781,0.135988215823918,0.119584136656057,True,0.360438605834855,0.0411792027929915,0.9861399348987,49.9747279774248
34875,1510:1564,Pancreas,YAPC,SIDM00411,909904,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.650722723822014,0.0580235380594744,0.724517227031183,12.4280088652787,107.63,0.883747117162709,0.893698720636472,0.0662065369670403,0.471459823429703,0.329976994769718,0.141482828659985,9.10058857525071,10.7221,3.32742029002801,96.9079,0.57507433124997,0.478744463585873,0.581550065768814,0.507055610595661,0.096329867664097,0.0744944551731529,True,0.360438605834855,0.0411792027929915,0.9861399348987,49.9747279774248
34875,1053:1564,Pancreas,YAPC,SIDM00411,909904,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.773393748169022,0.0580235380594744,0.724517227031183,12.4280088652787,107.63,0.883747117162709,0.893698720636472,0.074021476482671,0.560337093826673,0.428397558320098,0.131939535506575,9.76757140315383,17.024,2.6604374621249,90.606,0.683484495376035,0.611292301095097,0.691181003286901,0.624273972721068,0.0721921942809381,0.0669070305658332,True,0.360438605834855,0.0411792027929915,0.9861399348987,49.9747279774248
34875,1561:1564,Pancreas,YAPC,SIDM00411,909904,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,2,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.734199222592477,0.0580235380594744,0.724517227031183,12.4280088652787,107.63,0.883747117162709,0.893698720636472,0.117846402595554,0.531939984841152,0.2016152766757,0.330324708165452,5.55639718325507,0.9191,6.87161168202366,106.7109,0.648846446389204,0.37437946366154,0.656152905923189,0.435839977940718,0.274466982727663,0.220312927982471,True,0.360438605834855,0.0411792027929915,0.9861399348987,49.9747279774248
34875,1168:1564,Pancreas,YAPC,SIDM00411,909904,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.716539605929511,0.0580235380594744,0.724517227031183,12.4280088652787,107.63,0.883747117162709,0.893698720636472,0.0609947127456866,0.519145288346066,0.37795569659376,0.141189591752306,9.38997504385392,13.1037,3.03803382142481,94.5263,0.633239811073109,0.52649031719031,0.640370529104566,0.567258767396431,0.106749493882798,0.073111761708135,True,0.360438605834855,0.0411792027929915,0.9861399348987,49.9747279774248
34875,1011:1564,Pancreas,YAPC,SIDM00411,909904,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.899174176734739,0.0580235380594744,0.724517227031183,12.4280088652787,107.63,0.883747117162709,0.893698720636472,0.129936797986187,0.6514671811459,0.32943609287121,0.32203108827469,7.05803315815126,2.6026,5.36997570712747,105.0274,0.794642586516478,0.635160800798865,0.80359081137719,0.61035540544651,0.159481785717612,0.193235405930679,True,0.360438605834855,0.0411792027929915,0.9861399348987,49.9747279774248
34875,1558:1564,Pancreas,YAPC,SIDM00411,909904,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.940306348436591,0.0580235380594744,0.724517227031183,12.4280088652787,107.63,0.883747117162709,0.893698720636472,0.0833020805490627,0.681268148129096,0.479162639180789,0.202105508948307,9.13588359797724,10.9877,3.29212526730149,96.6423,0.83099302468063,0.686178268299784,0.840350580604134,0.734155691644626,0.144814756380846,0.106194888959508,True,0.360438605834855,0.0411792027929915,0.9861399348987,49.9747279774248
34875,1079:1564,Pancreas,YAPC,SIDM00411,909904,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.723862105821657,0.0580235380594744,0.724517227031183,12.4280088652787,107.63,0.883747117162709,0.893698720636472,0.0785575946495088,0.52445056566286,0.333195244588333,0.191255321074527,8.43588601171357,6.7637,3.99212285356516,100.8663,0.639711049243217,0.491404277322482,0.646914637890038,0.542083835840405,0.148306771920735,0.104830802049633,True,0.360438605834855,0.0411792027929915,0.9861399348987,49.9747279774248
37900,1073:1022,Pancreas,MZ1-PC,SIDM00053,753595,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in pancreas,10,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.779571596754186,0.0657750921364569,0.738214302760361,12.662803033464,12.6652,0.885710397193493,0.9000774834418,0.0628851821233492,0.575490902749673,0.422232115945993,0.15325878680368,9.58956630628025,1.5048,3.07323672718372,11.1604,0.690474668601915,0.619435569637256,0.701674840969213,0.62409873526998,0.0710390989646593,0.0775761056992332,True,0.378726748444834,0.0479323330353132,0.874245150374396,54.723680545061
37929,1011:1088,Pancreas,MZ1-PC,SIDM00053,753595,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,0.999872856400115,0.0811516262421848,0.63837725574694,11.0079648649005,20.1107,0.877329499535773,0.85303844619457,0.146483996955463,0.638296090164559,0.389618431803348,0.248677658361211,7.41466507409708,1.6662,3.5932997908034,18.4445,0.877217952704917,0.735716682722128,0.85292998781568,0.698153334099229,0.141501269982789,0.154776653716451,True,0.37524299391633,0.0469563495888611,0.913867881120172,53.1333975925966
38448,1564:1190,Pancreas,MZ1-PC,SIDM00053,753595,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,1,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.2,0.655884662201466,0.0672440686271483,0.771685989501821,13.3028182879381,3.9474,0.915676386731135,0.914542987726189,0.0337778784576983,0.506137004550006,0.359475158612711,0.146661845937295,9.68154790448222,0.3208,3.62127038345584,3.6266,0.600578097597009,0.521838274059952,0.599834718573511,0.527541692557854,0.0787398235370566,0.0722930260156563,True,0.630703348153611,0.0652184831603368,0.415469194605987,112.307503161709
38448,1372:1190,Pancreas,MZ1-PC,SIDM00053,753595,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.2,0.663755626295727,0.0672440686271483,0.771685989501821,13.3028182879381,3.9474,0.915676386731135,0.914542987726189,0.0474392948977725,0.512210917265419,0.323586358415472,0.188624558849947,8.82342466834034,0.177,4.47939361959773,3.7704,0.607785353558933,0.491960102591361,0.607033053592562,0.509380816287635,0.115825250967571,0.097652237304927,True,0.630703348153611,0.0652184831603368,0.415469194605987,112.307503161709
38448,1011:1190,Pancreas,MZ1-PC,SIDM00053,753595,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.2,0.89828318665879,0.0672440686271483,0.771685989501821,13.3028182879381,3.9474,0.915676386731135,0.914542987726189,0.136021833394653,0.693192549749637,0.320241277337786,0.372951272411851,6.91344542765063,0.0471,6.38937286028743,3.9003,0.82253670262105,0.642125912335333,0.821518589351132,0.603054065923126,0.180410790285717,0.218464523428006,True,0.630703348153611,0.0652184831603368,0.415469194605987,112.307503161709
38448,1022:1190,Pancreas,MZ1-PC,SIDM00053,753595,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.2,0.912719209643316,0.0672440686271483,0.771685989501821,13.3028182879381,3.9474,0.915676386731135,0.914542987726189,0.0930193418917685,0.704332626430922,0.482455103968584,0.221877522462338,9.40450096855017,0.2647,3.89831731938789,3.6827,0.835755427986288,0.71160756575696,0.834720952942284,0.723663189556061,0.124147862229328,0.111057763386223,True,0.630703348153611,0.0652184831603368,0.415469194605987,112.307503161709
36537,1510:1564,Pancreas,MZ1-PC,SIDM00053,753595,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.900972229260718,0.123790361145393,0.441300413074375,8.16658862600865,5.612,0.675478953184784,0.736429221238494,0.127714603941378,0.397599416941295,0.224143934281453,0.173455482659842,5.09545714329425,0.6678,3.0711314827144,4.9442,0.608587778269591,0.453019705861148,0.663502277151981,0.510307591755549,0.155568072408443,0.153194685396431,True,0.368817600545324,0.0559328613134607,0.962336596572033,51.1635766872659
36537,1011:1564,Pancreas,MZ1-PC,SIDM00053,753595,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.992256262856751,0.123790361145393,0.441300413074375,8.16658862600865,5.612,0.675478953184784,0.736429221238494,0.0951066925778063,0.43788309867432,0.135343831605334,0.302539267068986,2.47958471864079,0.1089,5.68700390736786,5.5031,0.670248221725524,0.377533444213533,0.730726506924616,0.405111681838287,0.292714777511991,0.325614825086329,True,0.368817600545324,0.0559328613134607,0.962336596572033,51.1635766872659
35914,1179:1005,Pancreas,DAN-G,SIDM00950,1290797,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.0,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,8.0,0.332107003541929,0.0647813663539943,0.830467504694184,12.4623539296818,88.1784,0.948932018740385,0.959972484451304,0.0427024680603608,0.275804074522929,0.127610317199662,0.148193757323267,7.97243455022247,3.9243,4.48991937945937,84.2541,0.315146969308863,0.248081015859075,0.318813585293824,0.264058524376067,0.0670659534497888,0.0547550609177572,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35914,1507:1005,Pancreas,DAN-G,SIDM00950,1290797,1507,Ruxolitinib,"JAK1, JAK2","Other, kinases",Targeted,Advanced clinical trials,10.0,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,8.0,0.956839063510024,0.0647813663539943,0.830467504694184,12.4623539296818,88.1784,0.948932018740385,0.959972484451304,0.116656872266156,0.79462374946709,0.538710369317722,0.255913380149368,9.55214132830905,11.7301,2.91021260137279,76.4483,0.907975224146227,0.749858388981973,0.918539173017778,0.838703837403308,0.158116835164255,0.0798353356144698,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35914,1190:1005,Pancreas,DAN-G,SIDM00950,1290797,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.01,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,8.0,0.633786805773568,0.0647813663539943,0.830467504694184,12.4623539296818,88.1784,0.948932018740385,0.959972484451304,0.050806260671448,0.526339347098873,0.477235834210595,0.0491035128882772,11.4288081258732,43.0759,1.03354580380863,45.1025,0.601420593053733,0.600550492213647,0.608417894550909,0.595066026091029,0.0008701008400862,0.01335186845988,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35914,1011:1005,Pancreas,DAN-G,SIDM00950,1290797,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,8.0,0.906570793236443,0.0647813663539943,0.830467504694184,12.4623539296818,88.1784,0.948932018740385,0.959972484451304,0.0600562635502113,0.752877584487695,0.466507040112651,0.286370544375044,9.12715391660115,8.7371,3.33520001308069,79.4413,0.86027405295693,0.730067747075927,0.870283016714178,0.777207582267813,0.130206305881003,0.0930754344463647,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35914,1022:1005,Pancreas,DAN-G,SIDM00950,1290797,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,8.0,0.854213796858217,0.0647813663539943,0.830467504694184,12.4623539296818,88.1784,0.948932018740385,0.959972484451304,0.0531521064300484,0.709396800352188,0.365818742005075,0.343578058347113,8.37028999222886,5.1705,4.09206393745298,83.0079,0.810590822688558,0.669958830322594,0.820021740822565,0.698870793063541,0.140631992365963,0.121150947759024,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35914,1080:1011,Pancreas,DAN-G,SIDM00950,1290797,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.39891551117268,0.155799437645964,0.511811582852332,9.10297023833565,10.7398,0.864299142823575,0.8561507192315,0.0543539662930642,0.204169579197636,0.0144005820407245,0.189768997156912,1.84251609502154,0.07,7.26045414331411,10.6698,0.344782334365576,0.0968302737749789,0.341531801803091,0.131062619126263,0.247952060590597,0.210469182676828,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35914,1088:1011,Pancreas,DAN-G,SIDM00950,1290797,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.883376803675602,0.155799437645964,0.511811582852332,9.10297023833565,10.7398,0.864299142823575,0.8561507192315,0.103287275039907,0.452122480144244,0.101273091512287,0.350849388631957,4.54570362429469,0.4562,4.55726661404096,10.2836,0.763501814207053,0.459015418255656,0.756303685819291,0.480997526917432,0.304486395951397,0.275306158901859,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35914,1372:1011,Pancreas,DAN-G,SIDM00950,1290797,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.663554756632884,0.155799437645964,0.511811582852332,9.10297023833565,10.7398,0.864299142823575,0.8561507192315,0.0475818085745741,0.33961501030147,0.122411220127036,0.217203790174434,5.76131382610897,1.0594,3.34165641222668,9.6804,0.573509807374308,0.429835979064055,0.568102882140727,0.425517482697301,0.143673828310253,0.142585399443426,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35914,1083:1011,Pancreas,DAN-G,SIDM00950,1290797,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.938703893209529,0.155799437645964,0.511811582852332,9.10297023833565,10.7398,0.864299142823575,0.8561507192315,0.14935949667412,0.480439525413215,0.156835044062166,0.323604481351049,5.49940792741528,0.8835,3.60356231092037,9.8563,0.811320970266149,0.548212956723392,0.803672013316747,0.582815708569812,0.263108013542757,0.220856304746936,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35914,1179:1011,Pancreas,DAN-G,SIDM00950,1290797,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.2,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.85444495022541,0.155799437645964,0.511811582852332,9.10297023833565,10.7398,0.864299142823575,0.8561507192315,0.0787942426956266,0.437314822435049,0.288595606667176,0.148719215767873,7.5328572750848,3.617,1.57011296325086,7.1228,0.738496038069754,0.682577515398915,0.731533658679208,0.656026784524538,0.0559185226708387,0.0755068741546701,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35914,1053:1011,Pancreas,DAN-G,SIDM00950,1290797,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.792212849329928,0.155799437645964,0.511811582852332,9.10297023833565,10.7398,0.864299142823575,0.8561507192315,0.0805275565281822,0.405463712371506,0.236924345259466,0.16853936711204,7.14401954355294,2.7624,1.95895069478271,7.9774,0.684708886609679,0.583508520540095,0.678253600738254,0.587901408404816,0.101200366069584,0.0903521923334374,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35914,1564:1011,Pancreas,DAN-G,SIDM00950,1290797,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.670978725006999,0.155799437645964,0.511811582852332,9.10297023833565,10.7398,0.864299142823575,0.8561507192315,0.0916614236344396,0.343414683306072,0.0839984136323194,0.259416269673753,4.76354813297694,0.5305,4.33942210535871,10.2093,0.579926336876405,0.373467877442922,0.574458918003777,0.377196512298785,0.206458459433483,0.197262405704992,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35914,1561:1011,Pancreas,DAN-G,SIDM00950,1290797,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.633102070826441,0.155799437645964,0.511811582852332,9.10297023833565,10.7398,0.864299142823575,0.8561507192315,0.0776795135557299,0.32402897297677,0.117363143024533,0.206665829952237,5.77432427535017,1.069,3.32864596298548,9.6708,0.547189577135124,0.402743900300749,0.54203079328501,0.406625164241243,0.144445676834374,0.135405629043767,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35914,1190:1011,Pancreas,DAN-G,SIDM00950,1290797,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.571108331034437,0.155799437645964,0.511811582852332,9.10297023833565,10.7398,0.864299142823575,0.8561507192315,0.0265741244341522,0.292299858886889,0.0992165936906337,0.193083265196255,5.6019271054191,0.9486,3.50104313291655,9.7912,0.493608440972467,0.351913862854617,0.488954808374235,0.359166935168454,0.14169457811785,0.129787873205781,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35914,1558:1011,Pancreas,DAN-G,SIDM00950,1290797,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.296284554202753,0.155799437645964,0.511811582852332,9.10297023833565,10.7398,0.864299142823575,0.8561507192315,0.05962053434686,0.151641866661208,0.0275405988434654,0.124101267817743,4.03596089554448,0.3204,5.06700934279117,10.4194,0.256078486229304,0.115674539906732,0.253664234177871,0.14901260459278,0.140403946322573,0.104651629585091,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35915,1053:1017,Pancreas,DAN-G,SIDM00950,1290797,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,5.0,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.796745303676953,0.070465380513431,0.882222683382035,13.3877972198537,209.3431,0.946209680823815,0.97298981358271,0.0975722822936173,0.702906779781916,0.481332726917253,0.221574052864663,9.92102551987628,18.9346,3.46677169997743,190.4085,0.753888119490043,0.638073296126888,0.775225064497538,0.710400600001349,0.115814823363155,0.0648244644961887,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35915,1022:1017,Pancreas,DAN-G,SIDM00950,1290797,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.969248948308008,0.070465380513431,0.882222683382035,13.3877972198537,209.3431,0.946209680823815,0.97298981358271,0.0639963393270132,0.855093408041506,0.712285833047592,0.142807574993915,11.2216209126087,46.6417,2.16617630724496,162.7014,0.917112738017339,0.873018919966777,0.943069353529446,0.904962575755354,0.0440938180505617,0.0381067777740925,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35915,1179:1017,Pancreas,DAN-G,SIDM00950,1290797,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.0,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.323193864847317,0.070465380513431,0.882222683382035,13.3877972198537,209.3431,0.946209680823815,0.97298981358271,0.0450754736378529,0.28512895869821,0.183393475650648,0.101735483047562,9.5914282423947,15.0674,3.79636897745902,194.2757,0.305809163701394,0.252954087101826,0.314464338308866,0.283833238526398,0.0528550765995683,0.0306310997824675,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35915,1179:1022,Pancreas,DAN-G,SIDM00950,1290797,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.2,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.82966842339308,0.0983068526611928,0.438497527914676,8.46120916182482,0.6883,0.84612087329219,0.823177591252727,0.0964062489848783,0.363807552646732,0.163416599066484,0.200390953580249,5.93767035833714,0.1197,2.52353880348768,0.5686,0.701999770944307,0.556612858988713,0.682964454307163,0.543277819106909,0.145386911955594,0.139686635200254,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35916,1564:1053,Pancreas,DAN-G,SIDM00950,1290797,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,1.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.7815632379095,0.0813316381417458,0.573864222702327,9.64855457853905,15.676,0.870500078219679,0.880622922997739,0.0758294117721034,0.44851118001565,0.198520111807225,0.249991068208424,6.65237893731275,1.9647,2.9961756412263,13.7113,0.680350859733846,0.563884907610736,0.688262503075442,0.553184463609099,0.11646595212311,0.135078039466342,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35916,1507:1053,Pancreas,DAN-G,SIDM00950,1290797,1507,Ruxolitinib,"JAK1, JAK2","Other, kinases",Targeted,Advanced clinical trials,10.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.924734534622661,0.0813316381417458,0.573864222702327,9.64855457853905,15.676,0.870500078219679,0.880622922997739,0.0826930514754088,0.530672064917232,0.328016024406965,0.202656040510267,7.69610658954234,4.0503,1.95244798899671,11.6257,0.804981484721465,0.680914006740829,0.814342428876362,0.719579364828142,0.124067477980635,0.0947630640482199,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35916,1372:1053,Pancreas,DAN-G,SIDM00950,1290797,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.705813891032078,0.0813316381417458,0.573864222702327,9.64855457853905,15.676,0.870500078219679,0.880622922997739,0.0574140008959441,0.405041339949629,0.109269472024104,0.295771867925525,5.30145583093987,0.7702,4.34709874759918,14.9058,0.614411047351961,0.40579420692057,0.621555891813077,0.427200261333512,0.20861684043139,0.194355630479565,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35916,1011:1053,Pancreas,DAN-G,SIDM00950,1290797,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.832077084045519,0.0813316381417458,0.573864222702327,9.64855457853905,15.676,0.870500078219679,0.880622922997739,0.0497567273213698,0.477499269064201,0.183999552715918,0.293499716348283,6.25643588517934,1.4932,3.39211869335971,14.1828,0.724323166746427,0.556889446857675,0.7327461539116,0.564854364644098,0.167433719888752,0.167891789267502,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35916,1558:1053,Pancreas,DAN-G,SIDM00950,1290797,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.882586733409951,0.0813316381417458,0.573864222702327,9.64855457853905,15.676,0.870500078219679,0.880622922997739,0.130027865308094,0.506484949735688,0.364914247770807,0.141570701964881,8.23803663029999,5.8969,1.41051794823907,9.7791,0.768291820469013,0.708925064294384,0.777226108974497,0.71548476658786,0.0593667561746291,0.0617413423866374,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35916,1594:1053,Pancreas,DAN-G,SIDM00950,1290797,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.274546752583559,0.0813316381417458,0.573864222702327,9.64855457853905,15.676,0.870500078219679,0.880622922997739,0.0176699875580958,0.157552558766812,0.124064143660294,0.0334884151065183,8.5793412447523,7.4708,1.06921333378675,8.2052,0.238992969598947,0.222965717543805,0.241772163759671,0.227759589666113,0.0160272520551422,0.0140125740935577,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35916,1168:1054,Pancreas,DAN-G,SIDM00950,1290797,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,2.5,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,8.0,0.905084373117423,0.0723894277114238,0.814956000424547,12.2304973105377,75.0873,0.935221076688014,0.955914631859997,0.0319377604865427,0.737603940762534,0.39546529881477,0.342138641947764,8.44739741963472,5.4543,3.78309989090302,69.633,0.846453981920373,0.724754798139202,0.865183395330777,0.744358382901813,0.121699183781171,0.120825012428964,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35916,1598:1054,Pancreas,DAN-G,SIDM00950,1290797,1598,LGK974,PORCN,WNT signaling,Targeted,Early clinical trials,2.5,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,8.0,0.826624475540573,0.0723894277114238,0.814956000424547,12.2304973105377,75.0873,0.935221076688014,0.955914631859997,0.068934749086567,0.673662576439584,0.385118754139111,0.288543822300473,8.70225926413156,6.5082,3.52823804640617,68.5791,0.77307663203172,0.690189811522675,0.79018243122283,0.691132221674964,0.0828868205090449,0.0990502095478661,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35916,1089:1054,Pancreas,DAN-G,SIDM00950,1290797,1089,Oxaliplatin,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved in pancreas,2.5,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,8.0,0.948096208169893,0.0723894277114238,0.814956000424547,12.2304973105377,75.0873,0.935221076688014,0.955914631859997,0.0640461143855605,0.772656693827815,0.31755005412412,0.455106639703695,7.50529375499806,2.8388,4.72520355553967,72.2485,0.886679556608471,0.712115794565525,0.906299037800582,0.726247505419339,0.174563762042945,0.180051532381243,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35916,1079:1054,Pancreas,DAN-G,SIDM00950,1290797,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.05,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,8.0,0.793488333053287,0.0723894277114238,0.814956000424547,12.2304973105377,75.0873,0.935221076688014,0.955914631859997,0.0990262296248483,0.646658078288648,0.481291568444345,0.165366509844303,9.94316965581897,15.382,2.28732765471877,59.7053,0.742087013177473,0.631258838862919,0.758507107775836,0.70817849439129,0.110828174314554,0.050328613384546,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35918,1510:1079,Pancreas,DAN-G,SIDM00950,1290797,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.673544179052433,0.108386607985243,0.707728225195681,10.9270802202446,7.6057,0.856394870881605,0.925584512154084,0.0580312318148035,0.47668622643166,0.159618358423075,0.317067868008586,6.45207725654544,0.342,4.47500296369918,7.2637,0.576819780252665,0.451803946268464,0.623422060382469,0.466958206470968,0.125015833984202,0.156463853911501,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35918,1053:1079,Pancreas,DAN-G,SIDM00950,1290797,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.82425114695219,0.108386607985243,0.707728225195681,10.9270802202446,7.6057,0.856394870881605,0.925584512154084,0.127791238125814,0.583345801347978,0.296076266396012,0.287269534951966,7.73875598370783,0.8344,3.1883242365368,6.7713,0.705884454568135,0.557681983125258,0.762914095744186,0.643585868584984,0.148202471442877,0.119328227159202,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35918,1083:1079,Pancreas,DAN-G,SIDM00950,1290797,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,1.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.954952753552995,0.108386607985243,0.707728225195681,10.9270802202446,7.6057,0.856394870881605,0.925584512154084,0.129033673686035,0.67584701741779,0.150119391936649,0.525727625481141,5.34096667577475,0.1583,5.58611354446988,7.4474,0.817816640077051,0.535122101714628,0.883889478527548,0.580981687092127,0.282694538362423,0.302907791435421,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35918,1179:1079,Pancreas,DAN-G,SIDM00950,1290797,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.377378709288637,0.108386607985243,0.707728225195681,10.9270802202446,7.6057,0.856394870881605,0.925584512154084,0.0782724781452422,0.267081564151484,0.130191374914959,0.136890189236525,7.60293576875123,0.7594,3.3241444514934,6.8463,0.323185191014709,0.240565261933362,0.349295888534261,0.291435261790538,0.082619929081347,0.0578606267437232,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35918,1561:1079,Pancreas,DAN-G,SIDM00950,1290797,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,2.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.450956663456473,0.108386607985243,0.707728225195681,10.9270802202446,7.6057,0.856394870881605,0.925584512154084,0.0647677357547868,0.319154759068216,0.038664935179773,0.280489823888443,3.84268065998381,0.056,7.08439956026081,7.5497,0.386196973574006,0.199348113573031,0.417398503347993,0.219684036470501,0.186848860000975,0.197714466877492,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35918,1080:1079,Pancreas,DAN-G,SIDM00950,1290797,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.0025,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.718372754989439,0.108386607985243,0.707728225195681,10.9270802202446,7.6057,0.856394870881605,0.925584512154084,0.0807554748850893,0.508412674917607,0.222221483476598,0.286191191441009,7.24979093483038,0.5945,3.67728928541424,7.0112,0.615210742754044,0.501754925626662,0.664914695971685,0.53821904995349,0.113455817127382,0.126695646018195,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35918,1085:1079,Pancreas,DAN-G,SIDM00950,1290797,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,1.25,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.993645098563263,0.108386607985243,0.707728225195681,10.9270802202446,7.6057,0.856394870881605,0.925584512154084,0.0812661388756352,0.703230682080565,0.575483863801584,0.127746818278982,9.69585975418208,3.2397,1.23122046606254,4.366,0.850952565886225,0.831308429280916,0.919702513807974,0.876982395919932,0.0196441366053094,0.042720117888042,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35918,1073:1079,Pancreas,DAN-G,SIDM00950,1290797,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in pancreas,1.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.72042526741748,0.108386607985243,0.707728225195681,10.9270802202446,7.6057,0.856394870881605,0.925584512154084,0.0436557164737525,0.509865295895497,0.570871633805011,-0.0610063379095143,11.9188283164821,15.1246,-0.99174809623749,-7.5189,0.616968503869839,0.679028790549162,0.666814469686083,0.684316276576534,-0.0620602866793234,-0.0175018068904508,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35918,1054:1079,Pancreas,DAN-G,SIDM00950,1290797,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,8.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.846644128563308,0.108386607985243,0.707728225195681,10.9270802202446,7.6057,0.856394870881605,0.925584512154084,0.154516488986599,0.599193946480454,0.375990572551708,0.223203373928746,8.51068137698894,1.4247,2.41639884325568,6.181,0.725061689163643,0.589408924800573,0.783640692704389,0.699225430271421,0.13565276436307,0.0844152624329682,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35918,1564:1079,Pancreas,DAN-G,SIDM00950,1290797,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,1.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.752647581901985,0.108386607985243,0.707728225195681,10.9270802202446,7.6057,0.856394870881605,0.925584512154084,0.0585254717804254,0.532669937337313,0.14589388497193,0.386776052365383,5.89435467035384,0.2323,5.03272554989078,7.3734,0.644563528722303,0.489853549497632,0.696638944918699,0.490351374620225,0.154709979224671,0.206287570298474,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35918,1057:1079,Pancreas,DAN-G,SIDM00950,1290797,1057,Dactolisib,"PI3K (class 1), MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.0125,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.510003681888074,0.108386607985243,0.707728225195681,10.9270802202446,7.6057,0.856394870881605,0.925584512154084,0.0565246521265638,0.360944000625909,0.165736963047912,0.195207037577998,7.40709840032399,0.663,3.51998181992063,6.9427,0.436764537299681,0.365544093079412,0.47205150909716,0.387411551843181,0.0712204442202686,0.0846399572539787,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35918,1168:1079,Pancreas,DAN-G,SIDM00950,1290797,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.555485652784872,0.108386607985243,0.707728225195681,10.9270802202446,7.6057,0.856394870881605,0.925584512154084,0.111633222135446,0.393132875167102,0.263199901755771,0.129932973411331,8.77159842704,1.7072,2.15548179320462,5.8985,0.475715063893284,0.388923559037433,0.514148916941478,0.466434135115637,0.0867915048558512,0.0477147818258414,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35918,1190:1079,Pancreas,DAN-G,SIDM00950,1290797,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.01,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.692584960435055,0.108386607985243,0.707728225195681,10.9270802202446,7.6057,0.856394870881605,0.925584512154084,0.101724625648622,0.490161924845923,0.145112302252888,0.345049622593035,6.10667658157097,0.2692,4.82040363867365,7.3365,0.593126207766321,0.411823987060259,0.641045912729536,0.462391761578131,0.181302220706062,0.178654151151405,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35918,1372:1079,Pancreas,DAN-G,SIDM00950,1290797,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.712257830420085,0.108386607985243,0.707728225195681,10.9270802202446,7.6057,0.856394870881605,0.925584512154084,0.0308677364890416,0.504084970204933,0.0829731873957185,0.421111782809215,4.58514498395326,0.0938,6.34193523629136,7.5119,0.609973952717021,0.383908752721033,0.6592548164973,0.390105360198807,0.226065199995988,0.269149456298493,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35918,1011:1079,Pancreas,DAN-G,SIDM00950,1290797,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.871089622602467,0.108386607985243,0.707728225195681,10.9270802202446,7.6057,0.856394870881605,0.925584512154084,0.100077227692654,0.61649471259082,0.347411557885428,0.269083154705392,8.10579881506543,1.0761,2.82128140517919,6.5296,0.745996684874946,0.635732496814059,0.806267063378989,0.69949223491883,0.110264188060888,0.106774828460159,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35918,1558:1079,Pancreas,DAN-G,SIDM00950,1290797,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,2.5,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.884778209630527,0.108386607985243,0.707728225195681,10.9270802202446,7.6057,0.856394870881605,0.925584512154084,0.147493457696253,0.626182511993625,0.396572225674255,0.22961028631937,8.54702532236921,1.4611,2.38005489787541,6.1446,0.757719520595393,0.643786935358167,0.818937007525435,0.732460464854467,0.113932585237226,0.0864765426709678,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35918,1088:1079,Pancreas,DAN-G,SIDM00950,1290797,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.886025379129008,0.108386607985243,0.707728225195681,10.9270802202446,7.6057,0.856394870881605,0.925584512154084,0.0877189716055181,0.627065169049303,0.280613517691581,0.346451651357722,7.32447855246765,0.6261,3.60260166777697,6.9796,0.758787590157012,0.665607560926704,0.82009136829726,0.668229458571038,0.0931800292303084,0.151861909726222,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35918,1005:1079,Pancreas,DAN-G,SIDM00950,1290797,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,8.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.891110496424777,0.108386607985243,0.707728225195681,10.9270802202446,7.6057,0.856394870881605,0.925584512154084,0.117763769345973,0.63066405008795,0.367127297577826,0.263536752510123,8.22480865333502,1.1686,2.70227156690961,6.4371,0.76314245852694,0.662209196923875,0.824798074108711,0.72171925124294,0.100933261603066,0.103078822865771,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35918,1022:1079,Pancreas,DAN-G,SIDM00950,1290797,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.848753457944374,0.108386607985243,0.707728225195681,10.9270802202446,7.6057,0.856394870881605,0.925584512154084,0.138799387915335,0.600686778419669,0.101364962843126,0.499321815576543,4.64661220210865,0.0978,6.28046801813597,7.5079,0.726868108026589,0.429923737658399,0.785593055310535,0.469097596744724,0.296944370368189,0.316495458565812,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35918,1594:1079,Pancreas,DAN-G,SIDM00950,1290797,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.333551532148703,0.108386607985243,0.707728225195681,10.9270802202446,7.6057,0.856394870881605,0.925584512154084,0.0729645350361679,0.236063833858902,0.119135557680784,0.116928276178118,7.71948120574357,0.8233,3.20759901450105,6.7824,0.28565182130685,0.227496652525618,0.308730132162105,0.260040182320603,0.0581551687812327,0.0486899498415013,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35919,1561:1083,Pancreas,DAN-G,SIDM00950,1290797,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,2.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.46747299090297,0.0982786961838115,0.464655015541091,8.69141445567249,6.4595,0.843384153331483,0.835522332470125,0.0405093737974031,0.21721366985306,0.0713144931523584,0.145899176700701,5.26358835878723,0.6002,3.42782609688526,5.8593,0.394259312638037,0.253922242081307,0.390584123726035,0.281537920212325,0.14033707055673,0.10904620351371,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35919,1011:1083,Pancreas,DAN-G,SIDM00950,1290797,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.904074316225701,0.0982786961838115,0.464655015541091,8.69141445567249,6.4595,0.843384153331483,0.835522332470125,0.106113617894687,0.420082665456154,0.133941051906456,0.286141613549699,5.18852307142661,0.5698,3.50289138424588,5.8897,0.762481951738752,0.525965837401607,0.75537428141923,0.539085639965482,0.236516114337144,0.216288641453748,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35919,1558:1083,Pancreas,DAN-G,SIDM00950,1290797,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.907801029757928,0.0982786961838115,0.464655015541091,8.69141445567249,6.4595,0.843384153331483,0.835522332470125,0.0930827997779843,0.421814301590389,0.206986756049736,0.214827545540652,6.34248333457254,1.2679,2.34893112109995,5.1916,0.765625002875838,0.642430629977405,0.758488033802125,0.622051923350006,0.123194372898433,0.136436110452119,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35919,1079:1083,Pancreas,DAN-G,SIDM00950,1290797,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.742347330300014,0.0982786961838115,0.464655015541091,8.69141445567249,6.4595,0.843384153331483,0.835522332470125,0.0673231492956578,0.34493541029744,0.186505407837257,0.158430002460184,6.62044971742952,1.5374,2.07096473824297,4.9221,0.626083974642963,0.528598559243625,0.620247772915237,0.523725434801609,0.0974854153993385,0.0965223381136288,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
35919,1558:1085,Pancreas,DAN-G,SIDM00950,1290797,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.311749604020619,0.100903563284053,0.474877281147961,8.78084301168058,8.5907,0.841443541126368,0.840162746512567,0.0285612986867775,0.148042804356265,0.0464049678558036,0.101637836500461,5.20059663629499,0.7182,3.58024637538559,7.8725,0.262319690751852,0.16923008004853,0.261920403538168,0.186191279929143,0.0930896107033227,0.075729123609025,True,0.377976297584006,0.0690941151463686,0.937047615347088,52.4912835992931
36086,1564:1088,Pancreas,DAN-G,SIDM00950,1290797,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,1.0,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,0.737400430011051,0.0654044075996284,0.76889620207721,11.6193857119876,30.7244,0.932005365906032,0.943399765291421,0.0666596751832564,0.566984390045599,0.459065904961758,0.10791848508384,10.0903204062097,10.6461,1.52906530577787,20.0783,0.687261157591715,0.651373108443754,0.695663392598218,0.662234285708216,0.0358880491479613,0.0334291068900026,True,0.275056571421478,0.0408420227744738,1.24992265661787,39.5667159156265
36086,1372:1088,Pancreas,DAN-G,SIDM00950,1290797,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,0.62572683034677,0.0654044075996284,0.76889620207721,11.6193857119876,30.7244,0.932005365906032,0.943399765291421,0.0835039322520453,0.481118983391442,0.353271312283109,0.127847671108333,9.56602647665187,7.4022,2.05335923533569,23.3222,0.583180763474563,0.512528424432042,0.590310544885687,0.548844273753798,0.0706523390425208,0.0414662711318893,True,0.275056571421478,0.0408420227744738,1.24992265661787,39.5667159156265
36086,1011:1088,Pancreas,DAN-G,SIDM00950,1290797,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,0.882253813685049,0.0654044075996284,0.76889620207721,11.6193857119876,30.7244,0.932005365906032,0.943399765291421,0.106646102148052,0.678361606610568,0.292780484029881,0.385581122580687,7.4751023379307,1.7375,4.14428337405686,28.9869,0.822265288445526,0.666382980161307,0.832318040757936,0.674089260913986,0.155882308284219,0.15822877984395,True,0.275056571421478,0.0408420227744738,1.24992265661787,39.5667159156265
36086,1022:1088,Pancreas,DAN-G,SIDM00950,1290797,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,0.836188614329454,0.0654044075996284,0.76889620207721,11.6193857119876,30.7244,0.932005365906032,0.943399765291421,0.144831531962045,0.642942249778122,0.315944996833628,0.326997252944493,7.91325539296209,2.3541,3.70613031902547,28.3703,0.779332275464581,0.596741066055387,0.788860142497765,0.66187161357936,0.182591209409193,0.126988528918405,True,0.275056571421478,0.0408420227744738,1.24992265661787,39.5667159156265
36967,1011:1190,Pancreas,DAN-G,SIDM00950,1290797,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.2,0.615824197055574,0.141140167870038,0.31527231537949,7.30997971057819,0.062,0.697675100588135,0.75322718787539,0.0393682872036929,0.194152320472426,0.0311609295961661,0.16299139087626,2.61137082990401,0.0024,4.69860888067418,0.0596,0.429645208625355,0.220414972503438,0.46385552817379,0.238844802707323,0.209230236121917,0.225010725466467,True,0.308702688103801,0.048280611784538,1.13254613004352,43.5498506637625
36967,1022:1190,Pancreas,DAN-G,SIDM00950,1290797,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.2,0.899937589040567,0.141140167870038,0.31527231537949,7.30997971057819,0.062,0.697675100588135,0.75322718787539,0.140605318732116,0.283725407393856,0.0411135740413024,0.242611833352554,2.3774419786913,0.002,4.93253773188689,0.06,0.627864047956921,0.339379208292545,0.677857459456385,0.332524080805205,0.288484839664376,0.345333378651179,True,0.308702688103801,0.048280611784538,1.13254613004352,43.5498506637625
36967,1080:1372,Pancreas,DAN-G,SIDM00950,1290797,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.025,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.361206025133439,0.152372482291439,0.522780604253272,9.19869586425823,1.1477,0.76171637108109,0.860681503350883,0.0595886663199874,0.188831504079182,0.02685271624986,0.161978787829322,3.50485894814731,0.0222,5.69383691611091,1.1255,0.275136542677268,0.140588105578175,0.310883344731245,0.166014596001806,0.134548437099093,0.144868748729439,True,0.308702688103801,0.048280611784538,1.13254613004352,43.5498506637625
36967,1011:1372,Pancreas,DAN-G,SIDM00950,1290797,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.615824197055574,0.152372482291439,0.522780604253272,9.19869586425823,1.1477,0.76171637108109,0.860681503350883,0.0421081598879006,0.321940945850499,0.029322607254489,0.29261833859601,2.47203165080791,0.0108,6.72666421345031,1.1369,0.469083372605098,0.219679866869587,0.530028495721642,0.232096624514085,0.249403505735512,0.297931871207557,True,0.308702688103801,0.048280611784538,1.13254613004352,43.5498506637625
36967,1594:1372,Pancreas,DAN-G,SIDM00950,1290797,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.342494245362678,0.152372482291439,0.522780604253272,9.19869586425823,1.1477,0.76171637108109,0.860681503350883,0.0386955666244308,0.179049348543969,0.0634692013557079,0.115580147188261,5.77341125824411,0.1068,3.42528460601412,1.0409,0.260883473693815,0.205473573241785,0.294778461987776,0.219951100471253,0.0554099004520301,0.0748273615165227,True,0.308702688103801,0.048280611784538,1.13254613004352,43.5498506637625
36967,1053:1372,Pancreas,DAN-G,SIDM00950,1290797,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.831708122558235,0.152372482291439,0.522780604253272,9.19869586425823,1.1477,0.76171637108109,0.860681503350883,0.0424103861146364,0.434800874873349,0.218350483542461,0.216450391330887,6.7493980841915,0.2101,2.44929778006672,0.9376,0.633525692913726,0.591298399998898,0.715835797272562,0.594433065611192,0.0422272929148277,0.121402731661371,True,0.308702688103801,0.048280611784538,1.13254613004352,43.5498506637625
36967,1561:1372,Pancreas,DAN-G,SIDM00950,1290797,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.619764880629416,0.152372482291439,0.522780604253272,9.19869586425823,1.1477,0.76171637108109,0.860681503350883,0.035739211994918,0.324001058790403,0.0549456496818183,0.269055409108585,3.92251333969238,0.0296,5.27618252456585,1.1181,0.472085055796544,0.291782735301919,0.533420169184207,0.305959739825666,0.180302320494625,0.22746042935854,True,0.308702688103801,0.048280611784538,1.13254613004352,43.5498506637625
36967,1190:1372,Pancreas,DAN-G,SIDM00950,1290797,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.592740586711644,0.152372482291439,0.522780604253272,9.19869586425823,1.1477,0.76171637108109,0.860681503350883,0.0733771210429252,0.309873282086552,0.119971334032517,0.189901948054035,6.01177986600177,0.126,3.18691599825646,1.0217,0.45150020870247,0.354603008838757,0.510160859268062,0.391478082081406,0.0968971998637134,0.118682777186656,True,0.308702688103801,0.048280611784538,1.13254613004352,43.5498506637625
36967,1558:1372,Pancreas,DAN-G,SIDM00950,1290797,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.15109946942175,0.152372482291439,0.522780604253272,9.19869586425823,1.1477,0.76171637108109,0.860681503350883,0.0557905511951433,0.0789918719266512,0.0497188657149937,0.0292730062116575,7.44744832501318,0.3409,1.75124753924504,0.8068,0.115094939520214,0.0798985605120081,0.130048518497433,0.115176760946507,0.0351963790082055,0.0148717575509258,True,0.308702688103801,0.048280611784538,1.13254613004352,43.5498506637625
36967,1079:1372,Pancreas,DAN-G,SIDM00950,1290797,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.05,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.717160987777226,0.152372482291439,0.522780604253272,9.19869586425823,1.1477,0.76171637108109,0.860681503350883,0.0860576502693493,0.374917854537051,0.0958754043654313,0.27904245017162,4.92796013360698,0.0595,4.27073573065124,1.0882,0.546273265090599,0.383453210298675,0.617247197104707,0.412668760887061,0.162820054791923,0.204578436217646,True,0.308702688103801,0.048280611784538,1.13254613004352,43.5498506637625
36089,1080:1507,Pancreas,DAN-G,SIDM00950,1290797,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.0025,1507,Ruxolitinib,"JAK1, JAK2","Other, kinases",Targeted,Advanced clinical trials,10.0,0.539877323331756,0.0948916906085672,0.893065384365807,13.6248611173585,246.73,0.923842622775101,0.975621130196036,0.0696791443524095,0.482145749271658,0.469244775084011,0.0129009741876472,13.1262804582653,174.6362,0.498580659093243,72.0938,0.498761682363611,0.483739886112561,0.526715724356138,0.523561829655801,0.0150217962510498,0.0031538947003373,True,0.275056571421478,0.0408420227744738,1.24992265661787,39.5667159156265
36089,1564:1507,Pancreas,DAN-G,SIDM00950,1290797,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,1.0,1507,Ruxolitinib,"JAK1, JAK2","Other, kinases",Targeted,Advanced clinical trials,10.0,0.661948382463971,0.0948916906085672,0.893065384365807,13.6248611173585,246.73,0.923842622775101,0.975621130196036,0.0292148977931955,0.591163186615511,0.542182134104387,0.0489810525111237,12.2904632488474,97.8426,1.33439786851109,148.8874,0.611536129797251,0.638311504331205,0.645810829030937,0.63348346277553,-0.0267753745339541,0.0123273662554078,True,0.275056571421478,0.0408420227744738,1.24992265661787,39.5667159156265
36089,1372:1507,Pancreas,DAN-G,SIDM00950,1290797,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1507,Ruxolitinib,"JAK1, JAK2","Other, kinases",Targeted,Advanced clinical trials,10.0,0.576174653134972,0.0948916906085672,0.893065384365807,13.6248611173585,246.73,0.923842622775101,0.975621130196036,0.0670631341467645,0.514561638063819,0.341253769295608,0.173307868768212,9.81360025972657,17.5759,3.81126085763196,229.1541,0.532294702728747,0.460491378134384,0.56212816628185,0.511288626549975,0.071803324594363,0.0508395397318754,True,0.275056571421478,0.0408420227744738,1.24992265661787,39.5667159156265
36089,1085:1510,Pancreas,DAN-G,SIDM00950,1290797,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,5.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.565962505907355,0.101306983689671,0.699990634868449,10.8461886255465,35.9549,0.878941491005708,0.923223497148694,0.113663997347048,0.396168453821828,0.105962222525071,0.290206231296756,5.80087203389041,1.0888,5.04531659165607,34.8661,0.497447928795537,0.30639535759168,0.522509883958826,0.364661888813247,0.191052571203857,0.15784799514558,True,0.275056571421478,0.0408420227744738,1.24992265661787,39.5667159156265
36089,1083:1510,Pancreas,DAN-G,SIDM00950,1290797,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,1.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.847814209082597,0.101306983689671,0.699990634868449,10.8461886255465,35.9549,0.878941491005708,0.923223497148694,0.0683859245526239,0.593462006466219,0.46969379928087,0.123768207185349,9.47256211248627,13.8757,1.3736265130602,22.0792,0.745179085026883,0.69228664843608,0.78272199904159,0.740214740535761,0.0528924365908024,0.0425072585058286,True,0.275056571421478,0.0408420227744738,1.24992265661787,39.5667159156265
36089,1594:1510,Pancreas,DAN-G,SIDM00950,1290797,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.25465519620225,0.101306983689671,0.699990634868449,10.8461886255465,35.9549,0.878941491005708,0.923223497148694,0.0589847185704156,0.178256252462162,0.0671397250047041,0.111116527457458,6.76195197934971,2.1197,4.08423664619677,33.8352,0.223827017842357,0.12618300178718,0.235103660804928,0.182232256294368,0.0976440160551762,0.0528714045105604,True,0.275056571421478,0.0408420227744738,1.24992265661787,39.5667159156265
36089,1053:1510,Pancreas,DAN-G,SIDM00950,1290797,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.717382362359614,0.101306983689671,0.699990634868449,10.8461886255465,35.9549,0.878941491005708,0.923223497148694,0.0793827795413347,0.502160935271534,0.353798463928815,0.148362471342719,8.94055036774405,9.5963,1.90563825780243,26.3586,0.630537123193556,0.561283669132819,0.662304253370434,0.60850672843014,0.0692534540607368,0.0537975249402945,True,0.275056571421478,0.0408420227744738,1.24992265661787,39.5667159156265
36089,1561:1510,Pancreas,DAN-G,SIDM00950,1290797,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.5,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.518022972233955,0.101306983689671,0.699990634868449,10.8461886255465,35.9549,0.878941491005708,0.923223497148694,0.0989098818867475,0.362611229210487,0.18990890801868,0.172702321191807,7.80847090310708,4.3784,3.0377177224394,31.5765,0.455311883590521,0.32809691218099,0.478250980029193,0.406716506414844,0.127214971409531,0.071534473614349,True,0.275056571421478,0.0408420227744738,1.24992265661787,39.5667159156265
36089,1558:1510,Pancreas,DAN-G,SIDM00950,1290797,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.226309218685499,0.101306983689671,0.699990634868449,10.8461886255465,35.9549,0.878941491005708,0.923223497148694,0.0428172610228205,0.158414333664245,0.0844727766651534,0.073941556999092,7.87072903512185,4.5715,2.97545959042463,31.3834,0.19891256209977,0.134781439869794,0.208933988311815,0.178546424888369,0.0641311222299751,0.0303875634234459,True,0.275056571421478,0.0408420227744738,1.24992265661787,39.5667159156265
36089,1079:1510,Pancreas,DAN-G,SIDM00950,1290797,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.05,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.762899794200425,0.101306983689671,0.699990634868449,10.8461886255465,35.9549,0.878941491005708,0.923223497148694,0.0930963871292256,0.534022711283365,0.250934282083733,0.283088429199631,7.44620878893715,3.4061,3.39997983660932,32.5488,0.670544282602469,0.516773897863582,0.704327015975735,0.581464844349498,0.153770384738887,0.122862171626237,True,0.275056571421478,0.0408420227744738,1.24992265661787,39.5667159156265
36968,1510:1558,Pancreas,DAN-G,SIDM00950,1290797,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.745216012149358,0.179971596340953,0.484350621429813,8.86355369436316,9.0976,0.877683433317757,0.844376707154096,0.080738949145972,0.360945838583988,0.199525972771901,0.161419865812087,6.80766527583966,2.188,2.05588841852351,6.9096,0.654063748106615,0.566374004534726,0.629243042457181,0.535687955246262,0.0876897435718892,0.0935550872109193,True,0.308702688103801,0.048280611784538,1.13254613004352,43.5498506637625
36968,1564:1561,Pancreas,DAN-G,SIDM00950,1290797,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.747456538510707,0.180335294828139,0.248822876775449,6.59239154539767,1.8847,0.670221233910147,0.703477888478109,0.0412072301600456,0.185984286176853,0.0435448300837958,0.142439456093058,2.93606576520812,0.1495,3.65632578018955,1.7352,0.500961243534853,0.293485323096782,0.525819147440669,0.309197474871249,0.207475920438071,0.21662167256942,True,0.308702688103801,0.048280611784538,1.13254613004352,43.5498506637625
36968,1011:1561,Pancreas,DAN-G,SIDM00950,1290797,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.849699903533252,0.180335294828139,0.248822876775449,6.59239154539767,1.8847,0.670221233910147,0.703477888478109,0.0734662357901196,0.211424774392965,0.0591841408207262,0.152240633572239,3.35188961710469,0.1994,3.24050192829298,1.6853,0.569486917799389,0.371913227040867,0.597745093977625,0.379975992847418,0.197573690758521,0.217769101130207,True,0.308702688103801,0.048280611784538,1.13254613004352,43.5498506637625
36968,1079:1561,Pancreas,DAN-G,SIDM00950,1290797,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.65264309821647,0.180335294828139,0.248822876775449,6.59239154539767,1.8847,0.670221233910147,0.703477888478109,0.0413069115329425,0.162392533205864,0.0289268977264494,0.133465635479415,2.30837139802623,0.0967,4.28402014737143,1.788,0.437415262589584,0.222292340491879,0.459119988663134,0.237644230335251,0.215122922097705,0.221475758327883,True,0.308702688103801,0.048280611784538,1.13254613004352,43.5498506637625
36968,1372:1561,Pancreas,DAN-G,SIDM00950,1290797,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.774442384878601,0.180335294828139,0.248822876775449,6.59239154539767,1.8847,0.670221233910147,0.703477888478109,0.0320230188463214,0.192698982102333,0.0443016002451554,0.148397381857178,2.89389150145244,0.1452,3.69850004394522,1.7395,0.519047730785653,0.310041153287115,0.544803093662349,0.317747645956787,0.209006577498538,0.227055447705563,True,0.308702688103801,0.048280611784538,1.13254613004352,43.5498506637625
36969,1011:1564,Pancreas,DAN-G,SIDM00950,1290797,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.641477113653981,0.0880113565705309,0.470462794558612,8.74225029390307,8.3639,0.804035474964126,0.838170894405702,0.0481702108055332,0.301791115535044,0.0227737482056871,0.279017367329357,1.80481134068797,0.0682,6.9374389532151,8.2957,0.515770355755395,0.204702118845288,0.537667446092145,0.208943191361567,0.311068236910107,0.328724254730578,True,0.308702688103801,0.048280611784538,1.13254613004352,43.5498506637625
36969,1561:1564,Pancreas,DAN-G,SIDM00950,1290797,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.631849830555052,0.0880113565705309,0.470462794558612,8.74225029390307,8.3639,0.804035474964126,0.838170894405702,0.0491933026918465,0.297261837024315,0.090729864705468,0.206531972318847,5.10879101410557,0.674,3.6334592797975,7.6899,0.508029678616333,0.374944269640789,0.529598137606419,0.37274227187475,0.133085408975544,0.156855865731669,True,0.308702688103801,0.048280611784538,1.13254613004352,43.5498506637625
36969,1053:1564,Pancreas,DAN-G,SIDM00950,1290797,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,5.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.850270171800407,0.0880113565705309,0.470462794558612,8.74225029390307,8.3639,0.804035474964126,0.838170894405702,0.0706621775091666,0.40002048115505,0.135717440454222,0.264303040700828,5.3804563563878,0.8136,3.36179393751527,7.5503,0.683647381431369,0.521213935912928,0.712671710384437,0.51994790192599,0.162433445518441,0.192723808458447,True,0.308702688103801,0.048280611784538,1.13254613004352,43.5498506637625
36969,1053:1594,Pancreas,DAN-G,SIDM00950,1290797,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.824441293119271,0.105981390274608,0.203698267356376,6.0292474834389,0.5102,0.661950035693464,0.661779413764115,0.109522019013023,0.167937262945445,0.0779316856839393,0.0900055772615062,4.07632081254617,0.1318,1.95292667089273,0.3784,0.545738943407467,0.41145558049143,0.5455982756434,0.417360306903925,0.134283362916037,0.128237968739475,True,0.308702688103801,0.048280611784538,1.13254613004352,43.5498506637625
34831,1022:1005,Pancreas,Hs-766T,SIDM00664,1298141,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,8.0,0.84443354228152,0.0799748900954935,0.827250892444627,13.5023008786281,181.3083,0.947467236783466,0.947330650262674,0.0664684892453984,0.698558401462565,0.44194096011323,0.256617441349335,9.26876852855325,9.6382,4.23353235007485,171.6701,0.800073114952746,0.7086724753659,0.799957776713165,0.693989158836672,0.091400639586846,0.105968617876494,True,0.506779323265705,0.0761582706803658,0.64125508989202,75.5116748244959
34831,1558:1011,Pancreas,Hs-766T,SIDM00664,1298141,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.474029583611523,0.120792633070361,0.527899098498177,9.32112195694981,12.493,0.867316621502426,0.824181586480037,0.0570367389195822,0.250239789849989,0.0939783853760098,0.156261404473979,4.98357292419863,0.6179,4.33754903275118,11.8751,0.411133736950148,0.235275188886679,0.390686454259416,0.26954720150388,0.175858548063468,0.121139252755536,True,0.506779323265705,0.0761582706803658,0.64125508989202,75.5116748244959
34832,1088:1022,Pancreas,Hs-766T,SIDM00664,1298141,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.991768565559192,0.0920468534897857,0.627094313066469,10.4941042569793,2.8169,0.896674412990306,0.871081726125451,0.108832819614446,0.621932427340258,0.343315116794878,0.27861731054538,7.17196009763397,0.2816,3.32214415934536,2.5353,0.889293496345026,0.657625264584621,0.863911474004263,0.705478423421741,0.231668231760405,0.158433050582523,True,0.506779323265705,0.0761582706803658,0.64125508989202,75.5116748244959
35345,1085:1053,Pancreas,Hs-766T,SIDM00664,1298141,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,1.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.888187070759427,0.103606707881216,0.800272647985891,12.9898609129693,158.8795,0.900595315227417,0.938158723158831,0.0670984616836139,0.710791819023479,0.761424284628829,-0.0506324656053508,14.1536876753413,355.971,-1.16382676237197,-197.0915,0.799897114971502,0.836342432026587,0.833260448229847,0.850178657678676,-0.0364453170550852,-0.0169182094488296,True,0.446845140179036,0.0669855827485741,0.7640415898497,63.7539938041663
35345,1190:1053,Pancreas,Hs-766T,SIDM00664,1298141,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.01,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.979756233278197,0.103606707881216,0.800272647985891,12.9898609129693,158.8795,0.900595315227417,0.938158723158831,0.0902377891969706,0.784072115186225,0.633803573642697,0.150268541543528,10.7403539159218,33.4117,2.24950699704753,125.4678,0.882363873755205,0.808598627192414,0.91916685681918,0.86178803846535,0.0737652465627905,0.0573788183538294,True,0.446845140179036,0.0669855827485741,0.7640415898497,63.7539938041663
35345,1372:1053,Pancreas,Hs-766T,SIDM00664,1298141,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.500354063922068,0.103606707881216,0.800272647985891,12.9898609129693,158.8795,0.900595315227417,0.938158723158831,0.0434014741979793,0.400419671665415,0.334219513346691,0.0662001583187238,11.0093041836151,40.2588,1.9805567293542,118.6207,0.450616525923214,0.411987541066079,0.469411529736459,0.444504989004672,0.0386289848571345,0.0249065407317874,True,0.446845140179036,0.0669855827485741,0.7640415898497,63.7539938041663
35345,1011:1053,Pancreas,Hs-766T,SIDM00664,1298141,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.70227683301446,0.103606707881216,0.800272647985891,12.9898609129693,158.8795,0.900595315227417,0.938158723158831,0.114266222022351,0.562012940775627,0.332809120899445,0.229203819876182,8.69962702130918,8.1204,4.29023389166016,150.7591,0.632467225805569,0.466400801122028,0.658847136964873,0.558323588293896,0.166066424683541,0.100523548670978,True,0.446845140179036,0.0669855827485741,0.7640415898497,63.7539938041663
35345,1558:1053,Pancreas,Hs-766T,SIDM00664,1298141,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.736750996638489,0.103606707881216,0.800272647985891,12.9898609129693,158.8795,0.900595315227417,0.938158723158831,0.0268658631991908,0.589601670986128,0.517630910470486,0.0719707605156413,11.4710777732805,55.4458,1.51878313968886,103.4337,0.663514496061753,0.664860813622886,0.691189374292361,0.664741825829871,-0.0013463175611323,0.0264475484624904,True,0.446845140179036,0.0669855827485741,0.7640415898497,63.7539938041663
35345,1594:1053,Pancreas,Hs-766T,SIDM00664,1298141,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.347173205479034,0.103606707881216,0.800272647985891,12.9898609129693,158.8795,0.900595315227417,0.938158723158831,0.0720688075810607,0.277833220458457,0.241704655162402,0.0361285652960541,11.3838676426238,52.1934,1.60599327034553,106.6861,0.312662562426904,0.253969308108026,0.32570357116717,0.312370401938152,0.058693254318878,0.0133331692290178,True,0.446845140179036,0.0669855827485741,0.7640415898497,63.7539938041663
35347,1372:1079,Pancreas,Hs-766T,SIDM00664,1298141,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.555385108213982,0.107799890912163,0.635893885246075,10.6028048595766,6.0747,0.81846886587949,0.874895136955148,0.0511661630648643,0.353165994270001,0.155076428841373,0.198089565428629,6.27402137602197,0.3023,4.32878348355467,5.7724,0.454565419646256,0.330516082111384,0.485903730313722,0.363945901738166,0.124049337534872,0.121957828575556,True,0.446845140179036,0.0669855827485741,0.7640415898497,63.7539938041663
38369,1011:1083,Pancreas,Hs-766T,SIDM00664,1298141,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.805323212890258,0.0740212263856292,0.75032941684553,12.1630585915012,71.6581,0.914959431011178,0.920366011457894,0.0692465626803399,0.604257696700116,0.361793094097864,0.242464602602251,8.41447546109978,5.3313,3.74858313040147,66.3268,0.736838068646164,0.638199854354511,0.741192113382263,0.628680654196173,0.0986382142916535,0.11251145918609,True,0.412578623947329,0.074038859160901,0.819166773089714,58.9218745761449
38369,1079:1083,Pancreas,Hs-766T,SIDM00664,1298141,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.767254050245365,0.0740212263856292,0.75032941684553,12.1630585915012,71.6581,0.914959431011178,0.920366011457894,0.0381967091167612,0.575693284092976,0.39352140591819,0.182171878174786,9.14831130751308,8.8662,3.01474728398816,62.7919,0.702006329253521,0.626715391481303,0.706154549999241,0.626364192622551,0.0752909377722185,0.0797903573766905,True,0.412578623947329,0.074038859160901,0.819166773089714,58.9218745761449
38370,1022:1088,Pancreas,Hs-766T,SIDM00664,1298141,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,0.919795913064739,0.0878059573636136,0.924935845360713,16.2190684478317,744.9483,0.943244176437217,0.978288344775629,0.0826917067387821,0.850752210409863,0.52614374804426,0.324608462365603,9.83392382191817,8.9126,6.38514462591355,736.0357,0.867592138509068,0.753949350471808,0.899825621323492,0.778140733749501,0.11364278803726,0.121684887573991,True,0.412578623947329,0.074038859160901,0.819166773089714,58.9218745761449
38371,1053:1168,Pancreas,Hs-766T,SIDM00664,1298141,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.885788872018067,0.0868550432780332,0.748422600910605,12.1338738071251,87.7789,0.919075936384461,0.919664371336163,0.0878826188165374,0.662944411453433,0.43935950733022,0.223584904123213,8.95411315863012,9.6869,3.17976064849496,78.092,0.81410723698894,0.659814643608736,0.814628466121065,0.715114262753531,0.154292593380204,0.0995142033675342,True,0.412578623947329,0.074038859160901,0.819166773089714,58.9218745761449
38371,1022:1179,Pancreas,Hs-766T,SIDM00664,1298141,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,4.0,0.997995021420448,0.086796942017636,0.64921510391696,10.7695413015074,13.6378,0.860679090067918,0.880573483573388,0.0594169223909269,0.647913441540084,0.555682141707447,0.092231299832637,9.65590972601751,6.3024,1.11363157548986,7.3354,0.858953446928463,0.839706731140427,0.878807952601101,0.836971336089133,0.0192467157880365,0.0418366165119686,True,0.412578623947329,0.074038859160901,0.819166773089714,58.9218745761449
38372,1011:1190,Pancreas,Hs-766T,SIDM00664,1298141,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.2,0.807355136470725,0.0417290520335667,0.909784077003812,15.6430682470484,19.9891,0.979935149501952,0.973699641556769,0.0628081051198332,0.734518847648305,0.385303473901055,0.34921537374725,8.73813948067467,0.1668,6.9049287663737,19.8223,0.791155676358609,0.640900988038203,0.786121406990562,0.643391202037285,0.150254688320407,0.142730204953276,True,0.412578623947329,0.074038859160901,0.819166773089714,58.9218745761449
38373,1594:1510,Pancreas,Hs-766T,SIDM00664,1298141,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.392790981876081,0.0953227473630787,0.831869766440964,13.5962100934996,241.8784,0.919840083430419,0.948872023926205,0.0491223724940203,0.326750942353372,0.355896875344341,-0.0291459329909685,15.5154036621489,914.8122,-1.91919356864935,-672.9338,0.36130488953961,0.348145651059218,0.372708373952718,0.38201442878566,0.0131592384803924,-0.0093060548329418,True,0.412578623947329,0.074038859160901,0.819166773089714,58.9218745761449
38086,1080:1011,Pancreas,KP-1N,SIDM00583,1298216,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.540461414159996,0.080000794768034,0.647013641751468,10.4276535655561,26.9009,0.900552069476767,0.899254876533613,0.0341396837211861,0.349685907801808,0.149003196873099,0.200682710928708,6.72421206426844,2.065,3.70344150128767,24.8359,0.486713644994125,0.369209958916032,0.486012562261629,0.381102616122203,0.117503686078093,0.104909946139426,True,0.26545189627022,0.0396774713456944,1.25397777780286,39.1824544315439
38087,1190:1022,Pancreas,KP-1N,SIDM00583,1298216,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.795283219282225,0.0545458580465887,0.869164315645056,13.4614970890422,22.0315,0.955689085770222,0.967470216798906,0.0419824958801602,0.691231795031432,0.408959525406786,0.282272269624645,9.13415801261692,1.0975,4.32733907642525,20.934,0.760043492764228,0.668839190075201,0.769412828575506,0.673184320751216,0.0912043026890275,0.09622850782429,True,0.26545189627022,0.0396774713456944,1.25397777780286,39.1824544315439
38088,1558:1053,Pancreas,KP-1N,SIDM00583,1298216,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.952001175869087,0.0591504181232595,0.785513120215468,12.0584332108352,83.3067,0.92678370949784,0.944040480476596,0.0596015343948129,0.747809414105722,0.751044916347698,-0.0032355022419767,12.1062376372806,86.1134,-0.0478044264453903,-2.80669999999999,0.882299181218258,0.88929453643316,0.898727647481738,0.899678446633586,-0.0069953552149012,-0.0009507991518484,True,0.26545189627022,0.0396774713456944,1.25397777780286,39.1824544315439
38088,1594:1053,Pancreas,KP-1N,SIDM00583,1298216,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.836384108250334,0.0591504181232595,0.785513120215468,12.0584332108352,83.3067,0.92678370949784,0.944040480476596,0.0457089224328338,0.656990690570352,0.400708774071838,0.256281916498513,8.80288257612989,8.7229,3.25555063470529,74.5838,0.775147166409287,0.687907257231691,0.789580455415634,0.694426226668394,0.0872399091775964,0.0951542287472406,True,0.26545189627022,0.0396774713456944,1.25397777780286,39.1824544315439
38090,1510:1079,Pancreas,KP-1N,SIDM00583,1298216,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.908704358032345,0.0970409340440818,0.674925135452797,10.7212438182458,6.5944,0.850865376491199,0.908991283519674,0.11452163551461,0.613307411931527,0.376433832563183,0.236873579368345,8.18382260913777,1.1359,2.53742120910807,5.4585,0.773185075716385,0.634168985093862,0.826004340747742,0.72432209786686,0.139016090622523,0.101682242880882,True,0.26545189627022,0.0396774713456944,1.25397777780286,39.1824544315439
38194,1088:1168,Pancreas,KP-1N,SIDM00583,1298216,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.905250524547333,0.057920711088845,0.87576768083518,13.6013496511795,242.7416,0.954810963771361,0.96922421138184,0.0466138751513858,0.792789152457648,0.363302398014251,0.429486754443397,8.05771167781966,5.2041,5.54363797335983,237.5375,0.864343125797569,0.700712986397841,0.877390725757386,0.715041198140727,0.163630139399728,0.162349527616658,True,0.33080575099409,0.0537833085710134,1.03124901802824,47.2296886177584
38194,1594:1168,Pancreas,KP-1N,SIDM00583,1298216,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.84997707415274,0.057920711088845,0.87576768083518,13.6013496511795,242.7416,0.954810963771361,0.96922421138184,0.0746771721979308,0.744382450993817,0.470326127591545,0.274056323402272,9.50461663753193,14.1875,4.09673301364756,228.5541,0.811567429355339,0.685196855950555,0.823818359388333,0.733770258815212,0.126370573404783,0.0900481005731206,True,0.33080575099409,0.0537833085710134,1.03124901802824,47.2296886177584
38195,1022:1190,Pancreas,KP-1N,SIDM00583,1298216,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.2,0.950364337481473,0.055157291204868,0.624317648024902,10.196701882319,0.4584,0.894417937468023,0.891030037013432,0.110795142991587,0.593329227943177,0.327888589472709,0.265440638470468,7.48966406951047,0.0702,2.70703781280849,0.3882,0.850022910573343,0.686917169375185,0.846803170802362,0.718096207120905,0.163105741198158,0.128706963681457,True,0.33080575099409,0.0537833085710134,1.03124901802824,47.2296886177584
38195,1053:1372,Pancreas,KP-1N,SIDM00583,1298216,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.697382531672596,0.100332609065971,0.780030661901677,11.9824640734876,7.9033,0.879411830975907,0.942420404125375,0.046531155179253,0.543979757779242,0.118410056109277,0.425569701669965,5.26062248879302,0.0749,6.72184158469462,7.8284,0.613286449068811,0.385819047163074,0.657227527328865,0.41716938326371,0.227467401905737,0.240058144065155,True,0.33080575099409,0.0537833085710134,1.03124901802824,47.2296886177584
38195,1561:1372,Pancreas,KP-1N,SIDM00583,1298216,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.890308887840402,0.100332609065971,0.780030661901677,11.9824640734876,7.9033,0.879411830975907,0.942420404125375,0.12568774915112,0.694468231079094,0.55232812571413,0.142140105364964,10.1572088733449,2.2303,1.82525520014275,5.673,0.782948169189851,0.692553991642397,0.839045261874965,0.791994448989935,0.0903941775474545,0.0470508128850295,True,0.33080575099409,0.0537833085710134,1.03124901802824,47.2296886177584
38195,1079:1372,Pancreas,KP-1N,SIDM00583,1298216,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.05,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.943268673398973,0.100332609065971,0.780030661901677,11.9824640734876,7.9033,0.879411830975907,0.942420404125375,0.127461513377042,0.735778487662517,0.444343635833283,0.291434851829234,8.72702721446267,0.8276,3.25543685902497,7.0757,0.829521631176005,0.689572476724049,0.888955644383466,0.779525230666105,0.139949154451956,0.109430413717361,True,0.33080575099409,0.0537833085710134,1.03124901802824,47.2296886177584
38587,1088:1510,Pancreas,KP-1N,SIDM00583,1298216,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.856836527349287,0.0439620332803062,0.814477013974044,12.4855451902037,112.0092,0.952022228143275,0.95241924082683,0.0393132280145434,0.697873656259337,0.408731055596526,0.289142600662811,8.7833060437832,8.6054,3.70223914642049,103.4038,0.815727419921614,0.686110736186691,0.816067594890706,0.710557666476494,0.129616683734923,0.105509928414211,True,0.138002283349972,0.0257068406814575,1.82203715738827,27.0429835437031
38587,1594:1510,Pancreas,KP-1N,SIDM00583,1298216,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.860005754563494,0.0439620332803062,0.814477013974044,12.4855451902037,112.0092,0.952022228143275,0.95241924082683,0.0796900697914649,0.70045491897737,0.363514609574169,0.336940309403201,8.26549326544355,6.0102,4.22005192476013,105.999,0.818744594675576,0.640976674388976,0.819086027868069,0.689452001168776,0.1777679202866,0.129634026699293,True,0.138002283349972,0.0257068406814575,1.82203715738827,27.0429835437031
38587,1079:1510,Pancreas,KP-1N,SIDM00583,1298216,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.05,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.848632669265257,0.0439620332803062,0.814477013974044,12.4855451902037,112.0092,0.952022228143275,0.95241924082683,0.0505941432807649,0.69119180242399,0.522245217423401,0.168946585000589,10.1074920890445,21.5471,2.37805310115917,90.4621,0.807917164669085,0.718415236747037,0.808254082602463,0.753345351459491,0.089501927922048,0.0549087311429721,True,0.138002283349972,0.0257068406814575,1.82203715738827,27.0429835437031
38588,1088:1558,Pancreas,KP-1N,SIDM00583,1298216,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.794442619442831,0.0825680145543811,0.706477702725243,11.0694567654459,41.9729,0.933268056682856,0.919534059471627,0.0584503743424674,0.561255996730996,0.252430337005549,0.308825659725447,7.19957437019976,2.8709,3.86988239524609,39.102,0.741427919593449,0.55789177577908,0.730517046873539,0.585519516758023,0.183536143814368,0.144997530115516,True,0.138002283349972,0.0257068406814575,1.82203715738827,27.0429835437031
38589,1510:1564,Pancreas,KP-1N,SIDM00583,1298216,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.927246906093903,0.0686825117788234,0.759889691025287,11.7144094634993,65.6325,0.938020777108387,0.936371206744677,0.0226558931822967,0.704605364975849,0.627977543546135,0.076627821429714,10.7462517425622,33.5486,0.968157720937148,32.0839,0.869776863425551,0.847685061315467,0.868247304409416,0.843594630280262,0.0220918021100838,0.0246526741291548,True,0.138002283349972,0.0257068406814575,1.82203715738827,27.0429835437031
38589,1053:1594,Pancreas,KP-1N,SIDM00583,1298216,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.874235082387403,0.0437145431734754,0.875190105511825,13.5888667558405,96.2601,0.977964581593238,0.969071315099278,0.0490870045902356,0.765121893996771,0.447123035368186,0.317998858628585,9.10787997514025,4.3106,4.48098678070029,91.9495,0.854970946561127,0.749601566970993,0.847196140995087,0.73892651746855,0.105369379590134,0.108269623526537,True,0.138002283349972,0.0257068406814575,1.82203715738827,27.0429835437031
38589,1510:1594,Pancreas,KP-1N,SIDM00583,1298216,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.852900176917948,0.0437145431734754,0.875190105511825,13.5888667558405,96.2601,0.977964581593238,0.969071315099278,0.0498712865148178,0.746449795827873,0.427493734849635,0.318956060978238,9.01153216101651,4.0321,4.57733459482402,92.228,0.83410616466036,0.726052195978958,0.826521096094283,0.716950355038597,0.108053968681402,0.109570741055686,True,0.138002283349972,0.0257068406814575,1.82203715738827,27.0429835437031
38653,1080:1011,Pancreas,KP-3,SIDM00571,1298219,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.0025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.922967293714595,0.163762691727457,0.503188227104427,9.03051977386817,10.2138,0.892482154513247,0.839234627055885,0.174306161040272,0.464426276199619,0.460199814854157,0.0042264613454612,8.98668475438188,9.9081,0.0438350194862842,0.305700000000002,0.823731838839663,0.840121512648591,0.774586112525348,0.772627663734351,-0.0163896738089282,0.0019584487909974,True,0.347072432253864,0.0355409668214554,0.996551159527555,49.0054395459439
38654,1073:1022,Pancreas,KP-3,SIDM00571,1298219,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in pancreas,10.0,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.81116652211065,0.0402244837122257,0.781881614540419,12.0552254540345,8.3122,0.948262838154944,0.942137140065811,0.0612558881252815,0.634236189969012,0.508771671188991,0.125464518780021,10.2450631871901,2.3703,1.81016226684445,5.9419,0.76919906847292,0.70355378784722,0.764230107258459,0.722372902320168,0.0656452806257003,0.0418572049382904,True,0.347072432253864,0.0355409668214554,0.996551159527555,49.0054395459439
38654,1179:1022,Pancreas,KP-3,SIDM00571,1298219,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.2,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.955743414325836,0.0402244837122257,0.781881614540419,12.0552254540345,8.3122,0.948262838154944,0.942137140065811,0.0534244432873371,0.747278203879457,0.513240233993053,0.234037969886404,9.35489241992967,1.2789,2.70033303410486,7.0333,0.906295962616514,0.776110584129256,0.900441367009677,0.816537897177496,0.130185378487257,0.083903469832181,True,0.347072432253864,0.0355409668214554,0.996551159527555,49.0054395459439
38654,1190:1022,Pancreas,KP-3,SIDM00571,1298219,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.849106577320592,0.0402244837122257,0.781881614540419,12.0552254540345,8.3122,0.948262838154944,0.942137140065811,0.0859950818175694,0.663900821592313,0.401283841744898,0.262616979847415,8.73740558803854,0.8336,3.31781986599599,7.4786,0.805176212906054,0.646422380853064,0.799974842367892,0.700247962346608,0.15875383205299,0.0997268800212838,True,0.347072432253864,0.0355409668214554,0.996551159527555,49.0054395459439
38655,1080:1053,Pancreas,KP-3,SIDM00571,1298219,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.025,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.664053377754501,0.0522850550333559,0.862140844831316,13.3870515769482,209.2349,0.953338587756455,0.965086638282502,0.0676192878728897,0.572507540110354,0.391442191489597,0.181065348620757,9.86581338111589,18.2237,3.52123819583227,191.0112,0.63306770934338,0.574019424466367,0.640869041977231,0.581748536401743,0.0590482848770126,0.0591205055754882,True,0.347072432253864,0.0355409668214554,0.996551159527555,49.0054395459439
38655,1558:1053,Pancreas,KP-3,SIDM00571,1298219,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.930163025927891,0.0522850550333559,0.862140844831316,13.3870515769482,209.2349,0.953338587756455,0.965086638282502,0.0235068759614077,0.801931537004326,0.785077406680243,0.0168541303240828,13.0406991580699,164.578,0.346352418878242,44.6569,0.886760305521367,0.904125444845857,0.897687907747428,0.893044369757218,-0.0173651393244899,0.0046435379902098,True,0.347072432253864,0.0355409668214554,0.996551159527555,49.0054395459439
38655,1594:1053,Pancreas,KP-3,SIDM00571,1298219,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.757880712680297,0.0522850550333559,0.862140844831316,13.3870515769482,209.2349,0.953338587756455,0.965086638282502,0.0715820468729251,0.653399917911551,0.520320335477531,0.13307958243402,10.8762681200461,36.7124,2.51078345690207,172.5225,0.72251692831449,0.640365592325173,0.731420549219774,0.690934744007157,0.0821513359893165,0.0404858052126167,True,0.347072432253864,0.0355409668214554,0.996551159527555,49.0054395459439
38656,1022:1073,Pancreas,KP-3,SIDM00571,1298219,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in pancreas,20.0,0.988967696420577,0.0732190958773617,0.740259859301662,11.5063713709699,113.6378,0.897778414075408,0.929308601255279,0.0657555506607745,0.732093087806185,0.552886742452461,0.179206345353724,9.56795009470693,29.6483,1.93842127626294,83.9895,0.887873850064275,0.827547078992036,0.919056186647262,0.854183053745464,0.060326771072239,0.0648731329017986,True,0.347072432253864,0.0355409668214554,0.996551159527555,49.0054395459439
38656,1011:1073,Pancreas,KP-3,SIDM00571,1298219,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in pancreas,20.0,0.787985419462922,0.0732190958773617,0.740259859301662,11.5063713709699,113.6378,0.897778414075408,0.929308601255279,0.0651649514476869,0.583313975743383,0.437310669182422,0.146003306560961,9.52836635812971,28.8459,1.97800501284017,84.7919,0.707436300199967,0.653579088972984,0.732281627970642,0.679248102774813,0.0538572112269825,0.0530335251958295,True,0.347072432253864,0.0355409668214554,0.996551159527555,49.0054395459439
38657,1564:1079,Pancreas,KP-3,SIDM00571,1298219,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.837659754723115,0.137119160285933,0.697293145474078,10.9969254045374,7.983,0.816998062650931,0.915302139609334,0.145185858423175,0.584094405207926,0.399695384581426,0.184399020626499,8.78118459049838,1.7185,2.21574081403904,6.2645,0.684366396769439,0.585585301486461,0.766711765762697,0.692672545818856,0.0987810952829781,0.0740392199438414,True,0.347072432253864,0.0355409668214554,0.996551159527555,49.0054395459439
38657,1372:1079,Pancreas,KP-3,SIDM00571,1298219,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.717678049201566,0.137119160285933,0.697293145474078,10.9969254045374,7.983,0.816998062650931,0.915302139609334,0.0592143608835921,0.50043198436546,0.274285038327755,0.226146946037705,7.85060702641508,0.9016,3.14631837812235,7.0814,0.586341575804779,0.510624859467358,0.656892253984846,0.556681598759525,0.0757167163374211,0.100210655225322,True,0.347072432253864,0.0355409668214554,0.996551159527555,49.0054395459439
38657,1011:1080,Pancreas,KP-3,SIDM00571,1298219,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.1,0.8625633571621,0.0631300217591149,0.411415014816926,8.14297524056426,0.0552,0.788401958511631,0.792641820566212,0.110406004418461,0.354871516367383,0.170779729183755,0.184091787183628,5.65225452527819,0.0098,2.49072071528608,0.0454,0.680046640126968,0.557614436209145,0.683703789774671,0.540682841637785,0.122432203917823,0.143020948136886,True,0.347072432253864,0.0355409668214554,0.996551159527555,49.0054395459439
38658,1057:1083,Pancreas,KP-3,SIDM00571,1298219,1057,Dactolisib,"PI3K (class 1), MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.0125,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.945502039470974,0.0475586394705695,0.784538090555337,12.0926674288702,68.2458,0.939134675174052,0.942933028138142,0.0255809939794557,0.741782364662734,0.700080384082479,0.0417019805802551,11.508519864644,45.5229,0.584147564226198,22.7229,0.887953750714977,0.860126423047798,0.891545101189154,0.878714838390272,0.027827327667179,0.0128302627988819,True,0.347072432253864,0.0355409668214554,0.996551159527555,49.0054395459439
38658,1558:1083,Pancreas,KP-3,SIDM00571,1298219,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.922302999132876,0.0475586394705695,0.784538090555337,12.0926674288702,68.2458,0.939134675174052,0.942933028138142,0.0780957631359457,0.723581833853167,0.581331296208377,0.14225053764479,10.2767855638517,19.3839,1.81588186501846,48.8619,0.866166727502707,0.783856435261418,0.869669959833252,0.822403864027213,0.0823102922412891,0.0472660958060398,True,0.347072432253864,0.0355409668214554,0.996551159527555,49.0054395459439
38658,1594:1083,Pancreas,KP-3,SIDM00571,1298219,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.770605419551359,0.0475586394705695,0.784538090555337,12.0926674288702,68.2458,0.939134675174052,0.942933028138142,0.025012989697824,0.604569304426418,0.464109156947255,0.140460147479163,9.99294341172599,15.9219,2.09972401714421,52.3239,0.72370227037773,0.662363806766223,0.726629301757226,0.67895248064201,0.0613384636115074,0.0476768211152168,True,0.347072432253864,0.0355409668214554,0.996551159527555,49.0054395459439
38661,1022:1190,Pancreas,KP-3,SIDM00571,1298219,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.2,0.944148414570477,0.0825086744053057,0.799604664347633,12.3116731279995,1.9858,0.931322713224929,0.947397614871263,0.0896174970116133,0.754945476126977,0.341879259903692,0.413066216223284,7.64489809798892,0.0782,4.66677503001055,1.9076,0.879306863144792,0.683228634043232,0.894483956048555,0.720642611528888,0.19607822910156,0.173841344519667,True,0.347072432253864,0.0355409668214554,0.996551159527555,49.0054395459439
38661,1079:1372,Pancreas,KP-3,SIDM00571,1298219,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.05,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.848955160995249,0.0803460180870064,0.797800147727956,12.2848131375346,9.746,0.931853905865344,0.946867263105091,0.0327507790080519,0.67729655285642,0.54664497479152,0.130651578064901,10.4175605253011,2.6713,1.8672526122335,7.0747,0.791102182677964,0.743492667737336,0.803847849790513,0.761234116539052,0.0476095149406284,0.0426137332514614,True,0.347072432253864,0.0355409668214554,0.996551159527555,49.0054395459439
38410,1594:1561,Pancreas,KP-3,SIDM00571,1298219,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.724173520277815,0.0900730426809515,0.728620840941619,11.3635420389607,51.4632,0.866842609878725,0.925594694105228,0.0750782704435818,0.527647919332474,0.542682838510427,-0.015034919177953,11.6212442929336,61.5281,-0.257702253972859,-10.0649,0.627744464322685,0.637804837815255,0.67029116798065,0.675059881565772,-0.0100603734925704,-0.0047687135851215,True,0.634466269697662,0.0638489013406232,0.40856771207993,113.874985665625
38410,1564:1561,Pancreas,KP-3,SIDM00571,1298219,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.89882037173454,0.0900730426809515,0.728620840941619,11.3635420389607,51.4632,0.866842609878725,0.925594694105228,0.162078788650026,0.65489925510868,0.446947028649691,0.207952226458989,8.97376689182395,9.8198,2.38977514713677,41.6434,0.779135796846535,0.623893863564493,0.831943367031179,0.751848689782773,0.155241933282042,0.0800946772484065,True,0.634466269697662,0.0638489013406232,0.40856771207993,113.874985665625
35928,1080:1011,Pancreas,KP-4,SIDM00301,753572,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.269400912991236,0.118598323175334,0.510163773213546,9.0691406829246,10.4909,0.872072553997039,0.886012330542042,0.0710096591331542,0.137438586278783,0.0172860964240318,0.120152489854751,4.4428767729495,0.4248,4.6262639099751,10.0661,0.234937142241401,0.0952431221661377,0.238692530769518,0.145422346517351,0.139694020075263,0.093270184252167,True,0.254284907115451,0.0410854841185055,1.29522204292935,37.9637512506747
35929,1022:1017,Pancreas,KP-4,SIDM00301,753572,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.991467584798611,0.0595726257039353,0.874493893033854,12.3010301866751,98.5619,0.957494060407091,0.977263664739456,0.0873260183351438,0.86703234804741,0.601126833585168,0.265905514462242,9.73422185219727,16.635,2.56680833447779,81.9269,0.949324323530833,0.85606943016444,0.968925245390668,0.907412802124523,0.093254893366393,0.0615124432661442,True,0.254284907115451,0.0410854841185055,1.29522204292935,37.9637512506747
35929,1088:1022,Pancreas,KP-4,SIDM00301,753572,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.615241701511073,0.0825689573201455,0.839028487677117,11.8074400449899,7.0004,0.927319734278212,0.970246712283549,0.0976718073960922,0.516205314374732,0.0667209179771779,0.449484396397554,5.41769181227955,0.0835,6.38974823271037,6.9169,0.570525771162124,0.348645104400921,0.596936238150856,0.385208602854387,0.221880666761202,0.211727635296468,True,0.254284907115451,0.0410854841185055,1.29522204292935,37.9637512506747
35929,1005:1022,Pancreas,KP-4,SIDM00301,753572,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,0.8,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,1.0,0.0825689573201455,0.839028487677117,11.8074400449899,7.0004,0.927319734278212,0.970246712283549,0.0212532479649955,0.839028487677117,0.953048090739655,-0.114019603062537,14.119216490736,34.7566,-2.31177644574609,-27.7562,0.927319734278212,1.0,0.970246712283549,0.991846035034935,-0.072680265721788,-0.0215993227513855,True,0.254284907115451,0.0410854841185055,1.29522204292935,37.9637512506747
35929,1017:1022,Pancreas,KP-4,SIDM00301,753572,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.937759188966356,0.0825689573201455,0.839028487677117,11.8074400449899,7.0004,0.927319734278212,0.970246712283549,0.0862641711097026,0.786806674123762,0.320114061124188,0.466692612999574,7.88241470157005,0.4609,3.92502534341986,6.5395,0.869602601929233,0.721733668100133,0.909857770008294,0.767226493603662,0.1478689338291,0.142631276404633,True,0.254284907115451,0.0410854841185055,1.29522204292935,37.9637512506747
35929,1190:1022,Pancreas,KP-4,SIDM00301,753572,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.424600290856988,0.0825689573201455,0.839028487677117,11.8074400449899,7.0004,0.927319734278212,0.970246712283549,0.0686109209935437,0.356251739905003,0.144217138086019,0.212034601818984,7.86949090137887,0.4568,3.93794914361105,6.5436,0.393740228891954,0.286759842075439,0.411967036238631,0.347027248890412,0.106980386816515,0.0649397873482192,True,0.254284907115451,0.0410854841185055,1.29522204292935,37.9637512506747
38068,1372:1053,Pancreas,KP-4,SIDM00301,753572,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.757487934088403,0.0891367450932208,0.677732196906737,10.2640478659855,24.0169,0.870592299733819,0.934078367640932,0.0963731035727377,0.513373961700079,0.261902970828394,0.251470990871685,7.91552544703333,4.7156,2.34852241895217,19.3013,0.659463162558642,0.543876961465754,0.707553092980997,0.621370914662758,0.115586201092888,0.0861821783182389,True,0.409449867074642,0.0537613100257018,0.837855458363471,57.9784640117392
38068,1558:1053,Pancreas,KP-4,SIDM00301,753572,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.983534869638782,0.0891367450932208,0.677732196906737,10.2640478659855,24.0169,0.870592299733819,0.934078367640932,0.0373472795622626,0.666573247934674,0.729417950550945,-0.0628447026162715,10.7930230176575,34.654,-0.528975151671961,-10.6371,0.856257884027229,0.91442959752343,0.91869864555013,0.933707437589622,-0.0581717134962008,-0.015008792039492,True,0.409449867074642,0.0537613100257018,0.837855458363471,57.9784640117392
35932,1083:1079,Pancreas,KP-4,SIDM00301,753572,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,1.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.800986742096688,0.101658349840705,0.83677007783737,11.7791658134715,13.7291,0.908580026442986,0.969789917515025,0.192757189513026,0.670241738530947,0.12010925680143,0.550132481729517,6.04978614859006,0.2588,5.72937966488147,13.4703,0.72776055531469,0.455870331515852,0.776788866548575,0.544689956555108,0.271890223798838,0.232098909993467,True,0.254284907115451,0.0410854841185055,1.29522204292935,37.9637512506747
35932,1179:1079,Pancreas,KP-4,SIDM00301,753572,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.431329090015383,0.101658349840705,0.83677007783737,11.7791658134715,13.7291,0.908580026442986,0.969789917515025,0.0278997108290885,0.360923276225695,0.144532412131963,0.216390864093731,7.83474645762683,0.8918,3.9444193558447,12.8373,0.391896996011806,0.335879595663532,0.41829860262785,0.351541853574562,0.0560174003482739,0.0667567490532874,True,0.254284907115451,0.0410854841185055,1.29522204292935,37.9637512506747
35932,1561:1079,Pancreas,KP-4,SIDM00301,753572,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,2.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.83570192246425,0.101658349840705,0.83677007783737,11.7791658134715,13.7291,0.908580026442986,0.969789917515025,0.119659802389144,0.69929036270925,0.4749256598331,0.22436470287615,9.46744883142093,2.7653,2.3117169820506,10.9638,0.759302074811023,0.676549618146898,0.810455298453753,0.755697385515134,0.082752456664125,0.0547579129386182,True,0.254284907115451,0.0410854841185055,1.29522204292935,37.9637512506747
35932,1564:1079,Pancreas,KP-4,SIDM00301,753572,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,1.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.719649710082925,0.101658349840705,0.83677007783737,11.7791658134715,13.7291,0.908580026442986,0.969789917515025,0.0822094537953479,0.60218134392173,0.394407115020687,0.207774228901043,9.32786393127062,2.5103,2.45130188220091,11.2188,0.653859352616831,0.596499802018952,0.697909032981031,0.646339327410611,0.0573595505978793,0.0515697055704206,True,0.254284907115451,0.0410854841185055,1.29522204292935,37.9637512506747
35932,1372:1079,Pancreas,KP-4,SIDM00301,753572,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.773795706314458,0.101658349840705,0.83677007783737,11.7791658134715,13.7291,0.908580026442986,0.969789917515025,0.14038164149656,0.647489093402972,0.233549503073009,0.413939590329963,7.57396644958675,0.7443,4.20519936388478,12.9848,0.703055323304659,0.514474519611502,0.750419274200179,0.617023078972442,0.188580803693157,0.133396195227737,True,0.254284907115451,0.0410854841185055,1.29522204292935,37.9637512506747
36564,1079:1083,Pancreas,KP-4,SIDM00301,753572,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.936748756324586,0.0674532554233376,0.333840342925898,7.82522954585476,3.5436,0.799927065858584,0.814391916373749,0.110985803734364,0.312724526046808,0.0886742904192582,0.22405023562755,5.16043063756386,0.5588,2.6647989082909,2.9848,0.749330684093404,0.561609058495487,0.762880614823905,0.565435082602854,0.187721625597917,0.197445532221051,True,0.257179332356438,0.039469590317983,1.30283383168008,37.8852395188822
38201,1053:1372,Pancreas,KP-4,SIDM00301,753572,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.860055064342694,0.147406733780348,0.601842302499901,9.70252826356203,1.6274,0.801160459823331,0.913972809058226,0.153136309631341,0.517617520200708,0.281587963836702,0.236029556364006,7.77579753943149,0.428,1.92673072413055,1.1994,0.689042110822178,0.575605572291955,0.786066943102045,0.697599967865916,0.113436538530223,0.0884669752361293,True,0.499388818305549,0.0778749642423169,0.641295764072827,74.6934036836966
38201,1561:1372,Pancreas,KP-4,SIDM00301,753572,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.772892808620316,0.147406733780348,0.601842302499901,9.70252826356203,1.6274,0.801160459823331,0.913972809058226,0.129884293294526,0.465159587525666,0.168479707940323,0.296679879585343,6.82779769376269,0.2219,2.87473056979934,1.4055,0.619211157948398,0.496490828908832,0.706403011395611,0.573999740310916,0.122720329039566,0.132403271084695,True,0.499388818305549,0.0778749642423169,0.641295764072827,74.6934036836966
38201,1079:1372,Pancreas,KP-4,SIDM00301,753572,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.05,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.894266958454719,0.147406733780348,0.601842302499901,9.70252826356203,1.6274,0.801160459823331,0.913972809058226,0.119643039942961,0.538207685325972,0.280999117849031,0.257208567476941,7.67289862302278,0.3986,2.02962964053925,1.2288,0.716451327640395,0.624034488533209,0.817335684066815,0.719153681124185,0.0924168391071856,0.0981820029426305,True,0.499388818305549,0.0778749642423169,0.641295764072827,74.6934036836966
38203,1053:1558,Pancreas,KP-4,SIDM00301,753572,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.860140764205788,0.0693916279916403,0.907370524309225,12.8802862263655,147.2592,0.956995443237525,0.983519534057975,0.028676797710259,0.780466376197143,0.746150601259298,0.0343157749378453,12.1947947912521,91.5649,0.68549143511334,55.6943,0.823150791887782,0.848317833109326,0.845965243635947,0.839409429893966,-0.0251670412215441,0.0065558137419805,True,0.499388818305549,0.0778749642423169,0.641295764072827,74.6934036836966
38203,1372:1561,Pancreas,KP-4,SIDM00301,753572,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.677522748036021,0.10027185257796,0.610782756636784,9.76622024172302,17.0081,0.839227282302325,0.916468717132523,0.129901098416487,0.41381921172957,0.180627031055626,0.233192180673944,7.279256398051,3.0339,2.48696384367202,13.9742,0.568595574532273,0.434840328707403,0.620928403720674,0.526098320898404,0.13375524582487,0.0948300828222705,True,0.499388818305549,0.0778749642423169,0.641295764072827,74.6934036836966
38203,1564:1561,Pancreas,KP-4,SIDM00301,753572,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.749551307296544,0.10027185257796,0.610782756636784,9.76622024172302,17.0081,0.839227282302325,0.916468717132523,0.169867514469038,0.457813013711289,0.167585923917267,0.290227089794021,6.88310899328176,2.3054,2.88311124844126,14.7027,0.629043906568634,0.44577479845034,0.68694032502307,0.559854942102642,0.183269108118294,0.127085382920428,True,0.499388818305549,0.0778749642423169,0.641295764072827,74.6934036836966
38203,1079:1561,Pancreas,KP-4,SIDM00301,753572,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.05,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.924494608932983,0.10027185257796,0.610782756636784,9.76622024172302,17.0081,0.839227282302325,0.916468717132523,0.102871276655364,0.564665365739933,0.331137014400099,0.233528351339834,8.00819839938702,5.0285,1.758021842336,11.9796,0.775861098157979,0.679163394322951,0.847270388244745,0.763875651768917,0.0966977038350275,0.0833947364758276,True,0.499388818305549,0.0778749642423169,0.641295764072827,74.6934036836966
38204,1053:1564,Pancreas,KP-4,SIDM00301,753572,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.897026134093022,0.105060962472058,0.560212138172193,9.41154337181219,13.3011,0.820789735295863,0.901842646048174,0.198953531781907,0.502524928576588,0.249530396705011,0.252994531871577,7.37858602982816,3.2502,2.03295734198403,10.0509,0.736269843155683,0.552169762795023,0.808976422344815,0.702960678110833,0.184100080360661,0.106015744233982,True,0.499388818305549,0.0778749642423169,0.641295764072827,74.6934036836966
38204,1561:1564,Pancreas,KP-4,SIDM00301,753572,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.847203592695907,0.105060962472058,0.560212138172193,9.41154337181219,13.3011,0.820789735295863,0.901842646048174,0.163631289796446,0.474613736131337,0.219075869709685,0.255537866421653,7.2088933609007,2.8895,2.20265001091149,10.4116,0.695376012590578,0.543883316517301,0.764044329778396,0.65350646836337,0.151492696073277,0.110537861415026,True,0.499388818305549,0.0778749642423169,0.641295764072827,74.6934036836966
38204,1079:1564,Pancreas,KP-4,SIDM00301,753572,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.891753813282687,0.105060962472058,0.560212138172193,9.41154337181219,13.3011,0.820789735295863,0.901842646048174,0.182048621662269,0.499571310462301,0.252780404127819,0.246790906334481,7.42311992257619,3.3521,1.988423449236,9.949,0.731942376353374,0.579107761093635,0.804221618594408,0.701656907471521,0.152834615259738,0.102564711122887,True,0.499388818305549,0.0778749642423169,0.641295764072827,74.6934036836966
35935,1022:1005,Pancreas,BxPC-3,SIDM00132,906693,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,8.0,0.972789020326683,0.103691882386543,0.709821702584275,11.9268081269645,60.8341,0.904696314447119,0.894092247000835,0.117674859460687,0.690506758663574,0.530673063534308,0.159833695129266,9.59737057351904,12.1037,2.32943755344545,48.7304,0.880078641424174,0.851165337804223,0.869763121041625,0.79213944404941,0.028913303619951,0.0776236769922143,True,0.314880243198491,0.0440165959695454,1.10619196739271,44.4799377208205
35935,1190:1011,Pancreas,BxPC-3,SIDM00132,906693,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.01,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.926918630417587,0.133094079333509,0.493324165394975,8.91262314493446,9.4123,0.78812212669517,0.784253307332126,0.128755265337242,0.457271359739809,0.435160390688425,0.0221109690513843,8.59993186707814,7.5782,0.31269127785632,1.8341,0.730525082278083,0.772043501324704,0.726939001532757,0.713306709806507,-0.0415184190466212,0.0136322917262502,True,0.314880243198491,0.0440165959695454,1.10619196739271,44.4799377208205
35935,1005:1011,Pancreas,BxPC-3,SIDM00132,906693,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,8.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.788296318049255,0.133094079333509,0.493324165394975,8.91262314493446,9.4123,0.78812212669517,0.784253307332126,0.0513713615417514,0.388885623185581,0.175570212498544,0.213315410687036,4.91047366546965,0.5874,4.00214947946482,8.8249,0.621273770646951,0.435389926342313,0.618223994587866,0.440157371453487,0.185883844304638,0.178066623134379,True,0.314880243198491,0.0440165959695454,1.10619196739271,44.4799377208205
35935,1372:1011,Pancreas,BxPC-3,SIDM00132,906693,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.620533388318228,0.133094079333509,0.493324165394975,8.91262314493446,9.4123,0.78812212669517,0.784253307332126,0.0736500286262608,0.306124115891806,0.188081511825386,0.11804260406642,6.27579894310189,1.5133,2.63682420183258,7.899,0.489056093686722,0.399700581552839,0.486655362098581,0.399030810928822,0.0893555121338828,0.0876245511697596,True,0.314880243198491,0.0440165959695454,1.10619196739271,44.4799377208205
35935,1022:1011,Pancreas,BxPC-3,SIDM00132,906693,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.940399606978898,0.133094079333509,0.493324165394975,8.91262314493446,9.4123,0.78812212669517,0.784253307332126,0.0499391081412761,0.463921851250628,0.246924702578739,0.216997148671889,5.62129358973538,0.9614,3.29132955519908,8.4509,0.741149738195511,0.556936628084089,0.737511501987033,0.567142049201319,0.184213110111423,0.170369452785713,True,0.314880243198491,0.0440165959695454,1.10619196739271,44.4799377208205
35935,1564:1011,Pancreas,BxPC-3,SIDM00132,906693,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.698824074106012,0.133094079333509,0.493324165394975,8.91262314493446,9.4123,0.78812212669517,0.784253307332126,0.114312871410413,0.344746803116264,0.19256821696676,0.152178586149505,5.8373719921966,1.1167,3.07525115273787,8.2956,0.550758715470213,0.446006143335137,0.548055091360951,0.430776567399716,0.104752572135076,0.117278523961234,True,0.314880243198491,0.0440165959695454,1.10619196739271,44.4799377208205
35935,1179:1011,Pancreas,BxPC-3,SIDM00132,906693,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.487758978122003,0.133094079333509,0.493324165394975,8.91262314493446,9.4123,0.78812212669517,0.784253307332126,0.0556978490212949,0.240623290795943,0.0875297693621514,0.153093521433792,4.02646328736838,0.3183,4.88615985756608,9.094,0.384413643152176,0.208454401825391,0.382526591773119,0.244710058434782,0.175959241326785,0.137816533338337,True,0.314880243198491,0.0440165959695454,1.10619196739271,44.4799377208205
35935,1080:1011,Pancreas,BxPC-3,SIDM00132,906693,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.492169628125542,0.133094079333509,0.493324165394975,8.91262314493446,9.4123,0.78812212669517,0.784253307332126,0.0695422094459672,0.242799171027788,0.0413096374982949,0.201489533529493,1.1798689660806,0.0442,7.73275417885387,9.3681,0.387889774013073,0.103628612697929,0.385985658625879,0.159920938311779,0.284261161315144,0.2260647203141,True,0.314880243198491,0.0440165959695454,1.10619196739271,44.4799377208205
35935,1558:1011,Pancreas,BxPC-3,SIDM00132,906693,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.611876910807545,0.133094079333509,0.493324165394975,8.91262314493446,9.4123,0.78812212669517,0.784253307332126,0.115071013849808,0.301853666348588,0.0983420314048595,0.203511634943728,3.59192381932478,0.2355,5.32069932560969,9.1768,0.482233732221313,0.261886229061837,0.479866490980982,0.28988369780648,0.220347503159476,0.189982793174502,True,0.314880243198491,0.0440165959695454,1.10619196739271,44.4799377208205
35936,1088:1022,Pancreas,BxPC-3,SIDM00132,906693,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.874180931276625,0.118493560138088,0.607070238369004,10.423337531611,2.6821,0.881879523399169,0.846511939137165,0.0554697439724998,0.530689226327739,0.309013678596527,0.221675547731212,7.02461280822782,0.2543,3.39872472338322,2.4278,0.770922263038872,0.598434679964328,0.740004595291709,0.600358216374394,0.172487583074544,0.139646378917315,True,0.314880243198491,0.0440165959695454,1.10619196739271,44.4799377208205
35936,1005:1022,Pancreas,BxPC-3,SIDM00132,906693,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,0.8,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.974261705056258,0.118493560138088,0.607070238369004,10.423337531611,2.6821,0.881879523399169,0.846511939137165,0.100388592142402,0.591445285522295,0.64293924355033,-0.0514939580280358,11.1691577589852,4.4976,-0.745820227374143,-1.8155,0.859181448121075,0.903832841015221,0.824724165174254,0.84940908254429,-0.0446513928941463,-0.0246849173700365,True,0.314880243198491,0.0440165959695454,1.10619196739271,44.4799377208205
35936,1073:1022,Pancreas,BxPC-3,SIDM00132,906693,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in pancreas,10.0,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.890735099462931,0.118493560138088,0.607070238369004,10.423337531611,2.6821,0.881879523399169,0.846511939137165,0.0670933629866044,0.5407387691546,0.308407356796137,0.232331412358463,6.92031730945065,0.2366,3.50302022216039,2.4455,0.785521044989281,0.564789246990333,0.754017896303901,0.606434420316833,0.220731797998949,0.147583475987069,True,0.314880243198491,0.0440165959695454,1.10619196739271,44.4799377208205
35936,1179:1022,Pancreas,BxPC-3,SIDM00132,906693,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.2,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.830644134092311,0.118493560138088,0.607070238369004,10.423337531611,2.6821,0.881879523399169,0.846511939137165,0.07253136524807,0.504259332483234,0.263410684486836,0.240848647996398,6.49023852469703,0.1756,3.93309900691401,2.5065,0.732528053087643,0.536182201509942,0.703150176683394,0.54474185225793,0.196345851577701,0.158408324425464,True,0.314880243198491,0.0440165959695454,1.10619196739271,44.4799377208205
35937,1168:1053,Pancreas,BxPC-3,SIDM00132,906693,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.683400396221406,0.0551626264398248,0.789806413412618,13.3312568711693,201.2974,0.92350522142811,0.926865487495955,0.0809855349714819,0.539754015864391,0.357697084778708,0.182056931085683,9.30657931962266,12.3677,4.02467755154663,188.9297,0.631123834236508,0.478784903393267,0.633420241398682,0.548022552732027,0.152338930843241,0.0853976886666551,True,0.314880243198491,0.0440165959695454,1.10619196739271,44.4799377208205
35937,1372:1053,Pancreas,BxPC-3,SIDM00132,906693,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.664037671707401,0.0551626264398248,0.789806413412618,13.3312568711693,201.2974,0.92350522142811,0.926865487495955,0.0343673934190007,0.524461211862088,0.217311612901517,0.307149598960571,6.6421983077289,1.9509,6.6890585634404,199.3465,0.61324225704675,0.419454555647107,0.615473600302759,0.441410797194884,0.193787701399643,0.174062803107876,True,0.314880243198491,0.0440165959695454,1.10619196739271,44.4799377208205
35937,1558:1053,Pancreas,BxPC-3,SIDM00132,906693,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.820548807898197,0.0551626264398248,0.789806413412618,13.3312568711693,201.2974,0.92350522142811,0.926865487495955,0.0546696287025921,0.648074710996074,0.515457845264197,0.132616865731877,10.7159532428605,32.8514,2.61530362830875,168.446,0.757781108530596,0.670095205255592,0.760538370846787,0.703104609440692,0.0876859032750038,0.057433761406095,True,0.314880243198491,0.0440165959695454,1.10619196739271,44.4799377208205
35937,1054:1053,Pancreas,BxPC-3,SIDM00132,906693,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,2.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.903637727131858,0.0551626264398248,0.789806413412618,13.3312568711693,201.2974,0.92350522142811,0.926865487495955,0.0371358499902872,0.713698872290343,0.679701493066011,0.0339973792243323,12.6328076171669,124.0464,0.698449254002352,77.251,0.834514159285701,0.809279118201117,0.837550622477807,0.823989020557007,0.0252350410845844,0.0135616019207998,True,0.314880243198491,0.0440165959695454,1.10619196739271,44.4799377208205
35937,1564:1053,Pancreas,BxPC-3,SIDM00132,906693,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.631777718310485,0.0551626264398248,0.789806413412618,13.3312568711693,201.2974,0.92350522142811,0.926865487495955,0.0572100527116452,0.498982093772812,0.291838171015262,0.20714392275755,8.50080581420763,7.075,4.83045105696166,194.2224,0.583450021641671,0.486668981660216,0.58557296287093,0.483156883856856,0.0967810399814542,0.102416079014074,True,0.314880243198491,0.0440165959695454,1.10619196739271,44.4799377208205
35937,1079:1053,Pancreas,BxPC-3,SIDM00132,906693,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.586069083835838,0.0551626264398248,0.789806413412618,13.3312568711693,201.2974,0.92350522142811,0.926865487495955,0.102952608949868,0.462881121116402,0.277644192580747,0.185236928535655,8.65599520441633,7.8785,4.67526166675296,193.4189,0.541237859039985,0.418786060537469,0.543207207095812,0.452578809245641,0.122451798502516,0.0906283978501702,True,0.314880243198491,0.0440165959695454,1.10619196739271,44.4799377208205
35938,1022:1073,Pancreas,BxPC-3,SIDM00132,906693,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in pancreas,20.0,0.929621934708662,0.0706475856167578,0.779303818152795,13.1279224438703,349.6701,0.896921807443216,0.922744777943176,0.0997326471133608,0.724457923157049,0.580677594568602,0.143780328588447,10.6663431635342,63.4818,2.46157928033608,286.1883,0.833798185917753,0.781749993874751,0.85780378571385,0.794969206666756,0.0520481920430023,0.0628345790470942,True,0.314880243198491,0.0440165959695454,1.10619196739271,44.4799377208205
35939,1083:1079,Pancreas,BxPC-3,SIDM00132,906693,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,1.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.929843241456711,0.0818073720180705,0.437998176256584,8.18433748289052,1.1363,0.735103503885284,0.749072539002414,0.0669274594356238,0.40726964396255,0.323860034850086,0.083409609112464,6.9499973265397,0.483,1.23434015635082,0.6533,0.683531024858879,0.609240067889468,0.696520037752213,0.634637318139275,0.0742909569694108,0.0618827196129385,True,0.314880243198491,0.0440165959695454,1.10619196739271,44.4799377208205
35939,1561:1079,Pancreas,BxPC-3,SIDM00132,906693,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,2.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.628846218064759,0.0818073720180705,0.437998176256584,8.18433748289052,1.1363,0.735103503885284,0.749072539002414,0.0474573090523678,0.275433496658215,0.106847302467126,0.168586194191089,3.80984030298608,0.0548,4.37449717990444,1.0815,0.462267058304414,0.285198196538409,0.471051433207835,0.306729687303839,0.177068861766005,0.164321745903996,True,0.314880243198491,0.0440165959695454,1.10619196739271,44.4799377208205
35939,1372:1079,Pancreas,BxPC-3,SIDM00132,906693,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.602657400070063,0.0818073720180705,0.437998176256584,8.18433748289052,1.1363,0.735103503885284,0.749072539002414,0.0488042715194486,0.263962842138222,0.182100688703866,0.0818621534343563,6.26132402588439,0.2996,1.92301345700613,0.8367,0.443015566433899,0.392515271257582,0.451434108819076,0.387012751064007,0.0505002951763175,0.064421357755069,True,0.314880243198491,0.0440165959695454,1.10619196739271,44.4799377208205
35939,1558:1079,Pancreas,BxPC-3,SIDM00132,906693,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.6050418862068,0.0818073720180705,0.437998176256584,8.18433748289052,1.1363,0.735103503885284,0.749072539002414,0.0860104047689083,0.265007242717422,0.0785094789528954,0.186497763764527,2.77319637388048,0.0267,5.41114110901005,1.1096,0.44476841054798,0.224361714190014,0.453220261903737,0.255084384592698,0.220406696357966,0.198135877311039,True,0.314880243198491,0.0440165959695454,1.10619196739271,44.4799377208205
35939,1080:1079,Pancreas,BxPC-3,SIDM00132,906693,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.0025,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.860046804472924,0.0818073720180705,0.437998176256584,8.18433748289052,1.1363,0.735103503885284,0.749072539002414,0.0307898488894451,0.376698931854444,0.406854118376759,-0.0301551865223151,8.64707995016694,1.566,-0.462742467276421,-0.4297,0.632223419473388,0.666260021435438,0.644237443487446,0.663786378456637,-0.0340366019620495,-0.0195489349691911,True,0.314880243198491,0.0440165959695454,1.10619196739271,44.4799377208205
35939,1079:1080,Pancreas,BxPC-3,SIDM00132,906693,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.05,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.1,0.797782279081478,0.0787303942352291,0.424377622810249,8.00262117842604,0.0501,0.750174993013358,0.739798505597959,0.0792646720952219,0.33856094711674,0.181249217663451,0.157311729453289,4.99436621875477,0.0062,3.00825495967127,0.0439,0.598476315636129,0.457382751062344,0.590198137857012,0.449707417070329,0.141093564573785,0.140490720786683,True,0.314880243198491,0.0440165959695454,1.10619196739271,44.4799377208205
35939,1011:1080,Pancreas,BxPC-3,SIDM00132,906693,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.1,0.845827701589552,0.0787303942352291,0.424377622810249,8.00262117842604,0.0501,0.750174993013358,0.739798505597959,0.159003733094539,0.35895034930763,0.154989255534145,0.203961093773486,4.10992467665083,0.0034,3.89269650177521,0.0467,0.634518790130446,0.438843877968085,0.625742069629307,0.428896332806605,0.195674912162361,0.196845736822702,True,0.314880243198491,0.0440165959695454,1.10619196739271,44.4799377208205
35940,1168:1083,Pancreas,BxPC-3,SIDM00132,906693,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.734816114160753,0.0906237574490827,0.682833117882548,11.5089952560319,45.5379,0.889607107370287,0.88224927813679,0.0892910526650642,0.501756778302725,0.419299325111169,0.0824574531915557,9.93045126199011,15.247,1.57854399404175,30.2909,0.653697637767623,0.639064085688754,0.648290986281606,0.60829499274167,0.0146335520788684,0.039995993539936,True,0.314880243198491,0.0440165959695454,1.10619196739271,44.4799377208205
35940,1558:1083,Pancreas,BxPC-3,SIDM00132,906693,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.68573593506884,0.0906237574490827,0.682833117882548,11.5089952560319,45.5379,0.889607107370287,0.88224927813679,0.0993085042534222,0.46824320658716,0.150926644808877,0.317316561778283,4.86061816211677,0.454,6.6483770939151,45.0839,0.61003556161645,0.374766987853674,0.604990033706941,0.380714830300162,0.235268573762777,0.224275203406779,True,0.314880243198491,0.0440165959695454,1.10619196739271,44.4799377208205
35940,1011:1083,Pancreas,BxPC-3,SIDM00132,906693,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.671098571874989,0.0906237574490827,0.682833117882548,11.5089952560319,45.5379,0.889607107370287,0.88224927813679,0.111333001120001,0.458248330239923,0.255346444056816,0.202901886183108,7.40503498977089,2.6482,4.10396026626097,42.8897,0.597014059286039,0.504771113049545,0.592076230595339,0.475132156741717,0.0922429462364943,0.116944073853623,True,0.314880243198491,0.0440165959695454,1.10619196739271,44.4799377208205
35940,1079:1083,Pancreas,BxPC-3,SIDM00132,906693,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.644317865457445,0.0906237574490827,0.682833117882548,11.5089952560319,45.5379,0.889607107370287,0.88224927813679,0.0963082739963509,0.439961576977735,0.229333557069009,0.210628019908726,7.05953414492066,2.0843,4.44946111111121,43.4536,0.573189752516595,0.461950990767759,0.568448971690468,0.44377043724491,0.111238761748836,0.124678534445558,True,0.314880243198491,0.0440165959695454,1.10619196739271,44.4799377208205
36558,1011:1190,Pancreas,BxPC-3,SIDM00132,906693,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.2,0.759620677942305,0.0931858467979868,0.480284140979553,8.74182987982002,0.1672,0.80835423351649,0.776295636190663,0.108499200247183,0.364833764775826,0.174423593998542,0.190410170777284,5.03944394900423,0.0128,3.70238593081578,0.1544,0.614042590881328,0.438084346060114,0.589690217446804,0.430368216163749,0.175958244821214,0.159322001283055,True,0.340433650194604,0.0547006637101056,1.03635336927785,47.5045657541501
36558,1080:1372,Pancreas,BxPC-3,SIDM00132,906693,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.025,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.416509815332707,0.0875846618866972,0.465438051434252,8.54693930104654,0.7305,0.722536672440609,0.766993765442657,0.0962698345389176,0.193859516851695,0.0882448416221597,0.105614675229535,4.70163603562773,0.0508,3.84530326541881,0.6797,0.300943616009346,0.175424677764191,0.319460431605858,0.227017412227049,0.125518938245155,0.0924430193788095,True,0.340433650194604,0.0547006637101056,1.03635336927785,47.5045657541501
36558,1011:1372,Pancreas,BxPC-3,SIDM00132,906693,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.759620677942305,0.0875846618866972,0.465438051434252,8.54693930104654,0.7305,0.722536672440609,0.766993765442657,0.0616101164046613,0.353556368170632,0.152986776426123,0.200569591744509,4.49266356566115,0.044,4.0542757353854,0.6865,0.548853796957512,0.394871705438126,0.582624324083072,0.403864755135039,0.153982091519387,0.178759568948034,True,0.340433650194604,0.0547006637101056,1.03635336927785,47.5045657541501
36558,1053:1372,Pancreas,BxPC-3,SIDM00132,906693,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.883626080489526,0.0875846618866972,0.465438051434252,8.54693930104654,0.7305,0.722536672440609,0.766993765442657,0.0382219394663816,0.411273201099531,0.161244878888829,0.250028322210701,4.09330788022897,0.0333,4.45363142081757,0.6972,0.63845224787864,0.432670697714523,0.677735694717998,0.44711819232747,0.205781550164117,0.230617502390528,True,0.340433650194604,0.0547006637101056,1.03635336927785,47.5045657541501
36558,1561:1372,Pancreas,BxPC-3,SIDM00132,906693,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.612003980470165,0.0875846618866972,0.465438051434252,8.54693930104654,0.7305,0.722536672440609,0.766993765442657,0.0531464028055563,0.28484994014004,0.0810134354954855,0.203836504644554,2.84833416695057,0.0141,5.69860513409597,0.7164,0.442195319569321,0.229525839460567,0.469403237446707,0.260921759379431,0.212669480108754,0.208481478067276,True,0.340433650194604,0.0547006637101056,1.03635336927785,47.5045657541501
36558,1558:1372,Pancreas,BxPC-3,SIDM00132,906693,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.515693316122754,0.0875846618866972,0.465438051434252,8.54693930104654,0.7305,0.722536672440609,0.766993765442657,0.108112479294044,0.240023292193843,0.0634864178936851,0.176536874300158,2.57615926606781,0.0116,5.97078003497873,0.7189,0.372607332631198,0.164207899804473,0.395533558346602,0.211032658730865,0.208399432826725,0.184500899615737,True,0.340433650194604,0.0547006637101056,1.03635336927785,47.5045657541501
36558,1079:1372,Pancreas,BxPC-3,SIDM00132,906693,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.05,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.783036649733763,0.0875846618866972,0.465438051434252,8.54693930104654,0.7305,0.722536672440609,0.766993765442657,0.0901010818471455,0.364455052453688,0.165803338331124,0.198651714122564,4.6992186397584,0.0507,3.84772066128814,0.6798,0.565772695297676,0.387852094425421,0.600584228458902,0.426670764477873,0.177920600872255,0.173913463981029,True,0.340433650194604,0.0547006637101056,1.03635336927785,47.5045657541501
36559,1594:1510,Pancreas,BxPC-3,SIDM00132,906693,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.563922354995975,0.0759451599005513,0.714080333551055,11.9947542362845,79.7096,0.894071446760154,0.895922449789482,0.0677854810519553,0.402685863352422,0.261872845404699,0.140813017947723,8.53299016515823,7.2346,3.46176407112622,72.475,0.504186875791645,0.386571115048162,0.505230697779048,0.432144433894705,0.117615760743483,0.0730862638843429,True,0.340433650194604,0.0547006637101056,1.03635336927785,47.5045657541501
36559,1564:1510,Pancreas,BxPC-3,SIDM00132,906693,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.680718823131102,0.0759451599005513,0.714080333551055,11.9947542362845,79.7096,0.894071446760154,0.895922449789482,0.0735272971441656,0.486087924275939,0.315087980017696,0.170999944258242,8.51322629428131,7.1362,3.48152794200315,72.5734,0.608611263033694,0.462565080975225,0.60987127563743,0.520995640620388,0.146046182058469,0.0888756350170423,True,0.340433650194604,0.0547006637101056,1.03635336927785,47.5045657541501
36559,1558:1510,Pancreas,BxPC-3,SIDM00132,906693,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.621840797293547,0.0759451599005513,0.714080333551055,11.9947542362845,79.7096,0.894071446760154,0.895922449789482,0.0737731604217786,0.444044283947029,0.134333625715922,0.309710658231108,4.78254233885847,0.5375,7.21221189742598,79.1721,0.555970101290729,0.301991401658082,0.557121130490279,0.342145453793545,0.253978699632647,0.214975676696734,True,0.340433650194604,0.0547006637101056,1.03635336927785,47.5045657541501
36559,1079:1510,Pancreas,BxPC-3,SIDM00132,906693,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.05,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.769515653657428,0.0759451599005513,0.714080333551055,11.9947542362845,79.7096,0.894071446760154,0.895922449789482,0.0960957739974371,0.549495994636454,0.321922371641453,0.227573622995001,7.92165262428879,4.7357,4.07310161199566,74.9739,0.688001973770082,0.495377787603,0.689426349576118,0.566059460865596,0.192624186167083,0.123366888710522,True,0.340433650194604,0.0547006637101056,1.03635336927785,47.5045657541501
36083,1053:1564,Pancreas,BxPC-3,SIDM00132,906693,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.814017436873731,0.138530074793341,0.514849942522932,9.19440952902308,11.4426,0.731609486257334,0.796980192357129,0.0858712574895824,0.419096830587105,0.211971702247767,0.207125128339338,5.58448750293755,0.9372,3.60992202608553,10.5054,0.595542878795702,0.446818836017566,0.648755773421683,0.489061567605348,0.148724042778136,0.159694205816336,True,0.558778680575379,0.0760685721714648,0.551920810350209,87.7338503990836
36083,1561:1564,Pancreas,BxPC-3,SIDM00132,906693,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,2.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.636339528288927,0.138530074793341,0.514849942522932,9.19440952902308,11.4426,0.731609486257334,0.796980192357129,0.0742940465859337,0.327619369564624,0.0756657597635447,0.251953609801079,2.44691885984336,0.1065,6.74749066917972,11.3361,0.465552035376696,0.213599149951192,0.507149999660154,0.255270127640791,0.251952885425504,0.251879872019363,True,0.558778680575379,0.0760685721714648,0.551920810350209,87.7338503990836
36083,1011:1564,Pancreas,BxPC-3,SIDM00132,906693,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.707416889429096,0.138530074793341,0.514849942522932,9.19440952902308,11.4426,0.731609486257334,0.796980192357129,0.0406992292867637,0.364213544862321,0.127653946463042,0.23655959839928,4.04858880693563,0.3232,5.14582072208745,11.1194,0.517552907044982,0.333315593240578,0.563797248613883,0.355920190550682,0.184237313804404,0.2078770580632,True,0.558778680575379,0.0760685721714648,0.551920810350209,87.7338503990836
36083,1558:1564,Pancreas,BxPC-3,SIDM00132,906693,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.798967340204464,0.138530074793341,0.514849942522932,9.19440952902308,11.4426,0.731609486257334,0.796980192357129,0.130635404609457,0.411348289181969,0.223931210545067,0.187417078636901,5.91425519869988,1.1779,3.2801543303232,10.2647,0.584532085303377,0.434526718628117,0.636761144483218,0.496274218151575,0.15000536667526,0.140486926331642,True,0.558778680575379,0.0760685721714648,0.551920810350209,87.7338503990836
34789,1022:1005,Pancreas,PANC-02-03,SIDM01139,1298475,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,8.0,0.828364771623067,0.0586543357449769,0.869281027350194,13.7298284933525,212.2806,0.962810500630109,0.965710189378592,0.061722111706247,0.720081779697208,0.451756933915192,0.268324845782017,9.45420495488553,10.9602,4.27562353846695,201.3204,0.797558300470751,0.710390129478466,0.799960300478666,0.706097505380441,0.0871681709922847,0.0938627950982246,True,0.421021199615924,0.0580147568595395,0.820347834806952,59.4535220477674
34789,1080:1011,Pancreas,PANC-02-03,SIDM01139,1298475,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.687225785730422,0.0711595339841642,0.688838191974551,10.9839174919348,39.5566,0.909599572805439,0.908990214331678,0.0952693730361851,0.473387367720835,0.142493794813774,0.33089357290706,5.65226292892497,0.9823,5.33165456300985,38.5743,0.625100281121275,0.404939125795801,0.624681514265353,0.428841773556762,0.220161155325473,0.195839740708591,True,0.421021199615924,0.0580147568595395,0.820347834806952,59.4535220477674
34789,1085:1011,Pancreas,PANC-02-03,SIDM01139,1298475,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,5.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.858210469873189,0.0711595339841642,0.688838191974551,10.9839174919348,39.5566,0.909599572805439,0.908990214331678,0.157043841178984,0.591168148401078,0.318557498895266,0.272610649505811,7.68405952389948,4.0166,3.29985796803535,35.54,0.780627876773808,0.601491128125706,0.78010491895172,0.65239032051783,0.179136748648102,0.127714598433891,True,0.421021199615924,0.0580147568595395,0.820347834806952,59.4535220477674
34789,1372:1011,Pancreas,PANC-02-03,SIDM01139,1298475,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.3567894021998,0.0711595339841642,0.688838191974551,10.9839174919348,39.5566,0.909599572805439,0.908990214331678,0.0570876908117564,0.245770166726991,0.0855159492541804,0.160254217472811,6.11802933834321,1.3566,4.86588815359162,38.2,0.324535487822446,0.21363389684728,0.324318075176868,0.234559318486216,0.110901590975167,0.0897587566906518,True,0.421021199615924,0.0580147568595395,0.820347834806952,59.4535220477674
34789,1073:1011,Pancreas,PANC-02-03,SIDM01139,1298475,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in pancreas,10.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.824498545170483,0.0711595339841642,0.688838191974551,10.9839174919348,39.5566,0.909599572805439,0.908990214331678,0.074618512996757,0.567946087140884,0.516386062573429,0.0515600245674542,10.2891446381263,24.4383,0.694772853808567,15.1183,0.749963524465778,0.702790605258072,0.749461109290674,0.730409882087254,0.0471729192077056,0.0190512272034201,True,0.421021199615924,0.0580147568595395,0.820347834806952,59.4535220477674
34789,1083:1011,Pancreas,PANC-02-03,SIDM01139,1298475,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.86324769118964,0.0711595339841642,0.688838191974551,10.9839174919348,39.5566,0.909599572805439,0.908990214331678,0.108577819977871,0.594637978825277,0.438823934569699,0.155814044255578,9.08329649961763,10.5944,1.9006209923172,28.9622,0.785209731131378,0.647342836223486,0.784683703835797,0.721198517208174,0.137866894907892,0.0634851866276229,True,0.421021199615924,0.0580147568595395,0.820347834806952,59.4535220477674
34789,1179:1011,Pancreas,PANC-02-03,SIDM01139,1298475,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.2,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.805123972160905,0.0711595339841642,0.688838191974551,10.9839174919348,39.5566,0.909599572805439,0.908990214331678,0.0279867765756103,0.554600141298687,0.650164487374515,-0.0955643460758281,12.5800728917927,119.594,-1.5961553998579,-80.0374,0.732340421132978,0.77710034649167,0.731849812018113,0.763027499179118,-0.0447599253586921,-0.0311776871610048,True,0.421021199615924,0.0580147568595395,0.820347834806952,59.4535220477674
34789,1564:1011,Pancreas,PANC-02-03,SIDM01139,1298475,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.429830673630977,0.0711595339841642,0.688838191974551,10.9839174919348,39.5566,0.909599572805439,0.908990214331678,0.0616160947977834,0.296083784079165,0.0739353467962018,0.222148437282964,5.07695403286887,0.6592,5.90696345906596,38.8974,0.390973797113411,0.222926741372412,0.390711876150151,0.249968953899189,0.168047055740999,0.140742922250963,True,0.421021199615924,0.0580147568595395,0.820347834806952,59.4535220477674
34789,1558:1011,Pancreas,PANC-02-03,SIDM01139,1298475,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.603376456530674,0.0711595339841642,0.688838191974551,10.9839174919348,39.5566,0.909599572805439,0.908990214331678,0.0830892232912066,0.415628747396601,0.0827351292691486,0.332893618127452,4.40797494361735,0.4146,6.57594254831748,39.142,0.548830967101161,0.300650925293347,0.548463294544506,0.320432983450658,0.248180041807813,0.228030311093848,True,0.421021199615924,0.0580147568595395,0.820347834806952,59.4535220477674
34790,1088:1022,Pancreas,PANC-02-03,SIDM01139,1298475,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.878750356843735,0.0738194626142976,0.606613559302362,10.0812141625441,2.1158,0.891635673158151,0.878142418954626,0.0541349334635766,0.533061881703199,0.215000981685181,0.318060900018018,6.18583916054343,0.1422,3.89537500200069,1.9736,0.783525165962329,0.552619362330816,0.771667964015998,0.58189963272851,0.230905803631513,0.189768331287488,True,0.421021199615924,0.0580147568595395,0.820347834806952,59.4535220477674
34790,1073:1022,Pancreas,PANC-02-03,SIDM01139,1298475,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in pancreas,10.0,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.776069215492236,0.0738194626142976,0.606613559302362,10.0812141625441,2.1158,0.891635673158151,0.878142418954626,0.0437240490961263,0.470774109074737,0.34427903699213,0.126495072082607,8.4345842932568,0.6758,1.64662986928731,1.44,0.691970997372738,0.623167875795966,0.681499298168571,0.622973067563614,0.0688031215767718,0.058526230604957,True,0.421021199615924,0.0580147568595395,0.820347834806952,59.4535220477674
34791,1168:1053,Pancreas,PANC-02-03,SIDM01139,1298475,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.848071778697765,0.0684974864688076,0.676684821780889,10.8438279343466,35.8961,0.892569073104958,0.90466387277439,0.098458518108724,0.573877300425498,0.418543699279261,0.155333601146237,8.93532726022024,9.5616,1.90850067412633,26.3345,0.756962641438737,0.643161566052099,0.767219899707385,0.702480768055525,0.113801075386638,0.0647391316518598,True,0.421021199615924,0.0580147568595395,0.820347834806952,59.4535220477674
34791,1564:1053,Pancreas,PANC-02-03,SIDM01139,1298475,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.411298301789482,0.0684974864688076,0.676684821780889,10.8438279343466,35.8961,0.892569073104958,0.90466387277439,0.0537699075229087,0.278319318045198,0.0996059499608946,0.178713368084303,6.15205533365801,1.3889,4.69177260068856,34.5072,0.367112143997881,0.249143454087801,0.372086714562403,0.271380746391285,0.11796868991008,0.100705968171117,True,0.421021199615924,0.0580147568595395,0.820347834806952,59.4535220477674
34791,1558:1053,Pancreas,PANC-02-03,SIDM01139,1298475,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.692276619452207,0.0684974864688076,0.676684821780889,10.8438279343466,35.8961,0.892569073104958,0.90466387277439,0.105648497976512,0.468453080857093,0.208824034876041,0.259629045981052,6.9043212720817,2.3396,3.93950666226486,33.5565,0.61790470055669,0.456761198581884,0.626277647584796,0.492285636096965,0.161143501974806,0.13399201148783,True,0.421021199615924,0.0580147568595395,0.820347834806952,59.4535220477674
34791,1372:1053,Pancreas,PANC-02-03,SIDM01139,1298475,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.371194769343294,0.0684974864688076,0.676684821780889,10.8438279343466,35.8961,0.892569073104958,0.90466387277439,0.0415932994586397,0.251181866339065,0.0925811269683234,0.158600739370742,6.24955202470206,1.486,4.5942759096445,34.4101,0.331316971214153,0.234588715646598,0.335806497587701,0.247457808142651,0.0967282555675544,0.0883486894450498,True,0.421021199615924,0.0580147568595395,0.820347834806952,59.4535220477674
34792,1022:1073,Pancreas,PANC-02-03,SIDM01139,1298475,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in pancreas,20.0,0.913277491468604,0.0934637422466866,0.728973111005581,11.4700411928621,110.8119,0.881798608120685,0.922767074021614,0.0505038965207651,0.665754734167242,0.690335996514412,-0.0245812623471705,11.8216677118595,141.3958,-0.351626518997461,-30.5839,0.805326820804966,0.812720523660251,0.842742398572283,0.850807315685738,-0.0073937028552848,-0.008064917113455,True,0.421021199615924,0.0580147568595395,0.820347834806952,59.4535220477674
38665,1510:1079,Pancreas,PANC-02-03,SIDM01139,1298475,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.837268446711131,0.0886141314275738,0.516192005730378,9.16174712182169,2.2373,0.811000563788787,0.839140532793532,0.123543490752549,0.432191278842577,0.148025011263373,0.284166267579204,5.15991720822525,0.1397,4.00182991359644,2.0976,0.679025182325289,0.44395129081462,0.702585890464391,0.492098739945924,0.235073891510669,0.210487150518467,True,0.198516970435106,0.0316313780823744,1.50188535768895,32.7086878167275
38665,1083:1079,Pancreas,PANC-02-03,SIDM01139,1298475,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,1.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.956176650210231,0.0886141314275738,0.516192005730378,9.16174712182169,2.2373,0.811000563788787,0.839140532793532,0.180046163349611,0.493570742904573,0.304681017011428,0.188889725893145,7.10267966814759,0.5369,2.05906745367411,1.7004,0.775459802402171,0.598221906273893,0.802366583702147,0.692294074448878,0.177237896128278,0.11007250925327,True,0.198516970435106,0.0316313780823744,1.50188535768895,32.7086878167275
38665,1561:1079,Pancreas,PANC-02-03,SIDM01139,1298475,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,2.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.563358439494002,0.0886141314275738,0.516192005730378,9.16174712182169,2.2373,0.811000563788787,0.839140532793532,0.0951188424738094,0.290801122827545,0.165843719955594,0.124957402871951,6.81763236132169,0.4406,2.34411476050001,1.7967,0.456884012044807,0.333635828540527,0.47273690107073,0.397383070098768,0.12324818350428,0.0753538309719622,True,0.198516970435106,0.0316313780823744,1.50188535768895,32.7086878167275
38665,1564:1079,Pancreas,PANC-02-03,SIDM01139,1298475,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,1.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.489141473083767,0.0886141314275738,0.516192005730378,9.16174712182169,2.2373,0.811000563788787,0.839140532793532,0.0297980950438993,0.252490918077021,0.128413073721636,0.124077844355385,6.42147702157131,0.3348,2.74027010025038,1.9025,0.396694010443413,0.315992915979227,0.410458436334925,0.331921528469655,0.0807010944641855,0.0785369078652698,True,0.198516970435106,0.0316313780823744,1.50188535768895,32.7086878167275
38665,1011:1080,Pancreas,PANC-02-03,SIDM01139,1298475,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.1,0.798345226892838,0.0683844407203839,0.559013053160871,9.59205354374038,0.1507,0.855532660832652,0.85837155044413,0.0649828553574654,0.446285402761773,0.179060484874279,0.267224917887494,5.90229290928408,0.0117,3.6897606344563,0.139,0.683010416226677,0.522912137161081,0.685276830197676,0.512596902735952,0.160098279065596,0.172679927461724,True,0.198516970435106,0.0316313780823744,1.50188535768895,32.7086878167275
38666,1011:1083,Pancreas,PANC-02-03,SIDM01139,1298475,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.848485384620754,0.100900779152605,0.521967844090486,9.2195083993269,9.3147,0.878494802076377,0.841822540295354,0.13371708646365,0.442882086952782,0.237672278447125,0.205209808505657,6.64359881865055,1.5622,2.57590958067634,7.7525,0.745390000027108,0.643604106220058,0.714274121884924,0.588619922526712,0.10178589380705,0.125654199358212,True,0.198516970435106,0.0316313780823744,1.50188535768895,32.7086878167275
38666,1011:1085,Pancreas,PANC-02-03,SIDM01139,1298475,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.848485384620754,0.112298603330665,0.646309374910155,10.5050031553239,28.3825,0.940020665469174,0.893511171194921,0.11893365294667,0.548384058554642,0.330720711816084,0.217663346738558,7.88097180441396,4.604,2.62403135090991,23.7785,0.797593795892069,0.687289707692415,0.758131169754263,0.654867384084904,0.110304088199654,0.103263785669359,True,0.198516970435106,0.0316313780823744,1.50188535768895,32.7086878167275
38667,1179:1088,Pancreas,PANC-02-03,SIDM01139,1298475,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.0,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,0.512545491471215,0.0758910966003595,0.828309446909441,12.9286565629879,76.1401,0.962038900666865,0.953915251934405,0.0492760457014901,0.424546272556449,0.404318794297133,0.0202274782593166,12.2902689532819,48.9147,0.638387609706015,27.2254,0.493088701156725,0.472722465277359,0.488924961624607,0.482818690706148,0.0203662358793667,0.0061062709184588,True,0.198516970435106,0.0316313780823744,1.50188535768895,32.7086878167275
38667,1022:1088,Pancreas,PANC-02-03,SIDM01139,1298475,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,0.945149623889831,0.0758910966003595,0.828309446909441,12.9286565629879,76.1401,0.962038900666865,0.953915251934405,0.0813132871707954,0.782876362210852,0.509094743512696,0.273781618698156,9.38661632953701,6.5366,3.54204023345086,69.6035,0.909270705132673,0.841428643454092,0.901592641588576,0.802815886415578,0.0678420616785812,0.098776755172998,True,0.198516970435106,0.0316313780823744,1.50188535768895,32.7086878167275
38667,1011:1089,Pancreas,PANC-02-03,SIDM01139,1298475,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1089,Oxaliplatin,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved in pancreas,10.0,0.894164735757131,0.0667136499898036,0.730106507977453,11.4843813603605,55.9594,0.942748952409086,0.923145301045805,0.0436971084057198,0.652835492780221,0.442182270569055,0.210653222211166,8.94527464562412,9.6278,2.53910671473639,46.3316,0.842972867916182,0.725945974062494,0.825443974175059,0.74109457003918,0.117026893853688,0.0843494041358795,True,0.198516970435106,0.0316313780823744,1.50188535768895,32.7086878167275
38668,1510:1168,Pancreas,PANC-02-03,SIDM01139,1298475,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.855584867469442,0.0743016400428064,0.748649936361884,11.7246948700952,66.102,0.928815478694944,0.92925342412209,0.0460070367208478,0.640533556583189,0.420216487689479,0.22031706889371,8.91156926978583,9.4055,2.81312560030935,56.6965,0.79468046824278,0.736907761304925,0.795055167723024,0.707709600783976,0.0577727069378544,0.0873455669390482,True,0.198516970435106,0.0316313780823744,1.50188535768895,32.7086878167275
38668,1053:1168,Pancreas,PANC-02-03,SIDM01139,1298475,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.880273877517091,0.0743016400428064,0.748649936361884,11.7246948700952,66.102,0.928815478694944,0.92925342412209,0.0407748287463588,0.659016982384199,0.434659224424914,0.224357757959285,8.93785760103751,9.5784,2.78683726905766,56.5236,0.817612002928691,0.739507960494501,0.817997514847986,0.729263335908924,0.0781040424341897,0.0887341789390624,True,0.198516970435106,0.0316313780823744,1.50188535768895,32.7086878167275
38668,1083:1168,Pancreas,PANC-02-03,SIDM01139,1298475,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,1.0,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.939635898397392,0.0743016400428064,0.748649936361884,11.7246948700952,66.102,0.928815478694944,0.92925342412209,0.0759329893936661,0.703458355538549,0.47233605882187,0.231122296716679,9.02676105410832,10.1872,2.69793381598685,55.9148,0.872748366768927,0.742345497184116,0.873159876013813,0.782483007741328,0.130402869584811,0.0906768682724847,True,0.198516970435106,0.0316313780823744,1.50188535768895,32.7086878167275
38668,1561:1168,Pancreas,PANC-02-03,SIDM01139,1298475,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,2.0,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.523243843742716,0.0743016400428064,0.748649936361884,11.7246948700952,66.102,0.928815478694944,0.92925342412209,0.052588284556912,0.391726470319732,0.28440309093585,0.107323379383882,9.43587020797887,13.5273,2.28882466211631,52.5747,0.485996981200073,0.434258977101149,0.486226133448723,0.44559002191255,0.051738004098924,0.040636111536173,True,0.198516970435106,0.0316313780823744,1.50188535768895,32.7086878167275
38668,1564:1168,Pancreas,PANC-02-03,SIDM01139,1298475,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,1.0,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.509289836851019,0.0743016400428064,0.748649936361884,11.7246948700952,66.102,0.928815478694944,0.92925342412209,0.035377165070657,0.38127980394827,0.133801563171693,0.247478240776576,6.42398271727522,1.677,5.30071215281995,64.425,0.473036283609249,0.33619034392924,0.47325932476439,0.345681691787907,0.136845939680009,0.127577632976483,True,0.198516970435106,0.0316313780823744,1.50188535768895,32.7086878167275
38668,1057:1168,Pancreas,PANC-02-03,SIDM01139,1298475,1057,Dactolisib,"PI3K (class 1), MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.0125,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.983586528473118,0.0743016400428064,0.748649936361884,11.7246948700952,66.102,0.928815478694944,0.92925342412209,0.0636171055099737,0.736361991947807,0.626601011926024,0.109760980021783,10.4045434302397,26.4734,1.32015143985547,39.6286,0.913570392281657,0.906635085144907,0.914001149504005,0.875404556933679,0.00693530713675,0.0385965925703261,True,0.198516970435106,0.0316313780823744,1.50188535768895,32.7086878167275
38668,1372:1168,Pancreas,PANC-02-03,SIDM01139,1298475,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.360474545541981,0.0743016400428064,0.748649936361884,11.7246948700952,66.102,0.928815478694944,0.92925342412209,0.0499831686377265,0.269869245580083,0.134870122045789,0.134999123534295,7.71564575963833,4.1055,4.00904911045685,61.9965,0.334814337574917,0.238318968311836,0.33497220575374,0.274704227607026,0.0964953692630817,0.0602679781467141,True,0.198516970435106,0.0316313780823744,1.50188535768895,32.7086878167275
38668,1088:1168,Pancreas,PANC-02-03,SIDM01139,1298475,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.681046144318644,0.0743016400428064,0.748649936361884,11.7246948700952,66.102,0.928815478694944,0.92925342412209,0.0436219007558342,0.509865152603659,0.354633039557467,0.155232113046193,9.20700566787804,11.5429,2.51768920221713,54.5591,0.632566200548667,0.546700461953162,0.632864461593247,0.572926425360387,0.0858657385955049,0.0599380362328598,True,0.198516970435106,0.0316313780823744,1.50188535768895,32.7086878167275
38668,1594:1168,Pancreas,PANC-02-03,SIDM01139,1298475,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.713936127837244,0.0743016400428064,0.748649936361884,11.7246948700952,66.102,0.928815478694944,0.92925342412209,0.0480793701929926,0.534488236671803,0.295152337268017,0.239335899403786,8.1265817950543,5.4585,3.59811307504087,60.6435,0.663114926334765,0.533976039627968,0.663427591397226,0.561051367439742,0.129138886706797,0.102376223957483,True,0.198516970435106,0.0316313780823744,1.50188535768895,32.7086878167275
38668,1079:1168,Pancreas,PANC-02-03,SIDM01139,1298475,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.5,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.61124990866696,0.0743016400428064,0.748649936361884,11.7246948700952,66.102,0.928815478694944,0.92925342412209,0.0392842197448436,0.457612205224728,0.377544569170753,0.080067636053975,10.1973693668602,22.9321,1.52732550323498,43.1699,0.567738376520744,0.523744847986937,0.568006070623088,0.53943723105526,0.043993528533807,0.0285688395678275,True,0.198516970435106,0.0316313780823744,1.50188535768895,32.7086878167275
38669,1083:1190,Pancreas,PANC-02-03,SIDM01139,1298475,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,1.0,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.2,0.969823768819349,0.0820021980219158,0.672579124087669,10.7971325953519,0.6951,0.906696855722572,0.903185223575502,0.0642860012519414,0.652283220951919,0.439971349159635,0.212311871792284,8.53593640175836,0.145,2.26119619359352,0.5501,0.879336161793519,0.752286999280711,0.87593049746994,0.783709770957782,0.127049162512808,0.0922207265121577,True,0.198516970435106,0.0316313780823744,1.50188535768895,32.7086878167275
38669,1011:1190,Pancreas,PANC-02-03,SIDM01139,1298475,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.2,0.791088183803997,0.0820021980219158,0.672579124087669,10.7971325953519,0.6951,0.906696855722572,0.903185223575502,0.0816166711967447,0.532069397738997,0.23930080671201,0.292768591026987,6.9143566895926,0.0471,3.88277590575928,0.648,0.717277168854365,0.578436781798382,0.714499158156951,0.563073664711346,0.138840387055983,0.151425493445605,True,0.198516970435106,0.0316313780823744,1.50188535768895,32.7086878167275
38669,1022:1190,Pancreas,PANC-02-03,SIDM01139,1298475,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.2,0.936475352322057,0.0820021980219158,0.672579124087669,10.7971325953519,0.6951,0.906696855722572,0.903185223575502,0.139482032199318,0.62985377219446,0.350555111665147,0.279298660529313,7.71765573144181,0.0822,3.07947686391007,0.6129,0.849099257412097,0.672302671193626,0.845810700459944,0.713765216553147,0.176796586218471,0.132045483906796,True,0.198516970435106,0.0316313780823744,1.50188535768895,32.7086878167275
38669,1011:1372,Pancreas,PANC-02-03,SIDM01139,1298475,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.791088183803997,0.0805289354549323,0.231667656284567,6.00695178005728,0.1256,0.633076983422072,0.649546204452517,0.02847337005647,0.183269545456286,0.0593670609225547,0.123902484533732,2.72974982412382,0.013,3.27720195593347,0.1126,0.50081972102348,0.302012126554841,0.513848327177121,0.319643296986486,0.198807594468639,0.194205030190635,True,0.198516970435106,0.0316313780823744,1.50188535768895,32.7086878167275
38669,1053:1372,Pancreas,PANC-02-03,SIDM01139,1298475,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.930038602075469,0.0805289354549323,0.231667656284567,6.00695178005728,0.1256,0.633076983422072,0.649546204452517,0.0381574434805986,0.215459863196999,0.0658218306190292,0.149638032577969,2.57194341637096,0.0116,3.43500836368633,0.114,0.588786032668019,0.349816579942064,0.604103043972445,0.364940990598601,0.238969452725955,0.239162053373844,True,0.198516970435106,0.0316313780823744,1.50188535768895,32.7086878167275
38670,1372:1510,Pancreas,PANC-02-03,SIDM01139,1298475,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.320608135807377,0.0542107424888774,0.787421532209589,12.2689915462399,96.3972,0.940424669860801,0.941561204046405,0.0678201808649123,0.252453749536305,0.11025089066741,0.142202858868895,7.38716750944143,3.2696,4.88182403679844,93.1276,0.30150780027134,0.192397679383209,0.301872182377868,0.237904187615086,0.109110120888131,0.0639679947627817,True,0.198516970435106,0.0316313780823744,1.50188535768895,32.7086878167275
38670,1168:1510,Pancreas,PANC-02-03,SIDM01139,1298475,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,2.5,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.84878751268265,0.0542107424888774,0.787421532209589,12.2689915462399,96.3972,0.940424669860801,0.941561204046405,0.0800554747193486,0.668353563756938,0.409738535806608,0.25861502795033,8.82751548239734,8.8731,3.44147606384254,87.5241,0.798220716396551,0.630084994985855,0.799185392421029,0.698561026246141,0.168135721410696,0.100624366174888,True,0.198516970435106,0.0316313780823744,1.50188535768895,32.7086878167275
38670,1594:1510,Pancreas,PANC-02-03,SIDM01139,1298475,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.681766172053563,0.0542107424888774,0.787421532209589,12.2689915462399,96.3972,0.940424669860801,0.941561204046405,0.0627285780330087,0.536837363807082,0.438455777186212,0.0983815866208703,10.4702157207746,27.7063,1.79877582546529,68.6909,0.641149727275734,0.565544886784799,0.641924577836861,0.608346630216093,0.0756048404909342,0.0335779476207674,True,0.198516970435106,0.0316313780823744,1.50188535768895,32.7086878167275
38670,1564:1510,Pancreas,PANC-02-03,SIDM01139,1298475,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.443980846192073,0.0542107424888774,0.787421532209589,12.2689915462399,96.3972,0.940424669860801,0.941561204046405,0.101686914787513,0.349600078180272,0.125040646937111,0.22455943124316,6.66240593728338,1.9784,5.60658560895649,94.4188,0.417530540704699,0.255787706316134,0.41803514011415,0.308566184456927,0.161742834388565,0.109468955657223,True,0.198516970435106,0.0316313780823744,1.50188535768895,32.7086878167275
38670,1558:1510,Pancreas,PANC-02-03,SIDM01139,1298475,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.619597922819382,0.0542107424888774,0.787421532209589,12.2689915462399,96.3972,0.940424669860801,0.941561204046405,0.02563946256079,0.487884745740316,0.278537259030773,0.209347486709543,8.49444623795903,7.0439,3.77454530828084,89.3533,0.582685172013855,0.48667450348771,0.583389366234469,0.499339850150187,0.0960106685261452,0.0840495160842815,True,0.198516970435106,0.0316313780823744,1.50188535768895,32.7086878167275
38670,1079:1510,Pancreas,PANC-02-03,SIDM01139,1298475,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.05,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.815082354618517,0.0542107424888774,0.787421532209589,12.2689915462399,96.3972,0.940424669860801,0.941561204046405,0.0433371198837486,0.641813396550712,0.364368973375548,0.277444423175164,8.4690920347755,6.9212,3.79989951146437,89.476,0.766523554251483,0.621528437365017,0.76744992321159,0.655787761371093,0.144995116886466,0.111662161840497,True,0.198516970435106,0.0316313780823744,1.50188535768895,32.7086878167275
38671,1372:1558,Pancreas,PANC-02-03,SIDM01139,1298475,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.435451064320879,0.0724281151943905,0.694583048354299,11.0511732798498,41.4443,0.918606379555629,0.911009454503977,0.0866018801791805,0.30245692766512,0.169126585412527,0.133330342252593,7.86643903370195,4.5579,3.18473424614786,36.8864,0.400008125669448,0.276992583781296,0.39670003657014,0.335715384928641,0.123015541888153,0.0609846516414993,True,0.198516970435106,0.0316313780823744,1.50188535768895,32.7086878167275
38671,1011:1558,Pancreas,PANC-02-03,SIDM01139,1298475,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.7938115099598,0.0724281151943905,0.694583048354299,11.0511732798498,41.4443,0.918606379555629,0.911009454503977,0.122102679974017,0.551368018406607,0.326446935225013,0.224921083181594,8.10416594966489,5.3744,2.94700733018492,36.0699,0.729200317213759,0.648415124283066,0.723169790667456,0.622821274917866,0.0807851929306931,0.10034851574959,True,0.198516970435106,0.0316313780823744,1.50188535768895,32.7086878167275
38671,1510:1558,Pancreas,PANC-02-03,SIDM01139,1298475,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.825781220082704,0.0724281151943905,0.694583048354299,11.0511732798498,41.4443,0.918606379555629,0.911009454503977,0.0877824580205483,0.573573637118777,0.423939930706791,0.149633706411986,9.13364672030354,10.9706,1.91752655954626,30.4737,0.758567896885203,0.728018789720786,0.752294498847173,0.691859725793121,0.0305491071644176,0.0604347730540515,True,0.198516970435106,0.0316313780823744,1.50188535768895,32.7086878167275
38671,1053:1558,Pancreas,PANC-02-03,SIDM01139,1298475,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,5.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.853407674321674,0.0724281151943905,0.694583048354299,11.0511732798498,41.4443,0.918606379555629,0.911009454503977,0.103981752503284,0.592762503919301,0.303031562745859,0.289730941173442,7.51020224026248,3.5606,3.54097103958733,37.8837,0.783945733993622,0.65772650202443,0.777462459853295,0.63974913945545,0.126219231969192,0.137713320397845,True,0.198516970435106,0.0316313780823744,1.50188535768895,32.7086878167275
38671,1564:1558,Pancreas,PANC-02-03,SIDM01139,1298475,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.405641572536044,0.0724281151943905,0.694583048354299,11.0511732798498,41.4443,0.918606379555629,0.911009454503977,0.0595790142389358,0.281751759991317,0.115323387039153,0.166428372952164,6.69517815326831,2.0239,4.3559951265815,39.4204,0.372624936344588,0.264770235765358,0.369543307720197,0.282814998187417,0.10785470057923,0.0867283095327806,True,0.198516970435106,0.0316313780823744,1.50188535768895,32.7086878167275
38671,1372:1561,Pancreas,PANC-02-03,SIDM01139,1298475,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.435451064320879,0.0921085012269138,0.436928927828706,8.36681042886553,6.4475,0.755232311378671,0.799088625844353,0.11566751534827,0.19026116665559,0.0379321210244314,0.152329045631159,3.13471405086188,0.1715,5.23209637800364,6.276,0.32886671379936,0.154706350800473,0.347963992610632,0.18912731090634,0.174160362998887,0.158836681704292,True,0.198516970435106,0.0316313780823744,1.50188535768895,32.7086878167275
38671,1564:1561,Pancreas,PANC-02-03,SIDM01139,1298475,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.405641572536044,0.0921085012269138,0.436928927828706,8.36681042886553,6.4475,0.755232311378671,0.799088625844353,0.0916968737687506,0.177236537370924,0.0476356304643106,0.129600906906613,3.96472536103672,0.305,4.40208506782881,6.1425,0.306353622417676,0.163969047565204,0.32414356678317,0.201730187444589,0.142384574852471,0.122413379338581,True,0.198516970435106,0.0316313780823744,1.50188535768895,32.7086878167275
38672,1510:1564,Pancreas,PANC-02-03,SIDM01139,1298475,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.861134760706972,0.0871916505797526,0.247320898277914,6.22156279796485,1.4575,0.636111176327165,0.66469463728703,0.0457515269790702,0.212976622556385,0.0735218135247141,0.139454809031671,3.0798411214964,0.1651,3.14172167646844,1.2924,0.547777445609524,0.353009286206666,0.572391657423375,0.37045896576343,0.194768159402858,0.201932691659945,True,0.198516970435106,0.0316313780823744,1.50188535768895,32.7086878167275
38672,1053:1564,Pancreas,PANC-02-03,SIDM01139,1298475,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.859568705486618,0.0871916505797526,0.247320898277914,6.22156279796485,1.4575,0.636111176327165,0.66469463728703,0.0468343970919444,0.212589304372534,0.058792211660378,0.153797092712156,2.48032243716879,0.109,3.74124036079605,1.3485,0.546781260381111,0.314618385392526,0.57135070891671,0.331504010380626,0.232162874988585,0.239846698536084,True,0.198516970435106,0.0316313780823744,1.50188535768895,32.7086878167275
38672,1083:1564,Pancreas,PANC-02-03,SIDM01139,1298475,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,1.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.910437378186543,0.0871916505797526,0.247320898277914,6.22156279796485,1.4575,0.636111176327165,0.66469463728703,0.0540306747049187,0.225170190198885,0.115913625825435,0.10925656437345,4.19457660160222,0.3576,2.02698619636263,1.0999,0.579139391610462,0.457797648667002,0.605162842866259,0.468717999216887,0.121341742943461,0.136444843649373,True,0.198516970435106,0.0316313780823744,1.50188535768895,32.7086878167275
38672,1561:1564,Pancreas,PANC-02-03,SIDM01139,1298475,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,2.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.626849620045277,0.0871916505797526,0.247320898277914,6.22156279796485,1.4575,0.636111176327165,0.66469463728703,0.0594535478542793,0.155033011114767,0.0411254217973862,0.113907589317381,2.36885544931727,0.1009,3.85270734864758,1.3566,0.398746049187237,0.212191404625708,0.416663580829508,0.236647435248269,0.186554644561529,0.180016145581239,True,0.198516970435106,0.0316313780823744,1.50188535768895,32.7086878167275
38672,1011:1564,Pancreas,PANC-02-03,SIDM01139,1298475,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.861012347462504,0.0871916505797526,0.247320898277914,6.22156279796485,1.4575,0.636111176327165,0.66469463728703,0.0784139953196996,0.212946347202802,0.0369210174453566,0.176025329757445,1.24725280574861,0.0464,4.97430999221623,1.4111,0.547699577176587,0.218806435932325,0.572310289996244,0.257389960552655,0.328893141244262,0.314920329443588,True,0.198516970435106,0.0316313780823744,1.50188535768895,32.7086878167275
38672,1372:1594,Pancreas,PANC-02-03,SIDM01139,1298475,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.354183827621931,0.052391917127259,0.706834656873299,11.1970316929983,18.3414,0.929205721807117,0.915261937297933,0.0452835306624566,0.250349404267219,0.148634964739028,0.101714439528191,8.19067275538581,2.2826,3.00635893761246,16.0588,0.329109639197844,0.248052839285507,0.324170976228846,0.279605671961874,0.0810567999123371,0.0445653042669721,True,0.198516970435106,0.0316313780823744,1.50188535768895,32.7086878167275
34803,1080:1011,Pancreas,PANC-04-03,SIDM01137,1298476,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.662101983686631,0.100200581896185,0.687745159462619,11.9397640037563,76.7286,0.900002112486069,0.871976914240318,0.091916777655307,0.455357434351078,0.305378967537119,0.14997846681396,8.42140579252903,6.6962,3.51835821122731,70.0324,0.595893183999185,0.483330429228498,0.577337644647462,0.490222068737049,0.112562754770687,0.0871155759104124,True,0.637311945120776,0.0818472420360246,0.429995454776877,112.628212479526
34803,1564:1011,Pancreas,PANC-04-03,SIDM01137,1298476,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.437673064947884,0.100200581896185,0.687745159462619,11.9397640037563,76.7286,0.900002112486069,0.871976914240318,0.0727533439526358,0.301007531845076,0.186148353594037,0.114859178251039,7.87935356107407,4.5989,4.06041044268227,72.1297,0.393906683031348,0.310530925362486,0.381640808619358,0.312717713236007,0.083375757668862,0.068923095383351,True,0.637311945120776,0.0818472420360246,0.429995454776877,112.628212479526
34803,1558:1011,Pancreas,PANC-04-03,SIDM01137,1298476,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.652196052339669,0.100200581896185,0.687745159462619,11.9397640037563,76.7286,0.900002112486069,0.871976914240318,0.0935458771496507,0.448544678017237,0.220819311606613,0.227725366410623,6.50686665049863,1.7762,5.4328973532577,74.9524,0.586977824860777,0.408243066704412,0.568699901198862,0.419574581488313,0.178734758156365,0.149125319710549,True,0.637311945120776,0.0818472420360246,0.429995454776877,112.628212479526
34805,1564:1053,Pancreas,PANC-04-03,SIDM01137,1298476,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,1.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.557580208544892,0.0685298307569971,0.720239863730981,12.5207667535592,114.7774,0.858654744907229,0.887546782439281,0.0583916022398709,0.401591493421465,0.316350873596711,0.0852406198247542,10.0093499564339,20.13,2.51141679712533,94.6474,0.478768891733434,0.414773208257703,0.494878520045842,0.450444015979475,0.0639956834757312,0.0444345040663675,True,0.637311945120776,0.0818472420360246,0.429995454776877,112.628212479526
34805,1372:1053,Pancreas,PANC-04-03,SIDM01137,1298476,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.453959047856158,0.0685298307569971,0.720239863730981,12.5207667535592,114.7774,0.858654744907229,0.887546782439281,0.0719452574852346,0.326959402767365,0.281806950225036,0.0451524525423288,10.8349127255663,35.675,1.68585402799288,79.1024,0.389794090435258,0.318913297584576,0.402909892283932,0.380270400760737,0.0708807928506814,0.0226394915231952,True,0.637311945120776,0.0818472420360246,0.429995454776877,112.628212479526
34805,1558:1053,Pancreas,PANC-04-03,SIDM01137,1298476,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.835507521330887,0.0685298307569971,0.720239863730981,12.5207667535592,114.7774,0.858654744907229,0.887546782439281,0.0585233164412143,0.601765823309568,0.566757470623939,0.035008352685629,11.7779985049284,68.59,0.742768248630826,46.1874,0.717412497596444,0.679236955241513,0.741552012261048,0.724673915531255,0.0381755423549313,0.0168780967297928,True,0.637311945120776,0.0818472420360246,0.429995454776877,112.628212479526
34806,1564:1057,Pancreas,PANC-04-03,SIDM01137,1298476,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,1.0,1057,Dactolisib,"PI3K (class 1), MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,0.499979002590757,0.0734492872214773,0.581132971884712,10.2190438028058,0.2328,0.827989102344603,0.815773918791995,0.0595563109846436,0.290554283655521,0.325720757616599,-0.0351664739610781,11.3288139481951,0.5024,-1.10977014538923,-0.2696,0.413977165546271,0.429093606450404,0.407869830257175,0.426876794479812,-0.0151164409041331,-0.0190069642226364,True,0.637311945120776,0.0818472420360246,0.429995454776877,112.628212479526
37949,1564:1168,Pancreas,PANC-04-03,SIDM01137,1298476,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.480845657836477,0.0628523989520838,0.671246454991283,11.6576611954694,63.1009,0.838273638038805,0.863815105084976,0.0645655761562968,0.322765943220687,0.172892865166339,0.149873078054348,6.85074316386395,2.2543,4.80691803160549,60.8466,0.403080238929746,0.274275067704458,0.415361742453671,0.318238896946916,0.128805171225289,0.0971228455067556,True,0.348765568471667,0.0482780117240611,0.97132243443711,49.87153460355
37949,1372:1168,Pancreas,PANC-04-03,SIDM01137,1298476,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.427193003465834,0.0628523989520838,0.671246454991283,11.6576611954694,63.1009,0.838273638038805,0.863815105084976,0.0579539931423068,0.28675178917352,0.180095351503664,0.106656437669856,7.82239038570352,4.4208,3.83527080976592,58.6801,0.358104633160028,0.259500254839505,0.369015769180406,0.304033350846247,0.098604378320523,0.0649824183341592,True,0.348765568471667,0.0482780117240611,0.97132243443711,49.87153460355
37950,1022:1190,Pancreas,PANC-04-03,SIDM01137,1298476,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.2,0.959297893949474,0.0610613539207369,0.710079773432656,12.3350571931327,2.0183,0.871027924507849,0.88274816289684,0.0274014387531215,0.681178031190066,0.509923988406817,0.171254042783249,9.47062503873321,0.2771,2.8644321543995,1.7412,0.83557525355156,0.748056507214033,0.846818453554705,0.754428903991661,0.0875187463375277,0.0923895495630442,True,0.348765568471667,0.0482780117240611,0.97132243443711,49.87153460355
37950,1011:1190,Pancreas,PANC-04-03,SIDM01137,1298476,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.2,0.903611098391413,0.0610613539207369,0.710079773432656,12.3350571931327,2.0183,0.871027924507849,0.88274816289684,0.0817083344926596,0.641635964017008,0.435944252066597,0.205691711950411,8.73848193995956,0.1668,3.59657525317315,1.8515,0.78707049959413,0.703740568207529,0.797661037078215,0.682137320814861,0.0833299313866016,0.115523716263354,True,0.348765568471667,0.0482780117240611,0.97132243443711,49.87153460355
37950,1011:1372,Pancreas,PANC-04-03,SIDM01137,1298476,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.903611098391413,0.0588795756761858,0.411527438936295,7.66841205367572,0.3973,0.697376374049639,0.704058284086518,0.138491900657144,0.37186076111543,0.207376882264843,0.164483878850587,4.49075990578759,0.0439,3.17765214788813,0.3534,0.630157031347215,0.489420120085134,0.636194879414992,0.477765328827063,0.140736911262081,0.15842955058793,True,0.348765568471667,0.0482780117240611,0.97132243443711,49.87153460355
37950,1561:1372,Pancreas,PANC-04-03,SIDM01137,1298476,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.748169167591181,0.0588795756761858,0.411527438936295,7.66841205367572,0.3973,0.697376374049639,0.704058284086518,0.0539334445474466,0.307892141429898,0.207719731094524,0.100172410335374,5.43991853711725,0.0848,2.22849351655847,0.3125,0.521755501270474,0.433230756982715,0.526754700340685,0.436696562883259,0.088524744287759,0.0900581374574261,True,0.348765568471667,0.0482780117240611,0.97132243443711,49.87153460355
37950,1558:1372,Pancreas,PANC-04-03,SIDM01137,1298476,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.68590226696937,0.0588795756761858,0.411527438936295,7.66841205367572,0.3973,0.697376374049639,0.704058284086518,0.0475298681470555,0.282267603286503,0.135472955561156,0.146794647725347,3.78047135404808,0.0268,3.88794069962764,0.3705,0.478332035891526,0.299122048250855,0.482915173133507,0.334129805713554,0.179209987640672,0.148785367419953,True,0.348765568471667,0.0482780117240611,0.97132243443711,49.87153460355
37951,1594:1510,Pancreas,PANC-04-03,SIDM01137,1298476,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.514427308753141,0.189221530950709,0.749179914538076,13.073989652135,168.4198,0.820415528966849,0.900885659849128,0.0741426443716151,0.385398607207731,0.272689339229686,0.112709267978044,9.44855609977058,13.6467,3.62543355236439,154.7731,0.4220441526257,0.346021599301361,0.463440185490484,0.404097353638453,0.0760225533243398,0.059342831852031,True,0.348765568471667,0.0482780117240611,0.97132243443711,49.87153460355
37951,1564:1510,Pancreas,PANC-04-03,SIDM01137,1298476,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.467231342255677,0.189221530950709,0.749179914538076,13.073989652135,168.4198,0.820415528966849,0.900885659849128,0.0752430478333837,0.350040337060619,0.199747518365631,0.150292818694988,7.91283309213568,4.7068,5.16115655999929,163.713,0.383323848806582,0.269457304208924,0.420922016070199,0.334602995249146,0.113866544597658,0.0863190208210524,True,0.348765568471667,0.0482780117240611,0.97132243443711,49.87153460355
37859,1372:1558,Pancreas,PANC-04-03,SIDM01137,1298476,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.563091859717724,0.08234955630482,0.789534950080426,13.9224168540736,303.246,0.937059808680168,0.918722441208541,0.0391868381357363,0.444580703352927,0.298657942627383,0.145922760725544,9.45313071659454,13.6901,4.4692861374791,289.5559,0.52765075033645,0.428764205912186,0.517325127984525,0.442431088174847,0.0988865444242635,0.0748940398096772,True,0.443763398937816,0.0512387775856909,0.783515460877759,62.6601112551757
37859,1372:1561,Pancreas,PANC-04-03,SIDM01137,1298476,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.504898876052651,0.0954531995704151,0.588541253562842,10.3326440370798,25.1864,0.803839049712807,0.819965859022967,0.0667973245026587,0.297153817434497,0.202424184707192,0.0947296327273051,7.50467859638356,3.547,2.82796544069628,21.6394,0.405857432727227,0.321009120312369,0.413999840622242,0.35131855533775,0.0848483124148586,0.062681285284492,True,0.443763398937816,0.0512387775856909,0.783515460877759,62.6601112551757
37859,1564:1561,Pancreas,PANC-04-03,SIDM01137,1298476,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.541575492520627,0.0954531995704151,0.588541253562842,10.3326440370798,25.1864,0.803839049712807,0.819965859022967,0.0630385558539406,0.318739519267003,0.134592118400273,0.18414740086673,4.88028977547633,0.5752,5.4523542616035,24.6112,0.435339529255526,0.261828214318192,0.444073413950462,0.298637464962675,0.173511314937334,0.145435948987786,True,0.443763398937816,0.0512387775856909,0.783515460877759,62.6601112551757
37953,1011:1564,Pancreas,PANC-04-03,SIDM01137,1298476,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.887603345345935,0.074343044849634,0.414434986516591,7.71306519240408,4.0982,0.703149968370556,0.706285111473152,0.122953206469851,0.367853880460524,0.147442159929789,0.220411720530735,2.99301277336217,0.1555,4.7200524190419,3.9427,0.624118264205594,0.36438576399509,0.626901027711597,0.391637753577504,0.259732500210505,0.235263274134093,True,0.348765568471667,0.0482780117240611,0.97132243443711,49.87153460355
37953,1561:1564,Pancreas,PANC-04-03,SIDM01137,1298476,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.745742799326834,0.074343044849634,0.414434986516591,7.71306519240408,4.0982,0.703149968370556,0.706285111473152,0.128613676495811,0.309061906983861,0.212651815865371,0.0964100911184904,5.57832672966745,0.9332,2.13473846273662,3.165,0.524369025759234,0.457597002758844,0.526707036152854,0.441167276105421,0.0667720230003892,0.0855397600474331,True,0.348765568471667,0.0482780117240611,0.97132243443711,49.87153460355
37953,1053:1564,Pancreas,PANC-04-03,SIDM01137,1298476,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,5.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.826601851122588,0.074343044849634,0.414434986516591,7.71306519240408,4.0982,0.703149968370556,0.706285111473152,0.033943798146685,0.342572727024579,0.13486040740172,0.207712319622859,2.91281692460523,0.1471,4.80024826779884,3.9511,0.581225065471891,0.338141602500966,0.583816580564031,0.360887878343174,0.243083462970925,0.222928702220857,True,0.348765568471667,0.0482780117240611,0.97132243443711,49.87153460355
37953,1564:1594,Pancreas,PANC-04-03,SIDM01137,1298476,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.49974548942981,0.0842040224389601,0.538265499361362,9.57098337107721,5.9421,0.823341005757867,0.79054466941096,0.056027200590011,0.268995755421525,0.112993143352175,0.156002612069351,4.41886989642967,0.1671,5.15211347464754,5.775,0.411460953890097,0.241580932274028,0.395071132730908,0.262129921410982,0.16988002161607,0.132941211319926,True,0.348765568471667,0.0482780117240611,0.97132243443711,49.87153460355
34796,1011:1005,Pancreas,PANC-10-05,SIDM01135,925348,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,8.0,0.651626445273616,0.0794603719751919,0.637853208501248,10.9112693010074,30.0912,0.866527758440976,0.857952959495464,0.0654391870351162,0.415642018862039,0.204871124507051,0.210770894354988,6.36761720186246,1.2902,4.54365209914498,28.801,0.564652402963808,0.414944943146906,0.559064837208008,0.420562361853171,0.149707459816902,0.138502475354837,True,0.503706153735019,0.072365194714124,0.655614271389737,74.3860304729108
34796,1080:1011,Pancreas,PANC-10-05,SIDM01135,925348,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.696887463866123,0.111142113753159,0.530693373797153,9.41506065590052,13.3335,0.836729524969163,0.80118139606239,0.0952988569668886,0.369833559356055,0.120632199025515,0.249201360330539,3.71988976498578,0.2574,5.69517089091474,13.0761,0.583106316597666,0.320511531237979,0.558333271198639,0.336161759195718,0.262594785359687,0.222171512002921,True,0.503706153735019,0.072365194714124,0.655614271389737,74.3860304729108
34796,1085:1011,Pancreas,PANC-10-05,SIDM01135,925348,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,5.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.752628886814874,0.111142113753159,0.530693373797153,9.41506065590052,13.3335,0.836729524969163,0.80118139606239,0.0960305214869402,0.399415163160981,0.212260088172625,0.187155074988356,5.84491017672891,1.1226,3.57015047917162,12.2109,0.629746810942679,0.457854514896529,0.602992262255223,0.46241160566014,0.17189229604615,0.140580656595083,True,0.503706153735019,0.072365194714124,0.655614271389737,74.3860304729108
34796,1088:1011,Pancreas,PANC-10-05,SIDM01135,925348,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.795186030413598,0.111142113753159,0.530693373797153,9.41506065590052,13.3335,0.836729524969163,0.80118139606239,0.139573370149282,0.421999957276558,0.188737633582659,0.233262323693899,5.05879707760444,0.651,4.35626357829608,12.6825,0.665355629490084,0.451548361999705,0.637088253976077,0.450323604753923,0.213807267490379,0.186764649222154,True,0.503706153735019,0.072365194714124,0.655614271389737,74.3860304729108
34796,1083:1011,Pancreas,PANC-10-05,SIDM01135,925348,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.958276642414878,0.111142113753159,0.530693373797153,9.41506065590052,13.3335,0.836729524969163,0.80118139606239,0.120192327056882,0.50855106439416,0.383945018612742,0.124606045781418,7.64027723237964,3.8966,1.77478342352089,9.4369,0.801818359796845,0.705936505157732,0.767753418183932,0.686455454236102,0.0958818546391138,0.0812979639478294,True,0.503706153735019,0.072365194714124,0.655614271389737,74.3860304729108
34796,1564:1011,Pancreas,PANC-10-05,SIDM01135,925348,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.659368309572054,0.111142113753159,0.530693373797153,9.41506065590052,13.3335,0.836729524969163,0.80118139606239,0.068774424962472,0.349922392781719,0.217778409609245,0.132143983172473,6.61317436170233,1.912,2.8018862941982,11.4215,0.551712932447945,0.445718853733195,0.528273622782236,0.434942940642588,0.10599407871475,0.0933306821396482,True,0.503706153735019,0.072365194714124,0.655614271389737,74.3860304729108
34796,1558:1011,Pancreas,PANC-10-05,SIDM01135,925348,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.345788140421311,0.111142113753159,0.530693373797153,9.41506065590052,13.3335,0.836729524969163,0.80118139606239,0.0617239039433837,0.183507474859229,0.0782780159566752,0.105229458902554,4.85071026418261,0.5636,4.56435039171791,12.7699,0.289331146474694,0.158651681049265,0.277039025084564,0.191349862630277,0.130679465425428,0.0856891624542862,True,0.503706153735019,0.072365194714124,0.655614271389737,74.3860304729108
34796,1079:1011,Pancreas,PANC-10-05,SIDM01135,925348,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.05,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.736648292300338,0.111142113753159,0.530693373797153,9.41506065590052,13.3335,0.836729524969163,0.80118139606239,0.103998774339021,0.390934367542778,0.235020631215982,0.155913736326796,6.44002558739835,1.6958,2.97503506850217,11.6377,0.616375375685807,0.484361733852672,0.59018890723216,0.478544867223287,0.132013641833134,0.111644040008873,True,0.503706153735019,0.072365194714124,0.655614271389737,74.3860304729108
34800,1011:1079,Pancreas,PANC-10-05,SIDM01135,925348,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.628270021799055,0.122275266806657,0.514303657298939,9.19323515304042,2.2866,0.748065400141437,0.791590788198649,0.0503465121019133,0.323121569982538,0.185263564490105,0.137858005492433,6.05639304665626,0.26,3.13684210638416,2.0266,0.469987065253979,0.379306607805797,0.497332761757496,0.393956610034535,0.0906804574481822,0.103376151722961,True,0.503706153735019,0.072365194714124,0.655614271389737,74.3860304729108
34800,1011:1080,Pancreas,PANC-10-05,SIDM01135,925348,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.1,0.628270021799055,0.109490447429348,0.542921181419339,9.58111538461926,0.1496,0.780117042840325,0.808163270182193,0.107288202191893,0.341101102485497,0.137281522963742,0.203819579521755,4.69709401621295,0.0051,4.8840213684063,0.1445,0.490124151511106,0.328578193696117,0.507744755374562,0.341641405331259,0.161545957814988,0.166103350043303,True,0.503706153735019,0.072365194714124,0.655614271389737,74.3860304729108
34801,1011:1083,Pancreas,PANC-10-05,SIDM01135,925348,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.660185252581162,0.134049679330471,0.623591959271885,10.7045086663017,26.0734,0.883852078458873,0.850925988863807,0.142206687816889,0.411686215139491,0.237049045020752,0.174637170118739,7.04359252081863,2.0614,3.66091614548308,24.012,0.583506107661755,0.481772936994541,0.561768788885927,0.451558656180062,0.101733170667214,0.110210132705866,True,0.503706153735019,0.072365194714124,0.655614271389737,74.3860304729108
34801,1558:1085,Pancreas,PANC-10-05,SIDM01135,925348,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.299930958902025,0.139499302771171,0.630770418064376,10.808168638215,35.0197,0.897924374442036,0.85448132199843,0.0586776943312342,0.18918757633708,0.103749682065631,0.0854378942714491,6.84900440954341,2.2516,3.95916422867162,32.7681,0.269315318647901,0.177403639908031,0.256285402270859,0.201876531894565,0.09191167873987,0.0544088703762944,True,0.503706153735019,0.072365194714124,0.655614271389737,74.3860304729108
34860,1558:1598,Pancreas,PANC-10-05,SIDM01135,925348,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,2.5,1598,LGK974,PORCN,WNT signaling,Targeted,Early clinical trials,10.0,0.851092992247053,0.0717722365079009,0.916127896894685,17.0726330316475,2692.1837,0.949303379683075,0.972017849739492,0.0855076675585869,0.779710033049097,0.633827997241661,0.145882035807436,12.6150311560624,122.5273,4.45760187558508,2569.6564,0.807945453964708,0.701004216933901,0.82727758025233,0.771444356000927,0.106941237030806,0.0558332242514028,True,0.524722154567363,0.0710666585990517,0.618737419540824,78.8982739336041
38820,1022:1005,Pancreas,PANC-03-27,SIDM01138,925346,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,8.0,0.449791722894732,0.0514912605050399,0.691747608871382,10.8641924447458,29.1251,0.921926559118033,0.916346089821102,0.0597740623588406,0.31114234880257,0.175678519980377,0.135463828822194,7.97395800087097,3.9284,2.89023444387481,25.1967,0.414674935408112,0.318902248823969,0.412164886508485,0.354364092105382,0.095772686584144,0.057800794403103,True,0.506212168950367,0.0457146802459805,0.638007704311463,75.6277239581174
38820,1080:1011,Pancreas,PANC-03-27,SIDM01138,925346,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.536665399757355,0.0791809609038411,0.825476489277227,12.5837720981384,119.901,0.933920523417384,0.956403688750453,0.0521355920794937,0.443004670108261,0.115490897556676,0.327513772551584,6.01597310300489,1.2639,6.56779899513353,118.6371,0.501202831041388,0.323528942315602,0.513268767952671,0.352301356712943,0.177673888725786,0.160967411239727,True,0.506212168950367,0.0457146802459805,0.638007704311463,75.6277239581174
38820,1372:1011,Pancreas,PANC-03-27,SIDM01138,925346,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.512724044263898,0.0791809609038411,0.825476489277227,12.5837720981384,119.901,0.933920523417384,0.956403688750453,0.150068696277383,0.423241644026983,0.112107644169758,0.311133999857226,6.06281575219349,1.3056,6.52095634594493,118.5954,0.478843507787617,0.295077016867412,0.490371167245042,0.338357099954041,0.183766490920206,0.152014067291002,True,0.506212168950367,0.0457146802459805,0.638007704311463,75.6277239581174
38820,1073:1011,Pancreas,PANC-03-27,SIDM01138,925346,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in pancreas,10.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.576618532081663,0.0791809609038411,0.825476489277227,12.5837720981384,119.901,0.933920523417384,0.956403688750453,0.0788338980646037,0.475985041514959,0.211072929199195,0.264912112315764,7.73340590698192,4.1564,4.8503661911565,115.7446,0.538515881293871,0.406673394736061,0.551480091084774,0.445951762517804,0.131842486557809,0.10552832856697,True,0.506212168950367,0.0457146802459805,0.638007704311463,75.6277239581174
38820,1564:1011,Pancreas,PANC-03-27,SIDM01138,925346,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.513195174042178,0.0791809609038411,0.825476489277227,12.5837720981384,119.901,0.933920523417384,0.956403688750453,0.0595686380317261,0.423630550582352,0.04813133876565,0.375499211816702,3.76874152088977,0.2662,8.81503057724865,119.6348,0.479283505556746,0.21686793325861,0.49082175750287,0.24716927287774,0.262415572298136,0.24365248462513,True,0.506212168950367,0.0457146802459805,0.638007704311463,75.6277239581174
38676,1190:1017,Pancreas,PANC-03-27,SIDM01138,925346,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.01,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.728646720310024,0.0659565613929025,0.812373563135183,12.3799085258168,104.1007,0.942771757367075,0.952772300816191,0.0400970522496588,0.59193333244502,0.647353308006131,-0.0554199755611113,13.7851867166531,275.7305,-1.40527819083634,-171.6298,0.686947549006437,0.728646720310024,0.694234412191953,0.709043158551259,-0.0416991713035872,-0.0148087463593061,True,0.372937468483931,0.0447603246852157,0.929766719435217,52.4646283034947
38677,1372:1053,Pancreas,PANC-03-27,SIDM01138,925346,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.516728078175221,0.0394529570143333,0.606715029775383,9.99984076311586,19.9978,0.879732389175414,0.886703421129744,0.0538257937129571,0.313506691335855,0.0853934680247006,0.228113223311155,5.26467310673434,0.7509,4.73516765638151,19.2469,0.454582426767107,0.298997467742844,0.458184554711766,0.309816547473727,0.155584959024263,0.148368007238039,True,0.372937468483931,0.0447603246852157,0.929766719435217,52.4646283034947
38677,1564:1053,Pancreas,PANC-03-27,SIDM01138,925346,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,1.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.552684516924224,0.0394529570143333,0.606715029775383,9.99984076311586,19.9978,0.879732389175414,0.886703421129744,0.0555354716585855,0.335322003142073,0.0809460516016901,0.254375951540383,4.93480838417901,0.5974,5.06503237893684,19.4004,0.486214470534007,0.305705557574253,0.490067251962149,0.317192370916404,0.180508912959754,0.172874881045745,True,0.372937468483931,0.0447603246852157,0.929766719435217,52.4646283034947
38678,1022:1073,Pancreas,PANC-03-27,SIDM01138,925346,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in pancreas,20.0,0.790062841150852,0.0706054411637402,0.47377984833212,8.75789112144502,16.9102,0.828417464112731,0.831044909369059,0.0953552209139979,0.374315853053295,0.171354480061809,0.202961372991486,6.03893446004213,2.5684,2.71895666140289,14.3418,0.654501855355888,0.499162373311924,0.656577702220071,0.519987489748081,0.155339482043965,0.13659021247199,True,0.372937468483931,0.0447603246852157,0.929766719435217,52.4646283034947
38678,1011:1073,Pancreas,PANC-03-27,SIDM01138,925346,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in pancreas,20.0,0.612504001138414,0.0706054411637402,0.47377984833212,8.75789112144502,16.9102,0.828417464112731,0.831044909369059,0.0669779241929584,0.290192052762175,0.0830649631987734,0.207127089563401,4.72827127766308,1.0354,4.02961984378194,15.8748,0.507409011381986,0.325377248938447,0.509018332114259,0.34159137917798,0.18203176244354,0.167426952936279,True,0.372937468483931,0.0447603246852157,0.929766719435217,52.4646283034947
38679,1083:1079,Pancreas,PANC-03-27,SIDM01138,925346,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,4.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.736808957447505,0.115729110719491,0.325634674830994,7.32101868903357,0.6246,0.686084050403249,0.747405864007129,0.0477705965143127,0.239930545270982,0.0532705777093866,0.186659967561596,3.11454058235846,0.0338,4.2064781066751,0.5908,0.505512873898979,0.308953880884626,0.550695335449244,0.316793413399705,0.196558993014353,0.233901922049539,True,0.372937468483931,0.0447603246852157,0.929766719435217,52.4646283034947
38679,1088:1079,Pancreas,PANC-03-27,SIDM01138,925346,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.664844708794527,0.115729110719491,0.325634674830994,7.32101868903357,0.6246,0.686084050403249,0.747405864007129,0.0597626488759841,0.216496490561413,0.0610839883579561,0.155412502203457,3.71641833593952,0.0513,3.60460035309405,0.5733,0.456139350698917,0.302597450534659,0.496908834007141,0.317446740979816,0.153541900164258,0.179462093027325,True,0.372937468483931,0.0447603246852157,0.929766719435217,52.4646283034947
38679,1561:1079,Pancreas,PANC-03-27,SIDM01138,925346,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.5,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.757530227671515,0.115729110719491,0.325634674830994,7.32101868903357,0.6246,0.686084050403249,0.747405864007129,0.0711812232712628,0.246678109362463,0.0929340214355552,0.153744087926908,4.46282739870395,0.0861,2.85819129032962,0.5385,0.519729406903768,0.396019357575858,0.566182534324345,0.406592322766056,0.12371004932791,0.159590211558289,True,0.372937468483931,0.0447603246852157,0.929766719435217,52.4646283034947
38679,1022:1079,Pancreas,PANC-03-27,SIDM01138,925346,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.383354685876445,0.115729110719491,0.325634674830994,7.32101868903357,0.6246,0.686084050403249,0.747405864007129,0.066256328781336,0.124833578480314,0.0409972265617276,0.0838363519185865,4.10520898802055,0.0672,3.21580970101302,0.5574,0.263013535627176,0.16865612358667,0.286521540218666,0.194882237789897,0.0943574120405062,0.0916393024287686,True,0.372937468483931,0.0447603246852157,0.929766719435217,52.4646283034947
38679,1179:1079,Pancreas,PANC-03-27,SIDM01138,925346,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.167028238912822,0.115729110719491,0.325634674830994,7.32101868903357,0.6246,0.686084050403249,0.747405864007129,0.0385517208826074,0.0543901862659704,0.0729451190642325,-0.0185549327982621,8.41311133190917,1.3316,-1.0920926428756,-0.707,0.11459541068503,0.11840553738718,0.124837885218227,0.135759543336709,-0.0038101267021499,-0.0109216581184826,True,0.372937468483931,0.0447603246852157,0.929766719435217,52.4646283034947
38679,1011:1080,Pancreas,PANC-03-27,SIDM01138,925346,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.1,0.743718055397196,0.0683633798362898,0.361522257760017,7.68825794688467,0.0403,0.768169633773786,0.770619974581729,0.0866688843034788,0.268870630524084,0.0807335553653945,0.188137075158689,4.14384804617139,0.0035,3.54440990071328,0.0368,0.571301626245417,0.381260271441303,0.57312398894616,0.380359603193495,0.190041354804114,0.192764385752665,True,0.372937468483931,0.0447603246852157,0.929766719435217,52.4646283034947
38680,1011:1083,Pancreas,PANC-03-27,SIDM01138,925346,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.644493075887244,0.0903479031192118,0.598395844976971,9.9197215919708,15.134,0.924967747197989,0.88358775082042,0.0963195630373791,0.385661978727355,0.165212540096252,0.220449438631103,6.54366100390767,1.4577,3.37606058806313,13.6763,0.596135308488126,0.473627508633572,0.569466187342544,0.447699630300187,0.122507799854554,0.121766557042357,True,0.372937468483931,0.0447603246852157,0.929766719435217,52.4646283034947
38680,1079:1083,Pancreas,PANC-03-27,SIDM01138,925346,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.591880764502083,0.0903479031192118,0.598395844976971,9.9197215919708,15.134,0.924967747197989,0.88358775082042,0.0663096252834417,0.35417899019984,0.160434115572042,0.193744874627798,6.71846247145907,1.6454,3.20125912051173,13.4886,0.547470617351315,0.403841822010546,0.522978593460266,0.418405601126855,0.143628795340769,0.104572992333412,True,0.372937468483931,0.0447603246852157,0.929766719435217,52.4646283034947
38681,1011:1088,Pancreas,PANC-03-27,SIDM01138,925346,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,0.667631054116915,0.0409203855919437,0.755572090903639,11.6027927885725,30.3731,0.941841141110827,0.936333374769803,0.0515120670078836,0.504443391511318,0.290173550991168,0.21426984052015,8.39349040574792,3.2839,3.20930238282458,27.0892,0.6288023938505,0.515629673481137,0.625125238002412,0.541929089459847,0.113172720369363,0.0831961485425647,True,0.372937468483931,0.0447603246852157,0.929766719435217,52.4646283034947
38681,1022:1088,Pancreas,PANC-03-27,SIDM01138,925346,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,0.389856814285947,0.0409203855919437,0.755572090903639,11.6027927885725,30.3731,0.941841141110827,0.936333374769803,0.0385834470781702,0.294564928323065,0.21970497575842,0.0748599525646452,9.58947897363519,7.5235,2.01331381493732,22.8496,0.367183186836908,0.306735566110298,0.365035946597365,0.339199192167469,0.0604476207266098,0.0258367544298966,True,0.372937468483931,0.0447603246852157,0.929766719435217,52.4646283034947
38681,1079:1088,Pancreas,PANC-03-27,SIDM01138,925346,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.5,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,0.584674201232347,0.0409203855919437,0.755572090903639,11.6027927885725,30.3731,0.941841141110827,0.936333374769803,0.0705441039603519,0.441763508722539,0.265865951779998,0.175897556942542,8.58118038755822,3.7402,3.02161240101428,26.6329,0.550670216866735,0.470413495920738,0.547449967980722,0.480508968364728,0.0802567209459967,0.0669409996159941,True,0.372937468483931,0.0447603246852157,0.929766719435217,52.4646283034947
38682,1083:1168,Pancreas,PANC-03-27,SIDM01138,925346,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,1.0,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.954334753004223,0.0544490838816602,0.589313617896805,9.83287318193954,17.8123,0.865160748700882,0.880137550246204,0.0945323241324613,0.562402465977573,0.395509327180011,0.166893138797562,8.20279587297114,5.7546,1.6300773089684,12.0577,0.825652969420405,0.715521882645056,0.839945851623953,0.764496350720359,0.110131086775349,0.0754495009035938,True,0.372937468483931,0.0447603246852157,0.929766719435217,52.4646283034947
38683,1011:1190,Pancreas,PANC-03-27,SIDM01138,925346,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.2,0.6384205887794,0.0945907533339091,0.328659441349112,7.35271056533514,0.0638,0.772274452687939,0.749455180438787,0.0573922559787097,0.209822954054009,0.0748303181865944,0.134992635867414,4.34332721426935,0.0079,3.00938335106579,0.0559,0.493035910784323,0.333816374960013,0.478467617559501,0.336616632932936,0.15921953582431,0.141850984626565,True,0.372937468483931,0.0447603246852157,0.929766719435217,52.4646283034947
38683,1011:1372,Pancreas,PANC-03-27,SIDM01138,925346,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.6384205887794,0.128709020963077,0.376782335089557,7.83940177684449,0.4473,0.709666131456768,0.779824382092013,0.0416930986962657,0.240545600209552,0.0285371826339481,0.212008417575604,1.93795252989524,0.0075,5.90144924694925,0.4398,0.453065469481429,0.191657946299705,0.497855941159715,0.217149897650533,0.261407523181724,0.280706043509182,True,0.372937468483931,0.0447603246852157,0.929766719435217,52.4646283034947
38683,1053:1372,Pancreas,PANC-03-27,SIDM01138,925346,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.783139180974925,0.128709020963077,0.376782335089557,7.83940177684449,0.4473,0.709666131456768,0.779824382092013,0.0448220802547376,0.295073009307855,0.140840701958164,0.154232307349692,5.50035659796807,0.0884,2.33904517887641,0.3589,0.555767352954697,0.471403889055102,0.610711027895817,0.483732215589648,0.0843634638995951,0.126978812306169,True,0.372937468483931,0.0447603246852157,0.929766719435217,52.4646283034947
38683,1561:1372,Pancreas,PANC-03-27,SIDM01138,925346,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.748524077308677,0.128709020963077,0.376782335089557,7.83940177684449,0.4473,0.709666131456768,0.779824382092013,0.0581955211314736,0.282030649719119,0.112327572481918,0.169703077237201,5.00066195986817,0.0625,2.83873981697632,0.3848,0.531202186245896,0.429529346472051,0.583717326068233,0.433440799141184,0.101672839773845,0.150276526927049,True,0.372937468483931,0.0447603246852157,0.929766719435217,52.4646283034947
38683,1558:1372,Pancreas,PANC-03-27,SIDM01138,925346,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.526981771611,0.128709020963077,0.376782335089557,7.83940177684449,0.4473,0.709666131456768,0.779824382092013,0.0807292524982036,0.198557422457224,0.0346090144186236,0.163948408038601,2.87647618168598,0.0143,4.9629255951585,0.433,0.373981115207413,0.199336556160796,0.410953234420303,0.216782639807763,0.174644559046617,0.19417059461254,True,0.372937468483931,0.0447603246852157,0.929766719435217,52.4646283034947
38684,1011:1510,Pancreas,PANC-03-27,SIDM01138,925346,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.668167757404731,0.0730266220859258,0.835046890852019,12.7404286682537,133.6538,0.942127877190787,0.959020388338345,0.0759919017413162,0.557951408388387,0.337620773563561,0.220330634824826,9.04883484365324,10.3443,3.69159382460046,123.3095,0.629499470891048,0.494645232766867,0.640786502181447,0.564938973068098,0.134854238124181,0.0758475291133487,True,0.372937468483931,0.0447603246852157,0.929766719435217,52.4646283034947
38685,1011:1558,Pancreas,PANC-03-27,SIDM01138,925346,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.641781476319212,0.0633041708824835,0.573893135887679,9.68670964291366,16.0961,0.878358390324694,0.874158672823563,0.0681122084308541,0.368313983999456,0.142396023734935,0.225917960264521,6.10612511482335,1.3454,3.58058452809031,14.7507,0.563714144479949,0.430076545010756,0.56101884358195,0.425568943617457,0.133637599469193,0.135449899964492,True,0.372937468483931,0.0447603246852157,0.929766719435217,52.4646283034947
38685,1079:1561,Pancreas,PANC-03-27,SIDM01138,925346,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.05,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.744368063342112,0.0803198095726011,0.436976166172611,8.4154821536591,6.6687,0.775063759066195,0.812923536349956,0.0598247377502005,0.325271102540567,0.102907708638646,0.222363393901922,4.7796562596124,0.5365,3.6358258940467,6.1322,0.576932709302761,0.394260960759571,0.605114318398038,0.418141173805744,0.18267174854319,0.186973144592294,True,0.372937468483931,0.0447603246852157,0.929766719435217,52.4646283034947
38685,1564:1561,Pancreas,PANC-03-27,SIDM01138,925346,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.610640740782197,0.0803198095726011,0.436976166172611,8.4154821536591,6.6687,0.775063759066195,0.812923536349956,0.0372351178669829,0.266835449815807,0.0426725299334971,0.22416291988231,3.03010343243101,0.1595,5.38537872122808,6.5092,0.473285507989615,0.235915848021053,0.49640423043602,0.258510607958068,0.237369659968562,0.237893622477953,True,0.372937468483931,0.0447603246852157,0.929766719435217,52.4646283034947
38685,1011:1561,Pancreas,PANC-03-27,SIDM01138,925346,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.801031277893258,0.0803198095726011,0.436976166172611,8.4154821536591,6.6687,0.775063759066195,0.812923536349956,0.0436437753783361,0.350031576798143,0.174523712872537,0.175507863925606,6.05230964298937,1.2962,2.36317251066973,5.3725,0.620850313373547,0.521583631099838,0.651177179151912,0.527996748586767,0.0992666822737086,0.123180430565145,True,0.372937468483931,0.0447603246852157,0.929766719435217,52.4646283034947
38685,1372:1561,Pancreas,PANC-03-27,SIDM01138,925346,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.569304899064395,0.0803198095726011,0.436976166172611,8.4154821536591,6.6687,0.775063759066195,0.812923536349956,0.0516807581429501,0.248772672176445,0.0432669630503089,0.205505709126136,3.23888432530334,0.1844,5.17659782835576,6.4843,0.441247595123651,0.231579323024302,0.462801351808783,0.250333855982577,0.209668272099349,0.212467495826206,True,0.372937468483931,0.0447603246852157,0.929766719435217,52.4646283034947
38686,1057:1564,Pancreas,PANC-03-27,SIDM01138,925346,1057,Dactolisib,"PI3K (class 1), MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.0125,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.940289398408084,0.12326670565707,0.356075127865413,7.63365127413892,3.8787,0.710491001301292,0.7672433930183,0.116402956460672,0.33481366776865,0.364899836301936,-0.0300861685332854,7.94965188864865,4.8285,-0.316000614509734,-0.9498,0.668067156187949,0.683738958934439,0.721430828453755,0.739448273163902,-0.0156718027464905,-0.0180174447101467,True,0.372937468483931,0.0447603246852157,0.929766719435217,52.4646283034947
38686,1011:1564,Pancreas,PANC-03-27,SIDM01138,925346,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.609335344830934,0.12326670565707,0.356075127865413,7.63365127413892,3.8787,0.710491001301292,0.7672433930183,0.0680061647230234,0.21696916082359,0.0260021690738299,0.19096699174976,1.82605370109709,0.0693,5.80759757304183,3.8094,0.432927279277198,0.164650172840975,0.467508517454062,0.202255355197565,0.268277106436223,0.265253162256497,True,0.372937468483931,0.0447603246852157,0.929766719435217,52.4646283034947
38686,1558:1564,Pancreas,PANC-03-27,SIDM01138,925346,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.814806926444484,0.12326670565707,0.356075127865413,7.63365127413892,3.8787,0.710491001301292,0.7672433930183,0.128564847510759,0.290132480519343,0.220367402537124,0.06976507798222,6.71139982068154,2.0467,0.922251453457376,1.832,0.57891298903677,0.504789348256403,0.625155230900079,0.575593960994589,0.0741236407803668,0.0495612699054897,True,0.372937468483931,0.0447603246852157,0.929766719435217,52.4646283034947
38686,1561:1564,Pancreas,PANC-03-27,SIDM01138,925346,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.769532886574513,0.12326670565707,0.356075127865413,7.63365127413892,3.8787,0.710491001301292,0.7672433930183,0.0623954205913664,0.27401152098366,0.0929894063246499,0.18102211465901,4.42310983562136,0.419,3.21054143851756,3.4597,0.546746191116599,0.393146513662521,0.590419022934596,0.410613983278609,0.153599677454078,0.179805039655987,True,0.372937468483931,0.0447603246852157,0.929766719435217,52.4646283034947
38686,1053:1564,Pancreas,PANC-03-27,SIDM01138,925346,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,5.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.791361171573591,0.12326670565707,0.356075127865413,7.63365127413892,3.8787,0.710491001301292,0.7672433930183,0.0779649672802658,0.281784030355789,0.0471719611925613,0.234612069163228,2.6380646518119,0.1216,4.99558662232702,3.7571,0.562254991182284,0.289917167796729,0.60716663038106,0.310947498026491,0.272337823385555,0.296219132354568,True,0.372937468483931,0.0447603246852157,0.929766719435217,52.4646283034947
38686,1079:1594,Pancreas,PANC-03-27,SIDM01138,925346,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.05,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.745127231359131,0.061615745252942,0.626794624052528,10.1957967909247,9.1629,0.895891239424696,0.894054577677405,0.0695084973580246,0.467041742851047,0.235737393505724,0.231304349345324,7.22300229137382,1.1672,2.97279449955084,7.9957,0.667552958831425,0.503638601583581,0.666184412148722,0.552150141624481,0.163914357247844,0.114034270524241,True,0.372937468483931,0.0447603246852157,0.929766719435217,52.4646283034947
38686,1510:1594,Pancreas,PANC-03-27,SIDM01138,925346,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.835418329904486,0.061615745252942,0.626794624052528,10.1957967909247,9.1629,0.895891239424696,0.894054577677405,0.0316157415264183,0.523635718019073,0.461809900055328,0.0618258179637448,9.48881019699891,5.6131,0.70698659392575,3.5498,0.74844396301624,0.717669924458023,0.746909582126719,0.723235351198681,0.0307740385582168,0.023674230928038,True,0.372937468483931,0.0447603246852157,0.929766719435217,52.4646283034947
38632,1022:1005,Pancreas,CAPAN-1,SIDM00934,753624,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,8.0,0.946931989932405,0.0726960991135004,0.760652181751576,12.464795587755,88.3278,0.924665585454784,0.921352690347203,0.0467290609504917,0.720285884112445,0.651421569656367,0.0688643144560777,11.3686381373336,41.3163,1.09615745042146,47.0115,0.875595422856711,0.876151568101536,0.872458336500052,0.845326165935656,-0.0005561452448249,0.0271321705643955,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38632,1088:1005,Pancreas,CAPAN-1,SIDM00934,753624,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.5,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,8.0,0.934057929901498,0.0726960991135004,0.760652181751576,12.464795587755,88.3278,0.924665585454784,0.921352690347203,0.0911999269847753,0.710493202261935,0.444145654109974,0.266347548151961,8.7061161872667,6.5256,3.75867940048833,81.8022,0.863691222601053,0.68558819224497,0.860596786654885,0.736749495267729,0.178103030356083,0.123847291387156,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38632,1011:1005,Pancreas,CAPAN-1,SIDM00934,753624,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,8.0,0.751427448464495,0.0726960991135004,0.760652181751576,12.464795587755,88.3278,0.924665585454784,0.921352690347203,0.11224689880066,0.571574928102538,0.169814633466993,0.401760294635545,5.31094466173955,0.6203,7.15385092601548,87.7075,0.694819101561217,0.464865968611333,0.692329701243497,0.442402985889062,0.229953132949884,0.249926715354434,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38632,1564:1011,Pancreas,CAPAN-1,SIDM00934,753624,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.642536695727056,0.187607027658433,0.502515008213282,9.03014572819548,10.2112,0.876587814503564,0.804159170897592,0.119709365857044,0.322884332930617,0.159721110213565,0.163163222717052,5.68519072535269,1.0049,3.34495500284279,9.2063,0.563239837845722,0.424694018824831,0.516701776507148,0.394168628171041,0.138545819020891,0.122533148336107,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38632,1190:1011,Pancreas,CAPAN-1,SIDM00934,753624,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.01,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.850648626034866,0.187607027658433,0.502515008213282,9.03014572819548,10.2112,0.876587814503564,0.804159170897592,0.0767258738334043,0.427463701298528,0.268748415049336,0.158715286249192,6.68508899252825,2.0098,2.34505673566723,8.2014,0.745668220006363,0.598030273288039,0.684056893837374,0.575840691311918,0.147637946718324,0.108216202525456,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38632,1089:1011,Pancreas,CAPAN-1,SIDM00934,753624,1089,Oxaliplatin,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved in pancreas,10.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.731583212950421,0.187607027658433,0.502515008213282,9.03014572819548,10.2112,0.876587814503564,0.804159170897592,0.0741045604124163,0.36763154426448,0.163946464454669,0.203685079809811,5.27844926748331,0.7581,3.75169646071217,9.4531,0.641296929767705,0.438982597962447,0.588309349968807,0.429136587314854,0.202314331805258,0.159172762653953,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38632,1080:1011,Pancreas,CAPAN-1,SIDM00934,753624,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.480567102635513,0.187607027658433,0.502515008213282,9.03014572819548,10.2112,0.876587814503564,0.804159170897592,0.0550469731290655,0.241492181527918,0.104193856427498,0.13729832510042,5.15143592180607,0.6942,3.87870980638941,9.517,0.421259266221575,0.27123651402966,0.386452442816032,0.277817221507022,0.150022752191914,0.10863522130901,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38632,1088:1011,Pancreas,CAPAN-1,SIDM00934,753624,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.444633098111583,0.187607027658433,0.502515008213282,9.03014572819548,10.2112,0.876587814503564,0.804159170897592,0.0396647597402997,0.223434804949439,0.060556729553215,0.162878075396224,3.46457548430596,0.2156,5.56557024388952,9.9956,0.389759955729582,0.173560897109905,0.357555783531038,0.206085007311069,0.216199058619677,0.151470776219969,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38632,1372:1011,Pancreas,CAPAN-1,SIDM00934,753624,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.554584529726895,0.187607027658433,0.502515008213282,9.03014572819548,10.2112,0.876587814503564,0.804159170897592,0.0836434218159645,0.27868704951067,0.120273888063778,0.158413161446892,5.15245373059442,0.6947,3.87769199760106,9.5165,0.486142040870786,0.327311631912318,0.445974235617811,0.320644694022472,0.158830408958468,0.125329541595339,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38632,1005:1011,Pancreas,CAPAN-1,SIDM00934,753624,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,0.8,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.85386994707137,0.187607027658433,0.502515008213282,9.03014572819548,10.2112,0.876587814503564,0.804159170897592,0.105898712733503,0.429082463465644,0.225971202905087,0.203111260560558,5.9376033763278,1.1971,3.09254235186768,9.0141,0.748491990773567,0.57215840735714,0.686647348691284,0.537822763572802,0.176333583416426,0.148824585118482,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38632,1179:1011,Pancreas,CAPAN-1,SIDM00934,753624,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.2,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.890634536113423,0.187607027658433,0.502515008213282,9.03014572819548,10.2112,0.876587814503564,0.804159170897592,0.102209812021134,0.44755722123007,0.320843635148006,0.126713586082064,7.2790299786643,3.0334,1.75111574953118,7.1778,0.780719381533062,0.673516656444412,0.716211930133732,0.634484794843138,0.10720272508865,0.0817271352905936,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38632,1017:1011,Pancreas,CAPAN-1,SIDM00934,753624,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.778775004929451,0.187607027658433,0.502515008213282,9.03014572819548,10.2112,0.876587814503564,0.804159170897592,0.0829866270741678,0.391346127998422,0.167188023404461,0.224158104593961,5.11364943908126,0.6762,3.91649628911422,9.535,0.68266467956111,0.458997159423312,0.626259062279835,0.448240888189569,0.223667520137798,0.178018174090266,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38633,1011:1017,Pancreas,CAPAN-1,SIDM00934,753624,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.711568368577382,0.0851071352858071,0.755608089238775,12.3823642096912,104.2781,0.919724557216017,0.91945138221191,0.0959761456592816,0.537666815343508,0.270890576315846,0.266776239027662,7.5418777256116,3.6397,4.84048648407955,100.6384,0.654446902718756,0.554396587813923,0.654252520026748,0.517628139086584,0.100050314904834,0.136624380940164,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38633,1088:1017,Pancreas,CAPAN-1,SIDM00934,753624,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.39248047178565,0.0851071352858071,0.755608089238775,12.3823642096912,104.2781,0.919724557216017,0.91945138221191,0.0422964486864551,0.296561419349488,0.294444828341903,0.0021165910075842,12.2954964188267,98.1846,0.0868677908644653,6.09349999999999,0.36097392812899,0.335811006809493,0.360866712274498,0.360063617351035,0.0251629213194973,0.0008030949234634,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38633,1011:1022,Pancreas,CAPAN-1,SIDM00934,753624,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.711568368577382,0.087444963635567,0.741676911164317,12.1604778307161,8.9413,0.941824048044821,0.914136648774006,0.0916597007381307,0.527753829688705,0.339912007676828,0.187841822011877,8.73245864421319,0.8307,3.4280191865029,8.1106,0.6701722013542,0.57361428065972,0.650470723824915,0.562168843300947,0.0965579206944798,0.0883018805239681,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38633,1005:1022,Pancreas,CAPAN-1,SIDM00934,753624,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,0.8,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.857900806271618,0.087444963635567,0.741676911164317,12.1604778307161,8.9413,0.941824048044821,0.914136648774006,0.0576941466186022,0.63628522008091,0.501732445712147,0.134552774368763,10.0268109983274,2.0375,2.1336668323887,6.9038,0.807991610183651,0.710124167842587,0.784238568025655,0.726405144240498,0.0978674423410644,0.0578334237851571,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38633,1190:1022,Pancreas,CAPAN-1,SIDM00934,753624,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.602981611448139,0.087444963635567,0.741676911164317,12.1604778307161,8.9413,0.941824048044821,0.914136648774006,0.0928047391416606,0.447217539067738,0.356082065431712,0.0911354736360253,10.0972786860352,2.1395,2.0631991446809,6.8018,0.567902582190676,0.452407748477238,0.551207589561551,0.512207537758322,0.115494833713438,0.0390000518032294,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38634,1564:1053,Pancreas,CAPAN-1,SIDM00934,753624,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,1.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.610794417816825,0.0634680081116009,0.893430933788154,15.3715090348196,827.9714,0.960210821644233,0.967500454495859,0.0384447993114913,0.545702627062678,0.306887383099486,0.238815243963192,9.02924341810179,10.2048,6.34226561671782,817.7666,0.586491409787605,0.464945238581073,0.590943876841312,0.491150386199207,0.121546171206532,0.0997934906421049,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38634,1372:1053,Pancreas,CAPAN-1,SIDM00934,753624,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.527476267689419,0.0634680081116009,0.893430933788154,15.3715090348196,827.9714,0.960210821644233,0.967500454495859,0.0644340261649837,0.471263614392848,0.265724317572992,0.205539296819856,9.04513437305225,10.3178,6.32637466176735,817.6536,0.506488420395891,0.369223624851871,0.510333528725293,0.424540897863962,0.137264795544019,0.0857926308613302,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38634,1558:1053,Pancreas,CAPAN-1,SIDM00934,753624,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.85915993216429,0.0634680081116009,0.893430933788154,15.3715090348196,827.9714,0.960210821644233,0.967500454495859,0.0816622559472973,0.767600060466909,0.741232823495622,0.026367236971287,14.5084173224173,455.1964,0.863091712402253,372.775,0.824974664387277,0.758291108271663,0.831237624853583,0.822601107801469,0.0666835561156142,0.0086365170521135,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38635,1011:1073,Pancreas,CAPAN-1,SIDM00934,753624,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in pancreas,20.0,0.76110282228851,0.0670580780722255,0.895771649714397,15.4459004145416,1743.5699,0.956392640468487,0.968253485474716,0.111235517354439,0.681774330723662,0.403898250846953,0.27787607987671,9.36814019508452,25.8138,6.07776021945703,1717.7561,0.727913137876525,0.554581391866949,0.736940460485493,0.623654822543237,0.173331746009576,0.113285637942256,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38636,1179:1079,Pancreas,CAPAN-1,SIDM00934,753624,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.514062054055503,0.0832549852832895,0.870741889767799,14.7160376571995,105.1305,0.940140207148595,0.96010138896238,0.0512099525587056,0.447615364406206,0.421001267818844,0.026614096587362,13.5229538582383,45.9806,1.19308379896115,59.1499,0.483290405986973,0.474121534954061,0.493551692111543,0.484504017349877,0.0091688710329122,0.0090476747616665,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38636,1564:1079,Pancreas,CAPAN-1,SIDM00934,753624,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,1.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.637164141615962,0.0832549852832895,0.870741889767799,14.7160376571995,105.1305,0.940140207148595,0.96010138896238,0.0663370806639555,0.55480550876296,0.320449010964728,0.234356497798232,9.03512099011393,2.0493,5.68091666708554,103.0812,0.599023628086487,0.48040689940008,0.611742177362508,0.512528262505835,0.118616728686407,0.0992139148566732,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38636,1372:1079,Pancreas,CAPAN-1,SIDM00934,753624,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.607672250492992,0.0832549852832895,0.870741889767799,14.7160376571995,105.1305,0.940140207148595,0.96010138896238,0.0514964357934813,0.529125683753719,0.342567194152874,0.186558489600845,9.76814264171785,3.4062,4.94789501548162,101.7243,0.571297115456935,0.474579342183329,0.583426971732217,0.508242916402376,0.096717773273606,0.0751840553298408,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38636,1088:1079,Pancreas,CAPAN-1,SIDM00934,753624,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.435081454380902,0.0832549852832895,0.870741889767799,14.7160376571995,105.1305,0.940140207148595,0.96010138896238,0.0843253053608691,0.378843647790549,0.308345426169242,0.0704982216213068,11.6642826362042,12.6782,3.05175502099524,92.4523,0.409037568648173,0.328973879380927,0.417722308662876,0.392082373778927,0.0800636892672464,0.0256399348839497,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38636,1011:1080,Pancreas,CAPAN-1,SIDM00934,753624,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.1,0.740142945662325,0.0960691540645348,0.39814380222622,7.7618062978485,0.0424,0.769989341191093,0.739714582314223,0.15748679700451,0.294683326576913,0.124050664108415,0.170632662468498,4.19739610433541,0.0036,3.56441019351309,0.0388,0.569902179117768,0.37392700824459,0.547494529903425,0.380044953117433,0.195975170873178,0.167449576785992,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38637,1168:1083,Pancreas,CAPAN-1,SIDM00934,753624,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.740975612366829,0.0831189292901549,0.726009303451525,11.9200521086484,60.5499,0.918812896016056,0.908044640220795,0.0870022114502321,0.537955188209009,0.355121533577176,0.182833654631832,8.75128811213666,6.7332,3.16876399651172,53.8167,0.680817948276037,0.612985831482831,0.672838933344021,0.586077407337506,0.0678321167932062,0.0867615260065148,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38637,1011:1083,Pancreas,CAPAN-1,SIDM00934,753624,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.704055483265676,0.0831189292901549,0.726009303451525,11.9200521086484,60.5499,0.918812896016056,0.908044640220795,0.136057093905004,0.51115083099694,0.299645586045012,0.211505244951928,8.1015462567045,4.2917,3.81850585194388,56.2582,0.64689525753532,0.581612698789735,0.639313807997459,0.533712946787017,0.0652825587455843,0.105600861210442,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38637,1558:1083,Pancreas,CAPAN-1,SIDM00934,753624,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.852267272617629,0.0831189292901549,0.726009303451525,11.9200521086484,60.5499,0.918812896016056,0.908044640220795,0.058696465965685,0.618753968947656,0.50758238192617,0.111171587021486,10.159753088238,17.8735,1.76029902041039,42.6764,0.78307416093351,0.749045835518307,0.773896728936034,0.726005263613633,0.0340283254152027,0.047891465322401,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38637,1011:1085,Pancreas,CAPAN-1,SIDM00934,753624,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.704055483265676,0.101174391241438,0.632192414018002,10.623037394786,30.8023,0.915378425446314,0.868721800386077,0.127502588624361,0.445098535568339,0.271155710271314,0.173942825297025,7.59817112541065,3.7845,3.02486626937534,27.0178,0.644477199698578,0.562583816158179,0.611628346994247,0.514393963484227,0.0818933835403984,0.0972343835100205,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38638,1011:1088,Pancreas,CAPAN-1,SIDM00934,753624,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,0.728765461973245,0.0913503348514007,0.596690635578658,10.1737364441016,11.2798,0.881709895634846,0.852383499783097,0.160708332809426,0.43484752669259,0.189745483153106,0.245102043539484,5.87138640047479,0.5717,4.30235004362682,10.7081,0.642559719418711,0.495437816962368,0.6211876549978,0.455902991154311,0.147121902456343,0.165284663843489,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38638,1372:1089,Pancreas,CAPAN-1,SIDM00934,753624,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,1089,Oxaliplatin,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved in pancreas,10.0,0.629207186587294,0.0733583239368062,0.797062842062814,13.0994029707604,171.4128,0.945439398883561,0.934730667867364,0.0309929629458747,0.501517668387616,0.35991467859343,0.141602989794186,9.86920810254952,18.2666,3.2301948682109,153.1462,0.594877264260308,0.509961578595976,0.588139253745687,0.528834704963788,0.0849156856643327,0.0593045487818986,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38638,1011:1089,Pancreas,CAPAN-1,SIDM00934,753624,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1089,Oxaliplatin,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved in pancreas,10.0,0.728765461973245,0.0733583239368062,0.797062842062814,13.0994029707604,171.4128,0.945439398883561,0.934730667867364,0.0818873136334579,0.580871870317614,0.277043393025846,0.303828477291768,7.53500381631971,3.6224,5.56439915444071,167.7904,0.689003580295086,0.560047482062383,0.68119942698892,0.529855143124486,0.128956098232703,0.151344283864433,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38639,1083:1168,Pancreas,CAPAN-1,SIDM00934,753624,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,1.0,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.935835812385847,0.0703024360615016,0.732626385577255,12.0204973478673,81.1447,0.887925581463808,0.910632672240781,0.0778704755329602,0.685618008721997,0.497751369281453,0.187866639440544,9.38262754900448,13.0371,2.63786979886282,68.1076,0.830952557867358,0.719588133584266,0.852202666611546,0.767426949233721,0.111364424283092,0.084775717377825,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38639,1372:1168,Pancreas,CAPAN-1,SIDM00934,753624,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.566151355363584,0.0703024360615016,0.732626385577255,12.0204973478673,81.1447,0.887925581463808,0.910632672240781,0.0260094704459461,0.414777421169686,0.26367892485658,0.151098496313106,8.58869851852893,7.5194,3.43179882933837,73.6253,0.502700271407733,0.440835103935548,0.51555592162748,0.443295145702729,0.0618651674721843,0.0722607759247513,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38639,1011:1168,Pancreas,CAPAN-1,SIDM00934,753624,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.752998447736595,0.0703024360615016,0.732626385577255,12.0204973478673,81.1447,0.887925581463808,0.910632672240781,0.0380570707215884,0.551666531110545,0.370986520499242,0.180680010611303,8.9122424902836,9.4098,3.10825485758369,71.7349,0.668606584547861,0.598046567273913,0.685704988655536,0.601377762394011,0.0705600172739478,0.0843272262615242,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38639,1088:1168,Pancreas,CAPAN-1,SIDM00934,753624,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.529876276868076,0.0703024360615016,0.732626385577255,12.0204973478673,81.1447,0.887925581463808,0.910632672240781,0.0631575220380902,0.388201341524991,0.24516046975773,0.143040871767261,8.55177919921698,7.3295,3.46871814865031,73.8152,0.470490701241964,0.38974990997689,0.482522649961372,0.413920773212462,0.0807407912650742,0.0686018767489103,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38639,1011:1179,Pancreas,CAPAN-1,SIDM00934,753624,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,4.0,0.752998447736595,0.0798536899757285,0.493996198091575,8.92803357370228,3.8054,0.83556695577796,0.799388563735341,0.10158072497692,0.371978370350736,0.177361951730594,0.194616418620141,5.47220054787509,0.3468,3.45583302582719,3.4586,0.629180620680796,0.465791140415612,0.601938347631098,0.45138225082321,0.163389480265184,0.150556096807887,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38640,1011:1190,Pancreas,CAPAN-1,SIDM00934,753624,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.2,0.774593416601452,0.0770779533739725,0.607562544289447,10.3097295081894,0.4958,0.863254044631127,0.857482159082694,0.144994057307302,0.470613946980234,0.158517986416916,0.312095960563318,4.93216822063451,0.0119,5.37756128755492,0.4839,0.668670899825847,0.454815563116478,0.664200035278654,0.436384822681859,0.213855336709369,0.227815212596795,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38640,1022:1190,Pancreas,CAPAN-1,SIDM00934,753624,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.2,0.94097932537952,0.0770779533739725,0.607562544289447,10.3097295081894,0.4958,0.863254044631127,0.857482159082694,0.117959124057781,0.571703793051348,0.316008937342624,0.255694855708724,6.95654575792391,0.0485,3.35318375026552,0.4473,0.81230420854814,0.624245642651473,0.806872983578608,0.652459864070925,0.188058565896666,0.154413119507682,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38640,1011:1372,Pancreas,CAPAN-1,SIDM00934,753624,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.774593416601452,0.0887657411132094,0.486890431405612,8.84282963700319,0.8968,0.754967384008596,0.795350340448877,0.0810212215931758,0.377142122773028,0.107450955730918,0.269691167042111,3.52837734779943,0.0225,5.31445228920376,0.8743,0.584792765401879,0.348777717103034,0.616073137603424,0.362381394049238,0.236015048298845,0.253691743554186,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38640,1168:1372,Pancreas,CAPAN-1,SIDM00934,753624,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,2.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.801799637242862,0.0887657411132094,0.486890431405612,8.84282963700319,0.8968,0.754967384008596,0.795350340448877,0.0642843460413231,0.39038857127804,0.281748693890969,0.108639877387071,7.16337574434274,0.28,1.67945389266045,0.6168,0.605332574628284,0.528845974456401,0.637711614452896,0.565786077457352,0.0764866001718835,0.0719255369955437,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38640,1017:1372,Pancreas,CAPAN-1,SIDM00934,753624,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.851657942202096,0.0887657411132094,0.486890431405612,8.84282963700319,0.8968,0.754967384008596,0.795350340448877,0.147025804030915,0.414664102888795,0.212243393108317,0.202420709780478,5.69533780023508,0.1012,3.14749183676811,0.7956,0.642973968694461,0.455928401115687,0.677366434276427,0.523020909252198,0.187045567578774,0.15434552502423,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38640,1561:1372,Pancreas,CAPAN-1,SIDM00934,753624,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.866819532014261,0.0887657411132094,0.486890431405612,8.84282963700319,0.8968,0.754967384008596,0.795350340448877,0.0398798091331745,0.422046135893235,0.208929717837138,0.213116418056097,5.56282924532842,0.0923,3.28000039167477,0.8045,0.654420474492362,0.50353138075148,0.689425209895279,0.524794422069782,0.150889093740882,0.164630787825496,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38640,1558:1372,Pancreas,CAPAN-1,SIDM00934,753624,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.779123833465017,0.0887657411132094,0.486890431405612,8.84282963700319,0.8968,0.754967384008596,0.795350340448877,0.0627761595972461,0.379347939394177,0.200175805088989,0.179172134305188,5.81760512745795,0.1102,3.02522450954524,0.7866,0.588213082369833,0.464846522758371,0.619676406198235,0.484687232376788,0.123366559611462,0.134989173821448,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38642,1564:1558,Pancreas,CAPAN-1,SIDM00934,753624,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,1.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.687885186919842,0.0776742113585329,0.80830878797796,13.3122220778564,198.659,0.936373764816791,0.938744761112035,0.051323481548974,0.55602364170717,0.388675392289542,0.167348249417629,9.7838982666108,17.2178,3.52832381124564,181.4412,0.644117642237835,0.53657567165294,0.645748615467575,0.575774337534949,0.107541970584894,0.0699742779326261,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38642,1011:1558,Pancreas,CAPAN-1,SIDM00934,753624,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.752370744714066,0.0776742113585329,0.80830878797796,13.3122220778564,198.659,0.936373764816791,0.938744761112035,0.0903232200166627,0.608147884769902,0.348898235249963,0.259249649519939,8.5645159947616,7.3945,4.74770608309484,191.2645,0.704500226765922,0.628759162859028,0.70628409501429,0.588202148659244,0.0757410639068939,0.118081946355046,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38642,1088:1558,Pancreas,CAPAN-1,SIDM00934,753624,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.500942107454053,0.0776742113585329,0.80830878797796,13.3122220778564,198.659,0.936373764816791,0.938744761112035,0.0869661695644192,0.404915907723311,0.24112580205312,0.16379010567019,8.77628875280362,8.5636,4.53593332505282,190.0954,0.469069047112009,0.337026440716936,0.470256778992914,0.396826504178762,0.132042606395073,0.0734302748141522,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38642,1372:1561,Pancreas,CAPAN-1,SIDM00934,753624,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.553182891098224,0.0974237916749433,0.716294973591467,11.7752833465505,68.461,0.881721512172544,0.90420427330972,0.0751105932277593,0.396242124370454,0.160785693466906,0.235456430903549,6.3264641674168,1.5674,5.44881917913372,66.8936,0.487753255247106,0.313389234323523,0.50019033405284,0.362148710539592,0.174364020923584,0.138041623513248,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38642,1011:1561,Pancreas,CAPAN-1,SIDM00934,753624,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.752370744714066,0.0974237916749433,0.716294973591467,11.7752833465505,68.461,0.881721512172544,0.90420427330972,0.0470552956434552,0.538919382715954,0.234866769986201,0.304052612729753,6.63272265079951,1.9381,5.142560695751,66.5229,0.663381470743669,0.478156753958778,0.680296842483675,0.506893387080482,0.185224716784891,0.173403455403193,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38642,1005:1561,Pancreas,CAPAN-1,SIDM00934,753624,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,0.8,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.802855987655414,0.0974237916749433,0.716294973591467,11.7752833465505,68.461,0.881721512172544,0.90420427330972,0.0927384803553919,0.575081708475386,0.524300493393161,0.0507812150822256,10.8951662821082,37.1965,0.880117064442354,31.2645,0.707895395492313,0.630628398050265,0.725945814890322,0.704842156635997,0.0772669974420481,0.021103658254325,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38642,1564:1561,Pancreas,CAPAN-1,SIDM00934,753624,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.639747185029622,0.0974237916749433,0.716294973591467,11.7752833465505,68.461,0.881721512172544,0.90420427330972,0.0742563889665499,0.458247693006009,0.159560872992353,0.298686820013656,5.69854595568535,1.0143,6.07673739086517,67.4467,0.564078855392447,0.345673334443305,0.578462138541649,0.393016325309315,0.218405520949142,0.185445813232334,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
38642,1089:1561,Pancreas,CAPAN-1,SIDM00934,753624,1089,Oxaliplatin,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved in pancreas,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.970243700904966,0.0974237916749433,0.716294973591467,11.7752833465505,68.461,0.881721512172544,0.90420427330972,0.138467443840439,0.69498068611701,0.447719268855573,0.247261417261437,8.53701576022649,7.2548,3.23826758632402,61.2062,0.855484743137812,0.657267138937808,0.877298500510108,0.7572067286698,0.198217604200004,0.120091771840308,True,0.305274045335564,0.0389814915922333,1.13207434836762,43.4340624718065
39368,1011:1564,Pancreas,CAPAN-1,SIDM00934,753624,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.767198858251203,0.107415676210893,0.352237943741631,7.17444727636459,2.8213,0.656908291322689,0.706294817894837,0.065930335046026,0.270236548271331,0.0813832470116052,0.188853301259726,2.61301789818355,0.1195,4.56142937818104,2.7018,0.503979291078515,0.287480998106878,0.54186857787766,0.311634086534667,0.216498292971637,0.230234491342993,True,0.612725676459437,0.0659993247272664,0.448566718225788,105.275715718148
38056,1053:1005,Pancreas,CFPAC-1,SIDM00130,906821,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,8.0,0.792250557077902,0.0748034097088562,0.793806896182218,12.0423853786412,65.9082,0.956025908353289,0.94858121058252,0.084706111006692,0.628893955712643,0.566410970499968,0.062482985212675,11.0752238681924,33.7128,0.967161510448776,32.1954,0.7574120584738,0.766106528633707,0.751513992517632,0.733098066475897,-0.0086944701599064,0.0184159260417343,True,0.314267536765588,0.0658033702660865,1.08440509005812,45.043648930332
38056,1011:1005,Pancreas,CFPAC-1,SIDM00130,906821,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,8.0,0.794358902419897,0.0748034097088562,0.793806896182218,12.0423853786412,65.9082,0.956025908353289,0.94858121058252,0.0713605616946389,0.630567574784652,0.319216773276878,0.311350801507774,8.10232575428621,4.294,3.94005962435496,61.6142,0.759427691244503,0.646155879964056,0.753513929294467,0.63406438008983,0.113271811280447,0.119449549204637,True,0.314267536765588,0.0658033702660865,1.08440509005812,45.043648930332
38056,1089:1005,Pancreas,CFPAC-1,SIDM00130,906821,1089,Oxaliplatin,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved in pancreas,10.0,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,8.0,0.70768733794638,0.0748034097088562,0.793806896182218,12.0423853786412,65.9082,0.956025908353289,0.94858121058252,0.125584788409493,0.561767089202672,0.420932894677621,0.140834194525051,9.86631124199664,14.584,2.17607413664453,51.3242,0.676567430090308,0.56416418670562,0.671298911743097,0.625998689239495,0.112403243384688,0.045300222503602,True,0.314267536765588,0.0658033702660865,1.08440509005812,45.043648930332
38056,1017:1005,Pancreas,CFPAC-1,SIDM00130,906821,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,8.0,0.892478891341139,0.0748034097088562,0.793806896182218,12.0423853786412,65.9082,0.956025908353289,0.94858121058252,0.0385996614223158,0.708455898643656,0.447345968422215,0.261109930221441,9.01119280346997,8.0623,3.0311925751712,57.8459,0.853232942780548,0.736360288394056,0.846588707167722,0.755732528258137,0.116872654386492,0.0908561789095849,True,0.314267536765588,0.0658033702660865,1.08440509005812,45.043648930332
38056,1080:1011,Pancreas,CFPAC-1,SIDM00130,906821,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.742141851980848,0.164998039717901,0.451976678191296,8.56512082755844,7.3976,0.855480416740917,0.824007094930823,0.120225171721395,0.33543080900504,0.0778245333531663,0.257606275651874,4.16048548851266,0.3493,4.40463533904578,7.0483,0.634887820813452,0.373963034277929,0.61153015147732,0.380636443021556,0.260924786535523,0.230893708455764,True,0.314267536765588,0.0658033702660865,1.08440509005812,45.043648930332
38056,1088:1011,Pancreas,CFPAC-1,SIDM00130,906821,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.373662076173411,0.164998039717901,0.451976678191296,8.56512082755844,7.3976,0.855480416740917,0.824007094930823,0.063809057660499,0.168886543954921,0.0310344859384939,0.137852058016427,3.57991191094512,0.2336,4.98520891661332,7.164,0.319660588645106,0.139067691617225,0.307900201873472,0.174235258880057,0.180592897027881,0.133664942993415,True,0.314267536765588,0.0658033702660865,1.08440509005812,45.043648930332
38056,1564:1011,Pancreas,CFPAC-1,SIDM00130,906821,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.696664952194706,0.164998039717901,0.451976678191296,8.56512082755844,7.3976,0.855480416740917,0.824007094930823,0.102450605351371,0.314876310905261,0.139467143727432,0.175409167177829,5.87396387885189,1.1454,2.69115694870654,6.2522,0.595983223632318,0.469818463668623,0.57405686339808,0.451067699165539,0.126164759963695,0.122989164232542,True,0.314267536765588,0.0658033702660865,1.08440509005812,45.043648930332
38056,1190:1011,Pancreas,CFPAC-1,SIDM00130,906821,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.435241053856448,0.164998039717901,0.451976678191296,8.56512082755844,7.3976,0.855480416740917,0.824007094930823,0.0329118924825318,0.196718805734516,0.0551998474094764,0.14151895832504,4.6456858910608,0.4889,3.91943493649764,6.9087,0.37234019813587,0.211568007412487,0.358641716382882,0.240139568079395,0.160772190723382,0.118502148303486,True,0.314267536765588,0.0658033702660865,1.08440509005812,45.043648930332
38056,1558:1011,Pancreas,CFPAC-1,SIDM00130,906821,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.575123759059799,0.164998039717901,0.451976678191296,8.56512082755844,7.3976,0.855480416740917,0.824007094930823,0.0662465072019786,0.259942526168739,0.0413590182130068,0.218583507955733,3.2275628964333,0.1829,5.33755793112514,7.2147,0.492007113078079,0.233265939720973,0.47390605792856,0.25200128248603,0.258741173357107,0.221904775442529,True,0.314267536765588,0.0658033702660865,1.08440509005812,45.043648930332
38057,1372:1017,Pancreas,CFPAC-1,SIDM00130,906821,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.715800379262968,0.0622623529645747,0.799730174543372,12.1249472495729,87.2374,0.942522986648621,0.950234045963596,0.0342092554462808,0.572447162246185,0.54622528766724,0.0262218745789454,11.6399963780401,62.333,0.484950871532813,24.9044,0.674658311307148,0.655094049235935,0.680177890489326,0.672718034154934,0.0195642620712124,0.007459856334392,True,0.314267536765588,0.0658033702660865,1.08440509005812,45.043648930332
38057,1073:1022,Pancreas,CFPAC-1,SIDM00130,906821,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in pancreas,10.0,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.842795591750506,0.0741540425124675,0.563693661794988,9.57814619498194,1.4929,0.883217531645935,0.872693596770627,0.0855912688270927,0.475078533258516,0.314150185259591,0.160928347998925,7.82539489090146,0.443,1.75275130408048,1.0499,0.744371842227957,0.639901755981241,0.735502316307177,0.658857122504794,0.104470086246716,0.0766451938023835,True,0.314267536765588,0.0658033702660865,1.08440509005812,45.043648930332
38057,1179:1022,Pancreas,CFPAC-1,SIDM00130,906821,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.2,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.978196605638439,0.0741540425124675,0.563693661794988,9.57814619498194,1.4929,0.883217531645935,0.872693596770627,0.0855412751059175,0.551403226587759,0.274526432161167,0.276876794426593,6.87564928347927,0.2294,2.70249691150267,1.2635,0.863960391496414,0.670249684078778,0.853665914123428,0.704307135328217,0.193710707417636,0.149358778795211,True,0.314267536765588,0.0658033702660865,1.08440509005812,45.043648930332
38058,1054:1053,Pancreas,CFPAC-1,SIDM00130,906821,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,8.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.78551034007676,0.0923685560321681,0.667015187286268,10.5679162514855,29.6476,0.864313459755695,0.909945163006783,0.064597198075743,0.5239473266016,0.304687218487403,0.219260108114197,7.97036343350386,4.8983,2.59755281798161,24.7493,0.678927159705617,0.594543674595423,0.714771334444661,0.620914346036158,0.0843834851101936,0.0938569884085033,True,0.314267536765588,0.0658033702660865,1.08440509005812,45.043648930332
38058,1564:1053,Pancreas,CFPAC-1,SIDM00130,906821,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,1.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.768341712515516,0.0923685560321681,0.667015187286268,10.5679162514855,29.6476,0.864313459755695,0.909945163006783,0.0509415828182755,0.512495591273389,0.298915181702971,0.213580409570419,7.98133609496811,4.9357,2.58658015651736,24.7119,0.664088083818902,0.58386396466503,0.699148824839843,0.607843299472138,0.0802241191538717,0.0913055253677044,True,0.314267536765588,0.0658033702660865,1.08440509005812,45.043648930332
38058,1168:1053,Pancreas,CFPAC-1,SIDM00130,906821,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.704777667055069,0.0923685560321681,0.667015187286268,10.5679162514855,29.6476,0.864313459755695,0.909945163006783,0.114678330009353,0.470097407585916,0.223216605051787,0.246880802534129,7.26467809250505,3.0034,3.30323815898042,26.6442,0.609148823770914,0.456811897187211,0.641309029131965,0.525930811211994,0.152336926583703,0.115378217919971,True,0.314267536765588,0.0658033702660865,1.08440509005812,45.043648930332
38058,1372:1053,Pancreas,CFPAC-1,SIDM00130,906821,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.700828671539752,0.0923685560321681,0.667015187286268,10.5679162514855,29.6476,0.864313459755695,0.909945163006783,0.0920586023131914,0.467463367602674,0.215421396336845,0.25204197126583,7.1664982002766,2.8058,3.40141805120887,26.8418,0.605735653794511,0.452147542190176,0.637715659764067,0.51842623868498,0.153588111604335,0.119289421079087,True,0.314267536765588,0.0658033702660865,1.08440509005812,45.043648930332
38058,1558:1053,Pancreas,CFPAC-1,SIDM00130,906821,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.867547674671505,0.0923685560321681,0.667015187286268,10.5679162514855,29.6476,0.864313459755695,0.909945163006783,0.0576329125134334,0.578667474700781,0.418530827835577,0.160136646865204,8.84131648127202,8.9584,1.72659977021346,20.6892,0.749833132198337,0.703262477599326,0.789420810245119,0.727311251303921,0.046570654599011,0.062109558941198,True,0.314267536765588,0.0658033702660865,1.08440509005812,45.043648930332
38058,1594:1053,Pancreas,CFPAC-1,SIDM00130,906821,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.493897083012536,0.0923685560321681,0.667015187286268,10.5679162514855,29.6476,0.864313459755695,0.909945163006783,0.0931442429121092,0.329436855325748,0.176587441127858,0.152849414197891,7.67730685938677,3.9979,2.8906093920987,25.6497,0.426881896581811,0.326837678616174,0.449419261710417,0.381609863907537,0.100044217965637,0.0678093978028799,True,0.314267536765588,0.0658033702660865,1.08440509005812,45.043648930332
36149,1022:1073,Pancreas,CFPAC-1,SIDM00130,906821,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in pancreas,20.0,0.932203486393228,0.0894285352695987,0.588618370032075,9.80855571065483,35.0291,0.847343298466277,0.882258544691479,0.127024505293458,0.548712096699,0.236896681017638,0.311815415681362,6.56991172571979,3.7111,3.23864398493504,31.318,0.789896377002201,0.612192221976943,0.822444491261613,0.651209469550081,0.177704155025258,0.171235021711532,True,0.153819654442303,0.0254477514493984,1.81327092325405,27.3831716055986
36149,1011:1073,Pancreas,CFPAC-1,SIDM00130,906821,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in pancreas,20.0,0.770291737611191,0.0894285352695987,0.588618370032075,9.80855571065483,35.0291,0.847343298466277,0.882258544691479,0.0658542377085756,0.453407867041875,0.152225008401094,0.301182858640781,5.83752500725264,2.2337,3.97103070340219,32.7954,0.652701541728787,0.494996035582766,0.67959646741272,0.4966184903295,0.157705506146021,0.182977977083221,True,0.153819654442303,0.0254477514493984,1.81327092325405,27.3831716055986
36149,1179:1073,Pancreas,CFPAC-1,SIDM00130,906821,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.2,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in pancreas,20.0,0.895987842592097,0.0894285352695987,0.588618370032075,9.80855571065483,35.0291,0.847343298466277,0.882258544691479,0.122811402986741,0.527394903475116,0.229418131033516,0.297976772441599,6.59277565981256,3.7704,3.21578005084227,31.2587,0.759209293927671,0.571794063872024,0.790492930066562,0.627367492693704,0.187415230055647,0.163125437372858,True,0.153819654442303,0.0254477514493984,1.81327092325405,27.3831716055986
36150,1510:1079,Pancreas,CFPAC-1,SIDM00130,906821,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.813813879121223,0.119816714247916,0.759812940362298,11.5991881092327,12.1189,0.851740570830004,0.938854059236039,0.124431874014752,0.618346316402744,0.407585894595589,0.210760421807155,9.00753168099696,2.0105,2.59165642823575,10.1084,0.69315829795209,0.609319855397243,0.764052463875588,0.688975461358686,0.0838384425548477,0.0750770025169013,True,0.153819654442303,0.0254477514493984,1.81327092325405,27.3831716055986
36150,1053:1079,Pancreas,CFPAC-1,SIDM00130,906821,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.819183990365352,0.119816714247916,0.759812940362298,11.5991881092327,12.1189,0.851740570830004,0.938854059236039,0.123737431791652,0.622426596417218,0.566403069414522,0.0560235270026962,10.8208418143813,7.0657,0.778346294851382,5.0532,0.697732239568586,0.671762246123871,0.769094214615687,0.751941319093019,0.025969993444715,0.0171528955226683,True,0.153819654442303,0.0254477514493984,1.81327092325405,27.3831716055986
36150,1179:1079,Pancreas,CFPAC-1,SIDM00130,906821,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.509111641590539,0.119816714247916,0.759812940362298,11.5991881092327,12.1189,0.851740570830004,0.938854059236039,0.0801472928315482,0.386829613369584,0.241357060174585,0.145472553194999,8.76574689120192,1.7002,2.83344121803079,10.4187,0.433631040224526,0.377228211082798,0.477981531311602,0.424857291052843,0.0564028291417281,0.0531242402587586,True,0.153819654442303,0.0254477514493984,1.81327092325405,27.3831716055986
36150,1564:1079,Pancreas,CFPAC-1,SIDM00130,906821,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,1.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.707461920465663,0.119816714247916,0.759812940362298,11.5991881092327,12.1189,0.851740570830004,0.938854059236039,0.0811878194586778,0.537538721983373,0.148241810188219,0.389296911795154,6.00349490450882,0.2506,5.59569320472389,11.8683,0.602574019977915,0.441309767313746,0.664203495784112,0.464940234159508,0.161264252664169,0.199263261624604,True,0.153819654442303,0.0254477514493984,1.81327092325405,27.3831716055986
36150,1057:1079,Pancreas,CFPAC-1,SIDM00130,906821,1057,Dactolisib,"PI3K (class 1), MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.0125,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.820378043040124,0.119816714247916,0.759812940362298,11.5991881092327,12.1189,0.851740570830004,0.938854059236039,0.0922865398976645,0.623333853090984,0.331309081312219,0.292024771778764,8.12103961635576,1.0875,3.47814849287695,11.0314,0.698749262675396,0.593895633083997,0.770215255816338,0.655723237535776,0.104853629591399,0.114492018280562,True,0.153819654442303,0.0254477514493984,1.81327092325405,27.3831716055986
36150,1168:1079,Pancreas,CFPAC-1,SIDM00130,906821,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.589757084022748,0.119816714247916,0.759812940362298,11.5991881092327,12.1189,0.851740570830004,0.938854059236039,0.0739475542436045,0.448105064110818,0.24133591238272,0.206769151728099,8.1712098999598,1.126,3.42797820927291,10.9929,0.502320035396574,0.415314427877963,0.553695832297966,0.473094725795591,0.0870056075186109,0.0806011065023749,True,0.153819654442303,0.0254477514493984,1.81327092325405,27.3831716055986
36150,1372:1079,Pancreas,CFPAC-1,SIDM00130,906821,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.671021433338738,0.119816714247916,0.759812940362298,11.5991881092327,12.1189,0.851740570830004,0.938854059236039,0.138274238297581,0.50985076831123,0.162345640043531,0.347505128267698,6.42241287700774,0.335,5.17677523222497,11.7839,0.571536178671104,0.385899159040432,0.629991196524459,0.461657492811726,0.185637019630672,0.168333703712733,True,0.153819654442303,0.0254477514493984,1.81327092325405,27.3831716055986
36150,1594:1079,Pancreas,CFPAC-1,SIDM00130,906821,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.513881600704941,0.119816714247916,0.759812940362298,11.5991881092327,12.1189,0.851740570830004,0.938854059236039,0.0858608820730289,0.390453890029705,0.214983835054685,0.17547005497502,8.25625835883631,1.1944,3.3429297503964,10.9245,0.437693807923462,0.345120072142347,0.482459826788547,0.414718074883601,0.0925737357811151,0.0677417519049457,True,0.153819654442303,0.0254477514493984,1.81327092325405,27.3831716055986
36150,1011:1080,Pancreas,CFPAC-1,SIDM00130,906821,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.1,0.792183396112274,0.106093801363313,0.415657102058706,8.23123239043745,0.0587,0.757549987118837,0.805612369742608,0.0601400175904609,0.329276654727052,0.0759960582853372,0.253280596441715,3.93714752264563,0.003,4.29408486779182,0.0557,0.60011852152061,0.377684576764779,0.638192743012756,0.392092353113915,0.222433944755831,0.246100389898841,True,0.153819654442303,0.0254477514493984,1.81327092325405,27.3831716055986
38551,1011:1083,Pancreas,CFPAC-1,SIDM00130,906821,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.89269739485386,0.0711175105959627,0.518341438192515,9.1656547501804,8.9734,0.856965359914849,0.854176153476385,0.129167494591272,0.462722051519261,0.230250084602791,0.232471966916471,6.61494650470204,1.5315,2.55070824547836,7.4419,0.765010744275986,0.641597715871486,0.762520826954659,0.626468236456645,0.123413028404499,0.136052590498015,True,0.464883638664183,0.0609165069772765,0.711457111782502,67.7003996980466
38551,1558:1083,Pancreas,CFPAC-1,SIDM00130,906821,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.91846309177642,0.0711175105959627,0.518341438192515,9.1656547501804,8.9734,0.856965359914849,0.854176153476385,0.0849060021140632,0.476077479918134,0.362736770952864,0.11334070896527,8.03720251251121,4.1045,1.12845223766919,4.8689,0.787091054012684,0.744300946735933,0.78452927084361,0.729632678412225,0.0427901072767514,0.0548965924313848,True,0.464883638664183,0.0609165069772765,0.711457111782502,67.7003996980466
38365,1011:1179,Pancreas,CFPAC-1,SIDM00130,906821,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,4.0,0.824221144029637,0.0843467107007972,0.388628867833155,7.97743743129852,1.969,0.811747133306991,0.790879522237275,0.0869590242187383,0.320316130048385,0.113939470622199,0.206376659426186,4.8698546969555,0.2284,3.10758273434303,1.7406,0.669059150877066,0.477219653770476,0.65185962460802,0.469446990977144,0.19183949710659,0.182412633630875,True,0.293157774847416,0.0425166141701456,1.14100021198174,42.7648364334743
38366,1011:1372,Pancreas,CFPAC-1,SIDM00130,906821,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.763453324425032,0.100262215186652,0.642696830038171,10.3250100207411,2.5053,0.839766440020478,0.901714504925522,0.0466431459055036,0.490669031490072,0.148808743949839,0.341860287540233,5.79882877371014,0.1087,4.52618124703101,2.3966,0.641122480374208,0.492350914511164,0.688416936467662,0.489972541816089,0.148771565863044,0.198444394651573,True,0.293157774847416,0.0425166141701456,1.14100021198174,42.7648364334743
38366,1053:1372,Pancreas,CFPAC-1,SIDM00130,906821,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.81225558766942,0.100262215186652,0.642696830038171,10.3250100207411,2.5053,0.839766440020478,0.901714504925522,0.0804211204910965,0.522034091375928,0.439409915789477,0.0826241755864506,9.37073957110323,1.293,0.954270449637917,1.2123,0.68210498324389,0.679021614577899,0.73242264510832,0.701469892290275,0.0030833686659903,0.0309527528180449,True,0.293157774847416,0.0425166141701456,1.14100021198174,42.7648364334743
38366,1561:1372,Pancreas,CFPAC-1,SIDM00130,906821,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.797737498113344,0.100262215186652,0.642696830038171,10.3250100207411,2.5053,0.839766440020478,0.901714504925522,0.0785347407709177,0.512703361240028,0.368590773515067,0.144112587724961,8.65669614153716,0.7882,1.66831387920399,1.7171,0.669913178861486,0.608361074480368,0.719331473171799,0.661206185063467,0.0615521043811176,0.0581252881083321,True,0.293157774847416,0.0425166141701456,1.14100021198174,42.7648364334743
38366,1558:1372,Pancreas,CFPAC-1,SIDM00130,906821,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.602464231631526,0.100262215186652,0.642696830038171,10.3250100207411,2.5053,0.839766440020478,0.901714504925522,0.0826361485650109,0.387201851880964,0.18639724690422,0.200804604976744,7.18777201896859,0.2848,3.13723800177256,2.2205,0.505929243036879,0.399850485973075,0.543250736360956,0.446515889751429,0.106078757063804,0.0967348466095274,True,0.293157774847416,0.0425166141701456,1.14100021198174,42.7648364334743
38366,1079:1372,Pancreas,CFPAC-1,SIDM00130,906821,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.05,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.706244929712712,0.100262215186652,0.642696830038171,10.3250100207411,2.5053,0.839766440020478,0.901714504925522,0.074004233478398,0.453901377556891,0.243071134579511,0.210830242977381,7.54485674437884,0.3647,2.78015327636231,2.1406,0.593080790407357,0.492708758857681,0.636831297152058,0.539809779242662,0.100372031549676,0.0970215179093965,True,0.293157774847416,0.0425166141701456,1.14100021198174,42.7648364334743
38180,1088:1510,Pancreas,CFPAC-1,SIDM00130,906821,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.409586713549036,0.0724203922948254,0.823871261308052,12.4819695922504,111.7319,0.936225719010704,0.956847920698464,0.0652306819466553,0.337446722306664,0.211611376973433,0.125835345333231,9.15033100005324,11.0982,3.33163859219712,100.6337,0.383465615389678,0.293272350154341,0.391912195205113,0.349563253314548,0.0901932652353364,0.0423489418905642,True,0.502183676309534,0.0724094325979286,0.632473164787291,75.4844644810485
38180,1594:1510,Pancreas,CFPAC-1,SIDM00130,906821,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.626469493861923,0.0724203922948254,0.823871261308052,12.4819695922504,111.7319,0.936225719010704,0.956847920698464,0.107701933328355,0.516130212079039,0.290477260693604,0.225652951385436,8.67147695038483,7.9635,3.81049264186553,103.7684,0.586516852329151,0.433135528537168,0.5994360325828,0.519735145757205,0.153381323791983,0.0797008868255951,True,0.502183676309534,0.0724094325979286,0.632473164787291,75.4844644810485
38180,1564:1510,Pancreas,CFPAC-1,SIDM00130,906821,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.81968572349747,0.0724203922948254,0.823871261308052,12.4819695922504,111.7319,0.936225719010704,0.956847920698464,0.140069058999498,0.675315510894064,0.454716170325146,0.220599340568918,9.49620463360369,14.105,2.98576495864666,97.6269,0.767410855844228,0.58747214638902,0.78431458015477,0.71243638120516,0.179938709455209,0.0718781989496101,True,0.502183676309534,0.0724094325979286,0.632473164787291,75.4844644810485
38180,1558:1510,Pancreas,CFPAC-1,SIDM00130,906821,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.641025784371502,0.0724203922948254,0.823871261308052,12.4819695922504,111.7319,0.936225719010704,0.956847920698464,0.0744464865479156,0.528122721501132,0.323353790435056,0.204768931066076,9.04000987063191,10.2812,3.44195972161845,101.4507,0.60014482587761,0.478197997055729,0.613364188889973,0.543704172498552,0.12194682882188,0.0696600163914215,True,0.502183676309534,0.0724094325979286,0.632473164787291,75.4844644810485
38181,1510:1558,Pancreas,CFPAC-1,SIDM00130,906821,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.915861995591324,0.0677505012343901,0.724068764287469,11.1773261641742,45.2314,0.934857294997776,0.928152741576078,0.110071659792818,0.663147063405665,0.343302307705425,0.319844755700241,7.84557435590553,4.4925,3.33175180826865,40.7389,0.85620026778977,0.687750741770653,0.850059822113426,0.717098119533509,0.168449526019117,0.132961702579917,True,0.502183676309534,0.0724094325979286,0.632473164787291,75.4844644810485
38181,1053:1558,Pancreas,CFPAC-1,SIDM00130,906821,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.888162110532362,0.0677505012343901,0.724068764287469,11.1773261641742,45.2314,0.934857294997776,0.928152741576078,0.0527540295150511,0.643090441860118,0.503755817746441,0.139334624113677,9.61025145151821,15.2653,1.56707471265597,29.9661,0.8303048281718,0.789834180548208,0.824350097854608,0.776306662962668,0.0404706476235922,0.0480434348919399,True,0.502183676309534,0.0724094325979286,0.632473164787291,75.4844644810485
38181,1080:1558,Pancreas,CFPAC-1,SIDM00130,906821,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.0025,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.940334787277035,0.0677505012343901,0.724068764287469,11.1773261641742,45.2314,0.934857294997776,0.928152741576078,0.096895299177562,0.680867047440203,0.440315426819485,0.240551620620718,8.71302065028335,8.1962,2.46430551389083,37.0352,0.879078835626118,0.725088296578049,0.872774310810539,0.782159467134378,0.153990539048069,0.0906148436761607,True,0.502183676309534,0.0724094325979286,0.632473164787291,75.4844644810485
38181,1054:1558,Pancreas,CFPAC-1,SIDM00130,906821,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,8.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.843760009040723,0.0677505012343901,0.724068764287469,11.1773261641742,45.2314,0.934857294997776,0.928152741576078,0.0940910264170396,0.610940267101299,0.399348403256115,0.211591863845185,8.75869731909496,8.4598,2.41862884507922,36.7716,0.788795199679109,0.727717701846176,0.783138165623403,0.703818442766767,0.0610774978329328,0.0793197228566369,True,0.502183676309534,0.0724094325979286,0.632473164787291,75.4844644810485
38181,1564:1558,Pancreas,CFPAC-1,SIDM00130,906821,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,1.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.910218806132341,0.0677505012343901,0.724068764287469,11.1773261641742,45.2314,0.934857294997776,0.928152741576078,0.0986172951142823,0.659061006187459,0.387156237584983,0.271904768602476,8.32095512088512,6.2458,2.85637104328906,38.9856,0.850924690956985,0.684951882235589,0.844822080345838,0.737884353397668,0.165972808721397,0.10693772694817,True,0.502183676309534,0.0724094325979286,0.632473164787291,75.4844644810485
38181,1011:1558,Pancreas,CFPAC-1,SIDM00130,906821,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.833267731633452,0.0677505012343901,0.724068764287469,11.1773261641742,45.2314,0.934857294997776,0.928152741576078,0.0943970207748677,0.603343136764455,0.282862116222149,0.320481020542306,7.49757948607847,3.5296,3.67974667809571,41.7018,0.778986417603781,0.658078800907989,0.773399729582468,0.63439351221566,0.120907616695792,0.139006217366808,True,0.502183676309534,0.0724094325979286,0.632473164787291,75.4844644810485
38181,1594:1561,Pancreas,CFPAC-1,SIDM00130,906821,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.615295314836022,0.085362928898266,0.520950268403357,9.18924287404209,11.4017,0.833821448108872,0.855283543361914,0.128448524726532,0.320538259411153,0.256559789137374,0.0639784702737792,8.24342793928198,5.919,0.945814934760104,5.4827,0.513046430431176,0.396121185912034,0.526251957086937,0.496115188113288,0.116925244519141,0.0301367689736492,True,0.502183676309534,0.0724094325979286,0.632473164787291,75.4844644810485
38181,1564:1561,Pancreas,CFPAC-1,SIDM00130,906821,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.795328264776725,0.085362928898266,0.520950268403357,9.18924287404209,11.4017,0.833821448108872,0.855283543361914,0.0679632955305216,0.414326473004211,0.197392116735717,0.216934356268493,6.49867735642607,1.7661,2.69056551761601,9.6356,0.663161765458045,0.510345085125973,0.68023117643412,0.551544164383839,0.152816680332072,0.12868701205028,True,0.502183676309534,0.0724094325979286,0.632473164787291,75.4844644810485
38182,1510:1564,Pancreas,CFPAC-1,SIDM00130,906821,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.863189256612742,0.0842208394157446,0.679040830605797,10.6912599485398,32.2939,0.909678429264676,0.913906996680102,0.124262264642555,0.586140749780317,0.358359765600669,0.227780984179648,8.22659217120476,5.8503,2.46466777733503,26.4436,0.785224647113622,0.62758115231594,0.788874701077481,0.69516839032016,0.157643494797683,0.0937063107573215,True,0.502183676309534,0.0724094325979286,0.632473164787291,75.4844644810485
38182,1053:1564,Pancreas,CFPAC-1,SIDM00130,906821,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.902409984293571,0.0842208394157446,0.679040830605797,10.6912599485398,32.2939,0.909678429264676,0.913906996680102,0.0816999183357577,0.612773225281671,0.364972660634922,0.247800564646749,8.12659634442809,5.4586,2.56466360411169,26.8353,0.820902897064937,0.658573471853726,0.824718798519876,0.72158101354334,0.162329425211211,0.103137784976535,True,0.502183676309534,0.0724094325979286,0.632473164787291,75.4844644810485
38182,1561:1564,Pancreas,CFPAC-1,SIDM00130,906821,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,2.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.782331973047511,0.0842208394157446,0.679040830605797,10.6912599485398,32.2939,0.909678429264676,0.913906996680102,0.0800559680718425,0.531235352787654,0.304596230563512,0.226639122224142,7.98422781130699,4.9456,2.70703213723279,27.3483,0.711670520405395,0.575712996512981,0.71497866389467,0.61904517620911,0.135957523892413,0.0959334876855595,True,0.502183676309534,0.0724094325979286,0.632473164787291,75.4844644810485
38182,1011:1564,Pancreas,CFPAC-1,SIDM00130,906821,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.844931164911712,0.0842208394157446,0.679040830605797,10.6912599485398,32.2939,0.909678429264676,0.913906996680102,0.104009438312331,0.573742760026372,0.160570777109828,0.413171982916544,5.72803484092511,1.0352,4.96322510761468,31.2587,0.768615654933659,0.526094074049222,0.772188503325883,0.537718008310165,0.242521580884436,0.234470495015717,True,0.502183676309534,0.0724094325979286,0.632473164787291,75.4844644810485
38182,1558:1564,Pancreas,CFPAC-1,SIDM00130,906821,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.939276609276558,0.0842208394157446,0.679040830605797,10.6912599485398,32.2939,0.909678429264676,0.913906996680102,0.0848377435603626,0.637807168931751,0.441395680555133,0.196411488376617,8.72822375799897,8.283,1.96303619054081,24.0109,0.85443967057175,0.721705223985692,0.858411465035809,0.782018434490018,0.132734446586058,0.0763930305457907,True,0.502183676309534,0.0724094325979286,0.632473164787291,75.4844644810485
38182,1079:1564,Pancreas,CFPAC-1,SIDM00130,906821,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.857318364559563,0.0842208394157446,0.679040830605797,10.6912599485398,32.2939,0.909678429264676,0.913906996680102,0.0803412193241763,0.582154174364129,0.205199247876406,0.376954926487723,6.39044913280251,1.6385,4.30081081573728,30.6554,0.779884023252304,0.577776989333886,0.783509251753328,0.587846663592294,0.202107033918418,0.195662588161034,True,0.502183676309534,0.0724094325979286,0.632473164787291,75.4844644810485
38182,1053:1594,Pancreas,CFPAC-1,SIDM00130,906821,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.902409984293571,0.0739844054211781,0.612752186888605,10.0356896737891,8.2004,0.887812462197763,0.891149045331972,0.0416033314601219,0.552953691345998,0.417262528301105,0.135691163044893,8.65979843733047,3.1597,1.37589123645861,5.0407,0.80117083006752,0.718028787440993,0.804181796001256,0.748110897020696,0.0831420426265269,0.0560708989805603,True,0.502183676309534,0.0724094325979286,0.632473164787291,75.4844644810485
38182,1079:1594,Pancreas,CFPAC-1,SIDM00130,906821,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.05,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.841989958786085,0.0739844054211781,0.612752186888605,10.0356896737891,8.2004,0.887812462197763,0.891149045331972,0.0602208683101254,0.51593118858442,0.300537011175883,0.215394177408537,7.6713861901638,1.5926,2.36430348362528,6.6078,0.747529178455667,0.617441969986379,0.750338547951326,0.65025405143128,0.130087208469288,0.100084496520047,True,0.502183676309534,0.0724094325979286,0.632473164787291,75.4844644810485
38182,1510:1594,Pancreas,CFPAC-1,SIDM00130,906821,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.863189256612742,0.0739844054211781,0.612752186888605,10.0356896737891,8.2004,0.887812462197763,0.891149045331972,0.0352948161690477,0.528921104688207,0.35883230517788,0.170088799510327,8.23167977134903,2.3484,1.80400990244005,5.852,0.766350179256015,0.685282155073498,0.76923028197126,0.695417871853573,0.0810680241825172,0.0738124101176868,True,0.502183676309534,0.0724094325979286,0.632473164787291,75.4844644810485
38114,1022:1005,Pancreas,SW1990,SIDM01165,910907,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,8.0,0.920894391061648,0.0648576974645823,0.707593796887303,11.6894802856493,51.6065,0.88415433559371,0.899403967667203,0.0954140263662105,0.651619158703532,0.446284875445132,0.205334283258401,8.81272828545321,7.0261,2.87675200019608,44.5804,0.814212768481085,0.766824532650675,0.828256069123319,0.728811130019261,0.0473882358304107,0.0994449391040579,True,0.339336687452299,0.042342449682687,1.01630724604075,48.0495712811403
38114,1011:1005,Pancreas,SW1990,SIDM01165,910907,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,8.0,0.654961685138466,0.0648576974645823,0.707593796887303,11.6894802856493,51.6065,0.88415433559371,0.899403967667203,0.0822587688153378,0.463446825602834,0.196600305563318,0.266846520039516,6.42385709163047,1.3415,5.26562319401882,50.265,0.579087213562937,0.455482613601984,0.589075138283534,0.431758214492558,0.123604599960953,0.157316923790976,True,0.339336687452299,0.042342449682687,1.01630724604075,48.0495712811403
38114,1190:1011,Pancreas,SW1990,SIDM01165,910907,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.01,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.869590505234118,0.10213474263219,0.44929647439282,8.38063864106002,6.5096,0.808042546587079,0.770154417224811,0.04641162795313,0.390703948167161,0.360651711905399,0.0300522362617617,7.95182756417243,4.8358,0.428811076887595,1.6738,0.702666126337321,0.664492326433881,0.669718968782811,0.65028716448237,0.0381737999034402,0.0194318043004413,True,0.339336687452299,0.042342449682687,1.01630724604075,48.0495712811403
38114,1085:1011,Pancreas,SW1990,SIDM01165,910907,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,1.25,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.931912989259712,0.10213474263219,0.44929647439282,8.38063864106002,6.5096,0.808042546587079,0.770154417224811,0.0979910028028227,0.418705220515263,0.344915705362805,0.073789515152458,7.38179433713474,3.2574,0.998844303925285,3.2522,0.753025345038994,0.691947904627211,0.717716905147545,0.667523311933661,0.0610774404117838,0.0501935932138836,True,0.339336687452299,0.042342449682687,1.01630724604075,48.0495712811403
38114,1080:1011,Pancreas,SW1990,SIDM01165,910907,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.7439937592398,0.10213474263219,0.44929647439282,8.38063864106002,6.5096,0.808042546587079,0.770154417224811,0.0726950674216288,0.334273772996703,0.0827219216630389,0.251551851333664,2.67386694605415,0.1246,5.70677169500588,6.385,0.601178611861022,0.277129796937005,0.572990080066224,0.305883231753161,0.324048814924017,0.267106848313063,True,0.339336687452299,0.042342449682687,1.01630724604075,48.0495712811403
38114,1088:1011,Pancreas,SW1990,SIDM01165,910907,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.874251966329248,0.10213474263219,0.44929647439282,8.38063864106002,6.5096,0.808042546587079,0.770154417224811,0.0857471197798365,0.392798326202721,0.161875608725284,0.230922717477437,4.49044383162632,0.439,3.8901948094337,6.0706,0.706432785231446,0.467576142091903,0.673309013635946,0.466071184307917,0.238856643139543,0.20723782932803,True,0.339336687452299,0.042342449682687,1.01630724604075,48.0495712811403
38114,1022:1011,Pancreas,SW1990,SIDM01165,910907,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.920894391061648,0.10213474263219,0.44929647439282,8.38063864106002,6.5096,0.808042546587079,0.770154417224811,0.072746347725056,0.413754603192121,0.360257439833359,0.0534971633587626,7.65406827693084,3.934,0.726570364129184,2.5756,0.744121848891211,0.683620812264614,0.70923088307368,0.673721515217176,0.0605010366265966,0.0355093678565038,True,0.339336687452299,0.042342449682687,1.01630724604075,48.0495712811403
38114,1005:1011,Pancreas,SW1990,SIDM01165,910907,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,0.8,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.94307756961527,0.10213474263219,0.44929647439282,8.38063864106002,6.5096,0.808042546587079,0.770154417224811,0.10577534873976,0.42372142710709,0.388262743619443,0.0354586834876474,7.91367298062225,4.7096,0.46696566043777,1.8,0.762046800981076,0.752114145369037,0.726315356024839,0.703311513514818,0.0099326556120386,0.0230038425100209,True,0.339336687452299,0.042342449682687,1.01630724604075,48.0495712811403
38114,1179:1011,Pancreas,SW1990,SIDM01165,910907,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.2,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.718358777909312,0.10213474263219,0.44929647439282,8.38063864106002,6.5096,0.808042546587079,0.770154417224811,0.0784596798082493,0.322756066263789,0.30075515867898,0.0220009075848089,8.00106534793632,5.0037,0.379573293123707,1.5059,0.580464456265022,0.553659215838559,0.553247185959073,0.539081940825366,0.0268052404264633,0.014165245133707,True,0.339336687452299,0.042342449682687,1.01630724604075,48.0495712811403
38116,1372:1053,Pancreas,SW1990,SIDM01165,910907,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.682423325241859,0.0725968120181995,0.862464864376704,14.5873152619997,480.7834,0.922705907917115,0.956780547329429,0.065530573965543,0.588566140652219,0.403185675549333,0.185380465102885,10.1179225359492,21.7034,4.46939272605043,459.08,0.629676033901106,0.527265453153114,0.652929362635274,0.578440850395506,0.102410580747992,0.0744885122397686,True,0.339336687452299,0.042342449682687,1.01630724604075,48.0495712811403
38116,1558:1053,Pancreas,SW1990,SIDM01165,910907,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.910485630744046,0.0725968120181995,0.862464864376704,14.5873152619997,480.7834,0.922705907917115,0.956780547329429,0.0649372970857,0.785261866036601,0.708347303198491,0.0769145628381095,12.8162955524744,140.8703,1.77101970952526,339.9131,0.840110470561172,0.797867216565856,0.871134940118868,0.843865798008895,0.042243253995316,0.0272691421099728,True,0.339336687452299,0.042342449682687,1.01630724604075,48.0495712811403
38117,1011:1073,Pancreas,SW1990,SIDM01165,910907,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in pancreas,20.0,0.851635440383604,0.0610709870762704,0.73836626136239,12.1574492075753,178.4501,0.89248281631257,0.911698357425379,0.0706857507136948,0.628818876159754,0.366014081704076,0.262804794455678,8.13947278161084,11.015,4.01797642596442,167.4351,0.760069996305155,0.618772172321687,0.776434632122971,0.645314771986226,0.141297823983468,0.131119860136744,True,0.339336687452299,0.042342449682687,1.01630724604075,48.0495712811403
38118,1561:1079,Pancreas,SW1990,SIDM01165,910907,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,2.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.78394194057345,0.0698095756915817,0.722207121391699,11.9077180230924,15.0086,0.875868220631945,0.905304330196566,0.0418980811908085,0.566168452239773,0.317276596764319,0.248891855475454,7.82576203818236,0.8862,4.08195598491,14.1224,0.686629832568821,0.562714686475171,0.709706033423843,0.580910257599446,0.12391514609365,0.128795775824397,True,0.339336687452299,0.042342449682687,1.01630724604075,48.0495712811403
38118,1558:1079,Pancreas,SW1990,SIDM01165,910907,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,2.5,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.864707203034584,0.0698095756915817,0.722207121391699,11.9077180230924,15.0086,0.875868220631945,0.905304330196566,0.0650265516542521,0.624497699950275,0.479894937365285,0.144602762584989,9.672004999246,3.1866,2.23571302384636,11.822,0.757369559289527,0.722452196851333,0.782823175259371,0.717530212061638,0.0349173624381941,0.0652929631977325,True,0.339336687452299,0.042342449682687,1.01630724604075,48.0495712811403
38118,1011:1080,Pancreas,SW1990,SIDM01165,910907,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.1,0.693219568645198,0.0728957647479088,0.647468286482341,10.8501359078328,0.3605,0.85681139797077,0.873846777392592,0.0962362410200788,0.448837686266733,0.138575134536672,0.310262551730062,4.77914607241192,0.0054,6.07098983542091,0.3551,0.593958427711586,0.372594213936295,0.605767686086088,0.383006568695682,0.221364213775291,0.222761117390407,True,0.339336687452299,0.042342449682687,1.01630724604075,48.0495712811403
38119,1558:1083,Pancreas,SW1990,SIDM01165,910907,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.89100473803467,0.0836074451523236,0.849643898394391,14.2704907872521,308.7918,0.926687299013817,0.952420448907777,0.0697191932413824,0.75703673911165,0.592039617989268,0.164997121122382,11.0793524813439,33.8094,3.19113830590824,274.9824,0.825682774097862,0.794682019817778,0.848611132577937,0.785234270769906,0.0310007542800843,0.0633768618080311,True,0.339336687452299,0.042342449682687,1.01630724604075,48.0495712811403
38260,1011:1088,Pancreas,SW1990,SIDM01165,910907,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,0.733107871461479,0.0638288488842429,0.735282697925599,12.1090545092759,43.1408,0.912518775561049,0.910488545650679,0.0863051390098288,0.539041533598689,0.325824573674271,0.213216959924418,8.3208788115273,3.1227,3.78817569774865,40.0181,0.668974697220196,0.586074323903753,0.667486319692027,0.562376859824024,0.0829003733164431,0.105109459868003,True,0.520907623391559,0.0668857988212235,0.603420252656573,79.3279578831798
38260,1022:1088,Pancreas,SW1990,SIDM01165,910907,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,0.694430244030288,0.0638288488842429,0.735282697925599,12.1090545092759,43.1408,0.912518775561049,0.910488545650679,0.0616969869839825,0.510602543351722,0.51977655073748,-0.0091740073857579,12.3190490356655,49.9003,-0.209994526389567,-6.7595,0.633680635995079,0.614579588912243,0.632270782942983,0.635846868977165,0.0191010470828368,-0.003576086034182,True,0.520907623391559,0.0668857988212235,0.603420252656573,79.3279578831798
38261,1053:1168,Pancreas,SW1990,SIDM01165,910907,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.959281237266738,0.0663455669024085,0.793659568433047,13.0997674442681,171.4561,0.929591440408889,0.932613731338692,0.0622782431900661,0.761342732775038,0.526044184374839,0.235298548400199,9.59071297956786,15.0599,3.5090544647002,156.3962,0.891739627108008,0.752772711686658,0.894638854090529,0.792741302570138,0.138966915421351,0.101897551520391,True,0.520907623391559,0.0668857988212235,0.603420252656573,79.3279578831798
38261,1561:1168,Pancreas,SW1990,SIDM01165,910907,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,2.0,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.875246916741443,0.0663455669024085,0.793659568433047,13.0997674442681,171.4561,0.929591440408889,0.932613731338692,0.0511714001487715,0.694648090213368,0.444211026629984,0.250437063583384,9.09163005436126,10.6557,4.00813738990679,160.8004,0.813622042047117,0.673822294313979,0.816267292864922,0.704092282602523,0.139799747733138,0.112175010262399,True,0.520907623391559,0.0668857988212235,0.603420252656573,79.3279578831798
38261,1057:1168,Pancreas,SW1990,SIDM01165,910907,1057,Dactolisib,"PI3K (class 1), MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.0125,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.970307913938177,0.0663455669024085,0.793659568433047,13.0997674442681,171.4561,0.929591440408889,0.932613731338692,0.0473412097401443,0.770094160223343,0.623351798060824,0.146742362162519,10.7831322231964,34.4173,2.31663522107166,137.0388,0.901989931357934,0.824342696479107,0.904922484165345,0.845723303182522,0.0776472348788274,0.059199180982823,True,0.520907623391559,0.0668857988212235,0.603420252656573,79.3279578831798
38261,1005:1168,Pancreas,SW1990,SIDM01165,910907,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,8.0,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.854022898162848,0.0663455669024085,0.793659568433047,13.0997674442681,171.4561,0.929591440408889,0.932613731338692,0.110893565675804,0.677803444787865,0.467183596082519,0.210619848705346,9.57431785559078,14.8897,3.52544958867728,156.5664,0.793892376045376,0.625219824812578,0.796473481704337,0.705165431425564,0.168672551232798,0.0913080502787725,True,0.520907623391559,0.0668857988212235,0.603420252656573,79.3279578831798
38261,1011:1179,Pancreas,SW1990,SIDM01165,910907,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,4.0,0.766993870221478,0.069870868966679,0.550923163539672,9.62206299387317,6.1563,0.840213572293757,0.827709539603639,0.099004182377292,0.422554689397953,0.245708959752359,0.176845729645595,6.71095415612243,0.8184,2.91110883775074,5.3379,0.644438659626203,0.551492346126528,0.634848143199833,0.519108794570357,0.0929463134996747,0.115739348629476,True,0.520907623391559,0.0668857988212235,0.603420252656573,79.3279578831798
38261,1168:1179,Pancreas,SW1990,SIDM01165,910907,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,2.5,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,4.0,0.92574469127336,0.069870868966679,0.550923163539672,9.62206299387317,6.1563,0.840213572293757,0.827709539603639,0.0863267578922268,0.510014193946377,0.280535822029057,0.22947837191732,6.46528451331705,0.6903,3.15677848055612,5.466,0.777823254086771,0.633288483675819,0.766247712204386,0.612634167980933,0.144534770410952,0.153613544223453,True,0.520907623391559,0.0668857988212235,0.603420252656573,79.3279578831798
38261,1089:1179,Pancreas,SW1990,SIDM01165,910907,1089,Oxaliplatin,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved in pancreas,2.5,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,4.0,0.885871472816781,0.069870868966679,0.550923163539672,9.62206299387317,6.1563,0.840213572293757,0.827709539603639,0.0970077700984419,0.48804711429377,0.224317907336568,0.263729206957202,5.70854557594099,0.4085,3.91351741793218,5.7478,0.74432123476852,0.564985011767482,0.733244268913176,0.543786779100399,0.179336223001038,0.189457489812777,True,0.520907623391559,0.0668857988212235,0.603420252656573,79.3279578831798
38261,1558:1179,Pancreas,SW1990,SIDM01165,910907,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,4.0,0.840173428423202,0.069870868966679,0.550923163539672,9.62206299387317,6.1563,0.840213572293757,0.827709539603639,0.0575364714491606,0.462871003108883,0.167159965788194,0.295711037320689,4.76119182948557,0.2119,4.8608711643876,5.9444,0.705925117641752,0.457151183761987,0.69541956162738,0.463188474809482,0.248773933879764,0.232231086817897,True,0.520907623391559,0.0668857988212235,0.603420252656573,79.3279578831798
38262,1011:1190,Pancreas,SW1990,SIDM01165,910907,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.2,0.746816888125432,0.0774509063170751,0.612481250725115,10.3931017859756,0.5253,0.844102909558374,0.857923346998075,0.0759805070069092,0.457411341701703,0.247351102094127,0.210060239607576,6.86135209145701,0.0454,3.53174969451861,0.4799,0.630390308174007,0.520936425335556,0.640711644255258,0.512218588050291,0.109453882838451,0.128493056204966,True,0.520907623391559,0.0668857988212235,0.603420252656573,79.3279578831798
38262,1053:1372,Pancreas,SW1990,SIDM01165,910907,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.947486709667279,0.105680161055176,0.642597309034154,10.785391564536,3.4471,0.80964313983058,0.871679177010687,0.121315254373535,0.608852409977818,0.5017052093568,0.107147200621017,9.35967357385619,1.2831,1.42571799067985,2.164,0.76712611456276,0.692179502293179,0.825904435311337,0.773580692109232,0.0749466122695814,0.0523237432021049,True,0.520907623391559,0.0668857988212235,0.603420252656573,79.3279578831798
38262,1561:1372,Pancreas,SW1990,SIDM01165,910907,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.875653008639418,0.105680161055176,0.642597309034154,10.785391564536,3.4471,0.80964313983058,0.871679177010687,0.09555880321572,0.562692266999351,0.306058727824601,0.25663353917475,7.10963694848674,0.2697,3.67575461604929,3.1774,0.708966451316912,0.56134458310177,0.76328849391774,0.613455055127292,0.147621868215142,0.149833438790448,True,0.520907623391559,0.0668857988212235,0.603420252656573,79.3279578831798
38263,1085:1510,Pancreas,SW1990,SIDM01165,910907,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,5.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.647743005621465,0.0726105154605954,0.861478214772111,14.5620773405558,472.4459,0.931863324729541,0.956447221462737,0.122525473236041,0.558016488113901,0.336282469613433,0.221734018500469,9.23335988369246,11.7557,5.32871745686333,460.6902,0.603607950788724,0.4370925384933,0.619531997948572,0.525230058206734,0.166515412295424,0.094301939741838,True,0.520907623391559,0.0668857988212235,0.603420252656573,79.3279578831798
38264,1372:1558,Pancreas,SW1990,SIDM01165,910907,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.719244027748948,0.0657286666990924,0.740951504297676,12.1983075253136,91.7881,0.886987464825164,0.912708963867118,0.0452295762820625,0.532924944317702,0.421024136351552,0.11190080796615,10.0495236890971,20.6985,2.14878383621647,71.0896,0.637960436763679,0.582360809013158,0.656460471334355,0.607750313472139,0.0555996277505209,0.0487101578622156,True,0.520907623391559,0.0668857988212235,0.603420252656573,79.3279578831798
38264,1079:1561,Pancreas,SW1990,SIDM01165,910907,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.803170601590662,0.0731897417110747,0.620373908126953,10.4946929993421,28.1804,0.840473612663668,0.861588953166078,0.0470441713526855,0.498266085001475,0.273089611862975,0.2251764731385,6.98156555054292,2.4683,3.51312744879919,25.7121,0.675043697104155,0.565079201939099,0.692002917838267,0.556618962350517,0.109964495165056,0.13538395548775,True,0.520907623391559,0.0668857988212235,0.603420252656573,79.3279578831798
38264,1372:1561,Pancreas,SW1990,SIDM01165,910907,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.784696603911959,0.0731897417110747,0.620373908126953,10.4946929993421,28.1804,0.840473612663668,0.861588953166078,0.0445816651695212,0.48680529886281,0.185126409885717,0.301678888977092,5.4235443491904,0.8383,5.07114865015171,27.3421,0.659516789534795,0.461323091775227,0.676085925517481,0.467103452222986,0.198193697759569,0.208982473294495,True,0.520907623391559,0.0668857988212235,0.603420252656573,79.3279578831798
38264,1564:1561,Pancreas,SW1990,SIDM01165,910907,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.750020596057995,0.0731897417110747,0.620373908126953,10.4946929993421,28.1804,0.840473612663668,0.861588953166078,0.0336677547879831,0.465293208352206,0.172498944444774,0.292794263907432,5.32256432004739,0.7816,5.17212867929472,27.3988,0.630372519941021,0.424953164160275,0.646209460210606,0.441483211349275,0.205419355780746,0.20472624886133,True,0.520907623391559,0.0668857988212235,0.603420252656573,79.3279578831798
38265,1053:1564,Pancreas,SW1990,SIDM01165,910907,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.968174730624721,0.078421332209166,0.62337178390968,10.5334925338095,28.9486,0.840094234253322,0.862969775268986,0.0753034830467795,0.603532808965806,0.461011836098666,0.142520972867139,8.70963932864447,8.177,1.82385320516502,20.7716,0.813358008947591,0.725296340481264,0.835505529708326,0.761431628448861,0.088061668466327,0.0740739012594652,True,0.520907623391559,0.0668857988212235,0.603420252656573,79.3279578831798
38265,1561:1564,Pancreas,SW1990,SIDM01165,910907,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,2.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.801222299493769,0.078421332209166,0.62337178390968,10.5334925338095,28.9486,0.840094234253322,0.862969775268986,0.0696640716625092,0.499459374143646,0.180233674669081,0.319225699474565,5.23520903384172,0.7357,5.29828349996777,28.2129,0.673102234159904,0.432609265387109,0.691430627734638,0.467003940730471,0.240492968772794,0.224426687004166,True,0.520907623391559,0.0668857988212235,0.603420252656573,79.3279578831798
38265,1168:1594,Pancreas,SW1990,SIDM01165,910907,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.754164244783054,0.079759874497961,0.644630455446111,10.8123673418331,14.0487,0.854637416349127,0.872585811489659,0.0442765470861387,0.486157240595672,0.529531710593135,-0.043374469997463,11.6097475274295,24.4159,-0.797380185596364,-10.3672,0.64453698166428,0.657555755434454,0.658073019530507,0.676616403173102,-0.0130187737701742,-0.018543383642595,True,0.520907623391559,0.0668857988212235,0.603420252656573,79.3279578831798
38266,1085:1598,Pancreas,SW1990,SIDM01165,910907,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,1.25,1598,LGK974,PORCN,WNT signaling,Targeted,Early clinical trials,10.0,0.969364253887764,0.0723943373054474,0.724443757814555,11.9417310152724,76.8333,0.907762117912384,0.906197398109233,0.0586909099649091,0.702249882777554,0.542369864268983,0.159880018508571,9.72789807159841,16.5622,2.21383294367401,60.2711,0.879952148137715,0.819940990732709,0.87843536469319,0.80661665214518,0.0600111574050061,0.0718187125480092,True,0.520907623391559,0.0668857988212235,0.603420252656573,79.3279578831798
35315,1179:1005,Pancreas,MIA-PaCa-2,SIDM00505,724870,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.0,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,8.0,0.624657594771055,0.059889265324322,0.821078493561957,13.0514469444694,132.6469,0.950207587401817,0.948925950988528,0.0592407348904351,0.512892916906653,0.246762964384841,0.266129952521812,7.86676705104651,3.6471,5.18467989342289,128.9998,0.593554386079626,0.458772125172955,0.59275380216033,0.47620584656782,0.134782260906672,0.11654795559251,True,0.313590183088734,0.0437245510185746,1.11922508169183,44.0838055198425
35315,1089:1005,Pancreas,MIA-PaCa-2,SIDM00505,724870,1089,Oxaliplatin,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved in pancreas,10.0,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,8.0,0.72775920590019,0.059889265324322,0.821078493561957,13.0514469444694,132.6469,0.950207587401817,0.948925950988528,0.0881561794381686,0.597547432456374,0.395443153384287,0.202104279072087,9.46245527489313,11.0231,3.58899166957627,121.6238,0.691522319247882,0.604558100218438,0.690589596549493,0.613471218087635,0.0869642190294432,0.0771183784618582,True,0.313590183088734,0.0437245510185746,1.11922508169183,44.0838055198425
35315,1022:1005,Pancreas,MIA-PaCa-2,SIDM00505,724870,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,8.0,0.915867828230705,0.059889265324322,0.821078493561957,13.0514469444694,132.6469,0.950207587401817,0.948925950988528,0.0487721998353648,0.751999376705529,0.5030047163027,0.248994660402829,9.52510907965894,11.5123,3.52633786481046,121.1346,0.870264559442041,0.769029541240578,0.86909074988362,0.774533805228754,0.101235018201463,0.0945569446548654,True,0.313590183088734,0.0437245510185746,1.11922508169183,44.0838055198425
35315,1080:1011,Pancreas,MIA-PaCa-2,SIDM00505,724870,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.435482097201787,0.177399487690534,0.608818806579207,10.1762094837259,22.5982,0.908747288973969,0.8719964223564,0.0605126789070356,0.265129690705002,0.0918829394861173,0.173246751218885,5.49288058030576,0.8795,4.68332890342016,21.7187,0.395743175228823,0.220677177053178,0.379738830760221,0.26497229042251,0.175065998175644,0.114766540337711,True,0.313590183088734,0.0437245510185746,1.11922508169183,44.0838055198425
35315,1558:1011,Pancreas,MIA-PaCa-2,SIDM00505,724870,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.646846585618333,0.177399487690534,0.608818806579207,10.1762094837259,22.5982,0.908747288973969,0.8719964223564,0.153470506738784,0.393812366295989,0.0535811134662715,0.340231252829717,2.6065729417624,0.119,7.56963654196352,22.4792,0.587820081062729,0.220791239550732,0.56404790847264,0.257839846613649,0.367028841511997,0.30620806185899,True,0.313590183088734,0.0437245510185746,1.11922508169183,44.0838055198425
35316,1088:1022,Pancreas,MIA-PaCa-2,SIDM00505,724870,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.696236072770011,0.0685679092718046,0.764791819344362,12.1353171608195,8.7867,0.920765147795018,0.930594156809018,0.045224387666833,0.53247565278695,0.192907719269296,0.339567933517654,6.44993431031318,0.1707,5.68538285050637,8.616,0.641069910444302,0.433083597546561,0.64791322107943,0.469536671726316,0.207986312897741,0.178376549353114,True,0.313590183088734,0.0437245510185746,1.11922508169183,44.0838055198425
35316,1005:1022,Pancreas,MIA-PaCa-2,SIDM00505,724870,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,0.8,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.993828923502843,0.0685679092718046,0.764791819344362,12.1353171608195,8.7867,0.920765147795018,0.930594156809018,0.0548281416671947,0.760072230522788,0.741538850656998,0.0185333798657897,11.8667987614975,7.2944,0.268518399322058,1.4923,0.915083035632059,0.949307084337196,0.924851389079543,0.918527315478974,-0.0342240487051371,0.0063240736005691,True,0.313590183088734,0.0437245510185746,1.11922508169183,44.0838055198425
35316,1083:1022,Pancreas,MIA-PaCa-2,SIDM00505,724870,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,1.0,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.955060050183597,0.0685679092718046,0.764791819344362,12.1353171608195,8.7867,0.920765147795018,0.930594156809018,0.0768748460767787,0.73042211336303,0.522817951981126,0.207604161381904,9.50586858540866,1.42,2.62944857541089,7.3667,0.879386008260417,0.744763815714036,0.888773302102583,0.806882545596136,0.134622192546381,0.0818907565064467,True,0.313590183088734,0.0437245510185746,1.11922508169183,44.0838055198425
35316,1179:1022,Pancreas,MIA-PaCa-2,SIDM00505,724870,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.2,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.890829632552806,0.0685679092718046,0.764791819344362,12.1353171608195,8.7867,0.920765147795018,0.930594156809018,0.119049855910401,0.68129921540593,0.390612448849402,0.290686766556528,8.34235817066547,0.6339,3.79295899015408,8.1528,0.820244878277666,0.760221461455552,0.829000850765966,0.702497676100736,0.0600234168221139,0.12650317466523,True,0.313590183088734,0.0437245510185746,1.11922508169183,44.0838055198425
35316,1190:1022,Pancreas,MIA-PaCa-2,SIDM00505,724870,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.467549681097602,0.0685679092718046,0.764791819344362,12.1353171608195,8.7867,0.920765147795018,0.930594156809018,0.0575786720866742,0.357578171240511,0.128849277376822,0.228728893863689,6.43014651173335,0.1684,5.70517064908619,8.6183,0.430503451217347,0.27659940941743,0.435099001247348,0.314695797272536,0.153904041799917,0.120403203974812,True,0.313590183088734,0.0437245510185746,1.11922508169183,44.0838055198425
35317,1372:1053,Pancreas,MIA-PaCa-2,SIDM00505,724870,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.526412467797044,0.0883527413162036,0.787647592613781,12.4854304915266,112.0003,0.911218402572153,0.938191001119234,0.0656843029062069,0.414627512982221,0.258518149755208,0.156109363227013,8.90526859841043,9.3645,3.58016189311614,102.6358,0.479676728000088,0.370722158448751,0.493875440164156,0.430209363574818,0.108954569551337,0.0636660765893377,True,0.313590183088734,0.0437245510185746,1.11922508169183,44.0838055198425
35317,1558:1053,Pancreas,MIA-PaCa-2,SIDM00505,724870,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.934310880858949,0.0883527413162036,0.787647592613781,12.4854304915266,112.0003,0.911218402572153,0.938191001119234,0.0511957554729039,0.735907716061412,0.678309805367231,0.0575979106941811,11.5909921757996,60.2513,0.894438315726923,51.749,0.851361268362073,0.885699053691403,0.876562060669651,0.856933025285481,-0.0343377853293293,0.0196290353841703,True,0.313590183088734,0.0437245510185746,1.11922508169183,44.0838055198425
35317,1564:1053,Pancreas,MIA-PaCa-2,SIDM00505,724870,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.528652466225116,0.0883527413162036,0.787647592613781,12.4854304915266,112.0003,0.911218402572153,0.938191001119234,0.084081825447127,0.41639184235155,0.319219627351416,0.097172215000134,10.1207065443714,21.7453,2.36472394715516,90.255,0.481717855789479,0.393615723778439,0.495976986531893,0.45987162271365,0.0881021320110396,0.0361053638182437,True,0.313590183088734,0.0437245510185746,1.11922508169183,44.0838055198425
35319,1510:1079,Pancreas,MIA-PaCa-2,SIDM00505,724870,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.662320652126592,0.106670889592723,0.901634936117265,14.8910847289833,118.6925,0.899288661983785,0.973141235027578,0.111946037965148,0.597171438869305,0.366960348472761,0.230211090396544,9.57715736995724,2.9838,5.31392735902603,115.7087,0.595617453055151,0.476912272758405,0.644531537394742,0.561594945596465,0.118705180296746,0.0829365917982776,True,0.313590183088734,0.0437245510185746,1.11922508169183,44.0838055198425
35319,1179:1079,Pancreas,MIA-PaCa-2,SIDM00505,724870,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.566095158555553,0.106670889592723,0.901634936117265,14.8910847289833,118.6925,0.899288661983785,0.973141235027578,0.092792721283327,0.510411172120529,0.247126092756842,0.263285079363687,8.32143463703176,1.2496,6.56965009195151,117.4429,0.509082957692922,0.382493096455021,0.550890541739883,0.445784073704457,0.126589861237901,0.105106468035427,True,0.313590183088734,0.0437245510185746,1.11922508169183,44.0838055198425
35319,1564:1079,Pancreas,MIA-PaCa-2,SIDM00505,724870,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,1.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.602531908726621,0.106670889592723,0.901634936117265,14.8910847289833,118.6925,0.899288661983785,0.973141235027578,0.102548281416226,0.543263819033341,0.313217694250168,0.230046124783173,9.21108524349334,2.3151,5.67999948548992,116.3774,0.541850114001299,0.418035641977395,0.586348645801748,0.50111996734069,0.123814472023904,0.0852286784610576,True,0.313590183088734,0.0437245510185746,1.11922508169183,44.0838055198425
35319,1372:1079,Pancreas,MIA-PaCa-2,SIDM00505,724870,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.557341742688768,0.106670889592723,0.901634936117265,14.8910847289833,118.6925,0.899288661983785,0.973141235027578,0.152151894382166,0.502518786564673,0.172231452154223,0.330287334410449,6.86032554193755,0.4539,8.03075918704572,118.2386,0.501211110050293,0.294136365019549,0.54237223181257,0.390823253484872,0.207074745030744,0.151548978327698,True,0.313590183088734,0.0437245510185746,1.11922508169183,44.0838055198425
35320,1558:1083,Pancreas,MIA-PaCa-2,SIDM00505,724870,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.920440606478824,0.0648591228398288,0.568108316794854,9.72893180554371,13.2593,0.847228151864774,0.8543102740228,0.0590958225624739,0.522909963656319,0.48491795562562,0.0379920080306988,9.28566440885516,9.7518,0.443267396688546,3.5075,0.779823193928346,0.80226288058094,0.786341866742636,0.768651212965671,-0.0224396866525942,0.0176906537769653,True,0.313590183088734,0.0437245510185746,1.11922508169183,44.0838055198425
35320,1558:1085,Pancreas,MIA-PaCa-2,SIDM00505,724870,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.681202638995479,0.108404740332611,0.553477135896428,9.57096725419366,14.8552,0.886343746573885,0.847655194062956,0.125115360763313,0.377030085596306,0.194400172021926,0.18262991357438,6.55919582152152,1.8418,3.01177143267214,13.0134,0.603779699223271,0.469090604221619,0.57742495515391,0.464330315583388,0.134689095001652,0.113094639570523,True,0.313590183088734,0.0437245510185746,1.11922508169183,44.0838055198425
35521,1179:1088,Pancreas,MIA-PaCa-2,SIDM00505,724870,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.0,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,0.737487290220303,0.0721931920124075,0.726935486822007,11.6035085740373,30.3881,0.908828650303395,0.917513390829207,0.0466424620113604,0.536105682341339,0.282442577352302,0.253663104989037,7.73186722885244,2.076,3.8716413451849,28.3121,0.670249578586826,0.538461433335156,0.676654464343474,0.556493323341016,0.13178814525167,0.120161141002457,True,,,,
35521,1022:1088,Pancreas,MIA-PaCa-2,SIDM00505,724870,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,0.951267971355163,0.0721931920124075,0.726935486822007,11.6035085740373,30.3881,0.908828650303395,0.917513390829207,0.0725634429043277,0.691510445855249,0.413718163190804,0.277792282664445,8.30377613775642,3.0859,3.29973243628093,27.3022,0.864539586483561,0.750521032635434,0.872801101985297,0.748198138243638,0.114018553848127,0.124602963741659,True,,,,
35522,1022:1179,Pancreas,MIA-PaCa-2,SIDM00505,724870,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.0625,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,4.0,0.959186595160382,0.0800797116290437,0.548237944702131,9.51466006778089,5.7146,0.86391222827329,0.845231027056702,0.0768316106884734,0.525862487516563,0.411192895701057,0.114669591815506,8.23633077633463,2.356,1.27832929144626,3.3586,0.828653028754876,0.764814894065306,0.810734270966431,0.750942679496523,0.0638381346895694,0.0597915914699073,True,,,,
35522,1190:1179,Pancreas,MIA-PaCa-2,SIDM00505,724870,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.1,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,4.0,0.943976619045218,0.0800797116290437,0.548237944702131,9.51466006778089,5.7146,0.86391222827329,0.845231027056702,0.102430698068814,0.517523801472218,0.312265228042437,0.20525857342978,7.12652051241885,1.0917,2.38813955536204,4.6229,0.815512944397241,0.720345299574909,0.797878327233103,0.67784808648056,0.0951676448223324,0.120030240752544,True,,,,
35523,1179:1190,Pancreas,MIA-PaCa-2,SIDM00505,724870,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.0,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.2,0.671673622109543,0.0799870400821049,0.565248613950191,9.69796516976321,0.3244,0.872302090133157,0.853022550974519,0.0651807310751703,0.379662583924324,0.138611025434889,0.241051558489435,5.41841026296057,0.0167,4.27955490680265,0.3077,0.585902304453463,0.404259059244368,0.572952746554177,0.405132104471277,0.181643245209095,0.1678206420829,True,,,,
35523,1022:1190,Pancreas,MIA-PaCa-2,SIDM00505,724870,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.2,0.959601492229165,0.0799870400821049,0.565248613950191,9.69796516976321,0.3244,0.872302090133157,0.853022550974519,0.110928585063223,0.542413413427071,0.180103372573432,0.362310040853638,5.10424356617735,0.0134,4.59372160358587,0.311,0.837062387366397,0.561548022547995,0.818561712820277,0.557204574946052,0.275514364818403,0.261357137874225,True,,,,
35523,1561:1372,Pancreas,MIA-PaCa-2,SIDM00505,724870,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.857145571063925,0.106551018877023,0.42232088904872,8.1670590583442,0.5614,0.714357213812277,0.779126634324169,0.121279793843466,0.361990479615889,0.215700008301362,0.146290471314527,6.10212365670562,0.1342,2.06493540163858,0.4272,0.612308121976758,0.504769150875825,0.667824943908903,0.557933278171515,0.107538971100933,0.109891665737389,True,,,,
35523,1079:1372,Pancreas,MIA-PaCa-2,SIDM00505,724870,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.05,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.930784731832801,0.106551018877023,0.42232088904872,8.1670590583442,0.5614,0.714357213812277,0.779126634324169,0.0847556601830042,0.393089835460603,0.169811033859766,0.223278801600836,5.01172823173194,0.063,3.15533082661226,0.4984,0.664912787691087,0.496737152086549,0.725199175393215,0.534254424971301,0.168175635604538,0.190944750421913,True,,,,
37945,1088:1510,Pancreas,MIA-PaCa-2,SIDM00505,724870,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.603414979465993,0.0491665921183561,0.918777604364415,15.4503503222644,874.4781,0.978231214265539,0.978021582649092,0.0973608338287352,0.554404169271368,0.293443814814558,0.26096035445681,8.85430502492291,9.0394,6.59604529734144,865.4387,0.590279368069034,0.417469031949755,0.5901528732115,0.491640202212446,0.172810336119278,0.0985126709990538,True,0.448307625429596,0.0590480514235753,0.738409164172256,65.0209490418883
37945,1594:1510,Pancreas,MIA-PaCa-2,SIDM00505,724870,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.526555401016262,0.0491665921183561,0.918777604364415,15.4503503222644,874.4781,0.978231214265539,0.978021582649092,0.0643218995848179,0.483787309910865,0.333975453849032,0.149811856061833,10.4639303124425,27.5859,4.98642000982184,846.8922,0.515092929314216,0.418608121671502,0.514982546654352,0.464675615662628,0.0964848076427144,0.0503069309917232,True,0.448307625429596,0.0590480514235753,0.738409164172256,65.0209490418883
37945,1564:1510,Pancreas,MIA-PaCa-2,SIDM00505,724870,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.421153599073134,0.0491665921183561,0.918777604364415,15.4503503222644,874.4781,0.978231214265539,0.978021582649092,0.0463251766411356,0.386946494825865,0.292375586558613,0.0945709082672521,11.1802471310912,45.3231,4.27010319117318,829.155,0.411985596613614,0.349329127364454,0.411897309503868,0.381425468975578,0.0626564692491595,0.0304718405282899,True,0.448307625429596,0.0590480514235753,0.738409164172256,65.0209490418883
35525,1510:1558,Pancreas,MIA-PaCa-2,SIDM00505,724870,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.801835268125514,0.0737112372703379,0.809011937153825,12.8385438557144,143.0595,0.936101460718708,0.9451010699257,0.0964098390346579,0.648694303544479,0.4292598151201,0.219434488424379,9.37657540533475,12.9826,3.46196845037964,130.0769,0.750599165748071,0.69106658857004,0.757815369809584,0.672876435499669,0.0595325771780311,0.0849389343099155,True,,,,
35525,1053:1558,Pancreas,MIA-PaCa-2,SIDM00505,724870,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.954571383574694,0.0737112372703379,0.809011937153825,12.8385438557144,143.0595,0.936101460718708,0.9451010699257,0.0671820838786959,0.77225964417737,0.673585742115975,0.0986739020613947,11.3247973977702,50.0995,1.51374645794423,92.96,0.893575666524549,0.85627092252275,0.902166435936899,0.868528927833293,0.037304744001799,0.0336375081036067,True,,,,
35525,1085:1558,Pancreas,MIA-PaCa-2,SIDM00505,724870,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,1.25,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.983767456651344,0.0737112372703379,0.809011937153825,12.8385438557144,143.0595,0.936101460718708,0.9451010699257,0.0572484493822938,0.795879615814395,0.82684688893882,-0.0309672731244243,13.4189431706867,213.9117,-0.580399314972297,-70.8522,0.920906153178852,0.967083955859068,0.92975967583927,0.93946441434322,-0.0461778026802164,-0.0097047385039493,True,,,,
35525,1054:1558,Pancreas,MIA-PaCa-2,SIDM00505,724870,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,8.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.927539197616719,0.0737112372703379,0.809011937153825,12.8385438557144,143.0595,0.936101460718708,0.9451010699257,0.103752548681601,0.750390283050006,0.421218138176845,0.329172144873161,8.51068994304395,7.1237,4.32785391267045,135.9358,0.868270797762869,0.748989066895346,0.876618288065586,0.73965355127603,0.119281730867523,0.136964736789557,True,,,,
35525,1011:1558,Pancreas,MIA-PaCa-2,SIDM00505,724870,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.831702115589972,0.0737112372703379,0.809011937153825,12.8385438557144,143.0595,0.936101460718708,0.9451010699257,0.166326700670811,0.672856939668378,0.408813503879001,0.264043435789377,8.90999343383006,9.3952,3.92855042188433,133.6643,0.778557565286613,0.701171459165303,0.786042559303551,0.679897269694743,0.0773861061213105,0.106145289608809,True,,,,
35525,1372:1561,Pancreas,MIA-PaCa-2,SIDM00505,724870,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.611805233990623,0.0856609098308386,0.762469746102119,12.1011095199444,85.8078,0.890593487823146,0.929810055595266,0.0937055792434083,0.466482981424778,0.247928982347922,0.218553999076855,7.97981638126111,4.9305,4.1212931386833,80.8773,0.544869757208165,0.397813414218474,0.568862658630296,0.470323702710427,0.14705634298969,0.0985389559198692,True,,,,
35525,1564:1561,Pancreas,MIA-PaCa-2,SIDM00505,724870,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.65707660007852,0.0856609098308386,0.762469746102119,12.1011095199444,85.8078,0.890593487823146,0.929810055595266,0.076753718550881,0.501001028431513,0.230240665424801,0.270760363006712,7.35866511872374,3.2056,4.74244440122067,82.6022,0.585188141030903,0.422836393587862,0.610956430049357,0.481232898579611,0.162351747443041,0.129723531469746,True,,,,
37946,1079:1564,Pancreas,MIA-PaCa-2,SIDM00505,724870,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,1.0,0.0822234456620379,0.219526394594799,5.62724510367054,0.9654,0.604243613558714,0.617951015436434,0.0818768275891645,0.219526394594799,0.100588399940782,0.118937994654016,3.17491220722484,0.1764,2.4523328964457,0.789,0.604243613558714,0.424202616939783,0.617951015436434,0.439553236213094,0.18004099661893,0.17839777922334,True,0.448307625429596,0.0590480514235753,0.738409164172256,65.0209490418883
37946,1005:1594,Pancreas,MIA-PaCa-2,SIDM00505,724870,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,0.8,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.987397624147223,0.0580799306008728,0.529494445201541,9.3140678838361,4.9728,0.852021724082696,0.836372855209603,0.0764501532276812,0.522821557191154,0.53068976965706,-0.0078682124659066,9.39920592524868,5.2751,-0.0851380414125753,-0.3023,0.841284226081075,0.867747617167085,0.825832570135191,0.829586748697502,-0.0264633910860105,-0.0037541785623106,True,0.448307625429596,0.0590480514235753,0.738409164172256,65.0209490418883
35527,1558:1598,Pancreas,MIA-PaCa-2,SIDM00505,724870,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,2.5,1598,LGK974,PORCN,WNT signaling,Targeted,Early clinical trials,10.0,0.953103894843117,0.0444060770068279,0.896581833732497,14.7429381774999,535.5458,0.954457520358696,0.971685405842358,0.0191727918694042,0.854535637776026,0.793940345864894,0.0605952919111321,13.2732198294061,193.3603,1.4697183480938,342.1855,0.909697180116176,0.904053092010701,0.926117144870565,0.907977422944208,0.0056440881054747,0.0181397219263577,True,,,,
38571,1022:1005,Pancreas,PSN1,SIDM00469,910546,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,8.0,0.924880540885026,0.0830397097957908,0.397456029399573,8.1793267658071,4.5294,0.82444328959326,0.819881208791966,0.0986846593146026,0.367599347449092,0.160282422736388,0.207316924712703,5.91828062596052,0.9449,2.26104613984658,3.5845,0.762511555608044,0.624976806523313,0.758292175848982,0.610527460989453,0.137534749084731,0.147764714859529,True,0.285165227878671,0.0370029438850035,1.16344452835307,41.9269351804705
38571,1080:1011,Pancreas,PSN1,SIDM00469,910546,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.423881948576822,0.0734372326632305,0.736131648778382,11.0236114112882,40.66,0.937321730560874,0.940019644480766,0.0417064369120784,0.31203291769325,0.0164320374881758,0.295600880205074,2.66721177140301,0.1241,8.35639963988523,40.5359,0.397313761593543,0.14051606301532,0.398457358602999,0.164245785825278,0.256797698578223,0.234211572777721,True,0.285165227878671,0.0370029438850035,1.16344452835307,41.9269351804705
38571,1085:1011,Pancreas,PSN1,SIDM00469,910546,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,5.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.586416044059238,0.0734372326632305,0.736131648778382,11.0236114112882,40.66,0.937321730560874,0.940019644480766,0.133792850058142,0.431679409383423,0.107990597412651,0.323688811970772,6.06415363757417,1.3068,4.95945777371406,39.3532,0.549660501246267,0.328763996823834,0.551242601254382,0.393887527801921,0.220896504422433,0.157355073452461,True,0.285165227878671,0.0370029438850035,1.16344452835307,41.9269351804705
38571,1088:1011,Pancreas,PSN1,SIDM00469,910546,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.420212405236811,0.0734372326632305,0.736131648778382,11.0236114112882,40.66,0.937321730560874,0.940019644480766,0.0861931466435096,0.309331650704104,0.0281003570083229,0.281231293695781,3.80118933039843,0.2723,7.22242208088981,40.3877,0.393874218879715,0.17754312508663,0.395007915777115,0.202980695655796,0.216331093793086,0.192027220121319,True,0.285165227878671,0.0370029438850035,1.16344452835307,41.9269351804705
38571,1372:1011,Pancreas,PSN1,SIDM00469,910546,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.173062533365968,0.0734372326632305,0.736131648778382,11.0236114112882,40.66,0.937321730560874,0.940019644480766,0.0370000232337455,0.127396808028454,0.0274974394063359,0.0998993686221179,5.71291815738814,1.0244,5.3106932539001,39.6356,0.162215273269838,0.0811040656380484,0.162682181087618,0.111385939832391,0.0811112076317898,0.0512962412552268,True,0.285165227878671,0.0370029438850035,1.16344452835307,41.9269351804705
38571,1005:1011,Pancreas,PSN1,SIDM00469,910546,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,0.8,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.855121779558044,0.0734372326632305,0.736131648778382,11.0236114112882,40.66,0.937321730560874,0.940019644480766,0.083968678436166,0.629482205492367,0.332168914220245,0.297313291272122,8.10482609550879,5.3768,2.91878531577944,35.2832,0.80152422625564,0.650831308780257,0.803831271207912,0.697292150185289,0.150692917475383,0.106539121022624,True,0.285165227878671,0.0370029438850035,1.16344452835307,41.9269351804705
38571,1073:1011,Pancreas,PSN1,SIDM00469,910546,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in pancreas,10.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.390762337370514,0.0734372326632305,0.736131648778382,11.0236114112882,40.66,0.937321730560874,0.940019644480766,0.0973655159816271,0.287652523689051,0.0870913064064849,0.200561217282566,6.53648340620486,1.813,4.48712800508338,38.847,0.366270030302143,0.210996167293872,0.367324273451504,0.276732970099258,0.155273863008271,0.0905913033522463,True,0.285165227878671,0.0370029438850035,1.16344452835307,41.9269351804705
38571,1083:1011,Pancreas,PSN1,SIDM00469,910546,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.93895452272626,0.0734372326632305,0.736131648778382,11.0236114112882,40.66,0.937321730560874,0.940019644480766,0.0813076753312309,0.691194140942401,0.564500324445842,0.126693816496559,9.80961813300362,17.5275,1.21399327828462,23.1325,0.880102478159738,0.790522677204077,0.882635696636746,0.84548999109865,0.0895798009556609,0.0371457055380964,True,0.285165227878671,0.0370029438850035,1.16344452835307,41.9269351804705
38571,1179:1011,Pancreas,PSN1,SIDM00469,910546,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.2,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.913165397608959,0.0734372326632305,0.736131648778382,11.0236114112882,40.66,0.937321730560874,0.940019644480766,0.0953311023691643,0.67220994974925,0.648800697663366,0.0234092520858832,10.7708220339878,34.1248,0.252789377300465,6.5352,0.855929770775138,0.850135593241011,0.858393412412511,0.852064590075276,0.0057941775341278,0.006328822337235,True,0.285165227878671,0.0370029438850035,1.16344452835307,41.9269351804705
38571,1564:1011,Pancreas,PSN1,SIDM00469,910546,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.176537425094623,0.0734372326632305,0.736131648778382,11.0236114112882,40.66,0.937321730560874,0.940019644480766,0.0444160461629958,0.129954785805995,0.035632385035182,0.0943224007708129,6.28826867154119,1.5265,4.73534273974704,39.1335,0.165472364798453,0.0924695569455679,0.165948647574997,0.121669602418129,0.0730028078528848,0.0442790451568686,True,0.285165227878671,0.0370029438850035,1.16344452835307,41.9269351804705
38571,1190:1011,Pancreas,PSN1,SIDM00469,910546,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.272781832931848,0.0734372326632305,0.736131648778382,11.0236114112882,40.66,0.937321730560874,0.940019644480766,0.0533783980674618,0.20080334043291,0.0481591243348276,0.152644216098083,5.96266268384385,1.2181,5.06094872744439,39.4419,0.255684339709247,0.1470549152931,0.256420281613408,0.181031408393268,0.108629424416147,0.07538887322014,True,0.285165227878671,0.0370029438850035,1.16344452835307,41.9269351804705
38571,1089:1011,Pancreas,PSN1,SIDM00469,910546,1089,Oxaliplatin,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved in pancreas,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.719391931891269,0.0734372326632305,0.736131648778382,11.0236114112882,40.66,0.937321730560874,0.940019644480766,0.0385479520288708,0.529567168940986,0.395508695275382,0.134058473665604,9.39406726204224,13.1409,1.629544149246,27.5191,0.674301690551855,0.620968867870642,0.676242548058762,0.635234590212469,0.0533328226812128,0.0410079578462933,True,0.285165227878671,0.0370029438850035,1.16344452835307,41.9269351804705
38572,1510:1017,Pancreas,PSN1,SIDM00469,910546,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.890549660163087,0.0698553648643466,0.810993842738083,11.8727778322968,73.2474,0.921630380276715,0.958967623683619,0.112878424172142,0.722230291044756,0.520149551216337,0.202080739828419,9.6696975334418,15.9074,2.20308029885499,57.34,0.820757621951404,0.706683030167084,0.854008291378849,0.796881246670557,0.11407459178432,0.0571270447082926,True,0.285165227878671,0.0370029438850035,1.16344452835307,41.9269351804705
38572,1005:1017,Pancreas,PSN1,SIDM00469,910546,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,8.0,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.326126187826975,0.0698553648643466,0.810993842738083,11.8727778322968,73.2474,0.921630380276715,0.958967623683619,0.13322190784146,0.264486330283321,0.154577388357343,0.109908941925978,8.7945282923737,8.6726,3.07824953992309,64.5748,0.300567802505171,0.164019380535183,0.312744455361432,0.278548429991368,0.136548421969987,0.0341960253700644,True,0.285165227878671,0.0370029438850035,1.16344452835307,41.9269351804705
38572,1088:1022,Pancreas,PSN1,SIDM00469,910546,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.423690039787268,0.050466552042897,0.72788631258343,10.9407036312964,3.8389,0.924992538782052,0.937816927311945,0.0525438125603831,0.308398180739081,0.121992387140364,0.186405793598718,7.21404813080693,0.29,3.72665550048948,3.5489,0.391910125559494,0.28422583804249,0.397343691245972,0.32093142967893,0.107684287517003,0.0764122615670411,True,0.285165227878671,0.0370029438850035,1.16344452835307,41.9269351804705
38572,1005:1022,Pancreas,PSN1,SIDM00469,910546,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,0.8,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.834801837598785,0.050466552042897,0.72788631258343,10.9407036312964,3.8389,0.924992538782052,0.937816927311945,0.0386028508373069,0.607640831307651,0.439619022635286,0.168021808672365,9.21018006589674,1.1568,1.73052356539967,2.6821,0.772185471140423,0.723270055160827,0.782891294251258,0.730136842983565,0.0489154159795951,0.052754451267693,True,0.285165227878671,0.0370029438850035,1.16344452835307,41.9269351804705
38572,1073:1022,Pancreas,PSN1,SIDM00469,910546,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in pancreas,10.0,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.387979494847943,0.050466552042897,0.72788631258343,10.9407036312964,3.8389,0.924992538782052,0.937816927311945,0.0649221871384341,0.282404963862851,0.134528622619287,0.147876341243564,7.75068909441313,0.4206,3.19001453688328,3.4183,0.358878137934777,0.263586271928272,0.363853737718338,0.307826080951181,0.0952918660065052,0.0560276567671568,True,0.285165227878671,0.0370029438850035,1.16344452835307,41.9269351804705
38572,1083:1022,Pancreas,PSN1,SIDM00469,910546,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,1.0,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.958408945732923,0.050466552042897,0.72788631258343,10.9407036312964,3.8389,0.924992538782052,0.937816927311945,0.0801964994816732,0.69761275345651,0.602132172880828,0.0954805805756818,10.0350599588091,2.0492,0.905643672487294,1.7897,0.886521123904926,0.840023222933041,0.89881213259553,0.87124618326192,0.0464979009718853,0.0275659493336099,True,0.285165227878671,0.0370029438850035,1.16344452835307,41.9269351804705
38572,1179:1022,Pancreas,PSN1,SIDM00469,910546,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.2,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.865549525386751,0.050466552042897,0.72788631258343,10.9407036312964,3.8389,0.924992538782052,0.937816927311945,0.110130099371335,0.6300216523921,0.242160486485273,0.387861165906827,7.13494779754354,0.2745,3.80575583375286,3.5644,0.800626852929091,0.69177518548135,0.811726996334515,0.65082926931892,0.108851667447741,0.160897727015595,True,0.285165227878671,0.0370029438850035,1.16344452835307,41.9269351804705
38572,1190:1022,Pancreas,PSN1,SIDM00469,910546,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.313653653626887,0.050466552042897,0.72788631258343,10.9407036312964,3.8389,0.924992538782052,0.937816927311945,0.0628183665897121,0.228304201366795,0.105821364000273,0.122482837366523,7.66866443078238,0.3974,3.27203920051403,3.4415,0.290127289366601,0.19456710854472,0.294149705684533,0.247193353653586,0.0955601808218804,0.0469563520309462,True,0.285165227878671,0.0370029438850035,1.16344452835307,41.9269351804705
38572,1079:1022,Pancreas,PSN1,SIDM00469,910546,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.05,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.824759107246727,0.050466552042897,0.72788631258343,10.9407036312964,3.8389,0.924992538782052,0.937816927311945,0.0600999052682934,0.600330865343422,0.279488887630028,0.320841977713394,7.68180082830891,0.401,3.2589028029875,3.4379,0.762896020495769,0.612750117384797,0.773473051730669,0.650704236040839,0.150145903110972,0.12276881568983,True,0.285165227878671,0.0370029438850035,1.16344452835307,41.9269351804705
38573,1179:1053,Pancreas,PSN1,SIDM00469,910546,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.338226320685064,0.0614480839510606,0.879573819563909,12.9219416554765,151.5731,0.941488455253216,0.97486006309675,0.0467740447697516,0.297495016762009,0.18876898356997,0.108726033192039,9.46058339453614,13.761,3.46135826094032,137.8121,0.31843617618776,0.256903396015879,0.329723332324023,0.299651429726837,0.061532780171881,0.0300719025971864,True,0.285165227878671,0.0370029438850035,1.16344452835307,41.9269351804705
38573,1054:1053,Pancreas,PSN1,SIDM00469,910546,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,8.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.733802374421509,0.0614480839510606,0.879573819563909,12.9219416554765,151.5731,0.941488455253216,0.97486006309675,0.0864481405342845,0.645433357274992,0.416544489053204,0.228888868221788,9.53704453775016,14.51,3.3848971177263,137.0631,0.690866463955248,0.574381820565824,0.715354629029097,0.652537107234494,0.116484643389425,0.0628175217946029,True,0.285165227878671,0.0370029438850035,1.16344452835307,41.9269351804705
38573,1564:1053,Pancreas,PSN1,SIDM00469,910546,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,1.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.264076292656999,0.0614480839510606,0.879573819563909,12.9219416554765,151.5731,0.941488455253216,0.97486006309675,0.0556167730372905,0.232274593388593,0.0930645133746898,0.139210080013903,7.79990769022287,4.3525,5.12203396525359,147.2206,0.248624780842634,0.15944730591775,0.257437431321958,0.210350643368175,0.0891774749248844,0.0470867879537828,True,0.285165227878671,0.0370029438850035,1.16344452835307,41.9269351804705
38573,1190:1053,Pancreas,PSN1,SIDM00469,910546,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.01,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.614956338698706,0.0614480839510606,0.879573819563909,12.9219416554765,151.5731,0.941488455253216,0.97486006309675,0.0550359810645304,0.540899495694257,0.476159834432589,0.0647396612616681,11.4314783567462,53.9446,1.49046329873024,97.6285,0.578974293369618,0.56011929307676,0.599496375145567,0.584151389197071,0.0188550002928581,0.0153449859484953,True,0.285165227878671,0.0370029438850035,1.16344452835307,41.9269351804705
38573,1372:1053,Pancreas,PSN1,SIDM00469,910546,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.259615386307696,0.0614480839510606,0.879573819563909,12.9219416554765,151.5731,0.941488455253216,0.97486006309675,0.0610129256387888,0.22835089695222,0.128514463511469,0.0998364334407514,8.96069780195399,9.7313,3.96124385352247,141.8418,0.2444248890148,0.16470408611348,0.253088671876808,0.223935969166829,0.0797208029013201,0.0291527027099793,True,0.285165227878671,0.0370029438850035,1.16344452835307,41.9269351804705
38573,1558:1053,Pancreas,PSN1,SIDM00469,910546,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.958738464273237,0.0614480839510606,0.879573819563909,12.9219416554765,151.5731,0.941488455253216,0.97486006309675,0.0396246988582314,0.843281252983647,0.792622812401581,0.0506584405820668,12.0822129885391,84.6913,0.839728666937395,66.8818,0.902641195720451,0.921415333683574,0.934635839774689,0.923006591487645,-0.0187741379631235,0.0116292482870441,True,0.285165227878671,0.0370029438850035,1.16344452835307,41.9269351804705
38573,1005:1053,Pancreas,PSN1,SIDM00469,910546,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,8.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.287103130079262,0.0614480839510606,0.879573819563909,12.9219416554765,151.5731,0.941488455253216,0.97486006309675,0.110018284523707,0.25252839673257,0.161910622966178,0.0906177737663925,9.50728787401759,14.2138,3.41465378145887,137.3593,0.270304282436687,0.156633657790086,0.279885375504344,0.254940919417958,0.113670624646601,0.0249444560863853,True,0.285165227878671,0.0370029438850035,1.16344452835307,41.9269351804705
38573,1079:1053,Pancreas,PSN1,SIDM00469,910546,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.529958349503371,0.0614480839510606,0.879573819563909,12.9219416554765,151.5731,0.941488455253216,0.97486006309675,0.108719241983999,0.466137489682465,0.270866803513603,0.195270686168862,9.0876652371025,10.6265,3.83427641837396,140.9466,0.498949667822473,0.363473579258704,0.516635230035505,0.460427446258701,0.135476088563769,0.0562077837768041,True,0.285165227878671,0.0370029438850035,1.16344452835307,41.9269351804705
38573,1561:1054,Pancreas,PSN1,SIDM00469,910546,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.5,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,8.0,0.879763209050645,0.0791983900621373,0.660720541988264,10.3146249439098,19.899,0.900779142807611,0.918893840911051,0.111608801415131,0.581277624305276,0.358686583716039,0.222591040589238,8.26340708451623,4.8012,2.05121785939355,15.0978,0.792472349322313,0.646313099446391,0.808408994256779,0.725652184980471,0.146159249875923,0.0827568092763082,True,0.285165227878671,0.0370029438850035,1.16344452835307,41.9269351804705
38574,1372:1057,Pancreas,PSN1,SIDM00469,910546,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,1057,Dactolisib,"PI3K (class 1), MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,0.168467294422745,0.057921405359166,0.718819985017678,10.8513355882979,0.3608,0.918100582963586,0.935366147007606,0.0302905577902452,0.121097658052926,0.057762701295521,0.0633349567574052,7.71690358592747,0.0411,3.13443200237047,0.3197,0.15466992121982,0.111796802294127,0.157578604080999,0.133297113302504,0.0428731189256933,0.0242814907784945,True,0.285165227878671,0.0370029438850035,1.16344452835307,41.9269351804705
38574,1005:1057,Pancreas,PSN1,SIDM00469,910546,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,0.8,1057,Dactolisib,"PI3K (class 1), MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,0.81166087048715,0.057921405359166,0.718819985017678,10.8513355882979,0.3608,0.918100582963586,0.935366147007606,0.0398500453828909,0.583438054763009,0.569052905579389,0.0143851491836193,10.68153219092,0.3208,0.169803397377919,0.04,0.745186318362984,0.757382132784464,0.759200101104405,0.755238685768157,-0.0121958144214802,0.0039614153362478,True,0.285165227878671,0.0370029438850035,1.16344452835307,41.9269351804705
38576,1372:1083,Pancreas,PSN1,SIDM00469,910546,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.249051630802676,0.0859938704440824,0.542122780157151,9.33312320813602,10.0779,0.859410640706061,0.880280545997675,0.0273483985244011,0.135016562493419,0.0657176410094429,0.0692989214839764,6.97642111755094,1.9676,2.35670209058508,8.1103,0.214037621597018,0.170512987780636,0.219235305544591,0.184458681732535,0.0435246338163816,0.034776623812056,True,0.285165227878671,0.0370029438850035,1.16344452835307,41.9269351804705
38576,1011:1083,Pancreas,PSN1,SIDM00469,910546,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.940551605637474,0.0859938704440824,0.542122780157151,9.33312320813602,10.0779,0.859410640706061,0.880280545997675,0.0640775718883243,0.509894451329459,0.250779788923935,0.259114662405524,7.00434364002392,2.006,2.3287795681121,8.0719,0.808320058018016,0.719082626529274,0.827949280949545,0.69849894586859,0.0892374314887423,0.129450335080955,True,0.285165227878671,0.0370029438850035,1.16344452835307,41.9269351804705
38576,1558:1083,Pancreas,PSN1,SIDM00469,910546,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.956889799431383,0.0859938704440824,0.542122780157151,9.33312320813602,10.0779,0.859410640706061,0.880280545997675,0.0566930089305997,0.51875175837176,0.54587233842542,-0.0271205800536601,9.55967030752272,11.7915,-0.226547099386694,-1.7136,0.82236127561442,0.882417403707985,0.842331475103064,0.85184136786801,-0.0600561280935653,-0.0095098927649461,True,0.285165227878671,0.0370029438850035,1.16344452835307,41.9269351804705
38576,1079:1083,Pancreas,PSN1,SIDM00469,910546,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.544793186901766,0.0859938704440824,0.542122780157151,9.33312320813602,10.0779,0.859410640706061,0.880280545997675,0.047686780019343,0.29534479709386,0.266096743002048,0.0292480540918116,8.90874991666287,7.5097,0.424373291473156,2.5682,0.468201061807543,0.448783661579914,0.4795708440217,0.468501069024253,0.0194174002276292,0.0110697749974463,True,0.285165227878671,0.0370029438850035,1.16344452835307,41.9269351804705
38576,1011:1085,Pancreas,PSN1,SIDM00469,910546,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.940551605637474,0.0856193182281902,0.497921797088109,8.98360363046978,9.887,0.886241284353916,0.863707045021904,0.104947295961,0.468321145733118,0.251539773450089,0.216781372283029,7.01248634434884,2.5217,1.97111728612094,7.3653,0.833555662981292,0.74113341185917,0.812361047995749,0.699047313726909,0.092422251122122,0.11331373426884,True,0.285165227878671,0.0370029438850035,1.16344452835307,41.9269351804705
38578,1564:1168,Pancreas,PSN1,SIDM00469,910546,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,1.0,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.228223795657369,0.0494604013981097,0.912487887006129,13.6241139015002,246.6022,0.976279232582858,0.982055386535217,0.0133381227873734,0.208251449063911,0.114574179002185,0.093677270061726,9.01598103514453,10.1114,4.60813286635572,236.4908,0.222810152081523,0.201003512602253,0.224128407860832,0.197483370214746,0.0218066394792699,0.0266450376460859,True,0.285165227878671,0.0370029438850035,1.16344452835307,41.9269351804705
38578,1372:1168,Pancreas,PSN1,SIDM00469,910546,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.247047865304854,0.0494604013981097,0.912487887006129,13.6241139015002,246.6022,0.976279232582858,0.982055386535217,0.0489185233591753,0.225428184601401,0.16977323496895,0.0556549496324509,10.5524800455582,29.3321,3.0716338559421,217.2701,0.241187700351056,0.202440246999132,0.242614686854659,0.228908250690671,0.0387474533519246,0.0137064361639876,True,0.285165227878671,0.0370029438850035,1.16344452835307,41.9269351804705
38578,1005:1168,Pancreas,PSN1,SIDM00469,910546,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,8.0,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.293392385604536,0.0494604013981097,0.912487887006129,13.6241139015002,246.6022,0.976279232582858,0.982055386535217,0.100542212593128,0.267716998003971,0.0793193129281624,0.188397685075808,7.04172051324966,2.5734,6.58239338825059,244.0288,0.286432893063651,0.14785519343539,0.288127572651352,0.218671049450104,0.138577699628261,0.0694565232012485,True,0.285165227878671,0.0370029438850035,1.16344452835307,41.9269351804705
38579,1079:1507,Pancreas,PSN1,SIDM00469,910546,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.5,1507,Ruxolitinib,"JAK1, JAK2","Other, kinases",Targeted,Advanced clinical trials,10.0,0.514879584400941,0.0553363455686282,0.878227052790495,12.8969835661328,148.9735,0.957117599329416,0.97455998308882,0.0599443461895293,0.452181179950433,0.390286008532908,0.0618951714175253,11.252142981024,47.639,1.64484058510879,101.3345,0.492800311765556,0.434092985569548,0.50178103906656,0.486946824394227,0.0587073261960084,0.0148342146723325,True,0.285165227878671,0.0370029438850035,1.16344452835307,41.9269351804705
38579,1085:1510,Pancreas,PSN1,SIDM00469,910546,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,5.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.593479409589112,0.056398290659004,0.829413269732577,12.1193169435888,86.8976,0.93640796825534,0.963363391895197,0.0869884385065047,0.492239697626265,0.299025332897916,0.193214364728349,9.03038545527267,10.2128,3.08893148831611,76.6848,0.55573884813472,0.443194206918988,0.571736337041726,0.513960814131789,0.112544641215732,0.0577755229099373,True,0.285165227878671,0.0370029438850035,1.16344452835307,41.9269351804705
38579,1372:1510,Pancreas,PSN1,SIDM00469,910546,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.194259402209477,0.056398290659004,0.829413269732577,12.1193169435888,86.8976,0.93640796825534,0.963363391895197,0.056774310713269,0.161121325962858,0.0786516048901353,0.082469721072723,8.24027614231177,5.9061,3.87904080127701,80.9915,0.181906052137474,0.109991590291725,0.187142396620055,0.159967653218481,0.071914461845749,0.0271747434015745,True,0.285165227878671,0.0370029438850035,1.16344452835307,41.9269351804705
38579,1594:1510,Pancreas,PSN1,SIDM00469,910546,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.675205994702966,0.056398290659004,0.829413269732577,12.1193169435888,86.8976,0.93640796825534,0.963363391895197,0.0663740354316932,0.560024811809624,0.431585078675861,0.128439733133762,10.1279253136687,21.8544,1.9913916299201,65.0432,0.63226827365363,0.565722071605855,0.650468737285019,0.616073097844879,0.0665462020477747,0.0343956394401407,True,0.285165227878671,0.0370029438850035,1.16344452835307,41.9269351804705
38579,1564:1510,Pancreas,PSN1,SIDM00469,910546,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.212184418401382,0.056398290659004,0.829413269732577,12.1193169435888,86.8976,0.93640796825534,0.963363391895197,0.0762010787068893,0.175988572252595,0.0820511319980923,0.0939374402545027,8.09029165607613,5.3229,4.02902528751265,81.5747,0.198691180130679,0.10279188285951,0.204410701018465,0.172835749145337,0.0958992972711685,0.0315749518731271,True,0.285165227878671,0.0370029438850035,1.16344452835307,41.9269351804705
38579,1079:1510,Pancreas,PSN1,SIDM00469,910546,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.05,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.7450783083658,0.056398290659004,0.829413269732577,12.1193169435888,86.8976,0.93640796825534,0.963363391895197,0.147566115440047,0.617977835948495,0.210635195370703,0.407342640577792,7.16349354771669,2.8,4.95582339587209,84.0976,0.697697264927944,0.456521449929986,0.717781166374812,0.561738928545812,0.241175814997958,0.156042237829,True,0.285165227878671,0.0370029438850035,1.16344452835307,41.9269351804705
38426,1088:1561,Pancreas,PSN1,SIDM00469,910546,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.651727680012883,0.0623172577739819,0.777586849154978,11.4687843800064,55.3577,0.927916334755173,0.950736197137508,0.0968562901571876,0.506774873208302,0.506036605099437,0.0007382681088643,11.4558885747538,54.8651,0.0128958052525601,0.492600000000003,0.604748760096046,0.589511652570535,0.619621096064699,0.619435204585334,0.0152371075255118,0.0001858914793649,True,0.649825479625236,0.0614096177339222,0.397017214516151,119.033578749027
38426,1372:1561,Pancreas,PSN1,SIDM00469,910546,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.244505319897397,0.0623172577739819,0.777586849154978,11.4687843800064,55.3577,0.927916334755173,0.950736197137508,0.0645738217459427,0.190124121300647,0.0877863628906765,0.10233775840997,7.85689366830208,4.5278,3.61189071170428,50.8299,0.226880480267334,0.131609739900444,0.232460058019141,0.195643355234703,0.0952707403668897,0.0368167027844384,True,0.649825479625236,0.0614096177339222,0.397017214516151,119.033578749027
38426,1564:1561,Pancreas,PSN1,SIDM00469,910546,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.29965194112627,0.0623172577739819,0.777586849154978,11.4687843800064,55.3577,0.927916334755173,0.950736197137508,0.0832156779043202,0.233005408743549,0.0356477781261519,0.197357630617397,5.0506861968604,0.6473,6.41809818314596,54.7104,0.278051930912161,0.111312616833445,0.284889946971262,0.176512132468505,0.166739314078716,0.108377814502756,True,0.649825479625236,0.0614096177339222,0.397017214516151,119.033578749027
38426,1079:1561,Pancreas,PSN1,SIDM00469,910546,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.05,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.81434140883105,0.0623172577739819,0.777586849154978,11.4687843800064,55.3577,0.927916334755173,0.950736197137508,0.168325014973061,0.633221170229362,0.25929899691225,0.373922173317112,7.49887210129976,3.5328,3.9699122787066,51.8249,0.755640695321872,0.501383963444258,0.774223854203633,0.632672210615512,0.254256731877614,0.141551643588122,True,0.649825479625236,0.0614096177339222,0.397017214516151,119.033578749027
38426,1054:1561,Pancreas,PSN1,SIDM00469,910546,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,2.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.911206811534247,0.0623172577739819,0.777586849154978,11.4687843800064,55.3577,0.927916334755173,0.950736197137508,0.10158418705313,0.708542433509469,0.493987881370909,0.21455455213856,9.33313987624039,12.5975,2.13564450376596,42.7602,0.845523684762806,0.71677317154015,0.866317298803864,0.802118316983705,0.128750513222656,0.0641989818201585,True,0.649825479625236,0.0614096177339222,0.397017214516151,119.033578749027
38427,1005:1594,Pancreas,PSN1,SIDM00469,910546,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,0.8,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.902241127253829,0.0636788636634315,0.67749671697104,10.464103166516,11.0357,0.901819827168196,0.923793111683952,0.0450796723405736,0.61126540163072,0.564899995666636,0.0463654059640844,10.0168840827937,8.0942,0.447219083722313,2.9415,0.813658937444087,0.78968456155106,0.833484138435051,0.819581284400845,0.0239743758930268,0.0139028540342064,True,0.649825479625236,0.0614096177339222,0.397017214516151,119.033578749027
38427,1564:1594,Pancreas,PSN1,SIDM00469,910546,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.323083489654325,0.0636788636634315,0.67749671697104,10.464103166516,11.0357,0.901819827168196,0.923793111683952,0.0546548203399537,0.218888003548353,0.0855602764409255,0.133327727107427,6.98608184284707,0.9904,3.47802132366894,10.0453,0.291363096800961,0.21604946907889,0.298462302241479,0.239514209129583,0.0753136277220716,0.0589480931118961,True,0.649825479625236,0.0614096177339222,0.397017214516151,119.033578749027
39391,1011:1598,Pancreas,PSN1,SIDM00469,910546,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1598,LGK974,PORCN,WNT signaling,Targeted,Early clinical trials,10.0,0.90738351198327,0.0515208743778656,0.673058043411849,10.4241767077939,26.8361,0.930261727788217,0.922508646090718,0.0474509142076106,0.610721771199632,0.434457161569158,0.176264609630474,8.83265613303868,8.9048,1.59152057475519,17.9313,0.844104153624097,0.771245660227958,0.837069135124728,0.776795315147748,0.0728584933961395,0.06027381997698,True,0.415790971847582,0.0381691401418174,0.806072520234728,59.6665611982988
35907,1022:1005,Pancreas,HuP-T3,SIDM00533,907285,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,8.0,0.6515306654203,0.0570876789645153,0.915728709334489,16.6706383296374,1629.9798,0.966929825501144,0.973011008775851,0.0494933822392795,0.596625335337172,0.336688768602136,0.259936566735036,9.21570825134836,9.2902,7.45493007828902,1620.6896,0.629984432623495,0.521172209503598,0.633946510009007,0.521793946919233,0.108812223119896,0.112152563089775,True,0.489442115244753,0.0646968318356043,0.677336585695036,71.7365152885609
35907,1080:1011,Pancreas,HuP-T3,SIDM00533,907285,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.474135434617761,0.171288037998888,0.556962625154128,9.73579876097284,16.6532,0.878178902331681,0.823031028735949,0.0686922752173043,0.264075716343301,0.147892571589158,0.116183144754143,6.456207932176,1.7149,3.27959082879683,14.9383,0.41637573552918,0.292472326923529,0.390228174513622,0.310836601216489,0.123903408605651,0.0793915732971324,True,0.489442115244753,0.0646968318356043,0.677336585695036,71.7365152885609
35907,1079:1011,Pancreas,HuP-T3,SIDM00533,907285,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.05,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.629917359256571,0.171288037998888,0.556962625154128,9.73579876097284,16.6532,0.878178902331681,0.823031028735949,0.0751971791351865,0.350840426041696,0.198044265025331,0.152796161016364,6.49323105754344,1.7595,3.24256770342939,14.8937,0.553180135111607,0.416470497567682,0.518441532207568,0.414359103182961,0.136709637543925,0.104082429024607,True,0.489442115244753,0.0646968318356043,0.677336585695036,71.7365152885609
37969,1088:1022,Pancreas,HuP-T3,SIDM00533,907285,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.919010372950739,0.0987295493579309,0.544695644932281,9.57637552086019,1.4911,0.848368132809218,0.816429708985221,0.0507818639030698,0.500580947793859,0.270789966444336,0.229790981349523,6.19341834567306,0.1429,3.38295717518713,1.3482,0.779659114132522,0.58773447359384,0.750307371342571,0.587908543722396,0.191924640538682,0.162398827620175,True,0.604942543826536,0.0765820801337218,0.468033224658346,102.037628948287
37969,1005:1022,Pancreas,HuP-T3,SIDM00533,907285,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,0.8,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.979315792568253,0.0987295493579309,0.544695644932281,9.57637552086019,1.4911,0.848368132809218,0.816429708985221,0.0977290063369728,0.533429047225332,0.533935942760694,-0.0005068955353618,9.58308672096794,1.4981,-0.00671120010775,-0.0069999999999999,0.830820310371708,0.842798626029264,0.79954250753113,0.799817985878981,-0.0119783156575554,-0.000275478347851,True,0.604942543826536,0.0765820801337218,0.468033224658346,102.037628948287
38065,1564:1053,Pancreas,HuP-T3,SIDM00533,907285,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,1.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.565085151881154,0.069805830485734,0.80598743188782,13.5790331594958,239.0156,0.910970710226345,0.934083500158676,0.0523187221231702,0.45545153036263,0.328272601292912,0.127178929069718,10.0500332848476,20.7058,3.5289998746482,218.3098,0.514776022147537,0.492951627666334,0.527836716556845,0.47215590484232,0.021824394481203,0.055680811714525,True,0.369808795563852,0.0642067048978295,0.926557537378413,52.4048352055779
38065,1372:1053,Pancreas,HuP-T3,SIDM00533,907285,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.552552550715366,0.069805830485734,0.80598743188782,13.5790331594958,239.0156,0.910970710226345,0.934083500158676,0.0658592991685012,0.445350411334142,0.316988201202062,0.12836221013208,9.95455528553126,19.3798,3.62447787396456,219.6358,0.503359189562556,0.409533200597054,0.516130220593813,0.459621135455197,0.0938259889655019,0.0565090851386166,True,0.369808795563852,0.0642067048978295,0.926557537378413,52.4048352055779
38065,1558:1053,Pancreas,HuP-T3,SIDM00533,907285,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.993661927193398,0.069805830485734,0.80598743188782,13.5790331594958,239.0156,0.910970710226345,0.934083500158676,0.0378847914399074,0.800879024863309,0.616292645847911,0.184586379015398,10.5770900178864,29.8367,3.00194314160944,209.1789,0.905196911540249,0.823006714861493,0.928163210927225,0.849656280490611,0.0821901966787563,0.0785069304366138,True,0.369808795563852,0.0642067048978295,0.926557537378413,52.4048352055779
38066,1011:1080,Pancreas,HuP-T3,SIDM00533,907285,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.1,0.840974638053407,0.0792380278968204,0.571599194664197,9.92722017794727,0.1902,0.823121183504274,0.830734189874524,0.133973574137779,0.480700425844342,0.261947733578838,0.218752692265504,6.44962299616374,0.0171,3.47759718178353,0.1731,0.692224039371599,0.569541176764937,0.698626384648318,0.550999764540755,0.122682862606662,0.147626620107564,True,0.369808795563852,0.0642067048978295,0.926557537378413,52.4048352055779
37973,1011:1083,Pancreas,HuP-T3,SIDM00533,907285,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.858342518881404,0.111697283673475,0.695463224574581,11.6551384931925,50.3925,0.888416879397566,0.889446326359252,0.18397735454514,0.596945655970729,0.417146571686102,0.179799084284628,8.81977859465821,7.0605,2.83535989853432,43.332,0.762565982078863,0.713515475250666,0.763449600177012,0.671922853931006,0.0490505068281976,0.0915267462460062,True,0.604942543826536,0.0765820801337218,0.468033224658346,102.037628948287
37973,1558:1083,Pancreas,HuP-T3,SIDM00533,907285,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.948370530499217,0.111697283673475,0.695463224574581,11.6551384931925,50.3925,0.888416879397566,0.889446326359252,0.0647853560711351,0.659556827232491,0.625666048588306,0.0338907786441849,11.1287753624087,34.9877,0.52636313078388,15.4048,0.842548387218728,0.861139647383164,0.843524684379903,0.828476369127167,-0.0185912601644359,0.015048315252736,True,0.604942543826536,0.0765820801337218,0.468033224658346,102.037628948287
37973,1079:1083,Pancreas,HuP-T3,SIDM00533,907285,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.497191361895838,0.111697283673475,0.695463224574581,11.6551384931925,50.3925,0.888416879397566,0.889446326359252,0.0561495639851485,0.345778307774707,0.335353445598797,0.0104248621759103,11.3426238180362,40.5779,0.312514675156358,9.8146,0.441713198198926,0.44906085087441,0.442225030335807,0.437643475198139,-0.0073476526754838,0.0045815551376672,True,0.604942543826536,0.0765820801337218,0.468033224658346,102.037628948287
37973,1558:1085,Pancreas,HuP-T3,SIDM00533,907285,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.884765811562232,0.149315262781665,0.641389854013426,10.8693720673426,36.5374,0.905538445883965,0.865121951964616,0.171849483879107,0.567479814713971,0.322303275540374,0.245176539173597,7.20962761185014,2.891,3.65974445549248,33.6464,0.801189457973328,0.640662466153653,0.765430325930275,0.618811727221946,0.160526991819675,0.146618598708329,True,0.604942543826536,0.0765820801337218,0.468033224658346,102.037628948287
36974,1011:1088,Pancreas,HuP-T3,SIDM00533,907285,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,0.98178843862737,0.0869705958714311,0.839652379960237,14.3233674662925,200.1996,0.948614787454569,0.946533924919396,0.0575893011544505,0.824360999110917,0.630752960123901,0.193608038987015,10.8842439492202,18.458,3.43912351707235,181.7416,0.931339031033856,0.823100205222127,0.92929606425445,0.849854122510055,0.108238825811729,0.079441941744395,True,0.313981693349164,0.0499614999477045,1.10163855141757,44.5667541160392
36974,1022:1088,Pancreas,HuP-T3,SIDM00533,907285,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,0.657929994070209,0.0869705958714311,0.839652379960237,14.3233674662925,200.1996,0.948614787454569,0.946533924919396,0.0938982288543174,0.552432485368276,0.271764979306748,0.280667506061527,7.87038303735381,2.2852,6.4529844289387,197.9144,0.624122121484897,0.440554387161873,0.62275305960947,0.483888933714012,0.183567734323024,0.138864125895458,True,0.313981693349164,0.0499614999477045,1.10163855141757,44.5667541160392
36974,1057:1088,Pancreas,HuP-T3,SIDM00533,907285,1057,Dactolisib,"PI3K (class 1), MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.0125,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,0.963561787738926,0.0869705958714311,0.839652379960237,14.3233674662925,200.1996,0.948614787454569,0.946533924919396,0.100266079961091,0.80905694831373,0.669046327522234,0.140010620791496,11.6382117128482,31.128,2.68515575344436,169.0716,0.914048960475306,0.884752627354453,0.912043920850876,0.856570203146242,0.0292963331208531,0.0554737177046339,True,0.313981693349164,0.0499614999477045,1.10163855141757,44.5667541160392
36975,1022:1179,Pancreas,HuP-T3,SIDM00533,907285,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,4.0,0.666728747166447,0.10809566039936,0.525453399877221,9.32764299536454,5.0198,0.858136982728368,0.805793715820324,0.119369021912785,0.35033488699449,0.165519011714274,0.184815875280215,5.43766135077886,0.3386,3.88998164458569,4.6812,0.57214459539168,0.339224777820986,0.53724583462348,0.395197948402332,0.232919817570694,0.142047886221149,True,0.313981693349164,0.0499614999477045,1.10163855141757,44.5667541160392
36976,1179:1190,Pancreas,HuP-T3,SIDM00533,907285,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.0,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.2,0.498457624473543,0.0882178238520519,0.756222844402469,12.63996529753,2.4933,0.91804045716863,0.914748007914008,0.0877359155007757,0.37694504259348,0.318016041432078,0.0589290011614017,10.8220852714781,0.7072,1.8178800260519,1.7861,0.457604265450881,0.370629136044893,0.455963119016721,0.430435133106794,0.0869751294059878,0.0255279859099276,True,0.313981693349164,0.0499614999477045,1.10163855141757,44.5667541160392
36976,1168:1190,Pancreas,HuP-T3,SIDM00533,907285,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.2,0.811310924804469,0.0882178238520519,0.756222844402469,12.63996529753,2.4933,0.91804045716863,0.914748007914008,0.042454707208287,0.613531855250433,0.630328931312855,-0.016797076062422,13.0121752907624,3.2271,-0.372209993232367,-0.7338,0.7448162523134,0.737996195496565,0.74214505226376,0.748786338849809,0.0068200568168345,-0.0066412865860493,True,0.313981693349164,0.0499614999477045,1.10163855141757,44.5667541160392
36976,1011:1190,Pancreas,HuP-T3,SIDM00533,907285,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.2,0.887969454226613,0.0882178238520519,0.756222844402469,12.63996529753,2.4933,0.91804045716863,0.914748007914008,0.08530491009436,0.671502786417757,0.37508105418303,0.296421732234727,7.99388536359313,0.0996,4.6460799339369,2.3937,0.815191883709979,0.663685479767025,0.812268289342283,0.658820196567166,0.151506403942955,0.153448092775117,True,0.313981693349164,0.0499614999477045,1.10163855141757,44.5667541160392
36976,1022:1190,Pancreas,HuP-T3,SIDM00533,907285,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.2,0.611857865844025,0.0882178238520519,0.756222844402469,12.63996529753,2.4933,0.91804045716863,0.914748007914008,0.0769383998072577,0.462700895678593,0.257907285240578,0.204793610438015,7.98217848040446,0.0988,4.65778681712557,2.3945,0.561710274881672,0.405586878261307,0.559695763907338,0.453589112630896,0.156123396620365,0.106106651276442,True,0.313981693349164,0.0499614999477045,1.10163855141757,44.5667541160392
36976,1558:1372,Pancreas,HuP-T3,SIDM00533,907285,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.72625051279128,0.120843627471871,0.465420569224278,8.55455797408896,0.7344,0.714723109055412,0.770151646907656,0.0420356488363872,0.338011927062741,0.163086936375578,0.174924990687163,5.01533962225983,0.0632,3.53921835182913,0.6712,0.519068024455271,0.393157765736142,0.559323028493734,0.410921827931501,0.125910258719129,0.148401200562233,True,0.313981693349164,0.0499614999477045,1.10163855141757,44.5667541160392
38188,1057:1510,Pancreas,HuP-T3,SIDM00533,907285,1057,Dactolisib,"PI3K (class 1), MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.0125,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.990881470891128,0.081833826056238,0.768652343492041,12.8606483442411,145.2683,0.88823035297313,0.919687384827356,0.115874881630063,0.761643364723306,0.54574549196466,0.215897872758646,9.65518810419902,15.7482,3.20546024004205,129.5201,0.880130998644161,0.754723396871263,0.911301188637745,0.812239651797683,0.125407601772898,0.0990615368400624,True,0.508548675357491,0.0864014437630406,0.610791230747544,77.424247392967
38188,1594:1510,Pancreas,HuP-T3,SIDM00533,907285,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.765751081704019,0.081833826056238,0.768652343492041,12.8606483442411,145.2683,0.88823035297313,0.919687384827356,0.0907249516169217,0.588596363483359,0.43565071799378,0.152945645489579,9.8920618607475,18.5583,2.96858648349357,126.71,0.680163353591517,0.578772119762648,0.704251609761088,0.63506616945663,0.101391233828869,0.0691854403044581,True,0.508548675357491,0.0864014437630406,0.610791230747544,77.424247392967
38188,1564:1510,Pancreas,HuP-T3,SIDM00533,907285,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.565105416630516,0.081833826056238,0.768652343492041,12.8606483442411,145.2683,0.88823035297313,0.919687384827356,0.0514914667781098,0.434369602813092,0.375983874228756,0.0583857285843362,11.2094037621474,46.2484,1.65124458209364,99.0199,0.501943783680751,0.458451950462294,0.519720322772692,0.495100513407661,0.0434918332184566,0.024619809365031,True,0.508548675357491,0.0864014437630406,0.610791230747544,77.424247392967
38188,1558:1510,Pancreas,HuP-T3,SIDM00533,907285,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.870522801603978,0.081833826056238,0.768652343492041,12.8606483442411,145.2683,0.88823035297313,0.919687384827356,0.120702844471789,0.669129391516154,0.405503689118806,0.263625702397348,8.55967138584602,7.3697,4.30097695839505,137.8986,0.773224775339859,0.596989373460434,0.800608838839745,0.670650767933275,0.176235401879425,0.12995807090647,True,0.508548675357491,0.0864014437630406,0.610791230747544,77.424247392967
38188,1079:1510,Pancreas,HuP-T3,SIDM00533,907285,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.05,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.75807484976857,0.081833826056238,0.768652343492041,12.8606483442411,145.2683,0.88823035297313,0.919687384827356,0.0860962441322813,0.582696009816988,0.283459003341771,0.299237006475217,7.34271903755137,3.1704,5.51792930668971,142.0979,0.67334509138999,0.474839451358213,0.697191876087047,0.535853908989259,0.198505640031777,0.161337967097788,True,0.508548675357491,0.0864014437630406,0.610791230747544,77.424247392967
38189,1510:1558,Pancreas,HuP-T3,SIDM00533,907285,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.801996264058835,0.0616397873368808,0.852716847250472,14.6462679938296,500.8366,0.958065053462458,0.95123866124152,0.0820581160927481,0.683875725794907,0.327429841967349,0.356445883827558,7.80671829489272,4.3731,6.83954969893685,496.4635,0.768364593602219,0.547635675173064,0.762889852544027,0.587143631843143,0.220728918429155,0.175746220700883,True,0.508548675357491,0.0864014437630406,0.610791230747544,77.424247392967
38189,1085:1558,Pancreas,HuP-T3,SIDM00533,907285,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,1.25,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.966413730419275,0.0616397873368808,0.852716847250472,14.6462679938296,500.8366,0.958065053462458,0.95123866124152,0.0773451116053409,0.824077269342692,0.807090783366455,0.0169864859762365,14.2168097343491,371.8915,0.429458259480516,128.9451,0.925887222300996,0.952417129871746,0.919290103129454,0.913157395110423,-0.0265299075707492,0.0061327080190316,True,0.508548675357491,0.0864014437630406,0.610791230747544,77.424247392967
38189,1564:1558,Pancreas,HuP-T3,SIDM00533,907285,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,1.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.729172318973331,0.0616397873368808,0.852716847250472,14.6462679938296,500.8366,0.958065053462458,0.95123866124152,0.0884749221748772,0.621777520937255,0.447023713329936,0.174753807607319,10.4796027270801,27.8872,4.1666652667495,472.9494,0.698594516760529,0.580387655219017,0.693616900514566,0.620964289780559,0.118206861541512,0.0726526107340073,True,0.508548675357491,0.0864014437630406,0.610791230747544,77.424247392967
38189,1079:1558,Pancreas,HuP-T3,SIDM00533,907285,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.524324494648694,0.0616397873368808,0.852716847250472,14.6462679938296,500.8366,0.958065053462458,0.95123866124152,0.075805841284472,0.447100330013031,0.369962812332834,0.0771375176801968,11.8104939328339,70.1525,2.83577406099569,430.6841,0.502336974997277,0.425230388290193,0.49875773034576,0.468645358398222,0.0771065867070836,0.0301123719475381,True,0.508548675357491,0.0864014437630406,0.610791230747544,77.424247392967
38189,1372:1561,Pancreas,HuP-T3,SIDM00533,907285,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.599088921529863,0.0701740646566855,0.578496038932255,10.0179674445374,20.2506,0.806622988384361,0.834300975442121,0.0826656721663856,0.346570568073222,0.196597486554313,0.149973081518909,6.6961985830772,2.0253,3.32176886146018,18.2253,0.483238896192381,0.35667855103232,0.499820471608933,0.40128623682663,0.126560345160061,0.0985342347823027,True,0.508548675357491,0.0864014437630406,0.610791230747544,77.424247392967
38189,1564:1561,Pancreas,HuP-T3,SIDM00533,907285,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.669962225229147,0.0701740646566855,0.578496038932255,10.0179674445374,20.2506,0.806622988384361,0.834300975442121,0.084040740044454,0.387570493529301,0.178309725190697,0.209260768338604,5.7388965618761,1.0431,4.27907088266128,19.2075,0.540406932218971,0.361712628151442,0.558950138018052,0.409802522952466,0.178694304067528,0.149147615065586,True,0.508548675357491,0.0864014437630406,0.610791230747544,77.424247392967
38189,1079:1561,Pancreas,HuP-T3,SIDM00533,907285,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.05,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.746778889402067,0.0701740646566855,0.578496038932255,10.0179674445374,20.2506,0.806622988384361,0.834300975442121,0.0852773176281875,0.432008629477325,0.217646668703265,0.21436196077406,6.14365183849836,1.3809,3.87431560603902,18.8697,0.602369019431849,0.4306479899527,0.623038355867729,0.475462395404234,0.17172102947915,0.147575960463495,True,0.508548675357491,0.0864014437630406,0.610791230747544,77.424247392967
38376,1053:1564,Pancreas,HuP-T3,SIDM00533,907285,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.90109958876536,0.106189246903609,0.533573274085053,9.43244131255644,13.4952,0.757028192942927,0.810324890055215,0.139615381933629,0.480802657854229,0.289886233415946,0.190916424438282,6.6015336798635,1.8967,2.83090763269294,11.5985,0.682157793344655,0.537423553737318,0.73018342519509,0.598546084880676,0.144734239607337,0.131637340314413,True,,,,
38376,1085:1594,Pancreas,HuP-T3,SIDM00533,907285,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,5.0,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.755304466896886,0.0606146507043674,0.785382973153137,13.1712420137231,72.0658,0.923618518231979,0.926218404524185,0.0601414164456424,0.593203267847322,0.389222875810647,0.203980392036675,9.19708377452983,4.5855,3.97415823919324,67.4803,0.697613192529297,0.60579684424891,0.699576898259224,0.604279362265399,0.0918163482803865,0.0952975359938256,True,,,,
38376,1088:1594,Pancreas,HuP-T3,SIDM00533,907285,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.964791575384944,0.0606146507043674,0.785382973153137,13.1712420137231,72.0658,0.923618518231979,0.926218404524185,0.140462324043518,0.757730875948926,0.395263062538573,0.362467813410353,7.82559349453213,1.7723,5.34564851919093,70.2935,0.891099365259738,0.626566021946541,0.893607713651417,0.707292555373336,0.264533343313197,0.186315158278082,True,,,,
38376,1073:1594,Pancreas,HuP-T3,SIDM00533,907285,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in pancreas,10.0,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.886320662111746,0.0606146507043674,0.785382973153137,13.1712420137231,72.0658,0.923618518231979,0.926218404524185,0.0469301318958394,0.69610115677638,0.501999125249253,0.194102031527127,9.85886327880533,7.2544,3.31237873491773,64.8114,0.818622176618037,0.718712951218957,0.820926509557961,0.73388355071096,0.0999092253990806,0.0870429588470006,True,,,,
38376,1083:1594,Pancreas,HuP-T3,SIDM00533,907285,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,1.0,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.958840805345512,0.0606146507043674,0.785382973153137,13.1712420137231,72.0658,0.923618518231979,0.926218404524185,0.0720001321121529,0.753057242482807,0.639129929045528,0.113927313437278,11.2271981953832,18.729,1.9440438183399,53.3368,0.885603123853579,0.80252123657564,0.888096000919805,0.840592835968988,0.0830818872779387,0.0475031649508166,True,,,,
38376,1190:1594,Pancreas,HuP-T3,SIDM00533,907285,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.1,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.86441955099695,0.0606146507043674,0.785382973153137,13.1712420137231,72.0658,0.923618518231979,0.926218404524185,0.0555086453765517,0.678900397013684,0.478967507497882,0.199932889515803,9.69841133748062,6.4909,3.47283067624244,65.5749,0.798393904822555,0.695382280652432,0.800641297363907,0.710118986113696,0.103011624170123,0.0905223112502115,True,,,,
38376,1079:1594,Pancreas,HuP-T3,SIDM00533,907285,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.05,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.747824768885415,0.0606146507043674,0.785382973153137,13.1712420137231,72.0658,0.923618518231979,0.926218404524185,0.0707064494860809,0.587328840384785,0.385783036553395,0.20154580383139,9.20422091067359,4.6083,3.96702110304947,67.4575,0.690704804935119,0.553289711294135,0.692649064300716,0.598532329097697,0.137415093640984,0.0941167352030191,True,,,,
38376,1510:1594,Pancreas,HuP-T3,SIDM00533,907285,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.780997489880607,0.0606146507043674,0.785382973153137,13.1712420137231,72.0658,0.923618518231979,0.926218404524185,0.0249320729954181,0.613382130627568,0.521086892505457,0.0922952381221117,11.2364852342172,18.8499,1.93475677950588,53.2159,0.721343744346421,0.689377263240786,0.723374249014609,0.68490765648075,0.0319664811056352,0.0384665925338589,True,,,,
38377,1564:2265,Pancreas,HuP-T3,SIDM00533,907285,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,2265,Galunisertib,TGFBR1,RTK signaling,Targeted,Early clinical trials,10.0,0.663582589001484,0.0575914711615875,0.899504965726094,16.0470573816142,1322.439,0.955905967800844,0.967544634411322,0.0706158533278477,0.596895833976212,0.555466692869053,0.0414291411071599,14.2621516342756,383.7651,1.78490574733862,938.6739,0.634322556955253,0.563207573800514,0.642045773477159,0.627481471268727,0.0711149831547385,0.0145643022084326,True,,,,
38377,1558:2265,Pancreas,HuP-T3,SIDM00533,907285,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,2265,Galunisertib,TGFBR1,RTK signaling,Targeted,Early clinical trials,10.0,0.825266491274669,0.0575914711615875,0.899504965726094,16.0470573816142,1322.439,0.955905967800844,0.967544634411322,0.0751098585665372,0.742331306948915,0.219452686063868,0.522878620885047,5.7350834526695,1.0403,10.3119739289447,1321.3987,0.788877164035519,0.453617963664339,0.798482165592264,0.504602551067425,0.33525920037118,0.293879614524839,True,,,,
37886,1011:1005,Pancreas,CAPAN-2,SIDM00943,910915,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,8.0,0.142643595221454,0.0318666829167345,0.94365227299802,18.6055348877697,6232.2392,0.990604244595143,0.981313016818866,0.0310138499976706,0.134605952859335,0.0740774169592326,0.0605285359001023,9.26350598481665,9.6031,9.34202890295303,6222.6361,0.141303350890684,0.109911282116039,0.139978016756655,0.11312343572596,0.0313920687746449,0.0268545810306947,True,0.411093680747564,0.0492537045884628,0.820640084551085,58.7632737527589
37886,1168:1011,Pancreas,CAPAN-2,SIDM00943,910915,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.872142439114171,0.192623287409083,0.158270200766938,3.30407677226994,0.1929,0.45684509634346,0.456583189809767,0.165063311131338,0.138034158935967,0.0765937092393384,0.0614404496966288,1.02264111411228,0.0397,2.28143565815766,0.1532,0.398433996622333,0.214487906619109,0.398205576819219,0.279819240317628,0.183946090003224,0.118386336501591,True,0.411093680747564,0.0492537045884628,0.820640084551085,58.7632737527589
37886,1089:1011,Pancreas,CAPAN-2,SIDM00943,910915,1089,Oxaliplatin,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved in pancreas,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.949403503923914,0.192623287409083,0.158270200766938,3.30407677226994,0.1929,0.45684509634346,0.456583189809767,0.131764057263327,0.150262283174873,0.0417286787280042,0.108533604446869,-1.4967625027946,0.0069,4.80083927506454,0.186,0.433730335218939,0.100938562217868,0.433481680238151,0.187029407785562,0.332791773001071,0.246452272452589,True,0.411093680747564,0.0492537045884628,0.820640084551085,58.7632737527589
38052,1372:1053,Pancreas,CAPAN-2,SIDM00943,910915,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.583745404890408,0.0701419759231678,0.782116034331276,13.3560404510761,204.7853,0.904211473087605,0.921251547271985,0.0749391736015789,0.456556641131991,0.321865375351522,0.134691265780468,9.70296657312844,16.2785,3.65307387794763,188.5068,0.527829292464077,0.419751358755501,0.5377763574682,0.473725732435417,0.108077933708575,0.0640506250327829,True,0.487097206065485,0.0579019911434073,0.666678122567989,72.0514840054505
38052,1011:1053,Pancreas,CAPAN-2,SIDM00943,910915,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.235107879155805,0.0701419759231678,0.782116034331276,13.3560404510761,204.7853,0.904211473087605,0.921251547271985,0.0636524024569497,0.183881642085375,0.172597612345113,0.0112840297402619,12.4616546198941,110.1696,0.894385831182001,94.6157,0.212587241745973,0.153157160878545,0.21659349744812,0.211868987770366,0.0594300808674279,0.0047245096777545,True,0.487097206065485,0.0579019911434073,0.666678122567989,72.0514840054505
38052,1558:1053,Pancreas,CAPAN-2,SIDM00943,910915,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.885874061235011,0.0701419759231678,0.782116034331276,13.3560404510761,204.7853,0.904211473087605,0.921251547271985,0.0415776699739201,0.692856307690069,0.638664930499594,0.0541913771904747,12.2350425625507,94.1553,1.12099788852538,110.63,0.801017489879409,0.777349487133007,0.816112849600871,0.793234060553007,0.0236680027464018,0.0228787890478637,True,0.487097206065485,0.0579019911434073,0.666678122567989,72.0514840054505
38053,1564:1057,Pancreas,CAPAN-2,SIDM00943,910915,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,1.0,1057,Dactolisib,"PI3K (class 1), MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,0.586937048707826,0.0675789333621805,0.755229522566594,12.8402180977691,1.4323,0.897122148755536,0.910140709573396,0.0210822721919765,0.443272187072257,0.473295467946622,-0.0300232808743642,13.8626269311573,2.9094,-1.02240883338817,-1.4771,0.526554226320998,0.545311197666426,0.534195301985856,0.546425277771082,-0.018756971345428,-0.0122299757852267,True,0.487097206065485,0.0579019911434073,0.666678122567989,72.0514840054505
38053,1011:1057,Pancreas,CAPAN-2,SIDM00943,910915,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1057,Dactolisib,"PI3K (class 1), MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,0.255129041264921,0.0675789333621805,0.755229522566594,12.8402180977691,1.4323,0.897122148755536,0.910140709573396,0.062709653591482,0.192680984027379,0.138506154041175,0.0541748299862044,9.58613548031724,0.1501,3.25408261745189,1.2822,0.228881913709526,0.153387459471444,0.232203326649635,0.205820193275177,0.0754944542380817,0.0263831333744578,True,0.487097206065485,0.0579019911434073,0.666678122567989,72.0514840054505
38054,1561:1079,Pancreas,CAPAN-2,SIDM00943,910915,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,2.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.742658141131024,0.151808152676888,0.21809542527502,4.64818746451381,0.0979,0.510862991737512,0.540450026909902,0.0927396518793005,0.161970343123927,0.0706341268408077,0.0913362162831192,1.32167992405086,0.0098,3.32650754046295,0.0881,0.379396559816415,0.223584523374795,0.401369612359119,0.250771942817468,0.15581203644162,0.150597669541652,True,0.487097206065485,0.0579019911434073,0.666678122567989,72.0514840054505
38054,1372:1079,Pancreas,CAPAN-2,SIDM00943,910915,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.583840223118664,0.151808152676888,0.21809542527502,4.64818746451381,0.0979,0.510862991737512,0.540450026909902,0.0581804131100235,0.127332881753728,0.0523385254147637,0.0749943563389641,1.09947775532492,0.0084,3.54870970918889,0.0895,0.298262363079097,0.14564270784692,0.315536464295565,0.189823210151552,0.152619655232177,0.125713254144013,True,0.487097206065485,0.0579019911434073,0.666678122567989,72.0514840054505
38054,1011:1079,Pancreas,CAPAN-2,SIDM00943,910915,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.249703748648142,0.151808152676888,0.21809542527502,4.64818746451381,0.0979,0.510862991737512,0.540450026909902,0.056559059493546,0.0544592452541832,0.03917732351248,0.0152819217417032,3.26877375883538,0.0376,1.37941370567843,0.0603,0.127564404082461,0.0558103414827274,0.134952397676391,0.113463075108361,0.071754062599734,0.0214893225680306,True,0.487097206065485,0.0579019911434073,0.666678122567989,72.0514840054505
38054,1372:1080,Pancreas,CAPAN-2,SIDM00943,910915,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.1,0.59931138923281,0.0887491139900502,0.732505132963034,12.4334940777888,1.0804,0.865120196302792,0.900458908168942,0.0720670944929413,0.438998668856241,0.340416189705044,0.0985824791511963,9.93302755045972,0.1909,2.50046652732907,0.8895,0.518476386699588,0.474500955532259,0.539655279201788,0.491874857138484,0.0439754311673285,0.0477804220633044,True,0.487097206065485,0.0579019911434073,0.666678122567989,72.0514840054505
38054,1011:1080,Pancreas,CAPAN-2,SIDM00943,910915,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.1,0.249703748648142,0.0887491139900502,0.732505132963034,12.4334940777888,1.0804,0.865120196302792,0.900458908168942,0.0462135087536445,0.182909277604875,0.0769785721460027,0.105930705458872,6.24543814210872,0.0148,6.18805593568007,1.0656,0.216023756048023,0.129267699922948,0.224847964873397,0.159147699039964,0.0867560561250756,0.0657002658334337,True,0.487097206065485,0.0579019911434073,0.666678122567989,72.0514840054505
38054,1564:1080,Pancreas,CAPAN-2,SIDM00943,910915,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.1,0.570957278403313,0.0887491139900502,0.732505132963034,12.4334940777888,1.0804,0.865120196302792,0.900458908168942,0.0455350878239564,0.418229137133031,0.362716519325279,0.0555126178077523,10.891397938215,0.371,1.54209613957384,0.7094,0.493946672772782,0.500998235616666,0.514123567522158,0.488520351107874,-0.0070515628438841,0.0256032164142834,True,0.487097206065485,0.0579019911434073,0.666678122567989,72.0514840054505
38054,1079:1080,Pancreas,CAPAN-2,SIDM00943,910915,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.05,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.1,0.433118494290849,0.0887491139900502,0.732505132963034,12.4334940777888,1.0804,0.865120196302792,0.900458908168942,0.0727424335230566,0.317261520249268,0.223032070112399,0.0942294501368686,9.20380914791459,0.1152,3.2296849298742,0.9652,0.374699556803269,0.312092970871795,0.390005406476914,0.342358254774259,0.0626065859314743,0.0476471517026555,True,0.487097206065485,0.0579019911434073,0.666678122567989,72.0514840054505
37891,1564:1085,Pancreas,CAPAN-2,SIDM00943,910915,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.646834999643719,0.0758566502242867,0.755243000549854,12.8404666068729,143.2503,0.943641503128043,0.910146371074327,0.0565958152946446,0.488517605991587,0.468340218386382,0.0201773876052043,12.2878394421966,97.6649,0.552627164676279,45.5854,0.610380351339627,0.577242595828326,0.588714527609595,0.580071759271626,0.0331377555113009,0.008642768337969,True,0.411093680747564,0.0492537045884628,0.820640084551085,58.7632737527589
37891,1179:1085,Pancreas,CAPAN-2,SIDM00943,910915,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.0,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.486220920728635,0.0758566502242867,0.755243000549854,12.8404666068729,143.2503,0.943641503128043,0.910146371074327,0.143701206988755,0.367214947101207,0.316217165337963,0.0509977817632442,11.1152667808289,43.327,1.72519982604395,99.9233,0.45881824048867,0.333764762179989,0.442532206541585,0.419593751932543,0.125053478308681,0.022938454609042,True,0.411093680747564,0.0492537045884628,0.820640084551085,58.7632737527589
37891,1598:1085,Pancreas,CAPAN-2,SIDM00943,910915,1598,LGK974,PORCN,WNT signaling,Targeted,Early clinical trials,2.5,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.938234019690479,0.0758566502242867,0.755243000549854,12.8404666068729,143.2503,0.943641503128043,0.910146371074327,0.0586684046733796,0.708594676248988,0.168937977446266,0.539656698802723,3.83309445646519,0.2784,9.0073721504077,142.9719,0.88535656062659,0.442083518352103,0.853930288239768,0.459327879772204,0.443273042274487,0.394602408467564,True,0.411093680747564,0.0492537045884628,0.820640084551085,58.7632737527589
37891,1190:1085,Pancreas,CAPAN-2,SIDM00943,910915,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.1,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.977757683050172,0.0758566502242867,0.755243000549854,12.8404666068729,143.2503,0.943641503128043,0.910146371074327,0.0766424613346862,0.738444646357485,0.62272122305286,0.115723423304625,10.9150921748712,37.7138,1.92537443200172,105.5365,0.922652729728457,0.869679668977201,0.889902607018156,0.83736008700258,0.052973060751256,0.0525425200155762,True,0.411093680747564,0.0492537045884628,0.820640084551085,58.7632737527589
37891,1089:1085,Pancreas,CAPAN-2,SIDM00943,910915,1089,Oxaliplatin,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved in pancreas,10.0,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.896393443420734,0.0758566502242867,0.755243000549854,12.8404666068729,143.2503,0.943641503128043,0.910146371074327,0.104162818442977,0.676994873882291,0.468463907296974,0.208530966585317,9.30845963708314,12.3838,3.53200696978975,130.8665,0.845874056343664,0.767775968208145,0.815849239584201,0.712626842193444,0.0780980881355192,0.103222397390757,True,0.411093680747564,0.0492537045884628,0.820640084551085,58.7632737527589
38547,1510:1168,Pancreas,CAPAN-2,SIDM00943,910915,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.830613385827341,0.0569617348992077,0.734573519403136,12.469562250161,110.7751,0.875396797623901,0.901351616578647,0.0483369934237862,0.610146598090545,0.419169096733746,0.1909775013568,9.06339843933366,10.4492,3.40616381082732,100.3259,0.727116298016801,0.6252353723601,0.748674718067337,0.651408244253372,0.101880925656701,0.0972664738139659,True,0.475553980886618,0.0499030077870783,0.691430343278734,69.6610259149328
38547,1011:1168,Pancreas,CAPAN-2,SIDM00943,910915,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.368921351006564,0.0569617348992077,0.734573519403136,12.469562250161,110.7751,0.875396797623901,0.901351616578647,0.0397469935325674,0.270999855191851,0.177981467426563,0.0930183877652883,8.76046215769712,8.4702,3.70910009246386,102.3049,0.322952569246229,0.252809121355296,0.332527856120145,0.284244836573313,0.0701434478909335,0.0482830195468312,True,0.475553980886618,0.0499030077870783,0.691430343278734,69.6610259149328
38547,1079:1168,Pancreas,CAPAN-2,SIDM00943,910915,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.5,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.478346540355731,0.0569617348992077,0.734573519403136,12.469562250161,110.7751,0.875396797623901,0.901351616578647,0.0391470553751208,0.351380701643424,0.203980818381808,0.147399883261616,7.98963508803184,4.9642,4.47992716212915,105.8109,0.418743029581879,0.321377391305847,0.431158427434441,0.350652630084229,0.097365638276032,0.0805057973502121,True,0.475553980886618,0.0499030077870783,0.691430343278734,69.6610259149328
38547,1011:1179,Pancreas,CAPAN-2,SIDM00943,910915,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,4.0,0.368921351006564,0.073786071716431,0.588883474771374,10.2248049431712,9.349,0.836593170169871,0.831943740997941,0.0592574257660803,0.217251687098095,0.141520166273918,0.0757315208241772,7.38349809026909,1.3045,2.8413068529021,8.0445,0.308637082581933,0.247978677655167,0.306921808890415,0.258754199615008,0.0606584049267656,0.0481676092754076,True,0.475553980886618,0.0499030077870783,0.691430343278734,69.6610259149328
38547,1079:1179,Pancreas,CAPAN-2,SIDM00943,910915,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.05,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,4.0,0.639911724270608,0.073786071716431,0.588883474771374,10.2248049431712,9.349,0.836593170169871,0.831943740997941,0.096113816174048,0.376833439735417,0.23575761859729,0.141075821138127,7.16291337476858,1.1195,3.06189156840262,8.2295,0.535345778036416,0.377383657381884,0.532370553798133,0.441158487676487,0.157962120654532,0.0912120661216457,True,0.475553980886618,0.0499030077870783,0.691430343278734,69.6610259149328
38548,1011:1372,Pancreas,CAPAN-2,SIDM00943,910915,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.334867324700111,0.0873868286695571,0.43110879653122,8.05475986456966,0.5193,0.700514603743842,0.736340661612594,0.0658055126920049,0.144364249349094,0.0913217125083293,0.0530425368407645,5.65667208634017,0.0985,2.39808777822949,0.4208,0.234579451269058,0.156100774594589,0.246576427422119,0.201705393363696,0.0784786766744696,0.0448710340584228,True,0.475553980886618,0.0499030077870783,0.691430343278734,69.6610259149328
38548,1079:1372,Pancreas,CAPAN-2,SIDM00943,910915,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.05,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.545385039423304,0.0873868286695571,0.43110879653122,8.05475986456966,0.5193,0.700514603743842,0.736340661612594,0.0702374285416198,0.235120287991912,0.229242452408787,0.0058778355831257,7.90450363291127,0.468,0.150256231658396,0.0513,0.382050184779435,0.343547303590265,0.401589180762566,0.397431692743084,0.0385028811891704,0.0041574880194819,True,0.475553980886618,0.0499030077870783,0.691430343278734,69.6610259149328
38549,1190:1510,Pancreas,CAPAN-2,SIDM00943,910915,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.1,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.966631736458748,0.0729658999705047,0.800565983575264,13.737079886854,266.6878,0.888831909370037,0.928671687314774,0.0606385274055351,0.773852486853163,0.854998836725368,-0.0811463498722049,15.9390560513072,1227.055,-2.20197616445316,-960.3672,0.859173131974303,0.930822241423493,0.897683525709155,0.928480698855281,-0.0716491094491899,-0.0307971731461263,True,0.475553980886618,0.0499030077870783,0.691430343278734,69.6610259149328
38549,1011:1510,Pancreas,CAPAN-2,SIDM00943,910915,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.749788988607496,0.0729658999705047,0.800565983575264,13.737079886854,266.6878,0.888831909370037,0.928671687314774,0.0389169994271611,0.600255559138463,0.341582068950648,0.258673490187815,8.39267459581786,6.5641,5.34440529103615,260.1237,0.66643637836863,0.532444102809098,0.696307805180161,0.564617683104073,0.133992275559532,0.131690122076088,True,0.475553980886618,0.0499030077870783,0.691430343278734,69.6610259149328
38360,1053:1558,Pancreas,CAPAN-2,SIDM00943,910915,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.88686858022915,0.0601003429642921,0.876581626631775,15.6819471421159,1026.7543,0.95163490987141,0.95764585278633,0.0479800660245949,0.777412702665881,0.664245537639029,0.113167165026853,12.7259392414639,132.3182,2.95600790065195,894.4361,0.843975101414153,0.839205981655854,0.849306017822947,0.804837460798535,0.0047691197582981,0.0444685570244119,True,0.535434602085843,0.0541472024283103,0.572908322133138,83.0448350476454
38360,1083:1558,Pancreas,CAPAN-2,SIDM00943,910915,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,1.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.97723837244546,0.0601003429642921,0.876581626631775,15.6819471421159,1026.7543,0.95163490987141,0.95764585278633,0.0442652661871971,0.85662920212523,0.774430794661668,0.082198407463562,13.5667809481674,236.9944,2.11516619394851,789.7599,0.929974150485018,0.907644505320049,0.935848274556058,0.904370602473636,0.0223296451649695,0.0314776720824218,True,0.535434602085843,0.0541472024283103,0.572908322133138,83.0448350476454
38360,1011:1558,Pancreas,CAPAN-2,SIDM00943,910915,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.368032469532004,0.0601003429642921,0.876581626631775,15.6819471421159,1026.7543,0.95163490987141,0.95764585278633,0.0594568448916754,0.322610500795673,0.13877396100183,0.183836539793843,7.28898308598474,3.0544,8.39296405613113,1023.6999,0.350232545972841,0.228228053983288,0.352444768138035,0.256252670612866,0.122004491989553,0.0961920975251692,True,0.535434602085843,0.0541472024283103,0.572908322133138,83.0448350476454
38360,1079:1558,Pancreas,CAPAN-2,SIDM00943,910915,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.55005864642151,0.0601003429642921,0.876581626631775,15.6819471421159,1026.7543,0.95163490987141,0.95764585278633,0.0362603858223564,0.48217130302304,0.237910182817907,0.244261120205132,8.07433423645828,5.2644,7.60761290565758,1021.4899,0.523455010411323,0.392158002912802,0.526761381534822,0.405571893885308,0.131297007498521,0.121189487649513,True,0.535434602085843,0.0541472024283103,0.572908322133138,83.0448350476454
38360,1011:1561,Pancreas,CAPAN-2,SIDM00943,910915,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.368032469532004,0.0801894679679063,0.644076052043713,11.0215059830004,40.6007,0.8366914889925,0.859925826044467,0.0805562385691393,0.237040900000071,0.0517723137086166,0.185268586291454,2.83183191885303,0.1391,8.18967406414734,40.4616,0.307929634930319,0.0851937127569809,0.316480625373494,0.157297135937892,0.222735922173338,0.159183489435601,True,0.535434602085843,0.0541472024283103,0.572908322133138,83.0448350476454
38360,1558:1561,Pancreas,CAPAN-2,SIDM00943,910915,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.883690187076523,0.0801894679679063,0.644076052043713,11.0215059830004,40.6007,0.8366914889925,0.859925826044467,0.0723556044704645,0.569163686922017,0.372575286109607,0.19658840081241,7.92242437715933,4.7382,3.09908160584104,35.8625,0.739376058433117,0.605825150130298,0.759908014089168,0.644769633929762,0.133550908302819,0.115138380159406,True,0.535434602085843,0.0541472024283103,0.572908322133138,83.0448350476454
38360,1079:1561,Pancreas,CAPAN-2,SIDM00943,910915,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.05,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.547518591642632,0.0801894679679063,0.644076052043713,11.0215059830004,40.6007,0.8366914889925,0.859925826044467,0.045530683717326,0.35264361292572,0.211823667956607,0.140819944969113,7.43061872331346,3.3695,3.59088725968691,37.2312,0.45810414569255,0.346722939289569,0.470825377192993,0.385403002625728,0.111381206402981,0.085422374567265,True,0.535434602085843,0.0541472024283103,0.572908322133138,83.0448350476454
38361,1053:1564,Pancreas,CAPAN-2,SIDM00943,910915,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.915928454459922,0.0963145670797863,0.538873194416972,9.53104931790944,14.4498,0.758044551829844,0.804438613398577,0.0719773251899291,0.493569292112219,0.363286216508767,0.130283075603452,7.57011927349725,3.7116,1.9609300444122,10.7382,0.694314574769273,0.603977333995304,0.736808215878041,0.651526898418259,0.0903372407739694,0.0852813174597825,True,0.535434602085843,0.0541472024283103,0.572908322133138,83.0448350476454
38361,1011:1564,Pancreas,CAPAN-2,SIDM00943,910915,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.372148958432059,0.0963145670797863,0.538873194416972,9.53104931790944,14.4498,0.758044551829844,0.804438613398577,0.0534489621173691,0.200541098029233,0.0619723060854493,0.138568791943783,3.51096845268518,0.2227,6.02008086522426,14.2271,0.282105490408573,0.121464440320031,0.29937099209881,0.174708286193052,0.160641050088543,0.124662705905758,True,0.535434602085843,0.0541472024283103,0.572908322133138,83.0448350476454
38361,1079:1564,Pancreas,CAPAN-2,SIDM00943,910915,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.450218130167591,0.0963145670797863,0.538873194416972,9.53104931790944,14.4498,0.758044551829844,0.804438613398577,0.0771721060437521,0.242610481987846,0.136168942703252,0.106441539284594,6.15178070156588,1.3887,3.37926861634357,13.0611,0.341285400708562,0.233018207746185,0.362172848358917,0.284470832338747,0.108267192962377,0.0777020160201705,True,0.535434602085843,0.0541472024283103,0.572908322133138,83.0448350476454
38361,1011:1594,Pancreas,CAPAN-2,SIDM00943,910915,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.372148958432059,0.0615219497495646,0.698302447863416,11.8604008345325,29.0487,0.877447990645377,0.885347714435022,0.0409379700064609,0.259872528642927,0.115406408322564,0.144466120320363,6.2746162426299,0.6048,5.58578459190255,28.4439,0.32654135579698,0.210053583208377,0.329481229777197,0.237822460572179,0.116487772588603,0.0916587692050186,True,0.535434602085843,0.0541472024283103,0.572908322133138,83.0448350476454
38646,1011:1005,Pancreas,HuP-T4,SIDM00531,907286,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,8.0,0.907177027940521,0.0548826219624348,0.711430857494517,10.6515650251759,25.1339,0.930248812827707,0.937996663611048,0.0938023241455843,0.645393730887052,0.31129277010026,0.334100960786792,7.8115590583532,3.5102,2.84000596682265,21.6237,0.843900353266237,0.747059838043398,0.850929025512795,0.730920456245099,0.0968405152228381,0.120008569267696,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38646,1594:1005,Pancreas,HuP-T4,SIDM00531,907286,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,8.0,0.845405774455729,0.0548826219624348,0.711430857494517,10.6515650251759,25.1339,0.930248812827707,0.937996663611048,0.0721411186787853,0.601447755051856,0.374742762609239,0.226704992442616,8.5828685441183,5.9913,2.06869648105755,19.1426,0.78643771804513,0.673610149868322,0.792987795836988,0.720338345436729,0.112827568176808,0.0726494504002593,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38646,1080:1011,Pancreas,HuP-T4,SIDM00531,907286,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.885671480431001,0.131111962200327,0.538790244529662,9.28456394053124,12.1804,0.917026307043128,0.887471417015899,0.0912992300576459,0.477191153514366,0.184569222037097,0.292621931477269,6.55721981270384,1.8393,2.7273441278274,10.3411,0.81218404695306,0.659054867029263,0.786008123748669,0.634027807564697,0.153129179923797,0.151980316183972,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38646,1085:1011,Pancreas,HuP-T4,SIDM00531,907286,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,5.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.499058241836179,0.131111962200327,0.538790244529662,9.28456394053124,12.1804,0.917026307043128,0.887471417015899,0.0762950714150841,0.268887712153458,0.0547606976928441,0.214127014460614,5.16821395654921,0.7023,4.11634998398202,11.4781,0.457649536510467,0.270711597560828,0.442899925055817,0.300301473095473,0.186937938949639,0.142598451960344,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38646,1088:1011,Pancreas,HuP-T4,SIDM00531,907286,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.355390144812938,0.131111962200327,0.538790244529662,9.28456394053124,12.1804,0.917026307043128,0.887471417015899,0.0743307481551728,0.191480743027194,0.0289413999562269,0.162539343070968,4.56516808125475,0.4624,4.71939585927649,11.718,0.32590211205733,0.15313740658785,0.315398595410623,0.195292981722441,0.172764705469481,0.120105613688183,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38646,1372:1011,Pancreas,HuP-T4,SIDM00531,907286,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.803062869362685,0.131111962200327,0.538790244529662,9.28456394053124,12.1804,0.917026307043128,0.887471417015899,0.0561276979677466,0.432682439756613,0.160519613515774,0.272162826240838,6.46133220687643,1.721,2.8232317336548,10.4594,0.736429777415121,0.545041692585807,0.712695342626156,0.568887194042753,0.191388084829314,0.143808148583403,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38646,1005:1011,Pancreas,HuP-T4,SIDM00531,907286,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,0.8,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.946705354987161,0.131111962200327,0.538790244529662,9.28456394053124,12.1804,0.917026307043128,0.887471417015899,0.123891809921085,0.510075609711073,0.427070923715954,0.0830046859951185,8.64093883611592,7.7967,0.643625104415323,4.3837,0.86815371554183,0.854726221178047,0.840173942886996,0.80966234166809,0.0134274943637831,0.0305116012189059,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38646,1564:1011,Pancreas,HuP-T4,SIDM00531,907286,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.794035042427753,0.131111962200327,0.538790244529662,9.28456394053124,12.1804,0.917026307043128,0.887471417015899,0.0558022725670691,0.427818334674769,0.144332283159833,0.283486051514937,6.24649304819422,1.4829,3.03807089233702,10.6975,0.728151022620356,0.559423754449486,0.704683404263638,0.54898803631719,0.16872726817087,0.155695367946448,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38646,1190:1011,Pancreas,HuP-T4,SIDM00531,907286,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.477538168458702,0.131111962200327,0.538790244529662,9.28456394053124,12.1804,0.917026307043128,0.887471417015899,0.107693016267441,0.257292906556111,0.0148529026547286,0.242440003901382,2.70584797622637,0.1274,6.57871596430486,12.053,0.437915063093823,0.179645299874871,0.423801475041222,0.185045992063377,0.258269763218951,0.238755482977845,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38646,1558:1011,Pancreas,HuP-T4,SIDM00531,907286,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.8815025563275,0.131111962200327,0.538790244529662,9.28456394053124,12.1804,0.917026307043128,0.887471417015899,0.0874585707204145,0.474944977877216,0.274917752964591,0.200027224912625,7.55154579522178,3.6641,1.73301814530945,8.5163,0.808361033878084,0.687224519610502,0.782308322767104,0.695015820196582,0.121136514267582,0.0872925025705222,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38647,1088:1017,Pancreas,HuP-T4,SIDM00531,907286,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,1017,Olaparib,"PARP1, PARP2",Genome integrity,Targeted,FDA approved,10.0,0.3441012864077,0.0564679265126426,0.894553939531736,12.9134248689884,150.6809,0.97004631397358,0.979696303081399,0.0629627263116679,0.307817161353946,0.236806166322568,0.0710109950313779,10.4489780447936,27.3015,2.46444682419477,123.3794,0.333794184513357,0.260675151152218,0.337114758179178,0.320686462046245,0.0731190333611386,0.0164282961329325,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38647,1011:1022,Pancreas,HuP-T4,SIDM00531,907286,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.852741891620907,0.0395008918567689,0.836353186559717,11.985852742809,7.9219,0.965182625667171,0.967443370068792,0.0575034804231205,0.713193398370106,0.564806420305926,0.14838697806418,10.2331627534951,2.3508,1.75268998931392,5.5711,0.823051657971057,0.806983081390078,0.824979489428567,0.788778759579477,0.0160685765809785,0.03620072984909,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38647,1005:1022,Pancreas,HuP-T4,SIDM00531,907286,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,0.8,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.964372852210078,0.0395008918567689,0.836353186559717,11.985852742809,7.9219,0.965182625667171,0.967443370068792,0.0232224377636493,0.806556307977581,0.792594994664671,0.0139613133129098,11.7987401313082,6.9583,0.187112611500813,0.9636,0.930795921618261,0.930795496062214,0.932976122144971,0.929909766400284,4.25556047844999e-07,0.003066355744687,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38647,1073:1022,Pancreas,HuP-T4,SIDM00531,907286,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in pancreas,10.0,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.901260036754506,0.0395008918567689,0.836353186559717,11.985852742809,7.9219,0.965182625667171,0.967443370068792,0.0459132289289372,0.753771703658558,0.740667562768883,0.013104140889675,11.7979562172611,6.9545,0.18789652554789,0.9674,0.869880528683605,0.87020742397064,0.871918047266102,0.869039845372897,-0.0003268952870353,0.0028782018932054,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38647,1179:1022,Pancreas,HuP-T4,SIDM00531,907286,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.2,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.958392690852853,0.0395008918567689,0.836353186559717,11.985852742809,7.9219,0.965182625667171,0.967443370068792,0.0326010534677683,0.801554780970325,0.580867308906095,0.22068747206423,9.78865069671732,1.7275,2.19720204609168,6.1944,0.925023973777582,0.884083321200867,0.927190654687982,0.87103865677476,0.0409406525767151,0.0561519979132223,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38647,1190:1022,Pancreas,HuP-T4,SIDM00531,907286,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.409517713858756,0.0395008918567689,0.836353186559717,11.985852742809,7.9219,0.965182625667171,0.967443370068792,0.0314750721994624,0.342501444938421,0.275047819021802,0.0674536259166191,10.3097756593836,2.479,1.67607708342542,5.4429,0.395259382319411,0.371921150872027,0.396185197198382,0.379838426099045,0.0233382314473848,0.0163467710993376,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38648,1080:1053,Pancreas,HuP-T4,SIDM00531,907286,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.0025,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.962276915112573,0.0504477815559968,0.870549442305802,12.4882445044029,112.219,0.959452985154622,0.974741650169047,0.0688309484467067,0.837709631794997,0.790883437761033,0.0468261940339643,11.7988836209397,69.5902,0.689360883463189,42.6288,0.923259458750139,0.884548890011411,0.937971388156409,0.927891176997217,0.0387105687387274,0.0100802111591922,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38648,1564:1053,Pancreas,HuP-T4,SIDM00531,907286,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,1.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.838858617034129,0.0504477815559968,0.870549442305802,12.4882445044029,112.219,0.959452985154622,0.974741650169047,0.0636509676847243,0.730267901232477,0.200704006839565,0.529563894392912,6.88279433467826,2.3049,5.60545016972464,109.9141,0.804845404236073,0.590689668894543,0.817670432626372,0.621323874111365,0.21415573534153,0.196346558515007,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38648,1168:1053,Pancreas,HuP-T4,SIDM00531,907286,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.772453540301281,0.0504477815559968,0.870549442305802,12.4882445044029,112.219,0.959452985154622,0.974741650169047,0.109241245480875,0.672458998716422,0.362166684980376,0.310292313736047,8.77166562670907,8.5362,3.71657887769383,103.6828,0.74113285513532,0.581073030197325,0.752942638552193,0.666038031940778,0.160059824937995,0.0869046066114152,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38648,1190:1053,Pancreas,HuP-T4,SIDM00531,907286,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.01,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.75796932120101,0.0504477815559968,0.870549442305802,12.4882445044029,112.219,0.959452985154622,0.974741650169047,0.092782754548546,0.659849769856446,0.22510902398444,0.434740745872006,7.42287182572684,3.3515,5.06537267867605,108.8675,0.727235927881931,0.561267577104798,0.738824266924985,0.590926034097183,0.165968350777133,0.147898232827802,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38648,1372:1053,Pancreas,HuP-T4,SIDM00531,907286,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.695904605835117,0.0504477815559968,0.870549442305802,12.4882445044029,112.219,0.959452985154622,0.974741650169047,0.0357536713396773,0.605819366507799,0.158573421576622,0.447245944931177,6.76629982000845,2.1261,5.72194468439445,110.0929,0.667687751451353,0.490041102721671,0.678327203851962,0.509338581973249,0.177646648729682,0.168988621878713,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38648,1558:1053,Pancreas,HuP-T4,SIDM00531,907286,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.899795328880927,0.0504477815559968,0.870549442305802,12.4882445044029,112.219,0.959452985154622,0.974741650169047,0.0238242294947412,0.783316321746656,0.727973755903188,0.0553425658434678,11.6426116659264,62.4461,0.845632838476499,49.7729,0.86331131432299,0.857097126107739,0.877067983687795,0.86506178250143,0.0062141882152511,0.0120062011863653,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38648,1088:1053,Pancreas,HuP-T4,SIDM00531,907286,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.338155837572369,0.0504477815559968,0.870549442305802,12.4882445044029,112.219,0.959452985154622,0.974741650169047,0.0822822355206148,0.294381375811077,0.262304372375086,0.0320770034359915,11.2709132581065,48.2629,1.21733124629641,63.9561,0.324444627806271,0.254857273353355,0.329614579129587,0.322510778842282,0.069587354452916,0.0071038002873055,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38648,1005:1053,Pancreas,HuP-T4,SIDM00531,907286,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,8.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.70839438393061,0.0504477815559968,0.870549442305802,12.4882445044029,112.219,0.959452985154622,0.974741650169047,0.109812752672418,0.616692335863355,0.374424847397209,0.242267488466145,9.2092796526565,11.5611,3.27896485174639,100.6579,0.679671106328993,0.560276487056317,0.690501510763009,0.626212488952309,0.119394619272676,0.0642890218107,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38648,1564:1054,Pancreas,HuP-T4,SIDM00531,907286,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,8.0,0.763078032791117,0.0491304672992038,0.885097496995696,12.7367786776818,106.6528,0.967149241239814,0.977760424221552,0.114919761482823,0.675398456835817,0.482496085777966,0.192902371057852,9.99222182344964,15.914,2.74455685423218,90.7388,0.738010340420699,0.604699799559253,0.74610750105599,0.699400403174962,0.133310540861446,0.046707097881028,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38648,1558:1054,Pancreas,HuP-T4,SIDM00531,907286,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,8.0,0.802141285093712,0.0491304672992038,0.885097496995696,12.7367786776818,106.6528,0.967149241239814,0.977760424221552,0.137504752301366,0.709973243673356,0.324982219735832,0.384991023937523,8.29701699140381,4.9144,4.43976168627801,101.7384,0.775790335245513,0.709815423146515,0.784302003198849,0.670401369812207,0.0659749120989984,0.113900633386642,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38649,1053:1057,Pancreas,HuP-T4,SIDM00531,907286,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1057,Dactolisib,"PI3K (class 1), MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,0.864231788659424,0.0616633073438199,0.808767829375,11.6393449760504,0.623,0.930480583531728,0.961336294415254,0.0601134275511458,0.698962867790956,0.602053511469095,0.0969093563218613,10.5215731867957,0.2871,1.11777178925468,0.3359,0.804150899018489,0.810341851457357,0.830817385225717,0.807341927277002,-0.0061909524388674,0.0234754579487144,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38649,1564:1057,Pancreas,HuP-T4,SIDM00531,907286,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,1.0,1057,Dactolisib,"PI3K (class 1), MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,0.848991206316662,0.0616633073438199,0.808767829375,11.6393449760504,0.623,0.930480583531728,0.961336294415254,0.0518486469970277,0.68663677509119,0.381406486811872,0.305230288279318,8.62713942629713,0.0772,3.01220554975328,0.5458,0.789969833066833,0.699854265288977,0.816166060271596,0.725454968238014,0.0901155677778563,0.0907110920335821,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38649,1372:1057,Pancreas,HuP-T4,SIDM00531,907286,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1057,Dactolisib,"PI3K (class 1), MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,0.683909405587634,0.0616633073438199,0.808767829375,11.6393449760504,0.623,0.930480583531728,0.961336294415254,0.0554825011421906,0.553123925446257,0.357117881378245,0.196006044068012,9.16242778812252,0.1119,2.47691718792789,0.5111,0.636364422794019,0.597312938922735,0.657466933683355,0.603059421946731,0.0390514838712831,0.0544075117366232,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38649,1011:1073,Pancreas,HuP-T4,SIDM00531,907286,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in pancreas,20.0,0.832729798007735,0.0495300650607581,0.928607740261139,13.695645252391,518.2748,0.975692384099472,0.986502759798832,0.109466253771104,0.773279335976078,0.549909022099215,0.223370313876863,10.2170428750751,46.4939,3.47860237731592,471.7809,0.812488121928839,0.722221998350643,0.821490243901355,0.769816076577835,0.0902661235781964,0.0516741673235206,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38650,1594:1079,Pancreas,HuP-T4,SIDM00531,907286,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.855191779268931,0.113607110615518,0.681668670862423,10.3936885007826,5.255,0.843785080375076,0.930222459273161,0.178406038399388,0.582957443506723,0.376390727084775,0.206566716421948,8.55952324403155,1.4738,1.83416525675107,3.7812,0.721598064206539,0.578177993595085,0.795518600061735,0.727572633162164,0.143420070611454,0.0679459668995703,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38650,1372:1079,Pancreas,HuP-T4,SIDM00531,907286,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.814786018007514,0.113607110615518,0.681668670862423,10.3936885007826,5.255,0.843785080375076,0.930222459273161,0.12727714704588,0.555414101932468,0.327930219541968,0.2274838823905,8.27672309732258,1.2114,2.11696540346005,4.0436,0.687504285692959,0.600715089507926,0.757932253452335,0.679993860235777,0.0867891961850326,0.0779383932165585,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38650,1089:1079,Pancreas,HuP-T4,SIDM00531,907286,1089,Oxaliplatin,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved in pancreas,2.5,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.939008831802639,0.113607110615518,0.681668670862423,10.3936885007826,5.255,0.843785080375076,0.930222459273161,0.088881872834544,0.640092902302982,0.760852446365791,-0.120759544062809,11.6571978970959,12.6161,-1.26350939631326,-7.3611,0.792321642615496,0.836702455521637,0.873487104798669,0.903020921196305,-0.0443808129061407,-0.0295338163976366,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38650,1510:1079,Pancreas,HuP-T4,SIDM00531,907286,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.912725297874353,0.113607110615518,0.681668670862423,10.3936885007826,5.255,0.843785080375076,0.930222459273161,0.120702214635837,0.622176240664519,0.415176810008449,0.206999430656071,8.66873553917971,1.5897,1.72495296160292,3.6653,0.770143988827277,0.684126181265967,0.849037571229509,0.781976040651144,0.0860178075613097,0.0670615305783648,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38650,1179:1079,Pancreas,HuP-T4,SIDM00531,907286,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.703904045819293,0.113607110615518,0.681668670862423,10.3936885007826,5.255,0.843785080375076,0.930222459273161,0.13166796406525,0.47982933532832,0.271628640672333,0.208200694655987,8.14959017111608,1.1093,2.24409832966654,4.1457,0.593943731877974,0.493523336277296,0.65478735259435,0.582091699437942,0.100420395600678,0.0726956531564085,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38650,1564:1079,Pancreas,HuP-T4,SIDM00531,907286,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,1.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.804468696509997,0.113607110615518,0.681668670862423,10.3936885007826,5.255,0.843785080375076,0.930222459273161,0.0972557556722491,0.548381107100396,0.480377151785124,0.0680039553152721,9.72030882280623,3.2951,0.673379677976392,1.9599,0.678798683743921,0.660916705421183,0.748334849275803,0.728969395891828,0.0178819783227383,0.0193654533839752,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38650,1190:1079,Pancreas,HuP-T4,SIDM00531,907286,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.01,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.7331379559038,0.113607110615518,0.681668670862423,10.3936885007826,5.255,0.843785080375076,0.930222459273161,0.143095772451797,0.499757175959737,0.191258353650909,0.308498822308828,7.09388480560638,0.5336,3.29980369517625,4.7214,0.618610869048307,0.461644881711298,0.681981392327331,0.554431882380642,0.156965987337009,0.127549509946689,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38650,1011:1080,Pancreas,HuP-T4,SIDM00531,907286,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.1,0.921377351700254,0.0541489661399064,0.644270558368113,10.0871073425174,0.2124,0.908993388047017,0.919960880306707,0.0586217397058065,0.593616300847656,0.248074423614713,0.345541877232943,7.17250038137844,0.0282,2.91460696113894,0.1842,0.837525920591802,0.697751432127661,0.847631119564828,0.702026438162143,0.139774488464141,0.145604681402685,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38650,1168:1080,Pancreas,HuP-T4,SIDM00531,907286,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.1,0.778365063566846,0.0541489661399064,0.644270558368113,10.0871073425174,0.2124,0.908993388047017,0.919960880306707,0.112551052296617,0.501477694118444,0.337795247373881,0.163682446744563,8.51381758295668,0.0714,1.5732897595607,0.141,0.707528696269059,0.590867759334076,0.716065409078942,0.660227253864847,0.116660936934984,0.0558381552140944,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38650,1372:1080,Pancreas,HuP-T4,SIDM00531,907286,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.1,0.814786018007514,0.0541489661399064,0.644270558368113,10.0871073425174,0.2124,0.908993388047017,0.919960880306707,0.0673979439759736,0.524942642772232,0.263372588821339,0.261570053950893,7.64755896768802,0.0392,2.43954837482936,0.1732,0.740635103041987,0.62721225585606,0.749571262387788,0.647681805553891,0.113422847185927,0.101889456833897,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38650,1053:1080,Pancreas,HuP-T4,SIDM00531,907286,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.1,0.945945198338723,0.0541489661399064,0.644270558368113,10.0871073425174,0.2124,0.908993388047017,0.919960880306707,0.0876316336883917,0.609444641119324,0.523905745859432,0.0855388952598921,9.39573600783306,0.1316,0.691371334684321,0.0808,0.859857930744723,0.802823762383938,0.870232577385593,0.844233415252349,0.0570341683607843,0.0259991621332439,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38650,1558:1080,Pancreas,HuP-T4,SIDM00531,907286,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.1,0.825112334554287,0.0541489661399064,0.644270558368113,10.0871073425174,0.2124,0.908993388047017,0.919960880306707,0.0909670050027177,0.531595584499708,0.248294174616692,0.283301409883016,7.457211317233,0.0343,2.62989602528438,0.1781,0.750021656505885,0.605614243085627,0.759071069648484,0.645230349219364,0.144407413420258,0.11384072042912,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38651,1011:1083,Pancreas,HuP-T4,SIDM00531,907286,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.936802763380383,0.0635205456317232,0.712023174578595,10.6568490001988,25.2262,0.915254904057771,0.938148080759859,0.0343901078443477,0.667025277536101,0.461545347254566,0.205479930281535,8.94641544699611,7.7083,1.71043355320273,17.5179,0.857413323318767,0.825937041565102,0.878859714515839,0.816171670612244,0.0314762817536655,0.0626880439035952,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38651,1168:1083,Pancreas,HuP-T4,SIDM00531,907286,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.875007863662665,0.0635205456317232,0.712023174578595,10.6568490001988,25.2262,0.915254904057771,0.938148080759859,0.124772620673051,0.623025876866325,0.448097785844348,0.174928091021977,9.08865652344664,8.507,1.5681924767522,16.7192,0.800855238306367,0.676082485873554,0.820886947944914,0.768475286092028,0.124772752432813,0.0524116618528859,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38651,1564:1083,Pancreas,HuP-T4,SIDM00531,907286,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.821883434662697,0.0635205456317232,0.712023174578595,10.6568490001988,25.2262,0.915254904057771,0.938148080759859,0.0224310903994998,0.585200052282093,0.336936497607107,0.248263554674986,8.33350311293085,5.0403,2.32334588726799,20.1859,0.752232844138878,0.69340968340835,0.77104836683713,0.688659402458063,0.0588231607305274,0.0823889643790675,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38651,1558:1083,Pancreas,HuP-T4,SIDM00531,907286,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.831241167920075,0.0635205456317232,0.712023174578595,10.6568490001988,25.2262,0.915254904057771,0.938148080759859,0.0877298387962,0.591862975222871,0.173220629654264,0.418642345568607,6.55714499893374,1.4714,4.0997040012651,23.7548,0.760797555393558,0.60715385364795,0.779827306332802,0.595057822361955,0.153643701745608,0.184769483970847,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38651,1372:1083,Pancreas,HuP-T4,SIDM00531,907286,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.813056691203641,0.0635205456317232,0.712023174578595,10.6568490001988,25.2262,0.915254904057771,0.938148080759859,0.0321165303661292,0.578915206383185,0.321382628129064,0.257532578254121,8.22178373510983,4.6647,2.43506526508901,20.5615,0.744154123901117,0.658625234315691,0.762767574401657,0.675893805096429,0.085528889585426,0.0868737693052283,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38651,1011:1085,Pancreas,HuP-T4,SIDM00531,907286,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.936802763380383,0.0798193300404809,0.527327684480335,9.20027170981311,11.4891,0.902511106707787,0.883566672996709,0.169404373648017,0.494002032028157,0.26787893514324,0.226123096884917,7.32502254656949,3.1317,1.87524916324363,8.3574,0.845474898745343,0.778603175798661,0.827727700894129,0.723946231027285,0.0668717229466816,0.103781469866844,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38651,1372:1085,Pancreas,HuP-T4,SIDM00531,907286,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.813056691203641,0.0798193300404809,0.527327684480335,9.20027170981311,11.4891,0.902511106707787,0.883566672996709,0.0495425772081206,0.428747302323659,0.53550138600299,-0.106754083679331,10.202846677,23.0193,-1.00257496718687,-11.5302,0.733792694194369,0.774192855269093,0.718389795604514,0.7512387991545,-0.0404001610747237,-0.0328490035499864,True,0.625139915971695,0.0673467344938681,0.426618586379464,109.970546077841
38390,1372:1089,Pancreas,HuP-T4,SIDM00531,907286,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,1089,Oxaliplatin,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved in pancreas,10.0,0.83686631991193,0.0339654943797247,0.935978236615841,13.909557161946,300.555,0.989599710094921,0.987943189419921,0.0724351169464026,0.783288662394356,0.627893067345228,0.155395595049128,11.0136363949761,40.3799,2.89592076696989,260.1751,0.828162667573049,0.81510361938303,0.826776381211904,0.793076717465148,0.0130590481900188,0.0336996637467556,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38390,1594:1089,Pancreas,HuP-T4,SIDM00531,907286,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,1089,Oxaliplatin,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved in pancreas,10.0,0.917608187603247,0.0339654943797247,0.935978236615841,13.909557161946,300.555,0.989599710094921,0.987943189419921,0.0676757168963312,0.858861293337145,0.404043744331726,0.454817549005419,8.56099669584161,7.3764,5.34856046610436,293.1786,0.908064796432899,0.796732751915897,0.906544759498585,0.780749682733071,0.111332044517002,0.125795076765515,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38391,1083:1168,Pancreas,HuP-T4,SIDM00531,907286,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,4.0,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.877918520467101,0.0966879849359462,0.790670197792766,11.4324220393601,53.9799,0.890899595396753,0.957216068195629,0.0534116688660888,0.694144010223654,0.467874276171315,0.22626973405234,9.24148064311547,11.8221,2.19094139624463,42.1578,0.782137254675456,0.740895902994138,0.840357714357642,0.777385897226817,0.0412413516813177,0.0629718171308251,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38391,1372:1168,Pancreas,HuP-T4,SIDM00531,907286,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.879090228471469,0.0966879849359462,0.790670197792766,11.4324220393601,53.9799,0.890899595396753,0.957216068195629,0.109475452263771,0.695070444823224,0.486864959331819,0.208205485491405,9.39562153672616,13.1551,2.03680050263394,40.8248,0.783181128862471,0.697271980614654,0.841479292086657,0.784562501630733,0.0859091482478166,0.0569167904559236,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38391,1011:1168,Pancreas,HuP-T4,SIDM00531,907286,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.833134607163292,0.0966879849359462,0.790670197792766,11.4324220393601,53.9799,0.890899595396753,0.957216068195629,0.0806434348820044,0.658734704633798,0.624372505015193,0.0343621996186049,11.0051953985952,40.1443,0.427226640764896,13.8356,0.74223928443281,0.756996404351007,0.797489832946556,0.78936535030779,-0.0147571199181976,0.0081244826387659,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38391,1080:1168,Pancreas,HuP-T4,SIDM00531,907286,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.025,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.901160641615618,0.0966879849359462,0.790670197792766,11.4324220393601,53.9799,0.890899595396753,0.957216068195629,0.0713443751523815,0.712520862749277,0.266974864126586,0.445545998622691,7.41644200279974,3.3366,4.01598003656036,50.6433,0.802843651002833,0.667508660685665,0.862605446179952,0.702158679633767,0.135334990317168,0.160446766546186,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38391,1561:1168,Pancreas,HuP-T4,SIDM00531,907286,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.5,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.8378461067177,0.0966879849359462,0.790670197792766,11.4324220393601,53.9799,0.890899595396753,0.957216068195629,0.0342355347670893,0.662459946918382,0.449881626004864,0.212578320913518,9.27101474310498,12.0666,2.16140729625512,41.9133,0.746436757479544,0.760587381040185,0.801999756025332,0.743043974341281,-0.0141506235606412,0.0589557816840505,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38391,1510:1168,Pancreas,HuP-T4,SIDM00531,907286,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.899976599842783,0.0966879849359462,0.790670197792766,11.4324220393601,53.9799,0.890899595396753,0.957216068195629,0.0501859386207012,0.711584676206554,0.517947756360854,0.1936369198457,9.55710546402187,14.7131,1.87531657533823,39.2668,0.801788788666481,0.811747419877645,0.86147206236958,0.809482061317438,-0.0099586312111642,0.0519900010521415,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38391,1594:1168,Pancreas,HuP-T4,SIDM00531,907286,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.914451142666462,0.0966879849359462,0.790670197792766,11.4324220393601,53.9799,0.890899595396753,0.957216068195629,0.116841497188077,0.723029265843912,0.484175001673131,0.23885426417078,9.21601133010482,11.6152,2.21641070925528,42.3647,0.814684153011649,0.712618272029764,0.875327327340191,0.808651909940878,0.102065880981885,0.0666754173993127,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38391,1053:1168,Pancreas,HuP-T4,SIDM00531,907286,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,5.0,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.964475176513537,0.0966879849359462,0.790670197792766,11.4324220393601,53.9799,0.890899595396753,0.957216068195629,0.104805803941005,0.762581778580171,0.423206283916381,0.33937549466379,8.54964131857266,7.3186,2.88278072078744,46.6613,0.859250544526122,0.751213717005237,0.923211136334573,0.820018693270208,0.108036827520885,0.103192443064366,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38391,1011:1179,Pancreas,HuP-T4,SIDM00531,907286,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,4.0,0.833134607163292,0.0639810235079511,0.664368392566257,10.2497746048691,9.5122,0.919737190268626,0.925546879772307,0.0687276421459325,0.553508299752396,0.300668300973332,0.252839998779065,7.95395806727586,1.9372,2.29581653759321,7.575,0.766264882707921,0.699649314486676,0.771105136090311,0.678859867862211,0.0666155682212457,0.0922452682281005,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38391,1190:1179,Pancreas,HuP-T4,SIDM00531,907286,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.1,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,4.0,0.842217562111652,0.0639810235079511,0.664368392566257,10.2497746048691,9.5122,0.919737190268626,0.925546879772307,0.109952716598411,0.559542727931191,0.348709074303757,0.210833653627434,8.36433081062087,2.5746,1.8854437942482,6.9376,0.774618814171463,0.629232746866249,0.779511836701879,0.707208509945917,0.145386067305214,0.0723033267559621,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38391,1079:1179,Pancreas,HuP-T4,SIDM00531,907286,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.05,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,4.0,0.952344049698595,0.0639810235079511,0.664368392566257,10.2497746048691,9.5122,0.919737190268626,0.925546879772307,0.0858073687372985,0.632707285468296,0.40213720956169,0.230570075906605,8.42619726593222,2.6874,1.82357733893686,6.8248,0.875906240438831,0.747060320473963,0.881439063668258,0.803075151427077,0.128845919964868,0.0783639122411806,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38392,1080:1372,Pancreas,HuP-T4,SIDM00531,907286,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.0025,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.980580270969739,0.105682558004385,0.752711423489583,11.037361423035,4.1049,0.875729724159189,0.948260556990948,0.136013488188211,0.738093971607434,0.590556311097037,0.147537660510397,9.75931505350498,1.6927,1.27804636952998,2.4122,0.858723290212273,0.783380762540485,0.9298455939241,0.890073240580961,0.0753425276717874,0.0397723533431388,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38392,1558:1372,Pancreas,HuP-T4,SIDM00531,907286,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.876419569599528,0.105682558004385,0.752711423489583,11.037361423035,4.1049,0.875729724159189,0.948260556990948,0.187649532151744,0.659691021807389,0.446214576851777,0.213476444955612,9.06687596593813,1.0474,1.97048545709683,3.0575,0.76750666793311,0.630463691002966,0.831074109226216,0.768788666853766,0.137042976930144,0.06228544237245,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38392,1079:1372,Pancreas,HuP-T4,SIDM00531,907286,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.05,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.909969469355302,0.105682558004385,0.752711423489583,11.037361423035,4.1049,0.875729724159189,0.948260556990948,0.188827947294251,0.68494441461049,0.511118351520468,0.173826063090022,9.45393968828769,1.3698,1.58342173474727,2.7351,0.796887312391802,0.699799952294991,0.862888155855616,0.814450419301091,0.097087360096811,0.0484377365545253,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38392,1053:1372,Pancreas,HuP-T4,SIDM00531,907286,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,5.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.98873102392635,0.105682558004385,0.752711423489583,11.037361423035,4.1049,0.875729724159189,0.948260556990948,0.170013084088101,0.744229136467916,0.0652063815473477,0.679022754920568,4.14851663408228,0.0346,6.88884478895268,4.0703,0.865861146850655,0.48624362802963,0.937574631462631,0.507253069770704,0.379617518821026,0.430321561691928,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38392,1510:1372,Pancreas,HuP-T4,SIDM00531,907286,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.876419569599528,0.105682558004385,0.752711423489583,11.037361423035,4.1049,0.875729724159189,0.948260556990948,0.135918028439354,0.659691021807389,0.250216815897377,0.409474205910012,7.32097509841647,0.3123,3.71638632461849,3.7926,0.76750666793311,0.580954690779506,0.831074109226216,0.677033408959743,0.186551977153604,0.154040700266472,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38392,1011:1372,Pancreas,HuP-T4,SIDM00531,907286,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.928014528030339,0.105682558004385,0.752711423489583,11.037361423035,4.1049,0.875729724159189,0.948260556990948,0.145172887203042,0.69852713641273,0.496526668409236,0.202000468003494,9.25697101524357,1.195,1.78039040779139,2.9099,0.812689906647729,0.699195638096965,0.879999573245741,0.822409893663212,0.113494268550763,0.0575896795825294,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38392,1083:1372,Pancreas,HuP-T4,SIDM00531,907286,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,4.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.809196809285784,0.105682558004385,0.752711423489583,11.037361423035,4.1049,0.875729724159189,0.948260556990948,0.184671337177474,0.609091682200732,0.328406267431828,0.280685414768904,8.30232338639129,0.6166,2.73503803664367,3.4883,0.708637698586336,0.546118695078487,0.767329417088636,0.676550752582924,0.162519003507849,0.0907786645057121,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38392,1057:1372,Pancreas,HuP-T4,SIDM00531,907286,1057,Dactolisib,"PI3K (class 1), MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.05,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.89258700784977,0.105682558004385,0.752711423489583,11.037361423035,4.1049,0.875729724159189,0.948260556990948,0.145361196892444,0.671860437266908,0.358246056232709,0.313614381034199,8.26821779919386,0.6022,2.7691436238411,3.5027,0.781664974172355,0.642677872148252,0.846405053226507,0.74447474037283,0.138987102024103,0.101930312853677,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38392,1190:1372,Pancreas,HuP-T4,SIDM00531,907286,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.01,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.855636277074826,0.105682558004385,0.752711423489583,11.037361423035,4.1049,0.875729724159189,0.948260556990948,0.179790320605864,0.64404720010632,0.0881183248269016,0.555928875279418,5.03833612225525,0.0642,5.99902530077972,4.0407,0.749306120903333,0.44568103588065,0.811366132680636,0.505318587980674,0.303625085022684,0.306047544699962,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38392,1089:1372,Pancreas,HuP-T4,SIDM00531,907286,1089,Oxaliplatin,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved in pancreas,10.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.887688545673178,0.105682558004385,0.752711423489583,11.037361423035,4.1049,0.875729724159189,0.948260556990948,0.152033359550475,0.668173308829056,0.400900956426369,0.267272352402687,8.64471290857994,0.7817,2.39264851445502,3.3232,0.777375245241644,0.653257011195852,0.841760034754533,0.759370763245841,0.124118234045793,0.0823892715086916,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38392,1088:1372,Pancreas,HuP-T4,SIDM00531,907286,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.397316715460858,0.105682558004385,0.752711423489583,11.037361423035,4.1049,0.875729724159189,0.948260556990948,0.133815616190205,0.299064830470748,0.11202949539008,0.187035335080669,7.28914996405176,0.3055,3.7482114589832,3.7994,0.347942057634373,0.21109201958029,0.376759769904728,0.30603452888678,0.136850038054083,0.0707252410179478,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38392,1594:1372,Pancreas,HuP-T4,SIDM00531,907286,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.886524681291795,0.105682558004385,0.752711423489583,11.037361423035,4.1049,0.875729724159189,0.948260556990948,0.169898144783726,0.667297254813796,0.0898348889938088,0.577462365819988,5.00537119471951,0.0627,6.03199022831545,4.0422,0.776356014607977,0.476242831076307,0.840656388067981,0.521041630824491,0.30011318353167,0.31961475724349,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38392,1561:1372,Pancreas,HuP-T4,SIDM00531,907286,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.828752288836719,0.105682558004385,0.752711423489583,11.037361423035,4.1049,0.875729724159189,0.948260556990948,0.13364814793009,0.623811315050537,0.270393677816943,0.353417637233595,7.67280378011632,0.3985,3.36455764291864,3.7064,0.725763013299277,0.571900849069822,0.785873107019831,0.660178193565993,0.153862164229455,0.125694913453838,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38393,1080:1510,Pancreas,HuP-T4,SIDM00531,907286,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.025,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.842969687600373,0.0833521681417942,0.887877569285563,12.7873475136099,138.0719,0.932517071925158,0.978331675675186,0.0575970718588569,0.74845387720803,0.497390073363792,0.251063803844238,9.66650883328046,15.8723,3.12083868032948,122.1996,0.786083624802766,0.719930185122369,0.824703947013462,0.762027071787954,0.0661534396803964,0.0626768752255077,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38393,1085:1510,Pancreas,HuP-T4,SIDM00531,907286,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,5.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.549969726624061,0.0833521681417942,0.887877569285563,12.7873475136099,138.0719,0.932517071925158,0.978331675675186,0.131876314583663,0.488305784055617,0.250063013434561,0.238242770621056,8.66732621569988,7.9406,4.12002129791006,130.1313,0.512856159118949,0.356102636800538,0.538052804218742,0.471143877522185,0.156753522318411,0.0669089266965566,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38393,1372:1510,Pancreas,HuP-T4,SIDM00531,907286,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.875762717969808,0.0833521681417942,0.887877569285563,12.7873475136099,138.0719,0.932517071925158,0.978331675675186,0.0825063576014825,0.777570073301951,0.468971993713728,0.308598079588223,9.26035043710418,11.9777,3.52699707650576,126.0942,0.816663685462423,0.738158245555052,0.856786407365258,0.776240601715568,0.0785054399073714,0.0805458056496894,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38393,1594:1510,Pancreas,HuP-T4,SIDM00531,907286,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.905922219787411,0.0833521681417942,0.887877569285563,12.7873475136099,138.0719,0.932517071925158,0.978331675675186,0.10921946240958,0.804348018466628,0.509997733810348,0.29435028465628,9.46340204068366,13.7879,3.32394547292628,124.284,0.844787935788096,0.711920385674104,0.886292403316002,0.811200371953132,0.132867550113992,0.07509203136287,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38393,1564:1510,Pancreas,HuP-T4,SIDM00531,907286,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.851712359402157,0.0833521681417942,0.887877569285563,12.7873475136099,138.0719,0.932517071925158,0.978331675675186,0.0858795930988692,0.756216299396459,0.367722058009783,0.388494241386676,8.49714623529732,7.0571,4.29020127831262,131.0148,0.794236315512168,0.657552561905076,0.833257179767179,0.721644678726448,0.136683753607091,0.111612501040732,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38393,1558:1510,Pancreas,HuP-T4,SIDM00531,907286,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.912377232980419,0.0833521681417942,0.887877569285563,12.7873475136099,138.0719,0.932517071925158,0.978331675675186,0.0969986976662123,0.810079279890143,0.235608450464627,0.574470829425516,7.06873699475278,2.622,5.71861051885716,135.4499,0.850807345790079,0.617788024831073,0.892607547189623,0.688309193662883,0.233019320959006,0.20429835352674,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38393,1079:1510,Pancreas,HuP-T4,SIDM00531,907286,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.05,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.93370801576557,0.0833521681417942,0.887877569285563,12.7873475136099,138.0719,0.932517071925158,0.978331675675186,0.111584741371888,0.82901840346038,0.575437336900168,0.253581066560213,9.86727517798989,18.2421,2.92007233562005,119.8298,0.870698664894759,0.753116206537368,0.913476127655283,0.851438452957884,0.117582458357391,0.0620376746973996,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38394,1510:1558,Pancreas,HuP-T4,SIDM00531,907286,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.830373301688304,0.0775025170681428,0.820451762464094,11.7809879250977,68.7323,0.924040904470562,0.96394789786618,0.0795005662451379,0.681281238873298,0.408697274945268,0.27258396392803,8.94277988966139,9.6111,2.83820803543627,59.1212,0.767298896740267,0.692837445325129,0.80043659860664,0.723295102506697,0.0744614514151376,0.0771414960999428,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38394,1053:1558,Pancreas,HuP-T4,SIDM00531,907286,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.953459601910771,0.0775025170681428,0.820451762464094,11.7809879250977,68.7323,0.924040904470562,0.96394789786618,0.0700342645342253,0.782267610826006,0.619690130316543,0.162577480509463,10.1325368268695,21.9244,1.64845109822817,46.8079,0.881035672925771,0.830041158860451,0.919085378962213,0.878664103919033,0.0509945140653199,0.0404212750431806,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38394,1083:1558,Pancreas,HuP-T4,SIDM00531,907286,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,1.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.943790913793549,0.0775025170681428,0.820451762464094,11.7809879250977,68.7323,0.924040904470562,0.96394789786618,0.114516925454874,0.774334918619515,0.838663630327955,-0.0643287117084399,12.8008833861202,139.3734,-1.01989546102256,-70.6411,0.872101409612889,0.850719920291168,0.909765267376493,0.923482632719099,0.0213814893217208,-0.0137173653426059,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38394,1080:1558,Pancreas,HuP-T4,SIDM00531,907286,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.0025,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.903708908644165,0.0775025170681428,0.820451762464094,11.7809879250977,68.7323,0.924040904470562,0.96394789786618,0.0449081849962487,0.741449566851609,0.82865244155492,-0.0872028747033113,13.3955905796374,210.477,-1.61460265453979,-141.7447,0.835063997321659,0.877955632175122,0.871128302770483,0.889430587109722,-0.042891634853463,-0.0183022843392392,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38394,1190:1558,Pancreas,HuP-T4,SIDM00531,907286,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.01,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.795057671766173,0.0775025170681428,0.820451762464094,11.7809879250977,68.7323,0.924040904470562,0.96394789786618,0.0890965497420541,0.652306468061156,0.648799048879006,0.0035074191821505,11.726692581821,66.1936,0.0542953432766122,2.53869999999999,0.734665810125073,0.701703397172713,0.766394171381382,0.765613667102163,0.0329624129523601,0.0007805042792193,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38394,1011:1558,Pancreas,HuP-T4,SIDM00531,907286,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.868306841865582,0.0775025170681428,0.820451762464094,11.7809879250977,68.7323,0.924040904470562,0.96394789786618,0.118386170121178,0.712403878768248,0.460667831205008,0.25173604756324,9.22383774639387,11.6784,2.55715017870379,57.0539,0.802351039515449,0.699578913554014,0.837002554919149,0.768163217769316,0.102772125961435,0.0688393371498331,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38394,1088:1558,Pancreas,HuP-T4,SIDM00531,907286,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.396151579236648,0.0775025170681428,0.820451762464094,11.7809879250977,68.7323,0.924040904470562,0.96394789786618,0.126950824605719,0.325023261387642,0.180841364300003,0.144181897087639,8.68068541768166,8.0145,3.100302507416,60.7178,0.366060263585273,0.230371862621414,0.381869482041534,0.339657567775663,0.13568840096386,0.0422119142658716,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38394,1594:1558,Pancreas,HuP-T4,SIDM00531,907286,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.897855898650078,0.0775025170681428,0.820451762464094,11.7809879250977,68.7323,0.924040904470562,0.96394789786618,0.100033740514327,0.73664745448624,0.387514838266945,0.349132616219294,8.49607071934426,7.0518,3.28491720575339,61.6805,0.829655576672847,0.710708904466229,0.865486306090493,0.760687147389964,0.118946672206618,0.104799158700529,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38394,1080:1561,Pancreas,HuP-T4,SIDM00531,907286,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.025,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.868146316275026,0.107417628288952,0.830487379597341,11.9085129397834,75.0844,0.899475784101901,0.966161698169495,0.108061017174107,0.720984559310331,0.402689688807201,0.31829487050313,8.73487527051514,8.3213,3.17363766926824,66.7631,0.780876588546656,0.660744057930334,0.838769719191871,0.74685885670606,0.120132530616322,0.0919108624858113,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38394,1372:1561,Pancreas,HuP-T4,SIDM00531,907286,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.880284628862328,0.107417628288952,0.830487379597341,11.9085129397834,75.0844,0.899475784101901,0.966161698169495,0.159050896610807,0.731065274723692,0.47573995338499,0.255325321338702,9.29670951280785,12.2834,2.61180342697553,62.801,0.791794706778793,0.645389167787617,0.85049729189413,0.781715818550576,0.146405538991176,0.0687814733435542,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38394,1168:1561,Pancreas,HuP-T4,SIDM00531,907286,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.855155983245548,0.107417628288952,0.830487379597341,11.9085129397834,75.0844,0.899475784101901,0.966161698169495,0.089162714716843,0.710196251672582,0.737295170816964,-0.0270989191443816,12.3558372210395,102.3782,-0.447324281256115,-27.2938,0.769192098559221,0.783833228549664,0.826218956972322,0.832050810371025,-0.0146411299904426,-0.0058318533987028,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38394,1073:1561,Pancreas,HuP-T4,SIDM00531,907286,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in pancreas,10.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.886001701193698,0.107417628288952,0.830487379597341,11.9085129397834,75.0844,0.899475784101901,0.966161698169495,0.0808844442916595,0.73581323114314,0.533847173866246,0.201966057276894,9.76147977393427,16.9523,2.14703316584911,58.1321,0.79693707489682,0.751389793549607,0.856020908206365,0.804299945526817,0.0455472813472128,0.0517209626795474,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38394,1083:1561,Pancreas,HuP-T4,SIDM00531,907286,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.943790913793549,0.107417628288952,0.830487379597341,11.9085129397834,75.0844,0.899475784101901,0.966161698169495,0.0810875759373373,0.783806442884184,0.736170504311156,0.0476359385730281,11.3167107503045,49.8195,0.591802189478909,25.2649,0.848917072212702,0.833018886901876,0.911854631987715,0.901080594956977,0.0158981853108257,0.010774037030738,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38394,1594:1561,Pancreas,HuP-T4,SIDM00531,907286,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.897855898650078,0.107417628288952,0.830487379597341,11.9085129397834,75.0844,0.899475784101901,0.966161698169495,0.179803520531274,0.745657992525919,0.436066406090585,0.309591586435333,8.89509671865817,9.2987,3.01341622112521,65.7857,0.807599638448796,0.632710733164349,0.867473979751257,0.779906550820342,0.174888905284447,0.0875674289309153,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38394,1564:1561,Pancreas,HuP-T4,SIDM00531,907286,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.874406814306677,0.107417628288952,0.830487379597341,11.9085129397834,75.0844,0.899475784101901,0.966161698169495,0.141261096102064,0.726183823915611,0.19888995014336,0.52729387377225,6.76203604104184,2.1199,5.14647689874154,72.9645,0.786507754922543,0.554256937811111,0.844818372601517,0.639703223309051,0.232250817111432,0.205115149292466,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38394,1558:1561,Pancreas,HuP-T4,SIDM00531,907286,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.82681704245139,0.107417628288952,0.830487379597341,11.9085129397834,75.0844,0.899475784101901,0.966161698169495,0.116989741387102,0.686661118991878,0.379675173353479,0.306985945638399,8.7006353851303,8.1261,3.20787755465308,66.9583,0.743701907567779,0.616198206551282,0.798838957810314,0.709793137130462,0.127503701016496,0.0890458206798527,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38394,1079:1561,Pancreas,HuP-T4,SIDM00531,907286,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.05,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.825816952857871,0.107417628288952,0.830487379597341,11.9085129397834,75.0844,0.899475784101901,0.966161698169495,0.0841054771586069,0.685830557205994,0.465672717667344,0.22015783953865,9.47034929617666,13.8544,2.43816364360672,61.23,0.742802351196476,0.678438917258451,0.797872709550318,0.739719380956781,0.064363433938025,0.0581533285935367,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38395,1005:1564,Pancreas,HuP-T4,SIDM00531,907286,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,8.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.415952747691121,0.106993286607326,0.785064594454337,11.3710308724566,51.7311,0.876282034315106,0.955920814434728,0.0716423141001377,0.326549775178297,0.141731779276249,0.184817995902048,7.79200178755567,4.3287,3.57902908490096,47.4024,0.364491919925733,0.283248506308316,0.397617889339259,0.334608020263332,0.0812434136174168,0.0630098690759273,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38395,1510:1564,Pancreas,HuP-T4,SIDM00531,907286,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.97505180731897,0.106993286607326,0.785064594454337,11.3710308724566,51.7311,0.876282034315106,0.955920814434728,0.132182419818084,0.765478651684835,0.303299247735692,0.462179403949144,7.54459510928597,3.6465,3.82643576317066,48.0846,0.854420381280088,0.67369985282895,0.932072317768403,0.768313863111426,0.180720528451138,0.163758454656977,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38395,1168:1564,Pancreas,HuP-T4,SIDM00531,907286,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.847917048872199,0.106993286607326,0.785064594454337,11.3710308724566,51.7311,0.876282034315106,0.955920814434728,0.100123469747676,0.665669654103771,0.739672110002414,-0.0740024558986435,12.5175016594799,114.5179,-1.14647078702324,-62.7868,0.743014476516192,0.770576336513053,0.810541555931004,0.826817424015958,-0.0275618599968611,-0.0162758680849542,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38395,1594:1564,Pancreas,HuP-T4,SIDM00531,907286,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.923140646162574,0.106993286607326,0.785064594454337,11.3710308724566,51.7311,0.876282034315106,0.955920814434728,0.135235909954545,0.724725037003935,0.337563283909521,0.387161753094414,7.99178436690285,4.9716,3.37924650555378,46.7595,0.808931563378302,0.708383508614201,0.882449358317529,0.754396769092335,0.100548054764101,0.128052589225193,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38395,1053:1564,Pancreas,HuP-T4,SIDM00531,907286,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,5.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.986150200393721,0.106993286607326,0.785064594454337,11.3710308724566,51.7311,0.876282034315106,0.955920814434728,0.0980613409775425,0.774191607143159,0.0954601211948194,0.67873148594834,4.91239898144509,0.5882,6.45863189101153,51.1429,0.864145703741259,0.530057011988963,0.942681502715336,0.571675134285332,0.334088691752296,0.371006368430004,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38395,1558:1564,Pancreas,HuP-T4,SIDM00531,907286,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.926756314441946,0.106993286607326,0.785064594454337,11.3710308724566,51.7311,0.876282034315106,0.955920814434728,0.128490504154658,0.727563570155362,0.189288328436678,0.538275241718685,6.51087259973036,1.7811,4.86015827272627,49.95,0.812099908533559,0.58529911825161,0.885905650883872,0.660099145336327,0.226800790281949,0.225806505547545,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38395,1073:1564,Pancreas,HuP-T4,SIDM00531,907286,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in pancreas,10.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.853472056086577,0.106993286607326,0.785064594454337,11.3710308724566,51.7311,0.876282034315106,0.955920814434728,0.102775730756937,0.670030693589717,0.402589796703433,0.267440896886284,8.79264813046516,8.6613,2.57838274199147,43.0698,0.747882229538642,0.694112761138687,0.815851702951563,0.736835307232415,0.0537694683999543,0.079016395719148,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38395,1088:1564,Pancreas,HuP-T4,SIDM00531,907286,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.917585638948196,0.106993286607326,0.785064594454337,11.3710308724566,51.7311,0.876282034315106,0.955920814434728,0.0222231534659246,0.720363997517989,0.787484157767598,-0.067120160249609,12.2955186355047,98.1861,-0.924487763048059,-46.455,0.804063810355852,0.904901940274614,0.87713921129697,0.892023766688161,-0.100838129918763,-0.0148845553911912,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38395,1083:1564,Pancreas,HuP-T4,SIDM00531,907286,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,1.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.929673274297195,0.106993286607326,0.785064594454337,11.3710308724566,51.7311,0.876282034315106,0.955920814434728,0.070903981088416,0.729853572061163,0.828079933522257,-0.0982263614610946,12.8402236771106,143.2262,-1.46919280465401,-91.4951,0.814655988049532,0.868042165563591,0.888694033524375,0.910070370543485,-0.0533861775140592,-0.0213763370191105,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38395,1561:1564,Pancreas,HuP-T4,SIDM00531,907286,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,2.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.910114535506823,0.106993286607326,0.785064594454337,11.3710308724566,51.7311,0.876282034315106,0.955920814434728,0.05942316479217,0.714498698724661,0.288570511576671,0.42592818714799,7.59566585987924,3.7779,3.77536501257739,47.9532,0.797517016633666,0.672845683309584,0.869997428010566,0.720290719474789,0.124671333324083,0.149706708535777,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38395,1054:1564,Pancreas,HuP-T4,SIDM00531,907286,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,8.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.999187932403477,0.106993286607326,0.785064594454337,11.3710308724566,51.7311,0.876282034315106,0.955920814434728,0.154967738443907,0.784427068936003,0.634314460108206,0.150112608827797,10.0121487401831,20.1691,1.35888213227355,31.562,0.875570434069623,0.788809364248222,0.955144542116484,0.916532039427283,0.0867610698214011,0.0386125026892004,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38395,1057:1564,Pancreas,HuP-T4,SIDM00531,907286,1057,Dactolisib,"PI3K (class 1), MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.0125,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.940097628839657,0.106993286607326,0.785064594454337,11.3710308724566,51.7311,0.876282034315106,0.955920814434728,0.0779488919356986,0.738037363732489,0.485444351661001,0.252593012071488,9.11993916723164,10.8669,2.25109170522499,40.8642,0.823790662654422,0.783436965204275,0.898658891008562,0.827057170412044,0.0403536974501468,0.0716017205965176,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38395,1190:1564,Pancreas,HuP-T4,SIDM00531,907286,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.01,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.878192103238983,0.106993286607326,0.785064594454337,11.3710308724566,51.7311,0.876282034315106,0.955920814434728,0.164636873889982,0.689437527382313,0.558940830951525,0.130496696430788,10.0250907560563,20.3509,1.3459401164003,31.3802,0.769543962745717,0.671361055335449,0.839482110558355,0.805956707998789,0.0981829074102689,0.0335254025595659,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38395,1011:1564,Pancreas,HuP-T4,SIDM00531,907286,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.798051246020678,0.106993286607326,0.785064594454337,11.3710308724566,51.7311,0.876282034315106,0.955920814434728,0.0728730414877986,0.626521777811002,0.470911193306717,0.155610584504285,9.66674608950831,15.8749,1.70428478294832,35.8562,0.699317969350705,0.656267821821488,0.762873797056737,0.721429440787196,0.0430501475292174,0.0414443562695404,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38395,1089:1564,Pancreas,HuP-T4,SIDM00531,907286,1089,Oxaliplatin,DNA alkylating agent,DNA replication,Chemotherapeutic,FDA approved in pancreas,10.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.916189649283774,0.106993286607326,0.785064594454337,11.3710308724566,51.7311,0.876282034315106,0.955920814434728,0.110157569686742,0.719268055458227,0.348035540887841,0.371232514570386,8.10298866772834,5.37,3.26804220472829,46.3611,0.802840529692829,0.702596808299977,0.875804755720013,0.75503486804503,0.100243721392852,0.120769887674983,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38395,1079:1594,Pancreas,HuP-T4,SIDM00531,907286,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.05,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.903151917274018,0.0661664246281247,0.886574072055805,12.7635026776403,54.3234,0.966551933708476,0.978064054019351,0.0709024906589377,0.800711072982633,0.591839514549503,0.208871558433131,10.175859401174,9.0371,2.58764327646638,45.2863,0.87294323207372,0.787132983933005,0.883340425604375,0.833653240562173,0.0858102481407148,0.049687185042202,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38395,1564:1594,Pancreas,HuP-T4,SIDM00531,907286,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,1.0,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.831009405978786,0.0661664246281247,0.886574072055805,12.7635026776403,54.3234,0.966551933708476,0.978064054019351,0.0543090945870276,0.736751392975288,0.411977896237917,0.324773496737371,8.96892794898195,3.9148,3.7945747286584,50.4086,0.803213748278728,0.68648043689592,0.812780428539824,0.724939352017061,0.116733311382807,0.0878410765227634,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38395,1510:1594,Pancreas,HuP-T4,SIDM00531,907286,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.917877599982146,0.0661664246281247,0.886574072055805,12.7635026776403,54.3234,0.966551933708476,0.978064054019351,0.106134470776811,0.81376648146498,0.633091306225458,0.180675175239522,10.4621870531634,11.021,2.30131562447697,43.3024,0.887176369170438,0.802064395189531,0.89774308653209,0.855794208149404,0.0851119739809066,0.0419488783826858,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38395,1561:1594,Pancreas,HuP-T4,SIDM00531,907286,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,2.0,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.910114535506823,0.0661664246281247,0.886574072055805,12.7635026776403,54.3234,0.966551933708476,0.978064054019351,0.161638183032547,0.806883949781461,0.51137568343381,0.295508266347651,9.4553762117436,5.4846,3.30812646589674,48.8388,0.879672964190311,0.669824131268291,0.890150312219742,0.814637119509844,0.209848832922021,0.0755131927098973,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38395,1190:1594,Pancreas,HuP-T4,SIDM00531,907286,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.01,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.878192103238983,0.0661664246281247,0.886574072055805,12.7635026776403,54.3234,0.966551933708476,0.978064054019351,0.077607775249081,0.778582349015837,0.32608917900156,0.452493170014276,8.03622734710799,2.0509,4.72727533053235,52.2725,0.848818275553152,0.686898805640099,0.8589281287017,0.720101118448339,0.161919469913053,0.138827010253361,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38395,1372:1594,Pancreas,HuP-T4,SIDM00531,907286,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.898340676715958,0.0661664246281247,0.886574072055805,12.7635026776403,54.3234,0.966551933708476,0.978064054019351,0.0993507472811647,0.796445551849435,0.374991841903968,0.421453709945467,8.38987844981217,2.6206,4.37362422782818,51.7028,0.868292918208791,0.686224767107811,0.878634724159297,0.755662318996067,0.18206815110098,0.122972405163231,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38396,1085:1598,Pancreas,HuP-T4,SIDM00531,907286,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,5.0,1598,LGK974,PORCN,WNT signaling,Targeted,Early clinical trials,10.0,0.481268833634983,0.0603558290471326,0.71807829980072,10.7112434933136,32.7443,0.910341977475014,0.939688841016861,0.0574710331617566,0.345588705803685,0.406130852668379,-0.0605421468646942,12.0883659449909,85.0532,-1.37712245167731,-52.3089,0.438119221708364,0.425507725067268,0.452242952495994,0.466385067674991,0.0126114966410964,-0.0141421151789972,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38396,1011:1598,Pancreas,HuP-T4,SIDM00531,907286,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1598,LGK974,PORCN,WNT signaling,Targeted,Early clinical trials,10.0,0.790540802708762,0.0603558290471326,0.71807829980072,10.7112434933136,32.7443,0.910341977475014,0.939688841016861,0.0703455463955151,0.567670195532205,0.344037492948155,0.22363270258405,8.52284615550887,7.1839,2.18839733780472,25.5604,0.71966247761258,0.666624359599707,0.742862370673936,0.67095464459339,0.0530381180128724,0.0719077260805461,True,0.972411985879737,0.103493972181074,0.0021042604173185,1830.03291845184
38275,1011:1005,Pancreas,KP-2,SIDM00582,1298218,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,8.0,0.388450697658061,0.0425782488570397,0.900495751152235,15.8208126848222,904.3972,0.965761177524943,0.968896879695539,0.0650218065690669,0.349798202773206,0.218746262174537,0.131051940598669,9.78606074797497,13.7949,6.03475193684722,890.6023,0.375150603180635,0.275992707101369,0.376368668876451,0.323015019702358,0.0991578960792657,0.0533536491740926,True,0.497357260224694,0.0809960593036928,0.636588578772835,74.7292218614352
38275,1080:1011,Pancreas,KP-2,SIDM00582,1298218,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.679374287000219,0.160078765377244,0.278246957261764,6.0484913724105,1.2927,0.685399098108375,0.634143150447756,0.0821736433623715,0.189033828199691,0.0557515599198697,0.133282268279821,1.52305296893412,0.0561,4.52543840347637,1.2366,0.46564252358797,0.180139100898138,0.430820550691517,0.230503762740593,0.285503422689832,0.200316787950924,True,0.497357260224694,0.0809960593036928,0.636588578772835,74.7292218614352
38275,1083:1011,Pancreas,KP-2,SIDM00582,1298218,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.944664855033092,0.160078765377244,0.278246957261764,6.0484913724105,1.2927,0.685399098108375,0.634143150447756,0.152300949089329,0.262850121545083,0.172210374912373,0.0906397466327096,4.35259014292834,0.399,1.69590122948216,0.8937,0.64747243965436,0.504575527298779,0.599052747287958,0.494573238830749,0.142896912355581,0.104479508457209,True,0.497357260224694,0.0809960593036928,0.636588578772835,74.7292218614352
38275,1179:1011,Pancreas,KP-2,SIDM00582,1298218,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.2,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.930539250106987,0.160078765377244,0.278246957261764,6.0484913724105,1.2927,0.685399098108375,0.634143150447756,0.179071685809417,0.258919714954913,0.265008594190906,-0.0060888792359935,6.14866808256179,1.3857,-0.100176710151294,-0.093,0.637790762777772,0.661483806137557,0.590095091678137,0.595937419900132,-0.0236930433597852,-0.0058423282219946,True,0.497357260224694,0.0809960593036928,0.636588578772835,74.7292218614352
38275,1558:1011,Pancreas,KP-2,SIDM00582,1298218,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.947989730827394,0.160078765377244,0.278246957261764,6.0484913724105,1.2927,0.685399098108375,0.634143150447756,0.158391579749807,0.263775258118121,0.113928298323601,0.14984695979452,2.83566921289453,0.1394,3.21282215951597,1.1533,0.649751306525097,0.375051418965883,0.601161194499004,0.400726960018055,0.274699887559214,0.200434234480949,True,0.497357260224694,0.0809960593036928,0.636588578772835,74.7292218614352
38276,1190:1022,Pancreas,KP-2,SIDM00582,1298218,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.911259291957927,0.0604913100272033,0.810029118649336,13.4905506320658,22.4797,0.94076075966795,0.937622255709707,0.0860363397547816,0.738146561125697,0.513884534138721,0.224262026986977,9.79616978585008,1.7365,3.69438084621568,20.7432,0.857276983756817,0.790295910490685,0.854416992862021,0.758129625294111,0.0669810732661328,0.0962873675679101,True,0.497357260224694,0.0809960593036928,0.636588578772835,74.7292218614352
38277,1510:1053,Pancreas,KP-2,SIDM00582,1298218,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.861732029648267,0.0514750166321865,0.833343764548147,13.9838661820636,316.4413,0.952566212231635,0.945989225616332,0.0647408514636258,0.718119013618802,0.47956126447483,0.238557749143972,9.70291953004686,16.278,4.2809466520167,300.1633,0.820856815440729,0.669437018369001,0.815189215415754,0.713633243874552,0.151419797071727,0.101555971541202,True,0.497357260224694,0.0809960593036928,0.636588578772835,74.7292218614352
38277,1083:1053,Pancreas,KP-2,SIDM00582,1298218,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,1.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.943165310929416,0.0514750166321865,0.833343764548147,13.9838661820636,316.4413,0.952566212231635,0.945989225616332,0.028882465541789,0.785980930801143,0.819938790923762,-0.0339578601226193,14.8685142722517,584.2501,-0.88464809018817,-267.8088,0.898427407740306,0.910592866857987,0.892224222114305,0.904006668356487,-0.0121654591176813,-0.0117824462421821,True,0.497357260224694,0.0809960593036928,0.636588578772835,74.7292218614352
38277,1179:1053,Pancreas,KP-2,SIDM00582,1298218,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.623623301916704,0.0514750166321865,0.833343764548147,13.9838661820636,316.4413,0.952566212231635,0.945989225616332,0.0537677984337309,0.519692590079212,0.354329504632092,0.16536308544712,9.84975645365251,18.022,4.13410972841106,298.4193,0.59404248656618,0.471279422219979,0.589940924456482,0.520180253114556,0.122763064346201,0.0697606713419266,True,0.497357260224694,0.0809960593036928,0.636588578772835,74.7292218614352
38277,1564:1053,Pancreas,KP-2,SIDM00582,1298218,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,1.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.683552680602199,0.0514750166321865,0.833343764548147,13.9838661820636,316.4413,0.952566212231635,0.945989225616332,0.0589081321617133,0.569634364120013,0.467776020841987,0.101858343278027,11.3959079536942,52.6308,2.58795822836937,263.8105,0.651129187822017,0.600573509152322,0.646633470990842,0.607095636351824,0.0505556786696955,0.0395378346390179,True,0.497357260224694,0.0809960593036928,0.636588578772835,74.7292218614352
38277,1011:1053,Pancreas,KP-2,SIDM00582,1298218,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.339016504489181,0.0514750166321865,0.833343764548147,13.9838661820636,316.4413,0.952566212231635,0.945989225616332,0.0633785203707857,0.282517290094968,0.120920165590621,0.161597124504347,7.17366130381493,2.8198,6.81020487824864,313.6215,0.322935667565268,0.183226108004754,0.320705960552876,0.238032718705506,0.139709559560514,0.08267324184737,True,0.497357260224694,0.0809960593036928,0.636588578772835,74.7292218614352
38277,1558:1053,Pancreas,KP-2,SIDM00582,1298218,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.959359999280435,0.0514750166321865,0.833343764548147,13.9838661820636,316.4413,0.952566212231635,0.945989225616332,0.0543819984525246,0.799476673357265,0.800087094219663,-0.0006104208623973,13.9980743605435,319.5732,-0.0142081784799171,-3.13189999999997,0.913853920681108,0.912738806357267,0.907544222806583,0.907760273945146,0.0011151143238403,-0.0002160511385633,True,0.497357260224694,0.0809960593036928,0.636588578772835,74.7292218614352
38278,1011:1057,Pancreas,KP-2,SIDM00582,1298218,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1057,Dactolisib,"PI3K (class 1), MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,0.319814354305644,0.0491662232240595,0.779373613402588,12.9078515373126,1.501,0.926474170354902,0.926265126678389,0.0651211225550535,0.249254868933205,0.11429729272684,0.134957576206365,7.18319908942887,0.0284,5.7246524478837,1.4726,0.29629973857291,0.169112249874388,0.296232883404484,0.22472619662246,0.127187488698522,0.0715066867820244,True,0.497357260224694,0.0809960593036928,0.636588578772835,74.7292218614352
38279,1083:1079,Pancreas,KP-2,SIDM00582,1298218,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,1.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.950582348862571,0.12447558949443,0.451167592643772,8.39322654485794,1.3133,0.700057617168295,0.768105050527827,0.147572137111582,0.428871949945988,0.345525300240376,0.083346649705612,7.26516139576235,0.6009,1.12806514909559,0.7124,0.665462414066973,0.583593527756614,0.730147103103946,0.672424062852092,0.081868886310359,0.057723040251854,True,0.497357260224694,0.0809960593036928,0.636588578772835,74.7292218614352
38279,1561:1079,Pancreas,KP-2,SIDM00582,1298218,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,2.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.762636406631906,0.12447558949443,0.451167592643772,8.39322654485794,1.3133,0.700057617168295,0.768105050527827,0.102522442182469,0.344076831642613,0.151810756272459,0.192266075370154,4.68911650750318,0.1008,3.70411003735477,1.2125,0.533889425592523,0.376949564618361,0.58578487565036,0.416351485512662,0.156939860974162,0.169433390137698,True,0.497357260224694,0.0809960593036928,0.636588578772835,74.7292218614352
38279,1372:1079,Pancreas,KP-2,SIDM00582,1298218,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.685413191496073,0.12447558949443,0.451167592643772,8.39322654485794,1.3133,0.700057617168295,0.768105050527827,0.112664884559389,0.309236219573568,0.12373437928962,0.185501840283948,4.31562786629652,0.0778,4.07759867856143,1.2355,0.479828725614457,0.315697337864368,0.52646933408653,0.357153742894359,0.164131387750089,0.169315591192171,True,0.497357260224694,0.0809960593036928,0.636588578772835,74.7292218614352
38279,1011:1079,Pancreas,KP-2,SIDM00582,1298218,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.250244059441894,0.12447558949443,0.451167592643772,8.39322654485794,1.3133,0.700057617168295,0.768105050527827,0.0667417531899265,0.112902009871804,0.0340820320014776,0.0788199778703267,3.27995535776652,0.0379,5.11327118709143,1.2754,0.175185259963414,0.0525363139304016,0.192213725921905,0.113113139732518,0.122648946033012,0.0791005861893867,True,0.497357260224694,0.0809960593036928,0.636588578772835,74.7292218614352
38279,1011:1080,Pancreas,KP-2,SIDM00582,1298218,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.1,0.250244059441894,0.0841379886486043,0.543193760340033,9.53633574946389,0.145,0.78369117489859,0.821162459647859,0.0616777803009913,0.135931011650997,0.04130902756706,0.0946219840839373,3.98074301532897,0.0031,5.55559273413492,0.1419,0.196114060955411,0.0751805401220716,0.205491027363571,0.124800060967011,0.120933520833339,0.0806909663965606,True,0.497357260224694,0.0809960593036928,0.636588578772835,74.7292218614352
38280,1011:1083,Pancreas,KP-2,SIDM00582,1298218,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.57690180770115,0.103269753448356,0.544417525578595,9.55161058694399,11.7258,0.851368539534568,0.821810202033471,0.0815643223685095,0.314075454650478,0.105001228307373,0.209074226343105,4.34658281040077,0.3179,5.20502777654322,11.4079,0.491156049477381,0.293574750082946,0.474103791140357,0.30180210667507,0.197581299394435,0.172301684465287,True,0.497357260224694,0.0809960593036928,0.636588578772835,74.7292218614352
38280,1558:1083,Pancreas,KP-2,SIDM00582,1298218,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.942977138387859,0.103269753448356,0.544417525578595,9.55161058694399,11.7258,0.851368539534568,0.821810202033471,0.194049545571756,0.513373280358302,0.282048111423515,0.231325168934787,6.36311239375529,1.2862,3.1884981931887,10.4396,0.802821069123759,0.678126825005991,0.774948232611471,0.616449821087738,0.124694244117767,0.158498411523734,True,0.497357260224694,0.0809960593036928,0.636588578772835,74.7292218614352
38280,1011:1085,Pancreas,KP-2,SIDM00582,1298218,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.57690180770115,0.106820265205206,0.601237671326421,10.2715018468154,24.1413,0.875071953333668,0.850484256422923,0.104526413535539,0.346855099446242,0.19237405408614,0.154481045360103,6.85543978024741,2.2616,3.41606206656802,21.8797,0.50483059174677,0.397831057931796,0.490645904951753,0.394317620218342,0.106999533814974,0.0963282847334105,True,0.497357260224694,0.0809960593036928,0.636588578772835,74.7292218614352
38562,1510:1168,Pancreas,KP-2,SIDM00582,1298218,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.783209073726784,0.060071335563793,0.89261904458202,15.5577086196015,942.0349,0.943704969606246,0.966295979136726,0.0341083433799671,0.699107335097971,0.439176152263762,0.259931182834209,9.75605284317044,16.8886,5.80165577643109,925.1463,0.739118295116671,0.652540988099244,0.756811778765591,0.65031595038262,0.0865773070174271,0.106495828382971,True,0.373937954989178,0.0600076390214254,0.923000315258153,52.7487959891857
38562,1083:1168,Pancreas,KP-2,SIDM00582,1298218,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,1.0,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.912045755718612,0.060071335563793,0.89261904458202,15.5577086196015,942.0349,0.943704969606246,0.966295979136726,0.0667956803802062,0.814109411084634,0.710087390607583,0.104022020477052,12.8933185839982,148.5955,2.66439003560335,793.4394,0.860702112179939,0.819614284264404,0.881306146539612,0.844517928523388,0.0410878279155351,0.0367882180162239,True,0.373937954989178,0.0600076390214254,0.923000315258153,52.7487959891857
38562,1564:1168,Pancreas,KP-2,SIDM00582,1298218,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,1.0,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.423251778924287,0.060071335563793,0.89261904458202,15.5577086196015,942.0349,0.943704969606246,0.966295979136726,0.0288377950578344,0.377802598521038,0.237328649155852,0.140473949365186,9.75589598192498,16.8868,5.80181263767655,925.1481,0.399424807165534,0.340986588669276,0.408986492137005,0.351432668930214,0.0584382184962586,0.0575538232067918,True,0.373937954989178,0.0600076390214254,0.923000315258153,52.7487959891857
38562,1372:1168,Pancreas,KP-2,SIDM00582,1298218,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.399250639699417,0.060071335563793,0.89261904458202,15.5577086196015,942.0349,0.943704969606246,0.966295979136726,0.0535240100516277,0.356378724557254,0.186301280470578,0.170077444086675,8.58603052148181,7.5056,6.97167809811972,934.5293,0.376774812802812,0.276697737468985,0.385794287809312,0.310488443212364,0.100077075333827,0.0753058445969478,True,0.373937954989178,0.0600076390214254,0.923000315258153,52.7487959891857
38562,1011:1168,Pancreas,KP-2,SIDM00582,1298218,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.30327000022816,0.060071335563793,0.89261904458202,15.5577086196015,942.0349,0.943704969606246,0.966295979136726,0.048041824807701,0.270704577854049,0.16508259110457,0.105621986749479,9.5506673941275,14.6476,6.00704122547403,927.3873,0.286197406347802,0.225580811928503,0.293048581813265,0.2492182646651,0.0606165944192991,0.0438303171481642,True,0.373937954989178,0.0600076390214254,0.923000315258153,52.7487959891857
38563,1053:1190,Pancreas,KP-2,SIDM00582,1298218,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.2,0.81019719452485,0.077931154862008,0.772137665761834,12.7790411855504,2.7456,0.913788374882147,0.923522503836536,0.064947878857812,0.625583770587204,0.592803835979316,0.0327799346078883,12.106275512852,1.7223,0.672765672698452,1.0233,0.740348777718938,0.734037381690771,0.748235341688926,0.735434572512632,0.0063113960281663,0.0128007691762948,True,0.373937954989178,0.0600076390214254,0.923000315258153,52.7487959891857
38563,1179:1190,Pancreas,KP-2,SIDM00582,1298218,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.0,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.2,0.372785692501017,0.077931154862008,0.772137665761834,12.7790411855504,2.7456,0.913788374882147,0.923522503836536,0.0533067587599881,0.287841874437144,0.20581672050652,0.0820251539306247,9.64772107193629,0.3133,3.13132011361412,2.4323,0.340647232129821,0.296612241687671,0.344275976132977,0.307864441402464,0.04403499044215,0.0364115347305127,True,0.373937954989178,0.0600076390214254,0.923000315258153,52.7487959891857
38563,1011:1190,Pancreas,KP-2,SIDM00582,1298218,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.2,0.341038848587185,0.077931154862008,0.772137665761834,12.7790411855504,2.7456,0.913788374882147,0.923522503836536,0.0698948115409369,0.263328940482213,0.0631584820267177,0.200170458455495,4.41239206694846,0.0083,8.36664911860194,2.7373,0.311637335222162,0.150848333358164,0.314957051352766,0.179908466547115,0.160789001863999,0.135048584805651,True,0.373937954989178,0.0600076390214254,0.923000315258153,52.7487959891857
38563,1022:1190,Pancreas,KP-2,SIDM00582,1298218,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.2,0.901886650291531,0.077931154862008,0.772137665761834,12.7790411855504,2.7456,0.913788374882147,0.923522503836536,0.107637276564691,0.696380652937862,0.449730846517112,0.246649806420751,8.98334843524232,0.1977,3.79569275030809,2.5479,0.824133536497802,0.726426348986111,0.832912617453981,0.718457249891228,0.0977071875116909,0.114455367562753,True,0.373937954989178,0.0600076390214254,0.923000315258153,52.7487959891857
38563,1561:1372,Pancreas,KP-2,SIDM00582,1298218,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.646458429519887,0.117118896013493,0.17801128029679,4.26271868291386,0.0375,0.491022525588952,0.517547254915527,0.0832701118656099,0.115076892697487,0.0585031524420514,0.056573740255436,1.85459566325644,0.0071,2.40812301965742,0.0304,0.317425650751122,0.212162909281022,0.33457278561502,0.232584336752863,0.1052627414701,0.101988448862157,True,0.373937954989178,0.0600076390214254,0.923000315258153,52.7487959891857
38564,1011:1507,Pancreas,KP-2,SIDM00582,1298218,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1507,Ruxolitinib,"JAK1, JAK2","Other, kinases",Targeted,Advanced clinical trials,10.0,0.289418523027554,0.0496479107134307,0.874189869733856,15.0026497017447,641.1765,0.961542412575694,0.960123903440706,0.0707442065112431,0.253006740944023,0.123383880490124,0.129622860453899,8.08065991047996,5.2875,6.92198979126475,635.889,0.278288184876009,0.180172601098511,0.277877642057259,0.21766249158286,0.098115583777498,0.0602151504743996,True,0.373937954989178,0.0600076390214254,0.923000315258153,52.7487959891857
38564,1085:1510,Pancreas,KP-2,SIDM00582,1298218,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,5.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.633977078004103,0.0626922846142445,0.743991020860054,12.303403173301,98.7242,0.90431662733152,0.912616961494132,0.118280360875136,0.471673253466146,0.200995208259753,0.270678045206393,6.62369576249908,1.926,5.67970741080193,96.7982,0.573316012986162,0.352062874072406,0.578578234585033,0.424530380002392,0.221253138913756,0.15404785458264,True,0.373937954989178,0.0600076390214254,0.923000315258153,52.7487959891857
38564,1372:1510,Pancreas,KP-2,SIDM00582,1298218,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.377959460315338,0.0626922846142445,0.743991020860054,12.303403173301,98.7242,0.90431662733152,0.912616961494132,0.0679143954325617,0.281198444723723,0.208953001954597,0.0722454427691266,9.6569931200856,15.7679,2.64641005321541,82.9563,0.341795024420408,0.277470527228777,0.344932214240946,0.312283135691354,0.0643244971916313,0.0326490785495915,True,0.373937954989178,0.0600076390214254,0.923000315258153,52.7487959891857
38564,1011:1510,Pancreas,KP-2,SIDM00582,1298218,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.289418523027554,0.0626922846142445,0.743991020860054,12.303403173301,98.7242,0.90431662733152,0.912616961494132,0.0672457619930923,0.215324782403079,0.0805272400893298,0.134797542313749,6.04835374380593,1.2926,6.25504942949508,97.4316,0.261725982631548,0.132582432275521,0.264128253085526,0.183530269941397,0.129143550356026,0.0805979831441287,True,0.373937954989178,0.0600076390214254,0.923000315258153,52.7487959891857
38564,1594:1510,Pancreas,KP-2,SIDM00582,1298218,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.521042925303392,0.0626922846142445,0.743991020860054,12.303403173301,98.7242,0.90431662733152,0.912616961494132,0.130304471549596,0.387651257908379,0.238538218649983,0.149113039258396,8.47617755137244,6.9553,3.82722562192857,91.7689,0.471187780905313,0.31265057458929,0.475512611298396,0.402377444586617,0.158537206316023,0.0731351667117787,True,0.373937954989178,0.0600076390214254,0.923000315258153,52.7487959891857
38564,1564:1510,Pancreas,KP-2,SIDM00582,1298218,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.468875372533013,0.0626922846142445,0.743991020860054,12.303403173301,98.7242,0.90431662733152,0.912616961494132,0.080794018504451,0.348839067066974,0.145038758522999,0.203800308543975,6.51276866031509,1.7835,5.79063451298592,96.9407,0.424011795527865,0.24799392951517,0.427903617800508,0.310816438859399,0.176017866012694,0.117087178941109,True,0.373937954989178,0.0600076390214254,0.923000315258153,52.7487959891857
38564,1558:1510,Pancreas,KP-2,SIDM00582,1298218,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.769245354552908,0.0626922846142445,0.743991020860054,12.303403173301,98.7242,0.90431662733152,0.912616961494132,0.0878073671396342,0.572311636625672,0.316362220684669,0.255949415941003,7.88914009773904,4.6302,4.41426307556197,94.094,0.695641364619725,0.515365214301045,0.702026358115551,0.57072940219931,0.180276150318679,0.131296955916241,True,0.373937954989178,0.0600076390214254,0.923000315258153,52.7487959891857
38564,1079:1510,Pancreas,KP-2,SIDM00582,1298218,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.05,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.587004051681368,0.0626922846142445,0.743991020860054,12.303403173301,98.7242,0.90431662733152,0.912616961494132,0.0656783698729875,0.436725743659409,0.253112560244645,0.183613183414764,8.14232437281467,5.5184,4.16107880048634,93.2058,0.530837524246432,0.400588993606683,0.535709854030195,0.443353563317351,0.13024853063975,0.0923562907128443,True,0.373937954989178,0.0600076390214254,0.923000315258153,52.7487959891857
38565,1510:1558,Pancreas,KP-2,SIDM00582,1298218,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.81169817680968,0.0914799716265331,0.79464969562799,13.1901421096842,182.5402,0.905882885713199,0.931976615709852,0.0633611144142257,0.645015709143607,0.286685669381893,0.358330039761714,7.12650353010202,2.7291,6.06363857958214,179.8111,0.735303486736495,0.557545088481429,0.756483719800943,0.567703085392684,0.177758398255066,0.188780634408259,True,0.373937954989178,0.0600076390214254,0.923000315258153,52.7487959891857
38565,1053:1558,Pancreas,KP-2,SIDM00582,1298218,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.77546403591005,0.0914799716265331,0.79464969562799,13.1901421096842,182.5402,0.905882885713199,0.931976615709852,0.0568150631040001,0.616222260106374,0.505721248330151,0.110501011776223,10.9462057035129,38.536,2.24393640617127,144.0042,0.702479598616999,0.693677008584239,0.722714347792151,0.677833728139902,0.0088025900327599,0.0448806196522497,True,0.373937954989178,0.0600076390214254,0.923000315258153,52.7487959891857
38565,1083:1558,Pancreas,KP-2,SIDM00582,1298218,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,1.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.883436849924583,0.0914799716265331,0.79464969562799,13.1901421096842,182.5402,0.905882885713199,0.931976615709852,0.0740251521302049,0.70202282389912,0.608221863632806,0.0938009602663145,11.4554892400842,54.8499,1.73465286959998,127.6903,0.800290322955059,0.801453453057012,0.823342485586085,0.786179434370176,-0.0011631301019534,0.0371630512159091,True,0.373937954989178,0.0600076390214254,0.923000315258153,52.7487959891857
38565,1085:1558,Pancreas,KP-2,SIDM00582,1298218,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,1.25,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.922264427218133,0.0914799716265331,0.79464969562799,13.1901421096842,182.5402,0.905882885713199,0.931976615709852,0.0457064371826277,0.732877146377412,0.649622207742888,0.0832549386345233,11.6884809431982,64.4634,1.50166116648593,118.0768,0.835463560718992,0.86413159560834,0.859528879668341,0.826890445429162,-0.028668034889348,0.0326384342391781,True,0.373937954989178,0.0600076390214254,0.923000315258153,52.7487959891857
38565,1054:1558,Pancreas,KP-2,SIDM00582,1298218,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,8.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.761195550495547,0.0914799716265331,0.79464969562799,13.1901421096842,182.5402,0.905882885713199,0.931976615709852,0.17230261069175,0.604883812514667,0.403458401691492,0.201425410823174,9.37243188814862,12.9453,3.81771022153553,169.5949,0.689554021874953,0.667192424968842,0.709416453044238,0.619696275205403,0.0223615969061112,0.0897201778388343,True,0.373937954989178,0.0600076390214254,0.923000315258153,52.7487959891857
38565,1564:1558,Pancreas,KP-2,SIDM00582,1298218,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,1.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.387664524112988,0.0914799716265331,0.79464969562799,13.1901421096842,182.5402,0.905882885713199,0.931976615709852,0.0431531295293862,0.308057496092155,0.232233719669859,0.0758237764222964,10.2433821309554,23.6753,2.94675997872874,158.8649,0.351178657792107,0.330050631718679,0.361294271213593,0.329294703099323,0.0211280260734276,0.0319995681142696,True,0.373937954989178,0.0600076390214254,0.923000315258153,52.7487959891857
38565,1507:1558,Pancreas,KP-2,SIDM00582,1298218,1507,Ruxolitinib,"JAK1, JAK2","Other, kinases",Targeted,Advanced clinical trials,10.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.980441246975815,0.0914799716265331,0.79464969562799,13.1901421096842,182.5402,0.905882885713199,0.931976615709852,0.116112304112573,0.779107338490458,0.53370518991011,0.245402148580348,9.55079300081144,14.6489,3.63934910887272,167.8913,0.888164946082698,0.735668517813562,0.913748315258867,0.805702667542637,0.152496428269136,0.108045647716231,True,0.373937954989178,0.0600076390214254,0.923000315258153,52.7487959891857
38565,1372:1558,Pancreas,KP-2,SIDM00582,1298218,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.404414485251751,0.0914799716265331,0.79464969562799,13.1901421096842,182.5402,0.905882885713199,0.931976615709852,0.0603559306590723,0.321367847612855,0.20213613076179,0.119231716851064,8.99782205329309,9.9849,4.19232005639107,172.5553,0.366352160924074,0.299394067041868,0.376904843308969,0.322433772593652,0.0669580938822069,0.0544710707153176,True,0.373937954989178,0.0600076390214254,0.923000315258153,52.7487959891857
38565,1011:1558,Pancreas,KP-2,SIDM00582,1298218,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.300123574951546,0.0914799716265331,0.79464969562799,13.1901421096842,182.5402,0.905882885713199,0.931976615709852,0.0481207553535722,0.23849310748603,0.0784483123063421,0.160044795179688,5.7834317736198,1.0758,7.40671033606436,181.4644,0.271876810147668,0.164396330693121,0.279708153678084,0.185282314402609,0.107480479454547,0.0944258392754752,True,0.373937954989178,0.0600076390214254,0.923000315258153,52.7487959891857
38565,1022:1558,Pancreas,KP-2,SIDM00582,1298218,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.905907991205394,0.0914799716265331,0.79464969562799,13.1901421096842,182.5402,0.905882885713199,0.931976615709852,0.0846632205143234,0.71987950947833,0.5102025236923,0.209676985786029,9.78693847656615,17.2541,3.40320363311801,165.2861,0.820646545263789,0.746935086745585,0.844285063788113,0.753337456142606,0.0737114585182039,0.0909476076455074,True,0.373937954989178,0.0600076390214254,0.923000315258153,52.7487959891857
38565,1079:1558,Pancreas,KP-2,SIDM00582,1298218,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.473574132751998,0.0914799716265331,0.79464969562799,13.1901421096842,182.5402,0.905882885713199,0.931976615709852,0.0693069836225316,0.376325540448664,0.257532464042919,0.118793076405746,9.543977042221,14.5799,3.64616506746316,167.9603,0.429002701976505,0.346725918819445,0.441360017529935,0.389034851276711,0.0822767831570603,0.0523251662532243,True,0.373937954989178,0.0600076390214254,0.923000315258153,52.7487959891857
38565,1085:1561,Pancreas,KP-2,SIDM00582,1298218,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,5.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.666784589838234,0.0709496106471092,0.33316437859511,6.85131126809506,2.2552,0.656231855833758,0.683264117214437,0.10386517008798,0.22214887353025,0.10378029421718,0.118368579313071,3.76377439672431,0.2653,3.08753687137075,1.9899,0.437565288830895,0.293799258348741,0.455589984148011,0.32287126233853,0.143766030482154,0.132718721809481,True,0.373937954989178,0.0600076390214254,0.923000315258153,52.7487959891857
38565,1011:1561,Pancreas,KP-2,SIDM00582,1298218,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.300123574951546,0.0709496106471092,0.33316437859511,6.85131126809506,2.2552,0.656231855833758,0.683264117214437,0.0620419698038728,0.0999904843504749,0.0318510631090509,0.0681394212414239,2.40155532028191,0.1032,4.44975594781315,2.152,0.196950650569915,0.0637170589615018,0.205063669494509,0.118399961757599,0.133233591608413,0.08666370773691,True,0.373937954989178,0.0600076390214254,0.923000315258153,52.7487959891857
38565,1079:1561,Pancreas,KP-2,SIDM00582,1298218,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.05,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.627253302953126,0.0709496106471092,0.33316437859511,6.85131126809506,2.2552,0.656231855833758,0.683264117214437,0.0565137080236168,0.208978456900109,0.0685402986606166,0.140438158239492,2.50286828131507,0.1107,4.34844298677999,2.1445,0.411623599074785,0.226940145634529,0.428579674312108,0.251555027520457,0.184683453440256,0.177024646791651,True,0.373937954989178,0.0600076390214254,0.923000315258153,52.7487959891857
38566,1510:1564,Pancreas,KP-2,SIDM00582,1298218,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.786375186612539,0.0956411476731056,0.255409860419541,5.68684927216785,1.0061,0.582800593984107,0.611176045019078,0.0499842712761412,0.200847976650099,0.0949994759645502,0.105848500685549,2.85401833293084,0.1412,2.83283093923702,0.8649,0.458299925852151,0.317257461524029,0.480613676454991,0.333356138649347,0.141042464328122,0.147257537805644,True,0.373937954989178,0.0600076390214254,0.923000315258153,52.7487959891857
38566,1561:1564,Pancreas,KP-2,SIDM00582,1298218,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,2.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.534064077166151,0.0956411476731056,0.255409860419541,5.68684927216785,1.0061,0.582800593984107,0.611176045019078,0.0638075622509301,0.136405231404098,0.0460618418260922,0.0903433895780056,1.69120897411165,0.0631,3.99564029805621,0.943,0.311252861398007,0.164831666816549,0.326407170469172,0.186722333699962,0.146421194581458,0.139684836769209,True,0.373937954989178,0.0600076390214254,0.923000315258153,52.7487959891857
38566,1168:1564,Pancreas,KP-2,SIDM00582,1298218,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.785813197418244,0.0956411476731056,0.255409860419541,5.68684927216785,1.0061,0.582800593984107,0.611176045019078,0.0966199020715922,0.200704439068427,0.0864304016613263,0.114274037407101,2.52564406369636,0.1125,3.1612052084715,0.8936,0.457972398215903,0.291191080365124,0.480270202121878,0.316302406080843,0.166781317850779,0.163967796041035,True,0.373937954989178,0.0600076390214254,0.923000315258153,52.7487959891857
38566,1558:1564,Pancreas,KP-2,SIDM00582,1298218,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.946938805241325,0.0956411476731056,0.255409860419541,5.68684927216785,1.0061,0.582800593984107,0.611176045019078,0.124896512920692,0.241857508072534,0.145555651728668,0.0963018563438663,3.71804046951927,0.257,1.96880880264858,0.7491,0.551876498161245,0.4280960558537,0.578746313862484,0.455637198588113,0.123780442307544,0.12310911527437,True,0.373937954989178,0.0600076390214254,0.923000315258153,52.7487959891857
38566,1011:1594,Pancreas,KP-2,SIDM00582,1298218,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.263559944978968,0.0786212790084488,0.445332186810112,8.3201655598725,2.4969,0.7778697353429,0.764413315209058,0.0427954378883544,0.117371726653037,0.049664308605136,0.0677074180479006,4.47847723401235,0.1742,3.84168832586015,2.3227,0.20501530464778,0.121313317295601,0.20146873129769,0.140196343212462,0.0837019873521782,0.0612723880852276,True,0.373937954989178,0.0600076390214254,0.923000315258153,52.7487959891857
38533,1083:1011,Pancreas,PANC-08-13,SIDM01136,925347,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,1.0,0.197169249579175,0.513399972470711,9.21435843855769,11.6019,0.747246505592608,0.763359738277921,0.102254364755988,0.513399972470711,0.370131266926645,0.143268705544066,6.87430213682472,2.2914,2.34005630173297,9.3105,0.747246505592608,0.660204340752728,0.763359738277921,0.654838727058736,0.0870421648398798,0.108521011219185,True,,,,
38533,1179:1011,Pancreas,PANC-08-13,SIDM01136,925347,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.2,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.907958020952494,0.197169249579175,0.513399972470711,9.21435843855769,11.6019,0.747246505592608,0.763359738277921,0.188214185640204,0.466145622961571,0.473244399010154,-0.0070987760485832,9.33955144317854,12.6536,-0.125193004620854,-1.0517,0.678468458381531,0.689060599043472,0.693098597241635,0.697777440828155,-0.0105921406619408,-0.0046788435865201,True,,,,
38533,1564:1011,Pancreas,PANC-08-13,SIDM01136,925347,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.916532808297372,0.197169249579175,0.513399972470711,9.21435843855769,11.6019,0.747246505592608,0.763359738277921,0.0865027675161292,0.470547918548374,0.236629807092483,0.233918111455891,4.78000760804342,0.5366,4.43435083051426,11.0653,0.68487593826119,0.48828332861245,0.69964424466501,0.497841330371325,0.19659260964874,0.201802914293684,True,,,,
38533,1561:1011,Pancreas,PANC-08-13,SIDM01136,925347,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.865452737441689,0.197169249579175,0.513399972470711,9.21435843855769,11.6019,0.747246505592608,0.763359738277921,0.12902474442996,0.444323411577264,0.272009057577741,0.172314353999523,5.88091775842414,1.151,3.33344068013354,10.4509,0.646706533808859,0.545319002933977,0.660651775145398,0.521897758043084,0.101387530874882,0.138754017102314,True,,,,
38533,1598:1011,Pancreas,PANC-08-13,SIDM01136,925347,1598,LGK974,PORCN,WNT signaling,Targeted,Early clinical trials,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.906435166369035,0.197169249579175,0.513399972470711,9.21435843855769,11.6019,0.747246505592608,0.763359738277921,0.0981855070083262,0.465363789460346,0.370203585295497,0.0951602041648494,7.51858692451555,3.5814,1.69577151404214,8.0205,0.677330510615515,0.649567759507266,0.69193611136537,0.622576396562966,0.0277627511082491,0.0693597148024044,True,,,,
38533,1190:1011,Pancreas,PANC-08-13,SIDM01136,925347,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.90858588345688,0.197169249579175,0.513399972470711,9.21435843855769,11.6019,0.747246505592608,0.763359738277921,0.0692005813881079,0.466467967554039,0.292018712579564,0.174449254974475,6.01189150307165,1.2603,3.20246693548604,10.3416,0.678937626443926,0.554137789024467,0.693577882198658,0.554245388762194,0.124799837419459,0.139332493436464,True,,,,
38533,1080:1011,Pancreas,PANC-08-13,SIDM01136,925347,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.0025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.98750575217046,0.197169249579175,0.513399972470711,9.21435843855769,11.6019,0.747246505592608,0.763359738277921,0.086546707652555,0.506985425978983,0.305736509476057,0.201248916502925,5.79351287664509,1.0833,3.4208455619126,10.5186,0.737910222561976,0.577322800041504,0.753822132524784,0.590883116588652,0.160587422520471,0.162939015936132,True,,,,
38533,1558:1011,Pancreas,PANC-08-13,SIDM01136,925347,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.855732749049534,0.197169249579175,0.513399972470711,9.21435843855769,11.6019,0.747246505592608,0.763359738277921,0.178145371881609,0.439333169804316,0.265641987496687,0.173691182307629,5.8088691650517,1.0949,3.40548927350599,10.507,0.63944330644842,0.553163054087182,0.653231927350298,0.512739428808651,0.0862802523612384,0.140492498541647,True,,,,
38533,1510:1011,Pancreas,PANC-08-13,SIDM01136,925347,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.879273992834972,0.197169249579175,0.513399972470711,9.21435843855769,11.6019,0.747246505592608,0.763359738277921,0.184060779481651,0.451419243715686,0.283262427399844,0.168156816315842,6.02573788487559,1.2725,3.1886205536821,10.3294,0.657034418604392,0.586569947485689,0.671202365045087,0.537011190838359,0.070464471118703,0.134191174206728,True,,,,
38534,1011:1022,Pancreas,PANC-08-13,SIDM01136,925347,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.444294887610204,0.0697613233095731,0.783453449324648,14.1414064557095,35.2954,0.896950429328209,0.911385107054995,0.0766976009307147,0.348084362215522,0.211234597735665,0.136849764479857,8.60685831320651,0.7615,5.53454814250299,34.5339,0.398510490190301,0.298755077075811,0.404923743708613,0.327600262436387,0.0997554131144908,0.0773234812722256,True,,,,
38534,1190:1022,Pancreas,PANC-08-13,SIDM01136,925347,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.921052923843311,0.0697613233095731,0.783453449324648,14.1414064557095,35.2954,0.896950429328209,0.911385107054995,0.0639125833521712,0.721602090195594,0.49925018327064,0.222351906924954,9.6739875417668,1.5955,4.4674189139427,33.6999,0.82613881547526,0.670711604418556,0.839433917600252,0.720192421703436,0.155427211056703,0.119241495896815,True,,,,
38537,1564:1079,Pancreas,PANC-08-13,SIDM01136,925347,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,1.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.896830887508024,0.0432688118085759,0.942948302952642,20.2153762974546,4755.4834,0.982861512570195,0.978491276002105,0.0618480537503436,0.845665163411203,0.496020954159305,0.349644209251898,9.85215574028993,3.6104,10.3632205571647,4751.873,0.881460562615808,0.686547013140635,0.877541199475827,0.707468009830008,0.194913549475172,0.170073189645819,True,,,,
38537,1372:1079,Pancreas,PANC-08-13,SIDM01136,925347,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.899966026465805,0.0432688118085759,0.942948302952642,20.2153762974546,4755.4834,0.982861512570195,0.978491276002105,0.114690757924244,0.848621437370964,0.44768422157524,0.400937215795723,8.95914831766111,1.9442,11.2562279797935,4753.5392,0.88454197003397,0.602817766613366,0.88060890559507,0.677344603226646,0.281724203420604,0.203264302368424,True,,,,
38537,1011:1079,Pancreas,PANC-08-13,SIDM01136,925347,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.468719408905337,0.0432688118085759,0.942948302952642,20.2153762974546,4755.4834,0.982861512570195,0.978491276002105,0.107153491561502,0.441978171188253,0.199045020934125,0.242933150254128,7.78578690153641,0.862,12.4295893959182,4754.6214,0.460686267207708,0.237214226115551,0.458637852506736,0.327952501634084,0.223472041092157,0.130685350872652,True,,,,
38537,1011:1080,Pancreas,PANC-08-13,SIDM01136,925347,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.1,0.468719408905337,0.0734778863585961,0.77140484676238,13.8629452716567,2.91,0.908427169504218,0.905827054050894,0.0725252337399146,0.361572423801175,0.197377787940264,0.164194635860911,7.72751285011312,0.0414,6.13543242154358,2.8686,0.425797445923565,0.284835896260277,0.424578721345198,0.326651038334432,0.140961549663289,0.0979276830107664,True,,,,
38538,1168:1083,Pancreas,PANC-08-13,SIDM01136,925347,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.718426581594696,0.103919720130677,0.746275200809737,13.3135160624885,159.0698,0.911079016024969,0.893979934423472,0.0996750216663825,0.536143941446635,0.323833508229871,0.212310433216764,8.20983879246837,4.6262,5.10367727002012,154.4436,0.654543383045478,0.541684550265278,0.642258948302106,0.516893514702558,0.1128588327802,0.125365433599548,True,,,,
38538,1372:1083,Pancreas,PANC-08-13,SIDM01136,925347,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.83112713573177,0.103919720130677,0.746275200809737,13.3135160624885,159.0698,0.911079016024969,0.893979934423472,0.117925817772323,0.620249570116648,0.488304045121563,0.131945524995085,10.414284732952,21.3222,2.89923132953652,137.7476,0.757222493014152,0.730073844662023,0.743010982299056,0.672990857494688,0.0271486483521285,0.0700201248043684,True,,,,
38538,1011:1083,Pancreas,PANC-08-13,SIDM01136,925347,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.465207296831373,0.103919720130677,0.746275200809737,13.3135160624885,159.0698,0.911079016024969,0.893979934423472,0.0842338789429073,0.347172668860988,0.155020893851903,0.192151775009085,6.22674232823772,1.1702,7.08677373425077,157.8996,0.423840606244763,0.277154008498963,0.415885988714631,0.28906255266918,0.1466865977458,0.126823436045452,True,,,,
38538,1558:1083,Pancreas,PANC-08-13,SIDM01136,925347,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.938359880045905,0.103919720130677,0.746275200809737,13.3135160624885,159.0698,0.911079016024969,0.893979934423472,0.121602267160503,0.700274707913058,0.608553094694289,0.0917216132187687,11.4492521250473,43.6906,1.86426393744117,115.3792,0.854919996189531,0.857789200112191,0.838874904029055,0.792200099278941,-0.0028692039226599,0.0466748047501144,True,,,,
38538,1011:1085,Pancreas,PANC-08-13,SIDM01136,925347,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.626767252881764,0.0887364162432035,0.763507805489027,13.6860110603617,257.4127,0.937977026802464,0.902141757362471,0.0655722643450329,0.478541689800142,0.364000679889873,0.114541009910269,10.3029965049839,24.6741,3.38301455537785,232.7386,0.587893284355186,0.512907016080784,0.565432910972004,0.50499800740972,0.0749862682744015,0.0604349035622835,True,,,,
38380,1011:1168,Pancreas,PANC-08-13,SIDM01136,925347,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.472158050861937,0.0663950888716233,0.77435946301962,13.9302451188039,304.896,0.907714208734268,0.907197193712159,0.0466848169148693,0.36562005472584,0.209755067028115,0.155864987697725,8.10462255750701,5.3761,5.82562256129687,299.5199,0.428584571535658,0.315575279902442,0.428340458730552,0.337420200360995,0.113009291633216,0.0909202583695576,True,0.588885004130016,0.0604990811819972,0.47660528781524,98.2207557140039
38380,1011:1179,Pancreas,PANC-08-13,SIDM01136,925347,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,4.0,0.472158050861937,0.064281114270641,0.74778821992236,13.3455280749021,81.3194,0.897914559020223,0.894703250319257,0.0579942429375596,0.353074228376059,0.203994363038701,0.149079865337359,7.90645091793948,1.8744,5.43907715696266,79.445,0.423957588027545,0.323031916557347,0.42244134277058,0.333053315248523,0.100925671470198,0.0893880275220578,True,0.588885004130016,0.0604990811819972,0.47660528781524,98.2207557140039
38381,1011:1372,Pancreas,PANC-08-13,SIDM01136,925347,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.4884308941569,0.0514244580071547,0.832564707583012,15.412889447924,85.2064,0.921685125333148,0.933273315010327,0.0558778910926179,0.406650324568249,0.272882857731514,0.133767466836735,9.94302845886141,1.9226,5.46986098906258,83.2838,0.450179489897584,0.333029633628625,0.455839519743268,0.386998626728204,0.11714985626896,0.0688408930150643,True,0.588885004130016,0.0604990811819972,0.47660528781524,98.2207557140039
38381,1079:1372,Pancreas,PANC-08-13,SIDM01136,925347,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.05,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,1.0,0.0514244580071547,0.832564707583012,15.412889447924,85.2064,0.921685125333148,0.933273315010327,0.0610626725581825,0.832564707583012,0.599787468466431,0.232777239116581,10.6176207212742,3.0687,4.79526872664982,82.1377,0.921685125333148,0.764073921864981,0.933273315010327,0.816914409719783,0.157611203468167,0.116358905290544,True,0.588885004130016,0.0604990811819972,0.47660528781524,98.2207557140039
38382,1011:1510,Pancreas,PANC-08-13,SIDM01136,925347,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.622927618866799,0.0730032588053585,0.82018231001944,15.0677149849786,670.7555,0.909484255320779,0.927866597560061,0.041589168302788,0.51091421341708,0.401420604443948,0.109493608973132,11.3771965297284,51.9526,3.69051845525021,618.8029,0.566542861563817,0.497511372971421,0.577993730244127,0.524505654052954,0.0690314885923954,0.0534880761911732,True,0.588885004130016,0.0604990811819972,0.47660528781524,98.2207557140039
38383,1011:1558,Pancreas,PANC-08-13,SIDM01136,925347,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.459021256663304,0.0621457187968456,0.865025766927369,16.4274974229868,1721.4702,0.949899225715345,0.947109688947901,0.0596770656330462,0.397065214581139,0.191247262974594,0.205817951606544,7.65427591275286,3.9346,8.77322151023391,1717.5356,0.436023936291357,0.305479662590675,0.434743479618856,0.318282155447952,0.130544273700682,0.116461324170904,True,0.588885004130016,0.0604990811819972,0.47660528781524,98.2207557140039
38383,1011:1561,Pancreas,PANC-08-13,SIDM01136,925347,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.459021256663304,0.082806546584653,0.655552000797986,11.5730279971348,59.5057,0.815202412288408,0.848027029231857,0.0540893872574477,0.300912303214435,0.12613911378357,0.174773189430865,5.12006127745286,0.6792,6.45296671968194,58.8265,0.374195235723582,0.209850278810501,0.389262432642455,0.257905391384684,0.164344956913081,0.131357041257771,True,0.588885004130016,0.0604990811819972,0.47660528781524,98.2207557140039
38383,1079:1561,Pancreas,PANC-08-13,SIDM01136,925347,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.05,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.992976524199589,0.082806546584653,0.655552000797986,11.5730279971348,59.5057,0.815202412288408,0.848027029231857,0.0539338314875277,0.650947747184471,0.442123276920742,0.208824470263729,8.12086051755482,5.4369,3.45216747957998,54.0688,0.809476857873264,0.672840127147355,0.842070931913953,0.7103603438068,0.136636730725909,0.131710588107152,True,0.588885004130016,0.0604990811819972,0.47660528781524,98.2207557140039
38384,1011:1564,Pancreas,PANC-08-13,SIDM01136,925347,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.429182036199018,0.0581710776087791,0.800794241394271,14.5626634327803,472.6379,0.902014775794896,0.919251229963442,0.0507955557884529,0.343686503098041,0.196534736713306,0.147151766384734,8.3255534414226,6.2657,6.23710999135769,466.3722,0.387128538157254,0.265449497354231,0.394526114654162,0.311052525947298,0.121679040803023,0.0834735887068638,True,0.588885004130016,0.0604990811819972,0.47660528781524,98.2207557140039
38384,1083:1594,Pancreas,PANC-08-13,SIDM01136,925347,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,1.0,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.975363632783914,0.0752356364184072,0.790358518310242,14.3060622808842,158.2501,0.894495292528862,0.914535948717509,0.0850612632694017,0.770886955620789,0.818738996050041,-0.0478520404292514,15.6128002878533,391.4815,-1.3067380069691,-233.2314,0.87245817802906,0.878744521706114,0.892005105252593,0.913169737105413,-0.0062863436770535,-0.0211646318528198,True,0.588885004130016,0.0604990811819972,0.47660528781524,98.2207557140039
38232,1080:1011,Pancreas,AsPC-1,SIDM00899,910702,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.941675842878267,0.0638199482951413,0.670338176189072,12.2439646727761,94.7394,0.851918868781521,0.841722142515375,0.0788949461045693,0.631241267076324,0.424678933104044,0.206562333972281,8.10090794620048,5.3622,4.14305672657566,89.3772,0.802231418823739,0.645898098249562,0.792629408022467,0.654010638481061,0.156333320574176,0.138618769541405,True,0.629507771316861,0.0776243047830664,0.431301911570614,110.594754115149
38232,1083:1011,Pancreas,AsPC-1,SIDM00899,910702,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.98182544211747,0.0638199482951413,0.670338176189072,12.2439646727761,94.7394,0.851918868781521,0.841722142515375,0.0439630575770739,0.658155076205054,0.552574818526035,0.105580257679019,10.1543457079057,22.2583,2.08961896487039,72.4811,0.836435619989632,0.738371603435038,0.826424214715222,0.761350999009186,0.0980640165545941,0.065073215706036,True,0.629507771316861,0.0776243047830664,0.431301911570614,110.594754115149
38232,1179:1011,Pancreas,AsPC-1,SIDM00899,910702,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.2,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.916520419694731,0.0638199482951413,0.670338176189072,12.2439646727761,94.7394,0.851918868781521,0.841722142515375,0.0575908261167061,0.614378626578208,0.634580801116525,-0.0202021745383169,12.7081600658664,130.6975,-0.464195393090227,-35.9581,0.7808010391615,0.805504628131847,0.771455531324539,0.78288882281378,-0.024703588970347,-0.0114332914892409,True,0.629507771316861,0.0776243047830664,0.431301911570614,110.594754115149
38232,1564:1011,Pancreas,AsPC-1,SIDM00899,910702,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.699307146034535,0.0638199482951413,0.670338176189072,12.2439646727761,94.7394,0.851918868781521,0.841722142515375,0.0841262143934465,0.468772276868775,0.327862498536903,0.140909778331872,8.42953889805473,6.734,3.8144257747214,88.0054,0.595752952780575,0.483923799400093,0.588622309236501,0.495418221839479,0.111829153380482,0.0932040873970224,True,0.629507771316861,0.0776243047830664,0.431301911570614,110.594754115149
38232,1561:1011,Pancreas,AsPC-1,SIDM00899,910702,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.846609545790012,0.0638199482951413,0.670338176189072,12.2439646727761,94.7394,0.851918868781521,0.841722142515375,0.118001518957465,0.567514698869135,0.369141393972653,0.198373304896482,7.82385241177964,4.4253,4.42011226099649,90.3141,0.721242646549065,0.590148999363411,0.712610000756338,0.577826422116547,0.131093647185654,0.13478357863979,True,0.629507771316861,0.0776243047830664,0.431301911570614,110.594754115149
38232,1510:1011,Pancreas,AsPC-1,SIDM00899,910702,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.859174930320436,0.0638199482951413,0.670338176189072,12.2439646727761,94.7394,0.851918868781521,0.841722142515375,0.110214122621349,0.575937755818374,0.438759940300985,0.137177815517389,9.19521945594157,11.449,3.04874521683457,83.2904,0.731947334724029,0.639391911316011,0.723186563144816,0.63535332376716,0.0925554234080179,0.0878332393776555,True,0.629507771316861,0.0776243047830664,0.431301911570614,110.594754115149
38233,1011:1022,Pancreas,AsPC-1,SIDM00899,910702,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.78907542342074,0.0587543778838764,0.760863845772375,14.2903406691092,39.1337,0.91261829470387,0.890915307007918,0.112229625678619,0.600378961268369,0.410763963511388,0.189614997756981,9.37618101682727,1.2979,4.91415965228194,37.8358,0.72012466731497,0.613417026138371,0.702999373109291,0.589070630446466,0.106707641176599,0.113928742662825,True,0.629507771316861,0.0776243047830664,0.431301911570614,110.594754115149
38237,1011:1083,Pancreas,AsPC-1,SIDM00899,910702,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.630071824642988,0.0677275460533691,0.748887137550786,13.9944474396892,255.0166,0.889133860099575,0.884702932537925,0.0720358579855247,0.471852685208288,0.366981142185011,0.104871543023277,10.5212154265476,22.9626,3.47323201314157,232.054,0.560218193584802,0.50030495645432,0.557426390971172,0.496678430586164,0.0599132371304818,0.0607479603850081,True,0.629507771316861,0.0776243047830664,0.431301911570614,110.594754115149
38237,1558:1085,Pancreas,AsPC-1,SIDM00899,910702,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.807863707168898,0.0993355897904792,0.665507988235927,12.1444248690491,88.4232,0.863342564177517,0.83894244867726,0.101947629143298,0.537639750526792,0.401672770625961,0.135966979900831,8.94887294832807,9.6518,3.19555192072107,78.7714,0.697463124453151,0.604455067569962,0.677751156689764,0.589515752972703,0.0930080568831887,0.0882354037170611,True,0.629507771316861,0.0776243047830664,0.431301911570614,110.594754115149
38170,1011:1179,Pancreas,AsPC-1,SIDM00899,910702,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,4.0,0.783504888005971,0.0874375592980899,0.711394437438549,13.1236202326117,69.7258,0.86844142192143,0.864690763844827,0.106275121321248,0.557381019033361,0.409746926456837,0.147634092576524,9.42019947359985,5.3525,3.70342075901181,64.3733,0.680428099022296,0.598296931239832,0.677489440086038,0.586239901597667,0.082131167782464,0.0912495384883709,True,0.755325171644131,0.10494938592446,0.247564959615334,183.06104131339
38172,1011:1510,Pancreas,AsPC-1,SIDM00899,910702,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.830168180853232,0.0912204591185029,0.724626088416039,13.4223668001583,214.4199,0.835578156339913,0.871853781589987,0.0515781644859484,0.601561521619136,0.433411736830946,0.16814978478819,9.40390127400136,13.2308,4.01846552615698,201.1891,0.693670398009403,0.584161922426881,0.723785267832571,0.620634405653122,0.109508475582522,0.103150862179448,True,0.755325171644131,0.10494938592446,0.247564959615334,183.06104131339
38172,1594:1510,Pancreas,AsPC-1,SIDM00899,910702,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.744077118354605,0.0912204591185029,0.724626088416039,13.4223668001583,214.4199,0.835578156339913,0.871853781589987,0.0583259920425191,0.539177691753176,0.426063387653972,0.113114304099204,10.3369294039464,25.2613,3.08543739621192,189.1586,0.621734586729457,0.529318581593979,0.648726449432043,0.58179427683806,0.0924160051354773,0.066932172593984,True,0.755325171644131,0.10494938592446,0.247564959615334,183.06104131339
38173,1011:1558,Pancreas,AsPC-1,SIDM00899,910702,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.786719022647423,0.0772376609344118,0.808885595059627,15.5946818178296,966.4893,0.903376906806629,0.915009549605099,0.099267951321596,0.636365684778889,0.420545822176112,0.215819862602777,9.63281343306701,15.5059,5.9618683847626,950.9834,0.710703797205163,0.585182321026015,0.719855418578382,0.595006891495652,0.125521476179148,0.12484852708273,True,0.755325171644131,0.10494938592446,0.247564959615334,183.06104131339
38173,1011:1561,Pancreas,AsPC-1,SIDM00899,910702,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.803863626761055,0.0916912200485974,0.674784141236369,12.3362433202588,100.9972,0.797674775089179,0.844265866962737,0.0861790425437961,0.542434427055112,0.295887898873771,0.246546528181341,6.52969780898017,1.8045,5.80654551127865,99.1927,0.641221737678997,0.46512094892368,0.678674621767232,0.501341361937836,0.176100788755316,0.177333259829396,True,0.755325171644131,0.10494938592446,0.247564959615334,183.06104131339
38174,1011:1564,Pancreas,AsPC-1,SIDM00899,910702,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.726878296910615,0.0775543963007828,0.559072331219939,10.0850986625552,21.2152,0.774471782305108,0.772962865269563,0.053299848750014,0.406377543966997,0.267142743809022,0.139234800157975,6.51865796234676,1.7908,3.56644070020846,19.4244,0.562946730127266,0.414448800655459,0.561849931082289,0.452950717184699,0.148497929471807,0.10889921389759,True,0.755325171644131,0.10494938592446,0.247564959615334,183.06104131339
38174,1558:1564,Pancreas,AsPC-1,SIDM00899,910702,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.896818985158079,0.0775543963007828,0.559072331219939,10.0850986625552,21.2152,0.774471782305108,0.772962865269563,0.0713222458035359,0.501386680714628,0.425518077921161,0.0758686027934666,8.53291310675374,7.2342,1.55218555580147,13.981,0.694560997840436,0.602492549014842,0.693207772395931,0.639207158971922,0.0920684488255946,0.0540006134240085,True,0.755325171644131,0.10494938592446,0.247564959615334,183.06104131339
38100,1080:1011,Pancreas,PA-TU-8988T,SIDM00453,1240201,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.541387052607002,0.120638774590335,0.514525360601347,9.15036988510574,11.0985,0.835629143016785,0.833136923396405,0.0618741383396252,0.278557368467518,0.0524775592800687,0.22607980918745,3.22561942654589,0.1827,5.92475045855984,10.9158,0.452398798810372,0.209579924186822,0.451049543375645,0.239477374333117,0.24281887462355,0.211572169042528,True,0.221295631603729,0.0355503362207888,1.42320343631463,34.5934987899097
38100,1083:1011,Pancreas,PA-TU-8988T,SIDM00453,1240201,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.9641299569139,0.120638774590335,0.514525360601347,9.15036988510574,11.0985,0.835629143016785,0.833136923396405,0.111857993655595,0.496069313747686,0.358174540037228,0.137894773710458,7.63961837516205,3.8948,1.51075150994369,7.2037,0.805655089652772,0.700273974997751,0.803252266057555,0.725814594316415,0.105381114655021,0.0774376717411407,True,0.221295631603729,0.0355503362207888,1.42320343631463,34.5934987899097
38101,1190:1022,Pancreas,PA-TU-8988T,SIDM00453,1240201,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.665666458485496,0.0496282045389308,0.856653695816919,13.6255508843736,24.6848,0.964018127561237,0.960874443841281,0.0648790898590603,0.57024563184296,0.162189922818257,0.408055709024703,6.06915313024941,0.1311,7.55639775412421,24.5537,0.641714532889508,0.412893399488878,0.639621888081047,0.433332563855313,0.228821133400631,0.206289324225734,True,0.221295631603729,0.0355503362207888,1.42320343631463,34.5934987899097
38101,1088:1022,Pancreas,PA-TU-8988T,SIDM00453,1240201,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.943119725461869,0.0496282045389308,0.856653695816919,13.6255508843736,24.6848,0.964018127561237,0.960874443841281,0.05184599686057,0.807926998414747,0.333428910106591,0.474498088308156,7.43848899443627,0.3388,6.18706188993735,24.346,0.909184511805819,0.671469003828362,0.906219641678915,0.69857946948947,0.237715507977457,0.207640172189445,True,0.221295631603729,0.0355503362207888,1.42320343631463,34.5934987899097
38101,1005:1022,Pancreas,PA-TU-8988T,SIDM00453,1240201,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,0.8,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.986143141337932,0.0496282045389308,0.856653695816919,13.6255508843736,24.6848,0.964018127561237,0.960874443841281,0.0264612109523477,0.844783166631646,0.910388310728441,-0.0656051440967952,15.4330558201752,86.4058,-1.80750493580163,-61.721,0.95065986461995,0.979925815828336,0.94755974248098,0.966193794873181,-0.0292659512083853,-0.0186340523922016,True,0.221295631603729,0.0355503362207888,1.42320343631463,34.5934987899097
38101,1179:1022,Pancreas,PA-TU-8988T,SIDM00453,1240201,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.2,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.932544338729033,0.0496282045389308,0.856653695816919,13.6255508843736,24.6848,0.964018127561237,0.960874443841281,0.111837427274192,0.798867554285371,0.494171657802007,0.304695896483364,9.30999706172321,1.2397,4.3155538226504,23.4451,0.898989647289395,0.818061184516838,0.896058022833595,0.783769089562628,0.0809284627725573,0.112288933270967,True,0.221295631603729,0.0355503362207888,1.42320343631463,34.5934987899097
38102,1179:1053,Pancreas,PA-TU-8988T,SIDM00453,1240201,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.32281993002691,0.0708401396156546,0.738402151315211,11.6848205661478,64.3001,0.903153324121721,0.923449357760262,0.0470555665883135,0.238370930819297,0.121789693187895,0.116581237631401,7.70333500219237,4.0707,3.98148556395546,60.2294,0.291555892896545,0.198286526319628,0.298107857055563,0.244241940384788,0.093269366576917,0.0538659166707751,True,0.221295631603729,0.0355503362207888,1.42320343631463,34.5934987899097
38102,1564:1053,Pancreas,PA-TU-8988T,SIDM00453,1240201,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,1.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.715676359647663,0.0708401396156546,0.738402151315211,11.6848205661478,64.3001,0.903153324121721,0.923449357760262,0.0379402306674936,0.528456963609273,0.370267400917673,0.158189562691601,9.17980994720605,11.3273,2.50501061894178,52.9728,0.646365483211119,0.589640181102195,0.660890874680837,0.597235640918045,0.0567253021089242,0.0636552337627916,True,0.221295631603729,0.0355503362207888,1.42320343631463,34.5934987899097
38102,1372:1053,Pancreas,PA-TU-8988T,SIDM00453,1240201,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.772188194815354,0.0708401396156546,0.738402151315211,11.6848205661478,64.3001,0.903153324121721,0.923449357760262,0.0838295655853908,0.570185424271867,0.268810843424388,0.301374580847479,7.37688505902524,3.2463,4.30793550712258,61.0538,0.697404334995038,0.517502661223939,0.713076692572295,0.569058069157939,0.179901673771099,0.144018623414356,True,0.221295631603729,0.0355503362207888,1.42320343631463,34.5934987899097
38102,1558:1053,Pancreas,PA-TU-8988T,SIDM00453,1240201,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.9385182058358,0.0708401396156546,0.738402151315211,11.6848205661478,64.3001,0.903153324121721,0.923449357760262,0.0605408589768795,0.693003862237647,0.678788135140587,0.0142157270970604,11.4855598477925,56.0052,0.199260718355326,8.2949,0.847625837349357,0.813035757101687,0.866674034425383,0.861784374256335,0.0345900802476696,0.0048896601690483,True,0.221295631603729,0.0355503362207888,1.42320343631463,34.5934987899097
38102,1594:1054,Pancreas,PA-TU-8988T,SIDM00453,1240201,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,8.0,0.589532711243357,0.0652380357925456,0.856758057681267,13.6277504324316,197.7797,0.957586940489657,0.960905193531037,0.112256298719576,0.505086900624429,0.403795642416428,0.101291258208002,11.0092601693192,32.2061,2.61849026311236,165.5736,0.564528825278099,0.432037075664174,0.566485043990175,0.533275282764906,0.132491749613925,0.033209761225269,True,0.221295631603729,0.0355503362207888,1.42320343631463,34.5934987899097
38104,1510:1079,Pancreas,PA-TU-8988T,SIDM00453,1240201,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.863368017185439,0.0998449063591103,0.436829841003109,8.34271979040965,1.2681,0.750193640033429,0.792614116743306,0.0886247078526577,0.377144913674285,0.162998229347487,0.214146684326798,5.22801224369939,0.1464,3.11470754671026,1.1217,0.647693195500789,0.475880136754291,0.684317678365856,0.510233679233258,0.171813058746497,0.174083999132599,True,0.221295631603729,0.0355503362207888,1.42320343631463,34.5934987899097
38104,1083:1079,Pancreas,PA-TU-8988T,SIDM00453,1240201,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,1.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.953060485604559,0.0998449063591103,0.436829841003109,8.34271979040965,1.2681,0.750193640033429,0.792614116743306,0.0834851115788028,0.416325260392986,0.313806633257678,0.102518627135308,7.1590512720246,0.5583,1.18366851838505,0.7098,0.714979914867712,0.663222584526421,0.755409195000404,0.689437011779974,0.0517573303412906,0.0659721832204303,True,0.221295631603729,0.0355503362207888,1.42320343631463,34.5934987899097
38104,1011:1080,Pancreas,PA-TU-8988T,SIDM00453,1240201,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.1,0.79130604578643,0.0862397093469784,0.39169105809949,7.8610330667785,0.0454,0.778190276439948,0.765783515063358,0.171653490737913,0.30994750235461,0.109555747275612,0.200391755078998,4.26976681427194,0.0038,3.59126625250656,0.0416,0.615786670519144,0.418955883404037,0.605969125233218,0.41159378636108,0.196830787115107,0.194375338872138,True,0.221295631603729,0.0355503362207888,1.42320343631463,34.5934987899097
38316,1372:1083,Pancreas,PA-TU-8988T,SIDM00453,1240201,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.803555958848501,0.0622145153689683,0.822180047482851,12.9616875066748,124.6455,0.936121651579826,0.950511570207643,0.115571607881532,0.660667676401188,0.36272967415132,0.297938002249868,8.49548879164325,5.6392,4.46619871503153,119.0063,0.752226131334069,0.561510305633259,0.763789236194797,0.643419896008234,0.19071582570081,0.120369340186563,True,0.222681557994576,0.0464644075464695,1.37103537802547,35.6037734061434
38316,1011:1083,Pancreas,PA-TU-8988T,SIDM00453,1240201,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.804195793157073,0.0622145153689683,0.822180047482851,12.9616875066748,124.6455,0.936121651579826,0.950511570207643,0.0964465511192552,0.661193735403391,0.309115081191878,0.352078654211513,7.78134928004075,3.4375,5.18033822663403,121.208,0.752825094083747,0.633491665347564,0.76439740610811,0.612123386294938,0.119333428736183,0.152274019813172,True,0.222681557994576,0.0464644075464695,1.37103537802547,35.6037734061434
38316,1558:1083,Pancreas,PA-TU-8988T,SIDM00453,1240201,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.954032605466266,0.0622145153689683,0.822180047482851,12.9616875066748,124.6455,0.936121651579826,0.950511570207643,0.0569506148394578,0.784386572862442,0.743417896235862,0.0409686766265801,12.2632120893066,76.8095,0.698475417368201,47.836,0.893090578290085,0.910904414289207,0.90681902985103,0.893922679079814,-0.0178138359991215,0.0128963507712155,True,0.222681557994576,0.0464644075464695,1.37103537802547,35.6037734061434
38316,1079:1083,Pancreas,PA-TU-8988T,SIDM00453,1240201,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.684433473462041,0.0622145153689683,0.822180047482851,12.9616875066748,124.6455,0.936121651579826,0.950511570207643,0.0521335871478891,0.562727545709874,0.200607216991926,0.362120328717948,6.72217459961484,1.6497,6.23951290705993,122.9958,0.640712993573803,0.476612290814666,0.650561935563076,0.475840918531579,0.164100702759137,0.174721017031497,True,0.222681557994576,0.0464644075464695,1.37103537802547,35.6037734061434
38218,1179:1088,Pancreas,PA-TU-8988T,SIDM00453,1240201,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.0,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,0.299595918148468,0.0694246351621747,0.864308405835355,13.7905570396485,138.3794,0.933723450215828,0.963120224188363,0.064893190447237,0.258943270409682,0.142289909604187,0.116653360805496,8.74042251206417,4.1767,5.05013452758431,134.2027,0.279739734364167,0.210076565543552,0.288546887853071,0.243656428262183,0.0696631688206146,0.0448904595908887,True,0.26756550262373,0.0538701661393178,1.24271970070205,39.4976191203835
38219,1594:1168,Pancreas,PA-TU-8988T,SIDM00453,1240201,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,0.520787192296951,0.0772504208526097,0.87357692640017,14.0012100250527,320.2685,0.939140141090485,0.965813637663314,0.0450390542652364,0.454947674755345,0.301714106700548,0.153233568054797,9.82813819778204,17.7539,4.17307182727071,302.5146,0.489092157251877,0.429077411200833,0.502983372640782,0.44927070818523,0.060014746051044,0.0537126644555525,True,0.26756550262373,0.0538701661393178,1.24271970070205,39.4976191203835
38220,1011:1190,Pancreas,PA-TU-8988T,SIDM00453,1240201,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.2,0.847178721975603,0.0843369890259793,0.500172788286804,9.00178824097872,0.2002,0.824245607490581,0.826113503121029,0.112136091584387,0.423735743547789,0.102313569386574,0.321422174161215,3.8637347184898,0.0057,5.13805352248892,0.1945,0.698283340347875,0.403424497332786,0.699865781780862,0.41496621227254,0.294858843015089,0.284899569508322,True,0.26756550262373,0.0538701661393178,1.24271970070205,39.4976191203835
38220,1022:1190,Pancreas,PA-TU-8988T,SIDM00453,1240201,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.2,0.953414108255306,0.0843369890259793,0.500172788286804,9.00178824097872,0.2002,0.824245607490581,0.826113503121029,0.135920620680422,0.476871792918034,0.167602459527868,0.309269333390165,5.00225961768016,0.0125,3.99952862329856,0.1877,0.785847390848985,0.543586186443839,0.787628268895803,0.547699342409652,0.242261204405146,0.239928926486151,True,0.26756550262373,0.0538701661393178,1.24271970070205,39.4976191203835
38220,1179:1190,Pancreas,PA-TU-8988T,SIDM00453,1240201,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.0,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.2,0.339896370351028,0.0843369890259793,0.500172788286804,9.00178824097872,0.2002,0.824245607490581,0.826113503121029,0.0524808393701014,0.170006915287038,0.0733972547087494,0.0966096605782885,5.66367902862434,0.0198,3.33810921235438,0.1804,0.280158090263826,0.176391259745589,0.28079298120881,0.211553551450889,0.103766830518237,0.0692394297579214,True,0.26756550262373,0.0538701661393178,1.24271970070205,39.4976191203835
38221,1085:1510,Pancreas,PA-TU-8988T,SIDM00453,1240201,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,5.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.495706557891861,0.100252593893762,0.846021834140709,13.4081221111992,212.3132,0.901670977600112,0.957722513029723,0.048244621156895,0.419378571303249,0.350777829478407,0.0686007418248425,11.2869688910107,48.803,2.12115322018843,163.5102,0.44696421665714,0.417358321589054,0.474749330349506,0.452457846039982,0.0296058950680864,0.0222914843095247,True,0.26756550262373,0.0538701661393178,1.24271970070205,39.4976191203835
38221,1594:1510,Pancreas,PA-TU-8988T,SIDM00453,1240201,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.505788235286502,0.100252593893762,0.846021834140709,13.4081221111992,212.3132,0.901670977600112,0.957722513029723,0.0553780741293774,0.427907890503879,0.314541731990159,0.11336615851372,10.2873350191006,24.4077,3.12078709209862,187.9055,0.456054572569416,0.392466221019235,0.484404779759457,0.445285069979465,0.0635883515501802,0.0391197097799924,True,0.26756550262373,0.0538701661393178,1.24271970070205,39.4976191203835
38221,1079:1510,Pancreas,PA-TU-8988T,SIDM00453,1240201,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.05,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.80999488691952,0.100252593893762,0.846021834140709,13.4081221111992,212.3132,0.901670977600112,0.957722513029723,0.0899603566695409,0.685273359876248,0.462608372787003,0.222664987089245,9.74112193839001,16.7148,3.66700017280917,195.5984,0.730348881539815,0.627284931608604,0.775750338641789,0.695876899319212,0.103063949931211,0.0798734393225764,True,0.26756550262373,0.0538701661393178,1.24271970070205,39.4976191203835
38222,1053:1558,Pancreas,PA-TU-8988T,SIDM00453,1240201,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,5.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.851715867821191,0.0621842148120596,0.833152116365705,13.1607717618656,178.8616,0.94084370993294,0.953855049719174,0.166685075608091,0.709608877817478,0.433970011298597,0.275638866518881,9.09858290478911,10.7072,4.06218885707649,168.1544,0.801331516889642,0.695920941758682,0.812413481447191,0.707529984084239,0.10541057513096,0.104883497362953,True,0.26756550262373,0.0538701661393178,1.24271970070205,39.4976191203835
36179,1598:1011,Pancreas,SU8686,SIDM01188,1240218,1598,LGK974,PORCN,WNT signaling,Targeted,Early clinical trials,10.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.747332348301324,0.160552905809208,0.451620886758423,8.03220166942416,5.1129,0.726023295982463,0.679141790677557,0.12498134425257,0.337510897843098,0.176765834175803,0.160745063667295,3.15800663868783,0.1743,4.87419503073633,4.9386,0.542580694708041,0.292180568234966,0.507544629256625,0.344569754421447,0.250400126473075,0.162974874835178,True,0.34929585216241,0.0353686353370659,1.01539368805041,48.5343226239962
36179,1080:1011,Pancreas,SU8686,SIDM01188,1240218,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.778886985083362,0.160552905809208,0.451620886758423,8.03220166942416,5.1129,0.726023295982463,0.679141790677557,0.139341304438083,0.351761630887943,0.221307874981663,0.13045375590628,4.39317835357227,0.4104,3.63902331585188,4.7025,0.565490096108066,0.379859387847693,0.528974701784959,0.403624737227524,0.185630708260373,0.125349964557435,True,0.34929585216241,0.0353686353370659,1.01539368805041,48.5343226239962
36183,1011:1080,Pancreas,SU8686,SIDM01188,1240218,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.1,0.516132713941942,0.0839300596394449,0.720054283311192,13.709927772712,2.6172,0.864985411926726,0.861682847836239,0.0875858652178083,0.371643571430926,0.263589262346584,0.108054309084342,9.21342173998026,0.1159,4.49650603273169,2.5013,0.44644726817793,0.37399427779185,0.444742706810939,0.374423684444027,0.0724529903860799,0.0703190223669122,True,0.34929585216241,0.0353686353370659,1.01539368805041,48.5343226239962
36542,1011:1190,Pancreas,SU8686,SIDM01188,1240218,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.2,0.608879871000262,0.0952442324552914,0.779062449477617,15.2827451213903,15.5713,0.880780606987284,0.89419993485502,0.0656218688855462,0.474355443739079,0.332176505850424,0.142178937888655,9.91094724230788,0.3761,5.37179787908247,15.1952,0.536289582361949,0.41272505077895,0.544460340982967,0.457186307071209,0.123564531582999,0.0872740339117575,True,0.497578854780933,0.0576856789646371,0.666463313851374,73.146771367176
37955,1564:1561,Pancreas,SU8686,SIDM01188,1240218,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.69224597420078,0.0582030916737794,0.632331693199528,11.7032859944862,65.1284,0.822354012745376,0.809047785339349,0.0546832651109721,0.437729068976936,0.356547317804277,0.0811817511726585,9.3003898318125,12.3148,2.40289616267369,52.8136,0.569271254690843,0.459500469367155,0.560060072337221,0.504433863970763,0.109770785323688,0.055626208366458,True,0.42323727711311,0.0507922310872659,0.796100381365245,60.5981007744114
36545,1168:1564,Pancreas,SU8686,SIDM01188,1240218,1168,Erlotinib,EGFR,EGFR signaling,Targeted,FDA approved in pancreas,10.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.684811860635692,0.112485146368219,0.547786421401963,9.95586861514871,19.3975,0.700743353267232,0.7524500612583,0.0704378558777227,0.375130638471245,0.264487356131583,0.110643282339662,6.69056267131734,2.0174,3.26530594383137,17.3801,0.479877359579027,0.370972446680056,0.515286726485737,0.426167896514313,0.108904912898971,0.0891188299714233,True,0.497578854780933,0.0576856789646371,0.666463313851374,73.146771367176
36545,1564:1594,Pancreas,SU8686,SIDM01188,1240218,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.759598223315511,0.0785469845991207,0.828137834783506,16.8395863120267,916.2429,0.915466743606612,0.919716124761157,0.0481787862944242,0.629052027961905,0.412774043505873,0.216277984456032,9.86788247397758,7.2999,6.97170383804916,908.943,0.695386911948019,0.533279940177873,0.698614734323201,0.569196253855577,0.162106971770146,0.129418480467624,True,0.497578854780933,0.0576856789646371,0.666463313851374,73.146771367176
35357,1179:1011,Pancreas,PA-TU-8902,SIDM00455,1298526,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.2,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.935847327232429,0.0946292137003454,0.677148070696391,11.441417354303,54.3175,0.901709094690747,0.878974104460089,0.0969122835193151,0.633707212101813,0.644577955404513,-0.0108707433026994,11.6182573246892,61.4008,-0.176839970386208,-7.08329999999999,0.843862046207508,0.879068031473244,0.822585566365492,0.82747050786558,-0.0352059852657357,-0.0048849415000881,True,0.374242121883825,0.0428499725745735,0.937328452010777,52.2796229438163
35357,1088:1011,Pancreas,PA-TU-8902,SIDM00455,1298526,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.928683613335511,0.0946292137003454,0.677148070696391,11.441417354303,54.3175,0.901709094690747,0.878974104460089,0.0945499119567513,0.628856317057495,0.591690270912734,0.0371660461447612,10.8554476659356,36.1864,0.585969688367328,18.1311,0.837402460234895,0.849981242228065,0.816288847358341,0.79897415476025,-0.0125787819931696,0.0173146925980905,True,0.374242121883825,0.0428499725745735,0.937328452010777,52.2796229438163
35357,1372:1011,Pancreas,PA-TU-8902,SIDM00455,1298526,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.603576877696417,0.0946292137003454,0.677148070696391,11.441417354303,54.3175,0.901709094690747,0.878974104460089,0.0936334778224408,0.408710918249081,0.193049906665822,0.215661011583258,6.51310711360285,1.7839,4.92831024070012,52.5336,0.544250759963904,0.411355945518557,0.530528445546025,0.396179383667394,0.132894814445347,0.134349061878631,True,0.374242121883825,0.0428499725745735,0.937328452010777,52.2796229438163
35357,1564:1011,Pancreas,PA-TU-8902,SIDM00455,1298526,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.60679177351202,0.0946292137003454,0.677148070696391,11.441417354303,54.3175,0.901709094690747,0.878974104460089,0.0974908658663773,0.410887878748106,0.148667297383727,0.262220581364379,5.29045686873521,0.7644,6.15096048556775,53.5531,0.547149660759316,0.353245127722225,0.533354255716477,0.353148366485061,0.19390453303709,0.180205889231416,True,0.374242121883825,0.0428499725745735,0.937328452010777,52.2796229438163
35357,1561:1011,Pancreas,PA-TU-8902,SIDM00455,1298526,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.578273756512442,0.0946292137003454,0.677148070696391,11.441417354303,54.3175,0.901709094690747,0.878974104460089,0.0750981719420454,0.391576958556755,0.208286747350718,0.183290211206037,7.10621183326183,2.691,4.33520552104114,51.6265,0.521434705468252,0.412780165377259,0.508287657263296,0.399276562567686,0.108654540090992,0.10901109469561,True,0.374242121883825,0.0428499725745735,0.937328452010777,52.2796229438163
35357,1080:1011,Pancreas,PA-TU-8902,SIDM00455,1298526,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.0025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.85141802897111,0.0946292137003454,0.677148070696391,11.441417354303,54.3175,0.901709094690747,0.878974104460089,0.0837788975425356,0.576536075673912,0.28843166410789,0.288104411566021,6.79556962873688,2.1697,4.64584772556608,52.1478,0.76773138010692,0.567325250207086,0.748374399536056,0.572841682502048,0.200406129899834,0.175532717034008,True,0.374242121883825,0.0428499725745735,0.937328452010777,52.2796229438163
35357,1558:1011,Pancreas,PA-TU-8902,SIDM00455,1298526,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.917437781698189,0.0946292137003454,0.677148070696391,11.441417354303,54.3175,0.901709094690747,0.878974104460089,0.139993953608839,0.621241223860906,0.326898655118418,0.294342568742488,7.0507266616784,2.5895,4.39069069262457,51.728,0.827261991570161,0.622561572921232,0.806404052566017,0.630593998748969,0.204700418648929,0.175810053817048,True,0.374242121883825,0.0428499725745735,0.937328452010777,52.2796229438163
35357,1079:1011,Pancreas,PA-TU-8902,SIDM00455,1298526,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.05,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.881210908279952,0.0946292137003454,0.677148070696391,11.441417354303,54.3175,0.901709094690747,0.878974104460089,0.1103067662097,0.596710266418385,0.392204628861542,0.204505637556842,8.27290538517269,6.0412,3.16851196913027,48.2763,0.794595890336726,0.678086816010963,0.774561568945833,0.663008798790475,0.116509074325764,0.111552770155358,True,0.374242121883825,0.0428499725745735,0.937328452010777,52.2796229438163
35357,1083:1011,Pancreas,PA-TU-8902,SIDM00455,1298526,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,4.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.681095790395239,0.0946292137003454,0.677148070696391,11.441417354303,54.3175,0.901709094690747,0.878974104460089,0.141576411948725,0.46120270042557,0.240655491761659,0.22054720866391,7.00780207263487,2.5136,4.43361528166809,51.8039,0.614150268554969,0.502630830077784,0.598665562414192,0.466495142557789,0.111519438477185,0.132170419856403,True,0.374242121883825,0.0428499725745735,0.937328452010777,52.2796229438163
35357,1085:1011,Pancreas,PA-TU-8902,SIDM00455,1298526,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,1.25,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.936252276556295,0.0946292137003454,0.677148070696391,11.441417354303,54.3175,0.901709094690747,0.878974104460089,0.0740181585378867,0.633981422755199,0.602108287168608,0.0318731355865914,10.9409658455119,38.3963,0.500451508791022,15.9212,0.844227192695727,0.828717292406497,0.822941506334789,0.808156195203594,0.0155099002892302,0.0147853111311951,True,0.374242121883825,0.0428499725745735,0.937328452010777,52.2796229438163
35358,1190:1022,Pancreas,PA-TU-8902,SIDM00455,1298526,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.753945660627549,0.0756239036323301,0.776932272743473,13.1131445112642,17.3053,0.937427431359207,0.921328959106783,0.0522753809280531,0.585764715636441,0.415598966489696,0.170165749146746,9.67784432915795,1.5997,3.43530018210622,15.7056,0.706769344026504,0.59540760006548,0.694631970729056,0.615485124447022,0.111361743961024,0.0791468462820336,True,0.374242121883825,0.0428499725745735,0.937328452010777,52.2796229438163
35359,1510:1053,Pancreas,PA-TU-8902,SIDM00455,1298526,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.7656456982809,0.0581041088671147,0.825899595500216,14.1315220584253,350.5436,0.937501321247647,0.940278533870043,0.0715448083850541,0.632346472506675,0.390450835024867,0.241895637481808,9.13137158493785,10.9533,5.00015047348748,339.5903,0.717793853745921,0.549053237471839,0.71992021464347,0.607108022602626,0.168740616274082,0.112812192040843,True,0.374242121883825,0.0428499725745735,0.937328452010777,52.2796229438163
35359,1564:1053,Pancreas,PA-TU-8902,SIDM00455,1298526,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.611805575523325,0.0581041088671147,0.825899595500216,14.1315220584253,350.5436,0.937501321247647,0.940278533870043,0.0695708670874359,0.505289977349491,0.350704604292392,0.154585373057099,9.97247522256259,19.622,4.15904683586274,330.9216,0.573568535399794,0.46602472322646,0.57526764956659,0.506688276906038,0.107543812173334,0.0685793726605521,True,0.374242121883825,0.0428499725745735,0.937328452010777,52.2796229438163
35359,1179:1053,Pancreas,PA-TU-8902,SIDM00455,1298526,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.611953312271667,0.0581041088671147,0.825899595500216,14.1315220584253,350.5436,0.937501321247647,0.940278533870043,0.0413663333024313,0.505411993070187,0.339037834067096,0.166374159003091,9.71509000349346,16.4159,4.41643205493187,334.1277,0.573707038796562,0.465553119825113,0.57540656325972,0.500503573684828,0.108153918971448,0.0749029895748917,True,0.374242121883825,0.0428499725745735,0.937328452010777,52.2796229438163
35359,1558:1053,Pancreas,PA-TU-8902,SIDM00455,1298526,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.88199300437338,0.0581041088671147,0.825899595500216,14.1315220584253,350.5436,0.937501321247647,0.940278533870043,0.166320384793811,0.728437665545995,0.360011505032658,0.368426160513337,7.77550715254233,4.2795,6.356014905883,346.2641,0.826869606931225,0.706600398419443,0.829319089035836,0.641108680140915,0.120269208511782,0.188210408894921,True,0.374242121883825,0.0428499725745735,0.937328452010777,52.2796229438163
35359,1372:1053,Pancreas,PA-TU-8902,SIDM00455,1298526,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.623412143814921,0.0581041088671147,0.825899595500216,14.1315220584253,350.5436,0.937501321247647,0.940278533870043,0.0601530756268061,0.514875837406665,0.291420836596224,0.223455000810441,8.57038351090621,7.4246,5.56113854751912,343.119,0.584449708508316,0.436498379877024,0.586181056583074,0.47812272817564,0.147951328631293,0.108058328407434,True,0.374242121883825,0.0428499725745735,0.937328452010777,52.2796229438163
35361,1510:1079,Pancreas,PA-TU-8902,SIDM00455,1298526,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.572627350280541,0.111037326017164,0.769620664739877,12.9756728191084,31.4649,0.881018715232178,0.918403624554785,0.0648361855957069,0.440705841971145,0.239008761600107,0.201697080371038,7.90075272893708,0.9335,5.07492009017133,30.5314,0.504495412450969,0.381870599477984,0.525903034016852,0.419986890811322,0.122624812972985,0.10591614320553,True,0.374242121883825,0.0428499725745735,0.937328452010777,52.2796229438163
35361,1053:1079,Pancreas,PA-TU-8902,SIDM00455,1298526,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.90000190956399,0.111037326017164,0.769620664739877,12.9756728191084,31.4649,0.881018715232178,0.918403624554785,0.059579074854853,0.692660067905797,0.374273607330476,0.318386460575321,7.87998965233115,0.9202,5.09568316677727,30.5447,0.792918526070573,0.632997265748941,0.826565015849796,0.659123805247711,0.159921260321633,0.167441210602085,True,0.374242121883825,0.0428499725745735,0.937328452010777,52.2796229438163
35361,1083:1079,Pancreas,PA-TU-8902,SIDM00455,1298526,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,1.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.954313483995737,0.111037326017164,0.769620664739877,12.9756728191084,31.4649,0.881018715232178,0.918403624554785,0.0960582036041204,0.734459377923028,0.655120962372389,0.0793384155506388,11.5832703779752,11.9859,1.39240244113325,19.479,0.840768039598668,0.818882257883513,0.87644496266319,0.842826635490537,0.0218857817151556,0.0336183271726526,True,0.374242121883825,0.0428499725745735,0.937328452010777,52.2796229438163
35361,1179:1079,Pancreas,PA-TU-8902,SIDM00455,1298526,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.577954864491977,0.111037326017164,0.769620664739877,12.9756728191084,31.4649,0.881018715232178,0.918403624554785,0.0327632974060995,0.444806006999961,0.329903653051549,0.114902353948412,9.93993712247909,3.8369,3.03573569662933,27.628,0.50918905217691,0.461733983814235,0.530795842378502,0.477914146922275,0.047455068362675,0.0528816954562265,True,0.374242121883825,0.0428499725745735,0.937328452010777,52.2796229438163
35361,1561:1079,Pancreas,PA-TU-8902,SIDM00455,1298526,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,2.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.466038460876373,0.111037326017164,0.769620664739877,12.9756728191084,31.4649,0.881018715232178,0.918403624554785,0.0894607987523662,0.358672830054024,0.262557338318483,0.0961154917355409,9.84016653671954,3.5805,3.13550628238888,27.8844,0.410588606050084,0.31559409216647,0.428011411650795,0.383521762339969,0.0949945138836141,0.0444896493108256,True,0.374242121883825,0.0428499725745735,0.937328452010777,52.2796229438163
35361,1564:1079,Pancreas,PA-TU-8902,SIDM00455,1298526,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,1.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.659128680061396,0.111037326017164,0.769620664739877,12.9756728191084,31.4649,0.881018715232178,0.918403624554785,0.0755271865013919,0.507279052897969,0.370894746894934,0.136384306003036,9.83110107498769,3.5581,3.14457174412072,27.9068,0.580704702880372,0.486225750536254,0.605346168816397,0.542183876387026,0.0944789523441188,0.0631622924293707,True,0.374242121883825,0.0428499725745735,0.937328452010777,52.2796229438163
35361,1190:1079,Pancreas,PA-TU-8902,SIDM00455,1298526,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.01,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.926240560474904,0.111037326017164,0.769620664739877,12.9756728191084,31.4649,0.881018715232178,0.918403624554785,0.0976739572128928,0.712853875861732,0.515690300397281,0.197163575464451,9.75153996357763,3.3672,3.22413285553078,28.0977,0.816035268585532,0.693772535559515,0.850662687949807,0.75892822679361,0.122262733026018,0.091734461156197,True,0.374242121883825,0.0428499725745735,0.937328452010777,52.2796229438163
35361,1372:1079,Pancreas,PA-TU-8902,SIDM00455,1298526,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.64373808345058,0.111037326017164,0.769620664739877,12.9756728191084,31.4649,0.881018715232178,0.918403624554785,0.0903167462333575,0.49543413170361,0.343590394121864,0.151843737581746,9.44555382462966,2.7237,3.53011899447875,28.7412,0.567145299227655,0.451160455206191,0.591211389104964,0.519259044693441,0.115984844021464,0.0719523444115221,True,0.374242121883825,0.0428499725745735,0.937328452010777,52.2796229438163
35361,1011:1079,Pancreas,PA-TU-8902,SIDM00455,1298526,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.91188801413717,0.111037326017164,0.769620664739877,12.9756728191084,31.4649,0.881018715232178,0.918403624554785,0.1189815291312,0.701807859608576,0.278166339292231,0.423641520316345,6.2860126227055,0.3048,6.68966019640291,31.1601,0.803390406650752,0.545062182646691,0.837481257371642,0.586295474662078,0.25832822400406,0.251185782709564,True,0.374242121883825,0.0428499725745735,0.937328452010777,52.2796229438163
35361,1011:1080,Pancreas,PA-TU-8902,SIDM00455,1298526,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.1,0.91188801413717,0.0803762167578484,0.547242381372085,9.62472818115423,0.1542,0.805977796003819,0.814159661039821,0.139341014566849,0.499023768401086,0.241401621864557,0.257622146536529,5.63288544596941,0.0097,3.99184273518482,0.1445,0.734961491836576,0.56475114195219,0.742422436496194,0.550126882301162,0.170210349884386,0.192295554195031,True,0.374242121883825,0.0428499725745735,0.937328452010777,52.2796229438163
35362,1011:1083,Pancreas,PA-TU-8902,SIDM00455,1298526,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,8.0,0.869353917197566,0.101643397298935,0.625793077849309,10.6948964535209,25.9003,0.887123192664744,0.854851675655487,0.145604049882494,0.544035663583418,0.308403625206591,0.235632038376827,7.02819046935266,2.0395,3.66670598416825,23.8608,0.771224022579907,0.644940178656983,0.743168652854001,0.596438488164695,0.126283843922924,0.146730164689306,True,0.374242121883825,0.0428499725745735,0.937328452010777,52.2796229438163
35571,1022:1190,Pancreas,PA-TU-8902,SIDM00455,1298526,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.2,0.95729881118576,0.0744730483441089,0.764276530119325,12.8771183448852,2.9387,0.903666026889777,0.916248921624372,0.0783542166293254,0.731641013700408,0.503340146852634,0.228300866847774,9.34035660440025,0.2532,3.536761740485,2.6855,0.865078413250543,0.756828679803315,0.877124003421246,0.767863949550099,0.108249733447228,0.109260053871147,True,,,,
35571,1011:1372,Pancreas,PA-TU-8902,SIDM00455,1298526,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.822611775058768,0.094355145881642,0.62300983561648,10.6557793546096,3.1509,0.809531905162388,0.853492507461272,0.081689530304027,0.512495226755544,0.202917168183634,0.30957805857191,5.32012547861337,0.078,5.33565387599624,3.0729,0.665930477472338,0.476539263394454,0.702092986562076,0.480280631294054,0.189391214077884,0.221812355268021,True,,,,
35571,1053:1372,Pancreas,PA-TU-8902,SIDM00455,1298526,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.916387593461884,0.094355145881642,0.62300983561648,10.6557793546096,3.1509,0.809531905162388,0.853492507461272,0.0814728851280979,0.57091848396367,0.372855707661537,0.198062776302134,7.7577057947057,0.4227,2.89807355990391,2.7282,0.741844994402375,0.617892407243863,0.782129944950184,0.665249818798699,0.123952587158512,0.116880126151485,True,,,,
35571,1561:1372,Pancreas,PA-TU-8902,SIDM00455,1298526,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.708764624245169,0.094355145881642,0.62300983561648,10.6557793546096,3.1509,0.809531905162388,0.853492507461272,0.0934849428088825,0.441567332041759,0.261377626538199,0.18018970550356,7.22847909217689,0.2929,3.42730026243272,2.858,0.573767576576896,0.427283874244109,0.604925296346855,0.494212055673708,0.146483702332787,0.110713240673148,True,,,,
35572,1079:1510,Pancreas,PA-TU-8902,SIDM00455,1298526,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.5,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.839713535278136,0.0755002011473173,0.670197134744994,11.3371963839825,50.532,0.864913141574764,0.875810594560888,0.0946316905687252,0.562773605349996,0.323692410419114,0.239081194930881,7.46284513079148,3.4456,3.87435125319106,47.0864,0.726279271820264,0.530911485867167,0.735430010592769,0.596329949824853,0.195367785953097,0.139100060767916,True,,,,
35573,1054:1558,Pancreas,PA-TU-8902,SIDM00455,1298526,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,8.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.922191641440155,0.0675048053504763,0.856493695008241,14.8883981283357,592.3583,0.931116533845658,0.951587810118946,0.0942420839197941,0.789851326482793,0.510797448002575,0.279053878480218,9.71334867632322,16.3961,5.17504945201252,575.9622,0.858667884719195,0.738910736066434,0.877546324588033,0.754175256221417,0.119757148652761,0.123371068366616,True,,,,
35574,1053:1564,Pancreas,PA-TU-8902,SIDM00455,1298526,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.937396898198336,0.12519407614591,0.653483497480519,11.0910099098824,42.6046,0.815463142112774,0.868077248981755,0.114560227121205,0.612573403562039,0.37380783839942,0.238765565162618,7.64667088449114,3.9139,3.44433902539129,38.6907,0.764412620011584,0.606801963928614,0.813732920592042,0.674979021696213,0.157610656082969,0.138753898895829,True,,,,
35574,1011:1564,Pancreas,PA-TU-8902,SIDM00455,1298526,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.805129919145847,0.12519407614591,0.653483497480519,11.0910099098824,42.6046,0.815463142112774,0.868077248981755,0.0533079718897848,0.526139115489635,0.118739858516278,0.407399256973357,3.21693556542902,0.1816,7.87407434445341,42.423,0.656553773675676,0.335555956457381,0.69891496528503,0.362315756129014,0.320997817218295,0.336599209156015,True,,,,
37924,1011:1088,Pancreas,BxPC-3,SIDM00132,906693,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,0.804125122461613,0.0571678506295267,0.820930913631956,13.1960424971179,91.6441,0.945624129411979,0.947216353163684,0.034382076853019,0.66013117145682,0.430468497470569,0.229662673986251,9.39003582210721,6.5521,3.80600667501069,85.092,0.760400118866063,0.649208291381954,0.76168046598539,0.670703588544996,0.111191827484109,0.0909768774403944,True,0.344306806381711,0.0480511788203858,0.981404205445745,49.3427750444841
37924,1022:1088,Pancreas,BxPC-3,SIDM00132,906693,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,0.830972719235411,0.0571678506295267,0.820930913631956,13.1960424971179,91.6441,0.945624129411979,0.947216353163684,0.100700806116973,0.682171193605157,0.418971771156902,0.263199422448255,9.04623515771348,5.1628,4.14980733940442,86.4813,0.78578785419209,0.660765970662811,0.787110948692676,0.680061379447633,0.12502188352928,0.107049569245043,True,0.344306806381711,0.0480511788203858,0.981404205445745,49.3427750444841
37926,1510:1558,Pancreas,BxPC-3,SIDM00132,906693,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.818444476597861,0.060104390119906,0.690602728777741,11.2126728755224,46.3533,0.89731358785253,0.901244103390999,0.0724192454580744,0.565219988891553,0.291181359850627,0.274038629040926,7.36378273445735,3.217,3.84889014106501,43.1363,0.734401349754112,0.575059459591647,0.737618258486754,0.595947341459258,0.159341890162465,0.141670917027496,True,0.344306806381711,0.0480511788203858,0.981404205445745,49.3427750444841
37926,1053:1558,Pancreas,BxPC-3,SIDM00132,906693,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.917918219370984,0.060104390119906,0.690602728777741,11.2126728755224,46.3533,0.89731358785253,0.901244103390999,0.039409950826614,0.633916827092407,0.459314746318574,0.174602080773833,9.00427068406108,10.0296,2.20840219146127,36.3237,0.823660490778983,0.727788985190635,0.827268382603265,0.749398435232342,0.0958715055883487,0.077869947370923,True,0.344306806381711,0.0480511788203858,0.981404205445745,49.3427750444841
37926,1083:1558,Pancreas,BxPC-3,SIDM00132,906693,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,1.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.946059217082431,0.060104390119906,0.690602728777741,11.2126728755224,46.3533,0.89731358785253,0.901244103390999,0.0416930665632827,0.65335107690246,0.714008231481212,-0.0606571545787519,12.0972551262913,85.5789,-0.884582250768959,-39.2256,0.848911790401192,0.872227428811318,0.852630290854246,0.87493310756913,-0.0233156384101263,-0.022302816714884,True,0.344306806381711,0.0480511788203858,0.981404205445745,49.3427750444841
37926,1080:1558,Pancreas,BxPC-3,SIDM00132,906693,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.0025,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.863679349830753,0.060104390119906,0.690602728777741,11.2126728755224,46.3533,0.89731358785253,0.901244103390999,0.0309931838444106,0.596459315782103,0.563840826593473,0.0326184891886301,10.7403132166829,33.4108,0.472359658839501,12.9425,0.774991216150773,0.764857728605694,0.778385921255538,0.765523198291708,0.010133487545079,0.0128627229638301,True,0.344306806381711,0.0480511788203858,0.981404205445745,49.3427750444841
37926,1564:1558,Pancreas,BxPC-3,SIDM00132,906693,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,1.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.680890167779696,0.060104390119906,0.690602728777741,11.2126728755224,46.3533,0.89731358785253,0.901244103390999,0.0541366914376653,0.470224607866592,0.218062827015149,0.252161780851443,6.92612651332006,2.3752,4.2865463622023,43.9781,0.61097199938391,0.461635844900072,0.613648248768359,0.4775318510105,0.149336154483838,0.136116397757859,True,0.344306806381711,0.0480511788203858,0.981404205445745,49.3427750444841
37926,1372:1558,Pancreas,BxPC-3,SIDM00132,906693,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.628056938718532,0.060104390119906,0.690602728777741,11.2126728755224,46.3533,0.89731358785253,0.901244103390999,0.0293083794549783,0.433737835706813,0.209679065117939,0.224058770588874,7.09633050753513,2.6726,4.11634236798723,43.6807,0.563564025057203,0.439756435155277,0.566032612613879,0.447118114251964,0.123807589901926,0.118914498361915,True,0.344306806381711,0.0480511788203858,0.981404205445745,49.3427750444841
37926,1079:1558,Pancreas,BxPC-3,SIDM00132,906693,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.60567339510865,0.060104390119906,0.690602728777741,11.2126728755224,46.3533,0.89731358785253,0.901244103390999,0.0453766343382437,0.418279699410113,0.234372167071744,0.183907532338369,7.73208462005871,4.1526,3.48058825546364,42.2007,0.543478967231766,0.470870926813164,0.545859575922478,0.454083311052947,0.0726080404186019,0.0917762648695309,True,0.344306806381711,0.0480511788203858,0.981404205445745,49.3427750444841
37926,1080:1561,Pancreas,BxPC-3,SIDM00132,906693,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.025,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.635511614968729,0.0889143686199498,0.516408386282288,9.18093255030291,11.3362,0.771838021165552,0.824653387828577,0.109722014619731,0.328183527549652,0.164023246463138,0.164160281086514,6.09027458199785,1.3307,3.09065796830506,10.0055,0.490512027325188,0.348163443060263,0.524076806288372,0.41119183550151,0.142348584264925,0.112884970786862,True,0.344306806381711,0.0480511788203858,0.981404205445745,49.3427750444841
37926,1372:1561,Pancreas,BxPC-3,SIDM00132,906693,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.653543344956114,0.0889143686199498,0.516408386282288,9.18093255030291,11.3362,0.771838021165552,0.824653387828577,0.0567747811526318,0.337495264134316,0.0627485436343371,0.274746720499978,2.82076021290572,0.138,6.3601723373972,11.1982,0.504429602116843,0.240477197001037,0.53894673351088,0.271705019301267,0.263952405115806,0.267241714209612,True,0.344306806381711,0.0480511788203858,0.981404205445745,49.3427750444841
37926,1564:1561,Pancreas,BxPC-3,SIDM00132,906693,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.633033227838428,0.0889143686199498,0.516408386282288,9.18093255030291,11.3362,0.771838021165552,0.824653387828577,0.0624217929889355,0.32690366765111,0.0595961695300447,0.267307498121066,2.76089637237474,0.1324,6.42003617792817,11.2038,0.488599113906854,0.227893365233145,0.522032995945019,0.260513245828761,0.260705748673709,0.261519750116257,True,0.344306806381711,0.0480511788203858,0.981404205445745,49.3427750444841
37926,1079:1561,Pancreas,BxPC-3,SIDM00132,906693,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.05,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.868799318528723,0.0889143686199498,0.516408386282288,9.18093255030291,11.3362,0.771838021165552,0.824653387828577,0.105703277176375,0.448655254084569,0.202096142709951,0.246559111374619,5.71077044698828,1.0229,3.47016210331463,10.3133,0.67057234680319,0.486317263191788,0.71645830136787,0.539741571066571,0.184255083611402,0.176716730301299,True,0.344306806381711,0.0480511788203858,0.981404205445745,49.3427750444841
37927,1011:1598,Pancreas,BxPC-3,SIDM00132,906693,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1598,LGK974,PORCN,WNT signaling,Targeted,Early clinical trials,10.0,0.812326678504313,0.0613867801702382,0.763617891646597,12.231405010309,93.9182,0.909282531900679,0.927937022400988,0.0759869605569141,0.620307185567747,0.271522721146389,0.348784464421358,7.10127952633584,2.6818,5.13012548397311,91.2364,0.738634458960871,0.583845082288302,0.753787999268177,0.578548545195684,0.154789376672569,0.175239454072493,True,0.344306806381711,0.0480511788203858,0.981404205445745,49.3427750444841
38327,1179:1005,Pancreas,HPAC,SIDM00670,1298136,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.0,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,8.0,0.26424861424841,0.0537907568133998,0.921677556954282,15.0069896155158,514.4866,0.976250326082132,0.98046897431573,0.0543373685060886,0.243552017209029,0.137798975833992,0.105753041375036,9.20942636549452,9.2498,5.7975632500213,505.2368,0.257972795826762,0.17899746135392,0.259087567776491,0.223295269151427,0.0789753344728421,0.0357922986250642,True,0.295135354184212,0.051198586310322,1.13105437860429,43.0883414409707
38327,1080:1011,Pancreas,HPAC,SIDM00670,1298136,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in pancreas,0.025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.442234844804716,0.102122567068023,0.537081120909752,9.36206561045506,12.8526,0.897242091214819,0.851983801960898,0.0451223433471274,0.237515986153067,0.0570466592948404,0.180469326858226,4.34651396370652,0.3973,5.01555164674854,12.4553,0.396791716960644,0.201336556339174,0.376776924436309,0.232944367406729,0.19545516062147,0.143832557029581,True,0.295135354184212,0.051198586310322,1.13105437860429,43.0883414409707
38327,1085:1011,Pancreas,HPAC,SIDM00670,1298136,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,5.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.621600135655225,0.102122567068023,0.537081120909752,9.36206561045506,12.8526,0.897242091214819,0.851983801960898,0.093858026544023,0.333849697615362,0.102014279421414,0.231835418193949,5.03348429134649,0.6397,4.32858131910857,12.2129,0.55772580561471,0.320894356723252,0.529593246874949,0.360115062066876,0.236831448891458,0.169478184808073,True,0.295135354184212,0.051198586310322,1.13105437860429,43.0883414409707
38327,1372:1011,Pancreas,HPAC,SIDM00670,1298136,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.339383855350662,0.102122567068023,0.537081120909752,9.36206561045506,12.8526,0.897242091214819,0.851983801960898,0.0509036056110055,0.182276661450407,0.0630867129372505,0.119189948513156,5.40128856945874,0.8254,3.96077704099632,12.0272,0.304509480099375,0.176584105839063,0.289149547405804,0.206014238995898,0.127925374260312,0.0831353084099064,True,0.295135354184212,0.051198586310322,1.13105437860429,43.0883414409707
38327,1083:1011,Pancreas,HPAC,SIDM00670,1298136,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.924987853453748,0.102122567068023,0.537081120909752,9.36206561045506,12.8526,0.897242091214819,0.851983801960898,0.0886822777000518,0.496793513160844,0.337494034341643,0.159299478819201,7.64937367062799,3.9212,1.71269193982707,8.9314,0.829938035981148,0.676885317425176,0.788074668153174,0.704137642361,0.153052718555972,0.0839370257921742,True,0.295135354184212,0.051198586310322,1.13105437860429,43.0883414409707
38327,1564:1011,Pancreas,HPAC,SIDM00670,1298136,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.307234932687248,0.102122567068023,0.537081120909752,9.36206561045506,12.8526,0.897242091214819,0.851983801960898,0.0533439328700771,0.1650100820303,0.0314821220749413,0.133527959955358,3.71246732149354,0.256,5.64959828896152,12.5966,0.275664113498551,0.0962218898656097,0.261759186046083,0.146798026606715,0.179442223632941,0.114961159439368,True,0.295135354184212,0.051198586310322,1.13105437860429,43.0883414409707
38327,1190:1011,Pancreas,HPAC,SIDM00670,1298136,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.759815612751372,0.102122567068023,0.537081120909752,9.36206561045506,12.8526,0.897242091214819,0.851983801960898,0.0559097677827594,0.408082620981237,0.197920158868435,0.210162462112802,6.45757101308498,1.7165,2.90449459737008,11.1361,0.68173854932271,0.489973875916017,0.647350594541164,0.519249363984362,0.191764673406693,0.128101230556802,True,0.295135354184212,0.051198586310322,1.13105437860429,43.0883414409707
38328,1088:1022,Pancreas,HPAC,SIDM00670,1298136,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.907766546607292,0.0758077731518939,0.652381508818857,10.5338700403072,2.8956,0.930037655472236,0.898061794126583,0.0914785824034394,0.592210109330949,0.262363728425487,0.329846380905462,6.80675200266428,0.2187,3.72711803764293,2.6769,0.844257070722775,0.652866333587305,0.815230453494238,0.642025030756888,0.19139073713547,0.17320542273735,True,0.295135354184212,0.051198586310322,1.13105437860429,43.0883414409707
38328,1005:1022,Pancreas,HPAC,SIDM00670,1298136,1005,Cisplatin,DNA crosslinker,DNA replication,Chemotherapeutic,FDA approved,0.8,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.928681656765405,0.0758077731518939,0.652381508818857,10.5338700403072,2.8956,0.930037655472236,0.898061794126583,0.0816889105664913,0.605854740453011,0.712710861928015,-0.106856121475004,11.9090831545182,7.5114,-1.37521311421096,-4.6158,0.863708910738169,0.903835322500595,0.834013514847187,0.869916804564791,-0.0401264117624264,-0.035903289717604,True,0.295135354184212,0.051198586310322,1.13105437860429,43.0883414409707
38328,1179:1022,Pancreas,HPAC,SIDM00670,1298136,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,0.2,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.923419183858634,0.0758077731518939,0.652381508818857,10.5338700403072,2.8956,0.930037655472236,0.898061794126583,0.125060066539745,0.602421600437973,0.32975047021609,0.272671130221883,7.56734134167086,0.3704,2.96652869863635,2.5252,0.85881461277397,0.751795188354662,0.82928748898699,0.698317919850604,0.107019424419308,0.130969569136386,True,0.295135354184212,0.051198586310322,1.13105437860429,43.0883414409707
38328,1190:1022,Pancreas,HPAC,SIDM00670,1298136,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.1,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,1.0,0.723200472317573,0.0758077731518939,0.652381508818857,10.5338700403072,2.8956,0.930037655472236,0.898061794126583,0.0563821577838376,0.471802615309048,0.188557712391674,0.283244902917374,6.4606348288943,0.172,4.0732352114129,2.7236,0.672603671710649,0.474990744266338,0.649478713682712,0.494380912983203,0.197612927444311,0.155097800699509,True,0.295135354184212,0.051198586310322,1.13105437860429,43.0883414409707
38329,1054:1053,Pancreas,HPAC,SIDM00670,1298136,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,8.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.948487706590057,0.0727864054106414,0.789889944974144,12.2266383055509,93.6084,0.930716586520306,0.943598315172697,0.115157189922403,0.749200902367071,0.501476731169346,0.247724171197725,9.28014068308008,12.1431,2.94649762247081,81.4653,0.882773240633971,0.728047960778898,0.894991401900393,0.804577368034085,0.154725279855073,0.0904140338663081,True,0.295135354184212,0.051198586310322,1.13105437860429,43.0883414409707
38329,1564:1053,Pancreas,HPAC,SIDM00670,1298136,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,1.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.325101233433373,0.0727864054106414,0.789889944974144,12.2266383055509,93.6084,0.930716586520306,0.943598315172697,0.0649587110985375,0.256794195387713,0.0396838097485734,0.21711038563914,4.19265285840251,0.3571,8.03398544714839,93.2513,0.30257711025465,0.115802755576932,0.306764976128296,0.167386736574785,0.186774354677718,0.139378239553511,True,0.295135354184212,0.051198586310322,1.13105437860429,43.0883414409707
38329,1057:1053,Pancreas,HPAC,SIDM00670,1298136,1057,Dactolisib,"PI3K (class 1), MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.0125,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.896187906847987,0.0727864054106414,0.789889944974144,12.2266383055509,93.6084,0.930716586520306,0.943598315172697,0.0970129587594045,0.707889816426649,0.586213425611556,0.121676390815093,10.5525584626638,29.3337,1.67407984288706,64.2747,0.834096949542336,0.759504308373828,0.845641398979907,0.805398322394149,0.0745926411685084,0.0402430765857578,True,0.295135354184212,0.051198586310322,1.13105437860429,43.0883414409707
38329,1372:1053,Pancreas,HPAC,SIDM00670,1298136,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.342451148220258,0.0727864054106414,0.789889944974144,12.2266383055509,93.6084,0.930716586520306,0.943598315172697,0.0769455544734767,0.270498718624032,0.059576289533387,0.210922429090645,5.20446307091749,0.7202,7.02217523463341,92.8882,0.318724963721518,0.158357456455672,0.323136326489591,0.202820150757983,0.160367507265846,0.120316175731608,True,0.295135354184212,0.051198586310322,1.13105437860429,43.0883414409707
38329,1558:1053,Pancreas,HPAC,SIDM00670,1298136,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.966655566156062,0.0727864054106414,0.789889944974144,12.2266383055509,93.6084,0.930716586520306,0.943598315172697,0.0495314368847023,0.763551511959962,0.763336656731694,0.0002148552282679,12.2233764212435,93.397,0.0032618843074292,0.211399999999998,0.899682368873624,0.917763704490461,0.91213456357717,0.912069657448239,-0.0180813356168372,6.49061289308417e-05,True,0.295135354184212,0.051198586310322,1.13105437860429,43.0883414409707
38329,1558:1054,Pancreas,HPAC,SIDM00670,1298136,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,8.0,0.860835774276415,0.0940408727279878,0.74940106479656,11.6690529228496,50.8809,0.892997455457068,0.931051025029968,0.0819685377782057,0.645111245857717,0.344906981214889,0.300204264642828,8.0188137101494,4.0525,3.65023921270022,46.8284,0.768724155995254,0.622489196279001,0.801482030022523,0.674109950166363,0.146234959716253,0.12737207985616,True,0.295135354184212,0.051198586310322,1.13105437860429,43.0883414409707
38330,1372:1057,Pancreas,HPAC,SIDM00670,1298136,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,1057,Dactolisib,"PI3K (class 1), MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,0.307072846904987,0.0771227491919428,0.607408375193094,10.0633893268994,0.209,0.881656223270141,0.881109911196816,0.0475779438047422,0.186518619004476,0.092668162099561,0.0938504569049152,6.95611897717615,0.0243,3.1072703497233,0.1847,0.270732686471061,0.194019588176891,0.270564928867407,0.220237789293262,0.0767130982941706,0.0503271395741448,True,0.295135354184212,0.051198586310322,1.13105437860429,43.0883414409707
38330,1053:1057,Pancreas,HPAC,SIDM00670,1298136,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1057,Dactolisib,"PI3K (class 1), MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,0.966303686283077,0.0771227491919428,0.607408375193094,10.0633893268994,0.209,0.881656223270141,0.881109911196816,0.0996351448178218,0.586940952028301,0.372571851389684,0.214369100638618,7.86457035108415,0.0455,2.1988189758153,0.1635,0.851947658580353,0.735053898114927,0.851419755210039,0.748025355909751,0.116893760465425,0.103394399300287,True,0.295135354184212,0.051198586310322,1.13105437860429,43.0883414409707
38330,1564:1057,Pancreas,HPAC,SIDM00670,1298136,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,1.0,1057,Dactolisib,"PI3K (class 1), MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,0.321132900543364,0.0771227491919428,0.607408375193094,10.0633893268994,0.209,0.881656223270141,0.881109911196816,0.0426032210202845,0.19505881334009,0.101160707037014,0.0938981063030758,7.10730623230584,0.0269,2.95608309459361,0.1821,0.283128820260848,0.228626539395963,0.282953381480139,0.23350650728825,0.0545022808648847,0.049446874191889,True,0.295135354184212,0.051198586310322,1.13105437860429,43.0883414409707
38330,1079:1073,Pancreas,HPAC,SIDM00670,1298136,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,0.5,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in pancreas,20.0,0.774707641086845,0.0681886604270131,0.713581208596033,11.2241882897756,93.4496,0.890817517106737,0.919384981843088,0.136801657863018,0.552816814835332,0.318424000949601,0.234392813885732,8.1234959185998,10.8937,3.10069237117577,82.5559,0.6901231373166,0.514824962784104,0.71225457053433,0.611291259234689,0.175298174532496,0.100963311299641,True,0.295135354184212,0.051198586310322,1.13105437860429,43.0883414409707
38330,1558:1073,Pancreas,HPAC,SIDM00670,1298136,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,1073,5-Fluorouracil,Antimetabolite (DNA & RNA),Other,Chemotherapeutic,FDA approved in pancreas,20.0,0.852866000333038,0.0681886604270131,0.713581208596033,11.2241882897756,93.4496,0.890817517106737,0.919384981843088,0.112131810121226,0.608589151288114,0.638280871610473,-0.0296917203223588,11.6560207136513,126.0584,-0.431832423875692,-32.6088,0.75974797284143,0.718559433670577,0.784112192230777,0.793788787909606,0.0411885391708532,-0.0096765956788286,True,0.295135354184212,0.051198586310322,1.13105437860429,43.0883414409707
38555,1510:1079,Pancreas,HPAC,SIDM00670,1298136,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.677773448918596,0.136378234323515,0.712742367668849,11.214196780622,9.2805,0.839417733809161,0.919104975932028,0.0977646921108304,0.483077852725322,0.350852541202949,0.132225311522373,9.17213718002082,2.2535,2.0420596006012,7.027,0.568935052527267,0.511440419235058,0.622944949455694,0.571555633654674,0.0574946332922096,0.0513893158010191,True,0.296161441710273,0.0493520129543105,1.13025045069769,43.146089012471
38555,1053:1079,Pancreas,HPAC,SIDM00670,1298136,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.941214533066424,0.136378234323515,0.712742367668849,11.214196780622,9.2805,0.839417733809161,0.919104975932028,0.100542788162633,0.670843474782093,0.325473353832717,0.345370120949376,7.44658347914085,0.6814,3.76761330148117,8.5991,0.790072170374865,0.658586918691274,0.86507496076089,0.70473977372135,0.131485251683591,0.16033518703954,True,0.296161441710273,0.0493520129543105,1.13025045069769,43.146089012471
38555,1083:1079,Pancreas,HPAC,SIDM00670,1298136,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,1.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.824000989813329,0.136378234323515,0.712742367668849,11.214196780622,9.2805,0.839417733809161,0.919104975932028,0.0924151799971034,0.587300416441027,0.612086536802412,-0.0247861203613855,11.5844325405209,11.9956,-0.370235759898852,-2.7151,0.69168104352561,0.711285902574223,0.757343409910346,0.765455677536617,-0.0196048590486126,-0.0081122676262709,True,0.296161441710273,0.0493520129543105,1.13025045069769,43.146089012471
38555,1179:1079,Pancreas,HPAC,SIDM00670,1298136,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.227803931957889,0.136378234323515,0.712742367668849,11.214196780622,9.2805,0.839417733809161,0.919104975932028,0.0350698758567859,0.16236551382794,0.096458942844702,0.0659065709832375,8.24781115515487,1.1874,2.96638562546716,8.0931,0.191222660316908,0.15801727545381,0.209375727399377,0.181337688530746,0.033205384863098,0.0280380388686311,True,0.296161441710273,0.0493520129543105,1.13025045069769,43.146089012471
38555,1564:1079,Pancreas,HPAC,SIDM00670,1298136,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,1.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.30257752868735,0.136378234323515,0.712742367668849,11.214196780622,9.2805,0.839417733809161,0.919104975932028,0.0324960420821669,0.215659824200011,0.0798644386835909,0.13579538551642,6.50118152179122,0.3538,4.7130152588308,8.9267,0.253988943432312,0.196220216464997,0.278100512221759,0.207693040892247,0.0577687269673147,0.0704074713295122,True,0.296161441710273,0.0493520129543105,1.13025045069769,43.146089012471
38555,1190:1079,Pancreas,HPAC,SIDM00670,1298136,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.01,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.726483598424799,0.136378234323515,0.712742367668849,11.214196780622,9.2805,0.839417733809161,0.919104975932028,0.109450164143171,0.517795640013877,0.383048392098924,0.134747247914953,9.26598138442156,2.4049,1.94821539620046,6.8756,0.60982321583927,0.534072765446826,0.667714690245238,0.615786497972598,0.075750450392444,0.05192819227264,True,0.296161441710273,0.0493520129543105,1.13025045069769,43.146089012471
38555,1372:1079,Pancreas,HPAC,SIDM00670,1298136,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.324520783482585,0.136378234323515,0.712742367668849,11.214196780622,9.2805,0.839417733809161,0.919104975932028,0.0623798412738564,0.231299711577127,0.0437172301944406,0.187582481382687,4.46821862914423,0.0865,6.74597815147779,9.194,0.272408500644925,0.136066842622986,0.298268666892204,0.173980890031347,0.136341658021938,0.124287776860857,True,0.296161441710273,0.0493520129543105,1.13025045069769,43.146089012471
38555,1022:1079,Pancreas,HPAC,SIDM00670,1298136,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.932382149169969,0.136378234323515,0.712742367668849,11.214196780622,9.2805,0.839417733809161,0.919104975932028,0.122706762462463,0.664548260571573,0.421235408829503,0.243312851742071,8.52861210187953,1.4425,2.68558467874249,7.838,0.782658110700371,0.662683423601853,0.856957072772316,0.756380707342568,0.119974687098517,0.100576365429749,True,0.296161441710273,0.0493520129543105,1.13025045069769,43.146089012471
38555,1594:1079,Pancreas,HPAC,SIDM00670,1298136,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,1079,Dasatinib,"ABL, SRC, Ephrins, PDGFR, KIT","Other, kinases",Targeted,FDA approved,2.0,0.494740719437506,0.136378234323515,0.712742367668849,11.214196780622,9.2805,0.839417733809161,0.919104975932028,0.0585473227671889,0.352622671754078,0.310775767844903,0.0418469039091753,10.2775503696047,4.8485,0.936646411017353,4.432,0.415294133533346,0.418939228011717,0.454718657031204,0.439863210687594,-0.0036450944783713,0.0148554463436096,True,0.296161441710273,0.0493520129543105,1.13025045069769,43.146089012471
39374,1179:1088,Pancreas,HPAC,SIDM00670,1298136,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.0,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,0.271676548471111,0.0433325320029212,0.884873714787184,13.9691486052086,156.6148,0.97519542762788,0.970721033782499,0.0544395825850609,0.240399436666192,0.157500277482125,0.0828991591840665,9.78380027270408,8.6083,4.18534833250457,148.0065,0.264937727862751,0.190254814549289,0.263722139986338,0.236375030924057,0.0746829133134616,0.0273471090622802,True,0.258578003967525,0.0391650501002069,1.2706433712277,38.6131626086359
39374,1022:1088,Pancreas,HPAC,SIDM00670,1298136,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1088,Irinotecan,TOP1,DNA replication,Chemotherapeutic,FDA approved in pancreas,5.0,0.911572362620778,0.0433325320029212,0.884873714787184,13.9691486052086,156.6148,0.97519542762788,0.970721033782499,0.0837464264727311,0.806626422809578,0.327202827696982,0.479423595112596,7.58691157026822,1.8775,6.38223703494043,154.7373,0.888961199979727,0.714605179087103,0.884882466210797,0.690452984662284,0.174356020892624,0.194429481548513,True,0.258578003967525,0.0391650501002069,1.2706433712277,38.6131626086359
39378,1179:1190,Pancreas,HPAC,SIDM00670,1298136,1179,MK-1775,"WEE1, PLK1",Cell cycle,Targeted,Early clinical trials,2.0,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.2,0.232402672216327,0.090935919017111,0.565122419318407,9.63832348775964,0.3113,0.8356585137049,0.864017637426304,0.0331497909636084,0.131335960378954,0.100232394873324,0.0311035655056293,8.32604963242069,0.1254,1.31227385533894,0.1859,0.194209271645343,0.176180433802535,0.200800007779911,0.186000288832887,0.0180288378428085,0.0147997189470244,True,0.258578003967525,0.0391650501002069,1.2706433712277,38.6131626086359
39378,1022:1190,Pancreas,HPAC,SIDM00670,1298136,1022,AZD7762,"CHEK1, CHEK2",Cell cycle,Targeted,Early clinical trials,0.25,1190,Gemcitabine,Pyrimidine antimetabolite,DNA replication,Chemotherapeutic,FDA approved in pancreas,0.2,0.856633134935995,0.090935919017111,0.565122419318407,9.63832348775964,0.3113,0.8356585137049,0.864017637426304,0.118735964907671,0.484102589683341,0.0854591620293389,0.398643427654002,3.63988147914278,0.0049,5.99844200861686,0.3064,0.715852772330982,0.396524297222589,0.740146137388487,0.404508971138768,0.319328475108393,0.335637166249719,True,0.258578003967525,0.0391650501002069,1.2706433712277,38.6131626086359
39378,1510:1372,Pancreas,HPAC,SIDM00670,1298136,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.71601480921523,0.0983644702500028,0.194828648501708,5.54268687403068,0.091,0.594293807179646,0.617545077381759,0.0715023521044971,0.139500197586611,0.0448971686367257,0.0946030289498857,2.41016568764525,0.0104,3.13252118638543,0.0806,0.425523166965527,0.244513914377963,0.442171420763305,0.271344022588895,0.181009252587564,0.170827398174409,True,0.258578003967525,0.0391650501002069,1.2706433712277,38.6131626086359
39381,1564:1507,Pancreas,HPAC,SIDM00670,1298136,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1507,Ruxolitinib,"JAK1, JAK2","Other, kinases",Targeted,Advanced clinical trials,10.0,0.339173202936316,0.048190653388822,0.954311035809669,16.4050160271298,1694.8526,0.974509550048887,0.988797743679639,0.0810893438577376,0.323676730613039,0.200412730912533,0.123263999700506,9.89575011171927,18.6058,6.50926591541055,1676.2468,0.330527525382109,0.227062903164188,0.335373697780025,0.296631880895025,0.103464622217921,0.0387418168850007,True,0.258578003967525,0.0391650501002069,1.2706433712277,38.6131626086359
39381,1372:1510,Pancreas,HPAC,SIDM00670,1298136,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.25,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.355803933659043,0.0826585637535084,0.670072663819866,10.726333038215,33.0886,0.878919145821212,0.904419820455233,0.0409797227143684,0.238414489624502,0.0833593082715098,0.155055181352992,6.11444793297419,1.3532,4.61188510524076,31.7354,0.312722889451433,0.197664859186856,0.321796129797177,0.234546990027059,0.115058030264578,0.0872491397701182,True,0.258578003967525,0.0391650501002069,1.2706433712277,38.6131626086359
39381,1564:1510,Pancreas,HPAC,SIDM00670,1298136,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.339173202936316,0.0826585637535084,0.670072663819866,10.726333038215,33.0886,0.878919145821212,0.904419820455233,0.0492639702091113,0.227270691587853,0.0442381333526203,0.183032558235233,4.37744463519015,0.4059,6.3488884030248,32.6827,0.298105821810231,0.133332313644274,0.306754967302889,0.179465728458873,0.164773508165957,0.127289238844016,True,0.258578003967525,0.0391650501002069,1.2706433712277,38.6131626086359
39381,1598:1510,Pancreas,HPAC,SIDM00670,1298136,1598,LGK974,PORCN,WNT signaling,Targeted,Early clinical trials,2.5,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.793752837641665,0.0826585637535084,0.670072663819866,10.726333038215,33.0886,0.878919145821212,0.904419820455233,0.0878307783094375,0.531872078333128,0.308077990119119,0.223794088214009,7.89091306357179,4.6359,2.83541997464317,28.4527,0.697644566053175,0.551856391248784,0.717885798905707,0.615680794940947,0.145788174804391,0.10220500396476,True,0.258578003967525,0.0391650501002069,1.2706433712277,38.6131626086359
39381,1057:1510,Pancreas,HPAC,SIDM00670,1298136,1057,Dactolisib,"PI3K (class 1), MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.05,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.715408679975241,0.0826585637535084,0.670072663819866,10.726333038215,33.0886,0.878919145821212,0.904419820455233,0.0676721539125474,0.479375799910864,0.298742924924326,0.180632874986538,8.18935569799657,5.7013,2.53697734021838,27.3873,0.62878638591692,0.514766476105087,0.647029789895323,0.567152973440684,0.114019909811833,0.0798768164546388,True,0.258578003967525,0.0391650501002069,1.2706433712277,38.6131626086359
39381,1054:1510,Pancreas,HPAC,SIDM00670,1298136,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,2.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.899842913034487,0.0826585637535084,0.670072663819866,10.726333038215,33.0886,0.878919145821212,0.904419820455233,0.11201234338713,0.602960137756447,0.432161259404228,0.170798878352219,8.8075388341274,8.7511,1.91879420408756,24.3375,0.790889164497543,0.677601137409947,0.813835765844565,0.742920386128257,0.113288027087596,0.0709153797163075,True,0.258578003967525,0.0391650501002069,1.2706433712277,38.6131626086359
39381,1594:1510,Pancreas,HPAC,SIDM00670,1298136,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.616801356489117,0.0826585637535084,0.670072663819866,10.726333038215,33.0886,0.878919145821212,0.904419820455233,0.117849308429206,0.41330172799037,0.192017469322296,0.221284258668074,7.0653890691046,2.6159,3.66094396911036,30.4727,0.54211852138678,0.368131431165844,0.557847372092432,0.446811486326356,0.173987090220936,0.111035885766076,True,0.258578003967525,0.0391650501002069,1.2706433712277,38.6131626086359
39382,1083:1558,Pancreas,HPAC,SIDM00670,1298136,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,1.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.894805266315111,0.112966481296796,0.639498650237579,10.3966063700104,26.3282,0.918369033660447,0.893325141906912,0.117830832240152,0.572226760033991,0.416961094856282,0.155265665177709,8.66791756066747,7.9439,1.72868880934291,18.3843,0.821761447740087,0.71886851756079,0.799352041509999,0.73240421335726,0.102892930179297,0.0669478281527393,True,0.258578003967525,0.0391650501002069,1.2706433712277,38.6131626086359
39382,1564:1561,Pancreas,HPAC,SIDM00670,1298136,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.345819904456978,0.0632467596678093,0.305722337715341,7.00155012381886,2.5027,0.708753618809895,0.720214295333383,0.0452708669347803,0.105724869619083,0.0233173561128861,0.082407513506197,2.59938043391844,0.1184,4.40216968990042,2.3843,0.245101108740375,0.0972269833509291,0.24906443880074,0.135916103063284,0.147874125389446,0.113148335737456,True,0.258578003967525,0.0391650501002069,1.2706433712277,38.6131626086359
39382,1372:1561,Pancreas,HPAC,SIDM00670,1298136,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.3282070643214,0.0632467596678093,0.305722337715341,7.00155012381886,2.5027,0.708753618809895,0.720214295333383,0.044083123134512,0.100340230959028,0.0304713157677732,0.0698689151912547,3.44606518209135,0.2129,3.55548494172751,2.2898,0.232617944556764,0.117827584413271,0.236379419553675,0.150086831049858,0.114790360143493,0.0862925885038177,True,0.258578003967525,0.0391650501002069,1.2706433712277,38.6131626086359
38249,1510:1564,Pancreas,HPAC,SIDM00670,1298136,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.769803010299451,0.108055684926245,0.167894230268126,5.09998740851483,0.6699,0.580229246500067,0.584372694157594,0.0794689644882486,0.129245483872312,0.0354743734376872,0.0937711104346252,1.61688072485669,0.0599,3.48310668365814,0.61,0.446662220619534,0.214664884900808,0.449851859099316,0.247723256344988,0.231997335718726,0.202128602754328,True,0.292515617713831,0.0454256397804089,1.13619206245154,42.8634315635585
38249,1053:1564,Pancreas,HPAC,SIDM00670,1298136,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.25,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.886625018392476,0.108055684926245,0.167894230268126,5.09998740851483,0.6699,0.580229246500067,0.584372694157594,0.0964809516891829,0.148859224999468,0.0554663196905163,0.0933929053089513,2.40413507567334,0.1034,2.69585233284149,0.5665,0.514445766349974,0.309576079826864,0.518119450705537,0.335603904048976,0.20486968652311,0.182515546656561,True,0.292515617713831,0.0454256397804089,1.13619206245154,42.8634315635585
38249,1083:1564,Pancreas,HPAC,SIDM00670,1298136,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,1.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.860693956911163,0.108055684926245,0.167894230268126,5.09998740851483,0.6699,0.580229246500067,0.584372694157594,0.127380817247787,0.144505549392027,0.129696075766108,0.0148094736259196,4.78666740283132,0.5391,0.313320005683504,0.1308,0.499399806085725,0.455578870455634,0.502966046445336,0.482455757243323,0.0438209356300913,0.0205102892020133,True,0.292515617713831,0.0454256397804089,1.13619206245154,42.8634315635585
38249,1561:1564,Pancreas,HPAC,SIDM00670,1298136,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,2.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.653936747312017,0.108055684926245,0.167894230268126,5.09998740851483,0.6699,0.580229246500067,0.584372694157594,0.0725511131219406,0.109792206833993,0.0190176485454453,0.0907745582885476,0.452245998568458,0.0267,4.64774140994637,0.6432,0.379433226151556,0.126851472923091,0.382142778835377,0.160197276494721,0.252581753228465,0.221945502340656,True,0.292515617713831,0.0454256397804089,1.13619206245154,42.8634315635585
38249,1011:1564,Pancreas,HPAC,SIDM00670,1298136,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,4.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.715953192782977,0.108055684926245,0.167894230268126,5.09998740851483,0.6699,0.580229246500067,0.584372694157594,0.0892354326951902,0.120204410210305,0.0393280897188031,0.0808763204915018,2.06756494297235,0.0819,3.03242246554248,0.588,0.415416981577784,0.223275442701447,0.418383496157319,0.253368059793878,0.192141538876337,0.165015436363441,True,0.292515617713831,0.0454256397804089,1.13619206245154,42.8634315635585
38249,1558:1564,Pancreas,HPAC,SIDM00670,1298136,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,10.0,0.911148739574944,0.108055684926245,0.167894230268126,5.09998740851483,0.6699,0.580229246500067,0.584372694157594,0.113791118355391,0.152976616290708,0.0722125677549478,0.0807640485357604,3.0242975180957,0.1589,2.07568989041912,0.511,0.528675146613055,0.374825297455353,0.532450443723705,0.38728441082553,0.153849849157702,0.145166032898175,True,0.292515617713831,0.0454256397804089,1.13619206245154,42.8634315635585
38249,1372:1594,Pancreas,HPAC,SIDM00670,1298136,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.295411081470875,0.0647792513321114,0.498977532227118,8.99003478803803,3.9725,0.812415291546299,0.834616742645886,0.04489570471965,0.147403492424882,0.0712175433805871,0.0761859490442945,6.20582997319489,0.5767,2.78420481484314,3.3958,0.239996479879169,0.18640264623736,0.24655503455872,0.196658044201212,0.0535938336418082,0.0498969903575082,True,0.292515617713831,0.0454256397804089,1.13619206245154,42.8634315635585
38249,1564:1594,Pancreas,HPAC,SIDM00670,1298136,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,4.0,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.28724445351639,0.0647792513321114,0.498977532227118,8.99003478803803,3.9725,0.812415291546299,0.834616742645886,0.064000426791646,0.143328528561536,0.0288382908449731,0.114490237716562,3.6570513877349,0.0986,5.33298340030313,3.8739,0.233361786448575,0.11072225534823,0.239739030136947,0.136019215596047,0.122639531100345,0.1037198145409,True,0.292515617713831,0.0454256397804089,1.13619206245154,42.8634315635585
38249,1510:1594,Pancreas,HPAC,SIDM00670,1298136,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.769803010299451,0.0647792513321114,0.498977532227118,8.99003478803803,3.9725,0.812415291546299,0.834616742645886,0.0818639848693374,0.384114406380227,0.225261650852495,0.158852755527733,6.84929803888797,0.9008,2.14073674915006,3.0717,0.625399737045647,0.52120015672568,0.642490480935126,0.546645230854916,0.104199580319967,0.0958452500802094,True,0.292515617713831,0.0454256397804089,1.13619206245154,42.8634315635585
